PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA
J	Fernandez-Cuesta, L				Fernandez-Cuesta, L.			Molecular Section	JOURNAL OF THORACIC ONCOLOGY			English	Meeting Abstract									[Fernandez-Cuesta, L.] Int Agcy Res Canc Iarc Who, Genet Sect, Lyon, France									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	OCT	2019	14	10		S		WS02.04	S1112	S1112					1	Oncology; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Respiratory System	JG6DQ	WOS:000492162206048					2022-02-25	
J	Saracci, R				Saracci, Rodolfo			My memories of Walter Holland: leader in promoting epidemiology collaboration in Europe	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Letter									[Saracci, Rodolfo] Int Agcy Res Canc, 150 Cours A Thomas, F-69008 Lyon, France		Saracci, R (corresponding author), Int Agcy Res Canc, 150 Cours A Thomas, F-69008 Lyon, France.	saracci@hotmail.com					Leeder S, 2018, INT J EPIDEMIOL, V47, P677, DOI 10.1093/ije/dyy063	1	0	0	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	JUN	2018	47	3					1009	1010		10.1093/ije/dyy122			3	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	GM7EL	WOS:000438342200039		Bronze			2022-02-25	
J	Saracci, R				Saracci, Rodolfo			Ciao Gianfranco!/A tribute to Gianfranco Domenighetti	EPIDEMIOLOGIA & PREVENZIONE			Italian	Editorial Material									[Saracci, Rodolfo] Int Agcy Res Canc, Lione, France		Saracci, R (corresponding author), Int Agcy Res Canc, Lione, France.						Domenighetti G, 2003, INT J EPIDEMIOL, V32, P816, DOI 10.1093/ije/dyg257; Domenighetti G., 2017, R P, V33, P1; Frank, 2016, LISTEN LIBERAL WHAT	3	0	0	0	1	INFERENZE SCARL	MILANO	VIA RICCIARELLI N 29, MILANO, 20148, ITALY	1120-9763			EPIDEMIOL PREV	Epidemiol. Prev.	JAN-FEB	2018	42	1					9	9		10.19191/EP18.1.P009.008			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	GS2LQ	WOS:000443381100007	29506354				2022-02-25	
J	Loomis, D; Guyton, KZ; Grosse, Y; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Vilahur, N; Mattock, H; Straif, K				Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Vilahur, Nadia; Mattock, Heidi; Straif, Kurt		Int Agency Res Canc Monograph Work	Carcinogenicity of benzene	LANCET ONCOLOGY			English	News Item							EXPOSED WORKERS; LEUKEMIA		[Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Vilahur, Nadia; Mattock, Heidi; Straif, Kurt] Int Agcy Res Canc, Lyon, France		Loomis, D (corresponding author), Int Agcy Res Canc, Lyon, France.		Loomis, Dana/AAE-3988-2019; Guha, Neela/AAG-3989-2021	Guha, Neela/0000-0003-3991-4662			Badham HJ, 2010, CARCINOGENESIS, V31, P1142, DOI 10.1093/carcin/bgq074; Benzene IARC., IARC MON EV IN PRESS, V120; FARRIS GM, 1993, FUND APPL TOXICOL, V20, P503, DOI 10.1006/faat.1993.1061; Houot J, 2015, AM J EPIDEMIOL, V182, P685, DOI 10.1093/aje/kwv111; IARC, 2012, IARC MON EV CARC RIS, V100F, P249; [IARC] International Agency for Research on Cancer, 1979, IARC MONOGR EVAL CAR, V1; Janitz AE, 2017, ENVIRON RES, V158, P167, DOI 10.1016/j.envres.2017.06.015; Lan Q, 2004, SCIENCE, V306, P1774, DOI 10.1126/science.1102443; Linet MS, 2015, INT J CANCER, V137, P2184, DOI 10.1002/ijc.29591; MALTONI C, 1989, ENVIRON HEALTH PERSP, V82, P109, DOI 10.2307/3430768; Schnatter AR, 2012, J NATL CANCER I, V104, P1724, DOI 10.1093/jnci/djs411; Smith MT, 2016, ENVIRON HEALTH PERSP, V124, P713, DOI 10.1289/ehp.1509912; Stenehjem JS, 2015, BRIT J CANCER, V112, P1603, DOI 10.1038/bjc.2015.108; Zhang GH, 2016, J OCCUP ENV MED; Zhang L, 2012, LEUKEMIA, V26, P2494, DOI 10.1038/leu.2012.143	15	73	75	2	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	DEC	2017	18	12					1574	1575		10.1016/S1470-2045(17)30832-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	FO6UC	WOS:000417001900034	29107678				2022-02-25	
J	Basu, P; Vale, D				Basu, Partha; Vale, Diama			Screening for Epithelial Ovarian Cancer: An Updated Review	INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY			English	Review						Ovarian cancer; Screening; CA-125 antigen; Randomized controlled trial	TUBAL INTRAEPITHELIAL CARCINOMA; RANDOMIZED CONTROLLED-TRIAL; BIOMARKER PERFORMANCE; SEROUS CARCINOMA; CA 125; MUTATIONS; MORTALITY; PROSTATE; WOMEN; LUNG	Introduction Epithelial ovarian cancer is an aggressive malignancy causing significant number of deaths across the world. The disease has much better prognosis if detected early and treated appropriately. The present article reviewed various screening options and their efficacies. Results Traditionally, the ovarian cancer screening strategies have relied on transvaginal ultrasound (TVS) of pelvis and serum CA-125 estimation. However, the randomized controlled trials evaluating these tests to screen the averagerisk women annually failed to demonstrate any significant reduction in mortality among the screened women compared to the unscreened. On the other hand, the false positive women underwent unnecessary surgeries and resulting complications. The recently published results of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) demonstrated delayed mortality benefits (7-14 years after screening) in the women undergoing multi-modality screening (MMS). Women undergoing MMS were assigned a risk score using an ovarian cancer risk algorithm (ROCA), and the women with intermediate or high risk had repeat CA125 estimation, and those with high risk had TVS. The reduction in the incidence of ovarian cancer and mortality from the disease through screening is likely to be more significant with the longer follow-up of the UKCTOCS trial. However, the feasibility and cost-effectiveness of such intensive screening need to be evaluated. Conclusion Currently, ovarian cancer screening is not recommended for the average-risk population.	[Basu, Partha; Vale, Diama] World Hlth Org, Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Basu, P (corresponding author), World Hlth Org, Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	basup@iarc.fr	Vale, Diama Bhadra/C-2628-2014	Vale, Diama Bhadra/0000-0003-2423-0225			Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Barrow E, 2009, CLIN GENET, V75, P141, DOI 10.1111/j.1399-0004.2008.01125.x; Buys SS, 2011, JAMA-J AM MED ASSOC, V305, P2295, DOI 10.1001/jama.2011.766; Cramer DW, 2011, CANCER PREV RES, V4, P365, DOI 10.1158/1940-6207.CAPR-10-0195; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Hollis RL, 2016, CANCER BIOL MED, V13, P236, DOI 10.20892/j.issn.2095-3941.2016.0024; Hori SS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003110; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; JACOBS I, 1989, HUM REPROD, V4, P1; Jacobs IJ, 2016, LANCET, V387, P945, DOI 10.1016/S0140-6736(15)01224-6; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kobayashi H, 2008, INT J GYNECOL CANCER, V18, P414, DOI 10.1111/j.1525-1438.2007.01035.x; Kuhn E, 2012, J PATHOL, V226, P421, DOI 10.1002/path.3023; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Menon U, 2009, LANCET ONCOL, V10, P327, DOI 10.1016/S1470-2045(09)70026-9; Moore LE, 2012, CANCER-AM CANCER SOC, V118, P91, DOI 10.1002/cncr.26241; National Cancer Registry Programme-Indian Council of Medical Research, 3 YEAR REP POP BAS C; Pal T, 2005, CANCER-AM CANCER SOC, V104, P2807, DOI 10.1002/cncr.21536; Partridge E, 2009, OBSTET GYNECOL, V113, P775, DOI 10.1097/AOG.0b013e31819cda77; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Pinsky PF, 2016, GYNECOL ONCOL, V143, P270, DOI 10.1016/j.ygyno.2016.08.334; Simmons AR, 2016, INT J GYNECOL CANCER, V26, P1070, DOI 10.1097/IGC.0000000000000737; Skates SJ, 2012, INT J GYNECOL CANCER, V22, pS24, DOI 10.1097/IGC.0b013e318256488a; van Nagell JR, 2007, CANCER-AM CANCER SOC, V109, P1887, DOI 10.1002/cncr.22594; Wilson JMG, 1968, PRINCIPLES PRACTICE; Yeole Balkrishna Bhika, 2004, Asian Pac J Cancer Prev, V5, P175; Zeppernick F, 2015, J OBSTET GYNAECOL RE, V41, P6, DOI 10.1111/jog.12550	28	0	0	0	2	SPRINGER INDIA	NEW DELHI	7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA	2363-8397	2363-8400		INDIAN J GYNECOL ONC	Indian J. Gynecol. Oncol.	MAR	2017	15	1							9	10.1007/s40944-017-0100-x			8	Obstetrics & Gynecology	Emerging Sources Citation Index (ESCI)	Obstetrics & Gynecology	ES0OH	WOS:000399225400009					2022-02-25	
J	Herceg, Z				Herceg, Z.			Role of early-life exposures on epigenome and cancer susceptibility in childhood and adulthood	TOXICOLOGY LETTERS			English	Meeting Abstract	14th International Congress of Toxicology in conjunction with the 10th Mexican Congress of Toxicology	OCT 02-09, 2016	Merida, MEXICO						[Herceg, Z.] Int Agcy Res Canc, Sect Mech Carcinogenesis, F-69008 Lyon, France; [Herceg, Z.] Int Agcy Res Canc, Epigenet Grp, F-69008 Lyon, France									0	0	0	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	OCT	2016	259			S		S09-1	S17	S17		10.1016/j.toxlet.2016.07.082			1	Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Toxicology	EO7CF	WOS:000396848100044					2022-02-25	
J	Ardin, M; Cahais, V; Castells, X; Bouaoun, L; Byrnes, G; Herceg, Z; Zavadil, J; Olivier, M				Ardin, Maude; Cahais, Vincent; Castells, Xavier; Bouaoun, Liacine; Byrnes, Graham; Herceg, Zdenko; Zavadil, Jiri; Olivier, Magali			MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes	BMC BIOINFORMATICS			English	Article						Galaxy; Mutation spectra; Mutation signatures; Single base substitutions	R PACKAGE; SIGNATURES	Background: The nature of somatic mutations observed in human tumors at single gene or genome-wide levels can reveal information on past carcinogenic exposures and mutational processes contributing to tumor development. While large amounts of sequencing data are being generated, the associated analysis and interpretation of mutation patterns that may reveal clues about the natural history of cancer present complex and challenging tasks that require advanced bioinformatics skills. To make such analyses accessible to a wider community of researchers with no programming expertise, we have developed within the web-based user-friendly platform Galaxy a first-of-its-kind package called MutSpec. Results: MutSpec includes a set of tools that perform variant annotation and use advanced statistics for the identification of mutation signatures present in cancer genomes and for comparing the obtained signatures with those published in the COSMIC database and other sources. MutSpec offers an accessible framework for building reproducible analysis pipelines, integrating existing methods and scripts developed in-house with publicly available R packages. MutSpec may be used to analyse data from whole-exome, whole-genome or targeted sequencing experiments performed on human or mouse genomes. Results are provided in various formats including rich graphical outputs. An example is presented to illustrate the package functionalities, the straightforward workflow analysis and the richness of the statistics and publication-grade graphics produced by the tool. Conclusions: MutSpec offers an easy-to-use graphical interface embedded in the popular Galaxy platform that can be used by researchers with limited programming or bioinformatics expertise to analyse mutation signatures present in cancer genomes. MutSpec can thus effectively assist in the discovery of complex mutational processes resulting from exogenous and endogenous carcinogenic insults.	[Ardin, Maude; Castells, Xavier; Zavadil, Jiri; Olivier, Magali] Int Agcy Res Canc, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon, France; [Cahais, Vincent; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon, France; [Bouaoun, Liacine; Byrnes, Graham] Int Agcy Res Canc, Biostat Grp, 150 Cours Albert Thomas, F-69372 Lyon, France		Olivier, M (corresponding author), Int Agcy Res Canc, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	olivierm@iarc.fr	Castells, Xavier/K-1060-2015; Zavadil, Jiri/ABG-1780-2020; Olivier, Magali/G-3728-2010	Zavadil, Jiri/0000-0003-0640-5562; Olivier, Magali/0000-0002-8202-342X; Byrnes, Graham/0000-0003-3893-7539	International Agency for Research on Cancer budget	This project was supported by the International Agency for Research on Cancer budget. We thank Estelle Chanudet and Catherine Voegele for testing the software and providing useful feedbacks.	Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Gunther F, 2015, BEHAV RES METHODS, V47, P930, DOI 10.3758/s13428-014-0529-0; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Maitra A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3873; Meier B, 2014, GENOME RES, V24, P1624, DOI 10.1101/gr.175547.114; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Olivier Magali, 2004, IARC Sci Publ, P247; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Segovia R, 2015, TRENDS GENET, V31, P465, DOI 10.1016/j.tig.2015.04.001; Severson PL, 2014, MUTAT RES-GEN TOX EN, V775, P48, DOI 10.1016/j.mrgentox.2014.10.011; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898	23	24	24	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2105			BMC BIOINFORMATICS	BMC Bioinformatics	APR 18	2016	17								170	10.1186/s12859-016-1011-z			10	Biochemical Research Methods; Biotechnology & Applied Microbiology; Mathematical & Computational Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Mathematical & Computational Biology	DJ5WD	WOS:000374280600004	27091472	gold, Green Published			2022-02-25	
J	Saracci, R; Wild, CP				Saracci, Rodolfo; Wild, Christopher P.			Fifty years of the International Agency for Research on Cancer (1965 to 2015)	INTERNATIONAL JOURNAL OF CANCER			English	Editorial Material									[Saracci, Rodolfo; Wild, Christopher P.] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			HIGGINSON J, 1960, J NATL CANCER I, V24, P589, DOI 10.1093/jnci/24.3.589	1	17	18	0	19	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	MAR 15	2016	138	6					1309	1311		10.1002/ijc.29929			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	DD7CI	WOS:000370080900001	26613677	Bronze			2022-02-25	
J	Ferrari, P				Ferrari, Pietro			Are complex models in nutritional epidemiology always worth the trouble?	ANNALS OF NUTRITION AND METABOLISM			English	Meeting Abstract									[Ferrari, Pietro] Int Agcy Res Canc, Nutr & Metab Sect, F-69372 Lyon, France									0	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0250-6807	1421-9697		ANN NUTR METAB	Ann. Nutr. Metab.		2015	67			1			27	27					1	Endocrinology & Metabolism; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Nutrition & Dietetics	DK5VM	WOS:000374988800051					2022-02-25	
J	Combes, JD; Chen, AA; Franceschi, S				Combes, Jean-Damien; Chen, Alyce A.; Franceschi, Silvia			Prevalence of Human Papillomavirus in Cancer of the Oropharynx by Gender	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Article							ORAL-CAVITY; WORLDWIDE	Oropharyngeal cancer (OPC) is more frequent in men than women mainly due to the heavier and longer duration of smoking in men. Human papillomavirus (HPV) has a role in the rising incidence of OPC in the United States and other high-income countries. To determine whether there is a difference in the proportion of HPV-attributable OPC between men and women, we systematically retrieved HPV prevalence data from 63 studies reporting separately on OPC by gender. The male/female (M/F) ratios of HPV prevalence in OPC across different countries and the corresponding M/F ratios of cumulative lung cancer risk (a proxy for smoking) were compared. The United States had the highest M/F ratios of HPV prevalence in OPC (1.5). The lowest M/F ratios (<= 0.7) were found in Asia and some European countries (e. g., France). The countries in which the M/F ratio of HPV prevalence in OPC was >= 1.0 had the most similar lung cancer risks for men and women. When HPV prevalence data were applied to age-standardized OPC incidence rates in the United States, Australia, the United Kingdom, and France, the M/F ratio for the HPV-positive OPC incidence rates was rather stable (around 4) in all countries. In contrast, the M/F ratio for the HPV-negative OPC incidence rates reached 10.2 in France versus < 3 elsewhere. We showed that HPV prevalence in OPC differs by gender and country mainly as a consequence of the vast international variation in male smoking habits. Nevertheless, HPV-positive OPC may affect men more heavily than women in different populations for reasons that are unclear. (C) 2014 AACR.	[Combes, Jean-Damien; Chen, Alyce A.; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014; Combes, Jean-Damien/B-9113-2018	franceschi, silvia/0000-0003-4181-8071; Chen, Alyce/0000-0002-5018-8908	Institut National du Cancer (INCa), SPLIT project [2011/196]; Association pour la Recherche sur le Cancer (ARC)Fondation ARC pour la Recherche sur le Cancer [20111204169]; International Agency for Research on Cancer; European Commission FP7 Marie Curie Actions-People-Co-funding of regional, national, and international programmes (COFUND)	This work was supported by the Institut National du Cancer (INCa), SPLIT project No 2011/196. J.-D. Combes was partly supported by a fellowship from the Association pour la Recherche sur le Cancer (ARC, No 20111204169). The work of A.A. Chen was undertaken during the tenure of a Postdoctoral Fellowship from the International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions-People-Co-funding of regional, national, and international programmes (COFUND).	Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Combes JD, 2014, ORAL ONCOL, V50, P370, DOI 10.1016/j.oraloncology.2013.11.004; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Ferlay J, 2013, CANC INCIDENCE MORTA; Franceschi S, 2000, ORAL ONCOL, V36, P106, DOI 10.1016/S1368-8375(99)00070-6; Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101; Hernandez BY, 2008, EMERG INFECT DIS, V14, P888, DOI 10.3201/eid1406.070616; *IARC, 2004, MON EV CARC RISKS HU, V85; Kreimer AR, 2010, SEX TRANSM DIS, V37, P386, DOI 10.1097/OLQ.0b013e3181c94a3b; Mehanna H, 2013, HEAD NECK-J SCI SPEC, V35, P747, DOI 10.1002/hed.22015	11	30	32	0	8	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965	1538-7755		CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	DEC	2014	23	12					2954	2958		10.1158/1055-9965.EPI-14-0580			5	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	AW0FU	WOS:000345967300037	25205515	Bronze			2022-02-25	
J	Wild, CP				Wild, Christopher Paul			Preventable exposures associated with human cancer.	CANCER RESEARCH			English	Meeting Abstract	104th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 06-10, 2013	Washington, DC	Amer Assoc Canc Res					[Wild, Christopher Paul] Int Agcy Res Canc, F-69372 Lyon, France				Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669				0	1	1	0	6	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	APR 15	2013	73	8		1		SY1401				10.1158/1538-7445.AM2013-SY14-01			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	AA6PP	WOS:000331220601374					2022-02-25	
J	Bouvard, V; Baan, RA; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Benbrahim-Tallaa, L; Guha, N; Straif, K				Bouvard, Veronique; Baan, Robert A.; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Benbrahim-Tallaa, Lamia; Guha, Neela; Straif, Kurt		WHO Int Agcy Res Canc	Carcinogenicity of malaria and of some polyomaviruses	LANCET ONCOLOGY			English	News Item							EPSTEIN-BARR-VIRUS; MERKEL CELL-CARCINOMA; BURKITT-LYMPHOMA; HUMAN CANCER; INFECTION; SV40; ANTIBODIES; KIDNEY; RISK; EBV		[Bouvard, Veronique; Baan, Robert A.; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Benbrahim-Tallaa, Lamia; Guha, Neela; Straif, Kurt; WHO Int Agcy Res Canc] Int Agcy Res Canc, F-69372 Lyon, France		Bouvard, V (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Guha, Neela/AAG-3989-2021; Waterboer, Tim/G-1252-2010; de Sanjosé Llongueras, Silvia/H-6339-2014; Troye-Blomberg, Marita/B-9210-2016	Guha, Neela/0000-0003-3991-4662; Troye-Blomberg, Marita/0000-0002-2804-0325; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Goel, Ajay/0000-0003-1396-6341; Dalianis, Tina/0000-0001-7022-2424; Butel, Janet/0000-0002-6876-3245; Pawlita, Michael/0000-0002-4720-8306	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [ZIABC011090] Funding Source: NIH RePORTER		BIGGAR RJ, 1978, INT J CANCER, V22, P239, DOI 10.1002/ijc.2910220304; Boldorini R, 2005, ARCH PATHOL LAB MED, V129, P69; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Carpenter LM, 2008, INT J CANCER, V122, P1319, DOI 10.1002/ijc.23254; Carter JJ, 2003, JNCI-J NATL CANCER I, V95, P1522, DOI 10.1093/jnci/djg074; Chang Y, 2012, ANNU REV PATHOL-MECH, V7, P123, DOI 10.1146/annurev-pathol-011110-130227; Donati D, 2006, J IMMUNOL, V177, P3035, DOI 10.4049/jimmunol.177.5.3035; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; He B, 2003, J IMMUNOL, V171, P5215, DOI 10.4049/jimmunol.171.10.5215; IARC, IARC MONOGR IN PRESS; Johne R, 2011, ARCH VIROL, V156, P1627, DOI 10.1007/s00705-011-1008-x; Lopez-Rios F, 2004, LANCET, V364, P1157, DOI 10.1016/S0140-6736(04)17102-X; Mutalima N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002505; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; Potup P, 2009, SE ASIAN J TROP MED, V40, P651; Rollison DE, 2005, CANCER EPIDEM BIOMAR, V14, P1448, DOI 10.1158/1055-9965.EPI-04-0674; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; Shuda M, 2008, P NATL ACAD SCI USA, V105, P16272, DOI 10.1073/pnas.0806526105; Stolt A, 2003, J GEN VIROL, V84, P1499, DOI 10.1099/vir.0.18842-0; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; WHO, 2011, WORLD MALARIA REPORT 2011, P1	22	99	100	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045			LANCET ONCOL	Lancet Oncol.	APR	2012	13	4					339	340		10.1016/S1470-2045(12)70125-0			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	918YG	WOS:000302287000037	22577663				2022-02-25	
J	Hussain, I; Fathallah, I; Accardi, R; Yue, JP; Saidj, D; Shukla, R; Hasan, U; Gheit, T; Niu, YM; Tommasino, M; Sylla, BS				Hussain, Ishraq; Fathallah, Ikbal; Accardi, Rosita; Yue, Jiping; Saidj, Djamel; Shukla, Ruchi; Hasan, Uzma; Gheit, Tarik; Niu, Yamei; Tommasino, Massimo; Sylla, Bakary S.			NF-kappa B Protects Human Papillomavirus Type 38 E6/E7-Immortalized Human Keratinocytes against Tumor Necrosis Factor Alpha and UV-Mediated Apoptosis	JOURNAL OF VIROLOGY			English	Article							GENE-EXPRESSION; KINASE ALPHA; CELL-SURVIVAL; P53 FUNCTIONS; TNF-ALPHA; IKK-ALPHA; SKIN; E6; E7; PROLIFERATION	Constitutive activation of NF-kappa B signaling is a key event in virus- and non-virus-induced carcinogenesis. We have previously reported that cutaneous human papillomavirus type 38 (HPV38) displays transforming properties in in vitro and in vivo experimental models. However, the involvement of NF-kappa B signaling in HPV38-induced cell growth transformation remains to be determined. In this study, we showed that HPV38 E6 and E7 activate NF-kappa B and that inhibition of the pathway with the I kappa B alpha superrepressor sensitizes HPV38E6E7-immortalized human keratinocytes to tumor necrosis factor alpha (TNF-alpha)- and UVB radiation-mediated apoptosis. Accordingly, inhibition of NF-kappa B signaling resulted in the downregulation of NF-kappa B-regulated antiapoptotic genes, including cIAP1, cIAP2, and xIAP genes. These findings demonstrate a critical role of NF-kappa B activity in the survival of HPV38E6E7-immortalized human keratinocytes exposed to cytokine or UV radiation. Our data provide additional evidence for cooperation between beta HPV infection and UV irradiation in skin carcinogenesis.	[Hussain, Ishraq; Fathallah, Ikbal; Accardi, Rosita; Yue, Jiping; Saidj, Djamel; Shukla, Ruchi; Hasan, Uzma; Gheit, Tarik; Niu, Yamei; Tommasino, Massimo; Sylla, Bakary S.] Int Agcy Res Canc, F-69372 Lyon 08, France		Tommasino, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	tommasino@iarc.fr; sylla@iarc.fr	Shukla, Ruchi/AAD-7610-2020; Hussain, Ishraq/AAC-9247-2020; hasan, uzma A/G-3247-2013	Hussain, Ishraq/0000-0001-8449-1617; Hasan, Uzma/0000-0002-1770-5539; Tommasino, Massimo/0000-0002-0890-8596; , Jiping/0000-0003-0717-8613	Association pour la Recherche Contre le Cancer et La Ligue Contre le Cancer du Comite du Rhone and Comite de la Drome; Institut National du Cancer (INCa)Institut National du Cancer (INCA) France; IARC; La Cooperation Francaise of the French Government	The study was partially supported by grants from the Association pour la Recherche Contre le Cancer et La Ligue Contre le Cancer du Comite du Rhone and Comite de la Drome (to B.S.S. and M.T.), from the Institut National du Cancer (INCa) (to B.S.S.), by the IARC fellowships program (to I.H.), and by a fellowship from La Cooperation Francaise of the French Government (to I.F.).	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Accardi R, 2011, MOL CELL BIOL, V31, P2210, DOI 10.1128/MCB.00964-10; An J, 2008, CANCER CELL, V14, P394, DOI 10.1016/j.ccr.2008.10.007; Basile JR, 2001, J BIOL CHEM, V276, P22522, DOI 10.1074/jbc.M010505200; Boccardo E, 2004, VIROLOGY, V328, P233, DOI 10.1016/j.virol.2004.07.026; Bouvard V, 2006, PAPILLOMAVIRUS RESEARCH: FROM NATURAL HISTORY TO VACCINES AND BEYOND, P269; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Descargues P, 2008, EMBO J, V27, P2639, DOI 10.1038/emboj.2008.196; Dong W, 2005, J VIROL, V79, P14899, DOI 10.1128/JVI.79.23.14899-14908.2005; Dong ZY, 1999, CANCER RES, V59, P872; Duffey DC, 1999, CANCER RES, V59, P3468; Filippova M, 2005, CELL DEATH DIFFER, V12, P1622, DOI 10.1038/sj.cdd.4401678; Gabet AS, 2008, FASEB J, V22, P622, DOI 10.1096/fj.07-8389com; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Havard L, 2005, VIROLOGY, V331, P357, DOI 10.1016/j.virol.2004.10.030; Havard L, 2002, VIROLOGY, V298, P271, DOI 10.1006/viro.2002.1468; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kfoury Y, 2005, CELL DEATH DIFFER, V12, P871, DOI 10.1038/sj.cdd.4401624; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 2008, VIROLOGY, V371, P374, DOI 10.1016/j.virol.2007.10.015; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Michel A, 2006, J VIROL, V80, P11153, DOI 10.1128/JVI.00954-06; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Niu Y, 2006, MOL CELL BIOL, V26, P4288, DOI 10.1128/MCB.01817-05; Park E, 2007, CANCER RES, V67, P9158, DOI 10.1158/0008-5472.CAN-07-0590; Pfister H, 2003, J NATL CANC I MONOGR, V31, P5; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Underbrink MP, 2008, J VIROL, V82, P10408, DOI 10.1128/JVI.00902-08; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Van Waes C, 2007, CLIN CANCER RES, V13, P4956, DOI 10.1158/1078-0432.CCR-07-1287; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yuan HD, 2005, ONCOGENE, V24, P5069, DOI 10.1038/sj.onc.1208691; Zhu F, 2009, HISTOL HISTOPATHOL, V24, P265, DOI 10.14670/HH-24.265	57	15	15	0	6	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	SEP	2011	85	17					9013	9022		10.1128/JVI.00002-11			10	Virology	Science Citation Index Expanded (SCI-EXPANDED)	Virology	804AO	WOS:000293626100050	21715489	Bronze, Green Published			2022-02-25	
J	Illner, A; Freisling, H; Slimani, N				Illner, A.; Freisling, H.; Slimani, N.			Feasibility, validity and potential of new dietary assessment technologies for large-scale epidemiological studies	ANNALS OF NUTRITION AND METABOLISM			English	Meeting Abstract						dietary assessment; technology; feasibility; validity; large-scale epidemiological studies			[Illner, A.; Freisling, H.; Slimani, N.] IARC, Nutr & Metab Sect, Dietary Exposure Assessment Grp, Lyon, France									0	0	0	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0250-6807			ANN NUTR METAB	Ann. Nutr. Metab.		2011	58			3			398	398					1	Endocrinology & Metabolism; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Nutrition & Dietetics	861IF	WOS:000298011900887					2022-02-25	
J	Wild, CP				Wild, Christopher Paul			OMICS technologies: an opportunity for "two-way" translation from basic science to both clinical and population-based research	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material							CANCER		Int Agcy Res Canc, F-69000 Lyon, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69000 Lyon, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Potter JD, 2003, TRENDS GENET, V19, P690, DOI 10.1016/j.tig.2003.10.005; Vlaanderen J, 2010, OCCUP ENVIRON MED, V67, P136, DOI 10.1136/oem.2008.042788; Wild CP, 2009, MUTAGENESIS, V24, P117, DOI 10.1093/mutage/gen061	4	5	5	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	FEB	2010	67	2					75	76		10.1136/oem.2009.051219			4	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	552NM	WOS:000274298800003	19914910				2022-02-25	
J	El Ghissassi, F; Baan, R; Straif, K; Grosse, Y; Secretan, B; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Freeman, C; Galichet, L; Cogliano, V				El Ghissassi, Fatiha; Baan, Robert; Straif, Kurt; Grosse, Yann; Secretan, Beatrice; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent; Cogliano, Vincent		WHO Int Agcy Res Canc Monograph Wo	A review of human carcinogens - Part D: radiation	LANCET ONCOLOGY			English	News Item							UVEAL MELANOMA; CANCER; RISK; DAMAGE		[El Ghissassi, Fatiha; Baan, Robert; Straif, Kurt; Grosse, Yann; Secretan, Beatrice; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent; Cogliano, Vincent; WHO Int Agcy Res Canc Monograph Wo] Int Agcy Res Canc, F-69372 Lyon, France		El Ghissassi, F (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Cardis, Elisabeth/C-3904-2017; Guha, Neela/AAG-3989-2021; Freeman, Crystal/AAF-3438-2020	Cardis, Elisabeth/0000-0003-0999-6839; Guha, Neela/0000-0003-3991-4662; Muirhead, Colin/0000-0001-5394-1267; Little, Mark/0000-0003-0980-7567; Sabatier, Laure/0000-0003-0552-6549; Lauby-Secretan, Beatrice/0000-0001-6559-3351			Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Cardis E, 2006, J RADIOL PROT, V26, P127, DOI 10.1088/0952-4746/26/2/001; Darby S, 2005, BMJ-BRIT MED J, V330, P223, DOI 10.1136/bmj.38308.477650.63; France The International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer, 2007, International Journal of Cancer, V120, P1116, DOI 10.1002/ijc.22453; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Grosse Y, 2009, LANCET ONCOL, V10, P13, DOI 10.1016/S1470-2045(08)70286-9; Ikehata H, 2008, J INVEST DERMATOL, V128, P2289, DOI 10.1038/jid.2008.61; Lutz JM, 2005, CANCER CAUSE CONTROL, V16, P437, DOI 10.1007/s10552-004-5029-6; [National Research Council Committee on Health Risks of Exposure to Radon], 1999, HLTH EFF EXP RAD BEI; National Research Council (US) Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation (BEIR VII Phase 2), 2006, HLTH RISKS EXP LOW L; Preston DL, 2008, JNCI-J NATL CANCER I, V100, P428, DOI 10.1093/jnci/djn045; Runger TM, 2008, PHOTODERMATOL PHOTO, V24, P2, DOI 10.1111/j.1600-0781.2008.00319.x; SEDDON JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1274, DOI 10.1001/archopht.1990.01070110090031; Shah CP, 2005, OPHTHALMOLOGY, V112, P1599, DOI 10.1016/j.ophtha.2005.04.020; *UN CHERN FOR EGH, 2006, HLTH EFF CHERN ACC S; Vajdic CM, 2004, INT J CANCER, V112, P896, DOI 10.1002/ijc.20476; Wakeford R, 2003, INT J RADIAT BIOL, V79, P293, DOI 10.1080/0955300031000114729	17	547	553	0	52	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	AUG	2009	10	8					751	752		10.1016/S1470-2045(09)70213-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	479YH	WOS:000268697700013	19655431				2022-02-25	
J	Boyle, P				Boyle, P.			Favorable trends in cancer mortality in the European Union but no room for complacency	ANNALS OF ONCOLOGY			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon 08, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	director@iarc.fr	Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610			Bosetti C, 2008, ANN ONCOL, V19, P631, DOI 10.1093/annonc/mdm597; Boyle P, 2003, ANN ONCOL, V14, P1312, DOI 10.1093/annonc/mdg353; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Levi F, 2007, ANN ONCOL, V18, P593, DOI 10.1093/annonc/mdl437; Quinn MJ, 2003, ANN ONCOL, V14, P1148, DOI 10.1093/annonc/mdg307	6	6	7	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	APR	2008	19	4					605	606		10.1093/annonc/mdm598			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	281BE	WOS:000254470400001	18364391	Bronze			2022-02-25	
J	Cogliano, VJ				Cogliano, Vincent James			The IARC Monographs: a resource for precaution and prevention	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material							TRANSPARENCY		Int Agcy Res Canc, F-69008 Lyon, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	cogliano@iarc.fr					Cogliano V, 2005, LANCET ONCOL, V6, P747, DOI 10.1016/S1470-2045(05)70380-6; Cogliano VJ, 2004, ENVIRON HEALTH PERSP, V112, P1269, DOI 10.1289/ehp.6950; Collingridge D, 2005, LANCET ONCOL, V6, P735, DOI 10.1016/S1470-2045(05)70364-8; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; International Agency for Research Cancer, IARC MON EV CARC RIS; Martuzzi M, 2007, OCCUP ENVIRON MED, V64, P569, DOI 10.1136/oem.2006.030601	6	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	SEP	2007	64	9					572	572		10.1136/oem.2006.031872			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	201RB	WOS:000248849200003	17704200	Green Published			2022-02-25	
J	Lambert, R				Lambert, Rene			Insertion of expandable metallic stents in esophageal cancer without fluoroscopy: is it safe?	GASTROINTESTINAL ENDOSCOPY			English	Editorial Material							MALIGNANT DYSPHAGIA; PLACEMENT; PALLIATION; CARCINOMA; STENOSIS; TERM		Int Agcy Res Canc, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.						Austin AS, 2001, GASTROINTEST ENDOSC, V54, P357, DOI 10.1067/mge.2001.117153; Ben Soussan E, 2005, GASTROEN CLIN BIOL, V29, P785, DOI 10.1016/S0399-8320(05)86348-1; Boyce Jr, 1999, Cancer Control, V6, P73; Christie NA, 2001, ANN THORAC SURG, V71, P1797, DOI 10.1016/S0003-4975(01)02619-4; Cwikiel W, 1998, RADIOLOGY, V207, P513, DOI 10.1148/radiology.207.2.9577503; Dua KS, 2001, GASTROINTEST ENDOSC, V53, P603, DOI 10.1067/mge.2001.114054; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Frenken M, 2001, DIS ESOPHAGUS, V14, P120, DOI 10.1046/j.1442-2050.2001.00168.x; Good S, 1997, CAN ASSOC RADIOL J, V48, P340; Johnson E, 2006, SCAND J GASTROENTERO, V41, P252, DOI 10.1080/00365520500206350; Laasch HU, 2003, ENDOSCOPY, V35, P1049, DOI 10.1055/s-2003-44602; *NAT CANC I, 2003, SEER CANC STAT REV 1; Neale JC, 2004, J PALLIAT CARE, V20, P28, DOI 10.1177/082585970402000106; Regueiro C, 2006, GASTROENTEROLOGY, V131, P1287, DOI 10.1053/j.gastro.2006.08.017; Sabharwal T, 2003, GUT, V52, P922, DOI 10.1136/gut.52.7.922; Saranovic D, 2005, DIS ESOPHAGUS, V18, P230, DOI 10.1111/j.1442-2050.2005.00484.x; Verschuur EML, 2006, GASTROINTEST ENDOSC, V63, P134, DOI 10.1016/j.gie.2005.07.051; White RE, 2001, GASTROINTEST ENDOSC, V53, P348, DOI 10.1067/mge.2001.112844; Wilkes EA, 2007, GASTROINTEST ENDOSC, V65, P923, DOI 10.1016/j.gie.2006.11.007	19	1	2	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	MAY	2007	65	6					929	931		10.1016/j.gie.2006.12.044			3	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	164EW	WOS:000246217300034	17466214				2022-02-25	
J	Ferlay, J; Autier, P; Boniol, M; Heanue, M; Colombet, M; Boyle, P				Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P.			Estimates of the cancer incidence and mortality in Europe in 2006	ANNALS OF ONCOLOGY			English	Article						cancer; deaths; Europe; incidence; mortality; predictions	COLORECTAL-CANCER; TRENDS; BREAST; DEATH; PREDICTION; COUNTRIES; PROGRESS; EU	Background: Monitoring the evolution of the cancer burden in Europe is of great value. Estimates of the cancer burden in Europe have been published for 2004 and estimates are now being presented for cancer incidence and mortality in Europe for 2006. Methods: The most recent sources of cancer incidence and mortality data have been collected and projections have been carried out using short-term prediction methods to produce estimated rates for 2006. Additional estimation was required where national incidence data were not available, and the method involved the projection of the aggregations of cancer incidence and mortality data from representative cancer registries. The estimated 2006 rates were applied to the corresponding estimated country population to obtain the best estimates of the cancer incidence and mortality in Europe in 2006. Results: In 2006 in Europe, there were an estimated 3 191 600 cancer cases diagnosed (excluding nonmelanoma skin cancers) and 1 703 000 deaths from cancer. The most common form of cancers was breast cancer (429 900 cases, 13.5% of all cancer cases), followed by colorectal cancers (412 900, 12.9%) and lung cancer (386 300, 12.1%). Lung cancer, with an estimated 334 800 deaths (19.7% of total), was the most common cause of death from cancer, followed by colorectal (207 400 deaths), breast (131 900) and stomach (118 200) cancers. Conclusions: The total number of new cases of cancer in Europe appears to have increased by 300 000 since 2004. With an estimated 3.2 million new cases (53% occurring in men, 47% in women) and 1.7 million deaths (56% in men, 44% in women) each year, cancer remains an important public health problem in Europe and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant. Evidence-based public health measures exist to reduce the mortality of breast and colorectal cancer while the incidence of lung cancer, and several other forms of cancer, could be diminished by improved tobacco control.	Int Agcy Res Canc, F-69372 Lyon 08, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	director@iarc.fr	Boyle, Peter/A-4380-2014; Ferlay, Jacques/ABD-5058-2021; Autier, Philippe/A-4402-2014; Boniol, Mathieu/F-9623-2011	Boyle, Peter/0000-0001-6251-0610; Autier, Philippe/0000-0003-1538-5321; Boniol, Mathieu/0000-0003-1052-5604			[Anonymous], 1993, WHO INT STAT CLASS D, V2; [Anonymous], 2002, IARC HDB CANC PREV, V7; BOYLE P, 1995, BRIT J CANCER, V72, P528, DOI 10.1038/bjc.1995.368; Boyle P, 2005, NAT CLIN PRACT ONCOL, V2, P424, DOI 10.1038/ncponc0288; Boyle P, 2003, ANN ONCOL, V14, P973, DOI 10.1093/annonc/mdg305; Boyle P, 2003, ANN ONCOL, V14, P1312, DOI 10.1093/annonc/mdg353; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; BOYLE P, 2003, TOBACCO PUBLIC HLTH; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Brock Anita, 2004, Health Stat Q, P7; *CANC REG NORW, 2002, ANC INC NORW; *CANC REG NORW, 2003, ANC INC NORW; Doll R, 1966, CANC INCIDENCE 5 CON; Dyba T, 2000, STAT MED, V19, P1741, DOI 10.1002/1097-0258(20000715)19:13<1741::AID-SIM496>3.0.CO;2-O; ENGHOLM G, 2006, NORDCAN CANC INCIDEN; *EUR NETW CANC REG, 2003, EUR VERS 4 0 EUR INC; FALVRE J, 2004, GASTROENTEROLOGY, V126, P1674; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Ferlay J, 1999, EUCAN CANC INCIDENCE; Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025; *FINN CANC REG, 2005, CANC SOC FINL PUBL, V66; International Agency for Research on Cancer IARC, 2004, MON EV CARC RISKS HU, V83; Levi F, 2005, EUR J CANCER PREV, V14, P497, DOI 10.1097/00008469-200512000-00002; *LITH CANC REG, 2005, CANC LITH 2001 2002; Lutz JM, 2004, EUR J CANCER PREV, V13, P77, DOI 10.1097/00008469-200402000-00012; Moller B, 2003, STAT MED, V22, P2751, DOI 10.1002/sim.1481; *NAT CANC REG SLOV, 2002, CANC INC SLOV; Pavillon G., 2005, B EPIDEMIOLOGIQUE HE, V4, P13; PERCY C, 1989, AM J EPIDEMIOL, V129, P934, DOI 10.1093/oxfordjournals.aje.a115226; Quinn MJ, 2003, ANN ONCOL, V14, P1148, DOI 10.1093/annonc/mdg307; Remontet L, 2003, REV EPIDEMIOL SANTE, V51, P3; Tyczynski JE, 2004, INT J CANCER, V112, P1056, DOI 10.1002/ijc.20514; *UN POP DIV, 2004, WORLD POP PROSP; *WHO, WHO STAT INF SYST; 2006, ENGLAND WALES NATL S	35	2014	2110	0	59	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	MAR	2007	18	3					581	592		10.1093/annonc/mdl498			12	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	142NE	WOS:000244655900027	17287242	Bronze			2022-02-25	
J	Dresler, CM; Leon, ME; Straif, K; Baan, R; Secretan, B				Dresler, Carolyn M.; Leon, Maria E.; Straif, Kurt; Baan, Robert; Secretan, Beatrice			Reversal of risk upon quitting smoking	LANCET			English	Editorial Material							MALE BRITISH DOCTORS; LUNG-FUNCTION; CESSATION; MORTALITY; CANCER; HEALTH; DISEASE; WOMEN		Int Agcy Res Canc, F-69008 Lyon, France		Dresler, CM (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	dresler@iarc.fr		Lauby-Secretan, Beatrice/0000-0001-6559-3351			[Anonymous], 2004, HLTH CONS SMOK REP S; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; Anthonisen NR, 2005, ANN INTERN MED, V142, P233, DOI 10.7326/0003-4819-142-4-200502150-00005; BROWN CA, 1991, THORAX, V46, P112, DOI 10.1136/thx.46.2.112; BURCHFIEL CM, 1995, AM J RESP CRIT CARE, V151, P1778, DOI 10.1164/ajrccm.151.6.7767520; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; GARFINKEL L, 1988, CANCER RES, V48, P6951; Hooi JD, 2001, AM J EPIDEMIOL, V153, P666, DOI 10.1093/aje/153.7.666; IARC WORK GRO, 2004, IARC MONOGR EVAL CAR, V83, P1; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Rajkumar T, 2006, INT J CANCER, V118, P1481; Scanlon PD, 2000, AM J RESP CRIT CARE, V161, P381, DOI 10.1164/ajrccm.161.2.9901044	14	38	41	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL-AUG	2006	368	9533					348	349		10.1016/S0140-6736(06)69086-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	069JJ	WOS:000239441900008	16876647				2022-02-25	
J	Baan, RA; Grosse, Y				Baan, RA; Grosse, Y			Man-made mineral (vitreous) fibres: evaluations of cancer hazards by the IARC Monographs Programme	MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS			English	Review						man-made mineral fibres; man-made vitreous fibres; glass wool; rock wool; stone wool; slag wool; refractory ceramic fibres; evaluation of cancer hazard; IARC monographs	CHRONIC INHALATION TOXICITY; REFRACTORY CERAMIC FIBER; SYRIAN GOLDEN-HAMSTER; NESTED CASE-CONTROL; HISTORICAL COHORT; PRODUCTION WORKERS; AMOSITE ASBESTOS; FIBROUS-GLASS; LUNG-CANCER; 2 FIBERGLASSES	Man-made vitreous (glass-like) fibres are non-crystalline, fibrous inorganic substances (silicates) made primarily from rock, slag, glass or other processed minerals. These materials, also called man-made mineral fibres, include glass fibres (used in glass wool and continuous glass filament), rock or stone wool, slag wool and refractory ceramic fibres. They are widely used for thermal and acoustical insulation and to a lesser extent for other purposes. These products are potentially hazardous to human health because they release airborne respirable fibres during their production, use and removal. Man-made mineral fibres and man-made vitreous fibres have been the subject of reviews by IARC Monographs Working Groups in 1987 and 200 1, respectively, which resulted in evaluations of the carcinogenic hazard to humans from exposure to these materials. These reviews and evaluations have been published as Volumes 43 and 81 of the IARC Monographs series [IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 43, Man-made Mineral Fibres and Radon (1988); IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 8 1, Man-made Vitreous Fibres (2002)]. The re-evaluation in 2001 was undertaken because there have been substantial improvements in the quality of the epidemiological information available on the carcinogenicity to humans of glass fibres, continuous glass filament and rock/slag wool. The new evaluations have addressed the limitations of earlier cohort studies, particularly concerning the lack of adjustment with respect to concomitant risk factors such as smoking and other sources of occupational exposure. In addition, the evaluation of the evidence for carcinogen city of glass fibres to experimental animals has been refined, by making a distinction between insulation glass wool and special-purpose glass fibres. The results of the evaluations in 1987 and 2001 are thus different in several aspects. In this paper, the reviews and evaluations of the carcinogenic hazards of exposure to man-made mineral fibres (MMMF, Monograph volume 43, [1]) and man-made vitreous fibres (MMVF, Monograph volume 81, [2]) are summarised, and the differences explained. In particular, the considerations of the respective IARC Monographs Working Groups (1987, 2001) in reachina their conclusions are discussed in some detail. (C) 2004 Elsevier B.V. All rights reserved.	WHO, Int Agcy Res Canc, Unit Carcinogen Identif & Evaluat, F-69372 Lyon 08, France		Baan, RA (corresponding author), WHO, Int Agcy Res Canc, Unit Carcinogen Identif & Evaluat, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	baan@iarc.fr					ADACHI S, 1991, ENVIRON RES, V54, P52, DOI 10.1016/S0013-9351(05)80194-X; ASGHARIAN B, 1989, J AEROSOL SCI, V20, P355, DOI 10.1016/0021-8502(89)90011-6; Asgharian B., 1988, J AEROSOL MED, V1, P37; BAILEY MR, 1982, ANN OCCUP HYG, V26, P273, DOI 10.1093/annhyg/26.2.273; Bernstein DM, 2001, INHAL TOXICOL, V13, P823; Bernstein DM, 2001, INHAL TOXICOL, V13, P851; Berry G, 1999, INHAL TOXICOL, V11, P111, DOI 10.1080/089583799197203; Boffetta P, 1997, EPIDEMIOLOGY, V8, P259, DOI 10.1097/00001648-199705000-00006; Boffetta P, 1999, SCAND J WORK ENV HEA, V25, P222, DOI 10.5271/sjweh.427; CARTHEW P, 1995, HUM EXP TOXICOL, V14, P657, DOI 10.1177/096032719501400806; Chiazze L, 1997, J OCCUP ENVIRON MED, V39, P432, DOI 10.1097/00043764-199705000-00009; Consonni D, 1998, CANCER CAUSE CONTROL, V9, P411, DOI 10.1023/A:1008871718323; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Cullen RT, 2000, INHAL TOXICOL, V12, P959; Dai YT, 1998, J AEROSOL MED, V11, P247, DOI 10.1089/jam.1998.11.247; Davis JM, 1996, TOXICOL PATHOL, V24, P662, DOI 10.1177/019262339602400527; Davis JMG, 1996, INHAL TOXICOL, V8, P747, DOI 10.3109/08958379608995209; DAVIS JMG, 1990, ENVIRON HEALTH PERSP, V88, P305, DOI 10.2307/3431092; DAVIS JMG, 1976, DHEW PUBL, P141; *ECFIA RCFC, 2001, ALK EARTH SIL AES WO; EIPPCB_(European_ Integrated_ Pollution_ Prevention_ and_ Control_ Bureau), 2000, REF DOC BEST AV TECH; ENTERLINE PE, 1987, ANN OCCUP HYG, V31, P625, DOI 10.1093/annhyg/31.4B.625; *EUR COMM, 1997, OFF J EUR COMM L, V343, P19; FERON VJ, 1985, CARCINOGENESIS, V6, P1495, DOI 10.1093/carcin/6.10.1495; GOLDSTEIN B, 1983, ENVIRON RES, V32, P344, DOI 10.1016/0013-9351(83)90117-2; Guldberg M, 2002, REGUL TOXICOL PHARM, V35, P217, DOI 10.1006/rtph.2001.1523; HESTERBERG TW, 1993, FUND APPL TOXICOL, V20, P464, DOI 10.1006/faat.1993.1057; Hesterberg TW, 1999, INHAL TOXICOL, V11, P747, DOI 10.1080/089583799196745; Hesterberg TW, 1997, ENVIRON HEALTH PERSP, V105, P1223, DOI 10.2307/3433537; Hesterberg TW, 2001, CRIT REV TOXICOL, V31, P1, DOI 10.1080/20014091111668; *IARC, 1977, IARC MON EV CARC RIS, V14; *IARC, 1988, IARC MON EV CARC RIS, V43, P33; JACOB TR, 1993, AM IND HYG ASSOC J, V54, P320, DOI 10.1202/0002-8894(1993)054<0320:AGFCDM>2.0.CO;2; Kane A. B, 1996, IARC SCI PUBLICATION, V140; KRANTZ S, 1988, SCAND J WORK ENV HEA, V14, P49; LeBouffant L, 1984, BIOL EFFECTS MAN MAD, V2, P143; LEE KP, 1981, ENVIRON RES, V24, P167, DOI 10.1016/0013-9351(81)90143-2; Lees P. S. J., 1993, APPL OCCUP ENV HYG, V8, P1022; Lemasters G, 2001, AM J EPIDEMIOL, V153, pS264; LUNDBORG M, 1995, EXP LUNG RES, V21, P51, DOI 10.3109/01902149509031744; Marchant Gary E, 2002, Appl Occup Environ Hyg, V17, P276, DOI 10.1080/10473220252826583; MARSH GM, 1990, J OCCUP ENVIRON MED, V32, P594, DOI 10.1097/00043764-199007000-00009; Marsh GM, 2001, J OCCUP ENVIRON MED, V43, P803, DOI 10.1097/00043764-200109000-00009; Marsh GM, 2001, J OCCUP ENVIRON MED, V43, P757, DOI 10.1097/00043764-200109000-00005; Marsh GM, 2001, J OCCUP ENVIRON MED, V43, P741, DOI 10.1097/00043764-200109000-00004; Marsh GM, 1996, J OCCUP HLTH SAFETY, V12, P297; MAST RW, 1995, INHAL TOXICOL, V7, P469, DOI 10.3109/08958379509015209; Maxim LD, 1998, GEFAHRST REINHALT L, V58, P97; Maxim LD, 2001, REGUL TOXICOL PHARM, V33, P319, DOI 10.1006/rtph.2001.1467; Maxim LD, 1997, REGUL TOXICOL PHARM, V26, P156, DOI 10.1006/rtph.1997.1153; MCCONNELL EE, 1995, INHAL TOXICOL, V7, P503, DOI 10.3109/08958379509015210; McConnell EE, 1999, INHAL TOXICOL, V11, P785, DOI 10.1080/089583799196754; MCCONNELL EE, 1994, INHAL TOXICOL, V6, P571, DOI 10.3109/08958379409003042; Miller BG, 1999, ANN OCCUP HYG, V43, P155, DOI 10.1016/S0003-4878(99)00018-6; MONCHAUX G, 1981, CARCINOGENESIS, V2, P229, DOI 10.1093/carcin/2.3.229; Moorman W.J., 1988, ANN OCCUP HYG     S1, V32, P757; MUHLE H, 1987, ANN OCCUP HYG, V31, P755, DOI 10.1093/annhyg/31.4B.755; *NAIMA EURIMA, 2001, BACKGR MAT PREP IARC; Oberdorster G, 2000, INT ARCH OCC ENV HEA, V73, pS60, DOI 10.1007/PL00014628; PIGOTT GH, 1992, INT J EXP PATHOL, V73, P137; POTT F, 1991, NATO ADV SCI I A-LIF, V223, P547; POTT F, 1995, ANN OCCUP HYG, V39, P771, DOI 10.1016/0003-4878(95)00055-J; POTT F, 1987, EXP PATHOL-JENA, V32, P129, DOI 10.1016/S0232-1513(87)80044-0; POTT F, 1976, ZBL BAKT MIK HYG B, V162, P467; Pott F, 1989, IARC Sci Publ, P173; POTT F, 1989, ILSI MONOGRAPHS, P243; POTT F, 1993, VDI BER, V1075, P17; POTT F, 1994, ANN OCCUP HYG     S1, V38, P357; POTT F, 1984, BIOL EFFECTS MAN MAD, V2, P286; POTT F, 1984, P 6 INT PNEUM C BOCH, V2, P746; POTT F, 1988, ANN OCCUP HYG, V32, P353; *REED GROUP, 2001, WORLD INS 2004; Roller M, 1996, EXP TOXICOL PATHOL, V48, P3, DOI 10.1016/S0940-2993(96)80084-4; ROLLER M, 1998, EUR J ONCOL, V3, P231; Schneider T, 1996, SCAND J WORK ENV HEA, V22, P274, DOI 10.5271/sjweh.142; SHANNON HS, 1987, ANN OCCUP HYG, V31, P657, DOI 10.1093/annhyg/31.4B.657; SHANNON HS, 1990, BRIT J IND MED, V47, P533; SIMONATO L, 1987, ANN OCCUP HYG, V31, P603, DOI 10.1093/annhyg/31.4B.603; SIMONATO L, 1986, CANCER LETT, V30, P189, DOI 10.1016/0304-3835(86)90088-1; SIMONATO L, 1986, SCAND J WORK ENV HEA, V12, P34; SIMONATO L, 1987, SCAND J WORK ENV HEA, V13, P192; SMITH DM, 1987, ANN OCCUP HYG, V31, P731, DOI 10.1093/annhyg/31.4B.731; SNIPES MB, 1989, CRIT REV TOXICOL, V20, P175, DOI 10.3109/10408448909017909; STANTON MF, 1977, J NATL CANCER I, V58, P587, DOI 10.1093/jnci/58.3.587; STANTON MF, 1981, J NATL CANCER I, V67, P965; Stone RA, 2001, J OCCUP ENVIRON MED, V43, P779, DOI 10.1097/00043764-200109000-00007; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Wagner J.C., 1984, BIOL EFFECTS MAN MAD, V2, P209; WAGNER JC, 1973, BRIT J CANCER, V28, P173, DOI 10.1038/bjc.1973.134; WAGNER JC, 1976, DHEW NIOSH76151 PUBL, P193; Walker AM, 2002, REGUL TOXICOL PHARM, V35, P95, DOI 10.1006/rtph.2001.1513; WONG O, 1991, BRIT J IND MED, V48, P818; World Health Organization (WHO), 1987, IARC MON EV CARC S7, V1-42, P106; Youk AO, 2001, J OCCUP ENVIRON MED, V43, P767, DOI 10.1097/00043764-200109000-00006; [No title captured]; [No title captured]; [No title captured]	98	41	49	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1386-1964	1873-135X		MUTAT RES-FUND MOL M	Mutat. Res.-Fundam. Mol. Mech. Mutagen.	SEP 3	2004	553	1-2					43	58		10.1016/j.mrfmmm.2004.06.019			16	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	848BX	WOS:000223443200006	15288532				2022-02-25	
J	Cogliano, VJ; Baan, RA; Straif, K; Grosse, Y; Secretan, MB; El Ghissassi, F; Kleihues, P				Cogliano, VJ; Baan, RA; Straif, K; Grosse, Y; Secretan, MB; El Ghissassi, F; Kleihues, P			The science and practice of carcinogen identification and evaluation	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Editorial Material								Several national and international health agencies have established programs with the aim of identifying agents and exposures that cause cancer in humans. Carcinogen identification is an activity grounded in the scientific evaluation of the results of human epidemiologic studies, long-term bioassays in experimental animals, and other data relevant to an evaluation of carcinogenicity and its mechanisms. In this commentary, after a brief discussion of the science basis common to the evaluation of carcinogens across different programs, we discuss in more detail the principles and procedures currently used by the IARC Monographs program.	Int Agcy Res Canc, Carcinogen Identificat & Evaluat, F-69372 Lyon 08, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, Carcinogen Identificat & Evaluat, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	cogliano@iarc.fr		Lauby-Secretan, Beatrice/0000-0001-6559-3351			Bonduelle M, 1995, HUM REPROD UPDATE, V1, P3; *CAL EPA, 2004, PROP 65; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; IARC, 2004, PREAMBL IARC MON; *IARC, 2003, IARC MON ADV GROUP P; *IPCS, 1999, IPCS WORKSH DEV CONC; KLEIHUES P, 2003, WORLD CANC REP; MELNICK RL, 1995, CARCINOGENESIS, V16, P157, DOI 10.1093/carcin/16.2.157; National Research Council [NRC], 1983, RISK ASS FED GOV MAN; National Research Council [NRC], 1994, SCI JUDGM RISK ASS; NTP (National Toxicology Program), 2002, REP CARC; U. S. EPA, 2003, EPA630P03001A; *US EPA, 2004, US EPAS PROC IRIS AS; *US EPA, 1999, GUID CARC RISK ASS R; US EPA (US Environmental Protection Agency), 1986, FED REG, V51, P33992; *WHO, 2004, DECL INT WHO EXP	16	47	50	0	1	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2004	112	13					1269	1274		10.1289/ehp.6950			6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	863FS	WOS:000224547000025	15345338	Green Published, gold			2022-02-25	
J	Ferrand, V; Li, CL; Romeo, G; Yin, L				Ferrand, V; Li, CL; Romeo, G; Yin, L			Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients	JOURNAL OF MEDICAL VIROLOGY			English	Article						genetic organisation; single nucleotide polymorphisms; SSCP; heteroduplex analysis	BARR-VIRUS-INFECTION; ACTIVATION MOLECULE SLAM; T-CELL ACTIVATION; GENE-PRODUCT SAP; ENCODING GENE; SH2D1A GENE; LYMPHOMA; RECEPTOR; XLP; SUSCEPTIBILITY	X-linked lymphoproliferative disease is a rare inherited immunodeficiency in which affected males present abnormal responses to Epstein-Barr virus (EBV) infection. The gene defective in X-linked lymphoproliferative disease, SH2D1A (also named SAP or DSHP), has been identified and shown to code for an adapter protein that interacts with signaling lymphocytic activation molecule (SLAM) and several other members of the CD2 superfamily. SH2D1A is mutated in no more than 60% of X-linked lymphoproliferative disease patients. It could be postulated that a certain percentage of patients without apparent maternal transmission might be caused by other gene(s) in SH2D1A-related signal transduction pathways. Being a partner of SH2D1A and having a key role in proliferation and differentiation of the T- and B-lymphocytes, SLAM was considered as a candidate gene for patients who manifest symptoms of X-linked lymphoproliferative disease but who have no mutations in SH2D1A. As a first step, SLAM mutations were screened for from cDNA of the lymphoblastoid cell line of all available patients. Then conditions for PCR, single-strand conformational polymorphism (SSCP), heteroduplex analysis, and sequencing were established in all eight exons of SLAM. A total of 31 typical and atypical patients were analysed, from which six novel nucleotide variants were identified; however, none of these variants seems to cause abnormal function of the SLAM gene. Therefore, mutations in coding regions or splicing sites of SLAM are unlikely to play a major role in the mechanism of EBV associated lymphoproliferation. (C) 2003Wiley-Liss, Inc.	Int Agcy Res Canc, Unit Genet Canc Susceptibil, F-69372 Lyon 08, France		Yin, L (corresponding author), Int Agcy Res Canc, Unit Genet Canc Susceptibil, 150 Cours Albert Thomas, F-69372 Lyon 08, France.						Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Benkwitz C, 1999, BIOCHEM BIOPH RES CO, V261, P515, DOI 10.1006/bbrc.1999.1064; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Brandau O, 1999, HUM MOL GENET, V8, P2407, DOI 10.1093/hmg/8.13.2407; Castro AG, 1999, J IMMUNOL, V163, P5860; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; FLEISHER G, 1982, J PEDIATR-US, V100, P727, DOI 10.1016/S0022-3476(82)80572-6; Fraser CC, 2002, IMMUNOGENETICS, V53, P843, DOI 10.1007/s00251-001-0415-7; Gilmour KC, 2000, EUR J IMMUNOL, V30, P1691, DOI 10.1002/1521-4141(200006)30:6<1691::AID-IMMU1691>3.0.CO;2-K; GRIERSON HL, 1991, AM J MED GENET, V40, P294, DOI 10.1002/ajmg.1320400309; HARRINGTON DS, 1987, CANCER-AM CANCER SOC, V59, P1419, DOI 10.1002/1097-0142(19870415)59:8<1419::AID-CNCR2820590807>3.0.CO;2-P; JONCAS JH, 1984, CAN MED ASSOC J, V130, P280; Lappalainen I, 2000, BIOCHEM BIOPH RES CO, V269, P124, DOI 10.1006/bbrc.2000.2146; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; Liechti-Gallati S, 1999, EUR J HUM GENET, V7, P590, DOI 10.1038/sj.ejhg.5200338; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; PURTILO D T, 1975, Lancet, V1, P935; PURTILO DT, 1991, CANCER GENET CYTOGEN, V51, P143, DOI 10.1016/0165-4608(91)90127-G; PURTILO DT, 1982, AM J MED, V73, P49, DOI 10.1016/0002-9343(82)90923-8; Sayos J, 2001, BLOOD, V97, P3867, DOI 10.1182/blood.V97.12.3867; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schuster V, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P222; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Strahm B, 2000, BRIT J HAEMATOL, V108, P377; Sumegi J, 2000, BLOOD, V96, P3118; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; Tangye SG, 1999, J IMMUNOL, V162, P6981; Yin L, 1999, HUM GENET, V105, P501, DOI 10.1007/s004390051137	30	4	5	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0146-6615			J MED VIROL	J. Med. Virol.	MAY	2003	70	1					131	136		10.1002/jmv.10373			6	Virology	Science Citation Index Expanded (SCI-EXPANDED)	Virology	682AN	WOS:000183067800019	12629654				2022-02-25	
J	Pearce, MS; Cardis, E				Pearce, MS; Cardis, E			Depleted uranium - Cause for concern or just a good story?	PEDIATRIC HEMATOLOGY AND ONCOLOGY			English	Article									Int Agcy Res Canc, Unit Radiat & Canc, F-69372 Lyon, France		Pearce, MS (corresponding author), Int Agcy Res Canc, Unit Radiat & Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	m.s.pearce@ncl.ac.uk	Cardis, Elisabeth/C-3904-2017	Cardis, Elisabeth/0000-0003-0999-6839; Pearce, Mark/0000-0002-0583-3779			de Haag PAMU, 2000, J HAZARD MATER, V76, P39, DOI 10.1016/S0304-3894(00)00183-7; FULCO CE, 2000, GULF WAR HUMAN HLTH; McDiarmid MA, 2000, ENVIRON RES, V82, P168, DOI 10.1006/enrs.1999.4012; Priest ND, 2001, LANCET, V357, P244, DOI 10.1016/S0140-6736(00)03605-9; *UN ENV PROGR UN C, 1999, KOS CONFL CONS ENV H; WHO, 2001, DEPL UR SOURC EXP HL	6	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0888-0018	1521-0669		PEDIATR HEMAT ONCOL	Pediatr. Hematol. Oncol.	SEP	2001	18	6					367	370		10.1080/088800101316921976			4	Oncology; Hematology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Hematology; Pediatrics	468BD	WOS:000170737500001	11554230				2022-02-25	
J	Kaaks, R; Lukanova, A				Kaaks, R; Lukanova, A			Energy balance and cancer: the role of insulin and insulin-like growth factor-I	PROCEEDINGS OF THE NUTRITION SOCIETY			English	Article; Proceedings Paper	Symposium on the Relative Contribution of Diet and Genotype to Development	JUN 27-30, 2000	CORK, IRELAND			cancer; insulin; insulin-like growth factors; energy balance	DEPENDENT DIABETES-MELLITUS; IGF-BINDING-PROTEINS; POLYCYSTIC-OVARY-SYNDROME; POSTMENOPAUSAL BREAST-CANCER; MESSENGER-RIBONUCLEIC-ACID; THECA-INTERSTITIAL CELLS; BODY-FAT DISTRIBUTION; IMMUNOREACTIVE SOMATOMEDIN-C; IGFBP-3 PROTEASE ACTIVITY; EXERCISE-INDUCED CHANGES	Recent theories propose that a Western lifestyle may increase cancer risk through alterations in the metabolism of insulin and insulin-like growth factors (IGF; McKeown-Eyssen, 1994; Giovannucci, 1995; Kaaks, 1996; Werner & LeRoith, 1996). Insulin regulates energy metabolism, and increases the bioactivity of IGF-I, by enhancing its synthesis, and by decreasing several of its binding proteins (IGFBP; IGFBP-1 and -2). Insulin and IGF-I both stimulate anabolic processes as a function of available energy and elementary substrates (e.g, amino acids). The anabolic signals by insulin or IGF-I can promote tumour development by inhibiting apoptosis, and by stimulating cell proliferation. Furthermore, both insulin and IGF-I stimulate the synthesis of sex steroids, and inhibit the synthesis of sex hormone-binding globulin (SHBG), a binding protein that regulates the bioavailability of circulating sex steroids to tissues. The present paper reviews epidemiological findings relating the risk of cancers of the colo-rectum, pancreas, breast, endometrium and prostate to body size (obesity, height) and physical activity, and discusses the relationships between obesity and physical activity and plasma levels of insulin, IGF-I and IGFBP. Subsequent sections review epidemiological findings relating cancer risk to indices of chronic hyperinsulinaemia, and to plasma levels of IGF-I and IGFBP. Conclusions are that chronic hyperinsulinaemia may be a cause of cancers of the colon, pancreas and endometrium, and also possibly of the breast. On the other hand, elevated plasma IGF-I, as total concentrations or relative to levels of IGFBP-3, appears to be related to an increased risk of prostate cancer, breast cancer in young women, and possibly cole-rectal cancer. For cancers of the endometrium, breast and prostate, these findings are discussed in the context of relationships between insulin and IGF-I and levels of bioavailable sex steroids.	Int Agcy Res Canc, F-69372 Lyon 08, France		Kaaks, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	kaaks@iarc.fr					Abate N, 1996, DIABETES CARE, V19, P292, DOI 10.2337/diacare.19.3.292; ADAMI HO, 1991, CANCER CAUSE CONTROL, V2, P307, DOI 10.1007/BF00051670; Argente J, 1997, J CLIN ENDOCR METAB, V82, P2084, DOI 10.1210/jc.82.7.2084; Ayabe T, 1997, ENDOCR J, V44, P419, DOI 10.1507/endocrj.44.419; BALLARDBARBASH R, 1994, CANCER-AM CANCER SOC, V74, P1090, DOI 10.1002/1097-0142(19940801)74:3+<1090::AID-CNCR2820741518>3.0.CO;2-X; BANG P, 1990, EUR J CLIN INVEST, V20, P285, DOI 10.1111/j.1365-2362.1990.tb01857.x; BANG P, 1994, J CLIN ENDOCR METAB, V78, P960, DOI 10.1210/jc.78.4.960; BARBIERI RL, 1988, FERTIL STERIL, V50, P197; BATES GW, 1982, FERTIL STERIL, V38, P406; BAUMANN G, 1993, NUTRITION, V9, P546; BAXTER RC, 1981, METABOLISM, V30, P1086, DOI 10.1016/0026-0495(81)90052-4; BAXTER RC, 1978, BIOCHEM BIOPH RES CO, V84, P350, DOI 10.1016/0006-291X(78)90177-8; BEBAKAR WMW, 1990, STEROIDS, V55, P266, DOI 10.1016/0039-128X(90)90043-B; Belfiore F, 1998, MOL GENET METAB, V65, P121, DOI 10.1006/mgme.1998.2727; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P2282, DOI 10.1210/jc.80.8.2282; Bereket A, 1999, HORM METAB RES, V31, P172, DOI 10.1055/s-2007-978716; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P1312, DOI 10.1210/jc.80.4.1312; Bermon S, 1999, ACTA PHYSIOL SCAND, V165, P51; Bernardi F, 1998, HUM REPROD, V13, P279, DOI 10.1093/humrep/13.2.279; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; BJORNTORP P, 1992, ANN MED, V24, P465, DOI 10.3109/07853899209166997; Bjorntorp Per, 1994, Current Opinion in Lipidology, V5, P166, DOI 10.1097/00041433-199405030-00003; Bohlke K, 1998, EPIDEMIOLOGY, V9, P570, DOI 10.1097/00001648-199809000-00018; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; BONISCHNETZLER M, 1990, MOL ENDOCRINOL, V4, P1320; Bonnefoy M, 1999, AGING-CLIN EXP RES, V11, P373, DOI 10.1007/BF03339815; BRUNING PF, 1995, INT J CANCER, V62, P266, DOI 10.1002/ijc.2910620306; BRUNING PF, 1992, INT J CANCER, V52, P511, DOI 10.1002/ijc.2910520402; Calle EE, 1998, CANCER CAUSE CONTROL, V9, P403, DOI 10.1023/A:1008819701485; CAPPON J, 1994, J APPL PHYSIOL, V76, P2490, DOI 10.1152/jappl.1994.76.6.2490; CARA JF, 1994, HORM RES, V42, P49, DOI 10.1159/000184145; CASANUEVA FF, 1992, ENDOCRIN METAB CLIN, V21, P483, DOI 10.1016/S0889-8529(18)30199-3; CAUFRIEZ A, 1984, CLIN ENDOCRINOL, V20, P65, DOI 10.1111/j.1365-2265.1984.tb00060.x; Chadan SG, 1999, MECH AGEING DEV, V109, P21, DOI 10.1016/S0047-6374(99)00017-2; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHANG TC, 1994, GERONTOLOGY, V40, P260; Chapman IM, 1998, J CLIN ENDOCR METAB, V83, P2836, DOI 10.1210/jc.83.8.2836; Chuzel F, 1996, EUR J BIOCHEM, V239, P8, DOI 10.1111/j.1432-1033.1996.0008u.x; CLEMMONS DR, 1981, J CLIN ENDOCR METAB, V53, P1247, DOI 10.1210/jcem-53-6-1247; CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141; Colditz GA, 1997, CANCER CAUSE CONTROL, V8, P649, DOI 10.1023/A:1018458700185; CONOVER CA, 1990, J CLIN ENDOCR METAB, V70, P1062, DOI 10.1210/jcem-70-4-1062; COPELAND KC, 1990, METABOLISM, V39, P584, DOI 10.1016/0026-0495(90)90022-5; CORDIDO F, 1991, HORM RES, V36, P187, DOI 10.1159/000182158; COULAM CB, 1983, OBSTET GYNECOL, V61, P403; COUNTS DR, 1992, J CLIN ENDOCR METAB, V75, P762, DOI 10.1210/jc.75.3.762; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P1283, DOI 10.1210/jc.80.4.1283; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; DAHLGREN E, 1991, EUR J OBSTET GYN R B, V41, P143, DOI 10.1016/0028-2243(91)90092-Y; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Del Giudice ME, 1998, BREAST CANCER RES TR, V47, P111, DOI 10.1023/A:1005831013718; DEMELLOW JSM, 1987, ACTA ENDOCRINOL-COP, V115, P483, DOI 10.1530/acta.0.1150483; deMoura MD, 1997, BIOL REPROD, V56, P946, DOI 10.1095/biolreprod56.4.946; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DiGiovanni J, 2000, CANCER RES, V60, P1561; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; DiLuigi L, 1997, INT J SPORTS MED, V18, P257, DOI 10.1055/s-2007-972630; Dunaif A, 1999, ENDOCRIN METAB CLIN, V28, P341, DOI 10.1016/S0889-8529(05)70073-6; Dunger DB, 1996, HORM RES, V46, P2, DOI 10.1159/000184969; Eaton NE, 1999, BRIT J CANCER, V80, P930, DOI 10.1038/sj.bjc.6690445; Ehrmann DA, 1999, ENDOCRIN METAB CLIN, V28, P423, DOI 10.1016/S0889-8529(05)70078-5; Eliakim A, 1998, AM J PHYSIOL-REG I, V275, pR308, DOI 10.1152/ajpregu.1998.275.1.R308; Elias AN, 2000, PSYCHONEUROENDOCRINO, V25, P453, DOI 10.1016/S0306-4530(99)00070-0; Erfurth EMT, 1996, CLIN ENDOCRINOL, V44, P659, DOI 10.1046/j.1365-2265.1996.731552.x; EVERHART J, 1995, JAMA-J AM MED ASSOC, V273, P1605, DOI 10.1001/jama.273.20.1605; Falkner B, 1999, METABOLISM, V48, P107, DOI 10.1016/S0026-0495(99)90018-5; Ferrini RL, 1998, AM J EPIDEMIOL, V147, P750; FISHBEIN L, 1991, ILSI MONOGRAPHS, P1; Frame LT, 1998, ENVIRON HEALTH PERSP, V106, P313; FRIEDMAN GD, 1993, INT J EPIDEMIOL, V22, P30, DOI 10.1093/ije/22.1.30; FRYSTYK J, 1995, METABOLISM, V44, P37, DOI 10.1016/0026-0495(95)90219-8; GAMA R, 1990, CLIN CHIM ACTA, V188, P31, DOI 10.1016/0009-8981(90)90143-G; Gammon MD, 1998, JNCI-J NATL CANCER I, V90, P100, DOI 10.1093/jnci/90.2.100; Gapstur SM, 2000, JAMA-J AM MED ASSOC, V283, P2552, DOI 10.1001/jama.283.19.2552; Giacosa A, 1999, EUR J CANCER PREV, V8, pS53; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Giovannucci E, 2000, CANCER EPIDEM BIOMAR, V9, P345; Giovannucci E, 1998, CANCER CAUSE CONTROL, V9, P3, DOI 10.1023/A:1008822917449; GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777; Giustina A, 1995, EUR J ENDOCRINOL, V133, P646, DOI 10.1530/eje.0.1330646; GOLDEN NH, 1994, J PEDIATR-US, V125, P655, DOI 10.1016/S0022-3476(94)70030-3; Goodman MT, 1997, CANCER RES, V57, P5077; GRADY D, 1996, CANC EPIDEMIOLOGY PR, P1058; Grimm JJ, 1999, PUBLIC HEALTH NUTR, V2, P363, DOI 10.1017/S136898009900049X; GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V77, P1610, DOI 10.1210/jc.77.6.1610; HAFFNER SM, 1993, INT J OBESITY, V17, P643; HAFFNER SM, 1994, DIABETES, V43, P212, DOI 10.2337/diabetes.43.2.212; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hill HA, 1996, CANCER CAUSE CONTROL, V7, P19, DOI 10.1007/BF00115635; Ho KKY, 1996, HORM RES, V45, P67, DOI 10.1159/000184762; HOCHBERG Z, 1992, METABOLISM, V41, P106, DOI 10.1016/0026-0495(92)90198-J; HOPKINS NJ, 1994, J CLIN ENDOCR METAB, V79, P1887, DOI 10.1210/jc.79.6.1887; Hornum M, 1997, J APPL PHYSIOL, V82, P1946, DOI 10.1152/jappl.1997.82.6.1946; Hu FB, 1999, JNCI-J NATL CANCER I, V91, P542, DOI 10.1093/jnci/91.6.542; HU HY, 1994, ENDOCR J, V41, P63, DOI 10.1507/endocrj.41.63; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; *INT AG RES CANC, 1997, IARC SCI PUBL, V8, P1240; JAHREIS G, 1991, GROWTH REGULAT, V1, P95; Jasper H, 1999, J ENDOCRINOL INVEST, V22, P29, DOI 10.1007/BF03345475; Ji BT, 1996, INT J CANCER, V66, P432; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Juul A, 1996, CLIN ENDOCRINOL, V44, P515, DOI 10.1046/j.1365-2265.1996.711531.x; JUUL A, 1994, CLIN ENDOCRINOL, V41, P85, DOI 10.1111/j.1365-2265.1994.tb03788.x; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; Kaaks R, 1996, CANCER CAUSE CONTROL, V7, P605, DOI 10.1007/BF00051703; Karas M, 1997, J BIOL CHEM, V272, P16514, DOI 10.1074/jbc.272.26.16514; Key TJ, 2001, P NUTR SOC, V60, P81, DOI 10.1079/PNS200068; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KIDDY DS, 1989, CLIN ENDOCRINOL, V31, P757, DOI 10.1111/j.1365-2265.1989.tb01297.x; Koistinen H, 1996, J APPL PHYSIOL, V80, P760, DOI 10.1152/jappl.1996.80.3.760; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; Kolonel LN, 1996, CANCER CAUSE CONTROL, V7, P83, DOI 10.1007/BF00115640; KOPELMAN PG, 1981, CLIN ENDOCRINOL, V15, P113, DOI 10.1111/j.1365-2265.1981.tb00644.x; Koziris LP, 1999, J APPL PHYSIOL, V86, P1436, DOI 10.1152/jappl.1999.86.4.1436; KRAEMER WJ, 1995, J APPL PHYSIOL, V79, P1310, DOI 10.1152/jappl.1995.79.4.1310; Kristiansen SB, 1997, STEROIDS, V62, P258, DOI 10.1016/S0039-128X(96)00223-1; Kritchevsky D, 1999, TOXICOL SCI, V52, P13, DOI 10.1093/toxsci/52.2.13; La Vecchia C, 1997, CANCER EPIDEM BIOMAR, V6, P1007; LAVECCHIA C, 1994, BRIT J CANCER, V70, P950, DOI 10.1038/bjc.1994.427; Lee AV, 1998, BREAST CANCER RES TR, V47, P295, DOI 10.1023/A:1005915420341; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; LeMarchand L, 1997, CANCER RES, V57, P4787; LIN T, 1986, BIOCHEM BIOPH RES CO, V137, P950, DOI 10.1016/0006-291X(86)90317-7; LONNING PE, 1995, J STEROID BIOCHEM, V52, P491, DOI 10.1016/0960-0760(94)00189-S; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MAES M, 1983, DIABETES, V32, P1060, DOI 10.2337/diabetes.32.11.1060; MAGOFFIN DA, 1990, MOL ENDOCRINOL, V4, P489, DOI 10.1210/mend-4-3-489; MAGOFFIN DA, 1993, BIOL REPROD, V48, P1166, DOI 10.1095/biolreprod48.5.1166; MAGOFFIN DA, 1993, ENDOCRINOLOGY, V132, P1945, DOI 10.1210/en.132.5.1945; Manousos O, 1999, INT J CANCER, V83, P15, DOI 10.1002/(SICI)1097-0215(19990924)83:1<15::AID-IJC4>3.0.CO;2-Y; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; MARIN P, 1993, INT J OBESITY, V17, P83; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; McTiernan A, 1998, CANCER CAUSE CONTROL, V9, P487, DOI 10.1023/A:1008853601471; MERIMEE TJ, 1982, J CLIN ENDOCR METAB, V55, P999, DOI 10.1210/jcem-55-5-999; Mesiano S, 1997, J CLIN ENDOCR METAB, V82, P1390, DOI 10.1210/jc.82.5.1390; MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2; Moore MA, 1998, EUR J CANCER PREV, V7, P177, DOI 10.1097/00008469-199806000-00002; Morales AJ, 1996, J CLIN ENDOCR METAB, V81, P2854, DOI 10.1210/jc.81.8.2854; MOSESON M, 1993, INT J EPIDEMIOL, V22, P1000, DOI 10.1093/ije/22.6.1000; Nam SY, 1997, INT J OBESITY, V21, P355, DOI 10.1038/sj.ijo.0800412; Nguyen UN, 1998, EUR J APPL PHYSIOL O, V78, P533, DOI 10.1007/s004210050456; NICKLAS BJ, 1995, INT J SPORTS MED, V16, P445, DOI 10.1055/s-2007-973035; Niwa K, 2000, ONCOL REP, V7, P89; Nyomba BLG, 1997, J CLIN ENDOCR METAB, V82, P2177, DOI 10.1210/jc.82.7.2177; Ochoa R, 1995, ARCH MED RES, V26, pS17; OMARA BA, 1985, J CHRON DIS, V38, P435, DOI 10.1016/0021-9681(85)90139-0; Parazzini F, 1999, INT J CANCER, V81, P539, DOI 10.1002/(SICI)1097-0215(19990517)81:4<539::AID-IJC6>3.0.CO;2-Q; PASQUALI R, 1991, METABOLISM, V40, P101, DOI 10.1016/0026-0495(91)90199-7; Pasquali R., 1997, Human Reproduction (Oxford), V12, P82; Penhoat A, 1996, STEROIDS, V61, P176, DOI 10.1016/0039-128X(96)00009-8; Petridou E, 2000, CANCER CAUSE CONTROL, V11, P383, DOI 10.1023/A:1008903727238; PEYRAT JP, 1993, EUR J CANCER, V29A, P492, DOI 10.1016/S0959-8049(05)80137-6; Pfeilschifter J, 1996, J CLIN ENDOCR METAB, V81, P2534, DOI 10.1210/jc.81.7.2534; Plymate S R, 1988, Steroids, V52, P339, DOI 10.1016/0039-128X(88)90136-5; Poretsky L, 1999, ENDOCR REV, V20, P535, DOI 10.1210/er.20.4.535; POSTELVINAY MC, 1982, MOL CELL ENDOCRINOL, V28, P657, DOI 10.1016/0303-7207(82)90153-8; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRELEVIC GM, 1992, HORM RES, V37, P125, DOI 10.1159/000182296; PUGEAT M, 1991, J STEROID BIOCHEM, V40, P841, DOI 10.1016/0960-0760(91)90310-2; Pugeat M, 1999, DRUGS, V58, P41, DOI 10.2165/00003495-199958001-00010; RAGOZZINO M, 1982, J CHRON DIS, V35, P13, DOI 10.1016/0021-9681(82)90025-X; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P796, DOI 10.1210/jc.80.3.796; RASMUSSEN MH, 1994, METABOLISM, V43, P315, DOI 10.1016/0026-0495(94)90099-X; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; Roelen CAM, 1997, INT J SPORTS MED, V18, P238, DOI 10.1055/s-2007-972626; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rutanen EM, 1998, GYNECOL ENDOCRINOL, V12, P399, DOI 10.3109/09513599809012842; RUTANEN EM, 1994, INT J CANCER, V59, P307, DOI 10.1002/ijc.2910590303; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Scheett TP, 1999, PEDIATR RES, V46, P429, DOI 10.1203/00006450-199910000-00011; SCHMIDT W, 1995, EUR J APPL PHYSIOL, V71, P424, DOI 10.1007/BF00635876; Schoen RE, 1999, JNCI-J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147; Schwarz AJ, 1996, J CLIN ENDOCR METAB, V81, P3492, DOI 10.1210/jc.81.10.3492; SEIDELL JC, 1990, METABOLISM, V39, P897, DOI 10.1016/0026-0495(90)90297-P; Sellers TA, 1998, EPIDEMIOLOGY, V9, P102, DOI 10.1097/00001648-199801000-00021; Shoff SM, 1998, AM J EPIDEMIOL, V148, P234, DOI 10.1093/oxfordjournals.aje.a009630; SHU XO, 1991, INT J CANCER, V49, P38, DOI 10.1002/ijc.2910490108; Silverman DT, 1998, JNCI-J NATL CANCER I, V90, P1710, DOI 10.1093/jnci/90.22.1710; Silverman DT, 1999, BRIT J CANCER, V80, P1830, DOI 10.1038/sj.bjc.6690607; SINGH A, 1990, J ENDOCRINOL, V124, pR1, DOI 10.1677/joe.0.124R001; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; SMITH GD, 1992, AM J EPIDEMIOL, V136, P1110, DOI 10.1093/oxfordjournals.aje.a116576; STATTIN P, 2000, IN PRESS J NATL CANC, V92; STEENLAND K, 1995, CANCER EPIDEM BIOMAR, V4, P807; STEIN P, 1995, J STEROID BIOCHEM, V52, P329, DOI 10.1016/0960-0760(94)00182-L; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STRAUS DS, 1990, MOL ENDOCRINOL, V4, P91, DOI 10.1210/mend-4-1-91; STRAUS DS, 1994, FASEB J, V8, P6, DOI 10.1096/fasebj.8.1.8299891; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; TANAKA T, 1985, ENDOCRINOL JAPON, V32, P891; TANNENBAUM GS, 1983, SCIENCE, V220, P77, DOI 10.1126/science.6338593; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Thomas HV, 1997, CANCER CAUSE CONTROL, V8, P922, DOI 10.1023/A:1018476631561; Tibblin G, 1996, DIABETES, V45, P1605, DOI 10.2337/diabetes.45.11.1605; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TONIOLO P, 2000, IN PRESS INT J CANC; Troisi R, 1997, AM J EPIDEMIOL, V146, P476, DOI 10.1093/oxfordjournals.aje.a009301; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; UNTERMAN TG, 1993, ADV EXP MED BIOL, V343, P215; URBAN RJ, 1990, ENDOCRINOLOGY, V127, P2481, DOI 10.1210/endo-127-5-2481; URSIN G, 1995, EPIDEMIOLOGY, V6, P137, DOI 10.1097/00001648-199503000-00009; VANCE ML, 1992, HORM RES, V38, P85, DOI 10.1159/000182577; VELDHUIS JD, 1995, J CLIN ENDOCR METAB, V80, P3209, DOI 10.1210/jc.80.11.3209; Vermeulen A., 1999, Journal of Endocrinological Investigation, V22, P110; Vermeulen A, 1996, J CLIN ENDOCR METAB, V81, P1821, DOI 10.1210/jc.81.5.1821; Vermeulen A, 1996, ANN MED, V28, P13, DOI 10.3109/07853899608999068; Vitiello MV, 1997, J GERONTOL A-BIOL, V52, pM149, DOI 10.1093/gerona/52A.3.M149; Wabitsch M, 1996, INT J OBESITY, V20, P1073; Wallace JD, 1999, J CLIN ENDOCR METAB, V84, P3591, DOI 10.1210/jc.84.10.3591; WEHRENBERG WB, 1992, ENDOCR REV, V13, P299, DOI 10.1210/er.13.2.299; Weiderpass E, 1997, INT J CANCER, V71, P360, DOI 10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W; Weiderpass E, 1998, SCAND J WORK ENV HEA, V24, P165, DOI 10.5271/sjweh.295; Weiderpass E, 2000, CANCER CAUSE CONTROL, V11, P185, DOI 10.1023/A:1008946825313; WEINDRUCH R, 1992, EXP GERONTOL, V27, P575, DOI 10.1016/0531-5565(92)90012-O; Weiss HA, 1999, INT J EPIDEMIOL, V28, P816, DOI 10.1093/ije/28.5.816; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Wideman L, 1999, J APPL PHYSIOL, V87, P1154, DOI 10.1152/jappl.1999.87.3.1154; Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360; Wilker E, 1999, MOL CARCINOGEN, V25, P122, DOI 10.1002/(SICI)1098-2744(199906)25:2<122::AID-MC7>3.0.CO;2-8; Will JC, 1999, EPIDEMIOLOGY, V10, P313, DOI 10.1097/00001648-199905000-00021; Will JC, 1998, AM J EPIDEMIOL, V147, P816, DOI 10.1093/oxfordjournals.aje.a009534; WILSON DM, 1992, ENDOCRIN METAB CLIN, V21, P519, DOI 10.1016/S0889-8529(18)30200-7; Wilson JD, 1996, PROSTATE, P88; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; *WORLD CANC RES FU, FOOD NUTR PREV CANC, V1, P97; WU AH, 1995, CANCER EPIDEM BIOMAR, V4, P735; Wyshak G, 2000, BRIT J CANCER, V82, P726; Yang XF, 1996, CANCER RES, V56, P1509	235	444	451	0	14	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0029-6651	1475-2719		P NUTR SOC	Proc. Nutr. Soc.	FEB	2001	60	1					91	106		10.1079/PNS200070			16	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Nutrition & Dietetics	414WJ	WOS:000167688900012	11310428	Bronze			2022-02-25	
J	Wild, CP				Wild, Christopher P.			The global impact of environmental carcinogenesis and interventions for prevention	CANCER PREVENTION RESEARCH			English	Meeting Abstract									[Wild, Christopher P.] Int Agcy Res Canc, Lyon, France				Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669				0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1940-6207	1940-6215		CANCER PREV RES	Cancer Prev. Res.	JUL	2020	13	7		S		IA01	13	13					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	MG4OK	WOS:000546012200002					2022-02-25	
J	Vaccarella, S; Laversanne, M; Ferlay, J; Bray, F				Vaccarella, S.; Laversanne, M.; Ferlay, J.; Bray, F.			Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends	INTERNATIONAL JOURNAL OF CANCER			English	Article						cervical cancer; incidence and mortality trends; screening; vaccination	CLINICAL-TRIALS; POPULATION; PREVENTION; INFECTIONS; BURDEN	The vast majority (86% or 453,000 cases) of the global burden of cervical cancer occurs in Africa, Latin America and the Caribbean and Asia, where one in nine new cancer cases are of the cervix. Although the disease has become rare in high-resource settings (e.g., in North America, parts of Europe, Japan) that have historically invested in effective screening programs, the patterns and trends are variable elsewhere. While favourable incidence trends have been recorded in many populations in Asia and Latin America and the Caribbean in the past decades, rising rates have been observed in sub-Saharan African countries, where high quality incidence series are available. The challenge for countries heavily affected by the disease in these regions is to ensure resource-dependent programmes of screening and vaccination are implemented to transform the situation, so that accelerated declines in cervical cancer are not the preserve of high-income countries, but become the norm in all populations worldwide.	[Vaccarella, S.] Int Agcy Res Canc, Infect & Canc Epidemiol Grp, Lyon, France; [Laversanne, M.; Ferlay, J.; Bray, F.] Int Agcy Res Canc, Sect Canc Surveillance, Lyon, France		Vaccarella, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	vaccarella@iarc.fr	Ferlay, Jacques/ABD-5058-2021	Vaccarella, Salvatore/0000-0002-2516-2167; Bray, Freddie/0000-0002-3248-7787			Arbyn M, 2012, VACCINE, V30, pF88, DOI 10.1016/j.vaccine.2012.06.095; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Chokunonga E, 2013, INT J CANCER, V133, P721, DOI 10.1002/ijc.28063; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; De Vuyst H, 2013, VACCINE, V31, pF32, DOI 10.1016/j.vaccine.2012.07.092; Ferlay J, GLOBOCAN 2012 V1 0 C; Giuliano AR, 2015, INT J CANCER, V136, P2752, DOI 10.1002/ijc.29082; IARC, 2014, IARC SCI PUBL, VX; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V90, P1; Lehtinen M, 2013, NAT REV CLIN ONCOL, V10, P400, DOI 10.1038/nrclinonc.2013.84; Parkin DM, 2014, CANCER EPIDEM BIOMAR, V23, P953, DOI 10.1158/1055-9965.EPI-14-0281; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Vaccarella S, 2014, BRIT J CANCER, V111, P965, DOI 10.1038/bjc.2014.362; Vaccarella S, 2016, LANCET ONCOL, V17, P1445, DOI 10.1016/S1470-2045(16)30275-3; Vaccarella S, 2013, VACCINE, V31, pG32, DOI 10.1016/j.vaccine.2012.06.098; Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024; Wabinga HR, 2014, INT J CANCER, V135, P432, DOI 10.1002/ijc.28661; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Bosch FX, 2016, NAT REV CLIN ONCOL, V13, P119, DOI 10.1038/nrclinonc.2015.146	21	53	55	1	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	NOV 15	2017	141	10					1997	2001		10.1002/ijc.30901			5	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	FH3OE	WOS:000411057400007	28734013	Bronze			2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, Rengaswamy			Progress in scaling up cervical cancer prevention in health services of developing countries	CANCER RESEARCH			English	Meeting Abstract									[Sankaranarayanan, Rengaswamy] Int Agcy Res Canc WHO IARC, Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	NOV	2017	77	22		S		IA1				10.1158/1538-7445.NEWFRONT17-IA1			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	VI3AM	WOS:000468801300064					2022-02-25	
J	Tommasino, M				Tommasino, Massimo			The biology of beta human papillomaviruses	VIRUS RESEARCH			English	Review						Beta HPV types; E6 and E7 oncoproteins; Skin cancer; UV irradiation	SQUAMOUS-CELL CARCINOMA; GAMMA HUMAN PAPILLOMAVIRUSES; UV-INDUCED APOPTOSIS; E6 PROTEINS; EPIDERMODYSPLASIA-VERRUCIFORMIS; SKIN-CANCER; TRANSCRIPTIONAL COACTIVATOR; KERATINOCYTE GROWTH; E6/E7 EXPRESSION; CUTANEOUS BETA	The beta genus comprises more than 50 beta human papillomavirus (HPV) types that are suspected to be involved, together with ultraviolet (UV) irradiation, in the development of non-melanoma skin cancer (NMSC), the most common form of human cancer. Two members of the genus beta, HPV5 and HPV8, were first identified in patients with a genetic disorder, epidermodysplasia verruciformis (EV), that confers high susceptibility to beta HPV infection and NMSC development. The fact that organ transplant recipients (OTRs) with an impaired immune system have an elevated risk of NMSC raised the hypothesis that beta HPV types may also be involved in skin carcinogenesis in non-EV patients. Epidemiological studies have shown that serological and viral DNA markers are weakly, but significantly, associated with history of NMSC in OTRs and the general population. Functional studies on mucosal high-risk (HR) HPV types have clearly demonstrated that the products of two early genes, E6 and E7, are the main viral oncoproteins, which are able to deregulate events closely linked to transformation, such as cell cycle progression and apoptosis. Studies on a small number of beta HPV types have shown that their E6 and E7 oncoproteins also have the ability to interfere with the regulation of key pathways/events associated with cellular transformation. However, the initial functional data indicate that the molecular mechanisms leading to cellular transformation are different from those of mucosal HR HPV types. Beta HPV types may act only at early stages of carcinogenesis, by potentiating the deleterious effects of other carcinogens, such as UV radiation. (C) 2016 Elsevier B.V. All rights reserved.	[Tommasino, Massimo] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France		Tommasino, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	tommasinom@iarc.fr		Tommasino, Massimo/0000-0002-0890-8596	European Commission, HPV-AHEADEuropean Commission [FP7-HEALTH-2011-282562]; INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission [ENV201610]; Fondation ARC pour la Recherche sur le CancerFondation ARC pour la Recherche sur le Cancer [JA 20151203192]	I apologize to those authors whose important contributions to HPV research could not be cited or adequately discussed due to space limitations. I thank the IARC Director, Dr Christopher P. Wild, and all members of the Infections and Cancer Biology Group for their constant support, Dr Karen Muller for the editing, and Mrs Nicole Suty for the preparation of this manuscript. The work performed in the group is partially supported by grants from the European Commission, HPV-AHEAD (FP7-HEALTH-2011-282562), INSERM (ENV201610), and Fondation ARC pour la Recherche sur le Cancer (JA 20151203192).	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Accardi R, 2011, MOL CELL BIOL, V31, P2210, DOI 10.1128/MCB.00964-10; Agalliu I, 2016, JAMA ONCOL; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Anforth R, 2012, PIGM CELL MELANOMA R, V25, P569, DOI 10.1111/j.1755-148X.2012.01031.x; Antonsson A, 2003, J GEN VIROL, V84, P1881, DOI 10.1099/vir.0.18836-0; Antonsson A, 2003, J CLIN MICROBIOL, V41, P2509, DOI 10.1128/JCM.41.6.2509-2514.2003; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Arron ST, 2011, J INVEST DERMATOL, V131, P1745, DOI 10.1038/jid.2011.91; Astori G, 1998, J INVEST DERMATOL, V110, P752, DOI 10.1046/j.1523-1747.1998.00191.x; Ateenyi-Agaba C, 2004, BRIT J CANCER, V90, P1777, DOI 10.1038/sj.bjc.6601743; Ateenyi-Agaba C, 2010, BRIT J CANCER, V102, P262, DOI 10.1038/sj.bjc.6605466; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Bavinck JNB, 2010, CANCER RES, V70, P9777, DOI 10.1158/0008-5472.CAN-10-0352; Bedard KM, 2008, J VIROL, V82, P3894, DOI 10.1128/JVI.01818-07; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002; Bottalico D, 2011, J INFECT DIS, V204, P787, DOI 10.1093/infdis/jir383; Boxman ILA, 2001, J INVEST DERMATOL, V117, P1397, DOI 10.1046/j.0022-202x.2001.01602.x; Boxman ILA, 1997, J INVEST DERMATOL, V108, P712, DOI 10.1111/1523-1747.ep12292090; BOYLE J, 1984, LANCET, V1, P702; Brimer N, 2012, ONCOGENE, V31, P4639, DOI 10.1038/onc.2011.589; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Bzhalava D, 2014, SCI REP-UK, V4, DOI 10.1038/srep05807; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; Campbell CMP, 2013, J CLIN VIROL, V58, P652, DOI 10.1016/j.jcv.2013.10.011; Chahoud J., 2015, JAMA DERMATOL, V77004; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; CHEN Z, 1995, CANCER GENE THER, V2, P263; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cohen DN, 2015, CLIN CANCER RES, V21, P2624, DOI 10.1158/1078-0432.CCR-14-2667; Cornet I, 2012, J VIROL, V86, P2366, DOI 10.1128/JVI.06579-11; Coussens LM, 1996, AM J PATHOL, V149, P1899; Crequer A, 2012, J CLIN INVEST, V122, P3239, DOI 10.1172/JCI62949; Dang C, 2006, BRIT J DERMATOL, V155, P129, DOI 10.1111/j.1365-2133.2006.07378.x; de Koning MNC, 2007, J GEN VIROL, V88, P1489, DOI 10.1099/vir.0.82732-0; de Koning MNC, 2009, J GEN VIROL, V90, P1611, DOI 10.1099/vir.0.010017-0; de Villiers EM, 2013, VIROLOGY, V445, P2, DOI 10.1016/j.virol.2013.04.023; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Dewson G, 2009, MOL CELL, V36, P696, DOI 10.1016/j.molcel.2009.11.008; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dona MG, 2016, J INFECTION, V73, P380, DOI 10.1016/j.jinf.2016.07.006; Dreer M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005556; DURST M, 1987, ONCOGENE, V1, P251; Ekstrom J, 2013, VIROLOGY, V447, P300, DOI 10.1016/j.virol.2013.09.010; Elson DA, 2000, CANCER RES, V60, P1267; Falchook GS, 2013, JAMA DERMATOL, V149, P322, DOI 10.1001/jamadermatol.2013.2023; Farzan SF, 2013, INT J CANCER, V133, P1713, DOI 10.1002/ijc.28176; FIRZLAFF J M, 1989, New Biologist, V1, P44; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Forslund O, 2004, J INVEST DERMATOL, V123, P388, DOI 10.1111/j.0022-202X.2004.23205.x; Forslund O, 2007, J INFECT DIS, V196, P876, DOI 10.1086/521031; Forslund O, 2013, J INFECT DIS, V208, P1335, DOI 10.1093/infdis/jit326; Frecha C, 2015, J VIROL, V89, P1461, DOI 10.1128/JVI.02936-14; Freiss G, 2011, ANTI-CANCER AGENT ME, V11, P78, DOI 10.2174/187152011794941262; Gabet AS, 2008, FASEB J, V22, P622, DOI 10.1096/fj.07-8389com; Ganti K, 2015, VIRUSES-BASEL, V7, P3530, DOI 10.3390/v7072785; Ganzenmueller T, 2012, INT J CANCER, V131, pE1173, DOI 10.1002/ijc.27581; Gaud G, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.27; Giampieri S, 2004, BRIT J CANCER, V90, P2203, DOI 10.1038/sj.bjc.6601829; Hamada K, 1996, GYNECOL ONCOL, V63, P219, DOI 10.1006/gyno.1996.0310; Hampras SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104843; Hazard K, 2007, J INVEST DERMATOL, V127, P116, DOI 10.1038/sj.jid.5700570; Heuser S, 2016, J GEN VIROL, V97, P463, DOI 10.1099/jgv.0.000363; Holloway A, 2015, INT J CANCER, V136, P2831, DOI 10.1002/ijc.29350; Howie HL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002211; Hsu JYC, 2009, J MED VIROL, V81, P1444, DOI 10.1002/jmv.21529; Hufbauer M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0453-7; Hufbauer M, 2013, J VIROL, V87, P12158, DOI 10.1128/JVI.01510-13; Iannacone MR, 2014, INT J CANCER, V134, P2231, DOI 10.1002/ijc.28552; IFTNER T, 1990, VIROLOGY, V179, P428, DOI 10.1016/0042-6822(90)90311-E; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Kalinska-Bienias A, 2016, POSTEP DERM ALERGOL, V33, P75, DOI 10.5114/ada.2016.59145; Karagas MR, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c2986; Kazem S, 2012, VIRUS RES, V163, P609, DOI 10.1016/j.virusres.2011.12.015; Kazemian M, 2015, J VIROL, V89, P8967, DOI 10.1128/JVI.00822-15; Kiviat NB, 1999, SEMIN CANCER BIOL, V9, P397, DOI 10.1006/scbi.1999.0143; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kurima K, 2003, GENOMICS, V82, P300, DOI 10.1016/S0888-7543(03)00154-X; Lace MJ, 2008, J VIROL, V82, P10841, DOI 10.1128/JVI.01481-08; Lacouture ME, 2013, ONCOLOGIST, V18, P314, DOI 10.1634/theoncologist.2012-0333; Lambert PF, 2006, PAPILLOMAVIRUS RESEARCH: FROM NATURAL HISTORY TO VACCINES AND BEYOND, P213; lannacone MR, 2012, CANCER EPIDEM BIOMAR, V21, P1303; Lazarczyk M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039995; Lazarczyk M, 2009, MICROBIOL MOL BIOL R, V73, P348, DOI 10.1128/MMBR.00033-08; Lazic D, 2012, J VIROL, V86, P7943, DOI 10.1128/JVI.00132-12; Li S.L., 2016, BR J DERMATOL; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Marcuzzi GP, 2009, J GEN VIROL, V90, P2855, DOI 10.1099/vir.0.012872-0; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Meyers JM, 2013, J VIROL, V87, P4762, DOI 10.1128/JVI.02527-12; Michel A, 2006, J VIROL, V80, P11153, DOI 10.1128/JVI.00954-06; Muench P, 2010, CANCER RES, V70, P6913, DOI 10.1158/0008-5472.CAN-10-1307; Muschik D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027655; Newton R, 1996, BRIT J CANCER, V74, P1511, DOI 10.1038/bjc.1996.581; Nunes EM, 2016, VIROLOGY, V495, P33, DOI 10.1016/j.virol.2016.04.031; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Orth G, 2008, CURR TOP MICROBIOL, V321, P59; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Ramoz N, 2002, NAT GENET, V32, P579, DOI 10.1038/ng1044; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Saidj D, 2013, J VIROL, V87, P12139, DOI 10.1128/JVI.01047-13; Sankovski E, 2014, J VIROL, V88, P961, DOI 10.1128/JVI.01841-13; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schmitt A, 1996, J VIROL, V70, P1912, DOI 10.1128/JVI.70.3.1912-1922.1996; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shamir ER, 2014, NAT REV MOL CELL BIO, V15, P647, DOI 10.1038/nrm3873; Straub E, 2014, J VIROL, V88, P937, DOI 10.1128/JVI.02296-13; STUBENRAUCH F, 1992, J VIROL, V66, P3485, DOI 10.1128/JVI.66.6.3485-3493.1992; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Tan MJA, 2012, P NATL ACAD SCI USA, V109, pE1473, DOI 10.1073/pnas.1205991109; Tommasino M, 2014, SEMIN CANCER BIOL, V26, P13, DOI 10.1016/j.semcancer.2013.11.002; Torres M, 2015, J CLIN VIROL, V67, P47, DOI 10.1016/j.jcv.2015.04.005; Underbrink MP, 2008, J VIROL, V82, P10408, DOI 10.1128/JVI.00902-08; Van Doorslaer K, 2013, NUCLEIC ACIDS RES, V41, pD571, DOI 10.1093/nar/gks984; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Viarisio D., 2016, J INVEST DERMATOL; Viarisio D, 2016, CANCER RES, V76, P4216, DOI 10.1158/0008-5472.CAN-16-0370; Viarisio D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002125; Wallace NA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004687; Wallace NA, 2014, J VIROL, V88, P6112, DOI 10.1128/JVI.03808-13; Wallace NA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002807; Waterboer T, 2008, BRIT J DERMATOL, V159, P457, DOI 10.1111/j.1365-2133.2008.08621.x; Weissenborn SJ, 2005, J INVEST DERMATOL, V125, P93, DOI 10.1111/j.0022-202X.2005.23733.x; White EA, 2014, J VIROL, V88, P8201, DOI 10.1128/JVI.01197-14; White EA, 2012, J VIROL, V86, P13174, DOI 10.1128/JVI.02172-12; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yamasaki S, 2007, J CELL BIOL, V177, P637, DOI 10.1083/jcb.200702081; YAMASHITA T, 1993, ONCOGENE, V8, P2433; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; Zwerschke W, 1996, ONCOGENE, V12, P213	138	81	86	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0168-1702	1872-7492		VIRUS RES	Virus Res.	MAR 2	2017	231				SI		128	138		10.1016/j.virusres.2016.11.013			11	Virology	Science Citation Index Expanded (SCI-EXPANDED)	Virology	EP0KT	WOS:000397076900015	27856220				2022-02-25	
J	Lauby-Secretan, B; Loomis, D; Baan, R; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Grosse, Y; Straif, K				Lauby-Secretan, Beatrice; Loomis, Dana; Baan, Robert; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Grosse, Yann; Straif, Kurt			Use of mechanistic data in the IARC evaluations of the carcinogenicity of polychlorinated biphenyls and related compounds	ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH			English	Article						Hazard identification; Carcinogenicity; Epidemiology; Cancer bioassays; Genotoxicity; Receptor-mediated effects	PCB MIXTURES; EXPOSURE; CONGENERS	The IARC Monographs are a series of scientific reviews that identify environmental factors that can increase the risk of cancer in humans. In its first part, the principles and procedures of the IARC Monographs evaluations are summarized. In a second part, we present the most recent IARC evaluation of polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs), performed in February 2013: PCBs and dioxin-like PCBs were both classified into group 1 "carcinogens," while PBBs were evaluated as "probably carcinogenic to humans" (group 2A). Noteworthy is that the relative contributions of different PCB congeners to the carcinogenicity of PCB mixtures are not known. The use of mechanistic data for the classification into a higher category is discussed in the context of the history of the consecutive evaluations of several related polychlorinated compounds.	[Lauby-Secretan, Beatrice; Loomis, Dana; Baan, Robert; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Grosse, Yann; Straif, Kurt] Int Agcy Res Canc, Sect IARC Monographs, F-69372 Lyon 08, France		Lauby-Secretan, B (corresponding author), Int Agcy Res Canc, Sect IARC Monographs, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	secretanb@iarc.fr	Guha, Neela/AAG-3989-2021; Loomis, Dana/AAE-3988-2019	Guha, Neela/0000-0003-3991-4662; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Loomis, Dana/0000-0003-3297-5200			Althouse R, 1979, IARC Monogr Eval Carcinog Risk Chem Hum Suppl, P1; [Anonymous], 1987, IARC Monogr Eval Carcinog Risks Hum Suppl, V7, P1; BAHN AK, 1977, NEW ENGL J MED, V296, P108; BAHN AK, 1976, NEW ENGL J MED, V295, P450; Brown AP, 1998, TOXICOL SCI, V46, P308, DOI 10.1006/toxs.1998.2551; Cogliano VJ, 2008, ENVIRON MOL MUTAGEN, V49, P100, DOI 10.1002/em.20370; Cogliano VJ, 2004, ENVIRON HEALTH PERSP, V112, P1269, DOI 10.1289/ehp.6950; Crinnion WJ, 2011, ALTERN MED REV, V16, P5; DAVIS D, 1990, CHEMOSPHERE, V20, P1141, DOI 10.1016/0045-6535(90)90234-K; EFSA Panel on Biological Hazards, 2012, EFSA Journal, V10, P2724; Faust D, 2013, ARCH TOXICOL, V87, P681, DOI 10.1007/s00204-012-0979-z; Fucic A, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-S1-S8; Gallagher RP, 2011, INT J CANCER, V128, P1872, DOI 10.1002/ijc.25503; Grimm FA, 2015, CRIT REV TOXICOL, V28, P1; Hamers T, 2011, TOXICOL SCI, V121, P88, DOI 10.1093/toxsci/kfr043; Hennig B, 2002, INT J HYG ENVIR HEAL, V205, P95, DOI 10.1078/1438-4639-00134; Herrick RF, 2004, ENVIRON HEALTH PERSP, V112, P1051, DOI 10.1289/ehp.6912; IARC, 1974, IARC MONOGR EVAL CAR, V7, P261; IARC, 2012, IARC MONOGRAPHS EVAL, V100, P9; IARC, 2006, PREAMBL IARC MON; IARC, 2015, IARC MONOGR EVAL CAR, V107; [IARC] International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V41, P261; IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, 1978, IARC MONOGR EVAL CAR, V18, P1; Lauby-Secretan B, 2013, LANCET ONCOL, V14, P287, DOI 10.1016/S1470-2045(13)70104-9; Loomis D, 1997, OCCUP ENVIRON MED, V54, P720, DOI 10.1136/oem.54.10.720; Ludewig G, 2013, CANCER LETT, V334, P46, DOI 10.1016/j.canlet.2012.11.041; Martinez JM, 2005, ENVIRON HEALTH PERSP, V113, P1022, DOI 10.1289/ehp.7735; Mayes BA, 1998, TOXICOL SCI, V41, P62; Narayanan PK, 1998, J LEUKOCYTE BIOL, V63, P216, DOI 10.1002/jlb.63.2.216; National Toxicology Program, 2006, Natl Toxicol Program Tech Rep Ser, P1; National Toxicology Program, 1993, Natl Toxicol Program Tech Rep Ser, V398, P1; National Toxicology Program, 2010, Natl Toxicol Program Tech Rep Ser, P1; National Toxicology Program, 2006, Natl Toxicol Program Tech Rep Ser, P4; National Toxicology Program, 2006, Natl Toxicol Program Tech Rep Ser, P4; National Toxicology Program, 2006, Natl Toxicol Program Tech Rep Ser, P1; NTP, 2011, REP CARCINOG, V12, P349; NTP, 1978, DHEW PUBL, P1; SAFE S, 1975, J AGR FOOD CHEM, V23, P851, DOI 10.1021/jf60201a039; Sartor MA, 2009, ENVIRON HEALTH PERSP, V117, P1139, DOI 10.1289/ehp.0800485; Schlezinger JJ, 2006, AQUAT TOXICOL, V77, P422, DOI 10.1016/j.aquatox.2006.01.012; SILBERHORN EM, 1990, CRIT REV TOXICOL, V20, P439, DOI 10.3109/10408449009029331; SILKWORTH JB, 1982, TOXICOL APPL PHARM, V65, P109, DOI 10.1016/0041-008X(82)90368-4; UNEP, 2009, BUILD CLIM CHANG SUM, P1; Van den Berg M, 2006, TOXICOL SCI, V93, P223, DOI 10.1093/toxsci/kfl055	44	43	45	1	24	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0944-1344	1614-7499		ENVIRON SCI POLLUT R	Environ. Sci. Pollut. Res.	FEB	2016	23	3					2220	2229		10.1007/s11356-015-4829-4			10	Environmental Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology	DB2YO	WOS:000368376800025	26077316				2022-02-25	
J	de Martel, C; Forman, D; Plummer, M				de Martel, Catherine; Forman, David; Plummer, Martyn			Gastric Cancer Epidemiology and Risk Factors	GASTROENTEROLOGY CLINICS OF NORTH AMERICA			English	Article						Gastric cancer; Epidemiology; Risk factors; Helicobacter; Cardia; Noncardia	HELICOBACTER-PYLORI INFECTION; POPULATION-BASED COHORT; ENDOSCOPIC RESECTION; CAGA SEROPOSITIVITY; PHYSICAL-ACTIVITY; ALCOHOL-DRINKING; DIETARY SALT; BODY-MASS; ADENOCARCINOMA; METAANALYSIS	Gastric cancer is one of the major malignancies in the world. This article summarizes the current understanding of the worldwide burden of this disease, its geographic variation, and temporal trends. An overview is presented of known risk factors, including genetic, dietary, and behavioral, but focuses on Helicobacter pylori infection as the most important factor in noncardia gastric cancer. When the data and the literature allow, we distinguish between cardia and noncardia. sub-sites, as it is now clear that these two anatomic locations present distinct and sometimes opposite epidemiological characteristics.	[de Martel, Catherine; Forman, David; Plummer, Martyn] Int Agcy Res Canc, F-69372 Lyon 08, France		Forman, D (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	formanD@iarc.fr		Plummer, Martyn/0000-0001-5130-6497			Annibale B, 2000, DIGEST LIVER DIS, V32, P756, DOI 10.1016/S1590-8658(00)80351-5; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1; Botterweck AAM, 2000, INT J EPIDEMIOL, V29, P645, DOI 10.1093/ije/29.4.645; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Brenner H, 2004, AM J EPIDEMIOL, V159, P252, DOI 10.1093/aje/kwh039; Brenner H, 2002, INT J CANCER, V98, P446, DOI 10.1002/ijc.10201; Chun N, 2012, CANCER J, V18, P355, DOI 10.1097/PPO.0b013e31826246dc; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; D'Elia L, 2012, CLIN NUTR, V31, P489, DOI 10.1016/j.clnu.2012.01.003; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; FERLAY J, 2010, IARC CANCERBASE; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fitzgerald RC, 2010, J MED GENET, V47, P436, DOI 10.1136/jmg.2009.074237; FORMAN D, 1993, LANCET, V341, P1359; Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9; Ge S, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/808120; Gonzalez CA, 2012, ANN ONCOL, V23, P1320, DOI 10.1093/annonc/mdr384; Gonzalez CA, 2006, INT J CANCER, V118, P2559, DOI 10.1002/ijc.21678; Gonzalez CA, 2011, AM J GASTROENTEROL, V106, P867, DOI 10.1038/ajg.2011.1; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HAENSZEL W, 1969, INT J CANCER, V4, P364, DOI 10.1002/ijc.2910040313; Hemminki K, 2003, INT J CANCER, V105, P692, DOI 10.1002/ijc.11150; Herrera V, 2009, CLIN MICROBIOL INFEC, V15, P971, DOI 10.1111/j.1469-0691.2009.03031.x; Huang JQ, 2003, GASTROENTEROLOGY, V125, P1636, DOI 10.1053/j.gastro.2003.08.033; Humans I.W.G.o.t.E.o.C.R.t., 2012, IARC MONOGR, V100, P1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P7; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010, IARC MONOG EVAL CARC, V96, P1; Jenab M, 2006, CARCINOGENESIS, V27, P2250, DOI 10.1093/carcin/bgl096; Joossens JV, 1996, INT J EPIDEMIOL, V25, P494, DOI 10.1093/ije/25.3.494; Kamineni A, 1999, CANCER CAUSE CONTROL, V10, P77, DOI 10.1023/A:1008849014992; Kuriyama S, 2005, INT J CANCER, V113, P148, DOI 10.1002/ijc.20529; Ladeiras-Lopes R, 2008, CANCER CAUSE CONTROL, V19, P689, DOI 10.1007/s10552-008-9132-y; Leitzmann MF, 2009, AM J PREV MED, V36, P112, DOI 10.1016/j.amepre.2008.09.033; Leivonen M, 1997, ANTICANCER RES, V17, P3893; Lukanova A, 2006, INT J CANCER, V118, P458, DOI 10.1002/ijc.21354; Lunet N, 2007, EUR J CANCER PREV, V16, P312, DOI 10.1097/01.cej.0000236255.95769.22; Ma JL, 2012, J NATL CANCER I, V104, P488, DOI 10.1093/jnci/djs003; Maehata Y, 2012, GASTROINTEST ENDOSC, V75, P39, DOI 10.1016/j.gie.2011.08.030; McColl KEL, 2010, GUT, V59, P282, DOI 10.1136/gut.2009.186825; Mezhir JJ, 2011, ANN SURG ONCOL, V18, P670, DOI 10.1245/s10434-010-1425-1; Mitchell H, 2008, ALIMENT PHARM THER, V28, P903, DOI 10.1111/j.1365-2036.2008.03792.x; Nagel G, 2007, INT J EPIDEMIOL, V36, P66, DOI 10.1093/ije/dyl275; PALLI D, 1994, CANCER EPIDEM BIOMAR, V3, P15; Parkin DM, 2010, INT J CANCER, V127, P2918, DOI 10.1002/ijc.25517; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; Peleteiro B, 2011, BRIT J CANCER, V104, P198, DOI 10.1038/sj.bjc.6605993; Plummer M, 2007, J NATL CANCER I, V99, P1328, DOI 10.1093/jnci/djm120; Power C, 2005, AM J PUBLIC HEALTH, V95, P1396, DOI 10.2105/AJPH.2004.047340; Ren JS, 2012, CANCER EPIDEM BIOMAR, V21, P905, DOI 10.1158/1055-9965.EPI-12-0202; Roesler Bruna Maria, 2012, ISRN Gastroenterol, V2012, P935410, DOI 10.5402/2012/935410; Rothenbacher D, 1999, J INFECT DIS, V179, P398, DOI 10.1086/314595; Sauvaget C, 2005, CANCER CAUSE CONTROL, V16, P773, DOI 10.1007/s10552-005-5385-x; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; Shikata K, 2006, INT J CANCER, V119, P196, DOI 10.1002/ijc.21822; Siman JH, 2007, SCAND J GASTROENTERO, V42, P933, DOI 10.1080/00365520601173863; Siman JH, 1997, SCAND J GASTROENTERO, V32, P1215, DOI 10.3109/00365529709028150; Sipponen Pentti, 2002, Gastric Cancer, V5, P213, DOI 10.1007/s101200200037; Sjodahl K, 2008, CANCER EPIDEM BIOMAR, V17, P1997, DOI 10.1158/1055-9965.EPI-08-0238; Sjodahl K, 2008, CANCER EPIDEM BIOMAR, V17, P135, DOI 10.1158/1055-9965.EPI-07-0704; Tramacere I, 2012, ANN ONCOL, V23, P287, DOI 10.1093/annonc/mdr136; Tramacere I, 2012, ANN ONCOL, V23, P28, DOI 10.1093/annonc/mdr135; Uemura N, 1997, CANCER EPIDEM BIOMAR, V6, P639; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; Yang P, 2009, EUR J CANCER, V45, P2867, DOI 10.1016/j.ejca.2009.04.019; Zamora-Ros R, 2012, AM J CLIN NUTR, V96, P1398, DOI 10.3945/ajcn.112.037358	68	256	265	5	62	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0889-8553	1558-1942		GASTROENTEROL CLIN N	Gastroenterol. Clin. North Am.	JUN	2013	42	2					219	+		10.1016/j.gtc.2013.01.003			23	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	153UJ	WOS:000319627700003	23639638		Y	N	2022-02-25	
J	Plummer, M				Plummer, Martyn			Portable C plus plus for R Packages	R JOURNAL			English	Article								Package checking errors are more common on Solaris than Linux. In many cases, these errors are due to non-portable C++ code. This article reviews some commonly recurring problems in C++ code found in R packages and suggests solutions.	Int Agcy Res Canc, F-69372 Lyon 08, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	plummerM@iarc.fr					Eddelbuettel D, 2011, J STAT SOFTW, V40, P1; JTC1/SC22/WG21-The C++ Standards Committee, 2011, TECHNICAL REPORT; Pemstein D, 2011, J STAT SOFTW, V42, P1	3	0	0	0	0	R FOUNDATION STATISTICAL COMPUTING	WIEN	WIRTSCHAFTSUNIVERSITAT, INST STATISTICS & MATHEMATICS, AUGASSE 2-6, WIEN, 1090, AUSTRIA	2073-4859			R J	R Journal	DEC	2011	3	2					60	63					4	Computer Science, Interdisciplinary Applications; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Mathematics	V27CB	WOS:000208590200011					2022-02-25	
J	Boffetta, P				Boffetta, Paolo			Integrating biomarkers, epidemiology and clinic	CANCER RESEARCH			English	Meeting Abstract									[Boffetta, Paolo] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	MAY 1	2009	69			9		SY37-3							2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	V43ST	WOS:000209701800049					2022-02-25	
J	De Vuyst, H; Franceschi, S				De Vuyst, Hugo; Franceschi, Silvia			Human papillomavirus vaccines in HIV-positive men and women	CURRENT OPINION IN ONCOLOGY			English	Review						anogenital cancers; HIV; human papillomavirus; vaccines	SQUAMOUS INTRAEPITHELIAL LESIONS; ACTIVE ANTIRETROVIRAL THERAPY; CERVICAL-CANCER; IMMUNE-RESPONSES; PARTICLE VACCINE; ANAL CANCER; SUSTAINED EFFICACY; ADVISORY-COMMITTEE; INFECTED PERSONS; HIGH PREVALENCE	Purpose of review Individuals with HIV are at greater risk of human papillornavirus-related cancers. This report will assess the potential and limitations of vaccines against human papillornavirus in HIV-positive individuals. Recent findings A worldwide meta-analysis of published data established the under-representation of HPV1 6, and increased prevalence of multiple-type human papillornavirus infections in HIV-positive women. Associations between HIV-related immunodepression, the progression of human papillomavirus infection to cervical lesions, and an increased risk of cervical cancer in women with HIV have also been shown. An increased incidence of human papillomavirus infection in anal and vulvar/vaginal neoplasia has been reported in individuals with HIV. A prophylactic vaccine against ll 11, 16 and 18 has been licensed, and one against HPV16 and 18 is under evaluation. Both have shown efficacy against persistent infection, as well as related human papillornavirus cervical lesions for up to 5 years. Preliminary results have also been reported on therapeutic vaccines, notably for the treatment of cervical intraepithelial neoplasia grades 2 and 3. Summary The safety and efficacy of human papillornavirus vaccines in individuals with HIV need to be assessed to prevent cervical cancer in current and future generations. Screening for human papillornavirus-related cancer among HIV patients should be undertaken.	Int Agcy Res Canc, F-69372 Lyon 08, France		De Vuyst, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	devuysth@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Block SL, 2006, PEDIATRICS, V118, P2135, DOI 10.1542/peds.2006-0461; Bower M, 2004, JAIDS-J ACQ IMM DEF, V37, P1563, DOI 10.1097/00126334-200412150-00004; Chiao EY, 2006, CLIN INFECT DIS, V43, P223, DOI 10.1086/505219; Chin-Hong Peter V, 2005, Dermatol Ther, V18, P67, DOI 10.1111/j.1529-8019.2005.05009.x; Ching N, 2007, EUR J PEDIATR, V166, P51, DOI 10.1007/s00431-006-0184-2; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Conley LJ, 2002, LANCET, V359, P108, DOI 10.1016/S0140-6736(02)07368-3; Cooper CL, 2005, AIDS, V19, P1473, DOI 10.1097/01.aids.0000183514.37513.d2; Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365; Delmas MC, 2000, AIDS, V14, P1775, DOI 10.1097/00002030-200008180-00013; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; Fagan SP, 2005, AM J SURG, V190, P732, DOI 10.1016/j.amjsurg.2005.07.011; Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Fonseca MO, 2005, VACCINE, V23, P2902, DOI 10.1016/j.vaccine.2004.11.057; Franceschi S, 1998, BRIT J CANCER, V78, P966, DOI 10.1038/bjc.1998.610; FRANCESCHI S, IN PRESS CLIN INFECT; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; Frisch M, 1997, NEW ENGL J MED, V337, P1350, DOI 10.1056/NEJM199711063371904; Garcia F, 2004, OBSTET GYNECOL, V103, P317, DOI 10.1097/01.AOG.0000110246.93627.17; Garcia-Hernandez E, 2006, CANCER GENE THER, V13, P592, DOI 10.1038/sj.cgt.7700937; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583; Hampl M, 2006, OBSTET GYNECOL, V108, P1361, DOI 10.1097/01.AOG.0000245786.86267.80; Hampl M, 2007, J CANCER RES CLIN, V133, P235, DOI 10.1007/s00432-006-0162-0; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Harris TG, 2005, JAMA-J AM MED ASSOC, V293, P1471, DOI 10.1001/jama.293.12.1471; Hasan UA, 2007, J IMMUNOL, V178, P3186, DOI 10.4049/jimmunol.178.5.3186; Hawes SE, 2006, J NATL CANCER I, V98, P100, DOI 10.1093/jnci/djj010; Heard I, 2004, ANTIVIR THER, V9, P13; Hessol NA, 2007, AM J EPIDEMIOL, V165, P1143, DOI 10.1093/aje/kwm017; *INT AG RES CANC, 1995, MON EV CARC RISKS HU, V64; Jamieson DJ, 2006, OBSTET GYNECOL, V107, P1023, DOI 10.1097/01.AOG.0000210237.80211.ff; Kadish AS, 2002, CANCER EPIDEM BIOMAR, V11, P483; Kanodia S, 2007, CURR CANCER DRUG TAR, V7, P79, DOI 10.2174/156800907780006869; Koshiol JE, 2006, INT J CANCER, V119, P1623, DOI 10.1002/ijc.22015; Kreimer AR, 2005, INT J CANCER, V115, P329, DOI 10.1002/ijc.20872; Kroger Andrew T., 2006, Morbidity and Mortality Weekly Report, V55, P1; Lenz P, 2005, EUR J IMMUNOL, V35, P1548, DOI 10.1002/eji.200425547; Leroy V, 1999, SEX TRANSM INFECT, V75, P103, DOI 10.1136/sti.75.2.103; Maiman M, 1998, J Natl Cancer Inst Monogr, P43; Massad LS, 2001, J ACQ IMMUN DEF SYND, V27, P432, DOI 10.1097/00126334-200108150-00003; Mbulaiteye SM, 2006, INT J CANCER, V118, P985, DOI 10.1002/ijc.21443; Molano M, 2003, AM J EPIDEMIOL, V158, P486, DOI 10.1093/aje/kwg171; Moscicki AB, 1999, PEDIATR CLIN N AM, V46, P783, DOI 10.1016/S0031-3955(05)70152-8; Natale C, 2000, IMMUNOL CELL BIOL, V78, P580, DOI 10.1046/j.1440-1711.2000.00949.x; *NVENT BIOPH CORP, 2007, NVENT ANN PRES POS H; Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226; Palefsky JM, 2006, VACCINE, V24, P140, DOI 10.1016/j.vaccine.2006.05.120; Palefsky JM, 2006, AIDS, V20, P1151, DOI 10.1097/01.aids.0000226955.02719.26; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Piersma SJ, 2007, CANCER RES, V67, P354, DOI 10.1158/0008-5472.CAN-06-3388; Piketty C, 2003, ANN INTERN MED, V138, P453, DOI 10.7326/0003-4819-138-6-200303180-00008; Saslow D, 2007, CA-CANCER J CLIN, V57, P7, DOI 10.3322/canjclin.57.1.7; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002; Shuman CF, 2003, ANTIVIR RES, V58, P235, DOI 10.1016/S0166-3542(03)00002-0; Sin JI, 2006, DNA CELL BIOL, V25, P277, DOI 10.1089/dna.2006.25.277; Sirera G, 2006, AIDS, V20, P1201, DOI 10.1097/01.aids.0000226963.10342.f4; Sitas F, 2000, INT J CANCER, V88, P489, DOI 10.1002/1097-0215(20001101)88:3&lt;489::AID-IJC25&gt;3.0.CO;2-Q; Six C, 1998, AIDS, V12, P1047, DOI 10.1097/00002030-199809000-00012; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Stanley M, 2006, VACCINE, V24, P16, DOI 10.1016/j.vaccine.2005.09.002; Strickler HD, 2003, JNCI-J NATL CANCER I, V95, P1062, DOI 10.1093/jnci/95.14.1062; Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073; Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222; Temmerman M, 1999, INT J GYNECOL OBSTET, V65, P171, DOI 10.1016/S0020-7292(99)00043-0; Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469	68	12	12	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-8746	1531-703X		CURR OPIN ONCOL	Curr. Opin. Oncol.	SEP	2007	19	5					470	475		10.1097/CCO.0b013e3282c8c8fc			6	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	201NA	WOS:000248837400009	17762573				2022-02-25	
J	Clifford, G; Fronceschi, S				Clifford, Gary; Fronceschi, Silvia			Immunity, infection, and cancer	LANCET			English	Editorial Material							HUMAN-PAPILLOMAVIRUS; HIV; IMMUNODEFICIENCY; COHORT; VIRUS; RISK		Int Agcy Res Canc, F-69372 Lyon 08, France		Clifford, G (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	clifford@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Galceran J, 2007, EUR J CANCER, V43, P1085, DOI 10.1016/j.ejca.2007.01.028; Giordano TP, 2004, ARCH INTERN MED, V164, P2349, DOI 10.1001/archinte.164.21.2349; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; IARC, 1996, MON EV CARC RISKS HU, V67; Mbulaiteye SM, 2006, INT J CANCER, V118, P985, DOI 10.1002/ijc.21443; Serraino D, 2005, BRIT J CANCER, V92, P572, DOI 10.1038/sj.bjc.6602346; Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073	12	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 7	2007	370	9581					6	7		10.1016/S0140-6736(07)61023-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187QE	WOS:000247862300005	17617251				2022-02-25	
J	Boffetta, P				Boffetta, Paolo			Endotoxins in lung cancer prevention	JOURNAL OF THE NATIONAL CANCER INSTITUTE			English	Editorial Material									Int Agcy Res Canc, Gene Environm Epidemiol Grp, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, Gene Environm Epidemiol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr					Astrakianakis G, 2007, JNCI-J NATL CANCER I, V99, P357, DOI 10.1093/jnci/djk063; *IARC, 2004, IARC MON EV CARC RIS, V83, P51; *IARC, 1998, IARC HDB CANC PREV, V2; Lee DJ, 2004, J OCCUP ENVIRON MED, V46, P538, DOI 10.1097/01.jom.0000128152.01896.ae; Mastrangelo G, 2002, TOXICOL IND HEALTH, V18, P171, DOI 10.1191/0748233702th139rr	5	3	3	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0027-8874			J NATL CANCER I	J. Natl. Cancer Inst.	MAR 7	2007	99	5					339	339		10.1093/jnci/djk084			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	145PV	WOS:000244877900001	17341719	Bronze			2022-02-25	
J	Boyle, P				Boyle, Peter			The globalisation of cancer	LANCET			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610			Doll R, 1966, CANC INCIDENCE 5 CON; Ferlay J, 2004, GLOBOCAN 2002 CANC I; *INT AG RES CANC, 2004, MON EV CARC RISKS HU, V83; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; United Nations, 2005, MILL DEV GOALS REP 2	5	37	40	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 19	2006	368	9536					629	630		10.1016/S0140-6736(06)69225-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	074YT	WOS:000239849200009	16920452				2022-02-25	
J	Cogliano, VJ; Baan, RA; Straif, K; Grosse, Y; Secretan, B; El Ghissassi, F				Cogliano, V. J.; Baan, R. A.; Straif, K.; Grosse, Y.; Secretan, B.; El Ghissassi, F.			The use of mechanistic data in IARC evaluations.	ENVIRONMENTAL AND MOLECULAR MUTAGENESIS			English	Meeting Abstract	37th Annual Meeting of the Environmental-Mutagen-Society	SEP 16-20, 2006	Vancouver, CANADA	Environm Mutagen Soc					Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	1	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0893-6692			ENVIRON MOL MUTAGEN	Environ. Mol. Mutagen.	JUL	2006	47	6					401	401					1	Environmental Sciences; Genetics & Heredity; Toxicology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Genetics & Heredity; Toxicology	072BP	WOS:000239647900007					2022-02-25	
J	Ohgaki, H				Ohgaki, H			Genetic pathways to glioblastomas	NEUROPATHOLOGY			English	Review						primary glioblastoma; secondary glioblastoma; LOH 10q; TP53 mutations; EGFR amplification; PTEN mutation; p16(INK4a) deletion	GROWTH-FACTOR-RECEPTOR; PRIMARY DE-NOVO; ASTROCYTIC BRAIN-TUMORS; DNA-REPAIR GENE; SECONDARY GLIOBLASTOMAS; MALIGNANT GLIOMAS; P53 MUTATIONS; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER HYPERMETHYLATION; HOMOZYGOUS DELETION	Glioblastomas, the most frequent and malignant human brain tumors, may develop de novo (primary glioblastoma) or by progression from low-grade or anaplastic astrocytoma (secondary glioblastoma). These glioblastoma subtypes constitute distinct disease entities that affect patients of different ages and develop through different genetic pathways. Our recent population-based study in the Canton of Zurich, Switzerland, shows that primary glioblastomas develop in older patients (mean age, 62 years) and typically show LOH on chromosome 10q (69%) and other genetic alterations (EGFR amplification, TP53 mutations, p16(INK4a) deletion, and PTEN mutations) at frequencies of 24-34%. Secondary glioblastomas develop in younger patients (mean, 45 years) and frequently show TP53 mutations (65%) and LOH 10q (63%). Common to both primary and secondary glioblastoma is LOH on 10q, distal to the PTEN locus; a putative suppressor gene at 10q25-qter may be responsible for the glioblastoma phenotype. Of the TP53 point mutations in secondary glioblastomas, 57% were located in hotspot codons 248 and 273, while in primary glioblastomas, mutations were more widely distributed. Furthermore, G:C-->A:T mutations at CpG sites were more frequent in secondary than in primary glioblastomas (56% vs 30%). These data suggest that the TP53 mutations in these glioblastoma subtypes arise through different mechanisms. There is evidence that G:C-->A:T transition mutations at CpG sites in the TP53 gene are significantly more frequent in low-grade astrocytomas with promoter methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene than in those without methylation. This suggests that, in addition to deamination of 5-methylcytosine (the best known mechanism of formation of G:C-->A:T transitions at CpG sites), involvement of alkylating agents that produce O-6-methylguanine or related adducts recognized by MGMT cannot be excluded in the pathway leading to secondary glioblastomas.	Int Agcy Res Canc, F-69372 Lyon, France		Ohgaki, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	ohgaki@iarc.fr					Afra D, 2002, LANCET, V359, P1011; Backlund LM, 2003, CLIN CANCER RES, V9, P4151; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Batchelor TT, 2004, CLIN CANCER RES, V10, P228, DOI 10.1158/1078-0432.CCR-0841-3; Belanich M, 1996, CANCER RES, V56, P783; BENTIVEGNA SS, 1994, CANCER RES, V54, P327; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; Biernat W, 1997, J NEUROPATH EXP NEUR, V56, P180, DOI 10.1097/00005072-199702000-00009; Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Esteller M, 1999, CANCER RES, V59, P793; Frederick L, 2000, NEURO-ONCOLOGY, V2, P159, DOI 10.1093/neuonc/2.3.159; Frederick L, 2000, CANCER RES, V60, P1383; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Fujisawa H, 2000, LAB INVEST, V80, P65, DOI 10.1038/labinvest.3780009; Fults D, 1998, INT J ONCOL, V12, P905; GOTH R, 1974, P NATL ACAD SCI USA, V71, P639, DOI 10.1073/pnas.71.3.639; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Huncharek M, 2000, ONCOL RES, V12, P107, DOI 10.3727/096504001108747576; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; Kamiryo T, 2002, J NEUROSURG, V96, P815, DOI 10.3171/jns.2002.96.5.0815; KARLBOM AE, 1993, HUM GENET, V92, P169; Kleihues P, 2000, TOXICOL PATHOL, V28, P164, DOI 10.1177/019262330002800121; KLEIHUES P, 1984, PROG EXP TUMOR RES, V27, P1; Kleihues P, 2000, WHO CLASSIFICATION T; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Knobbe CB, 2002, NEURO-ONCOLOGY, V4, P196; Labuhn M, 2001, ONCOGENE, V20, P1103, DOI 10.1038/sj.onc.1204197; MARGISON GP, 1975, BIOCHEM J, V148, P521, DOI 10.1042/bj1480521; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213; Nakamura M, 2001, BRAIN PATHOL, V11, P159; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; OHGAKI H, 2001, PROGNOSTIC FACTORS C, P725; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Qian XLC, 1997, CANCER RES, V57, P3672; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; RASHEED BKA, 1995, ONCOGENE, V10, P2243; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; SCHWECHHEIMER K, 1995, INT J CANCER, V62, P145, DOI 10.1002/ijc.2910620206; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shinojima N, 2003, CANCER RES, V63, P6962; Simmons ML, 2001, CANCER RES, V61, P1122; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tada K, 2001, J NEUROSURG, V95, P651, DOI 10.3171/jns.2001.95.4.0651; Terada K, 2002, J NEURO-ONCOL, V58, P107, DOI 10.1023/A:1016017711033; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; TORP SH, 1992, ACTA NEUROCHIR, V117, P182, DOI 10.1007/BF01400618; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Wikstrand CJ, 1998, J NEUROVIROL, V4, P148, DOI 10.3109/13550289809114515; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	63	163	169	0	9	BLACKWELL PUBLISHING ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0919-6544			NEUROPATHOLOGY	Neuropathology	MAR	2005	25	1					1	7		10.1111/j.1440-1789.2004.00600.x			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	899VW	WOS:000227174900001	15822813				2022-02-25	
J	Kaaks, R				Kaaks, R			Obesity, insulin resistance, and cancer.	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Meeting Abstract	3rd Annual AACR International Conference	OCT 16-20, 2004	Seattle, WA	AACR					Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965			CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	NOV	2004	13	11	2				1950S	1950S					1	Oncology; Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	870QO	WOS:000225073100425					2022-02-25	
J	Lambert, R				Lambert, R			Diagnosis of esophagogastric tumors	ENDOSCOPY			English	Review							HIGH-GRADE DYSPLASIA; INTESTINAL METAPLASIA; BARRETTS-ESOPHAGUS; MAGNIFICATION CHROMOENDOSCOPY; FLUORESCENCE SPECTROSCOPY; METHYLENE-BLUE; GASTRIC CARDIA; ENDOSCOPY; JUNCTION; CANCER	Esophagogastric tumors occur in three sectors: the esophagus, the EG junction and the non-cardia stomach. Neoplasia develops in the squamous stratified epithelium of the esophagus and in the columnar epithelium of the Barrett's esophagus or in the stomach. At the EG junction, tumors arise either in a very short Barrett's esophagus or in the gastric epithelium of the cardia. The prognosis of tumors detected at the advanced stage is poor. Secondary prevention requires detection at the early stage. Most superficial neoplastic lesions in the esophagus and in the stomach have a non-protruding appearance, which is similar for premalignant and malignant lesions. Improved accuracy in endoscopic diagnosis and prediction of histology prior to biopsy and treatment decision is based upon magnification with a optical zoom and electronic processing of the captured image with structure enhancement, enhancement of the color of hemoglobin and narrow band imaging. This applies particularly to the exploration of the Barrett's esophagus for identification of the areas with intestinal metaplasia and of flat neoplastic areas. in spite of the predictive value of endoscopy for histology, biopsy samples are still required for pathology and eventually studies with biological markers. Spectroscopic techniques provide a new perspective, up to the level of molecular endoscopy, but they are unlikely to be cost/effective. The classification in the sub-types 0 of neoplastic lesions has some relevance to prediction of depth of invasion. In the esophagus, EUS staging with high frequency miniprobes is a useful complement.	Int Agcy Res Canc, F-69372 Lyon 8, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 8, France.	lambert@iarc.fr					Brand S, 2002, GASTROINTEST ENDOSC, V56, P479, DOI 10.1067/mge.2002.128172; Cameron AJ, 2002, AM J GASTROENTEROL, V97, P1375, DOI 10.1016/S0002-9270(02)04025-X; Cilesiz I, 2002, GASTROINTEST ENDOSC, V56, P852, DOI 10.1016/S0016-5107(02)70359-3; Connor Michael J, 2003, Gastrointest Endosc Clin N Am, V13, P269; Dar MS, 2003, GUT, V52, P486, DOI 10.1136/gut.52.4.486; Dinis-Ribeiro M, 2003, GASTROINTEST ENDOSC, V57, P498, DOI 10.1067/mge.2003.145; Dixon MF, 2002, GUT, V51, P130, DOI 10.1136/gut.51.1.130; Ell C, 2003, GUT, V52, P30; Endo T, 2002, GASTROINTEST ENDOSC, V55, P641, DOI 10.1067/mge.2002.123420; Fennerty M Brian, 2003, Gastrointest Endosc Clin N Am, V13, P257, DOI 10.1016/S1052-5157(03)00010-2; Fockens P, 2002, BEST PRACT RES CL GA, V16, P999, DOI 10.1053/bega.2002.0337; Georgakoudi Irene, 2003, Gastrointest Endosc Clin N Am, V13, P297, DOI 10.1016/S1052-5157(03)00008-4; Guelrud M, 2002, AM J GASTROENTEROL, V97, P584; Haringsma J, 2002, SCAND J GASTROENTERO, V37, P9, DOI 10.1080/003655202320621382; Hunerbein M, 2003, SURG ENDOSC, V17, P615, DOI 10.1007/s00464-002-8622-3; Ichikura T, 2003, WORLD J SURG, V27, P334, DOI 10.1007/s00268-002-6776-8; Jenkins GJS, 2003, BRIT J CANCER, V88, P1271, DOI 10.1038/sj.bjc.6600891; Keller R, 2002, ENDOSCOPY, V34, P801, DOI 10.1055/s-2002-34254; Kendall C, 2003, J PATHOL, V200, P602, DOI 10.1002/path.1376; Kiesslich R, 2002, ENDOSCOPY, V34, P819, DOI 10.1055/s-2002-34259; Kodama M, 1998, SURGERY, V123, P432, DOI 10.1067/msy.1998.86778; Kouklakis GS, 2003, ENDOSCOPY, V35, P383, DOI 10.1055/s-2003-38768; Kumagai Y, 2002, ENDOSCOPY, V34, P369, DOI 10.1055/s-2002-25285; Lambert R, 2003, GASTROINTEST ENDOSC, V58, pS1, DOI 10.1016/S0016-5107(03)02168-0; Lambert R, 2003, ENDOSCOPY, V35, P437, DOI 10.1055/s-2003-38766; Mahmood U, 2003, MOL CANCER THER, V2, P489; Mataki N, 2003, GASTROINTEST ENDOSC, V57, P336, DOI 10.1067/mge.2003.133; Messmann H, 2002, DIGEST LIVER DIS, V34, P754, DOI 10.1016/S1590-8658(02)80028-7; Morales CP, 2003, AM J GASTROENTEROL, V98, P759, DOI [10.1016/S0002-9270(03)00057-1, 10.1111/j.1572-0241.2003.07393.x]; Moreto M, 2003, ENDOSCOPY, V35, P36, DOI 10.1055/s-2003-36398; Murata Y, 2003, ENDOSCOPY, V35, P429, DOI 10.1055/s-2003-38774; NAKAMURA K, 2002, DIGEST ENDOSC, V14, pS40, DOI DOI 10.1046/J.1443-1661.14.S1.12.X; Nakamura T, 2002, DIS ESOPHAGUS, V15, P219, DOI 10.1046/j.1442-2050.2002.00262.x; Olliver JR, 2003, LANCET, V362, P373, DOI 10.1016/S0140-6736(03)14026-3; Ortner MAEJ, 2003, GUT, V52, P28, DOI 10.1136/gut.52.1.28; Owens Michael M, 2003, Gastrointest Endosc Clin N Am, V13, P325, DOI 10.1016/S1052-5157(03)00014-X; Pfefer TJ, 2003, LASER SURG MED, V32, P10, DOI 10.1002/lsm.10136; Poneros John M, 2003, Gastrointest Endosc Clin N Am, V13, P309, DOI 10.1016/S1052-5157(03)00012-6; Reid Brian J, 2003, Gastrointest Endosc Clin N Am, V13, P369, DOI 10.1016/S1052-5157(03)00006-0; Sabet EA, 2002, ABDOM IMAGING, V28, P252, DOI 10.1007/s00261-002-0035-1; Sharma P, 2003, GUT, V52, P24, DOI 10.1136/gut.52.1.24; Spechler SJ, 2003, J CLIN GASTROENTEROL, V36, pS2, DOI 10.1097/00004836-200305001-00002; Tajiri H, 2002, ENDOSCOPY, V34, P772, DOI 10.1055/s-2002-34267; Taniere P, 2002, AM J SURG PATHOL, V26, P1213, DOI 10.1097/00000478-200209000-00012; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Wong Kee Song Louis-Michel, 2003, Gastrointest Endosc Clin N Am, V13, P279; YASUDA K, 2002, DIGEST ENDOSC, V14, pS18; Yoshida T, 2003, ENDOSCOPY, V35, P181, DOI 10.1055/s-2003-37015; [No title captured], DOI DOI 10.1046/J.0915-5635.2002.00191.X]; 2002, J GASTROENTEROL MASS, V40, P57	50	16	21	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	FEB	2004	36	2					110	119		10.1055/s-2004-814178			10	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	769DC	WOS:000188610300002	14765308				2022-02-25	
J	Kleihues, P				Kleihues, P			Transparency at the International Agency for Research on Cancer (IARC)	LANCET			English	Letter									Int Agcy Res Canc, F-69008 Lyon, France		Kleihues, P (corresponding author), Int Agcy Res Canc, F-69008 Lyon, France.						Drazen JM, 2002, NEW ENGL J MED, V346, P1901, DOI 10.1056/NEJMe020074; James A, 2003, LANCET, V361, P8, DOI 10.1016/S0140-6736(03)12184-8; 2003, LANCET, V361, P189	3	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 1	2003	361	9359					781	781		10.1016/S0140-6736(03)12634-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649WY	WOS:000181232000024	12620755				2022-02-25	
J	Lambert, R				Lambert, R			Treatment of esophagogastric tumors	ENDOSCOPY			English	Review							ENDOSCOPIC MUCOSAL RESECTION; GASTRIC OUTLET OBSTRUCTION; EXPANDABLE METAL STENTS; PALLIATIVE TREATMENT; PHOTODYNAMIC THERAPY; ESOPHAGEAL-CARCINOMA; INJECTION; CANCER; TERM; ADENOCARCINOMA	Esophageal and gastric tumors are often considered as a single group: they share similar symptoms - upper GI encloscopy with a flexible video-endoscope is the gold standard procedure of detection - similar techniques of endotherapy for cure or palliation are offered for both types of tumors. When the endoscopic procedure is performed for a superficial cancer or its precursors, with a curative intent, endoscopic mucosal resection (EMR) is generally preferred to mucosal ablation with a thermal (Nd:YAG) or non-thermal (photodynamic therapy) procedure. In addition to esophageal squamous cell cancer and gastric cancer, new indications of EMR arise in the Barrett esophagus, Guidelines for safe indications concern diameter, polypoid or non polypoid morphology with the subtypes elevated, flat and depressed, and depth of invasion. A superficial invasion in the sub-mucosa is a relative contra-indication in the esophagus, but not in the stomach. The technique of EMR is now codified with an injection into the submucosa for lifting the lesion and either suction with a cap, grasping with a forceps if a 2 channel instrument is used, or tissue incision with a needle knife. En bloc, gives better results than piecemeal resection. The most frequent complication is bleeding. When legitimate indications are respected, the results of EMR are equivalent to those of surgical resection and have reached the consensus level. The major indication in palliation is the relief of dysphagia from malignant esophageal obstruction. Increased indications are proposed for malignant pyloric obstruction. Multiple models of metal expandable and coated stents with appropriate balance between rigidity and flexibility (nitinol alloy) and enough expansive radial force are now offered. After stenting the survival period is short and there is a toll of complications.	Int Agcy Res Canc, F-69003 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69003 Lyon, France.	lambert@iarc.fr					Adler DG, 2002, AM J GASTROENTEROL, V97, P72; Ahmad NA, 2002, GASTROINTEST ENDOSC, V55, P390, DOI 10.1067/mge.2002.121881; Alexander P, 2002, GASTROINTEST ENDOSC, V55, P674, DOI 10.1067/mge.2002.123270; Amano Y, 1998, ENDOSCOPY, V30, P548, DOI 10.1055/s-2007-1001342; Ando N, 2002, ENDOSCOPY, V34, P667, DOI 10.1055/s-2002-33240; Aviv RI, 2002, CLIN RADIOL, V57, P587, DOI 10.1053/crad.2002.0934; Buttar NS, 2001, GASTROINTEST ENDOSC, V54, P682, DOI 10.1067/mge.2001.119875; Catalano F, 2002, ENDOSCOPY, V34, P582, DOI 10.1055/s-2002-33213; Conio M, 2002, GASTROINTEST ENDOSC, V56, P513, DOI 10.1067/mge.2002.128107; Conio M, 2001, ENDOSCOPY, V33, P791, DOI 10.1055/s-2001-16516; Dallal HJ, 2001, GASTROINTEST ENDOSC, V54, P549, DOI 10.1067/mge.2001.118947; Decker P, 2001, SURG ENDOSC-ULTRAS, V15, P1444, DOI 10.1007/s004640090099; Dormann AJ, 2001, Z GASTROENTEROL, V39, P957, DOI 10.1055/s-2001-18531; Espinel J, 2001, DIGEST DIS SCI, V46, P2322, DOI 10.1023/A:1012378509762; Goto H, 2002, GASTROINTEST ENDOSC, V56, P78, DOI 10.1067/mge.2002.125543; Hui Andrew, 2002, Australas Radiol, V46, P111, DOI 10.1046/j.1440-1673.2001.01007.x; Inoue H, 2002, J GASTROEN HEPATOL, V17, P382, DOI 10.1046/j.1440-1746.2002.02732.x; Javaid B, 2002, LASER MED SCI, V17, P51, DOI 10.1007/s10103-002-8266-5; Johnston SD, 2002, ULSTER MED J, V71, P30; KAMPLER JP, 2002, GASTROINTEST ENDOSC, V55, P923; Lee JM, 2001, CLIN RADIOL, V56, P560, DOI 10.1053/crad.2001.0700; Leiper K, 2002, ENDOSCOPY, V34, P139, DOI 10.1055/s-2002-19858; Maetani I, 2002, ENDOSCOPY, V34, P402, DOI 10.1055/s-2002-25282; Maetani I, 2001, GASTROINTEST ENDOSC, V54, P364, DOI 10.1067/mge.2001.116882; Makuuchi H, 2001, Gastrointest Endosc Clin N Am, V11, P445; May A, 2002, ENDOSCOPY, V34, P604, DOI 10.1055/s-2002-33236; May A, 2002, EUR J GASTROEN HEPAT, V14, P1085, DOI 10.1097/00042737-200210000-00009; Miyamoto S, 2002, GASTROINTEST ENDOSC, V55, P576, DOI 10.1067/mge.2002.122579; Naso P, 2001, DIGEST LIVER DIS, V33, P653, DOI 10.1016/S1590-8658(01)80040-2; Norberto L, 2002, Surg Endosc, V16, P361; Ohkuwa M, 2001, ENDOSCOPY, V33, P221, DOI 10.1055/s-2001-12805; Ohyama T, 2002, J GASTROEN HEPATOL, V17, P844, DOI 10.1046/j.1440-1746.2002.02814.x; Ono H, 2001, GUT, V48, P225, DOI 10.1136/gut.48.2.225; Razzaq R, 2001, CARDIOVASC INTER RAD, V24, P313, DOI 10.1007/s00270-001-0031-9; Rembacken BJ, 2001, ENDOSCOPY, V33, P709, DOI 10.1055/s-2001-16224; Shand AG, 2002, BRIT J SURG, V89, P349, DOI 10.1046/j.0007-1323.2002.02043.x; Shim CS, 2001, ENDOSCOPY, V33, P271, DOI 10.1055/s-2001-12816; Shimizu Y, 2002, GASTROINTEST ENDOSC, V56, P387, DOI 10.1067/mge.2002.127100; Siersema PD, 2001, GASTROINTEST ENDOSC, V54, P579, DOI 10.1067/mge.2001.118716; Spencer GM, 2002, GUT, V50, P224, DOI 10.1136/gut.50.2.224; Sun S, 2002, ENDOSCOPY, V34, P82, DOI 10.1055/s-2002-19386; Suzuki H, 2001, Gastrointest Endosc Clin N Am, V11, P511; Suzuki H, 2001, ENDOSCOPY, V33, P437, DOI 10.1055/s-2001-14269; Vakil N, 2001, AM J GASTROENTEROL, V96, P1791, DOI 10.1016/S0002-9270(01)02486-8; van den Bongard HJG, 2002, GASTROINTEST ENDOSC, V55, P110, DOI 10.1067/mge.2002.119731; Waxman I, 2002, GASTROINTEST ENDOSC, V55, P44, DOI 10.1067/mge.2002.119871; Wong YT, 2002, SURG ENDOSC, V16, P310, DOI 10.1007/s00464-001-9061-2; Yamamoto H, 2002, GASTROINTEST ENDOSC, V56, P507, DOI 10.1067/mge.2002.128108; Yamamoto H, 2001, GASTROINTEST ENDOSC, V54, P629, DOI 10.1067/mge.2001.118643; Yoshida Misao, 2002, Nihon Geka Gakkai Zasshi, V103, P337; Yoshikane H, 2001, ENDOSCOPY, V33, P795, DOI 10.1055/s-2001-16515	51	43	47	0	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	FEB	2003	35	2					118	126		10.1055/s-2003-37016			9	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	641YM	WOS:000180774700003	12561005				2022-02-25	
J	Kleihues, P; Rice, J				Kleihues, P; Rice, J			IARC Monographs Programme - Reply	INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH			English	Letter									WHO, Unit Carcinogen Identificat & Evaluat, Lyon, France; WHO, Int Agcy Res Canc, Monographys Program, F-69008 Lyon, France		Kleihues, P (corresponding author), WHO, Unit Carcinogen Identificat & Evaluat, Lyon, France.							0	1	1	0	0	ABEL PUBLICATION SERVICES	BURLINGTON	1611 AQUINAS COURT, BURLINGTON, NC 27215 USA	1077-3525			INT J OCCUP ENV HEAL	Int. J. Occup. Environ. Health	JAN-MAR	2003	9	1					80	81					2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	669EW	WOS:000182339800013	12749636				2022-02-25	
J	Norat, T; Lukanova, A; Ferrari, P; Riboli, E				Norat, T; Lukanova, A; Ferrari, P; Riboli, E			Meat consumption and colorectal cancer risk: Dose-response meta-analysis of epidemiological studies	INTERNATIONAL JOURNAL OF CANCER			English	Review						meat; colorectal cancer; attributable risk; preventable fraction	N-NITROSO COMPOUNDS; LARGE-BOWEL-CANCER; COLON-CANCER; FOOD GROUPS; RED MEAT; GASTROINTESTINAL CANCERS; HETEROCYCLIC AMINES; DIETARY FACTORS; BILE-ACIDS; POPULATION	The hypothesis that consumption of red and processed meat increases colorectal cancer risk is reassessed in a meta-analysis of articles published during 1973-99. The mean relative risk (RR) for the highest quantile of intake vs. the lowest was calculated and the RR per gram of intake was computed through log-linear models. Attributable fractions and preventable fractions for hypothetical reductions in red meat consumption in different geographical areas were derived using the RR log-linear estimates and prevalence of red meat consumption from FAO data and national dietary surveys. High intake of red meat, and particularly of processed meat, was associated with a moderate but significant increase in colorectal cancer risk. Average RRs and 95% confidence intervals (CI) for the highest quantile of consumption of red meat were 1.35 (CI: 1.21-1.51) and of processed meat, 1.31 (CI: 1.13-1.51). The RRs estimated by log-linear close-response analysis were 1.24 (CI: 1.08-1.41) for an increase of 120 g/day of red meat and 1.36 (CI: 1.15-1.61) for 30 g/day of processed meat. Total meat consumption was not significantly associated with colorectal cancer risk. The risk fraction attributable to current levels of red meat intake was in the range of 10-25% in regions where red meat intake is high. If average red meat intake is reduced to 70 g/week in these regions, colorectal cancer risk would hypothetically decrease by 7-24%. (C) 2002 Wiley-Liss, Inc.	IARC, Unit Nutr & Canc, F-69372 Lyon 08, France		Riboli, E (corresponding author), IARC, Unit Nutr & Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	Riboli@iarc.fr		Riboli, Elio/0000-0001-6795-6080			Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1; AUTRUP H, 1978, P SOC EXP BIOL MED, V159, P111; BABBS CF, 1990, FREE RADICAL BIO MED, V8, P191, DOI 10.1016/0891-5849(90)90091-V; Bartsch H, 1996, EUR J CANCER PREV, V5, P11, DOI 10.1097/00008469-199609001-00003; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BELL DA, 1995, CANCER RES, V55, P3537; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; BIDOLI E, 1992, INT J CANCER, V50, P223, DOI 10.1002/ijc.2910500211; Bingham SA, 1999, P NUTR SOC, V58, P243, DOI 10.1017/S0029665199000336; Bingham SA, 1996, CARCINOGENESIS, V17, P515, DOI 10.1093/carcin/17.3.515; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; Boutron-Ruault MC, 1999, EUR J CANCER PREV, V8, P229, DOI 10.1097/00008469-199906000-00011; Bruce WR, 2000, CANCER EPIDEM BIOMAR, V9, P1271; CENTONZE S, 1994, NUTR CANCER, V21, P233, DOI 10.1080/01635589409514322; Chen J, 1998, CANCER RES, V58, P3307; CHOMCHAI C, 1974, DIS COLON RECTUM, V17, P310, DOI 10.1007/BF02586971; CLINTON SK, 1988, CANCER RES, V48, P3035; COLDITZ GA, 1995, AM J EPIDEMIOL, V142, P371, DOI 10.1093/oxfordjournals.aje.a117644; *COMA, 1998, REP WORK GROUP DIET; DALES LG, 1979, AM J EPIDEMIOL, V109, P132, DOI 10.1093/oxfordjournals.aje.a112668; Deneo-Pellegrini H, 1999, EUR J CANCER PREV, V8, P501, DOI 10.1097/00008469-199912000-00005; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; *FAO UN STAT DIV, 1994, COMP FOOD CONS STAT, V1; *FAO UN STAT DIV, 1994, COMP FOOD CONS STAT, V2; FIELD CJ, 1990, J BIOL CHEM, V265, P11143; FORMAN D, 1987, CANCER SURV, V6, P719; Franceschi S, 1997, INT J CANCER, V72, P56, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;56::AID-IJC8&gt;3.0.CO;2-3; FRIEDMAN E, 1989, CANCER RES, V49, P544; Gaard M, 1996, EUR J CANCER PREV, V5, P445; GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; Giovannucci E, 1997, AM J CLIN NUTR, V66, P1564; GOLDBOHM RA, 1994, CANCER RES, V54, P718; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; HAENSZEL W, 1980, JNCI-J NATL CANCER I, V64, P17; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; HIRAYAMA T, 1990, LIFE STYLE MORTALITY, P73; HOTCHKISS JH, 1989, CANCER SURV, V8, P295; Hsing AW, 1998, INT J CANCER, V77, P549, DOI 10.1002/(SICI)1097-0215(19980812)77:4&lt;549::AID-IJC13&gt;3.0.CO;2-1; HU JF, 1991, INT J EPIDEMIOL, V20, P362, DOI 10.1093/ije/20.2.362; ILETT KF, 1987, CANCER RES, V47, P1466; ISCOVICH JM, 1992, INT J CANCER, V51, P851, DOI 10.1002/ijc.2910510603; Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15; KAMPMAN E, 1995, CANCER CAUSE CONTROL, V6, P225, DOI 10.1007/BF00051794; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; Kato I, 1999, INT J CANCER, V80, P693, DOI 10.1002/(SICI)1097-0215(19990301)80:5&lt;693::AID-IJC11&gt;3.0.CO;2-G; Knekt P, 1999, INT J CANCER, V80, P852, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;852::AID-IJC9&gt;3.0.CO;2-S; KNEKT P, 1994, INT J CANCER, V59, P756, DOI 10.1002/ijc.2910590608; KrebsSmith SM, 1997, AM J CLIN NUTR, V65, P1264, DOI 10.1093/ajcn/65.4.1264S; Kune S, 1987, Nutr Cancer, V9, P21; La Vecchia C, 1999, NUTR CANCER, V33, P196, DOI 10.1207/S15327914NC330212; LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675; LAVECCHIA C, 1988, INT J CANCER, V41, P492, DOI 10.1002/ijc.2910410404; LaVecchia C, 1996, INT J CANCER, V66, P60, DOI 10.1002/(SICI)1097-0215(19960328)66:1&lt;60::AID-IJC11&gt;3.0.CO;2-F; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; Levi F, 1999, BRIT J CANCER, V79, P1283, DOI 10.1038/sj.bjc.6690206; LYON JL, 1988, AM J EPIDEMIOL, V128, P1000; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MANOUSOS O, 1983, INT J CANCER, V32, P1, DOI 10.1002/ijc.2910320102; Marchand Loic Le, 1999, Journal of the National Cancer Institute Monographs, P101; MASTROMARINO A, 1976, AM J CLIN NUTR, V29, P1455, DOI 10.1093/ajcn/29.12.1455; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MILLER AB, 1983, INT J CANCER, V32, P155, DOI 10.1002/ijc.2910320204; MIRVISH SS, 1995, CANCER LETT, V97, P271, DOI 10.1016/0304-3835(95)04003-M; MIRVISH SS, 1995, CANCER LETT, V93, P17, DOI 10.1016/0304-3835(95)03786-V; Murata M, 1999, JPN J CANCER RES, V90, P711, DOI 10.1111/j.1349-7006.1999.tb00805.x; NAGAO M, 1977, CANCER LETT, V2, P221, DOI 10.1016/S0304-3835(77)80025-6; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; Norat T, 2001, NUTR REV, V59, P37, DOI 10.1111/j.1753-4887.2001.tb06974.x; PENCE BC, 1995, CARCINOGENESIS, V16, P1157, DOI 10.1093/carcin/16.5.1157; PETERS RK, 1989, CANCER RES, V49, P5459; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; PICKLE LW, 1984, CANCER RES, V44, P363; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; Platz EA, 2000, CANCER CAUSE CONTROL, V11, P579, DOI 10.1023/A:1008999232442; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894; REDDY BS, 1980, J NUTR, V110, P1880, DOI 10.1093/jn/110.9.1880; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; Riboli E, 1996, ALIMENTATION CANC EV; Roberts-Thomson IC, 1999, EUR J CANCER PREV, V8, P207, DOI 10.1097/00008469-199906000-00008; ROWLAND IR, 1991, CARCINOGENESIS, V12, P1395, DOI 10.1093/carcin/12.8.1395; SCANLAN RA, 1983, CANCER RES, V43, P2435; Scheppach W, 1999, EUR J CANCER PREV, V8, P57, DOI 10.1097/00008469-199902000-00008; Shannon J, 1996, CANCER EPIDEM BIOMAR, V5, P495; Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697; Sinha R, 1999, CANCER RES, V59, P4320; STEINMETZ KA, 1993, INT J CANCER, V53, P720, DOI 10.1002/ijc.2910530503; Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387; TAJIMA K, 1985, JPN J CANCER RES, V76, P705; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; VLAJINAC H, 1987, Archiv fuer Geschwulstforschung, V57, P493; Welfare MR, 1997, CARCINOGENESIS, V18, P1351, DOI 10.1093/carcin/18.7.1351; WEST DW, 1989, AM J EPIDEMIOL, V130, P883, DOI 10.1093/oxfordjournals.aje.a115421; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; Willett WC, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432305; Willett WC, 1998, NUTR EPIDEMIOLOGY, V2nd, P74, DOI [10.1093/acprof:oso/9780195122978.003.05, DOI 10.1093/ACPROF:OSO/9780195122978.001.0001]; WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; YOREK M, 1989, INVEST OPHTH VIS SCI, V30, P2087; YOUNG TB, 1988, INT J CANCER, V42, P167, DOI 10.1002/ijc.2910420205	108	352	366	0	58	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	MAR 10	2002	98	2					241	256		10.1002/ijc.10126			16	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	522ML	WOS:000173901100014	11857415	Bronze			2022-02-25	
J	Lambert, R				Lambert, R			Diagnosis of Esophagogastric tumors	ENDOSCOPY			English	Review							EARLY GASTRIC-CANCER; SPECIALIZED INTESTINAL METAPLASIA; HIGH-GRADE DYSPLASIA; BARRETTS-ESOPHAGUS; METHYLENE-BLUE; LONG-TERM; IN-VIVO; FOLLOW-UP; ENDOSCOPY; FLUORESCENCE	There is increasing concern regarding the need to establish guidelines for upper gastrointestinal endoscopy. This applies to the reliability of the diagnosis of early cancer, tolerance, and the need to reduce the use of conscious sedation in order to contain costs - one reason why nasogastroscopy with a thin fiberscope is being applied with increasing success. Recent advances that have been made in the early diagnosis of esophageal and gastric tumors now require high-resolution video gastroscopes and the routine use of chromoscopy. For a long time, the helpful contribution made by the zoom video endoscope to the indentification of the pit pattern in neoplastic lesions was limited to the colon. However, the most recent zoom endoscopes, with improved mechanical characteristics and a standard diameter, have now opened up relevant applications in the analysis of early esophageal or gastric malignancies. The best example of this is the identification of the pit pattern in intestinal metaplasia in Barrett's esophagus, although the classification of the pit pattern in upper gastrointestinal neoplasia is still being investigated. Spectroscopic analysis of the response of neoplastic tissue to an applied photon beam has been hampered by the complex origins of the efferent photons. Recent technology, available only through a physical laboratory allows simultaneous analysis of fluorescence, reflectance, and light scattering. In this situation, the method has obtained sensitivity and specificity rates of nearly 100% in classifying low-grade dysplasia, high-grade dysplasia, and cancer in Barrett's esophagus. With regard to depth exploration in the wall of the digestive tract, endosonographic examination using a high-frequency probe (20 - 30 MHz) may be challenged in the future by the technique of optical coherence tomography, a method that does not require acoustic transmission through water and provides a much higher resolution, of up to 10 mum. Optical coherence tomography could be used in the staging of intramucosal esophageal cancer and for detecting intestinal metaplasia in the esophagus. In conclusion, the increasing progress being made in the accuracy of endoscopic diagnosis emphasizes the need for cost-benefit analyses of screening and surveillance protocols.	Int Agcy Res Canc, F-69372 Lyon 08, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	lambert@iarc.fr					Backman V, 2000, NATURE, V406, P35, DOI 10.1038/35017638; Bouma BE, 2000, GASTROINTEST ENDOSC, V51, P467, DOI 10.1016/S0016-5107(00)70449-4; Bozzetti F, 2000, WORLD J SURG, V24, P583, DOI 10.1007/s002689910097; Buttar NS, 2001, GASTROENTEROLOGY, V120, P1630, DOI 10.1053/gast.2001.25111; Canto MIF, 2001, ENDOSCOPY, V33, P391, DOI 10.1055/s-2001-14427; Clarke GA, 2001, ENDOSCOPY, V33, P580, DOI 10.1055/s-2001-15313; Dave U, 2001, GASTROINTEST ENDOSC, V53, P333, DOI 10.1016/S0016-5107(01)70408-7; Davidson J, 2000, HEAD NECK-J SCI SPEC, V22, P449, DOI 10.1002/1097-0347(200008)22:5<449::AID-HED1>3.3.CO;2-C; El-Zimaity HMT, 2001, AM J GASTROENTEROL, V96, P1378; Endlicher E, 2001, GUT, V48, P314, DOI 10.1136/gut.48.3.314; Georgakoudi I, 2001, GASTROENTEROLOGY, V120, P1620, DOI 10.1053/gast.2001.24842; Guelrud M, 2001, GASTROINTEST ENDOSC, V53, P559, DOI 10.1067/mge.2001.114059; Hadzijahic N, 2000, GASTROINTEST ENDOSC, V52, P715, DOI 10.1067/mge.2000.108481; Hosokawa O, 2001, ENDOSCOPY, V33, P301, DOI 10.1055/s-2001-13685; Iseki K, 2000, GASTROINTEST ENDOSC, V52, P755, DOI 10.1067/mge.2000.110455; Isenberg G, 2001, GASTROINTEST ENDOSC, V53, P130, DOI 10.1067/mge.2001.112093; Jackle S, 2000, ENDOSCOPY, V32, P750, DOI 10.1055/s-2000-7705; Kiesslich R, 2001, GASTROINTEST ENDOSC, V53, P47, DOI 10.1067/mge.2001.111041; Kobayashi M, 2001, CANCER LETT, V165, P155, DOI 10.1016/S0304-3835(01)00405-0; Kokawa A, 2001, BRIT J SURG, V88, P439, DOI 10.1046/j.1365-2168.2001.01696.x; Krishnadath KK, 2001, MAYO CLIN PROC, V76, P438; Kulke MH, 2001, CANCER-AM CANCER SOC, V91, P1451, DOI 10.1002/1097-0142(20010415)91:8<1451::AID-CNCR1152>3.0.CO;2-Z; Lambert R, 2001, ENDOSCOPY, V33, P348, DOI 10.1055/s-2001-13690; Messmann H, 2000, Gastrointest Endosc Clin N Am, V10, P497; Mulcahy HE, 2001, ENDOSCOPY, V33, P311, DOI 10.1055/s-2001-13692; Namihisa A, 2001, GASTROINTEST ENDOSC, V53, P343, DOI 10.1016/S0016-5107(01)70414-2; Park DI, 2001, ENDOSCOPY, V33, P501, DOI 10.1055/s-2001-15089; Poneros JM, 2001, GASTROENTEROLOGY, V120, P7, DOI 10.1053/gast.2001.20911; Rajan E, 2001, MAYO CLIN PROC, V76, P217; Reid BJ, 2000, AM J GASTROENTEROL, V95, P1669, DOI 10.1111/j.1572-0241.2000.02196.x; REMBACKEN B, 2001, BAILLIERES BEST PRAC, V2, P317; ROLLINS AM, 2001, BAILLIERES BEST PRAC, V2, P227; Sarbia M, 2001, ANTICANCER RES, V21, P387; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Schnell TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/gast.2001.25065; Shimada S, 2001, SURGERY, V129, P714, DOI 10.1067/msy.2001.114217; Shimizu Y, 2001, GASTROINTEST ENDOSC, V53, P1, DOI 10.1067/mge.2001.111387; Sieg A, 2001, GASTROINTEST ENDOSC, V53, P620, DOI 10.1067/mge.2001.114422; Soma Y, 2001, GASTROINTEST ENDOSC, V53, P14, DOI 10.1067/mge.2001.111773; Spechler SJ, 2001, GASTROENTEROLOGY, V120, P1864, DOI 10.1053/gast.2001.25291; Tsukuma H, 2000, GUT, V47, P618, DOI 10.1136/gut.47.5.618; Vazquez-Sequeiros E, 2001, GASTROINTEST ENDOSC, V53, P751, DOI 10.1067/mge.2001.112741; Wallace MB, 2000, GASTROENTEROLOGY, V119, P677, DOI 10.1053/gast.2000.16511; Watson J P, 2001, J Qual Clin Pract, V21, P26, DOI 10.1046/j.1440-1762.2001.00391.x; Westbrook JI, 2001, GASTROINTEST ENDOSC, V53, P283, DOI 10.1016/S0016-5107(01)70399-9; Weston AP, 2000, AM J GASTROENTEROL, V95, P1888; Wolf C, 2001, EUR J GASTROEN HEPAT, V13, P113, DOI 10.1097/00042737-200102000-00005; Wong RCK, 2001, GASTROINTEST ENDOSC, V54, P122, DOI 10.1067/mge.2001.116115; Yacavone RF, 2001, GASTROINTEST ENDOSC, V53, P703, DOI 10.1067/mge.2001.115337; Yap CK, 2001, GASTROINTEST ENDOSC, V53, P93, DOI 10.1067/mge.2001.110453	50	23	24	0	7	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	FEB	2002	34	2					129	138		10.1055/s-2002-19852			10	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	518TH	WOS:000173683600006	11822008				2022-02-25	
J	Hainaut, P				Hainaut, P			Tumor-specific mutations in p53: The acid test	NATURE MEDICINE			English	Editorial Material							CANCER; DOMAIN	Tumor-specific, 'signature' mutations of p53 have been identified in several cancers. The molecular basis of these tissue-specific selections has been poorly understood. A recent report sheds light on this issue by identifying the molecular basis of one such signature mutation found in adrenal cortical carcinomas.	Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon, France		Hainaut, P (corresponding author), Int Agcy Res Canc, Mol Carcinogenesis Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.		Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; Hainaut P, 2000, ADV CANCER RES, V77, P81; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Spencer SJ, 1999, J CLIN ENDOCR METAB, V84, P1110, DOI 10.1210/jc.84.3.1110	8	22	23	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					21	23		10.1038/nm0102-21			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	WOS:000173056900019	11786899				2022-02-25	
J	Vainio, H; Weiderpass, E; Kleihues, P				Vainio, H; Weiderpass, E; Kleihues, P			Smoking cessation in cancer prevention	TOXICOLOGY			English	Article						tobacco addiction; disease prevention; pharmacological interventions	EMERGING TOBACCO HAZARDS; COST-EFFECTIVENESS; SUSTAINED-RELEASE; CIGARETTE-SMOKING; CONSUMPTION; MORTALITY; BUPROPION; BEHAVIOR; CHINA; RISK	Tobacco smoking is the largest preventable risk factor for morbidity and mortality in industrialized countries. WHO estimates that tobacco will become the largest single health problem by 2020, causing an estimated 8.4 million deaths annually. Tobacco has central importance in the etiology of cancers of the lung, head and neck, urinary tract, and pancreas. Reducing the number of young people who take up smoking and helping those who have started to smoke to quit the habit are the key ways of preventing these cancers. Tobacco- or nicotine-dependence is a common, chronic, relapsing medical condition. Studies of twins have implicated genetic factors in most of the differences in vulnerability to tobacco smoke and in the persistence of the smoking phenotype. The available interventions for reducing tobacco use and treatment for nicotine dependence offer public health officials and clinicians the greatest single Opportunity for disease prevention. Five medications nicotine chewing gum, nicotine patches, nicotine inhalers, nicotine nasal sprays and bupropion-and behavioural therapy appear to be both effective and safe: they double the quitting rates and are associated with a dropout rate due to adverse events of less than 5%. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon, France		Vainio, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Weiderpass, Elisabete/AAP-2747-2021; Weiderpass, Elisabete/M-4029-2016	Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128			Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1986, J NATL CANCER I, V76, P187; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; Goldstein MG, 1998, J CLIN PSYCHIAT, V59, P66; Gupta PC, 2000, B WORLD HEALTH ORGAN, V78, P877; HEATH AC, 1995, BEHAV GENET, V25, P103, DOI 10.1007/BF02196921; HUGHES JR, 2001, NCI MONOGRAPH; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; JEFFERY RW, 1994, PREV MED, V23, P78, DOI 10.1006/pmed.1994.1011; Lerman C, 1999, HEALTH PSYCHOL, V18, P14, DOI 10.1037/0278-6133.18.1.14; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; Longo DR, 1996, JAMA-J AM MED ASSOC, V275, P1252, DOI 10.1001/jama.275.16.1252; McKinney EF, 2000, PHARMACOGENETICS, V10, P483, DOI 10.1097/00008571-200008000-00001; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PATTEN CA, 1995, TOB CONTROL, V4, P139; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; Peto Richard., 2000, TOBACCO PUBLIC HLTH, V37, P154; Shields PG, 1998, CANCER EPIDEM BIOMAR, V7, P453; Swan GE, 1996, J SUBST ABUSE, V8, P19, DOI 10.1016/S0899-3289(96)90055-3; True WR, 1997, ADDICTION, V92, P1277, DOI 10.1111/j.1360-0443.1997.tb02847.x; WEISBURGER JH, 1977, MED PEDIATR ONCOL, V3, P137, DOI 10.1002/mpo.2950030205	24	16	16	0	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-483X			TOXICOLOGY	Toxicology	SEP 14	2001	166	1-2					47	52		10.1016/S0300-483X(01)00445-0			6	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pharmacology & Pharmacy; Toxicology	470VA	WOS:000170890800007	11518610				2022-02-25	
J	Lee, WJ; Colin, D; Boffette, P				Lee, WJ; Colin, D; Boffette, P		IARC Int Study Canc Risk Pulp Pape	Cancer risks among SO2 exposed workers in the pulp and paper industry	EPIDEMIOLOGY			English	Meeting Abstract									Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	JUL	2001	12	4				152	S36	S36					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	443GZ	WOS:000169334500136					2022-02-25	
J	Murillo, R; Herrero, R; Sierra, MS; Forman, D				Murillo, Raul; Herrero, Rolando; Sierra, Monica S.; Forman, David			Cervical cancer in Central and South America: Burden of disease and status of disease control	CANCER EPIDEMIOLOGY			English	Article						Cervix; Neoplasm; HPV; Screening; Central and south america; Latin america	SCREENING-PROGRAMS; LATIN-AMERICA; MORTALITY; TRENDS; COLOMBIA	Rationale and objective: More than 20 years after cytology-based screening was introduced in Central and South America (CSA), cervical cancer remains a leading cause of cancer incidence and mortality in the region. Although several population-based registries exist in the region, few comprehensive analyses have been conducted to describe the status of cervical cancer control. Methods: Population-based data from cancer registries in 13 countries and mortality data from 18 countries in CSA were analyzed. Standardized incidence and mortality rates were estimated and time trend analysis performed when information was available. In addition, a search of available data on HPV vaccination and cervical cancer screening was carried out. Results: Cervical cancer incidence and mortality have decreased in some CSA countries, with an annual percentage change from -4.2 to -6.7 for incidence and -0.2 to -8.3 for mortality. In total, seven countries have age-standardized mortality rates over 10 per 100,000 women, generally corresponding to those with the lowest income levels. All countries have implemented screening programs with different extents of coverage and levels of organization. To date, nine countries have introduced HPV vaccination in national immunization programs. Conclusions: Despite incidence declines observed in some countries, cervical cancer mortality remained almost stable in most countries in the region. Decreases in mortality trends in Chile and Costa Rica are probably the result of early detection programs. Better organized programs might favor greater impact on cancer incidence and mortality, but technological developments offer more suitable opportunities for prevention and alternative approaches for screening of precancerous lesions. (C) 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article under the CC BY-NC-ND IGO 3.0 license.	[Murillo, Raul; Herrero, Rolando] Int Agcy Res Canc, Sect Early Detect & Prevent, Prevent & Implementat Grp, 150 Cours Albert Thomas, F-69008 Lyon, France; [Sierra, Monica S.; Forman, David] Int Agcy Res Canc, Sect Canc Informat, Lyon, France		Murillo, R (corresponding author), Int Agcy Res Canc, Sect Early Detect & Prevent, Prevent & Implementat Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	raulhmurillo@yahoo.com	Murillo, Raúl/AAY-4416-2021; Sierra, Monica S./H-1751-2015	Sierra, Monica S./0000-0003-1286-057X	International Agency for Research on Cancer; European CommissionEuropean CommissionEuropean Commission Joint Research Centre	This work was undertaken during the tenure of a Postdoctoral Fellowship to Dr Monica S. Sierra from The International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions - People - Co-funding of regional, national and international programmes (COFUND).	Almonte M, 2008, VACCINE, V26, pL16, DOI 10.1016/j.vaccine.2008.06.008; [Anonymous], 2015, CANC INCIDENCE 5 CON, VX; Bosetti C, 2011, EUR J CANCER PREV, V20, P355, DOI 10.1097/CEJ.0b013e32834653c9; Bravo LE, 2012, COLOMB MEDICA, V43, P246; Bray F., 2014, IARC MONOGRAPH; Burchell AN, 2006, VACCINE, V24S3, pS3/52; Castellsague Xavier, 2003, J Natl Cancer Inst Monogr, P20; CEPAL, 2015, CEPALSTAT BAS DAT PU; de Vries E, 2015, J EPIDEMIOL COMMUN H, V69, P408, DOI 10.1136/jech-2014-204650; Di Cesare M., 2007, NOTAS POBLACION, V34, P11; Doll R., 1966, CANC INCIDENCE 5 CON, VI; ECLAC, 2013, SUST DEV LAT AM CAR; Esteve J., 1994, STAT METHODS CANC RE; Ferlay J, 2013, GLOBOCAN V1 0 CANC I; Gutierrez C., 2010, REV PERU EPIDEMIOL, V14, P1; Herrero R, 2015, LANCET ONCOL, V16, pE206, DOI 10.1016/S1470-2045(14)70481-4; IARC Social Inequalities and Cancer, 1997, IARC MON; Loos AH, 2004, EUR J CANCER, V40, P2794, DOI 10.1016/j.ejca.2004.09.007; Martinez G., 2011, NATL CTR HLTH STAT M; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; Murillo R, 2008, VACCINE, V26, pL37, DOI 10.1016/j.vaccine.2008.06.013; Murillo R, 2011, SALUD PUBLICA MEXICO, V53, P469; Ojeda G, 2011, ENCUESTA NACL DEMOGR; Paavonen J, 2008, CURR MED RES OPIN, V24, P1623, DOI 10.1185/03007990802068151; PAHO-WHO, 2013, CANC AM COUNTR PROF, P2013; Palacio-Mejia LS, 2003, SALUD PUBLICA MEXICO, V45, pS315; Parikh S, 2003, INT J CANCER, V105, P687, DOI 10.1002/ijc.11141; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; Pineros M, 2013, CANCER EPIDEMIOL, V37, P233, DOI 10.1016/j.canep.2013.02.003; Thuler LCS, 2014, REV BRAS GINECOL OBS, V36, P237, DOI 10.1590/S0100-720320140005010; Segi M., 1963, TRENDS CANC MORTALIT; Sepulveda C, 2005, CANCER DETECT PREV, V29, P405, DOI 10.1016/j.cdp.2005.07.001; Singh Gopal K, 2012, Int J MCH AIDS, V1, P17; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; UNAIDS, 2014, UNAIDS DAT UNAIDS UN; Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016/S0140-6736(06)69479-8	38	32	33	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	SEP	2016	44			1			S121	S130		10.1016/j.canep.2016.07.015			10	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	EE3RT	WOS:000389515600013	27678314	hybrid			2022-02-25	
J	Sierra, MS; Forman, D				Sierra, Monica S.; Forman, David			Burden of colorectal cancer in Central and South America	CANCER EPIDEMIOLOGY			English	Article						Colon; Rectum; Colorectum; Neoplasm; Central and South America	DIETARY PATTERNS; EPIDEMIOLOGIC TRANSITION; NUTRITION TRANSITION; MORTALITY-RATES; RISK; TRENDS; METAANALYSIS; ASSOCIATION; ASPIRIN; ADENOMAS	Rationale and objective: The colorectal cancer (CRC) burden is increasing in Central and South American due to an ongoing transition towards higher levels of human development. We describe the burden of CRC in the region and review the current status of disease control. Methods: We obtained regional- and national-level incidence data from 48 population-based cancer registries in 13 countries, as well as cancer deaths from the WHO mortality database for 18 countries. We estimated world population age-standardized incidence (ASR) and mortality (ASMR) rates per 100,000 person-years for 2003-2007 and the estimated annual percentage change for 1997-2008. Results: The CRC rate in males was 1-2 times higher than that in females. In 2003-2007, the highest ASRs were seen in Uruguayan, Brazilian and Argentinean males (25.2-34.2) and Uruguayan and Brazilian females (21.5-24.7), while El Salvador had the lowest ASR in both sexes (males: 1.5, females: 1.3). ASMRs were < 10 for both sexes, except in Uruguay, Cuba and Argentina (10.0-17.7 and 11.3-12.0). CRC incidence is increasing in Chilean males. Most countries have national screening guidelines. Uruguay and Argentina have implemented national screening programs. Conclusion: Geographic variation in CRC and sex gaps may be explained by differences in the prevalence of obesity, physical inactivity, diet, smoking and alcohol consumption, early detection, and cancer registration practices. Establishing optimal CRC screening programs is challenging due to lack of healthcare access and coverage, funding, regional differences and inadequate infrastructure, and may not be feasible. Given the current status of CRC in the region, data generated by population-based cancer registries is crucial for cancer control planning. (C) 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd.	[Sierra, Monica S.; Forman, David] Int Agcy Res Canc, Lyon, Rhone, France		Sierra, MS (corresponding author), Int Agcy Res Canc, Lyon, Rhone, France.	sierram@fellows.iarc.fr	Sierra, Monica S./H-1751-2015	Sierra, Monica S./0000-0003-1286-057X	International Agency for Research on Cancer; European Commission FP7 Marie Curie Actions	This work was undertaken during the tenure of a Postdoctoral Fellowship to Dr Monica S. Sierra from The International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions - People - Co-Funding of Regional, National and International Programs (COFUND).	Abreu MR, 2013, EUR J PUBLIC HEALTH, V23, P164, DOI 10.1093/eurpub/ckr210; Pou SA, 2014, NUTR HOSP, V29, P618, DOI [10.3305/NH.2014.29.3.7192, 10.3305/nh.2014.29.3.7192]; Pou SA, 2009, CANCER EPIDEMIOL, V33, P406, DOI 10.1016/j.canep.2009.09.009; [Anonymous], 2013, J. Coloproctol. (Rio J.), V33, P111, DOI 10.1016/j.jcol.2013.09.001; [Anonymous], 2014, CANC INCIDENCE 5 CON, VX; [Anonymous], 2008, PROGR NAC CONTR CANC; [Anonymous], 2014, MORT DAT; [Anonymous], 2014, IMPR OUTC TREATM MAN; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4; Aune D, 2012, ANN ONCOL, V23, P37, DOI 10.1093/annonc/mdr269; Aune D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6617; Barbosa IR, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000746; Bardou M, 2013, GUT, V62, P933, DOI 10.1136/gutjnl-2013-304701; Barrios E., 2010, ATLAS INCIDENCIA CAN; Bellolio F, 2013, COLORECTAL DIS, V15, P761, DOI 10.1111/codi.12196; Bianco E., 2005, PREVENTION CONTROL, V1, P311, DOI DOI 10.1016/J.PRECON.2006.05.001; Bishehsari F, 2014, WORLD J GASTROENTERO, V20, P6055, DOI 10.3748/wjg.v20.i20.6055; Bosetti C, 2005, ANN ONCOL, V16, P489, DOI 10.1093/annonc/mdi086; Bosetti C, 2011, EUR J CANCER PREV, V20, P355, DOI 10.1097/CEJ.0b013e32834653c9; Bosetti C, 2009, HUM REPROD UPDATE, V15, P489, DOI 10.1093/humupd/dmp017; Bosman F. T., 2014, WORLD CANC REPORT 20; Bouvard V, 2015, LANCET ONCOL, V16, P1599, DOI 10.1016/S1470-2045(15)00444-1; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Bretthauer M, 2011, J INTERN MED, V270, P87, DOI 10.1111/j.1365-2796.2011.02399.x; Butterworth AS, 2006, EUR J CANCER, V42, P216, DOI 10.1016/j.ejca.2005.09.023; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055-9965.EPI-09-0090; Chan DSM, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020456, 10.1371/journal.pone.0027218]; Chatenoud L, 2014, ANN ONCOL, V25, P1843, DOI 10.1093/annonc/mdu206; Chatenoud L, 2010, EUR J CANCER PREV, V19, P79, DOI 10.1097/CEJ.0b013e32833233be; Clark MA, 2004, LANCET ONCOL, V5, P149, DOI 10.1016/S1470-2045(04)01410-X; Cogliano VJ, 2011, JNCI-J NATL CANCER I, V103, P1827, DOI 10.1093/jnci/djr483; Cole BF, 2009, J NATL CANCER I, V101, P256, DOI 10.1093/jnci/djn485; Cortes A, 2014, SALUD PUBLICA MEXICO, V56, P457; De Stefani E, 2012, ASIAN PAC J CANCER P, V13, P231, DOI 10.7314/APJCP.2012.13.1.231; De Stefani E, 2011, ASIAN PAC J CANCER P, V12, P753; Din FVN, 2010, GUT, V59, P1670, DOI 10.1136/gut.2009.203000; Doll R., 1966, CANC INCIDENCE 5 CON, VI; Donoso A, 2006, REV MED CHILE, V134, P152; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Esteve J, 1994, IARC Sci Publ, P1; Fadda S., 2007, HDB FERMENTED MEAT P, P387; Fenocchi E, 2006, EUR J CANCER PREV, V15, P384, DOI 10.1097/00008469-200610000-00002; Ferlay J., 2014, GLOBOCAN 2012 V1 0; Franceschi S, 2013, MOL ONCOL, V7, P1, DOI 10.1016/j.molonc.2012.10.010; Fung Teresa T, 2013, Curr Nutr Rep, V2, P48; Gao RN, 2008, J PUBLIC HEALTH-UK, V30, P194, DOI 10.1093/pubmed/fdn019; Garcia-Osogobio S., 2015, ENDOSCOPIA, V27, P59; Gonzalez RS, 2014, MEDICC REV, V16, P73, DOI 10.37757/MR2014.V16.N3-4.14; Goss PE, 2013, LANCET ONCOL, V14, P391, DOI 10.1016/S1470-2045(13)70048-2; Harriss DJ, 2009, COLORECTAL DIS, V11, P689, DOI 10.1111/j.1463-1318.2009.01767.x; International Agency for Research Cancer, IARC MON EV CARC RIS; Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389; Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010; Lopez-Kostner F, 2012, REV MED CHILE, V140, P281, DOI 10.4067/S0034-98872012000300001; Loria Dora, 2010, Rev Cubana Salud Pública, V36, P115, DOI 10.1590/s0864-34662010000200004; Magalhaes B, 2012, EUR J CANCER PREV, V21, P15, DOI 10.1097/CEJ.0b013e3283472241; Muller Fernando, 2008, Int J Chron Obstruct Pulmon Dis, V3, P285; Okada T., 2015, CANCER; Perez RO, 2008, ABCD-ARQ BRAS CIR DI, V21, P12, DOI 10.1590/S0102-67202008000100003; Pineros M, 2006, SALUD PUBLICA MEXICO, V48, P455, DOI 10.1590/S0036-36342006000600003; Popkin BM, 1998, PUBLIC HEALTH NUTR, V1, P5, DOI 10.1079/PHN19980004; Reis RD, 2009, CAD SAUDE PUBLICA, V25, P1045, DOI 10.1590/S0102-311X2009000500011; Rivera JA, 2004, NUTR REV, V62, pS149, DOI 10.1111/j.1753-4887.2004.tb00086.x; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Samad AKA, 2005, COLORECTAL DIS, V7, P204, DOI 10.1111/j.1463-1318.2005.00747.x; Sankaranarayanan R, 2014, ANN GLOB HEALTH, V80, P412, DOI 10.1016/j.aogh.2014.09.014; Scholefield JH, 2011, COLORECTAL DIS, V13, P1, DOI 10.1111/j.1463-1318.2010.02493.x; Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086; Segi M., 1963, TRENDS CANC MORTALIT; StataCorp LP, 2011, STAT DAT AN STAT SOF; Torres P., 2007, REV CUBANA MED, V46; Verastegui E, 2010, EUR J HEALTH ECON, V10, P107, DOI 10.1007/s10198-009-0190-1; Webber L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039589; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; World Health Organization, 2014, GLOB HLTH OBS DAT RE; Xu XD, 2013, INT J CANCER, V132, P437, DOI 10.1002/ijc.27625; Zarate AJ, 2013, COLORECTAL DIS, V15, P47, DOI 10.1111/j.1463-1318.2012.03110.x	80	21	23	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	SEP	2016	44			1			S74	S81		10.1016/j.canep.2016.03.010			8	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	EE3RT	WOS:000389515600008	27678325	hybrid			2022-02-25	
J	Huskova, H; Ardin, M; Zhivagui, M; Guyton, K; Straif, K; Herceg, Z; Korenjak, M; Olivier, M; Hollstein, M; Zavadil, J				Huskova, H.; Ardin, M.; Zhivagui, M.; Guyton, K.; Straif, K.; Herceg, Z.; Korenjak, M.; Olivier, M.; Hollstein, M.; Zavadil, J.			In Vitro Modeling of Genome-Scale Mutational Signatures and of Functional Impact of Cancer-Risk Agents.	ENVIRONMENTAL AND MOLECULAR MUTAGENESIS			English	Meeting Abstract									[Huskova, H.; Ardin, M.; Zhivagui, M.; Guyton, K.; Straif, K.; Herceg, Z.; Korenjak, M.; Olivier, M.; Hollstein, M.; Zavadil, J.] Int Agcy Res Canc, F-69372 Lyon, France				Zavadil, Jiri/ABG-1780-2020; Olivier, Magali/G-3728-2010	Zavadil, Jiri/0000-0003-0640-5562; Olivier, Magali/0000-0002-8202-342X				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0893-6692	1098-2280		ENVIRON MOL MUTAGEN	Environ. Mol. Mutagen.	AUG	2015	56			1		11	S52	S52					1	Environmental Sciences; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Genetics & Heredity; Toxicology	CP9PJ	WOS:000360226400088					2022-02-25	
J	Muller, DC; Johansson, M; Brennan, P				Muller, David C.; Johansson, Mattias; Brennan, Paul			A model incorporating spirometry to predict absolute risk of lung cancer: The UK Biobank prospective cohort study	CANCER RESEARCH			English	Meeting Abstract	106th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 18-22, 2015	Philadelphia, PA	Amer Assoc Canc Res					[Muller, David C.; Johansson, Mattias; Brennan, Paul] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France				Johansson, Mattias/ABF-3365-2020					0	0	0	1	1	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	AUG 1	2015	75			15		5581				10.1158/1538-7445.AM2015-5581			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	DF8HA	WOS:000371597106239					2022-02-25	
J	Combes, JD; Franceschi, S				Combes, Jean-Damien; Franceschi, Silvia			Role of human papillomavirus in non-oropharyngeal head and neck cancers	ORAL ONCOLOGY			English	Review						Human papillomavirus; Cancer of the oral cavity; Cancer of the oropharynx; Cancer of the hypopharynx; Cancer of the larynx	UPPER AERODIGESTIVE TRACT; SQUAMOUS-CELL CARCINOMA; GLUTATHIONE-S-TRANSFERASE; RISK HUMAN-PAPILLOMAVIRUS; EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; INTERNATIONAL HEAD; SEXUAL-BEHAVIOR; POOLED ANALYSIS; P16 EXPRESSION	Accurate estimates of the fraction of head and neck cancer (HNC) attributable to human papillomavirus (HPV) infection are essential to predict the effectiveness of interventions based on vaccination against HPV or HPV-testing. In addition, if supported by currently on-going clinical trials, attribution of a HNC to HPV may allow better and less toxic treatments. Here we focused on studies in which the prevalence of molecular and serological HPV markers was similarly assessed in oropharyngeal and non-oropharyngeal HNC. Large data on HPV DNA detection by PCR and p16 expression in HNC biopsies suggests that the probability of a cancer of the oral cavity, larynx, and hypopharynx being attributable to HPV is at least 5-fold lower than that for oropharyngeal cancer. Seropositivity for HPV16 E6 or E7 shows larger differences across sites, but findings vary between studies. Because HPV DNA and p16 detection lack specificity, and E6 and E7 antibody detection lacks sensitivity, these tests are not totally satisfactory. Limited data on in situ hybridization or HPV E6/E7 mRNA, mainly from the United States, suggests that HPV-attributable HNC is rare in the oral cavity (similar to 3%), larynx (similar to 7%), and hypopharynx (similar to 0%). Data on HPV in other rarer HNCs are extremely limited and essentially negative. Available data do not allow the establishment of the way HPV infection and tobacco may interact in non-oropharyngeal HNC. The exclusion of oropharynx as a site of tumor origin and the identification of robust fingerprints of HPV-driven carcinogenesis are the priorities to improve the estimate of HPV-attributable non-oropharyngeal HNC. (C) 2013 Elsevier Ltd. All rights reserved.	[Combes, Jean-Damien; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	CombesJD@fellows.iarc.fr; FranceschiS@iarc.fr	Combes, Jean-Damien/B-9113-2018; franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071	Institut National du Cancer (INCa), SPLIT project [2011/196]; Association pour la Recherche sur le Cancer (ARC)Fondation ARC pour la Recherche sur le Cancer [20111204169]	This work was supported by the Institut National du Cancer (INCa), SPLIT project No2011/196. Dr. Jean-Damien Combes was supported by a fellowship from the Association pour la Recherche sur le Cancer (ARC, No20111204169). The funders had no role in the design of the study; the collection, analysis and interpretation of the data; the decision to submit for publication; or the writing of the manuscript. The views expressed in this publication are those of the authors and not necessarily those of the funders.	Anantharaman D, 2013, JNCI-J NATL CANCER I, V105, P536, DOI 10.1093/jnci/djt053; Anantharaman D, 2011, ORAL ONCOL, V47, P725, DOI 10.1016/j.oraloncology.2011.05.004; [Anonymous], 2010, CANC INC MORT WORLDW, V10; Atula T, 1998, ORAL ONCOL, V34, P391, DOI 10.1016/S1368-8375(98)00023-2; Barnes L, 2005, WHO CLASSIFICATION T; Bishop JA, 2013, AM J SURG PATHOL, V37, P185, DOI 10.1097/PAS.0b013e3182698673; Boland JM, 2012, MODERN PATHOL, V25, P529, DOI 10.1038/modpathol.2011.186; Brunner M, 2012, EUR ARCH OTO-RHINO-L, V269, P2265, DOI 10.1007/s00405-011-1894-2; Chaturvedi AK, 2013, J CLIN ONCOL; Curado MP, 2007, IARC SCI PUBLICATION, VIX; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; Dahlstrom KR, 2011, HEAD NECK-J SCI SPEC, V33, P847, DOI 10.1002/hed.21550; Dai M, 2004, CANCER RES, V64, P468, DOI 10.1158/0008-5472.CAN-03-3284; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Descamps G, 2012, ANTICANCER RES, V32, P3929; El-Naggar AK, 2012, HEAD NECK-J SCI SPEC, V34, P459, DOI 10.1002/hed.21974; Franceschi S, 1996, CANCER EPIDEM BIOMAR, V5, P567; Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Hashibe M, 2009, CANCER EPIDEM BIOMAR, V18, P541, DOI 10.1158/1055-9965.EPI-08-0347; Heck JE, 2010, INT J EPIDEMIOL, V39, P166, DOI 10.1093/ije/dyp350; Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]; IARC, 2012, MON EV CARC RISKS B, V100B; IARC, 2007, MON EV CARC RISKS HU, V90; IARC, 2012, MON EV CARC RISKS E, V100E; Isayeva T, 2012, HEAD NECK PATHOL, V6, pS104, DOI 10.1007/s12105-012-0368-1; Jour G, 2013, HEAD NECK PATHOL, V7, P224, DOI 10.1007/s12105-012-0417-9; Klingenberg B, 2010, HISTOPATHOLOGY, V56, P957, DOI 10.1111/j.1365-2559.2010.03576.x; Klussmann JP, 2001, CANCER-AM CANCER SOC, V92, P2875, DOI 10.1002/1097-0142(20011201)92:11&lt;2875::AID-CNCR10130&gt;3.0.CO;2-7; Kreimer AR, 2013, J CLIN ONCOL, V31, P2708, DOI 10.1200/JCO.2012.47.2738; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Maxwell JH, 2010, HEAD NECK-J SCI SPEC, V32, P562, DOI 10.1002/hed.21216; Mehanna H, 2012, HEAD NECK-J SCI SPEC, DOI [10.1002/hed.22015, DOI 10.1002/HED.22015]; Mirzamani N, 2006, EXP MOL PATHOL, V81, P231, DOI 10.1016/j.yexmp.2006.04.006; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Munoz N, 1990, RECENT PROGR EPIDEMO, P1; Punwaney R, 1999, HEAD NECK-J SCI SPEC, V21, P21, DOI 10.1002/(SICI)1097-0347(199901)21:1<21::AID-HED3>3.3.CO;2-Q; Quon H, 2013, J CLIN ONCOL, V31, P520, DOI 10.1200/JCO.2012.46.7746; RABKIN CS, 1992, AM J EPIDEMIOL, V136, P54, DOI 10.1093/oxfordjournals.aje.a116420; Ribeiro KB, 2011, INT J EPIDEMIOL, V40, P489, DOI 10.1093/ije/dyq249; Ringstrom E, 2002, CLIN CANCER RES, V8, P3187; Sehr P, 2001, J IMMUNOL METHODS, V253, P153, DOI 10.1016/S0022-1759(01)00376-3; Singhi AD, 2012, HEAD NECK-J SCI SPEC, V34, P213, DOI 10.1002/hed.21714; Smith EM, 2012, J ONCOL, V2012, DOI 10.1155/2012/571862; Smith EM, 2004, INT J CANCER, V108, P766, DOI 10.1002/ijc.11633; Snijders P., 1995, PAPILLOMAVIRUS REPOR, V6, P157; Snijders P J, 1994, Curr Top Microbiol Immunol, V186, P177; Tung Yi-Ching, 1999, Kaohsiung Journal of Medical Sciences, V15, P256; Vageli D, 2007, INT J BIOL MARKER, V22, P239, DOI 10.1177/172460080702200401; Waterboer T, 2005, CLIN CHEM, V51, P1845, DOI 10.1373/clinchem.2005.052381	51	88	89	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1368-8375	1879-0593		ORAL ONCOL	Oral Oncol.	MAY	2014	50	5					370	379		10.1016/j.oraloncology.2013.11.004			10	Oncology; Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Dentistry, Oral Surgery & Medicine	AF3AK	WOS:000334583600010	24331868				2022-02-25	
J	Munoz, N				Munoz, Nubia			Human papillomavirus in the etiology and prevention of genital cancers	CANCER RESEARCH			English	Meeting Abstract									[Munoz, Nubia] IARC, Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	APR 15	2012	72			8		PL01-02							2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	V43SR	WOS:000209701602356					2022-02-25	
J	Herceg, Z; Hernandez-Vargas, H				Herceg, Zdenko; Hernandez-Vargas, Hector			New concepts of old epigenetic phenomena and their implications for selecting specific cell populations for epigenomic research	EPIGENOMICS			English	Editorial Material						cancer stem cells; cell subpopulations; CpG islands; methylome; next-generation sequencing	DNA METHYLATION; STEM-CELLS; PROMOTER; 5-HYDROXYMETHYLCYTOSINE; DEMETHYLATION; PLURIPOTENT; CONVERSION; METHYLOME; GENE; CPG		[Herceg, Zdenko; Hernandez-Vargas, Hector] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon 08, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	herceg@iarc.fr		Hernandez-Vargas, Hector/0000-0001-6045-2103			Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Cuddapah S, 2010, CURR OPIN IMMUNOL, V22, P341, DOI 10.1016/j.coi.2010.02.007; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Hernandez-Vargas H, 2009, EPIGENOMICS-UK, V1, P261, DOI [10.2217/epi.09.19, 10.2217/EPI.09.19]; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Klug M, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-6-r63; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Schilling E, 2009, GENOME RES, V19, P2028, DOI 10.1101/gr.095562.109; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Zhang YY, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r138	22	9	9	0	1	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1750-1911			EPIGENOMICS-UK	Epigenomics	AUG	2011	3	4					383	386		10.2217/EPI.11.64			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	824OF	WOS:000295210700001	22126196				2022-02-25	
J	Hainaut, P; Plymoth, A				Hainaut, Pierre; Plymoth, Amelie			Biomarkers in cancer research and treatment: promises and challenges	CURRENT OPINION IN ONCOLOGY			English	Editorial Material									[Hainaut, Pierre; Plymoth, Amelie] Int Agcy Res Canc, F-69372 Lyon, France		Hainaut, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				0	2	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-8746			CURR OPIN ONCOL	Curr. Opin. Oncol.	JAN	2011	23	1					61	61		10.1097/CCO.0b013e328341623e			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	692EJ	WOS:000285134600009	21321519				2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R.			WHAT IS THE OPTIMUM SCREENING METHOD FOR CERVICAL CANCER IN DEVELOPING COUNTRIES?	ANNALS OF ONCOLOGY			English	Meeting Abstract	35th European-Society-for-Medical-Oncology (ESMO) Congress	OCT 08-12, 2010	Milan, ITALY	European Soc Med Oncol					[Sankaranarayanan, R.] Int Agcy Res Canc, Screening Grp SCR, F-69372 Lyon, France									0	0	0	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534			ANN ONCOL	Ann. Oncol.	OCT	2010	21			8			41	41					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	666LE	WOS:000283115900090					2022-02-25	
J	Franceschi, S				Franceschi, S.			Monitoring HPV16/18 immunisation in England and elsewhere	BRITISH JOURNAL OF CANCER			English	Editorial Material							VACCINE; INFECTION; TRIAL; WOMEN		Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Bach PB, 2010, LANCET, V375, P963, DOI 10.1016/S0140-6736(09)62029-8; Brotherton JML, 2008, COMMUN DIS INTELL, V32, P457; Butler D, 2010, NATURE, V464, P338, DOI 10.1038/464338a; Department of Health, 2010, ANN HPV VACC UPT ENG; DESAI S, 2010, LANCET IN PRESS; Ferlay J, 2010, IARC CANCERBASE; Franceschi S, 2005, BRIT J CANCER, V92, P601, DOI 10.1038/sj.bjc.6602348; Franceschi S, 2009, INT J CANCER, V125, P2246, DOI 10.1002/ijc.24634; *IARC, 1995, MON EV CARC RISKS HU, V64; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; LI N, 2010, INT J CANC; Molano M, 2002, BRIT J CANCER, V87, P324, DOI 10.1038/sj.bjc.6600442; *NAT HLTH SERV SCO, 2010, HUM PAP VIR HPV IMM; National Public Health Service of Wales, 2009, VACC UPT CHILDR WAL; Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9; Schiller JT, 2008, VACCINE, V26, pK53, DOI 10.1016/j.vaccine.2008.06.002	16	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920			BRIT J CANCER	Br. J. Cancer	JUL 13	2010	103	2					157	158		10.1038/sj.bjc.6605758			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	625JV	WOS:000279892300001	20628394	hybrid, Green Published			2022-02-25	
J	Jenab, M; Ferrari, P; Mckay, J; Slimani, N; Rinaldi, S; Norat, T; Bueno-De-Mesquita, HB; van Duijinhoven, FJB; Boffetta, P; Autier, P; Riboli, E				Jenab, M.; Ferrari, P.; Mckay, J.; Slimani, N.; Rinaldi, S.; Norat, T.; Bueno-de-Mesquita, H. B.; van Duijinhoven, F. J. B.; Boffetta, P.; Autier, P.; Riboli, E.		EPIC Study	Circulating vitamin d concentration, vitamin d receptor polymorphisms and the risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)	EJC SUPPLEMENTS			English	Meeting Abstract	20th Meeting of the European-Association-for-Cancer-Research	JUL 05-08, 2008	Lyon, FRANCE	European Assoc Canc Res					[Jenab, M.; Ferrari, P.; Mckay, J.; Slimani, N.; Rinaldi, S.; Norat, T.; Bueno-de-Mesquita, H. B.; van Duijinhoven, F. J. B.; Boffetta, P.; Autier, P.; Riboli, E.; EPIC Study] Int Agcy Res Canc, Environm & Canc Grp, F-69372 Lyon, France									0	1	1	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	JUL	2008	6	9					190	191		10.1016/S1359-6349(08)71854-8			2	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	330DF	WOS:000257919000674					2022-02-25	
J	Clifford, G; Franceschi, S				Clifford, Gary; Franceschi, Silvia			Members of the human papillornavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix	INTERNATIONAL JOURNAL OF CANCER			English	Letter							HUMAN-PAPILLOMAVIRUS TYPES; CANCER; WOMEN; METAANALYSIS; CARCINOMA; RISK		[Clifford, Gary; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Clifford, G (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	clifford@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Andersson S, 2001, EUR J CANCER, V37, P246, DOI 10.1016/S0959-8049(00)00376-2; Bulk S, 2006, BRIT J CANCER, V94, P171, DOI 10.1038/sj.bjc.6602915; Castle PE, 2005, JNCI-J NATL CANCER I, V97, P1066, DOI 10.1093/jnci/dji186; CASTLE PE, 2007, SEX TRANSM DIS  0629; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; De Vuyst H, 2008, INT J CANCER, V122, P244, DOI 10.1002/ijc.23045; El-Mansi MT, 2006, INT J GYNECOL CANCER, V16, P1025, DOI 10.1111/j.1525-1438.2006.00552.x; Lai CH, 2007, INT J CANCER, V120, P1999, DOI 10.1002/ijc.22538; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Peedicayil A, 2006, INT J GYNECOL CANCER, V16, P1591, DOI 10.1111/j.1525-1438.2006.00631.x; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002; Schwartz SM, 2001, J CLIN ONCOL, V19, P1906, DOI 10.1200/JCO.2001.19.7.1906; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527	15	55	57	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	APR 1	2008	122	7					1684	1685		10.1002/ijc.23282			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	266MW	WOS:000253441100030	18059025	Bronze			2022-02-25	
J	Boyle, P; Dresler, C				Boyle, P; Dresler, C			Preventing the lung cancer epidemic	ANNALS OF ONCOLOGY			English	Editorial Material							MORTALITY; EUROPE		Int Agcy Res Canc, F-69372 Lyon, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	boyle@iarc.fr	Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610			Borras JA, 2003, ANN ONCOL, V14, P159, DOI 10.1093/annonc/mdg016; Bosetti C, 2005, ANN ONCOL, V16, P1597, DOI 10.1093/annonc/mdi313; Boyle P, 2005, NAT CLIN PRACT ONCOL, V2, P424, DOI 10.1038/ncponc0288; Boyle P, 2005, LANCET, V365, P1990, DOI 10.1016/S0140-6736(05)66590-7; Boyle P, 2003, ANN ONCOL, V14, P973, DOI 10.1093/annonc/mdg305; Boyle P, 2003, ANN ONCOL, V14, P1312, DOI 10.1093/annonc/mdg353; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Hu J, 2005, ANN ONCOL, V16, P1605, DOI 10.1093/annonc/mdi312; International Agency for Research on Cancer IARC, 2004, MON EV CARC RISKS HU, V83; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; *UN, 2002, POP DIV WORLD POP PR; World Health Organization, FRAM CONV TOB CONTR, Vhttp://apps.who.int/iris/bitstream/10665/42811/1/9241591013.pdf?ua=1	13	19	20	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534			ANN ONCOL	Ann. Oncol.	OCT	2005	16	10					1565	1566		10.1093/annonc/mdi328			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	974NC	WOS:000232597700001	16172464	Bronze			2022-02-25	
J	Axon, A; Diebold, MD; Fujino, M; Fujita, R; Genta, RM; Gonvers, JJ; Guelrud, M; Inoue, H; Jung, M; Kashida, H; Kudo, S; Lambert, R; Lightdale, C; Nakamura, T; Neuhaus, H; Niwa, H; Ogoshi, K; Rey, JF; Riddell, R; Sasako, M; Shimoda, T; Suzuki, H; Tytgat, GNJ; Wang, K; Watanabe, H; Yamakawa, T; Yoshida, S				Axon, A; Diebold, MD; Fujino, M; Fujita, R; Genta, RM; Gonvers, JJ; Guelrud, M; Inoue, H; Jung, M; Kashida, H; Kudo, S; Lambert, R; Lightdale, C; Nakamura, T; Neuhaus, H; Niwa, H; Ogoshi, K; Rey, JF; Riddell, R; Sasako, M; Shimoda, T; Suzuki, H; Tytgat, GNJ; Wang, K; Watanabe, H; Yamakawa, T; Yoshida, S		Endoscopic Classificat Review Grp	Update on the Paris classification of superficial neoplastic lesions in the digestive tract	ENDOSCOPY			English	Review							BARRETTS-ESOPHAGUS; COLORECTAL-CANCER; METHYLENE-BLUE; RISK-FACTORS; INTESTINAL METAPLASIA; SERRATED ADENOMA; GASTRIC-CANCER; MAGNIFICATION; DIAGNOSIS; CHROMOENDOSCOPY	Background and Study Aims: Neoplastic lesions in the digestive-tract mucosa are termed "superficial" when the depth of invasion is limited to the mucosa and submucosa. The endoscopic appearance has a predictive value for invasion into the submucosa, which is critical for the risk of nodal metastases. Materials and Methods: The endoscopic morphology of superficial lesions can be assessed with a standard video endoscope after spraying of a dye - an iodine-potassium iodide solution for the stratified squamous epithelium, or an indigo carmine solution for the columnar epithelium. In 2002, a workshop was held in Paris to explore the relevance of the Japanese classification. The conclusions were revised in 2003 in Osaka in relation to the definition of the subtypes used in endoscopy and the evaluation of the depth of invasion into the submucosa. In Japan, the description of advanced cancer in the digestive-tract mucosa using types 1-4 is supplemented by a type 0 when the endoscopic appearance is that of a superficial lesion. Type 0 is divided into three categories: protruding (0-I), nonprotruding and nonexcavated (0-II), and excavated (0-III). Type 0-II lesions are then subdivided into slightly elevated (IIa), flat (IIb), or depressed (IIc). Nonprotruding depressed lesions are associated with a higher risk of submucosal invasion. After endoscopic resection, invasion into the submucosa is an important criterion for the necessity of additional surgical resection. Micrometer analysis of the depth of invasion in the specimen is more precise, and distinct cut-off limits have been established in the esophagus, stomach, and large bowel. Conclusions: The morphology of superficial and nonprotruding neoplastic lesions is relevant to the prognosis. Following endoscopic detection, the lesions are analyzed using chromoendoscopy and assigned a subtype of the type 0 classification. The choice between endoscopic or surgical treatment is based on this description.	Int Agcy Res Canc, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	lambert@iarc.fr		Kashida, Hiroshi/0000-0002-9774-9485			Bressler B, 2004, GASTROENTEROLOGY, V127, P452, DOI 10.1053/j.gastro.2004.05.032; Burgart LJ, 2002, GASTROENTEROL CLIN N, V31, P959, DOI 10.1016/S0889-8553(02)00056-0; Canto MIF, 2001, ENDOSCOPY, V33, P391, DOI 10.1055/s-2001-14427; Dixon MF, 2002, GUT, V51, P130, DOI 10.1136/gut.51.1.130; Egashira Y, 2004, MODERN PATHOL, V17, P503, DOI 10.1038/modpathol.3800030; Ell C, 2000, GASTROENTEROLOGY, V118, P670, DOI 10.1016/S0016-5085(00)70136-3; Endo T, 2002, GASTROINTEST ENDOSC, V55, P641, DOI 10.1067/mge.2002.123420; George SMC, 2000, CANCER, V89, P1901, DOI 10.1002/1097-0142(20001101)89:9<1901::AID-CNCR5>3.3.CO;2-R; Gorski TF, 1999, DIS COLON RECTUM, V42, P877, DOI 10.1007/BF02237093; Guelrud M, 2001, GASTROINTEST ENDOSC, V53, P559, DOI 10.1067/mge.2001.114059; Hosokawa O, 1998, ENDOSCOPY, V30, P669, DOI 10.1055/s-2007-1001386; Hurlstone DP, 2004, GUT, V53, P284, DOI 10.1136/gut.2003.027623; Hurlstone DP, 2002, BRIT J SURG, V89, P272, DOI 10.1046/j.0007-1323.2001.02040.x; Inoue H, 2001, ENDOSCOPY, V33, P75; Inoue H, 2000, DIGEST ENDOSC, V12, pS32; Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10; Japanese Society for Esophageal Diseases, 1999, GUID CLIN PATH STUD; JARAMILLO E, 1995, GASTROINTEST ENDOSC, V42, P114, DOI 10.1016/S0016-5107(95)70066-8; Jass JR, 2000, WORLD J SURG, V24, P1016, DOI 10.1007/s002680010152; Kato S, 2001, ENDOSCOPY, V33, P306, DOI 10.1055/s-2001-13700; Kiesslich R, 2001, GASTROINTEST ENDOSC, V53, P47, DOI 10.1067/mge.2001.111041; Kobayashi Masaaki, 1994, Stomach and Intestine, V29, P1151; Kodama M, 1998, SURGERY, V123, P432, DOI 10.1067/msy.1998.86778; Konishi K, 2003, GASTROINTEST ENDOSC, V57, P48, DOI 10.1067/mge.2003.31; Kudo S, 2001, ENDOSCOPY, V33, P367; Kudo S, 1997, Gastrointest Endosc Clin N Am, V7, P87; Kudo S, 2000, WORLD J SURG, V24, P1081, DOI 10.1007/s002680010154; Kumagai Y, 2002, ENDOSCOPY, V34, P369, DOI 10.1055/s-2002-25285; Lambert R, 2003, ENDOSCOPY, V35, P437, DOI 10.1055/s-2003-38766; Matsumoto T, 1999, GASTROINTEST ENDOSC, V49, P736, DOI 10.1016/S0016-5107(99)70292-0; Mohammed IA, 2002, MODERN PATHOL, V15, P611, DOI 10.1038/modpathol.3880574; Morita T, 2001, ENDOSCOPY, V33, P761, DOI 10.1055/s-2001-16525; *NAT REP GROUP MED, 2002, J GASTROENTEROL MASS, V40, P57; Ormsby AH, 2000, GASTROENTEROLOGY, V119, P683, DOI 10.1053/gast.2000.16482; Park DI, 2001, ENDOSCOPY, V33, P501, DOI 10.1055/s-2001-15089; Rex DK, 1996, GASTROENTEROLOGY, V111, P1178, DOI 10.1053/gast.1996.v111.pm8898630; Satodate H, 2003, GASTROINTEST ENDOSC, V58, P288, DOI 10.1067/mge.2003.361; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Sharma P, 2001, GASTROINTEST ENDOSC, V54, P289, DOI 10.1067/mge.2001.115728; Sharma P, 2003, GUT, V52, P24, DOI 10.1136/gut.52.1.24; Tajima Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055345; TANAKA S, 2004, DIG ENDOSC S2, V16, pS161; Tobita K, 2001, DIGEST ENDOSC, V13, P121; Tsukuma H, 2000, GUT, V47, P618, DOI 10.1136/gut.47.5.618; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/j.gastro.2004.04.022; WATANABE H, 1990, Stomach and Intestine (Tokyo), V25, P1075; Watanabe H, 1998, STOMACH INTESTINE, V33, P1001; WINAWER SJ, 1992, CANCER, V70, P1236, DOI 10.1002/1097-0142(19920901)70:3+<1236::AID-CNCR2820701508>3.0.CO;2-4; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; Yao K., 2001, DIGEST ENDOSC, V13, pS27, DOI DOI 10.1111/J.1443-1661.2001.00114.X; YOKOYAMA J, 2002, ACTA MED BIOL, V50, P1	51	504	520	1	32	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	JUN	2005	37	6					570	578		10.1055/s-2005-861352			9	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	932QI	WOS:000229568000010	15933932				2022-02-25	
J	Ohshima, H				Ohshima, H			Genetic and epigenetic damage induced by reactive nitrogen species: implications in carcinogenesis	TOXICOLOGY LETTERS			English	Article; Proceedings Paper	40th Congress of the European-Societies-of-Toxicology	SEP 15-18, 2002	BUDAPEST, HUNGARY	European Soc Toxicol		infection; inflammation; cancer; reactive nitrogen species; DNA damage; inducible nitric oxide synthase	NITRIC-OXIDE SYNTHASE; P53 TUMOR-SUPPRESSOR; DNA STRAND BREAKAGE; NITROXYL ANION; PEROXYNITRITE; PROTEIN; CYTOTOXICITY; INHIBITION; OXIDATION; NO	Chronic infection and inflammation are recognized risk factors for human cancer at various sites. Infection and inflammation can activate and induce a variety of oxidant-generating enzymes, including NADPH oxidase and inducible nitric oxide synthase. Reactive oxygen and nitrogen species produced by such enzymes react with each other to generate new and more potent reactive species. These oxidants not only can damage DNA and induce mutations, but also can activate oncogene products and/or inactivate tumor-suppressor proteins, thus contributing to most processes of carcinogenesis. Appropriate treatment of inflammation should be further explored for chemoprevention of human cancers, especially those associated with chronic inflammation. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.	Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Ohshima, Hiroshi/E-8044-2010				Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Calmels S, 1997, CANCER RES, V57, P3365; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Chazotte-Aubert L, 1999, J BIOL CHEM, V274, P20909, DOI 10.1074/jbc.274.30.20909; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Douki T, 1996, FREE RADICAL RES, V24, P369, DOI 10.3109/10715769609088035; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FELLEYBOSCO E, 1995, CARCINOGENESIS, V16, P2069, DOI 10.1093/carcin/16.9.2069; Gal A, 1996, P NATL ACAD SCI USA, V93, P15102, DOI 10.1073/pnas.93.26.15102; Garcia-Cardena G, 1998, J NATL CANCER I, V90, P560, DOI 10.1093/jnci/90.8.560; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; Huisman A, 2002, FASEB J, V16, P1135, DOI 10.1096/fj.01-0890fje; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jaiswal M, 2001, CANCER RES, V61, P6388; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LEJEUNE P, 1994, J IMMUNOL, V152, P5077; Li CQ, 2001, DIGEST DIS SCI, V46, P836, DOI 10.1023/A:1010764720524; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Masuda M, 2000, CHEM RES TOXICOL, V13, P301, DOI 10.1021/tx990120o; Masuda M, 2002, CHEM-BIOL INTERACT, V139, P187, DOI 10.1016/S0009-2797(01)00299-X; Mei JM, 2000, FASEB J, V14, P1188, DOI 10.1096/fasebj.14.9.1188; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; Niles JC, 1999, P NATL ACAD SCI USA, V96, P11729, DOI 10.1073/pnas.96.21.11729; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; Ohshima H, 1999, METHOD ENZYMOL, V301, P40; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Ohshima H, 1998, FREE RADICAL BIO MED, V25, P1057, DOI 10.1016/S0891-5849(98)00141-5; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Pignatelli B, 2001, CANCER RES, V61, P778; Pignatelli B, 2001, AM J GASTROENTEROL, V96, P1758, DOI 10.1111/j.1572-0241.2001.03869.x; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sandhu JK, 2000, AM J PATHOL, V156, P509, DOI 10.1016/S0002-9440(10)64755-4; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Souici AC, 2000, CARCINOGENESIS, V21, P281, DOI 10.1093/carcin/21.2.281; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; TANNENBAUM SR, 1994, ACS SYM SER, V553, P120; Vasa M, 2000, CIRC RES, V87, P540, DOI 10.1161/01.RES.87.7.540; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; Yoshie Y, 1997, ARCH BIOCHEM BIOPHYS, V342, P13, DOI 10.1006/abbi.1997.0100	51	67	68	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0378-4274			TOXICOL LETT	Toxicol. Lett.	APR 11	2003	140				SI		99	104		10.1016/S0378-4274(02)00506-4			6	Toxicology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Toxicology	668RX	WOS:000182307900012	12676455				2022-02-25	
J	Gutierrez-Enriquez, S; Hall, J				Gutierrez-Enriquez, S; Hall, J			Use of the cytokinesis-block micronucleus assay to measure radiation-induced chromosome damage in lymphoblastoid cell lines	MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS			English	Article						cytochalasin-B; lymphoblastoid cell lines; radiation-induced micronuclei; Ataxia telangiectasia gene (ATM)	ATAXIA-TELANGIECTASIA; DNA-DAMAGE; IONIZING-RADIATION; HUMAN-FIBROBLASTS; HUMAN-LYMPHOCYTES; CYTOCHALASIN-B; GAMMA-IRRADIATION; CANCER PATIENTS; BREAST-CANCER; WORKING GROUP	To establish the optimal experimental conditions for the use of the micronuclei (MN) test to determine the level of chromosomal damage induced by ionising radiation (IR) exposure in lymphoblastoid cell lines, a time-course study was performed comparing a normal and an ataxia telatigiectasia (AT) cell line, the latter being characterised by an extreme radiation sensitivity. Several. parameters we. re analysed: the use of cytochalasin-B (Cyt-B) to quantify MN, the optimum fixation time to measure radiation-induced MN, the most appropriate treatment dose of IR to distinguish between the normal and the radiosensitive cells and the cell-cycle distribution after irradiation. The results obtained showed that the spontaneous as well as the radiation-induced levels of MN Were significantly higher in the AT cell compared to the normal cells (P < 0.001 and P = 0.005, respectively). In both cell types the number of radiation-induced MN were lower in the cultures without Cyt-B than those with Cyt-B (P < 0.001), with the AT cells being distinguished in terms of IR-induced MN from, the normal cells only with the addition of Cyt-B. The level of MN formation was independent of the dose of Cyt-B used (3 or 6 mug/ml). The optimum time for radiation-induced MN measured was found to be between 48 and 72 h post-irradiation, with 2 and 4 Gy exposures inducing similar levels of MN. However, as the higher dose caused a greater delay in the cell-cycle, treatment with 2 Gy with MN measurement at 48 h in the presence of 3 mug/ml Cyt-B were chosen as the optimum experimental, conditions. This choice was validated using two additional normal and AT cell lines. In conclusion, our results show that the use of Cyt-B increases the sensitivity of the MN test for comparing differences in radiosensitivity between lymphoblastoid. cell lines. (C) 2002 Elsevier Science B.V. All rights reserved.	Int Agcy Res Canc, DNA Repair Grp, F-69372 Lyon 08, France		Hall, J (corresponding author), Int Agcy Res Canc, DNA Repair Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295; Gutierrez-Enriquez, Sara/0000-0002-1711-6101			Aardema M. J., 2001, GENETIC TOXICOLOGY C, P163; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANGELE S, IN PRESS HUMAN MUTAT; ANTOCCIA A, 1993, MUTAT RES, V287, P93, DOI 10.1016/0027-5107(93)90148-9; ARLETT CF, 1985, ATAXIA TELANGIECTASI, P101; ARTUSO M, 1995, ONCOGENE, V11, P1427; Baria K, 2002, INT J RADIAT BIOL, V78, P341, DOI 10.1080/09553000110117359; Baria K, 2001, BRIT J CANCER, V84, P892, DOI 10.1054/bjoc.2000.1701; Bishay K, 2000, ONCOGENE, V19, P916, DOI 10.1038/sj.onc.1203405; CHEN P, 1994, CANCER GENET CYTOGEN, V76, P43, DOI 10.1016/0165-4608(94)90069-8; Fenech M, 1999, MUTAGENESIS, V14, P605, DOI 10.1093/mutage/14.6.605; Fenech M, 2000, MUTAGENESIS, V15, P329, DOI 10.1093/mutage/15.4.329; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; FENECH M, 1985, CYTOBIOS, V43, P233; FENECH M, 1993, MUTAT RES, V285, P35, DOI 10.1016/0027-5107(93)90049-L; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Gatti RA, 2001, ACTA ONCOL, V40, P702, DOI 10.1080/02841860152619115; Hall J, 1999, MOL MED TODAY, V5, P157, DOI 10.1016/S1357-4310(99)01435-5; HENNIG UGG, 1988, MUTAT RES, V203, P405, DOI 10.1016/0165-1161(88)90013-1; Jaworska A, 2001, INT J RADIAT BIOL, V77, P269, DOI 10.1080/09553000010019638; Johnston PJ, 1997, MUTAT RES-DNA REPAIR, V385, P1, DOI 10.1016/S0921-8777(97)00034-7; Kalweit S, 1999, MUTAT RES-GEN TOX EN, V439, P183, DOI 10.1016/S1383-5718(98)00191-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kirsch-Volders M, 2001, MUTAGENESIS, V16, P51, DOI 10.1093/mutage/16.1.51; Kirsch-Volders M, 2000, ENVIRON MOL MUTAGEN, V35, P167, DOI 10.1002/(SICI)1098-2280(2000)35:3<167::AID-EM3>3.0.CO;2-G; LIU N, 1993, MUTAGENESIS, V8, P503, DOI 10.1093/mutage/8.6.503; Matsushima T, 1999, MUTAGENESIS, V14, P569, DOI 10.1093/mutage/14.6.569; Miller B, 1998, MUTAT RES-REV MUTAT, V410, P81, DOI 10.1016/S1383-5742(97)00030-6; Minissi S, 1999, MUTAGENESIS, V14, P43, DOI 10.1093/mutage/14.1.43; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; Nachtrab U, 1998, INT J RADIAT BIOL, V73, P279, DOI 10.1080/095530098142374; Papworth R, 2001, BRIT J CANCER, V84, P776, DOI 10.1054/bjoc.2000.1692; PATERSON MC, 1979, CANCER RES, V39, P3725; Ramirez MJ, 1999, MUTAT RES-GEN TOX EN, V440, P163, DOI 10.1016/S1383-5718(99)00023-6; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; RUDD NL, 1988, ENVIRON MOL MUTAGEN, V12, P3, DOI 10.1002/em.2860120104; Scott D, 1996, RADIAT RES, V145, P3, DOI 10.2307/3579189; Scott D, 1998, BRIT J CANCER, V77, P614, DOI 10.1038/bjc.1998.98; SLAVOTINEK A, 1995, MUTAGENESIS, V10, P439, DOI 10.1093/mutage/10.5.439; Speit G, 2000, CYTOGENET CELL GENET, V91, P261, DOI 10.1159/000056855; Stopper H, 1997, MUTAT RES-DNA REPAIR, V383, P107, DOI 10.1016/S0921-8777(96)00049-3; SURRALLES J, 1994, MUTAGENESIS, V9, P347, DOI 10.1093/mutage/9.4.347; SURRALLES J, 1992, MUTAGENESIS, V7, P407, DOI 10.1093/mutage/7.6.407; SURRALLES J, 1995, MUTAT RES-GENET TOX, V341, P169, DOI 10.1016/0165-1218(95)90007-1; Umegaki K, 2000, MUTAGENESIS, V15, P261, DOI 10.1093/mutage/15.3.261; WARD AJ, 1994, ENVIRON MOL MUTAGEN, V24, P103, DOI 10.1002/em.2850240205; WEIRICHSCHWAIGER H, 1994, MUTAT RES, V316, P37, DOI 10.1016/0921-8734(94)90006-X; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002	51	26	28	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1383-5718			MUTAT RES-GEN TOX EN	Mutat. Res. Genet. Toxicol. Environ. Mutagen.	FEB 5	2003	535	1					1	13	PII S1383-5718(02)00280-2	10.1016/S1383-5718(02)00280-2			13	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	640PB	WOS:000180696200001	12547278				2022-02-25	
J	Ohgaki, H; Kleihues, P				Ohgaki, H; Kleihues, P			Molecular genetics of gliomas	GLIA			English	Meeting Abstract									Int Agency Res Canc, Lyon, France									0	0	0	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	MAY	2002				1		W101	S11	S11					1	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	551WL	WOS:000175586100047					2022-02-25	
J	Bray, F; Guilloux, A; Sankila, R; Parkin, DM				Bray, F; Guilloux, A; Sankila, R; Parkin, DM			Practical implications of imposing a new world standard population	CANCER CAUSES & CONTROL			English	Article						age-standardized rates; neoplasms/epidemiology; risk assessment; standardization		Objective: The World Health Organization (WHO) has recently introduced a new world standard population for the production of age-standardized rates. In this study we compare cancer rates standardized to this population with those computed using reference populations in current practice. particularly the world standard of Segi (1960), in order to evaluate their adequacy as estimators of relative risk in diverse population groups and over time. Methods: Incidence and mortality rates standardized using these reference populations were calculated and compared for various cancers. Standardized rate ratios were compared with more efficient methods of approximating relative risk, the Mantel & Haenszel and maximum-likelihood estimators. The differences were tested by taking a synthesis of the relative risks and by taking into account whether effects were homogeneous across age strata or not. Results: There were no statistically significant differences between the relative risk estimates based on direct standardization and those obtained using Mantel & Haenszel (p < 0.99), or maximum-likelihood techniques (p > 0.99), regardless of whether the Segi or the WHO world population was used as the standard. Conclusions: Ratios of rates age-standardized using the world standard of Segi approximate relative risk as precisely as the WHO standard. For this, and important practical reasons, it is considered unnecessary to replace the Segi standard population for comparisons between cancer rates.	Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon 08, France		Bray, F (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon 08, France.						AHMAD OE, 2000, WHO STANDARD GPE DIS, V31; Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; Esteve J., 1994, IARC SCI PUBLICATION, VIV; Kosary, 2000, SEER CANC STAT REV 1; Parkin DM, 1997, IARC SCI PUBLICATION, VVII; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd; Segi M, 1960, CANC MORTALITY SELEC; Shalala DE, 1998, HHS POLICY CHANGING; Taylor TH, 2000, J NATL CANCER I, V92, P1269, DOI 10.1093/jnci/92.15.1269; *UN, 1999, WORLD POP GROWTH DEM; UNITED NATIONS POPULATION DIVISION, 1999, WORLD POP PROSP 1998, VI; World Health Organization, 1998, WORLD HLTH STAT ANN	12	80	83	0	3	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0957-5243			CANCER CAUSE CONTROL	Cancer Causes Control	MAR	2002	13	2					175	182		10.1023/A:1014344519276			8	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	534EM	WOS:000174571700009	11936824				2022-02-25	
J	Tuyns, AJ				Tuyns, AJ			Alcohol and cancer.	PATHOLOGIE BIOLOGIE			French	Article						alcohol; cancer; Europe; tobacco	ESOPHAGEAL CANCER; BREAST-CANCER; CONSUMPTION; RISK; BEVERAGE; WORKERS; BREWERY; TOBACCO; HEALTH; FRANCE	Regular consumption of alcoholic beverages increases the risk of cancer in the upper aero-digestive tract and in the liver. There is a dose-response relationship and the effects are combined with those of tobacco, according to a multiplicative model. The biologic mechanisms are unclear. Prevention is theoreticaly possible, but the risks concern levels of consumption generally considered as safe. (C) 2001 Editions scientifiques et medicales Elsevier SAS.	CIRC, F-69372 Lyon, France		Tuyns, AJ (corresponding author), CIRC, 150 Cours Albert Thomas, F-69372 Lyon, France.						BOYLE P, 1995, EUR J CANCER, pA31; DEAN G, 1979, BRIT J CANCER, V40, P581, DOI 10.1038/bjc.1979.223; FREUDENHEIM JL, 1990, NUTR CANCER, V13, P101, DOI 10.1080/01635589009514050; Gibel W, 1967, Arch Geschwulstforsch, V30, P181; GIBEL W, 1947, DTSCH GESUNDH WES, V25, P573; Griciute L, 1987, IARC Sci Publ, P264; GRICIUTE L, 1984, IARC SCI PUBL, V56, P413; HIATT RA, 1988, CANCER RES, V48, P2284; HORIE A, 1965, GANN, V56, P429; *IARC, 1997, IARC SCI PUBL, V143; *IARC, 1992, IARC SCI PUBLIC, V120; JENSEN OM, 1979, INT J CANCER, V23, P454, DOI 10.1002/ijc.2910230404; LASSERRE O, 1967, B INSERM, V22, P55; LE MG, 1984, AM J EPIDEMIOL, V120, P35; LIEBER CS, 1984, HEPATOLOGY, V4, P1243, DOI 10.1002/hep.1840040625; LONGNECKER MP, 1990, CANCER CAUSE CONTROL, V1, P5, DOI 10.1007/BF00053178; PEQUIGNOT G, 1978, INT J EPIDEMIOL, V7, P113, DOI 10.1093/ije/7.2.113; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; TUYNS AJ, 1983, INT J CANCER, V32, P443, DOI 10.1002/ijc.2910320408; TUYNS AJ, 1979, INT J CANCER, V23, P443, DOI 10.1002/ijc.2910230402; TUYNS AJ, 1988, INT J CANCER, V41, P483, DOI 10.1002/ijc.2910410403; TUYNS AJ, 1970, INT J CANCER, V5, P152, DOI 10.1002/ijc.2910050120; TUYNS AJ, 1977, B CANCER, V64, P45; Tuyns AJ, 1982, TRENDS CANCER INCIDE, P199; TUYNS AJ, 1982, CANCER EPIDEMIOL, P293; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; *WORLD CANC RES FU, 1997, NUTR PREV CANC GLOB; WYNDER EL, 1969, CANCER, V24, P730, DOI 10.1002/1097-0142(196910)24:4<730::AID-CNCR2820240411>3.0.CO;2-L; [No title captured]	29	5	5	0	1	EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS CEDEX 15	23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE	0369-8114			PATHOL BIOL	Pathol. Biol.	NOV	2001	49	9					759	763		10.1016/S0369-8114(01)00238-3			5	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	495VK	WOS:000172360900013	11762139				2022-02-25	
J	Montesano, R; Hall, J				Montesano, R; Hall, J			Environmental causes of human cancers	EUROPEAN JOURNAL OF CANCER			English	Review						causes; human cancer; environmental carcinogenesis	HEPATITIS-B-VIRUS; PARTICULATE AIR-POLLUTION; EMERGING TOBACCO HAZARDS; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; N-NITROSO COMPOUNDS; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; ESOPHAGEAL CANCER; BREAST-CANCER	Epidemiological studies have clearly shown a causal association between tobacco exposure and various human cancers, hepatitis B and C infection and hepatocellular carcinoma, human papilloma viruses and cervical cancer, and the occupational origin of certain human cancers is well established. The identification of the environmental causes of human cancers has been a long and difficult process. Much remains to be understood about the role of specific components of the diet and the interaction of different risk factors in the aetiology of human cancers. Withstanding the progress made on the understanding of the cancer process and their potential impact in the therapy of cancer, primary prevention remains, in developed and developing countries, the most effective measure to reduce cancer mortality. (C) 2001 Elsevier Science Ltd. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon 08, France		Montesano, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	montesano@iarc.fr	hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295			AHLQUIST KA, 1968, BRIT MED J, V1, P217, DOI 10.1136/bmj.1.5586.217; Anderson LM, 1996, INT J CANCER, V66, P130, DOI 10.1002/(SICI)1097-0215(19960328)66:1<130::AID-IJC22>3.0.CO;2-G; Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BARBER E, 1996, CLIN LAB MED, V16, P377; BARTSCH H, 1984, CARCINOGENESIS, V5, P1381, DOI 10.1093/carcin/5.11.1381; BEASLEY RP, 1981, LANCET, V2, P1129; Beeson WL, 1998, ENVIRON HEALTH PERSP, V106, P813, DOI 10.2307/3434125; Benhamou S, 2000, MUTAT RES-REV MUTAT, V462, P149, DOI 10.1016/S1383-5742(00)00032-6; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; Blaho JA, 1999, P NATL ACAD SCI USA, V96, P7619, DOI 10.1073/pnas.96.14.7619; BLOT WJ, 1992, CANCER RES, V52, pS2119; Blot WJ, 1999, AM J EPIDEMIOL, V150, P1138; Blumberg BS, 1997, P NATL ACAD SCI USA, V94, P7121, DOI 10.1073/pnas.94.14.7121; Boffetta P, 1999, JNCI-J NATL CANCER I, V91, P697, DOI 10.1093/jnci/91.8.697; Boffetta P, 2000, ENVIRON HEALTH PERSP, V108, P73, DOI 10.2307/3454298; Boffetta P, 1998, J NATL CANCER I, V90, P1440, DOI 10.1093/jnci/90.19.1440; Bourdes V, 2000, EUR J EPIDEMIOL, V16, P411, DOI 10.1023/A:1007691003600; BRAUNMUNZINGER P, 1995, PHYS LETT B, V344, P43, DOI 10.1016/0370-2693(94)01534-J; BRECHOT T, 1994, PRIMARY LIVER CANC E; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BULBROOK RD, 1964, NATURE, V201, P189, DOI 10.1038/201189a0; BUSBY W. F., 1984, CHEM CARCINOGENESIS, VII, P945; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Butel JS, 1996, TRENDS MICROBIOL, V4, P119, DOI 10.1016/0966-842X(96)81529-0; Butel JS, 1999, J NATL CANCER I, V91, P1166; Cairns J, 2000, Mutat Res, V462, P423, DOI 10.1016/S1383-5742(00)00030-2; CAIRNS J, 1978, CANC SCI SOC; Cairns J, 1997, MATTERS LIFE DEATH; CARDIS E, 1995, RADIAT RES, V142, P117, DOI 10.2307/3579020; Castellsague X, 1999, INT J CANCER, V82, P657, DOI 10.1002/(SICI)1097-0215(19990827)82:5&lt;657::AID-IJC7&gt;3.0.CO;2-C; Chang MH, 2000, JAMA-J AM MED ASSOC, V284, P3040, DOI 10.1001/jama.284.23.3040; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; Chow WH, 2000, NEW ENGL J MED, V343, P1305, DOI 10.1056/NEJM200011023431804; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CRAWFORD FG, 1994, J NATL CANCER I, V86, P1398, DOI 10.1093/jnci/86.18.1398; Danesh J, 1997, NATURE, V389, P21, DOI 10.1038/37879; Darby S, 1998, BRIT J CANCER, V78, P394, DOI 10.1038/bjc.1998.506; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Doll R, 1999, EUR J CANCER, V35, P16, DOI 10.1016/S0959-8049(98)00348-7; Doll R, 1998, Stat Methods Med Res, V7, P87, DOI 10.1191/096228098668199908; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; Doll R, 1967, PREVENTION CANC POIN; Doll R, 1981, CAUSES CANC QUANTITA; Dubrova YE, 1998, INT J RADIAT BIOL, V74, P689, DOI 10.1080/095530098140952; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; ELLERMANN V, 1908, ZBL BAKT, V46, P595; English DR, 1997, CANCER CAUSE CONTROL, V8, P271, DOI 10.1023/A:1018440801577; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; FERLEY J, 2000, GLOBOCAN 2000 CANC I; Feunteun J, 1998, MOL MED TODAY, V4, P263, DOI 10.1016/S1357-4310(98)01262-3; FLODERUS B, 1988, INT J EPIDEMIOL, V17, P332, DOI 10.1093/ije/17.2.332; Flood A, 2000, JNCI-J NATL CANCER I, V92, P1706, DOI 10.1093/jnci/92.21.1706; FORMAN D, 1989, CANCER SURV, V8, P443; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; French SW, 1996, CLIN LAB MED, V16, P289, DOI 10.1016/S0272-2712(18)30270-1; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; GAO YT, 1994, INT J CANCER, V58, P192, DOI 10.1002/ijc.2910580208; GAO YT, 1994, INT J CANCER, V58, P197, DOI 10.1002/ijc.2910580209; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1992, BMJ-BRIT MED J, V305, P815; Ginsburg ES, 1999, J STEROID BIOCHEM, V69, P299, DOI 10.1016/S0960-0760(99)00047-3; Goedert JJ, 2000, INFECT CAUSES CANC T; Green A, 1999, J Epidemiol, V9, pS7; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guengerich FP, 2000, CARCINOGENESIS, V21, P345, DOI 10.1093/carcin/21.3.345; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall AJ, 1999, BRIT J CANCER, V81, P1097, DOI 10.1038/sj.bjc.6690813; Hall L, 1996, CHEM BRIT, V32, P43; Hecht SS, 2000, J NATL CANCER I, V92, P782, DOI 10.1093/jnci/92.10.782; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HECHT SS, 1994, J NATL CANCER I, V86, P1369, DOI 10.1093/jnci/86.18.1369; HEGMANN KT, 1993, EPIDEMIOLOGY, V4, P444, DOI 10.1097/00001648-199309000-00010; HIGGINSON J, 1968, P ROY SOC MED, V61, P723, DOI 10.1177/003591576806100751; Hori H, 1997, J CLIN GASTROENTEROL, V25, P568, DOI 10.1097/00004836-199712000-00003; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Husgafvel-Pursiainen K, 2000, CANCER RES, V60, P2906; Hussain SP, 1998, CANCER RES, V58, P4023; *IARC, 2001, IARC HDB CANC PREV S, V5; *IARC MON WORK GRO, 1993, IARC MON EV CARC RIS, V56; *IARC MON WORK GRO, 1992, IARC MON EV CARC RIS, V55; *IARC MON WORK GRO, 1995, IARC MON EV CARC RIS, V64; *IARC MON WORK GRO, 2000, IARC MON EV CARC RIS, V75; *IARC MON WORK GRO, 1988, IARC MON EV CARC RIS, V44; *IARC MON WORK GRO, 1988, IARC MON EV CARC RIS, V43; *IARC MON WORK GRO, 1986, IARC MON EV CARC RIS, V38; *IARC MON WORK GRO, 1996, IARC MON EV CARC RIS, V67; *IARC MON WORK GRO, 1987, IARC MON, V1; *IARC MON WORK GRO, 1998, IARC MON EV CARC RIS, V70; *IARC MON WORK GRO, 1994, IARC MON EV CARC RIS, V61; *IARC MON WORK GRO, 1994, IARC MON EV CARC RIS, V59; Jankowski JA, 2000, LANCET, V356, P2079, DOI 10.1016/S0140-6736(00)03411-5; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.0.CO;2-Z; KELLERMANN G, 1973, NEW ENGL J MED, V289, P934, DOI 10.1056/NEJM197311012891802; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KEW MC, 1986, CANCER SURV, V5, P719; Key TJ, 1998, PUBLIC HEALTH NUTR, V1, P33, DOI 10.1079/PHN19980006; KINLEN L, 1988, LANCET, V2, P1323; Kinlen LJ, 1998, CANCER CAUSE CONTROL, V9, P237; KINLEN LJ, 1987, CANCER SURV, V6, P585; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Klebanoff MA, 1996, AM J EPIDEMIOL, V144, P1028, DOI 10.1093/oxfordjournals.aje.a008874; Klein G, 2000, P NATL ACAD SCI USA, V97, P9830, DOI 10.1073/pnas.190325697; Knekt P, 1999, INT J CANCER, V80, P852, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;852::AID-IJC9&gt;3.0.CO;2-S; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; MAGEE PN, 1989, CANCER SURV, V8, P207; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MCKEOWN T., 1988, ORIGINS HUMAN DIS; Michels KB, 2000, JNCI-J NATL CANCER I, V92, P1740, DOI 10.1093/jnci/92.21.1740; Montesano R, 1998, CANCER SURV, V32, P53; MONTESANO R, 1976, MUTAT RES, V32, P179, DOI 10.1016/0165-1110(76)90001-4; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; MONTESANO R, 1984, MUTATION CANC MALFOR, V31, P447; MONTESANO R, 1988, METHODS DETECTING DN, P75; MULLER F. H., 1939, ZEITSCHR KREBSJORSCH, V49, P57; MUNOZ N, 1996, CANC EPIDEMIOLOGY PR, P681; NAKAMURA Y, 2000, PATHOLOGY GENETICS T; Newton R, 1999, CANCER SURV, V33, P237; Niu SR, 1998, BRIT MED J, V317, P1423, DOI 10.1136/bmj.317.7170.1423; Omar RZ, 1999, BRIT J CANCER, V79, P1288, DOI 10.1038/sj.bjc.6690207; Ong EK, 2000, LANCET, V355, P1253, DOI 10.1016/S0140-6736(00)02098-5; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Parker L, 1999, LANCET, V354, P1407, DOI 10.1016/S0140-6736(99)04138-0; Parkin DM, 1999, CANCER SURV, V33, P5; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; PATERLINI P, 1994, PRIMARY LIVER CANC E; PERERA FP, 1982, J CHRON DIS, V35, P581, DOI 10.1016/0021-9681(82)90078-9; Petersen J, 1997, J VIROL, V71, P5455, DOI 10.1128/JVI.71.7.5455-5463.1997; Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; Porter R, 1997, GREATEST BENEFIT MAN; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; ROFFO A. H., 1931, ZEITSCHR KREBSFORSCH, V33, P321, DOI 10.1007/BF01792286; Rohan TE, 2000, CANCER CAUSE CONTROL, V11, P239, DOI 10.1023/A:1008933824645; Rous P, 1911, J AMER MED ASSOC, V56, P198; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SANKARANARAYANAN K, 1995, RADIAT RES, V143, P121, DOI 10.2307/3579149; SCHENKER M, 1993, NEW ENGL J MED, V329, P1807, DOI 10.1056/NEJM199312093292410; Schottenfeld D, 1996, CANC EPIDEMIOLOGY PR; Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sitas F, 1999, NEW ENGL J MED, V340, P1863, DOI 10.1056/NEJM199906173402403; Smith GD, 1996, BRIT MED J, V313, P929; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Sorahan T, 1997, BRIT J CANCER, V76, P1525, DOI 10.1038/bjc.1997.589; Stolley PD, 1995, INVESTIGATING DIS PA; Sugimura T, 2000, CARCINOGENESIS, V21, P387, DOI 10.1093/carcin/21.3.387; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; SWANN PF, 1984, CARCINOGENESIS, V5, P1337, DOI 10.1093/carcin/5.10.1337; The IARC Monograph Working Group, 1989, IARC MON EV CARC RIS, V46; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; Tomatis L, 1997, CARCINOGENESIS, V18, P97, DOI 10.1093/carcin/18.1.97; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; TUYNS A J, 1987, Nutrition and Cancer, V9, P81; TUYNS AJ, 1977, B CANCER, V64, P45; U.S. Department of Health and Human Services, 1989, RED HLTH CONS SMOK 2; *UNSCEAR, 1993, SOURC EFF ION RAD 19; UNSCEAR, 1988, SOURC EFF RISKS ION; van Dam RM, 1999, AM J EPIDEMIOL, V150, P459, DOI 10.1093/oxfordjournals.aje.a010034; Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4; WAGNER J C, 1960, Br J Ind Med, V17, P260; Weiss R, 2000, J NATL CANCER I, V92, P677, DOI 10.1093/jnci/92.9.677; WEISS RA, 1998, VIRUSES HUMAN CANC, P1; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; WILD CP, 1993, ENVIRON HEALTH PERSP, V99, P115, DOI 10.2307/3431466; Wild CP, 1999, CANCER SURV, V33, P35; Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; WOGAN GN, 1992, CANCER RES, V52, pS2114; Woodhead A D, 1999, J Epidemiol, V9, pS102; *WORLD CANC RES FU, 1997, NUTR PREV CANC GLOB; WYNDER EL, 1974, CANCER, V34, P801, DOI 10.1002/1097-0142(197409)34:3+<801::AID-CNCR2820340703>3.0.CO;2-P; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; Yokoyama A, 1996, CANCER EPIDEM BIOMAR, V5, P99; ZIEGLER RG, 1986, CANCER, V58, P1942, DOI 10.1002/1097-0142(19861015)58:8+<1942::AID-CNCR2820581423>3.0.CO;2-N; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; Zur Hausen H, 1999, MICROBES AND MALIGNANCY, P107	205	37	40	5	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	OCT	2001	37			8			S67	S87					21	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	491UA	WOS:000172126400004	11602374				2022-02-25	
J	Rice, JM; Boffetta, P				Rice, JM; Boffetta, P			1,3-Butadiene, isoprene and chloroprene: reviews by the IARC monographs programme, outstanding issues, and research priorities in epidemiology	CHEMICO-BIOLOGICAL INTERACTIONS			English	Article; Proceedings Paper	38th European Congress of Toxicology	SEP 12-14, 2001	LONDON, ENGLAND			1.3-butadiene; isoprene; chloroprene; IARC; monographs; epidemiology	MORTALITY; WORKERS	1,3-Butadiene, isoprene and chloroprene have all been evaluated more than once by the IARC Monographs Programme on the Evaluation of Carcinogenic Risks to Humans, most recently in February 1998 (Volume 71). Summaries are available on-line at http://monographs.iarc.fr. 1,3-Butadiene is currently classified in Group 2A (probably carcinogenic to humans), on the basis of limited evidence for increased occupational cancer risk in humans plus sufficient evidence of carcinogenicity at multiple organ sites in rats and especially in mice exposed by inhalation. Four epidemiologic studies are available on cancer risk among workers exposed to 1,3-butadiene, one large study among styrene-butadiene rubber (SBR) workers, and one large and two small studies among 1,3-butadiene production workers. The results of the study of SBR workers suggest an association between butadiene exposure and leukaemia risk, which is consistent with the results of the large study of production workers. This latter study also suggested an increased risk of lymphoreticulosarcoma (ICD-8, 200). The major factors hampering the assessment of the available results are (i) possible misclassification of lymphoid and haematopoietic neoplasms, (ii) limitations in the assessment of past exposure (with the exception of the study of SBR workers) and (iii) a potential confounding effect of agents other than butadiene. Future research priorities include (i) the incorporation of newly developed biomarkers of exposure, (ii) the possible application of intermediate biomarkers, (iii) the replication of the study among SBR workers, possibly in Europe, and (iv) reanalysis of existing data in light of revisions of the classifications of leukaemias and lymphomas in the International Classification of Diseases for Oncology, Third Edition (2000). Isoprene is classified in Group 2B (possibly, carcinogenic to humans), on the basis of sufficient evidence for carcinogenicity at multiple organ sites in both mice and rats, especially male mice. exposed by inhalation. No epidemiologic studies are available on cancer risk from occupational exposure to isoprene. Such studies could be conducted within the framework of existing or future studies of SBR workers. assuming that isoprene exposure can be disentangled from butadiene and styrene exposure. Chloroprene is classified in Group 2B on the basis of sufficient evidence for carcinogenicity at multiple organ sites in both mice and rats exposed by inhalation. Studies of chloroprene exposed workers now include chemical workers from the United States. China and Armenia as well as shoe workers from Russia. The results of the studies from China, Armenia and Russia suggest an excess risk of liver cancer. The risk of other neoplasms was not consistently increased. Limitations of available studies include possible bias from cohort enumeration, follow-up, and choice of reference population. In most studies the exposure assessment was poor, the possible confounding effect of co-exposures was not addressed and the statistical power was low. The pathology of the cases of liver cancer should be reviewed. Future research priorities include a replication of available studies in well-defined populations and the development of biomarkers of exposure. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Int Agcy Res Canc, IARC Monographs Programme, F-69372 Lyon 08, France; Int Agcy Res Canc, Unit Environm Canc Epidemiol, F-69372 Lyon 08, France		Rice, JM (corresponding author), Int Agcy Res Canc, IARC Monographs Programme, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	rice@iarc.fr					[Anonymous], 1999, IARC Monogr Eval Carcinog Risks Hum, V71 Pt 1, P109; [Anonymous], 1999, IARC Monogr Eval Carcinog Risks Hum, V71 Pt 3, P1015; Bulbulyan MA, 1998, CANCER CAUSE CONTROL, V9, P381, DOI 10.1023/A:1008863516506; Bulbulyan MA, 1999, INT J CANCER, V81, P31, DOI 10.1002/(SICI)1097-0215(19990331)81:1<31::AID-IJC6>3.0.CO;2-T; FRITZ A, 2000, INT CLASSIFICATION D, P13; GELMONT D, 1981, BIOCHEM BIOPH RES CO, V99, P1456, DOI 10.1016/0006-291X(81)90782-8; Harris NL, 2000, MODERN PATHOL, V13, P193, DOI 10.1038/modpathol.3880035; *IARC, 1986, IARC MON EV CARC RIS, V39; *IARC, 1974, IARC MON EV CARC RIS, V7, P291; *IARC, 1982, IARC MON EV CARC RIS, V28, P21; IARC, 1999, IARC MON EV CARC RIS, V73, P307; *IARC, 1991, IARC MON EV CARC RIS, V53, P423; IARC, 1994, IARC MON EV CARC RIS, V60, P45; *IARC, 1999, IARC MON EV CARC RIS, V71, P227; *IARC, 1987, IARC MON EV CARC R S, V7, P160; IARC, 1987, IARC MON EV CARC R S, V1-42, P373; *IARC, 1987, IARC MON EV CARC R S, V7, P136; *IARC, 1992, IARC MON EV CARC RIS, V54, P237; *IARC, 1974, IARC MON EV CARC RIS, V19; *IARC, 1987, IARC MON EV CARC RIS, V7, P332; IARC, 1994, IARC MON EV CARC RIS, V60; *IARC, 1992, IARC MON EV CARC RIS, V54, P13; IARC, 1987, IARC MON, V1-42, P17; IARC International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, V60, P321; INFANTE PF, 1977, ENVIRON HEALTH PERSP, V21, P251, DOI 10.2307/3428530; *INT PROGR CHEM SA, 1999, ENV HLTH CRIT WHO, V215, P190; Jackson MA, 2000, MUTAT RES-REV MUTAT, V463, P181, DOI 10.1016/S1383-5742(00)00056-9; Li S Q, 1989, Biomed Environ Sci, V2, P141; McGregor DB, 1999, IARC SCI PUBL, P1; PELL S, 1978, J OCCUP ENVIRON MED, V20, P21, DOI 10.1097/00043764-197801000-00006; *US DEP HHS, 2000, 9 US DEP HLTH HUM SE, P14; WHO INT AGCY RES CANC, 1994, IARC MONOG EVAL CARC, V60, P215; WHO INT AGCY RES CANC, 1994, IARC MONOG EVAL CARC, V60, P73; WHO INT AGCY RES CANC, 1994, IARC MONOG EVAL CARC, V60, P233; ZAJDELA F, 1980, CANCER RES, V40, P352	35	25	27	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0009-2797	1872-7786		CHEM-BIOL INTERACT	Chem.-Biol. Interact.	JUN 1	2001	135				SI		11	26		10.1016/S0009-2797(01)00175-2			16	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	470PU	WOS:000170881000002	11397378				2022-02-25	
J	Baussano, I; Bray, F				Baussano, Iacopo; Bray, Freddie			Modelling cervical cancer elimination	LANCET PUBLIC HEALTH			English	Editorial Material							TRENDS		[Baussano, Iacopo] Int Agcy Res Canc, Infect & Canc Epidemiol Grp, F-69372 Lyon 08, France; [Bray, Freddie] Int Agcy Res Canc, Sect Canc Surveillance, F-69372 Lyon 08, France		Baussano, I (corresponding author), Int Agcy Res Canc, Infect & Canc Epidemiol Grp, F-69372 Lyon 08, France.	baussanoi@iarc.fr		Bray, Freddie/0000-0002-3248-7787			Baussano I, 2013, INT J CANCER, V133, P1876, DOI 10.1002/ijc.28197; Boerma T, 2018, LANCET, V392, P607, DOI 10.1016/S0140-6736(18)30586-5; Bray, 2017, CANC INCIDENCE 5 CON, VXI; Brisson M, 2016, LANCET PUBLIC HEALTH, V1, pE8, DOI 10.1016/S2468-2667(16)30001-9; Campos NG, 2017, INT J CANCER, V140, P1293, DOI 10.1002/ijc.30551; Chokunonga E, 2013, INT J CANCER, V133, P721, DOI 10.1002/ijc.28063; Garnett GP, 2011, LANCET, V378, P515, DOI 10.1016/S0140-6736(10)61505-X; Hall MT, 2019, LANCET PUBLIC HEALTH, V4, pE19, DOI 10.1016/S2468-2667(18)30183-X; Hall MT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0185332; Wabinga HR, 2014, INT J CANCER, V135, P432, DOI 10.1002/ijc.28661; WHO, 2018, WHO DIR GEN CALLS AL; World Health Organization, 2018, WORLD HLTH STAT 2018	12	6	6	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2468-2667			LANCET PUBLIC HEALTH	Lancet Public Health	JAN	2019	4	1					E2	E3		10.1016/S2468-2667(18)30189-0			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	HG6UY	WOS:000455122800002	30291039	gold			2022-02-25	
J	Saracci, R				Saracci, Rodolfo			The hazards of hazard identification in environmental epidemiology	ENVIRONMENTAL HEALTH			English	Editorial Material						Bayes' theorem; Conflict of interest; Hazard identification; IARC Monographs; Linearity; Model assumptions; Risk assessment; Threshold	RISK; EXTRAPOLATION	Hazard identification is a major scientific challenge, notably for environmental epidemiology, and is often surrounded, as the recent case of glyphosate shows, by debate arising in the first place by the inherently problematic nature of many components of the identification process. Particularly relevant in this respect are components less amenable to logical or mathematical formalization and essentially dependent on scientists' judgment. Four such potentially hazardous components that are capable of distorting the correct process of hazard identification are reviewed and discussed from an epidemiologist perspective: (1) lexical mix-up of hazard and risk (2) scientific questions as distinct from testable hypotheses, and implications for the hierarchy of strength of evidence obtainable from different types of study designs (3) assumptions in prior beliefs and model choices and (4) conflicts of interest. Four suggestions are put forward to strengthen a process that remains in several aspects judgmental, but not arbitrary, in nature.	[Saracci, Rodolfo] Int Agcy Res Canc, Lyon, France		Saracci, R (corresponding author), Int Agcy Res Canc, Lyon, France.	saracci@hotmail.com					[Anonymous], 1976, JAMA, V235, P825; Bulmer MG, 1967, PRINCIPLES STAT; Calabrese EJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122034; Cardis E, 2010, INT J EPIDEMIOL, V39, P675, DOI 10.1093/ije/dyq079; Clayton D, 2013, STAT MODELS EPIDEMIO; Cressey D, 2015, NATURE, V523; CRUMP KS, 1976, CANCER RES, V36, P2973; Doll R, 1967, PREVENTION CANC POIN; Foucart S, 2017, MONDE; Grandjean P, 2016, BASIC CLIN PHARMACOL, V119, P126, DOI 10.1111/bcpt.12622; Higgins PTJ, COCHRANE HDB SYSTEMA; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; International Agency for Research on Cancer, MON EV CARC RISKS HU, V1-118; International Agency for Research on Cancer, MON EV CARC RISKS HU; Lawlor DA, 2017, TRIANGULATION AETIOL, DOI [10.1093/ije/dyw314, DOI 10.1093/IJE/DYW314.]; Lo B., 2009, CONFLICT INTEREST ME; Lundh A., 2017, COCHRANE DB SYST REV, P162; Mandrioli D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162198; Mastrandrea MD, 2017, GUIDENCE NOTE LEAD A; Michaels D, 2008, DOUBT IS THEIR PRODU; Morgan RL, 2016, ENVIRON INT, V92-93, P611, DOI 10.1016/j.envint.2016.01.004; National Academies of Sciences-Engineering-Medicine, 2017, US 21 CENT SCI IMPR; Pearl J, 2016, J CAUSAL INFERENCE, V4, DOI 10.1515/jci-2016-0021; PETO R, 1978, ENVIRON HEALTH PERSP, V22, P155, DOI 10.2307/3428568; Rhomberg LR, 2011, CRIT REV TOXICOL, V41, P1, DOI 10.3109/10408444.2010.536524; Ryan R, 2013, COCHRANE CONSUMERS C; Thoreau HD, 1854, THOREAU HD JOURNALS, P11; VanderWeele TJ, 2015, METHODS MEDIATION IN; Vineis P, 2015, J EPIDEMIOL COMMUN H, V69, P1018, DOI 10.1136/jech-2014-205012; White RH, 2009, ENVIRON HEALTH PERSP, V117, P283, DOI 10.1289/ehp.11502; Woolley AW, 2010, SCIENCE, V330, P686, DOI 10.1126/science.1193147	31	7	7	1	15	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1476-069X			ENVIRON HEALTH-GLOB	Environ. Health	AUG 9	2017	16								85	10.1186/s12940-017-0296-3			8	Environmental Sciences; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	FD0FC	WOS:000407214200001	28793913	Green Published, gold			2022-02-25	
J	Bray, F; Soerjomataram, I; Mery, L; Ferlay, J				Bray, Freddie; Soerjomataram, Isabelle; Mery, Les; Ferlay, Jacques			Improving the quality and coverage of cancer registries globally	LANCET			English	Letter							SYSTEMATIC ANALYSIS; MORTALITY		[Bray, Freddie; Soerjomataram, Isabelle; Mery, Les; Ferlay, Jacques] Int Agcy Res Canc, Canc Surveillance Sect, F-69372 Lyon 8, France		Bray, F (corresponding author), Int Agcy Res Canc, Canc Surveillance Sect, F-69372 Lyon 8, France.	brayf@iarc.fr	Ferlay, Jacques/ABD-5058-2021	Bray, Freddie/0000-0002-3248-7787			Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2; Krieger Nancy, 2012, Lancet, V379, P1391, DOI 10.1016/S0140-6736(12)60596-0; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; National Cancer Center Ministry of Health and Welfare, 2014, KOR CENTR CANC REG A	6	8	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2015	386	9998					1035	1036		10.1016/S0140-6736(15)00135-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR2VQ	WOS:000361189200014	26382988	Green Published			2022-02-25	
J	Grosse, Y; Loomis, D; Guyton, KZ; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Scoccianti, C; Mattock, H; Straif, K				Grosse, Yann; Loomis, Dana; Guyton, Kathryn Z.; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Scoccianti, Chiara; Mattock, Heidi; Straif, Kurt		Int Agcy Res Canc Monogr Grp	Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes	LANCET ONCOLOGY			English	News Item							INHALATION EXPOSURE; MESOTHELIOMA; INDUCTION; RATS		[Grosse, Yann; Loomis, Dana; Guyton, Kathryn Z.; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Scoccianti, Chiara; Mattock, Heidi; Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon, France		Grosse, Y (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Loomis, Dana/AAE-3988-2019; Guha, Neela/AAG-3989-2021; Vermeulen, Roel/F-8037-2011; JAURAND, MARIE-CLAUDE/S-3538-2017	Guha, Neela/0000-0003-3991-4662; Vermeulen, Roel/0000-0003-4082-8163; Loomis, Dana/0000-0003-3297-5200; JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; Lauby-Secretan, Beatrice/0000-0001-6559-3351			Belpoggi F, 2011, EUR J ONCOL, V16, P185; Bruno C, 2014, ANN I SUPER SANITA, V50, P111, DOI 10.4415/ANN_14_02_02; Bugge MD, 2012, OCCUP ENVIRON MED, V69, P527, DOI 10.1136/oemed-2011-100623; INFANTERIVARD C, 1994, AM J EPIDEMIOL, V140, P1009, DOI 10.1093/oxfordjournals.aje.a117190; International Agency for Research on Cancer, 2012, IARC MONOGR EVAL C C, V100C, P219; International Agency for Research on Cancer, 2014, IARC MON EV IN PRESS, V111; Johnson NF, 1996, OCCUP ENVIRON MED, V53, P813, DOI 10.1136/oem.53.12.813; Mercer RR, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-33; Nagai H, 2011, P NATL ACAD SCI USA, V108, pE1330, DOI 10.1073/pnas.1110013108; Pauluhn J, 2010, TOXICOL SCI, V113, P226, DOI 10.1093/toxsci/kfp247; Sakamoto Y, 2009, J TOXICOL SCI, V34, P65, DOI 10.2131/jts.34.65; Sargent LM, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-3; Sargent LM, 2012, MUTAT RES; Shvedova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL552, DOI 10.1152/ajplung.90287.2008; Shvedova AA, 2014, AM J PHYSIOL-LUNG C, V306, pL170, DOI 10.1152/ajplung.00167.2013; Siegrist KJ, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-6; Takagi A, 2012, CANCER SCI, V103, P1440, DOI 10.1111/j.1349-7006.2012.02318.x	17	195	199	1	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	DEC	2014	15	13					1427	1428		10.1016/S1470-2045(14)71109-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AX4OT	WOS:000346912300041	25499275	Green Submitted			2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R.			Screening for Cancer in Low- and Middle-Income Countries	ANNALS OF GLOBAL HEALTH			English	Review						breast cancer; cervical cancer; colorectal cancer; cytology; early detection; fecal occult blood test; HPV testing; oral cancer; screening; visual screen	CERVICAL-CANCER; RANDOMIZED-TRIAL; FOLLOW-UP; 3 ROUNDS; BREAST; MORTALITY; INDIA; PROGRAMS; BENEFITS; KERALA	Background: Screening programs involve testing asymptomatic individuals with an accurate screening test to identify those likely to have the disease of interest and to further investigate them to confirm or exclude the disease. The aim of cancer screening is to prevent cancer deaths and improve quality of life by finding cancers early and by effectively treating them. A decision to introduce a screening program in public health services depends on the evidence that the benefits outweigh the harms of screening, disease burden, availability of suitable screening test, effective treatment, adequate resources, and efficient health services. Screening programs should achieve high participation for testing, diagnosis, and treatment to be effective and efficient. Objective: To describe the current status of cancer screening programs in low-and middle-income countries (LMICs). Method: A review of literature and on-going cancer screening initiatives in LMICs was made to discuss cancer screening in these countries. Findings: Although population-based programs offering Papanicolaou testing every 3 to 5 years have reduced cervical cancer incidence and mortality in high-income countries, such programs have been less successful in reducing cervical cancer burden in LMICs due to poor organization, lack of coverage, and lack of quality assurance. The challenges in introducing high-quality cytology screening in LMICs have led to evaluation of alternative screening approaches such as visual inspection with acetic acid (VIA), human papillomavirus (HPV) testing-based screening, and novel paradigms such as a "single-visit screen and treat" in which treatment with cryotherapy or cold coagulation is provided to screen-positive women without clinical evidence of cancer. Both HPV testing and VIA have been found to prevent cervical neoplasia and cervical cancer deaths in clinical trials. Although mammography screening reduces breast cancer mortality, associated overdiagnosis and overtreatment and the balance between benefits and harms have received much attention in recent years. Although introduction of clinical breast examination screening in LMICs should wait for evidence from ongoing trials, improving breast awareness and access to early diagnosis and treatment in health services is a valuable breast cancer control option in LMICs. Organized colorectal cancer screening programs are still evolving and are in early stages of development in many high-income countries. To date, there is insufficient evidence to support the introduction of population-based stomach, lung, ovarian, and prostate cancer screening in public health services. Conclusions: Implementation of VIA screening in several LMICs is conducive to future HPV screening programs when affordable HPV tests become widely available. Both HPV vaccination and HPV screening have a huge potential to eliminate cervical cancer in LMICs. A mammography screening program is a complex undertaking involving substantial resources and infrastructure that may not be feasible in many LMICs.	WHO, IARC, Head Early Detect & Prevent Sect, Lyon, France		Sankaranarayanan, R (corresponding author), WHO, IARC, Head Early Detect & Prevent Sect, Lyon, France.	sankarr@iarc.fr			World Health OrganizationWorld Health Organization [001] Funding Source: Medline		Bach PB, 2012, JAMA-J AM MED ASSOC, V307, P2418, DOI 10.1001/jama.2012.5521; Baldur-Felskov B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt460; Choi KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050041; Garland SM, 2014, CLIN THER, V36, P17, DOI 10.1016/j.clinthera.2013.12.005; Gotzsche PC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001877.pub5; Hewitson P, 2008, AM J GASTROENTEROL, V103, P1541, DOI 10.1111/j.1572-0241.2008.01875.x; IARC, 2005, IARC HDB CANC PREV, V10; Ilic D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004720.pub3; International Agency for Cancer on Research (IARC) World Health Organization, 2002, IARC HDB CANC PREV, V7; Khuhaprema T, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003671; Madlensky L, 2003, EUR J CANCER, V39, P1648, DOI 10.1016/S0959-8049(03)00315-0; Menon U, 2014, GYNECOL ONCOL, V132, P490, DOI 10.1016/j.ygyno.2013.11.030; Miles A, 2004, CANCER-AM CANCER SOC, V101, P1201, DOI 10.1002/cncr.20505; Miller Anthony B, 2014, BMJ, V348, pg366, DOI 10.1136/bmj.g366; Mittra I, 2010, INT J CANCER, V126, P976, DOI 10.1002/ijc.24840; Murillo R, 2008, VACCINE, V26, pL37, DOI 10.1016/j.vaccine.2008.06.013; Mwanahamuntu MH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001032; Nene BM, 2008, INT J GYNECOL OBSTET, V103, P232, DOI 10.1016/j.ijgo.2008.07.016; Pace LE, 2014, JAMA-J AM MED ASSOC, V311, P1327, DOI 10.1001/jama.2014.1398; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Sahasrabuddhe VV, 2012, INT J CANCER, V130, P234, DOI 10.1002/ijc.25971; Sankaranarayanan R, 2005, LANCET, V365, P1927, DOI 10.1016/S0140-6736(05)66658-5; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 2007, LANCET, V370, P398, DOI 10.1016/S0140-6736(07)61195-7; Sankaranarayanan R, 2013, ORAL ONCOL, V49, P314, DOI 10.1016/j.oraloncology.2012.11.004; Sankaranarayanan R, 2012, BEST PRACT RES CL OB, V26, P221, DOI 10.1016/j.bpobgyn.2011.08.003; Sankaranarayanan R, 2011, JNCI-J NATL CANCER I, V103, P1476, DOI 10.1093/jnci/djr304; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Shastri SS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju009; Steele RJC, 2009, GUT, V58, P530, DOI 10.1136/gut.2008.162883; Steele RJC, 2004, BMJ-BRIT MED J, V329, P133, DOI 10.1136/bmj.38153.491887.7C; Subramanian S, 2009, B WORLD HEALTH ORGAN, V87, P198, DOI 10.2471/BLT.08.053231; Thomas DB, 2002, JNCI-J NATL CANCER I, V94, P1445, DOI 10.1093/jnci/94.19.1445; WHO, 2013, WHO GUID WHO GUID SC; World Health Organization, 2013, WHO GUID NOT COMP CE	35	120	125	2	18	UBIQUITY PRESS LTD	LONDON	2N, 6 OSBORNE ST, LONDON, E1 6TD, ENGLAND	2214-9996			ANN GLOB HEALTH	Ann. Glob. Health	SEP-OCT	2014	80	5					412	417		10.1016/j.aogh.2014.09.014			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	AZ6IN	WOS:000348323400008	25512156	gold			2022-02-25	
J	Sauvaget, C; Muwonge, R; Sankaranarayanan, R				Sauvaget, Catherine; Muwonge, Richard; Sankaranarayanan, Rengaswamy			Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia	INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS			English	Review						Cervical intraepithelial neoplasia; Cryotherapy; Effectiveness; Healthcare intervention; Pooled analysis; Safety	SINGLE-VISIT APPROACH; CANCER PREVENTION; VISUAL INSPECTION; ACETIC-ACID; ACCEPTABILITY; SAFETY; FEASIBILITY	Background: Cryotherapy can be used for the ablation of cervical intraepithelial neoplasia (CIN). Objectives: To provide an updated and comprehensive estimate of the efficacy of cryotherapy for CIN. Search strategy: A literature search identified original studies (randomized controlled trials and clinical reports). Selection criteria: Studies reporting cure rates, acceptability, and safety of cryotherapy were included in the analysis. Data collection and analysis: Number of persistent or recurrent lesions at follow-up, adverse events, and complications were recorded. Quality of the methodology was also assessed. Meta-analyses were performed according to CIN thresholds, geographic region, study year, setting, study design, presence of endocervical involvement, freezing method, duration of follow-up, and status of the cryotherapy provider. Main results: A total of 146 articles were retrieved; 77 papers-equivalent to 28 827 cases of treated CIN-were included in the meta-analysis. Cryotherapy achieved cure rates of 94.0% (CIN1), 92.0% (CIN2), and 85.0% (CIN3). Use of the double-freeze method and absence of endocervical involvement significantly increased cure rates. Minimal complications were reported as adverse effects. Conclusions: Cryotherapy is an effective, safe, and acceptable treatment for CIN. It has been shown to be successful in low-resource settings, enabling availability and accessibility of early detection services. (C) 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.	[Sauvaget, Catherine; Muwonge, Richard; Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Early Detect & Prevent Sect, Screening Grp, F-69372 Lyon 08, France		Sauvaget, C (corresponding author), Int Agcy Res Canc, Early Detect & Prevent Sect, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	sauvagetc@iarc.fr	Muwonge, Richard/P-6375-2015	Sauvaget, Catherine/0000-0002-8053-4963			Blumenthal PD, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.12.031; Blumenthal PD, 2005, INT J GYNECOL OBSTET, V89, pS30, DOI 10.1016/j.ijgo.2005.01.012; Castro W., 2003, EFFECTIVENESS SAFETY; Chumworathayi B, 2008, INT J GYNECOL CANCER, V18, P736, DOI 10.1111/j.1525-1438.2007.01112.x; Denny L, 2010, JNCI-J NATL CANCER I, V102, P1557, DOI 10.1093/jnci/djq342; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; FERENCZY A, 1985, OBSTET GYNECOL, V66, P793; Gaffikin L, 2003, LANCET, V361, P814, DOI 10.1016/S0140-6736(03)12707-9; Jacob M, 2005, INT J GYNECOL OBSTET, V89, pS13, DOI 10.1016/j.ijgo.2005.01.026; LICKRISH GM, 1977, CAN MED ASSOC J, V116, P641; Martin-Hirsch PPL, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001318.pub2, 10.1002/14651858.CD001421.pub3]; Nene BM, 2008, INT J GYNECOL OBSTET, V103, P232, DOI 10.1016/j.ijgo.2008.07.016; Phongsavan K, 2011, INT J GYNECOL OBSTET, V114, P268, DOI 10.1016/j.ijgo.2011.03.009; Sankaranarayanan R, 2007, BRIT J CANCER, V96, P738, DOI 10.1038/sj.bjc.6603633	14	56	59	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7292	1879-3479		INT J GYNECOL OBSTET	Int. J. Gynecol. Obstet.	MAR	2013	120	3					218	223		10.1016/j.ijgo.2012.10.014			6	Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology	095YF	WOS:000315370200002	23265830				2022-02-25	
J	Franceschi, S				Franceschi, S.			Childhood leukaemia and socioeconomic status	BRITISH JOURNAL OF CANCER			English	Letter									Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Dockerty JD, 2001, INT J EPIDEMIOL, V30, P1428, DOI 10.1093/ije/30.6.1428; Kroll ME, 2011, BRIT J CANCER, V105, P1783, DOI 10.1038/bjc.2011.415	2	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920			BRIT J CANCER	Br. J. Cancer	JUN 26	2012	107	1					215	215		10.1038/bjc.2012.170			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	967EE	WOS:000305888400033	22691972	Green Published, hybrid			2022-02-25	
J	de Martel, C; Ferlay, J; Franceschi, S; Vignat, J; Bray, F; Forman, D; Plummer, M				de Martel, Catherine; Ferlay, Jacques; Franceschi, Silvia; Vignat, Jerome; Bray, Freddie; Forman, David; Plummer, Martyn			Global burden of cancers attributable to infections in 2008: a review and synthetic analysis	LANCET ONCOLOGY			English	Article							HELICOBACTER-PYLORI INFECTION; C VIRUS-INFECTIONS; HEPATITIS-B; HEPATOCELLULAR-CARCINOMA; HUMAN-PAPILLOMAVIRUS; METAANALYSIS; PREVALENCE; FRACTION; RISK	Background Infections with certain viruses, bacteria, and parasites have been identified as strong risk factors for specific cancers. An update of their respective contribution to the global burden of cancer is warranted. Methods We considered infectious agents classified as carcinogenic to humans by the International Agency for Research on Cancer. We calculated their population attributable fraction worldwide and in eight geographical regions, using statistics on estimated cancer incidence in 2008. When associations were very strong, calculations were based on the prevalence of infection in cancer cases rather than in the general population. Estimates of infection prevalence and relative risk were extracted from published data. Findings Of the 12.7 million new cancer cases that occurred in 2008, the population attributable fraction (PAF) for infectious agents was 16.1%, meaning that around 2 million new cancer cases were attributable to infections. This fraction was higher in less developed countries (22.9%) than in more developed countries (7.4%), and varied from 3.3% in Australia and New Zealand to 32.7% in sub-Saharan Africa. Helicobacter pylori, hepatitis B and C viruses, and human papillomaviruses were responsible for 1.9 million cases, mainly gastric, liver, and cervix uteri cancers. In women, cervix uteri cancer accounted for about half of the infection-related burden of cancer; in men, liver and gastric cancers accounted for more than 80%. Around 30% of infection-attributable cases occur in people younger than 50 years. Interpretation Around 2 million cancer cases each year are caused by infectious agents. Application of existing public health methods for infection prevention, such as vaccination, safer injection practice, or antimicrobial treatments, could have a substantial effect on the future burden of cancer worldwide.	[de Martel, Catherine; Ferlay, Jacques; Franceschi, Silvia; Vignat, Jerome; Bray, Freddie; Forman, David; Plummer, Martyn] Int Agcy Res Canc, F-69372 Lyon 08, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	plummerm@iarc.fr	Ferlay, Jacques/ABD-5058-2021; franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Bray, Freddie/0000-0002-3248-7787; Plummer, Martyn/0000-0001-5130-6497	Fondation Innovations en Infectiologie (FINOVI); Bill & Melinda Gates Foundation (BMGF)Bill & Melinda Gates Foundation; Bill & Melinda Gates Foundation (BMGF), USA [35537]	Fondation Innovations en Infectiologie (FINOVI) and the Bill & Melinda Gates Foundation (BMGF).; CDM was funded by Fondation Innovations en Infectiologie (FINOVI) and the Bill & Melinda Gates Foundation (BMGF), USA (grant number 35537). We thank Veronique Chabanis for technical assistance.	Backes DM, 2009, CANCER CAUSE CONTROL, V20, P449, DOI 10.1007/s10552-008-9276-9; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Brenner H, 2004, AM J EPIDEMIOL, V159, P252, DOI 10.1093/aje/kwh039; Chang MH, 2009, JNCI-J NATL CANCER I, V101, P1348, DOI 10.1093/jnci/djp288; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; Dal Maso L, 2006, CANCER EPIDEM BIOMAR, V15, P2078, DOI 10.1158/1055-9965.EPI-06-0308; De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Dondog B, 2011, EUR J CANCER PREV, V20, P33, DOI 10.1097/CEJ.0b013e32833f0c8e; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Ferlay J, 2010, IARC CANCERBASE; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Herrera V, 2009, CLIN MICROBIOL INFEC, V15, P971, DOI 10.1111/j.1469-0691.2009.03031.x; IARC, 2011, IARC MON EV CARC R B, V100; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; Mitchell H, 2008, ALIMENT PHARM THER, V28, P903, DOI 10.1111/j.1365-2036.2008.03792.x; Parkin DM, 2011, BRIT J CANCER, V105, pS49, DOI 10.1038/bjc.2011.484; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; Shin A, 2011, ANN ONCOL, V22, P1435, DOI 10.1093/annonc/mdq592; Siman JH, 2007, SCAND J GASTROENTERO, V42, P933, DOI 10.1080/00365520601173863; UN (United Nations), 2009, WORLD POP PROSP 2008; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; WHO, 2010, WEEKL EP REP HEP B V; Xiang W, 2011, CANCER CAUSE CONTROL, V22, P1153, DOI 10.1007/s10552-011-9791-y	26	1309	1354	4	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUN	2012	13	6								10.1016/S1470-2045(12)70137-7			9	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	948YV	WOS:000304541200036	22575588		Y	N	2022-02-25	
J	Baan, R; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Islami, F; Galichet, L; Straif, K				Baan, Robert; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Islami, Farhad; Galichet, Laurent; Straif, Kurt		WHO Int Agcy Res Canc Monograph Wo	Carcinogenicity of radiofrequency electromagnetic fields	LANCET ONCOLOGY			English	News Item							CELLULAR-TELEPHONE USE; BRAIN-TUMORS; MOBILE; RISK; CANCER		[Baan, Robert; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Islami, Farhad; Galichet, Laurent; Straif, Kurt; WHO Int Agcy Res Canc Monograph Wo] Int Agcy Res Canc, F-69372 Lyon, France		Baan, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Röösli, Martin/A-2658-2008; Guha, Neela/AAG-3989-2021; Belyaev, Igor Y/I-4029-2018; Cardis, Elisabeth/C-3904-2017	Röösli, Martin/0000-0002-7475-1531; Guha, Neela/0000-0003-3991-4662; Cardis, Elisabeth/0000-0003-0999-6839; Sim, Malcolm/0000-0003-4739-2817; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Islami, Farhad/0000-0002-7357-5994; Mevissen, Meike/0000-0001-8766-9556			Auvinen A, 2002, EPIDEMIOLOGY, V13, P356, DOI 10.1097/00001648-200205000-00018; Cardis E, 2011, OCCUP ENVIRON MED, V68, P631, DOI 10.1136/oemed-2011-100155; Cardis E, 2010, INT J EPIDEMIOL, V39, P675, DOI 10.1093/ije/dyq079; Christ A, 2010, PHYS MED BIOL, V55, P1767, DOI 10.1088/0031-9155/55/7/001; Hardell L, 2011, INT J ONCOL, V38, P1465, DOI 10.3892/ijo.2011.947; Hruby R, 2008, MUTAT RES-GEN TOX EN, V649, P34, DOI 10.1016/j.mrgentox.2007.07.016; IARC, IARC MON EV IN PRESS, V102; Inskip PD, 2001, NEW ENGL J MED, V344, P79, DOI 10.1056/NEJM200101113440201; Kuhn S, 2009, PHYS MED BIOL, V54, P5493, DOI 10.1088/0031-9155/54/18/010; Muscat JE, 2000, JAMA-J AM MED ASSOC, V284, P3001, DOI 10.1001/jama.284.23.3001; Repacholi MH, 1997, RADIAT RES, V147, P631, DOI 10.2307/3579630; Sato Y, 2011, BIOELECTROMAGNETICS, V32, P85, DOI 10.1002/bem.20616; Schuz J, 2006, JNCI-J NATL CANCER I, V98, P1707, DOI 10.1093/jnci/djj464; SZMIGIELSKI S, 1982, BIOELECTROMAGNETICS, V3, P179, DOI 10.1002/bem.2250030202	14	350	373	3	94	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUL	2011	12	7					624	626		10.1016/S1470-2045(11)70147-4			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	791CU	WOS:000292640200013	21845765				2022-02-25	
J	de Martel, C; Plummer, M; Franceschi, S				de Martel, C.; Plummer, M.; Franceschi, S.			Cholangiocarcinoma: Descriptive epidemiology and risk factors	GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE			English	Article							PRIMARY SCLEROSING CHOLANGITIS; HEPATITIS-B-VIRUS; INTRAHEPATIC CHOLANGIOCARCINOMA; UNITED-STATES; EXTRAHEPATIC CHOLANGIOCARCINOMA; OPISTHORCHIS-VIVERRINI; NORTHEAST THAILAND; KLATSKIN-TUMORS; MORTALITY-RATES; BILIARY	In theory, the term of cholangiocarcinoma is reserved for the tumours originating from the intrahepatic bile ducts. The problems of classification of the most frequent hilar tumours and the absence of histopathological confirmation in a large percentage of cases in cancer registries from many countries show the difficulty of establishing the specific epidemiologic behaviour of intrahepatic cholangiocarcinoma (ICC). There are clearly two types of ICC: the first one is the consequence of the recurrent infection of the biliary ducts by the parasites Opisthorchis viverrini and Clonorchis sinensis, and is only seen in the areas of Southeast Asia where liver flukes are endemic. In these areas, incidence and mortality rates of ICC are extremely high. Both parasites have been classified class I carcinogens by the International Agency for Research on Cancer. The other type of ICC is a cancer much rarer but present in the whole world. Some risk factors have been well-established (chronic inflammation of biliary ducts, hepatitis, thorotrast, etc) but many patients do not have any of these factors. An increase in incidence and mortality of this second type of ICC has been seen in recent years, mostly in developed countries. There is an ongoing discussion in the literature about its authenticity and potential causes. (C) 2010 Elsevier Masson SAS. All rights reserved.	[de Martel, C.; Plummer, M.; Franceschi, S.] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497	International Agency for Research on Cancer; "Fondation innovations en infectiologie" [F1NOV1]	During the writing of this manuscript, Dr Catherine de Martel was the recipient of a fellowship from the International Agency for Research on Cancer. Financed by the "Fondation innovations en infectiologie" (F1NOV1).	Bergquist A, 2002, J HEPATOL, V36, P321, DOI 10.1016/S0168-8278(01)00288-4; Blendis Laurie, 2004, Gastroenterology, V127, P1008, DOI 10.1053/j.gastro.2004.07.035; Boberg KM, 2002, SCAND J GASTROENTERO, V37, P1205, DOI 10.1080/003655202760373434; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Chamberlain RS, 2000, ANN SURG ONCOL, V7, P55, DOI 10.1007/s10434-000-0055-4; Chapman RW, 1999, ANN ONCOL, V10, P308, DOI 10.1023/A:1008313809752; Choi BI, 2004, CLIN MICROBIOL REV, V17, P540, DOI 10.1128/CMR.17.3.540-552.2004; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; DeOliveira ML, 2007, ANN SURG, V245, P755, DOI 10.1097/01.sla.0000251366.62632.d3; Donato F, 2001, CANCER CAUSE CONTROL, V12, P959, DOI 10.1023/A:1013747228572; Endo I, 2008, ANN SURG, V248, P84, DOI 10.1097/SLA.0b013e318176c4d3; Fevery J, 2007, DIGEST DIS SCI, V52, P3123, DOI 10.1007/s10620-006-9681-4; Grainge MJ, 2009, BRIT J CANCER, V100, P178, DOI 10.1038/sj.bjc.6604765; HAMILTON SR, 2000, WHO CLASSIFICATION T; Hammill CW, 2008, J AM COLL SURGEONS, V207, P594, DOI 10.1016/j.jamcollsurg.2008.04.031; Honjo S, 2005, INT J CANCER, V117, P854, DOI 10.1002/ijc.21146; Hsing AW, 2008, INT J CANCER, V122, P1849, DOI 10.1002/ijc.23251; *IARC, 1994, MON EV CARC RISKS HU, V61; IARC, 1994, MON EV CARC RISKS HU; Jepsen P, 2007, JNCI-J NATL CANCER I, V99, P895, DOI 10.1093/jnci/djk201; Khan SA, 2008, HPB, V10, P77, DOI 10.1080/13651820801992641; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Khan SA, 2002, J HEPATOL, V37, P806, DOI 10.1016/S0168-8278(02)00297-0; Lee TY, 2008, AM J GASTROENTEROL, V103, P1716, DOI 10.1111/j.1572-0241.2008.01796.x; Lim MK, 2006, AM J TROP MED HYG, V75, P93, DOI 10.4269/ajtmh.2006.75.93; Maggs JRL, 2008, CURR OPIN GASTROEN, V24, P377, DOI 10.1097/MOG.0b013e3282f9e239; Martinez AT, 1999, SOLID STATE NUCL MAG, V15, P41, DOI 10.1016/S0926-2040(99)00045-4; Matull WR, 2007, J NATL CANCER I, V99, P407, DOI 10.1093/jnci/djk068; McGlynn KA, 2006, CANCER EPIDEM BIOMAR, V15, P1198, DOI 10.1158/1055-9965.EPI-05-0811; Mori T, 1999, RADIAT RES, V152, pS84, DOI 10.2307/3580120; Nakeeb A, 1996, ANN SURG, V224, P463, DOI 10.1097/00000658-199610000-00005; PARKIN DM, 1993, CANCER EPIDEM BIOMAR, V2, P537; PARKIN DM, 1991, INT J CANCER, V48, P323, DOI 10.1002/ijc.2910480302; Patel T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-10; PITT HA, 1995, CURR PROB SURG, V32, P1, DOI 10.1016/S0011-3840(05)80011-5; Shaib YH, 2007, AM J GASTROENTEROL, V102, P1016, DOI 10.1111/j.1572-0241.2007.01104.x; Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048; Shaib YH, 2004, J HEPATOL, V40, P472, DOI 10.1016/j.jhep.2003.11.030; SHAKED A, 1992, ANN SURG, V215, P598, DOI 10.1097/00000658-199206000-00006; Sriamporn S, 2004, TROP MED INT HEALTH, V9, P588, DOI 10.1111/j.1365-3156.2004.01234.x; Srinivasan R, 1997, J TOXICOL-CLIN TOXIC, V35, P199, DOI 10.3109/15563659709001194; Sripa B, 2008, CURR OPIN GASTROEN, V24, P349, DOI 10.1097/MOG.0b013e3282fbf9b3; Sripa B, 2007, PLOS MED, V4, P1148, DOI 10.1371/journal.pmed.0040201; Taylor-Robinson SD, 2001, GUT, V48, P816, DOI 10.1136/gut.48.6.816; Travis LB, 2003, RADIAT RES, V160, P691, DOI 10.1667/RR3095; Ulrich F, 2008, ANN SURG, V247, P357, DOI 10.1097/SLA.0b013e31815cca88; Welzel TM, 2006, J NATL CANCER I, V98, P873, DOI 10.1093/jnci/djj234; Welzel TM, 2007, INT J CANCER, V120, P638, DOI 10.1002/ijc.22283; Welzel TM, 2007, CLIN GASTROENTEROL H, V5, P1221, DOI 10.1016/j.cgh.2007.05.020; West J, 2006, BRIT J CANCER, V94, P1751, DOI 10.1038/sj.bjc.6603127; Wood R, 2003, EUR J CANCER, V39, P2087, DOI 10.1016/S0959-8049(03)00544-6; Yamamoto S, 2004, CANCER SCI, V95, P592, DOI 10.1111/j.1349-7006.2004.tb02492.x; Zhou YM, 2008, WORLD J GASTROENTERO, V14, P632, DOI 10.3748/wjg.14.632	53	29	30	0	6	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0399-8320			GASTROEN CLIN BIOL	Gastroenterol. Clin. Biol.	MAR	2010	34	3					173	180		10.1016/j.gcb.2010.01.008			8	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	583TO	WOS:000276703000004	20202771				2022-02-25	
J	Baan, RA				Baan, Robert A.			Carcinogenic hazards from inhaled carbon black, titanium dioxide, and talc not containing asbestos or asbestiform fibers: Recent evaluations by an IARC Monographs working group	INHALATION TOXICOLOGY			English	Article; Proceedings Paper	10th International Inhalation Symposium	MAY 31-JUN 03, 2006	Hannover, GERMANY	German Soc Toxicol, Fraunhofer Inst Toxicol & Expt Med, Natl Hlth & Environm Effects Res Lab, US EPA			CHRONIC INHALATION EXPOSURE; LUNG-CANCER MORTALITY; COHORT MORTALITY; OCCUPATIONAL-EXPOSURE; SUBCHRONIC INHALATION; PULMONARY RESPONSES; WORKERS; RISK; RATS; DUST	In February 2006, an IARC Monographs Working Group reevaluated the carcinogenic hazards to humans of carbon black, titanium dioxide, and talc, which belong to the group of poorly soluble, low-toxicity particles. The review of the relevant literature and the evaluations by the Working Group will be published in Volume 93 of the IARC Monographs series. This article summarizes the Working Group's conclusions. Epidemiological studies among workers in carbon black production and in the rubber industry provided inadequate evidence of carcinogenicity. The overall data from cancer studies in rodents exposed to carbon black provided sufficient evidence of carcinogenicity. The Working Group evaluated carbon black as possibly carcinogenic to humans, Group 2B. Reviewing the epidemiological studies in the titanium dioxide production industry, the Working Group concluded that there is inadequate evidence of carcinogenicity. Overall, the results from rodent cancer studies with titanium dioxide were considered to provide sufficient evidence. Titanium dioxide was evaluated as possibly carcinogenic to humans, Group 2B. Epidemiological studies on talc miners and millers provided inadequate evidence of carcinogenicity of inhaled talc not containing asbestos or asbestiform fibers. The evidence from rodent cancer studies was considered limited. The Working Group evaluated inhaled talc not containing asbestos or asbestiform fibers as not classifiable as to its carcinogenicity to humans, Group 3. The Working Group noted that prolonged exposure to inhaled particles at sufficiently high concentrations in experimental animals may lead to impairment of normal clearance mechanisms in the alveolar region of the lung, resulting in a continued buildup of particles that eventually leads to excessive lung burdens accompanied by chronic alveolar inflammation. The inflammatory response may give rise to increased generation of reactive oxygen species, cell injury, cell proliferation, fibrosis, induction of mutations, and, ultimately, cancer. Since many of these steps also occur in workers in dusty jobs, such as coal miners, data on cancer in animals obtained under conditions of impaired lung clearance were considered relevant to humans. In addition, impaired lung clearance in rodents exposed to ultrafine particles occurs at much lower mass concentrations than with fine particles, which adds to the human relevance.	WHO, Int Agcy Res Ctr, Cacinogen Indentificat & Evaluat Grp, F-69372 Lyon, France		Baan, RA (corresponding author), WHO, Int Agcy Res Ctr, Cacinogen Indentificat & Evaluat Grp, F-69372 Lyon, France.	baan@iarc.fr					American Chemistry Council, 2005, TIT DIOX; BELLMANN B, 1991, FUND APPL TOXICOL, V17, P300, DOI 10.1016/0272-0590(91)90220-X; Bermudez E, 2004, TOXICOL SCI, V77, P347, DOI 10.1093/toxsci/kfh019; Bermudez E, 2002, TOXICOL SCI, V70, P86, DOI 10.1093/toxsci/70.1.86; BLAIR A, 1990, AM J IND MED, V17, P683, DOI 10.1002/ajim.4700170604; Boffetta P, 2004, CANCER CAUSE CONTROL, V15, P697, DOI 10.1023/B:CACO.0000036188.23970.22; Boffetta P, 2001, SCAND J WORK ENV HEA, V27, P227, DOI 10.5271/sjweh.609; Boundy MG, 1979, DUSTS DIS, P365; BOURGUET CC, 1987, AM J IND MED, V11, P461, DOI 10.1002/ajim.4700110409; Brown D.P., 1979, DUSTS DISEASE, P317; Buchte SF, 2006, J OCCUP ENVIRON MED, V48, P1242, DOI 10.1097/01.jom.0000215710.17519.cd; CHEN JL, 1988, J OCCUP ENVIRON MED, V30, P937, DOI 10.1097/00043764-198812000-00011; Coggiola M, 2003, AM J IND MED, V44, P63, DOI 10.1002/ajim.10240; Dasenbrock C, 1996, TOXICOL LETT, V88, P15, DOI 10.1016/0378-4274(96)03712-5; Dell LD, 2006, J OCCUP ENVIRON MED, V48, P1219, DOI 10.1097/01.jom.0000218701.62658.a2; DEMENT JM, 1980, 80115 DHEW NIOSH; Elder A, 2005, TOXICOL SCI, V88, P614, DOI 10.1093/toxsci/kfi327; Fryzek JP, 2003, J OCCUP ENVIRON MED, V45, P400, DOI 10.1097/01.jom.0000058338.05741.45; GAMBLE J, 1982, ANN OCCUP HYG, V26, P841, DOI 10.1093/annhyg/26.8.841; HARBEN PW, 1996, IND MINERALS, P407; Harber P, 2003, J OCCUP ENVIRON MED, V45, P131, DOI 10.1097/01.jom.0000052956.59271.bd; HEINRICH U, 1995, INHAL TOXICOL, V7, P533, DOI 10.3109/08958379509015211; HEINRICH U, 1994, ILSI MONOGR, P57; HEINRICH U, 1994, ILSI MONOGR, P433; HODGSON JT, 1985, ARCH ENVIRON HEALTH, V40, P261, DOI 10.1080/00039896.1985.10545929; *IARC, 1987, SIL SOM SIL, V42, P185; *IARC, 1989, SOM ORG SOLV RES MON, V47, P307; *IARC, 1996, PRINT PROC PRINT INK, V65, P149; *IARC, 1987, UPD IARC MON, P349; JEHAN N, 1984, THESIS U PESHAWAR PA; Jurinski JB, 2001, AM MINERAL, V86, P392; KLEINFELD M, 1974, J OCCUP ENVIRON MED, V16, P345; KLEINFELD M, 1973, ENVIRON RES, V6, P132, DOI 10.1016/0013-9351(73)90026-1; KOIZUMI A, 1993, LAB INVEST, V68, P728; KOMAROVA L. T., 1965, NAUCH TR OMSK MED INST, V61, P115; LEE KP, 1985, TOXICOL APPL PHARM, V79, P179, DOI 10.1016/0041-008X(85)90339-4; LEE KP, 1986, ENVIRON RES, V41, P144, DOI 10.1016/S0013-9351(86)80177-3; LEE KP, 1985, EXP MOL PATHOL, V42, P331, DOI 10.1016/0014-4800(85)90083-8; LEOPHONTE P, 1983, Revue Francaise des Maladies Respiratoires, V11, P489; Leophonte P, 1990, HLTH RELATED EFFECTS, P203; MAUDERLY JL, 1994, POULMONARY TOXICITY; Morfeld P, 2006, J OCCUP ENVIRON MED, V48, P1230, DOI 10.1097/01.jom.0000215282.23531.b9; Morfeld P, 2006, J OCCUP ENVIRON MED, V48, P1253, DOI 10.1097/01.jom.0000215344.77132.99; MORROW PE, 1992, TOXICOL APPL PHARM, V113, P1, DOI 10.1016/0041-008X(92)90002-A; MORROW PE, 1988, FUND APPL TOXICOL, V10, P369, DOI 10.1016/0272-0590(88)90284-9; MUHLE H, 1989, EXP PATHOL-JENA, V37, P239, DOI 10.1016/S0232-1513(89)80059-3; Muhle H, 1995, SCAND J WORK ENV HEA, V21, P27; NIKULA KJ, 1995, FUND APPL TOXICOL, V25, P80, DOI 10.1006/faat.1995.1042; POTT F, 1991, NATO ADV SCI I A-LIF, V223, P547; POTT F, 1987, EXP PATHOL-JENA, V32, P129, DOI 10.1016/S0232-1513(87)80044-0; POTT F, 1994, ILSI MONOGR, P109; POTT F, 1994, ANN OCCUP HYG     S1, V38, P357; Puntoni R, 2001, LANCET, V358, P562, DOI 10.1016/S0140-6736(01)05717-8; Puntoni R, 2004, CANCER CAUSE CONTROL, V15, P511, DOI 10.1023/B:CACO.0000036446.29787.94; Renwick LC, 2004, OCCUP ENVIRON MED, V61, P442, DOI 10.1136/oem.2003.008227; Renwick LC, 2001, TOXICOL APPL PHARM, V172, P119, DOI 10.1006/taap.2001.9128; ROBERTSON JM, 1989, AM IND HYG ASSOC J, V50, P510, DOI 10.1202/0002-8894(1989)050<0510:ACSOCM>2.0.CO;2; ROBERTSON JM, 1980, ARCH ENVIRON HEALTH, V35, P181, DOI 10.1080/00039896.1980.10667489; Robertson JM, 1996, J OCCUP ENVIRON MED, V38, P569, DOI 10.1097/00043764-199606000-00006; Roller, 2005, EUR J ONCOL, V10, P249; Rubino G, 1979, DUSTS DIS, P357; RUBINO GF, 1976, J OCCUP ENVIRON MED, V18, P186, DOI 10.1097/00043764-197603000-00013; SANDS FW, 1961, P 13 INT C OCC HLTH, P531; SELEVAN SG, 1979, J ENVIRON PATHOL TOX, V2, P273; Siemiatycki J, 1991, RISK FACTORS CANC WO; SLEEUWENHOEK A, 2005, SUMMARY OCCUPATIONAL; Sorahan T, 2001, AM J IND MED, V39, P158, DOI 10.1002/1097-0274(200102)39:2<158::AID-AJIM1003>3.0.CO;2-L; STEINECK G, 1990, INT J CANCER, V45, P1012, DOI 10.1002/ijc.2910450605; STEINER PE, 1954, CANCER RES, V14, P103; STENBACK F, 1976, ONCOLOGY, V33, P29, DOI 10.1159/000225097; Straif K, 2000, AM J EPIDEMIOL, V152, P297, DOI 10.1093/aje/152.4.297; Tran CL, 2000, INHAL TOXICOL, V12, P1113, DOI 10.1080/08958370050166796; VALLYATHAN V, 1988, AM REV RESPIR DIS, V138, P1213, DOI 10.1164/ajrccm/138.5.1213; VIANNA NJ, 1981, NEW YORK STATE J MED, V81, P735; Wang M., 2003, KIRK OTHMER ENCY CHE, P761; Warheit DB, 2006, J OCCUP ENVIRON MED, V48, P1308, DOI 10.1097/01.jom.0000215385.71548.b0; Watson AY, 2001, AIHAJ, V62, P218, DOI 10.1080/15298660108984625; Wellmann J, 2006, OCCUP ENVIRON MED, V63, P513, DOI 10.1136/oem.2006.026526; WERGELAND E, 1990, AM J IND MED, V17, P505, DOI 10.1002/ajim.4700170408; Wild P, 2006, OCCUP ENVIRON MED, V63, P4, DOI 10.1136/oem.2005.020750; Wild P, 2002, OCCUP ENVIRON MED, V59, P98, DOI 10.1136/oem.59.2.98; WILD P, 1995, OCCUP ENVIRON MED, V52, P470, DOI 10.1136/oem.52.7.470; Wild P, 2000, INRSEETMT, P1; ZOCCOLILLO L, 1984, J CHROMATOGR, V288, P347, DOI 10.1016/S0021-9673(01)93711-2	84	121	128	2	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0895-8378	1091-7691		INHAL TOXICOL	Inhal. Toxicol.		2007	19			1			213	228		10.1080/08958370701497903			16	Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Toxicology	210CM	WOS:000249434300029	17886070				2022-02-25	
J	Suzuki, T; Friesen, MD; Ohshima, H				Suzuki, T; Friesen, MD; Ohshima, H			Formation of a diimino-imidazole nucleoside from 2 '-deoxyguanosine by singlet oxygen generated by methylene blue photooxidation	BIOORGANIC & MEDICINAL CHEMISTRY			English	Article							TEMPERATURE PHOTOSENSITIZED OXIDATION; AQUEOUS HYPOCHLOROUS ACID; CALF THYMUS DNA; SPIROIMINODIHYDANTOIN NUCLEOSIDE; MYELOPEROXIDASE-H2O2-CL SYSTEM; GUANOSINE; PRODUCT; DAMAGE; 8-OXO-7,8-DIHYDRO-2'-DEOXYGUANOSINE; CHLORINATION	Singlet oxygen (O-1(2)) is capable of inducing genotoxic, carcinogenic and mutagenic effects. It has previously been reported that the reaction Of O-1(2) with 2'-deoxyguanosine, which is a major target of O-1(2) among the DNA constituents, leads to formation of various oxidized products including 8-oxo-7,8-dihydro-2'-deoxyguanosine and spiroiminodihydantoin, amino-imidazolone and diamino-oxazolone nucleosides. In addition to these products, we report that a novel diimino-imidazole nucleoside, 2,5-diimino-4-[(2-deoxy-beta-D-erythro-pentofuranosyl)amino]-2H,5H-imidazole (M), is formed by reaction of 2'-deoxyguanosine with O-1(2) generated by irradiation with visible light in the presence of methylene blue under aerobic conditions. Its identification is based on identical chromatographic and spectroscopic data with an authentic compound, which we recently isolated and characterised from the reaction mixture of 2'-deoxyguanosine with reagent HOCl and a mycloperoxidase-H2O2-Cl- system. The yield of dD was increased by D2O and decreased by azide. dD was not generated from 8-oxo-7,8 -dihydro-2'-deoxyguanosine. These results indicate that dD is generated by O-1(2) directly from 2'-deoxyguanosine, but not via 8-oxo-7,8-dihydro-2'-deoxyguanosine. dD may play a role in the genotoxicity of singlet oxygen in cells. (C) 2003 Elsevier Science Ltd. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Ohshima, Hiroshi/E-8044-2010; Friesen, Marlin D/D-7328-2012				BERNOFSKY C, 1990, FREE RADICAL RES COM, V9, P303, DOI 10.3109/10715769009145689; CADET J, 1978, PHOTOCHEM PHOTOBIOL, V28, P661, DOI 10.1111/j.1751-1097.1978.tb06991.x; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; Duarte V, 2000, NUCLEIC ACIDS RES, V28, P1555, DOI 10.1093/nar/28.7.1555; EPE B, 1991, CHEM-BIOL INTERACT, V80, P239, DOI 10.1016/0009-2797(91)90086-M; FISCHER WH, 1995, P NATL ACAD SCI USA, V92, P5900, DOI 10.1073/pnas.92.13.5900; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; Kang P, 2002, J AM CHEM SOC, V124, P4865, DOI 10.1021/ja012038x; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KRINSKY NI, 1974, SCIENCE, V186, P363, DOI 10.1126/science.186.4161.363; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Martinez GR, 2002, BIOL CHEM, V383, P607, DOI 10.1515/BC.2002.063; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; Raoul S, 1996, J AM CHEM SOC, V118, P1892, DOI 10.1021/ja952347l; RAOUL S, 1995, J CHEM SOC P2, P371; RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P379, DOI 10.1021/tx00045a009; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd ed, pP. 3104, DOI DOI 10.1016/0307-4412(83)90068-7; Sheu C, 2002, J AM CHEM SOC, V124, P3905, DOI 10.1021/ja011696e; SHEU C, 1995, J AM CHEM SOC, V117, P6439, DOI 10.1021/ja00129a004; SHEU C, 1993, J AM CHEM SOC, V115, P10446, DOI 10.1021/ja00075a105; SHEU CM, 1995, J AM CHEM SOC, V117, P474, DOI 10.1021/ja00106a054; SIES H, 1992, MUTAT RES, V275, P367, DOI 10.1016/0921-8734(92)90039-R; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; Suzuki T, 2002, NUCLEIC ACIDS RES, V30, P2555, DOI 10.1093/nar/30.11.2555; Suzuki T, 2002, FEBS LETT, V516, P67, DOI 10.1016/S0014-5793(02)02503-6; Suzuki T, 2001, CHEM RES TOXICOL, V14, P1163, DOI 10.1021/tx010024z; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 1999, BIOMARKERS, V4, P303, DOI 10.1080/135475099230831	31	13	13	1	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0968-0896			BIOORGAN MED CHEM	Bioorg. Med. Chem.	MAY 15	2003	11	10					2157	2162		10.1016/S0968-0896(03)00124-X			6	Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	677EP	WOS:000182794200004	12713825				2022-02-25	
J	Bray, F; Sankila, R; Ferlay, J; Parkin, DM				Bray, F; Sankila, R; Ferlay, J; Parkin, DM			Estimates of cancer incidence and mortality in Europe in 1995	EUROPEAN JOURNAL OF CANCER			English	Article						neoplasms; epidemiology; registries; incidence; mortality; data collection; Europe; public health	BREAST-CANCER; PROSTATE-CANCER; RISK-FACTORS; EPIDEMIOLOGY; ETIOLOGY; SMOKING; MISCLASSIFICATION; MIGRANTS; MELANOMA; DISEASE	Cancer incidence and mortality estimates for 1995 are presented for the 38 countries in the four United Nations-defined areas of Europe, using World Health Organization mortality data and published estimates of incidence from national cancer registries. Additional estimation was required where national incidence data was not available, and the method involved incorporating the high quality incidence and mortality data available from the expanding number of population-based cancer registries in Europe. There were an estimated 2.6 million new cases of cancer in Europe in 1995, representing over one-quarter of the world burden of cancer. The corresponding number of deaths from cancer was approximately 1.6 million. After adjusting for differing population age structures, overall incidence rates in men were highest in the Western European countries (420.9 per 100000), with only Austria having a rate under 400. Eastern European men had the second highest rates of cancer (414.2), with extremely high rates being observed in Hungary (566.6) and in the Czech Republic (480.5). The lowest male all-cancer rate by area was observed in the Northern European countries, with fairly low rates seen in Sweden (356.6) and the UK (377.8). In contrast to men, the highest rates in women were observed in Northern Europe (315.9) and were particularly high in Denmark (396.2) and the other Nordic countries excepting Finland. The rates of cancer in Eastern European women were lower than in the other three areas, although as with men, female rates were very high in Hungary (357.2) and in the Czech Republic (333.6). There was greater disparity in the mortality rates within Europe -generally, rates were highest in Eastern European countries, notably in Hungary, reflecting a combination of poorer cancer survival rates and a higher incidence of the more lethal neoplasms, notably cancer of the lung. Lung cancer, with an estimated 377 000 cases, was the most common cancer in Europe in 1995. Rates were particularly high in much of Eastern Europe reflecting current and past tobacco smoking habits of many of its inhabitants. Together with cancers of colon and rectum (334000), and female breast (321000), the three cancers represented approximately 40% of new cases in Europe. In men, the most common primary sites were lung (22% of all cancer cases), colon and rectum (12%) and prostate (11%), and in females, breast (26%), colon and rectum (14%) and stomach (7%). The number of deaths is determined by survival, as well as incidence; by far the most common cause of death was lung cancer (330000)- about one-fifth of the total number of cancer deaths in Europe in 1995. Deaths from cancers of the colon and rectum (189 000) ranked second, followed by deaths from stomach cancer (152 000), which due to poorer survival ranked higher than breast cancer (124000). Lung cancer was the most common cause of death from cancer in men (29%). Breast cancer was the leading cause of death in females (17%). Cancer registries are a unique source of information on cancer incidence and survival, and are used here with national mortality to demonstrate the very substantial burden of cancer in Europe, and the scope for prevention. Despite some provisos about data quality, the general patterns which emerge in Europe verify the role of past exposures and interventions, and more importantly, firmly establish the need for cancer control measures which target specific populations. In particular, there is a clear urgency to combat the ongoing tobacco epidemic, now prevalent in much of Europe, particularly in the Eastern Countries. (C) 2002 Elsevier Science Ltd. All rights reserved.	Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon 08, France		Bray, F (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	bray@iarc.fr	Ferlay, Jacques/ABD-5058-2021				Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Berrino F, 1999, IARC SCI PUBLICATION, V151; Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3; Blanks RG, 2000, BRIT MED J, V321, P665, DOI 10.1136/bmj.321.7262.665; Bouchardy C, 1996, INT J EPIDEMIOL, V25, P5, DOI 10.1093/ije/25.1.5; BOYLE P, 1989, INT J PANCREATOL, V5, P327, DOI 10.1007/BF02924298; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; Buetow SA, 1995, EPIDEMIOL REV, V17, P433, DOI 10.1093/oxfordjournals.epirev.a036202; Castellsague X, 1999, INT J CANCER, V82, P657, DOI 10.1002/(SICI)1097-0215(19990827)82:5&lt;657::AID-IJC7&gt;3.0.CO;2-C; CORREA P, 1994, CANCER SURV, V20, P55; CORREA P, 1992, CANCER RES, V52, P6735; CUZICK J, 1994, CANCER SURV, V20, P455; Ekstrom AM, 1999, JNCI-J NATL CANCER I, V91, P786, DOI 10.1093/jnci/91.9.786; Elwood JM, 1998, INT J CANCER, V78, P276, DOI 10.1002/(SICI)1097-0215(19981029)78:3<276::AID-IJC2>3.0.CO;2-S; *EUR NETW CANC REG, 2001, EUROCIM VERS 4 0 EUR; FERLAY J, 1999, IARC CANC BASE; FERLAY J, 1998, IARC CANC BASE; Ferlay J., 2001, IARC CANC BASE, V5; Ferraris AM, 1997, ANN HEMATOL, V74, P131, DOI 10.1007/s002770050270; Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025; FRANCESCHI S, 1994, CANCER SURV, V20, P393; FRANCIS B, 1993, GLIM SYSTEM RELEASE; GREAVES MF, 1993, LEUKEMIA, V7, P349; Hardell L, 1998, ENVIRON HEALTH PERSP, V106, P679, DOI 10.2307/3433819; Harris NL, 1998, ANN ONCOL, V9, P45, DOI 10.1023/A:1008474526728; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; Hirayama T, 1978, IARC Sci Publ, P167; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; *IARC, 1986, TOB SMOK EV CARC RIS, V38; *INT AG RES CANC, 1994, HEP VIR EV CARC RISK, V59; *INT AG RES CANC, 1988, ALC DRINK EV CARC RI, V44; JENSEN OM, 1990, EUR J CANCER, V26, P1167; Johansson SL, 1997, SEMIN SURG ONCOL, V13, P291; Kelsey Jennifer L., 1994, Annals of Epidemiology, V4, P89, DOI 10.1016/1047-2797(94)90052-3; KINLEN U, 1994, CANCER SURV, V19, P475; Launoy G, 1998, INT J CANCER, V76, P7, DOI 10.1002/(SICI)1097-0215(19980330)76:1&lt;7::AID-IJC2&gt;3.0.CO;2-4; LaVecchia C, 1997, ORAL ONCOL, V33, P302; LOPEZABENTE G, 1995, CANCER EPIDEM BIOMAR, V4, P813; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; OBRAMS GI, 1991, CANCER SURV, V10, P91; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Parkin DM, 1997, INT J CANCER, V70, P654, DOI 10.1002/(SICI)1097-0215(19970317)70:6&lt;654::AID-IJC5&gt;3.0.CO;2-U; PARKIN DM, 1998, 19 IARC; Parkin DM, 1997, IARC SCI PUBLICATION, VVII; PERCY C, 1989, AM J EPIDEMIOL, V129, P934, DOI 10.1093/oxfordjournals.aje.a115226; PISANI P, 2000, AV CANC EUR EST AV F; Richard MA, 2000, INT J CANCER, V89, P271, DOI 10.1002/1097-0215(20000520)89:3<271::AID-IJC10>3.0.CO;2-7; Shibata A, 1997, PROSTATE, V32, P65; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; Thomson CS, 2001, J EPIDEMIOL COMMUN H, V55, P308, DOI 10.1136/jech.55.5.308; van den Akker-van Marle E, 1999, J MED SCREEN, V6, P30, DOI 10.1136/jms.6.1.30; Vaughan TL, 1996, CANCER EPIDEM BIOMAR, V5, P587; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Wynder EL, 1995, ENVIRON HEALTH PERSP, V103, P143, DOI 10.2307/3432301	56	531	552	0	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	JAN	2002	38	1					99	166		10.1016/S0959-8049(01)00350-1			68	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	514KC	WOS:000173437300020	11750846				2022-02-25	
J	Saleem, M; Gilibert, I; Ohshima, H				Saleem, M; Gilibert, I; Ohshima, H			Xanthine oxidase converts nitric oxide to nitroxyl anion which causes enzyme inactivation	FREE RADICAL BIOLOGY AND MEDICINE			English	Meeting Abstract									Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon, France									0	2	2	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.		2002	33			1		123	S49	S49					1	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	578AY	WOS:000177096300124					2022-02-25	
J	Parkin, DM; Bray, F; Ferlay, J; Pisani, P				Parkin, DM; Bray, F; Ferlay, J; Pisani, P			Estimating the world cancer burden: GLOBOCAN 2000	INTERNATIONAL JOURNAL OF CANCER			English	Review							PREVALENCE; MORTALITY; LIFE; DISABILITY	Describing the distribution of disease between different populations and over time has been a highly successful way of devising hypotheses about causation and for quantifying the potential for preventive activities.' Statistical data are also essential components of disease surveillance programs. These play a critical role in the development and implementation of health policy, through identification of health problems, decisions on priorities for preventive and curative programs and evaluation of outcomes of programs of prevention, early detection/screening and treatment in relation to resource inputs. Over the last 12 years, a series of estimates of the global burden of cancer have been published in the International Journal of Cancer.(2-6) The methods have evolved and been refined, but basically they rely upon the best available data on cancer incidence and/or mortality at country level to build up the global picture. The results are more or less accurate for different countries, depending on the extent and accuracy of locally available data. This "databased" approach is rather different from the modeling method used in other estimates.(7-10) Essentially, these use sets of regression models, which predict cause-specific mortality rates of different populations from the corresponding all-cause mortality." The constants of the regression equations derive from datasets with different overall mortality rates (often including historic data from western countries). Cancer deaths are then subdivided into the different cancer types, according to the best available information on relative frequencies. GLOBOCAN 2000 updates the previously published data-based global estimates of incidence, mortality and prevalence to the year 2000.(12)	Int Agcy Res Canc, Descript Epidemiol Unit, F-69372 Lyon, France		Parkin, DM (corresponding author), Int Agcy Res Canc, Descript Epidemiol Unit, 150 Cours Albert Thomas, F-69372 Lyon, France.	parkin@iarc.fr	Ferlay, Jacques/ABD-5058-2021				AOKI K, 1982, CANC PREVENTION DEV; BERRINO F, 1999, IARC SCI PUBL, V151; BULATAO RA, 1989, EVOLVING HLTH SECTOR; CAPOCACCIA R, 1990, CANCER CAUSE CONTROL, V1, P23, DOI 10.1007/BF00053180; COLDMAN AJ, 1992, STAT MED, V11, P1579, DOI 10.1002/sim.4780111205; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; Ferlay J., 2001, IARC CANC BASE; Ferlay J.J., 1999, IARC CANC BASE, V4; HAKAMA M, 1975, CANCER, V36, P2227, DOI 10.1002/cncr.2820360941; HAKULINEN T, 1986, INT J EPIDEMIOL, V15, P226, DOI 10.1093/ije/15.2.226; Hewitt M, 1999, J NATL CANCER I, V91, P1480, DOI 10.1093/jnci/91.17.1480; Jensen O, 1991, IARC SCI PUBL, V95; Lopez AD, 1996, GLOBAL BURDEN DIS CO; Merrill RM, 2000, INT J EPIDEMIOL, V29, P197, DOI 10.1093/ije/29.2.197; MORROW RH, 1995, AM J PUBLIC HEALTH, V85, P1356, DOI 10.2105/AJPH.85.10.1356; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; MURRAY JL, 1974, J NATL CANCER I, V52, P3, DOI 10.1093/jnci/52.1.3; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARKIN DM, 1997, CANC INCIDENCE 5 CON, V7, P1028; PISANI F, IN PRESS INT J CANC; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; PRESTON HS, 1976, MORTALITY PATTERNS N; RIES LAG, 1997, NIH PUBLICATION; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd; SANKARANARAYANA.R, 1998, IARC SCI PUBL, V145; Tomatis L., 1990, CANC CAUSES OCCURREN; TULINIUS H, 1982, ACTA PATH MICROB S31, V100, P146; UNITED NATIONS POPULATION DIVISION, 1999, WORLD POP PROSP 1998, VI	32	2904	3144	2	119	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	OCT 15	2001	94	2					153	156		10.1002/ijc.1440			4	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	473LT	WOS:000171045900001	11668491	Bronze			2022-02-25	
J	Guyton, KZ; Loomis, D; Grosse, Y; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Mattock, H; Straif, K				Guyton, Kathryn Z.; Loomis, Dana; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi; Straif, Kurt		Int Agcy Res Canc Monograph	Carcinogenicity of pentachlorophenol and some related compounds	LANCET ONCOLOGY			English	News Item							BREAST-CANCER; WORKERS; MORTALITY; PROPANIL; EXPOSURE; DIOXINS; RISK		[Guyton, Kathryn Z.; Loomis, Dana; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi; Straif, Kurt; Int Agcy Res Canc Monograph] Int Agcy Res Canc, Lyon, France		Guyton, KZ (corresponding author), Int Agcy Res Canc, Lyon, France.		Loomis, Dana/AAE-3988-2019; Guha, Neela/AAG-3989-2021	Guha, Neela/0000-0003-3991-4662; Loomis, Dana/0000-0003-3297-5200	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER		BUNCE NJ, 1979, CHEMOSPHERE, V8, P283, DOI 10.1016/0045-6535(79)90110-3; Collins JJ, 2009, J OCCUP ENVIRON MED, V51, P1212, DOI 10.1097/JOM.0b013e3181badd4e; DAVIS KJ, 1962, TOXICOL APPL PHARM, V4, P187, DOI 10.1016/0041-008X(62)90056-X; Demers PA, 2006, CANCER CAUSE CONTROL, V17, P749, DOI 10.1007/s10552-006-0007-9; Engel LS, 2005, AM J EPIDEMIOL, V161, P121, DOI 10.1093/aje/kwi022; EPSTEIN S S, 1975, Science of the Total Environment, V4, P1, DOI 10.1016/0048-9697(75)90013-3; Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P686; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; International Agency for Research on Cancer, 2016, IARC MON EV IN PRESS, V117; KOGEVINAS M, 1995, EPIDEMIOLOGY, V6, P396, DOI 10.1097/00001648-199507000-00012; National Toxicology Program, 1978, NAT CANC I CARC TECH, V21, P1; National Toxicology Program, 2010, NATL TOXICOL PROGRAM, V558, P1; National Toxicology Program, 1998, TOXIC REP SER, V65, P1; National Toxicology Program, 1979, NAT CANC I CARC TECH, V155, P1; POLAND A, 1976, SCIENCE, V194, P627, DOI 10.1126/science.136041; Ruder AM, 2011, CHEMOSPHERE, V83, P851, DOI 10.1016/j.chemosphere.2011.02.064; Smith MT, 2016, ENVIRON HEALTH PERSP, V124, P713, DOI 10.1289/ehp.1509912; Xiao HX, 2016, SCI TOTAL ENVIRON, V551, P304, DOI 10.1016/j.scitotenv.2016.02.019	18	35	37	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	DEC	2016	17	12					1637	1638		10.1016/S1470-2045(16)30513-7			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	EE3YG	WOS:000389537700031	27784619				2022-02-25	
J	Plummer, M				Plummer, Martyn			Cuts in Bayesian graphical models	STATISTICS AND COMPUTING			English	Article; Proceedings Paper	Joint IMS-ISBA Meeting (MCMSki 4)	JAN 06-08, 2014	Chamonix Mont Blanc, FRANCE			Bayesian inference; Cutting feedback; Multiple imputation	VS. SEQUENTIAL-ANALYSIS; REGRESSION; DISTRIBUTIONS; RISK	The cut function defined by the OpenBUGS software is described as a "valve" that prevents feedback in Bayesian graphical models. It is shown that the MCMC algorithm applied by OpenBUGS in the presence of a cut function does not converge to a well-defined limiting distribution. However, it may be improved by using tempered transitions. The cut algorithm is compared with multiple imputation as a gold standard in a simple example.	Int Agcy Res Canc, F-69372 Lyon, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	plummerm@iarc.fr		Plummer, Martyn/0000-0001-5130-6497			Bennett J, 2001, BIOMETRICS, V57, P803, DOI 10.1111/j.0006-341X.2001.00803.x; Carrigan G, 2007, J STAT SOFTW, V19, P1; Carroll R., 2007, MEASUREMENT ERROR NO; Choi J, 2009, COMPUT STAT DATA AN, V53, P2989, DOI 10.1016/j.csda.2008.05.018; Gelman A, 1998, STAT SCI, V13, P163; Haining R, 2007, STOCH ENV RES RISK A, V21, P501, DOI 10.1007/s00477-007-0134-1; He YL, 2009, BIOMETRICS, V65, P946, DOI 10.1111/j.1541-0420.2008.01164.x; Heckerman D, 2001, J MACH LEARN RES, V1, P49, DOI 10.1162/153244301753344614; Jackson C, 2008, J R STAT SOC A STAT, V171, P159; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Liu F, 2009, BAYESIAN ANAL, V4, P119, DOI 10.1214/09-BA404; Lunn D, 2009, J PHARMACOKINET PHAR, V36, P19, DOI 10.1007/s10928-008-9109-1; Maucort-Boulch D, 2008, CANCER EPIDEM BIOMAR, V17, P717, DOI 10.1158/1055-9965.EPI-07-2691; Moller J, 2006, BIOMETRIKA, V93, P451, DOI 10.1093/biomet/93.2.451; Mwalili SM, 2005, J R STAT SOC C-APPL, V54, P77, DOI 10.1111/j.1467-9876.2005.00471.x; Neal RM, 1996, STAT COMPUT, V6, P353, DOI 10.1007/BF00143556; Raghunathan TE., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186; RICHARDSON S, 1993, STAT MED, V12, P1703, DOI 10.1002/sim.4780121806; Rougier J, 2008, BAYESIAN ANAL, V3, P45, DOI 10.1214/08-BA301B; Scollnick D, 2004, ACTUAR RES CLEAR HOU, V2014; Spiegelhalter D., 2004, WINBUGS USER MANUAL; Zhang LP, 2003, J PHARMACOKINET PHAR, V30, P405, DOI 10.1023/B:JOPA.0000012999.36063.4e; Zhang LP, 2003, J PHARMACOKINET PHAR, V30, P387, DOI 10.1023/B:JOPA.0000012998.04442.1f	23	29	29	1	6	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0960-3174	1573-1375		STAT COMPUT	Stat. Comput.	JAN	2015	25	1			SI		37	43		10.1007/s11222-014-9503-z			7	Computer Science, Theory & Methods; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Computer Science; Mathematics	CA6MN	WOS:000349028500007					2022-02-25	
J	Espina, C; Villain, P; Lignini, T; von Karsa, L; Schuz, J				Espina, Carolina; Villain, Patricia; Lignini, Tracy; von Karsa, Lawrence; Schuez, Joachim			UPDATE OF THE EUROPEAN CODE AGAINST CANCER	ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY			English	Meeting Abstract									[Espina, Carolina; Villain, Patricia; Lignini, Tracy; von Karsa, Lawrence; Schuez, Joachim] IARC, Lyon, France									0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1743-7555	1743-7563		ASIA-PAC J CLIN ONCO	Asia-Pac. J. Clin. Oncol.	DEC	2014	10			9	SI	388	24	24					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AW5XG	WOS:000346343700067					2022-02-25	
J	Illner, AK; Slimani, N; Lachat, C				Illner, Anne-Kathrin; Slimani, Nadia; Lachat, Carl			Assessing food intake through a chest-worn camera device	PUBLIC HEALTH NUTRITION			English	Editorial Material									[Illner, Anne-Kathrin; Slimani, Nadia] WHO, Int Agcy Res Canc, Nutr & Metab Sect, Dietary Exposure Assessment Grp DEX, Lyon, France		Illner, AK (corresponding author), WHO, Int Agcy Res Canc, Nutr & Metab Sect, Dietary Exposure Assessment Grp DEX, Lyon, France.	IllnerA@fellows.iarc.fr; carl.lachat@ugent.be	lachat, carl/AAH-9764-2020	lachat, carl/0000-0002-1389-8855			Chen HC, 2013, MEAS SCI TECHNOL, V24, DOI 10.1088/0957-0233/24/10/105701; Illner AK, 2012, INT J EPIDEMIOL, V41, P1187, DOI 10.1093/ije/dys105; Jia WY, 2014, PUBLIC HEALTH NUTR, V17, P1671, DOI 10.1017/S1368980013003236; Sun MG, 2010, J AM DIET ASSOC, V110, P45, DOI 10.1016/j.jada.2009.10.013	4	1	1	0	2	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1368-9800	1475-2727		PUBLIC HEALTH NUTR	Public Health Nutr.	AUG	2014	17	8					1669	1670		10.1017/S136898001400130X			2	Public, Environmental & Occupational Health; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Nutrition & Dietetics	AM8YF	WOS:000340164600001	24983427	Green Published, Bronze			2022-02-25	
J	Ichim, G; Mola, M; Finkbeiner, MG; Cros, MP; Herceg, Z; Hernandez-Vargas, H				Ichim, G.; Mola, M.; Finkbeiner, M. G.; Cros, M-P; Herceg, Z.; Hernandez-Vargas, H.			The histone acetyltransferase component TRRAP is targeted for destruction during the cell cycle	ONCOGENE			English	Article						APC; Cdc20; Cdh1; TRRAP; mitosis; cell cycle	ANAPHASE-PROMOTING COMPLEX/CYCLOSOME; EARLY MITOTIC DEGRADATION; HAT COFACTOR TRRAP; CHROMATIN; MITOSIS; PROGRESSION; COMPLEX; ACETYLATION; TRANSCRIPTION; CHECKPOINT	Chromosomes are dynamic structures that must be reversibly condensed and unfolded to accommodate mitotic division and chromosome segregation. Histone modifications are involved in the striking chromatin reconfiguration taking place during mitosis. However, the mechanisms that regulate activity and function of histone-modifying factors as cells enter and exit mitosis are poorly understood. Here, we show that the anaphase-promoting complex or cyclosome (APC/C) is involved in the mitotic turnover of TRRAP (TRansformation/tRanscription domain-Associated Protein), a common component of histone acetyltransferase (HAT) complexes, and that the pre-mitotic degradation of TRRAP is mediated by the APC/C ubiquitin ligase activators Cdc20 and Cdh1. Ectopic expression of both Cdh1 and Cdc20 reduced the levels of coexpressed TRRAP protein and induced its ubiquitination. TRRAP overexpression or stabilization induces multiple mitotic defects, including lagging chromosomes, chromosome bridges and multipolar spindles. In addition, lack of sister chromatid cohesion and impaired chromosome condensation were found after TRRAP overexpression or stabilization. By using a truncated form of TRRAP, we show that mitotic delay is associated with a global histone H4 hyperacetylation induced by TRRAP overexpression. These results demonstrate that the chromatin modifier TRRAP is targeted for destruction in a cell cycle-dependent fashion. They also suggest that degradation of TRRAP by the APC/C is necessary for a proper condensation of chromatin and proper chromosome segregation. Chromatin compaction mediated by histone modifiers may represent a fundamental arm for APC/C orchestration of the mitotic machinery.	[Ichim, G.; Mola, M.; Finkbeiner, M. G.; Cros, M-P; Herceg, Z.; Hernandez-Vargas, H.] Int Agcy Res Canc IARC, Epigenet Grp, F-69008 Lyon, Rhone Alpes, France		Herceg, Z (corresponding author), Int Agcy Res Canc IARC, Epigenet Grp, 150 Rue Albert Thomas, F-69008 Lyon, Rhone Alpes, France.	herceg@iarc.fr; vargash@iarc.fr	Ichim, Gabriel/AAJ-5822-2021	Hernandez-Vargas, Hector/0000-0001-6045-2103; Ichim, Gabriel/0000-0002-8386-7405	Association pour la Recherche sur le Cancer (ARC), FranceFondation ARC pour la Recherche sur le Cancer; la Ligue Nationale (Francaise) Contre le Cancer (France)Ligue nationale contre le cancer; Institut National du Cancer (INCA, France)Institut National du Cancer (INCA) France; Association for International Cancer Research (AICR), UK	We thank Michael Cole for generous gift of the TRRAP expression vector. This work was supported by the Association pour la Recherche sur le Cancer (ARC), France, la Ligue Nationale (Francaise) Contre le Cancer (France), the Institut National du Cancer (INCA, France) and the Association for International Cancer Research (AICR), UK.	Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cummings WJ, 2007, PLOS BIOL, V5, P2145, DOI 10.1371/journal.pbio.0050246; Deran M, 2008, MOL CELL BIOL, V28, P435, DOI 10.1128/MCB.00607-07; Eot-Houllier G, 2008, GENE DEV, V22, P2639, DOI 10.1101/gad.484108; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Hernandez-Vargas H, 2007, ONCOGENE, V26, P2902, DOI 10.1038/sj.onc.1210102; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Ono T, 2004, MOL BIOL CELL, V15, P3296, DOI 10.1091/mbc.E04-03-0242; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Ramaswamy V, 2003, MOL CELL BIOL, V23, P9136, DOI 10.1128/MCB.23.24.9136-9149.2003; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Schueler MG, 2006, ANNU REV GENOM HUM G, V7, P301, DOI 10.1146/annurev.genom.7.080505.115613; Song L, 2011, CELL CYCLE, V10, P52, DOI 10.4161/cc.10.1.14387; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Valls E, 2005, J BIOL CHEM, V280, P42592, DOI 10.1074/jbc.M507407200; Vernarecci S, 2008, MOL CELL BIOL, V28, P988, DOI 10.1128/MCB.01366-07; Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210	30	16	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					181	192		10.1038/onc.2012.570			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	WOS:000329440700006	23318449	Bronze			2022-02-25	
J	Freisling, H; Knaze, V; Slimani, N				Freisling, H.; Knaze, V.; Slimani, N.			A multitude of predictors of diet quality in aging populations: a review of the evidence of public health relevance	EUROPEAN JOURNAL OF PUBLIC HEALTH			English	Meeting Abstract									[Freisling, H.; Knaze, V.; Slimani, N.] Int Agcy Res Canc, F-69372 Lyon, France			freislingh@iarc.fr						0	0	0	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1101-1262			EUR J PUBLIC HEALTH	Eur. J. Public Health	NOV	2012	22			2			105	105					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	027RH	WOS:000310370400255					2022-02-25	
J	Vaccarella, S; Plummer, M; Franceschi, S				Vaccarella, Salvatore; Plummer, Martyn; Franceschi, Silvia			Multiple Human Papillomavirus Infection: Don't Forget the Genetic Background Reply	JOURNAL OF INFECTIOUS DISEASES			English	Letter							PERSISTENCE; PREVALENCE; WOMEN; RISK		[Vaccarella, Salvatore; Plummer, Martyn; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Banura C, 2008, J INFECT DIS, V197, P555, DOI 10.1086/526792; Cervantes JL, 2011, J INFECT DIS, V204, P1816, DOI 10.1093/infdis/jir626; Chaturvedi AK, 2005, CANCER EPIDEM BIOMAR, V14, P2439, DOI 10.1158/1055-9965.EPI-05-0465; Chaturvedi AK, 2011, J INFECT DIS, V203, P910, DOI 10.1093/infdis/jiq139; Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784; Plummer M, 2011, J INFECT DIS, V203, P891, DOI 10.1093/infdis/jiq146; VACCARELLA S, 2011, J INFECT DIS, V39, P1179; Vaccarella S, 2011, J INFECT DIS, V204, P1500, DOI 10.1093/infdis/jir595; Vaccarella S, 2010, CANCER EPIDEM BIOMAR, V19, P503, DOI 10.1158/1055-9965.EPI-09-0983; Wang SS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008667	10	1	1	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-1899	1537-6613		J INFECT DIS	J. Infect. Dis.	DEC 1	2011	204	11								10.1093/infdis/jir627			2	Immunology; Infectious Diseases; Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases; Microbiology	838MZ	WOS:000296297900024		Bronze			2022-02-25	
J	Sankaranarayanan, R; Sauvaget, C; Ramadas, K; Ngoma, T; Teguete, I; Muwonge, R; Naud, P; Nessa, A; Kuhaprema, T; Qiao, Y				Sankaranarayanan, R.; Sauvaget, C.; Ramadas, K.; Ngoma, T.; Teguete, I.; Muwonge, R.; Naud, P.; Nessa, A.; Kuhaprema, T.; Qiao, Y.			Clinical trials of cancer screening in the developing world and their impact on cancer healthcare	ANNALS OF ONCOLOGY			English	Article							RANDOMIZED CONTROLLED-TRIAL; RESOURCE-POOR SETTINGS; ELECTROSURGICAL EXCISION PROCEDURE; HIV-INFECTED WOMEN; RURAL SOUTH-INDIA; CERVICAL-CANCER; VISUAL INSPECTION; ACETIC-ACID; ORAL-CANCER; DEMONSTRATION PROJECT	Several research and training initiatives were organized by the International Agency for Research on Cancer (IARC) in collaboration with national institutions in countries such as Angola, Brazil, Burkina Faso, China, Republic of Congo, Guinea, India, Mali, Mauritania, Nepal, Niger, Peru, Tanzania and Thailand among others, to address feasible and effective means of early detection and prevention of cervical, breast and oral cancers. The impact of these activities, that involved over 600 000 participants and more than 1200 healthcare personnel trained on strengthening the local health services in terms of infrastructure, human resources and service delivery aspects in host countries and other regions, is addressed here. These studies, inbuilt in appropriate health services platforms, have resulted in the development and sustenance of several continuing point of care services of screening and treatment in most host countries, particularly in sub-Saharan Africa, and have catalysed regional early detection programmes in India, China and Thailand. The IARC collaborative studies have evolved into major focal points of training and extending services in many countries. The large evidence base, resulting from ours and other studies is likely, in due course, to facilitate much wider scaling up of screening and treatment services through organised programmes.	[Sankaranarayanan, R.; Sauvaget, C.; Ramadas, K.; Ngoma, T.; Teguete, I.; Muwonge, R.; Naud, P.; Nessa, A.; Kuhaprema, T.; Qiao, Y.] Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.		Ngoma, Twalib/L-7874-2019; Muwonge, Richard/P-6375-2015; Qiao, You-Lin/B-4139-2012	Qiao, You-Lin/0000-0001-6380-0871; Sauvaget, Catherine/0000-0002-8053-4963	Bill & Melinda Gates FoundationBill & Melinda Gates Foundation; Cancer Research UKCancer Research UK; Association for International Cancer Research (AICR); Gunnar Nilsson Cancer Trust; Association pour la Recherche sur le Cancer (ARC)Fondation ARC pour la Recherche sur le Cancer; International Union Against Cancer (UICC); WHO AFROWorld Health Organization	We would like to record and express our sincere gratitude to the Bill & Melinda Gates Foundation, the Cancer Research UK, the Association for International Cancer Research (AICR), the Gunnar Nilsson Cancer Trust Fund, the Association pour la Recherche sur le Cancer (ARC), the International Union Against Cancer (UICC) and WHO AFRO as well as the large number of national institutions and collaborating colleagues for the support provided for our studies and for scaling up screening services. The authors thank Mrs Evelyn Bayle and Mrs Krittika Guinot for their help in the preparation of the manuscript.	Amarasinghe HK, 2010, BRIT J CANCER, V103, P303, DOI 10.1038/sj.bjc.6605778; Basu P, 2002, INT J CANCER, V100, P92, DOI 10.1002/ijc.10445; Basu P, 2010, J FAM PLAN REPROD H, V36, P131, DOI 10.1783/147118910791749218; Basu PS, 2003, INT J GYNECOL CANCER, V13, P626, DOI 10.1046/j.1525-1438.2003.13394.x; Batra P, 2010, SAMJ S AFR MED J, V100, P39; Bhatla N, 2009, INT J GYNECOL OBSTET, V105, P145, DOI 10.1016/j.ijgo.2008.12.010; Blumenthal PD, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.12.031; De Vuyst H, 2005, INT J GYNECOL OBSTET, V89, P120, DOI 10.1016/j.ijgo.2005.01.035; Deerasamee S, 2007, ASIAN PAC J CANCER P, V8, P547; Denny L, 2000, AM J OBSTET GYNECOL, V183, P383, DOI 10.1067/mob.2000.105871; Denny L, 2000, CANCER-AM CANCER SOC, V89, P826, DOI 10.1002/1097-0142(20000815)89:4&lt;826::AID-CNCR15&gt;3.0.CO;2-5; Denny L, 2002, CANCER-AM CANCER SOC, V94, P1699, DOI 10.1002/cncr.10381; Denny L, 2005, JAMA-J AM MED ASSOC, V294, P2173, DOI 10.1001/jama.294.17.2173; Ferlay J, 2010, IARC CANCERBASE; FERNANDEZ GL, 1995, EPIDEMIOLOGY, V6, P428; Gaffikin L, 1999, LANCET, V353, P869; Gaffikin L, 2003, LANCET, V361, P814, DOI 10.1016/S0140-6736(03)12707-9; Gaffikin L, 2008, CLIN TRIALS, V5, P496, DOI 10.1177/1740774508096139; Gaffikin L, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-36; Kuhn L, 2000, JNCI-J NATL CANCER I, V92, P818, DOI 10.1093/jnci/92.10.818; Kuhn L, 2010, AIDS, V24, P2545, DOI 10.1097/QAD.0b013e32833e163e; Kujan O, 2005, LANCET, V366, P1265, DOI 10.1016/S0140-6736(05)67524-1; KUJAN O, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004150.PUB2.; Mathew B, 1997, BRIT J CANCER, V76, P390, DOI 10.1038/bjc.1997.396; Megevand E, 1996, OBSTET GYNECOL, V88, P383, DOI 10.1016/0029-7844(96)00189-5; MEHTA FS, 1986, CANCER DETECT PREV, V9, P219; Mittra I, 2010, INT J CANCER, V126, P976, DOI 10.1002/ijc.24840; Muwonge R, 2009, BJOG-INT J OBSTET GY, V116, P829, DOI 10.1111/j.1471-0528.2009.02122.x; Muwonge R, 2010, INT J GYNECOL OBSTET, V111, P68, DOI 10.1016/j.ijgo.2010.04.024; Mwanahamuntu MH, 2009, AIDS, V23, pN1, DOI 10.1097/QAD.0b013e3283236e11; Nene B, 2007, B WORLD HEALTH ORGAN, V85, P264, DOI 10.2471/BLT.06.031195; Nene BM, 2008, INT J GYNECOL OBSTET, V103, P232, DOI 10.1016/j.ijgo.2008.07.016; Nessa A, 2010, INT J GYNECOL OBSTET, V111, P115, DOI 10.1016/j.ijgo.2010.06.004; Ngoma T, 2010, INT J GYNECOL OBSTET, V109, P100, DOI 10.1016/j.ijgo.2009.11.025; *NIH, OR CANC SCREEN; Pandey M, 2001, ORAL ONCOL, V37, P103, DOI 10.1016/S1368-8375(00)00070-1; Parashari A, 2000, B WORLD HEALTH ORGAN, V78, P964; Pimple S, 2010, INT J GYNECOL OBSTET, V108, P236, DOI 10.1016/j.ijgo.2009.10.005; Ramadas K, 2008, CANCER DETECT PREV, V32, P109, DOI 10.1016/j.cdp.2008.02.008; Ramadas K, 2003, ORAL ONCOL, V39, P580, DOI 10.1016/S1368-8375(03)00041-1; Ramadas K, 2006, LANCET ONCOL, V7, P962, DOI 10.1016/S1470-2045(06)70950-0; Rema P, 2008, INT J GYNECOL OBSTET, V103, P105, DOI 10.1016/j.ijgo.2008.06.020; Sangiva-Lugoma G, 2006, INT J CANCER, V119, P1389, DOI 10.1002/ijc.21972; Sankaranarayanan R, 2003, INT J CANCER, V106, P404, DOI 10.1002/ijc.11245; Sankaranarayanan R, 2005, INT J CANCER, V116, P617, DOI 10.1002/ijc.21050; Sankaranarayanan R, 2004, INT J CANCER, V110, P907, DOI 10.1002/ijc.20190; Sankaranarayanan R, 2004, INT J CANCER, V109, P461, DOI 10.1002/ijc.11726; Sankaranarayanan R, 2007, BRIT J CANCER, V96, P738, DOI 10.1038/sj.bjc.6603633; Sankaranarayanan R, 2000, CANCER, V88, P664, DOI 10.1002/(SICI)1097-0142(20000201)88:3&lt;664::AID-CNCR25&gt;3.0.CO;2-V; Sankaranarayanan R, 2005, LANCET, V365, P1927, DOI 10.1016/S0140-6736(05)66658-5; Sankaranarayanan R, 2004, CANCER DETECT PREV, V28, P345, DOI 10.1016/j.cdp.2004.04.004; Sankaranarayanan R, 2004, J MED SCREEN, V11, P77, DOI 10.1258/096914104774061056; Sankaranarayanan R, 2003, CANCER DETECT PREV, V27, P457, DOI 10.1016/j.cdp.2003.09.006; Sankaranarayanan R, 2002, ORAL ONCOL, V38, P131, DOI 10.1016/S1368-8375(01)00033-1; Sankaranarayanan R, 1998, CANCER-AM CANCER SOC, V83, P2150, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2150::AID-CNCR13>3.0.CO;2-0; Sankaranarayanan R, 1999, INT J CANCER, V80, P161, DOI 10.1002/(SICI)1097-0215(19990105)80:1<161::AID-IJC28>3.0.CO;2-8; Sankaranarayanan R, 2009, INT J GYNECOL OBSTET, V104, P95, DOI 10.1016/j.ijgo.2008.09.009; Sankaranarayanan R, 2007, LANCET, V370, P398, DOI 10.1016/S0140-6736(07)61195-7; Sankaranarayanan R, 2011, JNCI-J NATL CANCER I, V103, P1476, DOI 10.1093/jnci/djr304; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; SEHGAL A, 1991, LANCET, V338, P282, DOI 10.1016/0140-6736(91)90420-T; Shastri SS, 2005, B WORLD HEALTH ORGAN, V83, P186; SINGH V, 1992, BRIT MED J, V304, P534, DOI 10.1136/bmj.304.6826.534; Singh V., 2001, SMJ Singapore Medical Journal, V42, P351; Subramanian S, 2009, B WORLD HEALTH ORGAN, V87, P198, DOI 10.2471/BLT.08.053231; Swaminathan R, 2009, CANCER EPIDEMIOL, V33, P325, DOI 10.1016/j.canep.2009.09.008; Swaminathan R, 2009, CANCER EPIDEMIOL, V33, P89, DOI 10.1016/j.canep.2009.06.012; Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303; WARNAKULASURIYA KAAS, 1991, CANCER DETECT PREV, V15, P331; WARNAKULASURIYA KAAS, 1984, B WORLD HEALTH ORGAN, V62, P243; Wesley R, 1997, BRIT J CANCER, V75, P436, DOI 10.1038/bjc.1997.72; Wright TC, 2000, JAMA-J AM MED ASSOC, V284, P39, DOI 10.1001/jama.284.1.39	72	18	19	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	NOV	2011	22			7			20	28		10.1093/annonc/mdr422			9	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	855GK	WOS:000297551700006	22039141	Bronze, Green Published			2022-02-25	
J	Cogliano, VJ				Cogliano, Vincent J.			Identifying carcinogenic agents in the workplace and environment	LANCET ONCOLOGY			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon 8, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 8, France.	cogliano@iarc.fr					Brown J. R., 1957, OCCUP ENVIRON MED, V14, P68; Collins R., 1775, CHIRURG OBSERVATIONS; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Siemiatycki J, 2004, ENVIRON HEALTH PERSP, V112, P1447, DOI 10.1289/ehp.7047	4	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045			LANCET ONCOL	Lancet Oncol.	JUN	2010	11	6					602	602		10.1016/S1470-2045(09)70363-8			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	613YA	WOS:000279019500033	20522386				2022-02-25	
J	Swaminathan, R; Sankaranarayanan, R				Swaminathan, Rajaraman; Sankaranarayanan, Rengaswamy			Under-diagnosis and under-ascertainment of cases may be the reasons for low childhood cancer incidence in rural India	CANCER EPIDEMIOLOGY			English	Letter						Registry; Childhood cancer; Under-diagnosis; Under-ascertainment; Health services		Cancer statistics from India revealed that childhood cancer incidence is lesser in rural than urban India. This might be clue to under-diagnosis or under-ascertainment of cases or could even be true. With registries able to explicitly measure and appropriately streamline the ascertainment of cases to comply with acceptable standards, it is under-diagnosis that is variable and highly influenced by development or accessibility to specialized centres in or around the registry area. This is reflected implicitly by marked variation in incidence between different populations in India: weighted age standardized rates of all childhood cancers together was the highest (108 per million) in metropolitan areas, followed by other urban (86) and rural (53) areas in that order. A childhood cancer registry focusing on pertinent data collection and specific epidemiological studies is desirable to explain the variations in incidence an outcome of childhood cancers in India. (C) 2009 Elsevier Ltd. All rights reserved.	[Swaminathan, Rajaraman; Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Sect Early Detect & Prevent, F-69372 Lyon 08, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Sect Early Detect & Prevent, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	bayle@iarc.fr					CURADO MP, 1999, IARC SCI PUBLICATION, V149; Swaminathan I, 2008, INT J CANCER, V122, P2607, DOI 10.1002/ijc.23428; SWAMINATHAN R, 2009, CANC EPIDEMIOL   OCT	3	23	23	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	FEB	2010	34	1					107	108		10.1016/j.canep.2009.11.006			2	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	578CG	WOS:000276270400021	20022839				2022-02-25	
S	Mani, S; Herceg, Z		Herceg, Z; Ushijima, T		Mani, Samson; Herceg, Zdenko			DNA Demethylating Agents and Epigenetic Therapy of Cancer	EPIGENETICS AND CANCER, PT A	Advances in Genetics		English	Review; Book Chapter							HISTONE DEACETYLASE INHIBITORS; H3 LYSINE-9 METHYLATION; RISK MYELODYSPLASTIC SYNDROMES; CPG ISLAND HYPERMETHYLATION; ACUTE MYELOID-LEUKEMIA; HYDROXAMIC ACID SAHA; PROMOTER HYPERMETHYLATION; HEMATOLOGIC MALIGNANCIES; COLORECTAL-CANCER; TRANSFORMED-CELLS	Epigenetic events have been associated with virtually every step of tumor development and progression, and epigenetic alterations are believed to occur early in tumor development and may precede the malignant process. In contrast to genetic changes, epigenetic alterations arise in a gradual manner, leading to a progressive silencing of specific genes. An important distinction between epigenetic and genetic alterations is intrinsic reversibility of the former, making cancer-associated changes in DNA methylation, histone modifications, and expression of noncoding RNAs attractive targets for therapeutic intervention. This realization has triggered an impressive quest for the development of "epigenetic drugs" and epigenetic therapies. A number of agents have been subjected to an intensive investigation, many of which have been found capable of altering epigenetic states, including DNA methylation patterns and histone modification states. Many of these agents are currently being tested in clinical trials, while several of them are already used in clinics. This review will focus on the recent advances in the development of epigenetic drugs based on the inhibition of DNA methylation. Combinatorial therapies that couple DNA demethylating agents with histone deacetylase inhibitors will also be discussed. (C) 2010, Elsevier Inc.	[Mani, Samson; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69008 Lyon, France		Mani, S (corresponding author), Int Agcy Res Canc, Epigenet Grp, F-69008 Lyon, France.						Altucci L, 2009, EUR J CANCER, V45, P1137, DOI 10.1016/j.ejca.2009.03.001; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 2003, CANCER RES, V63, P7089; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Bicaku E, 2008, CANCER RES, V68, P1513, DOI 10.1158/0008-5472.CAN-07-2822; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cashen AF, 2010, J CLIN ONCOL, V28, P556, DOI 10.1200/JCO.2009.23.9178; David AJ, 2003, INVEST NEW DRUG, V21, P85, DOI 10.1023/A:1022976528441; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Flynn J, 2003, J BIOL CHEM, V278, P8238, DOI 10.1074/jbc.M209839200; Foubister V, 2003, DRUG DISCOV TODAY, V8, P430, DOI 10.1016/S1359-6446(03)02697-7; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297; Graham JS, 2009, EUR J CANCER, V45, P1129, DOI 10.1016/j.ejca.2009.01.003; Gravina G. L., 2010, PROSTATE; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Jones PA, 2005, CANCER RES, V65, P11241, DOI 10.1158/0008-5472.CAN-05-3865; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Joung KE, 2004, ARCH PHARM RES, V27, P640, DOI 10.1007/BF02980164; Kim JC, 2009, ANTICANCER RES, V29, P3027; Kim JS, 2004, BRIT J HAEMATOL, V124, P166, DOI 10.1046/j.1365-2141.2003.04759.x; Klisovic DD, 2005, MELANOMA RES, V15, P147, DOI 10.1097/00008390-200506000-00002; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Lin XH, 2001, CANCER RES, V61, P8611; Lin ZH, 2009, CLIN CANCER RES, V15, P570, DOI 10.1158/1078-0432.CCR-08-1813; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016/j.biocel.2008.08.020; Maier S, 2002, J NUTR, V132, p2440S, DOI 10.1093/jn/132.8.2440S; Marks PA, 2005, EXPERT OPIN INV DRUG, V14, P1497, DOI 10.1517/13543784.14.12.1497; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Marquez VE, 2005, ANN NY ACAD SCI, V1058, P246, DOI 10.1196/annals.1359.037; Maslak P, 2006, LEUKEMIA, V20, P212, DOI 10.1038/sj.leu.2404050; McKinsey TA, 2004, TRENDS GENET, V20, P206, DOI 10.1016/j.tig.2004.02.002; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Noguchi M, 2006, CANCER LETT, V234, P135, DOI 10.1016/j.canlet.2005.03.053; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; Oki Y, 2006, REV RECENT CLIN TRIA, V1, P169, DOI 10.2174/157488706776876490; Park SJ, 2009, EXP CELL RES, V315, P1809, DOI 10.1016/j.yexcr.2009.02.024; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Rudek MA, 2005, J CLIN ONCOL, V23, P3906, DOI 10.1200/JCO.2005.07.450; Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002; Sekeres M. A., J CLIN ONCO IN PRESS; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399; Steensma DP, 2009, LEUKEMIA RES, V33, pS12, DOI 10.1016/S0145-2126(09)70228-0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Urdinguio RG, 2009, LANCET NEUROL, V8, P1056, DOI 10.1016/S1474-4422(09)70262-5; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; van den Bosch J, 2004, LEUKEMIA RES, V28, P785, DOI 10.1016/j.leukres.2003.11.016; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Villar-Garea A, 2003, CANCER RES, V63, P4984; Xiao JJ, 2005, J PHARMACOL EXP THER, V313, P268, DOI 10.1124/jpet.104.072033; Yang H, 2005, LEUKEMIA RES, V29, P739, DOI 10.1016/j.leukres.2004.11.022; Zhou XL, 2010, INT J ONCOL, V36, P999, DOI 10.3892/ijo_00000580	74	36	38	0	6	ELSEVIER ACADEMIC PRESS INC	SAN DIEGO	525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA	0065-2660		978-0-12-380866-0	ADV GENET	Adv. Genet.		2010	70						327	340		10.1016/S0065-2660(10)70012-2			14	Oncology; Genetics & Heredity	Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Genetics & Heredity	BAD29	WOS:000303838800012	20920754				2022-02-25	
J	Clifford, GM; Franceschi, S				Clifford, Gary M.; Franceschi, Silvia			Cancer risk in HIV-infected persons: influence of CD4(+) count	FUTURE ONCOLOGY			English	Review						AIDS; anus; CD4(+); cervix; epidemiology; HIV; Hodgkin lymphoma; Kaposi sarcoma; liver; non-Hodgkin lymphoma	HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-PAPILLOMAVIRUS INFECTION; NON-HODGKIN-LYMPHOMA; INVASIVE CERVICAL-CANCER; AIDS-DEFINING CANCERS; CHRONIC HEPATITIS-C; KAPOSIS-SARCOMA; ANAL CANCER	Persons infected with HIV are at increased risk for all cancers known or suspected to have an infectious cause, an effect believed to be primarily mediated by lowered host immunity via the depletion of CD4(+), cells. Whereas Kaposi sarcoma and non-Hodgkin lymphoma were recognised as AIDS-defining illnesses early in the HIV epidemic, the influence of declining CD4(+) count on other infection-related cancers has taken longer to establish, undoubtedly because the association is weaker and the dose-response relationship is less steep, However, following improved survival made possible by combined antiretroviral therapy, declining CD4(+) count starts showing an impact on the natural history of various carcinogenic infections and on the risk for an increasingly wide range of cancers, including Hodgkin lymphoma, cervical, anal and liver cancers.	[Clifford, Gary M.; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Clifford, GM (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	clifford@iarc.fr; franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Ahdieh L, 2001, J INFECT DIS, V184, P682, DOI 10.1086/323081; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Bedimo R, 2004, CLIN INFECT DIS, V39, P1380, DOI 10.1086/424883; Besson C, 2001, BLOOD, V98, P2339, DOI 10.1182/blood.V98.8.2339; Bhaskaran K, 2004, AIDS, V18, P673, DOI [10.1097/00002030-200403050-00012, 10.1097/01.aids.0000111464.61782.64]; Biggar RJ, 2007, J NATL CANCER I, V99, P962, DOI 10.1093/jnci/djm010; Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109; Bower M, 2004, JAIDS-J ACQ IMM DEF, V37, P1563, DOI 10.1097/00126334-200412150-00004; Bower M, 2005, ANN INTERN MED, V143, P265, DOI 10.7326/0003-4819-143-4-200508160-00007; Brown EE, 2006, CANCER, V107, P2282, DOI 10.1002/cncr.22236; Carrieri MP, 2003, INT J CANCER, V103, P142, DOI 10.1002/ijc.10790; Chaturvedi AK, 2005, J MED VIROL, V75, P105, DOI 10.1002/jmv.20244; CLIFFORD G, 2009, BLOOD; Clifford GM, 2008, AIDS, V22, P2135, DOI 10.1097/QAD.0b013e32831103ad; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Colin JF, 1999, HEPATOLOGY, V29, P1306, DOI 10.1002/hep.510290447; Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d; D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe; Dal Maso L, 2009, BRIT J CANCER, V100, P840, DOI 10.1038/sj.bjc.6604923; Dal Maso L, 2003, LANCET ONCOL, V4, P110, DOI 10.1016/S1470-2045(03)00983-5; DALMASO L, 1995, SOZ PRAVENTIV MED, V40, P239, DOI 10.1007/BF01354479; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116; Del Maso L, 2003, BRIT J CANCER, V89, P94, DOI 10.1038/sj.bjc.6601017; Delmas MC, 2000, AIDS, V14, P1775, DOI 10.1097/00002030-200008180-00013; Di Martino V, 2001, HEPATOLOGY, V34, P1193, DOI 10.1053/jhep.2001.29201; Diamond C, 2005, SEX TRANSM DIS, V32, P314, DOI 10.1097/01.olq.0000162366.60245.02; El Amari EB, 2008, AIDS, V22, P1019, DOI 10.1097/QAD.0b013e3282fc9c03; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487; Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59; FERLAY J, 2004, INCIDENCE MORTALITY; Fontas E, 2009, JAIDS-J ACQ IMM DEF, V50, P206, DOI 10.1097/QAI.0b013e318190018c; Franceschi S, 2008, BRIT J CANCER, V99, P800, DOI 10.1038/sj.bjc.6604520; Franceschi S, 2003, JAIDS-J ACQ IMM DEF, V34, P84, DOI 10.1097/00126334-200309010-00013; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Galceran J, 2007, EUR J CANCER, V43, P1085, DOI 10.1016/j.ejca.2007.01.028; Gallafent JH, 2005, J CLIN ONCOL, V23, P1253, DOI 10.1200/JCO.2005.04.156; Gichangi P, 2002, INT J GYNECOL OBSTET, V76, P55, DOI 10.1016/S0020-7292(01)00560-4; Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909; Grulich AE, 2001, AIDS, V15, P629, DOI 10.1097/00002030-200103300-00013; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Harris TG, 2005, JAMA-J AM MED ASSOC, V293, P1471, DOI 10.1001/jama.293.12.1471; Hawes SE, 2006, J NATL CANCER I, V98, P100, DOI 10.1093/jnci/djj010; Hawes SE, 2003, J INFECT DIS, V188, P555, DOI 10.1086/376996; Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096; Hermans P, 1996, AIDS, V10, P911, DOI 10.1097/00002030-199607000-00015; Hessol NA, 2007, AM J EPIDEMIOL, V165, P1143, DOI 10.1093/aje/kwm017; Holly EA, 2001, J NATL CANCER I, V93, P843, DOI 10.1093/jnci/93.11.843; Kirk GD, 2007, CLIN INFECT DIS, V45, P103, DOI 10.1086/518606; Kirk O, 2001, BLOOD, V98, P3406, DOI 10.1182/blood.V98.12.3406; Koshiol J, 2006, AM J EPIDEMIOL, V164, P176, DOI 10.1093/aje/kwj165; Kramer JR, 2005, AM J GASTROENTEROL, V100, P56, DOI 10.1111/j.1572-0241.2005.40670.x; Krischer J, 1998, J AM ACAD DERMATOL, V38, P594, DOI 10.1016/S0190-9622(98)70124-0; Krown SE, 2008, NEW ENGL J MED, V358, P535, DOI 10.1056/NEJMc072994; Martin-Carbonero L, 2004, CLIN INFECT DIS, V38, P128, DOI 10.1086/380130; Martro E, 2007, INT J CANCER, V120, P1129, DOI 10.1002/ijc.22281; Massad LS, 2009, CANCER-AM CANCER SOC, V115, P524, DOI 10.1002/cncr.24067; Massad LS, 2001, J ACQ IMMUN DEF SYND, V27, P432, DOI 10.1097/00126334-200108150-00003; Maurer T, 2007, NEW ENGL J MED, V357, P1352, DOI 10.1056/NEJMc070508; Mbulaiteye SM, 2006, INT J CANCER, V118, P985, DOI 10.1002/ijc.21443; Mbulaiteye SM, 2003, JAIDS-J ACQ IMM DEF, V32, P527, DOI 10.1097/00126334-200304150-00010; Minkoff H, 2001, AIDS, V15, P2157, DOI 10.1097/00002030-200111090-00011; Minkoff H, 1998, AM J OBSTET GYNECOL, V178, P982, DOI 10.1016/S0002-9378(98)70535-6; Mocroft A, 2004, CANCER-AM CANCER SOC, V100, P2644, DOI 10.1002/cncr.20309; Moodley M, 2006, INT J GYNECOL CANCER, V16, P1036, DOI 10.1111/j.1525-1438.2006.00588.x; Moscicki AB, 2004, J INFECT DIS, V190, P37, DOI 10.1086/421467; Nasti G, 2003, J CLIN ONCOL, V21, P2876, DOI 10.1200/JCO.2003.10.162; Nawar EW, 2008, ANN EPIDEMIOL, V18, P517, DOI 10.1016/j.annepidem.2008.03.009; Newnham A, 2005, BRIT J CANCER, V92, P194, DOI 10.1038/sj.bjc.6602273; Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194; Paramsothy P, 2009, OBSTET GYNECOL, V113, P26, DOI 10.1097/AOG.0b013e31819225cb; Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005; Piketty C, 2003, ANN INTERN MED, V138, P453, DOI 10.7326/0003-4819-138-6-200303180-00008; Piketty C, 2008, AIDS, V22, P1203, DOI 10.1097/QAD.0b013e3283023f78; Polesel J, 2008, AIDS, V22, P301, DOI 10.1097/QAD.0b013e3282f2705d; Puoti M, 2000, J ACQ IMMUN DEF SYND, V24, P211; Rezza G, 2000, AIDS, V14, P1647, DOI 10.1097/00002030-200007280-00021; Rockstroh JK, 1996, AM J GASTROENTEROL, V91, P2563; Rowhani-Rahbar A, 2007, J INFECT DIS, V196, P887, DOI 10.1086/520883; Safaeian M, 2008, CANCER EPIDEM BIOMAR, V17, P1300, DOI 10.1158/1055-9965.EPI-07-2678; Schuman P, 2003, J INFECT DIS, V188, P128, DOI 10.1086/375783; Serraino D, 2005, TRANSPLANTATION, V80, P1699, DOI 10.1097/01.tp.0000187864.65522.10; Serraino D, 1999, INT J CANCER, V82, P334, DOI 10.1002/(SICI)1097-0215(19990730)82:3<334::AID-IJC5>3.0.CO;2-C; Simcock M, 2007, ANTIVIR THER, V12, P931; Stebbing J, 2006, LANCET, V367, P1495, DOI 10.1016/S0140-6736(06)68649-2; Stein L, 2008, INT J CANCER, V122, P2260, DOI 10.1002/ijc.23391; Strickler HD, 2003, JNCI-J NATL CANCER I, V95, P1062, DOI 10.1093/jnci/95.14.1062; Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073; Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1	91	38	40	1	5	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1479-6694	1744-8301		FUTURE ONCOL	Future Oncol.	JUN	2009	5	5					669	678		10.2217/FON.09.28			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	467LA	WOS:000267739200013	19519206				2022-02-25	
J	Franceschi, S; Mahe, C				Franceschi, S; Mahe, C			Human papillomavirus testing in cervical cancer screening	BRITISH JOURNAL OF CANCER			English	Editorial Material							RISK; POPULATION; NEOPLASIA; WOMEN; INFECTION; SMEARS; TRIAGE		Int Agcy Res Canc, F-69372 Lyon, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Bulkmans NWJ, 2004, INT J CANCER, V110, P94, DOI 10.1002/ijc.20076; Bulkmans NWJ, 2005, BRIT J CANCER, V92, P1800, DOI 10.1038/sj.bjc.6602541; CHUA KL, 1995, ANAL QUANT CYTOL, V17, P221; Clavel C, 2004, BRIT J CANCER, V90, P1803, DOI 10.1038/sj.bjc.6601726; Cuzick J, 2003, LANCET, V362, P1871, DOI 10.1016/S0140-6736(03)14955-0; Cuzick J, 1999, HEALTH TECHNOL ASSES, V3, P1; Dillner J, 2000, EUR J CANCER, V36, P2255, DOI 10.1016/S0959-8049(00)00320-8; Franco EL, 1999, AM J OBSTET GYNECOL, V181, P382, DOI 10.1016/S0002-9378(99)70586-7; Grainge MJ, 2005, BRIT J CANCER, V92, P1794, DOI 10.1038/sj.bjc.6602538; HUSMAN AMD, 1995, BRIT J CANCER, V72, P412, DOI 10.1038/bjc.1995.347; IARC, 2005, IARC HDB CANC PREV, V10; KITCHENER H, 2004, 21 INT PAP C MEX CIT; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Peto J, 2004, BRIT J CANCER, V91, P942, DOI 10.1038/sj.bjc.6602049; RONCO G, 2004, 21 INT PAP C MEX CIT; Schiffman M, 2005, J NATL CANCER I, V97, P147, DOI 10.1093/jnci/dji014; Sherman ME, 2003, JNCI-J NATL CANCER I, V95, P46, DOI 10.1093/jnci/95.1.46; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Whynes David K, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P61, DOI 10.1586/14737167.4.1.61	19	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920	1532-1827		BRIT J CANCER	Br. J. Cancer	MAY 9	2005	92	9					1591	1592		10.1038/sj.bjc.6602580			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	922UE	WOS:000228863500001	15870829	hybrid, Green Published			2022-02-25	
J	Brennan, P				Brennan, P			Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?	CARCINOGENESIS			English	Editorial Material							BLADDER-CANCER; LUNG-CANCER; SUSCEPTIBILITY; RISK; SMOKING; METAANALYSIS; VARIANTS; COLITIS; BIAS	One form of defence against cancer development involves a series of genes whose role is to metabolize and excrete potentially toxic compounds and to repair subtle mistakes in DNA. Much laboratory and epidemiological research over the past decade has concentrated on the identification of these genes and an assessment of their role in cancer aetiology. Of particular interest has been whether the risk of cancer associated with a particular environmental exposure differs with respect to functionally different polymorphisms of these genes, i.e. gene environment interaction. A large number of studies have been conducted for numerous genes and also for all common cancer sites, although results have been very inconsistent and therefore inconclusive. This is partially due to the inadequate sample size of most studies to detect modest effects and the over-reporting of positive associations identified in subgroups of the dataset. There is also much confusion about the meaning of 'gene-environment interaction', what type of studies should be conducted to study it and also how it should be measured. Furthermore, the very purpose of these studies is not clear; are they attempting to identify high-risk individuals, or are they simply trying to further understand the cancer process? This review will explore these questions and provide some recommendations to help ensure that the next phase of gene-environment interaction studies, which are likely to be much larger and based on many more genes, also provide some clearer answers.	Int Agcy Res Canc, Unit Environm Canc Epidemiol, F-69008 Lyon, France		Brennan, P (corresponding author), Int Agcy Res Canc, Unit Environm Canc Epidemiol, 150 Cours Albert Thomas, F-69008 Lyon, France.	brerman@iarc.fr					Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; Cloos J, 1999, J NATL CANCER I, V91, P1125, DOI 10.1093/jnci/91.13.1125; DeMarini DM, 2001, CANCER RES, V61, P6679; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Eriksson CJP, 2001, ALCOHOL CLIN EXP RES, V25, p157S, DOI 10.1111/j.1530-0277.2001.tb02391.x; Garcia-Closas M, 1999, AM J EPIDEMIOL, V149, P689; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Green J, 2000, BRIT J CANCER, V83, P412, DOI 10.1054/bjoc.2000.1265; Hirvonen A, 1999, IARC Sci Publ, P251; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; KINZLER KW, 1998, GENETIC BASIS HUMAN, P565; Koopmans JR, 1999, BEHAV GENET, V29, P383, DOI 10.1023/A:1021618719735; Lewontin R. C., 2000, TRIPLE HELIX GENE OR; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Pianezza ML, 1998, NATURE, V393, P750, DOI 10.1038/31623; Rose G, 2001, INT J EPIDEMIOL, V30, P427, DOI 10.1093/ije/30.3.427; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; Rothman N, 1999, IARC Sci Publ, P89; Seker H, 2001, CANCER RES, V61, P7430; Shanahan F, 2001, LANCET, V357, P246, DOI 10.1016/S0140-6736(00)03630-8; Sinha R, 1999, CANCER RES, V59, P4320; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; STRANGE RC, 1999, METABOLIC POLYMORPHI, V148, P231; Taioli E, 1999, CANCER EPIDEM BIOMAR, V8, P727; THOMAS DC, 1985, AM J EPIDEMIOL, V122, P1080, DOI 10.1093/oxfordjournals.aje.a114189; Umbach DM, 1997, STAT MED, V16, P1731, DOI 10.1002/(SICI)1097-0258(19970815)16:15<1731::AID-SIM595>3.0.CO;2-S; VOGELSTEIN B, 1998, GENETIC BASIS HUMAN; Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151; Weinberg CR, 2000, AM J EPIDEMIOL, V152, P197, DOI 10.1093/aje/152.3.197; WU X, 2000, CANCER EPIDEM BIOMAR, P1021; Yang QH, 1997, AM J EPIDEMIOL, V146, P713	37	188	200	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0143-3334	1460-2180		CARCINOGENESIS	Carcinogenesis	MAR	2002	23	3					381	387		10.1093/carcin/23.3.381			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	536PD	WOS:000174710400002	11895852	Bronze			2022-02-25	
J	Goldgar, DE				Goldgar, DE			Population aspects of cancer genetics	BIOCHIMIE			English	Article						cancer; genetics; risk; population-based	ASHKENAZI-JEWISH INDIVIDUALS; BREAST-CANCER; CARRIER FREQUENCY; OVARIAN-CANCER; BRCA1 MUTATIONS; FAMILY HISTORY; WOMEN; RISK; POLYMORPHISMS; PREVALENCE	A number of relatively rare, high-risk genes have been identified which predispose to common cancers such as breast, colon, and melanoma. Although these are clearly important in the clinical setting, it is also relevant to discuss the impact of these genes at the population level and to contrast these with that which could be ascribed to more common genetic variants which only confer a modest increased risk of cancer. In this review, we examine inferences about the role of genetics in cancer from ecological studies of incidence patterns from a number of population-based studies of familial and attributable risk. The relationship between the genetic model (genotypic risk, allele frequency, mode of inheritance) and the expected impact in the population in terms of both attributable risk and familial risk is presented. The advantages and limitations of using cancer occurrence in twins to measure the genetic contribution to specific cancer sites is discussed. The potential role of lower-penetrance genes in the overall cancer burden may be significant but may pose significant problems in the public health arena. (C) 2002 Societe francaise de biochimie et biologie moleculaire / Editions scientifiques et medicales Elsevier SAS.	Int Agcy Res Canc, F-69008 Lyon, France		Goldgar, DE (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.						Antoniou AC, 2001, GENET EPIDEMIOL, V21, P1, DOI 10.1002/gepi.1014; Cotton SC, 2000, AM J EPIDEMIOL, V151, P7, DOI 10.1093/oxfordjournals.aje.a010124; Cunningham JM, 2001, AM J HUM GENET, V69, P780, DOI 10.1086/323658; Dong CH, 2001, INT J CANCER, V92, P144; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; FORD D, 1995, AM J HUM GENET, V57, P1457; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; Healey CS, 2000, CARCINOGENESIS, V21, P189, DOI 10.1093/carcin/21.2.189; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; Lal G, 2000, CANCER RES, V60, P409; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Moslehi R, 2000, AM J HUM GENET, V66, P1259, DOI 10.1086/302853; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Parkin DM, 1997, IARC SCI PUBLICATION, VVII; Percesepe A, 2001, J CLIN ONCOL, V19, P3944, DOI 10.1200/JCO.2001.19.19.3944; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Riboli E, 2001, J NUTR, V131, p170S, DOI 10.1093/jn/131.1.170S; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; Stratton JF, 1997, NEW ENGL J MED, V336, P1125, DOI 10.1056/NEJM199704173361602; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Thorlacius S, 1997, AM J HUM GENET, V60, P1079; Tsao H, 2000, ARCH DERMATOL, V136, P1118, DOI 10.1001/archderm.136.9.1118; Warner E, 1999, J NATL CANCER I, V91, P1241, DOI 10.1093/jnci/91.14.1241	26	12	12	1	2	EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS CEDEX 15	23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE	0300-9084			BIOCHIMIE	Biochimie	JAN	2002	84	1					19	25	PII S0300-9084(01)01357-8	10.1016/S0300-9084(01)01357-8			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542UR	WOS:000175063100003	11900874				2022-02-25	
J	Bianchini, F; Vainio, H				Bianchini, F; Vainio, H			Allium vegetables and organosulfur compounds: Do they help prevent cancer?	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						Allium; cancer prevention; chemoprevention; garlic; organosulfur compounds; vegetables	N-ACETYLTRANSFERASE ACTIVITY; COMPONENTS DIALLYL SULFIDE; P34(CDC2) KINASE-ACTIVITY; MULTICENTER CASE-CONTROL; GARLIC SUPPLEMENT USE; COLON-CANCER; HELICOBACTER-PYLORI; STOMACH-CANCER; RISK-FACTORS; ORNITHINE-DECARBOXYLASE	Allium vegetables have been shown to have beneficial effects aga-inst several diseases, including cancer. Garlic, onions, leeks, and chives have been reported to protect against stomach a-nd colorectal cancers, although evidence for a protective effect against cancer at other sites, including the breast, is still insufficient. The protective effect appears to be related to the presence of organosulfur compounds and mainly allyl derivatives, which inhibit carcinogenesis in the forestomach, esophagus, colon, mammary gland, and lung of experimental animals. The exact mechanisms of the cancer-preventive effects are not clear, although several hypotheses have been proposed. Organosulfur compounds modulate the activity of several metabolizing enzymes that activate (cytochrome P450s) or detoxify (glutathione S transferases) carcinogens and inhibit the formation of DNA adducts in several target tissues. Antiproliferative activity has been described in several tumor cell lines, which is possibly mediated by induction of apoptosis and alterations of the cell cycle. Allium vegetables and organosulfur compounds are thus possible cancer-preventive agents. Clinical trials will be required to define the effective dose that has no toxicity in humans.	Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon 08, France		Bianchini, F (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	bianchini@iarc.fr					AMAGASE H, 1993, CARCINOGENESIS, V14, P1627, DOI 10.1093/carcin/14.8.1627; Amagase H, 1996, J NUTR, V126, P817, DOI 10.1093/jn/126.4.817; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAER AR, 1989, CANCER RES, V49, P5073; BELMAN S, 1983, CARCINOGENESIS, V4, P1063, DOI 10.1093/carcin/4.8.1063; BLOCK E, 1985, SCI AM, V252, P114, DOI 10.1038/scientificamerican0385-114; BOEING H, 1991, CANCER CAUSE CONTROL, V2, P227, DOI 10.1007/BF00052138; BRADY JF, 1991, TOXICOL APPL PHARM, V108, P342, DOI 10.1016/0041-008X(91)90123-V; BRADY JF, 1988, CANCER RES, V48, P5937; BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409; Cellini L, 1996, FEMS IMMUNOL MED MIC, V13, P273, DOI 10.1111/j.1574-695X.1996.tb00251.x; Challier B, 1998, EUR J EPIDEMIOL, V14, P737, DOI 10.1023/A:1007512825851; Chen GW, 1998, FOOD CHEM TOXICOL, V36, P761, DOI 10.1016/S0278-6915(98)00046-5; Chen LS, 1999, J BIOCHEM MOL TOXIC, V13, P127; Chung JG, 1998, AM J CHINESE MED, V26, P353, DOI 10.1142/S0192415X98000397; Chung JG, 1999, DRUG CHEM TOXICOL, V22, P343, DOI 10.3109/01480549909017839; Cohen LA, 1999, NUTR CANCER, V35, P58, DOI 10.1207/S1532791458-63; deRooij BM, 1996, ARCH TOXICOL, V70, P635, DOI 10.1007/s002040050322; deRooij BM, 1997, OCCUP ENVIRON MED, V54, P653, DOI 10.1136/oem.54.9.653; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; DORANT E, 1995, BREAST CANCER RES TR, V33, P163, DOI 10.1007/BF00682723; Dorant E, 1996, CARCINOGENESIS, V17, P477, DOI 10.1093/carcin/17.3.477; Dorant E, 1996, GASTROENTEROLOGY, V110, P12, DOI 10.1053/gast.1996.v110.pm8536847; DORANT E, 1994, CANCER RES, V54, P6148; EGENSCHWIND C, 1992, PLANTA MED, V58, P301, DOI 10.1055/s-2006-961471; Fanelli SL, 1998, RES COMMUN MOL PATH, V102, P163; Fleischauer AT, 2000, AM J CLIN NUTR, V72, P1047; Gail MH, 1998, CONTROL CLIN TRIALS, V19, P352, DOI 10.1016/S0197-2456(98)00016-6; Gao CM, 1999, JPN J CANCER RES, V90, P614, DOI 10.1111/j.1349-7006.1999.tb00791.x; GAO YT, 1994, INT J CANCER, V58, P197, DOI 10.1002/ijc.2910580209; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GONZALEZ CA, 1991, INT J CANCER, V49, P513, DOI 10.1002/ijc.2910490407; Graham DY, 1999, AM J GASTROENTEROL, V94, P1200, DOI 10.1016/S0002-9270(99)00122-7; GUDI VA, 1991, BIOCHEM PHARMACOL, V42, P1261, DOI 10.1016/0006-2952(91)90263-5; HABER D, 1995, J TOXICOL ENV HEALTH, V44, P423, DOI 10.1080/15287399509531971; HAENSZEL W, 1972, JNCI-J NATL CANCER I, V49, P969; HAENSZEL W, 1980, JNCI-J NATL CANCER I, V64, P17; Hageman GJ, 1997, NUTR CANCER, V27, P177, DOI 10.1080/01635589709514522; HANSSON LE, 1993, INT J CANCER, V55, P181, DOI 10.1002/ijc.2910550203; HAYES MA, 1987, CARCINOGENESIS, V8, P1155, DOI 10.1093/carcin/8.8.1155; Hong YS, 2000, EXP MOL MED, V32, P127, DOI 10.1038/emm.2000.22; HU JF, 1988, INT J CANCER, V41, P331, DOI 10.1002/ijc.2910410302; HU JF, 1991, INT J EPIDEMIOL, V20, P362, DOI 10.1093/ije/20.2.362; HU JF, 1994, INT J CANCER, V57, P38, DOI 10.1002/ijc.2910570108; Hu JF, 1999, INT J CANCER, V81, P20, DOI 10.1002/(SICI)1097-0215(19990331)81:1&lt;20::AID-IJC4&gt;3.0.CO;2-2; HU PJ, 1989, CANCER LETT, V47, P153, DOI 10.1016/0304-3835(89)90192-4; HUSSAIN SP, 1990, CANCER LETT, V49, P175, DOI 10.1016/0304-3835(90)90155-Q; IMAI J, 1994, PLANTA MED, V60, P417, DOI 10.1055/s-2006-959522; IP C, 1992, NUTR CANCER, V17, P279, DOI 10.1080/01635589209514197; ISCOVICH JM, 1992, INT J CANCER, V51, P851, DOI 10.1002/ijc.2910510603; JANDKE J, 1987, J CHROMATOGR-BIOMED, V421, P1, DOI 10.1016/0378-4347(87)80373-0; Jin JX, 1997, CHEM RES TOXICOL, V10, P318, DOI 10.1021/tx9601768; Jonkers D, 1999, J ANTIMICROB CHEMOTH, V43, P837, DOI 10.1093/jac/43.6.837; Kato T, 1998, MUTAT RES-GEN TOX EN, V420, P109, DOI 10.1016/S1383-5718(98)00151-X; KATSOUYANNI K, 1986, INT J CANCER, V38, P815, DOI 10.1002/ijc.2910380606; Key TJA, 1997, BRIT J CANCER, V76, P678, DOI 10.1038/bjc.1997.445; KNASMULLER S, 1989, ENVIRON MOL MUTAGEN, V13, P357, DOI 10.1002/em.2850130413; Knowles LM, 1998, NUTR CANCER, V30, P169, DOI 10.1080/01635589809514659; Knowles LM, 2000, CARCINOGENESIS, V21, P1129, DOI 10.1093/carcin/21.6.1129; LAAKSO I, 1989, PLANTA MED, P257, DOI 10.1055/s-2006-961998; Lawson LD., 1993, PLANTA MED, V59, pA688, DOI [DOI 10.1055/s-2006-959976, 10.1055/s-2006-959976, DOI 10.1055/S-2006-959976]; LEE ES, 1994, BBA-MOL CELL RES, V1221, P73, DOI 10.1016/0167-4889(94)90218-6; LeMarchand L, 1997, EPIDEMIOLOGY, V8, P658, DOI 10.1097/00001648-199710000-00008; LEVI F, 1993, NUTR CANCER, V19, P327, DOI 10.1080/01635589309514263; Levi F, 1999, BRIT J CANCER, V79, P1283, DOI 10.1038/sj.bjc.6690206; LIN XY, 1994, CARCINOGENESIS, V15, P349, DOI 10.1093/carcin/15.2.349; LIU JZ, 1992, CARCINOGENESIS, V13, P1847, DOI 10.1093/carcin/13.10.1847; Mei Xing, 1982, Acta Nutrimenta Sinica, V4, P53; MILLER AB, 2001, IARC SCI PUBL, V154, P1; MINAMI T, 1989, J FOOD SCI, V54, P763, DOI 10.1111/j.1365-2621.1989.tb04703.x; Munday R, 1999, NUTR CANCER, V34, P42, DOI 10.1207/S15327914NC340106; NISHINO H, 1989, ONCOLOGY, V46, P277; O'Gara EA, 2000, APPL ENVIRON MICROB, V66, P2269, DOI 10.1128/AEM.66.5.2269-2273.2000; PAN JM, 1993, BIOCHEM PHARMACOL, V45, P2323, DOI 10.1016/0006-2952(93)90206-C; PERCHELLET JP, 1986, CANCER BIOCHEM BIOPH, V8, P299; Pinto JT, 1997, AM J CLIN NUTR, V66, P398, DOI 10.1093/ajcn/66.2.398; REDDY BS, 1993, CANCER RES, V53, P3493; Reicks MM, 1996, NUTR CANCER, V25, P241, DOI 10.1080/01635589609514448; SADHANA AS, 1988, CANCER LETT, V40, P193, DOI 10.1016/0304-3835(88)90010-9; Sakamoto K, 1997, NUTR CANCER, V29, P152, DOI 10.1080/01635589709514617; SANKARANARAYANAN R, 1994, INT J CANCER, V58, P644, DOI 10.1002/ijc.2910580505; Schaffer EM, 1996, CANCER LETT, V102, P199, DOI 10.1016/0304-3835(96)04160-2; Seki T, 2000, CANCER LETT, V160, P29, DOI 10.1016/S0304-3835(00)00552-8; Sheen LY, 1999, FOOD CHEM TOXICOL, V37, P1139, DOI 10.1016/S0278-6915(99)00108-8; Sheen LY, 1999, NUTR CANCER, V35, P160, DOI 10.1207/S15327914NC352_10; SHENOY NR, 1992, CANCER LETT, V65, P227, DOI 10.1016/0304-3835(92)90236-O; Shinchi K, 1997, SCAND J GASTROENTERO, V32, P651, DOI 10.3109/00365529708996513; Siegers CP, 1999, PHYTOMEDICINE, V6, P7, DOI 10.1016/S0944-7113(99)80028-2; Singh A, 1998, CANCER LETT, V131, P209, DOI 10.1016/S0304-3835(98)00152-9; Singh SV, 1996, BIOCHEM BIOPH RES CO, V225, P660, DOI 10.1006/bbrc.1996.1226; Soni KB, 1997, CANCER LETT, V115, P129, DOI 10.1016/S0304-3835(97)04710-1; Sparnins V L, 1986, Nutr Cancer, V8, P211; SPARNINS VL, 1988, CARCINOGENESIS, V9, P131, DOI 10.1093/carcin/9.1.131; Srivastava SK, 1997, CANCER LETT, V118, P61, DOI 10.1016/S0304-3835(97)00237-1; STEINMETZ KA, 1993, INT J CANCER, V53, P711, DOI 10.1002/ijc.2910530502; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; SUMIYOSHI H, 1990, CANCER RES, V50, P5084; Sundaram SG, 1996, CARCINOGENESIS, V17, P669, DOI 10.1093/carcin/17.4.669; SUNDARAM SG, 1993, CANCER LETT, V74, P85, DOI 10.1016/0304-3835(93)90048-E; TAJIMA K, 1985, JPN J CANCER RES, V76, P705; TAKADA N, 1994, CANCER RES, V54, P2895; TAKAHASHI S, 1992, CARCINOGENESIS, V13, P1513, DOI 10.1093/carcin/13.9.1513; TAKEYAMA H, 1993, ONCOLOGY, V50, P63; Takezaki T, 1999, J Epidemiol, V9, P297; TRICHOPOULOS D, 1985, INT J CANCER, V36, P291, DOI 10.1002/ijc.1985.36.3.291; TUYNS AJ, 1992, INT J CANCER, V51, P1, DOI 10.1002/ijc.2910510102; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; VIRTANEN AI, 1959, ACTA CHEM SCAND, V13, P1898, DOI 10.3891/acta.chem.scand.13-1898; WARGOVICH MJ, 1987, CARCINOGENESIS, V8, P487, DOI 10.1093/carcin/8.3.487; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1989, CANCER RES, V49, P2689; WEISBERGER AS, 1958, CANCER RES, V18, P1301; WELCH C, 1992, CANCER LETT, V63, P211, DOI 10.1016/0304-3835(92)90263-U; XIAO OS, 1993, AM J EPIDEMIOL, V137, P155, DOI 10.1093/oxfordjournals.aje.a116655; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162; YU TH, 1989, J AGR FOOD CHEM, V37, P725, DOI 10.1021/jf00087a032; ZHANG YS, 1989, MUTAT RES, V227, P215, DOI 10.1016/0165-7992(89)90099-7; ZHENG W, 1992, INT J CANCER, V52, P557, DOI 10.1002/ijc.2910520410; ZHENG W, 1992, AM J EPIDEMIOL, V136, P178, DOI 10.1093/oxfordjournals.aje.a116484; ZOUMAS C, 1992, FASEB J, V6, pA1392	121	131	137	2	29	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2001	109	9					893	902					10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	481PT	WOS:000171529100019	11673117				2022-02-25	
J	Vaccarella, S; Bray, F				Vaccarella, Salvatore; Bray, Freddie			Are US trends a barometer of future cancer transitions in emerging economies?	INTERNATIONAL JOURNAL OF CANCER			English	Article						cancer incidence and mortality; socioeconomic development; emerging economies; United States; prevention	MORTALITY	The currently high cancer incidence rates in the U.S. and other high-income countries have been strongly affected by the acquisition of environmental and lifestyle risk factors that accompanied socioeconomic growth in the second half of the last century. The very same factors are now operating in many low- and middle-income countries (LMIC) undergoing rapid socioeconomic transition. A parallel is drawn between the past cancer trends in the U.S. and those anticipated in LMIC transitioning towards higher levels of socioeconomic development. We expect to see a major upsurge in the (still low to intermediate) cancer incidence and mortality rates in LMIC over the next decades, which coupled with population aging and growth, would translate to a scale of individuals diagnosed with, living and dying from cancer unparalleled in history. On account of resource constraints and organizational limitations, prevention strategies need to be prioritized in LMIC.	[Vaccarella, Salvatore; Bray, Freddie] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Vaccarella, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	vaccarellas@iarc.fr		Bray, Freddie/0000-0002-3248-7787; Vaccarella, Salvatore/0000-0002-2516-2167			Aggarwal A, 2017, ANN ONCOL, V28, P1738, DOI 10.1093/annonc/mdx110; Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; Bray F, 2015, CANC DIS CONTROL PRI, V3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carrera PM, 2018, CA-CANCER J CLIN, V68, P153, DOI 10.3322/caac.21443; Chaloupka FJ, 2011, TOB CONTROL, V20, P235, DOI 10.1136/tc.2010.039982; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Goding A, 2017, CANCER EPIDEM BIOMAR, V26, P1192, DOI 10.1158/1055-9965.EPI-17-0219; IARC, 2014, CI5 CANC INC 5 CONT, VI-X; Jha P, 2015, CANC DIS CONTROL PRI, V3; Mills RM, 2006, ADVANCES IN HEART DISEASE, P513; National Cancer Institute DCCPS Surveillance Research Program Surveillance Epidemiology and End Results Program, SEER STAT DAT INC SE; Pearce A, 2018, CANCER EPIDEMIOL, V53, P27, DOI 10.1016/j.canep.2017.12.013; Pinsky PF, 2017, CANCER-AM CANCER SOC, V123, P592, DOI 10.1002/cncr.30474; Sineshaw HM, 2015, J CLIN ONCOL, V33, P2337, DOI 10.1200/JCO.2014.60.5584; Sullivan R, 2011, LANCET ONCOL, V12, P933, DOI 10.1016/S1470-2045(11)70141-3; United Nations Development Programme, 2018, HUMAN DEV REPORTS; Vaccarella S, 2018, CA-CANCER J CLIN, V68, P324, DOI 10.3322/caac.21463; Vaccarella S, 2016, NEW ENGL J MED, V375, P614, DOI 10.1056/NEJMp1604412; World Health Assembly, 2017, CANC PREV CONTR CONT; World Health Organization, 2019, WHO MORT DAT	22	1	1	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	MAR 15	2020	146	6					1499	1502		10.1002/ijc.32485			4	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	KE6FQ	WOS:000508650300003	31162837				2022-02-25	
J	Korenjak, M; Zavadil, J				Korenjak, Michael; Zavadil, Jiri			Experimental identification of cancer driver alterations in the era of pan-cancer genomics	CANCER SCIENCE			English	Review						bioinformatics; carcinogenesis; epigenetics; experimental cell culture systems; genomic analysis	MAMMARY EPITHELIAL-CELLS; SOMATIC MUTATIONS; CHROMATIN ORGANIZATION; NETWORK ANALYSIS; P53 MUTATIONS; TRANSFORMATION; IMMORTALIZATION; ACCUMULATION; TRANSITION; SIGNATURES	Rapidly accumulating data from large-scale cancer genomics studies have been generating important information about genes and their somatic alterations underlying cell transformation, cancer onset and tumor progression. However, these events are usually defined by using computational techniques, whereas the understanding of their actual functional roles and impact typically warrants validation by experimental means. Critical information has been obtained from targeted genetic perturbation (gene knockout) studies conducted in animals, yet these investigations are cost-prohibitive and time-consuming. In addition, the 3R principles (replacement, reduction, refinement) have been set in place to reduce animal use burden and are increasingly observed in many areas of biomedical research. Consequently, the focus has shifted to new designs of innovative cell-based experimental models of cell immortalization and transformation in which the critical cancer driver events can be introduced by mutagenic insult and studied functionally, at the level of critical phenotypic readouts. From these efforts, primary cell-based selective barrier-bypass models of cell immortalization have emerged as an attractive system that allows studies of the functional relevance of acquired mutations as well as their role as candidate cancer driver events. In this review, we provide an overview of various experimental systems linking carcinogen exposure-driven cell transformation with the study of cancer driver events. We further describe the advantages and disadvantages of the currently available cell-based models while outlining future directions for in vitro modeling and functional testing of cancer driver events.	[Korenjak, Michael; Zavadil, Jiri] WHO, Int Agcy Res Canc, Mol Mech & Biomarkers Grp, Lyon, France		Zavadil, J (corresponding author), WHO, Int Agcy Res Canc, Mol Mech & Biomarkers Grp, Lyon, France.	zavadilj@iarc.fr	Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562	ITMO CANCER INCa - INSERM [ENV201507]	ITMO CANCER INCa - INSERM, Grant/Award Number: Plan Cancer 2015 Grant ENV201507	Artegiani B, 2019, CELL STEM CELL, V24, P927, DOI 10.1016/j.stem.2019.04.017; Bailey MH, 2018, CELL, V174, P1034, DOI 10.1016/j.cell.2018.07.034; Baylin SB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019505; Berger AH, 2016, CANCER CELL, V30, P214, DOI 10.1016/j.ccell.2016.06.022; Blokzijl F, 2016, NATURE, V538, P260, DOI 10.1038/nature19768; Boot A, 2018, GENOME RES, V28, P654, DOI 10.1101/gr.230219.117; Connor F, 2018, J HEPATOL, V69, P840, DOI 10.1016/j.jhep.2018.06.009; Creixell P, 2015, NAT METHODS, V12, P615, DOI [10.1038/NMETH.3440, 10.1038/nmeth.3440]; Cruickshanks HA, 2013, NAT CELL BIOL, V15, P1495, DOI 10.1038/ncb2879; Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276; Drost J, 2017, SCIENCE, V358, P234, DOI 10.1126/science.aao3130; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garbe JC, 2014, CELL CYCLE, V13, P3423, DOI 10.4161/15384101.2014.954456; Garcia-Nieto PE, 2017, EMBO J, V36, P2829, DOI 10.15252/embj.201796717; Gregoire JM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2683-5; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Herceg Z, 2018, INT J CANCER, V142, P874, DOI 10.1002/ijc.31014; Huang MN, 2017, GENOME RES, V27, P1475, DOI 10.1101/gr.220038.116; Huskova H, 2017, ONCOGENE, V36, P6041, DOI 10.1038/onc.2017.215; Jordan NV, 2013, MOL CELL BIOL, V33, P3011, DOI 10.1128/MCB.01443-12; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kaiser VB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1483-4; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim E, 2016, CANCER DISCOV, V6, P714, DOI 10.1158/2159-8290.CD-16-0160; Kohsaka S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan6566; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Li Z, 2002, CANCER RES, V62, P5980; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979; Mularoni L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0994-0; Ng PKS, 2018, CANCER CELL, V33, P450, DOI 10.1016/j.ccell.2018.01.021; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; PIERCE JH, 1991, ONCOGENE, V6, P1189; Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Reinbold M, 2008, ONCOGENE, V27, P2788, DOI 10.1038/sj.onc.1210932; Repana D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1612-0; Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002; Schuster-Bockler B, 2012, NATURE, V488, P504, DOI 10.1038/nature11273; Severson PL, 2014, MUTAT RES-GEN TOX EN, V775, P48, DOI 10.1016/j.mrgentox.2014.10.011; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Shaul YD, 2014, CELL, V158, P1094, DOI 10.1016/j.cell.2014.07.032; Smolen GA, 2010, GENE DEV, V24, P2654, DOI 10.1101/gad.1989110; Sneddon S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3382-6; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Supek F, 2015, NATURE, V521, P81, DOI 10.1038/nature14173; Tellez CS, 2016, CANCER RES, V76, P4741, DOI 10.1158/0008-5472.CAN-15-3367; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Tommasi S, 2013, NUCLEIC ACIDS RES, V41, P182, DOI 10.1093/nar/gks1051; Vaz M, 2017, CANCER CELL, V32, P360, DOI 10.1016/j.ccell.2017.08.006; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; vom Brocke J, 2006, CARCINOGENESIS, V27, P2141, DOI 10.1093/carcin/bg1101; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Whibley C, 2010, J BIOL CHEM, V285, P11326, DOI 10.1074/jbc.M109.064444; Yasaei H, 2013, ONCOGENE, V32, P171, DOI 10.1038/onc.2012.45; Yizhak K, 2019, SCIENCE, V364, P970, DOI 10.1126/science.aaw0726; Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x	67	6	6	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1347-9032	1349-7006		CANCER SCI	Cancer Sci.	DEC	2019	110	12					3622	3629		10.1111/cas.14210		OCT 2019	8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	JS2JU	WOS:000493423100001	31594033	gold, Green Published			2022-02-25	
J	Slimani, N; Casagrande, C; Nicolas, G; Le Moine, G; Huybrechts, I; Freisling, H; Crispim, S				Slimani, N.; Casagrande, C.; Nicolas, G.; Le Moine, G.; Huybrechts, I.; Freisling, H.; Crispim, S.			Towards a comprehensive web-based dietary infrastructure to support international monitoring and epidemiological nutritional studies	EUROPEAN JOURNAL OF PUBLIC HEALTH			English	Meeting Abstract									[Slimani, N.; Casagrande, C.; Nicolas, G.; Le Moine, G.; Huybrechts, I.; Freisling, H.; Crispim, S.] Int Agcy Res Canc, Dietary Exposure Assessment Grp, F-69372 Lyon, France			slimanin@iarc.fr	Crispim, Sergio Feliciano/ABI-6360-2020	Crispim, Sergio Feliciano/0000-0002-4060-8315				0	0	0	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1101-1262			EUR J PUBLIC HEALTH	Eur. J. Public Health	NOV	2012	22			2			143	143					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	027RH	WOS:000310370400351					2022-02-25	
J	Gouas, D; Shi, H; Hainaut, P				Gouas, Doriane; Shi, Hong; Hainaut, Pierre			The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy	CANCER LETTERS			English	Review						Aflatoxin; Hepatitis B virus; Codon 249; p.R249S; Biomarker; PRIMA-1	HEPATITIS-B-VIRUS; HEPATOCELLULAR-CARCINOMA PATIENTS; IONIZATION MASS-SPECTROMETRY; TUMOR-SUPPRESSOR GENE; HEPATOCYTE CELL-LINE; REPUBLIC-OF-CHINA; P53 CORE DOMAIN; KNOCK-IN MICE; MUTANT P53; PLASMA DNA	Hepatocellular Carcinoma (HCC) in high-incidence areas (sub-Saharan Africa, South-Eastern Asia) often contains a somatic mutation at codon 249 in TP53 (R249S). This mutation is rare in low-incidence areas of Europe and the United States. There is evidence that R249S occurs as the result of mutagenesis by aflatoxin in a context of HBV chronic infection. Here, we summarize the mechanisms of R249S formation and the possible role of p.R249S protein in HCC pathogenesis. Next, we discuss the significance of R249S as a biomarker to study the natural history of HCC and as a target for therapeutic approaches aimed at restoring wild-type p53 activity. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Gouas, Doriane; Shi, Hong; Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon 08, France		Hainaut, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610	Ligue Nationale Contre le CancerLigue nationale contre le cancer; Association pour la Recherche Sur le CancerFondation ARC pour la Recherche sur le CancerAustralian Research CouncilEuropean Commission	Hong Shi was funded by the Ligue Nationale Contre le Cancer (France, 2004-2006) and the Association pour la Recherche Sur le Cancer (France, 2007).	AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Allen D, 2004, ANN NY ACAD SCI, V1022, P76, DOI 10.1196/annals.1318.013; BARTEK J, 1991, ONCOGENE, V6, P1699; Bedard LL, 2006, CANCER LETT, V241, P174, DOI 10.1016/j.canlet.2005.11.018; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Denissenko MF, 1998, ONCOGENE, V17, P3007, DOI 10.1038/sj.onc.1202214; DUMENCO L, 1995, HEPATOLOGY, V22, P1279, DOI 10.1016/0270-9139(95)90640-1; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; Gormally E, 2004, INT J CANCER, V111, P746, DOI 10.1002/ijc.20327; Guengerich FP, 1998, MUTAT RES-FUND MOL M, V402, P121, DOI 10.1016/S0027-5107(97)00289-3; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; *INT AG RES CANC, 2002, AFL SOM TRAD HERB ME; IYER RS, 1994, J AM CHEM SOC, V116, P1603, DOI 10.1021/ja00084a001; Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101; Jackson PE, 2001, CANCER RES, V61, P33; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.0.CO;2-Z; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Johnson WW, 1997, P NATL ACAD SCI USA, V94, P6121, DOI 10.1073/pnas.94.12.6121; Jung K, 2004, CANCER LETT, V205, P173, DOI 10.1016/j.canlet.2003.11.023; Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x; KIRBY GM, 1994, MOL CARCINOGEN, V11, P74, DOI 10.1002/mc.2940110204; Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161; Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Laken SJ, 1998, NAT BIOTECHNOL, V16, P1352, DOI 10.1038/4333; Lin Y, 1997, CANCER RES, V57, P5137; Lleonart ME, 2005, CANCER EPIDEM BIOMAR, V14, P2956, DOI 10.1158/1055-9965.EPI-05-0612; Lunn RM, 1997, CANCER RES, V57, P3471; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Madden CR, 2002, J VIROL, V76, P11770, DOI 10.1128/JVI.76.22.11770-11774.2002; MCLEAN M, 1995, PHARMACOL THERAPEUT, V65, P163, DOI 10.1016/0163-7258(94)00054-7; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; PONCHEL F, 1994, CANCER RES, V54, P2064; PUISIEUX A, 1991, CANCER RES, V51, P6185; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Schleger C, 1999, HEPATOLOGY, V29, P834, DOI 10.1002/hep.510290305; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Shi H, 2008, CARCINOGENESIS, V29, P1428, DOI 10.1093/carcin/bgm266; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P617; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103; Taback B, 2004, CURR OPIN MOL THER, V6, P273; Tong WM, 2006, INT J CANCER, V119, P745, DOI 10.1002/ijc.21890; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5&lt;620::AID-IJC5&gt;3.0.CO;2-W; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Williams JH, 2004, AM J CLIN NUTR, V80, P1106, DOI 10.1093/ajcn/80.5.1106; WOGAN GN, 1992, CANCER RES, V52, pS2114; Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113	64	78	80	0	23	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3835	1872-7980		CANCER LETT	Cancer Lett.	DEC 1	2009	286	1			SI		29	37		10.1016/j.canlet.2009.02.057			9	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	526IZ	WOS:000272282900007	19376640				2022-02-25	
J	Secretan, B; Straif, K; Baan, R; Grosse, Y; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Freeman, C; Galichet, L; Cogliano, V				Secretan, Beatrice; Straif, Kurt; Baan, Robert; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent; Cogliano, Vincent		Who Int Agcy Res Canc Monograph	A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish	LANCET ONCOLOGY			English	News Item							CIGARETTE-SMOKING; GENETIC POLYMORPHISMS; RISK-FACTORS; CANCER RISK; ESOPHAGEAL; COHORT; TAIWAN; HEAD		[Secretan, Beatrice; Straif, Kurt; Baan, Robert; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent; Cogliano, Vincent; Who Int Agcy Res Canc Monograph] Int Agcy Res Canc, F-69372 Lyon, France		Secretan, B (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Guha, Neela/AAG-3989-2021; Freeman, Crystal/AAF-3438-2020; Weiderpass, Elisabete/M-4029-2016; Weiderpass, Elisabete/AAP-2747-2021; Filho, Victor Wunsch/C-4475-2012	Guha, Neela/0000-0003-3991-4662; Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Friborg, Jeppe/0000-0001-5423-0627; Norppa, Hannu/0000-0001-6637-904X			Baan R, 2007, LANCET ONCOL, V8, P292, DOI 10.1016/S1470-2045(07)70099-2; Boffetta P, 2008, LANCET ONCOL, V9, P667, DOI 10.1016/S1470-2045(08)70173-6; Cui Y, 2006, BREAST CANCER RES TR, V100, P293, DOI 10.1007/s10549-006-9255-3; Grosse Y, 2009, LANCET ONCOL, V10, P13, DOI 10.1016/S1470-2045(08)70286-9; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; IARC, 2004, IARC MONOGR EVAL CAR, V85, P1; *IARC, 2004, IARC MON EV CARC RIS, V83, P1; Kurian AW, 2005, GYNECOL ONCOL, V96, P520, DOI 10.1016/j.ygyno.2004.10.037; Lee CH, 2005, INT J CANCER, V113, P475, DOI 10.1002/ijc.20619; Lee KM, 2009, LEUKEMIA RES, V33, P250, DOI 10.1016/j.leukres.2008.06.031; Lee YCA, 2008, CANCER EPIDEM BIOMAR, V17, P1974, DOI 10.1158/1055-9965.EPI-08-0047; Liang PS, 2009, INT J CANCER, V124, P2406, DOI 10.1002/ijc.24191; Pang D, 2003, BRIT J CANCER, V88, P373, DOI 10.1038/sj.bjc.6600774; Reynolds P, 2004, J WOMENS HEALTH, V13, P778, DOI 10.1089/jwh.2004.13.778; Straif Kurt, 2006, Lancet Oncol, V7, P977, DOI 10.1016/S1470-2045(06)70969-X; Takezaki T, 2001, JPN J CANCER RES, V92, P1157, DOI 10.1111/j.1349-7006.2001.tb02135.x; TRAMACERE I, 2009, INT J CANCER; Wang LY, 2003, CANCER CAUSE CONTROL, V14, P241, DOI 10.1023/A:1023636619477; Yokoyama A, 2005, ALCOHOL, V35, P175, DOI 10.1016/j.alcohol.2005.04.003	19	711	740	5	92	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045			LANCET ONCOL	Lancet Oncol.	NOV	2009	10	11					1033	1034		10.1016/S1470-2045(09)70326-2			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	520NT	WOS:000271852800011	19891056				2022-02-25	
J	Cogliano, VJ				Cogliano, V. J.			Identifying tumour sites in the IARC Monographs	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Letter									Int Agcy Res Canc, IARC Monographs Programme, F-69372 Lyon, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, IARC Monographs Programme, 150 Cours Albert Thomas, F-69372 Lyon, France.	cogliano@iarc.fr					Cogliano VJ, 2006, ANN NY ACAD SCI, V1076, P592, DOI 10.1196/annals.1371.014; Huff J, 2009, OCCUP ENVIRON MED, V66, P140, DOI 10.1136/oem.2008.042036; *IARC, 2006, IARC MON EV CARC RIS, V88, P39; *IARC, 2007, 07001 IARC; *IARC, FUT M; IARC (International Agency for Research on Cancer), 2010, IARC MON EV CARC RIS	6	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JUL	2009	66	7					496	496					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	459XE	WOS:000267145600015	19541807				2022-02-25	
J	Herceg, Z; Paliwal, A				Herceg, Zdenko; Paliwal, Anupam			HBV protein as a double-barrel shot-gun targets epigenetic landscape in liver cancer	JOURNAL OF HEPATOLOGY			English	Editorial Material							VIRUS-X PROTEIN; HEPATITIS-B; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; HEPATOCARCINOGENESIS; PATHOGENESIS		[Herceg, Zdenko; Paliwal, Anupam] Int Agcy Res Canc IARC, Epigenet Grp, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc IARC, Epigenet Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr					Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Cougot D, 2007, J BIOL CHEM, V282, P4277, DOI 10.1074/jbc.M606774200; Feitelson MA, 2006, CANCER LETT, V239, P10, DOI 10.1016/j.canlet.2005.07.009; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Hussain SP, 2007, ONCOGENE, V26, P2166, DOI 10.1038/sj.onc.1210279; Jung JK, 2007, CANCER RES, V67, P5771, DOI 10.1158/0008-5472.CAN-07-0529; Li HP, 2005, CELL RES, V15, P262, DOI 10.1038/sj.cr.7290295; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; SHON JK, 2008, VIRUS RES; Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; Wright TL, 2006, AM J GASTROENTEROL, V101, pS1, DOI 10.1111/j.1572-0241.2006.00469.x; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019; Zoulim F, 2008, J HEPATOL, V48, pS2, DOI 10.1016/j.jhep.2008.01.011	16	10	10	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-8278			J HEPATOL	J. Hepatol.	FEB	2009	50	2					252	255		10.1016/j.jhep.2008.11.013			4	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	406QC	WOS:000263309000005	19070919	hybrid			2022-02-25	
J	Boyle, P; Boffetta, P; Autier, P				Boyle, P.; Boffetta, P.; Autier, P.			Diet, nutrition and cancer: public, media and scientific confusion	ANNALS OF ONCOLOGY			English	Editorial Material							MORTALITY		[Boyle, P.; Boffetta, P.; Autier, P.] Int Agcy Res Canc, F-69372 Lyon 08, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	director@iarc.fr	Boyle, Peter/A-4380-2014; Autier, Philippe/A-4402-2014	Boyle, Peter/0000-0001-6251-0610; Autier, Philippe/0000-0003-1538-5321			ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730; Bjelakovic G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007176; *DAIL MAIL, IS AN SAF EAT CANC R; Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2; Doll Richard, 1981, CAUSES CANC; Flegal KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/jama.298.17.2028; *GUARD, BLAM IT BAC; IARC, 2003, IARC HDB CANC PREV, V8; *IARC, OV EV CARC HUM; *IARC WORK GROUP, 2007, IARC WORK GROUP REP, V3; International Agency for Research on Cancer IARC, 2004, MON EV CARC RISKS HU, V83; *NAT AC SCI NAT RE, 1982, DIET NUTR CANC; Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Tannenbaum A, 1940, ARCH PATHOL, V30, P509; Trichopoulou A, 2000, CANCER EPIDEM BIOMAR, V9, P869; *WORLD CANC RES FU, 1997, FOOD NUTR PHYS ACT P; 2007, FOOD NUTR PREVENTION	19	40	41	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	OCT	2008	19	10					1665	1667		10.1093/annonc/mdn561			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	353PT	WOS:000259581200001	18809584	Bronze			2022-02-25	
J	Egevad, L				Egevad, Lars			Recent Trends in Gleason Grading of Prostate Cancer II. Prognosis, Reproducibility and Reporting	ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY			English	Article						Gleason grade; prognosis; prostate cancer	RADICAL RETROPUBIC PROSTATECTOMY; NEEDLE-BIOPSY; INTEROBSERVER REPRODUCIBILITY; STAGE T1C; DISEASE-FREE; FOLLOW-UP; SPECIMENS; SCORE; CARCINOMA; PREDICTION	Gleason grading of prostate cancer is the most important histopathologic predictor of prognosis. In recent years, a number of changes have been made in how Gleason grading is peformed and reported. A consensus conference was organized in 2005 by the International Society of Urological Pathology for the purpose of standardizing both the perception of histologic patterns and how the grade information is compiled and reported. The recommendations regarding reporting are summarized and discussed in this review. The prognostic importance Of the Gleason score, its reproducibility and its role in preoperative assessment are also discussed. (Anal Quant Cytol Histol 2008;30:254-260)	WHO, Int Agcy Res Canc, Pathol Grp, F-69372 Lyon 08, France		Egevad, L (corresponding author), WHO, Int Agcy Res Canc, Pathol Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	egevadl@iarc.fr		Egevad, Lars/0000-0001-8531-222X			AIHARA M, 1994, UROLOGY, V43, P60, DOI 10.1016/S0090-4295(94)80264-5; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Allsbrook WC, 2001, HUM PATHOL, V32, P74, DOI 10.1053/hupa.2001.21134; Allsbrook WC, 2001, HUM PATHOL, V32, P81, DOI 10.1053/hupa.2001.21135; Amin M, 2005, SCAND J UROL NEPHROL, V39, P20, DOI 10.1080/03008880510030923; Andren O, 2006, J UROLOGY, V175, P1337, DOI 10.1016/S0022-5347(05)00734-2; Arora R, 2004, CANCER-AM CANCER SOC, V100, P2362, DOI 10.1002/cncr.20243; Berney DM, 2007, BJU INT, V100, P1240, DOI 10.1111/j.1464-410X.2007.07199.x; Boccon-Gibod L, 2004, EUR UROL, V46, P177, DOI 10.1016/j.eururo.2004.04.006; Bostwick DG, 2000, ARCH PATHOL LAB MED, V124, P995; Burke HB, 2005, ANAL QUANT CYTOL, V27, P211; Carlson GD, 1998, UROLOGY, V51, P525, DOI 10.1016/S0090-4295(98)00002-8; Chan TY, 2000, UROLOGY, V56, P823, DOI 10.1016/S0090-4295(00)00753-6; Cheng L, 2005, J CLIN ONCOL, V23, P2911, DOI 10.1200/JCO.2005.03.018; Coogan CL, 2005, BJU INT, V96, P324, DOI 10.1111/j.1464-410X.2005.05624.x; Cookson MS, 1997, J UROLOGY, V157, P559, DOI 10.1016/S0022-5347(01)65201-7; CUMMING JA, 1990, BRIT J UROL, V65, P271, DOI 10.1111/j.1464-410X.1990.tb14725.x; Djavan B, 1998, EUR UROL, V33, P261, DOI 10.1159/000019578; Draisma G, 2006, INT J CANCER, V119, P2366, DOI 10.1002/ijc.22158; Eble JN, 2004, WHO CLASSIFICATION T; Egevad L, 2002, J UROLOGY, V168, P509, DOI 10.1016/S0022-5347(05)64669-1; Egevad L, 2002, BJU INT, V89, P538, DOI 10.1046/j.1464-410X.2002.02669.x; Egevad L, 2001, BJU INT, V88, P716, DOI 10.1046/j.1464-4096.2001.02419.x; Egevad L, 2001, UROLOGY, V57, P291, DOI 10.1016/S0090-4295(00)00922-5; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2005, SCAND J UROL NEPHROL, V39, P34, DOI 10.1080/03008880510030932; EPSTEIN JI, 1994, J UROLOGY, V151, P1587, DOI 10.1016/S0022-5347(17)35309-0; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Epstein JI, 2001, J UROLOGY, V166, P1688, DOI 10.1016/S0022-5347(05)65654-6; Epstein JI, 2007, HUM PATHOL, V38, P1305, DOI 10.1016/j.humpath.2007.05.015; Glaessgen A, 2004, VIRCHOWS ARCH, V445, P17, DOI 10.1007/s00428-004-1034-0; Glaessgen A, 2004, J UROLOGY, V171, P664, DOI 10.1097/01.ju.0000108198.98598.00; Glaessgen A, 2002, J UROLOGY, V168, P2006, DOI 10.1016/S0022-5347(05)64283-8; Glaessgen A, 2006, SCAND J UROL NEPHROL, V40, P465, DOI 10.1080/00365590600917578; Gleason DF, 1996, UROLOGY, V47, P289, DOI 10.1016/S0090-4295(99)80441-5; Green GA, 1998, CANCER-AM CANCER SOC, V83, P971, DOI 10.1002/(SICI)1097-0142(19980901)83:5<971::AID-CNCR24>3.0.CO;2-R; Gregori A, 2001, UROL INT, V66, P66, DOI 10.1159/000056573; Grober Ethan D, 2004, Can J Urol, V11, P2157; Grossfeld GD, 2001, J UROLOGY, V165, P851, DOI 10.1016/S0022-5347(05)66543-3; Han M, 2003, J UROLOGY, V169, P517, DOI 10.1016/S0022-5347(05)63946-8; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; Hattab EM, 2006, J UROLOGY, V175, P1695, DOI 10.1016/S0022-5347(05)00998-5; HELPAP B, ANAL QUANT IN PRESS; Helpap B, 2008, ANAL QUANT CYTOL, V30, P1; Helpap B, 2006, VIRCHOWS ARCH, V449, P622, DOI 10.1007/s00428-006-0310-6; Horninger W, 1999, PROSTATE, V40, P56; Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7; King CR, 2004, INT J RADIAT ONCOL, V59, P386, DOI 10.1016/j.ijrobp.2003.10.014; Kondylis FI, 2003, J UROLOGY, V170, P1189, DOI 10.1097/01.ju.0000085675.96097.76; Kronz JD, 2000, CANCER, V89, P1818, DOI 10.1002/1097-0142(20001015)89:8<1818::AID-CNCR23>3.3.CO;2-A; Makarov DV, 2002, J UROLOGY, V167, P2440, DOI 10.1016/S0022-5347(05)65000-8; Mazzucchelli R, 2005, ANAL QUANT CYTOL, V27, P125; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; Melia J, 2006, HISTOPATHOLOGY, V48, P644, DOI 10.1111/j.1365-2559.2006.02393.x; Montironi R., 2001, Pathologica (Genoa), V93, P226; Montironi R, 2003, EUR UROL, V44, P626, DOI 10.1016/S0302-2838(03)00381-6; Montironi R, 2006, VIRCHOWS ARCH, V449, P1, DOI 10.1007/s00428-006-0190-9; Noguchi M, 2003, J UROLOGY, V170, P459, DOI 10.1097/01.ju.0000070928.49986.04; NUMAO N, 2007, EUR UROL; Pan CC, 2000, AM J SURG PATHOL, V24, P563, DOI 10.1097/00000478-200004000-00011; Poulos CK, 2005, MODERN PATHOL, V18, P228, DOI 10.1038/modpathol.3800302; Ramos CG, 1999, J UROLOGY, V161, P1525, DOI 10.1016/S0022-5347(05)68944-6; Rubin MA, 2001, J UROLOGY, V165, P114, DOI 10.1097/00005392-200101000-00029; Rubin MA, 2000, AM J SURG PATHOL, V24, P1634, DOI 10.1097/00000478-200012000-00007; Rubin MA, 2004, AM J SURG PATHOL, V28, P946, DOI 10.1097/00000478-200407000-00016; Ruijter ET, 1996, J PATHOL, V180, P295; Sakr WA, 2000, UROLOGY, V56, P730, DOI 10.1016/S0090-4295(00)00791-3; San Francisco IF, 2003, J UROLOGY, V169, P136, DOI 10.1016/S0022-5347(05)64053-0; Sengupta S, 2006, CANCER-AM CANCER SOC, V106, P2630, DOI 10.1002/cncr.21924; Smith EB, 2002, CANCER-AM CANCER SOC, V94, P2282, DOI 10.1002/cncr.10457; SPIRES SE, 1994, ARCH PATHOL LAB MED, V118, P705; Srigley JR, 2006, ARCH PATHOL LAB MED, V130, P936; Stamey TA, 2000, J UROLOGY, V163, P1155, DOI 10.1016/S0022-5347(05)67713-0; Stamey TA, 1999, JAMA-J AM MED ASSOC, V281, P1395, DOI 10.1001/jama.281.15.1395; Steinberg DM, 1997, AM J SURG PATHOL, V21, P566, DOI 10.1097/00000478-199705000-00010; Veltri RW, 2002, J UROLOGY, V168, P100, DOI 10.1016/S0022-5347(05)64839-2; Vis AN, 2007, EUR UROL, V51, P931, DOI 10.1016/j.eururo.2006.07.051; ZAGARS GK, 1995, INT J RADIAT ONCOL, V31, P237, DOI 10.1016/0360-3016(94)00323-D	78	15	16	0	2	SCI PRINTERS & PUBL INC	ST LOUIS	PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA	0884-6812			ANAL QUANT CYTOL	Anal. Quant. Cytol. Histol.	OCT	2008	30	5					254	260					7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	361JF	WOS:000260123200002	18980156				2022-02-25	
J	Mounawar, M; Desira, S; Arandelovic, S; Hainaut, P				Mounawar, M.; Desira, S.; Arandelovic, S.; Hainaut, P.			Down-regulation of p53 protein expression in lung carcinoma cells in response to the tyrosine kinase inhibitor gefinitib	EJC SUPPLEMENTS			English	Meeting Abstract	20th Meeting of the European-Association-for-Cancer-Research	JUL 05-08, 2008	Lyon, FRANCE	European Assoc Canc Res					[Mounawar, M.; Desira, S.; Arandelovic, S.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, WHO, F-69372 Lyon, France				Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				0	0	0	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	JUL	2008	6	9					32	32		10.1016/S1359-6349(08)71299-0			1	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	330DF	WOS:000257919000125					2022-02-25	
J	Hery, C; Ferlay, J; Boniol, M; Autier, P				Hery, C.; Ferlay, J.; Boniol, M.; Autier, P.			Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations	ANNALS OF ONCOLOGY			English	Article						breast cancer; epidemiology; temporal trends	SCREENING MAMMOGRAPHY; FOOD-CONSUMPTION; SURVIVAL; TRENDS; AGE; PERFORMANCE; BENEFITS; THERAPY; RATES; STAGE	Background: Since 1985 considerable changes have taken place in the early detection and treatment of breast cancer. We quantified breast cancer trends for 35 countries with populations mainly of European ancestry. Methods: Incidence data were extracted from cancer registries and mortality data from World Health Organization database. Overall percentage change from 1990 to 2002 was quantified for all ages and for three different age-groups (35-49, 50-69 and >= 70 years of age). Results: The incidence percent change in women of all ages varied from 2.1% in Canada to 54.2% in Lithuania. Main increases in incidence were observed for women 50-69 years old, from 12.4% in Canada until 105.3% in Norway. Decreases in mortality of > 20% were observed in nine countries. Mortality decreases were highest in women 35-49 years old and lowest in women >= 70 years. The magnitude of mortality decrease from 1990 to 2002 was not related to the mortality rate observed in 1990. Conclusions: While increases in breast cancer incidence mainly concerned women >= 50 years, decreases in mortality were more marked in women 35-49 years old. Large disparities in changes in mortality rates probably reflect differences in detection of and management of breast cancer.	[Hery, C.; Ferlay, J.; Boniol, M.; Autier, P.] Int Agcy Res Canc, Data Anal & Interpretat Grp, Epidemiol Methods & Support Grp, F-69372 Lyon 08, France		Autier, P (corresponding author), Int Agcy Res Canc, Data Anal & Interpretat Grp, Epidemiol Methods & Support Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	autierp@iarc.fr	Boniol, Mathieu/F-9623-2011; Ferlay, Jacques/ABD-5058-2021; Autier, Philippe/A-4402-2014	Boniol, Mathieu/0000-0003-1052-5604; Autier, Philippe/0000-0003-1538-5321			[Anonymous], SWEDISH CANC REGISTR; AUGUST DA, 1993, J SURG ONCOL, V53, P161, DOI 10.1002/jso.2930530306; AUGUST DA, 1994, ANN SURG ONCOL, V1, P45, DOI 10.1007/BF02303540; Brock Anita, 2004, Health Stat Q, P7; Dofkova M, 2001, PUBLIC HEALTH NUTR, V4, P999, DOI 10.1079/PHN2001169; Eaker S, 2006, PLOS MED, V3, P321, DOI 10.1371/journal.pmed.0030025; Eaker S, 2005, CANCER EPIDEM BIOMAR, V14, P2914, DOI 10.1158/1055-9965.EPI-05-0317; ENGHOLM G, 2006, CANC INCIDENCE MORTA; *EP MAL TUM CZECH, MAT CANC REG CZECH R; FERLAY J, 2004, 5 IARC; Gilligan MA, 2007, AM J PUBLIC HEALTH, V97, P539, DOI 10.2105/AJPH.2005.075663; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; Glass AG, 2007, JNCI-J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Haller DG, 2006, J CLIN ONCOL, V24, p149S; Hermon C, 1996, BRIT J CANCER, V73, P955, DOI 10.1038/bjc.1996.171; Hertl K, 2006, NEOPLASMA, V53, P237; Ivanova L, 2006, ECON HUM BIOL, V4, P383, DOI 10.1016/j.ehb.2006.08.001; Jemal A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1672; Jolleys JV, 1996, MATURITAS, V23, P47, DOI 10.1016/0378-5122(95)00952-3; KARJALAINEN S, 1989, SOC SCI MED, V28, P233, DOI 10.1016/0277-9536(89)90266-9; Kliukiene J, 1998, EUR J CANCER, V34, P372, DOI 10.1016/S0959-8049(97)10092-2; Lutz JM, 2004, EUR J CANCER PREV, V13, P77, DOI 10.1097/00008469-200402000-00012; Monaghan P, 2005, J PUBLIC HEALTH, V27, P171, DOI 10.1093/pubmed/fdi003; *NZ HLTH INF SERV, NZ CANC REG; ONDRUSOVA M, 2006, CANC INCIDENCE SLOVA, P210; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Pavillon G., 2005, B EPIDEMIOLOGIQUE HE, V4, P13; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; *SEER PROGR, 2007, LIM US DAT 1973 2004; Segi M, 1960, CANC MORTALITY SELEC; Selby P, 1996, LANCET, V348, P313, DOI 10.1016/S0140-6736(96)02482-8; Smith-Bindman R, 2005, JNCI-J NATL CANCER I, V97, P358, DOI 10.1093/jnci/dji060; Theberge I, 2005, CAN MED ASSOC J, V172, P195, DOI 10.1503/cmaj.1040485; Veronesi U, 2005, LANCET, V365, P1727, DOI 10.1016/S0140-6736(05)66546-4; *VILN U I ONC, 2005, LITH CANC REG CANC L; Waskiewicz Anna, 2006, Kardiol Pol, V64, P16; *WHO, WHO STAT INF SYST; Zorbas H, 2004, JNCI-J NATL CANCER I, V96, P1258, DOI [10.1093/jnci/djh249, 10.1093/jnci/djh250]; Zorbas H, 2003, MED J AUSTRALIA, V179, P528, DOI 10.5694/j.1326-5377.2003.tb05678.x; ISRAEL ISRAEL CANC R; AUSTRIA STAT AUSTRIA; 2003, EUROCIM VERSION 4 1; CANC REGISTRY BULGAR; CANC REGISTRY NORWAY; NATL CANC REGISTRY I; SCOTTISH CANC REGIST; ENGLAND WALES NATL S	47	79	80	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	JUN	2008	19	6					1187	1194		10.1093/annonc/mdn025			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	306SM	WOS:000256268100022	18325921	Bronze			2022-02-25	
J	Hainaut, P; Boyle, P				Hainaut, Pierre; Boyle, Peter			Curbing the liver cancer epidemic in Africa	LANCET			English	Editorial Material							HEPATITIS-B; WEST-AFRICA; INFECTION; GAMBIA		[Hainaut, Pierre; Boyle, Peter] Int Agcy Res Canc, F-69372 Lyon, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	Boyle, Peter/A-4380-2014; Hainaut, Pierre/B-6018-2012	Boyle, Peter/0000-0001-6251-0610; Hainaut, Pierre/0000-0002-1303-1610			Boyle P, 2006, LANCET, V368, P629, DOI 10.1016/S0140-6736(06)69225-8; Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8; Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Raza SA, 2007, BRIT J CANCER, V96, P1127, DOI 10.1038/sj.bjc.6603649; Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5; VANDERSANDE MA, PLOS ONE, V2, pE753; Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4	8	36	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 2	2008	371	9610					367	368		10.1016/S0140-6736(08)60181-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260ED	WOS:000252992700008	18242399				2022-02-25	
J	Boffetta, P				Boffetta, Paolo			Human cancer from environmental pollutants: The epidemiological evidence	MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS			English	Article; Proceedings Paper	35th Annual Meeting of the European-Environmental-Mutagen-Society	JUL 03-07, 2005	Kos Isl, GREECE			human cancer; environmental pollutants; epidemiological evidence	LUNG-CANCER; AIR-POLLUTION; EXPOSURE; RISK; MORTALITY; SMOKING; BLADDER; EUROPE; RADON; FINE	An increased risk of mesothelioma has been reported among individuals experiencing residential exposure to asbestos, while results for lung cancer are less consistent. Several studies have reported an increased risk of lung cancer risk from outdoor air pollution: on the basis of the results of the largest study, the proportion of lung cancers attributable to urban air pollution in Europe can be as high as 10.7%. A causal association has been established between second-hand tobacco smoking and lung cancer, which may be responsible for 1.6% of lung cancers. Radon is another carcinogen present in indoor air, which may be responsible for 4.5% of lung cancers. An increased risk of bladder might be due to water chlorination by-products. The available evidence on cancer risk following exposure to other environmental pollutants, including, pesticides, dioxins and electro-magnetic fields, is inconclusive. (c) 2006 Elsevier B.V. All rights reserved.	Int Agcy Res Canc, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr					Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; Boffetta P, 2003, BRIT MED BULL, V68, P71, DOI 10.1093/bmp/ldg023; Boffetta P, 2002, SCAND J WORK ENV HEA, V28, P30; Boffetta P, 1998, J NATL CANCER I, V90, P1440, DOI 10.1093/jnci/90.19.1440; Bourdes V, 2000, EUR J EPIDEMIOL, V16, P411, DOI 10.1023/A:1007691003600; Cohen AJ, 2000, ENVIRON HEALTH PERSP, V108, P743, DOI 10.2307/3454411; Darby S, 2005, BMJ-BRIT MED J, V330, P223, DOI 10.1136/bmj.38308.477650.63; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; Hazenkamp-Von Arx ME, 2004, ATMOS ENVIRON, V38, P1943, DOI 10.1016/j.atmosenv.2004.01.016; *IARC, 2004, IARC MONOGRAPHS EVAL, V0084, P00039; *IARC, 1991, IARC MON EV CARC RIS, V52, P45; IARC, 1997, IARC MONOGRAPHS EVAL, P69; *IARC, 2004, IARC MON EV CARC RIS, V83, P1191; *IARC, 2002, IARC MON EV CARC RIS, V0080; Katsouyanni K, 1997, CANCER CAUSE CONTROL, V8, P284, DOI 10.1023/A:1018492818416; Kurttio P, 1999, ENVIRON HEALTH PERSP, V107, P705, DOI 10.2307/3434654; Lissowska J, 2005, AM J EPIDEMIOL, V162, P326, DOI 10.1093/aje/kwi204; LUBIN JH, 1995, J NATL CANCER I, V87, P817, DOI 10.1093/jnci/87.11.817; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; SARACCI R, 1994, EPIDEMIOLOGY LUNG CA, P465; Siemiatycki J, 2004, ENVIRON HEALTH PERSP, V112, P1447, DOI 10.1289/ehp.7047; Simonato L, 2001, INT J CANCER, V91, P876, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1139>3.0.CO;2-7; *UNSCEAR, 2000, 2000 REP GEN ASS SCI, V1; Villanueva CM, 2004, EPIDEMIOLOGY, V15, P357, DOI 10.1097/01.ede.0000121380.02594.fc; *WHO, 1987, WHO REG PUBL EUR SER, V23, P182; Zhong LJ, 1999, SCAND J WORK ENV HEA, V25, P309, DOI 10.5271/sjweh.440; [No title captured]	31	115	117	2	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1383-5718	1879-3592		MUTAT RES-GEN TOX EN	Mutat. Res. Genet. Toxicol. Environ. Mutagen.	SEP 28	2006	608	2			SI		157	162		10.1016/j.mrgentox.2006.02.015			6	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	088TY	WOS:000240835200007	16843042				2022-02-25	
J	Cogliano, VJ				Cogliano, VJ			Current criteria to establish human carcinogens	SEMINARS IN CANCER BIOLOGY			English	Article						tumors; carcinogenesis; multi-factorial view		Several national and international health agencies worldwide have established carcinogen identification programs with the aim of identifying the agents and exposures that contribute to the global burden of cancer. These programs have many features in common. IARC's program is described in some detail, with an emphasis on how evaluations can be changed by mechanistic data. Recently, several programs have expanded on the guidance they provide in assessing mechanistic data. The most comprehensive example is EPA's recent draft final Guidelines for Carcinogen Risk Assessment. In all programs, however, the principal role of mechanistic information has been to support the positive results observed in epidemiological studies or to discount the relevance of positive results observed in experimental animal bioassays. An alternative paradigm for carcinogen identification is proposed, one where mechanistic studies have a central role, rather than a supporting one. Under this paradigm, potentially carcinogenic agents would be identified by (1) identifying the key precursor events and processes involved in human cancer and (2) testing to see whether an agent can affect these events and processes. Under this paradigm, which is consistent with a multi-factorial view of carcinogenesis, it might be possible to identify carcinogens through mechanistic understanding alone, without waiting for epidemiological studies or 2-year carcinogenesis bioassays in rats and mice. This paradigm asks the question, "What is a human carcinogen? Is it an agent that we observe to induce tumors, or more generally, an agent with a clear role in tumor development?" (C) 2004 Elsevier Ltd. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	cogliano@iarc.fr					*EPA, 1999, NCEAF0664 USEPA; *EPA, 2003, EPA630P03001A; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; IARC, 2004, PREAMBL IARC MON; IARC, 1994, IARC MON EV CARC RIS, V60; International Agency for Research on Cancer (IARC), 1997, IARC MON EV CARC RIS, V69; *IPCS, 1999, IPCS996; NTP, 2000, REP CARC REP CARC, Vfourteenth; NTP (National Toxicology Program), 2002, REP CARC	9	3	4	0	0	ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1044-579X			SEMIN CANCER BIOL	Semin. Cancer Biol.	DEC	2004	14	6					407	412		10.1016/j.semcancer.2004.06.003			6	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	867MS	WOS:000224847300003	15489133				2022-02-25	
J	Suzuki, T; Ohshima, H				Suzuki, T; Ohshima, H			Modification by fluoride, bromide, iodide, thiocyanate and nitrite anions of reaction of a myeloperoxidase-H2O2-Cl- system with nucleosides	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						myeloperoxidase; nucleoside; bromide; iodide; thiocyanate; nitrite	AQUEOUS HYPOCHLOROUS ACID; CALF THYMUS DNA; EOSINOPHIL PEROXIDASE; SPIROIMINODIHYDANTOIN NUCLEOSIDE; HUMAN NEUTROPHILS; CHLORIDE; CHLORINATION; OXIDATION; 8-OXO-7,8-DIHYDRO-2'-DEOXYGUANOSINE; INFLAMMATION	The influence of fluoride (F-), bromide (Br-), iodide (I-), thiocyanate (SCN-) and nitrite (NO2-) on the reaction of a myeloperoxidase-H2O2-Cl- system with a nucleoside mixture was studied. The reaction was carried out under mildly acidic conditions and terminated by N-acetylcysteine. Without the additional anions, quantity of nucleosides consumed fell in the following order: 2'-deoxyguanosine>2'-deoxycytidine>>2'-deoxythymidine>2'deoxyadenosineapproximate to0. F- did not affect the reaction. Br- increased the consumption of 2'-deoxycytidine and 2'-deoxythymidine, but decreased that of 2'-deoxyguanosine. I-, SCN- and NO2- suppressed the reaction. These results suggest that Br- has a unique effect in relation to nucleoside damage caused by myeloperoxidase.	Int Agcy Res Canc, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohshima@iarc.fr	Ohshima, Hiroshi/E-8044-2010				BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; BERNOFSKY C, 1990, FREE RADICAL RES COM, V9, P303, DOI 10.3109/10715769009145689; BOYLAND E, 1971, FOOD COSMET TOXICOL, V9, P639, DOI 10.1016/0015-6264(71)90151-9; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; DEGIAMPIETRO P, 1987, J CLIN CHEM CLIN BIO, V25, P711; Delange F, 2001, THYROID, V11, P437, DOI 10.1089/105072501300176390; DENSEN PM, 1967, ARCH ENVIRON HEALTH, V14, P865, DOI 10.1080/00039896.1967.10664853; FARHANGRAZI ZS, 1992, BIOCHEMISTRY-US, V31, P10763, DOI 10.1021/bi00159a017; FORMAN D, 1989, CANCER SURV, V8, P443; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; Guy WS, 1976, BIOCH INVOLVING CARB, P117; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; Henderson JP, 2001, BIOCHEMISTRY-US, V40, P2052, DOI 10.1021/bi002015f; HOLZBECHER J, 1980, CLIN BIOCHEM, V13, P277, DOI 10.1016/S0009-9120(80)80009-9; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; KAMINSKY L S, 1990, Critical Reviews in Oral Biology and Medicine, V1, P261; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Kirk K. L., 1991, BIOCH ELEMENTAL HALO; Kleerekoper M, 1994, Adv Dent Res, V8, P32; KUMAR K, 1986, INORG CHEM, V25, P4344, DOI 10.1021/ic00244a012; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V200, P951, DOI 10.1006/bbrc.1994.1542; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; OKA S, 1981, ANAL CHEM, V53, P588, DOI 10.1021/ac00227a007; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; Shen ZZ, 2001, BIOCHEMISTRY-US, V40, P2041, DOI 10.1021/bi001961t; Suzuki T, 2002, NUCLEIC ACIDS RES, V30, P2555, DOI 10.1093/nar/30.11.2555; Suzuki T, 2002, FEBS LETT, V516, P67, DOI 10.1016/S0014-5793(02)02503-6; Suzuki T, 2001, CHEM RES TOXICOL, V14, P1163, DOI 10.1021/tx010024z; Takahashi K, 2001, J Epidemiol, V11, P170; Takegawa K, 1998, JPN J CANCER RES, V89, P105, DOI 10.1111/j.1349-7006.1998.tb00536.x; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 1999, BIOMARKERS, V4, P303, DOI 10.1080/135475099230831	39	8	8	0	6	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	MAR	2003	51	3					301	304					4	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Chemistry	649YB	WOS:000181234600013	12612415				2022-02-25	
J	Zavadil, J				Zavadil, J.			Genome-Wide Imprints of Human Carcinogens: Experimental Modeling in Support of Molecular Cancer Epidemiology.	ENVIRONMENTAL AND MOLECULAR MUTAGENESIS			English	Meeting Abstract	48th Annual Meeting of the Environmental-Mutagenesis-and-Genomics-Society (EMGS) on Environmental Health Sciences Bridging the Gap between Exposure, Mechanism and Public Health	SEP 09-13, 2017	Raleigh, NC	Environm Mutagenesis & Genom Soc, Genet & Environm Mutagenesis Soc N Carolina, Thermo Fisher Sci, Trevigen, Charles River, Elsevier, E I Dupont DE Nemours & Co, Environm & Mol Mutagenesis Editorial Off, Integrated Lab Syst Inc, Litron Labs, Gilead Sci					[Zavadil, J.] Int Agcy Res Canc, Lyon, France				Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562				0	1	1	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0893-6692	1098-2280		ENVIRON MOL MUTAGEN	Environ. Mol. Mutagen.	SEP	2017	58			1		S17	S29	S29					1	Environmental Sciences; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Environmental Sciences & Ecology; Genetics & Heredity; Toxicology	FE6JB	WOS:000408314700025					2022-02-25	
J	Saracci, R				Saracci, Rodolfo			Epidemiology, the International Epidemiological Association and the International Journal of Epidemiology: a personal chronicle	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Editorial Material							HEALTH		[Saracci, Rodolfo] Int Agcy Res Canc, 150 Cours A Thomas, F-69008 Lyon, France		Saracci, R (corresponding author), Int Agcy Res Canc, 150 Cours A Thomas, F-69008 Lyon, France.	saracci@hotmail.com					[Anonymous], 2003, INT J EPIDEMIOL, V32, P346; [Anonymous], 1989, INT J EPIDEMIOL S1, V18, P1; [Anonymous], 2002, INT J EPIDEMIOL, V31, P59; [Anonymous], 1993, INT J EPIDEMIOL S1, V22, P1; [Anonymous], 1992, INT J EPIDEMIOL S1, V21, P1; BRESLOW L, 1972, INT J EPIDEMIOL, V1, P347, DOI 10.1093/ije/1.4.347; DETELS R, 1987, INT J EPIDEMIOL, V16, P271, DOI 10.1093/ije/16.2.271; Doll R, 1972, INT J EPIDEMIOL, V1, P410; DUBOS R, 1966, PEDIATRICS, V38, P789; Ebrahim S, 2012, INT J EPIDEMIOL, V41, P1, DOI 10.1093/ije/dys015; Egger M, 2002, INT J EPIDEMIOL, V31, P1, DOI 10.1093/ije/31.1.1; Galton F, 2016, INT J EPIDEMIOL, V45, P13, DOI 10.1093/ije/dyw002; HENDERSON DA, 1972, INT J EPIDEMIOL, V1, P25, DOI 10.1093/ije/1.1.25; Holland WW, 1972, INT J EPIDEMIOL, V1, P3; Last JM., 2001, DICT EPIDEMIOLOGY, V4th; MacMahon B., 1960, EPIDEMIOLOGIC METHOD; Morris JN, 2007, INT J EPIDEMIOL, V36, P1165, DOI 10.1093/ije/dym227; Morris JN, 1957, USES EPIDEMIOLOGY; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Nathanson N., 1965, AM J EPIDEMIOL, V81, P1; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rose G, 2001, LANCET, V35, P1197; Rose G.A., 1992, STRATEGY PREVENTIVE; Saracci R, 2015, IARC 1 50 YEARS; Saracci R, 2007, INT J EPIDEMIOL, V36, P265, DOI 10.1093/ije/dym009; SCHWARTZ D, 1972, INT J EPIDEMIOL, V1, P51, DOI 10.1093/ije/1.1.51; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Smith GD, 2001, INT J EPIDEMIOL, V30, P1, DOI 10.1093/ije/30.1.1; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Winslow, 1943, CONQUEST EPIDEMIC DI; 2004, INT J EPIDEMIOL, V33, P262, DOI DOI 10.1093/IJE/DYH002	31	1	1	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	DEC	2016	45	6					1727	1732		10.1093/ije/dyw263			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	EQ7JU	WOS:000398261100004	27940485	Bronze			2022-02-25	
J	Lauby-Secretan, B; Loomis, D; Straif, K				Lauby-Secretan, Beatrice; Loomis, Dana; Straif, Kurt			Breast-Cancer Screening - Viewpoint of the IARC Working Group Reply	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Lauby-Secretan, Beatrice; Loomis, Dana; Straif, Kurt] Int Agcy Res Canc Lyon, Lyon, France		Lauby-Secretan, B (corresponding author), Int Agcy Res Canc Lyon, Lyon, France.		Loomis, Dana/AAE-3988-2019	Lauby-Secretan, Beatrice/0000-0001-6559-3351				0	23	25	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 8	2015	373	15					1479	1479					1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CS8XI	WOS:000362372800028	26444742				2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, Rengaswamy			Cancer prevention and care in India: an unfinished agenda	LANCET ONCOLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; MORTALITY; BREAST		Int Agcy Res Canc, Sect Early Detect & Prevent, F-69372 Lyon, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Sect Early Detect & Prevent, 150 Cours Albert Thomas, F-69372 Lyon, France.	sankarr@iarc.fr					[Anonymous], 2013, TIM TRENDS CANC INC; Badwe RA, 2014, LANCET ONCOL; Khuhaprema T, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003671; Krishnan S, 2013, ONCOLOGIST, V18, P1285, DOI 10.1634/theoncologist.2013-0292; Mallath MK, 2014, LANCET ONCOL; Mittra I, 2010, INT J CANCER, V126, P976, DOI 10.1002/ijc.24840; Pramesh CS, 2014, LANCET ONCOL; Sankaranarayanan R, 2005, LANCET, V365, P1927, DOI 10.1016/S0140-6736(05)66658-5; Sankaranarayanan R, 2007, LANCET, V370, P398, DOI 10.1016/S0140-6736(07)61195-7; Sankaranarayanan R, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-3; Sankaranarayanan R, 2011, JNCI-J NATL CANCER I, V103, P1476, DOI 10.1093/jnci/djr304; Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3; Shastri SS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju009	13	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	MAY	2014	15	6					554	555		10.1016/S1470-2045(14)70140-8			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AG6ES	WOS:000335512100033	24731886				2022-02-25	
J	Loomis, D; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Baan, R; Mattock, H; Straif, K				Loomis, Dana; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Baan, Robert; Mattock, Heidi; Straif, Kurt		IARC	The carcinogenicity of outdoor air pollution	LANCET ONCOLOGY			English	News Item							LUNG-CANCER; EXPOSURE; POLLUTANTS; MICE		[Loomis, Dana; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Baan, Robert; Mattock, Heidi; Straif, Kurt; IARC] Int Agcy Res Canc, F-69372 Lyon, France		Loomis, D (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Loomis, Dana/AAE-3988-2019; Forastiere, Francesco/J-9067-2016; Guha, Neela/AAG-3989-2021; Saldiva, Paulo HN/D-7385-2012; Knudsen, Lisbeth E./W-9392-2018	Forastiere, Francesco/0000-0002-9162-5684; Guha, Neela/0000-0003-3991-4662; Saldiva, Paulo HN/0000-0003-2005-8253; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Loomis, Dana/0000-0003-3297-5200; Phillips, David/0000-0001-8509-3485; Knudsen, Lisbeth E./0000-0002-9576-1202; Raaschou-Nielsen, Ole/0000-0002-1223-0909	Cancer Research UKCancer Research UK [14329] Funding Source: researchfish		Brauer M, 2012, ENVIRON SCI TECHNOL, V46, P652, DOI 10.1021/es2025752; DeMarini DM, 2013, MUTAGENESIS, V28, P485, DOI 10.1093/mutage/get042; EPSTEIN SS, 1979, ENVIRON RES, V19, P163, DOI 10.1016/0013-9351(79)90044-6; HUEPER WC, 1962, ARCH PATHOL, V74, P89; IARC, IARC MON EV IN PRESS, V109; Krewski Daniel, 2009, Res Rep Health Eff Inst, P5; Raaschou-Nielsen O, 2013, LANCET ONCOL, V14, P813, DOI 10.1016/S1470-2045(13)70279-1; Reymao MSF, 1997, ENVIRON RES, V74, P150, DOI 10.1006/enrs.1997.3740; Somers CM, 2011, SYST BIOL REPROD MED, V57, P63, DOI 10.3109/19396368.2010.500440; Sram RJ, 2007, TOXICOL LETT, V172, P12, DOI 10.1016/j.toxlet.2007.05.019; Turner MC, 2011, AM J RESP CRIT CARE, V184, P1374, DOI 10.1164/rccm.201106-1011OC; Unger N, 2010, P NATL ACAD SCI USA, V107, P3382, DOI 10.1073/pnas.0906548107	12	638	668	9	178	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	DEC	2013	14	13					1262	1263		10.1016/S1470-2045(13)70487-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	259PU	WOS:000327539600033	25035875				2022-02-25	
J	Marcel, V; Vijayakumar, V; Fernandez-Cuesta, L; Hafsi, H; Sagne, C; Hautefeuille, A; Olivier, M; Hainaut, P				Marcel, V.; Vijayakumar, V.; Fernandez-Cuesta, L.; Hafsi, H.; Sagne, C.; Hautefeuille, A.; Olivier, M.; Hainaut, P.			p53 regulates the transcription of its Delta 133p53 isoform through specific response elements contained within the TP53 P2 internal promoter	ONCOGENE			English	Article						p53; Delta 133p53 isoform; promoter; transcriptional regulation; genotoxic stress	CANCER-CELLS; GENE; ACTIVATION; ZEBRAFISH; DIFFERENTIATION; DELTA-113P53; SUPPRESSION; EXPRESSION; DELTA-NP73; MUTATIONS	The tumor suppressor p53 protein is activated by genotoxic stress and regulates genes involved in senescence, apoptosis and cell-cycle arrest. Nine p53 isoforms have been described that may modulate suppressive functions of the canonical p53 protein. Among them, Delta 133p53 lacks the 132 proximal residues and has been shown to modulate p53-induced apoptosis and cell-cycle arrest. Delta 133p53 is expressed from a specific mRNA, p53I4, driven by an alternative promoter P2 located between intron 1 and exon 5 of TP53 gene. Here, we report that the P2 promoter is regulated in a p53-dependent manner. Delta 133p53 expression is increased in response to DNA damage by doxorubicin in p53 wild-type cell lines, but not in p53-mutated cells. Chromatin immunoprecipitation and luciferase assays using P2 promoter deletion constructs indicate that p53 binds functional response elements located within the P2 promoter. We also show that Delta 133p53 does not bind specifically to p53 consensus DNA sequence in vitro, but competes with wild-type p53 in specific DNA-binding assays. Finally, we report that Delta 133p53 counteracts p53-dependent growth suppression in clonogenic assays. These observations indicate that D133p53 is a novel target of p53 that may participate in a negative feedback loop controlling p53 function. Oncogene (2010) 29, 2691-2700; doi:10.1038/onc.2010.26; published online 1 March 2010	[Marcel, V.; Vijayakumar, V.; Fernandez-Cuesta, L.; Hafsi, H.; Sagne, C.; Hautefeuille, A.; Olivier, M.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon 08, France		Hainaut, P (corresponding author), Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Olivier, Magali/G-3728-2010; Marcel, Virginie/H-3037-2011; MARCEL, Virginie/ABF-1904-2020; Fernandez-Cuesta, Lynnette/O-2415-2017; Fernandez-Cuesta, Lynnette/Z-1875-2019; Hainaut, Pierre/B-6018-2012	Olivier, Magali/0000-0002-8202-342X; Marcel, Virginie/0000-0002-9557-8221; MARCEL, Virginie/0000-0002-9557-8221; Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; Hainaut, Pierre/0000-0002-1303-1610; Vijayakumar, Vineetha/0000-0002-4295-7009	Association for International Cancer Research (AICR); Ligue Regionale du Rhone Contre le Cancer	VM is supported by la Ligue National Contre le Cancer. LF-C is supported by The Association for International Cancer Research (AICR). This project is funded by la Ligue Regionale du Rhone Contre le Cancer.	Bacus SS, 1996, ONCOGENE, V12, P2535; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hurd C, 1997, ONCOGENE, V15, P991, DOI 10.1038/sj.onc.1201233; Ishimoto O, 2002, CANCER RES, V62, P636; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Menendez D, 2007, ONCOGENE, V26, P2191, DOI 10.1038/sj.onc.1210277; MIYASHITA T, 1995, CELL, V80, P293; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	31	52	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2691	2700		10.1038/onc.2010.26			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	WOS:000277354600009	20190805	Bronze			2022-02-25	
J	Appleby, P; Beral, V; de Gonzalez, AB; Colin, D; Franceschi, S; Green, J; La Vecchia, C; Peto, J; Plummer, M; Sweetland, S				Appleby, Paul; Beral, Valerie; de Gonzalez, Amy Berrington; Colin, Didier; Franceschi, Silvia; Green, Jane; La Vecchia, Carlo; Peto, Julian; Plummer, Martyn; Sweetland, Sian		International Collaboration Epidem	Cervical Carcinoma and Sexual Behavior: Collaborative Reanalysis of Individual Data on 15,461 Women with Cervical Carcinoma and 29,164 Women without Cervical Carcinoma from 21 Epidemiological Studies	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Article							HUMAN-PAPILLOMAVIRUS INFECTION; ORAL-CONTRACEPTIVE USE; RISK-FACTORS; IN-SITU; INTRAEPITHELIAL NEOPLASIA; CIGARETTE-SMOKING; REPRODUCTIVE FACTORS; VENEREAL-DISEASES; INVASIVE CANCER; HPV INFECTION	High-risk human papillomavirus (HPV) types cause most cervical carcinomas and are sexually transmitted. Sexual behavior therefore affects HPV exposure and its cancer sequelae. The International Collaboration of Epidemiological Studies of Cervical Cancer has combined data on lifetime number of sexual partners and age at first sexual intercourse from 21 studies, or groups of studies, including 10,773 women with invasive cervical carcinoma, 4,688 women with cervical intraepithelial neoplasia grade 3 (CIN3)/carcinoma in situ, and 29,164 women without cervical carcinoma. Relative risks for invasive cancer and CIN3 were estimated by conditional logistic regression. Risk of invasive cervical carcinoma increased with lifetime number of sexual partners (P for linear trend <0.001). The relative risk for >= 6 versus 1 partner, conditioned on age, study, and age at first intercourse, was 2.27 [95% confidence interval (95% CI), 1.98-2.61] and increased to 2.78 (95% CI, 2.223.47) after additional conditioning on reproductive factors. The risk of invasive cervical carcinoma increased with earlier age at first intercourse (P for linear trend <0.001). The relative risk for age at first intercourse <= 14 versus >= 25 years, conditioned on age, study, and lifetime number of sexual partners was 3.52 (95% CI, 3.04-4.08), which decreased to 2.05 (95% CI, 1.54-2.73) after additional conditioning on reproductive factors. CIN3/carcinoma in situ showed a similar association with lifetime number of sexual partners; however, the association with age at first intercourse was weaker than for invasive carcinoma. Results should be interpreted with caution given the strong correlation between sexual and reproductive factors and the limited information on HPV status. (Cancer Epidemiol Biomarkers Prev 2009;18(4):1060-9)	[Plummer, Martyn] IARC, F-69372 Lyon 08, France		Plummer, M (corresponding author), IARC, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	plummer@iarc.fr	franceschi, silvia/M-2452-2014; Eluf-Neto, Jose/B-2522-2009; de gonzalez, amy berrington/L-7017-2017	franceschi, silvia/0000-0003-4181-8071; Eluf-Neto, Jose/0000-0001-7504-2115; de gonzalez, amy berrington/0000-0002-7332-8387; La Vecchia, Carlo/0000-0003-1441-897X	UNPD/UNFPA/WHO/World Bank Special Program of ResearchWorld Health Organization; Research Training in Human Reproduction; Department of Reproductive Health and Research; Cancer Research UKCancer Research UK; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0700474] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700474] Funding Source: researchfish; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [Z01CP010124] Funding Source: NIH RePORTER	UNPD/UNFPA/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction, Department of Reproductive Health and Research, WHO, IARC, and Cancer Research UK.	Appleby P, 2006, INT J CANCER, V119, P1108, DOI 10.1002/ijc.21953; Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5; Bayo S, 2002, INT J EPIDEMIOL, V31, P202, DOI 10.1093/ije/31.1.202; BERAL V, 1974, LANCET, V1, P1037; BERRY G, 1993, INT J CANCER, V55, P228; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOYCE JG, 1977, AM J OBSTET GYNECOL, V128, P761, DOI 10.1016/0002-9378(77)90717-7; BOYD JT, 1964, BRIT J CANCER, V18, P419, DOI 10.1038/bjc.1964.49; BRINTON LA, 1987, J NATL CANCER I, V79, P23; BUCKLEY JD, 1981, LANCET, V2, P1010; Burchell AN, 2006, AM J EPIDEMIOL, V163, P534, DOI 10.1093/aje/kwj077; Castle PE, 2002, SEX TRANSM DIS, V29, P182, DOI 10.1097/00007435-200203000-00009; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; Collins SI, 2005, INT J CANCER, V114, P498, DOI 10.1002/ijc.20732; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; CUZICK J, 1990, EUR J CANCER, V26, P684, DOI 10.1016/0277-5379(90)90117-C; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; de Gonzalez AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; EBELING K, 1987, INT J CANCER, V39, P427, DOI 10.1002/ijc.2910390402; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; Franceschi S, 2003, INT J CANCER, V107, P127, DOI 10.1002/ijc.11350; GRAM IT, 1992, AM J EPIDEMIOL, V135, P341, DOI 10.1093/oxfordjournals.aje.a116295; Green J, 2003, BRIT J CANCER, V89, P2078, DOI 10.1038/sj.bjc.6601296; Hammouda D, 2005, INT J CANCER, V113, P483, DOI 10.1002/ijc.20600; Hannaford PC, 2007, BRIT MED J, V335, P651, DOI 10.1136/bmj.39289.649410.55; HERRERO R, 1990, CANCER-AM CANCER SOC, V65, P380, DOI 10.1002/1097-0142(19900115)65:2<380::AID-CNCR2820650234>3.0.CO;2-9; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779; Hsieh CY, 1999, ANTICANCER RES, V19, P4495; International Agency for Research on Cancer (IARC), 1995, MON EV CARC RISK HUM, V64; International Collaboration of Epidemiological Studies of Cervical Cancer, 2006, Int J Cancer, V118, P1481, DOI 10.1002/ijc.21493; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; Kjaer SK, 2002, BRIT MED J, V325, P572, DOI 10.1136/bmj.325.7364.572; KJAER SK, 1992, CANCER CAUSE CONTROL, V3, P339, DOI 10.1007/BF00146887; Lacey JV, 1999, CANCER EPIDEM BIOMAR, V8, P1079; LAVECCHIA C, 1986, CANCER, V58, P935, DOI 10.1002/1097-0142(19860815)58:4<935::AID-CNCR2820580422>3.0.CO;2-O; LAZCANOPONCE EC, 1995, REV INVEST CLIN, V47, P377; Madeleine MM, 2001, CANCER EPIDEM BIOMAR, V10, P171; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; MUNOZ N, 1993, CANCER EPIDEM BIOMAR, V2, P423; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Parazzini F, 1998, EUR J CANCER, V34, P884, DOI 10.1016/S0959-8049(97)10139-3; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9; Plummer M, 2004, STAT MED, V23, P93, DOI 10.1002/sim.1485; Rolon PA, 2000, INT J CANCER, V85, P486, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;486::AID-IJC7&gt;3.0.CO;2-S; ROTKIN ID, 1973, CANCER RES, V33, P1353; Santos C, 2001, BRIT J CANCER, V85, P966, DOI [10.1038/sj.bjc.6691948, 10.1054/bjoc.2001.1948]; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0; Schroder KEE, 2003, ANN BEHAV MED, V26, P76, DOI 10.1207/S15324796ABM2602_02; Shapiro S, 2003, CANCER CAUSE CONTROL, V14, P485, DOI 10.1023/A:1024910808307; Silins I, 2004, GYNECOL ONCOL, V93, P484, DOI 10.1016/j.ygyno.2004.01.044; Sitas Freddy, 2007, Infect Agent Cancer, V2, P6, DOI 10.1186/1750-9378-2-6; SLATTERY ML, 1989, JAMA-J AM MED ASSOC, V261, P1593, DOI 10.1001/jama.261.11.1593; Stein L, 2008, INT J CANCER, V122, P2260, DOI 10.1002/ijc.23391; STONE KM, 1995, EPIDEMIOLOGY, V6, P409, DOI 10.1097/00001648-199507000-00014; STONE KM, 1995, CLIN INFECT DIS, V20, pS91, DOI 10.1093/clinids/20.Supplement_1.S91; TALBOTT EO, 1995, J WOMENS HLTH LARCHM, V4, P387; The Million Women Study, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Thomas DB, 2001, AM J EPIDEMIOL, V153, P732, DOI 10.1093/aje/153.8.732; Thomas DB, 2001, AM J EPIDEMIOL, V153, P723, DOI 10.1093/aje/153.8.723; THOMAS DB, 1973, AM J EPIDEMIOL, V98, P10, DOI 10.1093/oxfordjournals.aje.a121528; Ursin G, 1996, CANCER CAUSE CONTROL, V7, P391, DOI 10.1007/BF00052946; Vaccarella S, 2006, CANCER EPIDEM BIOMAR, V15, P326, DOI 10.1158/1055-9965.EPI-05-0577; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Winer RL, 2005, J INFECT DIS, V191, P731, DOI 10.1086/427557; Ylitalo N, 1999, INT J CANCER, V81, P357, DOI 10.1002/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.0.CO;2-1; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	72	68	70	0	7	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965	1538-7755		CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	APR	2009	18	4					1060	1069		10.1158/1055-9965.EPI-08-1186			10	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	432HV	WOS:000265125000006	19336546	hybrid			2022-02-25	
J	Grosse, Y; Baan, R; Straif, K; Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Galichet, L; Cogliano, V				Grosse, Yann; Baan, Robert; Straif, Kurt; Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Galichet, Laurent; Cogliano, Vincent		WHO Int Agcy Res Canc Monog Workin	Special Report: Policy A review of human carcinogens-Part A: pharmaceuticals	LANCET ONCOLOGY			English	News Item							OVARIAN-CANCER; THERAPY; RISK		[Grosse, Yann; Baan, Robert; Straif, Kurt; Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Galichet, Laurent; Cogliano, Vincent; WHO Int Agcy Res Canc Monog Workin] Int Agcy Res Canc, F-69372 Lyon, France		Grosse, Y (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Guha, Neela/AAG-3989-2021; Marques, M. Matilde/E-2535-2012	Guha, Neela/0000-0003-3991-4662; Marques, M. Matilde/0000-0002-7526-4962; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Phillips, David/0000-0001-8509-3485; Olsen, Jorgen Helge/0000-0001-9633-5662			Greiser CM, 2007, HUM REPROD UPDATE, V13, P453, DOI 10.1093/humupd/dmm012; Grollman AP, 2007, P NATL ACAD SCI USA, V104, P12129, DOI 10.1073/pnas.0701248104; *IARC, 1999, IARC MON EV CARC RIS, V72; International Agency for Research on Cancer (IARC), 2007, IARC MON EV CARC RIS, V91; Jemal A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1672; Lord GM, 2004, AM J KIDNEY DIS, V43, DOI 10.1053/j.ajkd.2003.11.024; MCCREDIE M, 1993, INT J CANCER, V53, P245, DOI 10.1002/ijc.2910530212; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; Pedersen-Bjergaard J, 2006, LEUKEMIA, V20, P1943, DOI 10.1038/sj.leu.2404381; Swerdlow S. H., 2017, CLASSIFICATION TUMOU; Zhou B, 2008, GYNECOL ONCOL, V108, P641, DOI 10.1016/j.ygyno.2007.12.003	11	103	104	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JAN	2009	10	1					13	14		10.1016/S1470-2045(08)70286-9			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	391EP	WOS:000262216900011	19115512				2022-02-25	
J	Egevad, L				Egevad, Lars			Recent trends in Gleason grading of prostate cancer - I. Pattern interpretation	ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY			English	Article						Gleason grade; Gleason pattern; prostate cancer	FOAMY GLAND CARCINOMA; PROGNOSTIC-SIGNIFICANCE; NEEDLE BIOPSIES; ENDOMETRIOID FEATURES; TRANSITION ZONE; ADENOCARCINOMA; SPECIMENS; RADIATION; DIAGNOSIS; SCORE	Histologic grading remains the most useful tissue-based predictor of prognosis of prostate cancer. The Gleason system is now the only grading system recommended by the World Health Organization (WHO) for prostatic carcinoma. In recent years, there has been a gradual shift of how the Gleason grading is applied in practice. There has been a general trend toward upgrading of prostate cancer. A consensus conference was organized in 2005 by the International Society of Urological Pathology with the purpose to standardize both the perception of histologic patterns and how grade information is compiled and reported. The recommendations regarding pattern interpretation are summarized and discussed in this review.	WHO, Pathol Grp, Int Agcy Res Canc, F-69372 Lyon 08, France		Egevad, L (corresponding author), WHO, Pathol Grp, Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	egevadl@iarc.fr		Egevad, Lars/0000-0001-8531-222X			AIHARA M, 1994, UROLOGY, V43, P60, DOI 10.1016/S0090-4295(94)80264-5; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Amin M, 2005, SCAND J UROL NEPHROL, V39, P20, DOI 10.1080/03008880510030923; ANDERSSON L, 1994, SCAND J UROL NEPHROL, P43; Arora R, 2004, CANCER-AM CANCER SOC, V100, P2362, DOI 10.1002/cncr.20243; Bailar J C 3rd, 1966, Cancer Chemother Rep, V50, P129; Berney DM, 2007, HISTOPATHOLOGY, V50, P683, DOI 10.1111/j.1365-2559.2007.02596.x; Berney DM, 2007, BJU INT, V100, P1240, DOI 10.1111/j.1464-410X.2007.07199.x; Boccon-Gibod L, 2004, EUR UROL, V46, P177, DOI 10.1016/j.eururo.2004.04.006; Bock BJ, 1999, AM J SURG PATHOL, V23, P781, DOI 10.1097/00000478-199907000-00005; BOCKING A, 1982, CANCER, V50, P288, DOI 10.1002/1097-0142(19820715)50:2<288::AID-CNCR2820500220>3.0.CO;2-S; BOSTWICK DG, 1985, AM J SURG PATHOL, V9, P595, DOI 10.1097/00000478-198508000-00004; Bostwick DG, 2000, ARCH PATHOL LAB MED, V124, P995; Carlson GD, 1998, UROLOGY, V51, P525, DOI 10.1016/S0090-4295(98)00002-8; Cheng L, 1999, AM J SURG PATHOL, V23, P1173, DOI 10.1097/00000478-199910000-00002; Civantos F, 1996, Semin Urol Oncol, V14, P22; EBLE JN, 2004, WHO CLASSIFICATION T, P179; EFROS MD, 1992, UROLOGY, V39, P407, DOI 10.1016/0090-4295(92)90234-N; Egevad L, 2005, HUM PATHOL, V36, P5, DOI 10.1016/j.humpath.2004.10.001; Egevad L, 2002, BJU INT, V89, P538, DOI 10.1046/j.1464-410X.2002.02669.x; Egevad L, 1999, J UROL PATHOL, V10, P23; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2005, SCAND J UROL NEPHROL, V39, P34, DOI 10.1080/03008880510030932; Epstein JI, 2000, AM J SURG PATHOL, V24, P477, DOI 10.1097/00000478-200004000-00001; EPSTEIN JI, 1986, CANCER, V57, P111, DOI 10.1002/1097-0142(19860101)57:1<111::AID-CNCR2820570123>3.0.CO;2-N; Epstein JI, 2007, HUM PATHOL, V38, P1305, DOI 10.1016/j.humpath.2007.05.015; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; GAETA JF, 1981, UROLOGY, V17, P33; GAETA JF, 1986, UROLOGY, V27, P306, DOI 10.1016/0090-4295(86)90302-X; Garcia JJ, 2007, LAB INVEST, V87, p147A; Gaudin PB, 1999, AM J SURG PATHOL, V23, P1021, DOI 10.1097/00000478-199909000-00004; GAUDIN PB, 1994, AM J SURG PATHOL, V18, P863, DOI 10.1097/00000478-199409000-00001; GAUDIN PB, 1998, J UROL PATHOL, V8, P55; Glaessgen A, 2002, J UROLOGY, V168, P2006, DOI 10.1016/S0022-5347(05)64283-8; Gleason D F, 1988, NCI Monogr, P15; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; GREENE DR, 1991, J UROLOGY, V146, P1069, DOI 10.1016/S0022-5347(17)38003-5; Hattab EM, 2006, J UROLOGY, V175, P1695, DOI 10.1016/S0022-5347(05)00998-5; Herawi M, 2005, AM J SURG PATHOL, V29, P874, DOI 10.1097/01.pas.0000159520.36806.3e; Humphrey PA, 1998, AM J SURG PATHOL, V22, P1239, DOI 10.1097/00000478-199810000-00009; Kondylis FI, 2003, J UROLOGY, V170, P1189, DOI 10.1097/01.ju.0000085675.96097.76; Kronz JD, 2001, AM J SURG PATHOL, V25, P147, DOI 10.1097/00000478-200102000-00002; Levi AW, 2000, AM J SURG PATHOL, V24, P1039, DOI 10.1097/00000478-200008000-00001; Lilleby W, 2001, CANCER-AM CANCER SOC, V92, P311, DOI 10.1002/1097-0142(20010715)92:2<311::AID-CNCR1324>3.0.CO;2-H; MCNEAL JE, 1991, HUM PATHOL, V22, P979, DOI 10.1016/0046-8177(91)90006-B; MELLINGER GT, 1967, J UROLOGY, V97, P331, DOI 10.1016/S0022-5347(17)63039-8; Millar EKA, 1996, HISTOPATHOLOGY, V29, P11, DOI 10.1046/j.1365-2559.1996.d01-483.x; MINIMO C, 1991, ANAL QUANT CYTOL, V13, P411; Montironi R., 2001, Pathologica (Genoa), V93, P226; Montironi R, 2003, EUR UROL, V44, P626, DOI 10.1016/S0302-2838(03)00381-6; Montironi R, 2006, VIRCHOWS ARCH, V449, P1, DOI 10.1007/s00428-006-0190-9; MOSTOFI FK, 1975, CANCER CHEMOTH REP 1, V59, P111; Mostofi FK, 1980, HISTOLOGIC TYPING PR, P17; MYERS RP, 1982, PROSTATE, V3, P423, DOI 10.1002/pros.2990030502; Nelson RS, 1996, AM J SURG PATHOL, V20, P419, DOI 10.1097/00000478-199604000-00004; Papandreou CN, 2002, J CLIN ONCOL, V20, P3072, DOI 10.1200/JCO.2002.12.065; Saito S, 1999, UROLOGY, V54, P141, DOI 10.1016/S0090-4295(98)00595-0; Samaratunga H, 2006, ANAL QUANT CYTOL, V28, P104; Schindler S, 1997, AM J SURG PATHOL, V21, P616, DOI 10.1097/00000478-199705000-00019; SCHROEDER FH, 1985, PROSTATE, V6, P81, DOI 10.1002/pros.2990060109; Sengupta S, 2006, CANCER-AM CANCER SOC, V106, P2630, DOI 10.1002/cncr.21924; Sheaff MT, 1997, HISTOPATHOLOGY, V30, P341, DOI 10.1046/j.1365-2559.1997.d01-621.x; SMITH DM, 1994, CANCER, V73, P1472, DOI 10.1002/1097-0142(19940301)73:5<1472::AID-CNCR2820730525>3.0.CO;2-M; Smith EB, 2002, CANCER-AM CANCER SOC, V94, P2282, DOI 10.1002/cncr.10457; Srigley JR, 2006, ARCH PATHOL LAB MED, V130, P936; Tannenbaum M, 1977, UROLOGIC PATHOLOGY P, P171; Tran TT, 2001, AM J SURG PATHOL, V25, P618, DOI 10.1097/00000478-200105000-00008; UTZ DC, 1969, J AMER MED ASSOC, V209, P1701, DOI 10.1001/jama.209.11.1701	70	19	19	0	1	SCI PRINTERS & PUBL INC	ST LOUIS	PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA	0884-6812			ANAL QUANT CYTOL	Anal. Quant. Cytol. Histol.	AUG	2008	30	4					190	198					9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	337EZ	WOS:000258419600002	18773736				2022-02-25	
J	Hery, C; Ferlay, J; Boniol, M; Autier, P				Hery, C.; Ferlay, J.; Boniol, M.; Autier, P.			Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations	ANNALS OF ONCOLOGY			English	Article						breast cancer; epidemiology; temporal trends	TEMPORAL VARIATION; TIME TRENDS; IMPACT; RATES; MAMMOGRAPHY; MODELS; PERIOD; USA	Background: Mammography screening and menopause hormone therapy is essentially offered to women 50-69 years old. Methods: In 28 European ancestry countries, we quantified changes in breast cancer incidence and mortality using a joinpoint regression analysis from 1960 until last year of available data. Results: Since 1960, increases in incidence often in the order of 2%-3% per year occurred in all countries, mainly in women 50-69 years old whose incidence in eight countries surpassed the incidence in women 70 years old and more. In 10 countries, a decrease in incidence in women >= 70 years was noticeable in the last years of observation, but the magnitude of this decrease was far from matching the magnitude of the increases observed in the 50-69 age-group. In the beginning of years 2000s, a persistent decrease in mortality of similar to 2% per year was observed in women 50-69 years old in most countries and parallel declines in mortality were observed in women 70 years or more. Conclusions: In years 2000s, in a number of countries, the incidence of breast cancer has become greater in middle-aged women than in older women. If trends remain unchanged, the same phenomenon is likely to happen in other countries.	[Autier, P.] Int Agcy Res Canc, Data Anal & Interpretat Grp, F-69372 Lyon, France; Int Agcy Res Canc, Epidemiol Methods & Support Grp, F-69372 Lyon, France		Autier, P (corresponding author), Int Agcy Res Canc, Data Anal & Interpretat Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	autierp@iarc.fr	Boniol, Mathieu/F-9623-2011; Ferlay, Jacques/ABD-5058-2021; Autier, Philippe/A-4402-2014	Boniol, Mathieu/0000-0003-1052-5604; Autier, Philippe/0000-0003-1538-5321			Anderson WF, 2006, BREAST CANCER RES TR, V99, P333, DOI 10.1007/s10549-006-9214-z; Botha JL, 2003, EUR J CANCER, V39, P1718, DOI 10.1016/S0959-8049(03)00118-7; Brock Anita, 2004, Health Stat Q, P7; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; DEBONO AM, 1978, J EPIDEMIOL COMMUN H, V32, P178, DOI 10.1136/jech.32.3.178; ENGHOLM G, 2006, NORDCAN CANC INC MOR; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Fracheboud J, 2004, BRIT J CANCER, V91, P861, DOI 10.1038/sj.bjc.6602075; Hermon C, 1996, BRIT J CANCER, V73, P955, DOI 10.1038/bjc.1996.171; Hertl K, 2006, NEOPLASMA, V53, P237; JOENSUU H, 1991, BRIT MED J, V303, P155, DOI 10.1136/bmj.303.6795.155; Jolleys JV, 1996, MATURITAS, V23, P47, DOI 10.1016/0378-5122(95)00952-3; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z; Kricker A, 1999, INT J CANCER, V81, P877, DOI 10.1002/(SICI)1097-0215(19990611)81:6<877::AID-IJC7>3.0.CO;2-F; Lerman PM, 1980, J R STAT SOC SER C A, V29, P77, DOI DOI 10.2307/2346413; Lutz JM, 2004, EUR J CANCER PREV, V13, P77, DOI 10.1097/00008469-200402000-00012; McCann J, 1998, J MED SCREEN, V5, P42, DOI 10.1136/jms.5.1.42; *NAT CANC I, 2007, PUBL US DAT 1973 200; *NAT CANC REG CZEC, 2006, EP MAL TUM CZECH RE; *NAT CTR HLTH STAT, 2005, HLTH US, P96602; *NZ HLTH INF SERV, NZ CANC REG; ONDRUSOVA M, 2006, CANC INC SLOVAK REPU; PARKIN DM, 2002, IARC SCI PUBL, V143; PARKIN DM, 2005, CANC INCIDENCE 5 CON, V1; Pavillon G., 2005, B EPIDEMIOLOGIQUE HE, V4, P13; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Schootman M, 2004, BREAST CANCER RES TR, V85, P219, DOI 10.1023/B:BREA.0000025410.41220.67; Segi M, 1960, CANC MORTALITY SELEC; Stefanick ML, 2005, AM J MED, V118, P1407, DOI 10.1016/j.amjmed.2005.10.014; The International Agency for Research on Cancer (IARC), 2002, IARC HDB CANC PREV; Tyczynski JE, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-136; Tyczynski JE, 2004, INT J CANCER, V112, P1056, DOI 10.1002/ijc.20514; Veronesi U, 2005, LANCET, V365, P1727, DOI 10.1016/S0140-6736(05)66546-4; *WHO, 2007, WHO DAT; 2003, EUROCIM VERSION 4 0	37	67	68	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	MAY	2008	19	5					1009	1018		10.1093/annonc/mdm593			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	296DU	WOS:000255524500029	18296422	Bronze			2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, Rengaswamy			Commentary: Cancer incidence among Asian Indians in India and abroad	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Editorial Material							MORTALITY; TRIAL; RISK		Int Agcy Res Canc, World Hlth Org, F-69372 Lyon, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, World Hlth Org, 150 Cours Albert Thomas, F-69372 Lyon, France.	sankar@iarc.fr					McCracken M, 2007, CA-CANCER J CLIN, V57, P190, DOI 10.3322/canjclin.57.4.190; Moradi T, 1998, EUR J CANCER PREV, V7, P117; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Rastogi T, 2008, INT J EPIDEMIOL, V37, P147, DOI 10.1093/ije/dym219; Reddy KS, 2005, LANCET, V366, P1744, DOI [10.1016/s0140-6736(05)67343-6, 10.1016/S0140-6736(05)67343-6]; Sankaranarayanan R, 2005, INT J CANCER, V116, P617, DOI 10.1002/ijc.21050; Sankaranarayanan R, 2007, LANCET, V370, P398, DOI 10.1016/S0140-6736(07)61195-7; Tominaga S, 1985, Natl Cancer Inst Monogr, V69, P83; TRAPIDO EJ, 1995, NATL CANC I MONOGR, V18, P17	9	5	5	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2008	37	1					160	161		10.1093/ije/dym249			3	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	258YP	WOS:000252906600026	18180241	Bronze			2022-02-25	
J	Ohgaki, H; Dessen, P; Jourde, B; Horstmann, S; Nishikawa, T; Burckhard, C; Di Patre, P; Kleihues, P				Ohgaki, H; Dessen, P; Jourde, B; Horstmann, S; Nishikawa, T; Burckhard, C; Di Patre, P; Kleihues, P			Population-based study on the incidence, survival rates, and genetic profile of glioblastomas.	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Meeting Abstract	80th Annual Meeting of the American-Association-of-Neuropathologists	JUN 24-27, 2004	Cleveland, OH	Amer Assoc Neuropathologists					Int Agcy Res Canc, Lyon, France									0	0	0	0	0	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2004	63	5				10	512	512					1	Clinical Neurology; Neurosciences; Pathology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	822SC	WOS:000221559400020					2022-02-25	
J	Brennan, P				Brennan, P			Commentary: Mendelian randomization and gene-environment interaction	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Editorial Material							LUNG-CANCER RISK; S-TRANSFERASE POLYMORPHISMS; ALCOHOL-DEHYDROGENASE 3; DIETARY-INTAKE; ISOTHIOCYANATES; CONSUMPTION; GENOTYPE; M1		Int Agcy Res Canc, F-69008 Lyon, France		Brennan, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	brennan@iarc.fr					[Anonymous], 1988, IARC MON EV CARC RIS; BOSRON WF, 1983, PHARMACOL BIOCHEM BE, V18, P223, DOI 10.1016/0091-3057(83)90175-2; Bouchardy C, 2000, INT J CANCER, V87, P734, DOI 10.1002/1097-0215(20000901)87:5<734::AID-IJC17>3.0.CO;2-E; BRENNAN P, IN PRESS AM J EPIDEM; Coutelle C, 1997, HUM GENET, V99, P319, DOI 10.1007/s004390050365; GRAY R, 1991, BONE MARROW TRANSPL, V7, P9; Harty LC, 1997, JNCI-J NATL CANCER I, V89, P1698, DOI 10.1093/jnci/89.22.1698; Hecht SS, 1996, ADV EXP MED BIOL, V401, P1; KATAN MB, 1986, LANCET, V1, P507; Lee J, 2002, MUTAT RES-GEN TOX EN, V514, P213, DOI 10.1016/S1383-5718(01)00340-0; Lewis S, 2001, CANCER EPIDEM BIOMAR, V10, P1105; London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3; MELBYE M, 2002, TXB CANC EPIDEMIOLOG, P535; Olshan AF, 2001, CARCINOGENESIS, V22, P57, DOI 10.1093/carcin/22.1.57; Osier M, 1999, AM J HUM GENET, V64, P1147, DOI 10.1086/302317; Schwartz SM, 2001, CANCER EPIDEM BIOMAR, V10, P1137; SING CF, 1985, AM J HUM GENET, V37, P268; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Spitz MR, 2000, CANCER EPIDEM BIOMAR, V9, P1017; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; Sturgis EM, 2001, CANCER EPIDEM BIOMAR, V10, P273; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Yokoyama A, 2001, CARCINOGENESIS, V22, P433, DOI 10.1093/carcin/22.3.433; Zavras AI, 2002, INT J CANCER, V97, P526, DOI 10.1002/ijc.1642; Zhao B, 2001, CANCER EPIDEM BIOMAR, V10, P1063	26	19	19	1	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2004	33	1					17	21		10.1093/ije/dyh033			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	809CO	WOS:000220615000006	15075140	Bronze			2022-02-25	
J	Vainio, H				Vainio, H			Eino Hietanen - 13.10.1947 16.09.2002 - Obituary	TOXICOLOGY LETTERS			English	Biographical-Item									Int Agcy Res Canc, WHO, Unit Chemoprevent, F-69008 Lyon, France		Vainio, H (corresponding author), Int Agcy Res Canc, WHO, Unit Chemoprevent, 150 Cours Albert Thomas, F-69008 Lyon, France.							0	0	0	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0378-4274			TOXICOL LETT	Toxicol. Lett.	JAN 13	2003	136	3					161	162	PII S0378-4274(02)00410-1	10.1016/S0378-4274(02)00410-1			2	Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Toxicology	641ED	WOS:000180730900001					2022-02-25	
J	Reis, RM; Hara, A; Kleihues, P; Ohgaki, H				Reis, RM; Hara, A; Kleihues, P; Ohgaki, H			Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas	ACTA NEUROPATHOLOGICA			English	Article						gemistocytic astrocytoma; low-grade diffuse astrocytoma; TP53 mutation; laser microdissection	CELLS; P53; GLIOBLASTOMA; EXPRESSION; MUTATIONS; GLIOMAS	Gemistocytic astrocytoma is characterized by a predominance of large astrocytes with plump processes and massive accumulation of glial fibrillary acidic protein (gemistocytes). This histological variant of low-grade diffuse astrocytoma (WHO grade II) is prone to more rapid progression to anaplastic astrocytoma and glioblastoma than the ordinary fibrillary astrocytoma. The biological basis of this unfavorable prognosis is unclear, since gemistocytes themselves have low proliferative activity, even if present in anaplastic astrocytomas or glioblastomas. This has raised the question of whether gemistocytes are neoplastic cells or dysplastic reactive astrocytes. In this study, gemistocytes and non-gemistocytic neoplastic cells were separated by laser-assisted microdissection from six gemistocytic astrocytomas carrying TP53 mutations. In all cases, identical TP53 mutations were identified in both cell types, indicating that gemistocytes are indeed neoplastic cells. Their lack of proliferative activity may indicate terminal differentiation.	Int Agcy Res Canc, Unit Mol Pathol, F-69372 Lyon, France		Ohgaki, H (corresponding author), Int Agcy Res Canc, Unit Mol Pathol, 150 Cours Albert Thomas, F-69372 Lyon, France.	ohgaki@iarc.fr	Reis, Rui Manuel/AAD-6470-2020; Reis, Rui Manuel/B-1744-2018	Reis, Rui Manuel/0000-0002-9639-7940; Reis, Rui Manuel/0000-0002-9639-7940			BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; BURGER PC, 1989, CANCER-AM CANCER SOC, V63, P2014, DOI 10.1002/1097-0142(19890515)63:10<2014::AID-CNCR2820631025>3.0.CO;2-L; Burger PC, 1994, TUMORS CENTRAL NERVO; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HOSHINO T, 1975, J NEUROPATH EXP NEUR, V34, P263, DOI 10.1097/00005072-197505000-00004; Ishii N, 1999, ONCOGENE, V18, P5870, DOI 10.1038/sj.onc.1203241; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Kleihues P., 2000, PATHOLOGY GENETICS T, P22; Kosel S, 2001, NEUROSURGERY, V48, P187; KRAUS JA, 1994, GENE CHROMOSOME CANC, V10, P143, DOI 10.1002/gcc.2870100211; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, P85; KROS JM, 1991, HUM PATHOL, V22, P33, DOI 10.1016/0046-8177(91)90058-W; Kros JM, 2000, J NEUROPATH EXP NEUR, V59, P679, DOI 10.1093/jnen/59.8.679; Kros JM, 1996, ACTA NEUROPATHOL, V91, P99; KROUWER HGJ, 1991, J NEUROSURG, V74, P399, DOI 10.3171/jns.1991.74.3.0399; LANTOS PL, 1996, GREENFIELDS NEUROPAT, P583; LIANG XH, 1995, J CELL BIOCHEM, V57, P509, DOI 10.1002/jcb.240570316; MCLENDON RE, 1998, RUSSELL RUBINSTEINS, P307; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Ohgaki H, 1999, ACTA NEUROPATHOL, V97, P525, DOI 10.1007/s004010051024; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PIRIS MA, 1994, BRIT J CANCER, V69, P337, DOI 10.1038/bjc.1994.61; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; SHAW EG, 1989, J NEUROSURG, V70, P853, DOI 10.3171/jns.1989.70.6.0853; STEFANIK DF, 1991, CANCER RES, V51, P5760; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Watanabe K, 1997, LAB INVEST, V76, P277; Watanabe K, 1998, ACTA NEUROPATHOL, V95, P559, DOI 10.1007/s004010050840; Zulch, 1986, BRAIN TUMORS THEIR B	31	20	22	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	NOV	2001	102	5					422	425					4	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	483XY	WOS:000171662200002	11699553				2022-02-25	
J	Vainio, H				Vainio, H			Use of biomarkers in risk assessment	INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH			English	Review						biomarkers; risk assessment; internal dose; DNA adducts; protein adducts; cytogenetic effects	AROMATIC DNA-ADDUCTS; BREAST-CANCER PATIENTS; PREDICT HUMAN CANCER; WHITE BLOOD-CELLS; LUNG-CANCER; BLADDER-CANCER; GENE-EXPRESSION; CHROMOSOMAL-ABERRATIONS; N-ACETYLTRANSFERASE; HEMOGLOBIN ADDUCTS	The systematic development and application of biomarkers in environmental health risk assessment is a relatively new field. At first, the major interest was in biomarkers of exposure, borrowing concepts from pharmacology, then it moved from the external estimates of exposure to internal measures of dose, and ultimately, to markers of target dose. While these markers provide evidence of exposures, they do not provide evidence of that toxicological damage has occurred. For this reason, measurements of DNA adducts and protein adducts are of interest, since they may provide bridges between exposures and disease end-points. In parallel, more quantitative and more sensitive end-points for diseases have been sought. Again, with advancing techniques in cytogenetics, extensive studies were conducted on such markers as chromosomal aberrations, micronuclei and other changes deemed to represent genomic damage. However, these types of end-points are quite unspecific for application to new hazards of uncertain human toxic (carcinogenic) potential. Recent work focusing on more specific early-effect markers such as certain oncogenes and tumour-suppressor genes have substantial promise as shown by work with aflatoxins and vinyl chloride. Such studies have also enhanced mechanistic insight. The advances in molecular genetics have led to an upsurge in interest in most susceptibility factors, and identification of polymorphisms of various enzymes has become possible. Ongoing search for "ultra-high risk" individuals may be fruitful, but probably only relevant to a small segment of potentially exposed populations. Factors associated with a small differential risk, however theoretically or mechanistically important, offer only little practical use.	WHO, Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon, France		Vainio, H (corresponding author), WHO, Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon, France.						Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Albertini RJ, 1996, ENVIRON HEALTH PERSP, V104, P503, DOI 10.1289/ehp.96104s3503; ALBERTINI RJ, 1995, ENV MUTAGENESIS, P341; ANSCHER MS, 1993, NEW ENGL J MED, V328, P1592, DOI 10.1056/NEJM199306033282203; ANTTILA S, 1992, ENVIRON HEALTH PERSP, V98, P179, DOI 10.2307/3431265; ARIAD S, 1991, BREAST CANCER RES TR, V20, P11, DOI 10.1007/BF01833352; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; BELL DA, 1995, CANCER RES, V55, P3537; Bonassi S, 2000, CANCER RES, V60, P1619; Brandt-Rauf PW, 1998, PHARMACOL THERAPEUT, V77, P135, DOI 10.1016/S0163-7258(97)00111-3; BrandtRauf PW, 1997, ENVIRON HEALTH PERSP, V105, P807, DOI 10.2307/3433287; BRANDTRAUF PW, 1992, INT J CANCER, V50, P881, DOI 10.1002/ijc.2910500610; BRANDTRAUF PW, 1995, BIOMARKERS AND OCCUPATIONAL HEALTH, P163; Breuer B, 1998, BREAST CANCER RES TR, V49, P261, DOI 10.1023/A:1006033214721; BRYANT MS, 1987, CANCER RES, V47, P602; Butkiewicz D, 2000, ENVIRON MOL MUTAGEN, V35, P99, DOI 10.1002/(SICI)1098-2280(2000)35:2<99::AID-EM4>3.3.CO;2-U; BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003; CARTWRIGHT RA, 1982, LANCET, V2, P842; Dallinga JW, 1998, CANCER EPIDEM BIOMAR, V7, P571; DEVIVO I, 1993, MED SCI RES, V21, P345; ELROUBY S, 1993, BLOOD, V82, P3452; FARMER PB, 1994, CLIN CHEM, V40, P1438; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gabbani G, 1998, MUTAGENESIS, V13, P187, DOI 10.1093/mutage/13.2.187; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Granath FN, 1999, RISK ANAL, V19, P309; GRANT DM, 1993, PHARMACOGENETICS, V3, P45, DOI 10.1097/00008571-199302000-00005; Greenblatt MS, 1995, CANCER SURV, V25, P293; Greim H, 2001, TOXICOL LETT, V120, P395, DOI 10.1016/S0378-4274(01)00271-5; GRZYBOWSKA E, 1993, CARCINOGENESIS, V14, P2523, DOI 10.1093/carcin/14.12.2523; GUENGERICH FP, 1994, TOXICOL LETT, V70, P133; Hagmar L, 1998, CANCER RES, V58, P4117; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P407, DOI 10.1093/oxfordjournals.jbchem.a123594; HAYES RB, 1993, CARCINOGENESIS, V14, P675, DOI 10.1093/carcin/14.4.675; Hemminki K, 1997, CARCINOGENESIS, V18, P345, DOI 10.1093/carcin/18.2.345; Hemminki K, 2000, REGUL TOXICOL PHARM, V32, P264, DOI 10.1006/rtph.2000.1431; Hemminki K, 1997, ENVIRON HEALTH PERSP, V105, P823, DOI 10.2307/3433289; HEMMINKI K, 1990, SCAND J WORK ENV HEA, V16, P158, DOI 10.5271/sjweh.1798; HIRVONEN A, 1992, CANCER EPIDEM BIOMAR, V1, P485; Hulka BS, 1990, BIOL MARKERS EPIDEMI; HUTTNER E, 1990, MUTAT RES, V243, P101, DOI 10.1016/0165-7992(90)90030-N; IKEYA K, 1989, MOL ENDOCRINOL, V3, P1399, DOI 10.1210/mend-3-9-1399; ILETT KF, 1993, CLIN PHARMACOL THER, V54, P317, DOI 10.1038/clpt.1993.153; Jongeneelen FJ, 2001, ANN OCCUP HYG, V45, P3, DOI 10.1093/annhyg/45.1.3; Kensler TW, 1997, CANCER EPIDEM BIOMAR, V6, P603; KERN JA, 1990, CANCER RES, V50, P5184; KETTERER B, 1993, STRUCTURE FUNCTION G, P15; MAO L, 1994, CANCER RES, V54, P1634; Marcus PM, 2000, CANCER EPIDEM BIOMAR, V9, P461; MAYER J, 1991, MUTAT RES, V248, P163, DOI 10.1016/0027-5107(91)90098-9; MCLEMORE TL, 1990, J NATL CANCER I, V82, P1333, DOI 10.1093/jnci/82.16.1333; MILLER ME, 1983, J UROLOGY, V130, P65, DOI 10.1016/S0022-5347(17)50956-8; MITSUDOMI T, 1991, CANCER RES, V51, P4999; Nair U, 2001, IARC Sci Publ, V154, P271; Nan HM, 2001, CARCINOGENESIS, V22, P787, DOI 10.1093/carcin/22.5.787; NEBERT DW, 1991, MUTAT RES, V247, P267, DOI 10.1016/0027-5107(91)90022-G; Nebert DW, 1996, DNA CELL BIOL, V15, P273, DOI 10.1089/dna.1996.15.273; Norppa H, 1997, ENVIRON HEALTH PERSP, V105, P829, DOI 10.2307/3433290; OstermanGolkar S, 1996, MUTAGENESIS, V11, P145, DOI 10.1093/mutage/11.2.145; OstermanGolkar S, 1996, ENVIRON HEALTH PERSP, V104, P907, DOI 10.2307/3433009; PARTANEN R, 1995, CLIN CHEM, V41, P1844; Perera F, 2001, INT J CANCER, V92, P926, DOI 10.1002/ijc.1274; PERERA F, 1987, ENVIRON HEALTH PERSP, V76, P141, DOI 10.2307/3430475; PERERA FP, 1992, NATURE, V360, P256, DOI 10.1038/360256a0; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; PHILLIPS DH, 1995, ENV MUTAGENESIS, P367; Poirier MC, 1997, ENVIRON HEALTH PERSP, V105, P907, DOI 10.2307/3433302; PRICEEVANS DA, 1960, BRIT MED J, V2, P485; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; RobertsThomson IC, 1996, LANCET, V347, P1372, DOI 10.1016/S0140-6736(96)91012-0; Rojas M, 1998, PHARMACOGENETICS, V8, P109; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SEIDEGARD J, 1986, CARCINOGENESIS, V7, P751, DOI 10.1093/carcin/7.5.751; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Sioris T, 2000, INT J CANCER, V86, P590, DOI 10.1002/(SICI)1097-0215(20000515)86:4<590::AID-IJC23>3.0.CO;2-E; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Smith CJ, 2000, MUTAT RES-GEN TOX EN, V470, P53, DOI 10.1016/S1383-5718(00)00097-8; Smith G, 1995, CANCER SURV, V25, P27; SORSA M, 1992, MECH CARCINOGENESIS, P543; Stacey M, 1996, BIOMARKERS, V1, P55, DOI 10.3109/13547509609079347; TANG BK, 1994, PHARMACOGENETICS, V4, P117, DOI 10.1097/00008571-199406000-00002; TATES AD, 1994, MUTAT RES-ENVIR MUTA, V313, P249, DOI 10.1016/0165-1161(94)90054-X; TATES AD, 1991, MUTAT RES, V250, P483, DOI 10.1016/0027-5107(91)90205-3; TEFRE T, 1991, PHARMACOGENETICS, V1, P20, DOI 10.1097/00008571-199110000-00004; Thier R, 2000, CRIT REV TOXICOL, V30, P595, DOI 10.1080/10408440008951121; Travis CC, 1996, TOXICOL APPL PHARM, V140, P19, DOI 10.1006/taap.1996.0193; TRIVERS GE, 1995, J NATL CANCER I, V87, P1400, DOI 10.1093/jnci/87.18.1400; VAINIO H, 1984, MONITORING HUMAN EXP, P247; Villa E, 1996, GASTROENTEROLOGY, V110, P1346, DOI 10.1053/gast.1996.v110.pm8613038; VINEIS P, 1995, ENVIRON HEALTH PERSP, V103, P156, DOI 10.2307/3432271; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; VODICKA P, 1994, CARCINOGENESIS, V15, P1949, DOI 10.1093/carcin/15.9.1949; Vodicka P, 1999, MUTAT RES-GEN TOX EN, V445, P205, DOI 10.1016/S1383-5718(99)00127-8; Wild C P, 2001, IARC Sci Publ, V154, P215; WOLF CR, 1994, GENETICS MALIGNANT D, P718; Yong LC, 2001, CANCER EPIDEM BIOMAR, V10, P539; Zhao C, 2001, ENVIRON MOL MUTAGEN, V37, P226, DOI 10.1002/em.1031	100	12	15	0	6	URBAN & FISCHER VERLAG	JENA	BRANCH OFFICE JENA, P O BOX 100537, D-07705 JENA, GERMANY	1438-4639			INT J HYG ENVIR HEAL	Int. J. Hyg. Environ. Health.	NOV	2001	204	2-3					91	102		10.1078/1438-4639-00088			12	Public, Environmental & Occupational Health; Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Infectious Diseases	496BF	WOS:000172374300002	11759167				2022-02-25	
J	Huybrechts, I; Aglago, EK; Yammine, S; Matta, M; Biessy, C; Casagrande, C; Gunter, MJ; Chajes, V				Huybrechts, Inge; Aglago, Elom K.; Yammine, Sahar; Matta, Michele; Biessy, Carine; Casagrande, Corinne; Gunter, Marc J.; Chajes, Veronique			Associations between fatty acid intakes and plasma phospholipid fatty acid concentrations in the European Prospective Investigation into Cancer and Nutrition	PROCEEDINGS OF THE NUTRITION SOCIETY			English	Meeting Abstract									[Huybrechts, Inge; Aglago, Elom K.; Yammine, Sahar; Matta, Michele; Biessy, Carine; Casagrande, Corinne; Gunter, Marc J.; Chajes, Veronique] Int Agcy Res Canc, Lyon, France									0	0	0	0	1	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0029-6651	1475-2719		P NUTR SOC	Proc. Nutr. Soc.		2020	79	OCE2					E82	E82		10.1017/S0029665120000300			1	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	MH3ND	WOS:000546638800015		Bronze			2022-02-25	
J							IARC Monographs Vol 121 Grp	Carcinogenicity of quinoline, styrene, and styrene-7,8-oxide	LANCET ONCOLOGY			English	News Item							REINFORCED-PLASTICS; CANCER-MORTALITY; CD-1 MICE; OXIDE; RATS; INHALATION; TUMORS; LIVER		[IARC Monographs Vol 121 Grp] Int Agcy Res Canc, Lyon, France		Int Agcy Res Canc, Lyon, France.		SUZUKI, TAKAYOSHI/ABA-2386-2020; Teixeira, Joao Paulo/F-5445-2013; Guha, Neela/AAG-3989-2021	SUZUKI, TAKAYOSHI/0000-0002-2261-5263; Teixeira, Joao Paulo/0000-0001-8693-5250; Guha, Neela/0000-0003-3991-4662; Hall, Amy/0000-0003-1502-2694	American Chemistry Council	Rogelio Tornero-Velez was invited to a workshop with significant travel costs paid by the American Chemistry Council. All other authors declare no competing interests.	BASTLOVA T, 1995, CARCINOGENESIS, V16, P2357, DOI 10.1093/carcin/16.10.2357; Christensen MS, 2018, EPIDEMIOLOGY, V29, P342, DOI 10.1097/EDE.0000000000000819; Coggon D, 2015, OCCUP ENVIRON MED, V72, P165, DOI 10.1136/oemed-2014-102382; Collins JJ, 2013, EPIDEMIOLOGY, V24, P195, DOI 10.1097/EDE.0b013e318281a30f; CONTI B, 1988, ANN NY ACAD SCI, V534, P203, DOI 10.1111/j.1749-6632.1988.tb30112.x; Cruzan G, 2012, REGUL TOXICOL PHARM, V62, P214, DOI 10.1016/j.yrtph.2011.10.007; Cruzan G, 2001, J APPL TOXICOL, V21, P185, DOI 10.1002/jat.737; Cruzan G, 2017, TOXICOL SCI, V159, P413, DOI 10.1093/toxsci/kfx141; HIRAO K, 1976, CANCER RES, V36, P329; International Agency for Research on Cancer, 2018, IARC MONOGR EVAL CAR; KOGEVINAS M, 1994, SCAND J WORK ENV HEA, V20, P251, DOI 10.5271/sjweh.1400; LAVOIE EJ, 1987, JPN J CANCER RES, V78, P139; LIJINSKY W, 1986, J NATL CANCER I, V77, P471; Matsumoto M, 2018, J TOXICOL SCI, V43, P113, DOI 10.2131/jts.43.113; Nissen MS, 2018, OCCUP ENVIRON MED, V0, P1; PONOMARKOV V, 1978, SCAND J WORK ENV HEA, V4, P127, DOI 10.5271/sjweh.2754; PONOMARKOV V, 1984, CANCER LETT, V24, P95, DOI 10.1016/0304-3835(84)90085-5; Rappaport SM, 1996, CANCER RES, V56, P5410; Suzuki T, 2000, MUTAT RES-FUND MOL M, V456, P73, DOI 10.1016/S0027-5107(00)00128-7	19	19	19	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUN	2018	19	6					728	729		10.1016/S1470-2045(18)30316-4			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	GI1TH	WOS:000434153000034	29680246				2022-02-25	
J	Franceschi, S; Vaccarella, S				Franceschi, Silvia; Vaccarella, Salvatore			Beral's 1974 paper: A step towards universal prevention of cervical cancer	CANCER EPIDEMIOLOGY			English	Article						Cervical cancer; Sexually transmitted infections; Human papillomavirus; Cervical cancer screening; HPV vaccination; Parity; Sex hormones	SQUAMOCOLUMNAR JUNCTION; GENITAL WARTS; RISK; NEOPLASIA; TRENDS; TIME; POPULATION; INFECTION; CARCINOMA; ESTROGEN	In 1974, Valerie Beral published a landmark paper on the sexually transmitted origin of cervical cancer (CC) using statistics routinely available in the United Kingdom (UK). Among women born between 1902 and 1947, CC mortality rates correlated remarkably well with the incidence rates of gonorrhoea when they were 20 years old and both were highest among women born after 1940. Hence, if CC prevention and treatment had remained unchanged, the youngest generations of women would have experienced a high risk of CC death as they grew older. Fortunately, progress in CC prevention has helped avoid this scenario. The adverse consequences of the "sexual revolution" were greatly mitigated in the UK and other high-resource countries by the implementation of high quality cytology-based CC screening. An age-period-cohort analysis suggests that >30,000 cases or approximately 35% of expected CC cases may have been prevented by screening programmes in the UK between 1983 and 2007 and this percentage has been steadily increasing. In addition, the discovery of the causal role of HPV is reshaping primary and secondary prevention of CC. Cheaper HPV tests are becoming available and HPV-based primary screening may at last facilitate CC screening in low-resource countries. In the long-term, however, HPV vaccination, which has already been adopted by many countries, represents the best hope for preventing CC and overcoming socio-economic differences in CC risk within and across countries. The additional elucidation of HPV cofactors to which Beral has greatly contributed may also help control HPV infection in unvaccinated women. (C) 2015 Elsevier Ltd. All rights reserved.	[Franceschi, Silvia; Vaccarella, Salvatore] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr; vaccarella@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Vaccarella, Salvatore/0000-0002-2516-2167			Appleby P, 2006, INT J CANCER, V119, P1108, DOI 10.1002/ijc.21953; Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5; Appleby P, 2009, CANCER EPIDEM BIOMAR, V18, P1060, DOI 10.1158/1055-9965.EPI-08-1186; BERAL V, 1974, LANCET, V1, P1037; BERAL V, 1988, LANCET, V2, P1331; Carozzi F, 2008, LANCET ONCOL, V9, P937, DOI 10.1016/S1470-2045(08)70208-0; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; de Gonzalez AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357; Dillner J, 2000, J CLIN VIROL, V19, P7, DOI 10.1016/S1386-6532(00)00126-8; Dillner J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1754; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; FRANCESCHI S, 1983, BRIT J CANCER, V48, P621, DOI 10.1038/bjc.1983.243; Hakama M., 1986, IARC SCI PUBL, V76, P289; HAUSEN HZ, 1982, LANCET, V2, P1370; Herfs M, 2013, J PATHOL, V229, P460, DOI 10.1002/path.4110; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; Herrero R, 2015, LANCET ONCOL, V16, pE206, DOI 10.1016/S1470-2045(14)70481-4; HOLFORD TR, 1983, BIOMETRICS, V39, P311, DOI 10.2307/2531004; *IARC, 2005, IARC HDB CANC PREV, V10, P1; IARC, 2007, MON EV CARC RISKS HU, V90, P1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; International Collaboration of Epidemiological Studies of Cervical Cancer, 2006, Int J Cancer, V118, P1481, DOI 10.1002/ijc.21493; KESSLER II, 1976, CANCER RES, V36, P783; KOSS LG, 1989, MODERN PATHOL, V2, P526; Laukkanen P, 2003, J GEN VIROL, V84, P2105, DOI 10.1099/vir.0.18995-0; MEISELS A, 1976, ACTA CYTOL, V20, P505; Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9; Peto J, 2004, BRIT J CANCER, V91, P942, DOI 10.1038/sj.bjc.6602049; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; Plummer M, 2012, INT J CANCER, V130, P2638, DOI 10.1002/ijc.26250; Poljak M, 2012, VACCINE, V30, pF100, DOI 10.1016/j.vaccine.2012.04.105; Qiao YL, 2014, INT J CANCER, V134, P2891, DOI 10.1002/ijc.28616; Richart R M, 1973, Pathol Annu, V8, P301; Rigoni S., 1987, STAT MED, V6, P881, DOI DOI 10.1002/SIM.4780060803; Rinaldi S, 2011, CANCER EPIDEM BIOMAR, V20, P2532, DOI 10.1158/1055-9965.EPI-11-0753; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Ronco Guglielmo, 2012, Epidemiol Prev, V36, pe1; ROTKIN ID, 1973, CANCER RES, V33, P1353; Sasieni P, 2001, LANCET, V357, P1490, DOI 10.1016/S0140-6736(00)04646-8; Schiffman M, 2013, CANCER EPIDEM BIOMAR, V22, P553, DOI 10.1158/1055-9965.EPI-12-1406; Schiller JT, 2015, LANCET ONCOL, V16, pE217, DOI 10.1016/S1470-2045(14)71179-9; Simms I, 1997, GENITOURIN MED, V73, P365; Snijders PJF, 2003, J PATHOL, V201, P1, DOI 10.1002/path.1433; Spurgeon ME, 2014, AM J PATHOL, V184, P530, DOI 10.1016/j.ajpath.2013.10.013; Steenbergen RDM, 2014, NAT REV CANCER, V14, P395, DOI 10.1038/nrc3728; Vaccarella S, 2014, BRIT J CANCER, V111, P965, DOI 10.1038/bjc.2014.362; Vaccarella S., 2015, INT J CANC; Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; World Health Organization (WHO), 2014, WKLY EPIDEMIOL REC, V89, P65, DOI DOI 10.1186/1750-9378-2-15	50	4	4	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	DEC	2015	39	6					1152	1156		10.1016/j.canep.2015.10.019			5	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	CZ9VE	WOS:000367444300052	26514971				2022-02-25	
J	Arnold, M; Soerjomataram, I; Ferlay, J; Forman, D				Arnold, Melina; Soerjomataram, Isabelle; Ferlay, Jacques; Forman, David			Global incidence of oesophageal cancer by histological subtype in 2012	GUT			English	Article							BODY-MASS INDEX; HIGH-RISK AREA; SQUAMOUS-CELL CARCINOMA; HELICOBACTER-PYLORI; BARRETTS-ESOPHAGUS; POOLED ANALYSIS; UNITED-STATES; ADENOCARCINOMA; SEX; POPULATION	Objective The two major histological types of oesophageal cancer-adenocarcinoma (AC) and squamous cell carcinoma (SCC)-are known to differ greatly in terms of risk factors and epidemiology. To date, global incidence estimates for individual subtypes are still lacking. This study for the first time quantified the global burden of oesophageal cancer by histological subtype. Design Where available, data from Cancer Incidence in Five Continents Vol. X (CI5X) were used to compute, age-specific, sex-specific and country-specific proportions of AC and SCC. Nine regional averages were computed for countries without CI5X data. The proportions were then applied to all oesophageal cancer cases from GLOBOCAN 2012 and age-standardised incidence rates calculated for both histological types. Results Worldwide, an estimated 398 000 SCCs and 52 000 ACs of the oesophagus occurred in 2012, translating to incidence rates of 5.2 and 0.7 per 100 000, respectively. Although SCCs were most common in South-Eastern and Central Asia (79% of the total global SCC cases), the highest burden of AC was found in Northern and Western Europe, Northern America and Oceania (46% of the total global AC cases). Men had substantially higher incidence than women, especially in the case of AC (male to female ratio AC: 4.4; SCC: 2.7). Conclusions These first global estimates of oesophageal cancer incidence by histology suggested a high concentration of AC in high-income countries with men being at much greater risk. This quantification of incidence will aid health policy makers to plan appropriate cancer control measures in the future.	[Arnold, Melina; Soerjomataram, Isabelle; Ferlay, Jacques; Forman, David] Int Agcy Res Canc, Sect Canc Surveillance, F-69008 Lyon, France		Arnold, M (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69008 Lyon, France.	arnoldm@fellows.iarc.fr	Ferlay, Jacques/ABD-5058-2021; Arnold, Melina/AAO-9525-2020; Arnold, Melina/L-9331-2015	Arnold, Melina/0000-0003-1700-6831	World Cancer Research FundWorld Cancer Research Fund International (WCRF) [SG 2012/619]	MA has been supported by the World Cancer Research Fund, grant number SG 2012/619.	[Anonymous], 2013, INT CLASSIFICATION D; [Anonymous], 2013, HUM DEV REP 2013; Brown LM, 2001, AM J EPIDEMIOL, V153, P114, DOI 10.1093/aje/153.2.114; Chen Q, 2012, J GASTROINTEST ONCOL, V3, P226, DOI 10.3978/j.issn.2078-6891.2012.026; Cook MB, 2009, BRIT J CANCER, V101, P855, DOI 10.1038/sj.bjc.6605246; Cook MB, 2005, AM J EPIDEMIOL, V162, P1050, DOI 10.1093/aje/kwi325; Cronin-Fenton DP, 2010, EUR J CANCER, V46, P2067, DOI 10.1016/j.ejca.2010.03.032; Curado MP, 2007, CANC INCIDENCE 5 CON, VIX; Dar NA, 2013, BRIT J CANCER, V109, P1367, DOI 10.1038/bjc.2013.437; De Angelis R, 2014, LANCET ONCOL, V15, P23, DOI 10.1016/S1470-2045(13)70546-1; De Stefani E, 2014, ASIAN PAC J CANCER P, V15, P2765, DOI 10.7314/APJCP.2014.15.6.2765; Edgren G, 2013, GUT, V62, P1406, DOI 10.1136/gutjnl-2012-302412; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Ferlay J, 1998, GLOBOCAN CANC INC MO; Ferlay J, 2013, CANC INCIDENCE MORTA, V11; Ferlay J., 2001, GLOBOCAN 2000 CANC I; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Forman D, 2013, CANC INCIDENCE 5 CON, VX; Ghasemi-Kebria F, 2013, ARCH IRAN MED, V16, P320, DOI 013166/AIM.003; Hoyo C, 2012, INT J EPIDEMIOL, V41, P1706, DOI 10.1093/ije/dys176; Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042; Khalifa MM, 2010, GUT PATHOG, V2, DOI 10.1186/1757-4749-2-2; Kroep S, 2014, AM J GASTROENTEROL, V109, P336, DOI 10.1038/ajg.2013.420; Kubo A, 2013, GUT, V62, P1684, DOI 10.1136/gutjnl-2012-303753; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lagergren J, 2011, NAT REV GASTRO HEPAT, V8, P340, DOI 10.1038/nrgastro.2011.73; Lane JA, 2011, ALIMENT PHARM THER, V33, P922, DOI 10.1111/j.1365-2036.2011.04610.x; Lao-Sirieix P, 2012, NAT REV CLIN ONCOL, V9, P278, DOI 10.1038/nrclinonc.2012.35; Lender N, 2014, ALIMENT PHARM THER, V40, P24, DOI 10.1111/apt.12790; Lin J, 2011, ASIAN PAC J CANCER P, V12, P2189; Lin YS, 2013, J EPIDEMIOL, V23, P233, DOI 10.2188/jea.JE20120162; Lindblad M, 2006, ANN SURG, V243, P479, DOI 10.1097/01.sla.0000205825.34452.43; Lu XJ, 2004, WORLD J GASTROENTERO, V10, P2931; Malekzadeh MM, 2013, AM J GASTROENTEROL, V108, P1757, DOI 10.1038/ajg.2013.336; Masclee GMC, 2014, ALIMENT PHARM THER, V39, P1321, DOI 10.1111/apt.12759; Mosavi-Jarrahi Alireza, 2006, Asian Pac J Cancer Prev, V7, P375; Ocama P, 2008, AFR HEALTH SCI, V8, P80; Pandeya N, 2013, CANCER EPIDEMIOL, V37, P579, DOI 10.1016/j.canep.2013.05.011; Roshandel G, 2014, ARCH IRAN MED, V17, P246, DOI 014174/AIM.006; Segi M, 1960, CANC MORTALITY SELEC; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.1136/bmj.g1502, 10.1001/jamaoto.2014.2530, 10.3322/caac.21254, 10.3322/caac.21208]; Somdyala NIM, 2010, INT J CANCER, V127, P2420, DOI 10.1002/ijc.25246; Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616; Umar A, 2012, NAT REV CANCER, V12, P835, DOI 10.1038/nrc3397; van Rensburg S J, 1983, Nutr Cancer, V4, P206, DOI 10.1080/01635588209513759; VIZCAINO AP, 1995, BRIT J CANCER, V72, P769, DOI 10.1038/bjc.1995.408; White RE, 2009, LANCET ONCOL, V10, P240, DOI 10.1016/S1470-2045(09)70004-X; World Population Prospects, 2013, THE 2012 REV	50	732	764	2	67	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0017-5749	1468-3288		GUT	Gut	MAR	2015	64	3					381	387		10.1136/gutjnl-2014-308124			7	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	CB1GZ	WOS:000349376600006	25320104	Bronze	Y	N	2022-02-25	
J	Wild, CP; Bray, F; Forman, D; Franceschi, S; Sankaranarayanan, R; Straif, K				Wild, Christopher P.; Bray, Freddie; Forman, David; Franceschi, Silvia; Sankaranarayanan, Rengaswamy; Straif, Kurt			Cancer in the 25x25 non-communicable disease targets	LANCET			English	Letter									[Wild, Christopher P.; Bray, Freddie; Forman, David; Franceschi, Silvia; Sankaranarayanan, Rengaswamy; Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	franceschi, silvia/M-2452-2014; Wild, Christopher/ABC-6260-2020	franceschi, silvia/0000-0003-4181-8071; Wild, Christopher/0000-0003-0249-8669; Bray, Freddie/0000-0002-3248-7787			[Anonymous], 2013, COMPR GLOB IN PRESS; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Ferlay J, 2013, IARC CANC BASE; Kontis V, 2014, LANCET, V384, P427, DOI 10.1016/S0140-6736(14)60616-4; Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2; Wild CP, 2012, J NATL CANCER I, V104, P1051, DOI 10.1093/jnci/djs262	6	6	6	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	2014	384	9953					1502	1503		10.1016/S0140-6736(14)61918-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AR9MO	WOS:000343899600020	25390574				2022-02-25	
J	Schuz, J				Schuez, Joachim			Airline crew cohorts: is there more to learn regarding their cancer risk?	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material									Int Agcy Res Canc IARC, Sect Environm & Radiat, F-69372 Lyon, France		Schuz, J (corresponding author), Int Agcy Res Canc IARC, Sect Environm & Radiat, F-69372 Lyon, France.	schuzj@iarc.fr					Brehmer F, 2012, DERMATOL PRACT CONCE, V2; Davis S, 2012, CANCER EPIDEM BIOMAR, V21, P609, DOI 10.1158/1055-9965.EPI-11-1128; Hammer GP, 2014, OCCUP ENVIRON MED, V71, P313, DOI 10.1136/oemed-2013-101395; Pukkala E, 2012, INT J CANCER, V131, P2886, DOI 10.1002/ijc.27551; Silva ID, 2013, INT J CANCER, V132, P374, DOI 10.1002/ijc.27612; Zeeb H, 2012, J RADIOL PROT, V32, pN15, DOI 10.1088/0952-4746/32/1/N15	6	4	4	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	MAY	2014	71	5					307	307		10.1136/oemed-2013-102026			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	AF0IM	WOS:000334397500002	24627305				2022-02-25	
J	Frecha, C				Frecha, Cecilia			Gene transfer using retrovirus-derived vectors: Current technology and applications	HUMAN GENE THERAPY			English	Meeting Abstract	Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy	OCT 25-29, 2012	Versailles, FRANCE	European Soc Gene & Cell Therapy, French Soc Cell & Gene Therapy					[Frecha, Cecilia] Int Agcy Res Canc, Infect Biol Grp, F-69372 Lyon, France				Frecha, Cecilia A/A-5786-2010	Frecha, Cecilia A/0000-0002-6729-2162				0	0	0	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1043-0342			HUM GENE THER	Hum. Gene Ther.	OCT	2012	23	10					A4	A4					1	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	027PE	WOS:000310364400003					2022-02-25	
J	Schuz, J				Schuez, Joachim			Exposure to extremely low-frequency magnetic fields and the risk of childhood cancer: Update of the epidemiological evidence	PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY			English	Review						Childhood leukaemia; Childhood brain tumour; Electromagnetic fields/adverse effects; Power lines; Epidemiology	POOLED ANALYSIS; ELECTROMAGNETIC-FIELDS; LEUKEMIA; SURVIVAL	There is an ongoing scientific controversy whether the observed association between exposure to residential extremely low-frequency magnetic fields (ELF-MF) and the risk of childhood leukaemia observed in epidemiological studies is causal or due to methodological shortcomings of those studies. Recent pooled analysis confirm results from previous studies, namely an approximately two-fold risk increase at ELF-MF exposures >= 0.4 mu T, and demonstrate consistency of studies across countries, with different design, different methods of exposure assessment, and different systems of power transmission and distribution. On the other hand, recent pooled analyses for childhood brain tumour show little evidence for an association with ELF-MF, also at exposures >= 0.4 mu T. Overall, the assessment that ELF-MF are a possible carcinogen and may cause childhood leukaemia remains valid. Ongoing research activities, mainly experimental and few new epidemiological studies, hopefully provide additional insight to bring clarity to a research area that has remained inconclusive. (C) 2011 Elsevier Ltd. All rights reserved.	Int Agcy Res Canc, Sect Environm & Radiat, F-69352 Lyon 08, France		Schuz, J (corresponding author), Int Agcy Res Canc, Sect Environm & Radiat, 150 Cours Albert Thomas, F-69352 Lyon 08, France.	schuzj@iarc.fr					Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; Does M, 2011, RADIAT RES, V175, P390, DOI 10.1667/RR2357.1; Foliart DE, 2006, BRIT J CANCER, V94, P161, DOI 10.1038/sj.bjc.6602916; Greenland S, 2000, EPIDEMIOLOGY, V11, P624, DOI 10.1097/00001648-200011000-00003; IARC, 2002, NONION RAD 1, V80; Kheifets L, 2010, BRIT J CANCER, V103, P1128, DOI 10.1038/sj.bjc.6605838; Kheifets L, 2010, AM J EPIDEMIOL, V172, P752, DOI 10.1093/aje/kwq181; Kroll ME, 2010, BRIT J CANCER, V103, P1122, DOI 10.1038/sj.bjc.6605795; Maslanyj M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-673; Mezei G, 2008, EPIDEMIOLOGY, V19, P424, DOI 10.1097/EDE.0b013e3181690715; Rossig C, 2008, RADIAT PROT DOSIM, V132, P114, DOI 10.1093/rpd/ncn269; Schuz J, 2008, RADIAT PROT DOSIM, V132, P202, DOI 10.1093/rpd/ncn270; Schuz J, 2007, HEALTH PHYS, V92, P642, DOI 10.1097/01.HP.0000243154.46491.7d; Schuz J, 2007, AM J EPIDEMIOL, V166, P263, DOI 10.1093/aje/kwm080; Scientific Committee on on Emerging and Newly Identified Health Risks (SCENIHR), 2009, HLTH EFF EXP EMF; Svendsen AL, 2007, CANCER EPIDEM BIOMAR, V16, P1167, DOI 10.1158/1055-9965.EPI-06-0887; Wunsch-Filho V., 2011, CANC EPIDEMIOL  0812	17	38	42	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0079-6107			PROG BIOPHYS MOL BIO	Prog. Biophys. Mol. Biol.	DEC	2011	107	3					339	342		10.1016/j.pbiomolbio.2011.09.008			4	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	871FB	WOS:000298722200006	21946043				2022-02-25	
J	Tommasino, M				Tommasino, Massimo			Role of papillomaviruses in cutaneous carcinogenesis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Meeting Abstract	Annual Congress of the French-Speaking-Society-for-Dermatological-Research	JUN 23-24, 2011	Besancon, FRANCE	Soc Investigat Dermatol					[Tommasino, Massimo] Int Agcy Res Canc, Infect & Canc Biol Grp, Lyon, France									0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X			J INVEST DERMATOL	J. Invest. Dermatol.	OCT	2011	131	10					2154	2154					1	Dermatology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Dermatology	822RV	WOS:000295068200092					2022-02-25	
J	Guha, N; Olsson, A; Benhaim-Luzon, V; Straif, K				Guha, N.; Olsson, A.; Benhaim-Luzon, V.; Straif, Kurt		SYNERGY Study Grp	LUNG CANCER RISK IN PAINTERS: RESULTS FROM THE SYNERGY POOLED ANALYSIS	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Meeting Abstract	3rd North American Congress of Epidemiology	JUN 21-24, 2011	Montreal, CANADA						[Guha, N.; Olsson, A.; Benhaim-Luzon, V.; Straif, Kurt; SYNERGY Study Grp] IARC, F-69008 Lyon, France									0	0	0	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	JUN 1	2011	173			11			S71	S71					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Public, Environmental & Occupational Health	810GU	WOS:000294114600275					2022-02-25	
J	Hafsi, H; Marcel, V; Hainaut, P				Hafsi, Hind; Marcel, Virginie; Hainaut, Pierre			Modulation of p53 transcriptional activity by Delta40p53, a p53 isoform lacking the transactivation domain	BULLETIN DU CANCER			English	Meeting Abstract									[Hafsi, Hind; Marcel, Virginie; Hainaut, Pierre] Int Agcy Res Canc, Lyon, France			hafsih@students.iarc.fr	Hainaut, Pierre/B-6018-2012; Marcel, Virginie/H-3037-2011; MARCEL, Virginie/ABF-1904-2020	Hainaut, Pierre/0000-0002-1303-1610; Marcel, Virginie/0000-0002-9557-8221; MARCEL, Virginie/0000-0002-9557-8221				0	0	0	0	0	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0007-4551			B CANCER	Bull. Cancer	MAR	2011	98			1		10	S13	S14					2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	753HG	WOS:000289762300012					2022-02-25	
J	Paliwal, A; Vaissiere, T; Herceg, Z				Paliwal, Anupam; Vaissiere, Thomas; Herceg, Zdenko			Quantitative detection of DNA methylation states in minute amounts of DNA from body fluids	METHODS			English	Review						DNA methylation; Cell-free circulating DNA; Epigenetic biomarkers; Body fluids; Cancer; Pyrosequencing; Molecular epidemiology	PROMOTER METHYLATION; CANCER; ASSAY; QUANTIFICATION; PLASMA; TUMORS; SPUTUM; MSP	Quantitative and reliable estimation of DNA methylation levels for multiple genomic regions pose a major challenge where starting DNA is available in very low quantity. Here we review major advances in the development of techniques for quantitative detection of DNA methylation in minute amount of DNA and describe a detailed protocol for quantitative Methylation Analysis of Minute DNA amounts after whole Bisulfitome Amplification (qMAMBA), a combination of techniques that allows quantitative and sensitive detection of DNA methylation at multiple CpG sites and for multiple gene assays. Recently we successfully used this technique to quantitatively detect DNA methylation for a set of cancer-related genes in lung cancer patient plasma samples [18]. This method involves genome-wide amplification of bisulfite-modified DNA template followed by quantitative methylation detection using pyrosequencing. This allows a precise assessment of DNA methylation at CpG sites and could be adapted for high-throughput settings. It can also be applied in conjunction with studies involving single-cells or laser capture microdissected samples. Thus, this method should facilitate DNA methylation studies aiming to discover epigenetic biomarkers, and should prove particularly valuable in profiling a large sample series of body fluids from molecular epidemiology studies. (C) 2010 Elsevier Inc. All rights reserved.	[Paliwal, Anupam; Vaissiere, Thomas; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	herceg@iarc.fr	Vaissiere, Thomas/E-1121-2011		la Ligue National (Francaise) Contre le Cancer; National Institutes of Health/National Cancer Institute (NIH/NCI), United StatesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); L'Association pour la Recherche sur le Cancer (ARC), FranceFondation ARC pour la Recherche sur le Cancer; la Ligue Nationale (Francaise) Contre le Cancer, FranceLigue nationale contre le cancer; Agence Nationale de Recherhe Contre le Sida et Hepatites Virales (ANRS, France)ANRS; Swiss Bridge Award	T. Vaissiere is supported by a Ph.D. fellowship from la Ligue National (Francaise) Contre le Cancer. The work in Epigenetics Group at IARC is supported by grants from the National Institutes of Health/National Cancer Institute (NIH/NCI), United States; L'Association pour la Recherche sur le Cancer (ARC), France, la Ligue Nationale (Francaise) Contre le Cancer, France, and Agence Nationale de Recherhe Contre le Sida et Hepatites Virales (ANRS, France), and the Swiss Bridge Award (to Z.H.).	Belinsky SA, 2002, CANCER RES, V62, P2370; Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625; Brena RM, 2006, NAT PROTOC, V1, P52, DOI 10.1038/nprot.2006.8; Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01; Derks S, 2004, CELL ONCOL, V26, P291; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Goessl C, 2002, EUR UROL, V41, P668, DOI 10.1016/S0302-2838(02)00126-4; Gonzalgo ML, 2002, METHODS, V27, P128, DOI 10.1016/S1046-2023(02)00064-6; Gormally E, 2006, CANCER RES, V66, P6871, DOI 10.1158/0008-5472.CAN-05-4556; Herceg Z, 2007, MOL ONCOL, V1, P26, DOI 10.1016/j.molonc.2007.01.004; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; KAWAMOTO K, 2006, BIOCHEM BIOPH RES CO, V339; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu Z, 2009, ANAL BIOCHEM, V391, P106, DOI 10.1016/j.ab.2009.05.012; Rand K, 2002, METHODS, V27, P114, DOI 10.1016/S1046-2023(02)00062-2; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Shames DS, 2007, CANCER LETT, V251, P187, DOI 10.1016/j.canlet.2006.10.014; Shaw RJ, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl424; Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972; Tost Jorg, 2007, V373, P89; Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489; Vaissiere T, 2009, EPIGENETICS-US, V4, P221, DOI 10.4161/epi.8833; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamamoto T, 2004, BIOTECHNIQUES, V36, P846, DOI 10.2144/04365RR02; Zhang ZJ, 2004, ANAL CHEM, V76, P6829, DOI 10.1021/ac049114+	30	24	26	0	26	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1046-2023	1095-9130		METHODS	Methods	NOV	2010	52	3					242	247		10.1016/j.ymeth.2010.03.008			6	Biochemical Research Methods; Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679TM	WOS:000284183700008	20362673				2022-02-25	
J	Lambert, R; Sauvaget, C; Sankaranarayanan, R				Lambert, Rene; Sauvaget, Catherine; Sankaranarayanan, Rengaswamy			Mass screening for colorectal cancer is not justified in most developing countries	INTERNATIONAL JOURNAL OF CANCER			English	Article						colorectal cancer; colorectal adenoma; screening; colonoscopy; epidemiology	RANDOMIZED CONTROLLED-TRIAL; FLEXIBLE SIGMOIDOSCOPY; ADENOMATOUS POLYPS; CERVICAL-CANCER; SURVEILLANCE; MORTALITY; CHINA; MANAGEMENT; SOCIETY; UPDATE	Most developed countries insist on the prevention or colorectal cancer (CRC) and offer screening to the population. Mass screening is proposed to both sexes in the population aged 50 years or more. Colonoscopy is then offered to persons having a positive faecal occult blood test. This recommendation should not be diffused over the world without considering the distinct dimensions or the risk and resources in developed and developing countries. A national screening policy is legitimate in developed countries like Japan, South Korea, and in North America and Europe. On the other hand, a mass screening policy for CRC is not recommended in most developing countries. The limited amount of resources attributed to health care for cancer should concern other indications in the control of common cancers, particularly in the cervix or liver. Indeed the risk of CRC is very low in most regions of Africa, and in some countries of South America and Asia. (C) 2009 UICC	[Lambert, Rene; Sauvaget, Catherine; Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Screening Grp, F-69372 Lyon 08, France		Lambert, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	lambert@iarc.fr		Sauvaget, Catherine/0000-0002-8053-4963			[Anonymous], 1973, SURVEILLANCE EPIDEMI; Atkin WS, 1998, EUR J GASTROEN HEPAT, V10, P219, DOI 10.1097/00042737-199803000-00005; Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932; Chen JG, 2003, J MED SCREEN, V10, P204, DOI 10.1258/096914103771773320; Curado MP, 2007, IARC SCI PUBLICATION, VIX; Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2; DAWSEY SM, 1994, CANCER, V74, P1686, DOI 10.1002/1097-0142(19940915)74:6<1686::AID-CNCR2820740608>3.0.CO;2-V; Denny L, 2006, VACCINE S3, V24, pS3/71; Ferlay J, 2004, IARC CANC BASE; Hewitson P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001216.pub2; Hewitson P, 2008, AM J GASTROENTEROL, V103, P1541, DOI 10.1111/j.1572-0241.2008.01875.x; Kudo S, 2000, WORLD J SURG, V24, P1081, DOI 10.1007/s002680010154; Levin B, 2008, GASTROENTEROLOGY, V134, P1570, DOI 10.1053/j.gastro.2008.02.002; Mandel JS, 2000, NEW ENGL J MED, V343, P1603, DOI 10.1056/NEJM200011303432203; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Sankaranarayanan R, 2005, LANCET, V365, P1927, DOI 10.1016/S0140-6736(05)66658-5; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 2007, LANCET, V370, P398, DOI 10.1016/S0140-6736(07)61195-7; Satodate H, 2003, GASTROINTEST ENDOSC, V58, P288, DOI 10.1067/mge.2003.361; Soetikno R, 2006, GASTROENTEROLOGY, V130, P566, DOI 10.1053/j.gastro.2005.12.006; Tsoi KKF, 2008, ALIMENT PHARM THER, V28, P353, DOI 10.1111/j.1365-2036.2008.03726.x; Weissfeld JL, 2005, JNCI-J NATL CANCER I, V97, P989, DOI 10.1093/jnci/dji175; Wilson JMG, 1968, PRINCIPLES PRACTICE; Winawer SJ, 2006, GASTROENTEROLOGY, V130, P1872, DOI 10.1053/j.gastro.2006.03.012; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; YANG CS, 1980, CANCER RES, V40, P2633; WHO GLOBAL INFOBASE	28	43	43	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	JUL 15	2009	125	2					253	256		10.1002/ijc.24371			4	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	460ZJ	WOS:000267231600001	19384945	Bronze			2022-02-25	
J	Plummer, M				Plummer, Martyn			Penalized loss functions for Bayesian model comparison	BIOSTATISTICS			English	Article						Bayesian model comparison; deviance information criterion; disease mapping; Markov chain Monte Carlo methods; mixture models	CROSS-VALIDATION; PREDICTION RULE; LINEAR-MODEL; ERROR RATE; SELECTION; CHOICE	The deviance information criterion (DIC) is widely used for Bayesian model comparison, despite the lack of a clear theoretical foundation. DIC is shown to be an approximation to a penalized loss function based on the deviance, with a penalty derived from a cross-validation argument. This approximation is valid only when the effective number of parameters in the model is much smaller than the number of independent observations. In disease mapping, a typical application of DIC, this assumption does not hold and DIC under-penalizes more complex models. Another deviance-based loss function, derived from the same decision-theoretic framework, is applied to mixture models, which have previously been considered an unsuitable application for DIC.	Int Agcy Res Canc, F-69372 Lyon, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	plummer@iarc.fr		Plummer, Martyn/0000-0001-5130-6497			AITKIN M, 1991, J ROY STAT SOC B MET, V53, P111; Banerjee S, 2004, HIERARCHICAL MODELIN; BECHTEL YC, 1993, CLIN PHARMACOL THER, V54, P134, DOI 10.1038/clpt.1993.124; Berger JO, 1996, J AM STAT ASSOC, V91, P109, DOI 10.2307/2291387; BERNARDO JM, 1979, ANN STAT, V7, P686, DOI 10.1214/aos/1176344689; BESAG J, 1991, ANN I STAT MATH, V43, P1, DOI 10.1007/BF00116466; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; Celeux G, 2000, J AM STAT ASSOC, V95, P957, DOI 10.2307/2669477; Celeux G, 2006, BAYESIAN ANAL, V1, P701, DOI 10.1214/06-BA122REJ; Celeux G, 2006, BAYESIAN ANAL, V1, P651, DOI 10.1214/06-BA122; CLAYTON D, 1987, BIOMETRICS, V43, P671, DOI 10.2307/2532003; Clements MS, 2005, BIOSTATISTICS, V6, P576, DOI 10.1093/biostatistics/kxi028; Daniels MJ, 2006, BIOSTATISTICS, V7, P1, DOI 10.1093/biostatistics/kxi036; EFRON B, 1986, J AM STAT ASSOC, V81, P461, DOI 10.2307/2289236; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Elliott MR, 2005, BIOSTATISTICS, V6, P119, DOI 10.1093/biostatistics/kxh022; GEISSER S, 1979, J AM STAT ASSOC, V74, P153, DOI 10.2307/2286745; GELFAND AE, 1994, J ROY STAT SOC B MET, V56, P501; Gelfand AE, 1998, BIOMETRIKA, V85, P1, DOI 10.1093/biomet/85.1.1; Gelman A., 2002, BAYESIAN DATA ANAL; Gneiting T, 2007, J AM STAT ASSOC, V102, P359, DOI 10.1198/016214506000001437; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; HURVICH CM, 1989, BIOMETRIKA, V76, P297, DOI 10.1093/biomet/76.2.297; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kemp I, 1985, IARC SCI PUBLICATION, V72; LAUD PW, 1995, J ROY STAT SOC B MET, V57, P247; Lindley D. V., 1991, J ROYAL STAT SOC B, V53, P130; LINDLEY DV, 1972, J ROY STAT SOC B, V34, P1; Liu X, 2005, BIOSTATISTICS, V6, P539, DOI 10.1093/biostatistics/kxi026; Marshall EC, 2003, STAT MED, V22, P1649, DOI 10.1002/sim.1403; NEAL R, 1996, STAT COMPUT, V4, P353; OHAGAN A, 1995, J ROY STAT SOC B MET, V57, P99; Peruggia M, 1997, J AM STAT ASSOC, V92, P199, DOI 10.2307/2291464; Plummer M., 2002, Journal of the Royal Statistical Society: Series B (Statistical Methodology), V64, DOI [10.1111/1467-9868.00353, DOI 10.1111/1467-9868.00353]; Plummer M, 2006, BAYESIAN ANAL, V1, P681, DOI 10.1214/06-BA122C; Richardson S, 1997, J ROY STAT SOC B MET, V59, P731, DOI 10.1111/1467-9868.00095; Ripley B.D, 1996, STAT PATTERN RECOGNI; Smith AFM., 2000, BAYESIAN THEORY; Spiegelhalter D., 2004, WINBUGS USER MANUAL; Spiegelhalter D. J., 1998, 98009 U MINN DIV BIO; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; STONE M, 1977, J R STAT SOC B, V39, P44, DOI 10.1111/j.2517-6161.1977.tb01603.x; STONE M, 2002, J ROYAL STAT SOC B, V64, P621; van der Linde A, 2005, STAT NEERL, V59, P45; van der Linde A, 2004, TEST-SPAIN, V13, P85, DOI 10.1007/BF02603002; Vehtari A, 2002, NEURAL COMPUT, V14, P2439, DOI 10.1162/08997660260293292; VEHTARI A, 2001, THESIS HELSINKI HELS; [No title captured]	48	226	228	1	29	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1465-4644	1468-4357		BIOSTATISTICS	Biostatistics	JUL	2008	9	3					523	539		10.1093/biostatistics/kxm049			17	Mathematical & Computational Biology; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology; Mathematics	316VE	WOS:000256977000012	18209015	Bronze			2022-02-25	
J	Cogliano, V				Cogliano, Vincent			Oral contraceptives, menopausal treatment, and cancer - Reply	LANCET ONCOLOGY			English	Editorial Material							TRANSPARENCY		Int Agcy Res Canc, IARC Monographs Programme, F-69372 Lyon, France		Cogliano, V (corresponding author), Int Agcy Res Canc, IARC Monographs Programme, 150 Cours Albert Thomas, F-69372 Lyon, France.	cogliano@iarc.fr					Cogliano V, 2005, LANCET ONCOL, V6, P747, DOI 10.1016/S1470-2045(05)70380-6; Cogliano V, 2005, LANCET ONCOL, V6, P737, DOI 10.1016/S1470-2045(05)70367-3; Collingridge D, 2005, LANCET ONCOL, V6, P735, DOI 10.1016/S1470-2045(05)70364-8; *IARC, PREAMB IARC MON; Szarewski A, 2005, LANCET ONCOL, V6, P736, DOI 10.1016/S1470-2045(05)70366-1	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1470-2045			LANCET ONCOL	Lancet Oncol.	OCT	2007	8	10					867	868		10.1016/S1470-2045(07)70298-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	221TA	WOS:000250249000013					2022-02-25	
J	Boffetta, P				Boffetta, P.			Epidemiology of peritoneal mesothelioma: a review	ANNALS OF ONCOLOGY			English	Review						asbestos; epidemiology; peritoneal mesothelioma; thorotrast	ASBESTOS CEMENT WORKERS; MALIGNANT MESOTHELIOMA; FOLLOW-UP; OCCUPATIONAL-EXPOSURE; CANCER INCIDENCE; LUNG-CANCER; RADIOACTIVE THOROTRAST; COHORT MORTALITY; CHRYSOTILE; MINERS	The epidemiology of peritoneal mesothelioma is complicated by possible geographic and temporal variations in diagnostic practices. The incidence rates in industrialized countries range between 0.5 and three cases per million in men and between 0.2 and two cases per million in women. Exposure to asbestos is the main known cause of peritoneal mesothelioma. Results on peritoneal mesothelioma have been reported for 34 cohorts exposed to asbestos, among which a strong correlation was present between the percentages of deaths from pleural and peritoneal mesothelioma (correlation coefficient 0.8, P < 0.0001). Studies of workers exposed only or predominantly to chrysotile asbestos resulted in a lower proportion of total deaths from peritoneal mesothelioma than studies of workers exposed to amphibole or mixed type of asbestos. Cases of peritoneal mesothelioma have also been reported following exposure to erionite and Thorotrast, providing further evidence of common etiological factors with the pleural form of the disease. The role of other suspected risk factors, such as simian virus 40 infection and genetic predisposition, is unclear at present. Control of asbestos exposure remains the main approach to prevent peritoneal mesothelioma.	Int Agcy Res Canc, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr					ACHESON ED, 1984, INT J EPIDEMIOL, V13, P3, DOI 10.1093/ije/13.1.3; ACHESON ED, 1982, BRIT J IND MED, V39, P344; ALIESPATIN AM, 1985, BRIT J IND MED, V42, P219; AMANDUS HE, 1987, AM J IND MED, V11, P15, DOI 10.1002/ajim.4700110103; ANDERSSON M, 1995, INT J CANCER, V63, P330, DOI 10.1002/ijc.2910630304; ARMSTRONG BK, 1988, BRIT J IND MED, V45, P5; BARIS I, 1987, INT J CANCER, V39, P10, DOI 10.1002/ijc.2910390104; BARIS YI, 1981, LANCET, V1, P984; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Cocco P, 1999, AM J IND MED, V35, P9, DOI 10.1002/(SICI)1097-0274(199901)35:1<9::AID-AJIM2>3.3.CO;2-M; COGGON D, 1995, OCCUP ENVIRON MED, V52, P775, DOI 10.1136/oem.52.11.775; DEMENT JM, 1994, AM J IND MED, V26, P431, DOI 10.1002/ajim.4700260402; ENTERLINE PE, 1987, BRIT J IND MED, V44, P396; *EUR NETW CANC REG, 2001, EUR INC DAT; FINKELSTEIN MM, 1984, AM REV RESPIR DIS, V129, P754, DOI 10.1164/arrd.1984.129.5.754; GARDNER MJ, 1986, BRIT J IND MED, V43, P726; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; Germani D, 1999, AM J IND MED, V36, P129, DOI 10.1002/(SICI)1097-0274(199907)36:1<129::AID-AJIM18>3.3.CO;2-0; GILKS B, 1988, CANCER, V61, P2019, DOI 10.1002/1097-0142(19880515)61:10<2019::AID-CNCR2820611015>3.0.CO;2-K; Heineman EF, 1996, CANCER, V77, P549, DOI 10.1002/(SICI)1097-0142(19960201)77:3<549::AID-CNCR18>3.0.CO;2-4; Hodgson JT, 2000, ANN OCCUP HYG, V44, P565, DOI 10.1093/annhyg/44.8.565; HUGHES JM, 1987, BRIT J IND MED, V44, P161; *INT AG RES CANC, 1997, IARC MON EV CARC RIS, V42, P225; *INT AG RES CANC, 2002, IARC MON EV CARC RIS, V81; ISHIKAWA Y, 1995, J CANCER RES CLIN, V121, P567, DOI 10.1007/BF01197771; JONES JSP, 1980, IARC SCI PUB INT AGE, V30, P637; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; KOLONEL LN, 1985, CANCER RES, V45, P3924; Krasuski P., 2002, Archives of Gynecology and Obstetrics, V266, P130, DOI 10.1007/s004040100189; Lopez-Rios F, 2004, LANCET, V364, P1157, DOI 10.1016/S0140-6736(04)17102-X; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; Magnani C, 1996, Med Lav, V87, P133; MCDONALD AD, 1982, ANN OCCUP HYG, V26, P417, DOI 10.1093/annhyg/26.3.417; MCDONALD AD, 1984, BRIT J IND MED, V41, P151; Menegozzo M, 1993, Med Lav, V84, P193; Metintas M, 1999, EUR RESPIR J, V13, P523, DOI 10.1183/09031936.99.13352399; MEURMAN LO, 1994, OCCUP ENVIRON MED, V51, P421, DOI 10.1136/oem.51.6.421; Mohamed Faheez, 2002, Curr Treat Options Oncol, V3, P375, DOI 10.1007/s11864-002-0003-6; NEUBERGER M, 1990, BRIT J IND MED, V47, P615; NEWHOUSE ML, 1965, BR J IND MED, V50, P769; NIELSEN AM, 1994, ACTA OBSTET GYN SCAN, V73, P581, DOI 10.3109/00016349409006277; Nyberg U, 2002, RADIAT RES, V157, P419, DOI 10.1667/0033-7587(2002)157[0419:CIASPE]2.0.CO;2; OHLSON CG, 1984, SCAND J WORK ENV HEA, V10, P283, DOI 10.5271/sjweh.2329; OHLSON CG, 1985, BRIT J IND MED, V42, P397; PETERSON JT, 1984, CANCER, V54, P951, DOI 10.1002/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A; PETO J, 1985, ANN OCCUP HYG, V29, P305, DOI 10.1093/annhyg/29.3.305; SANDEN A, 1992, EUR RESPIR J, V5, P281; SARACCI R, 1982, BRIT J CANCER, V45, P147, DOI 10.1038/bjc.1982.19; *SEER PROG, 2003, SEER STAT DAT; SEIDMAN H, 1986, AM J IND MED, V10, P479; SELIKOFF IJ, 1991, ANN NY ACAD SCI, V643, P1, DOI 10.1111/j.1749-6632.1991.tb24439.x; Shivapurkar N, 2000, INT J CANCER, V85, P743, DOI 10.1002/(SICI)1097-0215(20000301)85:5<743::AID-IJC24>3.0.CO;2-3; Silva ID, 2003, RADIAT RES, V159, P521, DOI 10.1667/0033-7587(2003)159[0521:MARIWR]2.0.CO;2; SLUISCREMER GK, 1992, BRIT J IND MED, V49, P566; SPIRTAS R, 1994, OCCUP ENVIRON MED, V51, P804, DOI 10.1136/oem.51.12.804; SZESZENIA-DABROWSKA N, 1986, Medycyna Pracy, V37, P243; Szeszenia-Dabrowska Neonila, 2002, Int J Occup Med Environ Health, V15, P267; THOMAS HF, 1982, BRIT J IND MED, V39, P273; Travis LB, 2003, RADIAT RES, V160, P691, DOI 10.1667/RR3095; Tulchinsky TH, 1999, AM J IND MED, V35, P1; Ulvestad B, 2002, SCAND J WORK ENV HEA, V28, P411, DOI 10.5271/sjweh.693; van Kaick G, 1999, RADIAT RES, V152, pS64, DOI 10.2307/3580117; VIANNA NJ, 1978, LANCET, V1, P1061; WAGNER JC, 1971, BRIT MED BULL, V27, P71, DOI 10.1093/oxfordjournals.bmb.a070818; WOITOWITZ HJ, 1986, INT ARCH OCC ENV HEA, V57, P161, DOI 10.1007/BF00405785; Yano E, 2001, AM J EPIDEMIOL, V154, P538, DOI 10.1093/aje/154.6.538	66	173	180	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	JUN	2007	18	6					985	990		10.1093/annonc/mdl345			6	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	204NU	WOS:000249052100004	17030547	Bronze			2022-02-25	
J	Herceg, Z; Hainaut, P				Herceg, Zdenko; Hainaut, Pierre			Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis	MOLECULAR ONCOLOGY			English	Review						Genetic changes; Epigenetic changes; Cancer biomarkers; Molecular signature; Prognosis	ISLAND METHYLATOR PHENOTYPE; CELL LUNG-CANCER; O-6-METHYLGUANINE DNA METHYLTRANSFERASE; ABERRANT PROMOTER HYPERMETHYLATION; PROTEIN-KINASE GENE; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; PLASMA DNA; PERIPHERAL-BLOOD; BLADDER-CANCER	The development of cancer is driven by the accumulation of scores of alterations affecting the structure and function of the genome. Equally important in this process are genetic alterations and epigenetic changes. Whereas the former disrupt normal patterns of gene expression, sometimes leading to the expression of abnormal, constitutively active proteins, the latter deregulate the mechanisms such as transcriptional control leading to the inappropriate silencing or activation of cancer-associated genes. Both types of changes are inheritable at the cellular level, thus contributing to the clonal expansion of cancer cells. In this review, we summarize current knowledge on how genetic alterations in oncogenes or tumour suppressor genes, as well as epigenetic changes, can be exploited in the clinics as biomarkers for cancer detection, diagnosis and prognosis. We propose a rationale for identifying alterations that may have a functional impact within a background of "passenger" alterations that may occur solely as the consequence of deregulated genetic and epigenetic stability. Such functional alterations may represent candidates for targeted therapeutic approaches. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.	[Herceg, Zdenko; Hainaut, Pierre] Int Agcy Res Canc, Grp Mol Carcinogenesis & Biomarkers, F-69008 Lyon, Rhone Alpes, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis & Biomarkers, 150 Cours Albert Thomas, F-69008 Lyon, Rhone Alpes, France.	herceg@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Abdel-Rahman WM, 2006, CRIT REV ONCOL HEMAT, V58, P208, DOI 10.1016/j.critrevonc.2005.11.001; Abe M, 2005, CANCER RES, V65, P828; Ahuja N, 1997, CANCER RES, V57, P3370; An CH, 2005, CLIN CANCER RES, V11, P656; An Q, 2002, CANCER LETT, V188, P109, DOI 10.1016/S0304-3835(02)00496-2; Balko JM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-289; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bazan V, 2006, ANN ONCOL, V17, pVII84, DOI 10.1093/annonc/mdl958; Bearzatto A, 2002, CLIN CANCER RES, V8, P3782; Belinsky SA, 2002, CANCER RES, V62, P2370; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bielas JH, 2006, P NATL ACAD SCI USA, V103, P18238, DOI 10.1073/pnas.0607057103; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chan MWY, 2002, CLIN CANCER RES, V8, P464; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dominguez G, 2002, CLIN CANCER RES, V8, P980; Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 1999, CANCER RES, V59, P2302; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2004, ONCOGENE, V23, P1, DOI 10.1038/sj.onc.1207316; Esteller M, 2002, J NATL CANCER I, V94, P26; Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garnis C, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-9; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; GOEL A, 2006, GASTROENTEROLOGY; Goessl C, 2002, EUR UROL, V41, P668, DOI 10.1016/S0302-2838(02)00126-4; Goessl C, 2000, UROLOGY, V55, P414, DOI 10.1016/S0090-4295(99)00477-X; Gormally E, 2007, MUTAT RES-REV MUTAT, V635, P105, DOI 10.1016/j.mrrev.2006.11.002; Gormally E, 2006, CANCER RES, V66, P6871, DOI 10.1158/0008-5472.CAN-05-4556; Grady WM, 2001, CANCER RES, V61, P900; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Issa JPJ, 2003, CLIN CANCER RES, V9, P2879; Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeronimo C, 2002, UROLOGY, V60, P1131; John RM, 2000, CELL, V101, P585, DOI 10.1016/S0092-8674(00)80870-3; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kane MF, 1997, CANCER RES, V57, P808; Kaneda A, 2002, CANCER RES, V62, P6645; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; KING CM, 1994, MUTAT RES-DNAGING G, V316, P79, DOI 10.1016/0921-8734(94)90010-8; Kurakawa E, 2001, INT J ONCOL, V19, P277; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526; Lee TL, 2002, CLIN CANCER RES, V8, P1761; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Loizou JI, 2006, CELL CYCLE, V5, P696, DOI 10.4161/cc.5.7.2616; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Luedi PP, 2005, GENOME RES, V15, P875, DOI 10.1101/gr.3303505; Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Muller HM, 2003, CANCER RES, V63, P7641; Nakayama H, 2002, CANCER LETT, V188, P115, DOI 10.1016/S0304-3835(01)00839-4; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Oakey RJ, 2002, TRENDS GENET, V18, P359, DOI 10.1016/S0168-9525(02)02708-7; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Papadopoulou E, 2004, ONCOL RES, V14, P439, DOI 10.3727/0965040041791473; Papadopoulou E, 2006, ANN NY ACAD SCI, V1075, P235, DOI 10.1196/annals.1368.032; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Pasquinelli AE, 2005, CURR OPIN GENET DEV, V15, P200, DOI 10.1016/j.gde.2005.01.002; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; Roman-Gomez J, 2005, J CLIN ONCOL, V23, P7043, DOI 10.1200/JCO.2005.01.4944; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010; Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772; SCHLESINGER Y, 2006, NATURE GENETICS; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sengupta S, 2005, ONCOGENE, V24, P1738, DOI 10.1038/sj.onc.1208380; Shaw RJ, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl424; Shen L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shibata DM, 2002, CANCER RES, V62, P5637; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Slattery ML, 2007, INT J CANCER, V120, P656, DOI 10.1002/ijc.22342; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUGIMURA T, 1992, ENVIRON HEALTH PERSP, V98, P5, DOI 10.2307/3431242; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; Taback B, 2006, ANN NY ACAD SCI, V1075, P197, DOI 10.1196/annals.1368.027; Tada Y, 2002, CANCER RES, V62, P4048; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Thibodeau SN, 1996, CANCER RES, V56, P4836; Toyooka S, 2005, NEW ENGL J MED, V352, P2136; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Usadel H, 2002, CANCER RES, V62, P371; Valenzuela MT, 2002, EUR UROL, V42, P622, DOI 10.1016/S0302-2838(02)00468-2; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang YC, 2006, ANN NY ACAD SCI, V1075, P179, DOI 10.1196/annals.1368.024; Ward RL, 2003, J CLIN ONCOL, V21, P3729, DOI 10.1200/JCO.2003.03.123; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; WIDSCHWENDTER M, 2006, NATURE GENETICS; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Wong IHN, 2000, CLIN CANCER RES, V6, P3516; Wong TS, 2004, CLIN CANCER RES, V10, P2401, DOI 10.1158/1078-0432.CCR-03-0139; Wong TS, 2003, EUR J CANCER, V39, P1881, DOI 10.1016/S0959-8049(03)00428-3; Wong TS, 2002, CLIN CANCER RES, V8, P433; Wong W, 1999, PC WEEK, V16, P73; Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042; Yamamoto H, 2002, GENE CHROMOSOME CANC, V33, P322, DOI 10.1002/gcc.10010; Yan PS, 2000, CLIN CANCER RES, V6, P1432; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhang YJ, 2006, INT J CANCER, V119, P985, DOI 10.1002/ijc.21699; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zou HZ, 2002, CLIN CANCER RES, V8, P188	151	111	112	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1574-7891	1878-0261		MOL ONCOL	Mol. Oncol.	JUN	2007	1	1					26	41		10.1016/j.molonc.2007.01.004			16	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	413XW	WOS:000263829000006	19383285	Green Published			2022-02-25	
J	Lambert, R; Hainaut, P				Lambert, R.; Hainaut, P.			Epidemiology of oesophagogastric cancer	BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY			English	Article						oesophageal cancer; stomach cancer; epidemiology; Helicabacter pylori; Barrett's oesophagus; endoscopy	SQUAMOUS-CELL CARCINOMA; ESOPHAGEAL CANCER; BARRETTS-ESOPHAGUS; DISTAL ESOPHAGUS; TIME TRENDS; RISK; EXPRESSION; P63; ADENOCARCINOMAS; PRECURSORS	Oesophagogastric cancer occurs in the oesophagus, the oesophagogastric region and the stomach, including the proximal and distal stomach. In 2005, the worldwide burden of oesophagogastric cancer was estimated to be 1500000 new cases (500000 oesophagus and 1000000 stomach). Squamous cell cancer is linked with alcohol and tobacco consumption in Western countries. Its incidence is much higher in regions of Asia with a low-socio-economic status, nutritional deficiencies, poor oral status, carcinogens absorbed with smoked meat, fat-cooked foodstuffs, vegetables containing toxic alkaloids or mycotoxins, and water containing nitrites, nitrates and nitrosamines. Adenocarcinoma develops in the columnar lined oesophagus. Its incidence is still low but there is an increasing trend. The incidence of stomach cancer is decreasing worldwide, but is still high in Japan. Causal factors include Helicobacter pylori infection with atrophic gastritis and a diet poor in fruit and vegetables. Preneoplastic conditions of the oesophagogastric mucosa include erosive oesophagitis in alcoholics, columnar lined oesophagus as a complication of gastro-oesophageal reflux disease, and atrophic gastritis following H. pylori infection.	[Lambert, R.] Int Agcy Res Canc, Grp Screening, F-69372 Lyon 8, France; [Hainaut, P.] Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 8, France		Lambert, R (corresponding author), Int Agcy Res Canc, Grp Screening, 150 Cours Albert Thomas, F-69372 Lyon 8, France.	lambert@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			[Anonymous], 1993, Gut, V34, P1672; Coleman MP, 2003, ANN ONCOL, V14, pV128, DOI 10.1093/annonc/mdg756; CORREA P, 1992, CANCER RES, V52, P6735; Dai M, 2007, INT J CANCER, V121, P1396, DOI 10.1002/ijc.22824; Daniely Y, 2004, AM J PHYSIOL-CELL PH, V287, pC171, DOI 10.1152/ajpcell.00226.2003; DAWSEY SM, 1994, CANCER, V74, P1686, DOI 10.1002/1097-0142(19940915)74:6<1686::AID-CNCR2820740608>3.0.CO;2-V; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Dixon MF, 2002, GUT, V51, P130, DOI 10.1136/gut.51.1.130; Ferlay F, 2004, GLOBOCAN 2002 CANC I; Hall PA, 2001, GUT, V49, P618, DOI 10.1136/gut.49.5.618; He YT, 2003, WORLD J GASTROENTERO, V9, P209, DOI 10.3748/wjg.v9.i2.209; International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, P177; Jacob J H, 1993, Eur J Cancer Prev, V2, P53, DOI 10.1097/00008469-199301000-00009; JASKIEWICZ K, 1987, J NATL CANCER I, V79, P961; Tian J, 2006, WORLD J GASTROENTERO, V12, P4569, DOI 10.3748/wjg.v12.i28.4569; Labenz J, 2004, AM J GASTROENTEROL, V99, P1652, DOI 10.1111/j.1572-0241.2004.30390.x; Lambert R, 2007, ENDOSCOPY, V39, P659, DOI 10.1055/S-2007-966589; Lambert R, 2007, ENDOSCOPY, V39, P550, DOI 10.1055/s-2007-966530; Lambert R, 2007, ENDOSCOPY, V39, P232, DOI 10.1055/s-2006-945109; Lambert R, 2004, SEMIN ONCOL, V31, P498, DOI 10.1053/j.seminoncol.2004.04.017; LAMBERT R, 2002, GASTROINTESTINAL ONC, P341; LEE CH, 2007, EUR J CANCER, P23; Levrero M, 2000, J CELL SCI, V113, P1661; Li K, 2002, INT J CANCER, V102, P271, DOI [10.1002/ijc.10706, 10.1002/jhc.10706]; Mandard AM, 1997, J PATHOL, V181, P153, DOI 10.1002/(SICI)1096-9896(199702)181:2<153::AID-PATH743>3.0.CO;2-A; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; *MIN HLTH LAB WELF, 2003, REP HLTH CTR ACT HLT, P550; Morita M, 2005, ANTICANCER RES, V25, P3533; MUNOZ N, 1982, LANCET, V1, P876; MUNOZ N, 1995, CANCER, V75, P2779, DOI 10.1002/1097-0142(19950601)75:11<2779::AID-CNCR2820751123>3.0.CO;2-B; *NAT CANC CTR, 2005, CANC STAT JAP FDN PR; *NAT CANC I, SEER CANC INC PUBL U; *OS CANC REG, 1998, SURV CANC PAT OS 197; PARKIN DM, 2002, IARC PUBL, V155; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; PARKIN M, 2000, INCIDENCE TIME TREND; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; Reid Brian J, 2003, Gastrointest Endosc Clin N Am, V13, P369, DOI 10.1016/S1052-5157(03)00006-0; Roman S, 2007, AM J PHYSIOL-GASTR L, V293, pG45, DOI 10.1152/ajpgi.00583.2006; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Satodate H, 2003, GASTROINTEST ENDOSC, V58, P288, DOI 10.1067/mge.2003.361; Siewert JR, 2003, WORLD J SURG, V27, P1058, DOI 10.1007/s00268-003-7061-1; Spechler SJ, 2000, GASTROENTEROLOGY, V119, P587, DOI 10.1053/gast.2000.9849; TAKUBO K, 2003, ESOPHAGUS, V1, P37, DOI [10.1007/s10388-003-0004, DOI 10.1007/S10388-003-0004-Y]]; Taniere P, 2002, AM J SURG PATHOL, V26, P1213, DOI 10.1097/00000478-200209000-00012; Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990; Taniere P, 2001, AM J PATHOL, V158, P33, DOI 10.1016/S0002-9440(10)63941-7; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Vizcaino AP, 2002, INT J CANCER, V99, P860, DOI 10.1002/ijc.10427; Wang GQ, 2005, GUT, V54, P187, DOI 10.1136/gut.2004.046631; Yokoyama T, 2003, CANCER EPIDEM BIOMAR, V12, P1227; Yoshihara Masahru, 1997, Hiroshima Journal of Medical Sciences, V46, P81; ZHENG TZ, 1993, CANCER, V72, P330, DOI 10.1002/1097-0142(19930715)72:2<330::AID-CNCR2820720205>3.0.CO;2-L; 2004, ENDOSCOPY, V37, P879; 2005, J GASTROENTEROL MASS, V43, P54; UNP ZHENGZH U INT S	58	122	130	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1521-6918	1532-1916		BEST PRACT RES CL GA	Best Pract. Res. Clin. Gastroenterol.		2007	21	6					921	945		10.1016/j.bpg.2007.10.001			25	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	247QI	WOS:000252094000002	18070696				2022-02-25	
J	Gray, N				Gray, Nigel			The consequences of the unregulated cigarette	TOBACCO CONTROL			English	Article							LUNG-CANCER INCIDENCE; HISTOLOGIC TYPE; CHANGING TRENDS; TOBACCO-SMOKE; ADENOCARCINOMA; RISK; CARCINOMA; HISTOPATHOLOGY; NITROSAMINES; EPIDEMIOLOGY	This article considers changes in cigarette design in relation to the concept of "dose'', drawing attention to the observation that there is not one smoking related epidemic of lung cancer, but at least two. Squamous carcinoma is declining in parallel with smoking prevalence while adenocarcinoma is increasing in the face of declining smoking prevalence. It is concluded that the adenocarcinoma epidemic is unnecessary and is due substantially to cigarette design changes, including increases in tobacco specific nitrosamines, manipulation of droplet size and ventilated filters. The need for regulation of smoke constituents is emphasised.	Int Agcy Res Canc, F-67008 Lyon, France		Gray, N (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-67008 Lyon, France.	nigel@uicc.org					Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470; Bain C, 2004, JNCI-J NATL CANCER I, V96, P826, DOI 10.1093/jnci/djh143; BATES C, 2002, TOBACCO ADDITIVES CI; BORGERDING MF, 2000, 1999 MASSACHUSSETTS; BOYLE P, 2004, TOBACCO SCI POLICY P; Charloux A, 1997, INT J EPIDEMIOL, V26, P14, DOI 10.1093/ije/26.1.14; CHOI JH, 1994, LUNG CANCER-J IASLC, V10, P287, DOI 10.1016/0169-5002(94)90658-0; COX JD, 1979, AM REV RESPIR DIS, V120, P1025; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; DEVESA SS, 1991, CANCER EPIDEM BIOMAR, V1, P29; DJORDJEVIC MV, 1995, CARCINOGENESIS, V16, P2627, DOI 10.1093/carcin/16.11.2627; DODDS L, 1986, J NATL CANCER I, V76, P21; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 2004, TOBACCO SCI POLICY P, P3; ELTORKY M, 1990, CANCER, V65, P2361, DOI 10.1002/1097-0142(19900515)65:10<2361::AID-CNCR2820651034>3.0.CO;2-C; FISCHER S, 1990, Archiv fuer Geschwulstforschung, V60, P169; Gray N, 2000, TOB CONTROL, V9, P351, DOI 10.1136/tc.9.3.351; Gray N, 2005, ADDICTION, V100, P575, DOI 10.1111/j.1360-0443.2005.01007.x; Gray N, 2000, TOB CONTROL, V9, P90, DOI 10.1136/tc.9.1.90; Gray N, 2004, TOB CONTROL, V13, P13, DOI 10.1136/tc.2003.005579; Harkness EF, 2002, INT J CANCER, V102, P179, DOI 10.1002/ijc.10661; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Henschke CI, 2004, LUNG CANCER, V43, P1, DOI 10.1016/j.lungcan.2003.08.024; Hoffmann I., 2001, NATL CANCER I MONOGR, P159, DOI DOI 10.1093/ACPR0F:0S0/9780199566655.003.0006; International Agency for Research on Cancer, 2004, TOB SMOK INV SMOK; Janssen-Heijnen MLG, 2001, LUNG CANCER, V31, P123, DOI 10.1016/S0169-5002(00)00197-5; JANSSENHEIJNEN MLG, 1995, EUR J CANCER, V31A, P949, DOI 10.1016/0959-8049(94)00519-2; JOHNSON WW, 1988, ACTA CYTOL, V32, P162; Kessler DA, 1996, NEW ENGL J MED, V335, P988, DOI 10.1056/NEJM199609263351321; Kozlowski LT, 2001, CIGARETTE DESIGN RIS, P13; Levi F, 1997, CANCER, V79, P906, DOI 10.1002/(SICI)1097-0142(19970301)79:5<906::AID-CNCR6>3.0.CO;2-9; *NCI, 2001, SMOK TOB CONTR MON, V13; O'Keefe A M, 1996, J Am Med Womens Assoc (1972), V51, P67; Pankow JF, 2004, CHEM RES TOXICOL, V17, P805, DOI 10.1021/tx0342316; Patel JD, 2005, J CLIN ONCOL, V23, P3212, DOI 10.1200/JCO.2005.11.486; RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857; Royal College of Physicians, 1962, SMOK HLTH REP ROYAL; Stellman SD, 1997, CANCER-AM CANCER SOC, V80, P382, DOI 10.1002/(SICI)1097-0142(19970801)80:3<382::AID-CNCR5>3.0.CO;2-U; Stellman SD, 1997, PREV MED, V26, P451, DOI 10.1006/pmed.1997.0212; THUN M, 2004, TOBACCO SCI POLICY P, P17; Thun MJ, 1997, PREV MED, V26, P422, DOI 10.1006/pmed.1997.0182; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; VINCENT RG, 1977, CANCER, V39, P1647, DOI 10.1002/1097-0142(197704)39:4<1647::AID-CNCR2820390439>3.0.CO;2-H; WAYNE GF, 2002, TOBACCO CONTROL S1, V11, P32, DOI DOI 10.1136/TC.11.SUPPL_1.I32; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; WU AH, 1986, JNCI-J NATL CANCER I, V77, P53; Wynder EL, 1995, ENVIRON HEALTH PERSP, V103, P143, DOI 10.2307/3432301; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; WYNDER EL, 1953, CANCER RES, V13, P855; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183; [No title captured]	52	19	19	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0964-4563	1468-3318		TOB CONTROL	Tob. Control	OCT	2006	15	5					405	408		10.1136/tc.2006.017277			4	Substance Abuse; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Substance Abuse; Public, Environmental & Occupational Health	086QO	WOS:000240688300016	16998176	Green Published			2022-02-25	
J	Hung, RJ; van der Hel, O; Tavtigian, SV; Brennan, P; Boffetta, P; Hashibe, M				Hung, RJ; van der Hel, O; Tavtigian, SV; Brennan, P; Boffetta, P; Hashibe, M			Perspectives on the molecular epidemiology of aerodigestive tract cancers	MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS			English	Article; Proceedings Paper	Satellite Meeting on Linking Toxicology to Epidemiology - Biomarkers and New Technologies	2004	Haikko, FINLAND			cancer; epidemiology; genotype; phenotype; methylation; head and neck cancer; lung cancer	SQUAMOUS-CELL CARCINOMA; ABERRANT PROMOTER METHYLATION; AMINO-ACID SUBSTITUTION; EXCISION-REPAIR GENES; LUNG-CANCER; DNA-REPAIR; NECK-CANCER; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; MULTIPLE GENES; EPIGENETIC INACTIVATION	Improving laboratory techniques and the greater availability of genetic data have led to a flurry of publications from molecular epidemologic studies on aerodigestive tract cancers. Inconsistent results have been observed in studies of sequence variants, due to limitations such as small sample size, possible detection of false positives, moderate prior probabilities that each SNP confers a substantial increase in cancer risk, and publication bias. Meta- and pooled-analyses were shown to be effective in elucidating modest increases in aerodigestive tract cancer risk attributable to sequence variants. Phenotypic assays developed to quantify an individual's DNA repair capacity have been applied to epidemiological studies on aerodigestive tract cancers. Epigenetic events have also been studied in tumor progression and as susceptibility factors for aerodigestive tract cancers, in smaller scale studies. It is imperative that limitations of previous studies are addressed for future research in the molecular epidemiology of aerodigestive tract cancers. Some recommendations for future research are to: (i) incorporate multiple markers of different types (ex. genotype and phenotype data), (ii) enhance statistical power by conducting studies with larger sample size, and developing consortia to coordinate research efforts, (iii) improve marker selection via a hybrid strategy of incorporating data on evolutionary biology and physico-chemical properties of amino acids, with haplotype/tag SNP data, (iv) employ novel statistical methods such as hierarchical modeling with Bayesian adjustments, false positive reporting probability and modeling of complex pathways. Consortia have been initiated for head and neck cancer (International Head and Neck Cancer Epidemiology Consortium (INHANCE)) and lung cancer (International Lung Cancer Consortium (ILCCO)) with the aim to share comparable data, to focus on rare subgroups such as nonsmokers and to coordinate laboratory analyses. Such collaborative efforts and integration across disciplines will be essential in contributing to the elucidation of genetic susceptibility to aerodigestive tract cancers. (c) 2005 Elsevier B.V. All rights reserved.	Int Agcy Res Canc, Genet & Epidemiol Cluster, F-69008 Lyon, France		Hashibe, M (corresponding author), Int Agcy Res Canc, Genet & Epidemiol Cluster, 150 Cours Albert Thomas, F-69008 Lyon, France.	hashibe@iarc.fr	Hung, Rayjean J/A-7439-2013	Hung, Rayjean/0000-0002-4486-7496	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R03CA113157, R01CA092039] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA92039, CA113157] Funding Source: Medline		Abkevich V, 2004, J MED GENET, V41, P492, DOI 10.1136/jmg.2003.015867; Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; Belinsky SA, 2002, CANCER RES, V62, P2370; Benhamou S, 2004, INT J CANCER, V112, P901, DOI 10.1002/ijc.20474; BENNER SA, 1994, PROTEIN ENG, V7, P1323, DOI 10.1093/protein/7.11.1323; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; BLOT WJ, 1988, CANCER RES, V48, P3282; Brabender J, 2003, CLIN CANCER RES, V9, P223; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; Brennan P, 2004, AM J EPIDEMIOL, V159, P1, DOI 10.1093/aje/kwh003; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheng L, 2002, CANCER-AM CANCER SOC, V94, P393, DOI 10.1002/cncr.10231; Cheng L, 2000, CARCINOGENESIS, V21, P1527, DOI 10.1093/carcin/21.8.1527; Conti DV, 2003, HUM HERED, V56, P83, DOI 10.1159/000073736; Cortezzi SS, 2004, CANCER GENET CYTOGEN, V150, P44, DOI 10.1016/j.cancergencyto.2003.07.010; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Elahi A, 2002, CARCINOGENESIS, V23, P1229, DOI 10.1093/carcin/23.7.1229; Esteller M, 1999, CANCER RES, V59, P67; Fan Chun-Yang, 2004, Curr Oncol Rep, V6, P152, DOI 10.1007/s11912-004-0027-0; Garber K, 2002, J NATL CANCER I, V94, P874; Gilliland FD, 2002, CANCER RES, V62, P2248; Giovannucci E, 2002, J NUTR, V132, p2350S, DOI 10.1093/jn/132.8.2350S; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Hamel N, 2000, BRIT J CANCER, V82, P757, DOI 10.1054/bjoc.1999.0993; Hanabata T, 2004, ONCOL REP, V12, P177; Hashibe M, 2003, CANCER EPIDEM BIOMAR, V12, P1509; Hayashi H, 2002, JPN J CANCER RES, V93, P184, DOI 10.1111/j.1349-7006.2002.tb01257.x; HSU TC, 1985, CANCER GENET CYTOGEN, V17, P307, DOI 10.1016/0165-4608(85)90114-1; Hung RJ, 2004, CANCER EPIDEM BIOMAR, V13, P1013; HUNG RJ, IN PRESS AM J EPIDEM; Johanning GL, 2002, J NUTR, V132, p3814S, DOI 10.1093/jn/132.12.3814S; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; JUKES TH, 1971, NATURE, V231, P114, DOI 10.1038/231114a0; Kietthubthew Suparp, 2003, Asian Pac J Cancer Prev, V4, P209; Kim DH, 2001, CANCER RES, V61, P3419; Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077; Kiyohara Chikako, 2004, Rev Environ Health, V19, P15; Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109; Li DH, 2001, INT J CANCER, V93, P436, DOI 10.1002/ijc.1347.abs; LI G, 2004, CARCINOGENESIS; Li GJ, 2004, CLIN CANCER RES, V10, P3996, DOI 10.1158/1078-0432.CCR-04-0089; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; McWilliams JE, 2000, HEAD NECK-J SCI SPEC, V22, P609, DOI 10.1002/1097-0347(200009)22:6<609::AID-HED10>3.0.CO;2-L; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; Momparler RL, 2000, ADV EXP MED BIOL, V465, P433; MUCCI L, 2002, TXB CANC EPIDEMIOLOG; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Nishimoto IN, 2004, ORAL ONCOL, V40, P604, DOI 10.1016/j.oraloncology.2003.12.009; Olshan AF, 2002, CANCER LETT, V178, P181, DOI 10.1016/S0304-3835(01)00822-9; Palmisano WA, 2000, CANCER RES, V60, P5954; Paz MF, 2002, CANCER RES, V62, P4519; Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014; Pulling LC, 2003, CANCER RES, V63, P4842; Rajaee-Behbahani N, 2002, INT J CANCER, V98, P780, DOI 10.1002/ijc.10234; Ralhan R, 2000, CLIN CANCER RES, V6, P2440; Schottenfeld D., 1996, CANC EPIDEMIOLOGY PR, P637; Shen HB, 2001, CANCER RES, V61, P3321; Shen HB, 2002, INT J CANCER, V99, P869, DOI 10.1002/ijc.10413; Shen HB, 2002, CANCER LETT, V183, P123, DOI 10.1016/S0304-3835(02)00117-9; Soria JC, 2002, CANCER RES, V62, P351; Spitz MR, 2003, CANCER EPIDEM BIOMAR, V12, P689; Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849; Sturgis EM, 2002, ARCH OTOLARYNGOL, V128, P1084, DOI 10.1001/archotol.128.9.1084; Sturgis EM, 2000, CARCINOGENESIS, V21, P2219, DOI 10.1093/carcin/21.12.2219; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; SUEK KJ, 2004, J CLIN ONCOL; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3; Tourasse NJ, 2000, MOL BIOL EVOL, V17, P656, DOI 10.1093/oxfordjournals.molbev.a026344; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Toyooka S, 2004, INT J CANCER, V110, P462, DOI 10.1002/ijc.20125; Usadel H, 2002, CANCER RES, V62, P371; Varzim G, 2002, ORL J OTO-RHINO-LARY, V64, P206, DOI 10.1159/000058026; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016; Zhang ZD, 2004, CANCER EPIDEM BIOMAR, V13, P1081; Zheng YL, 2003, CARCINOGENESIS, V24, P269, DOI 10.1093/carcin/24.2.269; Zheng YX, 2001, CARCINOGENESIS, V22, P2005, DOI 10.1093/carcin/22.12.2005; Zheng YX, 2002, CANCER EPIDEM BIOMAR, V11, P640; Zheng YX, 2001, CARCINOGENESIS, V22, P1195, DOI 10.1093/carcin/22.8.1195; Zhu Y, 2002, CANCER, V95, P563, DOI 10.1002/cncr.10689; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	88	31	33	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0027-5107	1873-135X		MUTAT RES-FUND MOL M	Mutat. Res.-Fundam. Mol. Mech. Mutagen.	DEC 30	2005	592	1-2					102	118		10.1016/j.mrfmmm.2005.06.007			17	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	996UC	WOS:000234199400012	16023150				2022-02-25	
J	Boyle, P; Ferlay, J				Boyle, P; Ferlay, J			Mortality and survival in breast and colorectal cancer	NATURE CLINICAL PRACTICE ONCOLOGY			English	Editorial Material									Int Agcy Res Canc, Descript Epidemiol Unit, F-69372 Lyon, France		Boyle, P (corresponding author), Int Agcy Res Canc, Descript Epidemiol Unit, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610			Boyle P, 2005, ANN ONCOL, V16, P25, DOI 10.1093/annonc/mdi031; Boyle P, 2003, ANN ONCOL, V14, P323, DOI 10.1093/annonc/mdg062; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Gatta G, 1996, EUR J CANCER, V32A, P831, DOI 10.1016/0959-8049(95)00642-7; McLaren G, 1998, DEPRIVATION HLTH SCO; Sant M, 2003, ANN ONCOL, V14, pV61, DOI 10.1093/annonc/mdg754; SANT M, 1995, INT J CANCER, V63, P43, DOI 10.1002/ijc.2910630109; Thomson CS, 2001, J EPIDEMIOL COMMUN H, V55, P308, DOI 10.1136/jech.55.5.308; Welch HG, 2000, JAMA-J AM MED ASSOC, V283, P2975, DOI 10.1001/jama.283.22.2975	10	47	54	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1743-4254			NAT CLIN PRACT ONCOL	Nat. Clin. Pract. Oncol.	SEP	2005	2	9					424	425		10.1038/ncponc0288			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	962QQ	WOS:000231747700002	16264992				2022-02-25	
J	Cogliano, VJ; Grosse, Y; Baan, RA; Straif, K; Secretan, MB; El Ghissassi, F				Cogliano, VJ; Grosse, Y; Baan, RA; Straif, K; Secretan, MB; El Ghissassi, F		Working Grp Volume 88	Meeting report: summary of IARC monographs on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						1-tert-butoxy-2-propanol; 2-butoxyethanoL; carcinogen; formaldehyde; glycol ethers; hazard identification; MRCMonographs; leukemia; nasopharyngeal cancer; sinonasal cancer	PROTEIN CROSS-LINKS; OCCUPATIONAL-EXPOSURE; NASAL TUMORS; NASOPHARYNGEAL CARCINOMA; HYDROGEN-CHLORIDE; SINONASAL CANCER; RATS; MORTALITY; INHALATION; RISK	An international, interdisciplinary working group of expert scientists met in June 2004 to develop IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans (IARC Monographs) on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol. Each IARC Monograph includes a critical review of the pertinent scientific literature and an evaluation of an agent's potential to cause cancer in humans. After a thorough discussion of the epidemiologic, experimental, and other relevant data, the working group concluded that formaldehyde is carcinogenic to humans, based on sufficient evidence in humans and in experimental animals. In the epidemiologic studies, there was sufficient evidence that formaldehyde causes nasopharyngeal cancer, "strong but not sufficient" evidence of leukemia, and limited evidence of sinonasal cancer. The working group also concluded that 2-butoxyethanol and 1-tert-butoxy-2-propanol are not classifiable as to their carcinogenicity to humans, each having limited evidence in experimental animals and inadequate evidence in humans. These three evaluations and the supporting data will be-published as Volume 88 of the IARC Monographs.	Int Agcy Res Canc, Carcinogen Identificat & Evaluat, F-69372 Lyon, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, Carcinogen Identificat & Evaluat, 150 Cours Albert Thomas, F-69372 Lyon, France.	cogliano@iarc.fr	Hauptmann, Michael/AAQ-8420-2021; Goldberg, Marcel/I-7834-2012	Hauptmann, Michael/0000-0001-8539-0148; Goldberg, Marcel/0000-0002-6161-5880; Lauby-Secretan, Beatrice/0000-0001-6559-3351			*AG TOX SUBST DIS, 1999, TOX PROF FORM; ALBERT RE, 1982, J NATL CANCER I, V68, P597; [Anonymous], 1982, IARC Monogr Eval Carcinog Risk Chem Hum, V29, P345; Armstrong RW, 2000, INT J EPIDEMIOL, V29, P991, DOI 10.1093/ije/29.6.991; CASANOVA M, 1988, FOOD CHEM TOXICOL, V26, P715, DOI 10.1016/0278-6915(88)90071-3; Coggon D, 2003, JNCI-J NATL CANCER I, V95, P1608, DOI 10.1093/jnci/djg046; Cogliano VJ, 2004, ENVIRON HEALTH PERSP, V112, P1269, DOI 10.1289/ehp.6950; DALBEY WE, 1982, TOXICOLOGY, V24, P9, DOI 10.1016/0300-483X(82)90058-0; Doi AM, 2004, TOXICOLOGY, V199, P1, DOI 10.1016/j.tox.2003.12.020; FERON VJ, 1988, CANCER LETT, V39, P101, DOI 10.1016/0304-3835(88)90045-6; GALLI CL, 1983, FOOD CHEM TOXICOL, V21, P313, DOI 10.1016/0278-6915(83)90066-2; GIBSON JE, 1984, CONCEPTS TOXICOL, V1, P276; HALL A, 1991, AM J IND MED, V20, P83, DOI 10.1002/ajim.4700200108; HANSEN J, 1995, CANCER CAUSE CONTROL, V6, P354, DOI 10.1007/BF00051411; Hauptmann M, 2004, AM J EPIDEMIOL, V159, P1117, DOI 10.1093/aje/kwh174; Hauptmann M, 2003, JNCI-J NATL CANCER I, V95, P1615, DOI 10.1093/jnci/djg083; HAYES RB, 1990, AM J IND MED, V18, P641, DOI 10.1002/ajim.4700180603; Heck H.D.A., 1983, FORMALDEHYDE TOXICIT, P26; HECK HD, 1985, AM IND HYG ASSOC J, V46, P1, DOI 10.1080/15298668591394275; Hildesheim A, 2001, CANCER EPIDEM BIOMAR, V10, P1145; *IARC, IN PRESS IARC MON EV, V88; *IARC, 2005, PREAMBL IARC MON; International Agency for Research on Cancer (IARC), 1987, IARC MON EV CARC S7, V1; IVERSEN O H, 1986, Environment International, V12, P541, DOI 10.1016/0160-4120(86)90148-0; Jeffcoat AR, 1983, FORMALDEHYDE TOXICIT, P38; Kamata Eiichi, 1997, Journal of Toxicological Sciences, V22, P239; KERNS WD, 1983, CANCER RES, V43, P4382; KITAEVA LV, 1990, TSITOLOGIYA+, V32, P1212; LEVINE RJ, 1984, J OCCUP ENVIRON MED, V26, P740, DOI 10.1097/00043764-198410000-00014; LOGUE JN, 1986, J OCCUP ENVIRON MED, V28, P91; Luce D, 2002, CANCER CAUSE CONTROL, V13, P147, DOI 10.1023/A:1014350004255; Monticello TM, 1996, CANCER RES, V56, P1012; MORGAN KT, 1986, TOXICOL APPL PHARM, V82, P264, DOI 10.1016/0041-008X(86)90201-2; *NTP, 2003, 515 TR NTP; *NTP, 2000, 484 TR NTP; OLSEN JH, 1984, INT J CANCER, V34, P639, DOI 10.1002/ijc.2910340509; OLSEN JH, 1986, BRIT J IND MED, V43, P769; Pinkerton LE, 2004, OCCUP ENVIRON MED, V61, P193, DOI 10.1136/oem.2003.007476; RIETBROCK N, 1965, N-S ARCH EX PATH PH, V251, P189, DOI 10.1007/BF00420161; ROUSH GC, 1987, JNCI-J NATL CANCER I, V79, P1221; SELLAKUMAR AR, 1985, TOXICOL APPL PHARM, V81, P401, DOI 10.1016/0041-008X(85)90411-9; Shaham J, 1996, CARCINOGENESIS, V17, P121, DOI 10.1093/carcin/17.1.121; Shaham J, 2003, OCCUP ENVIRON MED, V60, P403, DOI 10.1136/oem.60.6.403; Soffritti M, 2002, ANN NY ACAD SCI, V982, P87, DOI 10.1111/j.1749-6632.2002.tb04926.x; SOFFRITTI M, 1989, TOXICOL IND HEALTH, V5, P699, DOI 10.1177/074823378900500510; STROUP NE, 1986, J NATL CANCER I, V77, P1217; TAKAHASHI M, 1986, JPN J CANCER RES, V77, P118; TIL HP, 1989, FOOD CHEM TOXICOL, V27, P77, DOI 10.1016/0278-6915(89)90001-X; VAUGHAN TL, 1986, INT J CANCER, V38, P677, DOI 10.1002/ijc.2910380510; Vaughan TL, 2000, OCCUP ENVIRON MED, V57, P376, DOI 10.1136/oem.57.6.376; WALRATH J, 1983, INT J CANCER, V31, P407, DOI 10.1002/ijc.2910310403; WALRATH J, 1984, CANCER RES, V44, P4638; WEST S, 1993, INT J CANCER, V55, P722, DOI 10.1002/ijc.2910550504; WHO, 1995, IARC MONOG EVAL CARC, V62, P217; *WHO, 2005, DECL INT WHO EXP; WOUTERSEN RA, 1989, J APPL TOXICOL, V9, P39, DOI 10.1002/jat.2550090108	56	236	249	4	41	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2005	113	9					1205	1208		10.1289/ehp.7542			4	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	961QU	WOS:000231677700040	16140628	Green Published, gold			2022-02-25	
J	Ohgaki, H; Baeza, N; Masuoka, J; Kleihues, P				Ohgaki, H; Baeza, N; Masuoka, J; Kleihues, P			Involvement of the WNT pathway in the development of medulloblastomas.	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Meeting Abstract	79th Annual Meeting of the American-Association-of-Neuropathologists	JUN 19-22, 2003	ORLANDO, FLORIDA	Amer Assoc Neuropatholgists					Int Agcy Res Canc, F-69008 Lyon 08, France									0	0	0	0	0	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2003	62	5				173	581	581					1	Clinical Neurology; Neurosciences; Pathology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	680CQ	WOS:000182959100183					2022-02-25	
J	Cardis, E				Cardis, E			Epidemiological data and radiation risk estimates	REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE			French	Article						ionising radiation; epidemiology; public health; radiation protection	EXTERNAL IONIZING-RADIATION; BRITISH-NUCLEAR-FUELS; CAUSE-SPECIFIC MORTALITY; ATOMIC-ENERGY-AUTHORITY; CANCER MORTALITY; THYROID-CANCER; OAK-RIDGE; OCCUPATIONAL EXPOSURE; CHERNOBYL ACCIDENT; SELLAFIELD PLANT	The results of several major epidemiology studies on populations with particular exposure to ionizing radiation should become available during the first years of the 21s' century. These studies are expected to provide answers to a number of questions concerning public health and radiation protection. Most of the populations concerned were accidentally exposed to radiation in ex-USSR or elsewhere or in a nuclear industrial context. The results will complete and test information on risk coming from studies among survivors of the Hiroshima and Nagasaki atomic bombs, particularly studies on the effects of low dose exposure and prolonged low-dose exposure, of different types of radiation, and environmental and host-related factors which could modify the risk of radiation-induced effects. These studies are thus important to assess the currently accepted scientific evidence on radiation protection for workers and the general population. In addition, supplementary information on radiation protection could be provided by formal comparisons and analyses combining data from populations with different types of exposure. Finally, in order to provide pertinent information for public health and radiation protection, future epidemiology studies should be targeted and designed to answer specific questions, concerning, for example, the risk for specific populations (children, patients, people with genetic predisposition). An integrated approach, combining epidemiology and studies on the mechanisms of radiation induction should provide particularly pertinent information.	Ctr Int Rech Canc, Unite Rayonnement & Canc, F-69372 Lyon 08, France		Cardis, E (corresponding author), Ctr Int Rech Canc, Unite Rayonnement & Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Cardis, Elisabeth/C-3904-2017	Cardis, Elisabeth/0000-0003-0999-6839			ACQUAVELLA JF, 1985, HEALTH PHYS, V48, P735, DOI 10.1097/00004032-198506000-00002; AKLEYEV AV, 1994, SCI TOTAL ENVIRON, V142, P1, DOI 10.1016/0048-9697(94)90066-3; Artalejo FR, 1997, OCCUP ENVIRON MED, V54, P202, DOI 10.1136/oem.54.3.202; Ashmore JP, 1998, AM J EPIDEMIOL, V148, P564, DOI 10.1093/oxfordjournals.aje.a009682; BALONOV M, 1996, 1 INT C EUR COMM BEL, P835; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; Beir V, 1990, EFFECTS POPULATIONS; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BINKS K, 1989, RADIATION PROTECTION - THEORY AND PRACTICE, P49; Buzunov VN, 1996, 1 INT C EUR COMM BEL, P871; CARDIS E, 1995, RADIAT RES, V142, P117, DOI 10.2307/3579020; CARDIS E, 1994, LANCET, V344, P1039; CARDIS E, 1999, RAD THYROID CANC, P395; CARDIS E, 1995, 25 IARC; Cardis E., 1996, 1 INT C EUR COMM BEL, P835; CARDIS E, 1996, P JOINT EU IAEA WHO; CARPENTER L, 1994, RADIAT RES, V138, P224, DOI 10.2307/3578592; Carpenter LM, 1998, BRIT J CANCER, V78, P1224, DOI 10.1038/bjc.1998.659; CHECKOWAY H, 1988, AM J EPIDEMIOL, V127, P255, DOI 10.1093/oxfordjournals.aje.a114801; CHECKOWAY H, 1985, BRIT J IND MED, V42, P525; CRAGLE DL, 1988, AM J IND MED, V14, P379, DOI 10.1002/ajim.4700140404; DOUGLAS AJ, 1994, BRIT J CANCER, V70, P1232, DOI 10.1038/bjc.1994.479; DUNCAN KP, 1970, HEALTH PHYS, V19, P285, DOI 10.1097/00004032-197008000-00007; DUPREE EA, 1987, SCAND J WORK ENV HEA, V13, P100, DOI 10.5271/sjweh.2074; *EP STUD GROUP NUC, 1997, J HLTH PHYS, V32, P173; FRASER P, 1993, BRIT J CANCER, V67, P615, DOI 10.1038/bjc.1993.113; GILBERT ES, 1993, RADIAT RES, V136, P408, DOI 10.2307/3578555; GILBERT ES, 1993, HEALTH PHYS, V64, P577, DOI 10.1097/00004032-199306000-00001; GILBERT ES, 1989, RADIAT RES, V120, P19, DOI 10.2307/3577633; GRIBBIN MA, 1993, RADIAT RES, V133, P375, DOI 10.2307/3578225; HADJIMICHAEL OC, 1983, J OCCUP ENVIRON MED, V25, P48, DOI 10.1097/00043764-198301000-00015; HOWE GR, 1987, AECL9442; ICRP, 1991, 60 ICRP; ILYIN L A, 1990, Journal of Radiological Protection, V10, P3, DOI 10.1088/0952-4746/10/1/001; Ivanov VK, 1997, RADIAT ENVIRON BIOPH, V36, P9, DOI 10.1007/s004110050049; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KENDALL GM, 1992, NRPBR251; KENIGSBERG YI, 1995, 9 YEARS CHERNOBYL ME, P61; KNEALE GW, 1981, BRIT J IND MED, V38, P156; KNEALE GW, 1993, AM J IND MED, V23, P371, DOI 10.1002/ajim.4700230302; Koshurnikova NA, 1998, RADIAT RES, V149, P366, DOI 10.2307/3579699; Koshurnikova NA, 1999, RADIAT RES, V152, P352, DOI 10.2307/3580220; Kreisheimer M, 2000, RADIAT RES, V154, P3, DOI 10.1667/0033-7587(2000)154[0003:LCMAMN]2.0.CO;2; LIKHTAREV IA, 1994, HEALTH PHYS, V66, P643, DOI 10.1097/00004032-199406000-00004; LIKHTAREV IA, 1995, NATURE, V375, P65; Loomis DP, 1996, AM J IND MED, V29, P131, DOI 10.1002/(SICI)1097-0274(199602)29:2<131::AID-AJIM3>3.0.CO;2-V; LUCKEY TD, 1994, INT J OCCUP MED TOX, V3, P175; Matanoski GM, 1991, HLTH EFFECTS LOW LEV; Muirhead C. R., 1999, Journal of Radiological Protection, V19, P3, DOI 10.1088/0952-4746/19/1/002; OKEANOV AE, 1996, 1 INT C EUR COMM BEL, P851; Omar RZ, 1999, BRIT J CANCER, V79, P1288, DOI 10.1038/sj.bjc.6690207; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; PITKEVICH VA, 1996, RAD BIOL RADIOECOL, V365, P747; POLEDNAK AP, 1981, J OCCUP ENVIRON MED, V23, P169; Richardson DB, 1999, INT J EPIDEMIOL, V28, P428, DOI 10.1093/ije/28.3.428; RINSKY RA, 1980, AM J EPIDEMIOL, V217, P55; Ritz B, 1999, EPIDEMIOLOGY, V10, P531, DOI 10.1097/00001648-199909000-00012; Ritz B, 1999, AM J IND MED, V35, P21; RON E, 1992, NATURE, V360, P113, DOI 10.1038/360113a0; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; ROZINSON R, 1995, NAG S RAD HUM HLTH, P127; Sali D, 1996, INT J CANCER, V67, P343; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; Stewart A, 1997, ENVIRON HEALTH PERSP, V105, P1519, DOI 10.2307/3433663; Stewart AM, 1996, OCCUP ENVIRON MED, V53, P225, DOI 10.1136/oem.53.4.225; STSJAZHKO VA, 1995, BMJ-BRIT MED J, V310, P801, DOI 10.1136/bmj.310.6982.801; TRONKO M, 1999, RAD THYROID CANC, P61; TSYB AF, 2000, RADIAT RES, V154, P3; UNSCEAR, 2000, 2000 REP; *UNSCEAR, 1993, AD STIM RESP RAD CEL; UNSCEAR, 2010, SOURC EFF ION RAD; Voelz GL, 1997, HEALTH PHYS, V73, P611, DOI 10.1097/00004032-199710000-00004; WIGGS LD, 1991, HEALTH PHYS, V61, P71, DOI 10.1097/00004032-199107000-00007; WIGGS LD, 1991, J OCCUP ENVIRON MED, V33, P632; WILKINSON GS, 1987, AM J EPIDEMIOL, V125, P231, DOI 10.1093/oxfordjournals.aje.a114523; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; YOSHIMOTO Y, 1990, JAMA-J AM MED ASSOC, V264, P596, DOI 10.1001/jama.264.5.596; ZARIDZE DG, 1994, INT J CANCER, V59, P471, DOI 10.1002/ijc.2910590407	79	0	0	0	2	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0398-7620			REV EPIDEMIOL SANTE	Rev. Epidemiol. Sante Publique	JAN	2002	50	1					27	39					13	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	529KJ	WOS:000174298400004	11938114				2022-02-25	
J	Franceschi, S				Franceschi, S			HIV and cancer in Africa	INTERNATIONAL JOURNAL OF CANCER			English	Editorial Material							NON-HODGKINS-LYMPHOMA; AIDS; SPECTRUM; INFECTION; RISK		Int Agcy Res Canc, Unite Field & Intervent Studies, F-69372 Lyon 8, France		Franceschi, S (corresponding author), Int Agcy Res Canc, Unite Field & Intervent Studies, 150 Cours Albert Thomas, F-69372 Lyon 8, France.		franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Franceschi S, 1999, INT J CANCER, V83, P481, DOI 10.1002/(SICI)1097-0215(19991112)83:4<481::AID-IJC8>3.3.CO;2-X; Franceschi S, 1998, BRIT J CANCER, V78, P966, DOI 10.1038/bjc.1998.610; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Grulich AE, 1999, AIDS, V13, P839, DOI 10.1097/00002030-199905070-00014; Newton R, 2001, INT J CANCER, V92, P622, DOI 10.1002/1097-0215(20010601)92:5&lt;622::AID-IJC1256&gt;3.0.CO;2-K; Serraino D, 1999, AIDS, V13, P2589, DOI 10.1097/00002030-199912240-00013; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; Sitas F, 2000, INT J CANCER, V88, P489, DOI 10.1002/1097-0215(20001101)88:3&lt;489::AID-IJC25&gt;3.0.CO;2-Q; Wabinga HR, 2000, BRIT J CANCER, V82, P1585, DOI 10.1054/bjoc.1999.1071	10	2	2	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0020-7136			INT J CANCER	Int. J. Cancer	JUN 1	2001	92	5					621	621		10.1002/1097-0215(20010601)92:5<621::AID-IJC1302>3.0.CO;2-Z			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	427RZ	WOS:000168420400001	11340562	Bronze			2022-02-25	
J	Chazotte-Aubert, L; Pluquet, O; Hainaut, P; Ohshima, H				Chazotte-Aubert, L; Pluquet, O; Hainaut, P; Ohshima, H			Nitric oxide prevents gamma-radiation-induced cell cycle arrest by impairing p53 function in MCF-7 cells	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						apoptosis; Bax; cell cycle arrest; DNA binding; irradiation; MCF-7 cells; nitric oxide (NO); p53; p21(waf-1); S-nitrosoglutathione (GSNO)	WILD-TYPE P53; SEQUENCE-SPECIFIC DNA; ULCERATIVE-COLITIS; SYNTHASE ACTIVITY; CROHNS-DISEASE; APOPTOSIS; EXPRESSION; BAX; PROTEIN; BINDING	We previously reported that nitric oxide (NO) released from S-nitrosoglutathione induces conformational change of the p53 tumor-suppressor protein that impairs its DNA-binding activity in vitro. We now demonstrate that MCF-7 cells preincubated in the presence of 0.5-1 mM S-nitrosoglutathione for 4 h before gamma -irradiation failed to arrest in the G1 phase of the cell cycle, whereas those gamma -irradiated without S-nitrosoglutathione exhibited a normal cell cycle arrest. The S-nitrosoglutathione-treated cells did not express the p53 target gene p21(waf-1) after gamma -irradiation, although p21(waf-1) was strongly expressed in cells irradiated in the absence of S-nitrosoglutathione. These results strongly suggest that NO impairs the function of p53 possibly via conformational change and/or amino acid modifications. On the other hand, cells incubated for 16 h in the presence of 1 mM S-nitrosoglutathione underwent apoptosis with accumulation of the pro-apoptotic protein Bax. This Bax accumulation, however, was shown to occur via a p53-independent pathway. (C) 2001 Academic Press.	Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon 08, France; Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohshima@iarc.fr	Ohshima, Hiroshi/E-8044-2010; Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			BAE IS, 1995, CANCER RES, V55, P2387; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOUGHTONSMITH NK, 1993, LANCET, V342, P338, DOI 10.1016/0140-6736(93)91476-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Calmels S, 1997, CANCER RES, V57, P3365; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ho YS, 1999, MOL CARCINOGEN, V26, P201, DOI 10.1002/(SICI)1098-2744(199911)26:3<201::AID-MC9>3.3.CO;2-B; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; MESSMER UK, 1994, FEBS LETT, V355, P23; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718; Radi R, 1996, CHEM RES TOXICOL, V9, P828, DOI 10.1021/tx950176s; Sandau K, 1997, KIDNEY INT, V52, P378, DOI 10.1038/ki.1997.344; Siles E, 1996, BRIT J CANCER, V73, P581, DOI 10.1038/bjc.1996.101; Tamatani M, 1998, CELL DEATH DIFFER, V5, P911, DOI 10.1038/sj.cdd.4400439; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wink DA, 1997, J BIOL CHEM, V272, P11147; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	33	15	16	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	MAR 2	2001	281	3					766	771		10.1006/bbrc.2001.4423			6	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	409XJ	WOS:000167410700025	11237724				2022-02-25	
J	Kozlakidis, Z				Kozlakidis, Zisis			The Experts Speak on Biobank Education Expert Response	BIOPRESERVATION AND BIOBANKING			English	Editorial Material									[Kozlakidis, Zisis] IARC, Lab Serv & Biobank Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Kozlakidis, Z (corresponding author), IARC, Lab Serv & Biobank Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	kozlakidisz@iarc.fr						0	0	0	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1947-5535	1947-5543		BIOPRESERV BIOBANK	Biopreserv. Biobank.	FEB 1	2020	18	1					16	16					1	Cell Biology; Chemistry, Applied; Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Chemistry; Medical Laboratory Technology	KM7SB	WOS:000514339200013					2022-02-25	
J	Nagtegaal, ID; Odze, RD; Klimstra, D; Paradis, V; Rugge, M; Schirmacher, P; Washington, KM; Carneiro, F; Cree, IA				Nagtegaal, Iris D.; Odze, Robert D.; Klimstra, David; Paradis, Valerie; Rugge, Massimo; Schirmacher, Peter; Washington, Kay M.; Carneiro, Fatima; Cree, Ian A.		WHO Classification Tumours Edito	The 2019 WHO classification of tumours of the digestive system	HISTOPATHOLOGY			English	Editorial Material									[Nagtegaal, Iris D.; Odze, Robert D.; Klimstra, David; Paradis, Valerie; Rugge, Massimo; Schirmacher, Peter; Washington, Kay M.; Carneiro, Fatima; Cree, Ian A.; WHO Classification Tumours Edito] World Hlth Org, Int Agcy Res Canc, Lyon, France		Nagtegaal, ID (corresponding author), World Hlth Org, Int Agcy Res Canc, Lyon, France.		Nagtegaal, Iris D/A-2448-2014; Carneiro, Fatima/AAV-8677-2021	Nagtegaal, Iris D/0000-0003-0887-4127; Carneiro, Fatima/0000-0002-1964-1006			Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Bosman FT, 2010, WHO CLASSIFICATION T, V3; Kloppel G., 2017, WHO CLASSIFICATION T, V10; Rindi G, 2018, MODERN PATHOL, V31, P1770, DOI 10.1038/s41379-018-0110-y	4	559	610	8	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0309-0167	1365-2559		HISTOPATHOLOGY	Histopathology	JAN	2020	76	2					182	188		10.1111/his.13975		NOV 2019	7	Cell Biology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Pathology	OB9MT	WOS:000496028500001	31433515	Green Published, hybrid			2022-02-25	
J	Loomis, D; Guha, N; Hall, AL; Straif, K				Loomis, Dana; Guha, Neela; Hall, Amy L.; Straif, Kurt			Identifying occupational carcinogens: an update from the IARC Monographs	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Review								The recognition of occupational carcinogens is important for primary prevention, compensation and surveillance of exposed workers, as well as identifying causes of cancer in the general population. This study updates previously published lists of known occupational carcinogens while providing additional information on cancer type, exposure scenarios and routes, and discussing trends in the identification of carcinogens over time. Data were extracted from International Agency for Research on Cancer (IARC) Monographs covering the years 1971-2017, using specific criteria to ensure occupational relevance and provide high confidence in the causality of observed exposure-disease associations. Selected agents were substances, mixtures or types of radiation classified in IARC Group 1 with 'sufficient evidence of carcinogenicity' in humans from studies of exposed workers and evidence of occupational exposure documented in the pertinent monograph. The number of known occupational carcinogens has increased over time: 47 agents were identified as known occupational carcinogens in 2017 compared with 28 in 2004. These estimates are conservative and likely underestimate the number of carcinogenic agents present in workplaces. Exposure to these agents causes a wide range of cancers; cancers of the lung and other respiratory sites, followed by skin, account for the largest proportion. The dominant routes of exposure are inhalation and dermal contact. Important progress has been made in identifying occupational carcinogens; nevertheless, there is an ongoing need for research on the causes of work-related cancer. Most workplace exposures have not been evaluated for their carcinogenic potential due to inadequate epidemiologic evidence and a paucity of quantitative exposure data.	[Loomis, Dana; Guha, Neela; Hall, Amy L.; Straif, Kurt] Int Agcy Res Canc, IARC Monographs Programme, Lyon, France		Loomis, D (corresponding author), Int Agcy Res Canc, F-69372 Lyon, France.	dploomis@unr.edu	Guha, Neela/AAG-3989-2021; Loomis, Dana/AAE-3988-2019	Guha, Neela/0000-0003-3991-4662; Loomis, Dana/0000-0003-3297-5200; Hall, Amy/0000-0003-1502-2694			Ahouangninou C., 2012, Journal of Environmental Protection, V3, P241, DOI 10.4236/jep.2012.33030; [Anonymous], 1990, IARC Sci Publ, P1; [Anonymous], 2011, GLOB SCI COLL 21 CEN; [Anonymous], 2012, IARC MON EV CARC R C, V100C; Bornmann L, 2015, J ASSOC INF SCI TECH, V66, P2215, DOI 10.1002/asi.23329; BROWN J R, 1957, Br J Ind Med, V14, P68; Checkoway H, 2004, RES METHODS OCCUPATI, V5; Cogliano VJ, 2010, LANCET ONCOL, V11, P602, DOI 10.1016/S1470-2045(09)70363-8; Cogliano VJ, 2011, JNCI-J NATL CANCER I, V103, P1827, DOI 10.1093/jnci/djr483; Doll R, 1981, THE CAUSES OF CANC; Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; Guha N, 2017, LANCET ONCOL, V18, P581, DOI 10.1016/S1470-2045(17)30255-3; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; IARC, 2012, IARC MON EV CARC R D; IARC, 2006, IARC MON EV CARC RIS; IARC, 2017, AG CLASS IARC MON, V1-123; IARC, 2010, IARC MONOGRAPHS EVAL, V92; IARC, 2012, IARC MON EV CARC R F, V100F; Jeyaratnam J., 1994, V129, P23; Kromhout H, 2016, ANN OCCUP HYG, V60, P403, DOI 10.1093/annhyg/mev096; Loomis D, 2013, OCCUP ENVIRON MED, V70, P287, DOI 10.1136/oemed-2013-101514; Loomis D, 2012, OCCUP ENVIRON MED, V69, P609, DOI 10.1136/oemed-2012-101072; Lucchini RG, 2014, ANN GLOB HEALTH, V80, P251, DOI 10.1016/j.aogh.2014.09.006; Lynge E, 2009, OCCUP ENVIRON MED, V66, P428, DOI 10.1136/oem.2006.027086; Mabe M, 2001, SCIENTOMETRICS, V51, P147, DOI 10.1023/A:1010520913124; Negatu B, 2016, ANN OCCUP HYG, V60, P551, DOI 10.1093/annhyg/mew004; NIOSH National institute for occupational safety and health, 2017, NIOSH POCK GUID CHEM; Siemiatycki J, 2004, ENVIRON HEALTH PERSP, V112, P1447, DOI 10.1289/ehp.7047; Smith MT, 2016, ENVIRON HEALTH PERSP, V124, P713, DOI 10.1289/ehp.1509912; Takala J, 2015, IND HEALTH, V53, P307, DOI 10.2486/indhealth.53-307; Wilson MP, 2009, ENVIRON HEALTH PERSP, V117, P1202, DOI 10.1289/ehp.0800404	31	53	57	4	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	AUG	2018	75	8					593	603		10.1136/oemed-2017-104944			11	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	GR3EU	WOS:000442473600008	29769352	hybrid, Green Published	Y	N	2022-02-25	
J	Matejcic, M; Gunter, MJ; Ferrari, P				Matejcic, Marco; Gunter, Marc J.; Ferrari, Pietro			Alcohol metabolism and oesophageal cancer: a systematic review of the evidence	CARCINOGENESIS			English	Review							SQUAMOUS-CELL CARCINOMA; ALDEHYDE DEHYDROGENASE-2 GENOTYPES; GENOME-WIDE ASSOCIATION; MENDELIAN RANDOMIZATION; GENETIC POLYMORPHISMS; CIGARETTE-SMOKING; DNA METHYLATION; TOBACCO SMOKING; INTESTINAL PERMEABILITY; ACETALDEHYDE METABOLISM	Alcohol is a major risk factor for oesophageal squamous cell carcinoma (OSCC), the most prevalent histological subtype of oesophageal cancer (OC) worldwide. The metabolism of alcohol is regulated by specific enzymes whose activity and expression is influenced by genetic polymorphisms. We conducted a systematic review of current epidemiological evidence of the relationship between alcohol intake and OC risk, including the role of tobacco smoking and functional polymorphisms of alcohol dehydrogenases (ADHs) and aldehyde dehydrogenases (ALDHs). Potential biological mechanisms underlying oesophageal carcinogenesis are also discussed. Frequency and intensity of alcohol intake have been consistently associated with an increased risk of OSCC in regions with low and high incidence of the disease. The highest risk was reported among tobacco smokers, whereas the association between alcohol and OSCC risk was weak in the absence of tobacco use. The ADH1B, ADH1C and ALDH2 gene polymorphisms influence the risk of OSCC through modulation of acetaldehyde metabolism and propensity to alcohol intake. These functional variants may be suitable proxies of alcohol exposure for use in Mendelian randomization studies if complemented by reported alcohol intake data. Recent epidemiological and experimental studies investigating the role of alcohol consumption in OC development have implicated the microbiome as a new promising avenue for research, which entail novel potential mechanisms of alcohol-related oesophageal carcinogenesis. Microbial communities associated with alcohol consumption might be used as biomarkers to raise the potential of intervening among susceptible individuals.	[Matejcic, Marco; Gunter, Marc J.; Ferrari, Pietro] WHO, Int Agcy Res Canc, Nutr Epidemiol Grp, 150 Cours Albert, F-69372 Lyon 08, France		Matejcic, M (corresponding author), WHO, Int Agcy Res Canc, Nutr Epidemiol Grp, 150 Cours Albert, F-69372 Lyon 08, France.	matejcicm@fellows.iarc.fr	Gunter, Marc/AAP-8621-2020		Postdoctoral Fellowship from the International Agency for Research on Cancer; European Commission FP7 Marie Curie Actions-People-Cofunding of regional, national, and international programs (COFUND)	This work was supported by a Postdoctoral Fellowship from the International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions-People-Cofunding of regional, national, and international programs (COFUND).	Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649; Allen JP, 2003, ALCOHOL CLIN EXP RES, V27, P1667, DOI 10.1097/01.ALC.0000091224.78880.47; Allen NE, 2009, JNCI-J NATL CANCER I, V101, P296, DOI 10.1093/jnci/djn514; [Anonymous], 2017, HGNC DAT HUM GEN NAM; Aroor AR, 2004, LIFE SCI, V74, P2339, DOI 10.1016/j.lfs.2003.11.001; Assi N, 2015, MUTAGENESIS, V30, P743, DOI 10.1093/mutage/gev045; Auer PL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0138-2; Baba Y, 2013, SURG TODAY, V43, P1355, DOI 10.1007/s00595-012-0451-y; Bagnardi V, 2015, BRIT J CANCER, V112, P580, DOI 10.1038/bjc.2014.579; Blackett KL, 2013, ALIMENT PHARM THER, V37, P1084, DOI 10.1111/apt.12317; BODE JC, 1984, HEPATO-GASTROENTEROL, V31, P30; Boonyaphiphat P, 2002, CANCER LETT, V186, P193, DOI 10.1016/S0304-3835(02)00354-3; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; Brauner A, 2010, SCAND J GASTROENTERO, V45, P893, DOI 10.3109/00365521003734133; Brooks PJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000050; Brooks PJ, 2005, ALCOHOL, V35, P187, DOI 10.1016/j.alcohol.2005.03.009; Bye H, 2011, CARCINOGENESIS, V32, P1855, DOI 10.1093/carcin/bgr211; Castellsague X, 1999, INT J CANCER, V82, P657, DOI 10.1002/(SICI)1097-0215(19990827)82:5&lt;657::AID-IJC7&gt;3.0.CO;2-C; CAYUELA A, 1991, J EPIDEMIOL COMMUN H, V45, P273, DOI 10.1136/jech.45.4.273; Chen HJ, 2005, HUM MUTAT, V25, P150, DOI 10.1002/humu.20127; Chen YF, 2011, HEPATOLOGY, V54, P562, DOI 10.1002/hep.24423; Chen YJ, 2006, INT J CANCER, V119, P2827, DOI 10.1002/ijc.22199; Chou WY, 1999, ALCOHOL CLIN EXP RES, V23, P963, DOI 10.1111/j.1530-0277.1999.tb04213.x; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; Cui R, 2009, GASTROENTEROLOGY, V137, P1768, DOI 10.1053/j.gastro.2009.07.070; Cunningham-Rundles S, 2002, NUTR REV, V60, pS68, DOI 10.1301/00296640260130777; Ding JH, 2010, J HUM GENET, V55, P97, DOI 10.1038/jhg.2009.129; Edenberg HJ, 2007, ALCOHOL RES HEALTH, V30, P5; Engen PA, 2015, ALCOHOL RES-CURR REV, V37, P223; ENOMOTO N, 1991, ALCOHOL CLIN EXP RES, V15, P141, DOI 10.1111/j.1530-0277.1991.tb00532.x; Fan YH, 2008, NUTR CANCER, V60, P354, DOI 10.1080/01635580701883011; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ferrari P, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005245; Fillmore KM, 2007, ANN EPIDEMIOL, V17, pS16, DOI 10.1016/j.annepidem.2007.01.005; FINLAY IG, 1982, THORAX, V37, P181, DOI 10.1136/thx.37.3.181; Freedman ND, 2007, AM J EPIDEMIOL, V165, P1424, DOI 10.1093/aje/kwm051; FUKUI H, 1991, J HEPATOL, V12, P162, DOI 10.1016/0168-8278(91)90933-3; Gao Y, 2013, HUM GENET, V132, P649, DOI 10.1007/s00439-013-1276-5; GARRO AJ, 1986, ALCOHOL CLIN EXP RES, V10, pS73, DOI 10.1111/j.1530-0277.1986.tb05184.x; Gill K, 1999, J STUD ALCOHOL, V60, P149, DOI 10.15288/jsa.1999.60.149; Gonzalez FJ, 2005, MUTAT RES-FUND MOL M, V569, P101, DOI 10.1016/j.mrfmmm.2004.04.021; Hashibe M, 2006, CANCER EPIDEM BIOMAR, V15, P696, DOI 10.1158/1055-9965.EPI-05-0710; Hashibe M, 2008, NAT GENET, V40, P707, DOI 10.1038/ng.151; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; Hashibe M, 2007, INT J CANCER, V120, P1518, DOI 10.1002/ijc.22507; Hedrick VE, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-109; HELANDER A, 1991, ALCOHOL CLIN EXP RES, V15, P1, DOI 10.1111/j.1530-0277.1991.tb00510.x; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Homann N, 2006, INT J CANCER, V118, P1998, DOI 10.1002/ijc.21583; Homann N, 1997, CARCINOGENESIS, V18, P1739, DOI 10.1093/carcin/18.9.1739; Homann N, 2001, ORAL ONCOL, V37, P153, DOI 10.1016/S1368-8375(00)00076-2; Husemoen LLN, 2008, ALCOHOL CLIN EXP RES, V32, P1984, DOI 10.1111/j.1530-0277.2008.00780.x; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010, IARC MONOG EVAL CARC, V96, P1; Jackson Brian, 2011, Human Genomics, V5, P283; Kaakoush NO, 2015, CLIN MICROBIOL REV, V28, P687, DOI 10.1128/CMR.00006-15; Kamangar F, 2009, GASTROENTEROL CLIN N, V38, P27, DOI 10.1016/j.gtc.2009.01.004; Kang G, 2014, ALCOHOL CLIN EXP RES, V38, P1502, DOI 10.1111/acer.12427; Keshavarzian A, 1999, AM J GASTROENTEROL, V94, P200; Kimura Y, 2009, ALCOHOL ALCOHOLISM, V44, P261, DOI 10.1093/alcalc/agn123; Klatsky AL, 2001, AM J CLIN NUTR, V74, P279; Kumagai N, 2013, MOL CLIN ONCOL, V1, P811, DOI 10.3892/mco.2013.142; Lagergren J, 2000, INT J CANCER, V85, P340; LAU WF, 1981, AUST NZ J SURG, V51, P52, DOI 10.1111/j.1445-2197.1981.tb05905.x; Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034; Leclercq S, 2014, BIOL PSYCHIAT, V76, P725, DOI 10.1016/j.biopsych.2014.02.003; Lee CH, 2005, INT J CANCER, V113, P475, DOI 10.1002/ijc.20619; Lee CH, 2008, INT J CANCER, V122, P1347, DOI 10.1002/ijc.23264; Lee CH, 2007, EUR J CANCER, V43, P1188, DOI 10.1016/j.ejca.2007.01.039; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Lewis SJ, 2005, CANCER EPIDEM BIOMAR, V14, P1967, DOI 10.1158/1055-9965.EPI-05-0196; Li DP, 2008, CLIN CHEM LAB MED, V46, P323, DOI 10.1515/CCLM.2008.073; Li TK, 2001, ALCOHOL CLIN EXP RES, V25, P136, DOI 10.1097/00000374-200101000-00020; Lind Penelope A., 2008, Human Genomics, V3, P24; Lindblad M, 2005, CANCER CAUSE CONTROL, V16, P285, DOI 10.1007/s10552-004-3485-7; Linhart K, 2014, REDOX BIOL, V3, P56, DOI 10.1016/j.redox.2014.08.009; Linneberg A, 2010, CLIN EXP ALLERGY, V40, P123, DOI 10.1111/j.1365-2222.2009.03398.x; Liu N, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-130; Liu X, 2014, BRIT J CANCER, V110, P2785, DOI 10.1038/bjc.2014.172; Long E, 2014, THER ADV GASTROENTER, V7, P247, DOI 10.1177/1756283X14538689; Ma K, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0210-9; Macfarlane S, 2007, CLIN INFECT DIS, V45, P29, DOI 10.1086/518578; Maffei F, 2000, MUTAGENESIS, V15, P517, DOI 10.1093/mutage/15.6.517; Maly IP, 1999, HISTOCHEM CELL BIOL, V111, P391, DOI 10.1007/s004180050372; Matsuda T, 1998, NUCLEIC ACIDS RES, V26, P1769, DOI 10.1093/nar/26.7.1769; Matsuo K, 2001, CARCINOGENESIS, V22, P913, DOI 10.1093/carcin/22.6.913; Matsuo K, 2007, HUM MUTAT, V28, P506, DOI 10.1002/humu.20477; McKay JD, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001333; Melhado Rachel E, 2010, Cancers (Basel), V2, P1379, DOI 10.3390/cancers2031379; Millonig G, 2011, INT J CANCER, V128, P533, DOI 10.1002/ijc.25604; Moore S, 2007, J STUD ALCOHOL DRUGS, V68, P192, DOI 10.15288/jsad.2007.68.192; Morita M, 2005, FRONT BIOSCI-LANDMRK, V10, P2319, DOI 10.2741/1700; Mufti SI, 1998, CANCER DETECT PREV, V22, P195, DOI 10.1046/j.1525-1500.1998.00023.x; Munafo MR, 2010, BRIT J PSYCHIAT, V196, P425, DOI 10.1192/bjp.bp.109.074880; Mutlu E, 2009, ALCOHOL CLIN EXP RES, V33, P1836, DOI 10.1111/j.1530-0277.2009.01022.x; Mutlu EA, 2012, AM J PHYSIOL-GASTR L, V302, pG966, DOI 10.1152/ajpgi.00380.2011; Narikiyo M, 2004, CANCER SCI, V95, P569, DOI 10.1111/j.1349-7006.2004.tb02488.x; Nasrollahzadeh D, 2015, SCI REP-UK, V5, DOI 10.1038/srep08820; Osier MV, 2002, AM J HUM GENET, V71, P84, DOI 10.1086/341290; Otsuka M, 1999, ALCOHOL, V17, P119, DOI 10.1016/S0741-8329(98)00042-1; Oze I, 2009, CANCER EPIDEM BIOMAR, V18, P3097, DOI 10.1158/1055-9965.EPI-09-0499; Pandeya N, 2008, AM J EPIDEMIOL, V168, P105, DOI 10.1093/aje/kwn091; Pandeya N, 2009, GASTROENTEROLOGY, V136, P1215, DOI 10.1053/j.gastro.2008.12.052; Parlesak A, 2000, J HEPATOL, V32, P742, DOI 10.1016/S0168-8278(00)80242-1; Pasala S, 2015, ALCOHOL RES-CURR REV, V37, P185; Pei ZH, 2004, P NATL ACAD SCI USA, V101, P4250, DOI 10.1073/pnas.0306398101; Peng Giia-Sheun, 2009, Human Genomics, V3, P121; Peterson K, 2004, ALCOHOL RES HEALTH, V28, P30; Philibert Robert A., 2012, Frontiers in Genetics, V3, P54, DOI 10.3389/fgene.2012.00054; Pochareddy S, 2011, CHEM-BIOL INTERACT, V191, P38, DOI 10.1016/j.cbi.2010.12.007; Poschl G, 2004, ALCOHOL ALCOHOLISM, V39, P155, DOI 10.1093/alcalc/agh057; Prabhu A, 2014, AM J GASTROENTEROL, V109, P821, DOI 10.1038/ajg.2014.71; Rao RK, 2004, AM J PHYSIOL-GASTR L, V286, pG881, DOI 10.1152/ajpgi.00006.2004; Room R, 2004, BIOMED PHARMACOTHER, V58, P111, DOI 10.1016/j.biopha.2003.12.003; Salaspuro MP, 2003, CRIT REV CL LAB SCI, V40, P183, DOI 10.1080/713609333; Salaspuro V, 2004, INT J CANCER, V111, P480, DOI 10.1002/ijc.20293; Salujha S K, 2014, Ind Psychiatry J, V23, P44, DOI 10.4103/0972-6748.144956; Schatzkin A, 2004, JNCI-J NATL CANCER I, V96, P1564, DOI 10.1093/jnci/djh329; Schnabl B, 2014, GASTROENTEROLOGY, V146, P1513, DOI 10.1053/j.gastro.2014.01.020; Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610; Seitz HK, 2007, TRANSL RES, V149, P293, DOI 10.1016/j.trsl.2006.12.002; Seitz HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191; Sherva R, 2009, ALCOHOL CLIN EXP RES, V33, P848, DOI 10.1111/j.1530-0277.2009.00904.x; Shin NR, 2015, TRENDS BIOTECHNOL, V33, P496, DOI 10.1016/j.tibtech.2015.06.011; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Song JW, 2010, PLAST RECONSTR SURG, V126, P2234, DOI 10.1097/PRS.0b013e3181f44abc; Spence JP, 2003, ALCOHOL CLIN EXP RES, V27, P1389, DOI 10.1097/01.ALC.0000087086.50089.59; Steevens J, 2010, GUT, V59, P39, DOI 10.1136/gut.2009.191080; Takeshita T, 1996, HUM GENET, V97, P409, DOI 10.1007/BF02267057; Tanaka F, 2010, GUT, V59, P1457, DOI 10.1136/gut.2009.205724; Tappenden KA, 2007, J AM COLL NUTR, V26, p679S, DOI 10.1080/07315724.2007.10719647; Terry MB, 2007, CANCER CAUSE CONTROL, V18, P1039, DOI 10.1007/s10552-007-9046-0; The World Health Organization, 2010, INT CLASS DIS; THOMASSON HR, 1994, ALCOHOL CLIN EXP RES, V18, P640, DOI 10.1111/j.1530-0277.1994.tb00923.x; Thrift AP, 2014, AM J GASTROENTEROL, V109, P1586, DOI 10.1038/ajg.2014.206; Toh Y, 2010, INT J CLIN ONCOL, V15, P135, DOI 10.1007/s10147-010-0057-6; Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616; TUYNS AJ, 1977, B CANCER, V64, P45; Varela-Rey M, 2013, ALCOHOL RES-CURR REV, V35, P25; Wall TL, 1997, ALCOHOL ALCOHOLISM, V32, P129; Wang J, 2014, COMP BIOCHEM PHYS D, V11, P1, DOI 10.1016/j.cbd.2014.05.001; Wexler HM, 2007, CLIN MICROBIOL REV, V20, P593, DOI 10.1128/CMR.00008-07; Wu AH, 2001, CANCER CAUSE CONTROL, V12, P721, DOI 10.1023/A:1011290704728; Wu C, 2012, NAT GENET, V44, P1090, DOI 10.1038/ng.2411; Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849; Wu M, 2013, INT J CANCER, V132, P1868, DOI 10.1002/ijc.27803; Wu M, 2011, CANCER CAUSE CONTROL, V22, P649, DOI 10.1007/s10552-011-9737-4; Xiao Q, 1996, J CLIN INVEST, V98, P2027, DOI 10.1172/JCI119007; Yan AW, 2011, HEPATOLOGY, V53, P96, DOI 10.1002/hep.24018; Yang LY, 2009, GASTROENTEROLOGY, V137, P588, DOI 10.1053/j.gastro.2009.04.046; YIN SJ, 1993, ALCOHOL CLIN EXP RES, V17, P376, DOI 10.1111/j.1530-0277.1993.tb00779.x; Yokoyama A, 2006, ALCOHOL CLIN EXP RES, V30, P491, DOI 10.1111/j.1530-0277.2006.00053.x; Yokoyama A, 2005, ALCOHOL, V35, P175, DOI 10.1016/j.alcohol.2005.04.003; Yokoyama A, 1998, CARCINOGENESIS, V19, P1383, DOI 10.1093/carcin/19.8.1383; Yokoyama A, 2002, CARCINOGENESIS, V23, P1851, DOI 10.1093/carcin/23.11.1851; Yokoyama A, 1996, CANCER EPIDEM BIOMAR, V5, P99; Yokoyama A, 2001, CARCINOGENESIS, V22, P433, DOI 10.1093/carcin/22.3.433; Yokoyama A, 1999, ALCOHOL CLIN EXP RES, V23, P1705, DOI 10.1111/j.1530-0277.1999.tb04064.x; Yokoyama A, 2007, INT J CANCER, V121, P1047, DOI 10.1002/ijc.22792; Yokoyama T, 2003, CANCER EPIDEM BIOMAR, V12, P1227; Yu GQ, 2014, CANCER EPIDEM BIOMAR, V23, P735, DOI 10.1158/1055-9965.EPI-13-0855; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Yu HS, 2010, CHEM-BIOL INTERACT, V188, P367, DOI 10.1016/j.cbi.2010.08.005; Zakhari S, 2006, ALCOHOL RES HEALTH, V29, P245; Zambon P, 2000, INT J CANCER, V86, P144, DOI 10.1002/(SICI)1097-0215(20000401)86:1<144::AID-IJC23>3.0.CO;2-B; Zhang L, 2014, TUMOR BIOL, V35, P4705, DOI 10.1007/s13277-014-1616-7; Zhao TT, 2015, ONCOTARGETS THER, V8, P649, DOI 10.2147/OTT.S76526; Znaor A, 2003, INT J CANCER, V105, P681, DOI 10.1002/ijc.11114	168	39	39	4	26	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0143-3334	1460-2180		CARCINOGENESIS	Carcinogenesis	SEP	2017	38	9					859	872		10.1093/carcin/bgx067			14	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	FF9NK	WOS:000409343000001	28645180	Bronze			2022-02-25	
J	Plummer, M; de Martel, C; Franceschi, S				Plummer, Martyn; de Martel, Catherine; Franceschi, Silvia			Global burden of cancers attributable to liver flukes	LANCET GLOBAL HEALTH			English	Letter							CHOLANGIOCARCINOMA; CLONORCHIASIS; EPIDEMIOLOGY		[Plummer, Martyn; de Martel, Catherine; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Plummer, M (corresponding author), Int Agcy Res Canc, F-69372 Lyon 08, France.	plummerm@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497			Furst T, 2012, LANCET INFECT DIS, V12, P210, DOI 10.1016/S1473-3099(11)70294-8; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Qian MB, 2012, INFECT DIS POVERTY, V1, DOI 10.1186/2049-9957-1-4; Randi G, 2006, INT J CANCER, V118, P1591, DOI 10.1002/ijc.21683; Shin HR, 2010, ASIAN PAC J CANCER P, V11, P1159; Shin HR, 2010, J KOREAN MED SCI, V25, P1011, DOI 10.3346/jkms.2010.25.7.1011	6	2	2	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2214-109X			LANCET GLOB HEALTH	Lancet Glob. Health	FEB	2017	5	2					E140	E140		10.1016/S2214-109X(16)30293-5			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	EN9SW	WOS:000396340900014	28104178	gold			2022-02-25	
S	Herceg, Z		Roach, RC; Wagner, PD; Hackett, PH		Herceg, Zdenko			Epigenetic Mechanisms as an Interface Between the Environment and Genome	HYPOXIA: TRANSLATION IN PROGRESS	Advances in Experimental Medicine and Biology		English	Article; Book Chapter						Epigenome; Environment; DNA methylation; Histone modifications; Noncoding RNAs; Cancer	ABERRANT DNA METHYLATION; INHIBITOR TRICHOSTATIN-A; BASE-EXCISION-REPAIR; CANCER-RISK FACTORS; LUNG-CANCER; HELICOBACTER-PYLORI; GENE-EXPRESSION; MAMMALIAN DEVELOPMENT; HISTONE MODIFICATIONS; S-ADENOSYLMETHIONINE	Recent advances in epigenetics have had tremendous impact on our thinking and understanding of biological phenomena and the impact of environmental stressors on complex diseases, notably cancer. Environmental and lifestyle factors are thought to be implicated in the development of a wide range of human cancers by eliciting epigenetic changes, however, the underlying mechanisms remain poorly understood. Epigenetic mechanisms can be viewed as an interface between the genome and environmental influence, therefore aberrant epigenetic events associated with environmental stressors and factors in the cell microenvironment are likely to play an important role in the onset and progression of different human malignancies. At the cellular level, aberrant epigenetic events influence critical cellular events (such as gene expression, carcinogen detoxification, DNA repair, and cell cycle), which are further modulated by risk factor exposures and thus may define the severity/subtype of cancer. This review summarizes recent progress in our understanding of the epigenetic mechanisms through which environmental stressors and endogenous factors may promote tumor development and progression.	[Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, Lyon, France.	hercegz@iarc.fr					Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Brigati C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/263914; Buchen L, 2010, NATURE, V467, P146, DOI 10.1038/467146a; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Chen H, 2001, TOXICOL APPL PHARM, V175, P260, DOI 10.1006/taap.2001.9253; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; De Capoa A, 2003, ONCOL REP, V10, P545; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Franchina M, 2000, DNA CELL BIOL, V19, P521, DOI 10.1089/104454900439755; Grillo MA, 2008, AMINO ACIDS, V34, P187, DOI 10.1007/s00726-007-0500-9; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Hughes LAE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007951; Hur K, 2011, CARCINOGENESIS, V32, P35, DOI 10.1093/carcin/bgq219; Issa JPJ, 2001, CANCER RES, V61, P3573; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin SG, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000013; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Johansson M, 2010, JAMA-J AM MED ASSOC, V303, P2377, DOI 10.1001/jama.2010.808; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Ke QD, 2006, CARCINOGENESIS, V27, P1481, DOI 10.1093/carcin/bgl004; Krutovskikh VA, 2010, BIOESSAYS, V32, P894, DOI 10.1002/bies.201000040; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li H, 2003, ADV CANCER RES, V89, P133, DOI 10.1016/S0065-230X(03)01004-2; Li YQ, 2007, NUCLEIC ACIDS RES, V35, P390, DOI 10.1093/nar/gkl1052; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Ma DKK, 2009, CELL CYCLE, V8, P1526, DOI 10.4161/cc.8.10.8500; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Okada Y, 2010, NATURE, V463, P554, DOI 10.1038/nature08732; Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Patra SK, 2008, EXP CELL RES, V314, P1193, DOI 10.1016/j.yexcr.2008.01.012; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Rai K, 2010, CELL, V142, P930, DOI 10.1016/j.cell.2010.08.030; Rakyan V, 2003, CURR BIOL, V13, pR6, DOI 10.1016/S0960-9822(02)01377-5; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Sharath AN, 2000, BIOCHEMISTRY-US, V39, P14611, DOI 10.1021/bi001610e; Sincic N, 2011, CURR OPIN ONCOL, V23, P69, DOI 10.1097/CCO.0b013e3283412eb4; Song MJ, 2002, J VIROL, V76, P5000, DOI 10.1128/JVI.76.10.5000-5013.2002; Sutherland JE, 2003, ANN NY ACAD SCI, V983, P151, DOI 10.1111/j.1749-6632.2003.tb05970.x; Sutherland JE, 2001, MUTAT RES-FUND MOL M, V479, P225, DOI 10.1016/S0027-5107(01)00163-4; Szaleczky E, 2000, ANAL CELL PATHOL, V20, P131, DOI 10.1155/2000/830906; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100; VAIRAPANDI M, 1994, MUTAT RES-DNA REPAIR, V315, P85, DOI 10.1016/0921-8777(94)90009-4; Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; Van Tine BA, 2004, J VIROL, V78, P11172, DOI 10.1128/JVI.78.20.11172-11186.2004; Velicescu M, 2002, CANCER RES, V62, P2378; Vineis P, 2011, EPIGENETICS-US, V6, P195, DOI 10.4161/epi.6.2.13573; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zeisel SH, 2009, AM J CLIN NUTR, V89, p673S, DOI 10.3945/ajcn.2008.26811D; Zhang QW, 2003, TOXICOL APPL PHARM, V192, P201, DOI 10.1016/S0041-008X(03)00280-1; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907; Zheng ZM, 2006, FRONT BIOSCI-LANDMRK, V11, P2286, DOI 10.2741/1971	75	13	13	1	8	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	0065-2598		978-1-4899-7678-9; 978-1-4899-7676-5	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2016	903						3	15		10.1007/978-1-4899-7678-9_1	10.1007/978-1-4899-7678-9		13	Medicine, Research & Experimental; Physiology; Respiratory System	Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Physiology; Respiratory System	BH0SN	WOS:000396397300001	27343085				2022-02-25	
J	Franceschi, S; Vaccarella, S				Franceschi, Silvia; Vaccarella, Salvatore			Thyroid cancer: An epidemic of disease or an epidemic of diagnosis?	INTERNATIONAL JOURNAL OF CANCER			English	Letter							RISK; AGE		[Franceschi, Silvia; Vaccarella, Salvatore] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Vaccarella, Salvatore/0000-0002-2516-2167			Brito JP, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4706; Dal Maso L, 2009, CANCER CAUSE CONTROL, V20, P75, DOI 10.1007/s10552-008-9219-5; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; FRANCESCHI S, 1993, CRIT REV ONCOGENESIS, V4, P25; Franceschi S, 2013, MOL ONCOL, V7, P1, DOI 10.1016/j.molonc.2012.10.010; Ito Y, 2014, THYROID, V24, P27, DOI 10.1089/thy.2013.0367; Kilfoy BA, 2009, CANCER EPIDEM BIOMAR, V18, P1092, DOI 10.1158/1055-9965.EPI-08-0976; La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251; McLeod DSA, 2013, LANCET, V381, P1046, DOI 10.1016/S0140-6736(12)62205-3; Neta G, 2013, AM J EPIDEMIOL, V177, P800, DOI 10.1093/aje/kws315; Pellegriti G, 2009, JNCI-J NATL CANCER I, V101, P1575, DOI 10.1093/jnci/djp354; Rinaldi S, 2012, INT J CANCER, V131, pE1004, DOI 10.1002/ijc.27601	12	23	23	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	JUN 1	2015	136	11					2738	2739		10.1002/ijc.29311			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	CD8PL	WOS:000351357700024	25365909	Bronze			2022-02-25	
J	Almonte, M; Sankaranarayanan, R				Almonte, M.; Sankaranarayanan, R.			HPV TESTING IN PRIMARY SCREENING IN LOW RESOURCES SETTINGS	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Meeting Abstract									[Almonte, M.; Sankaranarayanan, R.] Int Agcy Res Canc, F-69372 Lyon, France				Almonte, Maribel/O-3286-2016					0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	OCT	2013	23	8		1									1	Oncology; Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Obstetrics & Gynecology	299EW	WOS:000330379500036					2022-02-25	
J	Benbrahim-Tallaa, L; Baan, RA; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Guha, N; Loomis, D; Straif, K				Benbrahim-Tallaa, Lamia; Baan, Robert A.; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Guha, Neela; Loomis, Dana; Straif, Kurt		Int Agcy Res Canc Monograph Workin	Carcinogenicity of diesel-engine and gasoline-engine exhausts and some nitroarenes	LANCET ONCOLOGY			English	News Item									[Benbrahim-Tallaa, Lamia; Baan, Robert A.; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Guha, Neela; Loomis, Dana; Straif, Kurt; Int Agcy Res Canc Monograph Workin] IARC, Lyon, France		Benbrahim-Tallaa, L (corresponding author), IARC, Lyon, France.		Vermeulen, Roel/F-8037-2011; Scheepers, Paul/C-4209-2016; Lunn, Ruth/AAP-8848-2021; Guha, Neela/AAG-3989-2021; Scheepers, Paul/L-4628-2015; Loomis, Dana/AAE-3988-2019	Vermeulen, Roel/0000-0003-4082-8163; Guha, Neela/0000-0003-3991-4662; Scheepers, Paul/0000-0002-8546-2161; Loomis, Dana/0000-0003-3297-5200; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Arlt, Volker Manfred/0000-0003-4314-9318; Penning, Trevor/0000-0002-3937-1066	Cancer Research UKCancer Research UK [14329] Funding Source: researchfish			0	312	318	6	93	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045			LANCET ONCOL	Lancet Oncol.	JUL	2012	13	7					663	664		10.1016/S1470-2045(12)70280-2			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	968CX	WOS:000305955700039	22946126	Green Submitted			2022-02-25	
J	Wild, CP; Cogliano, VJ				Wild, Christopher P.; Cogliano, Vincent J.			A plea on behalf of expert evaluation and the experts involved	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Letter							RE		[Cogliano, Vincent J.] WHO, IARC Monographs Programme, Int Agcy Res Canc, F-69372 Lyon 08, France		Cogliano, VJ (corresponding author), WHO, IARC Monographs Programme, Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	cogliano@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			McLaughlin JK, 2010, INT J EPIDEMIOL, V39, P1679, DOI 10.1093/ije/dyp359; McLaughlin JK, 2010, JNCI-J NATL CANCER I, V102, P134, DOI 10.1093/jnci/djp448	2	10	10	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2011	40	1					253	253		10.1093/ije/dyq038			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	739MC	WOS:000288720900032	20223796	Bronze, Green Submitted			2022-02-25	
J	Jenab, M; Boffetta, P				Jenab, M.; Boffetta, P.			Glycemic index and glycemic load: application in observational studies and association with hepatocellular carcinoma risk. Meaningful or error prone?	ANNALS OF ONCOLOGY			English	Editorial Material							DIET-HISTORY QUESTIONNAIRE; DIABETES-MELLITUS; CANCER; CARBOHYDRATE; VALIDITY; OBESITY; VALUES; REPRODUCIBILITY; METAANALYSIS; METHODOLOGY		[Jenab, M.; Boffetta, P.] Int Agcy Res Canc, Lifestyle & Canc Grp, F-69372 Lyon, France		Jenab, M (corresponding author), Int Agcy Res Canc, Lifestyle & Canc Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	boffetta@iarc.fr		Jenab, Mazda/0000-0002-0573-1852			Barclay AW, 2008, AM J CLIN NUTR, V87, P627, DOI 10.1093/ajcn/87.3.627; Barclay AW, 2008, PUBLIC HEALTH NUTR, V11, P573, DOI 10.1017/S1368980007001103; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Cornier MA, 2008, ENDOCR REV, V29, P777, DOI 10.1210/er.2008-0024; Du HD, 2006, ACTA CARDIOL, V61, P383, DOI 10.2143/AC.61.4.2017298; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007; Flood A, 2006, J AM DIET ASSOC, V106, P393, DOI 10.1016/j.jada.2005.12.008; Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5; George SM, 2009, AM J EPIDEMIOL, V169, P462, DOI 10.1093/aje/kwn347; Gnagnarella P, 2008, AM J CLIN NUTR, V87, P1793, DOI 10.1093/ajcn/87.6.1793; Henry CJK, 2005, BRIT J NUTR, V94, P922, DOI 10.1079/BJN20051594; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; Jenkins DJA, 2002, AM J CLIN NUTR, V76, p266S, DOI 10.1093/ajcn/76.1.266S; Key TJ, 2007, EUR J CLIN NUTR, V61, pS112, DOI 10.1038/sj.ejcn.1602941; Lagiou P, 2009, ANN ONCOL, V20, P1741, DOI 10.1093/annonc/mdp059; Larsson SC, 2007, BRIT J CANCER, V97, P1005, DOI 10.1038/sj.bjc.6603932; Levitan EB, 2007, AM J CLIN NUTR, V85, P548, DOI 10.1093/ajcn/85.2.548; Mazzanti R, 2008, MOL ASPECTS MED, V29, P130, DOI 10.1016/j.mam.2007.09.008; Mohammad Alizadeh Amir Houshang, 2006, Indian J Gastroenterol, V25, P286; Mulholland HG, 2009, AM J CLIN NUTR, V89, P568, DOI 10.3945/ajcn.2008.26823; Murakami K, 2008, BRIT J NUTR, V99, P639, DOI 10.1017/S0007114507812086; Neuhouser ML, 2006, J NUTR, V136, P1604, DOI 10.1093/jn/136.6.1604; Olendzki BC, 2006, NUTRITION, V22, P1087, DOI 10.1016/j.nut.2006.07.006; Persico M, 2009, WORLD J GASTROENTERO, V15, P462, DOI 10.3748/wjg.15.462; Polesel J, 2009, ANN ONCOL, V20, P353, DOI 10.1093/annonc/mdn565; Rossi M, 2009, ANN ONCOL, V20, P1736, DOI 10.1093/annonc/mdp058; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; van Bakel MME, 2009, J NUTR, V139, P568, DOI 10.3945/jn.108.097121; Wolever TMS, 2000, BRIT J NUTR, V83, pS97; World Cancer Research Fund/American Institute for Cancer, 2007, FOOD NUTR PHYS ACT P	32	3	3	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	MAR	2010	21	3					437	439		10.1093/annonc/mdq016			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	575DE	WOS:000276045300001	20176692	Bronze			2022-02-25	
J	Autier, P; Ouakrim, DA				Autier, P.; Ouakrim, D. A.			Determinants of the number of mammography units in 31 countries with significant mammography screening	BRITISH JOURNAL OF CANCER			English	Article						breast cancer; mammography screening; radiology	BREAST-CANCER MORTALITY; PERFORMANCE; WOMEN; AGE	In the 2000s, most of the female population of industrialised countries had access to mammography breast cancer screening, but with variable modalities among the countries. We assessed the number of mammography units (MUs) in 31 European, North American and Asian countries where significant mammography activity has existed for over 10 years, collecting data on the number of such units and of radiologists by contacting institutions in each country likely to provide the relevant information. Around 2004, there were 32 324 MU in 31 countries, the number per million women ranging from less than 25 in Turkey, Denmark, the Netherlands, the United Kingdom, Norway, Poland and Hungary to more than 80 in Cyprus, Italy, France, the United States and Austria. In a multivariate analysis, the number of MUs was positively associated with the number of radiologists (P = 0.0081), the number of women (P = 0.0023) and somewhat with the country surface area (P = 0.077). There is considerable variation in the density of MU across countries and the number of MUs in service are often well above what would be necessary according to local screening recommendations. High number of MUs in some countries may have undesirable consequences, such as unnecessarily high screening frequency and decreased age at which screening is started.	[Autier, P.; Ouakrim, D. A.] Int Agcy Res Canc, Epidemiol Methods & Support Grp, F-69372 Lyon, France		Autier, P (corresponding author), Int Agcy Res Canc, Epidemiol Methods & Support Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	autierp@iarc.fr	Autier, Philippe/A-4402-2014	Autier, Philippe/0000-0003-1538-5321; Ait Ouakrim, Driss/0000-0001-7715-2561			*ACBCS, 2006, NHSBSP PUBL, V61; BROWN ML, 1990, ANN INTERN MED, V113, P547, DOI 10.7326/0003-4819-113-7-547; *COCIR EUR COORD C, 2003, AG PROF MED UN; Colbert JA, 2004, CANCER-AM CANCER SOC, V101, P1850, DOI 10.1002/cncr.20583; DESTOUET JM, 2005, J AM COLL RADIOL, V7, P585; *EAR, 2005, RAD TRAIN PROGR EUR; *EUR, 2007, HLTH EUR UN SPEC EUR; Fischer R, 1998, PREV MED, V27, P697, DOI 10.1006/pmed.1998.0347; Hery C, 2008, ANN ONCOL, V19, P1009, DOI 10.1093/annonc/mdm593; Hery C, 2008, ANN ONCOL, V19, P1187, DOI 10.1093/annonc/mdn025; Hofvind S, 2007, EUR J EPIDEMIOL, V22, P447, DOI 10.1007/s10654-007-9137-y; International Agency for Cancer on Research (IARC) World Health Organization, 2002, IARC HDB CANC PREV, V7; Jensen A, 2005, INT J CANCER, V113, P464, DOI 10.1002/ijc.20604; Klug SJ, 2005, EUR J PUBLIC HEALTH, V15, P70, DOI 10.1093/eurpub/cki118; Lynge E, 2003, EUR J CANCER PREV, V12, P213, DOI 10.1097/00008469-200306000-00008; Moss SM, 2006, LANCET, V368, P2053, DOI 10.1016/S0140-6736(06)69834-6; *ORG EC COOP DEV, 2007, OECD HLTH DAT; Otto SJ, 2003, LANCET, V361, P1411, DOI 10.1016/S0140-6736(03)13132-7; Perry N., 2006, EUROPEAN GUIDELINES, V4th; *POP DIV DEP EC SO, 2007, UN SECR WORLD POP PR; Smith-Bindman R, 2005, JNCI-J NATL CANCER I, V97, P358, DOI 10.1093/jnci/dji060; Smith-Bindman R, 2003, JAMA-J AM MED ASSOC, V290, P2129, DOI 10.1001/jama.290.16.2129; Spyckerelle Y, 2002, B CANCER, V89, P957; Theberge I, 2005, CAN MED ASSOC J, V172, P195, DOI 10.1503/cmaj.1040485; *USPSTF, 2008, REC RAT SCREEN BREAS; Vatten Lars J, 2007, Tidsskr Nor Laegeforen, V127, P1492; Voyvoda N, 2007, DIAGN INTERV RADIOL, V13, P129; Yankaskas BC, 2004, J MED SCREEN, V11, P187, DOI 10.1258/0969141042467430	28	22	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920	1532-1827		BRIT J CANCER	Br. J. Cancer	SEP 30	2008	99	7					1185	1190		10.1038/sj.bjc.6604657			6	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	355AS	WOS:000259681600030	18781176	Green Published, hybrid			2022-02-25	
J	Cogliano, VJ; Boan, RA; Straif, K; Grosse, Y; Secretan, B; Ghissassi, FE				Cogliano, Vincent James; Boan, Robert A.; Straif, Kurt; Grosse, Yann; Secretan, Beatrice; Ghissassi, Fatiha El			Use of mechanistic data in IARC evaluations	ENVIRONMENTAL AND MOLECULAR MUTAGENESIS			English	Article; Proceedings Paper	37th Annual Meeting of the Environmental-Mutagen-Society	SEP 16-20, 2006	Vancouver, CANADA	Environm Mutagen Soc		carcinogenicity; mechanisms; risk assessment	LIVER-TUMOR INDUCTION; MICROCYSTIN-LR; COAL-MINERS; TRICHLOROETHYLENE; TRICHLOROACETATE; CARCINOGENICITY; DICHLOROACETATE; HEPATOCYTES; METABOLITES; APOPTOSIS	Consideration of mechanistic data has the potential to improve the analysis of both epidemiologic studies and cancer bioassays. IARC has a classification system in which mechanistic data can play a pivotal role. Since 1991, IARC has allowed an agent to be classified as carcinogenic to humans (Group 1) when there is less than sufficient evidence in humans but there is sufficient evidence in experimental animals and "strong evidence in exposed humans that the agent acts through a relevant mechanism of carcinogenicity." Mechanistic evidence can also substitute for conventional cancer bioassays when there is less than sufficient evidence in experimental animals, just as mechanistic evidence can substitute for conventional epidemiologic studies when there is less than sufficient evidence in humans. The IARC Monographs have used mechanistic data to raise or lower a classification that would be otherwise based on epidemiologic studies and cancer bioassays only. Recently, the IARC Monographs have evaluated several agents where mechanistic data were pivotal to the overall evaluation: benzo[a]pyrene, carbon black and other poorly soluble particles, ingested nitrates and nitrites, and microcystin-LR. In evaluating mechanistic data, it is important to consider alternative mechanistic hypotheses, because an agent may induce tumors through multiple mechanisms.	[Cogliano, Vincent James; Boan, Robert A.; Straif, Kurt; Grosse, Yann; Secretan, Beatrice; Ghissassi, Fatiha El] Int Agcy Res Canc, F-69372 Lyon, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	cogliano@iarc.fr		Lauby-Secretan, Beatrice/0000-0001-6559-3351			Baan R, 2006, LANCET ONCOL, V7, P295, DOI 10.1016/S1470-2045(06)70651-9; Bull RJ, 2000, ENVIRON HEALTH PERSP, V108, P241, DOI 10.1289/ehp.00108s2241; Bull RJ, 2002, TOXICOL APPL PHARM, V182, P55, DOI 10.1006/taap.2002.9427; Caldwell JC, 2006, ENVIRON HEALTH PERSP, V114, P1457, DOI 10.1289/ehp.8692; Chen T, 2005, MOL CELL PROTEOMICS, V4, P958, DOI 10.1074/mcp.M400185-MCP200; Cogliano VJ, 2004, ENVIRON HEALTH PERSP, V112, P1269, DOI 10.1289/ehp.6950; DeMarini DM, 2001, CANCER RES, V61, P6679; FALCONER IR, 1992, CHEM-BIOL INTERACT, V81, P181, DOI 10.1016/0009-2797(92)90033-H; Grosse Y, 2006, LANCET ONCOL, V7, P628, DOI 10.1016/S1470-2045(06)70789-6; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Humpage AR, 1999, ENVIRON TOXICOL, V14, P61; *IARC, 1987, IARC MON EV CARC S7, V1, P67; *IARC, 1994, SCHIST LIV FLUK HEL, V61, P177; *IARC, 1979, IARC MON, V1, P9; IARC, 2006, PREAMBL IARC MON; *IARC, 1992, IARC MON EV CARC RIS, V54, P13; Kuempel ED, 2001, REGUL TOXICOL PHARM, V34, P69, DOI 10.1006/rtph.2001.1479; *NTP, 2004, REP CARC; NTP, 2000, REP CARC REP CARC, Vfourteenth; Pavanello S, 1999, CARCINOGENESIS, V20, P431, DOI 10.1093/carcin/20.3.431; Soutar CA, 2004, OCCUP ENVIRON MED, V61, P477, DOI 10.1136/oem.2002.006726; Stauber AJ, 1997, TOXICOL APPL PHARM, V144, P235, DOI 10.1006/taap.1997.8159; Straif K, 2005, LANCET ONCOL, V6, P931, DOI 10.1016/S1470-2045(05)70458-7; Venitt, 1999, IARC SCI PUBL, V146; YOSHIZAWA S, 1990, J CANCER RES CLIN, V116, P609, DOI 10.1007/BF01637082; 2005, FED REG, V70, P17766	26	29	32	0	7	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0893-6692			ENVIRON MOL MUTAGEN	Environ. Mol. Mutagen.	MAR	2008	49	2					100	109		10.1002/em.20370			10	Environmental Sciences; Genetics & Heredity; Toxicology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Genetics & Heredity; Toxicology	267IZ	WOS:000253504000002	18240161				2022-02-25	
J	Boffetta, P				Boffetta, Paolo			Molecular cancer epidemiology: a tale of > 3842 publications	CARCINOGENESIS			English	Editorial Material							METABOLIC EPIDEMIOLOGY; RISK		Lifestyle Envronm Canc Grp, Int Agcy Res Canc, F-69008 Lyon, France		Boffetta, P (corresponding author), Lifestyle Envronm Canc Grp, Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fir					BEASLEY RP, 1978, AM J EPIDEMIOL, V108, P247; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; LOWER GM, 1979, ENVIRON HEALTH PERSP, V29, P71, DOI 10.2307/3429048; MCMICHAEL AJ, 1994, AM J EPIDEMIOL, V140, P1; Perera FP, 2000, JNCI-J NATL CANCER I, V92, P602, DOI 10.1093/jnci/92.8.602; PERERA FP, 1982, J CHRON DIS, V35, P581, DOI 10.1016/0021-9681(82)90078-9; REDDY BS, 1975, CANCER RES, V35, P3403; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; Soteriades ES, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-301; UGOLINI D, 2007, BIBLIOMETRIC ANAL SC; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; WYNDER EL, 1974, CANCER, V34, P801, DOI 10.1002/1097-0142(197409)34:3+<801::AID-CNCR2820340703>3.0.CO;2-P	12	1	1	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0143-3334	1460-2180		CARCINOGENESIS	Carcinogenesis	AUG	2007	28	8					1621	1621		10.1093/carcin/bgm139			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	209DY	WOS:000249370400001	17641115	Bronze			2022-02-25	
J	Gray, N				Gray, N			Mixed feelings on snus	LANCET			English	Editorial Material							SMOKELESS TOBACCO; PUBLIC-HEALTH		Int Agcy Res Canc, Tobacco Unit, F-69008 Lyon, France		Gray, N (corresponding author), Int Agcy Res Canc, Tobacco Unit, F-69008 Lyon, France.	nigel@uicc.org					Bates C, 2003, TOB CONTROL, V12, P360, DOI 10.1136/tc.12.4.360; Boffetta P, 2005, INT J CANCER, V114, P992, DOI 10.1002/ijc.20811; *BRIT AM TOB, 2005, SMOK SNUS BRIT AM TO; Cogliano V, 2004, LANCET ONCOL, V5, P708, DOI 10.1016/S1470-2045(04)01633-X; EKMAN I, 2005, INT HERALD TRIB 0527, P1; EKMAN I, 2005, INT HERALD TRIB 0527, P7; Foulds J, 2003, TOB CONTROL, V12, P349, DOI 10.1136/tc.12.4.349; Gray N, 2003, LANCET, V362, P845, DOI 10.1016/S0140-6736(03)14348-6; Hughes JR, 2005, TOB CONTROL, V14, P49, DOI 10.1136/tc.2004.008367; International Agency for Research on Cancer, 2004, TOB SMOK INV SMOK; WEINSTEIN ND, 2001, PUBL UND RISK REAS S, P193	11	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 17	2005	366	9490					966	967		10.1016/S0140-6736(05)67352-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	965MZ	WOS:000231955900008	16168760				2022-02-25	
J	Herceg, Z; Wang, ZQ				Herceg, Z; Wang, ZQ			Rendez-vous at mitosis - TRRAPed in the chromatin	CELL CYCLE			English	Article						cell cycle; chromatin and transcription; histone acetylation; Mad1 and Mad2; mitotic checkpoint; Trrap	HISTONE ACETYLTRANSFERASE COMPLEX; HAT COFACTOR TRRAP; C-MYC; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ACETYLASE COMPLEX; NUCLEAR RECEPTOR; DNA-REPAIR; BINDING; RECRUITMENT	Cell cycle progression and cell cycle checkpoints are guided by dynamic changes in gene expression that requires concerted efforts of chromatin modifying/remodeling activities and transcription machinery. Epigenetic modifications including acetylation of specific lysine residues within the amino-terminal tails of core histones play an important role in these processes. In the last few years, a flurry of biochemical studies has identified numerous histone acetyltransferases ( HAT) whose activity is dependent on the multiprotein assemblies and responsible for histone acetylation. In addition to their well-known involvement in the control of gene transcription, recent studies implicated HATs and histone acetylation in other important cellular processes, such as DNA replication, cell cycle control, DNA repair and genomic stability. With the exception of catalytic subunits of the HAT assemblies, the role of other components of these large multi-subunit complexes in cellular processes remains largely unknown. Recent genetic and cellular studies have shown that Trrap, a common component of HAT complexes, regulates the mitotic checkpoint function by modulation of mitotic checkpoint genes. This regulation involves a concerted and cell cycle stage-coupled recruitment of HAT activity to promoters of specific checkpoint genes, providing a functional link between specific chromatin modifications and cell cycle control. These findings shed new light on the role of HAT components and histone acetylation in cell cycle control and underscore functional significance of epigenetic modifications in cellular processes.	Int Agcy Res Canc, Grp Gene Environm Biol, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Grp Gene Environm Biol, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr					Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Fan WQ, 2004, MOL ENDOCRINOL, V18, P127, DOI 10.1210/me.2003-0110; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Memedula S, 2003, CURR BIOL, V13, P241, DOI 10.1016/S0960-9822(03)00048-4; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	48	22	22	0	0	LANDES BIOSCIENCE	GEORGETOWN	810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA	1538-4101			CELL CYCLE	Cell Cycle	MAR	2005	4	3					383	387		10.4161/cc.4.3.1546			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	932FB	WOS:000229538500011	15711126	Bronze			2022-02-25	
J	Riboli, E; Norat, T				Riboli, E; Norat, T			Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk	AMERICAN JOURNAL OF CLINICAL NUTRITION			English	Article; Proceedings Paper	4th International Congress on Vegetarian Nutrition	APR 08-11, 2002	LOMA LINDA, CA	Loma Linda Univ		fruit; vegetables; cancer risk; odds ratio; case-control study; cohort study	MULTICENTER CASE-CONTROL; CELL ESOPHAGEAL CANCER; LUNG-CANCER; STOMACH-CANCER; COLORECTAL-CANCER; DIETARY FACTORS; BREAST-CANCER; GASTRIC-CANCER; FOOD GROUPS; BLADDER-CANCER	Background: Diets rich in fruit and vegetables have been recommended for preventing cancer. The evidence supporting this recommendation is based on observational studies, although results of several prospective studies have cast some doubts on whether fruit and vegetables are associated with cancer risk reduction. Objective: We sought to summarize evidence from case-control and prospective studies on fruit and vegetable intake and cancer risk with a meta-analytic approach. Design: Published case-control and cohort studies that reported on total vegetable and fruit intake and risk of cancer of several sites were included. Relative risks were estimated by using linear logistic regression models. Results: Case-control studies overall support a significant reduction in the risks of cancers of the esophagus, lung, stomach, and colorectum associated with both fruit and vegetables; breast cancer is associated with vegetables but not with fruit; and bladder cancer is associated with fruit but not with vegetables. The overall relative risk estimates from cohort studies suggest a protective effect of both fruit and vegetables for most cancer sites considered, but the risk reduction is significant only for cancers of the lung and bladder and only for fruit. Conclusions: Prospective studies provide weaker evidence than do case-control studies of the association of fruit and vegetable consumption with reduced cancer risk. The discrepancies may be related to recall and selection biases in case-control studies. In contrast, the association may have been underestimated in prospective studies because of the combined effects of imprecise dietary measurements and limited variability of dietary intakes within each cohort.	Int Agcy Res Canc, Unit Nutr & Canc, F-69372 Lyon 08, France		Riboli, E (corresponding author), Int Agcy Res Canc, Unit Nutr & Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	riboli@iarc.fr		Riboli, Elio/0000-0001-6795-6080			Agudo A, 1997, EUR J CANCER, V33, P1256, DOI 10.1016/S0959-8049(97)00050-6; ALAVANJA MCR, 1993, J NATL CANCER I, V85, P1906, DOI 10.1093/jnci/85.23.1906; Axelsson G, 1996, INT J EPIDEMIOL, V25, P32, DOI 10.1093/ije/25.1.32; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; BIDOLI E, 1992, INT J CANCER, V50, P223, DOI 10.1002/ijc.2910500211; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BOEING H, 1991, INT J CANCER, V47, P858, DOI 10.1002/ijc.2910470612; BOEING H, 1991, CANCER CAUSE CONTROL, V2, P227, DOI 10.1007/BF00052138; Bosetti C, 2000, INT J CANCER, V87, P289, DOI 10.1002/1097-0215(20000715)87:2&lt;289::AID-IJC22&gt;3.0.CO;2-9; Botterweck AAM, 1998, AM J EPIDEMIOL, V148, P842, DOI 10.1093/oxfordjournals.aje.a009709; Boutron-Ruault MC, 1999, EUR J CANCER PREV, V8, P229, DOI 10.1097/00008469-199906000-00011; BROWN LM, 1988, JNCI-J NATL CANCER I, V80, P1620, DOI 10.1093/jnci/80.20.1620; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; Bruemmer B, 1996, AM J EPIDEMIOL, V144, P485, DOI 10.1093/oxfordjournals.aje.a008955; CANDELORA EC, 1992, NUTR CANCER, V17, P263, DOI 10.1080/01635589209514195; CENTONZE S, 1994, NUTR CANCER, V21, P233, DOI 10.1080/01635589409514322; CHENG KK, 1995, INT J CANCER, V60, P820, DOI 10.1002/ijc.2910600616; CHOW WH, 1992, CANCER CAUSE CONTROL, V3, P247, DOI 10.1007/BF00124258; Chyou P H, 1993, Ann Epidemiol, V3, P211; COGGON D, 1989, J NATL CANCER I, V81, P1178, DOI 10.1093/jnci/81.15.1178; *COMA, 1998, REP WORK GROUP DIET; CORNEE J, 1995, EUR J EPIDEMIOL, V11, P55, DOI 10.1007/BF01719946; CORREA P, 1985, JNCI-J NATL CANCER I, V75, P645; De Stefani E, 1998, NUTR CANCER, V30, P158, DOI 10.1080/01635589809514656; De Stefani E, 2000, INT J CANCER, V87, P129, DOI 10.1002/1097-0215(20000701)87:1&lt;129::AID-IJC19&gt;3.0.CO;2-M; De Stefani E, 1999, INT J CANCER, V82, P33, DOI 10.1002/(SICI)1097-0215(19990702)82:1&lt;33::AID-IJC7&gt;3.0.CO;2-7; De Stefani E, 2000, NUTR CANCER, V38, P23, DOI 10.1207/S15327914NC381_4; De Stefani E, 1999, ORAL ONCOL, V35, P17, DOI 10.1016/S1368-8375(98)00060-8; DESTEFANI E, 1990, REV EPIDEMIOL SANTE, V38, P297; DESTEFANI E, 1987, CANCER-AM CANCER SOC, V60, P3087, DOI 10.1002/1097-0142(19871215)60:12<3087::AID-CNCR2820601238>3.0.CO;2-6; DESTEFANI E, 1990, CANCER RES, V50, P426; DORGAN JF, 1993, CANCER CAUSE CONTROL, V4, P273; Esteve J, 1996, CANCER CAUSE CONTROL, V7, P240, DOI 10.1007/BF00051300; EWERTZ M, 1990, INT J CANCER, V46, P779, DOI 10.1002/ijc.2910460505; Feskanich D, 2000, JNCI-J NATL CANCER I, V92, P1812, DOI 10.1093/jnci/92.22.1812; Flood A, 2002, AM J CLIN NUTR, V75, P936, DOI 10.1093/ajcn/75.5.936; FONTHAM ETH, 1988, CANCER, V62, P2267, DOI 10.1002/1097-0142(19881115)62:10<2267::AID-CNCR2820621033>3.0.CO;2-E; Franceschi S, 1998, EPIDEMIOLOGY, V9, P338, DOI 10.1097/00001648-199805000-00020; Franceschi S, 1997, INT J CANCER, V72, P56, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;56::AID-IJC8&gt;3.0.CO;2-3; Franceschi S, 1999, BRIT J CANCER, V80, P614, DOI 10.1038/sj.bjc.6690400; FRASER GE, 1991, AM J EPIDEMIOL, V133, P683, DOI 10.1093/oxfordjournals.aje.a115943; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Galanis DJ, 1998, INT J EPIDEMIOL, V27, P173, DOI 10.1093/ije/27.2.173; GAO CM, 1993, JPN J CANCER RES, V84, P594, DOI 10.1111/j.1349-7006.1993.tb02018.x; GAO YT, 1994, INT J CANCER, V58, P197, DOI 10.1002/ijc.2910580209; Garrote LF, 2001, BRIT J CANCER, V85, P46, DOI 10.1054/bjoc.2000.1825; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; GUO WD, 1994, INT J EPIDEMIOL, V23, P444, DOI 10.1093/ije/23.3.444; HAENSZEL W, 1972, JNCI-J NATL CANCER I, V49, P969; HAENSZEL W, 1976, JNCI-J NATL CANCER I, V56, P265, DOI 10.1093/jnci/56.2.265; HANAOKA T, 1994, JPN J CLIN ONCOL, V24, P241; HANSSON LE, 1993, INT J CANCER, V55, P181, DOI 10.1002/ijc.2910550203; Harrison LE, 1997, CANCER-AM CANCER SOC, V80, P1021; Hirayama T, 1986, Prog Clin Biol Res, V206, P299; HIRAYAMA T, 1990, LIFE STYLE MORTALITY, P73; HOLMBERG L, 1994, ARCH INTERN MED, V154, P1805, DOI 10.1001/archinte.154.16.1805; HOSHIYAMA Y, 1992, CANCER CAUSE CONTROL, V3, P441, DOI 10.1007/BF00051357; Hsing AW, 1998, INT J CANCER, V77, P549, DOI 10.1002/(SICI)1097-0215(19980812)77:4&lt;549::AID-IJC13&gt;3.0.CO;2-1; HU JF, 1991, INT J EPIDEMIOL, V20, P362, DOI 10.1093/ije/20.2.362; Hu JF, 1997, INT J CANCER, V71, P924, DOI 10.1002/(SICI)1097-0215(19970611)71:6&lt;924::AID-IJC2&gt;3.0.CO;2-#; HU JF, 1994, INT J CANCER, V57, P38, DOI 10.1002/ijc.2910570108; Inoue M, 1996, INT J CANCER, V66, P309, DOI 10.1002/(SICI)1097-0215(19960503)66:3<309::AID-IJC7>3.0.CO;2-2; INOUE M, 1994, INT J CANCER, V56, P494, DOI 10.1002/ijc.2910560407; ISCOVICH JM, 1992, INT J CANCER, V51, P851, DOI 10.1002/ijc.2910510603; Jafarey N A, 1977, J Pak Med Assoc, V27, P340; JAIN M, 1990, INT J CANCER, V45, P287, DOI 10.1002/ijc.2910450214; Jansen MCJF, 2001, INT J CANCER, V92, P913, DOI 10.1002/ijc.1278; Jansen MCJF, 1999, NUTR CANCER, V34, P49, DOI 10.1207/S15327914NC340107; JEDRYCHOWSKI W, 1986, INT J CANCER, V37, P837, DOI 10.1002/ijc.2910370607; Ji BT, 1998, INT J CANCER, V76, P659, DOI 10.1002/(SICI)1097-0215(19980529)76:5&lt;659::AID-IJC8&gt;3.0.CO;2-P; KALANDIDI A, 1990, CANCER CAUSE CONTROL, V1, P15, DOI 10.1007/BF00053179; KAMPMAN E, 1995, CANCER CAUSE CONTROL, V6, P225, DOI 10.1007/BF00051794; KATO I, 1992, JPN J CANCER RES, V83, P568, DOI 10.1111/j.1349-7006.1992.tb00127.x; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; KATO I, 1990, CANCER RES, V50, P6559; KATO I, 1992, JPN J CANCER RES, V83, P1137, DOI 10.1111/j.1349-7006.1992.tb02736.x; KATSOUYANNI K, 1986, INT J CANCER, V38, P815, DOI 10.1002/ijc.2910380606; KNEKT P, 1991, AM J EPIDEMIOL, V134, P471, DOI 10.1093/oxfordjournals.aje.a116118; KNELLER RW, 1991, CANCER, V68, P672, DOI 10.1002/1097-0142(19910801)68:3<672::AID-CNCR2820680339>3.0.CO;2-T; Ko YC, 1997, INT J EPIDEMIOL, V26, P24, DOI 10.1093/ije/26.1.24; KOO LC, 1988, NUTR CANCER, V11, P155, DOI 10.1080/01635588809513983; KOTAKE K, 1995, JPN J CLIN ONCOL, V25, P195; KROMHOUT D, 1987, AM J CLIN NUTR, V45, P1361, DOI 10.1093/ajcn/45.5.1361; KUNE GA, 1993, NUTR CANCER, V20, P61, DOI 10.1080/01635589309514271; Kune S, 1987, Nutr Cancer, V9, P21; KVALE G, 1983, INT J CANCER, V31, P397, DOI 10.1002/ijc.2910310402; La Vecchia C, 1999, INT J CANCER, V82, P151, DOI 10.1002/(SICI)1097-0215(19990702)82:1<151::AID-IJC25>3.0.CO;2-9; La Vecchia C, 1987, Nutr Cancer, V10, P205; La Vecchia C, 1999, NUTR CANCER, V33, P196, DOI 10.1207/S15327914NC330212; Landa M C, 1994, Eur J Cancer Prev, V3, P313, DOI 10.1097/00008469-199407000-00003; Lanza E, 2001, AM J CLIN NUTR, V74, P387; Launoy G, 1998, INT J CANCER, V76, P7, DOI 10.1002/(SICI)1097-0215(19980330)76:1&lt;7::AID-IJC2&gt;3.0.CO;2-4; Le Marchand L, 1999, CANCER EPIDEM BIOMAR, V8, P45; LEE HH, 1990, ANTICANCER RES, V10, P875; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; LEE JK, 1995, INT J EPIDEMIOL, V24, P33, DOI 10.1093/ije/24.1.33; Lei YX, 1996, LUNG CANCER-J IASLC, V14, pS121, DOI 10.1016/S0169-5002(96)90218-4; LEMARCHAND L, 1989, JNCI-J NATL CANCER I, V81, P1158, DOI 10.1093/jnci/81.15.1158; LEVI F, 1993, NUTR CANCER, V19, P327, DOI 10.1080/01635589309514263; Levi F, 1998, INT J CANCER, V77, P705, DOI 10.1002/(SICI)1097-0215(19980831)77:5&lt;705::AID-IJC8&gt;3.0.CO;2-Z; Levi F, 1999, BRIT J CANCER, V79, P1283, DOI 10.1038/sj.bjc.6690206; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; MACLENNAN R, 1977, INT J CANCER, V20, P854, DOI 10.1002/ijc.2910200606; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; Maier H, 1997, ACTA OTO-LARYNGOL, P160; MANOUSOS O, 1983, INT J CANCER, V32, P1, DOI 10.1002/ijc.2910320102; Mathew A, 2000, EUR J CANCER PREV, V9, P89, DOI 10.1097/00008469-200004000-00004; MAYNE ST, 1994, J NATL CANCER I, V86, P33, DOI 10.1093/jnci/86.1.33; MCLAUGHLIN JK, 1988, J NATL CANCER I, V80, P1237, DOI 10.1093/jnci/80.15.1237; Memik Faruk, 1996, Journal of Environmental Pathology Toxicology and Oncology, V15, P209; Michaud DS, 2000, AM J EPIDEMIOL, V152, P1145, DOI 10.1093/aje/152.12.1145; Michaud DS, 1999, JNCI-J NATL CANCER I, V91, P605, DOI 10.1093/jnci/91.7.605; Michels KB, 2000, JNCI-J NATL CANCER I, V92, P1740, DOI 10.1093/jnci/92.21.1740; MILLER AB, 1983, INT J CANCER, V32, P155, DOI 10.1002/ijc.2910320204; Murata M, 1999, JPN J CANCER RES, V90, P711, DOI 10.1111/j.1349-7006.1999.tb00805.x; Nagano J, 2000, INT J CANCER, V86, P132, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;132::AID-IJC21&gt;3.0.CO;2-M; NEGRI E, 1992, EUR J CANCER, V28A, P1167, DOI 10.1016/0959-8049(92)90479-L; NEGRI E, 1991, INT J CANCER, V48, P350, DOI 10.1002/ijc.2910480307; NOMURA A, 1990, CANCER RES, V50, P627; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; NOTANI P N, 1987, Nutrition and Cancer, V10, P103; Ocke MC, 1997, AM J EPIDEMIOL, V145, P358, DOI 10.1093/oxfordjournals.aje.a009113; OREGGIA F, 1991, CANCER, V67, P180, DOI 10.1002/1097-0142(19910101)67:1<180::AID-CNCR2820670130>3.0.CO;2-R; Pawlega J, 1997, ACTA ONCOL, V36, P471, DOI 10.3109/02841869709001301; PETERS RK, 1989, CANCER RES, V49, P5459; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; PICKLE LW, 1984, CANCER RES, V44, P363; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; Pillow PC, 1997, NUTR CANCER, V29, P169, DOI 10.1080/01635589709514620; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Qi X Y, 1994, Asia Pac J Public Health, V7, P98; Rachtan J, 1997, LUNG CANCER, V18, P137, DOI 10.1016/S0169-5002(97)00062-7; RAMON JM, 1993, CANCER, V71, P1731, DOI 10.1002/1097-0142(19930301)71:5&lt;1731::AID-CNCR2820710505&gt;3.0.CO;2-X; Riboli E, 2000, AM J EPIDEMIOL, V151, P371; RIBOLI E, 1991, INT J CANCER, V49, P214, DOI 10.1002/ijc.2910490212; RICHARDSON S, 1991, INT J CANCER, V48, P1; Ronco A, 1999, NUTR CANCER, V35, P111, DOI 10.1207/S15327914NC352_3; SANCHEZDIEZ A, 1992, EUR J EPIDEMIOL, V8, P233, DOI 10.1007/BF00144806; SANDLER RS, 1993, JNCI-J NATL CANCER I, V85, P884, DOI 10.1093/jnci/85.11.884; Shannon J, 1996, CANCER EPIDEM BIOMAR, V5, P495; SHIBATA A, 1992, BRIT J CANCER, V66, P673, DOI 10.1038/bjc.1992.336; Slattery ML, 1998, AM J EPIDEMIOL, V148, P4, DOI 10.1093/aje/148.1.4-a; Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769; STEIMAN R, 1994, ENVIRON TOXIC WATER, V9, P1, DOI 10.1002/tox.2530090102; STEINMETZ KA, 1993, CANCER RES, V53, P536; STEINMETZ KA, 1993, INT J CANCER, V53, P720, DOI 10.1002/ijc.2910530503; SUZUKI I, 1994, LUNG CANCER-J IASLC, V11, P179, DOI 10.1016/0169-5002(94)90538-X; SWANSON CA, 1992, INT J CANCER, V50, P876, DOI 10.1002/ijc.2910500609; Takezaki T, 1996, JPN J CANCER RES, V87, P555, DOI 10.1111/j.1349-7006.1996.tb00259.x; Takezaki T, 2001, BRIT J CANCER, V84, P1199, DOI 10.1054/bjoc.2001.1722; Tavani A, 1996, EUR J CANCER PREV, V5, P313, DOI 10.1097/00008469-199610000-00002; Tavani A, 2001, EUR J CANCER PREV, V10, P191, DOI 10.1097/00008469-200104000-00015; Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525; Terry P, 1998, INT J CANCER, V76, P35, DOI 10.1002/(SICI)1097-0215(19980330)76:1&lt;35::AID-IJC7&gt;3.0.CO;2-Z; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; TONIOLO P, 1989, CANCER RES, V49, P5203; TRICHOPOULOS D, 1985, INT J CANCER, V36, P291, DOI 10.1002/ijc.1985.36.3.291; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; TUYNS A J, 1987, Nutrition and Cancer, V9, P81; TUYNS AJ, 1992, INT J CANCER, V51, P1, DOI 10.1002/ijc.2910510102; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; Tzonou A, 1996, INT J CANCER, V68, P300, DOI 10.1002/(SICI)1097-0215(19961104)68:3&lt;300::AID-IJC6&gt;3.0.CO;2-5; VANTVEER P, 1991, INT J CANCER, V47, P649, DOI 10.1002/ijc.2910470503; VICTORA CG, 1987, INT J CANCER, V39, P710, DOI 10.1002/ijc.2910390610; Voorrips LE, 2000, AM J EPIDEMIOL, V152, P1081, DOI 10.1093/aje/152.11.1081; Voorrips LE, 2000, CANCER CAUSE CONTROL, V11, P101, DOI 10.1023/A:1008906706084; Wakai K, 2000, NUTR CANCER, V38, P13, DOI 10.1207/S15327914NC381_3; WANG LD, 1985, CHINESE MED J-PEKING, V98, P206; Ward MH, 1999, AM J EPIDEMIOL, V149, P925, DOI 10.1093/oxfordjournals.aje.a009736; WINN DM, 1984, CANCER RES, V44, P1216; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; WUWILLIAMS AH, 1990, CANCER RES, V50, P2569; WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421; Xu ZY, 1996, AM J IND MED, V30, P7; YOU WC, 1988, CANCER RES, V48, P3518; YOUNG TB, 1988, INT J CANCER, V42, P167, DOI 10.1002/ijc.2910420205; YU GP, 1991, CANCER CAUSE CONTROL, V2, P169, DOI 10.1007/BF00056210; Yu Y, 1997, EUR J CANCER PREV, V6, P363, DOI 10.1097/00008469-199708000-00008; ZARIDZE D, 1991, INT J CANCER, V48, P493, DOI 10.1002/ijc.2910480404; ZATONSKI W, 1991, CANCER CAUSE CONTROL, V2, P3, DOI 10.1007/BF00052355; ZHENG W, 1992, AM J EPIDEMIOL, V136, P178, DOI 10.1093/oxfordjournals.aje.a116484	182	791	822	1	56	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0002-9165	1938-3207		AM J CLIN NUTR	Am. J. Clin. Nutr.	SEP	2003	78	3		S			559S	569S					11	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Nutrition & Dietetics	715RF	WOS:000184985500012	12936950	Bronze			2022-02-25	
J	Szymanska, K; Hainaut, P				Szymanska, K; Hainaut, P			TP53 and mutations in human cancer	ACTA BIOCHIMICA POLONICA			English	Article; Proceedings Paper	32nd Annual Meeting of the European-Environmental-Mutagen-Society	SEP 03-07, 2002	WARSAW, POLAND	European Enviro Mutagen Soc		TP53; mutation; cancer; mutation fingerprint; ser-249; CF DNA	HEPATOCELLULAR-CARCINOMA; P53 MUTATIONS; DNA; GENE	TP53 is the most frequently mutated gene in human cancer, with a predominance of missense mutations scattered over 200 codons. In many cancers, specific mutation patterns can be identified, which are shaped by site-specific mutagenesis and by biological selection. In tobacco-related cancers (lung, head and neck), organ-specific patterns are observed, with many mutations compatible with the ones experimentally induced by tobacco carcinogens. In several other cancers, such as squamous cell carcinoma of the oesophagus or hepatocellular carcinoma (HCC), mutation patterns show geographic variations between regions of high and low incidence, suggesting a role for region-specific risk factors. HCC from high-incidence regions showing also a high prevalence of a specific Ser-249 TP53 mutation is one of the most striking examples of a mutagen fingerprint. All such assessments are useful to generate clues on the mutagenic mechanisms involved in human cancer. Moreover, it has been shown that DNA retrieved from plasma can be successfully used for detection of TP53 mutations, which gives hope for earlier more accurate detection of human cancers.	Int Agcy Res Canc, Unit Mol Carcinogenesis, F-69008 Lyon 08, France		Szymanska, K (corresponding author), Int Agcy Res Canc, Unit Mol Carcinogenesis, 150 Cours Albert Thomas, F-69008 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Ambs S, 1998, CANCER RES, V58, P334; Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913; Appella E, 2000, PATHOL BIOL, V48, P227; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAYAGROSJEAN L, 1995, J PHOTOCH PHOTOBIO B, V28, P115, DOI 10.1016/1011-1344(95)07130-T; Denissenko MF, 1998, ONCOGENE, V17, P3007, DOI 10.1038/sj.onc.1202214; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Giglia G, 1998, CANCER RES, V58, P4402; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Hainaut P, 2000, ADV CANCER RES, V77, P81; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sherr CJ, 2000, CANCER RES, V60, P3689; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803	21	50	53	3	9	ACTA BIOCHIMICA POLONICA	WARSAW	PASTEURA 3, 02-093 WARSAW, POLAND	0001-527X	1734-154X		ACTA BIOCHIM POL	Acta Biochim. Pol.		2003	50	1					231	238					8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	662VZ	WOS:000181970800024	12673364				2022-02-25	
J	Rusyn, I; Belpoggi, F; Camacho, L; Kafferlein, HU; Cattley, R; Estill, CF; Kanno, J; Le Curieux, F; Roberts, GK; Mraz, J; Umemura, T; Vlaanderen, J; Stubbings, W				Rusyn, I.; Belpoggi, F.; Camacho, L.; Kaefferlein, H. U.; Cattley, R.; Estill, C. F.; Kanno, J.; Le Curieux, F.; Roberts, G. K.; Mraz, J.; Umemura, T.; Vlaanderen, J.; Stubbings, W.		IARC Monographs Vol 125 Grp	Carcinogenicity of some industrial chemical intermediates and solvents	LANCET ONCOLOGY			English	News Item									Int Agcy Res Canc, Lyon, France				Stubbings, William A./AAW-8154-2020	Stubbings, William A./0000-0002-8538-4693; Camacho, Luisa/0000-0002-3300-3895; Chung, Felicia/0000-0003-1043-4948; Li, Mengmeng/0000-0001-6630-7468	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline		International Agency for Research on Cancer, 2019, SOM CHEM INT SOLV; Japan Bioassay Research Center, 2005, SUMM INH CARC STUD B; Japan Bioassay Research Center, 2015, INH CARC STUD 2 3 EP; Japan Bioassay Research Center, 2003, INH CARC STUD ALL CH; Japan Bioassay Research Center, 2005, SUMM INH CARC STUD 1; Lee EG, 2015, J OCCUP ENVIRON HYG, V12, pD123, DOI 10.1080/15459624.2015.1009989; National Toxicology Program, 2018, NTP TECHN REP TOX CA NTP TECHN REP TOX CA; Organisation for Economic Co-operation and Development Screening Information Data Sets, 2000, GLYC METH; Styllou M, 2015, DENT MATER, V31, P1335, DOI 10.1016/j.dental.2015.08.156	9	1	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JAN	2020	21	1					25	26		10.1016/S1470-2045(19)30779-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	JZ6KU	WOS:000505211900037	31787538				2022-02-25	
J	Saracci, R				Saracci, Rodolfo			The Sextant	EPIDEMIOLOGIA & PREVENZIONE			Italian	Editorial Material									[Saracci, Rodolfo] Int Agcy Res Canc, Lione, France		Saracci, R (corresponding author), Int Agcy Res Canc, Lione, France.						Polanyi K, 1944, GREAT TRANSFORMATION; Ruttner R., 2018, CAN DEMOCRACY SURVIV	2	1	1	0	0	INFERENZE SCARL	MILANO	VIA RICCIARELLI N 29, MILANO, 20148, ITALY	1120-9763	2385-1937		EPIDEMIOL PREV	Epidemiol. Prev.	JAN-FEB	2019	43	1					10	10		10.19191/EP19.1.P10.010			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	NX0JM	WOS:000575405400007	31111705				2022-02-25	
J	Bray, F; Soerjomataram, I				Bray, Freddie; Soerjomataram, Isabelle			Population attributable fractions continue to unmask the power of prevention	BRITISH JOURNAL OF CANCER			English	Editorial Material							GLOBAL BURDEN; CANCER; DEATHS	The population attributable fraction is a critical driver of evidence-based cancer prevention. With an increasing recognition of the need for high-level investment in cancer control, there is an overwhelming need for a new generation of descriptive studies that globally promote the long-term public health and economic benefits of cancer prevention.	[Bray, Freddie; Soerjomataram, Isabelle] Int Agcy Res Canc, Canc Surveillance Sect, Lyon, France		Bray, F (corresponding author), Int Agcy Res Canc, Canc Surveillance Sect, Lyon, France.	brayf@iarc.fr		Bray, Freddie/0000-0002-3248-7787			Andersson TML, 2017, EUR J CANCER, V79, P106, DOI 10.1016/j.ejca.2017.03.028; Arnold M., GLOBAL BURDEN UNPUB; Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4; Bray F, 2015, CANC DIS CONTROL PRI, V3; Bray F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv273; Brown KF, 2018, BRIT J CANCER, V118, P1130, DOI 10.1038/s41416-018-0029-6; Islami F, 2018, CA-CANCER J CLIN, V68, P31, DOI 10.3322/caac.21440; Parkin DM, 2011, BRIT J CANCER, V105, pS2, DOI 10.1038/bjc.2011.474; Pearce A, 2018, CANCER EPIDEMIOL, V53, P27, DOI 10.1016/j.canep.2017.12.013; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Stewart BW, 2016, CARCINOGENESIS, V37, P2, DOI 10.1093/carcin/bgv166; Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2; Wilson LF, 2018, INT J CANCER, V142, P691, DOI 10.1002/ijc.31088; World Health Assembly, 2017, WHA7012; World Health Organization (WHO), 2016, GLOB HLTH OBS DAT RE; World Health Organization (WHO), 2017, UPD APP 3 WHO GLOB N	16	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920	1532-1827		BRIT J CANCER	Br. J. Cancer	APR	2018	118	8					1031	1032		10.1038/s41416-018-0062-5			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	GC8XB	WOS:000430080700001	29567981	hybrid, Green Published			2022-02-25	
J	Tommasino, M				Tommasino, Massimo			Human papillomaviruses and carcinogenesis: well-established and novel models	JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES			English	Meeting Abstract	19th Annual International Meeting of the Institute-of-Human-Virology (IHV)	OCT 23-26, 2017	Univ Maryland, Sch Med, Baltimore, MD	Inst Human Virol	Univ Maryland, Sch Med				[Tommasino, Massimo] Int Agcy Res Canc, Lyon, France									0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1525-4135	1077-9450		JAIDS-J ACQ IMM DEF	JAIDS	APR	2018	77			1		G-101	44	44		10.1097/01.qai.0000532614.95518.d8			1	Immunology; Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Immunology; Infectious Diseases	GP1GG	WOS:000440562500040					2022-02-25	
J	Fernandez-Jimenez, N; Sklias, A; Ecsedi, S; Cahais, V; Degli-Esposti, D; Jay, A; Ancey, PB; Woo, HD; Hernandez-Vargas, H; Herceg, Z				Fernandez-Jimenez, Nora; Sklias, Athena; Ecsedi, Szilvia; Cahais, Vincent; Degli-Esposti, Davide; Jay, Antonin; Ancey, Pierre Benoit; Woo, Hae Dong; Hernandez-Vargas, Hector; Herceg, Zdenko			Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer	EPIGENETICS			English	Article						breast cancer subtypes; DNA methylome; EBF1; lowly methylated regions; transcription factor binding sites	DNA METHYLATION; TRANSCRIPTION FACTORS; RISK-FACTORS; GENOME; LANDSCAPE; ASSOCIATION; METASTASIS; PATTERNS; INVASION; NETWORK	Breast cancer (BC) encompasses heterogeneous pathologies with different subtypes exhibiting distinct molecular changes, including those related to DNA methylation. However, the role of these changes in mediating BC heterogeneity is poorly understood. Lowly methylated regions (LMRs), non-CpG island loci that usually contain transcription factor (TF) binding sites, have been suggested to act as regulatory elements that define cellular identity. In this study, we aimed to identify the key subtype-specific TFs that may lead to LMR generation and shape the BC methylome and transcription program. We initially used whole-genome bisulfite sequencing (WGBS) data available at The Cancer Genome Atlas (TCGA) portal to identify subtype-specific LMRs. Differentially methylated regions (DMRs) within the BC PAM50 subtype-specific LMRs were selected by comparing tumors and normal tissues in a larger TCGA cohort assessed by HumanMethylation450 BeadChip (450K) arrays and TF enrichment analyses were performed. To assess the impact of LMRs on gene expression, TCGA RNA sequencing data were downloaded and Pearson correlations between methylation levels of loci presenting subtype-specific TF motifs and expression of the nearest genes were calculated. WGBS methylome data revealed a large number of LMRs for each of the BC subtypes. Analysis of these LMRs in the 450K datasets available for a larger sample set identified 7,765, 5,657, and 19 differentially methylated positions (DMPs) between normal adjacent tissues and tumor tissues from basal, luminal, and HER2-enriched subtypes, respectively. Unsupervised clustering showed that the discriminatory power of the top DMPs was remarkably strong for basal BC. Interestingly, in this particular subtype, we found 4,409 differentially hypomethylated positions grouped into 1,185 DMRs with a strong enrichment for the early B-cell factor 1 (EBF1) motifs. The methylation levels of the DMRs containing EBF1 motifs showed a strong negative correlation with the expression of 719 nearby genes, including BTS2 and CD74, two oncogenes known to be specific for basal BC subtype and for poor outcome. This study identifies LMRs specific to the three main BC subtypes and reveals EBF1 as a potentially important regulator of BC subtype-specific methylation and gene expression program.	[Fernandez-Jimenez, Nora; Sklias, Athena; Ecsedi, Szilvia; Cahais, Vincent; Degli-Esposti, Davide; Jay, Antonin; Ancey, Pierre Benoit; Woo, Hae Dong; Hernandez-Vargas, Hector; Herceg, Zdenko] IARC, Epigenet Grp, 150 Cours Albert Thomas, F-69008 Lyon 08, France		Fernandez-Jimenez, N; Herceg, Z (corresponding author), IARC, Epigenet Grp, 150 Cours Albert Thomas, F-69008 Lyon 08, France.	nora.fernandez@ehu.eus; hercegz@iarc.fr	Fernandez-Jimenez, Nora/T-1535-2019; Blanco, Leire/O-5114-2017; Degli Esposti, Davide/M-1917-2015	Degli Esposti, Davide/0000-0003-1390-4845; Fernandez-Jimenez, Nora/0000-0001-6307-0880; Hernandez-Vargas, Hector/0000-0001-6045-2103	Institut National du Cancer (INCa, France)Institut National du Cancer (INCA) France; European Commission (EC) Seventh Framework Programme (FP7) Translational Cancer Research (TRANSCAN) Framework; Fondation ARC pour la Recherche sur le Cancer (France)Fondation ARC pour la Recherche sur le Cancer; IARC Fellowship (Marie Curie actions - People - COFUND); Postdoctoral Fellowship of the Basque Government; Fonds National de la Recherche, Luxembourg (AFR)Luxembourg National Research Fund [10100060]	This work was partially supported by grants from the Institut National du Cancer (INCa, France) and the European Commission (EC) Seventh Framework Programme (FP7) Translational Cancer Research (TRANSCAN) Framework and the Fondation ARC pour la Recherche sur le Cancer (France) to ZH. NFJ was partially supported by an IARC Fellowship (Marie Curie actions - People - COFUND) and a Postdoctoral Fellowship of the Basque Government. AS is supported by the Fonds National de la Recherche, Luxembourg (AFR code: 10100060).	Boller S, 2016, IMMUNITY, V44, P527, DOI 10.1016/j.immuni.2016.02.021; Burger L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt599; Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19; Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Domcke S, 2015, NATURE, V528, P575, DOI 10.1038/nature16462; DROIT A., 2014, RGADEM DE NOVO MOTIF; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Feldmann A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003994; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Greenwood C, 2012, J PROTEOMICS, V75, P3031, DOI 10.1016/j.jprot.2011.11.033; Guilhamon P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3166; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268; Iwafuchi-Doi M, 2014, GENE DEV, V28, P2679, DOI 10.1101/gad.253443.114; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kristensen VN, 2014, NAT REV CANCER, V14, P299, DOI 10.1038/nrc3721; Lee ST, 2012, NUCLEIC ACIDS RES, V40, P11339, DOI 10.1093/nar/gks957; Lin YC, 2010, NAT IMMUNOL, V11, P635, DOI 10.1038/ni.1891; Liu J, 2010, MOL CELL BIOCHEM, V335, P29, DOI 10.1007/s11010-009-0237-8; Marchal C, 2015, J CELL PHYSIOL, V230, P743, DOI 10.1002/jcp.24836; Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293; Purrington KS, 2014, CARCINOGENESIS, V35, P1012, DOI 10.1093/carcin/bgt404; Sayeed A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067191; Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500; Tian BX, 2012, TUMOR BIOL, V33, P2273, DOI 10.1007/s13277-012-0489-x; Umer M, 2013, ANTIOXID REDOX SIGN, V18, P1972, DOI 10.1089/ars.2012.4923; Wu H, 2013, J APPL MATH, V2013, P12, DOI DOI 10.1155/2013/716172; Yi EH, 2013, BIOCHEM BIOPH RES CO, V435, P685, DOI 10.1016/j.bbrc.2013.05.043; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433	36	13	13	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1559-2294	1559-2308		EPIGENETICS-US	Epigenetics		2017	12	11					964	972		10.1080/15592294.2017.1373919			9	Biochemistry & Molecular Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Genetics & Heredity	FQ9VE	WOS:000418709000006	29099283	Green Published, Bronze			2022-02-25	
J	Forman, D; Sierra, MS				Forman, David; Sierra, Monica S.			Cancer in Central and South America: Introduction	CANCER EPIDEMIOLOGY			English	Article						Neoplasm; Health systems; Health policies; Cancer registration; Central and South America	LATIN-AMERICA	Central and South American countries ( including Cuba) are experiencing rapid socio-demographic and epidemiologic changes and the nature of health problems are undergoing transition from infectious to chronic diseases, including cancer. Countries are poorly prepared to respond effectively to the subsequent challenges posed by the new patterns of disease. Existing data delineating the number of cancer cases and the distribution of cancer types from each country in the region are sparse due to limitations on health information systems for recording incidence and mortality despite improvements made in recent years. There is an urgent need for reliable statistics on cancer to inform governmental entities responsible for cancer control in the region. We attempted to obtain the best available cancer data from each country located in the region to provide an overview of current geographic patterns of cancer incidence and mortality in the 21st century. (C) 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd.	[Forman, David; Sierra, Monica S.] Int Agcy Res Canc, Lyon 08, France		Forman, D (corresponding author), Int Agcy Res Canc, Lyon 08, France.	formand@iarc.fr	Sierra, Monica S./H-1751-2015	Sierra, Monica S./0000-0003-1286-057X	International Agency for Research on Cancer; European Commission FP7 Marie Curie Actions	This work was undertaken during the tenure of a Postdoctoral Fellowship to Dr Monica S. Sierra from The International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions - People - Co-funding of regional, national and international programmes (COFUND).	Allemani C, 2014, LANCET, DOI S0140-6736(14)62038-9; [Anonymous], 2015, WORLD POP PROSP 2015, P194; [Anonymous], 2014, CANC INCIDENCE 5 CON, VX; [Anonymous], 2014, WORLD URB PROSP 2014, P194; [Anonymous], 2011, NONC DIS NCD COUNTR; Assessing national capacity for the prevention and control of noncommunicable diseases, 2013, ASS NAT CAP PREV CON; Atun R, 2015, LANCET, V385, P1230, DOI 10.1016/S0140-6736(14)61646-9; Barreto SM, 2012, INT J EPIDEMIOL, V41, P557, DOI 10.1093/ije/dys017; Brenes-Camacho G, 2009, J AGING HEALTH, V21, P730, DOI 10.1177/0898264309338299; Contreras-Hernandez IPF, 2012, RESEARCH, V9, P117; De Maio FG, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-36; Ferlay J, 2014, GLOBOCAN 2012 V1 0 C; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Giedion U, 2009, HEALTH AFFAIR, V28, P853, DOI 10.1377/hlthaff.28.3.853; Glassman A, 2010, HEALTH AFFAIR, V29, P2142, DOI 10.1377/hlthaff.2010.1038; Goss PE, 2013, LANCET ONCOL, V14, P391, DOI 10.1016/S1470-2045(13)70048-2; Hospedales CJ, 2012, GLOB HEART, V7, P73, DOI 10.1016/j.gheart.2012.02.002; Ilbawi AM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3008853; de la Jara JJ, 2015, BIOL RES, V48, DOI 10.1186/0717-6287-48-10; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Magnusson RS, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/1744-8603-10-44; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; Miranda JJ, 2008, TROP MED INT HEALTH, V13, P1225, DOI 10.1111/j.1365-3156.2008.02116.x; Romero LI, 2013, HEALTH RES POLICY SY, V11, DOI 10.1186/1478-4505-11-33; Strasser-Weippl K, 2015, LANCET ONCOL, V16, P1405, DOI 10.1016/S1470-2045(15)00218-1; UNDP, 2013, COUNTR PROF HUM DEV; Unger JP, 2008, AM J PUBLIC HEALTH, V98, P636, DOI 10.2105/AJPH.2006.099598; Vargas-Zea Nicolas, 2012, Value Health Reg Issues, V1, P218, DOI 10.1016/j.vhri.2012.09.004; Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2; World Bank, 2012, WORLD DEV IND 2012	31	9	11	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	SEP	2016	44			1			S3	S10		10.1016/j.canep.2016.04.008			8	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology; Public, Environmental & Occupational Health	EE3RT	WOS:000389515600002	27678321	hybrid			2022-02-25	
J	Sierra, MS; Soerjomataram, I; Forman, D				Sierra, Monica S.; Soerjomataram, Isabelle; Forman, David			Prostate cancer burden in Central and South America	CANCER EPIDEMIOLOGY			English	Article						Prostate; Neoplasm; Screening; Central and South America	INTERNATIONAL TRENDS; NUTRITION TRANSITION; MORTALITY TRENDS; PATTERNS; SURVIVAL; OBESITY; RISK; PREVALENCE; ETHNICITY; RELATIVES	Rationale and objective: The incidence of prostate cancer has increased in Central and South America (CSA) in the last few decades. We describe the geographical patterns and trends of prostate cancer in CSA. Methods: We obtained regional and national-level cancer incidence data from 48 population-based registries in 13 countries and nation-wide cancer deaths from the WHO mortality database for 18 countries. We estimated world population age-standardized incidence (ASR) and mortality (ASMR) rates per 100,000 person-years for 2003-2007 and the estimated annual percent change (EAPC) to describe time trends. Results: Prostate cancer was the most common cancer diagnosis and one of the leading causes of cancer deaths among males in most CSA countries. From 2003-2007, ASRs varied between countries (6-fold) and within countries (Brazil: 3-6-fold). French Guyana (147.1) and Brazil (91.4) had the highest ASRs whereas Mexico (28.9) and Cuba (24.3) had the lowest. ASMRs varied by 4-fold. Belize, Uruguay and Cuba (24.128.9) had the highest ASMRs while Peru, Nicaragua, and El Salvador (6.8-9.7) had the lowest. In Argentina, Brazil, Chile and Costa Rica prostate cancer incidence increased by 2.8-4.8% annually whereas mortality remained stable between 1997 and 2008. Conclusion: The geographic and temporal variation of prostate cancer rates observed in CSA may in part reflect differences in diagnostic and registration practices, healthcare access, treatment and death certification, and public awareness. The incidence of prostate cancer is expected to increase given recent early detection activities and increased public awareness; however, the impact of these factors on mortality remains to be elucidated. (C) 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article under the CC BY-NC-ND IGO 3.0 license.	[Sierra, Monica S.; Soerjomataram, Isabelle; Forman, David] Int Agcy Res Canc, Sect Canc Surveillance, Lyon, France		Sierra, MS (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, Lyon, France.	sierram@fellows.iarc.fr	Sierra, Monica S./H-1751-2015	Sierra, Monica S./0000-0003-1286-057X	International Agency for Research on Cancer; European CommissionEuropean CommissionEuropean Commission Joint Research Centre	This work was undertaken during the tenure of a Postdoctoral Fellowship to Dr Monica S. Sierra from The International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions - People - Co-funding of regional, national and international programmes (COFUND).	Allott EH, 2013, EUR UROL, V63, P800, DOI 10.1016/j.eururo.2012.11.013; Alvarez YHG, 2004, EUR J CANCER PREV, V13, P377, DOI 10.1097/00008469-200410000-00004; Andriole GL, 2012, J NATL CANCER I, V104, P125, DOI 10.1093/jnci/djr500; [Anonymous], 2014, CANC INC 5 CONT, VX; [Anonymous], 2013, GPC201321 I NAC CANC; [Anonymous], 2013, GUIA MAN ENF ONC ISB; [Anonymous], 2012, PLAN NAC PREV CONTR; [Anonymous], 2010, DIAGN TRAT CANC PROS; [Anonymous], 2002, PROGR NAC CONTR CANC; [Anonymous], 2014, MORT DAT; [Anonymous], 2014, FOOD NUTR PHYS ACT P; [Anonymous], 2011, STAT DAT AN STAT SOF; Antonopoulos IM, 2001, INT BRAZ J UROL, V27, P227; Baade PD, 2004, CANCER CAUSE CONTROL, V15, P237, DOI 10.1023/B:CACO.0000024212.66334.26; Baade Peter D, 2015, Asian Pac J Cancer Prev, V16, P1259; Baechler R, 2001, REV MED CHILE, V129, P1305; Barros Milton S, 2003, Int. braz j urol., V29, P306, DOI 10.1590/S1677-55382003000400004; Belon AP, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-39; Bermudez Odilia I., 2003, Cad. Saúde Pública, V19, pS87, DOI 10.1590/S0102-311X2003000700010; Best Plummer Wallis S, 2009, Infect Agent Cancer, V4 Suppl 1, pS7, DOI 10.1186/1750-9378-4-S1-S7; Bishop Karen S., 2012, Current Pharmacogenomics & Personalized Medicine, V10, P70; Bosetti C, 2005, ANN ONCOL, V16, P489, DOI 10.1093/annonc/mdi086; BOUCHARDY C, 1991, CANCER EPIDEM BIOMAR, V1, P21; Bouchardy C, 2008, INT J CANCER, V123, P421, DOI 10.1002/ijc.23520; Bravo LE, 2012, COLOMB MEDICA, V43, P246; Bray F, 2010, EUR J CANCER, V46, P3040, DOI 10.1016/j.ejca.2010.09.013; Bray F, 2009, EUR J CANCER, V45, P747, DOI 10.1016/j.ejca.2008.11.032; Bruner DW, 2003, INT J CANCER, V107, P797, DOI 10.1002/ijc.11466; Buschemeyer WC, 2007, EUR UROL, V52, P331, DOI 10.1016/j.eururo.2007.04.069; Center MM, 2012, EUR UROL, V61, P1079, DOI 10.1016/j.eururo.2012.02.054; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Central Intelligence Agency, 2013, WORLD FACTBOOK; Chatenoud L, 2014, ANN ONCOL, V25, P1843, DOI 10.1093/annonc/mdu206; Chatenoud L, 2010, EUR J CANCER PREV, V19, P79, DOI 10.1097/CEJ.0b013e32833233be; Coldman AJ, 2003, CAN MED ASSOC J, V168, P31; Consenso nacional inter-sociedades para el diagnostico y tratamiento del cancer de prostata, 2014, CONS NAC INT DIAGN T; Doll R., 1966, CANC INCIDENCE 5 CON, VI; Esteve J, 1994, IARC Sci Publ, P1; Evans S, 2008, INT J CANCER, V123, P430, DOI 10.1002/ijc.23500; Faria EF, 2010, UROLOGY, V76, P1052, DOI 10.1016/j.urology.2010.02.044; Ferlay J, 2014, GLOBOCAN 2012 V1 0 C; Forman D., 2014, CANC INCIDENCE 5 CON; Freedland SJ, 2007, EPIDEMIOL REV, V29, P88, DOI 10.1093/epirev/mxm006; Galan Y, 2009, MEDICC REV, V11, P19, DOI 10.37757/MR2009V11.N3.6; Glina S, 2001, INT BRAZ J UROL, V27, P235; Gomez-Guerra LS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-91; Gonzalez RS, 2014, MEDICC REV, V16, P73, DOI 10.37757/MR2014.V16.N3-4.14; Guia Clinica, 2010, 2010 CANC PROST PERS; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; Humphrey P. A., 2014, WORLD CANC REPORT 20; Huynen MMTE, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-14; Ilic D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004720.pub3; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; de la Jara JJ, 2015, BIOL RES, V48, DOI 10.1186/0717-6287-48-10; Johns LE, 2003, BJU INT, V91, P789, DOI 10.1046/j.1464-410X.2003.04232.x; Kicinski M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027130; Kral M, 2011, BIOMED PAP, V155, P3, DOI 10.5507/bp.155.2011.001; Lima CA, 2013, REV ASSOC MED BRAS, V59, P15, DOI 10.1590/S0104-42302013000100006; Lopez M. A., 2004, REV ARGENTINA UROLOG, V69, P210; Martins ACP, 2000, BRAZ J UROL, V26, P516; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; Neppl-Huber C, 2012, ANN ONCOL, V23, P1325, DOI 10.1093/annonc/mdr414; Niclis C, 2011, CAD SAUDE PUBLICA, V27, P123, DOI 10.1590/S0102-311X2011000100013; Odedina Folakemi T, 2009, Infect Agent Cancer, V4 Suppl 1, pS2, DOI 10.1186/1750-9378-4-S1-S2; Oliver SE, 2001, INT J CANCER, V92, P893, DOI 10.1002/ijc.1260; Parkin DM, 2009, EUR J CANCER, V45, P756, DOI 10.1016/j.ejca.2008.11.033; Paschoalin Edson L, 2003, Int. braz j urol., V29, P300, DOI 10.1590/S1677-55382003000400003; Politis M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000970; Popiolek M, 2013, EUR UROL, V63, P428, DOI 10.1016/j.eururo.2012.10.002; Popkin BM, 1998, PUBLIC HEALTH NUTR, V1, P5, DOI 10.1079/PHN19980004; Pow-Sang Mariela, 2013, Rev. perú. med. exp. salud publica, V30, P124, DOI 10.1590/s1726-46342013000100023; Pow-Sang M, 2009, ACTAS UROL ESP, V33, P1057; Quinn M, 2002, BJU INT, V90, P162, DOI 10.1046/j.1464-410X.2002.2822.x; Quinn M, 2002, BJU INT, V90, P174, DOI 10.1046/j.1464-410X.2002.02823.x; Reyes-Ortiz Carlos A, 2007, Cancer Control, V14, P388; Rivera JA, 2004, NUTR REV, V62, pS149, DOI 10.1111/j.1753-4887.2004.tb00086.x; Salazar Miriam Rosario, 2013, Rev. perú. med. exp. salud publica, V30, P105, DOI 10.1590/s1726-46342013000100020; Sansone L, 1998, DADOS-REV CIENC SOC, V41, P751, DOI 10.1590/S0011-52581998000400003; Schroder FH, 2012, EUR UROL, V62, P745, DOI 10.1016/j.eururo.2012.05.068; Segi M., 1963, TRENDS CANC MORTALIT; Sighoko D., 2013, CANC EPIDEMIOLOGY LO, P63; Soerjomataram I, 2012, LANCET, V380, P1840, DOI 10.1016/S0140-6736(12)60919-2; Srougi V, 2011, INT BRAZ J UROL, V37, P507, DOI 10.1590/S1677-55382011000400010; Tobias-Machado M, 2013, INT BRAZ J UROL, V39, P328, DOI 10.1590/S1677-5538.IBJU.2013.03.05; Travassos Claudia, 2004, Cad. Saúde Pública, V20, P660, DOI 10.1590/S0102-311X2004000300003; Trucco C., 1998, REV CHILENA UROLOGIA, V63, P166; Uauy R, 2001, J NUTR, V131, p893S, DOI 10.1093/jn/131.3.893S; Welch HG, 2009, J NATL CANCER I, V101, P1325, DOI 10.1093/jnci/djp278; Yepez MC, 2012, COLOMB MEDICA, V43, P256; Zeegers MPA, 2003, CANCER-AM CANCER SOC, V97, P1894, DOI 10.1002/cncr.11262	90	17	18	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	SEP	2016	44			1			S131	S140		10.1016/j.canep.2016.06.010			10	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	EE3RT	WOS:000389515600014	27678315	hybrid			2022-02-25	
J	Franceschi, S				Franceschi, Silvia			beta- and gamma-Human Papillomavirus Types and Smoking in Head and Neck Cancer	JAMA ONCOLOGY			English	Letter									[Franceschi, Silvia] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Agalliu I, 2016, JAMA ONCOL, V2, P599, DOI 10.1001/jamaoncol.2015.5504; Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Rollison DE, 2016, JAMA ONCOL, V2, P606, DOI 10.1001/jamaoncol.2015.5686; Tommasino M, 2014, SEMIN CANCER BIOL, V26, P13, DOI 10.1016/j.semcancer.2013.11.002	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2374-2437	2374-2445		JAMA ONCOL	JAMA Oncol.	MAY	2016	2	5					687	687		10.1001/jamaoncol.2016.0970			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	DW5KS	WOS:000383684300028	27244680				2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, Rengaswamy			HPV vaccination: The most pragmatic cervical cancer primary prevention strategy	INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS			English	Article						Cervical cancer; HPV vaccination; National programs; Prevention; Screening	HUMAN-PAPILLOMAVIRUS VACCINATION; COST-EFFECTIVENESS; NATURAL-HISTORY; 3-DOSE SCHEDULE; IMMUNOGENICITY; ADOLESCENTS; COUNTRIES; NEOPLASIA; HEALTH; WOMEN	The evidence that high-risk HPV infections cause cervical cancers has led to two new approaches for cervical cancer control: vaccination to prevent HPV infections, and HPV screening to detect and treat cervical precancerous lesions. Two vaccines are currently available: quadrivalent vaccine targeting oncogenic HPV types 16, 18, 6, and 11, and bivalent vaccine targeting HPV 16 and 18. Both vaccines have demonstrated remarkable immunogenicity and substantial protection against persistent infection and high-grade cervical cancer precursors caused by HPV 16 and 18 in HPV-naive women, and have the potential to prevent 70% of cervical cancers in adequately vaccinated populations. HPV vaccination is now implemented in national programs in 62 countries, including some low- and middle-income countries. The early findings from routine national programs in high-income countries are instructive to encourage low- and middle-income countries with a high risk of cervical cancer to roll out HPV vaccination programs and to introduce resource-appropriate cervical screening programs. (C) 2015 Published by Elsevier Ireland Ltd.	Int Agcy Res Canc, F-69372 Lyon 08, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	sankarr@iarc.fr					[Anonymous], 2014, Wkly Epidemiol Rec, V89, P221; Baldur-Felskov B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt460; Baussano I, 2013, INT J CANCER, V133, P1876, DOI 10.1002/ijc.28197; Binagwaho A, 2013, B WORLD HEALTH ORGAN, V91, P697, DOI 10.2471/BLT.12.116087; Diaz M, 2008, BRIT J CANCER, V99, P230, DOI 10.1038/sj.bjc.6604462; Dobson SRM, 2013, JAMA-J AM MED ASSOC, V309, P1793, DOI 10.1001/jama.2013.1625; Elbasha EH, 2007, EMERG INFECT DIS, V13, P28, DOI 10.3201/eid1301.060438; Ferlay J, 2013, CANC INCIDENCE MORTA; Fesenfeld M, 2013, VACCINE, V31, P3786, DOI 10.1016/j.vaccine.2013.06.060; Garland SM, 2014, CLIN THER, V36, P17, DOI 10.1016/j.clinthera.2013.12.005; *INT AG RES CANC, 2007, IARC MON EV CARC RIS, V90; Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2; Kavanagh K, 2014, BRIT J CANCER, V110, P2804, DOI 10.1038/bjc.2014.198; Kreimer AR, 2011, JNCI-J NATL CANCER I, V103, P1444, DOI 10.1093/jnci/djr319; Lazcano-Ponce E, 2014, VACCINE, V32, P725, DOI 10.1016/j.vaccine.2013.11.059; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; Moscicki AB, 2012, VACCINE, V30, pF24, DOI 10.1016/j.vaccine.2012.05.089; Natunen K., 2013, Journal of Vaccines and Vaccination, V4, P1000172; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Reynales-Shigematsu LM, 2009, ARCH MED RES, V40, P503, DOI 10.1016/j.arcmed.2009.08.004; Romanowski B, 2014, HUM VACC IMMUNOTHER, V10, P1155, DOI 10.4161/hv.28022; Romanowski B, 2011, HUM VACCINES, V7, P1374, DOI 10.4161/hv.7.12.18322; Safaeian M, 2013, CANCER PREV RES, V6, P1242, DOI 10.1158/1940-6207.CAPR-13-0203; Salani R, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.09.012; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Smith Megan A, 2014, BMC Res Notes, V7, P109, DOI 10.1186/1756-0500-7-109	26	17	20	5	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7292	1879-3479		INT J GYNECOL OBSTET	Int. J. Gynecol. Obstet.	OCT	2015	131			1			S33	S35		10.1016/j.ijgo.2015.02.014			3	Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology	CT5NH	WOS:000362856600009	26433502	hybrid			2022-02-25	
J	Romieu, I; Scoccianti, C; Chajes, V; De Batlle, J; Rinaldi, S				Romieu, Isabelle; Scoccianti, Chiara; Chajes, Veronique; De Batlle, Jordi; Rinaldi, Sabina			Alcohol intake and breast cancer in the European Prospective investigation into Cancer and Nutrition (EPIC) study	CANCER RESEARCH			English	Meeting Abstract	105th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 05-09, 2014	San Diego, CA	Amer Assoc Canc Res					[Romieu, Isabelle; Scoccianti, Chiara; Chajes, Veronique; De Batlle, Jordi; Rinaldi, Sabina] Int Agcy Res Canc, F-69372 Lyon, France				de Batlle, Jordi/G-6724-2016	de Batlle, Jordi/0000-0003-3500-6608				0	1	1	1	2	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	OCT 1	2014	74	19		S		1271				10.1158/1538-7445.AM2014-1271			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	CB8UN	WOS:000349906901010					2022-02-25	
J	Plummer, M				Plummer, Martyn			Helicobacter pylori and Colonic Neoplasms	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Editorial Material							HUMAN-PAPILLOMAVIRUS; RISK-FACTOR; CANCERS	A large cross-sectional survey suggests an association between H. pylori gastritis and colonic neoplasms, but the results should be interpreted with caution. Am J Gastroenterol 2013; 108: 216-217; doi: 10.1038/ajg.2012.409	Int Agcy Res Canc, F-69372 Lyon 08, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	plummerm@iarc.fr		Plummer, Martyn/0000-0001-5130-6497			Antonsson A, 2010, CANCER EPIDEM BIOMAR, V19, P2080, DOI 10.1158/1055-9965.EPI-10-0033; Center MM, 2009, CANCER EPIDEM BIOMAR, V18, P1688, DOI 10.1158/1055-9965.EPI-09-0090; de Martel C, 2009, BRIT J CANCER, V100, P194, DOI 10.1038/sj.bjc.6604780; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; IARC, 2012, MON EV CARC RISKS B, V100B; Koshiol J, 2011, JNCI-J NATL CANCER I, V103, P501, DOI 10.1093/jnci/djr003; Koshiol J, 2010, CANCER EPIDEM BIOMAR, V19, P1889, DOI 10.1158/1055-9965.EPI-10-0506; Sonnenberg A, 2013, AM J GASTROENTEROL, V108, P208, DOI 10.1038/ajg.2012.407	9	6	7	2	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0002-9270	1572-0241		AM J GASTROENTEROL	Am. J. Gastroenterol.	FEB	2013	108	2					216	217		10.1038/ajg.2012.409			2	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	112NZ	WOS:000316600300010	23381070				2022-02-25	
J	da Costa, AN; Herceg, Z				da Costa, Andre Nogueira; Herceg, Zdenko			Detection of cancer-specific epigenomic changes in biofluids: Powerful tools in biomarker discovery and application	MOLECULAR ONCOLOGY			English	Review						Biomarkers; DNA methylation; Body fluids; Early cancer detection; Epigenomics	ABERRANT DNA METHYLATION; GENE-PROMOTER HYPERMETHYLATION; CIRCULATING FREE DNA; K-RAS MUTATIONS; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; QUANTITATIVE-ANALYSIS; CELL-FREE; SERUM DNA; PLASMA DNA	The genetic and epigenetic material originating from tumour that can be found in body fluids of individuals with cancer harbours tumour-specific alterations and represents an attractive target for biomarker discovery. Epigenetic changes (DNA methylation, histone modifications and non-coding RNAs) are present ubiquitously in virtually all types of human malignancies and may appear in early cancer development, and thus they provide particularly attractive markers with broad applications in diagnostics. In addition, because changes in the epigenome may constitute a signature of specific exposure to certain risk factors, they have the potential to serve as highly specific biomarkers for risk assessment. While reliable detection of cancer-specific epigenetic changes has proven to be technically challenging, a substantial progress has been made in developing the methodologies that allow an efficient and sensitive detection of epigenomic changes using the material originating from body fluids. In this review we discuss the application of epigenomics as a tool for biomarker research, with the focus on the analysis of DNA methylation in biofluids. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.	[da Costa, Andre Nogueira; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon 08, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	herceg@iacr.fr			National Cancer Institute (NIH), United States; l'Association pour la Recherche sur le Cancer (ARC), FranceFondation ARC pour la Recherche sur le Cancer; la Ligue Nationale Contre le Cancer, France; Swiss Bridge Award; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation; IARC; ECEuropean CommissionEuropean Commission Joint Research Centre	We apologize to authors whose relevant publications were not cited due to space limitation. The work of the IARC Epigenetics Group is supported by grants from the National Cancer Institute (NIH), United States; l'Association pour la Recherche sur le Cancer (ARC), France; la Ligue Nationale Contre le Cancer, France; the Swiss Bridge Award; and the Bill and Melinda Gates Foundation (to ZH). ANdC is a recipient of a Postdoctoral Fellowship from the IARC, partially supported by the EC FP7 Marie Curie Actions - People - Co-funding of regional, national and international programmes (COFUND).	Anglim P.P., 2008, MOL CANC, V7; Anker P, 1997, GASTROENTEROLOGY, V112, P1114, DOI 10.1016/S0016-5085(97)70121-5; Balassiano K, 2011, CANCER LETT, V311, P85, DOI 10.1016/j.canlet.2011.06.038; Baryshnikova E, 2008, CLIN CANCER RES, V14, P1913, DOI 10.1158/1078-0432.CCR-07-1741; Begum S, 2011, CLIN CANCER RES, V17, P4494, DOI 10.1158/1078-0432.CCR-10-3436; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Berdasco Maria, 2009, V507, P23, DOI 10.1007/978-1-59745-522-0_2; Board RE, 2007, BIOMARK INSIGHTS, V2, P307; Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708; Brawley OW, 2005, J CLIN ONCOL, V23, P293, DOI 10.1200/JCO.2005.06.107; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; Carmona FJ, 2010, MUTAT RES-FUND MOL M, V693, P53, DOI 10.1016/j.mrfmmm.2010.07.007; Chang H, 2008, EXP MOL PATHOL, V85, P96, DOI 10.1016/j.yexmp.2008.07.001; Christensen Brock C., 2011, Frontiers in Genetics, V2, P84, DOI 10.3389/fgene.2011.00084; Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745; Costa VL, 2010, CLIN CANCER RES, V16, P5842, DOI 10.1158/1078-0432.CCR-10-1312; Dabritz J, 2005, BRIT J CANCER, V92, P405, DOI 10.1038/sj.bjc.6602319; Dabritz J, 2009, PANCREAS, V38, P534, DOI 10.1097/MPA.0b013e31819f6376; Daniunaite K, 2011, MEDICINA-LITHUANIA, V47, P147; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Dobrzycka B, 2010, INT J CANCER, V127, P612, DOI 10.1002/ijc.25077; Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eissa S, 2011, CANCER EPIDEM BIOMAR, V20, P1657, DOI 10.1158/1055-9965.EPI-11-0237; Ellinger J, 2008, J UROLOGY, V179, P346, DOI 10.1016/j.juro.2007.08.091; Emes RD, 2012, J MOL ENDOCRINOL, V49, pR19, DOI 10.1530/JME-12-0045; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferlay J, 2010, IARC CANCERBASE; Frattini M, 2008, CANCER LETT, V263, P170, DOI 10.1016/j.canlet.2008.03.021; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fromont-Hankard G, 2002, ARCH PATHOL LAB MED, V126, P432; Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54; Gormally E, 2007, MUTAT RES-REV MUTAT, V635, P105, DOI 10.1016/j.mrrev.2006.11.002; Herceg Z, 2007, MOL ONCOL, V1, P26, DOI 10.1016/j.molonc.2007.01.004; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262; Herceg Z, 2011, MUTAT RES-REV MUTAT, V727, P55, DOI 10.1016/j.mrrev.2011.04.001; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749; Hitchins MP, 2011, CLIN GENET, V80, P428, DOI 10.1111/j.1399-0004.2011.01660.x; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Hu WW, 2003, BIOCHEMISTRY-US, V42, P10012, DOI 10.1021/bi034631s; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Huang ZH, 2006, CANCER LETT, V243, P64, DOI 10.1016/j.canlet.2005.11.027; Huang ZH, 2011, EXP MOL PATHOL, V91, P702, DOI 10.1016/j.yexmp.2011.08.004; Hutajulu SH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-48; Hwang SH, 2011, CLIN CHEM LAB MED, V49, P699, DOI 10.1515/CCLM.2011.108; Iyer P, 2010, EXP MOL PATHOL, V88, P107, DOI 10.1016/j.yexmp.2009.09.012; Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708; James SJ, 2002, J NUTR, V132, p2361S, DOI 10.1093/jn/132.8.2361S; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kalantari M, 2004, J VIROL, V78, P12762, DOI 10.1128/JVI.78.23.12762-12772.2004; Karimi M, 2006, EPIGENETICS-US, V1, P45; Kaur P, 2010, J INFECT DIS, V202, P700, DOI 10.1086/655398; Kimura T, 2004, ANN NY ACAD SCI, V1022, P55, DOI 10.1196/annals.1318.010; Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027; Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719; Lee HS, 2009, CLIN CANCER RES, V15, P812, DOI 10.1158/1078-0432.CCR-08-0266; Li B, 2011, EPIGENETICS-US, V6, P307, DOI 10.4161/epi.6.3.14182; Li CN, 2003, J CLIN LAB ANAL, V17, P103, DOI 10.1002/jcla.10081; Li H, 2003, ADV CANCER RES, V89, P133, DOI 10.1016/S0065-230X(03)01004-2; Liggett T, 2010, CANCER-AM CANCER SOC, V116, P1674, DOI 10.1002/cncr.24893; Lindforss U, 2005, ANTICANCER RES, V25, P657; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lister R, 2009, GENOME RES, V19, P959, DOI 10.1101/gr.083451.108; Liu JB, 2011, WORLD J GASTROENTERO, V17, P4718, DOI 10.3748/wjg.v17.i42.4718; Liu Y, 2003, CARCINOGENESIS, V24, P1897, DOI 10.1093/carcin/bgg169; Liu Y, 2008, ANTICANCER RES, V28, P2061; Melnikov A, 2009, J MOL DIAGN, V11, P60, DOI 10.2353/jmoldx.2009.080072; Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012; Mirza S, 2010, CLIN BIOCHEM, V43, P380, DOI 10.1016/j.clinbiochem.2009.11.016; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Paliwal A, 2010, METHODS, V52, P242, DOI 10.1016/j.ymeth.2010.03.008; Paliwal A, 2010, CANCER RES, V70, P2779, DOI 10.1158/0008-5472.CAN-09-4550; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; Perego RA, 2008, EUR J CANCER, V44, P1039, DOI 10.1016/j.ejca.2008.03.008; Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Selaru FM, 2009, AM J GASTROENTEROL, V104, P1910, DOI 10.1038/ajg.2008.145; Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992; SHAPIRO B, 1983, CANCER, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S; Shin KC, 2012, ONCOL REP, V27, P911, DOI 10.3892/or.2011.1566; Shirahata A, 2012, ANTICANCER RES, V32, P791; Silva JM, 2002, ANN SURG ONCOL, V9, P71, DOI 10.1245/aso.2002.9.1.71; Sincic N, 2011, CURR OPIN ONCOL, V23, P69, DOI 10.1097/CCO.0b013e3283412eb4; Skvortsova TE, 2006, BRIT J CANCER, V94, P1492, DOI 10.1038/sj.bjc.6603117; Srivastava S, 2000, LAB INVEST, V80, P1147, DOI 10.1038/labinvest.3780122; Stein RA, 2012, J EPIDEMIOL COMMUN H, V66, P8, DOI 10.1136/jech.2010.130690; Stroun M, 2001, ANN NY ACAD SCI, V945, P258; Sunami E, 2009, CLIN CHEM, V55, P559, DOI 10.1373/clinchem.2008.108498; Szymanska K, 2009, CANCER EPIDEM BIOMAR, V18, P1638, DOI 10.1158/1055-9965.EPI-08-1102; Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085; Talamonti M, 2007, ARCH SURG-CHICAGO, V142, P538; Taylor KH, 2007, CANCER RES, V67, P8511, DOI 10.1158/0008-5472.CAN-07-1016; Toyota M, 1999, CANCER RES, V59, P2307; Ulivi P, 2006, J CELL PHYSIOL, V206, P611, DOI 10.1002/jcp.20503; Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489; Vaissiere T, 2009, EPIGENETICS-US, V4, P221, DOI 10.4161/epi.8833; Villar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037707; Villar S, 2011, ENVIRON HEALTH PERSP, V119, P1635, DOI 10.1289/ehp.1103539; Warren JD, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-133; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Wong IHN, 2003, CLIN CANCER RES, V9, P1047; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Yeo W, 2005, LIVER INT, V25, P266, DOI 10.1111/j.1478-3231.2005.01084.x; Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027; Zazula M, 2006, DIAGN MOL PATHOL, V15, P24, DOI 10.1097/00019606-200603000-00004; Zhang RF, 2010, LUNG CANCER, V69, P225, DOI 10.1016/j.lungcan.2009.11.009; Zhang YJ, 2006, INT J CANCER, V119, P985, DOI 10.1002/ijc.21699; Zhang YJ, 2012, WORLD J HEPATOL, V4, P169, DOI [10.4254/wjh.v4.i5.169., 10.4254/wjh.v4.i5.169]; Zheng ZM, 2006, FRONT BIOSCI-LANDMRK, V11, P2286, DOI 10.2741/1971; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217; Ziegler A, 2002, CANCER TREAT REV, V28, P255, DOI 10.1016/S0305-7372(02)00077-4	127	16	16	0	37	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1574-7891	1878-0261		MOL ONCOL	Mol. Oncol.	DEC	2012	6	6			SI		704	715		10.1016/j.molonc.2012.07.005			12	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	052CQ	WOS:000312175700010	22925902	Green Published			2022-02-25	
J	Plummer, M				Plummer, Martyn			Comments on 'The BUGS project: Evolution, critique and future directions'	STATISTICS IN MEDICINE			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon 08, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	plummer@iarc.fr		Plummer, Martyn/0000-0001-5130-6497			Alexander C., 1977, PATTERN LANGUAGE TOW; Gamma E, 1995, DESIGN PATTERNS ELEM	2	0	0	0	8	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0277-6715			STAT MED	Stat. Med.	NOV 10	2009	28	25					3073	3074		10.1002/sim.3672			2	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics	514QG	WOS:000271409300004	19827065				2022-02-25	
J	Boffetta, P; Straif, K				Boffetta, Paolo; Straif, Kurt			Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SWEDISH MOIST SNUFF; NORTHERN SWEDEN; MEN; SMOKING; DISEASE; MORTALITY	Objective To assess whether people who use smokeless tobacco products are at increased risk of myocardial infarction and stroke. Design Meta-analysis of observational studies from Sweden and the United States. Data sources Electronic databases and reference lists. Data extraction Quantitative estimates of the association between use of smokeless tobacco products and risk of myocardial infarction and stroke among never smokers. Review methods Both authors independently abstracted risk estimates and study characteristics. Summary relative risks were estimated on the basis of random effects models. Results 11 studies, mainly in men, were included. Eight risk estimates were available for fatal myocardial infarction: the relative risk for ever use of smokeless tobacco products was 1.13 (95% confidence 1.06 to 1.21) and the excess risk was restricted to current users. The relative risk of fatal stroke, on the basis of five risk estimates, was 1.40 (1.28 to 1.54). The studies from both the United States and Sweden showed an increased risk of death from myocardial infarction and stroke. The inclusion of non-fatal myocardial infarction and non-fatal stroke lowered the summary risk estimates. Data on dose-response were limited but did not suggest a strong relation between risk of dying from either disease and frequency or duration of use of smokeless tobacco products. Conclusion An association was detected between use of smokeless tobacco products and risk of fatal myocardial infarction and stroke, which does not seem to be explained by chance.	[Boffetta, Paolo; Straif, Kurt] Int Agcy Res Canc, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr					Accortt NA, 2002, AM J EPIDEMIOL, V156, P730, DOI 10.1093/aje/kwf106; [Anonymous], 2008, MORT DAT; Asplund K, 2003, STROKE, V34, P1754, DOI 10.1161/01.STR.0000076011.02935.A1; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BROADSTOCK M, 2007, NZ HLTH TECHNOLOGY A, V10, P1; Critchley JA, 2004, EUR J CARDIOV PREV R, V11, P101, DOI 10.1097/01.hjr.0000114971.39211.d7; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; Greenland S, 2008, MODERN EPIDEMIOLOGY, P652; Haglund B, 2007, SCAND J PUBLIC HEALT, V35, P618, DOI 10.1080/14034940701436949; Henley SJ, 2005, CANCER CAUSE CONTROL, V16, P347, DOI 10.1007/s10552-004-5519-6; Hergens MP, 2007, J INTERN MED, V262, P351, DOI 10.1111/j.1365-2796.2007.01816.x; Hergens MP, 2008, EPIDEMIOLOGY, V19, P794, DOI 10.1097/EDE.0b013e3181878b33; Hergens MP, 2005, EPIDEMIOLOGY, V16, P12, DOI 10.1097/01.ede.0000147108.92895.ba; HUHTASAARI F, 1992, BRIT MED J, V305, P1252, DOI 10.1136/bmj.305.6864.1252; Huhtasaari F, 1999, J AM COLL CARDIOL, V34, P1784, DOI 10.1016/S0735-1097(99)00409-X; *INT AG RES CANC, 2008, IARC MON EV CARC RIS, V89; Lee PN, 2007, INT J EPIDEMIOL, V36, P789, DOI 10.1093/ije/dym039; Rodu B, 2002, J INTERN MED, V252, P398, DOI 10.1046/j.1365-2796.2002.01057.x; Rodu Brad, 2006, Harm Reduct J, V3, P37, DOI 10.1186/1477-7517-3-37; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P115; SCENIHR, 2008, SCI OP HLTH EFF SMOK; *SOC, 2006, 2005 SOC, P24; StataCorp LP, 2005, INT STAT 9 1 WIND; Stegmayr B, 2005, SCAND J PUBLIC HEALT, V33, P321, DOI 10.1080/14034940510032301; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tomar SL, 2003, NICOTINE TOB RES, V5, P561, DOI 10.1080/1462220031000118667; Wermberg P, 2007, J INTERN MED, V262, P360, DOI 10.1111/j.1365-2796.2007.01813.x	28	135	137	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2009	339								b3060	10.1136/bmj.b3060			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	486RZ	WOS:000269216700005	19690343	hybrid, Green Published			2022-02-25	
J	Franceschi, S; De Vuyst, H				Franceschi, Silvia; De Vuyst, Hugo			Human papillomavirus vaccines and anal carcinoma	CURRENT OPINION IN HIV AND AIDS			English	Article						anal intraepithelial lesion; anal squamous cell carcinoma; epidemiology; human immunodeficiency virus; human papillomavirus		Purpose of review To explore the possible role of current prophylactic vaccines against human papillomavirus (HPV) in the prevention of anal intraepithelial neoplasia and squamous cell carcinoma of the anus (SCCA). Recent findings SCCA incidence is increasing in several developed countries, particularly in HIV-positive men who have sex with men (MSM). Antiretroviral treatments against HIV do not seem to decrease SCCA risk. A meta-analysis of 955 SCCA showed that HPV prevalence was 85%, i.e., similar to that in cervical carcinoma, with an even stronger predominance of HPV16. In addition, more than 90% prevalence of HPV was found in anal intraepithelial neoplasia. Trials of the bivalent and quadrivalent vaccines against HPV16/18 have shown nearly 100% efficacy against high-grade lesions of the cervix, vulva and vagina in uninfected women under 26 years of age. The quadrivalent vaccine that includes HPV6/11/16/18 has also shown high efficacy against anogenital warts. Summary Currently available HPV vaccines could potentially prevent the vast majority of SCCA, but only if administered before the onset of sexual activity. Answers to some still open questions, notably vaccine efficacy in men and HIV-infected individuals and willingness to expand vaccination programmes to both sexes, are essential to predict the ultimate impact of HPV vaccines on the prevention of cancerous and precancerous anal lesions.	[Franceschi, Silvia; De Vuyst, Hugo] Int Agcy Res Canc, F-69372 Lyon 08, France		De Vuyst, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	devuysth@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071	OncoSuisse (ICP) [OCS 01355-03-2003]; Bill & Melinda Gates FoundationBill & Melinda Gates Foundation [35537]	This work was supported by a grant from the OncoSuisse (ICP OCS 01355-03-2003) and the Bill & Melinda Gates Foundation (35537). The funders had no role in the design of the study; the collection, analysis and interpretation of the data; the decision to submit for publication; or the writing of the manuscript.	ALBARRAN YCA, 2007, BIODRUGS, V21, P47, DOI DOI 10.2165/00063030-200721010-00006; Barnabas RV, 2006, PLOS MED, V3, P624, DOI 10.1371/journal.pmed.0030138; BARR E, VACCINE IN PRESS, DOI DOI 10.1016/J.VACCINE.2008.07.056; *CDCP, HPV MEN CDC FACT SHE; Chiao EY, 2008, J CLIN ONCOL, V26, P474, DOI 10.1200/JCO.2007.14.2810; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Coutlee F, 2006, J CLIN MICROBIOL, V44, P1998, DOI 10.1128/JCM.00104-06; Critchlow CW, 1998, AIDS, V12, P1177, DOI 10.1097/00002030-199810000-00010; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe; Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; Del Maso L, 2003, BRIT J CANCER, V89, P94, DOI 10.1038/sj.bjc.6601017; DEVUYST H, INT J CANC IN PRESS; Einstein MH, 2007, GYNECOL ONCOL, V106, P453, DOI 10.1016/j.ygyno.2007.04.038; Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59; European Centre for Disease Prevention and Control, 2008, GUID INTR HPV VACC E; FENGER C, 2000, WHO CLASSIFICATION T, P147; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; Garcia-Hernandez E, 2006, CANCER GENE THER, V13, P592, DOI 10.1038/sj.cgt.7700937; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005; Grulich AE, 2002, AIDS, V16, P1155, DOI 10.1097/00002030-200205240-00009; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Heard I, 2004, ANTIVIR THER, V9, P13; Hildesheim A, 2007, JAMA-J AM MED ASSOC, V298, P743, DOI 10.1001/jama.298.7.743; IARC, 2007, MON EV CARC RISKS HU, V90; Johnson LG, 2004, CANCER-AM CANCER SOC, V101, P281, DOI 10.1002/cncr.20364; Joura EA, 2007, LANCET, V369, P1693, DOI 10.1016/S0140-6736(07)60777-6; Kim JJ, 2007, BRIT J CANCER, V97, P1322, DOI 10.1038/sj.bjc.6604023; Kim JJ, 2008, NEW ENGL J MED, V359, P821, DOI 10.1056/NEJMsa0707052; Kroger Andrew T., 2006, Morbidity and Mortality Weekly Report, V55, P1; Kudjavu Y, 2007, EUROSURVEILLANCE, V12; Newnham A, 2005, BRIT J CANCER, V92, P194, DOI 10.1038/sj.bjc.6602273; Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; PALEFSKY JM, 2006, VACCINE S3, V24; Palefsky Joel, 2008, Curr HIV/AIDS Rep, V5, P78, DOI 10.1007/s11904-008-0013-5; Palefsky JM, 2006, AIDS, V20, P1151, DOI 10.1097/01.aids.0000226955.02719.26; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005; Piketty C, 2008, AIDS, V22, P1203, DOI 10.1097/QAD.0b013e3283023f78; Roman LD, 2007, GYNECOL ONCOL, V106, P558, DOI 10.1016/j.ygyno.2007.05.038; Saslow D, 2007, CA-CANCER J CLIN, V57, P7, DOI 10.3322/canjclin.57.1.7; Schiller JT, 2008, VACCINE, V26, pK53, DOI 10.1016/j.vaccine.2008.06.002; Shefer A, 2008, VACCINE, V26, pK68, DOI 10.1016/j.vaccine.2008.05.065; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Smith JF, 2007, HUM VACCINES, V3, P109, DOI 10.4161/hv.3.4.4058; Stanley M, 2008, GYNECOL ONCOL, V109, pS15, DOI 10.1016/j.ygyno.2008.02.003; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Wheeler CM, 2008, VACCINE, V26, pA28, DOI 10.1016/j.vaccine.2007.11.078	55	26	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1746-630X	1746-6318		CURR OPIN HIV AIDS	Curr. Opin. HIV AIDS	JAN	2009	4	1					57	63		10.1097/COH.0b013e32831b9c81			7	Immunology; Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases	V19OY	WOS:000208082900010	19339940				2022-02-25	
J	Herceg, Z				Herceg, Z.			Application of epigenetics to cancer epidemiology	EJC SUPPLEMENTS			English	Meeting Abstract	20th Meeting of the European-Association-for-Cancer-Research	JUL 05-08, 2008	Lyon, FRANCE	European Assoc Canc Res					[Herceg, Z.] IARC, Epigenet Grp, Lyon, France									0	0	0	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	JUL	2008	6	9					185	185		10.1016/S1359-6349(08)71834-2			1	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	330DF	WOS:000257919000653					2022-02-25	
J	Hall, J				Hall, J			The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants	CANCER LETTERS			English	Review						breast cancer; Ataxia-telangiectasia; ATM	ATM MISSENSE MUTATIONS; EARLY-ONSET; DNA-DAMAGE; CELLULAR-RESPONSE; ALLELIC VARIANTS; FAMILIAL BREAST; NO EVIDENCE; RISK; HETEROZYGOTES; HAPLOTYPES	The role of the Ataxia-telangiectaisa mutated (ATM) gene, as a risk factor for breast cancer has been a consistent theme in the literature since the first reports by Swift and colleagues who reported that ATM heterozygotes in AT families had increased risks of developing breast cancer. Loss of heterozygosity at the ATM locus has been reported in 30-40% of breast tumours and 50-70% show altered ATM protein levels. Germline ATM sequence variants have been reported in breast cancer cases, however, it is difficult to fully evaluate the increased risk associated with their presence. The potential role of such variants needs to be further assessed, together with functional studies to model their impact on ATM function. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Int Agcy Res Canc, DNA Repair Team, F-69372 Lyon, France		Hall, J (corresponding author), Int Agcy Res Canc, DNA Repair Team, 150 Cours Albert Thomas, F-69372 Lyon, France.	hall@iarc.fr	hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295			Allinen M, 2002, J MED GENET, V39, P192, DOI 10.1136/jmg.39.3.192; Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; Angele S, 2000, MUTAT RES-REV MUTAT, V462, P167, DOI 10.1016/S1383-5742(00)00034-X; Angele S, 2003, CANCER RES, V63, P8717; Angele S, 2003, HISTOPATHOLOGY, V43, P347, DOI 10.1046/j.1365-2559.2003.01713.x; Angele S, 2000, CLIN CANCER RES, V6, P3536; ANGELE S, 2004, J CLIN PATHOL; Angele S, 2003, HUM MUTAT, V21, P1, DOI 10.1002/humu.9107; Atencio DP, 2001, ENVIRON MOL MUTAGEN, V38, P200, DOI 10.1002/em.1072; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bay JO, 1998, INT J ONCOL, V12, P1385; Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; Bonnen PE, 2000, AM J HUM GENET, V67, P1437, DOI 10.1086/316908; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; Bretsky P, 2003, CANCER EPIDEM BIOMAR, V12, P733; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; Broeks A, 2003, HUM MUTAT, V21, P521, DOI 10.1002/humu.10204; Buchholz TA, 2004, CANCER, V100, P1345, DOI 10.1002/cncr.20133; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; CAVACIUTI E, 2004, GENES CHROMOSOMES CA; Chen JD, 1998, CANCER RES, V58, P1376; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Clarke RA, 1998, J CLIN PATHOL-MOL PA, V51, P224, DOI 10.1136/mp.51.4.224; Coutinho G, 2004, AM J MED GENET A, V126A, P33, DOI 10.1002/ajmg.a.20570; di Iasio MG, 1999, ONCOGENE, V18, P1635, DOI 10.1038/sj.onc.1202453; Ding SL, 2004, BRIT J CANCER, V90, P1995, DOI 10.1038/sj.bjc.6601804; Dork T, 2001, CANCER RES, V61, P7608; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Ejima Y, 1998, HUM GENET, V102, P403, DOI 10.1007/s004390050712; Feng JN, 2003, CANCER GENET CYTOGEN, V145, P179, DOI 10.1016/S0165-4608(03)00120-1; Fernet M, 2004, BRIT J CANCER, V90, P866, DOI 10.1038/sj.bjc.6601549; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; Gutierrez-Enriquez S, 2004, GENE CHROMOSOME CANC, V40, P109, DOI 10.1002/gcc.20025; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.3.CO;2-O; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Kairouz R, 1999, J CLIN PATHOL-MOL PA, V52, P252, DOI 10.1136/mp.52.5.252; Kovalev S, 2000, INT J ONCOL, V16, P825; Laake K, 2000, BRIT J CANCER, V83, P1650, DOI 10.1054/bjoc.2000.1519; Laake K, 2000, HUM MUTAT, V16, P232, DOI 10.1002/1098-1004(200009)16:3<232::AID-HUMU6>3.0.CO;2-L; Launonen V, 1999, BRIT J CANCER, V80, P879, DOI 10.1038/sj.bjc.6690435; Lei HX, 2002, J NATL CANCER I, V94, P951; Lindeman GJ, 2004, BREAST CANCER RES, V6, pR401, DOI 10.1186/bcr806; Luo LP, 1998, CANCER RES, V58, P2293; Maillet P, 2002, J MED GENET, V39, P751, DOI 10.1136/jmg.39.10.751; Meng ZH, 2004, GENE CHROMOSOME CANC, V41, P214, DOI 10.1002/gcc.20089; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; PIPPARD EC, 1988, CANCER RES, V48, P2929; Rio PG, 1998, INT J ONCOL, V13, P849; Rodriguez C, 2002, GENE CHROMOSOME CANC, V33, P141, DOI 10.1002/gcc.1222; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Savitsky K, 1996, GENOMICS, V33, P199, DOI 10.1006/geno.1996.0184; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Shen CY, 2000, CANCER RES, V60, P3884; Shiloh Y, 2004, DNA REPAIR, V3, P779, DOI 10.1016/j.dnarep.2004.05.012; Sommer SS, 2003, CANCER GENET CYTOGEN, V145, P115, DOI 10.1016/S0165-4608(03)00119-5; Spurdle AB, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr534; Stankovic T, 2002, LEUKEMIA LYMPHOMA, V43, P1563, DOI 10.1080/1042819021000002884; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Su Y, 2000, ANN INTERN MED, V133, P770, DOI 10.7326/0003-4819-133-10-200011210-00009; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Szabo CI, 2004, CANCER RES, V64, P840, DOI 10.1158/0008-5472.CAN-03-2678; Tamimi RM, 2004, BREAST CANCER RES, V6, pR416, DOI 10.1186/bcr809; Telatar M, 1998, AM J HUM GENET, V62, P86, DOI 10.1086/301673; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Thorstenson YR, 2003, CANCER RES, V63, P3325; Thorstenson YR, 2001, AM J HUM GENET, V69, P396, DOI 10.1086/321296; van Belzen MJ, 1998, HUM GENET, V102, P187, DOI 10.1007/s004390050675; Vorechovsky I, 1996, CANCER RES, V56, P4130; Waha A, 1998, INT J CANCER, V78, P306, DOI 10.1002/(SICI)1097-0215(19981029)78:3<306::AID-IJC8>3.0.CO;2-Z	80	30	32	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3835	1872-7980		CANCER LETT	Cancer Lett.	SEP 28	2005	227	2					105	114		10.1016/j.canlet.2004.12.001			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	963ZO	WOS:000231845600002	16112413				2022-02-25	
J	Seemann, S; Hainaut, P				Seemann, S; Hainaut, P			Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity	ONCOGENE			English	Article						p53; thioredoxin; APE/Ref-1; redox regulation; base excision repair	DNA-BINDING ACTIVITY; REPORTER GENE TRANSACTIVATION; NF-KAPPA-B; EXCISION-REPAIR; GENOTOXIC STRESS; REDOX REGULATION; TRANSCRIPTION FACTOR; DIRECT ASSOCIATION; METAL-IONS; IN-VITRO	The p53 protein is redox-sensitive in vitro but in vivo effectors of this sensitivity are not known. In yeasts deficient for thioredoxin (Trx) reductase (TRR), p53 accumulates in an inactive, oxidized form, suggesting a role for TRR-Trx in controlling p53. In mammalian cells, p53 binds to redox factor-1 (APE/Ref-1), an enzyme containing an abasic endonuclease domain involved in base excision repair, and a thiol reductase domain recycled by Trx and involved in regulating the transcription factor AP-1. To evaluate the role of TRR and APE/Ref-1 in p53 regulation, we have abrogated their expression using RNA interference in cell lines expressing wild-type p53. Inhibition of TRR resulted in accumulation of oxidized Trx and increased levels and DNA-binding activity of p53, with no phosphorylation of Ser15 or Ser20. In contrast, inhibition of APE/Ref-1 accelerated p53 protein turnover, resulting in a decrease in p53 levels and activity. However, inhibition of either TRR or APE/Ref-1 did not prevent activation and accumulation of p53 in response to DNA-damage by doxorubicin. When both factors were inhibited, basal levels of p53 were restored. These results suggest that TRR-Trx and APE/Ref-1 cooperate in the control of basal p53 activity, but not in its induction by DNA-damage.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France		Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bersani NA, 2002, METHOD ENZYMOL, V347, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Freemerman AJ, 1999, CANCER RES, V59, P4090; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; HAINAUT P, 1993, CANCER RES, V53, P4469; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kelley MR, 2003, CANCER RES, V63, P549; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Merrill GF, 1999, CANCER RES, V59, P3175; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Offer H, 2001, CANCER RES, V61, P88; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wei SJ, 2000, CANCER RES, V60, P6688; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	43	97	97	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3853	3863		10.1038/sj.onc.1208549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	WOS:000229435300001	15824742	Bronze			2022-02-25	
J	Plummer, M; Franceschi, S				Plummer, M; Franceschi, S			Strategies for HPV prevention	VIRUS RESEARCH			English	Article; Proceedings Paper	19th International Papillomavirus Conference	SEP 01-07, 2001	FLORIANOPOLIS, BRAZIL			vaccination; randomized trials; projections	HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER; INTERNATIONAL TRENDS; VISUAL INSPECTION; WOMEN; RISK; MORTALITY; ADENOCARCINOMA; CONTRACEPTION; DETERMINANTS	The HPV types that cause cervical cancer are sexually transmitted, but there is little evidence that infection can be avoided by behavioral change, such as condom use. In contrast, prophylactic vaccines against HPV infection are likely to have high efficacy. In principle, the effectiveness of HPV vaccination as a strategy for cervical cancer control can be measured either by monitoring secular trends in cervical cancer incidence or by conducting randomized trials. The former approach is unlikely to provide convincing evidence of effectiveness, since cervical cancer rates are subject to strong secular trends that are independent of intervention measures. A few phase III trials of HPV prophylactic vaccines are being started. Such trials are very expensive studies involving frequent and complicated investigations. It is important, however, to start as soon as possible simpler trials which may demonstrate the effectiveness of HPV vaccine in field conditions, i.e. in developing countries which do not have the resources to mount effective cytology-based screening programs, yet suffer the major burden of mortality from cervical cancer. Such trials may capture a difference in the most severe, and rarest, preinvasive cervical lesions. The design of such studies is briefly considered for two areas: Southern India and South Korea. Finally, projections of the number of cases of cervical cancer following the introduction of mass vaccination are given for developed and developing countries. (C) 2002 Elsevier Science B.V. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	plummer@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497			[Anonymous], 1987, CANCER RES, V47, P5782; BERAL V, 1994, CANCER SURV, V20, P265; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1989, INT J CANCER, V44, P199, DOI 10.1002/ijc.2910440202; Castellsague X, 2002, NEW ENGL J MED, V346, P1105, DOI 10.1056/NEJMoa011688; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; CLIFFORD GM, 2002, UNPUB HUMAN PAPILLOM; CRANCESCHI S, 2002, BRIT J CANCER, V86, P705; Ferlay J., 2001, IARC CANC BASE; Franceschi S, 2000, ANN ONCOL, V11, P1091, DOI 10.1023/A:1008344502623; Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284; HERMONAT PL, 1992, SEX TRANSM DIS, V19, P203, DOI 10.1097/00007435-199207000-00004; HILDESHEIM A, 1990, EPIDEMIOLOGY, V1, P262; Huang KY, 2000, VACCINE, V18, pS35, DOI 10.1016/S0264-410X(99)00460-0; *IARC, 1995, IARC MON EV CARC RIS, V64; Kjaer SK, 1997, CANCER EPIDEM BIOMAR, V6, P799; KOLS A, 2000, HPV VACCINES PROMISE; Lazcano-Ponce E, 2001, INT J CANCER, V91, P412, DOI 10.1002/1097-0215(20010201)91:3&lt;412::AID-IJC1071&gt;3.0.CO;2-M; Li HQ, 2000, INT J EPIDEMIOL, V29, P398, DOI 10.1093/ije/29.3.398; Molano M, 2002, BRIT J CANCER, V87, P324, DOI 10.1038/sj.bjc.6600442; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; PARAZZINI F, 1989, CONTRACEPTION, V40, P519, DOI 10.1016/0010-7824(89)90125-X; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 1997, IARC SCI PUBLICATION, VVII; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; PLUMMER M, UNPUB SMOKING CERVIC; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1998, CANCER-AM CANCER SOC, V83, P2150, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2150::AID-CNCR13>3.0.CO;2-0; Sasieni P, 2001, LANCET, V357, P1490, DOI 10.1016/S0140-6736(00)04646-8; Sasieni P, 1999, BRIT MED J, V318, P1244; SHERRIS J, 2000, OUTLOOK, V18, P1; SMITH JS, 2001, 19 INT PAP C, pO135; SMITH JS, 2002, IN PRESS J NATL CANC; SUKRIVACH S, 2001, 19 INT PAP C, pP243; Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4; Vizcaino AP, 2000, INT J CANCER, V86, P429, DOI 10.1002/(SICI)1097-0215(20000501)86:3<429::AID-IJC20>3.0.CO;2-D; Vizcaino AP, 1998, INT J CANCER, V75, P536, DOI 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wesley R, 1997, BRIT J CANCER, V75, P436, DOI 10.1038/bjc.1997.72; WRIGHT NH, 1978, BRIT J CANCER, V38, P273, DOI 10.1038/bjc.1978.198; [No title captured]; [No title captured]	43	38	40	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0168-1702	1872-7492		VIRUS RES	Virus Res.	NOV	2002	89	2					285	293	PII S0168-1702(02)00197-1	10.1016/S0168-1702(02)00197-1			9	Virology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Virology	626YZ	WOS:000179902500014	12445668				2022-02-25	
J	Halaburkova, A; Cahais, V; Novoloaca, A; Araujo, MGD; Khoueiry, R; Ghantous, A; Herceg, Z				Halaburkova, Andrea; Cahais, Vincent; Novoloaca, Alexei; Araujo, Mariana Gomes da Silva; Khoueiry, Rita; Ghantous, Akram; Herceg, Zdenko			Pan-cancer multi-omics analysis and orthogonal experimental assessment of epigenetic driver genes	GENOME RESEARCH			English	Article							DIFFERENTIAL EXPRESSION ANALYSIS; HISTONE ACETYLATION; EPIGENOME; GENOME; MUTATIONS; PATTERNS; PACKAGE	The recent identification of recurrently mutated epigenetic regulator genes (ERGs) supports their critical role in tumorigenesis. We conducted a pan-cancer analysis integrating (epi)genome, transcriptome, and DNA methylome alterations in a curated list of 426 ERGs across 33 cancer types, comprising 10,845 tumor and 730 normal tissues. We found that, in addition to mutations, copy number alterations in ERGs were more frequent than previously anticipated and tightly linked to expression aberrations. Novel bioinformatics approaches, integrating the strengths of various driver prediction and multiomics algorithms, and an orthogonal in vitro screen (CRISPR-Cas9) targeting all ERGs revealed genes with driver roles within and across malignancies and shared driver mechanisms operating across multiple cancer types and hallmarks. This is the largest and most comprehensive analysis thus far; it is also the first experimental effort to specifically identify ERG drivers (epidrivers) and characterize their deregulation and functional impact in oncogenic processes.	[Halaburkova, Andrea; Cahais, Vincent; Novoloaca, Alexei; Araujo, Mariana Gomes da Silva; Khoueiry, Rita; Ghantous, Akram; Herceg, Zdenko] Int Agcy Res Canc IARC, Epigenet Grp, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc IARC, Epigenet Grp, F-69008 Lyon, France.	hercegz@iarc.fr		Khoueiry, Rita/0000-0003-2089-4315; Gomes da Silva Araujo, Mariana/0000-0003-0484-5505	Institut National du Cancer (INCa, France)Institut National du Cancer (INCA) France; La direction generale de l'offre de soins (DGOS); Institut National de la Sante et de la Recherche Medicale (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm) [INCa-DGOS-Inserm_12563]	We thank Dr. Maria Ouzounova for her help with flow cytometry and Mr. Cyrille Cuenin for his excellent technical support with lentiviral library preparation and high-throughput sequencing. We also thank Drs. Hector Hernandez-Vargas, Davide DegliEsposti, Srikant Ambatipudi, Fazlur R. Talukdar, and Nora Fernandez Jimenez for their valuable input to initial stages of the project. We thank Dr. Claire Renard for her help with depositing the raw sequencing data on the NCBI database. We thank Drs. Michael Korenjak, Magali Olivier, Vlatka Zoldos, Aleksandar Vojta, Rabih Murr, Lynnette Fernandez-Cuesta, and Nino Sincfic for critical reading of the manuscript; and Karen Muller for editing the manuscript. This work was partially supported by the grant from the Institut National du Cancer (INCa, France), La direction generale de l'offre de soins (DGOS), and Institut National de la Sante et de la Recherche Medicale (INSERM) (SIRIC LYriCAN, INCa-DGOS-Inserm_12563). Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.	Ahuja N, 2016, ANNU REV MED, V67, P73, DOI 10.1146/annurev-med-111314-035900; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.07.034, 10.1016/j.cell.2018.02.060]; Bell O, 2011, NAT REV GENET, V12, P554, DOI 10.1038/nrg3017; Bertrand D, 2018, CANCER RES, V78, P290, DOI 10.1158/0008-5472.CAN-17-1345; Brien GL, 2016, CANCER CELL, V29, P464, DOI 10.1016/j.ccell.2016.03.007; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Ding L, 2018, CELL, V173, P305, DOI 10.1016/j.cell.2018.03.033; Gonzalez-Perez A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r106; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hess JM, 2019, CANCER CELL, V36, P288, DOI 10.1016/j.ccell.2019.08.002; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lahouel K, 2020, P NATL ACAD SCI USA, V117, P857, DOI 10.1073/pnas.1914589117; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Ng PKS, 2018, CANCER CELL, V33, P450, DOI 10.1016/j.ccell.2018.01.021; Parmigiani G, 2009, GENOMICS, V93, P17, DOI 10.1016/j.ygeno.2008.07.005; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537; Winter J, 2016, BIOINFORMATICS, V32, P632, DOI 10.1093/bioinformatics/btv617; Xu Y, 2017, NUCLEIC ACIDS RES, V45, pD264, DOI 10.1093/nar/gkw1011; Yang Z, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0699-9; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937	34	3	3	0	2	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	1088-9051	1549-5469		GENOME RES	Genome Res.	OCT	2020	30	10					1517	1532		10.1101/gr.268292.120			16	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity	NZ5EI	WOS:000577121300012	32963031	Green Published, hybrid			2022-02-25	
J	His, M				His, Mathilde			Stand out as a speaker	SCIENCE			English	Editorial Material									[His, Mathilde] Int Agcy Res Canc, Lyon, France		His, M (corresponding author), Int Agcy Res Canc, Lyon, France.			His, Mathilde/0000-0003-3850-8291				0	0	0	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	2019	365	6455			SI		834	834		10.1126/science.365.6455.834			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	IS9JH	WOS:000482464000056	31439800	Bronze			2022-02-25	
J	Benbrahim-Tallaa, L				Benbrahim-Tallaa, Lamia			Mechanistic data in IARC Monographs evaluations	TOXICOLOGY LETTERS			English	Meeting Abstract	53rd Congress of the European-Societies-of-Toxicology (EUROTOX)	SEP 10-13, 2017	Bratislava, SLOVAKIA	European Soc Toxicol					[Benbrahim-Tallaa, Lamia] Int Agcy Res Canc, IARC Monographs, Lyon, France									0	0	0	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	OCT 20	2017	280			1	SI	P-01-02-16	S97	S97		10.1016/j.toxlet.2017.07.268			1	Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Toxicology	FW7FX	WOS:000425486700217					2022-02-25	
J	Znaor, A				Znaor, A.			Melanoma burden, healthcare utilization and the potential for overdiagnosis in the elderly US population	BRITISH JOURNAL OF DERMATOLOGY			English	Editorial Material							HIDRADENITIS SUPPURATIVA; METABOLIC SYNDROME; PSORIASIS; IMPROVEMENT		[Znaor, A.] Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Znaor, A (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	znaora@iarc.fr	Znaor, A/H-6718-2019				Arun B, 2009, CLIN EXP DERMATOL, V34, P920, DOI 10.1111/j.1365-2230.2008.03121.x; Buysschaert M, 2014, BRIT J DERMATOL, V171, P155, DOI 10.1111/bjd.12886; Faurschou A, 2015, J EUR ACAD DERMATOL, V29, P555, DOI 10.1111/jdv.12629; Faurschou A, 2014, ACTA DIABETOL, V51, P147, DOI 10.1007/s00592-011-0359-9; Hogan AE, 2011, DIABETOLOGIA, V54, P2745, DOI 10.1007/s00125-011-2232-3; Jemec GBE, 2012, NEW ENGL J MED, V366, P158, DOI 10.1056/NEJMcp1014163; Jennings L, 2017, BRIT J DERMATOL, V177, P858, DOI 10.1111/bjd.15233; Miller IM, 2014, JAMA DERMATOL, V150, P1273, DOI 10.1001/jamadermatol.2014.1165; Shalom G, 2015, BRIT J DERMATOL, V173, P464, DOI 10.1111/bjd.13777; Verdolini R, 2013, J EUR ACAD DERMATOL, V27, P1101, DOI 10.1111/j.1468-3083.2012.04668.x; Zouboulis CC, 2015, J EUR ACAD DERMATOL, V29, P619, DOI 10.1111/jdv.12966	11	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-0963	1365-2133		BRIT J DERMATOL	Br. J. Dermatol.	SEP	2017	177	3					625	625		10.1111/bjd.15759			1	Dermatology	Science Citation Index Expanded (SCI-EXPANDED)	Dermatology	FH9KM	WOS:000411529400040	28940276				2022-02-25	
J	Fidler, MM; Bray, F; Vaccarella, S; Soerjomataram, I				Fidler, Miranda M.; Bray, Freddie; Vaccarella, Salvatore; Soerjomataram, Isabelle			Assessing global transitions in human development and colorectal cancer incidence	INTERNATIONAL JOURNAL OF CANCER			English	Article						cancer; incidence; human development; socioeconomic; international; colorectum	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RISK; METAANALYSIS; ASPIRIN; MORTALITY; COHORT; TRENDS	Colorectal cancer incidence has paralleled increases in human development across most countries. Yet, marked decreases in incidence are now observed in countries that have attained very high human development. Thus, in this study, we explored the relationship between human development and colorectal cancer incidence, and in particular assessed whether national transitions to very high human development are linked to temporal patterns in colorectal cancer incidence. For these analyses, we utilized the Human Development Index (HDI) and annual incidence data from regional and national cancer registries. Truncated (30-74 years) age-standardized incidence rates were calculated. Yearly incidence rate ratios and HDI ratios, before and after transitioning to very high human development, were also estimated. Among the 29 countries investigated, colorectal cancer incidence was observed to decrease after reaching the very high human development threshold for 12 countries; decreases were also observed in a further five countries, but the age-standardized incidence rates remained higher than that observed at the threshold. Such declines or stabilizations are likely due to colorectal cancer screening in some populations, as well as varying levels of exposure to protective factors. In summary, it appears that there is a threshold at which human development predicts a stabilization or decline in colorectal cancer incidence, though this pattern was not observed for all countries assessed. Future cancer planning must consider the increasing colorectal cancer burden expected in countries transitioning towards higher levels of human development, as well as possible declines in incidence among countries reaching the highest development level. What's new? Lifestyles associated with westernization are increasingly predominant in countries where social mobility and economic growth are on the rise. The incidence of colorectal cancer (CRC) has likewise risen in those countries, though some areas with very high human development are now experiencing alternate trends. Here, CRC incidence was found to have decreased for 12 out of 29 countries that have attained very high levels of human development. Though not evident for all countries analyzed, the data suggest the existence of a threshold at which CRC incidence stabilizes or declines according to the Human Development Index.	[Fidler, Miranda M.; Bray, Freddie; Soerjomataram, Isabelle] Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France; [Vaccarella, Salvatore] Int Agcy Res Canc, Sect Infect, F-69372 Lyon 08, France		Fidler, MM (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	fidlerm@fellows.iarc.fr		Vaccarella, Salvatore/0000-0002-2516-2167; Fidler-Benaoudia, Miranda/0000-0001-9594-9881; Bray, Freddie/0000-0002-3248-7787	Union's Seventh Framework Programme Marie Curie Actions-People-COFUND	Grant sponsor: Union's Seventh Framework Programme Marie Curie Actions-People-COFUND (which partially funded MMF's postdoctoral fellowship at the International Agency for Research on Cancer)	Administrative Data Liaison Service, 2015, STAT STAT SOFTW REL; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; BONNEUX L, 1995, EUR J CANCER, V31A, P1665, DOI 10.1016/0959-8049(95)00299-X; Brenner H, 2014, AM J GASTROENTEROL, V109, P427, DOI 10.1038/ajg.2013.424; Cho E, 2004, JNCI-J NATL CANCER I, V96, P1015, DOI 10.1093/jnci/djh185; Citarda F, 2001, GUT, V48, P812, DOI 10.1136/gut.48.6.812; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Danaei G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000058; Doll R, 1966, CANC INCIDENCE 5 CON; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Engholm G, 2015, NORDCAN CANC INCIDEN; Fidler MM, 2016, INT J CANCER, V139, P2436, DOI 10.1002/ijc.30382; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Harriss DJ, 2009, COLORECTAL DIS, V11, P689, DOI 10.1111/j.1463-1318.2009.01767.x; International Agency for Research on Cancer, 2016, CI5PLUS CANC INC 5 C CI5PLUS CANC INC 5 C; International Agency for Research on Cancer, 2014, WORLD CANC REP 2012; Larsson SC, 2007, AM J CLIN NUTR, V86, P556, DOI 10.1093/ajcn/86.3.556; MACLENNAN SC, 1995, MED J AUSTRALIA, V162, P491, DOI 10.5694/j.1326-5377.1995.tb140014.x; New Zealand National Ministry of Health, NZ HLTH STAT; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Rutherford MJ, 2010, STATA J, V10, P606, DOI 10.1177/1536867X1101000405; Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086; Steliarova-Foucher E., 2012, EUROPEAN CANC OBSERV; Surveillance E and End Results (SEER) Program, 2013, SEER STAT DAT INC SE; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; United Nations Development Programme, 2015, HUM DEV REP 2015, P1; Welch HG, 2016, NEW ENGL J MED, V374, P1605, DOI 10.1056/NEJMp1600448	28	16	16	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	JUN 15	2017	140	12					2709	2715		10.1002/ijc.30686			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	ET3DY	WOS:000400158800010	28281292	Bronze			2022-02-25	
J	Edmands, WMB; Barupal, DK; Scalbert, A				Edmands, William M. B.; Barupal, Dinesh K.; Scalbert, Augustin			MetMSLine: an automated and fully integrated pipeline for rapid processing of high-resolution LC-MS metabolomic datasets	BIOINFORMATICS			English	Article							MASS-SPECTROMETRY; SERUM	MetMSLine represents a complete collection of functions in the R programming language as an accessible GUI for biomarker discovery in large-scale liquid-chromatography high-resolution mass spectral datasets from acquisition through to final metabolite identification forming a backend to output from any peak-picking software such as XCMS. MetMSLine automatically creates subdirectories, data tables and relevant figures at the following steps: (i) signal smoothing, normalization, filtration and noise transformation (PreProc.QC.LSC.R); (ii) PCA and automatic outlier removal (Auto.PCA.R); (iii) automatic regression, biomarker selection, hierarchical clustering and cluster ion/artefact identification (Auto.MV.Regress.R); (iv) Biomarker-MS/MS fragmentation spectra matching and fragment/neutral loss annotation (Auto.MS.MS.match.R) and (v) semi-targeted metabolite identification based on a list of theoretical masses obtained from public databases (DBAnnotate.R).	[Edmands, William M. B.; Barupal, Dinesh K.; Scalbert, Augustin] Int Agcy Res Canc, Dept Biomarkers, Nutr & Metab Sect, F-69372 Lyon 08, France		Scalbert, A (corresponding author), Int Agcy Res Canc, Dept Biomarkers, Nutr & Metab Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ScalbertA@iarc.fr	Scalbert, Augustin/AAX-8160-2021; Barupal, Dinesh K/A-9341-2010	Scalbert, Augustin/0000-0001-6651-6710; barupal, dinesh/0000-0002-9954-8628	European Union (NutriTech); European Union (European Cancer Platform (EUROCAN)) [289511, 260791]	This work was supported by the European Union (NutriTech and the European Cancer Platform (EUROCAN) [grant No. 289511, 260791]).	Clasquin M.F., 2012, CURR PROTOC BIOINFOR, V3; Creek DJ, 2012, BIOINFORMATICS, V28, P1048, DOI 10.1093/bioinformatics/bts069; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395; Ritchie SA, 2013, INT J CANCER, V132, P355, DOI 10.1002/ijc.27673; Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y; Veselkov KA, 2011, ANAL CHEM, V83, P5864, DOI 10.1021/ac201065j; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Xia JG, 2012, NUCLEIC ACIDS RES, V40, pW127, DOI 10.1093/nar/gks374; Yu TW, 2009, BIOINFORMATICS, V25, P1930, DOI 10.1093/bioinformatics/btp291	10	20	20	2	34	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1367-4803	1460-2059		BIOINFORMATICS	Bioinformatics	MAR 1	2015	31	5					788	790		10.1093/bioinformatics/btu705			3	Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics	CF0XT	WOS:000352268500028	25348215	Green Published, Green Submitted, hybrid			2022-02-25	
J	Herceg, Z				Herceg, Zdenko			Epigenome changes induced by environmental factors and cancer	TOXICOLOGY LETTERS			English	Meeting Abstract	49th Congress of the European-Societies-of-Toxicology (EUROTOX)	SEP 01-04, 2013	Interlaken, SWITZERLAND	European Soc Toxicol (EUROTOX), ECETOC, Roche, Syngenta, AstraZeneca, Sanofi, Basilea Pharmaceutica, ACEA Biosciences Inc, European Crop Protect, Bioservice Sci Labs GmbH, Oekotoxzentrum Ctr Ecotox, Swiss Confederat, Fed Dept Home Affairs, Fed Off Publ Hlth (FOPH), BASF, SCAHT, Johnson & Johnson, Janssen Pharmaceut Co, Natl Ctr Replacement, Refinement & Reduct Anim Res, ILSI, SERVIER, RCC, Nestle, Suva Pro, Interpharma, Covance, Novartis, Merck, BioReliance					[Herceg, Zdenko] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274			TOXICOL LETT	Toxicol. Lett.	AUG 28	2013	221			S			S17	S17		10.1016/j.toxlet.2013.06.060			1	Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Toxicology	210WO	WOS:000323865800052					2022-02-25	
J	Bray, F; Ren, JS; Masuyer, E; Ferlay, J				Bray, Freddie; Ren, Jian-Song; Masuyer, Eric; Ferlay, Jacques			Global estimates of cancer prevalence for 27 sites in the adult population in 2008	INTERNATIONAL JOURNAL OF CANCER			English	Article						prevalence; neoplasms; healthcare facilities; development; survival	AGE 50 YEARS; BREAST-CANCER; REGISTRY DATA; SURVIVAL; STATISTICS; FRANCE	Recent estimates of global cancer incidence and survival were used to update previous figures of limited duration prevalence to the year 2008. The number of patients with cancer diagnosed between 2004 and 2008 who were still alive at the end of 2008 in the adult population is described by world region, country and the human development index. The 5-year global cancer prevalence is estimated to be 28.8 million in 2008. Close to half of the prevalence burden is in areas of very high human development that comprise only one-sixth of the world's population. Breast cancer continues to be the most prevalent cancer in the vast majority of countries globally; cervix cancer is the most prevalent cancer in much of Sub-Saharan Africa and Southern Asia and prostate cancer dominates in North America, Oceania and Northern and Western Europe. Stomach cancer is the most prevalent cancer in Eastern Asia (including China); oral cancer ranks as the most prevalent cancer in Indian men and Kaposi sarcoma has the highest 5-year prevalence among men in 11 countries in Sub-Saharan Africa. The methods used to estimate point prevalence appears to give reasonable results at the global level. The figures highlight the need for long-term care targeted at managing patients with certain very frequently diagnosed cancer forms. To be of greater relevance to cancer planning, the estimation of other time-based measures of global prevalence is warranted.	[Bray, Freddie; Ren, Jian-Song; Masuyer, Eric; Ferlay, Jacques] Int Agcy Res Canc, Sect Canc Informat, F-69372 Lyon 08, France		Bray, F (corresponding author), Int Agcy Res Canc, Sect Canc Informat, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	brayf@iarc.fr	Ferlay, Jacques/ABD-5058-2021	Bray, Freddie/0000-0002-3248-7787	Japanese Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan; IARC Fellowship Programme	Grant sponsors: Japanese Ministry of Health, Labour and Welfare, IARC Fellowship Programme	Berrino F, 2007, LANCET ONCOL, V8, P773, DOI 10.1016/S1470-2045(07)70245-0; Brenner H, 2005, J CLIN ONCOL, V23, P1585, DOI 10.1200/JCO.2005.05.127; Brenner H, 2004, J CLIN ONCOL, V22, P432, DOI 10.1200/JCO.2004.04.067; Capocaccia R, 2002, ANN ONCOL, V13, P831, DOI 10.1093/annonc/mdf152; Carpenter WR, 2011, CANCER CAUSE CONTROL, V22, P765, DOI 10.1007/s10552-011-9749-0; Colonna M, 2001, EUR J CANCER, V37, P93, DOI 10.1016/S0959-8049(00)00358-0; Colonna M, 2008, EUR J CANCER, V44, P115, DOI 10.1016/j.ejca.2007.10.022; De Angelis R, 2009, CANCER, V115, P1954, DOI 10.1002/cncr.24217; Engholm G, 2010, ACTA ONCOL, V49, P725, DOI 10.3109/02841861003782017; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Giles G, 2002, ANN ONCOL, V13, P815, DOI 10.1093/annonc/mdf204; Jung KW, 2011, CANCER RES TREAT, V43, P1, DOI 10.4143/crt.2011.43.1.1; Kruijshaar Michelle E, 2003, Popul Health Metr, V1, P5, DOI 10.1186/1478-7954-1-5; Louchini Rabia, 2006, Chronic Dis Can, V27, P110; Maddams J, 2009, BRIT J CANCER, V101, P541, DOI 10.1038/sj.bjc.6605148; Mariotto A, 2003, CANCER-AM CANCER SOC, V98, P1253, DOI 10.1002/cncr.11631; Mariotto AB, 2007, CANCER EPIDEM BIOMAR, V16, P566, DOI 10.1158/1055-9965.EPI-06-0782; Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495; Merrill RM, 2000, INT J EPIDEMIOL, V29, P197, DOI 10.1093/ije/29.2.197; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3; Soerjomataram I, LANCET IN PRESS; Soerjomataram I, BMC RES MET IN PRESS; Swaminathan R, 2011, IARC Sci Publ, P23; Tabata N, 2008, JPN J CLIN ONCOL, V38, P146, DOI 10.1093/jjco/hym156; Terracini B, 2010, EPIDEMIOL PREV, V34, P1; United Nations Development Program, 2009, HUM DEV REP 2009 OV; Verdecchia A, 2002, STAT MED, V21, P3511, DOI 10.1002/sim.1304	30	1198	1256	4	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	MAR 1	2013	132	5					1133	1145		10.1002/ijc.27711			13	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	078AU	WOS:000314071300016	22752881	Bronze	Y	N	2022-02-25	
J	McCormack, VA; Schuz, J				McCormack, Valerie A.; Schuez, Joachim			Africa's growing cancer burden: Environmental and occupational contributions	CANCER EPIDEMIOLOGY			English	Review						Africa; Cancer; Environment; Occupation; Hazardous waste	BLACK SOUTH-AFRICANS; LUNG-CANCER; RISK-FACTORS; MESOTHELIOMA; EXPOSURE; POPULATION; SMOKING; TOBACCO; HEALTH; MINERS	Background: Primary prevention measures are needed for Africa's cancer burden (715,000 new cases and 542,000 deaths in 2008), a burden projected to double by 2030 due to demographic changes alone. Control of cancer-causing infections and lifestyle-related carcinogens will play a significant role in prevention, but less often addressed are environmental and occupational contributions. Methods: We review environmental issues that contribute to Africa's Cancer burden. Results: We demonstrate evidence of the impact of environmental carcinogens on the cancer burden as of now and that circumstances present today may increase their contribution further. Suboptimal implementation and monitoring of environmental protection and of occupational health standards, including in the informal sector, use of outdated technologies in industry and lack of awareness of potential hazards in the specific employment structure give rise to high levels of exposures. Carcinogens of concern include (i) those that have been long present (e. g. indoor air pollution) whose contribution may increase as life-expectancy increases and long latency periods for cancer are realised, (ii) exposures in mining and agricultural sectors and (iii) modern environmental hazards, including urban air pollution and agents arising from the mis-management of hazardous waste from local, industrial and trans-boundary sources. Conclusions: Actions taken to reduce exposures and research to fill gaps in knowledge, adapted to local settings, could help mitigate the cancer burden. (C) 2011 Elsevier Ltd. All rights reserved.	[McCormack, Valerie A.; Schuez, Joachim] Int Agcy Res Canc, Sect Environm & Radiat, F-69372 Lyon 08, France		McCormack, VA (corresponding author), Int Agcy Res Canc, Sect Environm & Radiat, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	mccormackv@iarc.fr		McCormack, Valerie/0000-0001-7397-3442			Abratt RP, 2004, LUNG CANCER-J IASLC, V45, pS3, DOI 10.1016/j.lungcan.2004.04.007; Adebamowo E, 2009, Afr J Med Med Sci, V38 Suppl 2, P71; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V69, P33; [Anonymous], 1989, IARC Monogr Eval Carcinog Risks Hum, V46, P1; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V68, P41; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P45; Apple J, 2010, INDOOR AIR, V20, P399, DOI 10.1111/j.1600-0668.2010.00664.x; Asante KA, 2011, ENVIRON INT, V37, P921, DOI 10.1016/j.envint.2011.03.011; Awofeso N, 2011, AM J RESP CRIT CARE, V183, P1437, DOI 10.1164/ajrccm.183.10.1437; Baan R, 2009, LANCET ONCOL, V10, P1143, DOI 10.1016/S1470-2045(09)70358-4; Balme KH, 2010, CLIN TOXICOL, V48, P928, DOI 10.3109/15563650.2010.534482; Berthiller J, 2008, J THORAC ONCOL, V3, P1398, DOI 10.1097/JTO.0b013e31818ddcde; Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2; Ferlay J, 2010, INT J CANC; Franceschi S, 2011, INT J CANCER, V128, P2765, DOI 10.1002/ijc.25915; Fullerton DG, 2009, OCCUP ENVIRON MED, V66, P777, DOI 10.1136/oem.2008.045013; Gaafar RM, 2005, LUNG CANCER, V49, pS17, DOI 10.1016/j.lungcan.2005.03.025; Hnizdo E, 1997, THORAX, V52, P271, DOI 10.1136/thx.52.3.271; *IARC, 1991, IARC MON EV CARC RIS, V53; *IARC, 2003, IARC SCI PUBL, V153; KAMAL AAM, 1988, AM J IND MED, V13, P707, DOI 10.1002/ajim.4700130609; Kielkowski D, 2011, OCCUP ENVIRON MED, V68, P547, DOI 10.1136/oem.2010.062182; Liu Y, 2010, ENVIRON HEALTH PERSP, V118, P818, DOI 10.1289/ehp.0901388; Lloyd DC, 2001, RADIAT RES, V155, P809, DOI 10.1667/0033-7587(2001)155[0809:ASTVAR]2.0.CO;2; Loewenson R, 2001, B WORLD HEALTH ORGAN, V79, P863; Madkour M T, 2009, East Mediterr Health J, V15, P25; Mamuya SHD, 2006, ANN OCCUP HYG, V50, P197, DOI 10.1093/annhyg/mei052; Mzileni O, 1999, TOB CONTROL, V8, P398, DOI 10.1136/tc.8.4.398; Nelson G, 2010, ENVIRON HEALTH PERSP, V118, P421, DOI 10.1289/ehp.0900918; Ngowi A V, 2001, Int J Occup Environ Health, V7, P326; Nweke OC, 2009, ENVIRON HEALTH PERSP, V117, P863, DOI 10.1289/ehp.0800126; Pacella-Norman R, 2002, BRIT J CANCER, V86, P1751, DOI 10.1038/sj.bjc.6600338; PARKIN DM, 1994, CANCER EPIDEM BIOMAR, V3, P537; Plymoth A, 2009, CANCER LETT, V286, P15, DOI 10.1016/j.canlet.2009.08.024; Rushton L, 2008, OCCUP ENVIRON MED, V65, P789, DOI 10.1136/oem.2007.037002; Sasco AJ, 2002, CANCER CAUSE CONTROL, V13, P609, DOI 10.1023/A:1019504210176; Sasco AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008621; Schmidt CW, 2006, ENVIRON HEALTH PERSP, V114, pA232, DOI 10.1289/ehp.114-a232; Stein L, 2008, BRIT J CANCER, V98, P1586, DOI 10.1038/sj.bjc.6604303; Straif K, 2009, LANCET ONCOL, V10, P453, DOI 10.1016/S1470-2045(09)70134-2; Sylla BS, 2011, INT J CANC; Ugandan Government, 2009, UG NAT TRANSP MAST P; Ullrich A, 2011, LANCET, V377, P639, DOI 10.1016/S0140-6736(11)60233-X; United Nations Economic & Social Affairs/Population Division, 2011, WORLD POP PROSP 2008; United Nations Industrial Development Organization (UNIDO), 2004, IND ENV MILL DEV GOA; Van Dyk JC, 2010, SCI TOTAL ENVIRON, V408, P2745, DOI 10.1016/j.scitotenv.2010.03.002; Virta RL, 2011, 1298 US DEP INT GEOL; VIZCAINO P, 1994, CANCER CAUSE CONTROL, V5, P517, DOI 10.1007/BF01831379; World Health Organization, 2008, GLOBAL BURDEN DIS 20; Wright NJ, 2005, ARCH DIS CHILD, V90, P262, DOI 10.1136/adc.2003.043562	50	32	33	0	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	FEB	2012	36	1					1	7		10.1016/j.canep.2011.09.005			7	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	900ZY	WOS:000300932600011	21996568				2022-02-25	
J	Lambert, R				Lambert, R.			Upper gastrointestinal tumors	ENDOSCOPY			English	Editorial Material							SQUAMOUS-CELL CARCINOMA; CONFOCAL LASER ENDOMICROSCOPY; GASTRIC-CANCER; IN-VIVO; INTESTINAL METAPLASIA; ENDOSCOPIC RESECTION; MALIGNANT LESIONS; ESOPHAGUS; DIAGNOSIS; TRACT		Int Agcy Res Canc, SCR, Screening Grp, F-69372 Lyon 8, France		Lambert, R (corresponding author), Int Agcy Res Canc, SCR, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon 8, France.	lambert@iarc.fr					Gatenby PAC, 2008, SCAND J GASTROENTERO, V43, P524, DOI 10.1080/00365520701879831; Gheorghe C, 2008, J GASTROINTEST LIVER, V17, P95; Guo YT, 2008, ENDOSCOPY, V40, P547, DOI 10.1055/s-2007-995633; Hamashima C, 2008, JPN J CLIN ONCOL, V38, P259, DOI 10.1093/jjco/hyn017; Hosokawa O, 2008, SCAND J GASTROENTERO, V43, P1112, DOI 10.1080/00365520802085395; Inoue Haruhiro, 2008, Nihon Rinsho, V66, P1023; ISHIHARA R, 2008, GASTROINTEST EN 0710; Ishihara R, 2008, GASTROINTEST ENDOSC, V67, P799, DOI 10.1016/j.gie.2007.08.018; Ishihara R, 2008, CANCER-AM CANCER SOC, V112, P2166, DOI 10.1002/cncr.23418; Katada C, 2007, ENDOSCOPY, V39, P779, DOI 10.1055/s-2007-966761; Kiesslich Ralf, 2008, Gastrointest Endosc Clin N Am, V18, P451, DOI 10.1016/j.giec.2008.03.002; Lambert R, 2008, ENDOSCOPY, V40, P131, DOI 10.1055/s-2007-995319; Liu H, 2008, J GASTROEN HEPATOL, V23, P56, DOI 10.1111/j.1440-1746.2007.05221.x; Ogura M, 2008, SCAND J GASTROENTERO, V43, P574, DOI 10.1080/00365520701813954; Osawa H, 2008, GASTROINTEST ENDOSC, V67, P226, DOI 10.1016/j.gie.2007.06.067; Pech O, 2008, CLIN GASTROENTEROL H, V6, P89, DOI 10.1016/j.cgh.2007.10.013; Song LMWK, 2008, GASTROINTEST ENDOSC, V67, P581, DOI 10.1016/j.gie.2008.01.013; Srivastava A, 2007, AM J SURG PATHOL, V31, P1733, DOI 10.1097/PAS.0b013e318078ce91; Suzuki Haruhisa, 2006, Gastric Cancer, V9, P315, DOI 10.1007/s10120-006-0399-y; Takubo K, 2007, HISTOPATHOLOGY, V51, P733, DOI 10.1111/j.1365-2559.2007.02766.x; Takubo K, 2008, BEST PRACT RES CL GA, V22, P569, DOI 10.1016/j.bpg.2008.02.004; Wang A, 2008, GASTROINTEST ENDOSC, V68, P859, DOI 10.1016/j.gie.2008.02.064; Yagi K, 2008, DIGEST ENDOSC, V20, P115, DOI 10.1111/j.1443-1661.2008.00788.x; Zhang JN, 2008, GASTROINTEST ENDOSC, V67, P843, DOI 10.1016/j.gie.2008.01.036	24	0	0	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	JAN	2009	41	1					46	50		10.1055/s-2008-1077782			5	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	406BE	WOS:000263269200009	19058126				2022-02-25	
J	Franceschi, S				Franceschi, S.			Types of HPV vaccination in the pipeline and dreamed/proven efficacy and effectiveness at short/long term	EJC SUPPLEMENTS			English	Meeting Abstract	14th European Cancer Conference (ECCO 14)	SEP 23-27, 2007	Barcelona, SPAIN	European Canc Org					[Franceschi, S.] Int Agcy Res Canc, Infect & Canc Epidemiol Grp, F-69372 Lyon, France				franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071				0	2	2	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	SEP	2007	5	4				201	53	53		10.1016/S1359-6349(07)70316-6			1	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	221CC	WOS:000250204000167					2022-02-25	
J	Franceschi, S				Franceschi, Silvia			Fighting against HPV with a vaccine in Italy and in the world	EPIDEMIOLOGIA & PREVENZIONE			Italian	Editorial Material							HUMAN-PAPILLOMAVIRUS TYPE-16; PARTICLE VACCINE; EFFICACY; WOMEN		IARC, Infect & Canc Epidemiol Grp, Lyon, France		Franceschi, S (corresponding author), IARC, Infect & Canc Epidemiol Grp, Lyon, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			ABMA JC, 2002, VITAL HLTH STAT, V23, P1; CLIFFORD GM, 1924, VACCINE S3, V24, pS26; Dawson AJ, 2005, LANCET INFECT DIS, V5, P120, DOI 10.1016/S1473-3099(05)70087-6; FERLAY J, 2000, GLABOCAN 2000 INCIDE; Franceschi S, 2006, INT J CANCER, V119, P2677, DOI 10.1002/ijc.22241; *FUT STUD GROUP, 1911, NEW ENGL J MED, V356, P1915; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Goldie SJ, 2004, JNCI-J NATL CANCER I, V96, P604, DOI 10.1093/jnci/djh104; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; KOUTSKY LA, 2002, NEW ENGL J MED, V16, P347; Lehtinen M, 2006, VACCINE, V24, P233, DOI 10.1016/j.vaccine.2006.05.109; Saslow D, 2007, CA-CANCER J CLIN, V57, P7, DOI 10.3322/canjclin.57.1.7	13	0	0	0	0	INFERENZE SCARL	MILANO	VIA RICCIARELLI N 29, MILANO, 20148, ITALY	1120-9763	2385-1937		EPIDEMIOL PREV	Epidemiol. Prev.	MAR-JUN	2007	31	2-3					79	80					2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	279FL	WOS:000254340400005	18677854				2022-02-25	
J	Green, A; Autier, P; Boniol, M; Boyle, P; Dore, JF; Gandini, S; Newton-Bishop, J; Secretan, B; Walter, SJ; Weinstock, MA; Westerdahl, J				Green, Adele; Autier, Philippe; Boniol, Mathieu; Boyle, Peter; Dore, Jean-Francois; Gandini, Sara; Newton-Bishop, Julia; Secretan, Beatrice; Walter, Stephen J.; Weinstock, Martin A.; Westerdahl, Johan		Canc Working Grp	The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review	INTERNATIONAL JOURNAL OF CANCER			English	Review						artificial UV; sunbeds; melanoma; skin cancer; meta-analysis	INDOOR TANNING FACILITIES; BASAL-CELL CARCINOMA; RISK-FACTORS; SUN EXPOSURE; ULTRAVIOLET-LIGHT; DNA-DAMAGE; PROTECTIVE FACTOR; SUNSCREEN USE; BED USE; ADOLESCENTS	Exposure to solar ultraviolet (UV) radiation is a known cause of skin cancer. Sunbed use represents an increasingly frequent source of artificial UV exposure in light-skinned populations. To assess the available evidence of the association between sunbed use and cutaneous malignant melanoma (melanoma) and other skin cancers, a systematic review of the literature till March 2006 on epidemiological and biological studies on sunbed use was performed in Pubmed, ISI Web of Science, Embase, Pascal, Cochrane library, Lilacs and Medcarib. Search for keywords in the title and in the abstract was done systematically and supplemented by manual searches. Only case-control, cohort or cross-sectional studies were selected. Data were abstracted by means of a standardized data-collection protocol. Based on 19 informative studies, ever-use of sunbeds was positively associated with melanoma (summary relative risk, 1.15; 95% CI, 1.00-1.31), although there was no consistent evidence of a dose-response relationship. First exposure to sunbeds before 35 years of age significantly increased the risk of melanoma, based on 7 informative studies (summary relative risk, 1.75; 95% CI, 1.35-2.26). The summary relative risk of 3 studies of squamous cell carcinoma showed an increased risk. For basal cell carcinoma, the studies did not support an association. The evidence does not support a protective effect of the use of sunbeds against damage to the skin from subsequent sun exposure. Young adults should be discouraged from using indoor tanning equipment and restricted access to sunbeds by minors should be strongly considered. (c) 2006 Wiley-Liss, Inc.	Int Agcy Res Canc, F-69372 Lyon, France		Secretan, B (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	secretan@iarc.fr	Boniol, Mathieu/F-9623-2011; Green, Adele C/P-2736-2014; Green, Adele C/B-5324-2011; gandini, sara/J-4916-2018; Boyle, Peter/A-4380-2014	Boniol, Mathieu/0000-0003-1052-5604; Green, Adele C/0000-0002-2753-4841; gandini, sara/0000-0002-1348-4548; Boyle, Peter/0000-0001-6251-0610; Newton-Bishop, Julia/0000-0001-9147-6802			Aboutalebi Sina, 2006, J Drugs Dermatol, V5, P512; ADAM SA, 1981, BRIT J CANCER, V44, P45, DOI 10.1038/bjc.1981.145; AUBRY F, 1985, CANCER-AM CANCER SOC, V55, P907, DOI 10.1002/1097-0142(19850215)55:4<907::AID-CNCR2820550433>3.0.CO;2-5; Autier P, 2004, EUR J CANCER, V40, P2367, DOI 10.1016/j.ejca.2004.07.018; Autier P, 1991, Melanoma Res, V1, P69, DOI 10.1097/00008390-199104000-00009; Autier P, 1998, INT J CANCER, V77, P533, DOI 10.1002/(SICI)1097-0215(19980812)77:4<533::AID-IJC10>3.0.CO;2-7; AUTIER P, 1994, INT J CANCER, V58, P809, DOI 10.1002/ijc.2910580610; Bajdik CD, 1996, BRIT J CANCER, V73, P1612, DOI 10.1038/bjc.1996.303; Bataille V, 2004, EUR J CANCER, V40, P429, DOI 10.1016/j.ejca.2003.09.030; Bataille W, 2005, EUR J CANCER, V41, P2141, DOI 10.1016/j.ejca.2005.04.038; BEITNER H, 1990, BRIT J DERMATOL, V122, P43, DOI 10.1111/j.1365-2133.1990.tb08238.x; BLACK G, 1985, J INVEST DERMATOL, V85, P448, DOI 10.1111/1523-1747.ep12277170; Boldeman C, 1996, BRIT J DERMATOL, V135, P712; Boyd AS, 2002, J AM ACAD DERMATOL, V46, P706, DOI 10.1067/mjd.2002.120467; Bykov VJ, 2001, DERMATOLOGY, V202, P22, DOI 10.1159/000051579; Chen YT, 1998, INT J EPIDEMIOL, V27, P758, DOI 10.1093/ije/27.5.758; Cokkinides VE, 2002, PEDIATRICS, V109, P1124, DOI 10.1542/peds.109.6.1124; Corona R, 2001, ARCH DERMATOL, V137, P1162; Culley CA, 2001, J AM ACAD DERMATOL, V44, P53, DOI 10.1067/mjd.2001.110063; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; Demko CA, 2003, ARCH PEDIAT ADOL MED, V157, P854, DOI 10.1001/archpedi.157.9.854; Dunn-Lane J, 1993, IRAN MED J, V86, P135; Gallagher R P, 1986, Recent Results Cancer Res, V102, P38; Gallagher RP, 2005, CANCER EPIDEM BIOMAR, V14, P562, DOI 10.1158/1055-9965.EPI-04-0564; GANGE RW, 1985, J INVEST DERMATOL, V85, P362, DOI 10.1111/1523-1747.ep12276983; GARBE C, 1993, RECENT RES CANCER, V128, P69; Geller AC, 2002, PEDIATRICS, V109, P1009, DOI 10.1542/peds.109.6.1009; Gerber B, 2002, PHOTOCHEM PHOTOBIOL, V76, P664, DOI 10.1562/0031-8655(2002)076<0664:UESOS>2.0.CO;2; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Griffiths HR, 1998, CRIT REV CL LAB SCI, V35, P189, DOI 10.1080/10408369891234192; Halliday GA, 2005, MUTAT RES-FUND MOL M, V571, P107, DOI 10.1016/j.mrfmmm.2004.09.013; Hamlet N, 2004, J PUBLIC HEALTH, V26, P31, DOI 10.1093/pubmed/fdh117; Hemminki K, 1999, J NATL CANCER I, V91, P2046, DOI 10.1093/jnci/91.23.2046; HERITY B, 1989, IRISH MED J, V82, P151; HOGAN DJ, 1991, BRIT J DERMATOL, V125, P343, DOI 10.1111/j.1365-2133.1991.tb14169.x; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; HOLLY EA, 1995, AM J EPIDEMIOL, V141, P923, DOI 10.1093/oxfordjournals.aje.a117359; Holman C D, 1986, Recent Results Cancer Res, V102, P18; Hornung RL, 2003, J AM ACAD DERMATOL, V49, P655, DOI 10.1067/S0190-9622(03)01586-X; IARC, 1992, IARC MON EV CARC RIS, V55; Karagas MR, 2002, J NATL CANCER I, V94, P224, DOI 10.1093/jnci/94.3.224; Kaskel P, 2001, BRIT J DERMATOL, V145, P602, DOI 10.1046/j.1365-2133.2001.04432.x; KLEPP O, 1979, INT J CANCER, V23, P482, DOI 10.1002/ijc.2910230407; KRIPKE ML, 1974, J NATL CANCER I, V53, P1333, DOI 10.1093/jnci/53.5.1333; Kwon HT, 2002, J AM ACAD DERMATOL, V46, P700, DOI 10.1067/mjd.2002.119560; Lazovich DA, 2005, EUR J CANCER, V41, P20, DOI 10.1016/j.ejca.2004.09.015; Lazovich DA, 2004, ARCH PEDIAT ADOL MED, V158, P918, DOI 10.1001/archpedi.158.9.918; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; MACGINTLEY J, 1998, BRIT J DERMATOL, V139, P428; MACKIE RM, 1989, LANCET, V2, P487; MERMELSTEIN RJ, 1992, HEALTH PSYCHOL, V11, P371, DOI 10.1037/0278-6133.11.6.371; Miller SA, 1998, PHOTOCHEM PHOTOBIOL, V68, P63; Naldi L, 2000, EUR J CANCER PREV, V9, P133, DOI 10.1097/00008469-200004000-00011; OLIPHANT JA, 1994, AM J PUBLIC HEALTH, V84, P476, DOI 10.2105/AJPH.84.3.476; OLOUGHLIN C, 1985, IRISH J MED SCI, V154, P61, DOI 10.1007/BF02937144; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; Paul CL, 2005, EUR J CANCER, V41, P1178, DOI 10.1016/j.ejca.2005.01.019; Paul CL, 2004, AUST NZ J PUBL HEAL, V28, P90, DOI 10.1111/j.1467-842X.2004.tb00641.x; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Persson AE, 2002, PHOTODERMATOL PHOTO, V18, P287, DOI 10.1034/j.1600-0781.2002.02781.x; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Phan TA, 2006, FRONT BIOSCI-LANDMRK, V11, P394, DOI 10.2741/1807; Rhainds M, 1999, J AM ACAD DERMATOL, V40, P572, DOI 10.1016/S0190-9622(99)70439-1; RIVERS JK, 1989, BRIT J DERMATOL, V120, P767, DOI 10.1111/j.1365-2133.1989.tb01374.x; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; Robinson JK, 1997, PREV MED, V26, P364, DOI 10.1006/pmed.1997.0156; Ruegemer J, 2002, PHOTODERMATOL PHOTO, V18, P223, DOI 10.1034/j.1600-0781.2002.180501.x; Sheehan JM, 1998, PHOTOCHEM PHOTOBIOL, V68, P588, DOI 10.1111/j.1751-1097.1998.tb02518.x; SINGH RK, 1995, CANCER RES, V55, P3669; SWERDLOW AJ, 1988, BMJ-BRIT MED J, V297, P647, DOI 10.1136/bmj.297.6649.647; Ullrich SE, 2005, MUTAT RES-FUND MOL M, V571, P185, DOI 10.1016/j.mrfmmm.2004.06.059; *US DEP HHS PUBL H, 2002, NAT TOX PROGR; Veierod MB, 2004, J NATL CANCER I, V96, P337, DOI 10.1093/jnci/djh055; Veierod MB, 2003, J NATL CANCER I, V95, P1530, DOI 10.1093/jnci/djg075; Walter SD, 1999, INT J EPIDEMIOL, V28, P418, DOI 10.1093/ije/28.3.418; WALTER SD, 1990, AM J EPIDEMIOL, V131, P232, DOI 10.1093/oxfordjournals.aje.a115493; Walther U, 2004, BRIT J DERMATOL, V151, P170, DOI 10.1111/j.1365-2133.2004.06030.x; Wester U, 1999, HEALTH PHYS, V77, P436, DOI 10.1097/00004032-199910000-00012; WESTERDAHL J, 1994, AM J EPIDEMIOL, V140, P691, DOI 10.1093/oxfordjournals.aje.a117317; Westerdahl J, 2000, BRIT J CANCER, V82, P1593; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Whitmore SE, 2001, J AM ACAD DERMATOL, V44, P775, DOI 10.1067/mjd.2001.112581; Woollons A, 1997, BRIT J DERMATOL, V137, P687; Wright AL, 1996, PHOTODERMATOL PHOTO, V12, P12, DOI 10.1111/j.1600-0781.1996.tb00237.x; ZANETTI R, 1988, REV EPIDEMIOL SANTE, V36, P309	86	294	294	2	66	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	MAR 1	2007	120	5					1116	1122		10.1002/ijc.22453			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology	131TK	WOS:000243892700023	17131335	Bronze			2022-02-25	
J	Loizou, JI; Murr, R; Finkbeiner, MG; Sawan, C; Wang, ZQ; Herceg, Z				Loizou, Joanna I.; Murr, Rabih; Finkbeiner, Martin G.; Sawan, Carla; Wang, Zhao-Qi; Herceg, Zdenko			Epigenetic information in chromatin - The code of entry for DNA repair	CELL CYCLE			English	Article						epigenetic mechanisms; histone code; DNA repair; histone modifications; chromatin remodeling	DOUBLE-STRAND BREAK; DAMAGE RESPONSE; HISTONE H2AX; SACCHAROMYCES-CEREVISIAE; LINKER HISTONES; C-MYC; COMPLEX; ACETYLATION; PHOSPHORYLATION; PROTEIN	Epigenetic changes are important etiological factors of human cancer. Epigenetic information in chromatin (known as 'histone code') is a fascinating feature used by cells to extend and modulate the genetic (DNA) code. The histone code is thus proposed to be 'read' by cells to regulate accessibility to, and functions of, chromatin DNA. While the role of the epigenetic code involving chromatin modifying/remodeling complexes in transcriptional regulation is well established, it is only recently that these mechanisms have been implicated in DNA damage detection and DNA repair. However, how the components of the DNA damage sensing and repair machinery gain access to broken DNA in compacted chromatin remains a mystery. Recent studies provide important insights into DNA damage- and repair-specific modifications to histones and shed light on how the epigenetic code controls DNA repair.	IARC, Mol Carcinogenesis & Biomarkers Grp, F-69008 Lyon, France		Herceg, Z (corresponding author), IARC, Mol Carcinogenesis & Biomarkers Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr		Murr, Rabih/0000-0002-3346-6590; Loizou, Joanna/0000-0003-1853-0424			Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Cho KS, 2004, CURR OPIN GENET DEV, V14, P308, DOI 10.1016/j.gde.2004.04.015; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Downey M, 2006, NAT CELL BIOL, V8, P9, DOI 10.1038/ncb0106-9; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Downs JA, 2005, CELL CYCLE, V4, P1373, DOI 10.4161/cc.4.10.2108; Downs JA, 2003, NATURE, V424, P732, DOI 10.1038/424732a; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Harvey AC, 2004, MOL MICROBIOL, V53, P771, DOI 10.1111/j.1365-2958.2004.04195.x; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Huang J, 2005, CELL CYCLE, V4, P1713, DOI 10.4161/cc.4.12.2222; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Kysela B, 2005, P NATL ACAD SCI USA, V102, P1877, DOI 10.1073/pnas.0401179102; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; van Attikum H, 2005, CELL CYCLE, V4, P1011, DOI 10.4161/cc.4.8.1887; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Wolner B, 2005, J BIOL CHEM, V280, P10855, DOI 10.1074/jbc.M414388200; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	64	47	48	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	APR 1	2006	5	7					696	701		10.4161/cc.5.7.2616			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	053CY	WOS:000238282900008	16582631	Bronze			2022-02-25	
J	Boffetta, P; Hashibe, M				Boffetta, P; Hashibe, M			Alcohol and cancer	LANCET ONCOLOGY			English	Review							POOLED ANALYSIS; BREAST-CANCER; GENETIC POLYMORPHISMS; LUNG-CANCER; LINKAGE DISEQUILIBRIUM; COLORECTAL-CANCER; ESOPHAGEAL CANCER; TOBACCO SMOKING; RISK-FACTORS; DNA-ADDUCTS	A causal association has been established between alcohol consumption and cancers of the oral cavity, pharynx, larynx, oesophagus, liver, colon, rectum, and, in women, breast; an association is suspected for cancers of the pancreas and lung. Evidence suggests that the effect of alcohol is modulated by polymorphisms in genes encoding enzymes for ethanol metabolism (eg, alcohol dehydrogenases, aldehyde dehydrogenases, and cytochrome P450 2E1), folate metabolism, and DNA repair. The mechanisms by which alcohol consumption exerts its carcinogenic effect have not been defined fully, although plausible events include: a genotoxic effect of acetaldehyde, the main metabolite of ethanol; increased oestrogen concentration, which is important for breast carcinogenesis; a role as solvent for tobacco carcinogens; production of reactive oxygen species and nitrogen species; and changes in folate metabolism. Alcohol consumption is increasing in many countries and is an important cause of cancer worldwide.	Int Agcy Res Canc, Gene Environm Epidemiol Grp, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, Gene Environm Epidemiol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr					Bagnardi V, 2001, BRIT J CANCER, V85, P1700, DOI 10.1054/bjoc.2001.2140; Bandera EV, 2003, NUTR CANCER, V45, P24, DOI 10.1207/S15327914NC4501_3; Bandera EV, 2001, CANCER EPIDEM BIOMAR, V10, P813; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Bosetti C, 2002, BRIT J CANCER, V87, P516, DOI 10.1038/sj.bjc.6600469; BOSRON WF, 1983, PHARMACOL BIOCHEM BE, V18, P223, DOI 10.1016/0091-3057(83)90175-2; Boyle P, 2003, ANN ONCOL, V14, P973, DOI 10.1093/annonc/mdg305; Bray I, 2000, INT J CANCER, V87, P122, DOI 10.1002/1097-0215(20000701)87:1<122::AID-IJC18>3.0.CO;2-W; Brennan P, 2004, AM J EPIDEMIOL, V159, P1, DOI 10.1093/aje/kwh003; Brennan Paul, 2004, IARC Sci Publ, P393; Castellsague X, 1999, INT J CANCER, V82, P657, DOI 10.1002/(SICI)1097-0215(19990827)82:5&lt;657::AID-IJC7&gt;3.0.CO;2-C; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P866; Cho EY, 2004, ANN INTERN MED, V140, P603, DOI 10.7326/0003-4819-140-8-200404200-00007; Clemens DL, 2002, HEPATOLOGY, V35, P1196, DOI 10.1053/jhep.2002.32668; Connor PD, 1996, ALCOHOL HEALTH RES W, V20, P170; Cook RT, 1998, ALCOHOL CLIN EXP RES, V22, P1927, DOI 10.1111/j.1530-0277.1998.tb05900.x; Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027; Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x; Corrao G, 1999, ADDICTION, V94, P1551, DOI 10.1046/j.1360-0443.1999.9410155111.x; Corrao G, 1998, ALCOHOL ALCOHOLISM, V33, P381; DAVANZO B, 1994, NUTR CANCER, V22, P57, DOI 10.1080/01635589409514331; De Stefani E, 1998, CANCER CAUSE CONTROL, V9, P321, DOI 10.1023/A:1008829321668; Dennis LK, 2000, PROSTATE, V42, P56; ELGHISSASSI F, 1995, CHEM RES TOXICOL, V8, P278, DOI 10.1021/tx00044a013; Fang JL, 1997, CARCINOGENESIS, V18, P627, DOI 10.1093/carcin/18.4.627; Fioretti F, 1999, ORAL ONCOL, V35, P375, DOI 10.1016/S1368-8375(98)00125-0; FRANCESCHI S, 1994, DIGEST DIS, V12, P276, DOI 10.1159/000171463; Freudenheim JL, 2005, AM J CLIN NUTR, V82, P657, DOI 10.1093/ajcn/82.3.657; Gertig DM, 2002, TXB CANC EPIDEMIOLOG, P378; Giovannucci E, 2004, J NUTR, V134, p2475S, DOI 10.1093/jn/134.9.2475S; Hoek JB, 2002, ALCOHOL, V27, P63, DOI 10.1016/S0741-8329(02)00215-X; HUNG RJ, 2005, MUTAT RES; *INT AG RES CANC, 1988, IARC MON EV CARC RIS, V44; *INT AG RES CANC, 1999, IARC MON EV CARC RIS, V71, P319; Keil U, 1998, NOVART FDN SYMP, V216, P125; KOGEVINAS M, 2002, TXB CANC EPIDEMIOLOG, P446; Korte JE, 2002, AM J EPIDEMIOL, V155, P496, DOI 10.1093/aje/155.6.496; Kuntsche E, 2004, SOC SCI MED, V59, P113, DOI 10.1016/j.socscimed.2003.10.009; Latvala J, 2001, MOL MED, V7, P401, DOI 10.1007/BF03402186; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Lieber CS, 2003, ALCOHOL RES HEALTH, V27, P220; Lilla C, 2005, BRIT J CANCER, V92, P2039, DOI 10.1038/sj.bjc.6602608; LINDBLAD P, 2002, TXB CANC EPIDEMIOLOG, P467; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; Merikangas KR, 1998, ADDICT BEHAV, V23, P893, DOI 10.1016/S0306-4603(98)00076-8; Molina PE, 2003, ALCOHOL CLIN EXP RES, V27, P563, DOI 10.1097/01.ALC.0000057946.57330.F7; Moller H, 1997, IARC Sci Publ, P251; Morton LM, 2005, LANCET ONCOL, V6, P469, DOI 10.1016/S1470-2045(05)70214-X; NG SKC, 1993, J NATL CANCER I, V85, P743, DOI 10.1093/jnci/85.9.743; NOVORADOVSKY A, 1995, ALCOHOL CLIN EXP RES, V19, P1105, DOI 10.1111/j.1530-0277.1995.tb01587.x; Osier M, 1999, AM J HUM GENET, V64, P1147, DOI 10.1086/302317; Osier MV, 2002, AM J HUM GENET, V71, P84, DOI 10.1086/341290; Rehm J., 2004, COMP QUANTIFICATION, P959; Reynolds K, 2003, JAMA-J AM MED ASSOC, V289, P579, DOI 10.1001/jama.289.5.579; Rintala J, 2000, ALCOHOL ALCOHOLISM, V35, P458, DOI 10.1093/alcalc/35.5.458; Risch A, 2003, PHARMACOGENETICS, V13, P225, DOI 10.1097/00008571-200304000-00007; Sharp L, 2004, AM J EPIDEMIOL, V159, P423, DOI 10.1093/aje/kwh066; Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Thakker KD, 1998, ALCOHOL CLIN EXP RES, V22, p285S, DOI 10.1111/j.1530-0277.1998.tb04381.x; Vaca CE, 1998, CHEM-BIOL INTERACT, V108, P197, DOI 10.1016/S0009-2797(97)00107-5; Viitala K, 2000, ALCOHOL CLIN EXP RES, V24, P1103; Voigt Michael D, 2005, Clin Liver Dis, V9, P151, DOI 10.1016/j.cld.2004.10.003; Wang XD, 2003, J NUTR, V133, p287S, DOI 10.1093/jn/133.1.287S; Wight AJ, 1998, ORAL ONCOL, V34, P441, DOI 10.1016/S1368-8375(98)00022-0; Wong NACS, 2000, J CLIN PATHOL-MOL PA, V53, P88, DOI 10.1136/mp.53.2.88; World Health Organization, 1999, GLOB STAT REP ALC; Wu AH, 2001, CANCER CAUSE CONTROL, V12, P721, DOI 10.1023/A:1011290704728; Wu WJ, 1996, J PHARMACOL EXP THER, V278, P1325; Yang CX, 2005, WORLD J GASTROENTERO, V11, P2531, DOI 10.3748/wjg.v11.i17.2531; Yokoyama A, 2003, JPN J CLIN ONCOL, V33, P111, DOI 10.1093/jjco/hyg026; Zaridze D, 2000, CANCER CAUSE CONTROL, V11, P363, DOI 10.1023/A:1008907924938; ZHENG W, 1993, CANCER CAUSE CONTROL, V4, P361, DOI 10.1007/BF00051339	73	572	591	3	110	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	FEB	2006	7	2					149	156		10.1016/S1470-2045(06)70577-0			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology	012CN	WOS:000235315900032	16455479				2022-02-25	
J	Boyle, P; Ferlay, J				Boyle, P; Ferlay, J			Cancer incidence and mortality in Europe, 2004	ANNALS OF ONCOLOGY			English	Article						cancer; deaths; Europe; European Union; incidence	PROGRESS	Background: There are no recent estimates of the incidence and mortality from cancer at a European level. Those data that are available generally refer to the mid-1990s and are of limited use for cancer control planning. We present estimates of the cancer burden in Europe in 2004, including data for the (25 Member States) European Union. Methods: The most recent sources of incidence and mortality data available in the Descriptive Epidemiology Group at IARC were applied to population projections to derive the best estimates of the burden of cancer, in terms of incidence and mortality, for Europe in 2004. Results: In 2004 in Europe, there were an estimated 2886800 incident cases of cancer diagnosed and 1711000 cancer deaths. The most common incident form of cancer was lung cancer (13.3% of all incident cases), followed by colorectal cancer (13.2%) and breast cancer (13%). Lung cancer was also the most common cause of cancer death (341800 deaths), followed by colorectal (203700), stomach (137 900) and breast (129 900). Conclusions: With an estimated 2.9 million new cases (54% occurring in men, 46% in women) and 1.7 million deaths (56% in men, 44% in women) each year, cancer remains an important public health problem in Europe, and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant. To make great progress quickly against cancer in Europe, the need is evident to make a concerted attack on the big killers: lung, colorectal, breast and stomach cancer. Stomach cancer rates are falling everywhere in Europe and public health measures are available to reduce the incidence and mortality of lung cancer, colorectal cancer and breast cancer.	Int Agcy Res Canc, F-69372 Lyon, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	Boyle, Peter/A-4380-2014; Ferlay, Jacques/ABD-5058-2021	Boyle, Peter/0000-0001-6251-0610; 			BOYLE P, 1995, BRIT J CANCER, V72, P528, DOI 10.1038/bjc.1995.368; Boyle P, 2003, ANN ONCOL, V14, P973, DOI 10.1093/annonc/mdg305; Boyle P, 2003, ANN ONCOL, V14, P1312, DOI 10.1093/annonc/mdg353; BOYLE P, 2003, TOBACCO SCI POLICY P; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Early Breast Cancer Trialists' Collaborative Group, 2001, COCHRANE DB SYST REV; Faivre J, 2004, GASTROENTEROLOGY, V126, P1674, DOI 10.1053/j.gastro.2004.02.018; FERLAY J, 1999, 4 IARC; FERLAY J, 2004, 5 IARC; *IARC, 2002, IARC HDB CANC PREV, V70; International Agency for Research on Cancer IARC, 2004, MON EV CARC RISKS HU, V83; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Quinn MJ, 2003, ANN ONCOL, V14, P1148, DOI 10.1093/annonc/mdg307; Sant M, 2003, ANN ONCOL, V14, pV61, DOI 10.1093/annonc/mdg754; *UN POP DIV, 2002, WORLD POP PROSP; World Health Organization, WHO DAT; 2003, EUROCIM VERSION 4 1	18	967	1024	0	24	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534	1569-8041		ANN ONCOL	Ann. Oncol.	MAR	2005	16	3					481	488		10.1093/annonc/mdi098			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	905KQ	WOS:000227567400022	15718248	Bronze			2022-02-25	
J	Parkin, DM				Parkin, DM			International variation	ONCOGENE			English	Article						geography; incidence; mortality; migrants; ethnicity	HEMOGLOBIN ADDUCT LEVELS; S-TRANSFERASE M1; CANCER-MORTALITY; CERVICAL-CANCER; GASTRIC-CARCINOMA; AFRICAN MIGRANTS; C VIRUS; EPIDEMIOLOGY; BREAST; RISK	There were an estimated 10 million new cases, 6 million deaths and 22 million persons living with cancer in the year 2000. The most common cancers are, in terms of new cases, lung (1.2 million), breast (1.05 million), colon rectum (945000), stomach (876 000) and liver (564 000). The geographic distributions of some 20 types of cancer for which national estimates have been made are summmarized. These patterns are examined with respect to the likely reasons in terms of variation in exposure to carcinogens (in the external environment or through lifestyle choices) or in genetic susceptibility to them. Related data from studies of migrant populations (that allow comparisons of genetically similar populations living in different environments) and from comparisons between different ethnic groups living in the same country are used to help in the interpretation of the geographic patterns. Information on the burden of disease also has a very important role in the planning and monitoring of programmes of cancer control.	Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon 08, France		Parkin, DM (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	parkin@iarc.fr					[Anonymous], 1994, IARC MON EV CARC RIS, V61; [Anonymous], 1997, DIET NUTR PREV CANC; [Anonymous], 1992, IARC SCI PUBLICATION, V119; Arbyn M, 2002, INT J CANCER, V102, P649, DOI 10.1002/ijc.10761; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BASSETT MT, 1995, INT J CANCER, V63, P29, DOI 10.1002/ijc.2910630107; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Bouchardy C, 1996, INT J EPIDEMIOL, V25, P5, DOI 10.1093/ije/25.1.5; BOUCHARDY C, 1991, CANCER EPIDEM BIOMAR, V1, P21; BOUCHARDY C, 1995, CANCER CAUSE CONTROL, V6, P539, DOI 10.1007/BF00054163; BRESLOW N, 1977, INT J CANCER, V20, P680, DOI 10.1002/ijc.2910200506; Brinton LA, 1997, INT J CANCER, V73, P349, DOI 10.1002/(SICI)1097-0215(19971104)73:3<349::AID-IJC8>3.0.CO;2-#; COGGON D, 1990, BRIT J CANCER, V61, P573, DOI 10.1038/bjc.1990.128; CORREA P, 1973, JNCI-J NATL CANCER I, V51, P1449, DOI 10.1093/jnci/51.5.1449; Doll Richard, 1981, CAUSES CANC; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Dorn HF, 1959, PUBLIC HLTH MONOGRAP, V56; EASTON DF, 1994, BRIT MED BULL, V50, P527, DOI 10.1093/oxfordjournals.bmb.a072908; Editorial Committee for the Atlas of Cancer Mortality in the People's Republic of China, 1979, ATL CANC MORT PEOPL; FERLAY J, 2000, IARC CANC BASE, V5; Fu Y S, 1987, Appl Pathol, V5, P47; Geddes M, 1993, IARC SCI PUBLICATION, V123; GOEDDE HW, 1992, HUM GENET, V88, P344; GRIFFITH GW, 1968, BRIT J CANCER, V22, P163, DOI 10.1038/bjc.1968.23; Gustafsson L, 1997, INT J CANCER, V71, P159, DOI 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#; HARTGE P, 1992, CANCER RES, V52, pS5566; HIRSCH A, 1883, HDB GEOGRAPHICAL HIS, V1; Ishibe N, 1997, CANCER CAUSE CONTROL, V8, P504, DOI 10.1023/A:1018421724776; KOLONEL LN, 1980, GENETIC ENV FACTORS, P327; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LEE HP, 1988, IARC SCI PUBLICATION, V91; Lopez AD, 1996, GLOBAL BURDEN DIS CO; MAHBOUBI E, 1973, BRIT J CANCER, V28, P192, DOI 10.1038/bjc.1973.138; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MCMICHAEL AJ, 1980, INT J CANCER, V25, P431, DOI 10.1002/ijc.2910250402; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Miller BA, 1996, NIH PUBLICATION, V96-4104; MUNOZ N, 1988, INT CONGR SER, V795, P51; Munoz N, 1997, SALUD PUBLICA MEXICO, V39, P318; MUNOZ N, 1996, CANC EPIDEMIOLOGY PR, P681; Norppa H, 1997, ENVIRON HEALTH PERSP, V105, P829, DOI 10.2307/3433290; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Parkin DM, 1999, CANCER SURV, V33, P5; PARKIN DM, 1989, EUR J CANCER CLIN ON, V25, P1917; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 1996, EUR J CANCER, V32A, P761, DOI 10.1016/0959-8049(96)00062-7; PARKIN DM, 1993, CANCER EPIDEM BIOMAR, V2, P537; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Parkin DM, 2003, IARC SCI PUBLICATION, V153; Peto R, 1994, MORTALITY SMOKING DE; PHAM THA, 2002, INT J CANCER, V104, P213; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; PUKKALA E, 2001, CANC SOC FINLAND PUB, V62; ROSE EF, 1975, BRIT J CANCER, V31, P197, DOI 10.1038/bjc.1975.26; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd; Sadjadi A, 2003, INT J CANCER, V107, P113, DOI 10.1002/ijc.11359; Shibata A, 1997, PROSTATE, V32, P65; SIGURDSSON K, 1995, EUR J CANCER, V31A, P728, DOI 10.1016/0959-8049(94)00531-9; Silvi John, 2003, Epidemiol Bull, V24, P1; SITAS F, 1992, GUT, V33, P1582, DOI 10.1136/gut.33.11.1582; SMANS M, 1992, IARC SCI PUBLICATION, V107; TANAKA H, 1994, CANCER CAUSE CONTROL, V5, P409, DOI 10.1007/BF01694754; TUYNS AJ, 1975, INT J EPIDEMIOL, V4, P55, DOI 10.1093/ije/4.1.55; TUYNS AJ, 1973, INT J EPIDEMIOL, V2, P241, DOI 10.1093/ije/2.3.241; TYCZYNSKI J, 1994, EUR J CANCER, V30A, P478, DOI 10.1016/0959-8049(94)90423-5; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; World Health Organization, 2002, NAT CANC CONTR PROGR; YATANI R, 1982, INT J CANCER, V29, P611, DOI 10.1002/ijc.2910290602; Yokoyama A, 2002, CARCINOGENESIS, V23, P1851, DOI 10.1093/carcin/23.11.1851; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712; YU MC, 1995, CANCER EPIDEM BIOMAR, V4, P861; ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819	76	531	569	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6329	6340		10.1038/sj.onc.1207726			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	WOS:000223468800002	15322508	Bronze			2022-02-25	
J	Norat, T; Riboli, E				Norat, T; Riboli, E			Dairy products and colorectal cancer. A review of possible mechanisms and epidemiological evidence	EUROPEAN JOURNAL OF CLINICAL NUTRITION			English	Review						dairy products; milk; cheese; yoghurt; colorectal cancer; meta-analysis	EPITHELIAL-CELL PROLIFERATION; RECTAL MUCOSAL PROLIFERATION; CONJUGATED LINOLEIC-ACID; SUPPLEMENTAL DIETARY CALCIUM; CONTROLLED CLINICAL-TRIAL; ABERRANT CRYPT FOCI; CHAIN FATTY-ACIDS; COLON-CANCER; VITAMIN-D; RISK-FACTORS	Objectives: This review provides an overview of the principal hypotheses and epidemiological evidence of the possible links between colorectal cancer and intake of milk and/or dairy products. Methods: The first section outlines the main hypotheses about the possible effect of calcium, vitamin D, fats and other milk components. The possible role of acid lactic bateria in fermented products is also discussed. The second section is a summary of the published epidemiological evidence. The results on milk, cheese and yoghurt are summarized using a meta-analytical approach. The results of studies on calcium and vitamin D are briefly described. Results: Case-control studies are heterogeneous and, on average, do not provide evidence of association between total intake of total dairy products, milk, cheese or yoghurt and colorectal cancer risk. The average result from cohort studies support the hypothesis of a protective effect of total dairy products (odds ratio (OR): 0.62; 95% confidence interval (Cl): 0.52-0.74; P heterogeneity test: 0.93) and for milk (OR: 0.80; 95% Cl: 0.68-0.95; P heterogeneity: 0.77). No association was found between cheese (OR: 1.10; 95% Cl: 0.88-1.36; P heterogeneity: 0.55) or yoghurt (OR: 1.03; 95% Cl: 0.83-1.28; P heterogeneity: 0.69) in cohort studies. Conclusions: Cohort studies consistently found a protective effect of total dairy products and milk intake, but the evidence is not supported by case-control studies. No relationship was found with cheese or yoghurt intake. As the number of cohort studies is still limited, their results need to be confirmed by other prospective studies.	Int Agcy Res Canc, Unit Nutr & Canc, F-69372 Lyon, France		Riboli, E (corresponding author), Int Agcy Res Canc, Unit Nutr & Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	Riboli@iarc.fr		Riboli, Elio/0000-0001-6795-6080			ABDELALI H, 1995, NUTR CANCER, V24, P121, DOI 10.1080/01635589509514400; Alberts DS, 1997, CANCER EPIDEM BIOMAR, V6, P161; APPLETON GVN, 1987, BRIT J SURG, V74, P523, DOI 10.1002/bjs.1800740635; ARMITAGE NC, 1995, BRIT J CANCER, V71, P186, DOI 10.1038/bjc.1995.38; Aukema HM, 1997, J NUTR, V127, P18, DOI 10.1093/jn/127.1.18; Baron DP, 2001, J ECON MANAGE STRAT, V10, P7, DOI 10.1162/105864001300122548; BARON JA, 1995, JNCI-J NATL CANCER I, V87, P1303, DOI 10.1093/jnci/87.17.1303; BARSOUM GH, 1992, GUT, V33, P1515, DOI 10.1136/gut.33.11.1515; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; BergsmaKadijk JA, 1996, EPIDEMIOLOGY, V7, P590, DOI 10.1097/00001648-199611000-00005; BEZAULT J, 1994, CANCER RES, V54, P2310; BIDOLI E, 1992, INT J CANCER, V50, P223, DOI 10.1002/ijc.2910500211; Bird CL, 1996, CANCER EPIDEM BIOMAR, V5, P607; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; Bostick RM, 1997, CANCER EPIDEM BIOMAR, V6, P971; BOSTICK RM, 1993, J NATL CANCER I, V85, P132, DOI 10.1093/jnci/85.2.132; Bostick RM, 1997, CANCER EPIDEM BIOMAR, V6, P1021; BOSTICK RM, 1995, JNCI-J NATL CANCER I, V87, P1307, DOI 10.1093/jnci/87.17.1307; Boutron MC, 1996, BRIT J CANCER, V74, P145, DOI 10.1038/bjc.1996.330; Boutron-Ruault MC, 1999, EUR J CANCER PREV, V8, P229, DOI 10.1097/00008469-199906000-00011; Bruce WR, 2000, CANCER EPIDEM BIOMAR, V9, P1271; BUSET M, 1986, CANCER RES, V46, P5426; Cascinu S, 2000, CANCER INVEST, V18, P411, DOI 10.3109/07357900009032811; CATS A, 1995, JNCI-J NATL CANCER I, V87, P598, DOI 10.1093/jnci/87.8.598; CENTONZE S, 1994, NUTR CANCER, V21, P233, DOI 10.1080/01635589409514322; Chang WCL, 1997, CARCINOGENESIS, V18, P721, DOI 10.1093/carcin/18.4.721; CHENG JLC, 1993, J INT BUS STUD, V24, P1, DOI 10.1057/palgrave.jibs.8490222; CROSS HS, 1992, JNCI-J NATL CANCER I, V84, P1355, DOI 10.1093/jnci/84.17.1355; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESIMONE C, 1987, IMMUNOPHARM IMMUNOT, V9, P87; Forssen KM, 2000, J AM COLL NUTR, V19, p100S, DOI 10.1080/07315724.2000.10718071; Franceschi S, 1997, INT J CANCER, V72, P56, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;56::AID-IJC8&gt;3.0.CO;2-3; FREUDENHEIM JL, 1991, INT J EPIDEMIOL, V20, P368, DOI 10.1093/ije/20.2.368; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140-6736(89)91789-3; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777; Giovannucci E, 1997, AM J CLIN NUTR, V66, P1564; Giovannucci E, 1998, CANCER CAUSE CONTROL, V9, P567, DOI 10.1023/A:1008835903714; Govers MJAP, 1996, CANCER RES, V56, P3270; GREGOIRE RC, 1989, GUT, V30, P376, DOI 10.1136/gut.30.3.376; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; HAGUE A, 1995, EUR J CANCER PREV, V4, P359, DOI 10.1097/00008469-199510000-00005; Hofstad B, 1998, EUR J CANCER PREV, V7, P287, DOI 10.1097/00008469-199808000-00004; HOLICK MF, 1994, AM J CLIN NUTR, V60, P619, DOI 10.1093/ajcn/60.4.619; Holt PR, 1996, CANCER EPIDEM BIOMAR, V5, P937; Hsing AW, 1998, INT J CANCER, V77, P549, DOI 10.1002/(SICI)1097-0215(19980812)77:4&lt;549::AID-IJC13&gt;3.0.CO;2-1; Hu FB, 1999, JNCI-J NATL CANCER I, V91, P542, DOI 10.1093/jnci/91.6.542; HU JF, 1991, INT J EPIDEMIOL, V20, P362, DOI 10.1093/ije/20.2.362; Ip C, 1997, NUTR CANCER, V27, P131, DOI 10.1080/01635589709514514; IP C, 1994, CANCER, V74, P1050; ISCOVICH JM, 1992, INT J CANCER, V51, P851, DOI 10.1002/ijc.2910510603; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; Kampman E, 2000, CANCER CAUSE CONTROL, V11, P459, DOI 10.1023/A:1008914108739; KAMPMAN E, 1994, CANCER RES, V54, P3186; KAMPMAN E, 1994, INT J CANCER, V59, P170, DOI 10.1002/ijc.2910590205; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; Kearney J, 1996, AM J EPIDEMIOL, V143, P907, DOI 10.1093/oxfordjournals.aje.a008834; Kono S, 1998, CANCER CAUSE CONTROL, V9, P441, DOI 10.1023/A:1008879920140; KOTAKE K, 1995, JPN J CLIN ONCOL, V25, P195; KULKARNI N, 1994, P SOC EXP BIOL MED, V207, P278, DOI 10.3181/00379727-207-43817; Kune S, 1987, Nutr Cancer, V9, P21; LAPRE JA, 1993, CANCER RES, V53, P784; LAVECCHIA C, 1988, INT J CANCER, V41, P492, DOI 10.1002/ijc.2910410404; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; Levi F, 1999, BRIT J CANCER, V79, P1283, DOI 10.1038/sj.bjc.6690206; Lidbeck A, 1992, Eur J Cancer Prev, V1, P341, DOI 10.1097/00008469-199208000-00002; Liew C, 1995, CARCINOGENESIS, V16, P3037, DOI 10.1093/carcin/16.12.3037; Lin H, 1995, J DAIRY SCI, V78, P2358, DOI 10.3168/jds.S0022-0302(95)76863-1; LIPKIN M, 1989, CANCER RES, V49, P248; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; LIPKIN M, 1995, J CELL BIOCHEM, P65; LIPKIN M, 1991, AM J CLIN NUTR, V54, pS188, DOI 10.1093/ajcn/54.1.188S; LLOR X, 1991, CANCER RES, V51, P4305; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MANOUSOS O, 1983, INT J CANCER, V32, P1, DOI 10.1002/ijc.2910320102; Marchetti MC, 1997, NUTR CANCER, V28, P74, DOI 10.1080/01635589709514555; Marcus PM, 1998, INT J EPIDEMIOL, V27, P788, DOI 10.1093/ije/27.5.788; Martinez ME, 1996, JNCI-J NATL CANCER I, V88, P1375, DOI 10.1093/jnci/88.19.1375; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; METTLIN CJ, 1990, NUTR CANCER, V13, P89, DOI 10.1080/01635589009514049; Meydani SN, 2000, AM J CLIN NUTR, V71, P861; MILLER AB, 1983, INT J CANCER, V32, P155, DOI 10.1002/ijc.2910320204; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Murata M, 1999, JPN J CANCER RES, V90, P711, DOI 10.1111/j.1349-7006.1999.tb00805.x; NEGRI E, 1990, NUTR CANCER, V13, P255, DOI 10.1080/01635589009514067; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; OSULLIVAN KR, 1993, EUR J GASTROEN HEPAT, V5, P85, DOI 10.1097/00042737-199302000-00005; Ouwehand AC, 1999, FEMS MICROBIOL LETT, V172, P61, DOI 10.1016/S0378-1097(99)00013-0; Parodi PW, 1999, J DAIRY SCI, V82, P1339, DOI 10.3168/jds.S0022-0302(99)75358-0; Parodi PW, 1997, J NUTR, V127, P1055, DOI 10.1093/jn/127.6.1055; Perdigon G, 1999, J DAIRY SCI, V82, P1108, DOI 10.3168/jds.S0022-0302(99)75333-6; PETERS RK, 1989, CANCER RES, V49, P5459; PETERS RK, 1992, CANCER CAUSE CONTROL, V3, P457, DOI 10.1007/BF00051359; Philipps AF, 2000, J PEDIATR GASTR NUTR, V31, P128, DOI 10.1097/00005176-200008000-00008; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; PICKLE LW, 1984, CANCER RES, V44, P363; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; Pritchard RS, 1996, CANCER EPIDEM BIOMAR, V5, P897; ROZEN P, 1989, GUT, V30, P650, DOI 10.1136/gut.30.5.650; Rozen P, 2001, CANCER-AM CANCER SOC, V91, P833; Schoen RE, 1999, JNCI-J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147; Sekine K, 1997, CANCER LETT, V121, P211, DOI 10.1016/S0304-3835(97)00358-3; Sellers TA, 1998, CANCER CAUSE CONTROL, V9, P357; SHABAHANG M, 1994, CANCER RES, V54, P4057; SHABAHANG M, 1993, CANCER RES, V53, P3712; Shannon J, 1996, CANCER EPIDEM BIOMAR, V5, P495; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697; SITRIN MD, 1991, CANCER RES, V51, P5608; Slattery ML, 1997, CANCER CAUSE CONTROL, V8, P872, DOI 10.1023/A:1018416412906; STEIN RL, 1993, ADV PROTEIN CHEM, V11, P1; STERN HS, 1990, SURGERY, V108, P528; TAJIMA K, 1985, JPN J CANCER RES, V76, P705; Taniyama T, 2000, CARCINOGENESIS, V21, P173, DOI 10.1093/carcin/21.2.173; THOMAS MG, 1993, BRIT J SURG, V80, P499, DOI 10.1002/bjs.1800800432; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; URSIN G, 1990, BRIT J CANCER, V61, P454, DOI 10.1038/bjc.1990.100; VANDERMEER R, 1991, EUROPEAN JOURNAL OF CANCER PREVENTION, VOL 1, SUPPLEMENT 2, OCTOBER 1991, P55, DOI 10.1097/00008469-199110002-00010; Velazquez OC, 1996, JPEN-PARENTER ENTER, V20, P243, DOI 10.1177/0148607196020004243; VLAJINAC H, 1987, Archiv fuer Geschwulstforschung, V57, P493; WALLACH S, 1966, ENDOCRINOLOGY, V79, P773, DOI 10.1210/endo-79-4-773; WARGOVICH MJ, 1992, GASTROENTEROLOGY, V103, P1995, DOI 10.1016/0016-5085(92)91482-J; Weisgerber UM, 1996, GUT, V38, P396, DOI 10.1136/gut.38.3.396; Will JC, 1998, AM J EPIDEMIOL, V147, P816, DOI 10.1093/oxfordjournals.aje.a009534; Wolk A, 1998, AM J CLIN NUTR, V68, P291, DOI 10.1093/ajcn/68.2.291; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Yamada I., 1998, Materials Science in Semiconductor Processing, V1, P27, DOI 10.1016/S1369-8001(98)00006-7; Yoo YC, 1997, JPN J CANCER RES, V88, P184, DOI 10.1111/j.1349-7006.1997.tb00364.x; YOUNG TB, 1988, INT J CANCER, V42, P167, DOI 10.1002/ijc.2910420205; ZHANG XB, 1993, MUTAT RES, V298, P247; Zheng W, 1998, CANCER EPIDEM BIOMAR, V7, P221	137	127	129	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0954-3007	1476-5640		EUR J CLIN NUTR	Eur. J. Clin. Nutr.	JAN	2003	57	1					1	17		10.1038/sj.ejcn.1601522			17	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	642KQ	WOS:000180803900001	12548291	Bronze			2022-02-25	
J	DeMarini, DM; Carreon-Valencia, T; Gwinn, WM; Hopf, NB; Sandy, MS; Bahadori, T; Calaf, GM; Chen, G; de Conti, A; Fritschi, L; Gi, M; Josephy, PD; Kirkeleit, J; Kjaerheim, K; Langouet, S; McElvenny, DM; Sergi, CM; Stayner, LT; Toyoda, T				DeMarini, D. M.; Carreon-Valencia, T.; Gwinn, W. M.; Hopf, N. B.; Sandy, M. S.; Bahadori, T.; Calaf, G. M.; Chen, G.; de Conti, A.; Fritschi, L.; Gi, M.; Josephy, P. D.; Kirkeleit, J.; Kjaerheim, K.; Langouet, S.; McElvenny, D. M.; Sergi, C. M.; Stayner, L. T.; Toyoda, T.		IARC Monographs Vol 127 Grp	Carcinogenicity of some aromatic amines and related compounds	LANCET ONCOLOGY			English	News Item							GENOTOXIC MECHANISM; URINARY-BLADDER; IDENTIFICATION		[DeMarini, D. M.] Int Agcy Res Canc, Lyon, France		DeMarini, DM (corresponding author), Int Agcy Res Canc, Lyon, France.		Turner, Michelle/F-7659-2017; Sergi, Consolato/A-1126-2009; Langouet, Sophie A/I-2776-2015	Turner, Michelle/0000-0002-6431-1997; Chung, Felicia/0000-0003-1043-4948; Hopf, Nancy B/0000-0002-4490-6109; Langouet, Sophie/0000-0002-0016-5425	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline		European Chemicals Agency, 2019, BACKGR DOC OP ANN 15; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Iatropoulos MJ, 2015, EXP TOXICOL PATHOL, V67, P453, DOI 10.1016/j.etp.2015.06.002; International Agency for Research on Cancer, 2020, IARC MON ID CARC HAZ, V127; Kralik A, 2015, CHEM RES TOXICOL, V28, P1317, DOI 10.1021/acs.chemrestox.5b00120; National Toxicology Program, 1993, Natl Toxicol Program Tech Rep Ser, V416, P1; National Toxicology Program, 1978, Natl Cancer Inst Carcinog Tech Rep Ser, V89, P1; National Toxicology Program, 1978, Natl Cancer Inst Carcinog Tech Rep Ser, V130, P1; National Toxicology Program, 1978, Natl Cancer Inst Carcinog Tech Rep Ser, V100, P1; Stiborova M, 2005, INT J CANCER, V116, P667, DOI 10.1002/ijc.21122; Stiborova M, 2004, CARCINOGENESIS, V25, P833, DOI 10.1093/carcin/bgh061; Toyoda T, 2015, TOXICOL SCI, V148, P400, DOI 10.1093/toxsci/kfv192; United States Environmental Protection Agency, 1982, CIIT AN HYDR STUD 10; United States Environmental Protection Agency, 1982, CIIT AN HYDR STUD 10	14	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	AUG	2020	21	8					1017	1018		10.1016/S1470-2045(20)30375-2			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	MU1UD	WOS:000555457500016	32593317				2022-02-25	
J	Saracci, R				Saracci, Rodolfo			Migrants	EPIDEMIOLOGIA & PREVENZIONE			Italian	Editorial Material									[Saracci, Rodolfo] Int Agcy Res Canc, Lione, France		Saracci, R (corresponding author), Int Agcy Res Canc, Lione, France.						Amnesty International, 2017, PERF STORM FAIL EUR; Bena A, 2014, EPIDEMIOL PREV, V38, P208; Milanovic Branko, 2016, GLOBAL INEQUALITY NE; Pacelli B, 2016, EUR J EPIDEMIOL, V31, P691, DOI 10.1007/s10654-016-0177-z	4	1	1	0	0	INFERENZE SCARL	MILANO	VIA RICCIARELLI N 29, MILANO, 20148, ITALY	1120-9763			EPIDEMIOL PREV	Epidemiol. Prev.	MAY-AUG	2017	41	3-4					158	158					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	FT6TZ	WOS:000423288000007	28929707				2022-02-25	
J	Martin, M; Ancey, PB; Cros, MP; Durand, G; Le Calvez-Kelm, F; Hernandez-Vargas, H; Herceg, Z				Martin, Marion; Ancey, Pierre-Benoit; Cros, Marie-Pierre; Durand, Geoffroy; Le Calvez-Kelm, Florence; Hernandez-Vargas, Hector; Herceg, Zdenko			Dynamic imbalance between cancer cell subpopulations induced by Transforming Growth Factor Beta (TGF-beta) is associated with a DNA methylome switch	BMC GENOMICS			English	Article						HCC; Tumor-initiating cells; CD133; DNA methylation; TGF-beta pathway	EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; STEM-CELLS; CLINICAL-IMPLICATIONS; METHYLATION ARRAY; CD133; MICROARRAY; RECEPTORS; IDENTIFICATION; REPRESSION	Background: Distinct subpopulations of neoplastic cells within tumors, including hepatocellular carcinoma (HCC), display pronounced ability to initiate new tumors and induce metastasis. Recent evidence suggests that signals from transforming growth factor beta (TGF-beta) may increase the survival of these so called tumor initiating cells leading to poor HCC prognosis. However, how TGF-beta establishes and modifies the key features of these cell subpopulations is not fully understood. Results: In the present report we describe the differential DNA methylome of CD133-negative and CD133-expressing liver cancer cells. Next, we show that TGF-beta is able to increase the proportion of CD133+ cells in liver cancer cell lines in a way that is stable and persistent across cell division. This process is associated with stable genome-wide changes in DNA methylation that persist through cell division. Differential methylation in response to TGF-beta is under-represented at promoter CpG islands and enriched at gene bodies, including a locus in the body of the de novo DNA methyl-transferase DNMT3B gene. Moreover, phenotypic changes induced by TGF-beta, including the induction of CD133, are impaired by siRNA silencing of de novo DNA methyl-transferases. Conclusions: Our study reveals a self-perpetuating crosstalk between TGF-beta signaling and the DNA methylation machinery, which can be relevant in the establishment of cellular phenotypes. This is the first indication of the ability of TGF-beta to induce genome-wide changes in DNA methylation, resulting in a stable change in the proportion of liver cancer cell subpopulations.	[Martin, Marion; Ancey, Pierre-Benoit; Cros, Marie-Pierre; Hernandez-Vargas, Hector; Herceg, Zdenko] IARC, Epigenet Group, F-69008 Lyon, France; [Durand, Geoffroy; Le Calvez-Kelm, Florence] IARC, Genet Canc Susceptibil Grp, F-69008 Lyon, France		Hernandez-Vargas, H (corresponding author), IARC, Epigenet Group, 150 Rue Albert Thomas, F-69008 Lyon, France.	vargash@iarc.fr; herceg@iarc.fr		Le Calvez-Kelm, Florence/0000-0003-0063-5068; Hernandez-Vargas, Hector/0000-0001-6045-2103	la Ligue National (Francaise) Contre le Cancer; l'Association pour le Recherche Contre le Cancer (l'ARC); Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS)ANRSFrench National Research Agency (ANR); La Ligue National Contre le Cancer (La Ligue)	We thank Fabienne Barbet from the ProfileXpert platform for the scan of the Illumina 450K arrays (service de Genomique & Microgenomique, Universite Lyon 1, SFR sante LYON-EST, UCBL-INSERM US 7-CNRS UMS 3453, 8 av. Rockefeller 69373 Lyon Cedex 08)). This work was supported by la Ligue National (Francaise) Contre le Cancer, l'Association pour le Recherche Contre le Cancer (l'ARC), and the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS). PBA is supported by a fellowship from La Ligue National Contre le Cancer (La Ligue).	Abell AN, 2011, CELL STEM CELL, V8, P525, DOI 10.1016/j.stem.2011.03.008; Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1002/hep.1840210325; Bergman Y, 2013, NAT STRUCT MOL BIOL, V20, P274, DOI 10.1038/nsmb.2518; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470; Dedeurwaerder S, 2013, BRIEF BIOINFORM; Ding W, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.15; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Grosse-Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Hernandez-Vargas H, 2007, ONCOGENE, V26, P2902, DOI 10.1038/sj.onc.1210102; Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Ma S, 2013, EXP CELL RES, V319, P126, DOI 10.1016/j.yexcr.2012.09.007; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marabita F, 2013, EPIGENETICS-US, V8, P333, DOI 10.4161/epi.24008; Marquardt JU, 2010, SEMIN LIVER DIS, V30, P26, DOI 10.1055/s-0030-1247130; Martin M, 2012, GENOME MED, V4, DOI 10.1186/gm307; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mima K, 2012, CANCER RES, V72, P3414, DOI 10.1158/0008-5472.CAN-12-0299; Ohishi W, 2014, INT J CANCER, V134, P154, DOI 10.1002/ijc.28337; Ouzounova M, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-139; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293; Sasaki A, 2010, ONCOL REP, V24, P537, DOI 10.3892/or_00000890; Slieker RC, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-26; Smyth GK., 2004, STAT APPL GENET MOL, V3, pARTICL; Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680; Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439; Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005; You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544	47	21	21	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2164			BMC GENOMICS	BMC Genomics	JUN 5	2014	15								435	10.1186/1471-2164-15-435			18	Biotechnology & Applied Microbiology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity	AK2NT	WOS:000338257000002	24898317	gold, Green Published			2022-02-25	
J	Voegele, C; Bouchereau, B; Robinot, N; McKay, J; Damiecki, P; Alteyrac, L				Voegele, Catherine; Bouchereau, Baptiste; Robinot, Nivonirina; McKay, James; Damiecki, Philippe; Alteyrac, Lucile			A universal open-source Electronic Laboratory Notebook	BIOINFORMATICS			English	Article							MANAGEMENT-SYSTEM	Motivation: Laboratory notebooks remain crucial to the activities of research communities. With the increase in generation of electronic data within both wet and dry analytical laboratories and new technologies providing more efficient means of communication, Electronic Laboratory Notebooks (ELN) offer equivalent record keeping to paper-based laboratory notebooks (PLN). They additionally allow more efficient mechanisms for data sharing and retrieval, which explains the growing number of commercial ELNs available varying in size and scope but all are increasingly accepted and used by the scientific community. The International Agency for Research on Cancer (IARC) having already an LIMS and a Biobank Management System for respectively laboratory workflows and sample management, we have developed a free multidisciplinary ELN specifically dedicated to work notes that will be flexible enough to accommodate different types of data.	[Voegele, Catherine; Robinot, Nivonirina; McKay, James] IARC, Genet Canc Susceptibil Grp, F-69003 Lyon, France; [Bouchereau, Baptiste; Damiecki, Philippe; Alteyrac, Lucile] IARC, Informat Technol Serv Grp, F-69003 Lyon, France		Voegele, C (corresponding author), IARC, Genet Canc Susceptibil Grp, F-69003 Lyon, France.	voegele@iarc.fr		Ranoroarivony Robiniot, Nivonirina/0000-0002-2532-1455			Voegele C, 2007, BIOINFORMATICS, V23, P2504, DOI 10.1093/bioinformatics/btm365; Voegele C, 2010, BIOINFORMATICS, V26, P2798, DOI 10.1093/bioinformatics/btq502; Wright Jerry M, 2009, Autom Exp, V1, P5, DOI 10.1186/1759-4499-1-5	3	10	10	2	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1367-4803			BIOINFORMATICS	Bioinformatics	JUL 1	2013	29	13					1710	1712		10.1093/bioinformatics/btt253			3	Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics	182MD	WOS:000321746100067	23645817				2022-02-25	
J	Straif, K				Straif, Kurt			IARC Response	IEEE MICROWAVE MAGAZINE			English	Editorial Material									IARC Monographs, Lyon, France		Straif, K (corresponding author), IARC Monographs, Lyon, France.							0	0	0	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1527-3342			IEEE MICROW MAG	IEEE Microw. Mag.	OCT	2011	12	6											1	Engineering, Electrical & Electronic; Telecommunications	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Telecommunications	819UE	WOS:000294855600006					2022-02-25	
J	Lambert, R				Lambert, R.			Gastric and rectal carcinoids	ENDOSCOPY			English	Editorial Material							PROPOSED STAGING SYSTEM; NEUROENDOCRINE TUMORS; GASTROINTESTINAL-TRACT; GRADING SYSTEM		WHO Int Agcy Res Canc, Screening Grp, F-69372 Lyon 08, France		Lambert, R (corresponding author), WHO Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	lambert@iarc.fr					Borch K, 2005, ANN SURG, V242, P64, DOI 10.1097/01.sla.0000167862.52309.7d; Chetty R, 2008, CAN J GASTROENTEROL, V22, P357, DOI 10.1155/2008/270905; Fujishiro M, 2008, WORLD J GASTROENTERO, V14, P4289, DOI 10.3748/wjg.14.4289; Gustafsson BI, 2008, CURR OPIN ONCOL, V20, P1, DOI 10.1097/CCO.0b013e3282f1c595; Kloppel G, 2004, ANN NY ACAD SCI, V1014, P13, DOI 10.1196/annals.1294.002; Kwaan MR, 2008, ARCH SURG-CHICAGO, V143, P471, DOI 10.1001/archsurg.143.5.471; Landry CS, 2008, SURGERY, V144, P460, DOI 10.1016/j.surg.2008.05.005; Landry CS, 2009, ANN SURG ONCOL, V16, P51, DOI 10.1245/s10434-008-0192-8; Lee DS, 2010, ENDOSCOPY, V42, P647, DOI 10.1055/s-0030-1255591; Massironi S, 2008, WORLD J GASTROENTERO, V14, P5377, DOI 10.3748/wjg.14.5377; Massironi S, 2009, WORLD J GASTROENTERO, V15, P2177, DOI 10.3748/wjg.15.2177; Modlin IM, 2010, ALIMENT PHARM THER, V31, P169, DOI 10.1111/j.1365-2036.2009.04174.x; Modlin IM, 2008, LANCET ONCOL, V9, P61, DOI 10.1016/S1470-2045(07)70410-2; Modlin IM, 2006, J CLIN GASTROENTEROL, V40, P572, DOI 10.1097/00004836-200608000-00003; Rindi G, 2007, VIRCHOWS ARCH, V451, P757, DOI 10.1007/s00428-007-0452-1; Rindi G, 2006, VIRCHOWS ARCH, V449, P395, DOI 10.1007/s00428-006-0250-1; Scherubl H, 2010, ENDOSCOPY, V42, P664, DOI 10.1055/s-0030-1255564; Soga J, 2005, CANCER-AM CANCER SOC, V103, P1587, DOI 10.1002/cncr.20939; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377	19	6	7	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X			ENDOSCOPY	Endoscopy	AUG	2010	42	8					661	663		10.1055/s-0030-1255592			3	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	633HK	WOS:000280492300009	20669077				2022-02-25	
J	Baan, RA				Baan, Robert A.			Untitled	MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS			English	Editorial Material							HUMAN FIBROBLASTS; IN-VITRO; MHZ		IARC, Lyon, France		Baan, RA (corresponding author), IARC, Lyon, France.	baanmr@iarc.fr					Diem E, 2005, MUTAT RES-GEN TOX EN, V583, P178, DOI 10.1016/j.mrgentox.2005.03.006; Drexler H, 2009, INT ARCH OCC ENV HEA, V82, P143, DOI 10.1007/s00420-008-0360-y; Schwarz C, 2008, INT ARCH OCC ENV HEA, V81, P755, DOI 10.1007/s00420-008-0305-5; Wolf C, 2008, BIOELECTROMAGNETICS, V29, P658, DOI 10.1002/bem.20440	4	5	5	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1383-5718			MUTAT RES-GEN TOX EN	Mutat. Res. Genet. Toxicol. Environ. Mutagen.	FEB 19	2009	673	1					1	1		10.1016/j.mrgentox.2008.11.003			1	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	412TZ	WOS:000263748400001	19063993				2022-02-25	
J	Lambert, R; Hainaut, P; Parkin, DM				Lambert, R; Hainaut, P; Parkin, DM			Premalignant lesions of the esophagogastric mucosa	SEMINARS IN ONCOLOGY			English	Review							HELICOBACTER-PYLORI INFECTION; MEDICAL DECISION-ANALYSIS; HIGH-RISK POPULATIONS; BARRETTS-ESOPHAGUS; GASTRIC-CANCER; INTESTINAL METAPLASIA; HYPERPLASTIC POLYPS; MULTILAYERED EPITHELIUM; ENDOSCOPIC SURVEILLANCE; CYTOKERATIN EXPRESSION		Int Agcy Res Canc, F-69008 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.		Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Abraham SC, 2002, AM J PATHOL, V161, P1735, DOI 10.1016/S0002-9440(10)64450-1; Abraham SC, 2001, AM J SURG PATHOL, V25, P500, DOI 10.1097/00000478-200104000-00010; Blaser MJ, 2001, J CLIN INVEST, V107, P767, DOI 10.1172/JCI12672; Campbell DI, 2001, HELICOBACTER, V6, P263, DOI 10.1046/j.1083-4389.2001.00047.x; Canto MIF, 2001, ENDOSCOPY, V33, P391, DOI 10.1055/s-2001-14427; CORREA P, 1992, CANCER RES, V52, P6735; Couvelard A, 2001, GUT, V49, P761, DOI 10.1136/gut.49.6.761; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; DAWSEY SM, 1994, CANCER, V74, P1686, DOI 10.1002/1097-0142(19940915)74:6<1686::AID-CNCR2820740608>3.0.CO;2-V; DAWSEY SM, 1994, CANCER, V73, P2027, DOI 10.1002/1097-0142(19940415)73:8<2027::AID-CNCR2820730803>3.0.CO;2-3; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Dixon MF, 2002, GUT, V51, P130, DOI 10.1136/gut.51.1.130; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Endo T, 2002, GASTROINTEST ENDOSC, V55, P641, DOI 10.1067/mge.2002.123420; Fennerty MB, 2001, AM J GASTROENTEROL, V96, P2302; Ferlay J., 2001, GLOBOCAN 2000 CANC I; GAO HK, 1994, CANCER RES, V54, P4342; Glickman JN, 2001, AM J SURG PATHOL, V25, P569, DOI 10.1097/00000478-200105000-00002; Guelrud M, 2001, GASTROINTEST ENDOSC, V53, P559, DOI 10.1067/mge.2001.114059; Guindi M, 2001, BEST PRACT RES CL GA, V15, P191, DOI 10.1053/bega.2001.0169; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hosokawa O, 1998, ENDOSCOPY, V30, P669, DOI 10.1055/s-2007-1001386; Hosokawa O, 2001, ENDOSCOPY, V33, P301, DOI 10.1055/s-2001-13685; Inoue H, 2001, ENDOSCOPY, V33, P75; Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10; Japanese Society for Esophageal Diseases, 1999, GUID CLIN PATH STUD; Jass JR, 2001, BEST PRACT RES CL GA, V15, P175, DOI 10.1053/bega.2000.0168; Katakura T, 1998, Nihon Shokakibyo Gakkai Zasshi, V95, P992; Kodama M, 1998, SURGERY, V123, P432, DOI 10.1067/msy.1998.86778; Kokkola A, 2002, ALIMENT PHARM THER, V16, P515, DOI 10.1046/j.1365-2036.2002.01214.x; Kumagai Y, 2002, ENDOSCOPY, V34, P369, DOI 10.1055/s-2002-25285; Lambert R, 2003, ENDOSCOPY, V35, P437, DOI 10.1055/s-2003-38766; Lambert R, 2003, ENDOSCOPY, V35, P118, DOI 10.1055/s-2003-37016; Lambert R, 2002, INT J CANCER, V97, P811, DOI 10.1002/ijc.10150; Lee JH, 2002, AM J PATHOL, V161, P611, DOI 10.1016/S0002-9440(10)64216-2; Levine DS, 2000, AM J GASTROENTEROL, V95, P1152; Makuuchi H, 2001, Gastrointest Endosc Clin N Am, V11, P445; Malila N, 2002, CANCER CAUSE CONTROL, V13, P617, DOI 10.1023/A:1019556227014; May A, 2002, ENDOSCOPY, V34, P604, DOI 10.1055/s-2002-33236; Montesano R, 1998, CANCER SURV, V32, P53; Muehldorfer SM, 2002, GUT, V50, P465, DOI 10.1136/gut.50.4.465; Odze R, 2002, LANCET, V359, P1711, DOI 10.1016/S0140-6736(02)08661-0; Ohkusa T, 1998, ANN INTERN MED, V129, P712, DOI 10.7326/0003-4819-129-9-199811010-00006; Ono H, 2001, GUT, V48, P225, DOI 10.1136/gut.48.2.225; Park DI, 2001, ENDOSCOPY, V33, P501, DOI 10.1055/s-2001-15089; Parkin DM, 2003, CANC AFRICA EPIDEMIO; Pech O, 2002, EUR J GASTROEN HEPAT, V14, P657, DOI 10.1097/00042737-200206000-00011; Pech O, 2001, BEST PRACT RES CL GA, V15, P267, DOI 10.1053/bega.2001.0173; Petersson F, 2002, DIGEST DIS SCI, V47, P1558, DOI 10.1023/A:1015938303993; QIU SL, 1988, CANCER, V62, P551, DOI 10.1002/1097-0142(19880801)62:3<551::AID-CNCR2820620319>3.0.CO;2-Y; Rollins AM, 2001, BEST PRACT RES CL GA, V15, P227, DOI 10.1053/bega.2000.0171; Rugge M, 2000, AM J SURG PATHOL, V24, P167, DOI 10.1097/00000478-200002000-00001; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Schmitz J M, 1997, Gastrointest Endosc Clin N Am, V7, P29; Sharma P, 2003, GUT, V52, P24, DOI 10.1136/gut.52.1.24; Shen B, 2002, CANCER-AM CANCER SOC, V94, P820, DOI 10.1002/cncr.10215; Shields HM, 2001, AM J GASTROENTEROL, V96, P3268; Shim CS, 2001, ENDOSCOPY, V33, P271, DOI 10.1055/s-2001-12816; Shimizu Y, 2001, GASTROINTEST ENDOSC, V53, P1, DOI 10.1067/mge.2001.111387; Si HX, 2003, INT J CANCER, V103, P496, DOI 10.1002/ijc.10865; Sonnenberg A, 2003, GASTROENTEROLOGY, V124, P1758, DOI 10.1016/S0016-5085(03)00393-7; Sonnenberg A, 2002, ALIMENT PHARM THERAP, V16, P41, DOI 10.1046/j.1365-2036.2002.01146.x; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; STOLTE M, 1995, ENDOSCOPY, V27, P32, DOI 10.1055/s-2007-1005629; STOLTE M, 1994, ENDOSCOPY, V26, P659, DOI 10.1055/s-2007-1009061; Stolte M, 2001, AM J SURG PATHOL, V25, P1342, DOI 10.1097/00000478-200110000-00022; Tajiri H, 2002, ENDOSCOPY, V34, P772, DOI 10.1055/s-2002-34267; Taniere P, 2002, AM J SURG PATHOL, V26, P1213, DOI 10.1097/00000478-200209000-00012; Taniere P, 2001, AM J PATHOL, V158, P33, DOI 10.1016/S0002-9440(10)63941-7; Torbenson M, 2002, MODERN PATHOL, V15, P718, DOI 10.1097/01.MP.0000018976.15044.9B; Tsukuma H, 2000, GUT, V47, P618, DOI 10.1136/gut.47.5.618; Wambura C, 2002, HELICOBACTER, V7, P129, DOI 10.1046/j.1083-4389.2002.00069.x; WANG GQ, 1994, CANCER EPIDEM BIOMAR, V3, P161; Wang J, 2002, DIGEST DIS SCI, V47, P107, DOI 10.1023/A:1013223722331; Watanabe Hidenobu, 1998, Stomach and Intestine (Tokyo), V33, P985; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Whiting JL, 2002, GUT, V50, P378, DOI 10.1136/gut.50.3.378; Wu AH, 2003, INT J CANCER, V103, P815, DOI 10.1002/ijc.10887; Wu TT, 1998, AM J PATHOL, V153, P287, DOI 10.1016/S0002-9440(10)65570-8; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yao K., 2001, DIGEST ENDOSC, V13, pS27, DOI DOI 10.1111/J.1443-1661.2001.00114.X; Ye WM, 2001, GASTROENTEROLOGY, V121, P1286, DOI 10.1053/gast.2001.29569; Yokoyama A, 2003, JPN J CLIN ONCOL, V33, P111, DOI 10.1093/jjco/hyg026; Zhang Z, 2001, WORLD J GASTROENTERO, V7, P779, DOI 10.3748/wjg.v7.i6.779; Zhang ZF, 1999, CANCER DETECT PREV, V23, P357, DOI 10.1046/j.1525-1500.1999.99041.x; ZHONG XX, 1991, CANCER-AM CANCER SOC, V67, P2382, DOI 10.1002/1097-0142(19910501)67:9<2382::AID-CNCR2820670927>3.0.CO;2-T; 2002, J GASTROENTEROL MASS, V40, P57	87	18	20	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0093-7754	1532-8708		SEMIN ONCOL	Semin. Oncol.	AUG	2004	31	4					498	512		10.1053/j.seminoncol.2004.04.017			15	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	848EA	WOS:000223449000007	15297942				2022-02-25	
J	Brennan, P; Boffetta, P				Brennan, P; Boffetta, P			Proper controls for SNP studies?	CARCINOGENESIS			English	Letter									Int Agcy Res Canc, Unit Environm Canc Epidemiol, F-69008 Lyon, France		Brennan, P (corresponding author), Int Agcy Res Canc, Unit Environm Canc Epidemiol, 150 Cours Albert Thomas, F-69008 Lyon, France.	brennan@iarc.fr; boffetta@iarc.fr					Brennan P, 2002, CARCINOGENESIS, V23, P381, DOI 10.1093/carcin/23.3.381; Vineis P, 1999, IARC Sci Publ, P403	2	1	1	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0143-3334	1460-2180		CARCINOGENESIS	Carcinogenesis	DEC	2002	23	12					2135	2135		10.1093/carcin/23.12.2135			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	632YM	WOS:000180252500020	12507939	Bronze			2022-02-25	
J	Pisani, P; Mitton, N				Pisani, P; Mitton, N			Cooking methods, metabolic polymorphisms and colorectal cancer	EUROPEAN JOURNAL OF CANCER PREVENTION			English	Article; Proceedings Paper	7th International Vahouny Symposium on Dietary Fibre in Health and Disease	MAY 27-30, 2002	ROYAL COLL PHYS EDINBURGH, EDINBURGH, SCOTLAND		ROYAL COLL PHYS EDINBURGH		S-TRANSFERASE M1; GENETIC-POLYMORPHISM; RED MEAT; CYTOCHROME-P450 1A1; HETEROCYCLIC AMINES; CIGARETTE-SMOKING; NULL GENOTYPE; COLON-CANCER; FRIED FOODS; WELL-DONE		Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon, France		Pisani, P (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon, France.	pisani@iarc.fr					Abdel-Rahman SZ, 1999, CANCER LETT, V142, P97, DOI 10.1016/S0304-3835(99)00159-7; Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1; Brockton N, 2000, AM J EPIDEMIOL, V151, P846; Butler WJ, 1997, GASTROENTEROLOGY, V112, pA542; Chen J, 1998, CANCER RES, V58, P3307; CHENEVIXTRENCH G, 1995, CARCINOGENESIS, V16, P1655, DOI 10.1093/carcin/16.7.1655; Cotton SC, 2000, AM J EPIDEMIOL, V151, P7, DOI 10.1093/oxfordjournals.aje.a010124; Deakin M, 1996, CARCINOGENESIS, V17, P881, DOI 10.1093/carcin/17.4.881; DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408; EDMUND L, 1998, J TOXICOL SCI, V23, P140; Fritsche E, 1999, PHARMACOGENETICS, V9, P405, DOI 10.1097/00008571-199906000-00018; Gawronska-Szklarz B, 1999, EXP TOXICOL PATHOL, V51, P321, DOI 10.1016/S0940-2993(99)80014-1; Gertig DM, 1998, CANCER EPIDEM BIOMAR, V7, P1001; HIRVONEN A, 1999, IARC SCI PUBLICATION, V148; Inoue H, 2000, CANCER RES, V60, P3749; Ishibe N, 2000, CANCER EPIDEM BIOMAR, V9, P855; Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15; Katoh T, 1996, CARCINOGENESIS, V17, P1855, DOI 10.1093/carcin/17.9.1855; Kiss I, 2000, ANTICANCER RES, V20, P519; Landi MT, 1999, IARC SCI PUBLICATION; LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675; Lin HJ, 1998, CANCER EPIDEM BIOMAR, V7, P647; LIN HJ, 1995, CANCER RES, V55, P1224; LYON JL, 1988, AM J EPIDEMIOL, V128, P1000; MUSCAT JE, 1994, AM J PUBLIC HEALTH, V84, P856, DOI 10.2105/AJPH.84.5.856; ProbstHensch NM, 1997, CANCER CAUSE CONTROL, V8, P175, DOI 10.1023/A:1018416128894; RobertsThomson IC, 1996, LANCET, V347, P1372, DOI 10.1016/S0140-6736(96)91012-0; SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376, DOI 10.1093/oxfordjournals.aje.a115508; Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353; Sinha R, 1999, CANCER RES, V59, P4320; SIVARAMAN L, 1994, CANCER RES, V54, P3692; Slattery ML, 2000, CANCER CAUSE CONTROL, V11, P1, DOI 10.1023/A:1008913619957; Slattery ML, 1998, CANCER EPIDEM BIOMAR, V7, P1079; Welfare M, 1999, CANCER EPIDEM BIOMAR, V8, P289; Welfare MR, 1997, CARCINOGENESIS, V18, P1351, DOI 10.1093/carcin/18.7.1351; Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2; WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; Yoshioka Makoto, 1999, Journal of UOEH, V21, P133; Zhang H, 1999, INT J CANCER, V84, P135, DOI 10.1002/(SICI)1097-0215(19990420)84:2<135::AID-IJC7>3.0.CO;2-C; ZHONG S, 1993, CARCINOGENESIS, V14, P1821, DOI 10.1093/carcin/14.9.1821	41	4	4	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-8278	1473-5709		EUR J CANCER PREV	Eur. J. Cancer Prev.	FEB	2002	11	1					75	84		10.1097/00008469-200202000-00012			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	525JT	WOS:000174066300012	11917213				2022-02-25	
J	Guimaraes, DP; Hainaut, P				Guimaraes, DP; Hainaut, P			TP53: a key gene in human cancer	BIOCHIMIE			English	Article						TP53; mutation; DNA damage; P14(arf); hypoxia; multistep carcinogenesis	WILD-TYPE P53; CODON 72 POLYMORPHISM; TUMOR-SUPPRESSOR GENE; GAIN-OF-FUNCTION; LUNG-CANCER; BREAST-CANCER; DNA-DAMAGE; MUTANT P53; HEPATOCELLULAR-CARCINOMA; FUNCTIONAL INTERACTIONS	TP53 is mutated in most types of human cancers and is one of the most popular genes in cancer research. The p53 protein is a sensor of multiple forms of genotoxic, oncogenic and non-genotoxic stress. It suppresses growth and controls survival of stressed cells, and as such, is the focal point of selection pressures in tissues exposed to carcinogens or to oncogenic changes. Thus, the clonal expansion of cells with mutations in TP53 may be seen as the result of a selection process intrinsic to the natural history of cancer. In this review, we discuss the nature of these various forms of selection pressure. We present a hypothesis to explain why TP53 is often mutated as either an early or a late event in cancer. Furthermore, we also summarise current knowledge on the molecular consequences of mutation for loss of wild-type protein function, dominant-negative activity, and a possible gain of oncogenic function. (C) 2002 Societe francaise de biochimie et biologie moleculaire / Editions scientifiques et medicales Elsevier SAS.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France		Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	GUIMARÃES, DENISE P/G-4892-2012; Hainaut, Pierre/B-6018-2012	GUIMARÃES, DENISE P/0000-0002-0568-7038; Hainaut, Pierre/0000-0002-1303-1610			Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Allan JM, 2001, INT J CANCER, V91, P359, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1058>3.0.CO;2-E; Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Camplejohn RS, 2000, BRIT J CANCER, V82, P1145; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fan R, 2000, CANCER EPIDEM BIOMAR, V9, P1037; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; FORRESTER K, 1995, ONCOGENE, V10, P2103; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Geisler S, 2001, CANCER RES, V61, P2505; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Kleihues P, 1997, AM J PATHOL, V150, P1; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levrero M, 2000, J CELL SCI, V113, P1661; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Maurici D, 2001, ONCOGENE, V20, P3533, DOI 10.1038/sj.onc.1204428; MAURICI D, 2001, ENCY LIFE SUPPORT SY; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Minaguchi T, 1998, CANCER RES, V58, P4585; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; MONTESANO R, 1997, IARC SCI PUBL, V142, P291; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Murata M, 1998, INT J ONCOL, V12, P577; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NGUYEN KT, 1994, ONCOL RES, V6, P71; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Peixoto GD, 2001, CANC LETT, V162, P231; Petersen S, 2001, DIS COLON RECTUM, V44, P322, DOI 10.1007/BF02234727; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Ravi R, 2000, GENE DEV, V14, P34; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Rosenthal AN, 1998, LANCET, V352, P871, DOI 10.1016/S0140-6736(98)07357-7; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; STONE S, 1995, CANCER RES, V55, P2988; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thomas M, 1999, MOL CELL BIOL, V19, P1092; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang YC, 1999, CLIN CANCER RES, V5, P129; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yamashita T, 1999, CARCINOGENESIS, V20, P1733, DOI 10.1093/carcin/20.9.1733; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	97	127	136	0	7	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0300-9084	1638-6183		BIOCHIMIE	Biochimie	JAN	2002	84	1					83	93	PII S0300-9084(01)01356-6	10.1016/S0300-9084(01)01356-6			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542UR	WOS:000175063100009	11900880				2022-02-25	
J	Lambert, R				Lambert, R			Barrett's oesophagus: better left alone?	EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY			English	Article						adenocarcinoma; Barrett's oesophagus; endoscopy; surveillance	GASTROESOPHAGEAL REFLUX DISEASE; GASTRIC CARDIA; ESOPHAGEAL ADENOCARCINOMA; ENDOSCOPIC SURVEILLANCE; PUBLICATION BIAS; NATURAL-HISTORY; CANCER RISK; TIME TREND; BODY-MASS; CARCINOMA	The risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus is overrated in most publications, including meta-analyses. The upper limit of the overall risk is currently estimated at 0.5 per 100 patients per year. This means that one cancer may occur out of 200 patients followed for one year. Furthermore, a large fraction of patients with Barrett's oesophagus have a precarious health status, either from advanced age or from a chronic severe disease. Management is based upon a careful index endoscopy; accordingly, patients positive for dysplasia must be strictly observed or treated. Endoscopic surveillance protocols aiming at early detection of neoplasia - and treatment - in patients without dysplasia are unjustified in most cases. On the other hand, a minority of male patients - providing a good performance status should enter into surveillance protocols when high-risk factors such as a long history of reflux symptoms and smoking habits are present. Eur J Gastroenterol Hepatol 13:627-630 (C) 2001 Lippincott Williams & Wilkins.	Int Agcy Res Canc, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	lamberi@iarc.fr					[Anonymous], 1997, IARC SCI PUBL, VVII, p[i, 1]; Armstrong RW, 1996, INT J EPIDEMIOL, V25, P941, DOI 10.1093/ije/25.5.941; BEGG CB, 1989, J NATL CANCER I, V81, P107, DOI 10.1093/jnci/81.2.107; Botterweck AAM, 2000, INT J EPIDEMIOL, V29, P645, DOI 10.1093/ije/29.4.645; Bytzer P, 1999, AM J GASTROENTEROL, V94, P86; Cheng KK, 2000, BRIT J CANCER, V83, P127; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Ekstrom AM, 1999, JNCI-J NATL CANCER I, V91, P786, DOI 10.1093/jnci/91.9.786; El-Serag HB, 1998, GUT, V43, P327, DOI 10.1136/gut.43.3.327; FRANCIS B, 1605, ADV LEARNING; Gammon MD, 1997, J NATL CANCER I, V89, P1277, DOI 10.1093/jnci/89.17.1277; Gudlaugsdottir S, 2001, EUR J GASTROEN HEPAT, V13, P639, DOI 10.1097/00042737-200106000-00005; Hansen S, 1997, INT J CANCER, V71, P340, DOI 10.1002/(SICI)1097-0215(19970502)71:3<340::AID-IJC5>3.0.CO;2-Y; Hirota WK, 1999, GASTROENTEROLOGY, V116, P277, DOI 10.1016/S0016-5085(99)70123-X; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lagergren J, 1999, ANN INTERN MED, V130, P883, DOI 10.7326/0003-4819-130-11-199906010-00003; Lagergren J, 2000, GUT, V47, P26, DOI 10.1136/gut.47.1.26; Lagergren J, 2000, ANN INTERN MED, V133, P165, DOI 10.7326/0003-4819-133-3-200008010-00007; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; Lord RVN, 1998, J GASTROEN HEPATOL, V13, P356, DOI 10.1111/j.1440-1746.1998.tb00646.x; MCKINNEY PA, 1995, BRIT J CANCER, V71, P411, DOI 10.1038/bjc.1995.84; Moller H, 1992, Eur J Cancer Prev, V1, P159; Ormsby AH, 2000, GASTROENTEROLOGY, V119, P683, DOI 10.1053/gast.2000.16482; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; Rudolph RE, 2000, ANN INTERN MED, V132, P612, DOI 10.7326/0003-4819-132-8-200004180-00003; *SEER, 1998, CANC INC US DAT 1973; Shaheen NJ, 2000, GASTROENTEROLOGY, V119, P333, DOI 10.1053/gast.2000.9302; Soetikno RM, 1998, AM J GASTROENTEROL, V93, P485, DOI 10.1016/S0002-9270(98)80061-0; Soni A, 2000, AM J GASTROENTEROL, V95, P2086; Sonnenberg A, 1999, YALE J BIOL MED, V72, P81; Spechler SJ, 2000, GASTROENTEROLOGY, V119, P587, DOI 10.1053/gast.2000.9849; Spechler SJ, 1999, GASTROENTEROLOGY, V117, P218, DOI 10.1016/S0016-5085(99)70571-8; SPECHLER SJ, 1992, DIGESTION, V51, P24, DOI 10.1159/000200911; Streitz JM, 1998, AM J GASTROENTEROL, V93, P911; Thomas RJS, 1996, AUST NZ J SURG, V66, P271, DOI 10.1111/j.1445-2197.1996.tb01183.x; TYTGAT GNJ, 1995, ENDOSCOPY, V27, P19, DOI 10.1055/s-2007-1005627; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Vaughan TL, 1998, CANCER EPIDEM BIOMAR, V7, P749; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; ZHENG TZ, 1992, CANCER CAUSE CONTROL, V3, P481, DOI 10.1007/BF00051361	41	4	5	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0954-691X	1473-5687		EUR J GASTROEN HEPAT	Eur. J. Gastroenterol. Hepatol.	JUN	2001	13	6					627	630		10.1097/00042737-200106000-00002			4	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	442UD	WOS:000169302600002	11434585				2022-02-25	
J	Norat, T; Riboli, E				Norat, T; Riboli, E			Meat consumption and colorectal cancer: A review of epidemiologic evidence	NUTRITION REVIEWS			English	Review							N-NITROSO COMPOUNDS; LARGE-BOWEL-CANCER; COLON-CANCER; RISK-FACTORS; HETEROCYCLIC AMINES; DIETARY FACTORS; UNITED-STATES; FOOD GROUPS; RED MEAT; FRIED MEAT	This article reviews the epidemiologic evidence on colorectal cancer risk and meat consumption from 32 case-control and 13 cohort studies published in English from 1970 to 1999 and retrieved from the Medline database. The results support the hypothesis that meat consumption is associated with a modest increase in colorectal cancer risk. This association, however, seems to have been more consistently found for red meat and processed meat. The studies on cooking methods and meat "doneness" are not consistent and the evidence is not conclusive.	Int Agcy Res Canc, Unit Nutr & Canc, F-69372 Lyon 08, France		Norat, T (corresponding author), Int Agcy Res Canc, Unit Nutr & Canc, F-69372 Lyon 08, France.			Riboli, Elio/0000-0001-6795-6080			Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1; AUTRUP H, 1978, P SOC EXP BIOL MED, V159, P111; Bartsch H, 1996, EUR J CANCER PREV, V5, P11, DOI 10.1097/00008469-199609001-00003; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; BIDOLI E, 1992, INT J CANCER, V50, P223, DOI 10.1002/ijc.2910500211; Bingham SA, 1996, CARCINOGENESIS, V17, P515, DOI 10.1093/carcin/17.3.515; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; Boutron-Ruault MC, 1999, EUR J CANCER PREV, V8, P229, DOI 10.1097/00008469-199906000-00011; BOYLE P, 1995, EUR J CANCER, V31A, P1395, DOI 10.1016/0959-8049(95)00334-F; CANZIAN F, 1994, CANCER RES, V54, P6315; CENTONZE S, 1994, NUTR CANCER, V21, P233, DOI 10.1080/01635589409514322; Chen J, 1998, CANCER RES, V58, P3307; *COMA WORK GROUP D, 1998, 48 UK DEP HLTH REP H; CORPET DE, 1990, CANCER RES, V50, P6955; DALES LG, 1979, AM J EPIDEMIOL, V109, P132, DOI 10.1093/oxfordjournals.aje.a112668; DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408; FORMAN D, 1987, CANCER SURV, V6, P719; Franceschi S, 1997, INT J CANCER, V72, P56, DOI 10.1002/(SICI)1097-0215(19970703)72:1&lt;56::AID-IJC8&gt;3.0.CO;2-3; FRIEDMAN E, 1989, CANCER RES, V49, P544; Gaard M, 1996, EUR J CANCER PREV, V5, P445; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; Giovannucci E, 1997, AM J CLIN NUTR, V66, P1564; GOLDBOHM RA, 1994, CANCER RES, V54, P718; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; HAENSZEL W, 1980, JNCI-J NATL CANCER I, V64, P17; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HARRIS CC, 1987, IARC SCI PUBL, V84, P20; Hirayama T., 1992, NATL CANCER I MONOGR, P65; Hsing AW, 1998, INT J CANCER, V77, P549, DOI 10.1002/(SICI)1097-0215(19980812)77:4&lt;549::AID-IJC13&gt;3.0.CO;2-1; HU JF, 1991, INT J EPIDEMIOL, V20, P362, DOI 10.1093/ije/20.2.362; ISCOVICH JM, 1992, INT J CANCER, V51, P851, DOI 10.1002/ijc.2910510603; Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15; KAMPMAN E, 1995, CANCER CAUSE CONTROL, V6, P225, DOI 10.1007/BF00051794; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; KNEKT P, 1994, INT J CANCER, V59, P756, DOI 10.1002/ijc.2910590608; Kune S, 1987, Nutr Cancer, V9, P21; LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675; LAVECCHIA C, 1988, INT J CANCER, V41, P492, DOI 10.1002/ijc.2910410404; LaVecchia C, 1996, INT J CANCER, V66, P60, DOI 10.1002/(SICI)1097-0215(19960328)66:1&lt;60::AID-IJC11&gt;3.0.CO;2-F; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; LeMarchand L, 1997, CANCER CAUSE CONTROL, V8, P637, DOI 10.1023/A:1018406716115; Levi F, 1999, BRIT J CANCER, V79, P1283, DOI 10.1038/sj.bjc.6690206; LYON JL, 1988, AM J EPIDEMIOL, V128, P1000; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MANOUSOS O, 1983, INT J CANCER, V32, P1, DOI 10.1002/ijc.2910320102; MIRVISH SS, 1995, CANCER LETT, V93, P17, DOI 10.1016/0304-3835(95)03786-V; Murata M, 1999, JPN J CANCER RES, V90, P711, DOI 10.1111/j.1349-7006.1999.tb00805.x; NAGAO M, 1977, CANCER LETT, V2, P221, DOI 10.1016/S0304-3835(77)80025-6; OVERVIK E, 1990, FOOD CHEM TOXICOL, V28, P253, DOI 10.1016/0278-6915(90)90037-N; PARKIN DM, 1992, SCI PUBLICATION INT, V120; PETERS RK, 1989, CANCER RES, V49, P5459; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; PHILLIPS RL, 1985, JNCI-J NATL CANCER I, V74, P307; PICKLE LW, 1984, CANCER RES, V44, P363; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; REDDY BS, 1980, J NUTR, V110, P1880, DOI 10.1093/jn/110.9.1880; Roberts-Thomson IC, 1999, EUR J CANCER PREV, V8, P207, DOI 10.1097/00008469-199906000-00008; ROWLAND IR, 1991, CARCINOGENESIS, V12, P1395, DOI 10.1093/carcin/12.8.1395; SADRIEH N, 1995, CARCINOGENESIS, V16, P1549, DOI 10.1093/carcin/16.7.1549; SCANLAN RA, 1983, CANCER RES, V43, P2435; Scheppach W, 1999, EUR J CANCER PREV, V8, P57, DOI 10.1097/00008469-199902000-00008; Shannon J, 1996, CANCER EPIDEM BIOMAR, V5, P495; Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697; Sinha R, 1999, CANCER RES, V59, P4320; STEINMETZ KA, 1993, INT J CANCER, V53, P720, DOI 10.1002/ijc.2910530503; STEMMERMANN GN, 1984, CANCER RES, V44, P4633; Sugimura T, 1990, Princess Takamatsu Symp, V21, P279; TAJIMA K, 1985, JPN J CANCER RES, V76, P705; TANK ES, 1973, DIS COLON RECTUM, V16, P300, DOI 10.1007/BF02587705; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; *US DEP HHS, 1991, US DHHS PUBL PHS; VLAJINAC H, 1987, Archiv fuer Geschwulstforschung, V57, P493; WEISBURGER JH, 1990, CANCER LETT, V49, P89, DOI 10.1016/0304-3835(90)90143-L; *WHO, 1997, WORLD HLTH REP; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WOHLLEB JC, 1990, INT J CANCER, V46, P22, DOI 10.1002/ijc.2910460107; *WORLD CANC RES, 1997, FOOD NUTR PREV CANC; YOUNG TB, 1988, INT J CANCER, V42, P167, DOI 10.1002/ijc.2910420205; YOUNGMAN LD, 1992, NUTR CANCER, V18, P131, DOI 10.1080/01635589209514213	81	100	101	2	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0029-6643	1753-4887		NUTR REV	Nutr. Rev.	FEB	2001	59	2					37	47					11	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	412HU	WOS:000167549600002	11310774				2022-02-25	
J	Warnakulasuriya, S; Cronin-Fenton, D; Jinot, J; Kamangar, F; Malekzadeh, R; Dar, NA; Etemadi, A; Fortini, P; Glass, DC; Khanjani, N; Kikura-Hanajiri, R; Malats, N; Pourshams, A; Rahimi-Movaghar, A; Richardson, DB; Sewram, V				Warnakulasuriya, S.; Cronin-Fenton, D.; Jinot, J.; Kamangar, F.; Malekzadeh, R.; Dar, N. A.; Etemadi, A.; Fortini, P.; Glass, D. C.; Khanjani, N.; Kikura-Hanajiri, R.; Malats, N.; Pourshams, A.; Rahimi-Movaghar, A.; Richardson, D. B.; Sewram, V.		IARC Monographs Vol 126 Grp	Carcinogenicity of opium consumption	LANCET ONCOLOGY			English	News Item							CANCER		[Warnakulasuriya, S.] Int Agcy Res Canc, Lyon, France		Warnakulasuriya, S (corresponding author), Int Agcy Res Canc, Lyon, France.		Sheikh/E-9455-2015; Turner, Michelle/F-7659-2017; Khanjani, Nezhat/ABD-6185-2021; hosseini, Bayan/A-5026-2014; fortini, paola/K-1197-2018	Sheikh/0000-0003-3972-7824; Turner, Michelle/0000-0002-6431-1997; hosseini, Bayan/0000-0003-2670-9133; Pourshams, Akram/0000-0002-7950-3983; fortini, paola/0000-0001-6206-8498; Li, Mengmeng/0000-0001-6630-7468			Afshari M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178527; Alizadeh Hosniyeh, 2020, Asian Pac J Cancer Prev, V21, P783, DOI 10.31557/APJCP.2020.21.3.783; International Agency for Research on Cancer, 2020, IARC MON ID CARC HAZ, V126; Masjedi MR, 2013, RESPIRATION, V85, P112, DOI 10.1159/000338559; Mohebbi E, 2021, INT J CANCER, V148, P1066, DOI [10.1002/ijc.33289, 10.7302/89]; Naghibzadeh-Tahami A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07296-0; Rahimi-Movaghar A, 2018, COCHRANE DB SYST REV, V6; Ray R, 2006, OPIUM ABUSE ITS MANA; Sheikh M, 2020, LANCET GLOB HEALTH, V8, pE649, DOI 10.1016/S2214-109X(20)30059-0; United Nations Office On Drugs and Crime, 2020, WORLD DRUG REP 2020	10	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	NOV	2020	21	11					1407	1408		10.1016/S1470-2045(20)30611-2			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	OK2NT	WOS:000584488100040	33038940				2022-02-25	
J	Clifford, GM; Combes, JD				Clifford, Gary M.; Combes, Jean-Damien			Hopes for Prevention of Anal Cancer in Women	JOURNAL OF INFECTIOUS DISEASES			English	Editorial Material							HUMAN-PAPILLOMAVIRUS INFECTION; PREVALENCE		[Clifford, Gary M.; Combes, Jean-Damien] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Clifford, GM (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	CliffordG@iarc.fr					Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7; Castro FA, 2012, J INFECT DIS, V206, P1103, DOI 10.1093/infdis/jis458; Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; Donken R, 2018, J INFECT DIS, V217, P1579, DOI 10.1093/infdis/jiy067; Hernandez BY, 2005, CANCER EPIDEM BIOMAR, V14, P2550, DOI 10.1158/1055-9965.EPI-05-0460; Islami F, 2017, INT J EPIDEMIOL, V46, P924, DOI 10.1093/ije/dyw276; Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1; Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253; Kudo R, 2019, J INFECT DIS, V219, P382, DOI 10.1093/infdis/jiy516; Lin C, LANCET INF DIS; Lin CQ, 2018, LANCET INFECT DIS, V18, P198, DOI [10.1016/S1473-3099(17)30653-9, 10.1016/s1473-3099(17)30653-9]; Shiels MS, 2012, JNCI-J NATL CANCER I, V104, P1591, DOI 10.1093/jnci/djs371; van Lier EA, 2018, 20180008 RIVM CTR IN; Woestenberg PJ, 2019, INT J CANCER, V144, P2718, DOI 10.1002/ijc.31989; Woestenberg PJ, 2018, J INFECT DIS, V217, P213, DOI 10.1093/infdis/jix582; Woestenberg PJ, 2019, J INFECT DIS	17	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-1899	1537-6613		J INFECT DIS	J. Infect. Dis.	APR 15	2020	221	8					1210	1212		10.1093/infdis/jiz191			3	Immunology; Infectious Diseases; Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases; Microbiology	NE1LZ	WOS:000562359700003	31100126	Bronze			2022-02-25	
J	Arnold, M; Freisling, H; Gunter, MJ				Arnold, Melina; Freisling, Heinz; Gunter, Marc J.			Intentional Weight Loss and Cancer Risk: Never Too Late to Lose Weight	JNCI CANCER SPECTRUM			English	Editorial Material							POSTMENOPAUSAL WOMEN; EXERCISE; ADULTS		[Arnold, Melina] WHO, IARC, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69008 Lyon, France; [Freisling, Heinz; Gunter, Marc J.] WHO, IARC, Sect Nutr & Metab, Lyon, France		Arnold, M (corresponding author), WHO, IARC, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69008 Lyon, France.	arnoldm@iarc.fr	Arnold, Melina/AAO-9525-2020; Gunter, Marc/AAP-8621-2020; Arnold, Melina/L-9331-2015	Arnold, Melina/0000-0003-1700-6831			Arnold M, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002081; Arnold M, 2016, EUR J EPIDEMIOL, V31, P893, DOI 10.1007/s10654-016-0169-z; Beeken RJ, 2017, OBESITY, V25, pS95, DOI 10.1002/oby.21984; Campbell KL, 2012, J CLIN ONCOL, V30, P2314, DOI 10.1200/JCO.2011.37.9792; Dombrowski S U, 2014, BMJ, V348, pg2646, DOI 10.1136/bmj.g2646; Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602; Luo JH, 2019, JNCI CANCER SPECT, V3, DOI 10.1093/jncics/pkz054; van Gemert WA, 2016, CANCER EPIDEM BIOMAR, V25, P799, DOI 10.1158/1055-9965.EPI-15-1065	8	0	0	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND		2515-5091		JNCI CANCER SPECT	JNCI Cancer Spectr.	DEC	2019	3	4							pkz059	10.1093/jncics/pkz059			2	Oncology	Emerging Sources Citation Index (ESCI)	Oncology	JW8BI	WOS:000503271700010	32337485	Green Published, gold			2022-02-25	
J	Fernandez-Cuesta, L; Foll, M				Fernandez-Cuesta, Lynnette; Foll, Matthieu			Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities	TRANSLATIONAL LUNG CANCER RESEARCH			English	Editorial Material							SMALL-CELL CARCINOMA; TUMORS; MANAGEMENT; MUTATIONS		[Fernandez-Cuesta, Lynnette; Foll, Matthieu] IARC, WHO, Sect Genet, 150 Cours Albert Thomas, F-69008 Lyon, France		Fernandez-Cuesta, L (corresponding author), IARC, WHO, Sect Genet, 150 Cours Albert Thomas, F-69008 Lyon, France.	fernandezcuestal@iarc.fr	Fernandez-Cuesta, Lynnette/Z-1875-2019	Fernandez-Cuesta, Lynnette/0000-0002-0724-6703			Alcala N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11276-9; Amann RI, 2019, SCIENCE, V363, P350, DOI 10.1126/science.aaw1280; Argelaguet R, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20178124; Cancer.net, 2018, NEUROENDOCRINE TUMOR; Cieslik M, 2018, NAT REV GENET, V19, P93, DOI 10.1038/nrg.2017.96; Dinter H, 2019, J THORAC ONCOL, V14, P1472, DOI 10.1016/j.jtho.2019.04.015; Fabbri A, 2017, VIRCHOWS ARCH, V471, P31, DOI 10.1007/s00428-017-2130-2; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; George J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03099-x; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Longo DL, 2016, NEW ENGL J MED, V374, P276, DOI 10.1056/NEJMe1516564; Nagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975; Newton Y, 2017, CANCER RES, V77, pE111, DOI 10.1158/0008-5472.CAN-17-0580; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Pelosi G, 2005, AM J SURG PATHOL, V29, P179, DOI 10.1097/01.pas.0000149690.75462.29; Pelosi G, 2019, EXPERT REV MOL DIAGN, V19, P281, DOI 10.1080/14737159.2019.1595593; Pelosi G, 2019, CLIN PATHOL, V12, DOI 10.1177/2632010X19829259; Pelosi G, 2018, VIRCHOWS ARCH, V472, P567, DOI 10.1007/s00428-018-2307-3; Pelosi G, 2017, HISTOL HISTOPATHOL, V32, P223, DOI 10.14670/HH-11-822; Rekhtman N, 2019, MODERN PATHOL, V32, P1106, DOI 10.1038/s41379-019-0248-2; Rekhtman N, 2016, CLIN CANCER RES, V22, P3618, DOI 10.1158/1078-0432.CCR-15-2946; Rindi G, 2014, ENDOCR-RELAT CANCER, V21, P1, DOI 10.1530/ERC-13-0246; Rindi G, 2018, MODERN PATHOL, V31, P1770, DOI 10.1038/s41379-018-0110-y; Rudin CM, 2019, NAT REV CANCER, V19, P289, DOI 10.1038/s41568-019-0133-9; Simbolo M, 2019, J THORAC ONCOL, V14, P1651, DOI 10.1016/j.jtho.2019.05.003; Swarts DRA, 2012, BBA-REV CANCER, V1826, P255, DOI 10.1016/j.bbcan.2012.05.001; Travis WD, 2010, ANN ONCOL, V21, P65, DOI 10.1093/annonc/mdq380; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; van Panhuis WG, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1144; Wolin EM, 2017, CHEST, V151, P1141, DOI 10.1016/j.chest.2016.06.018	30	10	10	0	1	AME PUBL CO	SHATIN	FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA	2218-6751	2226-4477		TRANSL LUNG CANCER R	Transl. Lung Cancer Res.	DEC	2019	8			4			S430	S434		10.21037/tlcr.2019.11.08			5	Oncology; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Respiratory System	JZ6LW	WOS:000505215300027	32038931	gold, Green Published			2022-02-25	
J	Gheit, T				Gheit, Tarik			Mucosal and Cutaneous Human Papillomavirus Infections and Cancer Biology	FRONTIERS IN ONCOLOGY			English	Review						Papillomavirus; infection and cancer; transformation; anogenital cancer; skin cancer	RISK HUMAN-PAPILLOMAVIRUS; SQUAMOUS-CELL-CARCINOMA; TYPE-16 E7 ONCOPROTEIN; E6 PROTEIN BINDS; COMMON FRAGILE SITES; CERVICAL-CANCER; HPV INFECTION; E5 PROTEIN; GENETIC-VARIATION; MEDIATED DEGRADATION	Papillomaviridae is a family of small non-enveloped icosahedral viruses with double-stranded circular DNA. More than 200 different human papillomaviruses (HPVs) have been listed so far. Based on epidemiological data, a subgroup of alphapapillomaviruses (alpha HPVs) was referred to as high-risk (HR) HPV types. HR HPVs are the etiological agents of anogenital cancer and a subset of head and neck cancers. The cutaneous HPV types, mainly from beta and gamma genera, are widely present on the surface of the skin in the general population. However, there is growing evidence of an etiological role of betapapillomaviruses (beta HPVs) in non-melanoma skin cancer (NMSC), together with ultraviolet (UV) radiation. Studies performed on mucosal HR HPV types, such as 16 and 18, showed that both oncoproteins E6 and E7 play a key role in cervical cancer by altering pathways involved in the host immune response to establish a persistent infection and by promoting cellular transformation. Continuous expression of E6 and E7 of mucosal HR HPV types is essential to initiate and to maintain the cellular transformation process, whereas expression of E6 and E7 of cutaneous HPV types is not required for the maintenance of the skin cancer phenotype. Beta HPV types appear to play a role in the initiation of skin carcinogenesis, by exacerbating the accumulation of UV radiation-induced DNA breaks and somatic mutations (the hit-and-run mechanism), and they would therefore act as facilitators rather than direct actors in NMSC. In this review, the natural history of HPV infection and the transforming properties of various HPV genera will be described, with a particular focus on describing the state of knowledge about the role of cutaneous HPV types in NMSC.	[Gheit, Tarik] IARC, Infect & Canc Biol Grp, Lyon, France		Gheit, T (corresponding author), IARC, Infect & Canc Biol Grp, Lyon, France.	gheitt@iarc.fr					Abroi A, 2004, J VIROL, V78, P2100, DOI 10.1128/JVI.78.4.2100-2113.2004; Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Accardi R, 2014, PRESSE MED, V43, pE435, DOI 10.1016/j.lpm.2014.08.008; Accardi R, 2011, J VIROL, V85, P8208, DOI 10.1128/JVI.00114-11; Accardi R, 2011, MOL CELL BIOL, V31, P2210, DOI 10.1128/MCB.00964-10; Agalliu I, 2018, CANCER EPIDEM BIOMAR, V27, P1168, DOI [10.1158/1055-9965.EPI-18-0287, 10.1158/1055-9965.epi-18-0287]; Agalliu I, 2016, JAMA ONCOL, V2, P599, DOI 10.1001/jamaoncol.2015.5504; Akgul B, 2007, EXP DERMATOL, V16, P590, DOI 10.1111/j.1600-0625.2007.00569.x; Akgul B, 2005, CANCER RES, V65, P2216, DOI 10.1158/0008-5472.CAN-04-1952; Ammermann I, 2008, J VIROL, V82, P5127, DOI 10.1128/JVI.02647-07; Andersson K, 2008, CANCER EPIDEM BIOMAR, V17, P189, DOI 10.1158/1055-9965.EPI-07-0405; Antonsson A, 2003, J CLIN MICROBIOL, V41, P2509, DOI 10.1128/JCM.41.6.2509-2514.2003; Antonsson A, 2000, J VIROL, V74, P11636, DOI 10.1128/JVI.74.24.11636-11641.2000; Arron ST, 2011, J INVEST DERMATOL, V131, P1745, DOI 10.1038/jid.2011.91; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Asgari MM, 2017, JAMA DERMATOL, V153, P892, DOI 10.1001/jamadermatol.2017.1716; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Aydin I, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004162; Ball SLR, 2011, J MED VIROL, V83, P1345, DOI 10.1002/jmv.22111; BANKS L, 1990, ONCOGENE, V5, P1383; Barbaresi S, 2010, J GEN VIROL, V91, P521, DOI 10.1099/vir.0.016295-0; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Barrow-Laing L, 2010, VIROLOGY, V400, P233, DOI 10.1016/j.virol.2010.01.034; Bastien N, 2000, VIROLOGY, V270, P124, DOI 10.1006/viro.2000.0265; Bavinck JNB, 2018, AM J TRANSPLANT, V18, P1220, DOI 10.1111/ajt.14537; Bavinck JNB, 2010, CANCER RES, V70, P9777, DOI 10.1158/0008-5472.CAN-10-0352; Bedard KM, 2008, J VIROL, V82, P3894, DOI 10.1128/JVI.01818-07; Bentley P, 2018, J VIROL, V92, DOI 10.1128/JVI.00356-18; Bergant M, 2017, J GEN VIROL, V98, P715, DOI 10.1099/jgv.0.000734; Bernal-Silva S, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-31; Bienkowska-Haba M, 2012, J VIROL, V86, P9875, DOI 10.1128/JVI.00980-12; Boon SS, 2013, J VIROL, V87, P1586, DOI 10.1128/JVI.02074-12; Borbely AA, 2006, J GEN VIROL, V87, P287, DOI 10.1099/vir.0.81067-0; BOUVARD V, 2009, LANCET ONCOL, V10, P321, DOI [DOI 10.1016/S1470-2045(09)70096-8, 10.1016/s1470-2045(09)70096-8]; Branca M, 2006, DIAGN CYTOPATHOL, V34, P739, DOI 10.1002/dc.20554; Brancaccio RN, 2018, VIROLOGY, V520, P1, DOI 10.1016/j.virol.2018.04.017; Bravo IG, 2004, J VIROL, V78, P13613, DOI 10.1128/JVI.78.24.13613-13626.2004; Bravo Ignacio G., 2015, Evolution Medicine and Public Health, P32, DOI 10.1093/emph/eov003; Bravo IG, 2010, TRENDS MICROBIOL, V18, P432, DOI 10.1016/j.tim.2010.07.008; Brimer N, 2012, ONCOGENE, V31, P4639, DOI 10.1038/onc.2011.589; Brimer N, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006781; Broniarczyk J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18809-6; Bronnimann MP, 2016, J VIROL, V90, P6224, DOI 10.1128/JVI.00038-16; Bruggink SC, 2012, J CLIN VIROL, V55, P250, DOI 10.1016/j.jcv.2012.07.014; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Campbell CMP, 2013, J CLIN VIROL, V58, P652, DOI 10.1016/j.jcv.2013.10.011; Cerqueira C, 2015, J VIROL, V89, P7038, DOI 10.1128/JVI.00234-15; Chabeda A, 2018, PAPILLOMAVIRUS RES, V5, P46, DOI 10.1016/j.pvr.2017.12.006; Chattopadhyay Koushik, 2011, Indian J Hum Genet, V17, P132, DOI 10.4103/0971-6866.92087; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen AA, 2017, ORAL ONCOL, V75, P106, DOI 10.1016/j.oraloncology.2017.11.005; Chen AA, 2015, J VIROL, V89, P10680, DOI 10.1128/JVI.01747-15; Chen AA, 2014, J VIROL, V88, P4514, DOI 10.1128/JVI.03534-13; Chen AA, 2014, VIROLOGY, V448, P356, DOI 10.1016/j.virol.2013.10.033; Chen ZG, 2007, VIROLOGY, V360, P447, DOI 10.1016/j.virol.2006.10.022; Christiansen IK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119566; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Collins SI, 2009, CANCER RES, V69, P3828, DOI 10.1158/0008-5472.CAN-08-3099; Cornet I, 2013, BRIT J CANCER, V108, P240, DOI 10.1038/bjc.2012.508; Cornet I, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-4; Cornet I, 2012, J VIROL, V86, P2366, DOI 10.1128/JVI.06579-11; Culp TD, 2006, J VIROL, V80, P8940, DOI 10.1128/JVI.00724-06; Day PM, 2004, P NATL ACAD SCI USA, V101, P14252, DOI 10.1073/pnas.0404229101; Jong SJ, 2018, J EXP MED, V215, P2289, DOI 10.1084/jem.20170308; de Koning MNC, 2007, J GEN VIROL, V88, P1489, DOI 10.1099/vir.0.82732-0; de Koning MNC, 2009, J GEN VIROL, V90, P1611, DOI 10.1099/vir.0.010017-0; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DeMasi J, 2007, J VIROL, V81, P9419, DOI 10.1128/JVI.00422-07; Derkay CS, 2008, LARYNGOSCOPE, V118, P1236, DOI 10.1097/MLG.0b013e31816a7135; DiGiuseppe S, 2017, J VIROL, V91, DOI 10.1128/JVI.00537-17; DiGiuseppe S, 2016, J VIROL, V90, P8032, DOI 10.1128/JVI.01065-16; Dillner J, 1999, SEMIN CANCER BIOL, V9, P423, DOI 10.1006/scbi.1999.0146; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Dreer M, 2017, VIRUS RES, V231, P96, DOI 10.1016/j.virusres.2016.11.005; Dreer M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005556; Egawa N, 2015, VIRUSES-BASEL, V7, P3863, DOI 10.3390/v7072802; ElAmrani A, 2018, PAPILLOMAVIRUS RES, V5, P150, DOI 10.1016/j.pvr.2018.04.003; Faust H, 2016, CANCER EPIDEM BIOMAR, V25, P721, DOI 10.1158/1055-9965.EPI-15-1290; Favre-Bonvin A, 2005, J VIROL, V79, P4229, DOI 10.1128/JVI.79.7.4229-4237.2005; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; Filippova M, 2004, J BIOL CHEM, V279, P25729, DOI 10.1074/jbc.M401172200; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Filippova M, 2007, J VIROL, V81, P4116, DOI 10.1128/JVI.01924-06; Florin L, 2002, VIROLOGY, V295, P97, DOI 10.1006/viro.2002.1360; Forslund O, 2013, J INFECT DIS, V208, P1335, DOI 10.1093/infdis/jit326; Fujii T, 2006, INT J ONCOL, V29, P541; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gauson EJ, 2015, J VIROL, V89, P4980, DOI 10.1128/JVI.00335-15; Gheit T, 2011, CANCER EPIDEM BIOMAR, V20, P1315, DOI 10.1158/1055-9965.EPI-10-1187; Giuliano AR, 2002, CANCER CAUSE CONTROL, V13, P839, DOI 10.1023/A:1020668232219; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gottschling M, 2011, MOL BIOL EVOL, V28, P2101, DOI 10.1093/molbev/msr030; Grace M, 2017, VIROLOGY, V500, P71, DOI 10.1016/j.virol.2016.10.010; Gray E, 2010, CANCER RES, V70, P4081, DOI 10.1158/0008-5472.CAN-09-3335; Gray P, 2019, INT J CANCER, V145, P785, DOI 10.1002/ijc.32189; Gray P, 2018, INT J CANCER, V142, P2491, DOI 10.1002/ijc.31281; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Guo T, 2016, CANCER-AM CANCER SOC, V122, P2313, DOI 10.1002/cncr.29992; Haedicke J, 2013, RADIOTHER ONCOL, V108, P397, DOI 10.1016/j.radonc.2013.06.004; Halec G, 2013, INT J CANCER, V132, P63, DOI 10.1002/ijc.27605; Hampras SS, 2017, J INFECT DIS, V216, P92, DOI 10.1093/infdis/jix245; Handa K, 2007, J VIROL, V81, P1379, DOI 10.1128/JVI.01712-06; Harper DM, 2017, GYNECOL ONCOL, V146, P196, DOI 10.1016/j.ygyno.2017.04.004; Harris L, 2017, J VIROL, V91, DOI 10.1128/JVI.01853-16; Hasche D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006723; Haukioja A, 2014, J CLIN VIROL, V61, P101, DOI 10.1016/j.jcv.2014.06.012; Hazard K, 2007, J INVEST DERMATOL, V127, P116, DOI 10.1038/sj.jid.5700570; Hefferon K, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030044; Hemminki K, 1999, INT J CANCER, V82, P775, DOI 10.1002/(SICI)1097-0215(19990909)82:6<775::AID-IJC1>3.0.CO;2-V; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; Heuser S, 2016, ONCOGENE, V35, P4529, DOI 10.1038/onc.2015.512; Hogendoorn GK, 2018, BRIT J DERMATOL, V178, P253, DOI 10.1111/bjd.15758; Holloway A, 2015, INT J CANCER, V136, P2831, DOI 10.1002/ijc.29350; Hong AM, 2010, VACCINE, V28, P3269, DOI 10.1016/j.vaccine.2010.02.098; Hong D, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3124-9; Howie HL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002211; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; Howley PM, 2015, VIROLOGY, V479, P290, DOI 10.1016/j.virol.2015.02.004; Hsu JYC, 2009, J MED VIROL, V81, P1444, DOI 10.1002/jmv.21529; Hu LL, 2009, VIROLOGY, V393, P135, DOI 10.1016/j.virol.2009.07.034; Huber B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169533; Hufbauer M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0453-7; Hufbauer M, 2013, J VIROL, V87, P12158, DOI 10.1128/JVI.01510-13; Huh KW, 2005, P NATL ACAD SCI USA, V102, P11492, DOI 10.1073/pnas.0505337102; Huh K, 2007, J VIROL, V81, P9737, DOI 10.1128/JVI.00881-07; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUMMEL M, 1992, J VIROL, V66, P6070, DOI 10.1128/JVI.66.10.6070-6080.1992; Iannacone MR, 2014, INT J CANCER, V134, P2231, DOI 10.1002/ijc.28552; Iannacone MR, 2012, CANCER EPIDEM BIOMAR, V21, P1303, DOI 10.1158/1055-9965.EPI-12-0032; Torres-Rojas FI, 2018, ONCOL LETT, V15, P2278, DOI 10.3892/ol.2017.7596; James MA, 2006, INT J CANCER, V119, P1878, DOI 10.1002/ijc.22064; Jang MK, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004117; Jansma AL, 2014, J MOL BIOL, V426, P4030, DOI 10.1016/j.jmb.2014.10.021; Javier RT, 2008, ONCOGENE, V27, P7031, DOI 10.1038/onc.2008.352; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Jeong KW, 2007, ONCOGENE, V26, P487, DOI 10.1038/sj.onc.1209837; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kabsch K, 2004, INTERVIROLOGY, V47, P48, DOI 10.1159/000076642; Kalinska-Bienias A, 2016, POSTEP DERM ALERGOL, V33, P75, DOI 10.5114/ada.2016.59145; Kapil S, 2017, ONCOTARGET, V8, P26515, DOI 10.18632/oncotarget.15713; Katzenellenbogen RA, 2007, J VIROL, V81, P3786, DOI 10.1128/JVI.02007-06; Khan J, 2011, J VIROL, V85, P9984, DOI 10.1128/JVI.02158-10; Kim HJ, 2017, ARCH PHARM RES, V40, P1050, DOI 10.1007/s12272-017-0952-8; Kim SH, 2009, CARCINOGENESIS, V30, P753, DOI 10.1093/carcin/bgp066; Kines RC, 2009, P NATL ACAD SCI USA, V106, P20458, DOI 10.1073/pnas.0908502106; King CM, 2014, J AM PODIAT MED ASSN, V104, P141, DOI 10.7547/0003-0538-104.2.141; Kivipold P, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0335-z; Klein C, 2019, MBIO, V10, DOI 10.1128/mBio.02785-18; Knapp AA, 2009, VIROLOGY, V383, P60, DOI 10.1016/j.virol.2008.09.037; Kohler A, 2007, BRIT J DERMATOL, V156, P1078, DOI 10.1111/j.1365-2133.2007.07809.x; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kranjec C, 2016, PAPILLOMAVIRUS RES, V2, P70, DOI 10.1016/j.pvr.2016.04.001; Kranjec C, 2011, J VIROL, V85, P1757, DOI 10.1128/JVI.01756-10; Kreimer AR, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx005; Kreimer AR, 2013, J CLIN ONCOL, V31, P2708, DOI 10.1200/JCO.2012.47.2738; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Lace MJ, 2008, J VIROL, V82, P10841, DOI 10.1128/JVI.01481-08; Lanfredini S, 2017, J INVEST DERMATOL, V137, P2208, DOI 10.1016/j.jid.2017.04.039; Lazarczyk M, 2008, J EXP MED, V205, P35, DOI 10.1084/jem.20071311; Lebel R, 2007, BIOCHEMISTRY-US, V46, P10279, DOI 10.1021/bi700076m; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Leung TW, 2015, J MED VIROL, V87, P1022, DOI 10.1002/jmv.24129; Leverrier S, 2007, APOPTOSIS, V12, P549, DOI 10.1007/s10495-006-0004-1; Liao SJ, 2013, INT J MOL MED, V31, P120, DOI 10.3892/ijmm.2012.1168; Liu CZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep07653; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Lopez-Bueno A, 2016, J VIROL, V90, P8768, DOI 10.1128/JVI.01369-16; Lorenz LD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003717; Maglennon GA, 2011, VIROLOGY, V414, P153, DOI 10.1016/j.virol.2011.03.019; Magnusson PKE, 1999, NATURE, V400, P29, DOI 10.1038/21801; Marthaler AM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006406; Martinez-Zapien D, 2016, NATURE, V529, P541, DOI 10.1038/nature16481; Marusic MB, 2012, TRAFFIC, V13, P455, DOI 10.1111/j.1600-0854.2011.01320.x; Marx B, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01724; Massimi P, 1996, ONCOGENE, V12, P2325; Maucort-Boulch D, 2010, INT J CANCER, V126, P684, DOI 10.1002/ijc.24752; McBride AA, 2013, VIROLOGY, V445, P57, DOI 10.1016/j.virol.2013.06.006; McBride AA, 2013, VIRUSES-BASEL, V5, P1374, DOI 10.3390/v5061374; McKinney CC, 2016, MBIO, V7, DOI 10.1128/mBio.01644-16; McLaughlin-Drubin ME, 2008, J VIROL, V82, P8695, DOI 10.1128/JVI.00579-08; McLaughlin-Drubin ME, 2012, CURR OPIN VIROL, V2, P459, DOI 10.1016/j.coviro.2012.05.004; McNally KE, 2017, NAT CELL BIOL, V19, P1214, DOI 10.1038/ncb3610; McPhillips MG, 2006, J VIROL, V80, P9530, DOI 10.1128/JVI.01105-06; Meyers JM, 2013, J VIROL, V87, P4762, DOI 10.1128/JVI.02527-12; Michael KM, 2010, J INVEST DERMATOL, V130, P841, DOI 10.1038/jid.2009.356; Michael KM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000091; Mirabello L, 2017, CELL, V170, P1164, DOI 10.1016/j.cell.2017.08.001; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Mortensen F, 2015, P NATL ACAD SCI USA, V112, P9872, DOI 10.1073/pnas.1505923112; Moscicki AB, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofw216; Muench P, 2010, CANCER RES, V70, P6913, DOI 10.1158/0008-5472.CAN-10-1307; Muhr LSA, 2015, INT J CANCER, V136, P2546, DOI 10.1002/ijc.29325; Muhr LSA, 2018, VIROLOGY, V519, P74, DOI 10.1016/j.virol.2018.04.003; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Muschik D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027655; Nafz J, 2007, J GEN VIROL, V88, P2670, DOI 10.1099/vir.0.82955-0; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakatani Y, 2005, P NATL ACAD SCI USA, V102, P15093, DOI 10.1073/pnas.0507458102; Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339; Nindl I, 2008, AM J TRANSPLANT, V8, P2199, DOI 10.1111/j.1600-6143.2008.02392.x; Nobre RJ, 2009, J VIROL, V83, P2907, DOI 10.1128/JVI.02490-08; Nulton TJ, 2017, ONCOTARGET, V8, P17684, DOI 10.18632/oncotarget.15179; Nunes EM, 2017, VIROLOGY, V510, P55, DOI 10.1016/j.virol.2017.07.006; Oetke C, 2000, ARCH VIROL, V145, P2183, DOI 10.1007/s007050070048; Oh HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104374; Oh JM, 2010, CARCINOGENESIS, V31, P402, DOI 10.1093/carcin/bgp318; Oka N, 2013, INT J GYNECOL CANCER, V23, P235, DOI 10.1097/IGC.0b013e31827da1f6; Olthof NC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088718; Orth G, 2008, CURR TOP MICROBIOL, V321, P59; ORTH G, 1978, P NATL ACAD SCI USA, V75, P1537, DOI 10.1073/pnas.75.3.1537; Ostrbenk A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138628; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Parish JL, 2006, MOL CELL, V24, P867, DOI 10.1016/j.molcel.2006.11.005; Parish JL, 2006, J CELL SCI, V119, P4857, DOI 10.1242/jcs.03262; Pastrana DV, 2018, MSPHERE, V3, DOI 10.1128/mSphereDirect.00645-18; Pedroza-Saavedra A, 2010, VIROLOGY, V400, P44, DOI 10.1016/j.virol.2010.01.009; Peitsaro P, 2002, J CLIN MICROBIOL, V40, P886, DOI 10.1128/JCM.40.3.886-891.2002; Pentland L, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005752; PIM D, 1994, ONCOGENE, V9, P1869; Plasmeijer EI, 2010, INT J CANCER, V126, P2614, DOI 10.1002/ijc.24991; Plasmeijer Elsemieke I., 2009, V146, P143, DOI 10.1007/978-0-387-78574-5_13; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Pontillo A, 2016, J MED VIROL, V88, P1646, DOI 10.1002/jmv.24514; Popa A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004699; Pyeon D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000318; Rahman S, 2016, J GEN VIROL, V97, P3291, DOI 10.1099/jgv.0.000620; Rautava J, 2012, HEAD NECK PATHOL, V6, pS3, DOI 10.1007/s12105-012-0367-2; Rogers A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-379; Roman A, 2013, VIROLOGY, V445, P138, DOI 10.1016/j.virol.2013.04.013; Rous P, 1935, J EXP MED, V62, P523, DOI 10.1084/jem.62.4.523; Rubio I, 2011, VIROLOGY, V409, P348, DOI 10.1016/j.virol.2010.10.017; Ryndock EJ, 2014, EXPERT REV ANTI-INFE, V12, P1165, DOI 10.1586/14787210.2014.959497; Sabol I, 2016, J CLIN VIROL, V82, P159, DOI 10.1016/j.jcv.2016.07.019; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schelhaas M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002657; Schelhaas M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000148; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0; Schiller John T, 2010, Gynecol Oncol, V118, pS12, DOI 10.1016/j.ygyno.2010.04.004; Schmitt A, 1996, J VIROL, V70, P1912, DOI 10.1128/JVI.70.3.1912-1922.1996; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Schmitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039632; Schwarz T, 2009, J INVEST DERM SYMP P, V14, P63, DOI 10.1038/jidsymp.2009.3; Scott ML, 2018, VIROLOGY, V519, P1, DOI 10.1016/j.virol.2018.03.021; Shen CL, 2017, INT J CANCER, V141, P540, DOI 10.1002/ijc.30763; Shin MK, 2009, CANCER RES, V69, P5656, DOI 10.1158/0008-5472.CAN-08-3711; Siddiqa A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092619; Silverberg MJ, 2013, JNCI-J NATL CANCER I, V105, P350, DOI 10.1093/jnci/djs529; Simmonds M, 2008, INT J CANCER, V123, P2260, DOI 10.1002/ijc.23815; Smelov V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26589-w; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stepp WH, 2013, MBIO, V4, DOI 10.1128/mBio.00845-13; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; Szalmas A, 2017, J VIROL, V91, DOI 10.1128/JVI.00057-17; Tavalai N, 2011, J VIROL, V85, P9447, DOI 10.1128/JVI.00870-11; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thomas M, 1999, J GEN VIROL, V80, P1513, DOI 10.1099/0022-1317-80-6-1513; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Thomas M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005766; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Todorovic B, 2012, J VIROL, V86, P13313, DOI 10.1128/JVI.01637-12; Tommasino M, 2017, VIRUS RES, V231, P128, DOI 10.1016/j.virusres.2016.11.013; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; Van Doorslaer K, 2016, SCI REP-UK, V6, DOI 10.1038/srep33028; Van Doorslaer K, 2012, VIROLOGY, V433, P216, DOI 10.1016/j.virol.2012.08.006; Viarisio D, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006783; Viarisio D, 2017, CURR OPIN VIROL, V26, P56, DOI 10.1016/j.coviro.2017.07.014; Viarisio D, 2016, CANCER RES, V76, P4216, DOI 10.1158/0008-5472.CAN-16-0370; Vici P, 2016, EXPERT REV VACCINES, V15, P1327, DOI 10.1080/14760584.2016.1176533; Vinzon SE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003924; Vojtechova Z, 2016, INT J CANCER, V138, P386, DOI 10.1002/ijc.29712; Wallace NA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004687; Wallace NA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002807; Wang SS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008667; Weissenborn SJ, 2009, J VIROL, V83, P811, DOI 10.1128/JVI.01338-08; Weissenborn SJ, 2005, J INVEST DERMATOL, V125, P93, DOI 10.1111/j.0022-202X.2005.23733.x; Weissenborn S, 2012, MED MICROBIOL IMMUN, V201, P117, DOI 10.1007/s00430-011-0212-3; Westrich JA, 2018, J VIROL, V92, DOI 10.1128/JVI.01318-17; Wetherill LF, 2018, ANTIVIR RES, V158, P113, DOI 10.1016/j.antiviral.2018.08.005; Wetherill LF, 2012, J VIROL, V86, P5341, DOI 10.1128/JVI.06243-11; White EA, 2016, MBIO, V7, DOI 10.1128/mBio.01530-16; White EA, 2013, VIROLOGY, V435, P57, DOI 10.1016/j.virol.2012.09.046; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; Wolyniec K, 2012, BLOOD, V120, P822, DOI 10.1182/blood-2011-10-387647; Wong MCS, 2018, J INFECT DIS, V218, P388, DOI 10.1093/infdis/jiy160; Xu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066693; Xu M, 2008, MOL CELL BIOL, V28, P4819, DOI 10.1128/MCB.01969-07; Yang A, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0293-9; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002; Zhang RY, 2016, INT J CANCER, V138, P1163, DOI 10.1002/ijc.29872; Zhang Y, 2007, J VIROL, V81, P3618, DOI 10.1128/JVI.02044-06; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; Zobel T, 2003, MOL CELL BIOL, V23, P8352, DOI 10.1128/MCB.23.22.8352-8362.2003; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; 2006, VACCINE S3, V24, P52, DOI DOI 10.1016/J.VACCINE.2006.05.031; 2017, VIROLOGY, V500, P218, DOI DOI 10.1016/J.VIROL.2016.10.023; 2011, J AM ACAD DERMATOL, V65, P253, DOI DOI 10.1016/J.JAAD.2010.11.062; 2004, J VIROL, V78, P1236, DOI DOI 10.1128/JVI.78.22.12366-12377; 2015, J VIROL, V89, P1014, DOI DOI 10.1128/JVI.01499-15	306	59	59	2	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	2234-943X			FRONT ONCOL	Front. Oncol.	MAY 8	2019	9								355	10.3389/fonc.2019.00355			22	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	HX3NY	WOS:000467300000001	31134154	gold, Green Published			2022-02-25	
J	de Martel, C; Plummer, M; Vignat, J; Franceschi, S				de Martel, Catherine; Plummer, Martyn; Vignat, Jerome; Franceschi, Silvia			Worldwide burden of cancer attributable to HPV by site, country and HPV type	INTERNATIONAL JOURNAL OF CANCER			English	Article						human papillomavirus; cancer; attributable fraction; prevention; vaccine	HUMAN-PAPILLOMAVIRUS VACCINATION	HPV is the cause of almost all cervical cancer and is responsible for a substantial fraction of other anogenital cancers and oropharyngeal cancers. Understanding the HPV-attributable cancer burden can boost programs of HPV vaccination and HPV-based cervical screening. Attributable fractions (AFs) and the relative contributions of different HPV types were derived from published studies reporting on the prevalence of transforming HPV infection in cancer tissue. Maps of age-standardized incidence rates of HPV-attributable cancers by country from GLOBOCAN 2012 data are shown separately for the cervix, other anogenital tract and head and neck cancers. The relative contribution of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 was also estimated. 4.5% of all cancers worldwide (630,000 new cancer cases per year) are attributable to HPV: 8.6% in women and 0.8% in men. AF in women ranges from <3% in Australia/New Zealand and the USA to >20% in India and sub-Saharan Africa. Cervix accounts for 83% of HPV-attributable cancer, two-thirds of which occur in less developed countries. Other HPV-attributable anogenital cancer includes 8,500 vulva; 12,000 vagina; 35,000 anus (half occurring in men) and 13,000 penis. In the head and neck, HPV-attributable cancers represent 38,000 cases of which 21,000 are oropharyngeal cancers occurring in more developed countries. The relative contributions of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 are 73% and 90%, respectively. Universal access to vaccination is the key to avoiding most cases of HPV-attributable cancer. The preponderant burden of HPV16/18 and the possibility of cross-protection emphasize the importance of the introduction of more affordable vaccines in less developed countries.	[de Martel, Catherine; Plummer, Martyn; Vignat, Jerome; Franceschi, Silvia] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France		de Martel, C (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	deMartelC@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497; de Martel, Catherine/0000-0002-3642-277X	Fondation de FranceFondation de France [00039621]; Bill & Melinda Gates FoundationBill & Melinda Gates Foundation [OPP1053353]	Grant sponsor: Fondation de France; Grant number: 00039621; Grant sponsor: Bill & Melinda Gates Foundation; Grant number: OPP1053353	Alemany L, 2016, EUR UROL, V69, P953, DOI 10.1016/j.eururo.2015.12.007; Beachler DC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv302; Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Cameron RL, 2016, EMERG INFECT DIS, V22, P56, DOI 10.3201/eid2201.150736; Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Clifford GM, 2016, JAIDS-J ACQ IMM DEF, V73, P332, DOI 10.1097/QAI.0000000000001113; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; de Martel C, 2015, AIDS, V29, P2173, DOI 10.1097/QAD.0000000000000808; Ferlay J, 2013, IARC CANC BASE, V11; Forman D, 2013, CANC INCIDENCE 5 CON, VX; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V90, P1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1995, IARC Monogr Eval Carcinog Risks Hum, V64, P1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2; Kreimer AR, 2015, LANCET ONCOL, V16, P775, DOI 10.1016/S1470-2045(15)00047-9; Lehtinen M, 2013, NAT REV CLIN ONCOL, V10, P400, DOI 10.1038/nrclinonc.2013.84; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Pagliusi S, 2016, VACCINE, V34, P3562, DOI 10.1016/j.vaccine.2016.02.067; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Rietbergen MM, 2014, J ORAL PATHOL MED, V43, P137, DOI 10.1111/jop.12123; Santesso N, 2016, INT J GYNECOL OBSTET, V132, P252, DOI 10.1016/j.ijgo.2015.07.038; Serrano B, 2015, EUR J CANCER, V51, P1732, DOI 10.1016/j.ejca.2015.06.001; United Nations Development Programme, 2013, RIS S HUM PROGR DIV; Bosch FX, 2016, NAT REV CLIN ONCOL, V13, P119, DOI 10.1038/nrclinonc.2015.146	27	690	712	10	105	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	AUG 15	2017	141	4					664	670		10.1002/ijc.30716			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	EY2JT	WOS:000403795100003	28369882	hybrid, Green Published	Y	N	2022-02-25	
J	Guha, N; Loomis, D; Guyton, KZ; Grosse, Y; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Vilahur, N; Muller, K; Straif, K				Guha, Neela; Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Vilahur, Nadia; Muller, Karen; Straif, Kurt		Int Agcy Res Canc Monograph Workin	Carcinogenicity of welding, molybdenum trioxide, and indium tin oxide	LANCET ONCOLOGY			English	News Item							LUNG-CANCER; ULTRAVIOLET-RADIATION; OCULAR MELANOMA; MILD-STEEL; RISK; EXPOSURE; FUMES		[Guha, Neela; Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Vilahur, Nadia; Muller, Karen; Straif, Kurt; Int Agcy Res Canc Monograph Workin] Int Agcy Res Canc, Lyon, France		Guha, N (corresponding author), Int Agcy Res Canc, Lyon, France.		Loomis, Dana/AAE-3988-2019; Guha, Neela/AAG-3989-2021	Guha, Neela/0000-0003-3991-4662; Loomis, Dana/0000-0003-3297-5200	IMOA; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER	SH is a consultant for the International Molybdenum Association (IMOA), was a recent employee of RioTinto Ltd (until the end of 2015), and has received IMOA funding to travel to the IARC meeting. LL provides consulting expertise in occupational health toxicology to the IMOA. AO is employed by NiPERA Inc. All other observers declare no competing interests.	[Anonymous], 1990, IARC Monogr Eval Carcinog Risks Hum, V49, P1; Falcone LM, 2017, ARCH TOXICOL, V91, P2953, DOI 10.1007/s00204-016-1909-2; Guenel P, 2001, CANCER CAUSE CONTROL, V12, P451, DOI 10.1023/A:1011271420974; Holly EA, 1996, EPIDEMIOLOGY, V7, P55, DOI 10.1097/00001648-199601000-00010; International Agency for Research on Cancer, 2017, WELD IND TIN OX MOL, V118; Kendzia B, 2013, AM J EPIDEMIOL, V178, P1513, DOI 10.1093/aje/kwt201; Kim JY, 2005, OCCUP ENVIRON MED, V62, P157, DOI 10.1136/oem.2004.014795; Matrat M, 2016, OCCUP ENVIRON MED, V73, P254, DOI 10.1136/oemed-2015-102964; Nagano K, 2011, J OCCUP HEALTH, V53, P175, DOI 10.1539/joh.10-0057-OA; Program NT, 1997, NATL TOXICOL PROGRAM, V462, P1; SEDDON JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1274, DOI 10.1001/archopht.1990.01070110090031; Siew SS, 2008, SCAND J WORK ENV HEA, V34, P444, DOI 10.5271/sjweh.1296; Sorensen AR, 2007, SCAND J WORK ENV HEA, V33, P379, DOI 10.5271/sjweh.1157; Steenland K, 2002, SCAND J WORK ENV HEA, V28, P163, DOI 10.5271/sjweh.660; 't Mannetje A, 2012, AM J EPIDEMIOL, V175, P706, DOI 10.1093/aje/kwr358; Vajdic CM, 2004, INT J CANCER, V112, P896, DOI 10.1002/ijc.20476; Zeidler-Erdely PC, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-45	17	73	75	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	MAY	2017	18	5					581	582		10.1016/S1470-2045(17)30255-3			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	ET6KR	WOS:000400401100041	28408286	Green Submitted			2022-02-25	
J	Accardi, R; Gheit, T				Accardi, Rosita; Gheit, Tarik			Cutaneous HPV and skin cancer	PRESSE MEDICALE			English	Review							SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTION; BETA-HUMAN PAPILLOMAVIRUSES; GAMMA HUMAN PAPILLOMAVIRUSES; ORGAN TRANSPLANT RECIPIENTS; PLUCKED EYEBROW HAIRS; OPEN READING FRAME; EPIDERMODYSPLASIA-VERRUCIFORMIS; HIGH-RISK; BASAL-CELL	Papillomaviruses (HPVs) are small non-enveloped icosahedral viruses that infect the keratinocytes of skin and mucosa. The cutaneous HPV types are represented mainly by the beta and gamma genera, which are widely present in the skin of normal individuals. More than 40 beta-HPV types and 50 gamma-HPV types have been isolated, and these numbers are continuously growing. The main cause of non-melanoma skin cancer is exposure to ultraviolet radiation (UVR). However, cutaneous HPVs that belong to the beta genus may act as a co-carcinogen with UVR. The association between beta-HPVs and skin cancer was first reported in patients with epidermodysplasia verruciformis (EV), who frequently develop cutaneous squamous cell carcinoma (SCC) on sun-exposed areas. Isolation of HPVs from the lesions suggested that HPVs might act as a co-carcinogen with UVR in EV patients. Beta-HPVs may also play a role in cutaneous SCC in immunocompromised non-EV and in immunocompetent individuals. Several studies have reported an association of viral DNA and/or antibodies to beta HPV types with SCC. Interestingly, HPV prevalence and viral load decrease during skin carcinogenesis, being significantly higher in actinic keratosis than in SCC, suggesting that the virus may play a role in the early stages of tumour development (the "hit-and-run'' hypothesis). Concordantly, in vivo and in vitro studies have shown that E6 and E7 from certain cutaneous HPV types display transforming activities, further confirming their potential role in carcinogenesis.	[Accardi, Rosita; Gheit, Tarik] Int Agcy Res Canc, World Hlth Org, Infect & Canc Biol ICB Grp, F-69372 Lyon 08, France		Accardi, R (corresponding author), Int Agcy Res Canc, World Hlth Org, Infect & Canc Biol ICB Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	accardi@iarc.fr; gheit@iarc.fr			World Health OrganizationWorld Health Organization [001] Funding Source: Medline		Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Accardi R, 2011, MOL CELL BIOL, V31, P2210, DOI 10.1128/MCB.00964-10; Akgul B, 2007, EXP DERMATOL, V16, P590, DOI 10.1111/j.1600-0625.2007.00569.x; Akgul B, 2005, ARCH VIROL, V150, P145, DOI 10.1007/s00705-004-0398-4; Anantharaman D, 2013, JNCI-J NATL CANCER I, V105, P536, DOI 10.1093/jnci/djt053; Antonsson A, 2003, J CLIN MICROBIOL, V41, P2509, DOI 10.1128/JCM.41.6.2509-2514.2003; Arron ST, 2011, J INVEST DERMATOL, V131, P1745, DOI 10.1038/jid.2011.91; Banks L, 2012, NAT REV CANCER, V12, P876, DOI 10.1038/nrc3400; Bedard KM, 2008, J VIROL, V82, P3894, DOI 10.1128/JVI.01818-07; Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002; Borgogna C, 2014, MODERN PATHOL, V27, P1101, DOI 10.1038/modpathol.2013.240; Borgogna C, 2012, VIROLOGY, V423, P195, DOI 10.1016/j.virol.2011.11.029; Bottalico D, 2012, J GEN VIROL, V93, P1774, DOI 10.1099/vir.0.041897-0; Bottalico D, 2011, J INFECT DIS, V204, P787, DOI 10.1093/infdis/jir383; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Brimer N, 2012, ONCOGENE, V31, P4639, DOI 10.1038/onc.2011.589; Chen ZG, 2007, VIROLOGY, V360, P447, DOI 10.1016/j.virol.2006.10.022; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cornet I, 2012, J VIROL, V86, P2366, DOI 10.1128/JVI.06579-11; de Koning M, 2006, J CLIN MICROBIOL, V44, P1792, DOI 10.1128/JCM.44.5.1792-1800.2006; de Koning MNC, 2009, J GEN VIROL, V90, P1611, DOI 10.1099/vir.0.010017-0; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; de Villiers EM, 2013, VIROLOGY, V445, P2, DOI 10.1016/j.virol.2013.04.023; Dell'Oste V, 2009, J INVEST DERMATOL, V129, P1026, DOI 10.1038/jid.2008.317; Dillner J, 1999, SEMIN CANCER BIOL, V9, P423, DOI 10.1006/scbi.1999.0146; Dong W, 2005, J VIROL, V79, P14899, DOI 10.1128/JVI.79.23.14899-14908.2005; Egawa K, 2003, DERMATOLOGY, V207, P251, DOI 10.1159/000073085; Farzan SF, 2013, INT J CANCER, V133, P1713, DOI 10.1002/ijc.28176; Favre M, 1997, CLIN DERMATOL, V15, P181, DOI 10.1016/S0738-081X(97)00008-4; Forslund O, 2007, J INFECT DIS, V196, P876, DOI 10.1086/521031; Gabet AS, 2008, FASEB J, V22, P622, DOI 10.1096/fj.07-8389com; Gheit T, 2007, J CLIN MICROBIOL, V45, P2537, DOI 10.1128/JCM.00747-07; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; Holloway A, 2014, J GEN VIROL, V95, P123, DOI 10.1099/vir.0.057695-0; Howie HL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002211; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; Hufbauer M, 2013, J VIROL, V87, P12158, DOI 10.1128/JVI.01510-13; Iannacone MR, 2014, INT J CANCER, V134, P2231, DOI 10.1002/ijc.28552; Iannacone MR, 2013, J INVEST DERMATOL, V133, P1512, DOI 10.1038/jid.2012.478; Iannacone MR, 2012, CANCER EPIDEM BIOMAR, V21, P1303, DOI 10.1158/1055-9965.EPI-12-0032; Iannacone MR, 2010, J INFECT DIS, V201, P760, DOI 10.1086/650466; JABLONSKA S, 1972, CANCER RES, V32, P583; Karagas MR, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c2986; Karagas MR, 2006, J NATL CANCER I, V98, P389, DOI 10.1093/jnci/djj092; Kohler A, 2007, BRIT J DERMATOL, V156, P1078, DOI 10.1111/j.1365-2133.2007.07809.x; KRIPKE ML, 1994, CANCER RES, V54, P6102; Lazarczyk M, 2009, MICROBIOL MOL BIOL R, V73, P348, DOI 10.1128/MMBR.00033-08; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1111/j.1365-2133.2000.03703.x; Lomas A, 2012, BRIT J DERMATOL, V166, P1069, DOI 10.1111/j.1365-2133.2012.10830.x; Mackintosh LJ, 2009, BRIT J DERMATOL, V161, P56, DOI 10.1111/j.1365-2133.2009.09146.x; Martin E, 2014, J CLIN VIROL, V59, P30, DOI 10.1016/j.jcv.2013.10.028; McLaughlin-Drubin ME, 2012, CURR OPIN VIROL, V2, P459, DOI 10.1016/j.coviro.2012.05.004; Michael KM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000091; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Muench P, 2010, CANCER RES, V70, P6913, DOI 10.1158/0008-5472.CAN-10-1307; Muschik D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027655; Neale RE, 2013, CANCER EPIDEM BIOMAR, V22, P719, DOI 10.1158/1055-9965.EPI-12-0917-T; Nindl I, 2007, DIS MARKERS, V23, P247, DOI 10.1155/2007/942650; Nobre RJ, 2009, J VIROL, V83, P2907, DOI 10.1128/JVI.02490-08; Orth G, 2006, SEMIN IMMUNOL, V18, P362, DOI 10.1016/j.smim.2006.07.008; Paschos K, 2010, TRENDS MICROBIOL, V18, P439, DOI 10.1016/j.tim.2010.07.003; Patel AS, 2008, J INVEST DERMATOL, V128, P2888, DOI 10.1038/jid.2008.162; Patel AS, 2008, INT J CANCER, V122, P2377, DOI 10.1002/ijc.23377; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; Plasmeijer EI, 2010, J GEN VIROL, V91, P2073, DOI 10.1099/vir.0.019976-0; Proby CM, 2011, AM J TRANSPLANT, V11, P1498, DOI 10.1111/j.1600-6143.2011.03589.x; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rozenblatt-Rosen O, 2012, NATURE, V487, P491, DOI 10.1038/nature11288; Saidj D, 2013, J VIROL, V87, P12139, DOI 10.1128/JVI.01047-13; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schmitt A, 1996, J VIROL, V70, P1912, DOI 10.1128/JVI.70.3.1912-1922.1996; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Silverberg MJ, 2013, JNCI-J NATL CANCER I, V105, P350, DOI 10.1093/jnci/djs529; Simmonds M, 2008, INT J CANCER, V123, P2260, DOI 10.1002/ijc.23815; Stanley MA, 2009, INDIAN J MED RES, V130, P266; Struijk L, 2006, CANCER EPIDEM BIOMAR, V15, P529, DOI 10.1158/1055-9965.EPI-05-0747; Struijk L, 2003, J INVEST DERMATOL, V121, P1531, DOI 10.1046/j.1523-1747.2003.12632.x; Viarisio D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002125; Wallace NA, 2014, SEMIN CANCER BIOL, V26, P30, DOI 10.1016/j.semcancer.2013.12.003; Wallace NA, 2014, J VIROL, V88, P6112, DOI 10.1128/JVI.03808-13; Wallace NA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002807; Waterboer T, 2008, BRIT J DERMATOL, V159, P457, DOI 10.1111/j.1365-2133.2008.08621.x; Weissenborn SJ, 2009, J VIROL, V83, P811, DOI 10.1128/JVI.01338-08; Weissenborn SJ, 2005, J INVEST DERMATOL, V125, P93, DOI 10.1111/j.0022-202X.2005.23733.x; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	93	46	49	0	16	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0755-4982	2213-0276		PRESSE MED	Presse Med.	DEC	2014	43	12	2				E435	E443		10.1016/j.lpm.2014.08.008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW8KO	WOS:000346511000006	25451638				2022-02-25	
J	Herrero, R; Park, JY; Forman, D				Herrero, Rolando; Park, Jin Young; Forman, David			The fight against gastric cancer - the IARC Working Group report	BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY			English	Article						Gastric cancer; Helicobacter pylori; Eradication; Prevention		Gastric cancer is the third cause of cancer death worldwide, and Helicobacter pylori infection causes almost 90% of non-cardia cancers, the predominant type. H. pylori infection is treatable, and in clinical trials there is evidence of a 30-40% reduction in incidence of gastric cancer among treated subjects. However, with a few exceptions, there are no public health programmes for gastric cancer prevention. In December 2013, the International Agency for Research on Cancer (IARC), organized a Working Group of international experts to discuss and make recommendations for gastric cancer control. The Working Group considered that the enormous burden of disease, which is not expected to decline in the coming decades, requires decisive public health action to include gastric cancer in cancer control programmes. Interventions should be tailored to the local conditions and consider population-based screening and eradication of H. pylori, in the context of evaluation of feasibility, efficacy and adverse consequences. (C) 2014 Elsevier Ltd. All rights reserved.	[Herrero, Rolando; Park, Jin Young; Forman, David] Int Agcy Res Canc, F-69372 Lyon 08, France		Herrero, R (corresponding author), Int Agcy Res Canc, Sect Early Detect & Prevent, Prevent & Implementat Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	herreror@iarc.fr	Bornschein, Jan/U-9402-2018	Bornschein, Jan/0000-0001-8673-3122; Park, Jin Young/0000-0003-2491-5099			Abnet CC, 2014, IARC WORKING GROUP R, P136; Asaka M., 2014, IARC WORKING GROUP R, P21; Choi IJ, 2014, IARC WORKING GROUP R, P16; Choi IJ, 2014, IARC WORKING GROUP R, P154; Ferreccio C., 2014, IARC WORKING GROUP R, P37; Forman D, 2014, IARC WORKING GROUP R, V8, P5; Gisbert JP, 2014, IARC WORKING GROUP R, P95; Goodman KJ, 2014, IARC WORKING GROUP R, P88; Greenberg E. R., 2014, IARC WORKING GROUP R, V8, P64; IARC Helicobacter pylori Working Group, 2014, IARC WORK GROUP REP, V8; Lee Y-C, 2014, IARC WORKING GROUP R, P28; Lee Y-C, 2014, IARC WORKING GROUP R, P161; Leja M, 2014, IARC WROKING GROUP R, V8, P44; Leja M, 2014, IARC WORKING GROUP R, P147; Malekzadeh R., 2014, IARC WORKING GROUP R, P55; Malfertheiner P, 2012, GUT, V61, P646, DOI 10.1136/gutjnl-2012-302084; Megraud F, 2014, IARC WORKING GROUP R, P80; Moayyedi P, 2014, IARC WORKING GROUP R, V8, P111; Park JY, 2014, IARC WORKING GROUP R, V8, P1; Parsonnet J., 2014, IARC WORKING GROUP R, P72; Peleteiro B, 2014, DIGEST DIS SCI, V59, P1698, DOI 10.1007/s10620-014-3063-0; Torres J, 2014, 8 IARC, P122; Wald NJ, 2014, IARC WORKING GROUP R, P174; You W, 2014, IARC WORKING GROUP R, V8, P143	24	104	123	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1521-6918	1532-1916		BEST PRACT RES CL GA	Best Pract. Res. Clin. Gastroenterol.	DEC	2014	28	6					1107	1114		10.1016/j.bpg.2014.10.003			8	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	AY1PK	WOS:000347364500014	25439075				2022-02-25	
J	Scoccianti, C; Straif, K; Romieu, I				Scoccianti, Chiara; Straif, Kurt; Romieu, Isabelle			Recent evidence on alcohol and cancer epidemiology	FUTURE ONCOLOGY			English	Review						acetaldehyde; alcohol; cancer; carcinogenesis; drinking; ethanol; mechanism; polymorphism; tobacco smoking	POSTMENOPAUSAL BREAST-CANCER; UPPER AERODIGESTIVE TRACT; COLORECTAL-CANCER; FOLATE INTAKE; METHYLENETETRAHYDROFOLATE REDUCTASE; HEPATOCELLULAR-CARCINOMA; ALDEHYDE DEHYDROGENASE-2; DIETARY-INTAKE; RISK-FACTORS; NECK-CANCER	This review presents an overview of the impact of alcohol consumption on cancer risk. Results from the 2009 International Agency for Research on Cancer monograph as well as the most recent meta-analyses and epidemiological studies are considered. Alcohol consumption is one of the most important known risk factors for human cancer and potentially one of the most avoidable factors, but it is increasing worldwide. Ethanol in alcoholic beverages is carcinogenic to humans and causes several cancers (oral cavity, pharynx, larynx, esophagus, colorectum, liver and female breast). Cumulative lifetime consumption, frequency and drinking pattern appear to play a role in risk characterization. While the role of heavy drinking has been long recognized, new evidence suggests that light consumption (up to one drink/day) is also associated with adverse effects. In addition, some genetic polymorphisms interact with alcohol metabolism and may modify its impact.	[Scoccianti, Chiara; Romieu, Isabelle] Int Agcy Res Canc, Nutr & Metab Sect, F-69372 Lyon 08, France; [Straif, Kurt] Int Agcy Res Canc, Monographs Sect, F-69372 Lyon 08, France		Romieu, I (corresponding author), Int Agcy Res Canc, Nutr & Metab Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	romieui@iarc.fr					AHMAD K, 2013, PLOS ONE, V0008; Akhter M, 2007, EUR J CANCER, V43, P383, DOI 10.1016/j.ejca.2006.09.020; Allen NE, 2009, JNCI-J NATL CANCER I, V101, P296, DOI 10.1093/jnci/djn514; Alshatwi AA, 2010, FOOD CHEM TOXICOL, V48, P1881, DOI 10.1016/j.fct.2010.04.028; Altieri A, 2002, BRIT J CANCER, V87, P1227, DOI 10.1038/sj.bjc.6600638; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; [Anonymous], 2011, GLOB STAT REP ALC HL; Baglietto L, 2005, BMJ-BRIT MED J, V331, P807, DOI 10.1136/bmj.38551.446470.06; Balbo S, 2008, CANCER EPIDEM BIOMAR, V17, P3026, DOI 10.1158/1055-9965.EPI-08-0117; Benedetti A, 2009, CANCER DETECT PREV, V32, P352, DOI 10.1016/j.canep.2009.03.001; Berkey CS, 2010, PEDIATRICS, V125, pE1081, DOI 10.1542/peds.2009-2347; Brennan P, 2004, AM J EPIDEMIOL, V159, P1, DOI 10.1093/aje/kwh003; Cadoni G, 2012, ACTA OTORHINOLARYNGO, V32, P1; Castellsague X, 2004, INT J CANCER, V108, P741, DOI 10.1002/ijc.11627; Chang JS, 2012, MUTAGENESIS, V27, P275, DOI 10.1093/mutage/ger073; Chen WY, 2011, JAMA-J AM MED ASSOC, V306, P1884, DOI 10.1001/jama.2011.1590; Cho E, 2012, AM J CLIN NUTR, V95, P413, DOI 10.3945/ajcn.111.022145; Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043; Cogliano VJ, 2011, JNCI-J NATL CANCER I, V103, P1827, DOI 10.1093/jnci/djr483; Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027; Deandrea S, CANC EPIDEMIOL BIOMA, V17, P2025; Eaton DK, 2011, MMWR SURVEILL SUMM, V61, P1, DOI DOI 10.2307/24806047; Engeset D, 2009, EUR J CANCER PREV, V18, P69, DOI 10.1097/CEJ.0b013e328305a091; Ericson U, 2009, CANCER EPIDEM BIOMAR, V18, P1101, DOI 10.1158/1055-9965.EPI-08-0401; Eussen SJPM, 2010, CANCER EPIDEM BIOMAR, V19, P1328, DOI 10.1158/1055-9965.EPI-09-0841; Fedirko V, 2011, ANN ONCOL, V22, P1958, DOI 10.1093/annonc/mdq653; Fernandez SV, 2011, ALCOHOL CLIN EXP RES, V35, P389, DOI 10.1111/j.1530-0277.2010.01355.x; Ferrari P, 2007, INT J CANCER, V121, P2065, DOI 10.1002/ijc.22966; Freedman ND, 2007, AM J EPIDEMIOL, V165, P1424, DOI 10.1093/aje/kwm051; Friborg JT, 2007, CANCER-AM CANCER SOC, V109, P1183, DOI 10.1002/cncr.22501; Gao CM, 2008, WORLD J GASTROENTERO, V14, P5078, DOI 10.3748/wjg.14.5078; Guo HP, 2012, ALCOHOL CLIN EXP RES, V36, P272, DOI 10.1111/j.1530-0277.2011.01621.x; Gupta S, 2010, CANCER CAUSE CONTROL, V21, P1047, DOI 10.1007/s10552-010-9533-6; Gwack Jin, 2007, J Prev Med Public Health, V40, P23; Halsted CH, 2002, J NUTR, V132, p2367S, DOI 10.1093/jn/132.8.2367S; Hashibe M, 2009, CANCER EPIDEM BIOMAR, V18, P541, DOI 10.1158/1055-9965.EPI-08-0347; Hassan MM, 2008, INT J CANCER, V123, P1883, DOI 10.1002/ijc.23730; Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343; IARC, 1988, IARC MONOGR EVAL CAR, V44, P1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Islami F, 2011, INT J CANCER, V129, P2473, DOI 10.1002/ijc.25885; Islami F, 2010, ORAL ONCOL, V46, P802, DOI 10.1016/j.oraloncology.2010.07.015; Jarl J, 2012, ADDICTION, V107, P1234, DOI 10.1111/j.1360-0443.2011.03772.x; Kabat GC, 2008, BRIT J CANCER, V99, P816, DOI 10.1038/sj.bjc.6604540; Kayani MA, 2010, TOXICOL IN VITRO, V24, P56, DOI 10.1016/j.tiv.2009.09.003; Kim J, 2012, AM J CLIN NUTR, V95, P405, DOI 10.3945/ajcn.111.020255; Kontou N, 2012, DIS COLON RECTUM, V55, P703, DOI 10.1097/DCR.0b013e31824e612a; Lachenmeier DW, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-3; Lew JQ, 2009, AM J EPIDEMIOL, V170, P308, DOI 10.1093/aje/kwp120; Li CI, 2010, J NATL CANCER I, V102, P1422, DOI 10.1093/jnci/djq316; Lin J, 2008, AM J CLIN NUTR, V87, P734, DOI 10.1093/ajcn/87.3.734; Lin YS, 2005, INT J CANCER, V116, P779, DOI 10.1002/ijc.20980; Linderborg K, 2008, FOOD CHEM TOXICOL, V46, P476, DOI 10.1016/j.fct.2007.08.019; Liu Y, 2012, PEDIATRICS, V129, pE1192, DOI 10.1542/peds.2011-2601; MacArthur GJ, 2012, J PUBLIC HEALTH-UK, V34, pI20, DOI 10.1093/pubmed/fds006; Marron M, 2012, EUR J EPIDEMIOL, V27, P499, DOI 10.1007/s10654-012-9699-1; Mayne ST, 2009, CANCER EPIDEM BIOMAR, V18, P3368, DOI 10.1158/1055-9965.EPI-09-0944; Mizoue T, AM J EPIDEMIOL, V167; Muwonge R, 2008, ORAL ONCOL, V44, P446, DOI 10.1016/j.oraloncology.2007.06.002; Nagayoshi H, 2009, MUTAT RES-GEN TOX EN, V673, P74, DOI 10.1016/j.mrgentox.2008.11.009; Newcomb PA, 2009, CANCER EPIDEM BIOMAR, V18, P1007, DOI 10.1158/1055-9965.EPI-08-0801; Ohishi W, 2008, CANCER EPIDEM BIOMAR, V17, P846, DOI 10.1158/1055-9965.EPI-07-2806; Platek ME, 2009, CANCER EPIDEM BIOMAR, V18, P2453, DOI 10.1158/1055-9965.EPI-09-0159; Rebholz CE, 2012, PEDIATR BLOOD CANCER, V58, P256, DOI 10.1002/pbc.23289; Rehm J, 2010, ADDICTION, V105, P817, DOI 10.1111/j.1360-0443.2010.02899.x; Rehm J, 2007, INT J CANCER, V121, P1132, DOI 10.1002/ijc.22798; Rota M, 2010, STAT MED, V29, P2679, DOI 10.1002/sim.4041; Sangrajrang S, 2010, BREAST CANCER RES TR, V123, P885, DOI 10.1007/s10549-010-0804-4; Seitz HK, 2007, NAT REV CANCER, V7, P599, DOI 10.1038/nrc2191; Shih WL, 2012, INT J CANCER, V131, P2612, DOI 10.1002/ijc.27508; Shufelt C, 2012, J WOMENS HEALTH, V21, P281, DOI 10.1089/jwh.2011.3001; Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895; Suzuki R, 2008, INT J CANCER, V122, P1832, DOI 10.1002/ijc.23184; Szymanska K, 2011, CANCER CAUSE CONTROL, V22, P1037, DOI 10.1007/s10552-011-9779-7; Thygesen LC, 2008, EPIDEMIOLOGY, V19, P258, DOI 10.1097/EDE.0b013e31816339e0; Tjonneland A, 2006, EUR J CLIN NUTR, V60, P280, DOI 10.1038/sj.ejcn.1602313; Tjonneland A, 2004, J NUTR, V134, P173, DOI 10.1093/jn/134.1.173; Turati F, 2010, ORAL ONCOL, V46, P720, DOI 10.1016/j.oraloncology.2010.07.010; Weikert C, 2009, INT J CANCER, V125, P406, DOI 10.1002/ijc.24393; WHO, 2012, IARC MON EV CARC R E, V100E; *WHO, 2008, GLOB INF SYST ALC HL; WHO, 2013, WHO ATL SUBST AB; WHO, 2012, INT AG RES CANC MON, V100E; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; World Health Organization (WHO), 2009, GLOB HLTH RISKS MORT; Wu IC, 2009, J FORMOS MED ASSOC, V108, P155, DOI 10.1016/S0929-6646(09)60046-2; Yokoyama A, 2008, ALCOHOL CLIN EXP RES, V32, P1607, DOI 10.1111/j.1530-0277.2008.00739.x; Zhang SMM, 2007, AM J EPIDEMIOL, V165, P667, DOI 10.1093/aje/kwk054	88	29	29	1	30	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1479-6694	1744-8301		FUTURE ONCOL	Future Oncol.	SEP	2013	9	9					1315	1322		10.2217/fon.13.94			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	208CG	WOS:000323653100013	23980679				2022-02-25	
J	Partensky, C				Partensky, Christian			Toward a Better Understanding of Pancreatic Ductal Adenocarcinoma Glimmers of Hope?	PANCREAS			English	Review						pancreas; epidemiology; epigenetics; microRNAs; cancer stem cells		Pancreatic ductal adenocarcinoma (PDAC) imposes a heavy burden of disease, especially in the most developed countries, and the mortality rate has not declined over the past decades. Therefore, there is an urgent need for a better understanding of the molecular mechanisms of PDAC, which may help to improve early detection, prognosis, and treatment efficiency. This review focuses on PDAC epidemiology and on recent advances in our understanding of the molecular mechanisms of PDAC carcinogenesis. We discuss the cancer stem cell hypothesis, which provides a rationale for the pervasive resistance of PDAC to chemoradiotherapy and explains the disease recurrence after the currently used genotoxic treatment. Identification of an inherited predisposition to PDAC due to genetic factors should allow high-risk groups to benefit from early detection programs. The presence in biofluids of stable tumor-specific microRNAs (miRs) makes them the most promising biomarkers potentially capable of detecting tumors long before their clinical manifestation. The cancer stem cell hypothesis made it realistic to anticipate a clinical impact of miR-based therapy (miR mimics and antagomirs) to overcome the otherwise insurmountable barrier of frequent resistance of PDAC to chemoradiotherapy. The investigation of miRs in PDAC may provide exciting novel strategies for both diagnosis and treatment.	Int Agcy Res Canc, F-69372 Lyon 08, France		Partensky, C (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	partenskyc@visitors.iarc.fr						0	28	28	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-3177	1536-4828		PANCREAS	Pancreas	JUL	2013	42	5					729	739		10.1097/MPA.0b013e318288107a			11	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	301IF	WOS:000330525300001	23648843				2022-02-25	
J	Romieu, I				Romieu, I.			THE ESMAESTRAS STUDY: A LARGE COHORT STUDY AMONG MEXICAN TEACHERS	JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH			English	Meeting Abstract									[Romieu, I.] Int Agcy Res Canc, F-69372 Lyon, France; [Romieu, I.] Int Agcy Res Canc, Mexico City, DF, Mexico									0	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0143-005X			J EPIDEMIOL COMMUN H	J. Epidemiol. Community Health	AUG	2011	65			1			A17	A18		10.1136/jech.2011.142976a.43			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	807MG	WOS:000293901800044		Bronze			2022-02-25	
J	Ribeiro, KB; Levi, JE; Curado, MP; Eluf-Neto, J; Koifman, S; Wunsch, V; Menezes, A; Daudt, AW; Matos, E; Fernandez, L; Boffetta, P; Brennan, P				Ribeiro, K. B.; Levi, J. E.; Curado, M. P.; Eluf-Neto, J.; Koifman, S.; Wunsch Filho, V.; Menezes, A.; Daudt, A. W.; Matos, E.; Fernandez, L.; Boffetta, P.; Brennan, P.			Serologic response to HPV and the risk of head and neck cancer	EJC SUPPLEMENTS			English	Meeting Abstract	20th Meeting of the European-Association-for-Cancer-Research	JUL 05-08, 2008	Lyon, FRANCE	European Assoc Canc Res					[Ribeiro, K. B.; Levi, J. E.; Curado, M. P.; Eluf-Neto, J.; Koifman, S.; Wunsch Filho, V.; Menezes, A.; Daudt, A. W.; Matos, E.; Fernandez, L.; Boffetta, P.; Brennan, P.] IARC, Genet Epidemiol Grp, Lyon, France				de Cássia Braga Ribeiro, Karina/F-1626-2010; Filho, Victor Wunsch/C-4475-2012; Eluf-Neto, Jose/B-2522-2009	de Cássia Braga Ribeiro, Karina/0000-0002-8095-5979; Eluf-Neto, Jose/0000-0001-7504-2115				0	0	0	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	JUL	2008	6	9					188	189		10.1016/S1359-6349(08)71848-2			2	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	330DF	WOS:000257919000668					2022-02-25	
J	Cardis, E				Cardis, Elisabeth		INTERPHONE Study Grp	The INTERPHONE study: Cancer risk related to mobile telephone use	EPIDEMIOLOGY			English	Meeting Abstract	ISEE/ISEA 2006 Conference	2006	Paris, FRANCE	ISEE, ISEA					IARC, Lyon, France				Cardis, Elisabeth/C-3904-2017	Cardis, Elisabeth/0000-0003-0999-6839				0	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	NOV	2006	17	6		S			S72	S72		10.1097/00001648-200611001-00162			1	Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	097JL	WOS:000241443400162					2022-02-25	
J	Franceschi, S; Clifford, GM				Franceschi, S; Clifford, GM			Re: A study of the impact of adding HPV types to cervical cancer screening and triage tests	JOURNAL OF THE NATIONAL CANCER INSTITUTE			English	Letter							HUMAN-PAPILLOMAVIRUS TYPES; METAANALYSIS; LESIONS		Int Agcy Res Canc, F-69372 Lyon, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Clifford GM, 2003, BRIT J CANCER, V89, P101, DOI 10.1038/sj.bjc.6601024; Clifford GM, 2005, CANCER EPIDEM BIOMAR, V14, P1157, DOI 10.1158/1055-9965.EPI-04-0812; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Naucler P, 2004, J GEN VIROL, V85, P2189, DOI 10.1099/vir.0.80001-0; Schiffman M, 2005, J NATL CANCER I, V97, P147, DOI 10.1093/jnci/dji014; Wright TC, 2004, OBSTET GYNECOL, V103, P304, DOI 10.1097/01.AOG.0000109426.82624.f8	7	29	33	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0027-8874			J NATL CANCER I	J. Natl. Cancer Inst.	JUN 15	2005	97	12					938	939		10.1093/jnci/dji159			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	937FA	WOS:000229908800020	15956659	Bronze			2022-02-25	
J	Gray, N; Boyle, P				Gray, N; Boyle, P			Publishing tobacco tar measurements on packets	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Int Agcy Res Canc, F-69008 Lyon, France		Gray, N (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	nigel@uicc.org	Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610			DJORDJEVIC MV, 1995, CARCINOGENESIS, V16, P2627, DOI 10.1093/carcin/16.11.2627; FISCHER S, 1990, Archiv fuer Geschwulstforschung, V60, P169; Gray N, 2000, TOB CONTROL, V9, P351, DOI 10.1136/tc.9.3.351; Gray N, 2000, ANN ONCOL, V11, P909, DOI 10.1023/A:1008313631233; Kozlowski LT, 2002, TOB CONTROL, V11, pI40, DOI 10.1136/tc.11.suppl_1.i40; Levi F, 1997, CANCER, V79, P906, DOI 10.1002/(SICI)1097-0142(19970301)79:5<906::AID-CNCR6>3.0.CO;2-9; Public Health Service Office of the Assistant Secretary for Health Office on Smoking and Health, 1981, HLTH CONS SMOK CHANG; *US DEP HHS, 2001, RISKS ASS SMOK CIG L; *US PHS, 1996, FTC METH DET TAR NIC; WEINSTEIN ND, 2001, RISKS ASS SMOKING CI, P193; *WHO SCI ADV COMM, 2003, REC HLTH CLAIMS DERV; WYNDER EL, 1953, CANCER RES, V13, P855	12	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2004	329	7470					813	814		10.1136/bmj.329.7470.813			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862EK	WOS:000224472800005	15472240	Green Published			2022-02-25	
J	Boyle, P				Boyle, P			The global cancer patient	RADIOTHERAPY AND ONCOLOGY			English	Meeting Abstract	23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23)	OCT 24-28, 2004	Amsterdam, NETHERLANDS	European Soc Therapeut Radiol Oncol					Int Agcy Res Canc, F-69008 Lyon, France									0	0	0	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-8140			RADIOTHER ONCOL	Radiother. Oncol.	OCT	2004	73			1			S194	S194					1	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Radiology, Nuclear Medicine & Medical Imaging	886OH	WOS:000226237700425					2022-02-25	
J	Vainio, H; Stayner, L				Vainio, H; Stayner, L			Can health promotion at the workplace help prevent cancer?	SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH			English	Editorial Material							SMOKING CESSATION; NUTRITION		Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon, France		Vainio, H (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon, France.						Biener L, 1999, HEALTH EDUC BEHAV, V26, P478, DOI 10.1177/109019819902600407; COHEN A, 1998, HLTH PROMOTION INDIC, pCH12; International Agency for Research on Cancer (IARC), 2002, IARC HDB CANC PREV, V6, P1; Janer G, 2002, SCAND J WORK ENV HEA, V28, P141, DOI 10.5271/sjweh.658; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETO R, 1994, MORTALITY TOBACCO DE; Steenhuis IHM, 2001, HEALTH PROMOT INT, V16, P21, DOI 10.1093/heapro/16.1.21; Vainio H, 2001, TOXICOLOGY, V166, P47, DOI 10.1016/S0300-483X(01)00445-0; Weston J, 2000, IEEE ROBOT AUTOM MAG, V7, P56, DOI 10.1109/100.876911; Wolf AM, 1998, OBES RES, V6, P97, DOI 10.1002/j.1550-8528.1998.tb00322.x	10	1	1	0	1	SCAND J WORK ENV HEALTH	HELSINKI	TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND	0355-3140			SCAND J WORK ENV HEA	Scand. J. Work Environ. Health	JUN	2002	28	3					137	139		10.5271/sjweh.657			3	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	570JV	WOS:000176655900001	12109552	hybrid			2022-02-25	
J	Vainio, H				Vainio, H			The need for preventive drugs and vaccines in global cancer control: a challenge for public health and for industry	TOXICOLOGY AND INDUSTRIAL HEALTH			English	Article						cancer prevention; chemoprevention; health economics; immunization; pharmaceuticals; vaccines	HUMAN-PAPILLOMAVIRUS; HELICOBACTER-PYLORI; CERVICAL-CANCER; CHEMOPREVENTION; ASPIRIN; TRIAL	Ten million new cancer patients are diagnosed worldwide each year. There will be a dramatic increase over the next 20 years in the number of people contracting cancer, especially in the developing, poorer part of the world. Many types of cancer vary in incidence and mortality by more than an order of magnitude between different populations, and every type is rare in some part of the world, suggesting that cancers are in principle preventable. Many specific causes of cancer are known, from factors related to lifestyle, diet, infections and occupations. The remarkable advances in molecular understanding of the carcinogenesis process over the past 25 years have transformed the approaches in cancer control. About 15% of cancers worldwide are caused by known infectious agents. Human papillomavirus vaccines, which are already being tested, may, in the long run, be able to prevent almost all cervical cancers. New promising disciplines in prevention, such as chemoprevention, have emerged. Chemoprevention has been successfully achieved in numerous animal experiments, and has been validated in several clinical trials. But more effective and safer chemopreventive agents and vaccines are needed. Rising prices of medicines and vaccines are putting them beyond the reach of many people, even in rich countries. Future enhanced efforts on an international basis are needed to guarantee access to these lifesaving drugs and vaccines. Putting prevention high on the agenda requires political courage and a long-term perspective.	Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon 08, France		Vainio, H (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon 08, France.						BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Greenwald P, 2002, J CLIN ONCOL, V20, p14S, DOI 10.1200/JCO.2002.07.035; HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429; Imperiale TF, 2003, NEW ENGL J MED, V348, P879, DOI 10.1056/NEJMp030005; *INT AG RES CANC, 2001, 20002001 IARC, P82; International Agency for Research on Cancer, 2003, IARC HDB CANC PREV; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; LOVE R, 2001, BREAST CANC, P133; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Sporn MB, 2002, NAT REV CANCER, V2, P537, DOI 10.1038/nrc844; Stewart BW, 2003, WORLD CANC REPORT; Vainio H, 2002, PHARMACOL TOXICOL, V91, P49, DOI 10.1034/j.1600-0773.2002.910201.x; *WHO, 2000, GLOB BURD DIS COMPR; Widdus R, 2001, B WORLD HEALTH ORGAN, V79, P713; 2003, LANCET, V361, P1065	17	0	1	1	2	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0748-2337			TOXICOL IND HEALTH	Toxicol. Ind. Health		2002	18	2					84	90		10.1191/0748233702th136oa			7	Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Toxicology	694MR	WOS:000183778800005	12868797				2022-02-25	
S	Vainio, H; Bianchini, F		Osborne, MP		Vainio, H; Bianchini, F			Evaluation of cancer-preventive agents and strategies - A new program at the International Agency for Research on Cancer	CANCER PREVENTION: MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	4th Strang International Cancer Prevention Conference	NOV 10-11, 2000	STRANG CANC PREVENT CTR, NEW YORK, NEW YORK	Int Soc Canc Chemoprevent, Amer Hlth Fdn, Cornell Univ, Weill Med Coll, Janssen Pharmaceut, Merck, Pharmacia	STRANG CANC PREVENT CTR	cancer prevention; evidence-based evaluations; aspirin; vitamin A, beta-carotene; sunscreens; overweight; obesity; physical activity		About five years ago, the International Agency for Research on Cancer (IARC) initiated a new program, IARC Handbooks of Cancer Prevention, aimed at evaluating the evidence base for the cancer-preventive activity of various agents and strategies. To date (2001) 5 volumes have been published-1. Non-steroidal Anti-inflammatory Drugs, 2. Carotenoids, 3. Vitamin A, 4. Retinoids, and 5. Sunscreens-and volume 6 (Weight Control and Physical Activity) is in press. Future volumes will include evaluations of breast cancer screening (vol. 7) and fruits and vegetables (vol. 8).	Int Agcy Res Canc, Unit Chemoprevent, F-69373 Lyon, France		Vainio, H (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, F-69373 Lyon, France.						*IARC, 1999, IARC HDB CANC PREV, V4, P1; IARC, 1998, IARC HDB CANC PREV, V2, P1; IARC, 1998, IARC HDB CANC PREV, V3, P1; *IARC, 1997, IARC HDB CANC PREV, V1, P1; *IARC, 2001, IARC HDB CANC PREV, V5, P1; IARC Working Group on the Evaluation of Cancer-Preventive Agents, 2002, IARC HDB CANC PREV, V6	6	15	15	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-350-5	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	952						177	180		10.1111/j.1749-6632.2001.tb02740.x			4	Oncology; Multidisciplinary Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Science & Technology - Other Topics	BT69J	WOS:000173778200018	11795439				2022-02-25	
J	Brennan, P; Wild, CP				Brennan, Paul; Wild, Christopher P.			Genomics of Cancer and a New Era for Cancer Prevention	PLOS GENETICS			English	Review							HUMAN-PAPILLOMAVIRUS ANTIBODIES; LUNG-CANCER; MENDELIAN RANDOMIZATION; GENETIC EPIDEMIOLOGY; BETA-CAROTENE; RISK; PREDICTION; SIGNATURES; MORTALITY; PATTERNS	A primary justification for dedicating substantial amounts of research funding to large-scale cancer genomics projects of both somatic and germline DNA is that the biological insights will lead to new treatment targets and strategies for cancer therapy. While it is too early to judge the success of these projects in terms of clinical breakthroughs, an alternative rationale is that new genomics techniques can be used to reduce the overall burden of cancer by prevention of new cases occurring and also by detecting them earlier. In particular, it is now becoming apparent that studying the genomic profile of tumors can help to identify new carcinogens and may subsequently result in implementing strategies that limit exposure. In parallel, it may be feasible to utilize genomic biomarkers to identify cancers at an earlier and more treatable stage using screening or other early detection approaches based on pre-diagnostic biospecimens. While the potential for these techniques is large, their successful outcome will depend on international collaboration and planning similar to that of recent sequencing initiatives.	[Brennan, Paul] Int Agcy Res Canc, Genet Sect, F-69372 Lyon, France; [Wild, Christopher P.] Int Agcy Res Canc, Directors Off, F-69372 Lyon, France		Brennan, P (corresponding author), Int Agcy Res Canc, Genet Sect, 150 Cours Albert Thomas, F-69372 Lyon, France.	brennanp@iarc.fr; director@iarc.fr	Pinheiro, Maísa/E-7424-2012; Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7 260791]	This work has been funded by a European Commission grant, number FP7 260791, "EurocanPlatform - A European Platform for Translational Cancer Research." The funders had no role in the preparation of the article.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; [Anonymous], 2011, IARC MON EV CARC RIS, V100B; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Bianchi F, 2011, EMBO MOL MED, V3, P495, DOI 10.1002/emmm.201100154; Bozic I, 2013, SCIENCE, V342, P938, DOI 10.1126/science.1247887; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Burgess S, 2011, INT J EPIDEMIOL, V40, P755, DOI 10.1093/ije/dyr036; Chen L, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050052; Colditz GA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003218; Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Easton DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMsr1501341; Ebrahim S, 2008, HUM GENET, V123, P15, DOI 10.1007/s00439-007-0448-6; Ferlay J, 2013, CANC INCIDENCE MORTA; Forman D, 2013, CANC INCIDENCE 5 CON, VX; Goralczyk R, 2009, NUTR CANCER, V61, P767, DOI 10.1080/01635580903285155; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004; Huang LM, 2011, CURR OPIN IMMUNOL, V23, P237, DOI 10.1016/j.coi.2010.12.013; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Iorio MV, 2012, CARCINOGENESIS, V33, P1126, DOI 10.1093/carcin/bgs140; Jervis S, 2015, J MED GENET, V52, P465, DOI 10.1136/jmedgenet-2015-103077; Korte JE, 2002, AM J EPIDEMIOL, V155, P496, DOI 10.1093/aje/155.6.496; Kreimer AR, 2015, J CLIN ONCOL, V33, P877, DOI 10.1200/JCO.2014.57.8435; Kreimer AR, 2013, J CLIN ONCOL, V31, P2708, DOI 10.1200/JCO.2012.47.2738; Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0; Nead KT, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv178; Nordestgaard BG, 2014, LANCET, V384, P626, DOI 10.1016/S0140-6736(14)61177-6; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Parkin DM, 2011, BRIT J CANCER, V105, pS77, DOI 10.1038/bjc.2011.489; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; Pfeifer GP, 2015, CURR OPIN ONCOL, V27, P71, DOI 10.1097/CCO.0000000000000152; Pfeifer GP, 2010, GENOME MED, V2, DOI 10.1186/gm175; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Ridker PM, 2014, LANCET, V384, P607, DOI 10.1016/S0140-6736(14)61009-6; Riley JL, 2013, NEW ENGL J MED, V369, P187, DOI 10.1056/NEJMe1305484; Scelo G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6135; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Sozzi G, 2014, J CLIN ONCOL, V32, P768, DOI 10.1200/JCO.2013.50.4357; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Szulkin R, 2015, PROSTATE; Thrift AP, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju252; Trummer O, 2013, CLIN CHEM, V59, P793, DOI 10.1373/clinchem.2012.193185; VanderWeele TJ, 2014, EPIDEMIOLOGY, V25, P427, DOI 10.1097/EDE.0000000000000081; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2; Wetterstrand KA, DNA SEQUENCING COSTS; Wild CP, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju353	54	15	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-7404			PLOS GENET	PLoS Genet.	NOV	2015	11	11							e1005522	10.1371/journal.pgen.1005522			12	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	CY1PF	WOS:000366179000003	26540230	gold, Green Published, Green Submitted			2022-02-25	
J	Chen, AA; Gheit, T; Franceschi, S; Tommasino, M; Clifford, GM				Chen, Alyce A.; Gheit, Tarik; Franceschi, Silvia; Tommasino, Massimo; Clifford, Gary M.		IARC HPV Variant Study Grp	Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide	JOURNAL OF VIROLOGY			English	Article							REPUBLIC-OF-CHINA; TYPE-18 VARIANTS; SEQUENCE-ANALYSIS; MOLECULAR VARIANTS; HPV INFECTION; L1 REGIONS; WOMEN; PREVALENCE; E6; NEOPLASIA	Human papillomavirus 18 (HPV18) is the second most carcinogenic HPV type, after HPV16, and it accounts for approximately 12% of squamous cell carcinoma (SCC) as well as 37% of adenocarcinoma (ADC) of the cervix worldwide. We aimed to evaluate the worldwide diversity and carcinogenicity of HPV18 genetic variants by sequencing the entire long control region (LCR) and the E6 open reading frame of 711 HPV18-positive cervical samples from 39 countries, taking advantage of the International Agency for Research on Cancer biobank. A total of 209 unique HPV18 sequence variants were identified that formed three phylogenetic lineages (A, B, and C). A and B lineages each divided into four sublineages, including a newly identified candidate B4 sublineage. The distribution of lineages varied by geographical region, with B and C lineages found principally in Africa. HPV18 (sub) lineages were compared between 453 cancer cases and 236 controls, as well as between 81 ADC and 160 matched SCC cases. In region-stratified analyses, there were no significant differences in the distribution of HPV18 variant lineages between cervical cancer cases and controls or between ADC and SCC. In conclusion, our findings do not support the role of HPV18 (sub) lineages for discriminating cancer risk or explaining why HPV18 is more strongly linked with ADC than SCC.	[Chen, Alyce A.; Gheit, Tarik; Franceschi, Silvia; Tommasino, Massimo; Clifford, Gary M.; IARC HPV Variant Study Grp] Int Agcy Res Canc, F-69372 Lyon, France		Tommasino, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	tommasinom@iarc.fr; cliffordg@iarc.fr	franceschi, silvia/M-2452-2014; Eluf-Neto, Jose/B-2522-2009; de Sanjosé Llongueras, Silvia/H-6339-2014; Pique, Xavier Castellsagué/N-5795-2014; Frazer, Ian/A-1137-2007	franceschi, silvia/0000-0003-4181-8071; Eluf-Neto, Jose/0000-0001-7504-2115; Pique, Xavier Castellsagué/0000-0002-0802-3595; Chen, Alyce/0000-0002-5018-8908; Kordzaia, Dimitri/0000-0002-4773-2896; Tommasino, Massimo/0000-0002-0890-8596; Khodakarami, Nahid/0000-0001-6469-8717; Frazer, Ian/0000-0002-8002-4680; Pearce, Neil/0000-0002-9938-7852	Association for International Cancer Research, United Kingdom [08-0213]; Institut National du Cancer, FranceInstitut National du Cancer (INCA) France [07/3D1514/PL-89-05/NG-LC]; Fondation Innovations en Infectiologie (FINOVI) [AO1-project 2]; International Agency for Research on Cancer; European Commission FP7 Marie Curie Actions-People-Co-funding of Regional, National, and International Programmes (COFUND).	This work was supported by grants from The Association for International Cancer Research, United Kingdom (project grant 08-0213), the Institut National du Cancer, France (collaboration agreement 07/3D1514/PL-89-05/NG-LC), and the Fondation Innovations en Infectiologie (FINOVI) (project AO1-project 2). The work of A.A.C. was undertaken during the tenure of a postdoctoral fellowship from the International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions-People-Co-funding of Regional, National, and International Programmes (COFUND).	Alibegashvili T, 2011, CANCER EPIDEMIOL, V35, P465, DOI 10.1016/j.canep.2010.12.006; Arias-Pulido H, 2005, VIROLOGY, V338, P22, DOI 10.1016/j.virol.2005.04.022; Arroyo SL, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-258; Aruhuri B, 2012, CANCER PREV RES, V5, P746, DOI 10.1158/1940-6207.CAPR-11-0515; Bardin A, 2008, EUR J CANCER, V44, P557, DOI 10.1016/j.ejca.2007.12.001; Bokal EV, 2010, J OBSTET GYNAECOL RE, V36, P1204, DOI 10.1111/j.1447-0756.2010.01316.x; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Burk RD, 2003, CANCER RES, V63, P7215; Burk RD, 2013, VIROLOGY, V445, P232, DOI 10.1016/j.virol.2013.07.018; Cerqueira DM, 2008, VIRUS GENES, V37, P282, DOI 10.1007/s11262-008-0263-8; Chen AA, 2014, J VIROL, V88, P4514, DOI 10.1128/JVI.03534-13; Chen AA, 2014, VIROLOGY, V448, P356, DOI 10.1016/j.virol.2013.10.033; Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072565; Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; Cornet I, 2012, J VIROL, V86, P6855, DOI 10.1128/JVI.00483-12; Dai M, 2006, BRIT J CANCER, V95, P96, DOI 10.1038/sj.bjc.6603208; De Boer MA, 2005, INT J CANCER, V114, P422, DOI 10.1002/ijc.20727; De la Cruz-Hernandez E, 2005, J GEN VIROL, V86, P2459, DOI 10.1099/vir.0.80945-0; De Vuyst H, 2012, INT J CANCER, V131, P949, DOI 10.1002/ijc.26470; Dondog B, 2008, CANCER EPIDEM BIOMAR, V17, P1731, DOI 10.1158/1055-9965.EPI-07-2796; Foliaki S, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-14; Franceschi S, 2003, INT J CANCER, V107, P127, DOI 10.1002/ijc.11350; Guan P, 2013, INT J CANCER, V132, P248, DOI 10.1002/ijc.27663; Halec G, 2013, INT J CANCER, V132, P63, DOI 10.1002/ijc.27605; Hammouda D, 2005, INT J CANCER, V113, P483, DOI 10.1002/ijc.20600; HECHT JL, 1995, INT J CANCER, V60, P369, DOI 10.1002/ijc.2910600317; Keita N, 2009, BRIT J CANCER, V101, P202, DOI 10.1038/sj.bjc.6605140; Khodakarami N, 2012, INT J CANCER, V131, pE156, DOI 10.1002/ijc.26488; Li LK, 2006, BRIT J CANCER, V95, P1593, DOI 10.1038/sj.bjc.6603450; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Lizano M, 1997, J NATL CANCER I, V89, P1227, DOI 10.1093/jnci/89.16.1227; Lurchachaiwong W, 2010, INTERVIROLOGY, V53, P161, DOI 10.1159/000274977; Meissner J, 1997, HUMAN PAPILLOMAVIRUS, pIII; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Okolo Clement, 2010, Infect Agent Cancer, V5, P24, DOI 10.1186/1750-9378-5-24; ONG CK, 1993, J VIROL, V67, P6424, DOI 10.1128/JVI.67.11.6424-6431.1993; Ong CK, 1997, J MOL EVOL, V44, P199, DOI 10.1007/PL00006136; Perez S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104678; Pim D, 2012, FEBS J, V279, P3530, DOI 10.1111/j.1742-4658.2012.08709.x; Pista A, 2007, J MED VIROL, V79, P1889, DOI 10.1002/jmv.21002; Raza SA, 2010, BRIT J CANCER, V102, P1657, DOI 10.1038/sj.bjc.6605664; Rose BR, 1997, GYNECOL ONCOL, V66, P282, DOI 10.1006/gyno.1997.4740; Schlecht NF, 2005, J GEN VIROL, V86, P2709, DOI 10.1099/vir.0.81060-0; Sherpa ATL, 2010, CANCER CAUSE CONTROL, V21, P323, DOI 10.1007/s10552-009-9467-z; Sichero L, 2005, J INFECT DIS, V191, P739, DOI 10.1086/427825; Sichero L, 2007, INT J CANCER, V120, P1763, DOI 10.1002/ijc.22481; Sotlar K, 2004, J MED VIROL, V74, P107, DOI 10.1002/jmv.20153; Sun ZR, 2012, INT J GYNECOL CANCER, V22, P930, DOI 10.1097/IGC.0b013e318253a994; Tshomo U, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-408; van den Brule AJC, 2002, J CLIN MICROBIOL, V40, P779, DOI 10.1128/JCM.40.3.779-787.2002; Van Doorslaer K, 2013, NUCLEIC ACIDS RES, V41, pD571, DOI 10.1093/nar/gks984; Villa LL, 2000, J GEN VIROL, V81, P2959, DOI 10.1099/0022-1317-81-12-2959; Wu RF, 2007, INT J CANCER, V121, P1306, DOI 10.1002/ijc.22726; Xi LF, 2007, CANCER EPIDEM BIOMAR, V16, P4, DOI 10.1158/1055-9965.EPI-06-0670; Xi LF, 2006, J NATL CANCER I, V98, P1045, DOI 10.1093/jnci/djj297; Yang LJ, 2014, J MED VIROL, V86, P1926, DOI 10.1002/jmv.24043	58	48	48	1	10	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	OCT	2015	89	20					10680	10687		10.1128/JVI.01747-15			8	Virology	Science Citation Index Expanded (SCI-EXPANDED)	Virology	CU3ZG	WOS:000363464700045	26269181	Green Published, Bronze			2022-02-25	
J	Schuz, J				Schuez, Joachim			Power Lines and Cancer in Adults Settling a Long-standing Debate?	EPIDEMIOLOGY			English	Editorial Material									Int Agcy Res Canc, Sect Environm & Radiat, F-69372 Lyon, France		Schuz, J (corresponding author), Int Agcy Res Canc, Sect Environm & Radiat, 150 Cours Albert Thomas, F-69372 Lyon, France.	schuzj@iarc.fr					[Anonymous], 2002, EVALUATION, V80; Elliott P, 2013, EPIDEMIOLOGY, V24, P184, DOI 10.1097/EDE.0b013e31827e95b9; SCENIHR, 2009, RES NEEDS METH ADDR; Sienkiewicz Z, 2012, EFHRAN PROJECT RISK; STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569	5	3	3	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	MAR	2013	24	2					191	192		10.1097/EDE.0b013e31828216cd			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	086ZB	WOS:000314728000003	23377088				2022-02-25	
J	Clifford, GM; Howell-Jones, R; Franceschi, S				Clifford, Gary M.; Howell-Jones, Rebecca; Franceschi, Silvia			Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer	INTERNATIONAL JOURNAL OF CANCER			English	Letter									[Clifford, Gary M.; Howell-Jones, Rebecca; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Clifford, GM (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	clifford@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Castle PE, 2008, J CLIN MICROBIOL, V46, P2595, DOI 10.1128/JCM.00824-08; Castle Philip E, 2009, Infect Agent Cancer, V4, P7, DOI 10.1186/1750-9378-4-7; Kreuter A, 2009, BRIT J DERMATOL, V161, P1262, DOI 10.1111/j.1365-2133.2009.09343.x; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Schiffman M, 2005, J NATL CANCER I, V97, P147, DOI 10.1093/jnci/dji014; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002; Schiffman Mark, 2009, Infect Agent Cancer, V4, P8, DOI 10.1186/1750-9378-4-8; Vaccarella S, 2010, CANCER EPIDEM BIOMAR, V19, P503, DOI 10.1158/1055-9965.EPI-09-0983; *WHO I CAT ONC, WHO ICO INF CTR HPV	10	11	11	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0020-7136			INT J CANCER	Int. J. Cancer	OCT 1	2011	129	7					1792	1794		10.1002/ijc.25833			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	798XX	WOS:000293246600025	21140454	Bronze			2022-02-25	
J	Slimani, N				Slimani, N.			GLOBAL NUTRITIONAL BURDEN: A MAJOR METHODOLOGICAL CHALLENGE FOR NUTRITIONAL EPIDEMIOLOGICAL RESEARCH	JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH			English	Meeting Abstract									[Slimani, N.] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0143-005X			J EPIDEMIOL COMMUN H	J. Epidemiol. Community Health	AUG	2011	65			1			A442	A442		10.1136/jech.2011.142976p.24			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	807MG	WOS:000293901802274		Bronze			2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R.			Global trends in oral cancer burden and control	ORAL ONCOLOGY			English	Meeting Abstract	3rd World Congress of the International-Academy-of-Oral-Oncology	JUL 14-17, 2011	Singapore, SINGAPORE	Int Acad Oral Oncol					[Sankaranarayanan, R.] Int Agcy Res Canc WHO IARC, Early Detect & Prevent Sect, Lyon, France; [Sankaranarayanan, R.] Int Agcy Res Canc WHO IARC, Screening Grp, Lyon, France									0	0	0	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1368-8375			ORAL ONCOL	Oral Oncol.	JUL	2011	47			1			S1	S1		10.1016/j.oraloncology.2011.06.018			1	Oncology; Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology; Dentistry, Oral Surgery & Medicine	793IX	WOS:000292815100002					2022-02-25	
J	Wild, CP				Wild, Christopher P.			How Much of a Contribution Do Exposures Experienced between Conception and Adolescence Make to the Burden of Cancer in Adults?	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Editorial Material							IN-UTERO; CHILDHOOD; DISEASE; HEALTH; RISK; SUSCEPTIBILITY; MORTALITY; COHORT		Int Agcy Res Cancer, Directors Off, F-69008 Lyon, France		Wild, CP (corresponding author), Int Agcy Res Cancer, Directors Off, 150 Cours Albert Thomas, F-69008 Lyon, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			Brown RC, 2007, INT J EPIDEMIOL, V36, P724, DOI 10.1093/ije/dyl299; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Fry RC, 2007, PLOS GENET, V3, P2180, DOI 10.1371/journal.pgen.0030207; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Hughes LAE, 2010, INT J EPIDEMIOL, V39, P1333, DOI 10.1093/ije/dyq062; Hughes LAE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007951; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Korde LA, 2009, CANCER EPIDEM BIOMAR, V18, P1050, DOI 10.1158/1055-9965.EPI-08-0405; Merlo DF, 2009, CANCER EPIDEM BIOMAR, V18, P5, DOI 10.1158/1055-9965.EPI-08-0876; Pedersen M, 2009, ENVIRON RES, V109, P1012, DOI 10.1016/j.envres.2009.08.011; Peto R., 1977, ORIGINS HUMAN CANC, P1403; Smith AH, 2006, ENVIRON HEALTH PERSP, V114, P1293, DOI 10.1289/ehp.8832; Vlaanderen J, 2010, OCCUP ENVIRON MED, V67, P136, DOI 10.1136/oem.2008.042788; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Wild CP, 2003, CANCER EPIDEM BIOMAR, V12, P1389; Yuan Y, 2010, EPIDEMIOLOGY, V21, P103, DOI 10.1097/EDE.0b013e3181c21e46	17	13	13	0	4	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965	1538-7755		CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	APR	2011	20	4					580	581		10.1158/1055-9965.EPI-11-0187			2	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	743CE	WOS:000288993000006	21454421	Bronze			2022-02-25	
J	De Vuyst, H; Clifford, G; Li, N; Franceschi, S				De Vuyst, Hugo; Clifford, Gary; Li, Ni; Franceschi, Silvia			HPV infection in Europe	EUROPEAN JOURNAL OF CANCER			English	Article						Human papillomavirus/prevalence/testing/types/vaccination; Europe; Epidemiology; Screening trials; Review	HUMAN-PAPILLOMAVIRUS PREVALENCE; GRADE CERVICAL LESIONS; GENOTYPE DISTRIBUTION; SCREENING POPULATION; FEMALE-POPULATION; WOMEN; CANCER; CYTOLOGY; AGE; WORLDWIDE	In order to estimate the impact of primary cervical cancer screening with human papillomavirus (HPV) testing, and implementation of the current HPV vaccines, we have summarised the most recent and largest HPV studies in Europe. Eighteen studies including between 897 and 46,900 women from 14, mostly Northern and Western European, countries were included. Everywhere, high-risk (HR) HPV prevalence peaked before age 25 or 30 years with steady declines thereafter. For women in the 30-64-year age-range, for whom primary HPV testing is considered, age-adjusted HR HPV prevalence ranged from 2% in Spain to approximately 12% in Belgium and France, where sustained elevated levels were found in women aged >= 35 years. HPV16 and 18, the two HR types prevented by current HPV vaccines, accounted for 30% (range 19-43%) and 12% (range 0-22%) of all HR HPV positives, respectively, and varied according to the presence of cervical lesions. Based on an updated meta-analysis of HPV type distribution in the whole of Europe, HPV16 and/or 18 are estimated to be present in 52%, 61% and 76% of cytologically detected high-grade squamous intraepithelial, lesions, histologically confirmed cervical intraepithelial neoplasia grade 2/3, and invasive cervical carcinoma, respectively. (C) 2009 Elsevier Ltd. All rights reserved.	[De Vuyst, Hugo; Clifford, Gary; Li, Ni; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071	Bill & Melinda Gates FoundationBill & Melinda Gates Foundation [35537]	This work has received financial support from the Bill & Melinda Gates Foundation (Grant No. 35537). We gratefully thank those authors who have kindly provided more detailed data, or updated data that were only partly available in the published articles: Dr. Marc Arbyn (Scientific Institute of Public Health, Brussels, Belgium); Dr. Veerle Coupe (VU University Medical Centre, Amsterdam, The Netherlands); Dr. Silvia de Sanjose (Institut Catala d'Oncologia, Barcelona, Spain); Dr. Samantha Hibbitts (Cardiff University, Cardiff, United Kingdom); Dr. Susanne Kjaer (Institute of Cancer Epidemiology, Copenhagen, Denmark); Dr. Laura Kotaniemi-Talonen and Dr. Maarit Leinonen (Finnish Cancer Registry, Helsinki, Finland); Dr. Alicja Bardin (Maria Sklodowska-Curie Memorial Cancer Centre and institute of Oncology, Warsaw, Poland). Ms. Annie Arslan and Ms. Trudy Perdrix-Thoma provided skilful technical assistance.	Agorastos T, 2004, EUR J CANCER PREV, V13, P145, DOI 10.1097/00008469-200404000-00010; Arbyn M, 2008, EUROPEAN GUIDELINES, P69; Arbyn M, 2009, CANCER EPIDEM BIOMAR, V18, P321, DOI 10.1158/1055-9965.EPI-08-0510; Arbyn M, 2006, VACCINE, V24, P78, DOI 10.1016/j.vaccine.2006.05.117; Arbyn M, 2009, EUR J CANCER, V45, P2671, DOI 10.1016/j.ejca.2009.07.016; Arbyn M, 2009, EUR J CANCER, V45, P2640, DOI 10.1016/j.ejca.2009.07.018; Bardin A, 2008, EUR J CANCER, V44, P557, DOI 10.1016/j.ejca.2007.12.001; Castle PE, 2002, CANCER EPIDEM BIOMAR, V11, P1394; Clavel C, 2001, BRIT J CANCER, V84, P1616, DOI 10.1054/bjoc.2001.1845; Clifford GM, 2005, CANCER EPIDEM BIOMAR, V14, P1157, DOI 10.1158/1055-9965.EPI-04-0812; Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9; Coupe VMH, 2008, BRIT J CANCER, V98, P646, DOI 10.1038/sj.bjc.6604162; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; Cuschieri KS, 2004, J CLIN PATHOL, V57, P68, DOI 10.1136/jcp.57.1.68; Cuzick J, 2003, LANCET, V362, P1871, DOI 10.1016/S0140-6736(03)14955-0; Cuzick J, 2006, INT J CANCER, V119, P1095, DOI 10.1002/ijc.21955; De Sanjose S, 2003, SEX TRANSM DIS, V30, P788, DOI 10.1097/01.OLQ.0000080177.82204.E0; de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5; Franceschi S, 2006, INT J CANCER, V119, P2677, DOI 10.1002/ijc.22241; Hibbitts S, 2008, BRIT J CANCER, V99, P1929, DOI 10.1038/sj.bjc.6604748; IARC, 2005, IARC HDB CANC PREV C, V10; Keegan H, 2007, BRIT J BIOMED SCI, V64, P18, DOI 10.1080/09674845.2007.11732750; Kjaer SK, 2008, INT J CANCER, V123, P1864, DOI 10.1002/ijc.23712; Klug SJ, 2007, J MED VIROL, V79, P616, DOI 10.1002/jmv.20863; Leinonen M, 2008, INT J CANCER, V123, P1344, DOI 10.1002/ijc.23670; Levy-Bruhl D, 2009, EUR J CANCER, V45, P2709, DOI 10.1016/j.ejca.2009.07.023; Maucort-Boulch D, 2008, CANCER EPIDEM BIOMAR, V17, P717, DOI 10.1158/1055-9965.EPI-07-2691; Naucler P, 2007, NEW ENGL J MED, V357, P1589, DOI 10.1056/NEJMoa073204; Nicula FA, 2009, EUR J CANCER, V45, P2679, DOI 10.1016/j.ejca.2009.07.025; Nielsen A, 2008, SEX TRANSM DIS, V35, P276, DOI 10.1097/OLQ.0b013e31815ac5c7; Petignat P, 2005, CANCER CYTOPATHOL, V105, P126, DOI 10.1002/cncr.21060; Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9; Peto J, 2004, BRIT J CANCER, V91, P942, DOI 10.1038/sj.bjc.6602049; RONCO G, 2009, J CANC, V45, P2659; Ronco G, 2008, J NATL CANCER I, V100, P492, DOI 10.1093/jnci/djn065; Sargent A, 2008, BRIT J CANCER, V98, P1704, DOI 10.1038/sj.bjc.6604324; Silins I, 2005, INT J CANCER, V116, P110, DOI 10.1002/ijc.20970; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527	38	136	140	1	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	OCT	2009	45	15			SI		2632	2639		10.1016/j.ejca.2009.07.019			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	536CA	WOS:000273018600002	19709878				2022-02-25	
J	Herceg, Z				Herceg, Zdenko			Epigenetic changes in cancer as a signature of exposure to environmental and dietary factors	TOXICOLOGY LETTERS			English	Meeting Abstract	46th Congress of the European-Societies-of-Toxicology	SEP 13-16, 2009	Dreden, GERMANY	European Soc Toxicol					[Herceg, Zdenko] IARC, Lyon 08, France									0	0	0	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274			TOXICOL LETT	Toxicol. Lett.	SEP 13	2009	189						S17	S17		10.1016/j.toxlet.2009.06.006			1	Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Toxicology	493ZM	WOS:000269778800046					2022-02-25	
J	Munoz, N				Munoz, Nubia			From Causality to Prevention - The Example of Cervical Cancer: My Personal Contribution to This Fascinating History	PUBLIC HEALTH GENOMICS			English	Article						Cervical cancer, causation; Cervical cancer, prevention; Cytomegalovirus; Herpes simplex type 2; Human papillomavirus	HUMAN-PAPILLOMAVIRUS; LATIN-AMERICA; PARTICLE VACCINE; HPV; DNA; INFECTION; EFFICACY; COLOMBIA	The history of the generation of an hypothesis linking human papillomavirus to cervical cancer, as well as a summary of the various molecular epidemiological studies undertaken to confirm such hypothesis are described. Copyright (C) 2009 S. Karger AG, Basel	[Munoz, Nubia] IARC Emeritus Scientist, Lyon, France		Munoz, N (corresponding author), 24 Quai Fulchiron, FR-69005 Lyon, France.	nubia.munoz@free.fr					[Anonymous], 1992, IARC SCI PUBLICATION, V119; Castellsague X, 2002, NEW ENGL J MED, V346, P1105, DOI 10.1056/NEJMoa011688; Cuzick J, 2006, INT J CANCER, V119, P1095, DOI 10.1002/ijc.21955; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Franco EL, 2008, VACCINE, V26, pL88, DOI 10.1016/j.vaccine.2008.05.026; GISSMANN L, 1976, P NATL ACAD SCI USA, V73, P1310, DOI 10.1073/pnas.73.4.1310; Goldie SJ, 2008, VACCINE, V26, pL59, DOI 10.1016/j.vaccine.2008.05.063; Mun ~oz N, 1989, IARC SCI PUBLICATION, V94; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; Munoz N, 1996, JNCI-J NATL CANCER I, V88, P1068, DOI 10.1093/jnci/88.15.1068; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; MUNOZ N, 1988, BRIT J CANCER, V57, P1, DOI 10.1038/bjc.1988.1; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; MUNOZ N, 1976, CANCER RES, V36, P792; Munoz N, 2008, VACCINE, V26, pL96, DOI 10.1016/j.vaccine.2008.05.062; Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Qiao YL, 2008, LANCET ONCOL, V9, P929, DOI 10.1016/S1470-2045(08)70210-9; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; ZURHAUSEN H, 1976, CANCER RES, V36, P794	24	10	10	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1662-4246	1662-8063		PUBLIC HEALTH GENOM	Pub. Health Genomics		2009	12	5-6					368	371		10.1159/000214927			4	Genetics & Heredity; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Genetics & Heredity; Public, Environmental & Occupational Health	482NA	WOS:000268894500012	19684449				2022-02-25	
J	Arandelovic, S; Cros, MP; Hainaut, P				Arandelovic, S.; Cros, M. P.; Hainaut, P.			Role of PI3K/Akt/m-TOR pathway in cell response to Cisplatin treatment in Non-Small-Cell-Lung-Cancer - correlation to p53 status	EJC SUPPLEMENTS			English	Meeting Abstract	20th Meeting of the European-Association-for-Cancer-Research	JUL 05-08, 2008	Lyon, FRANCE	European Assoc Canc Res					[Arandelovic, S.; Cros, M. P.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, F-69372 Lyon, France				Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				0	0	0	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	JUL	2008	6	9					104	104		10.1016/S1359-6349(08)71574-X			1	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	330DF	WOS:000257919000396					2022-02-25	
J	Cogliano, V				Cogliano, V.			The IARC Monographs: a resource for precaution and prevention? The new Preamble does not fit - Author's reply	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Letter									Int Agcy Res Canc, IARC Monographs Programme, Lyon, France		Cogliano, V (corresponding author), Int Agcy Res Canc, IARC Monographs Programme, Lyon, France.	cogliano@iarc.fr					*IARC, 2008, PROC AM PREAMBL IARC; *IARC, 2008, 06001 IARC; *IARC, 2008, 03001 IARC; *IARC, 2008, 05001 IARC; *IARC, 2006, IARC MON EV CARC RIS, V88, P39	5	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JUL	2008	65	7					500	500					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	315OU	WOS:000256890100011					2022-02-25	
J	Cardis, E; Kesminiene, A				Cardis, E; Kesminiene, A			Re: Risk of thyroid cancer after exposure to I-131 in childhood - Response	JOURNAL OF THE NATIONAL CANCER INSTITUTE			English	Letter									Int Agcy Res Canc, F-69372 Lyon, France		Cardis, E (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	cardis@iarc.fr	Cardis, Elisabeth/C-3904-2017	Cardis, Elisabeth/0000-0003-0999-6839				0	0	0	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0027-8874			J NATL CANCER I	J. Natl. Cancer Inst.	APR 19	2006	98	8					561	561		10.1093/jnci/djj136			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	043UO	WOS:000237627900015		Bronze			2022-02-25	
J	Sawa, T; Ohshima, H				Sawa, T; Ohshima, H			Nitrative DNA damage in inflammation and its possible role in carcinogenesis	NITRIC OXIDE-BIOLOGY AND CHEMISTRY			English	Review						chronic inflammation; carcinogenesis; reactive nitrogen species; 8-nitroguanine; DNA damage; inducible nitric oxide synthase; peroxynitrite; nitroxyl; nitrative stress; 3-nitrotyrosine	NITRIC-OXIDE SYNTHASE; P53 TUMOR-SUPPRESSOR; PEROXYNITRITE IN-VITRO; STRAND BREAKAGE; REACTIVE OXYGEN; OPISTHORCHIS-VIVERRINI; SYNERGISTIC INDUCTION; NITROXYL ANION; BOWEL-DISEASE; WILD-TYPE	Chronic inflammation has long been recognized as a risk factor for human cancer at various sites. Examples include Helicobacter pylori-induced gastritis for gastric cancer, inflammatory bowel disease (ulcerative colitis and Crohn's disease) for colorectal cancer and chronic viral hepatitis for liver cancer. Here we review the role in carcinogenesis of nitrative damage to nucleic acids, DNA and RNA, which occurs during inflammation through the generation of reactive nitrogen species, such as peroxynitrite.. nitroxyl, and nitrogen dioxide. Enhanced formation of 8-nitroguanine, representative of nitrative damage to nucleobases, has been detected in various inflammatory conditions. The biochemical nature of DNA damage mediated by reactive nitrogen species is discussed in relation to its possible involvement in mutations, genetic instability, and cell death. Better understanding of the mechanisms and role of such nitrative damage in chronic inflammation-associated human cancer is a necessary basis to develop new strategies for cancer prevention by modulating the process of inflammation, (c) 2005 Elsevier Inc. All rights reserved.	Int Agcy Res Canc, F-69008 Lyon, France		Sawa, T (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	sawa@iarc.fr	Ohshima, Hiroshi/E-8044-2010				Ahn B, 2001, CANCER RES, V61, P8357; Akaike T, 2003, P NATL ACAD SCI USA, V100, P685, DOI 10.1073/pnas.0235623100; Akaike T, 2000, FASEB J, V14, P1447, DOI 10.1096/fj.14.10.1447; Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Alam MS, 2002, INFECT IMMUN, V70, P3130, DOI 10.1128/IAI.70.6.3130-3142.2002; Ambs S, 1999, J NATL CANCER I, V91, P86, DOI 10.1093/jnci/91.1.86; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bishop Alexander J. R., 2002, Journal of Biomedicine & Biotechnology, V2, P75, DOI 10.1155/S1110724302204052; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Calmels S, 1997, CANCER RES, V57, P3365; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Chazotte-Aubert L, 1999, J BIOL CHEM, V274, P20909, DOI 10.1074/jbc.274.30.20909; Chien YH, 2004, FREE RADICAL BIO MED, V36, P1011, DOI 10.1016/j.freeradbiomed.2004.01.011; Cobbs CS, 2003, CANCER RES, V63, P8670; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crowell JA, 2003, MOL CANCER THER, V2, P815; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Ding XH, 2005, CANCER SCI, V96, P157, DOI 10.1111/j.1349-7006.2005.00024.x; Epe B, 1996, NUCLEIC ACIDS RES, V24, P4105, DOI 10.1093/nar/24.21.4105; FELLEYBOSCO E, 1995, CARCINOGENESIS, V16, P2069, DOI 10.1093/carcin/16.9.2069; Fukunaga-Takenaka R, 2003, BIOCHEM BIOPH RES CO, V308, P966, DOI 10.1016/S0006-291X(03)01516-X; Fukuto JM, 2005, ANNU REV PHARMACOL, V45, P335, DOI 10.1146/annurev.pharmtox.45.120403.095959; GRANGER DL, 1988, J CLIN INVEST, V81, P1129, DOI 10.1172/JCI113427; Graziewicz M, 1996, CARCINOGENESIS, V17, P2501, DOI 10.1093/carcin/17.11.2501; Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252; Hofseth LJ, 2003, FREE RADICAL BIO MED, V34, P955, DOI 10.1016/S0891-5849(02)01363-1; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Iacopini F, 2003, HELICOBACTER, V8, P503, DOI 10.1046/j.1523-5378.2003.00172.x; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jaiswal M, 2001, CANCER RES, V61, P6388; JAMES SL, 1995, MICROBIOL REV, V59, P533, DOI 10.1128/MMBR.59.4.533-547.1995; Joffe A, 2003, CHEM RES TOXICOL, V16, P966, DOI 10.1021/tx025578w; Juedes MJ, 1996, MUTAT RES-FUND MOL M, V349, P51, DOI 10.1016/0027-5107(95)00152-2; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kimura H, 1998, GUT, V42, P180, DOI 10.1136/gut.42.2.180; Kisley LR, 2002, CANCER RES, V62, P6850; Kiziltepe T, 2005, CHEM BIOL, V12, P357, DOI 10.1016/j.chembiol.2004.12.011; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kruidenier L, 2003, J PATHOL, V201, P28, DOI 10.1002/path.1409; LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443; Li CQ, 2002, P NATL ACAD SCI USA, V99, P10364, DOI 10.1073/pnas.162356399; Li CQ, 2002, CHEM RES TOXICOL, V15, P527, DOI 10.1021/tx010171x; Lirk Philipp, 2002, Current Drug Targets - Inflammation and Allergy, V1, P89, DOI 10.2174/1568010023344913; Liu LP, 2002, CANCER RES, V62, P3037; Ma N, 2004, BIOCHEM BIOPH RES CO, V319, P506, DOI 10.1016/j.bbrc.2004.04.193; Mabley JG, 2004, MUTAT RES-FUND MOL M, V548, P107, DOI 10.1016/j.mrfmmm.2004.01.006; Majano PL, 1998, J CLIN INVEST, V101, P1343, DOI 10.1172/JCI774; Mannick EE, 1996, CANCER RES, V56, P3238; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Masuda M, 2002, CHEM-BIOL INTERACT, V139, P187, DOI 10.1016/S0009-2797(01)00299-X; Nam KT, 2004, GUT, V53, P1250, DOI 10.1136/gut.2003.030684; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Neeley WL, 2004, J BIOL CHEM, V279, P43568, DOI 10.1074/jbc.M407117200; Niles JC, 2004, CHEM RES TOXICOL, V17, P1510, DOI 10.1021/tx0400048; Niles JC, 2001, J AM CHEM SOC, V123, P12147, DOI 10.1021/ja004296k; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; OHSHIMA H, 1994, CARCINOGENESIS, V15, P271, DOI 10.1093/carcin/15.2.271; Ohshima H, 1999, NATO ADV SCI I A-LIF, V302, P329; Ohshima H, 1999, METHOD ENZYMOL, V301, P40; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Ohshima H, 1998, FREE RADICAL BIO MED, V25, P1057, DOI 10.1016/S0891-5849(98)00141-5; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pignatelli B, 2001, AM J GASTROENTEROL, V96, P1758, DOI 10.1111/j.1572-0241.2001.03869.x; Pinlaor S, 2004, CARCINOGENESIS, V25, P1535, DOI 10.1093/carcin/bgh157; Pinlaor S, 2003, BIOCHEM BIOPH RES CO, V309, P567, DOI 10.1016/j.bbrc.2003.08.039; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Sawa T, 2003, BIOCHEM BIOPH RES CO, V311, P300, DOI 10.1016/j.bbrc.2003.10.003; SAWA T, 2005, P AM ASSOC CANC RES, V46, P4787; Scott DJ, 2001, GASTROENTEROLOGY, V121, P889, DOI 10.1053/gast.2001.27994; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Souici AC, 2000, CARCINOGENESIS, V21, P281, DOI 10.1093/carcin/21.2.281; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Suzuki N, 2005, BIOCHEMISTRY-US, V44, P9238, DOI 10.1021/bi050276p; Suzuki T, 2004, FREE RADICAL BIO MED, V37, P671, DOI 10.1016/j.freeradbiomed.2004.05.030; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Tamir S, 1996, CHEM RES TOXICOL, V9, P821, DOI 10.1021/tx9600311; TANNENBAUM SR, 1994, ACS SYM SER, V553, P120; Tatemichi M, 2005, CANCER LETT, V217, P197, DOI 10.1016/j.canlet.2004.09.002; Tatemichi M, 2004, INT J CANCER, V111, P819, DOI 10.1002/ijc.20350; Uppu RM, 1996, FREE RADICAL BIO MED, V21, P407, DOI 10.1016/0891-5849(96)00220-1; Wilson KT, 1998, CANCER RES, V58, P2929; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; WINK DA, 1994, CARCINOGENESIS, V15, P2125, DOI 10.1093/carcin/15.10.2125; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; YERMILOV V, 1995, CARCINOGENESIS, V16, P2045, DOI 10.1093/carcin/16.9.2045; Yermilov V, 1996, FEBS LETT, V399, P67, DOI 10.1016/S0014-5793(96)01288-4; Yoshie Y, 1997, ARCH BIOCHEM BIOPHYS, V342, P13, DOI 10.1006/abbi.1997.0100; Yoshie Y, 1997, CARCINOGENESIS, V18, P1359, DOI 10.1093/carcin/18.7.1359; Yoshie Y, 1998, FREE RADICAL BIO MED, V24, P341, DOI 10.1016/S0891-5849(97)00269-4; Yoshie Y, 1997, CHEM RES TOXICOL, V10, P1015, DOI 10.1021/tx970025k; Yoshitake J, 2004, J VIROL, V78, P8709, DOI 10.1128/JVI.78.16.8709-8719.2004	103	146	152	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1089-8603			NITRIC OXIDE-BIOL CH	Nitric Oxide-Biol. Chem.	MAR	2006	14	2			SI		91	100		10.1016/j.niox.2005.06.005			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	014HE	WOS:000235469500002	16099698				2022-02-25	
J	Murr, R; Loizou, JI; Yang, YG; Cuenin, C; Li, H; Wang, ZQ; Herceg, Z				Murr, R; Loizou, JI; Yang, YG; Cuenin, C; Li, H; Wang, ZQ; Herceg, Z			Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks	NATURE CELL BIOLOGY			English	Article							HAT COFACTOR TRRAP; BINDING PROTEIN; C-MYC; HOMOLOGOUS RECOMBINATION; NUCLEOSOME ACETYLATION; CELLULAR-RESPONSE; DAMAGE RESPONSE; COMPLEX; 53BP1; ROLES	DNA is packaged into chromatin, a highly compacted DNA protein complex; therefore, all cellular processes that use the DNA as a template, including DNA repair, require a high degree of coordination between the DNA- repair machinery and chromatin modification/ remodelling, which regulates the accessibility of DNA in chromatin. Recent studies have implicated histone acetyltransferase ( HAT) complexes and chromatin acetylation in DNA repair; however, the precise underlying mechanism remains poorly understood(1,2). Here, we show that the HAT cofactor Trrap and Tip60 HAT bind to the chromatin surrounding sites of DNA double- strand breaks ( DSBs) in vivo. Trrap depletion impairs both DNA- damage-induced histone H4 hyperacetylation and accumulation of repair molecules at sites of DSBs, resulting in defective homologous recombination ( HR) repair, albeit with the presence of a functional ATM- dependent DNA- damage signalling cascade. Importantly, the impaired loading of repair proteins and the defect in DNA repair in Trrap- deficient cells can be counteracted by chromatin relaxation, indicating that the DNA- repair defect that was observed in the absence of Trrap is due to impeded chromatin accessibility at sites of DNA breaks. Thus, these data reveal that cells may use the same basic mechanism involving HAT complexes to regulate distinct cellular processes, such as transcription and DNA repair.	Int Agcy Res Canc, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr		Loizou, Joanna/0000-0003-1853-0424; Murr, Rabih/0000-0002-3346-6590			Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Masson JY, 2001, TRENDS BIOCHEM SCI, V26, P131, DOI 10.1016/S0968-0004(00)01742-4; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	35	448	461	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2006	8	1					91	U36		10.1038/ncb1343			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	002ZN	WOS:000234651500017	16341205				2022-02-25	
J	Lambert, R				Lambert, R			Can endoscopic autofluorescence imaging improve the detection of neoplasia in patients with Barrett's esophagus?	NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY			English	Editorial Material						Barrett's esophagus; early neoplasia; endoscopic video fluorescence; high-grade dysplasia; screening			Int Agcy Res Canc, WHO, Screening Grp, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, WHO, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	lambert@iarc.fr					Canto MIF, 2001, ENDOSCOPY, V33, P391, DOI 10.1055/s-2001-14427; Chiyo M, 2005, LUNG CANCER, V48, P307, DOI 10.1016/j.lungcan.2004.11.023; Endlicher E, 2001, GUT, V48, P314, DOI 10.1136/gut.48.3.314; Endo T, 2002, GASTROINTEST ENDOSC, V55, P641, DOI 10.1067/mge.2002.123420; Hamamoto Y, 2004, J GASTROENTEROL, V39, P14, DOI 10.1007/s00535-003-1239-z; Kara MA, 2005, GASTROINTEST ENDOSC, V61, P679, DOI 10.1016/S0016-5107(04)02577-5	6	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA	1743-4378			NAT CLIN PRACT GASTR	Nat. Clin. Pract. Gastroenterol. Hepatol.	DEC	2005	2	12					570	571		10.1038/ncpgasthep0344			2	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	989CT	WOS:000233651200008	16327835				2022-02-25	
J	Suzuki, T; Nakano, T; Masuda, M; Ohshima, H				Suzuki, T; Nakano, T; Masuda, M; Ohshima, H			Epigallocatechin gallate markedly enhances formation of 8-oxo-7,8-dihydro-2 '-deoxyguanosine in the reaction of 2-deoxyguanosine with hypochlorous acid	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						8-oxo-7,8-dihydro-2 '-deoxyguanosine; epigallocatechin gallate; 2 '-deoxyguanosine; hypochlorous acid; spiroiminodihydantoin; free radicals	ONE-ELECTRON OXIDATION; SPIROIMINODIHYDANTOIN NUCLEOSIDE; 8-OXOGUANINE OXIDATION; SODIUM-HYPOCHLORITE; HYDANTOIN PRODUCTS; TEA CATECHINS; DNA-DAMAGE; GREEN TEA; REPAIR; CHLORINATION	A tea polyphenol, (-)-epigallocatechin gallate (EGCG), which can scavenge a variety of reactive oxygen species, enhances the yield of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG) up to 20-fold in the reaction of 2'-deoxyguanosine with hypochlorous acid (HOCl), compared with the reaction without EGCG. Certain concentrations of EGCG inhibited HOCl-mediated oxidation of T-deoxyguanosine to 8-oxo-dG to a limited extent, but efficiently inhibited further oxidation of 8-oxo-dG to spiroiminodihydantoin nucleoside, resulting in the accumulation of 8-oxo-dG in the reaction mixture. Conversely, EGCG inhibited dose-dependently an increase in 8-oxo-dG levels in calf thymus DNA incubated with HOCI. However, addition of HOCl to the DNA preoxidized with an oxidant-generating system (CUCl2, ascorbate, H2O2), led to the extensive loss of 8-oxo-dG due to its further oxidation. EGCG effectively inhibited this HOCl-mediated loss of 8-oxo-dG in the oxidized DNA, resulting in an apparent increase in 8-oxo-dG levels in the oxidized DNA, compared with the levels found without EGCG. The conversion of 8-oxo-dG into other oxidized lesions will inevitably affect recognition by DNA repair enzymes as well as the rates of mutations and DNA synthesis. Thus, our results suggest that as a biomarker of oxidative DNA damage, not only 8-oxo-dG but also the products of its further oxidation should be analyzed. (C) 2004 Elsevier Inc. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohshima@iarc.fr	Ohshima, Hiroshi/E-8044-2010				Anderson RF, 2001, CARCINOGENESIS, V22, P1189, DOI 10.1093/carcin/22.8.1189; BERNOFSKY C, 1990, FREE RADICAL RES COM, V9, P303, DOI 10.3109/10715769009145689; BUCHTA RM, 1995, ADOLESCENT PEDIAT G, V8, P17, DOI 10.1016/S0932-8610(12)80155-1; Burrows CJ, 2002, ENVIRON HEALTH PERSP, V110, P713, DOI 10.1289/ehp.02110s5713; Duarte V, 2001, CHEM RES TOXICOL, V14, P46, DOI 10.1021/tx0001629; Duarte V, 1999, NUCLEIC ACIDS RES, V27, P496, DOI 10.1093/nar/27.2.496; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Fujiki H, 2002, CANCER LETT, V188, P9, DOI 10.1016/S0304-3835(02)00379-8; Guo Q, 1999, BBA-GEN SUBJECTS, V1427, P13, DOI 10.1016/S0304-4165(98)00168-8; HAYATSU H, 1971, NATURE, V233, P495, DOI 10.1038/233495a0; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazra TK, 2001, NUCLEIC ACIDS RES, V29, P1967, DOI 10.1093/nar/29.9.1967; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Henderson PT, 2002, BIOCHEMISTRY-US, V41, P914, DOI 10.1021/bi0156355; Hickerson RP, 1999, J AM CHEM SOC, V121, P9423, DOI 10.1021/ja991929q; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; *IARC WORK GROUP, 1991, CHLOR DRINK WAT CHLO, P159; Kasai H, 2002, FREE RADICAL BIO MED, V33, P450, DOI 10.1016/S0891-5849(02)00818-3; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Kornyushyna O, 2002, BIOCHEMISTRY-US, V41, P15304, DOI 10.1021/bi0264925; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Masuda M, 2002, CHEM-BIOL INTERACT, V139, P187, DOI 10.1016/S0009-2797(01)00299-X; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; Niles JC, 1999, P NATL ACAD SCI USA, V96, P11729, DOI 10.1073/pnas.96.21.11729; Nishimura S, 2002, FREE RADICAL BIO MED, V32, P813, DOI 10.1016/S0891-5849(02)00778-5; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; Ravanat JL, 2003, J AM CHEM SOC, V125, P2030, DOI 10.1021/ja028608q; SAKAGAMI H, 1995, ANTICANCER RES, V15, P917; Schmittinger P., 2000, CHLORINE PRINCIPLES, P159; SHEU CM, 1995, J ORG CHEM, V60, P4498, DOI 10.1021/jo00119a029; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; Suzuki T, 2003, CHEM RES TOXICOL, V16, P382, DOI 10.1021/tx025638y; Suzuki T, 2002, NUCLEIC ACIDS RES, V30, P2555, DOI 10.1093/nar/30.11.2555; Suzuki T, 2002, FEBS LETT, V516, P67, DOI 10.1016/S0014-5793(02)02503-6; Suzuki T, 2001, CHEM RES TOXICOL, V14, P1163, DOI 10.1021/tx010024z; Uppu RM, 1996, FREE RADICAL BIO MED, V21, P407, DOI 10.1016/0891-5849(96)00220-1; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 2002, BIOCHEM BIOPH RES CO, V296, P883, DOI 10.1016/S0006-291X(02)02018-1; Whiteman M, 1999, BIOMARKERS, V4, P303, DOI 10.1080/135475099230831; WLODKOWSKI TJ, 1975, MUTAT RES, V31, P39, DOI 10.1016/0165-1161(75)90061-8; YANAGAWA H, 1992, J BIOL CHEM, V267, P13320	43	12	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAY 1	2004	36	9					1087	1093		10.1016/j.freeradbiomed.2004.02.004			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	817IV	WOS:000221172100003	15082062				2022-02-25	
J	Vainio, H				Vainio, H			Acrylamide in heat-processed foods - a carcinogen looking for human cancer?	EUROPEAN JOURNAL OF EPIDEMIOLOGY			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon, France		Vainio, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.						Abramsson-Zetterberg L, 2003, MUTAT RES-GEN TOX EN, V535, P215, DOI 10.1016/S1383-5718(02)00322-4; DYBING E, IN PRESS TOXICOL SCI; Granath F, 2003, JNCI-J NATL CANCER I, V95, P842, DOI 10.1093/jnci/95.12.842; Granath F, 2001, OCCUP ENVIRON MED, V58, P608, DOI 10.1136/oem.58.9.608; IARC, 1994, IARC MON EV CARC RIS, V60; Marsh GM, 1999, OCCUP ENVIRON MED, V56, P181, DOI 10.1136/oem.56.3.181; Mucci LA, 2003, BRIT J CANCER, V88, P84, DOI 10.1038/sj.bjc.6600726; Pelucchi C, 2003, INT J CANCER, V105, P558, DOI 10.1002/ijc.11118; Schulz MR, 2001, OCCUP ENVIRON MED, V58, P609, DOI 10.1136/oem.58.9.609; Tareke E, 2000, CHEM RES TOXICOL, V13, P517, DOI 10.1021/tx9901938; United State Environemental Protection Agency (US EPA), 1996, EPA600P92003C US EPA	11	11	11	0	5	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0393-2990			EUR J EPIDEMIOL	Eur. J. Epidemiol.	DEC	2003	18	12					1105	1106					2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	750BT	WOS:000186972000001	14758864				2022-02-25	
J	Lambert, R				Lambert, R			Early diagnosis and prevention of colorectal cancer	ENDOSCOPY			English	Article; Proceedings Paper	3rd European Endoscopy Forum	JUN 08-10, 2001	FARO, PORTUGAL					The experts participating at the Faro meeting worked on a consensus review of the current trends on early detection and prevention of colorectal cancer. This was published in Endoscopy: Early diagnosis and prevention of sporadic colorectal cancer.	Int Agcy Res Canc, F-69372 Lyon 08, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.							0	1	1	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X			ENDOSCOPY	Endoscopy	MAR	2002	34	3					244	246					3	Gastroenterology & Hepatology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	528MY	WOS:000174248600014	11905419				2022-02-25	
J	Riboli, E				Riboli, E			The European Prospective Investigation into Cancer and Nutrition (EPIC): Plans and progress	JOURNAL OF NUTRITION			English	Article; Proceedings Paper	10th Annual Research Conference on The Role of Nutrition in Preventing and Treating Breast and Prostate Cancer	AUG 31-SEP 01, 2000	WASHINGTON, D.C.	Amer Inst Canc Res			DIETARY-INTAKE MEASUREMENTS; SEX-HORMONE LEVELS; BREAST-CANCER; PROSPECTIVE COHORT; PROSTATE-CANCER; RISK; INSULIN; CALIBRATION		Int Agcy Res Canc, Unit Nutr & Canc, F-69372 Lyon, France		Riboli, E (corresponding author), Int Agcy Res Canc, Unit Nutr & Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.			Riboli, Elio/0000-0001-6795-6080			ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; COGHLAN A, 1991, NEW SCI, V1797, P29; *COMA WORK GROUP D, 1998, 48 COMA WORK GROUP D; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; GIOVANNUCCI E, 1995, CANCER CAUSE CONTROL, V6, P164, DOI 10.1007/BF00052777; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; KAAKS R, 1994, AM J CLIN NUTR, V59, p245S, DOI 10.1093/ajcn/59.1.245S; Kaaks R, 1996, CANCER CAUSE CONTROL, V7, P605, DOI 10.1007/BF00051703; KAAKS R, 1995, AM J EPIDEMIOL, V142, P557, DOI 10.1093/oxfordjournals.aje.a117674; Kaaks R, 1997, INT J EPIDEMIOL, V26, pS15, DOI 10.1093/ije/26.suppl_1.S15; KAAKS R, 1995, AM J EPIDEMIOL, V142, P548, DOI 10.1093/oxfordjournals.aje.a117673; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; Margetts BM, 1997, INT J EPIDEMIOL, V26, pS1, DOI 10.1093/ije/26.suppl_1.S1; National Research Council, 1982, DIET NUTR CANC; Riboli E, 1996, ALIMENTATION CANC EV; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; Slimani N, 1999, COMPUT METH PROG BIO, V58, P251, DOI 10.1016/S0169-2607(98)00088-1; TANNENBAUM A., 1942, Cancer Research, V2, P468; Tannenbaum A, 1940, ARCH PATHOL, V30, P509; TANNEBAUM A., 1940, American Journal of Cancer, V38, P335; TANNENBAUM ALBERT, 1942, CANCER RES, V2, P460; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Voss S, 1998, Z ERNAHRUNGSWISS, V37, P227, DOI 10.1007/s003940050021; *WCRF AICR, 1997, FOOD NUTR PREV CANC	28	48	49	0	0	AMER INST NUTRITION	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3166			J NUTR	J. Nutr.	JAN	2001	131	1					170S	175S		10.1093/jn/131.1.170S			6	Nutrition & Dietetics	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	394AD	WOS:000166501100030	11208958	Bronze			2022-02-25	
J	Znaor, A; Laversanne, M; Bray, F				Znaor, Ariana; Laversanne, Mathieu; Bray, Freddie			Less overdiagnosis of kidney cancer? an age-period-cohort analysis of incidence trends in 16 populations worldwide.	INTERNATIONAL JOURNAL OF CANCER			English	Article						kidney cancer; incidence trends; age-period-cohort analysis	RENAL-CELL CARCINOMA; UNITED-STATES; INTERNATIONAL SOCIETY; TEMPORAL VARIATION; RISK-FACTORS; EPIDEMIOLOGY; MORTALITY; RATES; CLASSIFICATION; METAANALYSIS	The increasing rates of kidney cancer incidence, reported in many populations globally, have been attributed both to increasing exposures to environmental risk factors, as well as increasing levels of incidental diagnosis due to widespread use of imaging. To better understand these trends, we examine long-term cancer registry data worldwide, focusing on the roles of birth cohort and calendar period, proxies for changes in risk factor prevalence and detection practice respectively. We used an augmented version of the Cancer Incidence in Five Continents series to analyze kidney cancer incidence rates 1978-2007 in 16 geographically representative populations worldwide by sex for ages 30-74, using age-period-cohort (APC) analysis. The full APC model provided the best fit to the data in most studied populations. While kidney cancer incidence rates have been increasing in successive generations born from the early twentieth century in most countries, equivalent period-specific rises were observed from the late-1970s, although these have subsequently stabilized in certain European countries (the Czech Republic, Lithuania, Finland, Spain) as well as Japan from the mid-1990s, and from the mid-2000s, in Colombia, Costa Rica and Australia. Our results indicate that the effects of both birth cohort and calendar period contribute to the international kidney cancer incidence trends. While cohort-specific increases may partly reflect the rising trends in obesity prevalence and the need for more effective primary prevention policies, the attenuations in period-specific increases (observed in 8 of the 16 populations) highlight a possible change in imaging practices that could lead to mitigation of overdiagnosis and overtreatment.	[Znaor, Ariana; Laversanne, Mathieu; Bray, Freddie] Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Znaor, A (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	znaora@iarc.fr	Znaor, A/H-6718-2019	Bray, Freddie/0000-0002-3248-7787; Laversanne, Mathieu/0000-0002-1568-7218			[Anonymous], 2012, TOB SMOK REV HUM CAR; Arnold M, 2016, CANCER EPIDEMIOL, V41, P8, DOI 10.1016/j.canep.2016.01.003; Bao PP, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2313-2; Brownlee S, 2017, LANCET; Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; Doll R, 1966, CANC INCIDENCE 5 CON; Ebele JN, 2004, PATHOLOGY GENETICS T; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Esserman LJ, 2014, LANCET ONCOL, V15, pE234, DOI 10.1016/S1470-2045(13)70598-9; FERLAY J, 2010, 9 IARC, V1; Fritz A, 2000, INT CLASSIFICATION D, V3rd; Gandaglia G, 2014, CUAJ-CAN UROL ASSOC, V8, P247, DOI 10.5489/cuaj.1760; GLOBOCAN 2012, 2014, CNAC INC MORT WORLD; Hollingsworth JM, 2006, JNCI-J NATL CANCER I, V98, P1331, DOI 10.1093/jnci/djj362; Hunt JD, 2005, INT J CANCER, V114, P101, DOI 10.1002/ijc.20618; Marcos-Gragera R, 2015, EUR J CANC; Mindrup SR, 2005, BJU INT, V95, P31, DOI 10.1111/j.1464-410X.2005.05243.x; Moch H., 2016, WHO CLASSIFICATION T; Morgan DJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4534; Nguyen MM, 2006, J UROLOGY, V176, P2397, DOI 10.1016/j.juro.2006.07.144; Ondrusova M, 2011, NEOPLASMA, V58, P165, DOI 10.4149/neo_2011_02_165; Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9; R Core Team, 2017, R LANG ENV STAT COMP, DOI 10.1007/978-3-540-74686-7; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Scelo G, 2016, ANN ONCOL, V27, P1382, DOI 10.1093/annonc/mdw186; Scelo G, 2007, NAT CLIN PRACT UROL, V4, P205, DOI 10.1038/ncpuro0760; Smith-Bindman R, 2012, JAMA-J AM MED ASSOC, V307, P2400, DOI 10.1001/jama.2012.5960; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Sun M, 2012, ANN SURG ONCOL, V19, P2380, DOI 10.1245/s10434-012-2247-0; Tyson MD, 2013, UROLOGY, V82, P43, DOI 10.1016/j.urology.2013.02.065; Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024; Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099; Williamson S. R., 2016, UROL ONCOL, V34, P292; Znaor A, 2015, EUR UROL, V67, P519, DOI 10.1016/j.eururo.2014.10.002	38	13	14	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	SEP 1	2017	141	5					925	932		10.1002/ijc.30799			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	EZ6QJ	WOS:000404842200008	28543047	Bronze			2022-02-25	
J	Abedi-Ardekani, B; Avogbe, PH; Foll, M; Olivier, M; Carreira, C; Scelo, G; Mckay, JD				Abedi-Ardekani, Behnoush; Avogbe, Patrice H.; Foll, Matthieu; Olivier, Magali; Carreira, Christine; Scelo, Ghislaine; McKay, James D.			Detection of Somatic Mutations in Histologically Normal Lung Tissue: Sectioning and Genomic Method	LABORATORY INVESTIGATION			English	Meeting Abstract	106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)	MAR 04-10, 2017	San Antonio, TX	US & Canadian Acad Pathol					[Abedi-Ardekani, Behnoush; Avogbe, Patrice H.; Foll, Matthieu; Olivier, Magali; Carreira, Christine; Scelo, Ghislaine; McKay, James D.] Int Agcy Res Canc, Lyon, France				Abedi-Ardekani, Behnoush/O-7829-2016	Abedi-Ardekani, Behnoush/0000-0002-0980-0587				0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	FEB	2017	97			1		1821	453A	453A					1	Medicine, Research & Experimental; Pathology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Research & Experimental Medicine; Pathology	EK1YT	WOS:000393724402302					2022-02-25	
J	Wild, C; Brennan, P; Plummer, M; Bray, F; Straif, K; Zavadil, J				Wild, Christopher; Brennan, Paul; Plummer, Martyn; Bray, Freddie; Straif, Kurt; Zavadil, Jiri			Cancer risk: Role of chance overstated	SCIENCE			English	Letter									[Wild, Christopher; Brennan, Paul; Plummer, Martyn; Bray, Freddie; Straif, Kurt; Zavadil, Jiri] Int Agcy Res Canc, F-69008 Lyon, France		Wild, C (corresponding author), Int Agcy Res Canc, F-69008 Lyon, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020; Zavadil, Jiri/ABG-1780-2020	Wild, Christopher/0000-0003-0249-8669; Zavadil, Jiri/0000-0003-0640-5562; Bray, Freddie/0000-0002-3248-7787; Plummer, Martyn/0000-0001-5130-6497			ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; Stewart B.W., 2014, WORLD CANC REPORT 20	2	25	26	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	2015	347	6223					728	728		10.1126/science.aaa6799			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA9DT	WOS:000349221300031	25656657				2022-02-25	
J	Zavadil, J				Zavadil, J.			Multi-'Omics Approaches to Environmental Cancer Risk Factors: A Spotlight on Exposure to Aristolochic Acid and Its Biological Consequences	ENVIRONMENTAL AND MOLECULAR MUTAGENESIS			English	Meeting Abstract	45th Annual Meeting of the Environmental-Mutagenesis-and-Genomics-Society (EMGS)	SEP 13-17, 2014	Orlando, FL	Environm Mutagenesis & Genom Soc					[Zavadil, J.] Int Agcy Res Canc, F-69372 Lyon, France				Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562				0	0	0	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0893-6692	1098-2280		ENVIRON MOL MUTAGEN	Environ. Mol. Mutagen.	SEP	2014	55			1		S15	S23	S23					1	Environmental Sciences; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Environmental Sciences & Ecology; Genetics & Heredity; Toxicology	AO2ST	WOS:000341176900025					2022-02-25	
J	Lambert, R				Lambert, Rene			Endoscopic diagnosis of dysplasia in Barrett's esophagus	EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY			English	Article						Barrett's esophagus; esophageal cancer; intestinal metaplasia; narrow band imaging; random biopsy; white light endoscopy	SPECIALIZED INTESTINAL METAPLASIA; CONFOCAL LASER ENDOMICROSCOPY; HIGH-GRADE DYSPLASIA; MULTICENTER; AGREEMENT; NEOPLASIA	Barrett's esophagus, or columnar metaplasia with gastric cardiac cells or intestinal cells, develops in the squamous epithelium of the esophageal mucosa in relation to gastroesophageal reflux. An increased risk of neoplasia justifies surveillance at regular intervals. Conventional guidelines recommend detection of areas with intestinal metaplasia or dysplasia by taking random four-quadrant biopsies at every 1 or 2 cm. Alternatively, image processing with narrow band imaging (NBI), is proposed to improve detection. This international and randomized study in persons with Barrett's esophagus compares conventional endoscopy in white light with random four-quadrant biopsies and NBI imaging with focused biopsies only. Randomization enrolled 123 patients with Barrett's esophagus who successively underwent exploration with the two methods. The study confirmed that NBI had the same efficacy as white light in the detection of intestinal metaplasia, with a higher proportion of dysplasia detected (30 vs 21%) and a lower number of biopsies per patient (3.6 vs 7.6).	Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	lambert@iarc.fr					Curvers WL, 2010, GASTROENTEROLOGY, V139, P1106, DOI 10.1053/j.gastro.2010.06.045; Gorospe EC, 2012, NAT REV GASTRO HEPAT, V9, P250, DOI 10.1038/nrgastro.2012.62; Jayasekera C, 2012, ENDOSCOPY, V44, P1089, DOI 10.1055/s-0032-1325734; Mannath J, 2010, ENDOSCOPY, V42, P351, DOI 10.1055/s-0029-1243949; Norimura D, 2010, DIGEST ENDOSC, V22, P101, DOI 10.1111/j.1443-1661.2010.00940.x; Reid BJ, 2000, AM J GASTROENTEROL, V95, P3089, DOI 10.1111/j.1572-0241.2000.03182.x; Sharma P, 2013, GUT, V62, P15; Sharma P, 2011, GASTROINTEST ENDOSC, V74, P465, DOI 10.1016/j.gie.2011.04.004; Silva FB, 2011, GASTROINTEST ENDOSC, V73, P7, DOI 10.1016/j.gie.2010.09.023; Singh M, 2011, ENDOSCOPY, V43, P745, DOI 10.1055/s-0030-1256631; Singh R, 2011, WORLD J GASTROENTERO, V17, P4271, DOI 10.3748/wjg.v17.i38.4271; Takubo K, 2009, HUM PATHOL, V40, P65, DOI 10.1016/j.humpath.2008.06.008	12	1	1	0	1	EXPERT REVIEWS	LONDON	UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND	1747-4124			EXPERT REV GASTROENT	Expert Rev. Gastroenterol. Hepatol.	MAY	2013	7	4					303	305		10.1586/EGH.13.12			3	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	138YS	WOS:000318548700008	23639088				2022-02-25	
J	Franceschi, S; Wild, CP				Franceschi, Silvia; Wild, Christopher P.			Meeting the global demands of epidemiologic transition - The indispensable role of cancer prevention	MOLECULAR ONCOLOGY			English	Review						Cancer prevention; Cancer burden; Risk factors; Epidemiology	HEPATOCELLULAR-CARCINOMA; THYROID-CANCER; HEPATITIS-B; CERVICAL-CANCER; UNITED-STATES; PROSTATE; RISK; DISEASE; BURDEN; WOMEN	The number of new cancer cases each year is projected to rise worldwide by about 70% by 2030 due to demographic changes alone, with the largest increases in the lower-income countries. Wider adoption of specific aspects of westernized lifestyles would translate to still greater increases in certain cancer types. In many countries the burden of cancer and other non-communicable diseases will add to communicable diseases and malnutrition to impose a "double burden" on the poorest. These trends represent major challenges to health, poverty, sustainable development and equality. Prevention is, however, possible based on implementing existing knowledge about risk factors and the natural history of the disease. Both primary and secondary cancer prevention offer therefore many opportunities to combat the projected increases. Tobacco control, reductions in obesity and physical inactivity, reduced consumption of alcohol, vaccination against hepatitis B and human papilloma viruses, safe sex, avoidance of environmental and occupational carcinogens and excessive sun exposure as well as the early detection and screening for breast, cervix and colorectal cancers would all make significant contributions. At the same time, for a number of major cancers (e.g., colon, prostate, kidney, pancreas, brain, lympho-haematological malignancies) research is needed to identify as yet unknown risk factors whilst for existing prevention strategies additional work is needed on their implementation into health services. Finally, there is a remarkable opportunity for advances in understanding the molecular basis of carcinogenesis to provide new tools and insights into aetiology and prevention. It is only by complementing efforts to improve treatment with those aimed at prevention that the impending epidemic of this disease can be addressed. (c) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.	[Franceschi, Silvia; Wild, Christopher P.] Int Agcy Res Canc, F-69372 Lyon 08, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	FranceschiS@iarc.fr; director@iarc.fr	Wild, Christopher/ABC-6260-2020; franceschi, silvia/M-2452-2014	Wild, Christopher/0000-0003-0249-8669; franceschi, silvia/0000-0003-4181-8071			Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Andriole GL, 2012, J NATL CANCER I, V104, P125, DOI 10.1093/jnci/djr500; [Anonymous], 2009, Wkly Epidemiol Rec, V84, P118; [Anonymous], 2002, IARC HDB CANC PREV B, V7; Autier P, 2012, NEW ENGL J MED, V366, P2230, DOI 10.1056/NEJMc1204298; Beral V, 2011, J MED SCREEN, V18, P210, DOI 10.1258/jms.2011.011134; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; Brawley OW, 2009, JNCI-J NATL CANCER I, V101, P1295, DOI 10.1093/jnci/djp310; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Chang MH, 2003, LIVER INT, V23, P309, DOI 10.1034/j.1478-3231.2003.00865.x; Cogliano VJ, 2011, JNCI-J NATL CANCER I, V103, P1827, DOI 10.1093/jnci/djr483; Dal Maso L, 2011, ANN ONCOL, V22, P957, DOI 10.1093/annonc/mdq467; Danaei G, 2005, LANCET, V366, P1784, DOI 10.1016/S0140-6736(05)67725-2; Darby S, 2005, BMJ-BRIT MED J, V330, P223, DOI 10.1136/bmj.38308.477650.63; DAY NE, 1990, STAT MED, V9, P677, DOI 10.1002/sim.4780090614; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Ezzati M, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P241; Farmer P, 2010, LANCET, V376, P1186, DOI 10.1016/S0140-6736(10)61152-X; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; FORMAN D, 1993, LANCET, V341, P1359; Franceschi S, 2010, BRIT J CANCER, V103, P416, DOI 10.1038/sj.bjc.6605756; Franceschi S, 2006, INT J CANCER, V119, P2677, DOI 10.1002/ijc.22241; Franceschi S, 2011, INT J CANCER, V128, P2765, DOI 10.1002/ijc.25915; Giovino GA, 2012, LANCET, V380, P668, DOI 10.1016/S0140-6736(12)61085-X; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; HARACH HR, 1985, CANCER, V56, P531, DOI DOI 10.1002/1097-0142(19850801)56:3!; Harford JB, 2011, LANCET ONCOL, V12, P306, DOI 10.1016/S1470-2045(10)70273-4; Harris R, 2011, JNCI-J NATL CANCER I, V103, P1726, DOI 10.1093/jnci/djr446; IARC, 2005, IARC HDB CANC PREV C, V10; IARC, 2012, MON EV CARC RISKS D, V100D; IARC, 2012, MON EV CARC RISKS F, V100F; IARC, 2012, MON EV CARC RISKS B, V100B; IARC, 2012, MON EV CARC RISKS A, V100A; IARC (International Agency for Research on Cancer), 2012, MON EV CARC RISKS C, V100C; Keita N, 2009, BRIT J CANCER, V101, P202, DOI 10.1038/sj.bjc.6605140; Kilfoy BA, 2009, CANCER CAUSE CONTROL, V20, P525, DOI 10.1007/s10552-008-9260-4; Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027; Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8; Liu Y, 2010, ENVIRON HEALTH PERSP, V118, P818, DOI 10.1289/ehp.0901388; Maule M, 2012, LANCET ONCOL, V13, P745, DOI 10.1016/S1470-2045(12)70268-1; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Qiao YL, 2008, LANCET ONCOL, V9, P929, DOI 10.1016/S1470-2045(08)70210-9; Raza SA, 2007, BRIT J CANCER, V96, P1127, DOI 10.1038/sj.bjc.6603649; Riboli E., 1991, IARC SCI PUBLICATION, V112; Rushton L, 2012, BRIT J CANCER, V107, pS3, DOI 10.1038/bjc.2012.112; Sankaranarayanan R., 2011, IARC SCI PUBLICATION, V162; Sankaranarayanan R, 2011, JNCI-J NATL CANCER I, V103, P1476, DOI 10.1093/jnci/djr304; Shibata A, 2001, J NATL CANCER I, V93, P1109, DOI 10.1093/jnci/93.14.1109; Singer S, 2012, THYROID, V22, P117, DOI 10.1089/thy.2011.0139; United Nations Department of Economic and Social Affairs Population Division, 2012, STESASERA318 UN DEP; UNSCEAR editor, 2011, REP UN SCI COMM EFF; von Karsa, 2010, EUROPEAN GUIDELINES; Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099; Wild CP, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-S1-S15; Wild CP, 2010, CARCINOGENESIS, V31, P71, DOI 10.1093/carcin/bgp264; Wild CP, 2012, J NATL CANCER I, V104, P1051, DOI 10.1093/jnci/djs262; Wild CP, 2010, OCCUP ENVIRON MED, V67, P75, DOI 10.1136/oem.2009.051219; Wolters T, 2010, INT J CANCER, V126, P2387, DOI 10.1002/ijc.24870; World Health Organization, 2010, GLOBAL STATUS REPORT	62	45	50	0	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1574-7891	1878-0261		MOL ONCOL	Mol. Oncol.	FEB	2013	7	1					1	13		10.1016/j.molonc.2012.10.010			13	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	082HB	WOS:000314381800001	23218182	Green Published, hybrid			2022-02-25	
J	Siouda, M; Yue, JP; Shukla, R; Guillermier, S; Herceg, Z; Creveaux, M; Accardi, R; Tommasino, M; Sylla, BS				Siouda, Maha; Yue, Jiping; Shukla, Ruchi; Guillermier, Sophie; Herceg, Zdenko; Creveaux, Marion; Accardi, Rosita; Tommasino, Massimo; Sylla, Bakary S.			Transcriptional Regulation of the Human Tumor Suppressor DOK1 by E2F1	MOLECULAR AND CELLULAR BIOLOGY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; DNA METHYLATION; GENE; CELLS; TRANSLOCATION; ACTIVATION; APOPTOSIS; P62(DOK); PROTEIN; GROWTH	The expression of the tumor suppressor DOK1 is repressed in a variety of human tumors as a result of hypermethylation of its promoter region. However, the molecular mechanisms by which DOK1 expression is regulated have been poorly investigated. Here, we show that the expression of DOK1 is regulated mainly by the transcription factor E2F1. We identified three putative E2F1 response elements (EREs) in the DOK1 promoter region. E2F1 had a relatively higher binding affinity for the ERE located between bp -498 and -486 compared with the other two EREs. E2F1 gene silencing strongly inhibited DOK1 expression. E2F1-driven DOK1 transcription occurred in the presence of cellular stresses, such as accumulation of DNA damage induced by etoposide. DOK1 silencing promoted cell proliferation and protected against etoposide-induced apoptosis, indicating that DOK1 acts as a key mediator of cellular stress-induced cell death. Most importantly, we observed that DNA methylation of the DOK1 core promoter region found in head and neck cancer cell lines hampered the recruitment of E2F1 to the DOK1 promoter and compromised DOK1 expression. In summary, our data show that E2F1 is a key factor in DOK1 expression and provide novel insights into the regulation of these events in cancer cells.	[Siouda, Maha; Yue, Jiping; Shukla, Ruchi; Guillermier, Sophie; Herceg, Zdenko; Creveaux, Marion; Accardi, Rosita; Tommasino, Massimo; Sylla, Bakary S.] Int Agcy Res Canc, F-69372 Lyon, France		Sylla, BS (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	syllab@iarc.fr	Shukla, Ruchi/AAD-7610-2020	, Jiping/0000-0003-0717-8613; Tommasino, Massimo/0000-0002-0890-8596	IARCWorld Health Organization; La Ligue Regionale de Lutte contre le Cancer du Rhone et de la Drome	M.S. and R. S. were supported by the IARC Fellowship Program. This work was partially supported by grants from La Ligue Regionale de Lutte contre le Cancer du Rhone et de la Drome (to B.S.S.).	Balassiano K, 2011, CANCER LETT, V311, P85, DOI 10.1016/j.canlet.2011.06.038; Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Gong YH, 2006, NUCLEIC ACIDS RES, V34, P6158, DOI 10.1093/nar/gkl834; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; INABA T, 1991, LEUKEMIA, V5, P719; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027; Lamkin TJ, 2006, AM J HEMATOL, V81, P603, DOI 10.1002/ajh.20667; Lee S, 2004, ONCOGENE, V23, P2287, DOI 10.1038/sj.onc.1207385; Lin WC, 2001, GENE DEV, V15, P1833; Mashima R, 2010, LAB INVEST, V90, P1357, DOI 10.1038/labinvest.2010.121; Mashima R, 2009, IMMUNOL REV, V232, P273, DOI 10.1111/j.1600-065X.2009.00844.x; Mercier PL, 2011, MOL ONCOL, V5, P438, DOI 10.1016/j.molonc.2011.07.003; Miao L, 2003, EUR J BIOCHEM, V270, P2721, DOI 10.1046/j.1432-1033.2003.03639.x; Nelms K, 1998, GENOMICS, V53, P243, DOI 10.1006/geno.1998.5514; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; Saulnier A, 2012, INT J CANCER, V130, P2484, DOI 10.1002/ijc.26299; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Woodring PJ, 2004, J CELL BIOL, V165, P493, DOI 10.1083/jcb.200312171; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Yasuda T, 2004, J EXP MED, V200, P1681, DOI 10.1084/jem.20041247; YOFFE G, 1990, J PEDIATR-US, V116, P114, DOI 10.1016/S0022-3476(05)81658-0; Yun J, 2012, LAB INVEST, V92, P1033, DOI 10.1038/labinvest.2012.61; Zannetti C, 2010, J BIOL CHEM, V285, P34773, DOI 10.1074/jbc.M110.133884; Zhang HJ, 2009, J CELL BIOCHEM, V106, P464, DOI 10.1002/jcb.22033	37	15	16	0	8	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0270-7306			MOL CELL BIOL	Mol. Cell. Biol.	DEC	2012	32	23					4877	4890		10.1128/MCB.01050-12			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	036LU	WOS:000311028500011	23028047	Green Published, Bronze			2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R.			'See-and-treat' works for cervical cancer prevention: what about controlling the high burden in India?	INDIAN JOURNAL OF MEDICAL RESEARCH			English	Editorial Material							ELECTROSURGICAL EXCISION PROCEDURE; RANDOMIZED CONTROLLED-TRIAL; SINGLE-VISIT APPROACH; INTRAEPITHELIAL NEOPLASIA; VISUAL INSPECTION; RURAL INDIA; DEVELOPING-COUNTRIES; SCREENING TRIAL; ACETIC-ACID; SAFETY		Int Agcy Res Canc, Sect Early Detect & Prevent, F-69372 Lyon 08, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Sect Early Detect & Prevent, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	sankar@iarc.fr					American Cancer Society, GLOB FIGHT CANC BRAZ; Arrossi S, 2010, REV PANAM SALUD PUBL, V28, P249, DOI 10.1590/S1020-49892010001000003; Cho H, 2009, J GYNECOL ONCOL, V30, P164, DOI 10.3802/jgo.2009.20.3.164; Chumworathayi B, 2010, J OBSTET GYNAECOL RE, V36, P79, DOI 10.1111/j.1447-0756.2009.01089.x; Denny L, 2010, JNCI-J NATL CANCER I, V102, P1557, DOI 10.1093/jnci/djq342; Ferenczy A, 1996, OBSTET GYNECOL, V87, P332, DOI 10.1016/0029-7844(95)00453-X; Ferlay J, 2010, GLOBOCAN 2008 V2 0 C; Ferris DG, 1996, J FAM PRACTICE, V42, P253; Gaffikin L, 2003, LANCET, V361, P814, DOI 10.1016/S0140-6736(03)12707-9; Gupta H, 2011, INDIAN EXPRESS  0214; Khuhaprema T, 2012, INT J GYNAE IN PRESS; Kjellberg L, 2007, ACTA OBSTET GYN SCAN, V86, P1140, DOI 10.1080/00016340701505267; Kuhn L, 2010, 17 INT AIDS C MEX CI, V24, P2553; LaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.08986, 10.2471/BLT.11.089862]; Lazcano-Ponce E, 2011, LANCET, V378, P1868, DOI 10.1016/S0140-6736(11)61522-5; Lazcano-Ponce E, 2010, CANCER CAUSE CONTROL, V21, P1693, DOI 10.1007/s10552-010-9598-2; Li ZG, 2009, INT J GYNECOL OBSTET, V106, P202, DOI 10.1016/j.ijgo.2009.04.011; McAdam M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013266; Nene B, 2007, B WORLD HEALTH ORGAN, V85, P264, DOI 10.2471/BLT.06.031195; Nene BM, 2008, INT J GYNECOL OBSTET, V103, P232, DOI 10.1016/j.ijgo.2008.07.016; Nessa A, 2010, INT J GYNECOL OBSTET, V111, P115, DOI 10.1016/j.ijgo.2010.06.004; Numnum T Michael, 2005, J Low Genit Tract Dis, V9, P2, DOI 10.1097/00128360-200501000-00002; Rema P, 2008, INT J GYNECOL OBSTET, V103, P105, DOI 10.1016/j.ijgo.2008.06.020; Sahasrabuddhe VV, 2012, INT J CANCER, V130, P234, DOI 10.1002/ijc.25971; Sahasrabuddhe VV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008634; Sankaranarayanan R, 2005, INT J CANCER, V116, P617, DOI 10.1002/ijc.21050; Sankaranarayanan R, 2007, BRIT J CANCER, V96, P738, DOI 10.1038/sj.bjc.6603633; Sankaranarayanan R, 2004, J MED SCREEN, V11, P77, DOI 10.1258/096914104774061056; Sankaranarayanan R, 2011, ANN ONCOL, V22, P20, DOI 10.1093/annonc/mdr422; Sankaranarayanan R, 2009, INT J GYNECOL OBSTET, V104, P95, DOI 10.1016/j.ijgo.2008.09.009; Sankaranarayanan R, 2007, LANCET, V370, P398, DOI 10.1016/S0140-6736(07)61195-7; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Santos C, 1996, GYNECOL ONCOL, V61, P11, DOI 10.1006/gyno.1996.0088; Shastri SS, 2005, B WORLD HEALTH ORGAN, V83, P186; Shetty P, 2011, NATURE, V474, P427, DOI 10.1038/474427a; Singla S, 2012, INDIAN J MED RES, V135, P614; Vedantham H, 2010, CANCER EPIDEM BIOMAR, V19, P1373, DOI 10.1158/1055-9965.EPI-09-1282	37	10	10	0	5	INDIAN COUNCIL MEDICAL RES	NEW DELHI	PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA	0971-5916			INDIAN J MED RES	Indian J. Med. Res.	MAY	2012	135	5					576	579					4	Immunology; Medicine, General & Internal; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; General & Internal Medicine; Research & Experimental Medicine	994GU	WOS:000307919700002	22771586				2022-02-25	
J	Plummer, M; Vaccarella, S; Franceschi, S				Plummer, Martyn; Vaccarella, Salvatore; Franceschi, Silvia			Multiple Human Papillomavirus Infections: The Exception or the Rule?	JOURNAL OF INFECTIOUS DISEASES			English	Editorial Material							HPV TYPES; CERVICAL COINFECTION; PERSISTENCE; ACQUISITION; NEOPLASIA; WOMEN; PREVALENCE; CONCURRENT; DIAGNOSIS; CANCER		[Plummer, Martyn; Vaccarella, Salvatore; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschiS@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497; Vaccarella, Salvatore/0000-0002-2516-2167			Rodriguez AC, 2010, JNCI-J NATL CANCER I, V102, P315, DOI 10.1093/jnci/djq001; CHATURVEDI A, 2010, J INFECT DI IN PRESS; Chaturvedi AK, 2005, CANCER EPIDEM BIOMAR, V14, P2439, DOI 10.1158/1055-9965.EPI-05-0465; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Cuschieri K, 2008, CANCER EPIDEM BIOMAR, V17, P2536, DOI 10.1158/1055-9965.EPI-08-0306; *IARC, 1995, MON EV CARC RISKS HU, V64; Klug SJ, 2008, J MED VIROL, V80, P1264, DOI 10.1002/jmv.21191; Li N, 2010, INT J CANCER, V128, P327; Liaw KL, 2001, J INFECT DIS, V183, P8, DOI 10.1086/317638; Maucort-Boulch D, 2010, INT J CANCER, V126, P684, DOI 10.1002/ijc.24752; Mendez F, 2005, J INFECT DIS, V192, P1158, DOI 10.1086/444391; Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784; Rousseau MC, 2001, J INFECT DIS, V184, P1508, DOI 10.1086/324579; Schmitt M, 2010, J CLIN MICROBIOL, V48, P143, DOI 10.1128/JCM.00991-09; Snijders PJF, 2003, J PATHOL, V201, P1, DOI 10.1002/path.1433; Thomas KK, 2000, J INFECT DIS, V182, P1097, DOI 10.1086/315805; Trottier H, 2006, CANCER EPIDEM BIOMAR, V15, P1274, DOI 10.1158/1055-9965.EPI-06-0129; VACCARELLA S, 2010, INT J CANC IN PRESS; Vaccarella S, 2010, CANCER EPIDEM BIOMAR, V19, P503, DOI 10.1158/1055-9965.EPI-09-0983; Wentzensen N, 2009, INT J CANCER, V125, P2151, DOI 10.1002/ijc.24528; Xue XN, 2010, CANCER EPIDEM BIOMAR, V19, P159, DOI 10.1158/1055-9965.EPI-09-0546	21	37	37	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-1899	1537-6613		J INFECT DIS	J. Infect. Dis.	APR 1	2011	203	7					891	893		10.1093/infdis/jiq146			3	Immunology; Infectious Diseases; Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases; Microbiology	737FF	WOS:000288553800002	21402540	Bronze			2022-02-25	
J	Hainaut, P; Boffetta, P; Chemin, IA; Plymoth, A				Hainaut, Pierre; Boffetta, Paolo; Chemin, Isabelle A.; Plymoth, Amelie			Cancer letters special issue hepatocellular carcinoma featuring the guest editors	CANCER LETTERS			English	Editorial Material									[Hainaut, Pierre; Boffetta, Paolo; Chemin, Isabelle A.; Plymoth, Amelie] Int Agcy Res Canc, F-69372 Lyon, France		Hainaut, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012; Chemin, Isabelle/I-3032-2016	Hainaut, Pierre/0000-0002-1303-1610; Chemin, Isabelle/0000-0002-7188-5489				0	0	0	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3835	1872-7980		CANCER LETT	Cancer Lett.	DEC 1	2009	286	1			SI		1	2		10.1016/j.canlet.2009.03.001			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	526IZ	WOS:000272282900001					2022-02-25	
J	Hainaut, P				Hainaut, Pierre			Aflatoxin-induced R249S TP53 mutations in liver cancer: evidence for interactions with hepatitis B virus	MUTAGENESIS			English	Meeting Abstract									[Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon, France				Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				0	0	0	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0267-8357			MUTAGENESIS	Mutagenesis	NOV	2009	24	6				18	529	529					1	Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity; Toxicology	516XD	WOS:000271575700027					2022-02-25	
J	Lambert, R				Lambert, R.			Colonoscopy: Maximizing detection and characterization	GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE			French	Article							COLORECTAL-CANCER; FLUORESCENCE ENDOSCOPY; FLEXIBLE SIGMOIDOSCOPY; POLYETHYLENE-GLYCOL; NEOPLASTIC LESIONS; SODIUM-PHOSPHATE; PIT PATTERN; DIAGNOSIS; POLYPS; COLON	The endoscopic analysis of the colonic lumen with a flexible tube began around 1960, at first with a gastrocamera, then with a fibrocolonoscope. After 1990, the electronic imaging brought a three points revolution with increased resolution of the image, transfer of the image on a television monitor giving access to multiple observers, electronic image processing. The recent colonoscopes have an increased resolution with more pixels in the Charged Coupled Device (CCD) sensor, a High Definition Television (HDTV) image and an electronic and/or optical zoom for magnification. Colonoscopy is now often performed in a similar environment to that of surgery. Therapeutic applications justify a strict strategy for endoscopic diagnosis. At first, detection of the lesion in standard vision, then characterization with the help of chromoscopy for the evaluation of morphology and with the help of magnification for the evaluation of the pit pattern. Then, comes the time for treatment decision between abstention, endoscopic resection or surgery. The legitimacy of the management is controlled in retrospective by the analysis of the tissue samples. Recent alternatives to colonoscopy (3D radiological imaging, colon capsule) should not invalidate the priority attributed to colonoscopy which associates treatment to the early detection of colorectal cancer and precursors. (C) 2009 Elsevier Masson SAS. All rights reserved.	Int Agcy Res Canc, Grp Screening, F-69372 Lyon 08, France		Lambert, R (corresponding author), Int Agcy Res Canc, Grp Screening, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	lambert@iarc.fr					Adler DG, 2008, GASTROINTEST ENDOSC, V68, P621, DOI 10.1016/j.gie.2008.06.046; Alencar H, 2007, RADIOLOGY, V244, P232, DOI 10.1148/radiol.2441052114; Anandasabapathy S, 2008, CURR OPIN GASTROEN, V24, P64, DOI 10.1097/MOG.0b013e3282f2df8d; Atkin WS, 1998, EUR J GASTROEN HEPAT, V10, P219, DOI 10.1097/00042737-199803000-00005; Chen Yang K, 2004, Gastrointest Endosc Clin N Am, V14, P697, DOI 10.1016/j.giec.2004.04.007; Consolo P, 2008, DIS COLON RECTUM, V51, P1374, DOI 10.1007/s10350-008-9304-6; East JE, 2008, ENDOSCOPY, V40, P811, DOI 10.1055/s-2008-1077586; FERLAY J, 2004, MORTALITY PREVALENCE, V5; Fu, 2005, DIGEST ENDOSC, V17, P105, DOI DOI 10.1111/J.1443-1661.2005.00483.X; George SMC, 2000, CANCER, V89, P1901, DOI 10.1002/1097-0142(20001101)89:9<1901::AID-CNCR5>3.3.CO;2-R; Goetz M, 2008, ANTICANCER RES, V28, P353; Gono K, 2004, J BIOMED OPT, V9, P568, DOI 10.1117/1.1695563; Heresbach D, 2008, ENDOSCOPY, V40, P284, DOI 10.1055/s-2007-995618; Hewitson P, 2008, AM J GASTROENTEROL, V103, P1541, DOI 10.1111/j.1572-0241.2008.01875.x; Huppertz-Hauss G, 2005, ENDOSCOPY, V37, P537, DOI 10.1055/s-2005-861315; Hurlstone David P, 2005, Gastrointest Endosc Clin N Am, V15, P687, DOI 10.1016/j.giec.2005.08.014; Igarashi M, 2005, ENDOSCOPY, V37, P386, DOI 10.1055/s-2005-861094; Kiesslich R, 2005, EUR J GASTROEN HEPAT, V17, P793, DOI 10.1097/00042737-200508000-00003; Kimura T, 2007, GASTROINTEST ENDOSC, V66, P37, DOI 10.1016/j.gie.2007.01.009; Kudo S, 2001, ENDOSCOPY, V33, P367; Kudo SE, 2008, GASTROINTEST ENDOSC, V68, pS3, DOI 10.1016/j.gie.2008.07.052; Kuznetsov K, 2006, ENDOSCOPY, V38, P76, DOI 10.1055/s-2005-921114; Lambert R, 2004, ENDOSCOPY, V36, P723, DOI 10.1055/s-2004-825671; Lapalus MG, 2006, ENDOSCOPY, V38, P444, DOI 10.1055/s-2006-925265; Leung FW, 2008, DIGEST DIS SCI, V53, P1462, DOI 10.1007/s10620-007-0025-9; Levin B, 2008, GASTROENTEROLOGY, V134, P1570, DOI 10.1053/j.gastro.2008.02.002; Machida H, 2004, ENDOSCOPY, V36, P1094, DOI 10.1055/s-2004-826040; Mathus-Vliegen EMH, 2006, ALIMENT PHARM THERAP, V23, P543, DOI 10.1111/j.1365-2036.2006.02777.x; Matsuda T, 2008, AM J GASTROENTEROL, V103, P1926, DOI 10.1111/j.1572-0241.2008.01931.x; Mayinger B, 2008, ENDOSCOPY, V40, P106, DOI 10.1055/s-2007-967019; McCallum AL, 2008, GASTROINTEST ENDOSC, V68, P283, DOI 10.1016/j.gie.2007.10.039; McFarland EG, 1997, RADIOLOGY, V205, P701, DOI 10.1148/radiology.205.3.9393524; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Morse JWI, 2008, CAN J GASTROENTEROL, V22, P619, DOI 10.1155/2008/265465; Nakamura K, 2008, NEW CHALLENGES IN GASTROINTESTINAL ENDOSCOPY, P40, DOI 10.1007/978-4-431-78889-8_3; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Pohl J, 2009, GUT, V58, P73, DOI 10.1136/gut.2008.153601; Radaelli F, 2008, AM J GASTROENTEROL, V103, P1122, DOI 10.1111/j.1572-0241.2007.01778.x; Ransohoff DF, 2005, GASTROENTEROLOGY, V128, P1685, DOI 10.1053/j.gastro.2005.04.005; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Rex Douglas K, 2003, Rev Gastroenterol Disord, V3, P70; Sasajima K, 2006, GASTROINTEST ENDOSC, V63, P1010, DOI 10.1016/j.gie.2006.01.021; Satodate H, 2003, GASTROINTEST ENDOSC, V58, P288, DOI 10.1067/mge.2003.361; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Sikka S, 2008, ENDOSCOPY, V40, P818, DOI 10.1055/s-2008-1077437; Soetikno R, 2006, GASTROENTEROLOGY, V130, P566, DOI 10.1053/j.gastro.2005.12.006; Steele RJC, 2004, BMJ-BRIT MED J, V329, P133, DOI 10.1136/bmj.38153.491887.7C; Tanaka S, 2001, DIGEST ENDOSC, V13, pS2; Tanaka S, 2007, GASTROINTEST ENDOSC, V66, P100, DOI 10.1016/j.gie.2007.02.032; Tanaka W, 2000, J GASTROENTEROL, V35, P120, DOI 10.1007/s005350050024; VILLARDELL F, 2006, DIGESTIVE ENDOSCOPY, V1; Weissfeld JL, 2005, JNCI-J NATL CANCER I, V97, P989, DOI 10.1093/jnci/dji175; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	53	0	0	0	3	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0399-8320			GASTROEN CLIN BIOL	Gastroenterol. Clin. Biol.	AUG-SEP	2009	33	8-9					737	746		10.1016/j.gcb.2009.07.014			10	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	517KR	WOS:000271612800014	19683885				2022-02-25	
J	Curado, MP; Hashibe, M				Curado, Maria Paula; Hashibe, Mia			Recent changes in the epidemiology of head and neck cancer	CURRENT OPINION IN ONCOLOGY			English	Review						incidence; larynx; mortality; oral cavity; oropharynx; prevalence	SQUAMOUS-CELL CARCINOMA; AERODIGESTIVE TRACT CANCERS; HUMAN-PAPILLOMAVIRUS; CIGARETTE-SMOKING; TOBACCO SMOKING; POOLED ANALYSIS; INTERNATIONAL HEAD; SOCIAL-INEQUALITY; ALCOHOL-DRINKING; NEVER DRINKERS	Purpose of review To review the most recent epidemiological studies on head and neck cancer and changes in knowledge about risk factors. The main review concerned the squamous cell carcinoma of the oral cavity, oropharynx, larynx and hypopharynx. Recent findings Overall, the incidence of head and neck cancer is increasing in women, whereas it is decreasing in men. Chewing tobacco is a newly recognized risk factor of great public health concern. Human papillomavirus infection has been found to be a factor of good prognosis for oral cavity and oropharynx squamous cell cancer. The role of tobacco smoking and alcohol in the genesis of this cancer has been reinforced. Summary The presence or absence of human papillomavirus in patients with squamous cell carcinoma of the head and neck is a new parameter for prediction of long-term outcome of cancer of the oral cavity and of the oropharynx. Head and neck cancer among women in developing countries should deserve more attention, as the mortality rates appear to be higher than those of women in developed countries. For never smokers and never drinkers, more research needs to be done to identify their risk factor patterns.	[Curado, Maria Paula] Int Agcy Res Canc, BEC, DEP, F-69372 Lyon 08, France; [Hashibe, Mia] Int Agcy Res Canc, GEC, GEE, GET, F-69372 Lyon, France		Curado, MP (corresponding author), Int Agcy Res Canc, BEC, DEP, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	curadomp@iarc.fr	Curado, Maria Paula/M-6200-2013	Curado, Maria Paula/0000-0001-8172-2483			Andersen ZJ, 2008, EUR J CANCER, V44, P1950, DOI 10.1016/j.ejca.2008.06.019; Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233; Bosetti C, 2008, AM J EPIDEMIOL, V167, P468, DOI 10.1093/aje/kwm318; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; Conway DI, 2008, INT J CANCER, V122, P2811, DOI 10.1002/ijc.23430; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; Dahlstrom KR, 2008, HEAD NECK-J SCI SPEC, V30, P75, DOI 10.1002/hed.20664; Dalton SO, 2008, EUR J CANCER, V44, P1938, DOI [10.1016/j.ejca.2008.06.010, 10.1016/j.ejca.2008.06.034]; DE SE, 2007, INT J CANCER, V121, P1086; FERLAY J, 2002, IARC CANCERBASE, V5; Freedman ND, 2008, INT J CANCER, V122, P2330, DOI 10.1002/ijc.23319; Freedman ND, 2007, CANCER, V110, P1593, DOI 10.1002/cncr.22957; Gandini S, 2008, INT J CANCER, V122, P155, DOI 10.1002/ijc.23033; Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025; Guha N, 2007, AM J EPIDEMIOL, V166, P1159, DOI 10.1093/aje/kwm193; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; Hiraki A, 2008, CANCER EPIDEM BIOMAR, V17, P1222, DOI 10.1158/1055-9965.EPI-07-2761; *IARC WORK GROUP, 2004, IARC WORK GROUP EV C; Ide R, 2008, ORAL DIS, V14, P314, DOI 10.1111/j.1601-0825.2007.01378.x; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kingsley K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-87; La Vecchia C, 2008, EUR J CANCER PREV, V17, P116, DOI 10.1097/CEJ.0b013e3282b6fd40; Lee YCA, 2008, CANCER EPIDEM BIOMAR, V17, P1974, DOI 10.1158/1055-9965.EPI-08-0047; Mackay J, 2002, TOBACCO ATLAS; Peters ES, 2008, HEAD NECK-J SCI SPEC, V30, P1193, DOI 10.1002/hed.20846; Polesel J, 2008, INT J CANCER, V122, P2398, DOI 10.1002/ijc.23385; Purdue MP, 2009, AM J EPIDEMIOL, V169, P132, DOI 10.1093/aje/kwn306; Ragin CCR, 2007, INT J CANCER, V121, P1813, DOI 10.1002/ijc.22851; Sapkota A, 2007, INT J CANCER, V121, P1793, DOI 10.1002/ijc.22832; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; [No title captured]	32	202	215	0	36	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-8746			CURR OPIN ONCOL	Curr. Opin. Oncol.	MAY	2009	21	3					194	200		10.1097/CCO.0b013e32832a68ca			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	438MS	WOS:000265560100002	19363341				2022-02-25	
J	Straif, K				Straif, Kurt			The burden of occupational cancer	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material							GREAT-BRITAIN; CARCINOGENS; WORK; MORTALITY; EXPOSURE		IARC, Lyon, France		Straif, K (corresponding author), IARC, 150 Cours Albert Thomas, Lyon, France.	straif@iarc.fr					Cherrie JW, 2007, ANN OCCUP HYG, V51, P653, DOI 10.1093/annhyg/mem049; DEVOCHT F, 1970, OCCUP ENVIRON MED, V65, P384; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Driscoll T, 2005, AM J IND MED, V48, P419, DOI 10.1002/ajim.20209; Hamalainen P, 2007, AM J IND MED, V50, P28, DOI 10.1002/ajim.20411; Hodgson JT, 2005, BRIT J CANCER, V92, P587, DOI 10.1038/sj.bjc.6602307; Kauppinen T, 2000, OCCUP ENVIRON MED, V57, P10, DOI 10.1136/oem.57.1.10; Nurminen M, 2001, SCAND J WORK ENV HEA, V27, P161, DOI 10.5271/sjweh.605; Steenland K, 2003, AM J IND MED, V43, P461, DOI 10.1002/ajim.10216; Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X; WHO, EL ASB REL DIS	11	28	29	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	DEC	2008	65	12					787	788		10.1136/oem.2007.038224			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	373US	WOS:000260999600001	19017708				2022-02-25	
J	Vaissiere, T; Sawan, C; Herceg, Z				Vaissiere, Thomas; Sawan, Carla; Herceg, Zdenko			Epigenetic interplay between histone modifications and DNA methylation in gene silencing	MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH			English	Article; Proceedings Paper	5th International Conference on Environmental Mutagens in Human Populations	MAY 20-24, 2007	Antalya, TURKEY			epigenetic cross-talk; DNA methylation; histone acetylation; environmental agents; gene silencing; cancer	CHROMATIN-STRUCTURE; BINDING PROTEIN; PROMOTER DNA; CANCER; TRANSCRIPTION; H3; DEACETYLASE; LUNG; DEMETHYLATION; ACETYLATION	Knowledge on heritable changes in gene expression that result from epigenetic events is of increasing relevance in the development of strategies for prevention, early diagnosis and treatment of cancer. Histone acetylation and DNA methylation are epigenetic modifications whose patterns can be regarded as heritable marks that ensure accurate transmission of the chromatin states and gene expression profiles over many cell generations. Importantly, patterns and levels of DNA methylation and histone acetylation are profoundly altered in human cancers. Accumulating evidence suggests that an epigenetic cross-talk, i.e. interplay between DNA methylation and histone acetylation, may be involved in the process of gene transcription and aberrant gene silencing in tumours. Although the molecular mechanism of gene activation is relatively well understood, the hierarchical order of events and dependencies leading to gene silencing in the course of cancer development remain largely unknown. While some studies suggest that DNA methylation patterns guide histone modifications (including histone acetylation and methylation) during gene silencing, other studies argue that DNA methylation takes its cues primarily from histone modification states. In this review, we summarize current knowledge on the interplay between DNA methylation and histone modifications during gene silencing and its importance in the integration of environmental and intrinsic stimuli in the control of gene expression. We also discuss the importance of an epigenetic cross-talk in the protection against genetic changes in response to environmental genotoxins as well as the implication for cancer therapy and prevention. (C) 2008 Elsevier B.V. All rights reserved.	[Vaissiere, Thomas; Sawan, Carla; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr	Vaissiere, Thomas/E-1121-2011				Bannister AJ, 2004, METHOD ENZYMOL, V376, P269; Bartee L, 2001, GENE DEV, V15, P1753, DOI 10.1101/gad.905701; Belinsky SA, 2004, CARCINOGENESIS, V25, P1063, DOI 10.1093/carcin/bgh096; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Ben-Porath I, 2001, MOL CELL, V8, P933, DOI 10.1016/S1097-2765(01)00399-9; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Broday L, 2000, CANCER RES, V60, P238; Bulger M, 2005, J BIOL CHEM, V280, P21689, DOI 10.1074/jbc.R500004200; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; CHEN CJ, 1992, BRIT J CANCER, V66, P888, DOI 10.1038/bjc.1992.380; CHIANG HS, 1993, BRIT J UROL, V71, P274, DOI 10.1111/j.1464-410X.1993.tb15942.x; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; DOLL R, 1970, BRIT J CANCER, V24, P623, DOI 10.1038/bjc.1970.76; Dong E, 2007, P NATL ACAD SCI USA, V104, P4676, DOI 10.1073/pnas.0700529104; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Hande MP, 2003, AM J HUM GENET, V72, P1162, DOI 10.1086/375041; Henikoff S, 1998, GENETICS, V149, P307; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Johnsen ML, 1998, J AM ACAD DERMATOL, V38, P369, DOI 10.1016/S0190-9622(98)70495-5; Johnson ML, 1998, J AM ACAD DERMATOL, V38, P393; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kang J, 2003, TOXICOL SCI, V74, P279, DOI 10.1093/toxsci/kfg137; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kawamoto K, 2007, CLIN CANCER RES, V13, P2541, DOI 10.1158/1078-0432.CCR-06-2225; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; LEE YW, 1995, MOL CELL BIOL, V15, P2547; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; MABUCHI K, 1979, ARCH ENVIRON HEALTH, V34, P312, DOI 10.1080/00039896.1979.10667423; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Milutinovic S, 2007, CARCINOGENESIS, V28, P560, DOI 10.1093/carcin/bgl167; Mittal A, 2003, NEOPLASIA, V5, P555, DOI 10.1016/S1476-5586(03)80039-8; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Mutskov VJ, 2002, GENE DEV, V16, P1540, DOI 10.1101/gad.988502; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okoji RS, 2002, CARCINOGENESIS, V23, P777, DOI 10.1093/carcin/23.5.777; Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032; Papa CM, 2001, PLANT CELL, V13, P1919, DOI 10.1105/tpc.13.8.1919; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Reik W, 1999, NAT GENET, V23, P380, DOI 10.1038/70476; Reik W, 1997, NATURE, V389, P669, DOI 10.1038/39461; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Schubeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Waalkes MP, 2000, J INORG BIOCHEM, V79, P241, DOI 10.1016/S0162-0134(00)00009-X; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Yan Y, 2003, TOXICOL APPL PHARM, V190, P272, DOI 10.1016/S0041-008X(03)00169-8; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	82	395	418	1	51	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1383-5742	1388-2139		MUTAT RES-REV MUTAT	Mutat. Res.-Rev. Mutat. Res.	JUL-AUG	2008	659	1-2					40	48		10.1016/j.mrrev.2008.02.004			9	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	342VF	WOS:000258811000006	18407786				2022-02-25	
J	Herceg, Z				Herceg, Zdenko			Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors	MUTAGENESIS			English	Review							ABERRANT DNA METHYLATION; GENE O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; H3 LYSINE-9 METHYLATION; C-TERMINAL TAIL; PROMOTER HYPERMETHYLATION; HISTONE ACETYLATION; LUNG-CANCER; HELICOBACTER-PYLORI; FREQUENT HYPOMETHYLATION; TRANSPOSABLE ELEMENTS	While the field of cancer genetics has enjoyed a great deal of attention among cancer researchers in the last few decades, the appreciation of cancer epigenetics is more recent, -owing to the fact that epigenetic mechanisms have emerged as key mechanisms in cancer development. All critical changes in cancer cells, such as silencing of tumour-suppressor genes, activation of oncogenes and defects in DNA repair, are caused not only by genetic but also by epigenetic mechanisms. Epigenetic events can affect many steps in tumour development; therefore, better understanding of epigenetic mechanisms is fundamental to our ability to successfully prevent, diagnose and treat cancer. Various environmental and dietary agents and lifestyles are suspected to be implicated in the development of a wide range of human cancers by eliciting epigenetic changes, though the contribution of epigenetic mechanisms to a given human cancer type and the precise targets of epigenetic alterations during cancer development are largely unknown. The major obstacle in establishing a relationship between epigenetic changes and exposure to dietary, lifestyle and environmental factors and cancer is the fact that studies are typically too small and lack statistical power to identify the interactions between epigenetic changes and exposures. Tremendous advances in our understanding of basic epigenetic mechanisms and rapid progress that is being made in developing new powerful technologies, such as those for sensitive and quantitative detection of epigenetic changes as well as for genome-wide analysis (epigenomics), hold great promise that these issues may be addressed in near future. Therefore, experimental evidence on the precise role of epigenetic changes induced by environment, diet and lifestyle is eagerly awaited.	Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, Epigenet Team, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, Epigenet Team, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr					Adorjan P, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e21; Bal W, 2000, CHEM RES TOXICOL, V13, P616, DOI 10.1021/tx000044l; Barbot W, 2002, NUCLEIC ACIDS RES, V30, P2365, DOI 10.1093/nar/30.11.2365; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Belinsky SA, 2002, CANCER RES, V62, P2370; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 2004, CARCINOGENESIS, V25, P1063, DOI 10.1093/carcin/bgh096; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bennett-Baker PE, 2003, GENETICS, V165, P2055; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Broday L, 1999, MUTAT RES-GEN TOX EN, V440, P121, DOI 10.1016/S1383-5718(99)00018-2; Broday L, 2000, CANCER RES, V60, P238; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Campbell JH, 1988, PROG BRAIN RES, P535; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chen H, 2001, TOXICOL APPL PHARM, V175, P260, DOI 10.1006/taap.2001.9253; Chen JX, 1998, CANCER RES, V58, P2070; Cho BS, 2003, BIOCHEM BIOPH RES CO, V307, P52, DOI 10.1016/S0006-291X(03)01121-5; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; CONWAY K, 1989, CANCER RES, V49, P6032; Cooney CA, 2002, J NUTR, V132, p2393S; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dannenberg LO, 2006, ALCOHOL CLIN EXP RES, V30, P928, DOI 10.1111/j.1530-0277.2006.00107.x; De Capoa A, 2003, ONCOL REP, V10, P545; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 2001, CANCER RES, V61, P4689; Farber E, 1996, CLIN LAB MED, V16, P377; Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Feng QH, 2005, JNCI-J NATL CANCER I, V97, P273, DOI 10.1093/jnci/dji041; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 2004, MOL CELL BIOL, V24, P1640, DOI 10.1128/MCB.24.4.1640-1648.2004; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Heijmans BT, 2003, CANCER RES, V63, P1249; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; Hu WW, 2003, BIOCHEMISTRY-US, V42, P10012, DOI 10.1021/bi034631s; Hung RJ, 2005, JNCI-J NATL CANCER I, V97, P567, DOI 10.1093/jnci/dji101; Hung RJ, 2005, MUTAT RES-FUND MOL M, V592, P102, DOI 10.1016/j.mrfmmm.2005.06.007; *IARC, IARC MONOGR EVAL CAR, V39, P13; Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jablonka E, 2004, INT J EPIDEMIOL, V33, P929, DOI 10.1093/ije/dyh231; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; James SJ, 2002, J NUTR, V132, p2361S, DOI 10.1093/jn/132.8.2361S; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Jones BE, 1998, EXTREMOPHILES, V2, P191, DOI 10.1007/s007920050060; Jones PA, 2005, CANCER RES, V65, P11241, DOI 10.1158/0008-5472.CAN-05-3865; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Kalantari M, 2004, J VIROL, V78, P12762, DOI 10.1128/JVI.78.23.12762-12772.2004; Kane MF, 1997, CANCER RES, V57, P808; Karaczyn AA, 2005, CHEM RES TOXICOL, V18, P1934, DOI 10.1021/tx050122a; Karaczyn AA, 2003, CHEM RES TOXICOL, V16, P1555, DOI 10.1021/tx0300277; Ke QD, 2006, CARCINOGENESIS, V27, P1481, DOI 10.1093/carcin/bgl004; KING CM, 1994, MUTAT RES-DNAGING G, V316, P79, DOI 10.1016/0921-8734(94)90010-8; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li H, 2003, ADV CANCER RES, V89, P133, DOI 10.1016/S0065-230X(03)01004-2; LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758; Loizou JI, 2006, CELL CYCLE, V5, P696, DOI 10.4161/cc.5.7.2616; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Maier S, 2002, J NUTR, V132, p2440S, DOI 10.1093/jn/132.8.2440S; Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051; Mathers JC, 2004, MUTAT RES-FUND MOL M, V551, P43, DOI 10.1016/j.mrfmmm.2004.01.011; MAYSHOOPES L, 1986, DEV GENET, V7, P65, DOI 10.1002/dvg.1020070202; McKinsey TA, 2004, TRENDS GENET, V20, P206, DOI 10.1016/j.tig.2004.02.002; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MILLAR SE, 1995, DEVELOPMENT, V121, P3223; Mittal A, 2003, NEOPLASIA, V5, P555, DOI 10.1016/S1476-5586(03)80039-8; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Okoji RS, 2002, CARCINOGENESIS, V23, P777, DOI 10.1093/carcin/23.5.777; Olaharski AJ, 2005, PLOS GENET, V1, P689, DOI 10.1371/journal.pgen.0010077; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Palmisano WA, 2000, CANCER RES, V60, P5954; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Poirier LA, 2002, J NUTR, V132, p2336S, DOI 10.1093/jn/132.8.2336S; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Puri SK, 2005, AM J OTOLARYNG, V26, P12, DOI 10.1016/j.amjoto.2004.06.007; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; Rakyan V, 2003, CURR BIOL, V13, pR6, DOI 10.1016/S0960-9822(02)01377-5; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; Rutherford SL, 2003, NAT GENET, V33, P6, DOI 10.1038/ng0103-6; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Sato N, 2003, CANCER RES, V63, P4158; Scelo G, 2004, CANCER CAUSE CONTROL, V15, P445, DOI 10.1023/B:CACO.0000036444.11655.be; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; SIRACUSA LD, 1995, J HERED, V86, P121, DOI 10.1093/oxfordjournals.jhered.a111541; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Song MJ, 2002, J VIROL, V76, P5000, DOI 10.1128/JVI.76.10.5000-5013.2002; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sugiyama A, 1998, CANCER RES, V58, P2067; Sutherland JE, 2003, ANN NY ACAD SCI, V983, P151, DOI 10.1111/j.1749-6632.2003.tb05970.x; Sutherland JE, 2001, MUTAT RES-FUND MOL M, V479, P225, DOI 10.1016/S0027-5107(01)00163-4; Szaleczky E, 2000, ANAL CELL PATHOL, V20, P131, DOI 10.1155/2000/830906; Takiguchi M, 2003, EXP CELL RES, V286, P355, DOI 10.1016/S0014-4827(03)00062-4; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; van Doorn R, 2005, SEMIN ONCOL, V32, P479, DOI 10.1053/j.seminoncol.2005.07.001; van Engeland M, 2003, CANCER RES, V63, P3133; van Steensel B, 2003, BIOTECHNIQUES, V35, P346; Van Tine BA, 2004, J VIROL, V78, P11172, DOI 10.1128/JVI.78.20.11172-11186.2004; Velicescu M, 2002, CANCER RES, V62, P2378; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Waterland RA, 2006, J NUTR, V136, p1706S, DOI 10.1093/jn/136.6.1706S; *WHO INT AG RES CA, IARC MON EV CARC RIS, V49, P1; Wiley DJ, 2005, JAIDS-J ACQ IMM DEF, V39, P143; WILSON VL, 1987, J BIOL CHEM, V262, P9948; WILSON VL, 1983, SCIENCE, V220, P1054; Wistuba II, 2002, ONCOGENE, V21, P7298, DOI 10.1038/sj.onc.1205806; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yoon JH, 2001, CANCER RES, V61, P7110; Zazula M, 2006, DIAGN MOL PATHOL, V15, P24, DOI 10.1097/00019606-200603000-00004; Zhang J, 2005, CLIN CANCER RES, V11, P6544, DOI 10.1158/1078-0432.CCR-05-0374; Zhang JC, 2006, MOL CARCINOGEN, V45, P530, DOI 10.1002/mc.20188; Zhang QW, 2003, TOXICOL APPL PHARM, V192, P201, DOI 10.1016/S0041-008X(03)00280-1; Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zhang YJ, 2006, INT J CANCER, V119, P985, DOI 10.1002/ijc.21699; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907; Zheng ZM, 2006, FRONT BIOSCI-LANDMRK, V11, P2286, DOI 10.2741/1971; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217; Zoroddu MA, 2000, BBA-GEN SUBJECTS, V1475, P163, DOI 10.1016/S0304-4165(00)00066-0	179	242	257	0	30	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0267-8357	1464-3804		MUTAGENESIS	Mutagenesis	MAR	2007	22	2					91	103		10.1093/mutage/gel068			13	Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity; Toxicology	142PT	WOS:000244662700001	17284773	Bronze			2022-02-25	
J	Baan, RA				Baan, Robert A.			IARC monographs evaluations: Molecular epidemiology and mechanistic considerations	MUTAGENESIS			English	Meeting Abstract									WHO, Int Agcy Res Canc, Lyon, France								Cogliano VJ, 2004, ENVIRON HEALTH PERSP, V112, P1269, DOI 10.1289/ehp.6950; IARC, 2006, IARC MON EV CARC RIS	2	0	0	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0267-8357			MUTAGENESIS	Mutagenesis	JUL	2006	21	4				5	270	271					2	Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity; Toxicology	088TJ	WOS:000240833700015					2022-02-25	
J	Lambert, R				Lambert, R			Controversy concerning the cutoff value for depth of submucosal invasion after endoscopic mucosal resection of early gastric cancer - Reply to the letter of Dr. Cho et al.	ENDOSCOPY			English	Letter									Int Agcy Res Canc, F-69003 Lyon, Rhone, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69003 Lyon, Rhone, France.	lambert@iarc.fr						0	0	0	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	APR	2006	38	4					430	430		10.1055/s-2006-925280			1	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	039ME	WOS:000237309100023					2022-02-25	
J	Tong, WM; Ohgaki, H; Huang, HT; Granier, C; Kleihues, P; Wang, ZQ				Tong, WM; Ohgaki, H; Huang, HT; Granier, C; Kleihues, P; Wang, ZQ			Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; SPORADIC MEDULLOBLASTOMAS; HUMAN HOMOLOG; NEUROECTODERMAL TUMORS; CELL-DEATH; GENE; P53; PARP; TUMORIGENESIS; EXPRESSION	Medulloblastoma is an invasive embryonal tumor of the cerebellum with predominant neuronal differentiation. Although several genes have been implicated in medulloblasoma formation, such as Patcbed (Ptc1) and the adenomatous polyposis coli gene (Apc), the majority of these tumors cannot be explained by mutations in these genes. The cellular origin as well as the genetic and molecular changes involved in the genesis and progression of human medulloblastomas remain largely unknown. Here we show that disruption of poly(ADP-ribose) polymerase (PARP-1) causes a high incidence (49%) of aggressive brain tumors in P53 null mice, with typical features of human cerebellar medulloblastomas. At as early as 8 weeks of age, lesions started on the outer surface of the cerebellum. from remnant granule cell precursors of the developmental external germinal layer. Progression of these tumors is associated with the re-activation of the neuronal specific transcription factor Math1, dysregulation of Shh/Ptc1 signaling pathway, and chromosomal aberrations, including triradial and quadriradial chromosomes. The present study indicates that the loss of function of DNA double-strand break-sensing and repair molecules is an etiological factor in the evolution of the cerebellar medulloblastomas. These PARP-1/p53 double null mice represent a novel model for the pathogenesis of human medulloblastomas.	Int Agcy Res Canc, F-69008 Lyon, France		Wang, ZQ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.			Christelle, GRANIER/0000-0001-8987-0632			AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dahmen RP, 2001, CANCER RES, V61, P7039; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fulda S, 1997, CANCER RES, V57, P4956; German J, 1998, GENETIC BASIS HUMAN, P301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Helms AW, 1998, DEVELOPMENT, V125, P919; Helms AW, 2000, DEVELOPMENT, V127, P1185; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JULURI K, 2002, PHARM TOXIC, P1; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kleihues P, 1997, AM J PATHOL, V150, P1; KLEIHUES P, 2000, WHO CLASSIFICATION T, P129; Kraus JA, 1996, INT J CANCER, V67, P11, DOI 10.1002/(SICI)1097-0215(19960703)67:1<11::AID-IJC3>3.0.CO;2-2; LANTOS PL, 2002, GREENFIELDS NEUROPAT, P117; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MALKIN D, 1998, GENETIC BASIS HUMAN, P393; Marino S, 2000, GENE DEV, V14, P994; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; MENESSIERDEMURC.J, 1997, P NATL ACAD SCI USA, V94, P7303; Michiels EMC, 1999, PHYSIOL GENOMICS, V1, P83, DOI 10.1152/physiolgenomics.1999.1.2.83; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)82296-0; Pietsch T, 1997, CANCER RES, V57, P2085; Pietsch T, 1997, KLIN PADIATR, V209, P150, DOI 10.1055/s-2008-1043965; Raffel C, 1997, CANCER RES, V57, P842; Reardon DA, 1997, CANCER RES, V57, P4042; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2000, COLD SPRING HARB SYM, V65, P583, DOI 10.1101/sqb.2000.65.583; Tong WM, 1998, INT J CANCER, V75, P467, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;467::AID-IJC22&gt;3.0.CO;2-4; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Vrieling H, 2001, NAT GENET, V28, P101, DOI 10.1038/88794; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1997, CANCER RES, V57, P2369; Yokota N, 1996, CANCER RES, V56, P377; Zurawel RH, 1998, CANCER RES, V58, P896	56	121	128	0	5	AMER SOC INVESTIGATIVE PATHOLOGY, INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA	0002-9440			AM J PATHOL	Am. J. Pathol.	JAN	2003	162	1					343	352		10.1016/S0002-9440(10)63825-4			10	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	628RG	WOS:000180009800035	12507917	Green Published			2022-02-25	
J	Lambert, R				Lambert, R			Screening for sporadic colorectal cancer - Reply to Hoff et al.	ENDOSCOPY			English	Editorial Material							TELEMARK POLYP; PREVENTION		Int Agcy Res Canc, F-69372 Lyon 08, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.						Black WC, 2002, JNCI-J NATL CANCER I, V94, P167, DOI 10.1093/jnci/94.3.167; Hoff G, 2001, EUR J CANCER PREV, V10, P131, DOI 10.1097/00008469-200104000-00003; Lambert R, 2001, ENDOSCOPY, V33, P1042, DOI 10.1055/s-2001-18938; MULLER AD, 1995, ANN INTERN MED, V123, P904, DOI 10.7326/0003-4819-123-12-199512150-00002; Thiis-Evensen E, 1999, SCAND J GASTROENTERO, V34, P414	5	0	0	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X			ENDOSCOPY	Endoscopy	JUN	2002	34	6					509	510		10.1055/s-2002-31998			2	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	560JQ	WOS:000176079300021					2022-02-25	
J	Suzuki, T; Masuda, M; Friesen, MD; Ohshima, H				Suzuki, T; Masuda, M; Friesen, MD; Ohshima, H			Identification of products formed by reaction of 2'-deoxyguanosine with hypochlorous acid or a myeloperoxidase-H2O2-Cl- system	FREE RADICAL BIOLOGY AND MEDICINE			English	Meeting Abstract									Int Agcy Res Canc, Unit Nutr & Canc, F-69372 Lyon 08, France; Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon, France				Friesen, Marlin D/D-7328-2012					0	0	0	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.		2002	33			1		719	S269	S270					2	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	578AY	WOS:000177096300717					2022-02-25	
J	Vainio, H; Bianchini, F				Vainio, H; Bianchini, F			Physical activity and cancer prevention - is 'no pain, no gain' passe?	EUROPEAN JOURNAL OF CANCER PREVENTION			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon 08, France		Vainio, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.						*IARC, 2001, IN PRESS IARC HDB CA, V6; Lee IM, 2001, JAMA-J AM MED ASSOC, V285, P1447, DOI 10.1001/jama.285.11.1447; *US DHHS, 1996, PHYS ACT HLTH REP SU	3	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-8278			EUR J CANCER PREV	Eur. J. Cancer Prev.	AUG	2001	10	4					301	302		10.1097/00008469-200108000-00001			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	462ZQ	WOS:000170452700001	11535870				2022-02-25	
J	Ohgaki, H; Nakamura, M; Watanabe, T; Kleihues, P				Ohgaki, H; Nakamura, M; Watanabe, T; Kleihues, P			Promoter hypermethylation of O-6-methylguanine-DNA methyltransferase gene in gliomas	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Meeting Abstract									Int Agcy Res Canc, F-69372 Lyon, France									0	1	1	0	0	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2001	60	5				126	534	534					1	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	433XW	WOS:000168786800137					2022-02-25	
J	Tommasino, M				Tommasino, Massimo			Role of human papillomaviruses in carcinogenesis.	CANCER RESEARCH			English	Meeting Abstract	AACR Special Conference on the Microbiome, Viruses, and Cancer	FEB 21-24, 2020	Orlando, FL	Amer Assoc Canc Res					[Tommasino, Massimo] Int Agcy Res Canc IARC WHO, Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	APR	2020	80	8		S		IA15	21	22					2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	LD5GG	WOS:000526057000014					2022-02-25	
J	Chung, FFL; Herceg, Z				Chung, Felicia Fei-Lei; Herceg, Zdenko			The Promises and Challenges of Toxico-Epigenomics: Environmental Chemicals and Their Impacts on the Epigenome	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article							GLOBAL DNA METHYLATION; EPIGENETIC TRANSGENERATIONAL INHERITANCE; ENDOCRINE DISRUPTOR VINCLOZOLIN; BISPHENOL-A; GENE-EXPRESSION; IN-VITRO; MECHANISM LINKING; PRENATAL EXPOSURE; NONCODING RNA; GENOMIC DNA	BACKGROUND: It has been estimated that a substantial portion of chronic and noncommunicable diseases can he caused or exacerbated by exposure to environmental chemicals. Multiple lines of evidence indicate that early life exposure to environmental chemicals at relatively low concentrations could have lasting effects on individual and population health. Although the potential adverse effects of environmental chemicals are known to the scientific community, regulatory agencies, and the public, little is known about the mechanistic basis by which these chemicals can induce long-term or transgenerational effects. To address this question, epigenetic mechanisms have emerged as the potential link between genetic and environmental factors of health and disease. OBJECTIVES: We present an overview of epigenetic regulation and a summary of reported evidence of environmental toxicants as epigenetic disruptors. We also discuss the advantages and challenges of using epigenetic biomarkers as an indicator of toxicant exposure, using measures that can he taken to improve risk assessment, and our perspectives on the future role of epigenetics in toxicology. DISCUSSION: Until recently, efforts to apply epigenomic data in toxicology and risk assessment were restricted by an incomplete understanding of epigenomic variability across tissue types and populations. This is poised to change with the development of new tools and concerted efforts by researchers across disciplines that have led to a better understanding of epigenetic mechanisms and comprehensive maps of epigenomic variation. With the foundations now in place, we foresee that unprecedented advancements will take place in the field in the coming years.	[Chung, Felicia Fei-Lei; Herceg, Zdenko] IARC, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Herceg, Z (corresponding author), IARC, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	Hercegz@iarc.fr	Chung, Felicia FL/E-5846-2016	Chung, Felicia FL/0000-0003-1043-4948	Institut National du Cancer (INCa, France)Institut National du Cancer (INCA) France; European Commission (EC) Seventh Framework Programme (FP7) Translational Cancer Research (TRANSCAN) Framework; Foundation ARC pour la Recherche sur le Cancer (France); Plan Cancer-Eva-Inserm research grant; IARC - EC FP7 Marie Curie Actions People Co funding of regional, national, and international programs (COFUND); French ministry of Foreign Affairs (the Hubert Curien Partnership Hibiscus Mobility grant)	The work in the Epigenetics Group at the International Agency for Research on Cancer (IARC) is supported by grants from the Institut National du Cancer (INCa, France), the European Commission (EC) Seventh Framework Programme (FP7) Translational Cancer Research (TRANSCAN) Framework, the Foundation ARC pour la Recherche sur le Cancer (France), and Plan Cancer-Eva-Inserm research grant to Z.H. The preparation of this paper was undertaken during the tenure of a postdoctoral fellowship (to F.C.) from the IARC, partially supported by the EC FP7 Marie Curie Actions People Co funding of regional, national, and international programs (COFUND). F.F.-L.C. and Z.H. are also supported by the French ministry of Foreign Affairs (the Hubert Curien Partnership Hibiscus Mobility grant). The authors certify that their freedom to design, conduct, interpret, and publish research was not compromised by any controlling sponsor.	Adjakly M, 2011, EPIGENOMICS-UK, V3, P795, DOI [10.2217/EPI.11.103, 10.2217/epi.11.103]; Almeida S, 2018, COMPR REV FOOD SCI F, V17, P1503, DOI 10.1111/1541-4337.12388; Alofe O, 2019, ENVIRON INT, V131, DOI 10.1016/j.envint.2019.104969; Ambatipudi S, 2016, EPIGENOMICS-UK, V8, P599, DOI 10.2217/epi-2016-0001; Amer Soc Reprod Med, 2013, FERTIL STERIL, V100, P931, DOI 10.1016/j.fertnstert.2013.08.043; Andersen AM, 2015, GENES-BASEL, V6, P991, DOI 10.3390/genes6040991; Anderson OS, 2017, ENDOCRINOLOGY, V158, P31, DOI 10.1210/en.2016-1441; Anderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692; Angrand PO, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00165; Ankley GT, 2010, ENVIRON TOXICOL CHEM, V29, P730, DOI 10.1002/etc.34; Ankolkar M, 2018, ANDROLOGIA, V50, DOI 10.1111/and.13060; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Ashe A, 2012, CELL, V150, P88, DOI 10.1016/j.cell.2012.06.018; Baba Y, 2019, ANAL LETT, V52, P754, DOI 10.1080/00032719.2018.1494739; Bai WL, 2014, EXP MOL PATHOL, V96, P426, DOI 10.1016/j.yexmp.2014.04.011; Bai WL, 2014, EXP MOL PATHOL, V96, P354, DOI 10.1016/j.yexmp.2014.02.016; Bansal A, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1674; Barouki R, 2018, ENVIRON INT, V114, P77, DOI 10.1016/j.envint.2018.02.014; Barrett JR, 2017, ENVIRON HEALTH PERSP, V125, pA72, DOI 10.1289/ehp.125-A72; Basak S, 2018, REPROD TOXICOL, V82, P72, DOI 10.1016/j.reprotox.2018.10.009; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Beck D, 2017, ENVIRON EPIGENETICS, V3, DOI 10.1093/eep/dvx016; Ben Maamar M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23612-y; Bend EG, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0658-5; Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002; Bianco-Miotto T, 2017, J DEV ORIG HLTH DIS, V8, P513, DOI 10.1017/S2040174417000733; Bijlsma N, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13020181; Bintu B, 2018, SCIENCE, V362, P419, DOI 10.1126/science.aau1783; Bintu L, 2016, SCIENCE, V351, P720, DOI 10.1126/science.aab2956; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Blewitt M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017939; Bock C, 2016, NAT BIOTECHNOL, V34, P726, DOI 10.1038/nbt.3605; Bojesen SE, 2017, THORAX, V72, P646, DOI 10.1136/thoraxjnl-2016-208789; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Bopp SK, 2019, CRIT REV TOXICOL, V49, P174, DOI 10.1080/10408444.2019.1579169; Bornehag CG, 2019, RISK ANAL, V39, P2259, DOI 10.1111/risa.13323; Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Breeze CE, 2016, CELL REP, V17, P2137, DOI 10.1016/j.celrep.2016.10.059; Breton CV, 2017, ENVIRON HEALTH PERSP, V125, P511, DOI [10.1289/EHP595, 10.1289/ehp595]; Brieno-Enriquez MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124296; Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533; Bromer JG, 2009, ENDOCRINOLOGY, V150, P3376, DOI 10.1210/en.2009-0071; BROWN P, 1995, ENVIRON RES, V69, P15, DOI 10.1006/enrs.1995.1021; Brzoska K, 2019, MATERIALS, V12, DOI 10.3390/ma12071038; Buckley BA, 2012, NATURE, V489, P447, DOI 10.1038/nature11352; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Bujold D, 2016, CELL SYST, V3, P496, DOI 10.1016/j.cels.2016.10.019; Burton NO, 2011, P NATL ACAD SCI USA, V108, P19683, DOI 10.1073/pnas.1113310108; Byun HM, 2015, TOXICOLOGY, V328, P152, DOI 10.1016/j.tox.2014.12.019; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Campa CC, 2019, NAT METHODS, V16, P887, DOI 10.1038/s41592-019-0508-6; Casati L, 2013, EPIGENETICS-US, V8, P1061, DOI 10.4161/epi.25811; Castillo P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044139; Cazaly E, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00126; Cedergreen N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096580; Chen CH, 2018, ENVIRON RES, V162, P261, DOI 10.1016/j.envres.2018.01.009; Chen JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126403; Chen ML, 2013, CLIN CHEM, V59, P824, DOI 10.1373/clinchem.2012.193938; Chen RJ, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/EHP1447, 10.1289/ehp1447]; Chen Z, 2017, ANNU REV BIOMED ENG, V19, P195, DOI 10.1146/annurev-bioeng-071516-044720; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Cheng HR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209014; Cheong A, 2018, EPIGENETICS-US, V13, P704, DOI 10.1080/15592294.2018.1497388; Chou WC, 2017, TOXICOL IN VITRO, V41, P133, DOI 10.1016/j.tiv.2017.02.012; Coady KK, 2017, INTEGR ENVIRON ASSES, V13, P302, DOI 10.1002/ieam.1862; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; Coulter JB, 2013, J BIOL CHEM, V288, P28792, DOI 10.1074/jbc.M113.491365; Creech AL, 2015, METHODS, V72, P57, DOI 10.1016/j.ymeth.2014.10.033; Cronican AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053478; Crujeiras AB, 2019, INT J OBESITY, V43, P176, DOI 10.1038/s41366-018-0065-6; Curtis SW, 2019, EPIGENETICS-US, V14, P52, DOI 10.1080/15592294.2019.1565590; de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058; De Jager PL, 2014, NAT NEUROSCI, V17, P1156, DOI 10.1038/nn.3786; Dekker J, 2017, NATURE, V549, P219, DOI 10.1038/nature23884; Delfosse V, 2014, VITAM HORM, V94, P229, DOI 10.1016/B978-0-12-800095-3.00009-2; Ding TB, 2018, BIOL REPROD, V99, P864, DOI 10.1093/biolre/ioy111; Ding X, 2019, CRISPR J, V2, P51, DOI 10.1089/crispr.2018.0036; Ding ZM, 2017, CHEM-BIOL INTERACT, V278, P222, DOI 10.1016/j.cbi.2017.10.030; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9; Doi T, 2011, TOXICOL SCI, V120, P475, DOI 10.1093/toxsci/kfr022; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Doshi T, 2012, J BIOCHEM MOL TOXIC, V26, P337, DOI 10.1002/jbt.21425; Doshi T, 2011, TOXICOLOGY, V289, P74, DOI 10.1016/j.tox.2011.07.011; Drobna Z, 2018, ENDOCRINOLOGY, V159, P132, DOI 10.1210/en.2017-00730; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Esner M, 2018, METHODS MOL BIOL, V1683, P149, DOI 10.1007/978-1-4939-7357-6_10; Espin-Perez A, 2018, ENVIRON POLLUT, V242, P182, DOI 10.1016/j.envpol.2018.06.051; Esposti DD, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0419-z; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; European Commission, 2012, TOX ASS CHEM MIXT; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Farhy C, 2019, ELIFE, V8, DOI 10.7554/eLife.49683; Fasanelli F, 2019, EPIGENETICS-US, V14, P977, DOI 10.1080/15592294.2019.1629230; Faulk C, 2015, ENVIRON EPIGENETICS, V1, DOI 10.1093/eep/dvv006; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Fenner-Crisp PA, 2000, ECOTOXICOLOGY, V9, P85, DOI 10.1023/A:1008972330318; Fraga MF, 2009, CURR OPIN IMMUNOL, V21, P446, DOI 10.1016/j.coi.2009.04.003; Fudhaili A, 2019, ONCOL REP, V41, P1377, DOI 10.3892/or.2018.6898; Fustinoni S, 2012, MED LAV, V103, P84; Gao YS, 2019, TOXICOL LETT, V315, P31, DOI 10.1016/j.toxlet.2019.08.007; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Ghantous A, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/1472-6750-14-60; Ghosh K, 2019, EPIGENOMICS-UK, V11, P899, DOI 10.2217/epi-2018-0175; Gonzalez-Rojo S, 2019, ENVIRON POLLUT, V248, P368, DOI 10.1016/j.envpol.2019.01.127; Goodrich J, 2019, EUR NEUROPSYCHOPHARM, V29, pS747, DOI 10.1016/j.euroneuro.2017.06.086; Goodrich JM, 2016, ENVIRON EPIGENETICS, V2, DOI 10.1093/eep/dvw018; Goodson WH, 2015, CARCINOGENESIS, V36, pS254, DOI 10.1093/carcin/bgv039; Goyal D, 2019, J ENDOCRINOL, V242, pT105, DOI 10.1530/JOE-19-0009; Grandjean P, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0340-3; Greenberg MVC, 2019, NAT REV MOL CELL BIO, V20, P590, DOI 10.1038/s41580-019-0159-6; Grindler NM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24505-w; Guerrero-Bosagna C, 2012, REPROD TOXICOL, V34, P694, DOI 10.1016/j.reprotox.2012.09.005; Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100; Guillette LJ, 2016, GEN COMP ENDOCR, V238, P4, DOI 10.1016/j.ygcen.2016.04.012; Gupta C, 2015, 2015 SECOND INTERNATIONAL CONFERENCE ON ADVANCES IN COMPUTING AND COMMUNICATION ENGINEERING ICACCE 2015, P355, DOI 10.1109/ICACCE.2015.61; Gutierrez-Garcia AK, 2019, CHEM RES TOXICOL, V32, P1863, DOI 10.1021/acs.chemrestox.9b00206; Han WG, 2013, EPIGENETICS-US, V8, P1176, DOI 10.4161/epi.26195; Hanly DJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0074; Hartung T, 2017, CHEM RES TOXICOL, V30, P870, DOI 10.1021/acs.chemrestox.7b00003; Hattori N, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0267-2; Herceg Z, 2018, INT J CANCER, V142, P874, DOI 10.1002/ijc.31014; Houseman EA, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1140-4; Howden Sara, 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P2258; Hu JJ, 2014, ENVIRON TOXICOL, V29, P108, DOI 10.1002/tox.20777; Hung CH, 2010, ENVIRON HEALTH PERSP, V118, P67, DOI 10.1289/ehp.0901011; Hussain I, 2015, BBA-GENE REGUL MECH, V1849, P697, DOI 10.1016/j.bbagrm.2015.02.003; Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103; Itoh K, 2012, NEUROPATHOLOGY, V32, P447, DOI 10.1111/j.1440-1789.2011.01287.x; Jadhav RR, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050144; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jefferson WN, 2013, MOL ENDOCRINOL, V27, P1666, DOI 10.1210/me.2013-1211; Jia ZF, 2017, JOVE-J VIS EXP, DOI 10.3791/55565; Jiang W, 2016, AGE, V38, P405, DOI 10.1007/s11357-016-9947-5; Jo WJ, 2009, TOXICOL APPL PHARM, V241, P294, DOI 10.1016/j.taap.2009.08.027; Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965; Jorgensen EM, 2016, FASEB J, V30, P3194, DOI 10.1096/fj.201500089R; Karaman EF, 2019, MYCOTOXIN RES, V35, P309, DOI 10.1007/s12550-019-00358-8; Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kienzler A, 2016, REGUL TOXICOL PHARM, V80, P321, DOI 10.1016/j.yrtph.2016.05.020; Kitraki E, 2015, MOL CELL ENDOCRINOL, V417, P191, DOI 10.1016/j.mce.2015.09.028; Klukovich R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38741-1; Kobets T, 2019, TOXICOL RES-UK, V8, P123, DOI [10.1039/c8tx00250a, 10.1039/C8TX00250A]; Kortenkamp A, 2014, CURR OPIN PHARMACOL, V19, P105, DOI 10.1016/j.coph.2014.08.006; Krauskopf J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10167-7; Kucab JE, 2019, CELL, V177, P821, DOI 10.1016/j.cell.2019.03.001; Kumamoto T, 2013, J TOXICOL SCI, V38, P485, DOI 10.2131/jts.38.485; Kumar D, 2017, J TOXICOL SCI, V42, P281, DOI 10.2131/jts.42.281; Kumar N, 2018, CHEM REC, V18, P1672, DOI 10.1002/tcr.201800039; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Kundakovic M, 2013, P NATL ACAD SCI USA, V110, P9956, DOI 10.1073/pnas.1214056110; Laing LV, 2016, EPIGENETICS-US, V11, P526, DOI 10.1080/15592294.2016.1182272; LaKind JS, 2016, J EXPO SCI ENV EPID, V26, P529, DOI 10.1038/jes.2016.35; Lamb YN, 2017, MOL DIAGN THER, V21, P225, DOI 10.1007/s40291-017-0259-y; LaRocca J, 2016, ENVIRON HEALTH PERSP, V124, P380, DOI 10.1289/ehp.1408409; LaRocca J, 2014, ENVIRON RES, V133, P396, DOI 10.1016/j.envres.2014.04.032; Lee HJ, 2014, CELL STEM CELL, V14, P710, DOI 10.1016/j.stem.2014.05.008; Li A, 2019, ENVIRON HEALTH PERSP, V127, DOI [10.1289/ehp3986, 10.1289/EHP3986]; Li GQ, 2014, TOXICOL LETT, V228, P192, DOI 10.1016/j.toxlet.2014.04.012; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Li J, 2018, ENVIRON POLLUT, V234, P127, DOI 10.1016/j.envpol.2017.11.042; Li J, 2017, BIOMARKERS, V22, P470, DOI 10.1080/1354750X.2016.1274335; Lichtenfels AJDC, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/EHP2045, 10.1289/ehp2045]; Lim SJ, 2010, BIOINFORMATION, V4, P331, DOI 10.6026/97320630004331; Liu WJ, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0620-6; Liu Y, 2016, J THORAC DIS, V8, P403, DOI 10.21037/jtd.2016.02.56; Lu WC, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00057; Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290; Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662; Mancini M, 2017, TOXICOL IN VITRO, V40, P1, DOI 10.1016/j.tiv.2016.12.007; Mao QN, 2010, J PHYS D APPL PHYS, V43, DOI 10.1088/0022-3727/43/39/395104; Mao ZX, 2015, TOXICOL LETT, V238, P30, DOI 10.1016/j.toxlet.2015.08.009; Marczylo EL, 2016, CRIT REV TOXICOL, V46, P676, DOI 10.1080/10408444.2016.1175417; Fernandez JM, 2016, CELL SYST, V3, P491, DOI 10.1016/j.cels.2016.10.021; Marsit CJ, 2015, J EXP BIOL, V218, P71, DOI 10.1242/jeb.106971; Martin EM, 2018, ANNU REV PUBL HEALTH, V39, P309, DOI 10.1146/annurev-publhealth-040617-014629; Martinez-Arguelles DB, 2015, ENDOCRINOLOGY, V156, P124, DOI 10.1210/en.2014-1436; McGregor K, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0935-y; McHale CM, 2011, ENVIRON HEALTH PERSP, V119, P628, DOI 10.1289/ehp.1002546; Meakin CJ, 2019, CHEM RES TOXICOL, V32, P493, DOI 10.1021/acs.chemrestox.8b00352; Mensaert K, 2014, ENVIRON MOL MUTAGEN, V55, P155, DOI 10.1002/em.21841; Meruvu S, 2016, TOXICOL IN VITRO, V31, P35, DOI 10.1016/j.tiv.2015.11.010; Messerlian C, 2017, NAT REV ENDOCRINOL, V13, P740, DOI 10.1038/nrendo.2017.81; Meunier L, 2012, ENDOCRINOLOGY, V153, P1936, DOI 10.1210/en.2011-1109; Miao M, 2014, ANDROLOGY-US, V2, P138, DOI 10.1111/j.2047-2927.2013.00166.x; Milesi MM, 2017, MOL CELL ENDOCRINOL, V454, P1, DOI 10.1016/j.mce.2017.05.028; MOLDEN RC, 2014, CURR PROTOC PROTEIN, V77, P27; Nadal A, 2005, PFLUG ARCH EUR J PHY, V449, P335, DOI 10.1007/s00424-004-1343-9; Niedzwiecki MM, 2017, ENVIRON HEALTH PERSP, V125, DOI [10.1289/EHP1712, 10.1289/ehp1712]; Novo M, 2018, ECOTOX ENVIRON SAFE, V150, P159, DOI 10.1016/j.ecoenv.2017.12.030; O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402; Perrier F, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0637-x; Perrot-Applanat M, 2018, MOL CELL ENDOCRINOL, V475, P29, DOI 10.1016/j.mce.2018.06.015; Philibert R, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00055; Pietryk EW, 2018, REPROD TOXICOL, V78, P9, DOI 10.1016/j.reprotox.2018.03.005; Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P1466, DOI 10.1289/ehp.0800497; Prins Gail S, 2008, Fertil Steril, V89, pe41, DOI 10.1016/j.fertnstert.2007.12.023; Priya ES, 2018, REPROD SCI, V25, P818, DOI 10.1177/1933719117699707; Rasoulpour RJ, 2011, TOXICOL MECH METHOD, V21, P298, DOI 10.3109/15376516.2011.557883; Ray PD, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00201; Renaud L, 2017, GENES-BASEL, V8, DOI 10.3390/genes8100269; Roetker NS, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.117.001937; Ronco AM, 2010, TOXICOL IN VITRO, V24, P1532, DOI 10.1016/j.tiv.2010.07.003; Rose NR, 2014, BBA-GENE REGUL MECH, V1839, P1362, DOI 10.1016/j.bbagrm.2014.02.007; Rotroff DM, 2013, ENVIRON HEALTH PERSP, V121, P7, DOI 10.1289/ehp.1205065; Sales LB, 2013, TOXICOL IN VITRO, V27, P1634, DOI 10.1016/j.tiv.2013.04.005; Sato K, 2009, ENDOCR J, V56, P131, DOI 10.1507/endocrj.K08E-239; Sato S, 2006, INT J EMERG ELECTR P, V6, DOI 10.2202/1553-779X.1306; Schuster A, 2016, ENVIRON EPIGENETICS, V2, DOI 10.1093/eep/dvw001; Sears ME, 2012, J ENVIRON PUBLIC HEA, V2012, DOI 10.1155/2012/356798; Senyildiz M, 2017, TOXICOL IN VITRO, V44, P313, DOI 10.1016/j.tiv.2017.07.028; Singh NP, 2018, TOXICOLOGY, V410, P49, DOI 10.1016/j.tox.2018.08.012; Skinner MK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003745; Smeester L, 2011, CHEM RES TOXICOL, V24, P165, DOI 10.1021/tx1004419; Smith CM, 2019, AQUAT TOXICOL, V210, P215, DOI 10.1016/j.aquatox.2019.03.005; Song Y, 2018, TOXICOL LETT, V297, P34, DOI 10.1016/j.toxlet.2018.08.015; Song Y, 2014, HUM REPROD, V29, P2512, DOI 10.1093/humrep/deu208; Sonkar R, 2016, MOL CELL ENDOCRINOL, V431, P109, DOI 10.1016/j.mce.2016.04.025; Soubry A, 2017, ENVIRON EPIGENETICS, V3, DOI 10.1093/eep/dvx003; Stelzer Y, 2015, CELL, V163, P218, DOI 10.1016/j.cell.2015.08.046; Stouder C, 2011, REPRODUCTION, V141, P207, DOI 10.1530/REP-10-0400; Stouder C, 2010, REPRODUCTION, V139, P373, DOI 10.1530/REP-09-0340; Stueve TR, 2016, EPIGENOMICS-UK, V8, P817, DOI 10.2217/epi-2016-0005; Sturla SJ, 2014, CHEM RES TOXICOL, V27, P314, DOI 10.1021/tx400410s; Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682; Taylor JA, 2018, ENDOCRINOLOGY, V159, P779, DOI 10.1210/en.2017-00711; Thirlwell C, 2010, METHODS, V52, P248, DOI 10.1016/j.ymeth.2010.04.012; Tindula G, 2018, EPIGENOMICS-UK, V10, P1011, DOI 10.2217/epi-2017-0178; Tonge DP, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0057-9; Tryndyak VP, 2007, MOL CARCINOGEN, V46, P187, DOI 10.1002/mc.20263; Tryndyak VP, 2006, CARCINOGENESIS, V27, P1713, DOI 10.1093/carcin/bgl050; Ueda J, 2014, STEM CELL REP, V2, P910, DOI 10.1016/j.stemcr.2014.05.008; Urich MA, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2014.114; Uzumcu M, 2004, REPROD TOXICOL, V18, P765, DOI 10.1016/j.reprotox.2004.05.008; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; van der Weijden VA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25831-9; Vandenberg LN, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-46; Vandenberg LN, 2014, DOSE-RESPONSE, V12, P259, DOI 10.2203/dose-response.13-020.Vandenberg; Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050; Vanhees K, 2011, FASEB J, V25, P797, DOI 10.1096/fj.10-172155; Varin T, 2010, J CHEM INF MODEL, V50, P2067, DOI 10.1021/ci100203e; Venturelli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073097; Vilahur N, 2014, ENVIRON INT, V71, P81, DOI 10.1016/j.envint.2014.06.006; VonHandorf A, 2018, EPIGENETICS-US, V13, P363, DOI 10.1080/15592294.2018.1454243; Vrijheid M, 2014, ENVIRON HEALTH PERSP, V122, P535, DOI 10.1289/ehp.1307204; Wang T, 2016, ONCOTARGET, V7, P32554, DOI 10.18632/oncotarget.8689; Wang T, 2018, NAT BIOTECHNOL, V36, P225, DOI 10.1038/nbt.4099; Wei HY, 2015, INT J MOL SCI, V16, P27058, DOI 10.3390/ijms161126001; Weinhouse C, 2015, EPIGENETICS-US, V10, P1099, DOI 10.1080/15592294.2015.1107694; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Wishart D, 2015, NUCLEIC ACIDS RES, V43, pD928, DOI 10.1093/nar/gku1004; Wong CCY, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12226; Wong NC, 2008, BIOTECHNIQUES, V45, P423, DOI 10.2144/000112945; Woo HD, 2018, INT J CANCER, V143, P597, DOI 10.1002/ijc.31381; Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950; Xia B, 2018, TOXICOL LETT, V292, P78, DOI 10.1016/j.toxlet.2018.04.022; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Yang J, 2014, EXP MOL PATHOL, V96, P346, DOI 10.1016/j.yexmp.2014.02.013; Yang PJ, 2018, ONCOL REP, V40, P2766, DOI 10.3892/or.2018.6675; Yang YM, 2018, P NATL ACAD SCI USA, V115, P613, DOI 10.1073/pnas.1716016115; Yoshida W, 2016, ANAL CHEM, V88, P9264, DOI 10.1021/acs.analchem.6b02565; Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499; Zhang L, 2016, KOREAN J FOOD SCI AN, V36, P223, DOI 10.5851/kosfa.2016.36.2.223; Zhong J, 2019, REPROD SCI, V26, P289, DOI 10.1177/1933719118770550; Zhou X, 2009, TOXICOL APPL PHARM, V236, P78, DOI 10.1016/j.taap.2009.01.009; Zhou ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep15293; ZOBER A, 1995, OCCUP ENVIRON MED, V52, P233, DOI 10.1136/oem.52.4.233; ZOGHBI HY, 2016, COLD SPRING HARB PER, V8, DOI DOI 10.1101/CSHPERSPECT.A019497; Zou J, 2014, NAT METHODS, V11, P309, DOI [10.1038/nmeth.2815, 10.1038/NMETH.2815]	274	14	15	7	12	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2020	128	1							015001	10.1289/EHP6104			20	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	KD9RW	WOS:000508199700002	31950866	Green Published, gold			2022-02-25	
J	Tommasino, M				Tommasino, Massimo			HPV and skin carcinogenesis	PAPILLOMAVIRUS RESEARCH			English	Review						Cutaneous beta HPVs; Ultraviolet radiation; Cutaneous squamous cell carcinoma	SQUAMOUS-CELL CARCINOMA; CUTANEOUS HUMAN PAPILLOMAVIRUSES; GAMMA HUMAN PAPILLOMAVIRUSES; BETA; E6; ASSOCIATION; MASTERMIND; PROTEINS; MAML1; E7	Epidemiological and biological studies provide several lines of evidence for the involvement of cutaneous beta human papillomaviruses (HPVs), together with ultraviolet (UV) radiation, in the development of cutaneous squamous cell carcinoma. These viruses appear to act with a hit-and-run mechanism, being necessary at an early stage of carcinogenesis and being dispensable for the maintenance of the malignant phenotype. Studies in experimental models show that beta HPVs, mainly via the E6 and E7 oncoproteins, are able to promote proliferation and to circumvent cellular stresses induced by UV radiation. These findings support a model of skin carcinogenesis in which beta HPV-infected keratinocytes remain alive despite the accumulation of UV-induced DNA mutations. In this manner, these cells become highly susceptible to progression towards malignancy. Thus, UV radiation is the main driver of skin cancer development, while beta HPVs act as facilitators of the accumulation of UV-induced DNA mutations.	[Tommasino, Massimo] IARC, Infect & Canc Biol Grp, Lyon, France		Tommasino, M (corresponding author), IARC, Infect & Canc Biol Grp, Lyon, France.	tommasinom@iarc.fr		Tommasino, Massimo/0000-0002-0890-8596	European Commission, HPV-AHEADEuropean Commission [FP7-HEALTH-2011-282562]; Fondation ARC pour la Recherche sur le CancerFondation ARC pour la Recherche sur le Cancer [JA 20151203192]; InsermInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission [ENV201610]	I apologize to those authors whose important contributions to HPV research could not be cited or adequately discussed due to space limitations. I thank all the members of the Infections and Cancer Biology Group for their constant support and Dr Karen Muller for editing this manuscript. The work performed in the group is partially supported by grants from the European Commission, HPV-AHEAD (FP7-HEALTH-2011-282562), Inserm (ENV201610), and Fondation ARC pour la Recherche sur le Cancer (JA 20151203192).	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Bavinck JNB, 2018, AM J TRANSPLANT, V18, P1220, DOI 10.1111/ajt.14537; Bavinck JNB, 2010, CANCER RES, V70, P9777, DOI 10.1158/0008-5472.CAN-10-0352; Brimer N, 2012, ONCOGENE, V31, P4639, DOI 10.1038/onc.2011.589; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; Chahoud J, 2016, JAMA DERMATOL, V152, P1354, DOI 10.1001/jamadermatol.2015.4530; Cornet I, 2012, J VIROL, V86, P2366, DOI 10.1128/JVI.06579-11; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Farzan SF, 2013, INT J CANCER, V133, P1713, DOI 10.1002/ijc.28176; Forslund O, 2007, J INFECT DIS, V196, P876, DOI 10.1086/521031; Hasche D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006723; Howley PM, 2015, VIROLOGY, V479, P290, DOI 10.1016/j.virol.2015.02.004; Iannacone MR, 2014, INT J CANCER, V134, P2231, DOI 10.1002/ijc.28552; Iannacone MR, 2012, CANCER EPIDEM BIOMAR, V21, P1303, DOI 10.1158/1055-9965.EPI-12-0032; Karagas MR, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c2986; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1111/j.1365-2133.2000.03703.x; Marcuzzi GP, 2009, J GEN VIROL, V90, P2855, DOI 10.1099/vir.0.012872-0; Meyers JM, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00389; Meyers JM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006171; Meyers JM, 2013, J VIROL, V87, P4762, DOI 10.1128/JVI.02527-12; Rollison DE, 2019, J VIROL, V93, DOI 10.1128/JVI.01003-18; Strati K, 2006, P NATL ACAD SCI USA, V103, P14152, DOI 10.1073/pnas.0606698103; Tan MJA, 2012, P NATL ACAD SCI USA, V109, pE1473, DOI 10.1073/pnas.1205991109; Tommasino M, 2017, VIRUS RES, V231, P128, DOI 10.1016/j.virusres.2016.11.013; Tommasino M, 2014, SEMIN CANCER BIOL, V26, P13, DOI 10.1016/j.semcancer.2013.11.002; Viarisio D, 2016, CANCER RES, V76, P4216, DOI 10.1158/0008-5472.CAN-16-0370; Viarisio D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002125; Waterboer T, 2008, BRIT J DERMATOL, V159, P457, DOI 10.1111/j.1365-2133.2008.08621.x; Weissenborn SJ, 2005, J INVEST DERMATOL, V125, P93, DOI 10.1111/j.0022-202X.2005.23733.x; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	30	25	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2405-8521			PAPILLOMAVIRUS RES	Papillomavirus Res.	JUN	2019	7						129	131		10.1016/j.pvr.2019.04.003			3	Virology	Emerging Sources Citation Index (ESCI)	Virology	IA8HU	WOS:000469800500019	30953864	gold, Green Published			2022-02-25	
J	Plummer, M; de Martel, C; Vignat, J; Ferlay, J; Bray, F; Franceschi, S				Plummer, Martyn; de Martel, Catherine; Vignat, Jerome; Ferlay, Jacques; Bray, Freddie; Franceschi, Silvia			Global burden of cancers attributable to infections in 2012: a synthetic analysis	LANCET GLOBAL HEALTH			English	Article							HUMAN-PAPILLOMAVIRUS; PREVALENCE; HEAD; HCV	Background Infections with certain viruses, bacteria, and parasites are strong risk factors for specific cancers. As new cancer statistics and epidemiological findings have accumulated in the past 5 years, we aimed to assess the causal involvement of the main carcinogenic agents in different cancer types for the year 2012. Methods We considered ten infectious agents classified as carcinogenic to human beings by the International Agency for Research on Cancer. We calculated the number of new cancer cases in 2012 attributable to infections by country, by combining cancer incidence estimates (from GLOBOCAN 2012) with estimates of attributable fraction (AF) for the infectious agents. AF estimates were calculated from the prevalence of infection in cancer cases and the relative risk for the infection (for some sites). Estimates of infection prevalence, relative risk, and corresponding 95% CIs for AF were obtained from systematic reviews and pooled analyses. Findings Of 14 million new cancer cases in 2012, 2 . 2 million (15 . 4%) were attributable to carcinogenic infections. The most important infectious agents worldwide were Helicobacter pylori (770 000 cases), human papillomavirus (640 000), hepatitis B virus (420 000), hepatitis C virus (170 000), and Epstein-Barr virus (120 000). Kaposi's sarcoma was the second largest contributor to the cancer burden in sub-Saharan Africa. The AFs for infection varied by country and development status-from less than 5% in the USA, Canada, Australia, New Zealand, and some countries in western and northern Europe to more than 50% in some countries in sub-Saharan Africa. Interpretation A large potential exists for reducing the burden of cancer caused by infections. Socioeconomic development is associated with a decrease in infection-associated cancers; however, to reduce the incidence of these cancers without delay, population-based vaccination and screen-and-treat programmes should be made accessible and available. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.	[Plummer, Martyn; de Martel, Catherine; Vignat, Jerome; Ferlay, Jacques; Bray, Freddie; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Plummer, M (corresponding author), Int Agcy Res Canc, F-69372 Lyon 08, France.	plummerm@iarc.fr	Ferlay, Jacques/ABD-5058-2021; franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497; Bray, Freddie/0000-0002-3248-7787	Fondation de FranceFondation de France	Fondation de France.	[Anonymous], 2015, HUM DEV REP 2013 WOR; Bohlius J, 2014, INT J CANCER, V135, P2644, DOI 10.1002/ijc.28894; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Bruggmann P, 2014, J VIRAL HEPATITIS, V21, P5, DOI 10.1111/jvh.12247; Casella G., 2004, MONTE CARLO STAT MET; Clifford GM, 2016, J ACQUIR IMMUNE DEFI; Combes JD, 2014, ORAL ONCOL, V50, P370, DOI 10.1016/j.oraloncology.2013.11.004; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; de Martel C., 2012, LANCET ONCOL, V13, P607, DOI DOI 10.1016/S1470-2045(12)70137-7; de Martel C, 2015, AIDS, V29, P2173, DOI 10.1097/QAD.0000000000000808; de Martel C, 2015, HEPATOLOGY, V62, P1190, DOI 10.1002/hep.27969; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Hanson CM, 2015, VACCINES-BASEL, V3, P408, DOI 10.3390/vaccines3020408; Herrero R, 2014, BEST PRACT RES CL GA, V28, P1107, DOI 10.1016/j.bpg.2014.10.003; Hung GY, 2015, J HEPATOL, V63, P1390, DOI 10.1016/j.jhep.2015.07.032; IARC Helicobacter pylori Working Group, 2014, IARC WORK GROUP REP, V8; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Lee JH, 2014, ARCH MED RES, V45, P417, DOI 10.1016/j.arcmed.2014.06.001; Ndiaye C, 2014, LANCET ONCOL, V15, P1319, DOI 10.1016/S1470-2045(14)70471-1; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; Robey RC, 2015, CURR OPIN INFECT DIS, V28, P31, DOI 10.1097/QCO.0000000000000122; Shimakawa Y, 2013, INT J CANCER, V132, P658, DOI 10.1002/ijc.27646; Shin HR, 2016, JPN J CLIN ONCOL, V46, P13, DOI 10.1093/jjco/hyv092; Smith BD, 2014, AM J PUBLIC HEALTH, V104, P474, DOI 10.2105/AJPH.2013.301549; United Nations Development Programme, 2013, HUM DEV REP 2013 RIS; WHO, 2011, GLOBAL STATUS REPORT; WHO, 2015, GLOB IMM DAT 2015; WHO, 2015, WHO GUID APPR GUID R; WHO Publication, 2010, Vaccine, V28, P589, DOI 10.1016/j.vaccine.2009.10.110; World Health Organization, 2015, POL BRIEF CONS GUID; World Health Organization (WHO), 2014, WKLY EPIDEMIOL REC, V89, P65, DOI DOI 10.1186/1750-9378-2-15	33	669	728	10	70	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2214-109X			LANCET GLOB HEALTH	Lancet Glob. Health	SEP	2016	4	9					E609	E616		10.1016/S2214-109X(16)30143-7			8	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	DU4VV	WOS:000382211700017	27470177	Green Published, Green Accepted, gold	Y	N	2022-02-25	
J	Bray, F				Bray, Freddie			The Evolving Scale and Profile of Cancer Worldwide: Much Ado About Everything	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Article							TEMPORAL VARIATION; AGE PERIOD; COHORT; MORTALITY; TRENDS; RATES; MODELS	Today, cancer is responsible for one in three premature deaths from noncommunicable diseases worldwide, and the number of annual cancer diagnoses will rise to well over 20 million by the year 2030. That cancer is of profound importance to future global health reflects both recent gains in human development as well as mortality transitions that are centuries old. Still, cancer is complex, and the extensive geographical and temporal heterogeneity alerts us to the need for targeted, local approaches to cancer control. The study of trends in specific cancer types remains essential in monitoring and evaluating such strategies and as a descriptive tool for hypothesizing possible contributory factors. Of greatest necessity is an expansion of the availability of high-quality data. To improve the limited cancer incidence data available in low-and middle-income countries (LMIC), the Global Initiative for Cancer Registry Development (http://gicr.iarc.fr) is an international partnership supporting countries to redraw the surveillance map. (C) 2015 AACR.	[Bray, Freddie] Int Agcy Res Canc, Canc Surveillance Sect, F-69372 Lyon 08, France		Bray, F (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	brayf@iarc.fr		Bray, Freddie/0000-0002-3248-7787			BARRETT JC, 1978, J EPIDEMIOL COMMUN H, V32, P314, DOI 10.1136/jech.32.4.314; BERAL V, 1974, LANCET, V1, P1037; Bray F, 2015, INT J CANCER, V137, P2060, DOI 10.1002/ijc.29670; Bray F., 2014, IARC TECHNICAL PUBLI, V43; Bray F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv273; Bray F, 2013, VACCINE, V31, pH32, DOI 10.1016/j.vaccine.2013.02.071; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Caldwell JC, 2001, B WORLD HEALTH ORGAN, V79, P159; CASE R A, 1956, Br J Prev Soc Med, V10, P159; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; ESTEVE J, 1990, ANN NY ACAD SCI, V609, P77, DOI 10.1111/j.1749-6632.1990.tb32058.x; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233; HOLFORD TR, 1983, BIOMETRICS, V39, P311, DOI 10.2307/2531004; KORTEWEG R, 1951, BRIT J CANCER, V5, P21, DOI 10.1038/bjc.1951.2; Kvale R, 2007, JNCI-J NATL CANCER I, V99, P1881, DOI 10.1093/jnci/djm249; MACMAHON B, 1957, CANCER, V10, P1037, DOI 10.1002/1097-0142(195709/10)10:5<1037::AID-CNCR2820100526>3.0.CO;2-Z; MacMahon B, 1970, EPIDEMIOLOGY PRINCIP; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; Moore SP, 2015, LANCET ONCOL, V16, P1483, DOI 10.1016/S1470-2045(15)00232-6; MUIR CS, 1994, CANCER SURV, V20, P5; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Parkin DM, 2014, CANCER EPIDEM BIOMAR, V23, P953, DOI 10.1158/1055-9965.EPI-14-0281; Tomatis L., 1990, INT AGENCY RES CANC, V100; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Vaccarella S, 2015, THYROID, V25, P1127, DOI 10.1089/thy.2015.0116; [No title captured]	29	17	19	1	4	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965	1538-7755		CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	JAN	2016	25	1					3	5		10.1158/1055-9965.EPI-15-1109			3	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	DG6DC	WOS:000372171400001	26667885	Bronze			2022-02-25	
J	de Martel, C				de Martel, Catherine			Infection causing cancer: An update on the global burden	CANCER RESEARCH			English	Meeting Abstract	106th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 18-22, 2015	Philadelphia, PA	Amer Assoc Canc Res					[de Martel, Catherine] Int Agcy Res Canc, F-69372 Lyon, France								[Anonymous], 2012, IARC MONOGR EVAL CAR, V100, P1, DOI DOI 10.1016/S1470-2045(09)70096-8; de Martel C., 2012, LANCET ONCOL, V13, P607, DOI DOI 10.1016/S1470-2045(12)70137-7; Maucort-Boulch O, 2015, WORLDWIDE RELA UNPUB; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; Shiels M, CANC ATTRIBUTABLE IN	5	0	0	0	2	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	AUG 1	2015	75			15		SY34-01				10.1158/1538-7445.AM2015-SY34-01			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	DF8HA	WOS:000371597101021					2022-02-25	
J	Scalbert, A				Scalbert, Augustin			Food metabolome and dietary biomarkers: opportunities and challenges for nutritional epidemiology	ANNALS OF NUTRITION AND METABOLISM			English	Meeting Abstract									[Scalbert, Augustin] Int Agcy Res Canc, Nutr & Metab Sect, Biomarkers Grp, F-69372 Lyon 08, France				Scalbert, Augustin/AAX-8160-2021	Scalbert, Augustin/0000-0001-6651-6710				0	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0250-6807	1421-9697		ANN NUTR METAB	Ann. Nutr. Metab.		2015	67			1			30	30					1	Endocrinology & Metabolism; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Nutrition & Dietetics	DK5VM	WOS:000374988800059					2022-02-25	
J	Freisling, H; Moskal, A; Ferrari, P; Byrnes, G; Pisa, PT; Slimani, N				Freisling, H.; Moskal, A.; Ferrari, P.; Byrnes, G.; Pisa, P. T.; Slimani, N.		EPIC Grp	Nutrient patterns: a first application to colorectal cancer in the EPIC Study	EUROPEAN JOURNAL OF CANCER			English	Meeting Abstract	European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO	SEP 27-OCT 01, 2013	Amsterdam, NETHERLANDS	European Conf Clin Oncol, European Soc Therapeut Radiol & Oncol, European Soc Med Oncol, European Soc Surg Oncol, European Assoc Canc Res, European Oncol Nursing Soc, European Soc Paediat Oncol					[Freisling, H.; Moskal, A.; Ferrari, P.; Byrnes, G.; Pisa, P. T.; Slimani, N.; EPIC Grp] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	SEP	2013	49			2		2221	S503	S504					2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	250HY	WOS:000326843603276					2022-02-25	
J	Voegele, C; Alteyrac, L; Caboux, E; Smans, M; Lesueur, F; Le Calvez-Kelm, F; Hainaut, P				Voegele, C.; Alteyrac, L.; Caboux, E.; Smans, M.; Lesueur, F.; Le Calvez-Kelm, F.; Hainaut, P.			A sample storage management system for biobanks	BIOINFORMATICS			English	Article								Establishment of large-scale biobanks of human specimens is essential to conduct molecular pathological or epidemiological studies. This requires automation of procedures for specimen cataloguing and tracking through complex analytical processes. The International Agency for Research on Cancer (IARC) develops a large portfolio of studies broadly aimed at cancer prevention and including cohort, case-control and case-only studies in various parts of the world. This diversity of study designs, structure, annotations and specimen collections is extremely difficult to accommodate into a single sample management system (SMS). Current commercial or academic SMS are often restricted to a few sample types and tailored to a limited number of analytic workflows [ Voegele et al. (2007) A laboratory information management system (LIMS) for a high throughput genetic platform aimed at candidate gene mutation screening. Bioinformatics, 23, 2504-2506]. Thus, we developed a system based on a three-tier architecture and relying on an Oracle database and an Oracle Forms web application. Data are imported through forms or csv files, and information retrieval is enabled via multi-criteria queries that can generate different types of reports including tables, Excel files, trees, pictures and graphs. The system is easy to install, flexible, expandable and implemented with a high degree of data security and confidentiality. Both the database and the interface have been modeled to be compatible with and adaptable to almost all types of biobanks.	[Voegele, C.; Lesueur, F.; Le Calvez-Kelm, F.] IARC, Genet Canc Susceptibil Grp, Lyon, France; [Alteyrac, L.; Smans, M.] IARC, Informat Technol Serv, Lyon, France; [Caboux, E.] IARC, Lab Serv, Lyon, France; [Caboux, E.] IARC, Biobank Grp, Lyon, France; [Hainaut, P.] IARC, Mol Carcinogenesis Grp, Lyon, France		Voegele, C (corresponding author), IARC, Genet Canc Susceptibil Grp, Lyon, France.	voegele@iarc.fr	Hainaut, Pierre/B-6018-2012; Caboux, Elodie/AAJ-3233-2020; Lesueur, Fabienne/R-2178-2017	Hainaut, Pierre/0000-0002-1303-1610; Lesueur, Fabienne/0000-0001-7404-4549; Le Calvez-Kelm, Florence/0000-0003-0063-5068; Caboux, Elodie/0000-0001-8393-6979			Caboux E, 2007, IARC WORKING GROUP R, P1; Hansson MG, 2009, BRIT J CANCER, V100, P8, DOI 10.1038/sj.bjc.6604795; Voegele C, 2007, BIOINFORMATICS, V23, P2504, DOI 10.1093/bioinformatics/btm365	3	8	8	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1367-4803			BIOINFORMATICS	Bioinformatics	NOV	2010	26	21					2798	2800		10.1093/bioinformatics/btq502			3	Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics	673LT	WOS:000283665000029	20807837	Bronze			2022-02-25	
J	Lambert, R; Hainaut, P				Lambert, R.; Hainaut, P.			Esophageal cancer: Cases and causes (Part I)	ENDOSCOPY			English	Article							SQUAMOUS-CELL CARCINOMA; BARRETTS-ESOPHAGUS; PRECURSOR LESIONS; HISTOLOGIC-FINDINGS; RISK POPULATION; MORPHOLOGY; EXPRESSION; CHINA; EPITHELIUM; LINXIAN		Int Agcy Res Canc, Screening & Mol Carcinogenesis & Biomarkers Grp, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	lambert@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CRESPI M, 1984, INT J CANCER, V34, P599, DOI 10.1002/ijc.2910340503; CRESPI M, 1979, LANCET, V2, P217; DAWSEY SM, 1994, CANCER, V73, P2027, DOI 10.1002/1097-0142(19940415)73:8<2027::AID-CNCR2820730803>3.0.CO;2-3; DESTEFANI E, 1990, CANCER RES, V50, P426; Dixon MF, 2002, GUT, V51, P130, DOI 10.1136/gut.51.1.130; Endo T, 2002, GASTROINTEST ENDOSC, V55, P641, DOI 10.1067/mge.2002.123420; FERLAY J, 2004, GLOBOCAN 2000 CANC I; Hall PA, 2001, GUT, V49, P618, DOI 10.1136/gut.49.5.618; He YT, 2003, WORLD J GASTROENTERO, V9, P209, DOI 10.3748/wjg.v9.i2.209; Jacob J H, 1993, Eur J Cancer Prev, V2, P53, DOI 10.1097/00008469-199301000-00009; JASKIEWICZ K, 1987, J NATL CANCER I, V79, P961; Kodama M, 1998, SURGERY, V123, P432, DOI 10.1067/msy.1998.86778; Kumagai Y, 2002, ENDOSCOPY, V34, P369, DOI 10.1055/s-2002-25285; Labenz J, 2004, AM J GASTROENTEROL, V99, P1652, DOI 10.1111/j.1572-0241.2004.30390.x; Lambert R, 2004, SEMIN ONCOL, V31, P498, DOI 10.1053/j.seminoncol.2004.04.017; LAMBERT R, 2007, IN PRESS ENDOSCOPY; Levrero M, 2000, J CELL SCI, V113, P1661; Li K, 2002, INT J CANCER, V102, P271, DOI [10.1002/ijc.10706, 10.1002/jhc.10706]; Lu XJ, 2004, WORLD J GASTROENTERO, V10, P2931; Mandard AM, 1997, J PATHOL, V181, P153, DOI 10.1002/(SICI)1096-9896(199702)181:2<153::AID-PATH743>3.0.CO;2-A; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; MUNOZ N, 1987, INT J CANCER, V39, P708, DOI 10.1002/ijc.2910390609; MUNOZ N, 1982, LANCET, V1, P876; MUNOZ N, 1995, CANCER, V75, P2779, DOI 10.1002/1097-0142(19950601)75:11<2779::AID-CNCR2820751123>3.0.CO;2-B; *NAT CANC I, 1998, SEER CANC INC PUBL U; Noori P, 2001, CARCINOGENESIS, V22, P1825, DOI 10.1093/carcin/22.11.1825; Paris Workshop on Columnar, 2005, ENDOSCOPY, V37, P879, DOI DOI 10.1055/S-2005-870305; Parkin D.M., 2002, CANC INCIDENCE 5 CON; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Saidi F, 2002, DIS ESOPHAGUS, V15, P214, DOI 10.1046/j.1442-2050.2002.00250.x; Saidi F, 2000, BRIT J CANCER, V83, P1249, DOI 10.1054/bjoc.2000.1414; Satodate H, 2003, GASTROINTEST ENDOSC, V58, P288, DOI 10.1067/mge.2003.361; Sewram V, 2003, CANCER EPIDEM BIOMAR, V12, P508; Somdyala NIM, 2003, SAMJ S AFR MED J, V93, P144; Spechler SJ, 2000, GASTROENTEROLOGY, V119, P587, DOI 10.1053/gast.2000.9849; Takubo K, 2005, HUM PATHOL, V36, P269, DOI 10.1016/j.humpath.2005.01.012; TAKUBO K, 2003, ESOPHAGUS, V1, P37, DOI [10.1007/s10388-003-0004, DOI 10.1007/S10388-003-0004-Y]]; Taniere P, 2002, AM J SURG PATHOL, V26, P1213, DOI 10.1097/00000478-200209000-00012; Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990; TANIERE P, 2005, CANC RISK ASSESSEMEN, P601; Vizcaino AP, 2002, INT J CANCER, V99, P860, DOI 10.1002/ijc.10427; Wang GQ, 2005, GUT, V54, P187, DOI 10.1136/gut.2004.046631; 2005, ZHENGZH U INT S ES C	44	41	41	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	JUN	2007	39	6					550	555		10.1055/s-2007-966530			6	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	184ES	WOS:000247624500015	17554654				2022-02-25	
S	Cogliano, VJ		Mehlman, MA; Soffritti, M; Landrigan, P; Bingham, E; Belpoggi, F		Cogliano, Vincent James			Use of carcinogenicity bioassays in the IARC Monographs	LIVING IN A CHEMICAL WORLD: FRAMING THE FUTURE IN LIGHT OF THE PAST	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Framing the Future in Light of the Past - Living in a Chemical World	SEP 18-21, 2005	Bologna, ITALY	Comuni Carpi, European Ramazzini Fdn, Natl Ramazzini Inst, Collegium Ramazzini		IARC Monographs; bioassays; carcinogenicity; hazard identification; risk assessment; mechanisms of carcinogenesis; conflicts of interests; freedom from interference		Carcinogenicity bioassays generally provide the best means of assessing the potential for a chemical to be a human carcinogenic hazard. The results of carcinogenicity bioassays are usually the key determinants of IARC Monograph evaluations. Along with carcinogenicity bioassays and epidemiological studies, the International Agency for Research on Cancer (IARC) also encourages the consideration of mechanistic data and other relevant data. During 2005 IARC is updating the Preamble to the IARC Monographs, which describes the principles and procedures used in developing the Monographs, including the criteria that guide the evaluations. Proposed revisions to the Preamble make some changes in the criteria for evaluating carcinogenicity in experimental animals to reflect the greater confidence that can be placed in Good Laboratory Practice (GLP) studies. Other changes will give more specific guidance for the evaluation of mechanistic data. Sections on mechanistic Monographs and will be more closely linked with toxicokinetics. Future Monographs will also include a new section on susceptible individuals, populations, and life stages that will often be based on the understanding of mechanisms. In addition, the draft Preamble discusses IARC's procedures for promoting impartial evaluations by avoiding conflicts of interests and ensuring that working groups are free from interference.	Int Agcy Res Canc, F-69372 Lyon, France		Cogliano, VJ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	cogliano@iarc.fr					Cogliano V, 2005, LANCET ONCOL, V6, P747, DOI 10.1016/S1470-2045(05)70380-6; Cogliano VJ, 2004, ENVIRON HEALTH PERSP, V112, P1269, DOI 10.1289/ehp.6950; *IARC, 1982, IARC MON EV CARC R S, V4, P7; *IARC, 2005, DRAFT PREAMBL IARC M; *IARC, 1992, IARC MON EV CARC RIS, V54, P13; IARC (International Agency for Research on Cancer), 2005, 05001 IARC; MCGREGOR DB, 1999, USE SHORT MEDIUM TER; Tomatis L, 2002, INT J OCCUP ENV HEAL, V8, P144; *WHO, 2005, DECL INT WHO EXP	9	6	6	1	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		1-57331-653-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2006	1076						592	600		10.1196/annals.1371.014			9	Environmental Sciences; Public, Environmental & Occupational Health; Multidisciplinary Sciences; Toxicology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Science & Technology - Other Topics; Toxicology	BFH91	WOS:000241943500046	17119235				2022-02-25	
J	Boyle, P				Boyle, P			Breast cancer control: Signs of progress, but more work required	BREAST			English	Article; Proceedings Paper	9th International Conference on Primary Therapy of Early Breast Cancer	JAN 26-29, 2005	St Gallen, SWITZERLAND			breast cancer; mortality	HORMONE-REPLACEMENT THERAPY; COLLABORATIVE REANALYSIS; POOLED ANALYSIS; INDIVIDUAL DATA; HYSTERECTOMIZED WOMEN; RISK; TAMOXIFEN; COHORT; PREVENTION; TRIAL	Breast cancer represents 10% of the global cancer burden and there is no population, or population sub-group, which has yet been identified to be at a truly low risk of developing the disease. Mortality rates have been steadily growing for nearly a century in many countries and it is only during the past decade that there have been signs of a sustainable decrease in mortality rates in a number of western-lifestyle countries. This represents considerable progress in breast cancer control and, although different factors contribute to different degrees in different countries, is mainly due to increased breast awareness, earlier detection and the delivery of the most appropriate therapy to women with the disease. The failure to prevent the incidence from continuing to rise represents to a great extent the failure to understand the precise mechanisms of breast carcinogenesis and the rote of risk determinants whose alteration in society could lead to a reduced risk of developing the disease. The declines seen in mortality represent a considerable success, but there is no room for complacency until research can impact positively on reducing incidence. (c) 2005 Published by Elsevier Ltd.	Int Agcy Res Canc, F-69372 Lyon, France		Boyle, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610			Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beatson CT, 1896, LANCET, V148, P162, DOI DOI 10.1016/S0140-6736(01)72384-7; Beral V, 2004, LANCET, V363, P1007, DOI 10.1016/S0140-6736(04)15835-2; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BOICE JD, 1978, LATE BIOL EFFECTS IO, V1, P231; Boyle P, 2003, BREAST, V12, P351, DOI 10.1016/S0960-9776(03)00135-8; Boyle P, 2003, ANN ONCOL, V14, P973, DOI 10.1093/annonc/mdg305; Boyle P, 2003, ANN ONCOL, V14, P1312, DOI 10.1093/annonc/mdg353; Boyle P, 2001, BREAST, V10, P1; Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; CASE RAM, 1976, SERIAL MORTALITY TAB, V4; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Cho E, 2003, CANCER EPIDEM BIOMAR, V12, P1153; Cho EY, 2003, JNCI-J NATL CANCER I, V95, P1079, DOI 10.1093/jnci/95.14.1079; Clarke M, 1998, LANCET, V351, P1451; Colditz GA, 2003, BRIT J CANCER, V89, P847, DOI 10.1038/sj.bjc.6601175; Cuzick J, 2002, LANCET, V360, P817; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Ferlay J, 2004, IARC CANC BASE; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; HENDERSON BE, 1996, CANC EPIDEMIOLOGY PR; Holmes MD, 2004, AM J EPIDEMIOL, V159, P732, DOI 10.1093/aje/kwh112; *IARC, 2004, MON EV CARC RISK HUM, V83; IARC, 2002, HDB CANC PREV; *IARC, 2002, HDB CANC PREV WEIGHT, V6, P144; Key TJ, 1999, AM J CLIN NUTR, V70, p516S, DOI 10.1093/ajcn/70.3.516s; Laden F, 2001, JNCI-J NATL CANCER I, V93, P768, DOI 10.1093/jnci/93.10.768; Lahmann PH, 2004, INT J CANCER, V111, P762, DOI 10.1002/ijc.20315; MACMAHON B, 1993, CANCER, V71, P3185, DOI 10.1002/1097-0142(19930515)71:10<3185::AID-CNCR2820711047>3.0.CO;2-C; MACMAHON B, 1994, ADV ONCOL, V10, P2; Melbye M, 1997, NEW ENGL J MED, V336, P81, DOI 10.1056/NEJM199701093360201; Missmer SA, 2002, INT J EPIDEMIOL, V31, P78, DOI 10.1093/ije/31.1.78; MODAN B, 1989, LANCET, V1, P629, DOI 10.1016/S0140-6736(89)92140-5; PARKIN DM, 2005, IARC CANC BASE; Powles T, 1998, LANCET, V352, P98; Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769; Smith-Warner SA, 2001, INT J CANCER, V92, P767, DOI 10.1002/1097-0215(20010601)92:5&lt;767::AID-IJC1247&gt;3.0.CO;2-0; van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514, DOI 10.1093/aje/152.6.514; Veronesi U, 1998, LANCET, V352, P93; Veronesi U, 2002, LANCET, V359, P1122, DOI 10.1016/S0140-6736(02)08159-X	46	38	40	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0960-9776	1532-3080		BREAST	Breast	DEC	2005	14	6					429	438		10.1016/j.breast.2005.10.001			10	Oncology; Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology; Obstetrics & Gynecology	989WP	WOS:000233705000002	16286232				2022-02-25	
J	Krutovskikh, V				Krutovskikh, V			Implication of direct host-tumor intercellular interactions in non-immune host resistance to neoplastic growth	SEMINARS IN CANCER BIOLOGY			English	Article						cadherins; connexins; gap junctions; carcinogenesis	E-CADHERIN; RAT-LIVER; CELL-ADHESION; GENE MUTATION; HELA-CELLS; IN-VIVO; COMMUNICATION; MICE; CONNEXIN43; EXPRESSION	The hallmark of cancer as a disease is impaired homeostasis, which in normal tissue is maintained by the network of direct intercellular contacts. The cell-cell interaction machinery consists of intercellular junctions of various types, each of which has a role in the control of cell growth, differentiation, and motility. In cancer, the function of intercellular junctions is altered, often at quite advanced stages of tumor progression, while proper intercellular interactions between normal and tumor cells may control and even suppress, otherwise, aberrant growth and behavior of neoplastic cells. This type of host resistance to neoplastic growth implies a homotypic functional partnership between tumor cells and their normal host counterparts and, thus, is to a certain extent complementary to immune defense against tumorigenesis, which is effective only when tumor cells became 'foreign' for the host. Functional interactions between host and tumor cells could be lost at different stages of tumorigenesis through a range of mechanisms. In some cases, host-tumor interactions may be impaired reversibly, which in turn gives rise to the possibility of restoring this component of host defense against cancer by correctional interventions. This review highlights the role that direct intercellular host-tumor interactions may play in natural host resistance against neoplastic growth, with an emphasis on the underlying mechanisms of both their function and impairment.	WHO, Unit Gene Environm Interact, IARC, F-69008 Lyon, France		Krutovskikh, V (corresponding author), WHO, Unit Gene Environm Interact, IARC, F-69008 Lyon, France.	krutovskikh@iarc.fr					Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; Bringuier PP, 1999, INT J CANCER, V83, P591, DOI 10.1002/(SICI)1097-0215(19991126)83:5<591::AID-IJC3>3.0.CO;2-6; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BUDUNOVA IV, 1994, CELL BIOL TOXICOL, V10, P71, DOI 10.1007/BF00756491; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; CROW JM, 1994, INVEST OPHTH VIS SCI, V35, P3332; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Francis D, 1999, DEV GENET, V24, P123, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<123::AID-DVG12>3.0.CO;2-H; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; Goodenough D.A., 1992, Seminars in Cell Biology, V3, P49; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huang RP, 1998, CANCER RES, V58, P5089; Jiang WG, 1998, INT J MOL MED, V1, P621; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; Jothy S, 1995, CANCER METAST REV, V14, P363, DOI 10.1007/BF00690604; Kemler R, 1992, Semin Cell Biol, V3, P149; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Knudsen KA, 1998, J CELL BIOCHEM, P168; Krutovskikh V, 1997, JPN J CANCER RES, V88, P1121, DOI 10.1111/j.1349-7006.1997.tb00338.x; Krutovskikh V, 1996, CARCINOGENESIS, V17, P1761, DOI 10.1093/carcin/17.8.1761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; KRUTOVSKIKH VA, 1991, CARCINOGENESIS, V12, P1701, DOI 10.1093/carcin/12.9.1701; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; MARCEL M, 1996, J CELL BIOCHEM, V61, P524; MESNIL M, 1995, CANCER RES, V55, P629; NEVEU MJ, 1994, J CELL SCI, V107, P83; Omori Y, 1996, CARCINOGENESIS, V17, P2077, DOI 10.1093/carcin/17.9.2077; OYAMADA M, 1990, MOL CARCINOGEN, V3, P273, DOI 10.1002/mc.2940030507; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Piechocki MP, 1999, CARCINOGENESIS, V20, P401, DOI 10.1093/carcin/20.3.401; Prowse DM, 1997, CELL BIOL INT, V21, P833, DOI 10.1006/cbir.1997.0202; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; Ruch RJ, 1999, ANTICANCER RES, V19, P4831; Saito T, 1997, CANCER RES, V57, P375; Saito T, 2000, INT J CANCER, V86, P67, DOI 10.1002/(SICI)1097-0215(20000401)86:1<67::AID-IJC10>3.0.CO;2-1; Schlemmer SR, 2000, MOL CARCINOGEN, V28, P70, DOI 10.1002/1098-2744(200006)28:2<70::AID-MC2>3.3.CO;2-0; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simon AM, 1997, NATURE, V385, P525, DOI 10.1038/385525a0; Simon AM, 1999, TRENDS CELL BIOL, V9, P169, DOI 10.1016/S0962-8924(99)01547-0; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; STUTENKEMPER R, 1992, EXP CELL RES, V201, P43, DOI 10.1016/0014-4827(92)90346-A; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Vos CBJ, 1997, BRIT J CANCER, V76, P1131, DOI 10.1038/bjc.1997.523; White TW, 1998, J CELL BIOL, V143, P815, DOI 10.1083/jcb.143.3.815; WIJHOVEN BP, 1999, LANCET, V354, P356; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMASAKI H, 2000, CARCINOGENESIS, V7, P1051	59	12	16	0	0	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1044-579X	1096-3650		SEMIN CANCER BIOL	Semin. Cancer Biol.	AUG	2002	12	4					267	276		10.1016/S1044-579X(02)00013-5			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	591WG	WOS:000177902800003	12322675				2022-02-25	
J	Mery, L; Bray, F				Mery, Les; Bray, Freddie			Population-based cancer registries: a gateway to improved surveillance of non-communicable diseases	ECANCERMEDICALSCIENCE			English	Article						cancer registries; surveillance; cancer; non-communicable diseases; Sustainable Development Goals		Timely and accurate data on health enable policymakers to make informed decisions that can reduce the burden and suffering from disease. Yet many LMICs are not able to adequately collect the health indicators necessary to track progress in the Sustainable Development Goals (SDG) at present, and a major investment in primary data collection is needed. We argue that cancer surveillance, with an established history of international standards and best practices, represents a feasible entry point in the development of surveillance programmes for NCDs. The International Agency for Research on Cancer (IARC) has served to support population-based cancer registries (PBCR) since its inception over 50 years ago. Based on this longstanding experience and collaboration with PBCR worldwide, IARC and other key partners implemented the Global Initiative for Cancer Registry Development (GICR, http://gicr.iarc.fr/) as a new way to deliver capacity-building in cancer surveillance. We describe some of the critical aspects of the GICR and the prospects of a step-change in the quality and use of cancer data over the next years. Ultimately, the decision on how to proceed resides with countries. The cancer and NCD burden will not be tackled without committed and sustainable action by governments.	[Mery, Les; Bray, Freddie] Int Agcy Res Canc, Canc Surveillance Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Mery, L (corresponding author), Int Agcy Res Canc, Canc Surveillance Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	meryf@iarc.fr					Boerma T, 2018, LANCET, V392, P607, DOI 10.1016/S0140-6736(18)30586-5; Bray F, 2014, PLANNING DEV POPULAT, P9; Bray F, 2017, INCIDENCE 5 CONTINEN, VXI; DOLL R, 1996, CANC INCIDENCE 5 CON; Mahajan M, 2019, GLOB POLICY, V10, P110, DOI 10.1111/1758-5899.12605; Pineros M, 2017, EPIDEMIOL REV, V39, P161, DOI 10.1093/epirev/mxx003; WHO, 2019, WORLD HLTH STAT 2019; World Health Organization, 2018, WORLD HLTH STAT 2018	8	3	3	0	1	CANCER INTELLIGENCE LTD	BRISTOL	11 ALMA VALE RD,, BRISTOL, BS8 2HL, ENGLAND	1754-6605			ECANCERMEDICALSCIENC	eCancerMedicalScience	JAN 16	2020	14								ed95	10.3332/ecancer.2020.ed95			3	Oncology	Emerging Sources Citation Index (ESCI)	Oncology	QI6PT	WOS:000619100600001	32153658	gold, Green Published			2022-02-25	
J	Guha, N; Loomis, D; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Baan, R; Mattock, H; Straif, K				Guha, Neela; Loomis, Dana; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Baan, Robert; Mattock, Heidi; Straif, Kurt		Int Agcy Res Canc Monograph	Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites	LANCET ONCOLOGY			English	News Item							MORTALITY; WORKERS; CANCER; EXPOSURE; COHORT		[Guha, Neela; Loomis, Dana; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Baan, Robert; Mattock, Heidi; Straif, Kurt; Int Agcy Res Canc Monograph] IARC, Lyon, France		Guha, N (corresponding author), IARC, Lyon, France.		Loomis, Dana/AAE-3988-2019; Fritschi, Lin/K-2096-2012; Kromhout, Hans/A-9159-2008; Guha, Neela/AAG-3989-2021	Fritschi, Lin/0000-0002-7692-3560; Kromhout, Hans/0000-0002-4233-1890; Guha, Neela/0000-0003-3991-4662; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Lynge, Elsebeth/0000-0003-4785-5236; Loomis, Dana/0000-0003-3297-5200	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER		Blair A, 2003, ANN EPIDEMIOL, V13, P50, DOI 10.1016/S1047-2797(02)00250-8; Boice JD, 2006, J OCCUP ENVIRON MED, V48, P1070, DOI 10.1097/01.jom.0000240661.33413.b5; Calvert GM, 2011, OCCUP ENVIRON MED, V68, P709, DOI 10.1136/oem.2010.060665; Charbotel B, 2006, ANN OCCUP HYG, V50, P777, DOI 10.1093/annhyg/me1039; IARC, 2006, IARC MON EV CARC RIS; *IARC, IARC MON EV IN PRESS; Ikbal M, 2004, MUTAT RES-GEN TOX EN, V564, P159, DOI 10.1016/j.mrgentox.2004.08.007; Kauppinen T, 2000, OCCUP ENVIRON MED, V57, P10, DOI 10.1136/oem.57.1.10; Lynge E, 2006, ENVIRON HEALTH PERSP, V114, P213, DOI 10.1289/ehp.8425; Mirabelli D, 2005, INT J OCCUP ENV HEAL, V11, P53, DOI 10.1179/oeh.2005.11.1.53; Moore LE, 2010, CANCER RES, V70, P6527, DOI 10.1158/0008-5472.CAN-09-4167; Raaschou-Nielsen O, 2001, AM J IND MED, V39, P320, DOI 10.1002/1097-0274(200103)39:3<320::AID-AJIM1020>3.0.CO;2-8; Scott CS, 2011, INT J ENV RES PUB HE, V8, P4238, DOI 10.3390/ijerph8114238; Zhao YX, 2005, AM J IND MED, V48, P249, DOI 10.1002/ajim.20216	14	123	131	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045			LANCET ONCOL	Lancet Oncol.	DEC	2012	13	12					1192	1193		10.1016/S1470-2045(12)70485-0			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	042YR	WOS:000311509400032	23323277				2022-02-25	
J	Cogliano, VJ; Baan, R; Straif, K; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Freeman, C; Galichet, L; Wild, CP				Cogliano, Vincent James; Baan, Robert; Straif, Kurt; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent; Wild, Christopher P.			Preventable Exposures Associated With Human Cancers	JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE			English	Review							HUMAN CARCINOGENS; IARC-MONOGRAPHS; AGENTS; SITES	Information on the causes of cancer at specific sites is important to cancer control planners, cancer researchers, cancer patients, and the general public. The International Agency for Research on Cancer (IARC) Monograph series, which has classified human carcinogens for more than 40 years, recently completed a review to provide up-to-date information on the cancer sites associated with more than 100 carcinogenic agents. Based on IARC's review, we listed the cancer sites associated with each agent and then rearranged this information to list the known and suspected causes of cancer at each site. We also summarized the rationale for classifications that were based on mechanistic data. This information, based on the forthcoming IARC Monographs Volume 100, offers insights into the current state-of-the-science of carcinogen identification. Use of mechanistic data to identify carcinogens is increasing, and epidemiological research is identifying additional carcinogens and cancer sites or confirming carcinogenic potential under conditions of lower exposure. Nevertheless, some common human cancers still have few (or no) identified causal agents.	[Cogliano, Vincent James; Baan, Robert; Straif, Kurt; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent] World Hlth Org, Int Agcy Res Canc, Sect IARC Monographs, F-69372 Lyon 08, France		Cogliano, VJ (corresponding author), World Hlth Org, Int Agcy Res Canc, Sect IARC Monographs, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	imo@iarc.fr	Guha, Neela/AAG-3989-2021; Freeman, Crystal/AAF-3438-2020; Wild, Christopher/ABC-6260-2020	Guha, Neela/0000-0003-3991-4662; Wild, Christopher/0000-0003-0249-8669; Lauby-Secretan, Beatrice/0000-0001-6559-3351	International Agency for Research on Cancer; National Cancer Institute at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA033193]; European Commission Directorate-General for Employment, Social Affairs and Equal Opportunities [VS/2010/0211]; National Institute of Environmental Health Sciences at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS); NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER	This work was supported by the International Agency for Research on Cancer; the National Cancer Institute at the National Institutes of Health (CA033193); the European Commission Directorate-General for Employment, Social Affairs and Equal Opportunities (VS/2010/0211); and the National Institute of Environmental Health Sciences at the National Institutes of Health.	[Anonymous], 2011, IARC MON EV CARC RIS, V100B; [Anonymous], 2011, GLOB STAT REP ALC HL; Baan R, 2007, LANCET ONCOL, V8, P292, DOI 10.1016/S1470-2045(07)70099-2; Baan R, 2009, LANCET ONCOL, V10, P1143, DOI 10.1016/S1470-2045(09)70358-4; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Cogliano V, 2008, OCCUP ENVIRON MED, V65, P500; Cogliano VJ, 2009, OCCUP ENVIRON MED, V66, P496; El Ghissassi F, 2009, LANCET ONCOL, V10, P751, DOI 10.1016/S1470-2045(09)70213-X; Grosse Y, 2009, LANCET ONCOL, V10, P13, DOI 10.1016/S1470-2045(08)70286-9; Huff J, 2009, OCCUP ENVIRON MED, V66, P140, DOI 10.1136/oem.2008.042036; IARC, 2010, IARC MON EV CARC RIS, VV92; [IARC International Agency for Research on Cancer], 2002, IARC MON EV CARC RIS, V82; IARC, 2010, IARC MON EV CARC RIS, V94; IARC, 2010, IARC MON EV CARC RIS, V93; IARC, 1988, IARC MON EV CARC RIS, V43; IARC, 2010, IARC MON EV CARC RIS, V96; IARC, 2010, IARC MON EV CARC RIS, V95; *IARC, 1979, IARC MON, V1, P9; IARC, 2006, PREAMBL IARC MON; IARC, 2010, IARC MON EV CARC RIS, V99; IARC, 2010, GLOBOCAN 2008; *IARC, 2008, IARC MON EV CARC RIS, V97; *IARC, 1992, IARC MON EV CARC RIS, V54, P13; IARC: International Agency for Research on Cancer, 2007, IARC MON EV CARC RIS, V90; International Agency for Research on Cancer (IARC), 2004, IARC MON EV CARC RIS, V83; International Agency for Research on Cancer (IARC), 1997, IARC MON EV CARC RIS, V69; International Agency for Research on Cancer (IARC), 2007, IARC MON EV CARC RIS, V91; International Agency for Research on Cancer[IARC], 1973, IARC MON EV CARC RIS, V2; International Agency for Research on Cancer (IARC), 2010, IARC MON EV CARC RIS, V98; International Agency for Research on Cancer (IARC), 1987, IARC MON EV CARC S7, V1; *MAK, 2010, 46 MAK; *NTP, 2000, REP CARC 9 ED CARC P; Rudel RA, 2007, CANCER-AM CANCER SOC, V109, P2635, DOI 10.1002/cncr.22653; Secretan B, 2009, LANCET ONCOL, V10, P1033, DOI 10.1016/S1470-2045(09)70326-2; State of California, CHEM KNOWN STAT CAUS; Straif K, 2009, LANCET ONCOL, V10, P453, DOI 10.1016/S1470-2045(09)70134-2; US EPA Risk Assessment Forum, 2005, GUIDELINES CARCINOGE; WCRF/AICR, 2007, FOOD NUTR PHYS ACT P	38	360	384	5	37	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0027-8874	1460-2105		JNCI-J NATL CANCER I	JNCI-J. Natl. Cancer Inst.	DEC	2011	103	24					1827	1839		10.1093/jnci/djr483			13	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	866OQ	WOS:000298391000008	22158127	Green Published, hybrid	Y	N	2022-02-25	
J	Vaissiere, T; Herceg, Z				Vaissiere, Thomas; Herceg, Zdenko			Histone code in the cross-talk during DNA damage signaling	CELL RESEARCH			English	Editorial Material							DOUBLE-STRAND BREAKS; REPAIR; ACTIVATION; ATM; ACETYLTRANSFERASE; HETEROCHROMATIN; ACETYLATION; PROTEINS; COMPLEX; TIP60		[Vaissiere, Thomas; Herceg, Zdenko] IARC, Epigenet Grp, F-69008 Lyon, France		Herceg, Z (corresponding author), IARC, Epigenet Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr	Vaissiere, Thomas/E-1121-2011				Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Goodarzi AA, 2009, BIOCHEM SOC T, V37, P569, DOI 10.1042/BST0370569; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Loizou JI, 2006, CELL CYCLE, V5, P696, DOI 10.4161/cc.5.7.2616; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541	10	5	5	0	0	INST BIOCHEMISTRY & CELL BIOLOGY	SHANGHAI	SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA	1001-0602	1748-7838		CELL RES	Cell Res.	FEB	2010	20	2					113	115		10.1038/cr.2010.14			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	572GQ	WOS:000275816100001	20118964	Bronze			2022-02-25	
J	Baan, RA				Baan, Robert A.			Letter of Concern	MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS			English	Editorial Material							HUMAN FIBROBLASTS; IN-VITRO; MHZ		IARC, Lyon, France		Baan, RA (corresponding author), IARC, Lyon, France.	baanmr@iarc.fr					Baan RA, 2009, MUTAT RES-GEN TOX EN, V673, P1, DOI 10.1016/j.mrgentox.2008.11.003; Diem E, 2005, MUTAT RES-GEN TOX EN, V583, P178, DOI 10.1016/j.mrgentox.2005.03.006; Drexler H, 2009, INT ARCH OCC ENV HEA, V82, P143, DOI 10.1007/s00420-008-0360-y; Rudiger HW, 2009, MUTAT RES-GEN TOX EN, V673, P2, DOI 10.1016/j.mrgentox.2008.11.002; Schwarz C, 2008, INT ARCH OCC ENV HEA, V81, P755, DOI 10.1007/s00420-008-0305-5; Wolf C, 2008, BIOELECTROMAGNETICS, V29, P658, DOI 10.1002/bem.20440	6	2	2	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1383-5718			MUTAT RES-GEN TOX EN	Mutat. Res. Genet. Toxicol. Environ. Mutagen.	JAN	2010	695	1-2					1	1		10.1016/j.mrgentox.2009.11.004			1	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	560AP	WOS:000274874300001	19914398				2022-02-25	
S	Sawan, C; Herceg, Z		Herceg, Z; Ushijima, T		Sawan, Carla; Herceg, Zdenko			Histone Modifications and Cancer	EPIGENETICS AND CANCER, PT A	Advances in Genetics		English	Review; Book Chapter							MODIFICATIONS PREDICT PROGNOSIS; NUCLEOSOME CORE PARTICLE; ARGININE METHYLTRANSFERASE; CHROMATIN MODIFICATIONS; QUANTITATIVE-ANALYSIS; H3 PHOSPHORYLATION; LYSINE METHYLATION; STRUCTURAL BASIS; DNA METHYLATION; IN-VITRO	It is now widely recognized that epigenetic events are important mechanisms underlying cancer development and progression. Epigenetic information in chromatin includes covalent modifications (such as acetylation, methylation, phosphorylation, and ubiquitination) of core nucleosomal proteins (histones). A recent progress in the field of histone modifications and chromatin research has tremendously enhanced our understanding of the mechanisms underlying the control of key physiological and pathological processes. Histone modifications and other epigenetic mechanisms appear to work together in establishing and maintaining gene activity states, thus regulating a wide range of cellular processes. Different histone modifications themselves act in a coordinated and orderly fashion to regulate cellular processes such as gene transcription, DNA replication, and DNA repair. Interest in histone modifications has further grown over the last decade with the discovery and characterization of a large number of histone-modifying molecules and protein complexes. Alterations in the function of histone-modifying complexes are believed to disrupt the pattern and levels of histone marks and consequently deregulate the control of chromatin-based processes, ultimately leading to oncogenic transformation and the development of cancer. Consistent with this notion, aberrant patterns of histone modifications have been associated with a large number of human malignancies. In this chapter, we discuss recent advances in our understanding of the mechanisms controlling the establishment and maintenance of histone marks and how disruptions of these chromatin-based mechanisms contribute to tumorigenesis. We also suggest how these advances may facilitate the development of novel strategies to prevent, diagnose, and treat human malignancies. (C) 2010, Elsevier Inc.	[Sawan, Carla; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69008 Lyon, France		Sawan, C (corresponding author), Int Agcy Res Canc, Epigenet Grp, F-69008 Lyon, France.						Ahn SH, 2005, CELL CYCLE, V4, P780, DOI 10.4161/cc.4.6.1745; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Anand R, 2007, J BIOL CHEM, V282, P35425, DOI 10.1074/jbc.R700027200; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Baker SP, 2010, NAT CELL BIOL, V12, P294, DOI 10.1038/ncb2030; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599; BARSOUM J, 1985, J BIOL CHEM, V260, P7688; Bergink S, 2006, GENE DEV, V20, P1343, DOI 10.1101/gad.373706; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Bulger M, 2005, J BIOL CHEM, V280, P21689, DOI 10.1074/jbc.R500004200; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Chan KCA, 2003, CANCER RES, V63, P2028; Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cho YY, 2004, CANCER RES, V64, P3855, DOI 10.1158/0008-5472.CAN-04-0201; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Clausell J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007243; DAWSON BA, 1991, J CELL BIOCHEM, V46, P166, DOI 10.1002/jcb.240460210; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Deligezer U, 2008, CLIN CHEM, V54, P1125, DOI 10.1373/clinchem.2007.101766; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Downs JA, 2005, CELL CYCLE, V4, P1373, DOI 10.4161/cc.4.10.2108; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Edmondson DG, 2002, J BIOL CHEM, V277, P29496, DOI 10.1074/jbc.M200651200; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gardner RG, 2005, MOL CELL BIOL, V25, P6123, DOI 10.1128/MCB.25.14.6123-6139.2005; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GOLDKNOPF IL, 1975, BIOCHEM BIOPH RES CO, V65, P951, DOI 10.1016/S0006-291X(75)80478-5; Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Grant PA, 2001, GENOME BIOL, V2; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; GUTIERRE.RM, 1967, SCIENCE, V157, P1324, DOI 10.1126/science.157.3794.1324; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; KLEINSMI.LJ, 1966, P NATL ACAD SCI USA, V55, P1182, DOI 10.1073/pnas.55.5.1182; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krishnamoorthy T, 2006, GENE DEV, V20, P2580, DOI 10.1101/gad.1457006; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LANGAN TA, 1968, SCIENCE, V162, P579, DOI 10.1126/science.162.3853.579; Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; Lin CM, 2003, CURR BIOL, V13, P1019, DOI 10.1016/S0960-9822(03)00382-8; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Liu B, 2009, J BIOL CHEM, V284, P32288, DOI 10.1074/jbc.M109.045856; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; LOIDL P, 1994, CHROMOSOMA, V103, P441; Loizou JI, 2006, CELL CYCLE, V5, P696, DOI 10.4161/cc.5.7.2616; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; NICKEL BE, 1989, BIOCHEMISTRY-US, V28, P958, DOI 10.1021/bi00429a006; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Ozdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; PARLOW MH, 1990, J BIOL CHEM, V265, P7507; Perry P, 2004, CELL CYCLE, V3, P1645; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; RUMORE PM, 1990, J CLIN INVEST, V86, P69, DOI 10.1172/JCI114716; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Santos-Rosa H, 2009, NAT STRUCT MOL BIOL, V16, P17, DOI 10.1038/nsmb.1534; Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Thiriet C, 2009, J BIOL CHEM, V284, P2823, DOI 10.1074/jbc.M805617200; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Unnikrishnan A, 2010, NAT STRUCT MOL BIOL, V17, P430, DOI 10.1038/nsmb.1780; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489; Vaissiere T, 2009, EPIGENETICS-US, V4, P221, DOI 10.4161/epi.8833; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Walkinshaw DR, 2008, J CELL BIOCHEM, V104, P1541, DOI 10.1002/jcb.21746; Wang HB, 2006, MOL CELL, V22, P383, DOI 10.1016/j.molcel.2006.03.035; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhang JM, 2002, NATURE, V420, P198, DOI 10.1038/nature01150; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025	150	133	135	0	29	ELSEVIER ACADEMIC PRESS INC	SAN DIEGO	525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA	0065-2660		978-0-12-380866-0	ADV GENET	Adv. Genet.		2010	70						57	85		10.1016/S0065-2660(10)70003-1			29	Oncology; Genetics & Heredity	Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Genetics & Heredity	BAD29	WOS:000303838800003	20920745				2022-02-25	
J	Autier, P; Hery, C; Haukka, J; Boniol, M; Byrnes, G				Autier, Philippe; Hery, Clarisse; Haukka, Jari; Boniol, Mathieu; Byrnes, Graham			Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening	JOURNAL OF CLINICAL ONCOLOGY			English	Article							LYMPH-NODE DISSECTION; FOLLOW-UP; AGE 40; PROGNOSTIC-FACTORS; WOMEN; INSIGHTS; STUDY-2; UPDATE	Purpose We assessed changes in advanced cancer incidence and cancer mortality in eight randomized trials of breast cancer screening. Patients and Methods Depending on published data, advanced cancer was defined as cancer > 20 mm in size (four trials), stage II+ (four trials), and >= one positive lymph node (one trial). For each trial, we obtained the estimated relative risk (RR) and 95% CI between the intervention and control groups, for both breast cancer mortality and diagnosis of advanced breast cancer. Using a meta-regression approach, log(RR-mortality) was regressed on log(RR-advanced cancer), weighting each trial by the reciprocal of the square of the standard error of log(RR) for mortality. Results RR for advanced breast cancer ranged from 0.69 (95% CI, 0.61 to 0.78) in the Swedish Two-County Trial to 0.97 (95% CI, 0.97 to 1.25) in the Canadian National Breast Screening Study-1 (NBSS-1) trial. Log(RR)s for advanced cancer were highly predictive of log(RR) s for mortality (R-2 = 0.95; P < .0001), and the linear regression curve had a slope of 1.00 (95% CI, 0.76 to 1.25) after fixing the intercept to zero. The slope changed only slightly after excluding the Two-County Trial and the Canadian NBSS-1 and NBSS-2 trials. Conclusion In trials on breast cancer screening, for each unit decrease in incidence of advanced breast cancer, there was an equal decrease in breast cancer mortality. Monitoring of incidence of advanced breast cancer may provide information on the current impact of screening on breast cancer mortality in the general population.	[Autier, Philippe; Hery, Clarisse; Haukka, Jari; Boniol, Mathieu; Byrnes, Graham] Int Agcy Res Canc, Epidemiol & Biostat Cluster, F-69372 Lyon 08, France		Autier, P (corresponding author), Int Agcy Res Canc, Epidemiol & Biostat Cluster, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	pre@iarc.fr	Boniol, Mathieu/F-9623-2011; Haukka, Jari/G-1484-2014; Autier, Philippe/A-4402-2014	Boniol, Mathieu/0000-0003-1052-5604; Haukka, Jari/0000-0003-1450-6208; Autier, Philippe/0000-0003-1538-5321; Byrnes, Graham/0000-0003-3893-7539			American Joint Committee on Cancer, 2002, AJCC CANC STAG MAN, P171; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDERSSON I, 1995, J NATL CANCER I, V87, P1263; Berg AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00011; Bjurstam N, 2003, CANCER-AM CANCER SOC, V97, P2387, DOI 10.1002/cncr.11361; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; CUTLER SJ, 1969, CANCER, V24, P653, DOI 10.1002/1097-0142(196910)24:4<653::AID-CNCR2820240402>3.0.CO;2-B; DAY NE, 1989, BRIT J CANCER, V59, P954, DOI 10.1038/bjc.1989.203; DAY NE, 1990, CANC SCREENING, P391; Duffy SW, 2003, EUR J CANCER, V39, P1755, DOI 10.1016/S0959-8049(03)00259-4; Frisell J, 1997, BREAST CANCER RES TR, V45, P263, DOI 10.1023/A:1005872617944; Gotzsche PC, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001877.pub2; Lee SJ, 2003, ANN ONCOL, V14, P1199, DOI 10.1093/annonc/mdg323; Miller AB, 2000, JNCI-J NATL CANCER I, V92, P1490, DOI 10.1093/jnci/92.18.1490; Miller AB, 2002, ANN INTERN MED, V137, P305, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00005; Moss S, 2005, BRIT J CANCER, V92, P955, DOI 10.1038/sj.bjc.6602395; Moss SM, 2006, LANCET, V368, P2053, DOI 10.1016/S0140-6736(06)69834-6; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; Petrik DW, 2003, J SURG ONCOL, V82, P84, DOI 10.1002/jso.10198; Rijnsburger AJ, 2004, INT J CANCER, V110, P756, DOI 10.1002/ijc.20143; Schaapveld M, 2004, J SURG ONCOL, V87, P4, DOI 10.1002/jso.20061; Shapiro S, 1985, Natl Cancer Inst Monogr, V67, P65; SHAPIRO S, 1988, SCREENING BREAST CAN, P3; Smith RA, 2004, RADIOL CLIN N AM, V42, P793, DOI 10.1016/j.rcl.2004.06.014; Tabar L, 2000, RADIOL CLIN N AM, V38, P625, DOI 10.1016/S0033-8389(05)70191-3; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; Tabar L, 1999, JPN J CLIN ONCOL, V29, P608, DOI 10.1093/jjco/29.12.608; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; *UICC, 2002, TNM CLASS MAL TUM; Vainio H, 2002, IARC HDB CANC PREVEN, V7	31	74	78	0	7	AMER SOC CLINICAL ONCOLOGY	ALEXANDRIA	2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA	0732-183X	1527-7755		J CLIN ONCOL	J. Clin. Oncol.	DEC 10	2009	27	35					5919	5923		10.1200/JCO.2009.22.7041			5	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	531GQ	WOS:000272652700013	19884547				2022-02-25	
J	Baan, R; Grosse, Y; Straif, K; Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Freeman, C; Galichet, L; Cogliano, V				Baan, Robert; Grosse, Yann; Straif, Kurt; Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent; Cogliano, Vincent		WHO Int Agcy Res Canc Monograph Wo	Special Report: Policy A review of human carcinogens-Part F: Chemical agents and related occupations	LANCET ONCOLOGY			English	News Item									[Baan, Robert; Grosse, Yann; Straif, Kurt; Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Freeman, Crystal; Galichet, Laurent; Cogliano, Vincent; WHO Int Agcy Res Canc Monograph Wo] Int Agcy Res Canc, F-69372 Lyon, France		Baan, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Freeman, Laura E. Beane/C-4468-2015; Kromhout, Hans/A-9159-2008; Freeman, Crystal/AAF-3438-2020; Ruder, Avima/I-4155-2012; Savitz, David A/I-2211-2014; Guha, Neela/AAG-3989-2021	Freeman, Laura E. Beane/0000-0003-1294-4124; Kromhout, Hans/0000-0002-4233-1890; Ruder, Avima/0000-0003-0419-6664; Guha, Neela/0000-0003-3991-4662; Lauby-Secretan, Beatrice/0000-0001-6559-3351	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P42ES004705] Funding Source: NIH RePORTER; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01 ES006052] Funding Source: Medline		Baan R, 2008, LANCET ONCOL, V9, P322, DOI 10.1016/S1470-2045(08)70089-5; Grosse Y, 2009, LANCET ONCOL, V10, P13, DOI 10.1016/S1470-2045(08)70286-9; HAUPTMANN M, 2009, J NATL CANC IN PRESS; *IARC, 2006, IARC MON EV CARC RIS, V88, P39; IARC International Agency for Research on Cancer, 2008, MONOGRAPHS EVALUATIO, V97, P185; National Toxicology Program, 2006, Natl Toxicol Program Tech Rep Ser, P1; National Toxicology Program, 2006, NATL TOXICOL PROGRAM, V520, P1; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Somorovska M, 1999, MUTAT RES-GEN TOX EN, V445, P181, DOI 10.1016/S1383-5718(99)00125-4; Xue WL, 2005, TOXICOL APPL PHARM, V206, P73, DOI 10.1016/j.taap.2004.11.006; ZHANG L, 2009, CANC EPIDEM IN PRESS	11	373	383	6	67	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	DEC	2009	10	12					1143	1144		10.1016/S1470-2045(09)70358-4			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	531SF	WOS:000272687900014	19998521				2022-02-25	
J	Cogliano, V; Baan, R; Straif, K; Grosse, Y; Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N				Cogliano, Vincent; Baan, Robert; Straif, Kurt; Grosse, Yann; Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela			Future priorities for IARC Monographs	LANCET ONCOLOGY			English	News Item									[Cogliano, Vincent; Baan, Robert; Straif, Kurt; Grosse, Yann; Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela] Int Agcy Res Canc, F-69372 Lyon, France		Cogliano, V (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Guha, Neela/AAG-3989-2021	Guha, Neela/0000-0003-3991-4662; Lauby-Secretan, Beatrice/0000-0001-6559-3351				0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045			LANCET ONCOL	Lancet Oncol.	AUG	2008	9	8					708	708		10.1016/S1470-2045(08)70189-X			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	334VG	WOS:000258248800007	19274804				2022-02-25	
J	Cardis, E				Cardis, E.			Commentary: Low dose-rate exposures to ionizing radiation	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Editorial Material							TECHA RIVER COHORT; LINEAR NO-THRESHOLD; SOLID CANCER; MORTALITY; RISKS		Int Agcy Res Canc, Radiat Grp, F-69372 Lyon, France		Cardis, E (corresponding author), Int Agcy Res Canc, Radiat Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	cardis@iarc.fr	Cardis, Elisabeth/C-3904-2017	Cardis, Elisabeth/0000-0003-0999-6839			Balonov M, 2006, HEALTH PHYS, V90, P97, DOI 10.1097/01.HP.0000175628.64637.8c; Brenner DJ, 2006, RADIAT ENVIRON BIOPH, V44, P253, DOI 10.1007/s00411-006-0029-4; Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095; Cardis E, 2005, BMJ-BRIT MED J, V331, P77, DOI 10.1136/bmj.38499.599861.E0; Cardis E, 2001, HEALTH PHYS, V80, P349, DOI 10.1097/00004032-200104000-00011; *ICRP, 2007, IN PRESS ANN ICRP, V103; Kossenko MM, 2005, RADIAT RES, V164, P591, DOI 10.1667/RR3451.1; Krestinina LY, 2007, INT J EPIDEMIOL, V36, P1038, DOI 10.1093/ije/dym121; Krestinina LY, 2005, RADIAT RES, V164, P602, DOI 10.1667/RR3452.1; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Tubiana M, 2006, J RADIOL PROT, V26, P317, DOI 10.1088/0952-4746/26/3/N01	11	7	7	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	OCT	2007	36	5					1046	1047		10.1093/ije/dym192			3	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	227TO	WOS:000250680900020	17890279	Bronze			2022-02-25	
J	Hery, C; Ferlay, J; Bonoil, M; Autier, R				Hery, C.; Ferlay, J.; Bonoil, M.; Autier, R.			Temporal trends in age-specific incidence and mortality of breast cancer in 38 countries	EJC SUPPLEMENTS			English	Meeting Abstract	14th European Cancer Conference (ECCO 14)	SEP 23-27, 2007	Barcelona, SPAIN	European Canc Org					[Hery, C.; Ferlay, J.; Autier, R.] Int Agcy Res Canc, Data Anal & Interpretat Grp, Lyon, France; [Bonoil, M.] Int Agcy Res Canc, Biostat Grp, F-69372 Lyon, France									0	0	0	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	SEP	2007	5	4					164	164		10.1016/S1359-6349(07)70692-4			1	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	221CC	WOS:000250204000543					2022-02-25	
J	Cust, A; Slimani, N; Kaaks, R; van Bakel, M; Biessy, C; Ferrari, P; Laville, M				Cust, A.; Slimani, N.; Kaaks, R.; van Bakel, M.; Biessy, C.; Ferrari, P.; Laville, M.		EPIC collaborating ctrs I	Dietary carbohydrates, glycemic index, glycemic load and endometrial cancer risk within the european prospective investigation into cancer and nutrition (EPIC) cohort.	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Meeting Abstract	40th Annual Meeting of the Society-for-Epidemiologic-Research	JUN 19-22, 2007	Boston, MA	Soc Epidemiol Res					Int Agcy Res Canc, Nutr & Hormones Unit, F-69008 Lyon, France				Cust, Anne/J-1797-2019	Cust, Anne/0000-0002-5331-6370				0	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JUN 1	2007	165	11		S			S60	S60					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Public, Environmental & Occupational Health	175SO	WOS:000247034500238					2022-02-25	
J	Boyle, P				Boyle, P.			Colorectal cancer can be prevented: epidemiology and primary prevention	EJC SUPPLEMENTS			English	Meeting Abstract									Int Agcy Res Canc, Div Epidemiol Biostat, F-69372 Lyon, France									0	0	0	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	OCT	2005	3	2		S			18	18					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	183HV	WOS:000247564800059					2022-02-25	
J	Cogliano, V; Grosse, Y; Baan, R; Straif, K				Cogliano, V; Grosse, Y; Baan, R; Straif, K			Oral oestrogen-progestagen contraceptives, menopausal treatment, and cancer - Authors' reply	LANCET ONCOLOGY			English	Letter									WHO, Int Agcy Res Canc, Carcinogen Identificat & Evaluat Grp, F-69372 Lyon, France		Cogliano, V (corresponding author), WHO, Int Agcy Res Canc, Carcinogen Identificat & Evaluat Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	cogliano@iarc.fr					Cogliano V, 2005, LANCET ONCOL, V6, P552, DOI 10.1016/S1470-2045(05)70273-4; *IARC, 1999, IARC MON, V72	2	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	OCT	2005	6	10					737	737		10.1016/S1470-2045(05)70367-3			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	972WK	WOS:000232483700007					2022-02-25	
J	Ohshima, H; Tatemichi, M; Sawa, T				Ohshima, H; Tatemichi, M; Sawa, T			Chemical basis of inflammation-induced carcinogenesis	ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS			English	Review						cancer; DNA damage; hypochlorous acid; inflammation; mutation; nitric oxide; 8-nitroguanine; nitrotyrosine; nitroxyl; peroxynitrite	NITRIC-OXIDE PRODUCTION; NECROSIS-FACTOR-ALPHA; OXIDATIVE DNA-DAMAGE; P53 TUMOR-SUPPRESSOR; LIPID PEROXYL RADICALS; EOSINOPHIL PEROXIDASE; HYPOCHLOROUS ACID; HYDROGEN-PEROXIDE; MYELOPEROXIDASE-H2O2-CL-SYSTEM; HUMAN-NEUTROPHILS	Chronic inflammation induced by biological, chemical, and physical factors has been associated with increased risk of human cancer at various sites. Inflammation activates a variety of inflammatory cells, which induce and activate several oxidant-generating enzymes such as NADPH oxidase, inducible nitric oxide synthase, myeloperoxidase, and eosinophil peroxidase. These enzymes produce high concentrations of diverse free radicals and oxidants including superoxide anion, nitric oxide, nitroxyl, nitrogen dioxide, hydrogen peroxide, hypochlorous acid, and hypobromous acid, which react with each other to generate other more potent reactive oxygen and nitrogen species such as peroxynitrite. These species can damage DNA, RNA, lipids, and proteins by nitration, oxidation, chlorination, and bromination reactions, leading to increased mutations and altered functions of enzymes and proteins (e.g., activation of oncogene products and/or inhibition of tumor-suppressor proteins) and thus contributing to the multistage carcinogenesis process. Appropriate treatment of inflammation should be explored further for chemoprevention of human cancers. (C) 2003 Elsevier Science (USA). All rights reserved.	Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Ohshima, Hiroshi/E-8044-2010				Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ahn B, 2001, CANCER RES, V61, P8357; Akaike T, 2003, P NATL ACAD SCI USA, V100, P685, DOI 10.1073/pnas.0235623100; Akaike T, 2000, FASEB J, V14, P1447, DOI 10.1096/fj.14.10.1447; AKASAKA S, 1995, BIOCHEM BIOPH RES CO, V213, P74, DOI 10.1006/bbrc.1995.2100; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bartberger MD, 2001, P NATL ACAD SCI USA, V98, P2194, DOI 10.1073/pnas.041481598; BAZYLINSKI DA, 1985, INORG CHEM, V24, P4285, DOI 10.1021/ic00219a017; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Burrows CJ, 2002, ENVIRON HEALTH PERSP, V110, P713, DOI 10.1289/ehp.02110s5713; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Calmels S, 1997, CANCER RES, V57, P3365; Cascorbi I, 2000, CANCER RES, V60, P644; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Chazotte-Aubert L, 1999, J BIOL CHEM, V274, P20909, DOI 10.1074/jbc.274.30.20909; Christen S, 1999, MICROBES AND MALIGNANCY, P35; Cobbs CS, 2001, ARCH BIOCHEM BIOPHYS, V394, P167, DOI 10.1006/abbi.2001.2540; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; DIZDAROGLU M, 1994, METHOD ENZYMOL, V234, P3; Douki T, 1996, FREE RADICAL RES, V24, P369, DOI 10.3109/10715769609088035; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; FELLEYBOSCO E, 1995, CARCINOGENESIS, V16, P2069, DOI 10.1093/carcin/16.9.2069; Gal A, 1996, P NATL ACAD SCI USA, V93, P15102, DOI 10.1073/pnas.93.26.15102; Garcia-Cardena G, 1998, J NATL CANCER I, V90, P560, DOI 10.1093/jnci/90.8.560; Goodwin DC, 1999, FASEB J, V13, P1121, DOI 10.1096/fasebj.13.10.1121; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hegardt P, 2000, CELL IMMUNOL, V200, P116, DOI 10.1006/cimm.2000.1625; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; Huisman A, 2002, FASEB J, V16, P1135, DOI 10.1096/fj.01-0890fje; *IARC WORK GROUP E, 1994, IARC MON EV CARC RIS, V61; *IARC WORK GROUP E, 1996, IARC MON EV CARC RIS, V67; *IARC WORK GROUP E, 1997, IARC HDB CANC PREV N, V1; *IARC WORK GROUP E, 1994, IARC MON EV CARC RIS, V59; *IARC WORK GROUP E, 1995, IARC MON EV CARC RIS, V64; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. World Health Organization, 1997, IARC MON EV CARC RIS, V70; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jaiswal M, 2001, CANCER RES, V61, P6388; Jeong JK, 1998, CHEM RES TOXICOL, V11, P550, DOI 10.1021/tx980008a; Kanazawa A, 2000, CANCER LETT, V156, P51, DOI 10.1016/S0304-3835(00)00439-0; Karp JE, 1999, MICROBES AND MALIGNANCY, P131; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kirsch M, 2002, J BIOL CHEM, V277, P13379, DOI 10.1074/jbc.M108079200; Kisley LR, 2002, CANCER RES, V62, P6850; Koppenol WH, 1996, METHOD ENZYMOL, V268, P7; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443; LEJEUNE P, 1994, J IMMUNOL, V152, P5077; Li CQ, 2001, DIGEST DIS SCI, V46, P836, DOI 10.1023/A:1010764720524; London SJ, 1997, CANCER RES, V57, P5001; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Masuda M, 2002, CHEM-BIOL INTERACT, V139, P187, DOI 10.1016/S0009-2797(01)00299-X; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; Mei JM, 2000, FASEB J, V14, P1188, DOI 10.1096/fasebj.14.9.1188; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; MORAES EC, 1989, NUCLEIC ACIDS RES, V17, P8301, DOI 10.1093/nar/17.20.8301; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; Niles JC, 1999, P NATL ACAD SCI USA, V96, P11729, DOI 10.1073/pnas.96.21.11729; Niles JC, 2001, J AM CHEM SOC, V123, P12147, DOI 10.1021/ja004296k; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; Oh BR, 2000, J UROLOGY, V163, P1584, DOI 10.1016/S0022-5347(05)67683-5; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Ohshima H, 1999, METHOD ENZYMOL, V301, P40; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; PARKIN DM, 2002, 1 APOCP C INFL CANC, P24; Pignatelli B, 2001, CANCER RES, V61, P778; Pignatelli B, 2001, AM J GASTROENTEROL, V96, P1758, DOI 10.1111/j.1572-0241.2001.03869.x; Ravanat JL, 2002, CARCINOGENESIS, V23, P1911, DOI 10.1093/carcin/23.11.1911; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sandhu JK, 2000, AM J PATHOL, V156, P509, DOI 10.1016/S0002-9440(10)64755-4; Saran M, 1999, FREE RADICAL BIO MED, V26, P482, DOI 10.1016/S0891-5849(98)00187-7; Sawa T, 1998, CANCER EPIDEM BIOMAR, V7, P1007; Shafirovich V, 2002, P NATL ACAD SCI USA, V99, P7340, DOI 10.1073/pnas.112202099; Shen ZZ, 2001, BIOCHEMISTRY-US, V40, P2041, DOI 10.1021/bi001961t; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SINGER B, 1999, EXOCYCLIC DNA ADDUCT, V150; Souici AC, 2000, CARCINOGENESIS, V21, P281, DOI 10.1093/carcin/21.2.281; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Suganuma M, 1999, CANCER RES, V59, P4516; Suzuki T, 2003, CHEM RES TOXICOL, V16, P382, DOI 10.1021/tx025638y; Suzuki T, 2002, NUCLEIC ACIDS RES, V30, P2555, DOI 10.1093/nar/30.11.2555; Suzuki T, 2001, CHEM RES TOXICOL, V14, P1163, DOI 10.1021/tx010024z; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; TANNENBAUM SR, 1994, ACS SYM SER, V553, P120; Toyokuni S, 1997, LAB INVEST, V76, P365; Toyokuni S, 2000, ANTIOXID REDOX SIGN, V2, P681, DOI 10.1089/ars.2000.2.4-681; Vasa M, 2000, CIRC RES, V87, P540, DOI 10.1161/01.RES.87.7.540; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Warzocha K, 1998, BLOOD, V91, P3574; Weisburger JH, 2001, MUTAT RES-FUND MOL M, V480, P23, DOI 10.1016/S0027-5107(01)00166-X; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; WEITZMAN SA, 1990, BLOOD, V76, P655; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; Wentworth P, 2003, P NATL ACAD SCI USA, V100, P1490, DOI 10.1073/pnas.0437831100; Wink D. A., 1996, METHODS NITRIC OXIDE, P403; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zur Hausen H, 1999, MICROBES AND MALIGNANCY, P107	121	510	526	2	61	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0003-9861			ARCH BIOCHEM BIOPHYS	Arch. Biochem. Biophys.	SEP 1	2003	417	1					3	11		10.1016/S0003-9861(03)00283-2			9	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	714XJ	WOS:000184939300002	12921773				2022-02-25	
J	Yang, BH; Bray, FI; Parkin, DM; Sellors, JW; Zhang, ZF				Yang, BH; Bray, FI; Parkin, DM; Sellors, JW; Zhang, ZF			Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost.	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Meeting Abstract	36th Annual Meeting of the Society-for-Epidemiologic-Research	JUN 11-14, 2003	ATLANTA, GEORGIA	Soc Epidemiol Res					Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JUN 1	2003	157	11		S		63	S16	S16					1	Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	687PJ	WOS:000183385400063					2022-02-25	
J	Vainio, H; Weiderpass, E				Vainio, H; Weiderpass, E			Smokeless tobacco: harm reduction or nicotine overload?	EUROPEAN JOURNAL OF CANCER PREVENTION			English	Editorial Material							ORAL SNUFF; RATS; CARCINOGENESIS; ALCOHOL		Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon 08, France; Int Agcy Res Canc, Unit Field Intervent Studies, F-69372 Lyon 08, France		Vainio, H (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	vainio@iarc.fr	Weiderpass, Elisabete/M-4029-2016; Weiderpass, Elisabete/AAP-2747-2021	Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128			BATES C, 2002, 3 INT C SMOK TOB STO; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; HOFFMANN D, 1993, CANCER RES, V53, P2758; Hoffmann D, 1997, Adv Dent Res, V11, P322; *IARC, 2003, MON EV CARC RISKS HU, V83; IARC, 1985, MON EV CARC RISKS HU, V37; JOHANSSON SL, 1991, CANCER RES, V51, P4388; JOHANSSON SL, 1989, CANCER RES, V49, P3063; Lewin F, 1998, CANCER-AM CANCER SOC, V82, P1367, DOI 10.1002/(SICI)1097-0142(19980401)82:7&lt;1367::AID-CNCR21&gt;3.0.CO;2-3; MATCH S, 2001, AFFARSVARLDEN, V4, P34; Prokopczyk B, 2002, CHEM RES TOXICOL, V15, P677, DOI 10.1021/tx0101088; RIVENSON A, 1988, CANCER RES, V48, P6912; Schildt EB, 1998, INT J CANCER, V77, P341, DOI 10.1002/(SICI)1097-0215(19980729)77:3<341::AID-IJC6>3.3.CO;2-Q; Stratton K., 2001, CLEARING SMOKE ASSES	14	9	10	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-8278	1473-5709		EUR J CANCER PREV	Eur. J. Cancer Prev.	APR	2003	12	2					89	92		10.1097/00008469-200304000-00001			4	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	677DW	WOS:000182792500001	12671531				2022-02-25	
J	Pisani, P; Bray, F; Parkin, DM				Pisani, P; Bray, F; Parkin, DM			Estimates of the world-wide prevalence of cancer for 25 sites in the adult population	INTERNATIONAL JOURNAL OF CANCER			English	Article						prevalence; neoplasms; health care facilities; developing countries; survival	MORTALITY	In health services planning, in addition to the basic measures of disease occurrence incidence and mortality, other indexes expressing the demand of care are also required to develop strategies for service provision. One of these is prevalence of the disease, which measures the absolute number, and relative proportion in the population, of individuals affected by the disease and that require some form of medical attention. For most cancer sites, cases surviving 5 years from diagnosis experience thereafter the same survival as the general population, so most of the workload is therefore due to medical acts within these first 5 years. This article reports world-wide estimates of 1-, 2-3- and 4-5-year point prevalence in 1990 in the population aged IS years or over, and hence describes the number of cancer cases diagnosed between 1986 and 1990 who were still alive at the end of 1990. These estimates of prevalence at 1, 2-3 and 4-5 years are applicable to the evaluation of initial treatment, clinical follow-up and point of cure, respectively, for the majority of cancers. We describe the computational procedure and data sources utilised to obtain these figures and compare them with data published by 2 cancer registries. The highest prevalence of cancer is in North America with 1.5% of the population affected and diagnosed in the previous 5 years (about 0.5% of the population in years 4-5 and 2-3 of follow-up and 0.4% within the first year of diagnosis). This corresponds to over 3.2 million individuals. Western Europe and Australia and New Zealand show very similar percentages with 1.2% and 1.1% of the population affected (about 3.9 and 0.2 million cases respectively). Japan and Eastern Europe form the next batch with 1.0% and 0.7%, followed by Latin America and the Caribbean (overall prevalence of 0.4%), and all remaining regions are around 0.2%. Cancer prevalence in developed countries is very similar in men and women, 1.1% of the sex-specific population, while in developing countries the prevalence is some 25% greater in women than men, reflecting a preponderance of cancer sites with poor survival such as liver, oesophagus and stomach in males. The magnitude of disease incidence is the primary determinant of crude prevalence of cases diagnosed within I year so that differences by region mainly reflect variation in risk. In the long-term period however different demographic patterns with long-life expectancy in high-income countries determine a higher prevalence in these areas even for relatively uncommon cancer sites such as the cervix. (C) 2002 Wiley-Liss, Inc.	Int Agcy Res Canc, Unit Descrip Epidemiol, F-69372 Lyon, France		Pisani, P (corresponding author), Int Agcy Res Canc, Unit Descrip Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon, France.	pisani@iarc.fr					ADAMI HO, 1989, ACTA ONCOL, V28, P463, DOI 10.3109/02841868909092251; BENJAMIN B, 1968, DEMOGRAPHIC ANAL; Berrino F., 1995, IARC SCI PUBLICATION, V132; BYRNE J, 1992, CANCER, V69, P2154, DOI 10.1002/1097-0142(19920415)69:8&lt;2154::AID-CNCR2820690823&gt;3.0.CO;2-R; *CANC REG NORW, 1998, CANC NORW 1995; CAPOCACCIA R, 1990, CANCER CAUSE CONTROL, V1, P23, DOI 10.1007/BF00053180; COLDMAN AJ, 1992, STAT MED, V11, P1579, DOI 10.1002/sim.4780111205; Colonna M, 2000, INT J CANCER, V87, P301, DOI 10.1002/1097-0215(20000715)87:2<301::AID-IJC24>3.0.CO;2-Y; Colonna M, 2001, EUR J CANCER, V37, P93, DOI 10.1016/S0959-8049(00)00358-0; Desai MM, 2001, AM J EPIDEMIOL, V153, P299, DOI 10.1093/aje/153.3.299; Hewitt M, 1999, J NATL CANCER I, V91, P1480, DOI 10.1093/jnci/91.17.1480; Lopez AD, 1996, GLOBAL BURDEN DIS CO; Merrill RM, 2000, INT J EPIDEMIOL, V29, P197, DOI 10.1093/ije/29.2.197; Micheli A, 1999, TUMORI J, V85, P309, DOI 10.1177/030089169908500502; *NAT CANC CTR, 1991, FDN PROM CANC RES FI; *NCI CAN, 1995, CAN CANC STAT 1995; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Pisani P, 1999, INT J CANCER, V83, P870; Ries LAG, 1997, NIH PUB, V97-2789; Sankaranarayanan R, 1998, IARC SCI PUBLICATION, V145; SCHRIJVERS CTM, 1994, AM J EPIDEMIOL, V139, P409; *SO AUSTR CANC REG, 1994, EP CANC S AUSTR; Thomson H., 1996, CANC ESTONIA 1968 19; Tulinius H, 1992, APMIS Suppl, V31, P1; VERDECCHIA A, 1989, STAT MED, V8, P201, DOI 10.1002/sim.4780080207; WIEBELT H, 1991, J NATL CANCER I, V83, P579, DOI 10.1093/jnci/83.8.579	26	508	542	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	JAN 1	2002	97	1					72	81		10.1002/ijc.1571			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	499JE	WOS:000172567400011	11774246	Bronze			2022-02-25	
J	Parkin, DM				Parkin, DM			Global cancer statistics in the year 2000	LANCET ONCOLOGY			English	Review								Estimation of the burden of cancer in terms of incidence, mortality, and prevalence is a first step to appreciating appropriate control measures in a global context. The latest results of such an exercise, based on the most recent available international data, show that there were 10 million new cases, 6 million deaths, and 22 million people living with cancer in 2000. The most common cancers in terms of new cases were lung (1.2 million), breast (1.05 million), colorectal (945 000), stomach (876 000), and liver (564 000). The profile varies greatly in different populations, and the evidence suggests that this variation is mainly a consequence of different lifestyle and environmental factors, which should be amenable to preventive interventions. World population growth and ageing imply a progressive increase in the cancer burden - 15 million new cases and 10 million new deaths are expected in 2020, even if current rates remain unchanged.	Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon, France		Parkin, DM (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon, France.	parkin@iarc.fr	qiao, zhixin/I-3408-2012				Berrino F, 1999, IARC SCI PUBLICATION, V151; Blanks RG, 2000, BRIT MED J, V321, P665, DOI 10.1136/bmj.321.7262.665; BLOT WJ, 1987, AM J PUBLIC HEALTH, V77, P296, DOI 10.2105/AJPH.77.3.296; BROWN L, 2001, STATE WORLD 2000; BULATAO RA, 1989, EVOLVING HLTH SECTOR; CHAMBERLAIN J, 1997, HEALTH TECHNOL ASSES, V1, P1; Danesh J, 1999, ALIMENT PHARM THERAP, V13, P851; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Doll Richard, 1981, CAUSES CANC; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033; Ferlay J., 2001, GLOBOCAN 2000 CANC I; Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025; Geddes M, 1993, IARC SCI PUBLICATION, V123; GILLILAND FD, 1994, CANCER SURV, V20, P175; Grosclaude P, 1997, Prog Urol, V7, P647; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; HAKULINEN T, 1986, INT J EPIDEMIOL, V15, P226, DOI 10.1093/ije/15.2.226; Hankey BF, 1999, JNCI-J NATL CANCER I, V91, P1017, DOI 10.1093/jnci/91.12.1017; Hermon C, 1996, BRIT J CANCER, V73, P955, DOI 10.1038/bjc.1996.171; HERRERO R, 2000, 18 INT PAP C BARC; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; *IARC, 1994, IARC MON EV CARC RIS, V61; *IARC, 1995, IARC MON EV CARC RIS, V64; Jin F, 1999, INT J CANCER, V83, P435, DOI 10.1002/(SICI)1097-0215(19991112)83:4&lt;435::AID-IJC1&gt;3.0.CO;2-J; Koo LC, 1997, NUTR CANCER, V28, P289, DOI 10.1080/01635589709514590; Laheij RJF, 1999, INT J EPIDEMIOL, V28, P391, DOI 10.1093/ije/28.3.391; Legler JM, 1998, CANCER CAUSE CONTROL, V9, P519, DOI 10.1023/A:1008805718310; Lopez AD, 1996, GLOBAL BURDEN DIS CO; LOPEZABENTE G, 1995, CANCER EPIDEM BIOMAR, V4, P813; MACKAY J, 1993, STATE HLTH ATLAS; McMichael A. J., 1994, V19-20, P77; MCMICHAEL AJ, 1980, INT J CANCER, V25, P431, DOI 10.1002/ijc.2910250402; Mercer SL, 1997, CAN J PUBLIC HEALTH, V88, P327, DOI 10.1007/BF03403900; Munoz N, 1996, CANC EPIDEMIOLOGY PR; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARKIN DM, 1993, CANCER EPIDEM BIOMAR, V2, P537; PARKIN DM, 1999, INFECT HUMAN CANC, V33; PISANI F, IN PRESS INT J CANC; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Post PN, 1998, EUR J CANCER, V34, P705, DOI 10.1016/S0959-8049(97)10154-X; PRESTON HS, 1976, MORTALITY PATTERNS N; RIES LAG, 1997, NIH PUBLICATION; Sankaranarayanan R, 1998, IARC SCI PUBLICATION, V145; Shibata A, 1997, PROSTATE, V32, P65; TANAKA H, 1994, CANCER CAUSE CONTROL, V5, P409, DOI 10.1007/BF01694754; Threlfall TJ, 1998, MED J AUSTRALIA, V169, P21, DOI 10.5694/j.1326-5377.1998.tb141472.x; TYCZYNSKI J, 1994, EUR J CANCER, V30A, P478, DOI 10.1016/0959-8049(94)90423-5; *UN, 1999, WORLD POPULATION PRO, V1; *UN ENV PROGR, 1997, GLOB ENV OUTL 1997; UNDP ( United Nations Development Programme), 2000, HUM DEV REP 2000; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; *WCRF PAN, 1997, DIET NUTR PREV CANC; World Bank, 1993, WORLD DEV REP 1993 I; World Health Organization, 2000, WORLD HLTH REP 2000; ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819	59	1814	1979	3	114	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	SEP	2001	2	9					533	543		10.1016/S1470-2045(01)00486-7			11	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	V41YX	WOS:000202836300018	11905707				2022-02-25	
J	Plummer, M; Franceschi, S; Vignat, J; Forman, D; de Martel, C				Plummer, Martyn; Franceschi, Silvia; Vignat, Jerome; Forman, David; de Martel, Catherine			Global burden of gastric cancer attributable to Helicobacter pylori	INTERNATIONAL JOURNAL OF CANCER			English	Article						Helicobacter pylori; gastric cancer; attributable fraction; immunoblot	INFECTION; RISK; IMMUNOBLOT; CAGA; ASSOCIATION	We previously estimated that 660,000 cases of cancer in the year 2008 were attributable to the bacterium Helicobacter pylori (H. pylori), corresponding to 5.2% of the 12.7 million total cancer cases that occurred worldwide. In recent years, evidence has accumulated that immunoblot (western blot) is more sensitive for detection of anti-H. pylori antibodies than ELISA, the detection method used in our previous analysis. The purpose of this short report is to update the attributable fraction (AF) estimate for H. pylori after briefly reviewing new evidence, and to reassess the global burden of cancer attributable to H. pylori. We therefore reviewed the literature for studies comparing the risk of developing non-cardia gastric cancer (NCGC) in cases and controls, using both ELISA and multiple antigen immunoblot for detection of H. pylori. The results from prospective studies were combined, and the new pooled estimates were applied to the calculation of the AF for H. pylori in NCGC, then to the burden of infection-related cancers worldwide. Using the immunoblot-based data, the worldwide AF for H. pylori in NCGC increased from 74.7% to 89.0%. This implies approximately 120,000 additional cases of NCGC attributable to H. pylori infection for a total of around 780,000 cases (6.2% instead of 5.2% of all cancers). These updated estimates reinforce the role of H. pylori as a major cause of cancer. What's new? Some 5.2 percent of the estimated 12.7 million new cancer cases in 2008, including 75% of non-cardia gastric cancer cases (NCGC), were attributed to the bacterium Helicobacter pylori. However, those percentages may be an underestimate, given the low sensitivity of detection of anti-H. pylori antibodies. Here, using improved estimates from prospective studies based on immunoblot, the fraction of all cancers and NCGC attributable to H. pylori was found to be 6.2 and 89% percent, respectively. Our findings reinforce the significance of the bacterium as a major cause of cancer.	[Plummer, Martyn; Franceschi, Silvia; Vignat, Jerome; Forman, David; de Martel, Catherine] Int Agcy Res Canc, F-69372 Lyon, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	plummer@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497	Fondation de FranceFondation de France [00039621]	Grant sponsor: Fondation de France; Grant number: 00039621	Brenner H, 2004, AM J EPIDEMIOL, V159, P252, DOI 10.1093/aje/kwh039; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Ferlay J, 2013, CANC INCIDENCE MORTA; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gonzalez CA, 2012, ANN ONCOL, V23, P1320, DOI 10.1093/annonc/mdr384; Gonzalez CA, 2011, AM J GASTROENTEROL, V106, P867, DOI 10.1038/ajg.2011.1; IARC, 2012, MON EV CARC RISKS HU; Mitchell H, 2008, ALIMENT PHARM THER, V28, P903, DOI 10.1111/j.1365-2036.2008.03792.x; Monteiro L, 2001, AM J GASTROENTEROL, V96, P353, DOI 10.1111/j.1572-0241.2001.03518.x; Peleteiro B, 2010, CANCER CAUSE CONTROL, V21, P1257, DOI 10.1007/s10552-010-9553-2; Plummer M, 2007, J NATL CANCER I, V99, P1328, DOI 10.1093/jnci/djm120; Siman FH, 2005, CLIN DIAGN LAB IMMUN, V12, P304, DOI 10.1128/CDLI.12.2.304-309.2005; Siman JH, 2007, SCAND J GASTROENTERO, V42, P933, DOI 10.1080/00365520601173863; Siman JH, 1997, SCAND J GASTROENTERO, V32, P1215, DOI 10.3109/00365529709028150; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Yang KC, 2006, WORLD J GASTROENTERO, V12, P7029, DOI 10.3748/wjg.v12.i43.7029	17	411	438	11	105	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	JAN 15	2015	136	2					487	490		10.1002/ijc.28999			4	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AS9ZK	WOS:000344596600026	24889903	Bronze	Y	N	2022-02-25	
J	Guha, N; Straif, K; Benbrahim-Tallaa, L				Guha, Neela; Straif, Kurt; Benbrahim-Tallaa, Lamia			The IARC Monographs on the carcinogenicity of crystalline silica	MEDICINA DEL LAVORO			English	Article						Silica; carcinogenesis; humans; rodents; IARC	CAROLINA DUSTY TRADES; AFRICAN GOLD MINERS; DIATOMACEOUS-EARTH INDUSTRY; ALVEOLAR EPITHELIAL-CELLS; VERMONT GRANITE WORKERS; LUNG-CANCER RISK; EXPOSED WORKERS; DNA-DAMAGE; SURFACE-PROPERTIES; COMMERCIAL QUARTZ	Background: Through extensive review of the published literature, two independent expert panels convened by the International Agency for Research on Cancer (IARC) Monographs Programme have classified crystalline silica as carcinogenic to humans while amorphous silica was not classifiable as to its carcinogenicity in humans. The panel remarked that crystalline silica in the form of quartz or cristobalite dust causes lung cancer in humans. Objectives: We discuss the literature and rationale used to support the IARC evaluations of silica. Methods: A critical review, with a focus on lung tumors, was conducted of the pertinent literature on the carcinogenic effects of crystalline silica in humans and experimental animals as well as supportive mechanistic evidence. Results: The strongest supportive evidence comes from pooled and meta-analyses that employed quantitative exposure assessment, focused on silicotics, accounted for potential confounding and demonstrated exposure-response trends. Consistency of the effect was observed despite some heterogeneity between individual studies. Tumor site concordance was observed with rodents and further supported by mechanistic data. Conclusions: Several million workers worldwide are exposed to crystalline silica. Silicosis and lung cancer in these workers are completely preventable diseases. The IARC evaluations are critical to supporting public health interventions to protect persons at high-risk.	[Straif, Kurt] Int Agcy Res Canc, WHO, IARC Monographs, F-69372 Lyon 08, France		Straif, K (corresponding author), Int Agcy Res Canc, WHO, IARC Monographs, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	straif@iarc.fr	Guha, Neela/AAG-3989-2021	Guha, Neela/0000-0003-3991-4662			Amandus HE, 1995, SCAND J WORK ENV HEA, V21, P81; AMANDUS HE, 1991, AM J IND MED, V20, P57, DOI 10.1002/ajim.4700200106; AMANDUS HE, 1992, AM J IND MED, V22, P147, DOI 10.1002/ajim.4700220202; BROWN DP, 1986, SILICA SILICOSIS CAN, P335; Burgess GL, 1998, ANN OCCUP HYG, V42, P209, DOI 10.1016/S0003-4878(98)00005-2; Cakmak GD, 2004, INT J HYG ENVIR HEAL, V207, P105, DOI 10.1078/1438-4639-00276; Carta P, 2001, OCCUP ENVIRON MED, V58, P786, DOI 10.1136/oem.58.12.786; Castranova V, 2004, FREE RADICAL BIO MED, V37, P916, DOI 10.1016/j.freeradbiomed.2004.05.032; CASTRANOVA V, 1991, J LEUKOCYTE BIOL, V50, P412, DOI 10.1002/jlb.50.4.412; Checkoway H, 1996, OCCUP ENVIRON MED, V53, P645, DOI 10.1136/oem.53.9.645; CHECKOWAY H, 1993, BRIT J IND MED, V50, P586; CHEN JQ, 1992, J OCCUP ENVIRON MED, V34, P311, DOI 10.1097/00043764-199203000-00017; CHERRY N, 1995, APPL OCCUP ENV HYG, V10, P1042; CHERRY NM, 1997, ANN OCCUP HYG, V41, P408; COSTELLO J, 1995, AM J IND MED, V27, P625, DOI 10.1002/ajim.4700270502; COSTELLO J, 1988, AM J IND MED, V13, P483, DOI 10.1002/ajim.4700130408; DAGLE GE, 1986, SILICA SILICOSIS CAN, P255; Damm C, 2009, LANGMUIR, V25, P2264, DOI 10.1021/la803502x; DAVIS LK, 1983, AM J IND MED, V4, P705, DOI 10.1002/ajim.4700040604; Deshpande A, 2002, TOXICOL SCI, V67, P275, DOI 10.1093/toxsci/67.2.275; Donaldson Ken, 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P109; Dong DP, 1995, SCAND J WORK ENV HEA, V21, P69; Driscoll KE, 1997, CARCINOGENESIS, V18, P423, DOI 10.1093/carcin/18.2.423; Duffin R, 2001, TOXICOL APPL PHARM, V176, P10, DOI 10.1006/taap.2001.9268; Ebbesen P, 1991, Eur J Cancer Prev, V1, P39, DOI 10.1097/00008469-199110000-00008; Elias Z, 2000, TOXICOL IN VITRO, V14, P409, DOI 10.1016/S0887-2333(00)00039-4; Erren TC, 2009, INT ARCH OCC ENV HEA, V82, P997, DOI 10.1007/s00420-008-0387-0; Fenoglio I, 2003, FREE RADICAL BIO MED, V35, P752, DOI 10.1016/S0891-5849(03)00398-8; Fenoglio I, 2000, CHEM RES TOXICOL, V13, P971, DOI 10.1021/tx000125h; Fubini B, 1999, CHEM RES TOXICOL, V12, P737, DOI 10.1021/tx980261a; Fubini B, 2004, INT J HYG ENVIR HEAL, V207, P89, DOI 10.1078/1438-4639-00277; Fubini Bice, 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P95; Gilmour PS, 1995, CARCINOGENESIS, V16, P2973, DOI 10.1093/carcin/16.12.2973; Groth D., 1986, SILICA SILICOSIS CAN, P243; GUENEL P, 1989, SCAND J WORK ENV HEA, V15, P147, DOI 10.5271/sjweh.1876; HNIZDO E, 1991, BRIT J IND MED, V48, P53; Hnizdo E, 1997, THORAX, V52, P271, DOI 10.1136/thx.52.3.271; HOLLAND LM, 1983, HLTH ISSUES RELATED, P485; HOLLAND LM, 1986, SILICA SILICOSIS CAN, P267; *INT AG RES CANC, 1997, IARC MON EV CARC RIS, V68; *INT AG RES CANC, 1987, IARC MON EV CARC S7, V1; International Agency for Research on Cancer, 1987, IARC MON EV CARC RIS, V42; International Agency for Research on Cancer, 2006, IARC MON EV CARC RIS; JOHNSON NF, 1987, AM J IND MED, V11, P93, DOI 10.1002/ajim.4700110110; Kauppinen T, 2000, OCCUP ENVIRON MED, V57, P10, DOI 10.1136/oem.57.1.10; Knaapen AM, 2004, INT J CANCER, V109, P799, DOI 10.1002/ijc.11708; Knaapen AM, 2002, CARCINOGENESIS, V23, P1111, DOI 10.1093/carcin/23.7.1111; Kurihara N, 2004, IND HEALTH, V42, P303, DOI 10.2486/indhealth.42.303; Lacasse Y, 2005, SCAND J WORK ENV HEA, V31, P450, DOI 10.5271/sjweh.949; Lacasse Y, 2009, CANCER CAUSE CONTROL, V20, P925, DOI 10.1007/s10552-009-9296-0; McDonald AD, 1997, ANN OCCUP HYG, V41, P707, DOI 10.1016/S0003-4878(97)00020-3; McDonald JC, 1995, SCAND J WORK ENV HEA, V21, P63; MCDONALD JC, 1978, AM REV RESPIR DIS, V118, P271; MCLAUGHLIN JK, 1992, BRIT J IND MED, V49, P167; Merlo F, 1991, Epidemiology, V2, P299, DOI 10.1097/00001648-199107000-00012; MUHLE H, 1989, AM J IND MED, V15, P343, DOI 10.1002/ajim.4700150309; MUHLE H, 1991, FUND APPL TOXICOL, V17, P280, DOI 10.1016/0272-0590(91)90219-T; Muhle H, 1995, SCAND J WORK ENV HEA, V21, P27; PARTANEN T, 1994, J OCCUP ENVIRON MED, V36, P616; Pelucchi C, 2006, ANN ONCOL, V17, P1039, DOI 10.1093/annonc/mdj125; POTT F, 1994, ANN OCCUP HYG     S1, V38, P357; PUNTONI R, 1988, TUMORI, V74, P27, DOI 10.1177/030089168807400105; PUNTONI R, 1985, SILICE SILICOSI CANC, P79; Reid PJ, 1996, OCCUP ENVIRON MED, V53, P11, DOI 10.1136/oem.53.1.11; Rushton L, 2008, OCCUP ENVIRON MED, V65, P789, DOI 10.1136/oem.2007.037002; SAFFIOTTI U, 1992, PROG CLIN BIOL RES, V374, P51; SAFFIOTTI U, 1996, SILICA SILICA INDUCE, P345; SAFFIOTTI U, 1990, ENV HYGIENE, V2, P235; Schins RPF, 2002, MUTAT RES-GEN TOX EN, V517, P77, DOI 10.1016/S1383-5718(02)00039-6; Schins RPF, 2002, CHEM RES TOXICOL, V15, P1166, DOI 10.1021/tx025558u; Schins RPF, 2002, INHAL TOXICOL, V14, P57, DOI 10.1080/089583701753338631; SMITH AH, 1995, EPIDEMIOLOGY, V6, P617, DOI 10.1097/00001648-199511000-00010; SPIETHOFF A, 1992, HEALTH PHYS, V63, P101, DOI 10.1097/00004032-199207000-00011; STEENLAND K, 1995, AM J IND MED, V27, P217, DOI 10.1002/ajim.4700270207; Steenland K, 2001, CANCER CAUSE CONTROL, V12, P773, DOI 10.1023/A:1012214102061; Steenland K, 1997, CANCER CAUSE CONTROL, V8, P491, DOI 10.1023/A:1018469607938; Straif K, 2009, LANCET ONCOL, V10, P453, DOI 10.1016/S1470-2045(09)70134-2; Tsuda T, 1997, J OCCUP HEALTH, V39, P285, DOI 10.1539/joh.39.285; VALLYATHAN V, 1995, AM J RESP CRIT CARE, V152, P1003, DOI 10.1164/ajrccm.152.3.7663775; WAGNER JC, 1969, BRIT J CANCER, V23, P567, DOI 10.1038/bjc.1969.70; WAGNER JC, 1970, AEC S SERIES, V21, P347; WAGNER MMF, 1976, J NATL CANCER I, V57, P509, DOI 10.1093/jnci/57.3.509; WAGNER MMF, 1972, J NATL CANCER I, V49, P81; Warheit DB, 2007, TOXICOL SCI, V95, P270, DOI 10.1093/toxsci/kfl128; WINTER PD, 1990, OCCUPATIONAL EXPOSUR, P83; Xu ZY, 1996, AM J IND MED, V30, P7; Yu ITS, 2007, INT J CANCER, V120, P133, DOI 10.1002/ijc.22133	87	31	32	0	19	MATTIOLI 1885	FIDENZA	VIA CODURO 1-B, FIDENZA, 43046 PR, ITALY	0025-7818			MED LAV	Med. Lav.	JUL-AUG	2011	102	4					310	320					11	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	785YR	WOS:000292269600002	21834268				2022-02-25	
J	Hafsi, H; Hainaut, P				Hafsi, Hind; Hainaut, Pierre			Pharmacological rescue of p53 in cancer cells: The soloist meets the PRIMA donna	CELL CYCLE			English	Editorial Material							MUTANT P53		[Hafsi, Hind; Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon, France		Hafsi, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Bao WJ, 2011, CELL CYCLE, V10, P301, DOI 10.4161/cc.10.2.14538; Bao WJ, 2004, J CELL BIOL, V167, P745, DOI 10.1083/jcb.200404018; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Hafsi H, 2011, ANTIOXID REDOX SIGNA; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003	5	2	2	0	3	LANDES BIOSCIENCE	AUSTIN	1806 RIO GRANDE ST, AUSTIN, TX 78702 USA	1538-4101			CELL CYCLE	Cell Cycle	MAR 15	2011	10	6					875	876		10.4161/cc.10.6.15120			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	734UX	WOS:000288366400010	21358263	Bronze			2022-02-25	
J	Boffetta, P				Boffetta, P.			The causes of cancer	EJC SUPPLEMENTS			English	Meeting Abstract	15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology	SEP 20-24, 2009	Berlin, GERMANY	European Canc Org, European Soc Med Oncol					[Boffetta, P.] Int Agcy Res Canc, Coordinator Genet & Epidemiol Cluster, F-69372 Lyon, France									0	0	0	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	SEP	2009	7	2					64	64		10.1016/S1359-6349(09)70224-1			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	504VM	WOS:000270645900217					2022-02-25	
J	Plummer, M; Franceschi, S; van Doorn, L				Plummer, M.; Franceschi, S.; van Doorn, Lj			Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions	BULLETIN DU CANCER			English	Meeting Abstract									Int Agcy Res Canc, F-69372 Lyon, France			plummer@iarc.fr	Canzian, Federico/I-2804-2014; franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071				0	0	0	0	0	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0007-4551			B CANCER	Bull. Cancer	MAR	2008	95				SI		S33	S34					2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	277PE	WOS:000254225900054					2022-02-25	
J	Appleby, P; Beral, V; de Gonzalez, AB; Colin, D; Franceschi, S; Green, J; La Vecchia, C; Peto, J; Plummer, M; Randi, G; Sweetland, S				Appleby, P.; Beral, V.; de Gonzalez, A. Berrington; Colin, D.; Franceschi, S.; Green, J.; La Vecchia, C.; Peto, J.; Plummer, M.; Randi, G.; Sweetland, S.		Int Collaboration Epidemiological	Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies	INTERNATIONAL JOURNAL OF CANCER			English	Article						cervical carcinoma; cervical intraepithelial neoplasia; reproductive factors; full-term pregnancy; age at first full-term pregnancy; collaborative reanalysis; relative risk	ORAL-CONTRACEPTIVE USE; SQUAMOUS-CELL CARCINOMA; FLOATING ABSOLUTE RISK; HUMAN-PAPILLOMAVIRUS; IN-SITU; INTRAEPITHELIAL NEOPLASIA; CIGARETTE-SMOKING; SEXUAL-BEHAVIOR; YOUNG-WOMEN; UTERINE CERVIX	The International Collaboration of Epidemiological Studies of Cervical Cancer has combined individual data on 11,161 women with invasive carcinoma, 5,402 women with cervical intraepithelial neoplasia (CIN)3/carcinoma in situ and 33,542 women without cervical carcinoma from 25 epidemiological studies. Relative risks (RRs) and 95% confidence intervals (CIs) of cervical carcinoma in relation to number of full-term pregnancies, and age at first fullterm pregnancy, were calculated conditioning by study, age, lifetime number of sexual partners and age at first sexual intercourse. Number of full-term pregnancies was associated with a risk of invasive cervical carcinoma. After controlling for age at first fullterm pregnancy, the RR for invasive cervical carcinoma among parous women was 1.76 (95% CI: 1.53-2.02) for >= 7 full-term pregnancies compared with 1-2. For CIN3/carcinoma in situ, no significant trend was found with increasing number of births after controlling for age at first full-term pregnancy among parous women. Early age at first full-term pregnancy was also associated with risk of both invasive cervical carcinoma and CIN3/carcinoma in situ. After controlling for number of full-term pregnancies, the RR for first full-term pregnancy at age < 17 years compared with >= 25 years was 1.77 (95% CI: 1.42-2.23) for invasive cervical carcinoma, and 1.78 (95% CI: 1.26-2.51) for CIN3/carcinoma in situ. Results were similar in analyses restricted to high-risk human papilloma virus (HPV)-positive cases and controls. No relationship was found between cervical HPV positivity and number of fullterm pregnancies, or age at first full-term pregnancy among controls. Differences in reproductive habits may have contributed to differences in cervical cancer incidence between developed and developing countries. (c) 2006 Wiley-Liss, Inc.	Int Agcy Res Canc, Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, Lyon 08, France.	ice@iarc.fr	de gonzalez, amy berrington/L-7017-2017; franceschi, silvia/M-2452-2014; Eluf-Neto, Jose/B-2522-2009; Moreno, Victor/A-1697-2010	de gonzalez, amy berrington/0000-0002-7332-8387; franceschi, silvia/0000-0003-4181-8071; Eluf-Neto, Jose/0000-0001-7504-2115; La Vecchia, Carlo/0000-0003-1441-897X; Canfell, Karen/0000-0002-6443-6618; Sitas, Freddy/0000-0001-9679-1481; Moreno, Victor/0000-0002-2818-5487			Altekruse SF, 2003, AM J OBSTET GYNECOL, V188, P657, DOI 10.1067/mob.2003.132; Bayo S, 2002, INT J EPIDEMIOL, V31, P202, DOI 10.1093/ije/31.1.202; Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; BERRY G, 1993, INT J CANCER, V55, P228; BOCCIOLONE L, 1993, GYNECOL ONCOL, V51, P335, DOI 10.1006/gyno.1993.1300; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOYCE JG, 1977, AM J OBSTET GYNECOL, V128, P761, DOI 10.1016/0002-9378(77)90717-7; BOYD JT, 1964, BRIT J CANCER, V13, P419; BRINTON LA, 1987, J NATL CANCER I, V79, P23; BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486, DOI 10.1093/oxfordjournals.aje.a115362; Castle PE, 2002, SEX TRANSM DIS, V29, P182, DOI 10.1097/00007435-200203000-00009; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; CUZICK J, 1990, EUR J CANCER, V26, P684, DOI 10.1016/0277-5379(90)90117-C; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; DESTAVOLA B, 1987, STAT MED, V6, P881, DOI 10.1002/sim.4780060803; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; EBELING K, 1987, INT J CANCER, V39, P427, DOI 10.1002/ijc.2910390402; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; Franceschi S, 2003, INT J CANCER, V107, P127, DOI 10.1002/ijc.11350; GRAM IT, 1992, AM J EPIDEMIOL, V135, P341, DOI 10.1093/oxfordjournals.aje.a116295; Green J, 2003, BRIT J CANCER, V89, P2078, DOI 10.1038/sj.bjc.6601296; Hammouda D, 2005, INT J CANCER, V113, P483, DOI 10.1002/ijc.20600; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779; Hsieh CY, 1999, ANTICANCER RES, V19, P4495; *IARC, 1995, MON EV CARC RISKS HU, V64; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; Kjaer SK, 2002, BRIT MED J, V325, P572, DOI 10.1136/bmj.325.7364.572; KJAER SK, 1992, CANCER CAUSE CONTROL, V3, P339, DOI 10.1007/BF00146887; LAZCANOPONCE EC, 1995, REV INVEST CLIN, V47, P377; Madeleine MM, 2001, CANCER EPIDEM BIOMAR, V10, P171; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; MUNOZ N, 1993, CANCER EPIDEM BIOMAR, V2, P423; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; PARAZZINI F, 1989, BRIT J CANCER, V59, P805, DOI 10.1038/bjc.1989.168; Parkin D, 1992, IARC SCI PUBLICATION, VVI; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; PETRUCCO OM, 1976, BRIT J OBSTET GYNAEC, V83, P245, DOI 10.1111/j.1471-0528.1976.tb00818.x; Plummer M, 2004, STAT MED, V23, P93, DOI 10.1002/sim.1485; Rolon PA, 2000, INT J CANCER, V85, P486, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;486::AID-IJC7&gt;3.0.CO;2-S; ROTKIN ID, 1967, CANCER RES, V27, P603; Santos C, 2001, BRIT J CANCER, V85, P966, DOI [10.1038/sj.bjc.6691948, 10.1054/bjoc.2001.1948]; Shapiro S, 2003, CANCER CAUSE CONTROL, V14, P485, DOI 10.1023/A:1024910808307; Silins I, 2004, GYNECOL ONCOL, V93, P484, DOI 10.1016/j.ygyno.2004.01.044; Sitas F, 2000, INT J CANCER, V88, P489, DOI 10.1002/1097-0215(20001101)88:3&lt;489::AID-IJC25&gt;3.0.CO;2-Q; Skegg DCG, 2002, LANCET, V359, P1080, DOI 10.1016/S0140-6736(02)08125-4; SLATTERY ML, 1989, JAMA-J AM MED ASSOC, V261, P1593, DOI 10.1001/jama.261.11.1593; Smith JS, 2003, LANCET, V361, P1159, DOI 10.1016/S0140-6736(03)12949-2; STONE KM, 1995, EPIDEMIOLOGY, V6, P409, DOI 10.1097/00001648-199507000-00014; STONE KM, 1995, CLIN INFECT DIS   S1, V20, P91; TALBOTT EO, 1995, J WOMENS HLTH LARCHM, V4, P387; Tavassoli FA, 2003, WHO CLASSIFICATION T; The Million Women Study, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Thomas DB, 1996, AM J EPIDEMIOL, V144, P281, DOI 10.1093/oxfordjournals.aje.a008923; THOMAS DB, 1973, AM J EPIDEMIOL, V98, P10, DOI 10.1093/oxfordjournals.aje.a121528; THOMSENSCHMIDT P, 2000, P 1 TOP C FABR METR, V1, P153; Ursin G, 1996, CANCER CAUSE CONTROL, V7, P391, DOI 10.1007/BF00052946; WYNDER EL, 1954, AM J OBSTET GYNECOL, V68, P1016; Ylitalo N, 1999, INT J CANCER, V81, P357, DOI 10.1002/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.0.CO;2-1; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	66	145	151	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	SEP 1	2006	119	5					1108	1124		10.1002/ijc.21953			17	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	067FR	WOS:000239287800020	16570271				2022-02-25	
J	Sankaranarayanan, R; Ferlay, J				Sankaranarayanan, R; Ferlay, J			Worldwide burden of gynaecological cancer: The size of the problem	BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY			English	Article						burden; cervical cancer; control; early detection; gynaecological cancer; ovarian cancer; prevention; screening; uterine body cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CANCER; RADIATION-THERAPY; PARTICLE VACCINE; YOUNG-WOMEN; SURVIVAL; TRIAL; ADENOCARCINOMA; STATISTICS; INFECTION	The estimation of cancer burden is valuable to set up priorities for disease control. The comprehensive global cancer statistics from the International Agency for Research on Cancer indicate that gynaecological cancers accounted for 19% of the 5.1 million estimated new cancer cases, 2.9 million cancer deaths and 13 million 5-year prevalent cancer cases among women in the world in 2002. Cervical cancer accounted for 493 000 new cases and 273 000 deaths; uterine body cancer for 199 000 new cases and 50 000 deaths; ovarian cancer for 204 000 new cases and 125 000 deaths; cancers of the vagina, vulva and choriocarcinoma together constituted 45 900 cases. More than 80% of the cervical cancer cases occurred in developing countries and two-thirds of corpus uteri cases occurred in the developed world. Political will and advocacy to invest in healthcare infrastructure and human resources to improve service delivery and accessibility are vital to reduce the current burden in low- and medium-resource countries.	Int Agcy Res Canc, Screening Grp, F-69008 Lyon, France; Int Agcy Res Canc, Descript Epidemiol Grp, F-69008 Lyon, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	sankar@iarc.fr	Ferlay, Jacques/ABD-5058-2021				Alliance for Cervical Cancer Prevention (ACCP), 2004, PLANN IMPL CERV CANC; Altieri A, 2003, LANCET ONCOL, V4, P670, DOI 10.1016/S1470-2045(03)01245-2; ARMSTRONG BK, 1992, CANCER CAUSE CONTROL, V3, P569, DOI 10.1007/BF00052754; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; Bray F, 2005, CANCER EPIDEM BIOMAR, V14, P1132, DOI 10.1158/1055-9965.EPI-04-0871; Castellsague X, 2002, NEW ENGL J MED, V346, P1105, DOI 10.1056/NEJMoa011688; Chia KS, 2001, INT J CANCER, V93, P142, DOI 10.1002/ijc.1293; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Franco Eduardo L, 2003, J Natl Cancer Inst Monogr, P89; Gondos A, 2005, BRIT J CANCER, V92, P1808, DOI 10.1038/sj.bjc.6602540; Gondos A, 2004, INT J CANCER, V112, P860, DOI 10.1002/ijc.20471; Gustafsson L, 1997, INT J CANCER, V71, P159, DOI 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; IARC, 2005, IARC HDB CANC PREV, V10; *IARC, 1995, IARC MON EV CARC RIS, V64; Jacobs IJ, 1999, LANCET, V353, P1207, DOI 10.1016/S0140-6736(98)10261-1; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; KRAMER BS, 1993, CANCER, V71, P589; Levin CV, 1999, RADIOTHER ONCOL, V52, P79, DOI 10.1016/S0167-8140(99)00069-9; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; *NAT CANC REG PROG, 2002, 5 YEAR CONS REP HOSP, P90; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Ries L G., 2004, SEER CANC STAT REV 1; SANKARANARAYANA.R, 2005, INT J CANC; Sankaranarayanan R, 2005, INT J GYNECOL OBSTET, V89, pS4, DOI 10.1016/j.ijgo.2005.01.009; Sankaranarayanan R, 2004, INT J CANCER, V109, P461, DOI 10.1002/ijc.11726; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1996, CANCER-AM CANCER SOC, V78, P2461, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2461::AID-CNCR2>3.0.CO;2-N; Sankaranarayanan R, 1988, IARC SCI PUBLICATION, V15; Sant M, 2003, ANN ONCOL, V14, pV61, DOI 10.1093/annonc/mdg754; Schiller JT, 2004, NAT REV MICROBIOL, V2, P343, DOI 10.1038/nrmicro867; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Stewart BW, 2003, WORLD CANC REPORT; Tatsuzaki H, 2001, RADIOTHER ONCOL, V60, P81, DOI 10.1016/S0167-8140(01)00330-9; U.S. Preventive Services Task Force, 2004, SCREEN OV CANC BRIEF; Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7; Vizcaino AP, 1998, INT J CANCER, V75, P536, DOI 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; World Health Organization, 2002, NAT CANC CONTR PROGR	44	462	487	0	31	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1521-6934	1532-1932		BEST PRACT RES CL OB	Best Pract. Res. Clin. Obstet. Gynaecol.	APR	2006	20	2					207	225		10.1016/j.bpobgyn.2005.10.007			19	Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology	030CO	WOS:000236611100002	16359925				2022-02-25	
J	Lambert, R				Lambert, R			Upper gastrointestinal tumors	ENDOSCOPY			English	Article							BARRETTS-ESOPHAGUS; GASTROESOPHAGEAL-REFLUX; CANCER-RISK; PREVALENCE; SURVEILLANCE; ENDOSCOPY; JAPANESE		Int Agcy Res Canc, F-69372 Lyon 08, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	lambert@iarc.fr					Azuma N, 2000, J GASTROENTEROL, V35, P583, DOI 10.1007/s005350070057; Canto MIF, 2001, ENDOSCOPY, V33, P391, DOI 10.1055/s-2001-14427; Chiyo M, 2005, LUNG CANCER, V48, P307, DOI 10.1016/j.lungcan.2004.11.023; Cho YS, 2005, AM J GASTROENTEROL, V100, P747, DOI 10.1111/j.1572-0241.2005.41245.x; Endo T, 2002, GASTROINTEST ENDOSC, V55, P641, DOI 10.1067/mge.2002.123420; ENDO T, 2005, DIGEST ENDOSC, V17, P210, DOI DOI 10.1111/J.1443-1661.2005.00503.X; Gudlaugsdottir S, 2001, EUR J GASTROEN HEPAT, V13, P639, DOI 10.1097/00042737-200106000-00005; Hamamoto Y, 2004, J GASTROENTEROL, V39, P14, DOI 10.1007/s00535-003-1239-z; Hanai Masaaki, 2005, Nihon Rinsho, V63, P1333; Kara MA, 2005, GASTROINTEST ENDOSC, V61, P679, DOI 10.1016/S0016-5107(04)02577-5; Kumagai Y, 2002, LANCET ONCOL, V3, P604, DOI 10.1016/S1470-2045(02)00874-4; Mishima I, 2005, SCAND J GASTROENTERO, V40, P1005, DOI 10.1080/00365520510023260; Muto M, 2005, CARCINOGENESIS, V26, P1008, DOI 10.1093/carcin/bgi035; Shaheen NJ, 2005, GASTROENTEROLOGY, V129, P429, DOI 10.1053/j.gastro.2005.05.055; Shaheen NJ, 2000, GASTROENTEROLOGY, V119, P333, DOI 10.1053/gast.2000.9302; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Yao K, 2002, GASTROINTEST ENDOSC, V56, P279, DOI 10.1067/mge.2002.126061; Yokoyama T, 2003, CANCER EPIDEM BIOMAR, V12, P1227	18	1	1	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X			ENDOSCOPY	Endoscopy	FEB	2006	38	2					133	136		10.1055/s-2005-921208			4	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	020EY	WOS:000235892400005	16479419				2022-02-25	
J	Boffetta, P; Brennan, P				Boffetta, P; Brennan, P			Proper controls for SNP studies?	CARCINOGENESIS			English	Letter									Int Agcy Res Canc, Unit Environm Canc Epidemiol, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, Unit Environm Canc Epidemiol, 150 Cours Albert Thomas, F-69008 Lyon, France.							0	1	1	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0143-3334			CARCINOGENESIS	Carcinogenesis	DEC	2002	23	12					2139	2139		10.1093/carcin/23.12.2139			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	632YM	WOS:000180252500022		Bronze			2022-02-25	
J	Montesano, R				Montesano, R			Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study	JOURNAL OF MEDICAL VIROLOGY			English	Article; Proceedings Paper	Congress on Progress in Prevention and Control of Hepatitis B	SEP 20-21, 2001	ROME, ITALY			HBV; hepatocellular carcinoma; The Gambia	EXPANDED PROGRAM; VACCINATION; CANCER; PREVENTION; INFECTION; CHILDREN; TAIWAN	The Gambia Hepatitis Intervention Study (GHIS) was initiated by the International Agency for Research on Cancer (IARC) in 1986. It consisted of a randomized trial in the Gambian population, aiming to evaluate the protection provided by HBV vaccination administered during the first year of life against primary infection, the development of chronic carriage, and primary liver cancer. The results, reported at 9 years from the introduction of the vaccine as conferring a high degree of protection (83% against primary infection and 95% against chronic carriage), are briefly discussed. It is expected that HBV vaccination will result in a reduction of mortality from hepatocellular carcinoma, the most frequent cancer in males in sub-Sahara Africa. J. Med. Virol. 67.444-446,2002. (C) 2002Wiley-Liss, Inc.	Int Agcy Res Canc, F-69372 Lyon 08, France		Montesano, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	montesano@iarc.fr					Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730; Chang MH, 2000, JAMA-J AM MED ASSOC, V284, P3040, DOI 10.1001/jama.284.23.3040; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHOTARD J, 1992, J INFECT DIS, V166, P764, DOI 10.1093/infdis/166.4.764; FERLAY J, 2001, GLOBOCAN 2000; FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P; HALL A J, 1987, Cancer Research, V47, P5782; Hall AJ, 1999, BRIT J CANCER, V81, P1097, DOI 10.1038/sj.bjc.6690813; HALL AJ, 1989, LANCET, V1, P1057; HALL AJ, 1993, T ROY SOC TROP MED H, V87, P333, DOI 10.1016/0035-9203(93)90154-I; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Montesano R, 2001, EUR J CANCER, V37, pS67, DOI 10.1016/S0959-8049(01)00266-0; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SUN ZT, 1991, CANCER DETECT PREV, V15, P313; Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4; WHITTLE HC, 1983, LANCET, V1, P1203; Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2	20	15	15	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0146-6615	1096-9071		J MED VIROL	J. Med. Virol.	JUL	2002	67	3					444	446		10.1002/jmv.10093			3	Virology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Virology	558RH	WOS:000175980000024	12116042				2022-02-25	
J	Boffetta, P				Boffetta, P			Molecular epidemiology (Reprinted from Journal of Internal Medicine, vol 248, pg 447-454, 2000)	JOURNAL OF INTERNAL MEDICINE			English	Reprint						bias; biomarkers; confounding; molecular epidemiology; statistical power	CANCER; SUSCEPTIBILITY; POLYMORPHISMS; RISK	The use of biomarkers in epidemiology is not new, but recent developments in molecular biology and genetics have increased the opportunities for their use, However, epidemiological studies based on biomarkers, which belong to the discipline defined as 'molecular epidemiology' are subject to the same problems of design and analysis as 'traditional' epidemiological studies. If biomarkers offer new opportunities to overcome some of the limitations of epidemiology, their added value over traditional approaches should be systematically assessed. Biomarkers should be validated though transitional studies: consideration to sources of bias and confounding in molecular epidemiology studies should be no less stringent than in traditional studies.	Int Agcy Res Canc, Unit Environm Canc Epidemiol, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, Unit Environm Canc Epidemiol, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr					Ambrosone CB, 1996, JAMA-J AM MED ASSOC, V276, P1494, DOI 10.1001/jama.276.18.1494; BLOT WJ, 1996, CANC EPIDEMIOLOGY PR, P666; Boffetta P, 2000, J INTERN MED, V248, P447, DOI 10.1046/j.1365-2796.2000.00777.x; Bonassi S, 2000, CANCER RES, V60, P1619; d'Errico A, 1999, IARC Sci Publ, P323; GREENLAND S, 1994, ENVIRON HEALTH PERSP, V102, P33, DOI 10.1289/ehp.94102s833; NAKACHI K, 1993, CANCER RES, V53, P2994; PERERA FP, 1982, J CHRON DIS, V35, P581, DOI 10.1016/0021-9681(82)90078-9; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; ROTHMAN KJ, 1996, MODERN EPIDEMIOLOGY; ROTHMAN N, 1993, MOL EPIDEMIOLOGY PRI, P565; SANTELLA RM, 1988, CARCINOGENESIS, V9, P1265, DOI 10.1093/carcin/9.7.1265; SCHULTE PA, 1997, IARC SCI PUBL, V142, P19; Schulte PA., 1993, MOL EPIDEMIOLOGY PRI; Slattery ML, 1998, CANCER EPIDEM BIOMAR, V7, P1079; SMITH G, 1999, IARC SCI PUBL, V148, P209; Taioli E, 1999, CANCER EPIDEM BIOMAR, V8, P727; Toniolo P, 1997, IARC SCI PUBLICATION, V142; TRUETT J, 1967, J CHRON DIS, V20, P511, DOI 10.1016/0021-9681(67)90082-3; TUCKER JD, 1997, IARC SCI PUBL, V142, P1855; Vineis P, 1997, IARC Sci Publ, P59; Vineis P, 1999, IARC SCI PUBLICATION, V148; Yang Q, 1999, NEUROPATHOLOGY, V19, P33, DOI 10.1046/j.1440-1789.1999.00212.x	23	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-6820	1365-2796		J INTERN MED	J. Intern. Med.	FEB	2001	249			741			129	136		10.1046/j.1365-2796.2001.00777.x			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	415TF	WOS:000167738200014		Bronze			2022-02-25	
J	Mendy, M; Caboux, E; Wild, CP; Herrero, R; Accardi-Gheit, R; Clifford, G; Francon, E; Kesminiene, A; Mckay, J; Rinaldi, S; Scalbert, A; Scello, G; Seleiro, E; Zavadil, J				Mendy, Maimuna; Caboux, Elodie; Wild, Christopher P.; Herrero, Rolando; Accardi-Gheit, Rosita; Clifford, Gary; Francon, Elisabeth; Kesminiene, Ausrele; Mckay, James; Rinaldi, Sabina; Scalbert, Augustin; Scello, Ghislaine; Seleiro, Eduardo; Zavadil, Jiri		IARC Biobank Steering Comm Members	Centralization of the IARC Biobank: Combining Multiple Sample Collections into a Common Platform	BIOPRESERVATION AND BIOBANKING			English	Article						biobank; database; dataset; harmonization; centralization; governance	CANCER-RESEARCH; BIOSPECIMEN USE	The International Agency for Research on Cancer (IARC) is the World Health Organization's (WHO) cancer research agency. The agency conducts research on cancer with worldwide collaborations, adopting a multidisciplinary approach of epidemiology and laboratory-based studies on cancer causes, as well as preventive interventions. The IARC Biobank stores multiple collections of samples and conducts preanalytical services for studies conducted worldwide in support of the research activities. Traditionally, the multiple collections from these studies were managed by the individual research groups in different project-specific databases. In 2010, a program to centralize sample collections into a single platform was initiated by adopting a common database with the introduction of a minimum dataset for sample collections received at IARC. The process involved checking data files, verifying the storage location of samples, conducting data harmonization, and importing or migrating existing data from project-specific spreadsheets and databases into the common database. In addition to the creation of a common biobank database and an up-to-date inventory of IARC's biological resources, a governance structure was established. The creation of the Biobank Steering Committee and the adoption of an access policy is to facilitate and guide the sharing of IARC's resources in a transparent manner, while taking into account Ethical, Legal, and Social Issues.	[Mendy, Maimuna; Caboux, Elodie; Wild, Christopher P.] Int Agcy Res Canc, Lab Serv & Biobank Grp, 150 Cours Albert Thomas, F-69372 Lyon 8, France		Mendy, M (corresponding author), Int Agcy Res Canc, Lab Serv & Biobank Grp, 150 Cours Albert Thomas, F-69372 Lyon 8, France.	mendym@visitors.iarc.fr	Wild, Christopher/ABC-6260-2020; Zavadil, Jiri/ABG-1780-2020; Scalbert, Augustin/AAX-8160-2021; Caboux, Elodie/AAJ-3233-2020; Mendy, Maimuna/ABD-5038-2021	Wild, Christopher/0000-0003-0249-8669; Zavadil, Jiri/0000-0003-0640-5562; Scalbert, Augustin/0000-0001-6651-6710; Caboux, Elodie/0000-0001-8393-6979			[Anonymous], 2012, BIOPRESERV BIOBANK, V10, P79, DOI DOI 10.1089/BIO.2012.1022; BBMRI ERIC, 2016, BBMRI ERIC DIR 2 0; Caboux E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079826; Caboux E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039821; Childs EJ, 2015, NAT GENET, V47, P911, DOI 10.1038/ng.3341; Cole A, 2012, BIOPRESERV BIOBANK, V10, P518, DOI 10.1089/bio.2012.0038; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Hughes SE, 2010, BIOPRESERV BIOBANK, V8, P89, DOI 10.1089/bio.2010.0005; [ISBER Board I. B. P. E.], BEST PRACTICES, P103; Le Calvez-Kelm F, 2016, ONCOTARGET, V7, P78827, DOI 10.18632/oncotarget.12386; Lemoine M, 2016, LANCET GLOB HEALTH, V4, pE559, DOI 10.1016/S2214-109X(16)30130-9; Maimuna Mendy EC, 2017, COMMON MINIMUM TECHN; Mendy M, 2014, PATHOBIOLOGY, V81, P252, DOI 10.1159/000362093; National Cancer Institute and Biorepositories and Biospecimen Research, 2016, NCI BEST PRACT BIOSP; Norlin L, 2012, BIOPRESERV BIOBANK, V10, P343, DOI 10.1089/bio.2012.0003; Peto TJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-7; Scelo G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6135; Turesky RJ, 2016, BRIT J CANCER, V114, P76, DOI 10.1038/bjc.2015.402; Vinayanuwattikun C, 2016, SCI REP-UK, V6, DOI 10.1038/srep31628; Voegele C, 2010, BIOINFORMATICS, V26, P2798, DOI 10.1093/bioinformatics/btq502; Wang YF, 2014, NAT GENET, V46, P736, DOI 10.1038/ng.3002	21	0	0	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1947-5535	1947-5543		BIOPRESERV BIOBANK	Biopreserv. Biobank.	OCT 1	2019	17	5					433	443		10.1089/bio.2018.0036		MAY 2019	11	Cell Biology; Chemistry, Applied; Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Chemistry; Medical Laboratory Technology	JD7JY	WOS:000469282100001	31091138				2022-02-25	
J	Lin, CQ; Franceschi, S; Clifford, GM				Lin, Chunqing; Franceschi, Silvia; Clifford, Gary M.			Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis	LANCET INFECTIOUS DISEASES			English	Article							ANAL INTRAEPITHELIAL NEOPLASIA; POSITIVE WOMEN; MEN; RISK; HPV; PREVALENCE; LESIONS; DNA; IMMUNODEFICIENCY; CARCINOMAS	Background Data on carcinogenicity of human papillomavirus (HPV) types in the anus are needed to inform anal cancer prevention through vaccination and screening. This is particularly the case for people infected with HIV, who are at an increased risk of anal cancer. Methods We did a systematic review of studies published from January, 1986, to July, 2017, in MEDLINE, Embase, and the Cochrane Library on anal HPV infection, without any language restrictions. Eligible studies reported type-specific HPV prevalence by strata of cytopathological or histopathological anal diagnosis, sex, and HIV status. Data requests were made to authors when necessary. We did a meta-analysis of type-specific HPV prevalence across the full spectrum of anal diagnoses, from normal cytology to anal cancer. We assessed the main outcome of type-specific HPV prevalence ratios [PR], calculated across strata of anal diagnoses, gender, or HIV status, by use of generalised linear models. Findings 95 studies were identified from the search, published between 1992-2017, from which 18 646 individuals fulfilled the criteria for inclusion in the analyses: 8534 people with normal cytology, 5730 with low-grade lesions, 2024 with high-grade lesions, and 2358 with anal cancer. HPV prevalence varied in normal cytology from 42% in HIV-negative women to 76% in HIV-positive men and, for each diagnosis, was higher in individuals who were HIV positive than those who were HIV negative. HPV16 positivity increased with diagnosis severity, being the only HPV type accounting for more HPV infection in anal cancer than normal cytology, both in individuals who were HIV negative (PR 5.0, 95% CI 3.8-6.6, p< 0.0001) and those who were HIV positive (2.3, 1.9-2.7, p< 0.0001). HPV16 positivity increased even between high-grade lesions and anal cancer, whereas other high-risk HPV types accounted for high proportions of low-grade or high-grade lesions but their prevalence decreased in anal cancer. However, HPV16 was less frequent in HIV-positive than HIV-negative anal cancer, both in men (PR 0.8, 95% CI 0.7-0.9, p< 0.0001) and women (0.8, 0.6-1.0, p= 0.063), and in HIV-positive versus HIV-negative high-grade lesions in women (0.6, 0.5-0.9, p= 0.0077). Type-specific attribution of the non-HPV16 fraction of HIV-positive anal cancer is hindered by a high prevalence of multiple HPV infections. Interpretation HPV16 is by far the most carcinogenic HPV type in the anus, with enrichment of HPV16 even from high-grade lesions to anal cancer, both in individuals who are HIV negative and those who are HIV positive. Nevertheless, the fraction of anal cancer attributable to HPV16 is smaller in the HIV-positive population.	[Lin, Chunqing; Franceschi, Silvia; Clifford, Gary M.] Int Agcy Res Canc, F-69372 Lyon 08, France		Clifford, GM (corresponding author), Int Agcy Res Canc, F-69372 Lyon 08, France.	cliffordg@iarc.fr	Lin, Chunqing/ABF-2894-2020; franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071	International Agency for Research on Cancer; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [UM1AI035043] Funding Source: NIH RePORTER	International Agency for Research on Cancer.	Alemany L, 2015, INT J CANCER, V136, P98, DOI 10.1002/ijc.28963; Castle PE, 2013, CANCER EPIDEM BIOMAR, V22, P42, DOI 10.1158/1055-9965.EPI-12-0984; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Clifford GM, 2017, CLIN INFECT DIS, V64, P1228, DOI 10.1093/cid/cix135; Clifford GM, 2016, JAIDS-J ACQ IMM DEF, V73, P332, DOI 10.1097/QAI.0000000000001113; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Cornall AM, 2013, INT J CANCER, V133, P2253, DOI 10.1002/ijc.28228; D'Souza G, 2008, JAIDS-J ACQ IMM DEF, V48, P491, DOI 10.1097/QAI.0b013e31817aebfe; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; de Martel C, 2015, AIDS, V29, P2173, DOI 10.1097/QAD.0000000000000808; de Pokomandy A, 2011, CLIN INFECT DIS, V52, P1174, DOI 10.1093/cid/cir064; De Vuyst H, 2013, INT J CANCER, V133, P1441, DOI 10.1002/ijc.28131; De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116; Grulich AE, 2017, 31 INT PAP C CAP TOW; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; Guimera N, 2013, AM J SURG PATHOL, V37, P1299, DOI 10.1097/PAS.0b013e31828b6be4; Hoots BE, 2009, INT J CANCER, V124, P2375, DOI 10.1002/ijc.24215; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Jin F, 2017, AIDS, V31, P1303, DOI [10.1097/QAD.0000000000001462, 10.1097/qad.0000000000001462]; Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3; Nyitray AG, 2011, J INFECT DIS, V204, P1711, DOI 10.1093/infdis/jir637; Palefsky JM, 2009, CURR OPIN ONCOL, V21, P433, DOI 10.1097/CCO.0b013e32832f511a; Phanuphak N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078291; Phanuphak N, 2013, AIDS, V27, P1753, DOI 10.1097/QAD.0b013e328360a509; Quint W, 2012, J PATHOL, V227, P62, DOI 10.1002/path.3970; Shiels MS, 2015, CANCER EPIDEM BIOMAR, V24, P1548, DOI 10.1158/1055-9965.EPI-15-0044; Shiels MS, 2012, JNCI-J NATL CANCER I, V104, P1591, DOI 10.1093/jnci/djs371; Silverberg MJ, 2015, ANN INTERN MED, V163, P507, DOI 10.7326/M14-2768; Silverberg MJ, 2012, CLIN INFECT DIS, V54, P1026, DOI 10.1093/cid/cir1012; Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Yanik EL, 2016, AIDS, V30, P1663, DOI 10.1097/QAD.0000000000001077	32	154	156	2	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1473-3099	1474-4457		LANCET INFECT DIS	Lancet Infect. Dis.	FEB	2018	18	2					198	206		10.1016/S1473-3099(17)30653-9			9	Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED)	Infectious Diseases	FU4HL	WOS:000423814000038	29158102	Green Published, hybrid	Y	N	2022-02-25	
J	Loomis, D; Guyton, K; Grosse, Y; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Mattock, H; Straif, K				Loomis, Dana; Guyton, Kathryn; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi; Straif, Kurt		Int Agcy Res Canc Monograph Workin	Carcinogenicity of lindane, DDT, and 2,4-dichlorophenoxyacetic acid	LANCET ONCOLOGY			English	News Item							NON-HODGKINS-LYMPHOMA; HEPATOCELLULAR-CARCINOMA; RISK; CANCER; DICHLORODIPHENYLTRICHLOROETHANE; PESTICIDES; WORKERS; MEN		[Loomis, Dana; Guyton, Kathryn; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi; Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon, France		Loomis, D (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Guha, Neela/AAG-3989-2021; Loomis, Dana/AAE-3988-2019; Martin, Francis L/J-4585-2019; Guenel, Pascal/H-3728-2018	Guha, Neela/0000-0003-3991-4662; Martin, Francis L/0000-0001-8562-4944; Guenel, Pascal/0000-0002-8359-518X; Reif, David/0000-0001-7815-6767; Naidoo, Saloshni/0000-0002-8844-0160; Loomis, Dana/0000-0003-3297-5200	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER		Alavanja MCR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109332; Blair A, 1998, AM J IND MED, V33, P82, DOI 10.1002/(SICI)1097-0274(199801)33:1&lt;82::AID-AJIM9&gt;3.0.CO;2-Y; Burns C, 2011, INT J ENV RES PUB HE, V8, P3579, DOI 10.3390/ijerph8093579; Cocco P, 2005, CANCER RES, V65, P9588, DOI 10.1158/0008-5472.CAN-05-1487; ERIKSSON M, 1992, BRIT J IND MED, V49, P95; IARC, 2015, IARC MONOGR EVAL CAR, V113; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KOGEVINAS M, 1995, EPIDEMIOLOGY, V6, P396, DOI 10.1097/00001648-199507000-00012; McDuffie HH, 2001, CANCER EPIDEM BIOMAR, V10, P1155; McGlynn KA, J NATL CANC I, V100, P663; McGlynn KA, 2006, JNCI-J NATL CANCER I, V98, P1005, DOI 10.1093/jnci/djj266; National Technical Information Service, 1968, EV CARC TER MUT ACT, V1; Persson EC, 2012, INT J CANCER, V131, P2078, DOI 10.1002/ijc.27459; Silva E, 2010, TOXICOL APPL PHARM, V245, P159, DOI 10.1016/j.taap.2010.02.015; Spinelli JJ, 2007, INT J CANCER, V121, P2767, DOI 10.1002/ijc.23005; US EPA, 1997, CARC PEER REV 4 2 4; Zhao BH, 2012, J EXPO SCI ENV EPID, V22, P541, DOI 10.1038/jes.2011.29	17	139	142	2	63	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	AUG	2015	16	8					891	892		10.1016/S1470-2045(15)00081-9			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	CN6OS	WOS:000358554700039	26111929				2022-02-25	
J	Tommasino, M				Tommasino, Massimo			The human papillomavirus family and its role in carcinogenesis	SEMINARS IN CANCER BIOLOGY			English	Review						Human papillomavirus; Cancer; E6 and E7 oncoproteins; Viral persistence; Cellular transformation	SQUAMOUS-CELL CARCINOMA; CUTANEOUS HUMAN PAPILLOMAVIRUSES; GAMMA HUMAN PAPILLOMAVIRUSES; NF-KAPPA-B; CERVICAL-CANCER; E7 ONCOPROTEIN; E6 ONCOPROTEIN; SKIN-CANCER; TYPE-16 E6; BETAPAPILLOMAVIRUS INFECTION	Human papillomaviruses (HPVs) are a family of small double-stranded DNA viruses that have a tropism for the epithelia of the genital and upper respiratory tracts and for the skin. Approximately 150 HPV types have been discovered so far, which are classified into several genera based on their DNA sequence. Approximately 15 high-risk mucosal HPV types are clearly associated with cervical cancer; HPV16 and HPV18 are the most carcinogenic since they are responsible for approximately 50% and 20% of all cervical cancers worldwide, respectively. It is now also clear that these viruses are linked to a subset of other genital cancers, as well as head and neck cancers. Due to their high level of carcinogenic activity, HPV16 and HPV18 are the most studied HPV types so far. Biological studies have highlighted the key roles in cellular transformation of the products of two viral early genes, E6 and E7. Many of the mechanisms of E6 and E7 in subverting the regulation of fundamental cellular events have been fully characterized, contributing not only to our knowledge of how the oncogenic viruses promote cancer development but also to our understanding of basic cell biology. Despite HPV research resulting in extraordinary achievements in the last four decades, significantly improving the screening and prophylaxis of HPV-induced lesions, additional research is necessary to characterize the biology and epidemiology of the vast number of HPV types that have been poorly investigated so far, with a final aim of clarifying their potential roles in other human diseases. (C) 2013 Elsevier Ltd. All rights reserved.	Int Agcy Res Canc, World Hlth Org, Infect & Canc Biol Grp, F-69372 Lyon 08, France		Tommasino, M (corresponding author), Int Agcy Res Canc, World Hlth Org, Infect & Canc Biol Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	tommasino@iarc.fr		Tommasino, Massimo/0000-0002-0890-8596	European Commission, HPV-AHEAD [FP7-HEALTH-2011-282562]	I apologize to those authors whose important contributions to HPV research could not be cited or adequately discussed due to space limitations. I thank the IARC Director, Dr. Christopher P. Wild, and all members of the Infections and Cancer Biology Group for their constant support, Drs. Karen Muller and Rachel Purcell for the editing and Isabelle Rondy for the preparation of this manuscript. The work performed in the group is partially supported by a grant from the European Commission, HPV-AHEAD (FP7-HEALTH-2011-282562).	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Accardi R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003186; Accardi R, 2011, MOL CELL BIOL, V31, P2210, DOI 10.1128/MCB.00964-10; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Astori G, 1998, J INVEST DERMATOL, V110, P752, DOI 10.1046/j.1523-1747.1998.00191.x; Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Banks L, 2012, NAT REV CANCER, V12, P876, DOI 10.1038/nrc3400; Bavinck JNB, 2010, CANCER RES, V70, P9777, DOI 10.1158/0008-5472.CAN-10-0352; Bedard KM, 2008, J VIROL, V82, P3894, DOI 10.1128/JVI.01818-07; Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002; Bousarghin L, 2003, J VIROL, V77, P3846, DOI 10.1128/JVI.77.6.3846-3850.2003; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; BOYLE J, 1984, LANCET, V1, P702; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; Chen ZG, 2007, VIROLOGY, V360, P447, DOI 10.1016/j.virol.2006.10.022; Clifford GM, 2009, FUTURE ONCOL, V5, P669, DOI [10.2217/fon.09.28, 10.2217/FON.09.28]; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cornet I, 2012, J VIROL, V86, P2366, DOI 10.1128/JVI.06579-11; Day PM, 2003, VIROLOGY, V307, P1, DOI 10.1016/S0042-6822(02)00143-5; de Koning MNC, 2009, J GEN VIROL, V90, P1611, DOI 10.1099/vir.0.010017-0; de Villiers EM, 2013, VIROLOGY, V445, P2, DOI 10.1016/j.virol.2013.04.023; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dong W, 2005, J VIROL, V79, P14899, DOI 10.1128/JVI.79.23.14899-14908.2005; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Einstein MH, 2009, LANCET INFECT DIS, V9, P347, DOI 10.1016/S1473-3099(09)70108-2; Evander M, 1997, J VIROL, V71, P2449, DOI 10.1128/JVI.71.3.2449-2456.1997; Farzan SF, 2013, INT J CANCER, V133, P1713, DOI 10.1002/ijc.28176; Fertey J, 2011, J VIROL, V85, P2918, DOI 10.1128/JVI.01647-10; Forslund O, 2007, J INFECT DIS, V196, P876, DOI 10.1086/521031; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gabet AS, 2008, FASEB J, V22, P622, DOI 10.1096/fj.07-8389com; Gambhira R, 2007, J VIROL, V81, P13927, DOI 10.1128/JVI.00936-07; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Ghittoni R, 2010, VIRUS GENES, V40, P1, DOI 10.1007/s11262-009-0412-8; Giampieri S, 2004, BRIT J CANCER, V90, P2203, DOI 10.1038/sj.bjc.6601829; Grabowska Agnieszka K, 2012, Open Virol J, V6, P249, DOI 10.2174/1874357901206010249; Halec G, 2013, BRIT J CANCER, V109, P172, DOI 10.1038/bjc.2013.296; Hasan UA, 2007, J IMMUNOL, V178, P3186, DOI 10.4049/jimmunol.178.5.3186; He WX, 2003, J VIROL, V77, P10566, DOI 10.1128/JVI.77.19.10566-10574.2003; Howie HL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002211; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; Huh K, 2007, J VIROL, V81, P9737, DOI 10.1128/JVI.00881-07; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Iannacone MR, 2012, CANCER EPIDEM BIOMAR, V21, P1303, DOI 10.1158/1055-9965.EPI-12-0032; Iannacone MR, 2013, INT J CANC; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; Karagas MR, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c2986; Kawana Y, 2001, J VIROL, V75, P2331, DOI 10.1128/JVI.75.5.2331-2336.2001; Kiviat NB, 1999, SEMIN CANCER BIOL, V9, P397, DOI 10.1006/scbi.1999.0143; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Lambert PF, 2006, PAPILLOMAVIRUS RESEARCH: FROM NATURAL HISTORY TO VACCINES AND BEYOND, P213; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Liu XF, 2005, J BIOL CHEM, V280, P10807, DOI 10.1074/jbc.M410343200; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; McLaughlin-Drubin ME, 2008, J VIROL, V82, P8695, DOI 10.1128/JVI.00579-08; McLaughlin-Drubin ME, 2012, CURR OPIN VIROL, V2, P459, DOI 10.1016/j.coviro.2012.05.004; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; Michel A, 2006, J VIROL, V80, P11153, DOI 10.1128/JVI.00954-06; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3; MORENO V, 1995, CANCER EPIDEM BIOMAR, V4, P459; Muench P, 2010, CANCER RES, V70, P6913, DOI 10.1158/0008-5472.CAN-10-1307; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Muschik D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027655; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nobre RJ, 2009, J VIROL, V83, P2907, DOI 10.1128/JVI.02490-08; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PFISTER H., 2003, JNCI-J NATL CANCER I, V31, P52, DOI DOI 10.1093/0XF0RDJ0UR-NALS.JNCIM0N0GRAPHS.A003483; Pim D, 2010, APMIS, V118, P471, DOI 10.1111/j.1600-0463.2010.02618.x; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Proby CM, 2011, AM J TRANSPLANT, V11, P1498, DOI 10.1111/j.1600-6143.2011.03589.x; Rodriguez AC, 2008, JNCI-J NATL CANCER I, V100, P513, DOI 10.1093/jnci/djn044; Saidj D, 2013, J VIROL, V87, P12139, DOI 10.1128/JVI.01047-13; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sekaric P, 2008, J VIROL, V82, P71, DOI 10.1128/JVI.01776-07; Shafti-Keramat S, 2003, J VIROL, V77, P13125, DOI 10.1128/JVI.77.24.13125-13135.2003; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076; Sibbet G, 2000, J GEN VIROL, V81, P327, DOI 10.1099/0022-1317-81-2-327; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Snijders PJF, 2006, INT J CANCER, V119, P1102, DOI 10.1002/ijc.21956; Surviladze Z, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002519; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; TOMMASINO M, 1993, ONCOGENE, V8, P195; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Underbrink MP, 2008, J VIROL, V82, P10408, DOI 10.1128/JVI.00902-08; Vande Pol SB, 2013, VIROLOGY, V445, P115, DOI 10.1016/j.virol.2013.04.026; Vasiljevic N, 2008, J GEN VIROL, V89, P2467, DOI 10.1099/vir.0.2008/001925-0; Veldman T, 2003, P NATL ACAD SCI USA, V100, P8211, DOI 10.1073/pnas.1435900100; Viarisio D, 2013, J GEN VIROL, V94, P749, DOI 10.1099/vir.0.048991-0; Viarisio D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002125; WALDER BK, 1971, LANCET, V2, P1282; WALDER BK, 1976, AUSTRALAS J DERMATOL, V17, P94, DOI 10.1111/j.1440-0960.1976.tb00798.x; Wallace NA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002807; Waterboer T, 2008, BRIT J DERMATOL, V159, P457, DOI 10.1111/j.1365-2133.2008.08621.x; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Weissenborn SJ, 2005, J INVEST DERMATOL, V125, P93, DOI 10.1111/j.0022-202X.2005.23733.x; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; Woodham AW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043519; Xu M, 2010, J VIROL, V84, P11461, DOI 10.1128/JVI.00538-10; Yuan H, 2013, GENOME ANNOUNC, V1; Zanier K, 2013, SCIENCE, V339, P694, DOI 10.1126/science.1229934; Zanier K, 2012, STRUCTURE, V20, P604, DOI 10.1016/j.str.2012.02.001; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; ZURHAUSEN H, 1976, CANCER RES, V36, P794	123	216	239	9	93	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1044-579X	1096-3650		SEMIN CANCER BIOL	Semin. Cancer Biol.	JUN	2014	26						13	21		10.1016/j.semcancer.2013.11.002			9	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AK4QR	WOS:000338409700003	24316445		Y	N	2022-02-25	
J	Slimani, N; Casagrande, C; Nicolas, G; Le Moine, G; Huybrechts, I; Freisling, H; Crispim, S				Slimani, N.; Casagrande, C.; Nicolas, G.; Le Moine, G.; Huybrechts, I.; Freisling, H.; Crispim, S.			TOWARDS A COMPREHENSIVE WEB-BASED DIETARY RESEARCH INFRASTRUCTURE TO SUPPORT INTERNATIONAL MONITORING AND EPIDEMIOLOGICAL NUTRITIONAL STUDIES	ANNALS OF NUTRITION AND METABOLISM			English	Meeting Abstract						research infrastructure; standardisation; dietary assessment			[Slimani, N.; Casagrande, C.; Nicolas, G.; Le Moine, G.; Huybrechts, I.; Freisling, H.; Crispim, S.] Int Agcy Res Canc, Dietary Exposure Assessment Grp, F-69372 Lyon, France				Crispim, Sergio Feliciano/ABI-6360-2020	Crispim, Sergio Feliciano/0000-0002-4060-8315				0	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0250-6807	1421-9697		ANN NUTR METAB	Ann. Nutr. Metab.		2013	63			1			242	242					1	Endocrinology & Metabolism; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Nutrition & Dietetics	219YR	WOS:000324548201503					2022-02-25	
J	Krutovskikh, V; Partensky, C				Krutovskikh, V.; Partensky, C.			New insights in oncology: Epigenetics and cancer stem cells	CANCER RADIOTHERAPIE			French	Review						Cancer; Epigenetics; Cancer stem cells; Radiotherapy	MICRORNAS; IDENTIFICATION; RESISTANCE; SURVIVAL; MARKERS; PRION	Cancer is a multi-etiologic, multistage disease with a prevalent genetic component, which happens when a large number of genes, critical for cell growth, death, differentiation, migration, and metabolic plasticity are altered irreversibly, so as to either "gain" (oncogenes) or "lose" (tumour suppressors) their function. Recent discoveries have revealed the previously underestimated etiologic importance of multiple epigenetic, that is to say, reversible factors (histone modifications, DNA methylation, non-coding RNA) involved in the transcriptional and post-transcriptional regulation of proteins, indispensable for the control of cancerous phenotype. Stable alterations of epigenetic machinery ("epimutations") turn out to play a critical role at different steps of carcinogenesis. In addition, due to substantial recent progress in stem cell biology, the new concept of cancer stem cells has emerged. This, along with newly discovered epigenetic cancer mechanisms, gives rise to a hope to overcome radio- and chemo-resistance and to eradicate otherwise incurable neoplasms. (C) 2011 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.	[Krutovskikh, V.; Partensky, C.] Ctr Int Rech Canc, F-69372 Lyon 08, France		Partensky, C (corresponding author), Ctr Int Rech Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	partenskyc@visitors.iarc.fr					Aigner A, 2011, J MOL MED, V89, P445, DOI 10.1007/s00109-010-0716-0; Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; Alison MR, 2010, J CELL SCI, V123, P2357, DOI 10.1242/jcs.054296; Atkinson RL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001447; Aypar U, 2011, INT J RADIAT BIOL, V87, P179, DOI 10.3109/09553002.2010.522686; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550; Costa Fabricio F, 2010, Cancer Manag Res, V2, P255, DOI 10.2147/CMR.S7280; De Schutter H, 2009, ANTI-CANCER AGENT ME, V9, P99, DOI 10.2174/187152009787047707; Derdowski A, 2010, SCIENCE, V330, P680, DOI 10.1126/science.1197785; Eaves CJ, 2008, NATURE, V456, P581, DOI 10.1038/456581a; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Fabrizi E, 2010, WORLD J GASTROENTERO, V16, P3871, DOI 10.3748/wjg.v16.i31.3871; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Greaves M, 2010, SEMIN CANCER BIOL, V20, P65, DOI 10.1016/j.semcancer.2010.03.002; Halfmann R, 2010, SCIENCE, V330, P629, DOI 10.1126/science.1191081; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harless WW, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-1; Herceg Zdenko, 2009, Eur J Cancer, V45 Suppl 1, P442, DOI 10.1016/S0959-8049(09)70082-6; Hermann PC, 2010, SEMIN CANCER BIOL, V20, P77, DOI 10.1016/j.semcancer.2010.03.004; Hermann PC, 2009, EXPERT OPIN BIOL TH, V9, P1271, DOI 10.1517/14712590903246362; Hiraoka S, 2010, HUM PATHOL, V41, P38, DOI 10.1016/j.humpath.2009.06.002; Hittelman WN, 2010, FUTURE ONCOL, V6, P1563, DOI [10.2217/fon.10.121, 10.2217/FON.10.121]; Hoshino I, 2010, SURG TODAY, V40, P809, DOI 10.1007/s00595-010-4300-6; Hu HL, 2011, J MOL CELL BIOL, V3, P151, DOI 10.1093/jmcb/mjq042; Huang EH, 2007, SURGERY, V141, P415, DOI 10.1016/j.surg.2006.12.015; Huang ZH, 2010, INT J CANCER, V127, P118, DOI 10.1002/ijc.25007; Katakowski M, 2010, CANCER RES, V70, P8259, DOI 10.1158/0008-5472.CAN-10-0604; Kato M, 2009, ONCOGENE, V28, P2419, DOI 10.1038/onc.2009.106; Kelleher FC, 2011, CARCINOGENESIS, V32, P445, DOI 10.1093/carcin/bgq280; Kitamura H, 2009, LUNG CANCER, V66, P275, DOI 10.1016/j.lungcan.2009.07.019; Krishnamurthy S, 2010, CANCER RES, V70, P9969, DOI 10.1158/0008-5472.CAN-10-1712; Krutovskikh VA, 2010, BIOESSAYS, V32, P894, DOI 10.1002/bies.201000040; Li CY, 2009, J CLIN INVEST, V119, P2725, DOI 10.1172/JCI39542; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Lima SC, 2010, CURR OPIN MOL THER, V12, P316; Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930; Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Mardin W, 2009, ANN SURG ONCOL, V16, P3183, DOI 10.1245/s10434-009-0623-1; Mazeron R, 2009, CANCER RADIOTHER, V13, P568, DOI 10.1016/j.canrad.2009.06.015; Mees ST, 2011, J SURG RES, V169, P241, DOI 10.1016/j.jss.2009.10.005; Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009; Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931; Miyoshi N, 2010, SURG TODAY, V40, P608, DOI 10.1007/s00595-009-4106-6; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; Morrison R, 2011, J ONCOL, V2011, DOI 10.1155/2011/941876; Mueller MT, 2009, GASTROENTEROLOGY, V137, P1102, DOI 10.1053/j.gastro.2009.05.053; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Nana-Sinkam SP, 2010, ANN NY ACAD SCI, V1210, P25, DOI 10.1111/j.1749-6632.2010.05822.x; Olempska M, 2007, HEPATOB PANCREAT DIS, V6, P92; Ortholan C, 2010, CANCER RADIOTHER, V14, P312, DOI 10.1016/j.canrad.2010.02.009; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Rangwala F, 2011, J ONCOL, V2011, DOI 10.1155/2011/465343; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reynoird N, 2010, B CANCER, V97, P1265, DOI 10.1684/bdc.2010.1204; Scatena R, 2011, EXPERT OPIN BIOL TH, V11, P875, DOI 10.1517/14712598.2011.573780; Schatton T, 2008, PIGM CELL MELANOMA R, V21, P39, DOI 10.1111/j.1755-148X.2007.00427.x; Shackleton M, 2010, SEMIN CANCER BIOL, V20, P85, DOI 10.1016/j.semcancer.2010.04.002; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Soto C, 2011, TRENDS BIOCHEM SCI, V36, P151, DOI 10.1016/j.tibs.2010.11.001; Stephan MT, 2010, NAT MED, V16, P1035, DOI 10.1038/nm.2198; Szafranska AE, 2008, CLIN CHEM, V54, P1716, DOI 10.1373/clinchem.2008.109603; Tang C, 2010, STEM CELLS, V28, P1686, DOI 10.1002/stem.473; Valeri N, 2009, MAMM GENOME, V20, P573, DOI 10.1007/s00335-009-9206-5; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2010, MOL ONCOL, V4, P369, DOI 10.1016/j.molonc.2010.07.001; Wang J, 2009, CANCER PREV RES, V2, P807, DOI 10.1158/1940-6207.CAPR-09-0094; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Worthley DL, 2007, WORLD J GASTROENTERO, V13, P3784; Worthley Daniel L, 2010, Clin Biochem Rev, V31, P31; Wouters MD, 2011, MUTAT RES-FUND MOL M, V717, P54, DOI 10.1016/j.mrfmmm.2011.03.012	73	2	3	1	20	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	1278-3218	1769-6658		CANCER RADIOTHER	Cancer Radiother.	DEC	2011	15	8					716	722		10.1016/j.canrad.2011.05.012			7	Oncology; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Radiology, Nuclear Medicine & Medical Imaging	878GA	WOS:000299242300010	22079560				2022-02-25	
J	Boffetta, P				Boffetta, Paolo			Lymphoma in Mediterranean countries	JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY			English	Meeting Abstract									Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1077-4114			J PEDIAT HEMATOL ONC	J. Pediatr. Hematol. Oncol.	JUN	2007	29			1			S5	S5					1	Oncology; Hematology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Hematology; Pediatrics	179BP	WOS:000247264600009					2022-02-25	
J	Boffetta, P; de Vocht, F				Boffetta, Paolo; de Vocht, Frank			Occupation and the risk of non-Hodgkin lymphoma	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Article							MULTICENTER CASE-CONTROL; SOFT-TISSUE SARCOMA; UNITED-STATES; CANCER-MORTALITY; HEMATOPOIETIC CANCER; MALIGNANT-LYMPHOMA; DEATH-CERTIFICATE; ORGANIC-SOLVENTS; AGRICULTURAL USE; MEAT INDUSTRY	Although thus far no occupational agents have been classified as established causes of non-Hodgkin lymphoma (NHL), employment as a farmer, teacher, dry cleaner, meat worker, printer, or wood worker has been associated with elevated risk in the peer-reviewed literature. We conducted several meta-analyses to assess risk in these occupations and industries from articles published in MEDLINE up to August 1, 2006. The summary risk estimates suggest a homogeneous excess risk for NHL among workers in the printing industry [relative risk (RR), 1.86; 95% confidence interval (95% CI), 1.37-2.52] and wood workers (RR, 1.15, 95% CI, 1.00-1.31). Considerable heterogeneity but elevated risks were found for farmers (RR, 1.11; 95% CI, 1.05-1.17), especially in animal husbandry (RR, 1.31; 95% CI, 1.08-1.60), and teaching (RR, 1.47, 95% CI, 1.34-1.61). An increased risk was absent for employment in the meat processing industry (RR, 0.99; 95% CI, 0.77-1.29). These results suggest that although excess risk is found for employment in the printing industry, wood processing industry, teaching, and farming, it is unlikely that occupation represents a major risk factor for NHL in most populations. At present, no conclusive evidence of causal relations between occupations and increased NHL risk exists; this can be ascribed to methodologic problems in studying the link between NHL risk and occupation, including heterogeneity of disease and exposure circumstances and low statistical power. Implementing state-of-the-art exposure assessment technologies, including biomarker-based assessment, and aiming to identify susceptible subgroups can increase the statistical power enough to analyze etiologically relevant NHL subtypes and provide clues on possible causal agents in future studies. These goals can be best attained within the framework of large-scale, international collaborative projects.	IARC, Gene Environm Epidemiol Grp, F-69008 Lyon, France		Boffetta, P (corresponding author), IARC, Gene Environm Epidemiol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr		de Vocht, Frank/0000-0003-3631-627X			AMADORI D, 1995, OCCUP ENVIRON MED, V52, P374, DOI 10.1136/oem.52.6.374; Baker P, 1999, SCAND J WORK ENV HEA, V25, P5, DOI 10.5271/sjweh.377; Band PR, 2004, J OCCUP ENVIRON MED, V46, P479, DOI 10.1097/01.jom.0000126028.99599.36; Baris D, 1998, OCCUP ENVIRON MED, V55, P522, DOI 10.1136/oem.55.8.522; Besson H, 2006, J OCCUP ENVIRON MED, V48, P289, DOI 10.1097/01.jom.0000184867.83288.d0; BLAIR A, 1993, AM J IND MED, V23, P301, DOI 10.1002/ajim.4700230207; Boffetta P, 2000, CANCER CAUSE CONTROL, V11, P627, DOI 10.1023/A:1008947531573; Cano MI, 2001, INT ARCH OCC ENV HEA, V74, P443, DOI 10.1007/s004200100248; Chiu BCH, 2004, CANCER EPIDEM BIOMAR, V13, P525; COGGON D, 1989, BRIT J IND MED, V46, P188; Costantini AS, 2001, EPIDEMIOLOGY, V12, P78; DEAR KBG, 1992, STAT SCI, V7, P237, DOI DOI 10.1214/SS/1177011363; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Descatha A, 2005, CANCER CAUSE CONTROL, V16, P939, DOI 10.1007/s10552-005-2301-3; Dryver E, 2004, INT J OCCUP ENV HEAL, V10, P13, DOI 10.1179/oeh.2004.10.1.13; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fabbro-Peray P, 2001, CANCER CAUSE CONTROL, V12, P201, DOI 10.1023/A:1011274922701; Fontana A, 1998, ARCH ENVIRON HEALTH, V53, P384, DOI 10.1080/00039899809605725; Fritschi L, 2005, CANCER CAUSE CONTROL, V16, P599, DOI 10.1007/s10552-004-7845-0; Fritschi L, 2002, CANCER CAUSE CONTROL, V13, P563, DOI 10.1023/A:1016331128897; JAPPINEN P, 1989, SCAND J WORK ENV HEA, V15, P18, DOI 10.5271/sjweh.1887; Johnson ES, 1997, INT J EPIDEMIOL, V26, P1142, DOI 10.1093/ije/26.6.1142; JOHNSON ES, 1994, OCCUP ENVIRON MED, V51, P541, DOI 10.1136/oem.51.8.541; Kato I, 2005, CANCER CAUSE CONTROL, V16, P1215, DOI 10.1007/s10552-005-0385-4; Kato I, 2004, ENVIRON HEALTH PERSP, V112, P1275, DOI 10.1289/ehp.7070; KAWACHI I, 1989, CANCER, V64, P2609, DOI 10.1002/1097-0142(19891215)64:12&lt;2609::AID-CNCR2820641234&gt;3.0.CO;2-E; Kelleher C, 1998, J EPIDEMIOL COMMUN H, V52, P651, DOI 10.1136/jech.52.10.651; KellerByrne JE, 1997, AM J IND MED, V31, P442, DOI 10.1002/(SICI)1097-0274(199704)31:4&lt;442::AID-AJIM10&gt;3.0.CO;2-#; Khuder SA, 1998, SCAND J WORK ENV HEA, V24, P255, DOI 10.5271/sjweh.318; Lee E, 2002, AM J IND MED, V42, P410, DOI 10.1002/ajim.10131; Mao Y, 2000, ANN ONCOL, V11, P69, DOI 10.1023/A:1008342315673; McDuffie HH, 2002, AM J IND MED, P54, DOI 10.1002/ajim.10041; Mester B, 2006, OCCUP ENVIRON MED, V63, P17, DOI 10.1136/oem.2005.020453; Metayer C, 1998, AM J EPIDEMIOL, V147, P727, DOI 10.1093/oxfordjournals.aje.a009517; Miligi L, 2003, AM J IND MED, V44, P627, DOI 10.1002/ajim.10289; Miligi L, 1999, AM J IND MED, V36, P60, DOI 10.1002/(SICI)1097-0274(199907)36:1<60::AID-AJIM9>3.0.CO;2-Z; Mills PK, 2005, CANCER CAUSE CONTROL, V16, P823, DOI 10.1007/s10552-005-2703-2; OLSSON H, 1988, SCAND J WORK ENV HEA, V14, P246, DOI 10.5271/sjweh.1925; PEARCE N, 1988, AM J IND MED, V14, P63, DOI 10.1002/ajim.4700140108; PEARCE NE, 1986, BRIT J IND MED, V43, P75; PEARCE NE, 1987, INT J CANCER, V39, P155, DOI 10.1002/ijc.2910390206; Rafnsson V, 2001, OCCUP ENVIRON MED, V58, P523, DOI 10.1136/oem.58.8.523; REIF J, 1989, INT J CANCER, V43, P49, DOI 10.1002/ijc.2910430112; REIF JS, 1989, SCAND J WORK ENV HEA, V15, P24, DOI 10.5271/sjweh.1886; Schroeder JC, 2001, EPIDEMIOLOGY, V12, P701, DOI 10.1097/00001648-200111000-00020; SCHUMACHER MC, 1988, AM J IND MED, V13, P317, DOI 10.1002/ajim.4700130303; Settimi L, 1999, AM J IND MED, V36, P135, DOI 10.1002/(SICI)1097-0274(199907)36:1&lt;135::AID-AJIM19&gt;3.0.CO;2-H; Svec MA, 2005, OCCUP ENVIRON MED, V62, P726, DOI 10.1136/oem.2005.021550; Tatham L, 1997, EPIDEMIOLOGY, V8, P551, DOI 10.1097/00001648-199709000-00013; Waddell BL, 2001, CANCER CAUSE CONTROL, V12, P509, DOI 10.1023/A:1011293208949; Zheng TZ, 2002, J OCCUP ENVIRON MED, V44, P469, DOI 10.1097/00043764-200205000-00015; Zheng TZ, 2001, J OCCUP ENVIRON MED, V43, P641, DOI 10.1097/00043764-200107000-00012	52	37	40	0	5	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965	1538-7755		CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	MAR	2007	16	3					369	372		10.1158/1055-9965.EPI-06-1055			4	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	148SC	WOS:000245093900003	17372232				2022-02-25	
J	Saleem, M; Ohshima, H				Saleem, M; Ohshima, H			Xanthine oxidase converts nitric oxide to nitroxyl that inactivates the enzyme	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						xanthine oxidase; nitric oxide; nitroxyl; Angeli's salt; peroxynitrite	DNA STRAND BREAKAGE; S-NITROSOTHIOLS; ANGELIS SALT; SODIUM TRIOXODINITRATE; SYNERGISTIC INDUCTION; AQUEOUS-SOLUTION; PEROXYNITRITE; SYNTHASE; ANION; DEHYDROGENASE	Xanthine oxidase (XO) was found to convert nitric oxide (NO(.)) released from spermine-NONOate to nitroxyl (HNO), the one-electron reduction product of NO(.), in the presence of its substrate hypoxanthine under anaerobic conditions. Under these conditions, XO lost its activity. Upon aerobic incubation of XO with its substrate, neither conversion of NO(.) to HNO nor inactivation of the enzyme was observed. Angeli's salt (an HNO generator) or synthetic peroxynitrite inactivated XO at low concentrations, whereas high concentrations of diethylamine-NONOate (an NO(.) donor) and SIN-1 (which generates peroxynitrite by releasing both NO(.) and superoxide) were required to inactivate XO. These results suggest that HNO generated by XO under anaerobic conditions inactivates XO. As both XO and NO(.) synthase are activated and/or induced in ischemia-reperfusion injury, HNO formed by XO may contribute to pathogenesis by exerting its potent oxidation activity against a variety of biological compounds. (C) 2004 Elsevier Inc. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohshima@iarc.fr	Ohshima, Hiroshi/E-8044-2010	SALEEM, Mohammad/0000-0002-7422-7967			Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Bai P, 2001, FREE RADICAL BIO MED, V31, P1616, DOI 10.1016/S0891-5849(01)00756-0; Bartberger MD, 2001, P NATL ACAD SCI USA, V98, P2194, DOI 10.1073/pnas.041481598; BAZYLINSKI DA, 1985, INORG CHEM, V24, P4285, DOI 10.1021/ic00219a017; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P7983; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Chazotte-Aubert L, 2000, PORTL PR P, V16, P125; Chazotte-Aubert L, 1999, J BIOL CHEM, V274, P20909, DOI 10.1074/jbc.274.30.20909; Cook NM, 2003, ARCH BIOCHEM BIOPHYS, V410, P89, DOI 10.1016/S0003-9861(02)00656-2; Cote CG, 1996, AM J PHYSIOL-LUNG C, V271, pL869, DOI 10.1152/ajplung.1996.271.5.L869; DeMaster EG, 1998, BIOCHEM PHARMACOL, V55, P2007, DOI 10.1016/S0006-2952(98)00080-X; FEELISCH M, 1996, METHODS NITRIC OXIDE, P71; FUKAHORI M, 1994, FREE RADICAL RES, V21, P203, DOI 10.3109/10715769409056572; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Godber BLJ, 2001, BIOCHEM J, V358, P325, DOI 10.1042/0264-6021:3580325; Godber BLJ, 2000, FEBS LETT, V475, P93, DOI 10.1016/S0014-5793(00)01639-2; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; HASSOUN PM, 1995, AM J PHYSIOL-LUNG C, V268, pL809, DOI 10.1152/ajplung.1995.268.5.L809; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Houston M, 1998, ARCH BIOCHEM BIOPHYS, V355, P1, DOI 10.1006/abbi.1998.0675; Hughes MN, 1999, METHOD ENZYMOL, V301, P279; Huisman A, 2002, FASEB J, V16, P1135, DOI 10.1096/fj.01-0890fje; Ichimori K, 1999, J BIOL CHEM, V274, P7763, DOI 10.1074/jbc.274.12.7763; Kirsch M, 2002, J BIOL CHEM, V277, P13379, DOI 10.1074/jbc.M108079200; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; Martinez GR, 2000, P NATL ACAD SCI USA, V97, P10307, DOI 10.1073/pnas.190256897; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Millar TM, 2002, REDOX REP, V7, P65, DOI 10.1179/135100002125000280; Miranda KM, 2001, J BIOL CHEM, V276, P1720, DOI 10.1074/jbc.M006174200; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Ohshima H, 1998, FREE RADICAL BIO MED, V25, P1057, DOI 10.1016/S0891-5849(98)00141-5; Pagliaro P, 2003, FREE RADICAL BIO MED, V34, P33, DOI 10.1016/S0891-5849(02)01179-6; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; Poss WB, 1996, AM J PHYSIOL-LUNG C, V270, pL941, DOI 10.1152/ajplung.1996.270.6.L941; RINALDO JE, 1994, AM J RESP CELL MOL, V11, P625, DOI 10.1165/ajrcmb.11.5.7524568; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SERGEEV N S, 1985, Journal of Applied Biochemistry, V7, P86; Shafirovich V, 2002, P NATL ACAD SCI USA, V99, P7340, DOI 10.1073/pnas.112202099; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Stoyanovsky DA, 1999, J AM CHEM SOC, V121, P5093, DOI 10.1021/ja990318v; Takahira R, 2001, FREE RADICAL BIO MED, V31, P809, DOI 10.1016/S0891-5849(01)00658-X; TERADA LS, 1992, P NATL ACAD SCI USA, V89, P3362, DOI 10.1073/pnas.89.8.3362; Trujillo M, 1998, J BIOL CHEM, V273, P7828, DOI 10.1074/jbc.273.14.7828; Vaananen AJ, 2003, FREE RADICAL RES, V37, P381, DOI 10.1080/1071576031000061011; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Yoshie Y, 1998, FREE RADICAL BIO MED, V24, P341, DOI 10.1016/S0891-5849(97)00269-4; Yoshie Y, 1997, CHEM RES TOXICOL, V10, P1015, DOI 10.1021/tx970025k; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226	57	46	46	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X			BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	MAR 5	2004	315	2					455	462		10.1016/j.bbrc.2004.01.081			8	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	776ZW	WOS:000189150300030	14766230				2022-02-25	
J	Parkin, DM				Parkin, D. M.			Cancer in the developing world: epidemiology and etiological aspects	ANNALS OF ONCOLOGY			English	Meeting Abstract									[Parkin, D. M.] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534			ANN ONCOL	Ann. Oncol.		2004	15			3			9	9					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	V14FS	WOS:000207720900032					2022-02-25	
J	Suzuki, T; Ohshima, H				Suzuki, T; Ohshima, H			Nicotine-modulated formation of spiroiminodihydantoin nucleoside via 8-oxo-7,8-dihydro-2 '-deoxyguanosine in 2 '-deoxyguanosine-hypochlorous acid reaction	FEBS LETTERS			English	Article						spiroiminodihydantoin; 8-oxo-7,8-dihydro-2 '-deoxyguanosine; 8-chloro-2 '-deoxyguanosine; 2 '-deoxyguanosine; hypochlorous acid	AQUEOUS HYPOCHLOROUS ACID; CALF THYMUS DNA; SODIUM-HYPOCHLORITE; MYELOPEROXIDASE; CHLORINATION; OXIDATION; PRODUCT; 8-OXO-7,8-DIHYDROGUANOSINE; GUANOSINE; DAMAGE	Hypochlorous acid (HOCl) is generated by myeloperoxidase of activated neutrophils which kill invading microorganisms, but also cause DNA damage in inflamed tissues. We report here that spiroiminodihydantoin nucleoside (dS), a further oxidized product of 8-oxo-7,8-dihydro-2'-deoxguanosine (8-oxo-dG), is formed, in addition to 8-chloro-2'-deoxyguanosine and 8-oxo-dG, by reaction of 2'-deoxyguanosine with HOCl. Presence of low concentrations of nicotine significantly enhanced the yields of these HOCl-modified nuelcosides. Our results imply that nicotine may enhance genotoxicity and tissue damage caused by neutrophil activation. dS may also serve as a new biomarker for oxidative DNA damage induced by oxidants such as HOCl. (C) 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.	Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Ohshima, Hiroshi/E-8044-2010				Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; BERNOFSKY C, 1990, FREE RADICAL RES COM, V9, P303, DOI 10.3109/10715769009145689; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; HAYATSU H, 1971, NATURE, V233, P495, DOI 10.1038/233495a0; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Helbock HJ, 1999, METHOD ENZYMOL, V300, P156; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Sugden KD, 2001, CHEM RES TOXICOL, V14, P1315, DOI 10.1021/tx010088+; Suzuki T, 2001, CHEM RES TOXICOL, V14, P1163, DOI 10.1021/tx010024z; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 1999, BIOMARKERS, V4, P303, DOI 10.1080/135475099230831; WLODKOWSKI TJ, 1975, MUTAT RES, V31, P39, DOI 10.1016/0165-1161(75)90061-8	21	19	19	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-5793			FEBS LETT	FEBS Lett.	APR 10	2002	516	1-3					67	70	PII S0014-5793(02)02503-6	10.1016/S0014-5793(02)02503-6			4	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Cell Biology	544TU	WOS:000175178000014	11959105				2022-02-25	
J	Miranda, A; Bray, F				Miranda-Filho, Adalberto; Bray, Freddie			Global patterns and trends in cancers of the lip, tongue and mouth	ORAL ONCOLOGY			English	Article						Lip cancer; Tongue cancer; Mouth cancer; Incidence; Mortality	ORAL-CANCER; ALCOHOL-CONSUMPTION; TOBACCO SMOKING; UNITED-STATES; ARECA NUT; RISK; OROPHARYNGEAL; EPIDEMIOLOGY; PROTECTION; REGRESSION	Objectives: Global descriptions of international patterns and trends in oral cancer are informative in providing insight into the shifting epidemiologic patterns and the potential prevention of these tumours. We present global statistics on these cancers using the comprehensive set of national estimates and recorded data collated at the International Agency for Research on Cancer (IARC). Methods: The estimated number of lip and oral cavity cases and deaths in the 185 countries for the year 2018 was extracted from IARC's GLOBOCAN database of national estimates. To examine trends, recorded data series on lip and oral cavity cancers, as well as corresponding population-at-risk data were extracted from successive volumes of Cancer Incidence in Five Continents. Results: Globally, the highest incidence was found in South-Central Asia and parts of Oceania, with the highest estimated incidence rates in Papua New Guinea, Pakistan and India. The highest observed rates of lip cancer were in Australia, while India had the highest incidence rates of mouth and oral tongue cancer. Trends are diverse, with lip cancer incidence rates continuing to decrease for both sexes; the incidence rates of mouth cancer are also in decline in males, although increasing rates among females were observed in some populations. Conclusion: There are some grounds for optimism given the prospects for control of these cancers. Primary prevention should however focus on the reduction of the main causes, namely, tobacco and alcohol consumption.	[Miranda-Filho, Adalberto; Bray, Freddie] Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Bray, F (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	brayf@iarc.fr					Abreu L, 2009, AUST DENT J, V54, P130, DOI 10.1111/j.1834-7819.2009.01105.x; Ariyawardana A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-333; Bagnardi V, 2015, BRIT J CANCER, V112, P580, DOI 10.1038/bjc.2014.579; Bast RC, 2016, NEOPLASMS HEAD NECK, P1; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bray FI, 2010, INT J CANCER, V126, P1454, DOI 10.1002/ijc.24855; Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Greinert R, 2015, CANCER EPIDEMIOL, V39, pS75, DOI 10.1016/j.canep.2014.12.014; Gupta M, 2014, INT J MECH MATER ENG, V9, DOI 10.1186/s40712-014-0011-x; Gupta PC, 2002, ADDICT BIOL, V7, P77, DOI 10.1080/13556210020091437; Han AY, 2016, JAMA OTOLARYNGOL, V142, P1216, DOI 10.1001/jamaoto.2016.3455; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC Monogr Eval Carcinog Risks Hum, V83, P1; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z; Koutros S, 2010, J OCCUP ENVIRON MED, V52, P1098, DOI 10.1097/JOM.0b013e3181f72b7c; Lupu M, 2018, MOL CLIN ONCOL, V8, P640, DOI 10.3892/mco.2018.1599; Marks MA, 2014, CANCER EPIDEM BIOMAR, V23, P160, DOI 10.1158/1055-9965.EPI-13-0181; Muwonge R, 2008, ORAL ONCOL, V44, P446, DOI 10.1016/j.oraloncology.2007.06.002; Nelson DE, 1996, PREV MED, V25, P91, DOI 10.1006/pmed.1996.9999; Neville BW, 2002, CA-CANCER J CLIN, V52, P195, DOI 10.3322/canjclin.52.4.195; Oxford Cancer Intelligence Unit, HEAD NECK CANC ENGL; Parada C, 2012, J DENT RES, V91, P528, DOI 10.1177/0022034511434055; Patel SC, 2011, J CLIN ONCOL, V29, P1488, DOI 10.1200/JCO.2010.31.7883; Pi?eros M., 2017, CANC INCIDENCE 5 CON; Pogoda JM, 1996, CANCER CAUSE CONTROL, V7, P458, DOI 10.1007/BF00052672; R Development Core Team, 2014, R FDN STAT COMP; Rigel DS, 2008, J AM ACAD DERMATOL, V58, pS129, DOI 10.1016/j.jaad.2007.04.034; SANKARANARAYANAN R, 1989, INT J CANCER, V44, P617, DOI 10.1002/ijc.2910440410; SANKARANARAYANAN R, 1990, ORAL SURG ORAL MED O, V69, P325, DOI 10.1016/0030-4220(90)90294-3; Sankaranarayanan R., 2015, CANC DIS CONTROL PRI, V3; Schottenfeld D, 2006, CANC EPIDEMIOLOGY PR, P1392; Secretan B, 2009, LANCET ONCOL, V10, P1033, DOI 10.1016/S1470-2045(09)70326-2; SEGI MITSUO, 1960, TOHOKU JOUR EXPTL MED, V72, P91; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; Slootweg, 2017, WHO CLASSIFICATION H, P347; SPITZER WO, 1975, NEW ENGL J MED, V293, P419, DOI 10.1056/NEJM197508282930903; Stanton WR, 2004, HEALTH PROMOT INT, V19, P369, DOI 10.1093/heapro/dah310; Subramanian S, 2009, B WORLD HEALTH ORGAN, V87, P198, DOI 10.2471/BLT.08.053231; Travasso Cheryl, 2013, BMJ, V347, pf7536, DOI 10.1136/bmj.f7536; World Health Organization, 2015, WHO GLOB REP TRENDS; World Health Organization, 2011, GLOB STAT REP ALC HL, P286; World Health Organization International Agency for Research on Cancer, 2007, MONOGRAPHS EVALUATIO, V89, P1; Zheng TZ, 1997, ORAL ONCOL, V33, P82, DOI 10.1016/S0964-1955(96)00056-5	45	45	46	4	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1368-8375	1879-0593		ORAL ONCOL	Oral Oncol.	MAR	2020	102								104551	10.1016/j.oraloncology.2019.104551			8	Oncology; Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Dentistry, Oral Surgery & Medicine	KS9PN	WOS:000518642200009	31986342				2022-02-25	
J	Clifford, GM; Tully, S; Franceschi, S				Clifford, Gary M.; Tully, Stephen; Franceschi, Silvia			Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer	CLINICAL INFECTIOUS DISEASES			English	Article						human papillomavirus; human immunodeficiency virus; cervical cancer; epidemiology	IMMUNE STATUS; RISK; NEOPLASIA; IMMUNODEFICIENCY; PREVALENCE; GUIDELINES; PRECANCER	Background. Data on the relative carcinogenic potential of human papillomavirus (HPV) types among women infected with human immunodeficiency virus (HIV) (WHIV) are needed to inform prevention programs for this population. Methods. A systematic literature review and meta-analysis of high-risk HPV-type distribution in 19 883 HIV-positive women was performed. The women, from 86 studies worldwide, included 11 739 with normal cytological findings; 1784 with atypical squamous cells of undetermined significance (ASCUS); 2173 with low-grade and 1282 with high-grade squamous intraepithelial lesions (HSILs) diagnosed cytologically; 1198 with cervical intraepithelial neoplasia grade 1 (CIN1), 456 with CIN2, and 455 with CIN3 diagnosed histologically; and 796 with invasive cervical cancers (ICCs). A large proportion of WHIV, and almost all with ICCs, were from Africa. Results. In Africa, HPV 16 accounted for 13% of HPV-positive WHIV with normal cytological findings, but this proportion increased through ASCUS, low-grade squamous intraepithelial lesions, CIN1, and CIN2 (18%-25%), up to 41%-47% for CIN3 and ICCs. Only HPV 16, HPV 18, and HPV 45 accounted for a greater proportion of HPV infections in ICCs compared with normal cytological findings (ICC: normal ratios, 3.68, 2.47, and 2.55, respectively). Other high-risk types accounted for important proportions of low-and/or high-grade lesions, but their contribution dropped in ICCs, with ICC: normal ratios in Africa ranging from 0.79 for HPV 33 down to 0.38 for HPV 56. Findings for HPV 16 and HPV 18 in Europe/North America, Asia, and Latin America were compatible with those from Africa. Conclusions. HPV 16 and HPV 18 in particular, but also HPV 45, at least in Africa, warrant special attention in WHIV. Broad consistency of findings with those in HIV-uninfected population would suggest that the risk stratification offered by partial HPV genotyping tests also have relevance for HIV-positive women.	[Clifford, Gary M.; Tully, Stephen; Franceschi, Silvia] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Clifford, GM (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	cliffordg@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071	European Commission from the International Agency for Research on Cancer; Fondation de FranceFondation de France [00039621]; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1053353]	This work was partially supported by the European Commission FP7 Marie Curie Actions-People -Co-funding of regional, national and international programs (COFUND) (to S. T. during the tenure of a postdoctoral fellowship from the International Agency for Research on Cancer), the Fondation de France (grant 00039621), and the Bill & Melinda Gates Foundation (grant OPP1053353).	Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V63, pE163, DOI 10.1097/QAI.0b013e31829cb7c3; Anastos K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013525; Ault KA, 2011, INT J CANCER, V128, P1344, DOI 10.1002/ijc.25723; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Chen HC, 2011, JNCI-J NATL CANCER I, V103, P1387, DOI 10.1093/jnci/djr283; Chung MH, 2013, AIDS, V27, P2909, DOI 10.1097/01.aids.0000432472.92120.1b; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Clifford GM, 2016, JAIDS-J ACQ IMM DEF, V73, P332, DOI 10.1097/QAI.0000000000001113; Clifford GM, 2016, INT J CANCER, V138, P1732, DOI 10.1002/ijc.29913; Einstein MH, 2014, J CLIN MICROBIOL, V52, P2089, DOI 10.1128/JCM.00176-14; Einstein MH, 2010, GYNECOL ONCOL, V118, P116, DOI 10.1016/j.ygyno.2010.04.013; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; Huh WK, 2015, OBSTET GYNECOL, V125, P330, DOI [10.1016/j.ygyno.2014.12.022, 10.1097/AOG.0000000000000669]; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Keller MJ, 2015, CLIN INFECT DIS, V61, P1573, DOI 10.1093/cid/civ569; Keller MJ, 2012, JAMA-J AM MED ASSOC, V308, P362, DOI 10.1001/jama.2012.5664; Kjaer SK, 2010, JNCI-J NATL CANCER I, V102, P1478, DOI 10.1093/jnci/djq356; Massad LS, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.09.086; Massad LS, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.12.003; Massad LS, 2014, AIDS, V28, P2601, DOI 10.1097/QAD.0000000000000455; Rowhani-Rahbar A, 2007, J INFECT DIS, V196, P887, DOI 10.1086/520883; Santesso N, 2016, INT J GYNECOL OBSTET, V132, P252, DOI 10.1016/j.ijgo.2015.07.038; Saslow D, 2012, AM J CLIN PATHOL, V137, P516, DOI [10.1309/AJCPTGD94EVRSJCG, 10.3322/caac.21139]; Schiffman M, 2015, CANCER EPIDEM BIOMAR, V24, P1304, DOI 10.1158/1055-9965.EPI-14-1353; Schiffman M, 2011, CANCER EPIDEM BIOMAR, V20, P1398, DOI 10.1158/1055-9965.EPI-11-0206; Schiffman Mark, 2009, Infect Agent Cancer, V4, P8, DOI 10.1186/1750-9378-4-8; Sinayobye JD, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-40; Strickler HD, 2003, JNCI-J NATL CANCER I, V95, P1062, DOI 10.1093/jnci/95.14.1062; Wright TC, 2015, GYNECOL ONCOL, V136, P189, DOI 10.1016/j.ygyno.2014.11.076	30	75	82	1	18	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1058-4838	1537-6591		CLIN INFECT DIS	Clin. Infect. Dis.	MAY 1	2017	64	9					1228	1235		10.1093/cid/cix135			8	Immunology; Infectious Diseases; Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases; Microbiology	ES2SB	WOS:000399377100013	28199532	Green Published, hybrid			2022-02-25	
J	Guyton, KZ; Loomis, D; Straif, K				Guyton, Kathryn Z.; Loomis, Dana; Straif, Kurt			Reply to "the critical role of pre-publication peer review-a case study of glyphosate" by FN Dost	ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH			English	Letter									[Guyton, Kathryn Z.; Loomis, Dana; Straif, Kurt] Int Agcy Res Canc, IARC Monographs Sect, Lyon, France		Straif, K (corresponding author), Int Agcy Res Canc, IARC Monographs Sect, Lyon, France.	straifk@iarc.fr	Loomis, Dana/AAE-3988-2019	Loomis, Dana/0000-0003-3297-5200			Dost FN, 2016, ENVIRON SCI POLLUT R, V23, P15774, DOI 10.1007/s11356-016-7104-4; Guyton KZ, 2015, LANCET ONCOL, V16, P490, DOI 10.1016/S1470-2045(15)70134-8; Hardell L, 1999, CANCER, V85, P1353, DOI 10.1002/(SICI)1097-0142(19990315)85:6&lt;1353::AID-CNCR19&gt;3.0.CO;2-1; IARC (International Agency for Research on Cancer), 2015, IARC MONOGRAPHS EVAL, V112; Paganelli A, 2010, CHEM RES TOXICOL, V23, P1586, DOI 10.1021/tx1001749; RANK J, 1993, MUTAT RES, V300, P29, DOI 10.1016/0165-1218(93)90136-2	6	1	1	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0944-1344	1614-7499		ENVIRON SCI POLLUT R	Environ. Sci. Pollut. Res.	MAR	2017	24	8					7850	7851		10.1007/s11356-016-7675-0			2	Environmental Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology	ER9RQ	WOS:000399164600085	27726074				2022-02-25	
J	Dean, PB; Von Karsa, L				Dean, Peter B.; Von Karsa, Lawrence			A Tactical Approach To Bringing Breast Cancer To Early And Effective Therapy: Preoperative And Postoperative Interdisciplinary Management	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Meeting Abstract						breast cancer; breast cancer management; breast cancer screening			[Dean, Peter B.] Int Agcy Res Canc, Screening Grp, Lyon, France; [Von Karsa, Lawrence] Int Agcy Res Canc, Screening Grp, Qual Assurance Grp, Lyon, France									0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	SEP	2016	26			2		PP-116	66	66					1	Oncology; Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Obstetrics & Gynecology	EB1JW	WOS:000387108300055					2022-02-25	
J	Sierra, MS; Forman, D				Sierra, Monica S.; Forman, David			Cancer in Central and South America: Methodology	CANCER EPIDEMIOLOGY			English	Article						Neoplasm; Incidence; Mortality; Trends; EAPC; Central and South America	MORTALITY; TRENDS; PATTERNS	Statistics on cancer incidence from Central and South American countries are scarce because of the small number of population-based cancer registries that continuously collect data. Similarly, comparable statistics on cancer mortality are sparse in spite of efforts made to improve coverage in the last decade. The aim of this study is to describe geographical patterns and trends in cancer incidence and mortality in Central and South America in the 21st century. The primary objective was to obtain the best quality cancer data available from each country within the region. Cancer incidence data were obtained from population-based cancer registries within the region and, in countries where these did not exist, from hospital-based registries; national mortality data were obtained from the World Health Organization mortality database. Given the variability in data quality - mainly due to the age and development in maturity of the registries, an exhaustive review of the data was necessary in order to appropriately analyze, describe and interpret patterns of cancer incidence and mortality between countries and within cancer-specific sites. This paper presents the methods employed in the collection, quality control and analysis of the datasets received for the project. (C) 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd.	[Sierra, Monica S.; Forman, David] Int Agcy Res Canc, Sect Canc Surveillance, Lyon, France		Sierra, MS (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, Lyon, France.	sierram@fellows.iarc.fr; monica.sierra@alumni.uth.edu	Sierra, Monica S./H-1751-2015	Sierra, Monica S./0000-0003-1286-057X	International Agency for Research on Cancer; European Commission FP7 Marie Curie Actions	This work was undertaken during the tenure of a Postdoctoral Fellowship to Dr Monica S. Sierra from The International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions - People - Co-funding of regional, national and international programmes (COFUND).	[Anonymous], 2011, STAT DAT AN STAT SOF; [Anonymous], 2014, CANC INCIDENCE 5 CON, VX; [Anonymous], 2015, LATEX DOC PREP SYST; [Anonymous], 2014, MORT DAT; Antoni S, 2016, B WORLD HEALTH ORGAN, V94, P174, DOI 10.2471/BLT.15.164384; Barbosa IR, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000746; Bosetti C, 2005, ANN ONCOL, V16, P489, DOI 10.1093/annonc/mdi086; Bosetti C, 2011, EUR J CANCER PREV, V20, P355, DOI 10.1097/CEJ.0b013e32834653c9; Bravo LE, 2012, COLOMB MEDICA, V43, P246; Bray F., 2014, IARC TECHNICAL PUBLI, V43; Bray F, 2009, EUR J CANCER, V45, P747, DOI 10.1016/j.ejca.2008.11.032; Chatenoud L, 2014, ANN ONCOL, V25, P1843, DOI 10.1093/annonc/mdu206; Chatenoud L, 2010, EUR J CANCER PREV, V19, P79, DOI 10.1097/CEJ.0b013e32833233be; Doll R., 1966, CANC INCIDENCE 5 CON, VI; Esteve J, 1994, IARC Sci Publ, P1; Ferlay J, 2014, GLOBOCAN 2012 V1 0 C; Ferlay J, 2005, CHECK CONVERSION PRO; Forman D., 2014, CANC INCIDENCE 5 CON, P164; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jensen O, 1991, IARC SCI PUBLICATION; Loos AH, 2004, EUR J CANCER, V40, P2794, DOI 10.1016/j.ejca.2004.09.007; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; May Susanne, 2005, Dose-Response, V3, P474, DOI 10.2203/dose-response.003.04.004; Parkin DM, 2009, EUR J CANCER, V45, P756, DOI 10.1016/j.ejca.2008.11.033; Pheby D., 1997, RECOMMENDATIONS FOR; Pineros M, 2013, CANCER EPIDEMIOL, V37, P233, DOI 10.1016/j.canep.2013.02.003; Politis M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000970; Registro Estatal de cancer Jalisco, 2010, REG EST CANC JAL B E; Segi M., 1963, TRENDS CANC MORTALIT, P1950; United Nations, 2013, COMP MACR CONT REG G	30	9	9	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	SEP	2016	44			1			S11	S22		10.1016/j.canep.2016.07.020			12	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	EE3RT	WOS:000389515600003	27678312	hybrid			2022-02-25	
J	Romieu, I				Romieu, Isabelle			Fiber intake modulates the effect of alcohol on breast cancer	CANCER RESEARCH			English	Meeting Abstract	106th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 18-22, 2015	Philadelphia, PA	Amer Assoc Canc Res					[Romieu, Isabelle] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	AUG 1	2015	75			15		LB-186				10.1158/1538-7445.AM2015-LB-186			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	DF8HA	WOS:000371597100286					2022-02-25	
J	Sylla, BS; Wild, CP				Sylla, Bakary S.; Wild, Christopher P.			A million africans a year dying from cancer by 2030: What can cancer research and control offer to the continent?	INTERNATIONAL JOURNAL OF CANCER			English	Review						cancer; Africa; etiology; prevention	INDIGENOUS AFRICANS; CERVICAL-CANCER; INTERVENTION; INFECTION; EXPOSURE; BURDEN	In Africa, there were an estimated 681,000 new cancer cases and 512,000 deaths in 2008. Projections to 2030 show a startling rise, with corresponding figures of 1.27 million cases and 0.97 million deaths resulting from population growth and aging alone. The figures make no assumptions about incidence rates which may increase due to the further introduction of tobacco and a more westernized lifestyle. The current situation in many parts of Africa with respect to health care systems suggests that improved cancer treatment would be an insufficient response to this increasing burden. Much could be achieved through cancer prevention by applying current knowledge about major risk factors and the natural history of the disease. For example, vaccination against hepatitis B virus and human papilloma viruses would prevent the occurrence of two of the most common cancers in Africa, liver and cervix, respectively, in the long-term. Strong measures to prevent the widespread introduction of tobacco must be a priority. Early detection and treatment of cervical and breast cancers using approaches applicable now in Africa would provide immediate value, as would the management of human immunodeficiency virus (HIV) infection in respect to HIV-associated malignancies. In parallel, further research is needed into the causes of cancer and the barriers to implementation of promising prevention strategies. Underpinning all is the need for African governments to look forward and prioritize cancer through national cancer control plans, to invest in public health infrastructure and to ensure the adequate training and support for people in cancer prevention and control. Given this core commitment from within Africa, international partners can provide complementary support in a cooperation that permits action now to mitigate the impending tragedy of cancer in the continent of Africa.	[Sylla, Bakary S.; Wild, Christopher P.] Int Agcy Res Canc, F-69372 Lyon 08, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669	NIEHS, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES06052]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01ES006052] Funding Source: NIH RePORTER	The authors would like to thank Jacques Ferlay, Silvia Franceschi, Rengwaswamy Sankaranarayanan, Vincent Cogliano, Kurt Straif and Eduardo Seleiro for their insightful comments. Drs. Wild and Sylla were responsible for the planning and writing of this article. The two authors have no conflicts of interest to declare. Dr. Wild acknowledges support from the NIEHS, USA; grant no. ES06052.	[Anonymous], 2011, LANCET, V377, P1544, DOI 10.1016/S0140-6736(11)60622-3; [Anonymous], UICC DECL; [Anonymous], 2010, UN GEN ASS RES 64 SE; [Anonymous], WHO UNICEF COV EST 1; BOUVARD V, 2009, LANCET ONCOL, V10, P321, DOI [DOI 10.1016/S1470-2045(09)70096-8, 10.1016/s1470-2045(09)70096-8]; Bower M, 2006, CURR OPIN INFECT DIS, V19, P14, DOI 10.1097/01.qco.0000200295.30285.13; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Chang MH, 2009, JNCI-J NATL CANCER I, V101, P1348, DOI 10.1093/jnci/djp288; Curado MP, 2008, IARC SCI PUBLICATION, VIX; Denny L, 2010, JNCI-J NATL CANCER I, V102, P1557, DOI 10.1093/jnci/djq342; Dye TD, 2010, GLOB PUBLIC HEALTH, V22, P1; Farmer P, 2010, LANCET, V376, P1186, DOI 10.1016/S0140-6736(10)61152-X; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gotch F, 2007, NAT IMMUNOL, V8, P1273, DOI 10.1038/ni1531; *INT AG RES CANC, 2008, WORLD CANC REP; Ly A, 2007, ONCOLOGIE, V9, P370, DOI 10.1007/s10269-007-0636-y; Mutalima N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002505; Parkin DM, 2008, LANCET ONCOL, V9, P683, DOI 10.1016/S1470-2045(08)70175-X; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Parkin DM, 2010, INT J CANCER, V126, P1187, DOI 10.1002/ijc.24838; Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Sitas F, 2008, LANCET ONCOL, V9, P786, DOI 10.1016/S1470-2045(08)70198-0; Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5; Union for International Cancer Control, 2010, UICC SPEC REP; United Nations, WORLD POP PROSP 2010; van der Westhuizen L, 2011, CANCER EPIDEM BIOMAR, V20, P483, DOI 10.1158/1055-9965.EPI-10-1002; Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303; WHO, 2008, AFRRC589 WHO; Wild CP, 2010, CARCINOGENESIS, V31, P71, DOI 10.1093/carcin/bgp264; World Health Organization, 2008, The global burden of disease: 2004 update; World Health Organization, 2004, GLOB STRAT DIET PHYS; Ziraba AK, 2009, BMC PUBLIC HEALTH, V9, DOI [10.1186/1471-2458-9-465, 10.1186/1472-6963-9-46]	33	92	92	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	JAN 15	2012	130	2					245	250		10.1002/ijc.26333			6	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	864QI	WOS:000298254400001	21796634	Green Accepted			2022-02-25	
J	Cogliano, VJ; Baan, R; Straif, K				Cogliano, Vincent James; Baan, Robert; Straif, Kurt		IARC Monographs Programme Staff	Updating IARC's Carcinogenicity Assessment of Benzene	AMERICAN JOURNAL OF INDUSTRIAL MEDICINE			English	Editorial Material									[Cogliano, Vincent James; Baan, Robert; Straif, Kurt; IARC Monographs Programme Staff] Int Agcy Res Canc, F-69372 Lyon, France		Cogliano, VJ (corresponding author), 150 Cours Albert Thomas, F-69008 Lyon, France.	cogliano@iarc.fr					Baan R, 2009, LANCET ONCOL, V10, P1143, DOI 10.1016/S1470-2045(09)70358-4; IARC, 1999, IARC MON EV CARC RIS, V71; *IARC, 2007, 07001 IARC, V100; *IARC, 2008, IARC MON EV CARC RIS, V97, P39; *IARC, 2008, 08001 IARC; IARC, 1982, IARC MON EV CARC RIS, V29, P93; IARC, 2006, PREAMBL IARC MON; International Agency for Research on Cancer (IARC), 1987, IARC MON EV CARC S7, V1	8	21	21	0	7	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0271-3586			AM J IND MED	Am. J. Ind. Med.	FEB	2011	54	2					165	167		10.1002/ajim.20916			3	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	712XH	WOS:000286699100009	21259300				2022-02-25	
J	Fernandez-Cuesta, L; Anaganti, S; Hainaut, P; Olivier, M				Fernandez-Cuesta, Lynnette; Anaganti, Suresh; Hainaut, Pierre; Olivier, Magali			Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines	BREAST CANCER RESEARCH AND TREATMENT			English	Article						p53; Estrogen receptor; Breast; Estradiol; Doxorubicin; Apoptosis	TUMOR-SUPPRESSOR GENE; RECEPTOR-ALPHA; MUTANT P53; IN-VIVO; MDM2; PROMOTER; BINDING; PROTEIN; DEGRADATION; ACTIVATION	A large proportion of breast cancers expresses the estrogen receptor alpha (ER alpha) and are dependent on estrogens for their proliferation and survival. The tumor suppressor TP53 encodes the p53 protein, an important mediator of the anti-proliferative and apoptotic effects of several treatments used for breast cancer. A significant proportions of breast tumors (20-30%) carry mutations in TP53 gene and these mutations are associated with poor survival and poor response to several types of chemotherapeutic treatments. While there is mounting evidence for functional interactions between p53 and ER alpha pathways in breast and other tissues, the impact of these interactions on response to chemotherapy and anti-hormone treatments remain largely unknown. Here, using estrogen-dependent breast cancer cell lines with different p53 status, we show that estrogens, through ER alpha, influence p53 protein levels and activities. Estrogen deprivation reduced, while estradiol increased p53 levels, in a time and dose-dependent manner. Both wild-type and endogenously expressed mutant p53 proteins were affected. This reduction in p53 protein levels resulted in reduced p53-dependent responses induced by DNA damage in p53 wild-type cells, lowering the capacity of doxorubicine to induce apoptosis. The p53 response appeared to be quantitatively but not qualitatively affected. These results suggest that ER alpha activity is required for a strong p53 response in estrogen-dependent breast cancer cells. These results are in line with previous observations that we made in a clinical series, where a larger effect of TP53 mutation status was found for patient survival in cases with progesterone receptor positive status, a marker of a functional ER alpha pathway. It would thus be important to further characterize the influence of ER alpha pathway on the predictive value of TP53 mutation status in specifically designed clinical trials, as it may open perspectives for improving breast cancer treatment.	[Fernandez-Cuesta, Lynnette; Anaganti, Suresh; Hainaut, Pierre; Olivier, Magali] Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon, France		Olivier, M (corresponding author), Int Agcy Res Canc, Mol Carcinogenesis Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	molivier@iarc.fr	Fernandez-Cuesta, Lynnette/O-2415-2017; Olivier, Magali/G-3728-2010; Fernandez-Cuesta, Lynnette/Z-1875-2019; Hainaut, Pierre/B-6018-2012	Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; Olivier, Magali/0000-0002-8202-342X; Fernandez-Cuesta, Lynnette/0000-0002-0724-6703; Hainaut, Pierre/0000-0002-1303-1610	Association for International Cancer Research	This study has been supported by a grant from the Association for International Cancer Research. We thank Ke-Seay Smoth for her technical help.	Adhikari Amit S., 2009, Fukuoka Acta Medica, V100, P217; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Becker KA, 2005, ONCOGENE, V24, P6345, DOI 10.1038/sj.onc.1208787; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253; Dunphy KA, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2094; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Guillot C, 1996, CLIN CANCER RES, V2, P1439; Hainaut P, 2000, ADV CANCER RES, V77, P81; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hurd C, 1999, ONCOGENE, V18, P1067, DOI 10.1038/sj.onc.1202398; Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256; Jin W, 2008, J BIOL CHEM, V283, P29671, DOI 10.1074/jbc.M802785200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lewandowski SA, 2005, ONCOGENE, V24, P4789, DOI 10.1038/sj.onc.1208595; Liu G, 1999, BIOCHEM BIOPH RES CO, V264, P359, DOI 10.1006/bbrc.1999.1525; Liu GZ, 2000, CANCER RES, V60, P1810; Liu WS, 2006, J BIOL CHEM, V281, P9837, DOI 10.1074/jbc.C600001200; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Menendez D, 2007, MOL CELL BIOL, V27, P2590, DOI 10.1128/MCB.01742-06; Molinari AM, 2000, CANCER RES, V60, P2594; Moudgil VK, 2001, J STEROID BIOCHEM, V76, P105, DOI 10.1016/S0960-0760(00)00151-5; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Olivier M, 2005, 25 YEARS OF P53 RESEARCH, P321, DOI 10.1007/1-4020-2922-5_14; Salvat C, 1999, MOL BIOL REP, V26, P45, DOI 10.1023/A:1006960021281; Santen RJ, 2009, STEROIDS, V74, P586, DOI 10.1016/j.steroids.2008.11.020; Schiff R, 2003, CLIN CANCER RES, V9, p447S; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shirley SH, 2009, CANCER RES, V69, P3405, DOI 10.1158/0008-5472.CAN-08-3628; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	34	25	28	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-6806	1573-7217		BREAST CANCER RES TR	Breast Cancer Res. Treat.	JAN	2011	125	1					35	42		10.1007/s10549-010-0819-x			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	689UV	WOS:000284956400004	20221692	Green Submitted			2022-02-25	
J	Ohgaki, H; Watanabe, T; Nobusawa, S; Kleihues, P				Ohgaki, H.; Watanabe, T.; Nobusawa, S.; Kleihues, P.			IDH1 mutations in gliomas	VIRCHOWS ARCHIV			English	Meeting Abstract									[Ohgaki, H.; Watanabe, T.; Nobusawa, S.; Kleihues, P.] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317			VIRCHOWS ARCH	Virchows Arch.	AUG	2009	455						21	21					1	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	474TT	WOS:000268307700056					2022-02-25	
J	Cogliano, V				Cogliano, V.			The IARC Monographs: a resource for precaution and prevention? The new Preamble does not fit	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Letter									Intl Agency Res Canc, IARC Monographs Programme, Lyon, France		Cogliano, V (corresponding author), Intl Agency Res Canc, IARC Monographs Programme, Lyon, France.	cogliano@iarc.fr					2008, OCCUP ENVIRON MED, V64, P572	1	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JUL	2008	65	7					500	500					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	315OU	WOS:000256890100010	18562686				2022-02-25	
J	Hung, RJ; Hall, J; Brennan, P; Boffetta, P				Hung, RJ; Hall, J; Brennan, P; Boffetta, P			Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Review						apurinic/apyrimidinic endonuclease; DNA repair; meta-analysis; neoplasms; 8-oxoguanine DNA glycosylase, human; polymorphism, genetic; XRCC1 protein	SQUAMOUS-CELL CARCINOMA; HOGG1 SER(326)CYS POLYMORPHISM; OXIDATIVELY DAMAGED DNA; SINGLE NUCLEOTIDE POLYMORPHISMS; LUNG-CANCER; BREAST-CANCER; SER326CYS POLYMORPHISM; XRCC1 POLYMORPHISMS; BLADDER-CANCER; CHINESE POPULATION	Genetic variations in DNA repair genes are thought to modulate DNA repair capacity and are suggested to be related to cancer risk. However, epidemiologic findings have been inconsistent. The authors conducted meta-analyses of associations between genes in the base excision repair pathway and cancer risk, focusing on three key genes: 8-oxoguanine DNA glycosylase (OGG1), apurinic/apyrimidinic endonuclease (APE1/APEX1), and x-ray repair cross-complementing group 1 (XRCC1). They found increased lung cancer risk among subjects carrying the OGG1 Cys/Cys genotype (odds ratio (OR) = 1.24, 95% confidence interval (CI): 1.01, 1.53), using 3,253 cases and 3,371 controls from seven studies; this is consistent with experimental evidence that this isoform exhibits decreased activity. They found a protective effect of the XRCC1 194Trp allele for tobacco-related cancers (OR = 0.86, 95% CI: 0.77, 0.95), using 4,895 cases and 5,977 controls from 16 studies; this is compatible with evidence of lower mutagen sensitivity for this allele. The XRCC1 399Gln/399Gln genotype was associated with increased risk of tobacco-related cancers among light smokers (OR = 1.38, 95% CI: 0.99, 1.94) but decreased risk among heavy smokers (OR = 0.71, 95% CI: 0.51, 0.99), suggesting effect modification by tobacco smoking. There was no association between cancer risk and the APE1/APEX1 Asp148Glu and XRCC1 Arg280His polymorphisms. Recommendations for future studies include pooling of individual data to facilitate evaluation of multigenic effects and detailed analysis of effect modification by environmental exposure.	Int Agcy Res Canc, Genet Epidemiol Grp, F-69008 Lyon, France		Hung, RJ (corresponding author), Int Agcy Res Canc, Genet Epidemiol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	hung@iarc.fr	hall, janet/G-1372-2013; Hung, Rayjean J/A-7439-2013	hall, janet/0000-0002-4397-6295; Hung, Rayjean/0000-0002-4486-7496	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA092039, R03CA119704] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA 092039-01A2, R03 CA 119704-01] Funding Source: Medline		Abdel-Rahman SZ, 2000, CANCER LETT, V159, P79, DOI 10.1016/S0304-3835(00)00537-1; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Antoniou AC, 2001, GENET EPIDEMIOL, V21, P1, DOI 10.1002/gepi.1014; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Chacko P, 2005, BREAST CANCER RES TR, V89, P15, DOI 10.1007/s10549-004-1004-x; Chen SQ, 2002, CARCINOGENESIS, V23, P1321, DOI 10.1093/CARCIN/23.8.1321; Cho EY, 2003, CANCER EPIDEM BIOMAR, V12, P1100; Choi JY, 2003, BREAST CANCER RES TR, V79, P59, DOI 10.1023/A:1023305826726; David-Beabes GL, 2001, LUNG CANCER-J IASLC, V34, P333, DOI 10.1016/S0169-5002(01)00256-2; Deligezer U, 2004, EXP MOL MED, V36, P572, DOI 10.1038/emm.2004.73; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dianov GL, 2003, MUTAT RES-FUND MOL M, V531, P157, DOI 10.1016/j.mrfmmm.2003.09.003; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Duell EJ, 2002, CANCER RES, V62, P4630; Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elahi A, 2002, CARCINOGENESIS, V23, P1229, DOI 10.1093/carcin/23.7.1229; Fan JS, 2004, NUCLEIC ACIDS RES, V32, P2193, DOI 10.1093/nar/gkh556; Forsti A, 2004, ONCOL REP, V11, P917; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Han JL, 2003, CANCER RES, V63, P8536; Hanaoka T, 2001, CANCER LETT, V170, P53, DOI 10.1016/S0304-3835(01)00565-1; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Harms C, 2004, ENVIRON MOL MUTAGEN, V44, P74, DOI 10.1002/em.20031; Hu JJ, 2001, CARCINOGENESIS, V22, P917, DOI 10.1093/carcin/22.6.917; Hung RJ, 2005, JNCI-J NATL CANCER I, V97, P567, DOI 10.1093/jnci/dji101; *IARC, 2004, IARC MON EV CARC RIS, V83, P1; Ide H, 2004, BIOL PHARM BULL, V27, P480, DOI 10.1248/bpb.27.480; Ito H, 2004, CARCINOGENESIS, V25, P1395, DOI 10.1093/carcin/bgh153; Ito Hidemi, 2002, J Epidemiol, V12, P258; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Janssen K, 2001, MUTAT RES-DNA REPAIR, V486, P207, DOI 10.1016/S0921-8777(01)00096-9; Kelsey KT, 2004, CANCER EPIDEM BIOMAR, V13, P1337; Kim JI, 2003, WORLD J GASTROENTERO, V9, P956; Kim SU, 2002, PHARMACOGENETICS, V12, P335, DOI 10.1097/00008571-200206000-00010; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Lan Q, 2004, CARCINOGENESIS, V25, P2177, DOI 10.1093/carcin/bgh240; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; Lee JM, 2001, INT J CANCER, V95, P240, DOI 10.1002/1097-0215(20010720)95:4<240::AID-IJC1041>3.0.CO;2-1; Lee SG, 2002, CANCER LETT, V187, P53, DOI 10.1016/S0304-3835(02)00381-6; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141; Lunn RM, 1999, CANCER RES, V59, P2557; Matsuo K, 2004, CANCER GENET CYTOGEN, V149, P77, DOI 10.1016/S0165-4608(03)00296-6; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Misra RR, 2003, CANCER LETT, V191, P171, DOI 10.1016/S0304-3835(02)00638-9; Moullan N, 2003, CANCER EPIDEM BIOMAR, V12, P1168; Nelson HH, 2002, CANCER RES, V62, P152; Nia AB, 2001, CARCINOGENESIS, V22, P395, DOI 10.1093/carcin/22.3.395; Olshan AF, 2002, CANCER LETT, V178, P181, DOI 10.1016/S0304-3835(01)00822-9; Palli D, 2001, INT J CANCER, V94, P121, DOI 10.1002/ijc.1433; Park J, 2004, PHARMACOGENETICS, V14, P103, DOI 10.1097/00008571-200402000-00004; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P23; Popanda O, 2004, CARCINOGENESIS, V25, P2433, DOI 10.1093/carcin/bgh264; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; Rybicki BA, 2004, CANCER EPIDEM BIOMAR, V13, P23, DOI 10.1158/1055-9965.EPI-03-0053; Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058; Seedhouse C, 2002, BLOOD, V100, P3761, DOI 10.1182/blood-2002-04-1152; Shen HB, 2000, INT J CANCER, V88, P601, DOI 10.1002/1097-0215(20001115)88:4&lt;601::AID-IJC13&gt;3.0.CO;2-C; Shen M, 2003, CANCER EPIDEM BIOMAR, V12, P1234; Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952; Shu XO, 2003, CANCER EPIDEM BIOMAR, V12, P1462; Smith TR, 2003, CANCER LETT, V190, P183, DOI 10.1016/S0304-3835(02)00595-5; Smith TR, 2003, CANCER EPIDEM BIOMAR, V12, P1200; Spitz MR, 2003, CANCER EPIDEM BIOMAR, V12, P689; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P125; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; Sugimura H, 1999, CANCER EPIDEM BIOMAR, V8, P669; Sunaga N, 2002, CANCER EPIDEM BIOMAR, V11, P730; Takezaki T, 2002, INT J CANCER, V99, P624, DOI 10.1002/ijc.10400; Tuimala J, 2002, CARCINOGENESIS, V23, P1003, DOI 10.1093/carcin/23.6.1003; van Gils CH, 2002, CANCER EPIDEM BIOMAR, V11, P1279; van Zeeland AA, 1999, MUTAT RES-GEN TOX EN, V439, P249, DOI 10.1016/S1383-5718(98)00192-2; Varzim G, 2003, EUR J CANCER PREV, V12, P495, DOI 10.1097/00008469-200312000-00008; Vogel U, 2004, CANCER EPIDEM BIOMAR, V13, P1680; Vogel U, 2003, CANCER EPIDEM BIOMAR, V12, P170; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Winsey SL, 2000, CANCER RES, V60, P5612; Xing DY, 2002, INT J CANCER, V100, P600, DOI 10.1002/ijc.10528; Xing DY, 2001, INT J CANCER, V95, P140, DOI 10.1002/1097-0215(20010520)95:3&lt;140::AID-IJC1024&gt;3.0.CO;2-2; Xu HY, 2005, HUM GENET, V116, P121, DOI 10.1007/s00439-004-1212-9; Xu JF, 2002, CANCER RES, V62, P2253; Yeh CC, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-12; Yin JY, 2002, CANCER EPIDEM BIOMAR, V11, P1449; Yu HP, 2004, CANCER DETECT PREV, V28, P194, DOI 10.1016/j.cdp.2004.01.004; Yu MW, 2003, J NATL CANCER I, V95, P1485, DOI 10.1093/jnci/djg051; Zhang XM, 2005, CANCER RES, V65, P722; Zhang ZD, 2004, CANCER EPIDEM BIOMAR, V13, P1081; Zhou W, 2003, CANCER EPIDEM BIOMAR, V12, P359	96	425	446	1	42	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	NOV 15	2005	162	10					925	942		10.1093/aje/kwi318			18	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	983GG	WOS:000233218800001	16221808	Bronze			2022-02-25	
J	Kleihues, P				Kleihues, P			The causes of cancer: A global perspective	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Meeting Abstract	2nd Annual AACR International Conference on Frontiers in Cancer Prevention Research	OCT 26-30, 2003	PHOENIX, ARIZONA	Amer Assoc Canc Res, Pfizer, AstraZeneca, Canc Res & Prevent Fdn, SuperGen, AFLAC Inc, Avon Fdn, Bristol Myers Squibb, Eli Lilly & Co, NCI, Takeda Pharmaceut N Amer Inc, Calif Breast Canc Res Program					Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965			CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	NOV	2003	12	11	2	S			1357S	1358S					2	Oncology; Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	752GT	WOS:000187153300312					2022-02-25	
J	Herceg, Z; Wang, ZQ				Herceg, Z; Wang, ZQ			Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death	MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS			English	Review						PARP; DNA repair; cell death; knock-out mice	SISTER-CHROMATID EXCHANGES; ANTISENSE RNA EXPRESSION; NITRIC-OXIDE TOXICITY; BINDING DOMAIN; GENE-DISRUPTION; HOMOLOGOUS RECOMBINATION; ADP-RIBOSYLATION; MICE RESISTANT; P53 PROTEIN; INHIBITION	Poly(ADP-ribose) polymerase (PARP) is responsible for post-translational modification of proteins in the response to numerous endogenous and environmental genotoxic agents. PARP and poly(ADP ribosyl)ation are proposed to be important for the regulation of many cellular processes such as DNA repair, cell death, chromatin functions and genomic stability. Activation of PARP is one of the early DNA damage responses, among other DNA sensing molecules, such as DNA-PK, ATM and p53. The generation and characterization of PARP deficient mouse models have been instrumental in defining the biological role of the molecule and its involvement in the pathogenesis of various diseases including diabetes, stroke. Parkinson disease, general inflammation as well as tumorigenesis, and have, therefore, provided information for the development of pharmaceutical strategies for the treatment of diseases. (C) 2001 Elsevier Science B.V. All rights reserved.	Int Agcy Res Canc, F-69008 Lyon, France		Wang, ZQ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	zqwang@iarc.fr					Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; AGARWAL S, 1988, J IMMUNOL, V140, P4187; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Aoufouchi S, 1999, J MOL BIOL, V290, P943, DOI 10.1006/jmbi.1999.2930; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Bernardi R, 1997, BBA-PROTEIN STRUCT M, V1338, P60, DOI 10.1016/S0167-4838(96)00188-4; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; BURKLE A, 1990, CANCER RES, V50, P5756; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CATENA C, 1994, MUTAT RES, V312, P1, DOI 10.1016/0165-1161(94)90002-7; CHATTERJEE S, 1991, CANCER COMMUN, V3, P71, DOI 10.3727/095535491820873551; CHATTERJEE S, 1989, EXP CELL RES, V184, P1, DOI 10.1016/0014-4827(89)90358-3; COLLINGE MA, 1994, MOL GEN GENET, V245, P686, DOI 10.1007/BF00297275; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuzzocrea S, 1999, LIFE SCI, V65, P957, DOI 10.1016/S0024-3205(99)00325-2; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 1999, NAT GENET, V23, P76; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; LAGUEUX J, 1994, MOL CELL BIOCHEM, V138, P45, DOI 10.1007/BF00928442; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MALORNI W, 1995, BIOCHEM BIOPH RES CO, V207, P715, DOI 10.1006/bbrc.1995.1246; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; MONTI D, 1994, BIOCHEM BIOPH RES CO, V199, P525, DOI 10.1006/bbrc.1994.1260; MORGAN WF, 1982, MUTAT RES, V104, P361, DOI 10.1016/0165-7992(82)90170-1; Morrison C, 1996, NUCLEIC ACIDS RES, V24, P2053, DOI 10.1093/nar/24.11.2053; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schmid G, 1999, BIOCHEM BIOPH RES CO, V255, P399, DOI 10.1006/bbrc.1999.0191; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Shah GM, 1996, BBA-MOL CELL RES, V1312, P1, DOI 10.1016/0167-4889(96)00004-3; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; SHALL S, 1995, BIOCHIMIE, V77, P313, DOI 10.1016/0300-9084(96)88140-5; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; SIMS JL, 1983, BIOCHEMISTRY-US, V22, P5188, DOI 10.1021/bi00291a019; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; STEVNSNER T, 1994, NUCLEIC ACIDS RES, V22, P4620, DOI 10.1093/nar/22.22.4620; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; VanGool L, 1997, EUR J BIOCHEM, V244, P15; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WALDMAN AS, 1991, NUCLEIC ACIDS RES, V19, P5943, DOI 10.1093/nar/19.21.5943; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; WHITACRE CM, 1995, CANCER RES, V55, P3697; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	105	337	359	3	24	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1386-1964	1873-135X		MUTAT RES-FUND MOL M	Mutat. Res.-Fundam. Mol. Mech. Mutagen.	JUN 2	2001	477	1-2			SI		97	110		10.1016/S0027-5107(01)00111-7			14	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	441WQ	WOS:000169252900011	11376691				2022-02-25	
J	de Martel, C; Georges, D; Bray, F; Ferlay, J; Clifford, GM				de Martel, Catherine; Georges, Damien; Bray, Freddie; Ferlay, Jacques; Clifford, Gary M.			Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis	LANCET GLOBAL HEALTH			English	Article							GASTRIC-CANCER; HEPATITIS-C; RISK	Background Infectious pathogens are strong and modifiable causes of cancer. The aim of this study was to improve estimates of the global and regional burden of infection-attributable cancers to inform research priorities and facilitate prevention efforts. Methods We used the GLOBOCAN 2018 database of cancer incidence and mortality rates and estimated the attributable fractions and global incidence for specific anatomical cancer sites, subsites, or histological subtypes known to be associated with ten infectious pathogens classified as human carcinogens. We calculated absolute numbers and age-standardised incidence rates (ASIR) of infection-attributable cancers at the country level. Estimates were stratified for sex, age group, and country, and were aggregated according to geographical regions and World Bank income groups. Findings We found that, for 2018, an estimated 2.2 million infection-attributable cancer cases were diagnosed worldwide, corresponding to an infection-attributable ASIR of 25.0 cases per 100 000 person-years. Primary causes were Helicobacter pylori (810000 cases, ASIR 8.7 cases per 100 000 person-years), human papillomavirus (690 000, 8.0), hepatitis B virus (360 000, 4.1) and hepatitis C virus (160 000, 1.7). Infection-attributable ASIR was highest in eastern Asia (37.9 cases per 100 000 person-years) and sub-Saharan Africa (33.1), and lowest in northern Europe (13.6) and western Asia (13.8). China accounted for a third of worldwide cancer cases attributable to infection, driven by high ASIR of H pylori (15.6) and hepatitis B virus (11.7) infection. The cancer burden attributed to human papillomavirus showed the clearest relationship with country income level (from ASIR of 6. 9 cases per 100 000 person-years in high-income countries to 16.1 in low-income countries). Interpretation Infection-attributable cancer incidence, in addition to the absolute number of cases, allows for refined geographic analyses and identification of populations with a high infection-associated cancer burden. When cancer prevention is largely considered in a non-communicable disease context, there is a crucial need for resources directed towards cancer prevention programmes that target infection, particularly in high-risk populations. Such interventions can markedly reduce the increasing cancer burden and associated mortality. Copyright (C) 2019 International Agency for Research on Cancer; licensee Elsevier.	[de Martel, Catherine; Georges, Damien; Clifford, Gary M.] Int Agcy Res Canc, Infect & Canc Epidemiol Grp, Lyon, France; [Bray, Freddie; Ferlay, Jacques] Int Agcy Res Canc, Canc Surveillance Sect, Lyon, France		de Martel, C (corresponding author), Int Agcy Res Canc, F-69372 Lyon 08, France.	demartelc@iarc.fr	Ferlay, Jacques/ABD-5058-2021	Bray, Freddie/0000-0002-3248-7787	International Agency for Research on Cancer	International Agency for Research on Cancer.	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Camargo MC, 2011, BRIT J CANCER, V105, P38, DOI 10.1038/bjc.2011.215; Chen WQ, 2019, LANCET GLOB HEALTH, V7, pE257, DOI 10.1016/S2214-109X(18)30488-1; Cooke GS, 2019, LANCET GASTROENTEROL, V4, P135, DOI 10.1016/S2468-1253(18)30270-X; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003; Ghebreyesus TA, 2018, CERVICAL CANC NON CO; Hammerl L, 2019, CANCER EPIDEMIOL, V61, P150, DOI 10.1016/j.canep.2019.06.007; Herrero R, 2014, BEST PRACT RES CL GA, V28, P1107, DOI 10.1016/j.bpg.2014.10.003; Hoff PM, 2017, SURG ONCOL CLIN N AM, V26, P57, DOI 10.1016/j.soc.2016.07.013; International Agency for Research on Cancer, 2018, DAT METH; International Agency for Research on Cancer, 2012, BIOL AG B; Li M, 2018, J VIRAL HEPATITIS, V25, P894, DOI 10.1111/jvh.12892; Mahale P, 2017, CANCER-AM CANCER SOC, V123, P1202, DOI 10.1002/cncr.30559; Marques MM, 2019, LANCET ONCOL, V20, P763, DOI 10.1016/S1470-2045(19)30246-3; Odutola M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00216; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pi?eros M., 2017, CANC INCIDENCE 5 CON; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; Plummer M, 2017, LANCET GLOB HEALTH, V5, pE140, DOI 10.1016/S2214-109X(16)30293-5; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; Qian MB, 2017, LANCET GLOB HEALTH, V5, pE139, DOI 10.1016/S2214-109X(16)30301-1; Shield KD, 2018, EUR J EPIDEMIOL, V33, P263, DOI 10.1007/s10654-017-0334-z; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; The World Bank, 2018, WORLD BANK COUNTR LE; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; WHO, 2019, CERV CANC EL STRAT; World Health Organization (WHO), 2016, GLOB HLTH SECT STRAT; Zhou X, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5718-x; Znaor A, 2018, LANCET ONCOL, V19, pE85, DOI 10.1016/S1470-2045(18)30019-6	32	274	281	35	70	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2214-109X			LANCET GLOB HEALTH	Lancet Glob. Health	FEB	2020	8	2					E180	E190		10.1016/S2214-109X(19)30488-7			11	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	KE6DZ	WOS:000508645900019	31862245	gold	Y	Y	2022-02-25	
J	Zavadil, J				Zavadil, Jiri			Integrative experimental modelling reveals novel genome-scale mutation fingerprints of carcinogens	ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY			English	Meeting Abstract	Fall National Meeting and Exposition of the American-Chemical-Society (ACS)	AUG 25-29, 2019	San Diego, CA	Amer Chem Soc					[Zavadil, Jiri] WHO, IARC, Mech Carcinogenesis, Lyon, Rhone Alpes, France			zavadilj@iarc.fr	Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562				0	0	0	0	0	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0065-7727			ABSTR PAP AM CHEM S	Abstr. Pap. Am. Chem. Soc.	AUG 25	2019	258					35							1	Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Chemistry	LC1AO	WOS:000525061505407					2022-02-25	
J	Loomis, D; Guyton, KZ; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Mattock, H; Straif, K				Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi; Straif, Kurt		Int Agcy Res Canc Monograph	Carcinogenicity of drinking coffee, mate, and very hot beverages	LANCET ONCOLOGY			English	News Item							BLADDER-CANCER; ESOPHAGEAL CANCER; SOUTH-AMERICA; RISK; CONSUMPTION; METAANALYSIS; TEA		[Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi; Straif, Kurt; Int Agcy Res Canc Monograph] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France		Loomis, D (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Loomis, Dana/AAE-3988-2019; Guha, Neela/AAG-3989-2021; Lachenmeier, Dirk W./A-3210-2008	Guha, Neela/0000-0003-3991-4662; Lachenmeier, Dirk W./0000-0002-3115-864X; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Loomis, Dana/0000-0003-3297-5200	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER		[Anonymous], 1991, IARC Monogr Eval Carcinog Risks Hum, V51, P1; Bravi F, EUR J CANC IN PRESS; Castellsague X, 2000, INT J CANCER, V88, P658, DOI 10.1002/1097-0215(20001115)88:4&lt;658::AID-IJC22&gt;3.0.CO;2-T; Correa TAF, 2012, PLANT FOOD HUM NUTR, V67, P277, DOI 10.1007/s11130-012-0297-x; International Agency for Research on Cancer, 2016, IARC MONOGR IN PRESS, V116; Islami F, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b929; Je Y, 2012, INT J CANCER, V131, P1700, DOI 10.1002/ijc.27408; Jiang WJ, 2013, GYNECOL ONCOL, V129, P620, DOI 10.1016/j.ygyno.2013.03.014; Li ZG, 2003, ONCOL REP, V10, P421; Lubin JH, 2014, CANCER EPIDEM BIOMAR, V23, P107, DOI 10.1158/1055-9965.EPI-13-0796; Michaud DS, 1999, NEW ENGL J MED, V340, P1390, DOI 10.1056/NEJM199905063401803; Nagano J, 2000, INT J CANCER, V86, P132, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;132::AID-IJC21&gt;3.0.CO;2-M; Rapozo DC, 2016, EXP MOL PATHOL, V1, P1; Tai J, 2010, NUTR CANCER, V62, P1044, DOI 10.1080/01635581.2010.492083; Zeegers MPA, 2001, CANCER CAUSE CONTROL, V12, P231, DOI 10.1023/A:1011245627593	15	132	134	4	44	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUL	2016	17	7					877	878		10.1016/S1470-2045(16)30239-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	DQ1FO	WOS:000378947100049	27318851				2022-02-25	
J	Wild, CP; Straif, K				Wild, Christopher P.; Straif, Kurt			Expert Working Groups-a reliable recipe Response	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Letter							PLEA		[Wild, Christopher P.; Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon 08, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			Erren TC, 2011, INT J EPIDEMIOL, V40, P1727, DOI 10.1093/ije/dyr155; McLaughlin JK, 2010, INT J EPIDEMIOL, V39, P1679, DOI 10.1093/ije/dyp359; Michaels D, 2008, DOUBT THEIR PRODUCT; Wild CP, 2011, INT J EPIDEMIOL, V40, P253, DOI 10.1093/ije/dyq038	4	4	4	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	DEC	2011	40	6					1730	1731		10.1093/ije/dyr157			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	859HW	WOS:000297868500036		Bronze			2022-02-25	
J	Herceg, Z				Herceg, Z.			Is epigenetics the holy grail of cancer research?	EJC SUPPLEMENTS			English	Meeting Abstract	21st Meeting of the European-Association-for-Cancer-Research	JUN 26-29, 2010	Oslo, NORWAY	European Assoc Canc Res					[Herceg, Z.] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon, France									0	0	0	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	JUN	2010	8	5				317	84	84		10.1016/S1359-6349(10)71121-6			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	737XF	WOS:000288603100310					2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R.			HPV vaccination: the promise & problems	INDIAN JOURNAL OF MEDICAL RESEARCH			English	Review						Cervical cancer; challenges; effectiveness; prevention; vaccination	HUMAN-PAPILLOMAVIRUS TYPE-16; PARTICLE VACCINE; YOUNG-WOMEN; CERVICAL-CANCER; DOUBLE-BLIND; EFFICACY; INFECTION	Four-fifths of the cervical cancer burden in the world is experienced in developing countries. HPV genotypes 16 and 18 account for 70 per cent of cervical cancers and currently available vaccines targeting these two types confer a high degree of protection against HPV 16/18 infection and related cervical precancerous lesions. However, widespread implementation of HPV vaccination programs are challenged by the unaffordable high costs of the vaccines and the lack of effective vaccine delivery platforms for sexually naive girls. Other unresolved issues include long-term protection, cross-protection against HPV types not included in the vaccine and whether booster doses will be needed. Sensitivities associated with a vaccine preventing a sexually transmitted infection in girls, lack of awareness, public demand and political will, lack of coordination between cancer control, sexual and reproductive health and vaccine delivery services are additional challenges. Reduced costs, simple vaccine regimes and strengthening vaccine delivery platforms for adolescents should eventually facilitate HPV vaccine introduction in developing countries.	Int Agcy Res Canc, Screening Grp, F-69008 Lyon, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	sankar@iarc.fr					Agosti JM, 2007, NEW ENGL J MED, V356, P1908, DOI 10.1056/NEJMp078053; Brown DR, 2004, VACCINE, V22, P2936, DOI 10.1016/j.vaccine.2003.11.059; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; FERLAY J, 2004, 5 IARC; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; IARC: International Agency for Research on Cancer, 2007, IARC MON EV CARC RIS, V90; Kane MA, 2006, VACCINE, V24, P132, DOI 10.1016/j.vaccine.2006.05.128; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Koutsky LA, 2006, VACCINE, V24, P114, DOI 10.1016/j.vaccine.2006.06.014; Mahoney RT, 1999, VACCINE, V17, P646, DOI 10.1016/S0264-410X(98)00246-1; Mao C, 2006, OBSTET GYNECOL, V107, P18, DOI 10.1097/01.AOG.0000192397.41191.fb; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Sankaranarayanan R, 2006, INT J GYNECOL OBSTET, V95, pS205, DOI 10.1016/S0020-7292(06)60035-0; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Villa LL, 2006, VACCINE, V24, P5571, DOI 10.1016/j.vaccine.2006.04.068	20	23	24	0	7	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0971-5916			INDIAN J MED RES	Indian J. Med. Res.	SEP	2009	130	3					322	326					5	Immunology; Medicine, General & Internal; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; General & Internal Medicine; Research & Experimental Medicine	517KM	WOS:000271612300015	19901441				2022-02-25	
J	Franceschi, S; Clifford, GM				Franceschi, Silvia; Clifford, Gary M.			Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials	INTERNATIONAL JOURNAL OF CANCER			English	Letter							YOUNG-WOMEN; INFECTION; LESIONS		[Franceschi, Silvia; Clifford, Gary M.] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Clifford G, 2006, VACCINE, V24, P26, DOI 10.1016/j.vaccine.2006.05.026; *FUTURE 2 STUD GRO, 2007, LANCET, V139, P1861; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Winer RL, 2005, J INFECT DIS, V191, P731, DOI 10.1086/427557; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4	8	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	FEB 1	2008	122	3					719	720		10.1002/ijc.23112			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	248DX	WOS:000252132900034	17943728	Bronze			2022-02-25	
J	Mansour, M; Touka, M; Hasan, U; Bellopede, A; Smet, A; Accardi, R; Gabet, AS; Sylla, BS; Tommasino, M				Mansour, Mariam; Touka, Majid; Hasan, Uzma; Bellopede, Angelica; Smet, Anouk; Accardi, Rosita; Gabet, Anne-Sophie; Sylla, Bakary S.; Tommasino, Massimo			E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development	VIROLOGY			English	Article						HPV26, 53 and 66; E7; cell cycle deregulation; intermediate risk; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPES; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GROWTH ARREST; PHOSPHORYLATION; DEGRADATION	Epidemiological studies have demonstrated that 15 different mucosal human papillomavirus (HPV) types of the genus alpha of the HPV phylogetic tree are classified as high risk for cervical cancer development. Three additional HPV types of the same genus, HPV26, 53 and 66, are classified as probable high-risk types. In this study, we have characterized the biological properties of the E7 oncoproteins from these three HPV types. All of the corresponding E7 proteins were able to associate with retinoblastoma protein (pRb) and up-regulated the expression of several positive cell cycle regulators, i.e. CDK2, cyclin A and cylin E. However, HPV26 E7 appears to be more efficient than HPV53 and 66 E7 in up-regulating the transcription of cyclin A. Unlike E7 from the high-risk type HPV16 protein, HPV26, 53 and 66 did not efficiently promote pRb degradation. In addition, E7 from these viruses was able to promote proliferation of primary human keratinocytes and circumvent G1 arrest imposed by overexpression of p16(INK4a) but with less efficiency than the high-risk HPV16 E7. Together, our data show that in vitro properties of these E7 proteins correlate with the epidemiological classification of HPV26, 53 and 66 as HPV types with an intermediate risk for cervical cancer development. (C) 2007 Elsevier Inc. All rights reserved.	Int Agcy Res Canc, Infect & Canc Biol Grp, F-69008 Lyon, France		Tommasino, M (corresponding author), Int Agcy Res Canc, Infect & Canc Biol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	tommasino@iarc.fr	hasan, uzma A/G-3247-2013	Hasan, Uzma/0000-0002-1770-5539			Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Hiller T, 2006, CANCER EPIDEM BIOMAR, V15, P1262, DOI 10.1158/1055-9965.EPI-05-0778; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Malanchi I, 2004, J VIROL, V78, P13769, DOI 10.1128/JVI.78.24.13769-13778.2004; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; O'Brien PM, 2003, TRENDS MICROBIOL, V11, P300, DOI 10.1016/S0966-842X(03)00145-8; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tomakidi P, 1998, CELL TISSUE RES, V292, P355, DOI 10.1007/s004410051066; Tomakidi P, 1997, J PERIODONTAL RES, V32, P388, DOI 10.1111/j.1600-0765.1997.tb00549.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; [No title captured]	23	15	15	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0042-6822			VIROLOGY	Virology	OCT 10	2007	367	1					1	9		10.1016/j.virol.2007.05.005			9	Virology	Science Citation Index Expanded (SCI-EXPANDED)	Virology	216TS	WOS:000249902500001	17568647	Bronze			2022-02-25	
J	Vrijheid, M				Vrijheid, Martine			Recall error and bias in epidemiologic studies of mobile phone use and cancer risk	EPIDEMIOLOGY			English	Meeting Abstract	ISEE/ISEA 2006 Conference	2006	Paris, FRANCE	ISEE, ISEA					Int Agcy Res Canc, Radiat Grp, F-69372 Lyon, France				Vrijheid, Martine/H-2702-2014	Vrijheid, Martine/0000-0002-7090-1758				0	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	NOV	2006	17	6		S			S73	S73		10.1097/00001648-200611001-00164			1	Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	097JL	WOS:000241443400164					2022-02-25	
J	Gray, N				Gray, N			The future of the cigarette and its market	LANCET			English	Editorial Material							SMOKING		Int Agcy Res Canc, Directors Off, F-69008 Lyon, France		Gray, N (corresponding author), Int Agcy Res Canc, Directors Off, F-69008 Lyon, France.	nigel@uicc.org					Borland R, 2004, ADDICTION, V99, P529, DOI 10.1111/j.1360-0443.2004.00649.x; Borland R, 2003, TOB CONTROL, V12, P374, DOI 10.1136/tc.12.4.374; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; Gray N, 2000, TOB CONTROL, V9, P90, DOI 10.1136/tc.9.1.90; Gray N, 2003, ANN ONCOL, V14, P353, DOI 10.1093/annonc/mdg103; GRAY N, IN PRESS NICOTINE TO; Henningfield JE, 1998, TOB CONTROL, V7, P281, DOI 10.1136/tc.7.3.281; Jarvis MJ, 2001, JNCI-J NATL CANCER I, V93, P134, DOI 10.1093/jnci/93.2.134; Kozlowski LT, 2002, TOB CONTROL, V11, pI40, DOI 10.1136/tc.11.suppl_1.i40; Kozlowski LT, 2000, LANCET, V355, P2159, DOI 10.1016/S0140-6736(00)02390-4; Laugesen M, 2003, TOB CONTROL, V12, P406, DOI 10.1136/tc.12.4.406; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; *US PHS, 1996, FTC METH DET TAR NIC	13	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					231	232		10.1016/S0140-6736(04)16692-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	WOS:000222784900009	15262086				2022-02-25	
J	Biernat, W; Huang, H; Yokoo, H; Kleihues, P; Ohgaki, H				Biernat, W; Huang, H; Yokoo, H; Kleihues, P; Ohgaki, H			Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas	BRAIN PATHOLOGY			English	Article							GROWTH-FACTOR-RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; MONOCLONAL-ANTIBODY; GENE AMPLIFICATION; MALIGNANT GLIOMAS; CANCER-THERAPY; BRAIN-TUMORS; CELLS; MUTATIONS; VARIANT	EGFR amplification is a frequent genetic alteration in primary (de novo) glioblastomas, and is often associated with structural alterations. Most common is variant III (EGFRvIII), which results from a non-random 801 bp in-frame deletion of exons 2 to 7 of the EGFR gene. We assessed amplification and overexpression of EGFRvIII and wild-type EGFR in 30 glioblastoma biopsies. Immunohistochemically, EGFR overexpression was observed in 20 (67%) of 30 glioblastomas. Eight (27%) cases also showed immunoreactivity to an EGFRvIII antibody. In 6 of these cases, the pattern of EGFR and EGFRvIII overexpression was compared in serial sections: In 4 cases, areas with immunoreactivity to EGFRvIII largely coincided with wild-type EGFR expression. In the other 2 cases, the areas immunoreactive to EGFRvIII were significantly less extensive than EGFR-positive areas. To assess whether EGFRvIII is predominantly amplified in tumors with concurrent wild-type EGFR amplification, we carried out real-time quantitative PCR using 2 sets of primers located in exon 2 and intron 15 of the EGFR gene. A >5-fold ratio of relative copy numbers between intron 15 (present both in wild-type EGFR and EGFRvIII) and exon 2 (present only in wild-type EGFR, but missing in EGFRvIII) suggested predominant amplification of EGFRvIII in only 3 (10%) of 30 glioblastomas. The observation that intratumoral wild-type EGFR overexpression is often more extensive and that predominant amplification of EGFRvIII is a rare event would limit the effectiveness of therapeutic approaches based on selective targeting of EGFRvIII.	Int Agcy Res Canc, F-69372 Lyon, France		Ohgaki, H (corresponding author), Int Agcy Res Canc, Unit Mol Pathol, 150 Cours Albert Thomas, F-60372 Lyon 08, France.	ohgaki@iarc.fr					Archer GE, 1999, CLIN CANCER RES, V5, P2646; Cavenee WK, 2002, CARCINOGENESIS, V23, P683, DOI 10.1093/carcin/23.5.683; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; DIEDRICH U, 1995, J NEUROL, V242, P683, DOI 10.1007/BF00866920; Ding H, 2003, CANCER RES, V63, P1106; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Feldkamp MM, 1999, NEUROSURGERY, V45, P1442, DOI 10.1097/00006123-199912000-00034; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; Frederick L, 2000, NEURO-ONCOLOGY, V2, P159, DOI 10.1093/neuonc/2.3.159; Frederick L, 2000, CANCER RES, V60, P1383; Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Kuan CT, 1999, CLIN CANCER RES, V5, P1539; Lal A, 2002, CANCER RES, V62, P3335; Mishima K, 2001, CANCER RES, V61, P5349; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Narita Y, 2002, CANCER RES, V62, P6764; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Sampson JH, 2000, P NATL ACAD SCI USA, V97, P7503, DOI 10.1073/pnas.130166597; SCHWECHHEIMER K, 1995, INT J CANCER, V62, P145, DOI 10.1002/ijc.2910620206; Scott JN, 1998, CAN J NEUROL SCI, V25, P197, DOI 10.1017/S0317167100034016; Stewart JE, 2002, RADIOLOGY, V225, P337; Stragliotto G, 1996, EUR J CANCER, V32A, P636, DOI 10.1016/0959-8049(95)00592-7; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1998, J NEUROVIROL, V4, P148, DOI 10.3109/13550289809114515; Wikstrand CJ, 1997, CANCER RES, V57, P4130; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	38	112	116	0	6	INT SOC NEUROPATHOLOGY	LOS ANGELES	UCLA MEDICAL CENTER, SECTION NEUROPATHOLGY, C H S 18-126, LOS ANGELES, CA 90095-1732 USA	1015-6305			BRAIN PATHOL	Brain Pathol.	APR	2004	14	2					131	136		10.1111/j.1750-3639.2004.tb00045.x			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	820SZ	WOS:000221410900002	15193025	Green Published			2022-02-25	
J	Bray, F; Tyczynski, JE; Parkin, DM				Bray, F; Tyczynski, JE; Parkin, DM			Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries	EUROPEAN JOURNAL OF CANCER			English	Article						lung neoplasms; mortality; epidemiology; European Union; smoking; time trends; registries; data collection; public health	PERIOD-COHORT MODELS; CIGARETTE-SMOKING; AGE-PERIOD; TEMPORAL VARIATION; BETA-CAROTENE; TRENDS; RATES; SPAIN; RISK	Lung cancer, the most common cause of cancer death in the European Union (EU), continues to have an enormous impact on the health experience of the men and women living in the constituent countries. Information on the course of the lung cancer epidemic is essential in order to formulate an effective cancer control policy. This paper examines recent trends in lung cancer mortality rates in men and women in each of the 15 countries, comparing cross-sectional rates of death in younger (aged 30-64 years) and older populations (aged 65 years or over), and the age, period of death, and birth cohort influences in the younger age group. The latter analysis establishes the importance of year of birth, related to modifications in the tobacco habit among recently born generations. The stage of evolution of the lung cancer epidemic varies markedly by sex and country in terms of the direction, magnitude, and phase of development of national trends. In males, there is some consistency in the direction of the trends between EU countries, declines are apparent in most countries, at least in younger men, with rates in older men either reaching a plateau, or also falling. In younger persons, a decreasing risk of lung cancer death reflects changes in successive birth cohorts, due to modifications in the smoking habit from generation to generation, although these developments are in very different phases across countries. Portugal is the exception to the male trends; there are increases in mortality in both age groups, with little sign of a slowing down by birth cohort. In women, there are unambiguous upsurges in rates seen in younger and older women in almost all EU countries in recent decades, and little sign that the epidemic has or will soon reach a peak. The exceptions are the United Kingdom (UK) and Ireland, where lung cancer death rates are now declining in younger women and stabilising in older women, reflecting a declining risk in women born since about 1950. It is too early to say whether the observed plateau or decline in rates in women born very recently in several countries is real or random. To ascertain whether recent trends in lung cancer mortality will continue, trends in cigarette consumption should also be evaluated. Where data are available by country, the proportion of adult male smokers has, by and large, fallen steadily in the last five decades. In women, recent smoking trends are downwards in Belgium, Denmark, Sweden and the Netherlands, although in Austria and Spain, large increases in smoking prevalence amongst adults are emerging. Unambiguous public health messages must be effectively conveyed to the inhabitants of the EU if the lung cancer epidemic is to be controlled. It is imperative that antitobacco strategies urgently target women living in the EU, in order to halt their rapidly increasing risk of lung cancer, and prevent unnecessary, premature deaths among future generations of women. (C) 2003 Elsevier Ltd. All rights reserved.	Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon 08, France		Bray, F (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	bray@iarc.fr					Agudo A, 2000, INT J CANCER, V88, P820, DOI 10.1002/1097-0215(20001201)88:5&lt;820::AID-IJC21&gt;3.0.CO;2-J; Ahrens W, 1998, Int J Occup Environ Health, V4, P236; Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; DAY NE, 1982, TRENDS CANCER INCIDE, P51; DOLL R, 1967, INT J CANCER, V2, P269, DOI 10.1002/ijc.2910020310; Doll R., 1950, BRIT MED J, V143, P329; ESTEVE J, 1990, ANN NY ACAD SCI, V609, P77, DOI 10.1111/j.1749-6632.1990.tb32058.x; *EUR NETW SMOK PRE, 1998, SOM LIK LIGHT WOM SM; Ferlay J.J., 1999, IARC CANC BASE, V4; FOREY B, 2002, INT SMOKING STAT COL; Geddes M, 1994, Eur J Cancer Prev, V3, P31, DOI 10.1097/00008469-199401000-00005; Haidinger G, 1998, PREV MED, V27, P50, DOI 10.1006/pmed.1997.0234; HOLFORD TR, 1983, BIOMETRICS, V39, P311, DOI 10.2307/2531004; *INT AG RES CANC, 1986, TOB SMOK EV CARC RIS, V38; Janssen-Heijnen MLG, 1998, EUR J CANCER, V34, P2191, DOI 10.1016/S0959-8049(98)00312-8; Kreuzer M, 2000, BRIT J CANCER, V82, P227; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; LOPEZ AD, 1990, IARC SCI PUBL, V103, P57; LOPEZABENTE G, 1995, CANCER EPIDEM BIOMAR, V4, P813; LOPEZABENTE G, 1993, CANCER CAUSE CONTROL, V4, P539, DOI 10.1007/BF00052429; McNally RJQ, 1997, INT J EPIDEMIOL, V26, P32, DOI 10.1093/ije/26.1.32; Molarius A, 2001, AM J PUBLIC HEALTH, V91, P206, DOI 10.2105/AJPH.91.2.206; MUIR CS, 1994, CANCER SURV, V20, P5; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PERCY C, 1989, AM J EPIDEMIOL, V129, P934, DOI 10.1093/oxfordjournals.aje.a115226; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; Peto R, 1986, IARC Sci Publ, P23; PISANI P, 2000, SOC96200504 EU; Regidor E, 2001, PREV MED, V33, P241, DOI 10.1006/pmed.2001.0872; *ROYAL COLL PHYS, 1971, SMOK HLTH NOW NEW RE; *ROYAL COLL PHYS, 1977, SMOK HLTH THIRD REP; Rylander R, 1996, LUNG CANCER-J IASLC, V14, pS75; Samet J.M., 1994, EPIDEMIOLOGY LUNG CA; SARACCI R, 1994, EPIDEMIOLOGY LUNG CA, P465; Simonato L, 2001, INT J CANCER, V91, P876, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1139>3.0.CO;2-7; *STAT SWED, 1997, TOB CONS 1970 1994 M; *US DHHS, 1982, HLTH CONS SMOK CANC; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P328; Xu ZY, 1996, LUNG CANCER-J IASLC, V14, pS149, DOI 10.1016/S0169-5002(96)90220-2	41	84	86	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	JAN	2004	40	1					96	125		10.1016/j.ejca.2003.08.005			30	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	770XW	WOS:000188757500022	14687795				2022-02-25	
J	Parkin, D				Parkin, D			Trends in global cancer mortality revisited	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Meeting Abstract	2nd Annual AACR International Conference on Frontiers in Cancer Prevention Research	OCT 26-30, 2003	PHOENIX, ARIZONA	Amer Assoc Canc Res, Pfizer, AstraZeneca, Canc Res & Prevent Fdn, SuperGen, AFLAC Inc, Avon Fdn, Bristol Myers Squibb, Eli Lilly & Co, NCI, Takeda Pharmaceut N Amer Inc, Calif Breast Canc Res Program					IARC, Unit Descript Epidemiol, Lyon, France									0	0	0	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965			CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	NOV	2003	12	11	2	S			1362S	1363S					2	Oncology; Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	752GT	WOS:000187153300327					2022-02-25	
J	Boffetta, P				Boffetta, P			Molecular epidemiology: A tool for understanding mechanisms of disease	EUROPEAN JOURNAL OF SURGERY			English	Article						biomarkers; molecular epidemiology; bias; confounding; statistical power	RISK; SUSCEPTIBILITY; POLYMORPHISMS; ENVIRONMENT; BIOMARKERS; EXPOSURE	The use of biomarkers in medicine, and in epidemiology in particular, is not new but recent developments in molecular biology and genetics have increased the opportunities for their use. Epidemiological studies based on biomarkers, which belong to the discipline defined as 'molecular epidemiology', offer new avenues to investigate associations between genetic and environmental factors, diseases, and medical interventions. Important recent contributions of molecular epidemiology to cancer research include the definitive evidence of the carcinogenicity of aflatoxin in humans, and the elucidation of the mechanisms of tobacco-related carcinogenesis. However, molecular epidemiology studies are subject to problems of design and analysis similar to those of 'traditional' epidemiological studies. If biomarkers offer new opportunities to overcome some of the limitations of epidemiology, their added value over traditional approaches should be systematically assessed. Biomarkers should be validated though transitional studies; consideration to sources of bias and confounding in molecular epidemiology studies should be no less stringent than in traditional studies.	Int Agcy Res Canc, Unit Environm Canc Epidemiol, FR-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, Unit Environm Canc Epidemiol, 150 Cours Albert Thomas, FR-69008 Lyon, France.	boffetta@iarc.fr					Ambrosone CB, 1996, JAMA-J AM MED ASSOC, V276, P1494, DOI 10.1001/jama.276.18.1494; [Anonymous], 1987, IARC MON EV CARC S7, V1 to 42, P83; BLOT WJ, 1996, CANC EPIDEMIOLOGY PR, P666; Bonassi S, 2000, CANCER RES, V60, P1619; d'Errico A, 1999, IARC Sci Publ, P323; GREENLAND S, 1994, ENVIRON HEALTH PERSP, V102, P33, DOI 10.1289/ehp.94102s833; HERNANDEZ TM, 1999, ENV HLTH PERSPECT, V106, P385; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; INT AGCY RES CANC, 1993, IARC MONOG EVAL CARC, V56, P245; International Agency for Research on Cancer. Ethylene oxide, 1994, IARC MON EV CARC RIS, V60, P73; London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3; PEARCE N, 1995, EPIDEMIOLOGY, V6, P190, DOI 10.1097/00001648-199503000-00020; PERERA FP, 1982, J CHRON DIS, V35, P581, DOI 10.1016/0021-9681(82)90078-9; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; ROTHMAN KJ, 1996, MODERN EPIDEMIOLOGY, V2; ROTHMAN N, 1993, MOL EPIDEMIOLOGY PRI, P565; SANTELLA RM, 1988, CARCINOGENESIS, V9, P1265, DOI 10.1093/carcin/9.7.1265; SCHULTE PA, 1993, MOL EPIDEMIOLOGY; SCHULTE PA, 1997, IARC SCI PUBL, V142, P19; Slattery ML, 1998, CANCER EPIDEM BIOMAR, V7, P1079; SMITH G, 1999, IARC SCI PUBL, V148, P209; Taioli E, 1999, CANCER EPIDEM BIOMAR, V8, P727; Toniolo P, 1997, IARC SCI PUBLICATION, V142; TRUETT J, 1967, J CHRON DIS, V20, P511, DOI 10.1016/0021-9681(67)90082-3; Tucker J D, 1997, IARC Sci Publ, P185; Vineis P, 1997, IARC Sci Publ, P59; Vineis P, 1999, IARC SCI PUBLICATION, V148; Yang QH, 1997, EPIDEMIOL REV, V19, P33, DOI 10.1093/oxfordjournals.epirev.a017944; [No title captured]	31	4	4	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1102-4151			EUR J SURG	Eur. J. Surg.		2002	168			587			62	69					8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	670DE	WOS:000182391500010	16144203				2022-02-25	
J	White, V				White, ValerieA.			Understanding and Classification of Ocular Lymphomas	OCULAR ONCOLOGY AND PATHOLOGY			English	Article						Non-Hodgkin lymphoma; Ocular adnexal lymphoma; Vitreoretinal lymphoma	POLYMERASE-CHAIN-REACTION; AMERICAN JOINT COMMITTEE; B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; ADNEXAL LYMPHOMA; 7TH EDITION; EPIDEMIOLOGY; MUTATIONS; ORBIT; FREQUENCY	Background: Lymphomas that involve the tissues of the ocular adnexae and the eye itself can be confusing for both the new and seasoned learner alike. In this review, I present a simple way of classifying these disorders that will help to facilitate understanding of these myriad entities. Summary: Classifications of lymphomas have changed significantly over the last 40 years, but in recent decades, the basic structure of the WHO classification has remained the same, facilitating understanding. Key Messages: The ocular lymphomas can be divided into those that are external to the eye (ocular adnexae) and those that are internal (vitreoretinal and uveal). At each of these sites specific subtypes of lymphoma are common. Focusing on these common subtypes can aid the learner to create a scaffold that enables current understanding and upon which they can build for the future. (c) 2019 S. Karger AG, Basel	[White, ValerieA.] Int Agcy Res Canc, WHO IARC Classificat Tumours Grp, 150 Cours Albert Thomas, FR-69372 Lyon 08, France		White, V (corresponding author), Int Agcy Res Canc, WHO IARC Classificat Tumours Grp, 150 Cours Albert Thomas, FR-69372 Lyon 08, France.	whitev@iarc.fr					Allen CE, 2018, NEW ENGL J MED, V379, P856, DOI 10.1056/NEJMra1607548; Araujo I, 2017, ASIA-PAC J OPHTHALMO, V6, P283, DOI 10.22608/APO.2017150; Bonzheim I, 2015, BLOOD, V126, P76, DOI 10.1182/blood-2015-01-620518; Coupland SE, 2008, CLIN EXP OPHTHALMOL, V36, P564, DOI 10.1111/j.1442-9071.2008.01843.x; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01690636, 10.1182/blood-2016-01-690636]; Emile JF, 2014, BLOOD, V124, P3016, DOI 10.1182/blood-2014-04-570937; Ferlay J, 2018, GLOBAL CANC OBSERVAT; Ferry JA, 2007, AM J SURG PATHOL, V31, P170, DOI 10.1097/01.pas.0000213350.49767.46; Go H, 2014, HISTOPATHOLOGY, V65, P261, DOI 10.1111/his.12416; Hassan WM, 2016, INT J OPHTHALMOL-CHI, V9, P1808, DOI 10.18240/ijo.2016.12.18; Husain A, 2007, CANCER, V110, P809, DOI 10.1002/cncr.22843; Jaffe E.S., 2001, PATHOLOGY GENETICS T; Kim UR, 2010, OPHTHAL PLAST RECONS, V26, P315, DOI 10.1097/IOP.0b013e3181c32f2f; KNOWLES DM, 1990, HUM PATHOL, V21, P959, DOI 10.1016/0046-8177(90)90181-4; Knudsen MKH, 2017, JAMA OPHTHALMOL, V135, P1367, DOI 10.1001/jamaophthalmol.2017.4810; Levasseur SD, 2013, JAMA OPHTHALMOL, V131, P50, DOI 10.1001/jamaophthalmol.2013.569; Looi A, 2005, OPHTHALMOLOGY, V112, P114, DOI 10.1016/j.ophtha.2004.07.025; Moslehi R, 2011, EXPERT REV OPHTHALMO, V6, P175, DOI 10.1586/EOP.11.16; Moslehi R, 2011, EXPERT REV OPHTHALMO, V6, P181, DOI 10.1586/EOP.11.15; Munch-Petersen HD, 2015, JAMA OPHTHALMOL, V133, P165, DOI 10.1001/jamaophthalmol.2014.4644; Olsen TG, 2019, AM J OPHTHALMOL, V199, P44, DOI 10.1016/j.ajo.2018.11.002; Olsen TG, 2019, SURV OPHTHALMOL, V64, P45, DOI 10.1016/j.survophthal.2018.08.002; Peleg A, 2009, ORBIT, V28, P80, DOI 10.1080/01676830802656869; Rasmussen PK, 2015, ACTA OPHTHALMOL, V93, P184, DOI 10.1111/aos.12525; Rasmussen PK, 2014, JAMA OPHTHALMOL, V132, P851, DOI 10.1001/jamaophthalmol.2014.376; Rath S, 2014, ORBIT, V33, P23, DOI 10.3109/01676830.2013.842257; Schreuder MI, 2017, J HEMATOP, V10, P91, DOI 10.1007/s12308-017-0302-2; Shiels MS, 2016, BRIT J HAEMATOL, V174, P417, DOI 10.1111/bjh.14073; Sivak-Callcott JA, 2006, BRIT J OPHTHALMOL, V90, P602, DOI 10.1136/bjo.2005.085894; Smith A, 2015, BRIT J CANCER, V112, P1575, DOI 10.1038/bjc.2015.94; Sniegowski MC, 2014, BRIT J OPHTHALMOL, V98, P1255, DOI 10.1136/bjophthalmol-2013-304847; Swerdlow S., 2017, WHO CLASSIFICATION T; Swerdlow S. H., 2017, CLASSIFICATION TUMOU; Swerdlow SH, 2013, MODERN PATHOL, V26, pS1, DOI 10.1038/modpathol.2012.177; WHITE V, 1987, CAN J OPHTHALMOL, V22, P362; White VA, 1999, ARCH OPHTHALMOL-CHIC, V117, P761; White VA, 1996, MODERN PATHOL, V9, P1052; Wittenberg LA, 2008, OPHTHALMOLOGY, V115, P1944, DOI 10.1016/j.ophtha.2008.05.022; Wotherspoon AC, 2013, MODERN PATHOL, V26, pS29, DOI 10.1038/modpathol.2012.183	39	5	6	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	2296-4681	2296-4657		OCUL ONCOL PATHOL	Ocul. Oncol. Pathol.	OCT	2019	5	6					379	386		10.1159/000499845			8	Ophthalmology	Emerging Sources Citation Index (ESCI)	Ophthalmology	JE1OA	WOS:000490463200001	31768360	Green Published, Bronze			2022-02-25	
J	Franceschi, S; Rinaldi, S				Franceschi, Silvia; Rinaldi, Sabina			TSH, Thyroid Hormone, and PTC-Letter	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Letter							CANCER		[Franceschi, Silvia; Rinaldi, Sabina] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	Franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Huang H, 2017, CANCER EPIDEM BIOMAR, V26, P1209, DOI 10.1158/1055-9965.EPI-16-0845; Kussmaul T, 2014, CLIN LAB, V60, P1551, DOI 10.7754/Clin.Lab.2014.130328; Laurberg P, 2011, NAT REV ENDOCRINOL, V7, P232, DOI 10.1038/nrendo.2011.13; Rinaldi S, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju097; Vaccarella S, 2016, NEW ENGL J MED, V375, P614, DOI 10.1056/NEJMp1604412	5	3	3	0	1	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965	1538-7755		CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	FEB	2018	27	2					227	227		10.1158/1055-9965.EPI-17-0727			1	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	FU8PP	WOS:000424116400014	29431627	Bronze			2022-02-25	
J	Lee, HS				Lee, Ho-Sun			Impact of Maternal Diet on the Epigenome during In Utero Life and the Developmental Programming of Diseases in Childhood and Adulthood	NUTRIENTS			English	Review						epigenetics; development; maternal nutrients; metabolic syndrome	DIFFERENTIALLY METHYLATED REGIONS; FOLIC-ACID USE; DNA METHYLATION; INSULIN-RESISTANCE; GENE-EXPRESSION; IGF2 GENE; GLUCOCORTICOID-RECEPTOR; EPIGENETIC REGULATION; PROMOTER METHYLATION; CHROMATIN-STRUCTURE	Exposure to environmental factors in early life can influence developmental processes and long-term health in humans. Early life nutrition and maternal diet are well-known examples of conditions shown to influence the risk of developing metabolic diseases, including type 2 diabetes mellitus and cardiovascular diseases, in adulthood. It is increasingly accepted that environmental compounds, including nutrients, can produce changes in the genome activity that, in spite of not altering the DNA sequence, can produce important, stable and, in some instances, transgenerational alterations in the phenotype. Epigenetics refers to changes in gene function that cannot be explained by changes in the DNA sequence, with DNA methylation patterns/histone modifications that can make important contributions to epigenetic memory. The epigenome can be considered as an interface between the genome and the environment that is central to the generation of phenotypes and their stability throughout the life course. To better understand the role of maternal health and nutrition in the initiation and progression of diseases in childhood and adulthood, it is necessary to identify the physiological and/or pathological roles of specific nutrients on the epigenome and how dietary interventions in utero and early life could modulate disease risk through epigenomic alteration.	[Lee, Ho-Sun] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon 08, France		Lee, HS (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hs4369@gmail.com	Lee, Ho-Sun/AAD-6112-2019	Lee, Ho-Sun/0000-0003-2864-015X			Aagaard-Tillery KM, 2008, J MOL ENDOCRINOL, V41, P91, DOI 10.1677/JME-08-0025; Aiken CE, 2014, HUM REPROD UPDATE, V20, P63, DOI 10.1093/humupd/dmt043; Alejandro EU, 2014, J CLIN INVEST, V124, P4395, DOI 10.1172/JCI74237; Balbus JM, 2013, LANCET, V381, P3, DOI 10.1016/S0140-6736(12)61609-2; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Barker DJP, 2002, J HYPERTENS, V20, P1951, DOI 10.1097/00004872-200210000-00013; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Blom HJ, 2011, J INHERIT METAB DIS, V34, P75, DOI 10.1007/s10545-010-9177-4; Bogdarina I, 2007, CIRC RES, V100, P520, DOI 10.1161/01.RES.0000258855.60637.58; Borengasser SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084209; Burdge GC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028282; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Chango A, 2015, NUTRIENTS, V7, P2748, DOI 10.3390/nu7042748; Chen G, 2015, MOL NUTR FOOD RES, V59, P293, DOI 10.1002/mnfr.201400483; Chen H, 2008, ENDOCRINOLOGY, V149, P5348, DOI 10.1210/en.2008-0582; Chen PY, 2013, PHYSIOL GENOMICS, V45, P565, DOI 10.1152/physiolgenomics.00034.2013; COLE TJ, 1993, J STEROID BIOCHEM, V47, P49, DOI 10.1016/0960-0760(93)90056-3; Cooper WN, 2012, FASEB J, V26, P1782, DOI 10.1096/fj.11-192708; Coppieters N, 2011, CURR PHARM DESIGN, V17, P3398, DOI 10.2174/138161211798072544; Davison JM, 2009, J BIOL CHEM, V284, P1982, DOI 10.1074/jbc.M807651200; Doblhammer G, 2013, POP STUD-J DEMOG, V67, P309, DOI 10.1080/00324728.2013.809140; Dobson CC, 2012, NUTR DIABETES, V2, DOI 10.1038/nutd.2012.31; Drake AJ, 2012, CLIN ENDOCRINOL, V77, P808, DOI 10.1111/j.1365-2265.2012.04453.x; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Forsen T, 1999, BRIT MED J, V319, P1403, DOI 10.1136/bmj.319.7222.1403; Fryer AA, 2009, EPIGENETICS-US, V4, P292; Fu Q, 2009, FASEB J, V23, P2438, DOI 10.1096/fj.08-124768; GARRO AJ, 1991, ALCOHOL CLIN EXP RES, V15, P395, DOI 10.1111/j.1530-0277.1991.tb00536.x; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979; Gong L, 2010, EPIGENETICS-US, V5, P619, DOI 10.4161/epi.5.7.12882; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gueant JL, 2014, PFLUG ARCH EUR J PHY, V466, P833, DOI 10.1007/s00424-013-1339-4; Gueant JL, 2013, TRENDS ENDOCRIN MET, V24, P279, DOI 10.1016/j.tem.2013.01.010; Haggarty P, 2013, AM J CLIN NUTR, V97, P94, DOI 10.3945/ajcn.112.042572; Halsted CH, 2002, J NUTR, V132, p2367S, DOI 10.1093/jn/132.8.2367S; Haycock PC, 2009, BIOL REPROD, V81, P618, DOI 10.1095/biolreprod.108.074682; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Hernandez-Valero MA, 2013, J DEV ORIG HLTH DIS, V4, P499, DOI 10.1017/S204017441300041X; Hernandez-Vargas H, 2015, INT J EPIDEMIOL, V44, P1238, DOI 10.1093/ije/dyv027; Hoyo C, 2011, EPIGENETICS-US, V6, P928, DOI 10.4161/epi.6.7.16263; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jahan Sanzida, 2015, Adv Biol Regul, V57, P173, DOI 10.1016/j.jbior.2014.09.003; Jiang XY, 2012, FASEB J, V26, P3563, DOI 10.1096/fj.12-207894; Kim EJ, 2008, BMB REP, V41, P751, DOI 10.5483/BMBRep.2008.41.11.751; Kovacheva VP, 2007, J BIOL CHEM, V282, P31777, DOI 10.1074/jbc.M705539200; Kuehnen P, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002543; Lee HS, 2013, AM J CLIN NUTR, V98, P480, DOI 10.3945/ajcn.112.052241; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Liang FX, 2009, NAT REV ENDOCRINOL, V5, P367, DOI 10.1038/nrendo.2009.101; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Lillycrop KA, 2011, P NUTR SOC, V70, P64, DOI 10.1017/S0029665110004027; Martinez D, 2014, CELL METAB, V19, P941, DOI 10.1016/j.cmet.2014.03.026; Medici V, 2014, EPIGENETICS-US, V9, P286, DOI 10.4161/epi.27110; Mehedint MG, 2010, P NATL ACAD SCI USA, V107, P12834, DOI 10.1073/pnas.0914328107; Moverare-Skrtic S, 2009, ENDOCRINE, V35, P204, DOI 10.1007/s12020-009-9153-7; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Nogueiras R, 2012, PHYSIOL REV, V92, P1479, DOI 10.1152/physrev.00022.2011; Ouko LA, 2009, ALCOHOL CLIN EXP RES, V33, P1615, DOI 10.1111/j.1530-0277.2009.00993.x; Pan SF, 2013, BRIT J NUTR, V109, P1731, DOI 10.1017/S0007114512003728; Pasternak Y, 2013, J MATERN-FETAL NEO M, V26, P439, DOI 10.3109/14767058.2012.745505; Garcia AP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017313; Plagemann A, 2009, J PHYSIOL-LONDON, V587, P4963, DOI 10.1113/jphysiol.2009.176156; Portha B, 2014, BIOCHIMIE, V97, P1, DOI 10.1016/j.biochi.2013.10.003; Radford EJ, 2014, SCIENCE, V345, P785, DOI 10.1126/science.1255903; Radford EJ, 2012, PLOS GENET, V8, P41, DOI 10.1371/journal.pgen.1002605; Reamon-Buettner SM, 2014, REPROD TOXICOL, V45, P117, DOI 10.1016/j.reprotox.2014.02.009; Refsum H, 2001, AM J CLIN NUTR, V74, P233; Roszer T, 2010, PPAR RES, V2010, DOI 10.1155/2010/698730; Sandovici I, 2011, P NATL ACAD SCI USA, V108, P5449, DOI 10.1073/pnas.1019007108; Schaible TD, 2011, HUM MOL GENET, V20, P1687, DOI 10.1093/hmg/ddr044; Schalinske KL, 2012, ADV NUTR, V3, P755, DOI 10.3945/an.112.002758; Schalinske KL, 2005, NUTR REV, V63, P387, DOI 10.1301/nr.2005.nov.387-391; Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192; Shankar K, 2008, AM J PHYSIOL-REG I, V294, pR528, DOI 10.1152/ajpregu.00316.2007; Shankar K, 2007, ALCOHOL RES HEALTH, V30, P55; Shen L, 2014, CELL STEM CELL, V15, P459, DOI 10.1016/j.stem.2014.09.002; Shiell AW, 2001, HYPERTENSION, V38, P1282, DOI 10.1161/hy1101.095332; Silver MJ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0660-y; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845; Stepanow S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017711; Stouder C, 2011, REPROD TOXICOL, V31, P507, DOI 10.1016/j.reprotox.2011.02.009; Suter MA, 2012, FASEB J, V26, P5106, DOI 10.1096/fj.12-212878; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Ungerer M, 2013, ALCOHOL RES-CURR REV, V35, P37; van Straten EME, 2010, AM J PHYSIOL-REG I, V298, pR275, DOI 10.1152/ajpregu.00413.2009; Veenendaal MVE, 2013, BJOG-INT J OBSTET GY, V120, P548, DOI 10.1111/1471-0528.12136; Vickers MH, 2014, NUTRIENTS, V6, P2165, DOI 10.3390/nu6062165; Vucetic Z, 2010, ENDOCRINOLOGY, V151, P4756, DOI 10.1210/en.2010-0505; Wadhwa PD, 2009, SEMIN REPROD MED, V27, P358, DOI 10.1055/s-0029-1237424; Wang JJ, 2012, ANTIOXID REDOX SIGN, V17, P282, DOI 10.1089/ars.2011.4381; Waterland RA, 2008, INT J OBESITY, V32, P1373, DOI 10.1038/ijo.2008.100; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230; Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252; Williams-Wyss O, 2014, AM J PHYSIOL-ENDOC M, V307, pE141, DOI 10.1152/ajpendo.00051.2012; Wu G, 2008, AMINO ACIDS, V35, P691, DOI 10.1007/s00726-008-0052-7; Wu GY, 2009, AMINO ACIDS, V37, P1, DOI 10.1007/s00726-009-0269-0; Wu H, 2014, CELL, V156, P45, DOI 10.1016/j.cell.2013.12.019; Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y; Yao XH, 2008, AM J PHYSIOL-REG I, V294, pR1797, DOI 10.1152/ajpregu.00804.2007; Yao XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059680; Zhang J, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-62; Zheng SS, 2011, EPIGENETICS-US, V6, P161, DOI 10.4161/epi.6.2.13472	105	115	120	1	39	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2072-6643		NUTRIENTS	Nutrients	NOV	2015	7	11					9492	9507		10.3390/nu7115467			16	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	CX4GJ	WOS:000365656900042	26593940	gold, Green Published, Green Submitted			2022-02-25	
J	Perdomo, S; Anantharaman, D; Mckay, J; Brennan, P				Perdomo, Sandra; Anantharaman, Devasena; Mckay, James; Brennan, Paul			Circulating tumor DNA as a 'liquid biopsy' in head and neck cancer	CANCER RESEARCH			English	Meeting Abstract	106th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 18-22, 2015	Philadelphia, PA	Amer Assoc Canc Res					[Perdomo, Sandra; Anantharaman, Devasena; Mckay, James; Brennan, Paul] IARC, Lyon, France									0	1	1	0	1	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	AUG 1	2015	75			15		5230				10.1158/1538-7445.AM2015-5230			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	DF8HA	WOS:000371597105400					2022-02-25	
J	Chajes, V; Biessy, C; Ferrari, P; Romieu, I; Slimani, N				Chajes, Veronique; Biessy, Carine; Ferrari, Pietro; Romieu, Isabelle; Slimani, Nadia			Plasma Elaidic Acid Level as Biomarker of Industrial trans Fatty Acids and Risk of Weight Change: Report from the EPIC Study	FASEB JOURNAL			English	Meeting Abstract									[Chajes, Veronique; Biessy, Carine; Ferrari, Pietro; Romieu, Isabelle; Slimani, Nadia] Int Agcy Res Canc, Nutr & Metab, F-69372 Lyon, France									0	0	0	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2015	29			1		598.17							1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CR6PV	WOS:000361470505138					2022-02-25	
J	Straif, K; Loomis, D; Guyton, K; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Mattock, H				Straif, Kurt; Loomis, Dana; Guyton, Kathryn; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi			Future priorities for the IARC Monographs	LANCET ONCOLOGY			English	News Item									[Straif, Kurt; Loomis, Dana; Guyton, Kathryn; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Mattock, Heidi] Int Agcy Res Canc, Monographs Advisory Grp, F-69372 Lyon, France		Straif, K (corresponding author), Int Agcy Res Canc, Monographs Advisory Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.		Loomis, Dana/AAE-3988-2019					0	27	27	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUN	2014	15	7					683	684		10.1016/S1470-2045(14)70168-8			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AH9ZR	WOS:000336505900036					2022-02-25	
J	Wild, CP				Wild, Christopher P.			Cancer control: a reminder of the need for a balanced approach between prevention and treatment	EASTERN MEDITERRANEAN HEALTH JOURNAL			English	Editorial Material							BURDEN		Int Agcy Res Canc, F-69372 Lyon, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			Alwan A, 2011, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2010, pVII; Bray F, 2014, IARC TECHNICAL PUBLI, V42; Chaloupka FJ, 2011, TOB CONTROL, V20, P235, DOI 10.1136/tc.2010.039982; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; GLOBOCAN, 2012, GLOBOCAN 2012 EST CA; Lee BL, 2012, LANCET ONCOL, V13, pE95, DOI 10.1016/S1470-2045(11)70323-0; Mokdad AH, 2014, LANCET, V383, P309, DOI 10.1016/S0140-6736(13)62189-3; Murillo R, 2008, VACCINE, V26, pL37, DOI 10.1016/j.vaccine.2008.06.013; Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3; Soerjomataram I, 2012, LANCET, V380, P1840, DOI 10.1016/S0140-6736(12)60919-2; Stewart B.W., 2014, WORLD CANC REPORT 20; Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2; Wild CP, 2012, J NATL CANCER I, V104, P1051, DOI 10.1093/jnci/djs262; Wild CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/ije/dyr236	14	4	4	0	4	WHO EASTERN MEDITERRANEAN REGIONAL OFFICE	NASR CITY, CAIRO	P. O. BOX 7608, NASR CITY, CAIRO, EGYPT	1020-3397	1687-1634		E MEDITERR HEALTH J	East Mediterr. Health J.	JUN	2014	20	6					360	362		10.26719/2014.20.6.360			3	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	AK2EQ	WOS:000338232300002	24960511	Bronze			2022-02-25	
J	Amadou, A; Ferrari, P; Muwonge, R; Moskal, A; Biessy, C; Romieu, I; Hainaut, P				Amadou, A.; Ferrari, P.; Muwonge, R.; Moskal, A.; Biessy, C.; Romieu, I.; Hainaut, P.			Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis	OBESITY REVIEWS			English	Review						Breast cancer; ethnicity; obesity; overweight	BODY-MASS INDEX; PROGESTERONE-RECEPTOR STATUS; ESTROGEN-RECEPTOR; FAT DISTRIBUTION; ANTHROPOMETRIC MEASURES; PHYSICAL-ACTIVITY; AFRICAN-AMERICAN; SIZE; WOMEN; HEIGHT	The association of overweight and obesity with premenopausal breast cancer remained unclear, ethnicity could play a role. A MEDLINE and PUBMED search of all studies on obesity and premenopausal breast cancer published from 2000 to 2010 was conducted. Dose-response meta-analysis was used to determine the risk of premenopausal breast cancer associated with different anthropometric measurements in different ethnic groups. For body mass index (BMI), each 5kgm(-2) increase was inversely associated with the risk of premenopausal breast cancer (RR=0.95, 95% confidence interval [CI]: 0.94, 0.97). After stratification by ethnicity, the inverse association remained significant only among Africans (RR=0.95, 95% CI: 0.91, 0.98) and Caucasians (RR=0.93, 95% CI: 0.91, 0.95). In contrast, among Asian women, a significant positive association was observed. For waist-to-hip ratio (WHR), each 0.1 unit increase was positively associated with premenopausal breast cancer (RR=1.08, 95% CI: 1.01, 1.16); the largest effect was detected in Asian women (RR=1.19, 95% CI: 1.15, 1.24), while small effects of 5% and 6% were observed in African and Caucasian women, respectively. Our results suggest the importance of considering both fat distribution and ethnicity when studying premenopausal breast cancer.	[Amadou, A.; Ferrari, P.; Moskal, A.; Biessy, C.; Romieu, I.] Int Agcy Res Canc, Nutr & Metab Sect, Nutr Epidemiol Grp, F-69372 Lyon 08, France; [Muwonge, R.] Int Agcy Res Canc, Screening Grp, F-69372 Lyon 08, France; [Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon 08, France		Romieu, I (corresponding author), Int Agcy Res Canc, Nutr & Metab Sect, Nutr Epidemiol Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	romieui@iarc.fr	Hainaut, Pierre/B-6018-2012; Muwonge, Richard/P-6375-2015	Hainaut, Pierre/0000-0002-1303-1610; 			Adebamowo CA, 2003, ANN EPIDEMIOL, V13, P455, DOI 10.1016/S1047-2797(02)00426-X; Adebamowo CA, 2003, BREAST CANCER RES, V5, pR18, DOI 10.1186/bcr567; Berstad P, 2010, CANCER EPIDEM BIOMAR, V19, P1532, DOI 10.1158/1055-9965.EPI-10-0025; Britton JA, 2002, AM J EPIDEMIOL, V156, P507, DOI 10.1093/aje/kwf065; BRUNING PF, 1992, INT J CANCER, V52, P511, DOI 10.1002/ijc.2910520402; Chow Louis W C, 2005, Asian J Surg, V28, P179, DOI 10.1016/S1015-9584(09)60338-9; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Enger SM, 2000, CANCER EPIDEM BIOMAR, V9, P681; Friedenreich CM, 2002, INT J CANCER, V99, P445, DOI 10.1002/ijc.10389; Hall IJ, 2000, AM J EPIDEMIOL, V151, P754, DOI 10.1093/oxfordjournals.aje.a010275; Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013; Harris HR, 2011, JNCI-J NATL CANCER I, V103, P273, DOI 10.1093/jnci/djq500; Harvie M, 2003, Obes Rev, V4, P157, DOI 10.1046/j.1467-789X.2003.00108.x; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hirose K, 2001, CANCER CAUSE CONTROL, V12, P349, DOI 10.1023/A:1011232602348; Huang WY, 2000, AM J EPIDEMIOL, V151, P703, DOI 10.1093/oxfordjournals.aje.a010265; Huo DZ, 2009, J CLIN ONCOL, V27, P4515, DOI 10.1200/JCO.2008.19.6873; Iwasaki M, 2007, ANN EPIDEMIOL, V17, P304, DOI 10.1016/j.annepidem.2006.09.003; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jordan S, 2009, BREAST, V18, P299, DOI 10.1016/j.breast.2009.09.004; Kuriyama S, 2005, INT J CANCER, V113, P148, DOI 10.1002/ijc.20529; Lahmann PH, 2004, INT J CANCER, V111, P762, DOI 10.1002/ijc.20315; Lukanova A, 2006, INT J CANCER, V118, P458, DOI 10.1002/ijc.21354; Lundqvist E, 2007, INT J CANCER, V121, P810, DOI 10.1002/ijc.22746; Ma HY, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1514; Manders P, 2011, BREAST CANCER RES TR, V126, P193, DOI 10.1007/s10549-010-1120-8; McCredie MRE, 2003, BRIT J CANCER, V89, P1661, DOI 10.1038/sj.bjc.6601293; Michels KB, 2006, ARCH INTERN MED, V166, P2395, DOI 10.1001/archinte.166.21.2395; Nichols HB, 2005, CANCER EPIDEM BIOMAR, V14, P41; Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052; Ogundiran TO, 2010, AM J EPIDEMIOL, V172, P682, DOI 10.1093/aje/kwq180; Olopade OI, 2008, CLIN CANCER RES, V14, P7988, DOI 10.1158/1078-0432.CCR-08-1211; Orsini N, 2006, STATA J, V6, P40, DOI 10.1177/1536867X0600600103; Palmer JR, 2007, CANCER EPIDEM BIOMAR, V16, P1795, DOI 10.1158/1055-9965.EPI-07-0336; Pan WH, 2008, ASIA PAC J CLIN NUTR, V17, P370; Pandey Shilpi, 2010, J Hum Reprod Sci, V3, P62, DOI 10.4103/0974-1208.69332; Parkin DM, 2010, INT J CANCER, V127, P2918, DOI 10.1002/ijc.25517; Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Rose DP, 2007, ENDOCR REV, V28, P763, DOI 10.1210/er.2006-0019; Rose DP, 2010, MATURITAS, V66, P33, DOI 10.1016/j.maturitas.2010.01.019; Rose DP, 2009, EXPERT REV ANTICANC, V9, P1091, DOI 10.1586/ERA.09.71; Rose DP, 2001, CANCER DETECT PREV, V25, P16; Rush EC, 2009, BRIT J NUTR, V102, P632, DOI 10.1017/S0007114508207221; Shin A, 2009, BREAST CANCER RES TR, V113, P153, DOI 10.1007/s10549-008-9903-x; Shu XO, 2001, INT J CANCER, V94, P449, DOI 10.1002/ijc.1487; Sighoko D, 2010, INT J CANCER, V127, P2248, DOI 10.1002/ijc.25244; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Suzuki R, 2009, INT J CANCER, V124, P698, DOI 10.1002/ijc.23943; Tehard B, 2006, INT J OBESITY, V30, P156, DOI 10.1038/sj.ijo.0803133; Tian YF, 2007, ENDOCR-RELAT CANCER, V14, P669, DOI 10.1677/ERC-06-0089; van den Brandt PA, 2000, AM J EPIDEMIOL, V152, P514, DOI 10.1093/aje/152.6.514; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1371/journal.pmed.0040296; Wang Y, 2007, EPIDEMIOL REV, V29, P6, DOI 10.1093/epirev/mxm007; Weiderpass E, 2004, CANCER EPIDEM BIOMAR, V13, P1121; Wu AH, 2007, INT J CANCER, V120, P844, DOI 10.1002/ijc.22387; Wu MH, 2006, ANN EPIDEMIOL, V16, P223, DOI 10.1016/j.annepidem.2005.02.015	59	118	120	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-7881	1467-789X		OBES REV	Obes. Rev.	AUG	2013	14	8					665	678		10.1111/obr.12028			14	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	185PT	WOS:000321982800007	23615120				2022-02-25	
J	Wild, CP; Scalbert, A; Herceg, Z				Wild, Christopher P.; Scalbert, Augustin; Herceg, Zdenko			Measuring the exposome: A powerful basis for evaluating environmental exposures and cancer risk	ENVIRONMENTAL AND MOLECULAR MUTAGENESIS			English	Review						exposure assessment; omics; transcriptomics; epigenomics; metabolomics	BLOOD MONONUCLEAR-CELLS; GLOBAL GENE-EXPRESSION; DIFFERENTIAL DNA METHYLATION; HUMAN METABOLIC PHENOTYPES; HEPATOCELLULAR-CARCINOMA; MICROARRAY ANALYSIS; ARSENIC EXPOSURE; LUNG-CANCER; PARTICULATE MATTER; INSULIN-RESISTANCE	Advances in laboratory sciences offer much in the challenge to unravel the complex etiology of cancer and to therefore provide an evidence-base for prevention. One area where improved measurements are particularly important to epidemiology is exposure assessment; this requirement has been highlighted through the concept of the exposome. In addition, the ability to observe genetic and epigenetic alterations in individuals exposed to putative risk factors also affords an opportunity to elucidate underlying mechanisms of carcinogenesis, which in turn may allow earlier detection and more refined molecular classification of disease. In this context the application of omics technologies to large population-based studies and their associated biobanks raise exciting new avenues of research. This review considers the areas of genomics, transcriptomics, epigenomics and metabolomics and the evidence to date that people exposed to well-defined factors (for example, tobacco, diet, occupational exposures, environmental pollutants) have specific omics profiles. Although in their early stages of development these approaches show promising evidence of distinct exposure-derived biological effects and indicate molecular pathways that may be particularly relevant to the carcinogenic process subsequent to environmental and lifestyle exposures. Such an interdisciplinary approach is vital if the full benefits of advances in laboratory sciences and investments in large-scale prospective cohort studies are to be realized in relation to cancer prevention. (c) 2013 Wiley Periodicals, Inc.	[Wild, Christopher P.; Scalbert, Augustin; Herceg, Zdenko] Int Agcy Res Canc, F-69372 Lyon, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020; Scalbert, Augustin/AAX-8160-2021	Wild, Christopher/0000-0003-0249-8669; Scalbert, Augustin/0000-0001-6651-6710	Eurocanplatform: A European Platform for Translational Cancer Research [260791]; Exposomics: Enhanced exposure assessment and omic profiling for high priority environmental exposures in Europe [308610]; Application of new technologies and methods in nutrition research-the example of phenotypic flexibility-NutriTech [289511]; French National Cancer Institute (INCa) (Biomarkers of B vitamins, Epigenome, genetic polymorphisms, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study)	Grant sponsor: Eurocanplatform: A European Platform for Translational Cancer Research; Grant number: 260791.; Grant sponsor: Exposomics: Enhanced exposure assessment and omic profiling for high priority environmental exposures in Europe; Grant number: 308610.; Grant sponsor: Application of new technologies and methods in nutrition research-the example of phenotypic flexibility-NutriTech; Grant number: 289511.; Grant sponsor: French National Cancer Institute (INCa) (Biomarkers of B vitamins, Epigenome, genetic polymorphisms, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study).	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Altmaier E, 2011, EUR J EPIDEMIOL, V26, P145, DOI 10.1007/s10654-010-9524-7; Argos M, 2006, CANCER EPIDEM BIOMAR, V15, P1367, DOI 10.1158/1055-9965.EPI-06-0106; Asiago VM, 2010, CANCER RES, V70, P8309, DOI 10.1158/0008-5472.CAN-10-1319; Assfalg M, 2008, P NATL ACAD SCI USA, V105, P1420, DOI 10.1073/pnas.0705685105; Bailey KA, 2013, J BIOCHEM MOL TOXIC, V27, P106, DOI 10.1002/jbt.21462; Barouki Robert, 2012, Environ Health, V11, P42, DOI 10.1186/1476-069X-11-42; Beane J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r201; Beane J, 2011, CANCER PREV RES, V4, P803, DOI 10.1158/1940-6207.CAPR-11-0212; Bingham S, 2004, NAT REV CANCER, V4, P206, DOI 10.1038/nrc1298; Biron VL, 2004, DEV BIOL, V276, P337, DOI 10.1016/j.ydbio.2004.08.038; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Bollati V, 2010, ENVIRON HEALTH PERSP, V118, P763, DOI 10.1289/ehp.0901300; Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008; Cdc Centers for Disease Control and Prevention, 2009, 4 CDCP; Chadeau-Hyam M, 2011, BIOMARKERS, V16, P83, DOI 10.3109/1354750X.2010.533285; Chajes V, 2008, AM J EPIDEMIOL, V167, P1312, DOI 10.1093/aje/kwn069; Chajes V, 2011, AM J CLIN NUTR, V94, P1304, DOI 10.3945/ajcn.110.005892; Chen CH, 2012, P NATL ACAD SCI USA, V109, P8241, DOI 10.1073/pnas.1119920109; Chen R, 2012, CELL, V148, P1293, DOI 10.1016/j.cell.2012.02.009; Connolly PH, 2004, J APPL PHYSIOL, V97, P1461, DOI 10.1152/japplphysiol.00316.2004; da Costa AN, 2012, MOL ONCOL, V6, P704, DOI 10.1016/j.molonc.2012.07.005; Dunn WB, 2011, CHEM SOC REV, V40, P387, DOI 10.1039/b906712b; Eady JJ, 2005, PHYSIOL GENOMICS, V22, P402, DOI 10.1152/physiolgenomics.00080.2005; Edmands WMB, 2011, J PROTEOME RES, V10, P4513, DOI 10.1021/pr200326k; Enea C, 2010, ANAL BIOANAL CHEM, V396, P1167, DOI 10.1007/s00216-009-3289-4; Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142; Forrest MS, 2005, ENVIRON HEALTH PERSP, V113, P801, DOI 10.1289/ehp.7635; Fortney K, 2011, HUM GENET, V130, P465, DOI 10.1007/s00439-011-0983-z; Fry RC, 2007, PLOS GENET, V3, P2180, DOI 10.1371/journal.pgen.0030207; Fuhrer T, 2011, ANAL CHEM, V83, P7074, DOI 10.1021/ac201267k; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Fustinoni S, 2012, MED LAV, V103, P84; Gallo V, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001117; Ghosh P, 2008, MUTAT RES-REV MUTAT, V659, P293, DOI 10.1016/j.mrrev.2008.06.003; Gouas DA, 2012, CARCINOGENESIS, V33, P1219, DOI [10.1093/carcin/bgs135, 10.1093/carcin/bgs068]; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hackett NR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-82; Heinzmann SS, 2012, J PROTEOME RES, V11, P643, DOI 10.1021/pr2005764; Heinzmann SS, 2010, AM J CLIN NUTR, V92, P436, DOI 10.3945/ajcn.2010.29672; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Herceg Z, 2011, EPIGENOMICS-UK, V3, P383, DOI [10.2217/EPI.11.64, 10.2217/epi.11.64]; Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262; Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749; Hochstenbach K, 2012, CANCER EPIDEM BIOMAR, V21, P1756, DOI 10.1158/1055-9965.EPI-12-0304; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmes E, 2008, NATURE, V453, P396, DOI 10.1038/nature06882; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Huffman KM, 2009, DIABETES CARE, V32, P1678, DOI 10.2337/dc08-2075; IARC, 2012, IARC MON EV CARC R C, V100C; IARC, 2012, IARC MON EV CARC R F, V100F; Idaghdour Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000052; Ji Z, 2010, LEUKEMIA, V24, P986, DOI 10.1038/leu.2010.43; Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412; Kawai T, 2007, BIOL PSYCHOL, V76, P147, DOI 10.1016/j.biopsycho.2007.07.008; Keun HC, 2009, CLIN CANCER RES, V15, P6716, DOI 10.1158/1078-0432.CCR-09-1452; Kile ML, 2012, ENVIRON HEALTH PERSP, V120, P1061, DOI 10.1289/ehp.1104173; Kim JY, 2010, J PROTEOME RES, V9, P4368, DOI 10.1021/pr100101p; Kuo CH, 2012, CHEM RES TOXICOL, V25, P676, DOI 10.1021/tx200465e; Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027; Lambrou A, 2012, EPIDEMIOLOGY, V23, P668, DOI 10.1097/EDE.0b013e31825afb0b; Lampe JW, 2004, CANCER EPIDEM BIOMAR, V13, P445; Lee DH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015977, 10.1371/journal.pone.0026172]; Lehmann R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011519; Llorach R, 2009, J PROTEOME RES, V8, P5060, DOI 10.1021/pr900470a; Lloyd AJ, 2011, AM J CLIN NUTR, V94, P981, DOI 10.3945/ajcn.111.017921; Martin J, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-663; Maxeiner A, 2010, PROSTATE, V70, P710, DOI 10.1002/pros.21103; McHale CM, 2007, TOXICOLOGY, V229, P101, DOI 10.1016/j.tox.2006.10.004; McHale CM, 2011, ENVIRON HEALTH PERSP, V119, P628, DOI 10.1289/ehp.1002546; McHale CM, 2010, MUTAT RES-REV MUTAT, V705, P172, DOI 10.1016/j.mrrev.2010.04.001; McHale CM, 2009, GENOMICS, V93, P343, DOI 10.1016/j.ygeno.2008.12.006; Milosavljevic A, 2011, TRENDS GENET, V27, P242, DOI 10.1016/j.tig.2011.03.001; Monick MM, 2012, AM J MED GENET B, V159B, P141, DOI 10.1002/ajmg.b.32021; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Nicholson G, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.57; O'Sullivan A, 2011, AM J CLIN NUTR, V93, P314, DOI 10.3945/ajcn.110.000950; Oberbach A, 2011, J PROTEOME RES, V10, P4769, DOI 10.1021/pr2005555; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Pagmantidis V, 2008, AM J CLIN NUTR, V87, P181, DOI 10.1093/ajcn/87.1.181; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; Pechlivanis A, 2010, J PROTEOME RES, V9, P6405, DOI 10.1021/pr100684t; Pere-Trepat E, 2010, CHEMOMETR INTELL LAB, V104, P95, DOI 10.1016/j.chemolab.2010.06.001; PERERA FP, 1982, CARCINOGENESIS, V3, P1405, DOI 10.1093/carcin/3.12.1405; Peretz A, 2007, INHAL TOXICOL, V19, P1107, DOI 10.1080/08958370701665384; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Pfeifer GP, 2011, CURR OPIN ONCOL, V23, P62, DOI 10.1097/CCO.0b013e3283414d00; Pfeifer GP, 2009, HUM GENET, V125, P493, DOI 10.1007/s00439-009-0657-2; Pietilainen KH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000218; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Pleil JD, 2011, J BREATH RES, V5, DOI 10.1088/1752-7155/5/4/046005; Poirier MC, 2004, NAT REV CANCER, V4, P630, DOI 10.1038/nrc1410; Rasmussen LG, 2012, GENES NUTR, V7, P281, DOI 10.1007/s12263-011-0250-x; Rhee EP, 2011, J CLIN INVEST, V121, P1402, DOI 10.1172/JCI44442; Rudkowska I, 2011, J NUTRIGENET NUTRIGE, V4, P192, DOI 10.1159/000330226; Saadatian-Elahi M, 2009, AM J CLIN NUTR, V89, P331, DOI 10.3945/ajcn.2008.26834; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Scoccianti C, 2011, EPIGENETICS-US, V6, P1114, DOI 10.4161/epi.6.9.16515; Shah SH, 2012, AM HEART J, V163, P844, DOI 10.1016/j.ahj.2012.02.005; Skinner MK, 2011, REPROD TOXICOL, V31, P337, DOI 10.1016/j.reprotox.2010.10.012; Smeester L, 2011, CHEM RES TOXICOL, V24, P165, DOI 10.1021/tx1004419; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; Steiling K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005043; Stella C, 2006, J PROTEOME RES, V5, P2780, DOI 10.1021/pr060265y; Stidley CA, 2010, CANCER RES, V70, P568, DOI 10.1158/0008-5472.CAN-09-3410; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Suter M, 2011, EPIGENETICS-US, V6, P1284, DOI 10.4161/epi.6.11.17819; Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898; Tilley AE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022798; Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804; UMBENHAUER D, 1985, INT J CANCER, V36, P661, DOI 10.1002/ijc.2910360607; Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489; van Dijk SJ, 2012, J NUTR, V142, P1219, DOI 10.3945/jn.111.155283; Van Dorsten FA, 2006, J AGR FOOD CHEM, V54, P6929, DOI 10.1021/jf061016x; van Leeuwen DM, 2007, CARCINOGENESIS, V28, P691, DOI 10.1093/carcin/bgl199; Vedin I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035425; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1371/journal.pmed.0040296; Wan ES, 2012, HUM MOL GENET, V21, P3073, DOI 10.1093/hmg/dds135; Wang TJ, 2011, NAT MED, V17, P448, DOI 10.1038/nm.2307; Wang ZX, 2005, ENVIRON HEALTH PERSP, V113, P233, DOI 10.1289/txg.7273; Wang-Sattler R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003863; Wild C, 2008, MOL EPIDEMIOLOGY CHR; Wild CP, 2009, MUTAGENESIS, V24, P117, DOI 10.1093/mutage/gen061; Wild CP, 2012, J NATL CANCER I, V104, P1051, DOI 10.1093/jnci/djs262; Wild CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/ije/dyr236; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Wright WR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030120; Wurtz P, 2013, DIABETES CARE, V36, P648, DOI 10.2337/dc12-0895; Wurtz P, 2012, DIABETES, V61, P1372, DOI 10.2337/db11-1355; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356; Xu JJ, 2010, ANAL BIOANAL CHEM, V396, P1451, DOI 10.1007/s00216-009-3338-z; Zhang L, 2012, LEUKEMIA, V26, P2494, DOI 10.1038/leu.2012.143; Zhang L, 2008, CANCER PREV RES, V1, P112, DOI 10.1158/1940-6207.CAPR-07-0017; Zieker D, 2005, PHYSIOL GENOMICS, V23, P287, DOI 10.1152/physiolgenomics.00096.2005	136	118	120	7	134	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0893-6692	1098-2280		ENVIRON MOL MUTAGEN	Environ. Mol. Mutagen.	AUG	2013	54	7			SI		480	499		10.1002/em.21777			20	Environmental Sciences; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Genetics & Heredity; Toxicology	201EU	WOS:000323124300004	23681765				2022-02-25	
J	Wild, CP				Wild, Christopher Paul			The exposome: from concept to utility	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Review						Exposome; exposure assessment; biomarkers; cancer epidemiology	SOCIAL DETERMINANTS; DNA METHYLATION; SYSTEMS BIOLOGY; CANCER; EXPOSURE; HEALTH; EPIDEMIOLOGY; RISK; ENVIRONMENT; CHALLENGE		Int Agcy Res Canc, F-69008 Lyon, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			Andersen CE, 2007, RADIAT PROT DOSIM, V123, P83, DOI 10.1093/rpd/ncl082; Burdge GC, 2009, BRIT J NUTR, V101, P619, DOI 10.1017/S0007114508145883; Chadeau-Hyam M, 2011, BIOMARKERS, V16, P83, DOI 10.3109/1354750X.2010.533285; Entringer S, 2011, P NATL ACAD SCI USA, V108, pE513, DOI 10.1073/pnas.1107759108; Friel S, 2011, ANNU REV PUBL HEALTH, V32, P225, DOI 10.1146/annurev-publhealth-031210-101220; Groopman JD, 2008, ANNU REV PUBL HEALTH, V29, P187, DOI 10.1146/annurev.publhealth.29.020907.090859; Hewitt Robert, 2011, Journal of the National Cancer Institute Monographs, P50, DOI 10.1093/jncimonographs/lgr005; Hiatt RA, 2008, AM J PREV MED, V35, pS141, DOI 10.1016/j.amepre.2008.05.006; Illner AK, 2011, PUBLIC HEALTH NUTR, V14, P1055, DOI 10.1017/S1368980010003587; Kanaly RA, 2007, MUTAT RES-FUND MOL M, V625, P83, DOI 10.1016/j.mrfmmm.2007.05.006; Khalil MB, 2010, MASS SPECTROM REV, V29, P877, DOI 10.1002/mas.20294; Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/B978-0-12-380866-0.60002-2, 10.1016/S0065-2660(10)70002-X]; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Merlo DF, 2009, CANCER EPIDEM BIOMAR, V18, P5, DOI 10.1158/1055-9965.EPI-08-0876; Offit K, 2011, HUM GENET, V130, P3, DOI 10.1007/s00439-011-1028-3; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Rappaport SM, 2012, TOXICOL LETT, V213, P83, DOI 10.1016/j.toxlet.2011.04.002; Rappaport SM, 2010, SCIENCE, V330, P460, DOI 10.1126/science.1192603; Rolland B, 2011, CANCER EPIDEM BIOMAR, V20, P2115, DOI 10.1158/1055-9965.EPI-11-0391; Rubino FM, 2009, MASS SPECTROM REV, V28, P725, DOI 10.1002/mas.20207; Schatzkin A, 2009, CANCER EPIDEM BIOMAR, V18, P1026, DOI 10.1158/1055-9965.EPI-08-1129; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Schmiedel S, 2009, BIOELECTROMAGNETICS, V30, P81, DOI 10.1002/bem.20460; Smeester L, 2011, CHEM RES TOXICOL, V24, P165, DOI 10.1021/tx1004419; Smith GD, 2007, PLOS MED, V4, P1985, DOI 10.1371/journal.pmed.0040352; Smith GD, 2011, INT J EPIDEMIOL, V40, P537, DOI 10.1093/ije/dyr117; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500; Teschke K, 2002, OCCUP ENVIRON MED, V59, P575, DOI 10.1136/oem.59.9.575; Thayer ZM, 2011, EPIGENETICS-US, V6, P798, DOI 10.4161/epi.6.7.16222; Venter J. C., 2007, LIFE DECODED MY GENO; Vineis P, 2001, LANCET, V357, P709, DOI 10.1016/S0140-6736(00)04136-2; Vineis P, 2007, CANCER EPIDEM BIOMAR, V16, P1954, DOI 10.1158/1055-9965.EPI-07-0457; Wagner S, 2007, ANAL CHEM, V79, P2918, DOI 10.1021/ac062153w; Walsh MC, 2007, AM J CLIN NUTR, V86, P1687; Wild CP, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-S1-S15; Wild CP, 2011, CANCER EPIDEM BIOMAR, V20, P580, DOI 10.1158/1055-9965.EPI-11-0187; Wild CP, 2009, MUTAGENESIS, V24, P117, DOI 10.1093/mutage/gen061; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; Wolkowitz OM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017837; World Health Organization, 2010, GLOBAL STATUS REPORT; Yan Q, 2010, METHODS MOL BIOL, V662, P203, DOI 10.1007/978-1-60761-800-3_10; Zhang LP, 2010, CHEM-BIOL INTERACT, V184, P86, DOI 10.1016/j.cbi.2009.12.011	45	514	531	12	186	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2012	41	1					24	32		10.1093/ije/dyr236			9	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	915LH	WOS:000302026800007	22296988	Bronze	Y	N	2022-02-25	
J	Couto, E; Ferrari, P; Trichopoulou, A; Spencer, E; De Carli, A; Gonzales, C; Noethlins, U; Boffetta, P; Trichopoulos, D				Couto, E.; Ferrari, P.; Trichopoulou, A.; Spencer, E.; De Carli, A.; Gonzales, C.; Noethlins, U.; Boffetta, P.; Trichopoulos, D.			Adherence to Mediterranean diet and cancer risk	EJC SUPPLEMENTS			English	Meeting Abstract	20th Meeting of the European-Association-for-Cancer-Research	JUL 05-08, 2008	Lyon, FRANCE	European Assoc Canc Res					[Couto, E.; Ferrari, P.; Trichopoulou, A.; Spencer, E.; De Carli, A.; Gonzales, C.; Noethlins, U.; Boffetta, P.; Trichopoulos, D.] Int Agcy Res Canc, Environm & Canc group, F-69372 Lyon, France				Decarli, Adriano/C-3129-2017; Decarli, Adriano/AAF-3314-2021	Decarli, Adriano/0000-0003-1451-8292; Decarli, Adriano/0000-0003-1451-8292				0	1	1	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	JUL	2008	6	9					194	194		10.1016/S1359-6349(08)71865-2			1	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	330DF	WOS:000257919000684					2022-02-25	
J	Hussain, J; Accardi, R; Fathallah, I; Hasan, UA; Tommasino, M; Sylla, BS				Hussain, J.; Accardi, R.; Fathallah, I.; Hasan, U. A.; Tommasino, M.; Sylla, B. S.			Role of NF-kB signalling pathway in the survival of high-risk cutaneous HPV38-immortalised human keratinocytes	BULLETIN DU CANCER			English	Meeting Abstract									IARC, Lyon, France				hasan, uzma A/G-3247-2013					0	0	0	0	1	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0007-4551			B CANCER	Bull. Cancer	JUN	2007	94	6					617	618					2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	197OM	WOS:000248565200205					2022-02-25	
J	Kaaks, R; Riboli, E				Kaaks, R; Riboli, E			Epidemiologic studies of nutrition and cancer: Let us not throw out the baby with the bath water	INTERNATIONAL JOURNAL OF CANCER			English	Editorial Material							COLORECTAL-CANCER; POOLED ANALYSIS; BREAST-CANCER; DIETARY-FAT; C-PEPTIDE; RISK; METAANALYSIS; VEGETABLES		Int Agcy Res Canc, Hormones & Canc Grp, F-69372 Lyon, France		Kaaks, R (corresponding author), Int Agcy Res Canc, Hormones & Canc Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	kaaks@iarc.fr		Riboli, Elio/0000-0001-6795-6080			Bingham SA, 2003, LANCET, V362, P212, DOI 10.1016/S0140-6736(03)13913-X; Boyd NF, 2003, BRIT J CANCER, V89, P1672, DOI 10.1038/sj.bjc.6601314; Cho E, 2004, JNCI-J NATL CANCER I, V96, P1015, DOI 10.1093/jnci/djh185; Cho EY, 2004, ANN INTERN MED, V140, P603, DOI 10.7326/0003-4819-140-8-200404200-00007; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; FRIEDENREICH CM, 1991, EPIDEMIOLOGY, V2, P424, DOI 10.1097/00001648-199111000-00006; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; Hunter DJ, 1999, CANCER EPIDEM BIOMAR, V8, P9; IARC, 1998, INT INCIDENCE CHILDH, P1; International Agency for Research on Cancer, 2003, IARC Sci Publ, P1; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; Ma J, 2004, JNCI-J NATL CANCER I, V96, P546, DOI 10.1093/jnci/djh082; Michels KB, 2005, INT J CANCER, V114, P163, DOI 10.1002/ijc.20662; Miller AB, 2004, INT J CANCER, V108, P269, DOI 10.1002/ijc.11559; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; Peters U, 2003, LANCET, V361, P1491, DOI 10.1016/S0140-6736(03)13173-X; Riboli E, 2003, AM J CLIN NUTR, V78, p559S, DOI 10.1093/ajcn/78.3.559S; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; Smith-Warner SA, 2001, INT J CANCER, V92, P767, DOI 10.1002/1097-0215(20010601)92:5&lt;767::AID-IJC1247&gt;3.0.CO;2-0; World Bank Group, 2004, FOOD NUTR PREV CANC, P1	20	10	10	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	SEP 20	2005	116	5					662	664		10.1002/ijc.21027			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	953BG	WOS:000231050000002	15849731				2022-02-25	
J	Parkin, DM				Parkin, DM			World cancer statistics: Completing the picture and guessing the future.	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Meeting Abstract	3rd Annual AACR International Conference	OCT 16-20, 2004	Seattle, WA	AACR					IARC Unit Descript Epidemiol, Lyon, France									0	1	1	0	1	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965			CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	NOV	2004	13	11	2				1947S	1947S					1	Oncology; Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	870QO	WOS:000225073100417					2022-02-25	
J	Munoz, N				Munoz, N			Value of human papilloma virus testing in the diagnosis and screening of cervical neoplasia	MEDICINA CLINICA			Spanish	Editorial Material							RISK; CANCER; MANAGEMENT; CYTOLOGY; LESIONS; HPV		Int Agcy Res Canc, Cient Emerita, F-69372 Lyon 08, France		Munoz, N (corresponding author), Int Agcy Res Canc, Cient Emerita, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	nubia@iarc.fr					Clavel C, 2001, BRIT J CANCER, V84, P1616, DOI 10.1054/bjoc.2001.1845; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; LFNER T, 2003, J NATL CANC I MONOGR, V31, P80; MILLER AB, 1990, INT J CANCER, V46, P761, DOI 10.1002/ijc.2910460502; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Ordi J, 2003, MED CLIN-BARCELONA, V121, P441, DOI 10.1157/13052788; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87; Schneider A, 2000, INT J CANCER, V89, P529, DOI 10.1002/1097-0215(20001120)89:6&lt;529::AID-IJC11&gt;3.0.CO;2-G; Sherman ME, 2003, JNCI-J NATL CANCER I, V95, P46, DOI 10.1093/jnci/95.1.46; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F	11	5	6	0	0	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	0025-7753	1578-8989		MED CLIN-BARCELONA	Med. Clin.	OCT 11	2003	121	12					455	456		10.1157/13052790			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738TN	WOS:000186304100004	14572370				2022-02-25	
J	Fukunaga-Takenaka, R; Fukunaga, K; Tatemichi, M; Ohshima, H				Fukunaga-Takenaka, R; Fukunaga, K; Tatemichi, M; Ohshima, H			Nitric oxide prevents UV-induced phosphorylation of the p53 tumor-suppressor protein at serine 46: a possible role in inhibition of apoptosis	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						nitric oxide; p53; Ser-46 phosphorylation; apoptosis	CELL-CYCLE ARREST; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; HELICOBACTER-PYLORI; IONIZING-RADIATION; GASTRIC-MUCOSA; MCF-7 CELLS; KINASE; EXPRESSION; ACTIVATION	Ser-46 of p53 is phosphorylated in response to DNA-damage in vivo, and it plays a pivotal role for apoptotic signaling by p53 through regulating the transcriptional activation of genes involved in apoptosis. We found that the presence of the nitric oxide (NO) donor S-nitroso-N-acetyl-D,L-penicillamine (200-800 muM) during UV-irradiation of MCF-7 cells resulted in a significant reduction in the Ser-46 phosphorylation, compared to the UV-irradiated cells without NO. This reduction occurred independently of cyclic GMP generation and without affecting activities of p53 kinases such as the PI3K family, p38 MAPK, and HIPK2. The presence of NO was found to protect HCT116 human colon tumor cells containing wild-type p53 from UV-induced apoptosis, whereas no apparent inhibitory effect of NO on UV-induced apoptosis was observed in those deficient in p53. Our results suggest that NO-mediated protection of apoptosis is p53-dependent, occurring at least partly through NO-inhibition of phosphorylation of p53 on Ser-46. (C) 2003 Elsevier Inc. All rights reserved.	Int Agcy Res Canc, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohshima@iarc.fr	Ohshima, Hiroshi/E-8044-2010				Ambs S, 1998, CANCER RES, V58, P334; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Calmels S, 1997, CANCER RES, V57, P3365; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chazotte-Aubert L, 2000, BIOCHEM BIOPH RES CO, V267, P609, DOI 10.1006/bbrc.1999.2003; Chazotte-Aubert L, 2001, BIOCHEM BIOPH RES CO, V281, P766, DOI 10.1006/bbrc.2001.4423; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Fukunaga K, 2000, J BIOL CHEM, V275, P5208, DOI 10.1074/jbc.275.7.5208; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hanafy K A, 2001, Med Sci Monit, V7, P801; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Kane JM, 1997, J SURG RES, V69, P321, DOI 10.1006/jsre.1997.5057; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Li CQ, 2000, DIGEST DIS SCI, V45, P55, DOI 10.1023/A:1005453125433; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Matsuda K, 2002, CANCER RES, V62, P2883; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pignatelli B, 2001, AM J GASTROENTEROL, V96, P1758, DOI 10.1111/j.1572-0241.2001.03869.x; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277	45	17	19	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	SEP 5	2003	308	4					966	974		10.1016/S0006-291X(03)01516-X			9	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	718VY	WOS:000185168200044	12927814				2022-02-25	
J	Clifford, GM; Smith, JS; Plummer, M; Munoz, N; Franceschi, S				Clifford, GM; Smith, JS; Plummer, M; Munoz, N; Franceschi, S			Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis	BRITISH JOURNAL OF CANCER			English	Article						human papillomavirus; cervical carcinoma; squamous cell carcinoma; adenocarcinoma; epidemiology; literature review	POLYMERASE-CHAIN-REACTION; PROGNOSIS; IDENTIFICATION; HYBRIDIZATION; ASSOCIATION; PREVALENCE; DNA; HPV; ADENOCARCINOMA; SEQUENCES	This study investigated regional variations in the contribution made by different human papilloma (HPV) types to invasive cervical cancer (ICC). A total of 85 studies using polymerase chain reaction to estimate HPV prevalence in ICC were identified. Data on HPV prevalence were extracted separately for squamous cell carcinoma (SCC) and for adeno- and adenosquamous-carcinoma (ADC). A total of 10058 cases (8550 SCC, 1508 ADC) were included in pooled analyses. The most common HPV types in ICC were, in order of decreasing prevalence, HPV 16, 18, 45, 31, 33, 58, 52, 35, 59, 56, 6, 5 1, 68, 39, 82, 73, 66 and 70. In SCC, HPV 16 was the predominant type (46-63%) followed by HPV 18 (10-14%), 45 (2-8%), 31 (2-7%) and 33 (3-5%) in all regions except Asia, where HPV types 58 (6%) and 52 (4%) were more frequently identified. In ADC, HPV prevalence was significantly lower (76.4%) than in SCC (87.3%), and HPV 18 was the predominant type in every region (37-41%), followed by 16 (26-36%.) and 45 (5-7%). The overall detection of HPV DNA was similar in different regions (83-89%). A majority of ICC was associated with HPV 16 or 18 in all regions, but approximately a quarter of all ICC cases were associated with one of 16 other HPV types, their distribution varying by region. (C) 2003 Cancer Research UK.	Int Agcy Res Canc, F-69008 Lyon, France		Clifford, GM (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	clifford@iarc.fir	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497			Andersson S, 2001, EUR J CANCER, V37, P246, DOI 10.1016/S0959-8049(00)00376-2; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; Burger RA, 1996, JNCI-J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361; CHAN SY, 1995, J VIROL, V69, P3074, DOI 10.1128/JVI.69.5.3074-3083.1995; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; Chen S, 1999, INT J GYNECOL OBSTET, V67, P163, DOI 10.1016/S0020-7292(99)00167-8; Combita AL, 2002, INT J CANCER, V97, P796, DOI 10.1002/ijc.10153; Davies NM, 2000, J HIGH ENERGY PHYS; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; GRAVITT P, 1991, MOL CELL PROBE, V5, P65, DOI 10.1016/0890-8508(91)90039-M; GUERRERO E, 1992, J CLIN MICROBIOL, V30, P2951, DOI 10.1128/JCM.30.11.2951-2959.1992; Harima Y, 2002, INT J RADIAT ONCOL, V52, P1345, DOI 10.1016/S0360-3016(01)02796-1; Hildesheim A, 1999, AM J OBSTET GYNECOL, V180, P571, DOI 10.1016/S0002-9378(99)70256-5; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; *IARC, 1995, MON EV CARC RISKS HU, V64, P96; ILLADESAGUIAR B, 2000, P 18 INT PAP C PAR; Kleter B, 1999, J CLIN MICROBIOL, V37, P2508, DOI 10.1128/JCM.37.8.2508-2517.1999; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Liaw KL, 2001, J INFECT DIS, V183, P8, DOI 10.1086/317638; Lin P, 2001, CANCER EPIDEM BIOMAR, V10, P1037; Meyer T, 1998, J INFECT DIS, V178, P252, DOI 10.1086/517447; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; Nakagawa S, 1996, CANCER-AM CANCER SOC, V78, P1935, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1935::AID-CNCR14>3.3.CO;2-9; NINDL I, 2001, P 19 INT PAP C PAR, V20; O'Leary JJ, 1998, HUM PATHOL, V29, P383, DOI 10.1016/S0046-8177(98)90120-4; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 1997, IARC SCI PUBLICATION, VVII; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997; RABELOSANTOS SH, 2001, P 19 INT PAP C; Sasieni P, 2001, LANCET, V357, P1490, DOI 10.1016/S0140-6736(00)04646-8; SCHIFFMAN MH, 1991, J CLIN MICROBIOL, V29, P573, DOI 10.1128/JCM.29.3.573-577.1991; Schwartz SM, 2001, J CLIN ONCOL, V19, P1906, DOI 10.1200/JCO.2001.19.7.1906; Sebbelov AM, 2000, MICROBES INFECT, V2, P121, DOI 10.1016/S1286-4579(00)00276-8; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; WONG YF, 2000, P 18 INT PAP C PAR; Yang YC, 1997, GYNECOL ONCOL, V64, P59, DOI 10.1006/gyno.1996.4543	41	1092	1245	3	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920	1532-1827		BRIT J CANCER	Br. J. Cancer	JAN 13	2003	88	1					63	73		10.1038/sj.bjc.6600688			11	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	647EF	WOS:000181078900012	12556961	Green Published, hybrid			2022-02-25	
J	Merrill, R; Sasco, A				Merrill, R; Sasco, A			A case-control study assessing the relationship between lung cancer and several potential risk factors in Casablanca, Morocco.	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Meeting Abstract									Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JUN 1	2002	155	11		S		050	s13	s13					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	558FK	WOS:000175955500051					2022-02-25	
J	Bray, I; Brennan, P; Boffetta, P				Bray, I; Brennan, P; Boffetta, P			Recent trends and future projections of lymphoid neoplasms - a Bayesian age-period-cohort analysis	CANCER CAUSES & CONTROL			English	Article						lymphomas; projections; trends		Objectives: A steady increase in incidence of lymphoid neoplasms has been reported, especially for non-Hodgkin's lymphoma (NHL). Using high-quality incidence data from 1973-1992 in nine population-based cancer registries (Alberta, Bombay, Denmark, Israel, New Zealand, Osaka, Oxford, Slovenia, Utah), we have examined past increases in specific lymphoid neoplasms. Further, by using a Bayesian age-period-cohort approach, we have calculated 5-, 10- and 15-year projections for each group of lymphoid neoplasms. Results: NHL incidence increased in all centers by an average of 77% in men and 66% in women between 1973 and 1992. Fifteen-year projections of these rates to 2003-2007 indicate that they will increase by an average of 55% among men and 79% among women. High projected incidence rates above 15/100,000 in men and 10/100,000 in women are expected in Alberta, Denmark, Israel, New Zealand, Oxford, and Utah by 2003-2007. The one notable exception was among men from Osaka, where no increase was projected. Modest increases in leukemia and multiple myeloma rates were observed in most of the nine registries with further projected increases by 2007. Projected incidence rates of Hodgkin's disease indicated little change. Conclusion: Increases in NHL rates are occurring worldwide and provide no evidence of peaking. A key assumption in the projected rates is that the effect of environmental agents determining the trends during 1973-1992 will remain stable during the subsequent projection period.	Int Agcy Res Canc, Unit Environm Canc Epidemiol, F-69372 Lyon 08, France		Brennan, P (corresponding author), Int Agcy Res Canc, Unit Environm Canc Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon 08, France.			Bray, Isabelle/0000-0002-5353-3287			BERZUINI C, 1994, STAT MED, V13, P823, DOI 10.1002/sim.4780130804; BRAY I, 2001, UNPUB J ROYAL STAT C; CARLI PM, 1994, BRIT J CANCER, V70, P713, DOI 10.1038/bjc.1994.380; Cartwright R, 1999, EUR J CANCER, V35, P627, DOI 10.1016/S0959-8049(98)00401-8; HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233; *IARC, 1997, IARC SCI PUBL, V143; *IARC, 1976, IARC SCI PUBL, V15; *IARC, 1993, IARC SCI PUBL, V121; *IARC, 1992, IARC SCI PUBL, V120; *IARC, 1987, IARC SCI PUBL, V88; *IARC, 1982, IARC SCI PUBL, V42; THOMAS A, 1992, BAYESIAN STAT, V0004, P00837; *UICC, 1970, CANC INC 5 CONT, V2	13	43	44	0	3	KLUWER ACADEMIC PUBL	DORDRECHT	SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0957-5243			CANCER CAUSE CONTROL	Cancer Causes Control	NOV	2001	12	9					813	820		10.1023/A:1012240117335			8	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	479HB	WOS:000171398000006	11714109				2022-02-25	
J	Vainio, H; Bianchini, F				Vainio, H; Bianchini, F			Prevention of disease with pharmaceuticals	PHARMACOLOGY & TOXICOLOGY			English	Review							BETA-CAROTENE SUPPLEMENTATION; COA REDUCTASE INHIBITORS; CORONARY HEART-DISEASE; BREAST-CANCER; CARDIOVASCULAR-DISEASE; LUNG-CANCER; ALPHA-TOCOPHEROL; RANDOMIZED TRIAL; POSTMENOPAUSAL WOMEN; STROKE PREVENTION	The idea that diseases such as cardiovascular disease and cancer can be prevented by taking a 'pill' is attractive to many people. Chemoprevention is an established method in the primary and secondary prevention of cardiovascular disease such as myocardial infarctions and stroke, Clinical trials have demonstrated beyond reasonable doubt that both fatal and non-fatal coronary events and strokes can be prevented. Antihypertensive drugs have been shown to be effective through clinical trials in preventing myocardial infarctions, stroke and other cardiovascular morbidity and mortality. Statins are commonly used to lower the blood cholesterol concentration, and aspirin is widely used to prevent occlusive vascular disease. Aspirin and other non-steroidal antiinflammatory agents have shown promise in the chemoprevention of colorectal cancer. While observational epidemiological studies have consistently suggested that diets rich in antioxidants such as p-carotene might be useful in preventing coronary heart disease and cancer, the published reports of randomized trials clearly indicate that beta -carotene supplements are of no value in persons of high risk for such conditions. Although the chemoprevention of cancer is decades behind that of cardiovascular disease, there is no reason to believe that progress in cancer chemoprevention will differ substantially from that in cardiovascular disease. Better understanding of the molecular steps critical to carcinogenesis should open new avenues for cancer chemoprevention.	Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon 08, France		Vainio, H (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	vainio@iarc.fr					Agmon Y, 2000, CIRCULATION, V102, P2087, DOI 10.1161/01.CIR.102.17.2087; Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; BLOT WJ, 1995, AM J CLIN NUTR, V62, P1424, DOI 10.1093/ajcn/62.6.1424S; BLOT WJ, 1994, NEW ENGL J MED, V331, P614, DOI 10.1056/NEJM199409013310913; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Ebrahim S, 2000, BRIT MED BULL, V56, P557, DOI 10.1258/0007142001903201; Fenton JW, 1999, HAEMOSTASIS, V29, P166; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; Fournier DB, 2000, J CELL BIOCHEM, P97; Frieling UM, 2000, ARCH DERMATOL, V136, P179, DOI 10.1001/archderm.136.2.179; Goodman GE, 1996, CANCER EPIDEM BIOMAR, V5, P815; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hess DC, 2000, NEUROLOGY, V54, P790, DOI 10.1212/WNL.54.4.790; IARC, 1998, IARC HDB CANC PREV, V2, P1; *IARC, 1997, IARC HDB CANC PREV, V1, P1; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Marshall JR, 1999, J NATL CANCER I, V91, P2068, DOI 10.1093/jnci/91.24.2068; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; MILLER AB, 2001, IARC SCI PUBL, V154, P1; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Osborne MP, 1999, ANN NY ACAD SCI, V889, P146, DOI 10.1111/j.1749-6632.1999.tb08732.x; Pearson B J, 2000, Curr Hypertens Rep, V2, P551, DOI 10.1007/s11906-996-0040-9; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Powles T, 1998, LANCET, V352, P98; ROSE G, 1997, STRATEGY PREVENTIVE; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; Tavani A, 1999, BIOMED PHARMACOTHER, V53, P409, DOI 10.1016/S0753-3322(99)80120-6; Trenkwalder P, 2000, BLOOD PRESSURE, V9, P40, DOI 10.1080/080370500439227; Vainio H, 2000, ANN CHIR GYNAECOL FE, V89, P173; Veronesi U, 1998, LANCET, V352, P93; Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502	43	3	3	0	2	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0901-9928			PHARMACOL TOXICOL	Pharmacol. Toxicol.	MAR	2001	88	3					111	118		10.1034/j.1600-0773.2001.d01-91.x			8	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	407WD	WOS:000167293000001	11245405				2022-02-25	
J	Lambert, R				Lambert, R			A new special section in endoscopy: The expert approach	ENDOSCOPY			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.							0	0	0	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X			ENDOSCOPY	Endoscopy	JAN	2001	33	1					74	74					1	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	392VK	WOS:000166433100012					2022-02-25	
J	Ostroumova, E; Schuz, J; Kesminiene, A				Ostroumova, Evgenia; Schuz, Joachim; Kesminiene, Ausrele			Future of Chernobyl research: the urgency for consolidated action	LANCET			English	Letter									[Ostroumova, Evgenia; Schuz, Joachim; Kesminiene, Ausrele] Int Agcy Res Canc, F-69008 Lyon, France		Ostroumova, E (corresponding author), Int Agcy Res Canc, F-69008 Lyon, France.	ostroumovae@iarc.fr					[Anonymous], 2011, SOURC EFF ION RAD, VII; International Agency for Research on Cancer, 2016, COOP CHERN HLTH RES; Yablokov AV, 2009, ANN NY ACAD SCI, V1181, P192, DOI [10.1111/j.1749-6632.2009.04828.x, 10.1111/j.1749-6632.2009.04822.x]	3	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	2020	395	10229					1037	1038		10.1016/S0140-6736(20)30675-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY5YW	WOS:000522650100030	32199076	Green Published, Bronze			2022-02-25	
J	Brennan, P; Johansson, M; Robbins, H				Brennan, P.; Johansson, M.; Robbins, H.			Biomarkers	JOURNAL OF THORACIC ONCOLOGY			English	Meeting Abstract						Lung cancer; biomarkers; risk			[Brennan, P.; Johansson, M.] Int Agcy Res Canc, Lyon, France; [Robbins, H.] Int Agcy Res Canc, Genet Sect, Lyon, France				Johansson, Mattias/ABF-3365-2020					0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	OCT	2019	14	10		S		S01.19	S200	S200		10.1016/j.jtho.2019.08.397			1	Oncology; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Respiratory System	JG6DQ	WOS:000492162201082		Bronze			2022-02-25	
J	Fernandez-Cuesta, L				Fernandez-Cuesta, L.			Machine Learning and Integrative Multi-Omics Analysis Identify Novel Molecular Groups of Lung Neuroendocrine Tumors	JOURNAL OF THORACIC ONCOLOGY			English	Meeting Abstract						lung neuroendocrine neoplasms; lungNENomics project; supra-carcinoids			[Fernandez-Cuesta, L.] Iarc, Genet Sect, Lyon, France								Alcala N, NAT COMMUN; Derks JL, 2018, J THORAC ONCOL; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; George J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03099-x; Peifer M, 2012, NAT GENET	5	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	OCT	2019	14	10		S		ES12.04	S44	S45		10.1016/j.jtho.2019.08.124			2	Oncology; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Respiratory System	JG6DQ	WOS:000492162200075		Bronze			2022-02-25	
J	Cree, I				Cree, I.			The future of cancer classification: evidence-informed pathology	VIRCHOWS ARCHIV			English	Meeting Abstract									[Cree, I.] WHO, IARC, Lyon, France									0	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	SEP	2018	473			1		E-PS-15-01	S291	S291					1	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	GS2UG	WOS:000443414104005					2022-02-25	
J	Fidler, MM; Bray, F; Soerjomataram, I				Fidler, Miranda M.; Bray, Freddie; Soerjomataram, Isabelle			The global cancer burden and human development: A review	SCANDINAVIAN JOURNAL OF PUBLIC HEALTH			English	Review						Cancer; incidence; human development; socioeconomic; global; review; inequalities	DOSE-RESPONSE METAANALYSIS; HUMAN-DEVELOPMENT INDEX; LIFE-STYLE FACTORS; BODY-MASS INDEX; COLORECTAL-CANCER; ENVIRONMENTAL-FACTORS; PHYSICAL-ACTIVITY; BREAST-CANCER; AIR-POLLUTION; RISK-FACTORS	Aims: This review examines the links between human development and cancer overall and for specific types of cancer, as well as cancer-related risk-factors and outcomes, such as disability and life expectancy. Methods: To assess human development, the Human Development Index was utilized continuously and according to four levels (low, medium, high, very high), where the low and very high categories include the least and most developed countries, respectively. All studies that assessed aspects of the global cancer burden using this measure were reviewed. Results: Although the present cancer incidence burden is greater in higher Human Development Index countries, a greater proportion of the global mortality burden is observed in less developed countries, with a higher mean fatality rate in the latter countries. Further, the future cancer burden is expected to disproportionally affect less developed regions; in particular, it has been estimated that low and medium Human Development Index countries will experience a 100% and 81% increase in cancer incidence from 2008 to 2030, respectively. Disparities were also observed in risk factors and average health outcomes, such as a greater number of years of life lost prematurely and fewer cancer-related gains in life expectancy observed in lower versus higher Human Development Index settings. Conclusions: From a global perspective, there remain clear disparities in the cancer burden according to national Human Development Index scores. International efforts are needed to aid countries in social and economic transition in order to efficiently plan, implement and evaluate cancer control initiatives as a means to reduce the widening gap in cancer occurrence and survival worldwide.	[Fidler, Miranda M.; Bray, Freddie; Soerjomataram, Isabelle] Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Fidler, MM (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	fidlerm@fellows.iarc.fr		Bray, Freddie/0000-0002-3248-7787	European Commission's Seventh Framework Programme Marie Curie Actions - People - COFUND - International Agency for Research on Cancer	This research was supported by the European Commission's Seventh Framework Programme Marie Curie Actions - People - COFUND, which partially funded MMF's postdoctoral fellowship at the International Agency for Research on Cancer.	ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4; ASANO T, 2002, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD14003430; Atun R, 2015, LANCET ONCOL, V16, P1153, DOI 10.1016/S1470-2045(15)00222-3; Baade PD, 2009, MOL NUTR FOOD RES, V53, P171, DOI 10.1002/mnfr.200700511; Bagnardi V, 2015, BRIT J CANCER, V112, P580, DOI 10.1038/bjc.2014.579; Botteri E, 2008, JAMA-J AM MED ASSOC, V300, P2765, DOI 10.1001/jama.2008.839; Bouvard V, 2015, LANCET ONCOL, V16, P1599, DOI 10.1016/S1470-2045(15)00444-1; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Bray F, 2004, BREAST CANCER RES, V6, P229, DOI 10.1186/bcr932; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Cao B, 2017, BMJ IN PRESS; Delongchamps Nicolas B, 2007, Curr Probl Cancer, V31, P226, DOI 10.1016/j.currproblcancer.2007.01.004; Doll R, 1966, CANC INCIDENCE 5 CON; Fedirko V, 2011, ANN ONCOL, V22, P1958, DOI 10.1093/annonc/mdq653; Ferlay J, 2014, CANC INCIDENCE 5 CON; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fidler MM, 2017, INT J CANCER, V140, P2709, DOI 10.1002/ijc.30686; Fidler MM, 2016, INT J CANCER, V139, P2436, DOI 10.1002/ijc.30382; Fleischer AB, 2016, DERM-ENDOCRINOL, V8, DOI 10.1080/19381980.2016.1162366; Gharibvand L, 2017, ENVIRON HEALTH PERSP, V125, P378, DOI 10.1289/EHP124; Ginsburg O, 2017, LANCET, V389, P847, DOI [10.1016/S0140-6736(16)31392-7, 10.1]; Grant WB, 2014, NUTRIENTS, V6, P163, DOI 10.3390/nu6010163; Harriss DJ, 2009, COLORECTAL DIS, V11, P689, DOI 10.1111/j.1463-1318.2009.01767.x; Harriss DJ, 2009, COLORECTAL DIS, V11, P547, DOI 10.1111/j.1463-1318.2009.01766.x; Hrushesky WJM, 2005, CANCER EPIDEM BIOMAR, V14, P1940, DOI 10.1158/1055-9965.EPI-04-0940; Huncharek M, 2009, NUTR CANCER, V61, P47, DOI 10.1080/01635580802395733; IARC (International Agency for Research on Cancer), 2010, ALC CONS ETH CARB; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC Monogr Eval Carcinog Risks Hum, V83, P1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P7; Larsson SC, 2007, AM J CLIN NUTR, V86, P556, DOI 10.1093/ajcn/86.3.556; Larsson SC, 2006, INT J CANCER, V119, P2657, DOI 10.1002/ijc.22170; Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602; Liang PS, 2009, INT J CANCER, V124, P2406, DOI 10.1002/ijc.24191; Lin YS, 2017, ANN EPIDEMIOL, V27, P215, DOI 10.1016/j.annepidem.2016.11.004; Moskal A, 2007, INT J CANCER, V120, P664, DOI 10.1002/ijc.22299; Park Y, 2005, JAMA-J AM MED ASSOC, V294, P2849, DOI 10.1001/jama.294.22.2849; Parkin DM, 2011, BRIT J CANCER, V105, pS77, DOI 10.1038/bjc.2011.489; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Samad AKA, 2005, COLORECTAL DIS, V7, P204, DOI 10.1111/j.1463-1318.2005.00747.x; SCHUTZE M, 2011, BMJ, V342; Segi M., 1950, CANC MORTALITY SELEC; Singh Gopal K, 2012, Int J MCH AIDS, V1, P17; Soerjomataram I, 2012, LANCET, V380, P1840, DOI 10.1016/S0140-6736(12)60919-2; Stewart B.W., 2014, WORLD CANC REPORT 20; Sullivan R, 2015, LANCET ONCOL, V16, P1193, DOI 10.1016/S1470-2045(15)00223-5; Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616; United Nations Development Programme, 2015, HUM DEV REP 2015; Wong MCS, 2016, EUR UROL, V70, P862, DOI 10.1016/j.eururo.2016.05.043; World Health Organization, 2014, REV CANC MED WHO LIS; Yang WS, 2016, EUR J CANCER PREV, V25, P163, DOI 10.1097/CEJ.0000000000000158	53	106	113	17	84	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1403-4948	1651-1905		SCAND J PUBLIC HEALT	Scand. J. Public Health	FEB	2018	46	1			SI		27	36		10.1177/1403494817715400			10	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	GB0SR	WOS:000428758000004	28669281		Y	N	2022-02-25	
J	Zavadil, J				Zavadil, Jiri			Genome-wide imprints of human carcinogens: implications for cancer epidemiology and prevention	CANCER SCIENCE			English	Meeting Abstract						carcinogens; massively parallel sequencing; mutational signature			[Zavadil, Jiri] Int Agcy Res Canc, Mol Mech & Biomarkers, Lyon, France				Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562				0	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1349-7006			CANCER SCI	Cancer Sci.	JAN	2018	109			1		S2-5	137	137					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	FS8VY	WOS:000422694001253					2022-02-25	
J	Franceschi, S				Franceschi, Silvia			Embryonic cells in the squamous-columnar junction of the cervix: scope for prophylactic ablation?	INTERNATIONAL JOURNAL OF CANCER			English	Editorial Material							SCREEN-AND-TREAT; INTRAEPITHELIAL NEOPLASIA; COLLABORATIVE REANALYSIS; SQUAMOCOLUMNAR JUNCTION; CANCER PREVENTION; INDIVIDUAL DATA; LONG-TERM; WOMEN; ESTROGEN; RISK		Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschis@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Allen E, 1941, CANCER RES, V1, P359; Appleby P, 2006, INT J CANCER, V119, P1108, DOI 10.1002/ijc.21953; Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5; Arbyn M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1284; Banks L, 2012, NAT REV CANCER, V12, P876, DOI 10.1038/nrc3400; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Castanon A, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5174; Chung MH, 2011, AIDS, V25, P1915, DOI 10.1097/QAD.0b013e32834a3654; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Denny L, 2005, JAMA-J AM MED ASSOC, V294, P2173, DOI 10.1001/jama.294.17.2173; Garsia S, 1982, Ann Ostet Ginecol Med Perinat, V103, P372; Herfs M, 2013, J PATHOL, V229, P460, DOI 10.1002/path.4110; Herfs M, 2012, P NATL ACAD SCI USA, V109, P10516, DOI 10.1073/pnas.1202684109; Hwang LY, 2012, J INFECT DIS, V206, P504, DOI 10.1093/infdis/jis398; KAURANIEMI T, 1978, AM J OBSTET GYNECOL, V131, P533, DOI 10.1016/0002-9378(78)90115-1; Kocken M, 2011, LANCET ONCOL, V12, P441, DOI 10.1016/S1470-2045(11)70078-X; Kuhn L, 2010, AIDS, V24, P2545, DOI 10.1097/QAD.0b013e32833e163e; PEYTON FW, 1978, AM J OBSTET GYNECOL, V131, P374, DOI 10.1016/0002-9378(78)90410-6; Rinaldi S, 2011, CANCER EPIDEM BIOMAR, V20, P2532, DOI 10.1158/1055-9965.EPI-11-0753; Spurgeon ME, 2014, AM J PATHOL, V184, P530, DOI 10.1016/j.ajpath.2013.10.013; WHO Guidelines Approved by the Guidelines Review Committee, 2013, WHO GUID SCREEN TREA; [No title captured]	22	4	4	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	MAR 1	2015	136	5					989	990		10.1002/ijc.29057			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AW5ZY	WOS:000346350500024	24990544	Bronze			2022-02-25	
J	Franceschi, S; Baussano, I				Franceschi, Silvia; Baussano, Iacopo			Naturally Acquired Immunity Against Human Papillomavirus (HPV): Why It Matters in the HPV Vaccine Era	JOURNAL OF INFECTIOUS DISEASES			English	Editorial Material						HPV; HPV vaccine; immunity; antibodies; mathematical models	COST-EFFECTIVENESS ANALYSIS; CERVICAL-CANCER; SEROPREVALENCE; TRANSMISSION; INFECTIONS; PROGRAMS; IMPACT; MODEL; PREVALENCE; ANTIBODY		[Franceschi, Silvia; Baussano, Iacopo] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Barnabas RV, 2006, PLOS MED, V3, P624, DOI 10.1371/journal.pmed.0030138; Baussano I, 2014, BRIT J CANCER, V110, P7, DOI 10.1038/bjc.2013.740; Baussano I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081171; Baussano I, 2011, VACCINE, V29, P1270, DOI 10.1016/j.vaccine.2010.11.082; Baussano I, 2010, EPIDEMICS-NETH, V2, P21, DOI 10.1016/j.epidem.2010.02.002; Bogaards JA, 2010, AM J EPIDEMIOL, V171, P817, DOI 10.1093/aje/kwp466; Carter JJ, 2000, J INFECT DIS, V181, P1911, DOI 10.1086/315498; Castellsague X, 2014, J INFECT DIS, V210, P517, DOI 10.1093/infdis/jiu139; Choi YH, 2010, VACCINE, V28, P4091, DOI 10.1016/j.vaccine.2009.09.125; Clifford GM, 2007, CANCER EPIDEM BIOMAR, V16, P1874, DOI 10.1158/1055-9965.EPI-07-0349; Elbasha EH, 2007, EMERG INFECT DIS, V13, P28, DOI 10.3201/eid1301.060438; Garnett GP, 2005, J INFECT DIS, V191, pS97, DOI 10.1086/425271; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; Hughes JP, 2002, EPIDEMIOLOGY, V13, P631, DOI 10.1097/00001648-200211000-00006; Johnson HC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049614; Kim JJ, 2007, BRIT J CANCER, V97, P1322, DOI 10.1038/sj.bjc.6604023; Korostil IA, 2013, SEX TRANSM DIS, V40, P833, DOI 10.1097/OLQ.0000000000000030; Lehtinen M, 2006, INT J CANCER, V119, P2612, DOI 10.1002/ijc.22131; Lin SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053067; Lu BB, 2012, CANCER RES, V72, P676, DOI 10.1158/0008-5472.CAN-11-0751; Markowitz LE, 2009, J INFECT DIS, V200, P1059, DOI 10.1086/604729; Olsen J, 2010, INT J TECHNOL ASSESS, V26, P183, DOI 10.1017/S0266462310000085; Ribassin-Majed L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032251; Safaeian M, 2010, JNCI-J NATL CANCER I, V102, P1653, DOI 10.1093/jnci/djq384; Schiffman M, 2009, SEX TRANSM DIS, V36, P675, DOI 10.1097/OLQ.0b013e3181bce102; Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; Tully SP, 2012, VACCINE, V30, P425, DOI 10.1016/j.vaccine.2011.10.067; Turner HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075552; Vaccarella S, 2010, CANCER EPIDEM BIOMAR, V19, P2379, DOI 10.1158/1055-9965.EPI-10-0336; Van de Velde N, 2010, VACCINE, V28, P5473, DOI 10.1016/j.vaccine.2010.05.056; Vanni T, 2012, VACCINE, V30, P4866, DOI 10.1016/j.vaccine.2012.04.087; Vanska S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072088; Wentzensen N, 2011, J INFECT DIS, V204, P94, DOI 10.1093/infdis/jir209; Zechmeister I, 2009, VACCINE, V27, P5133, DOI 10.1016/j.vaccine.2009.06.039	35	11	11	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-1899	1537-6613		J INFECT DIS	J. Infect. Dis.	AUG 15	2014	210	4					507	509		10.1093/infdis/jiu143			3	Immunology; Infectious Diseases; Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases; Microbiology	AN0AN	WOS:000340243500001	24610878	Bronze			2022-02-25	
J	Benbrahim-Tallaa, L; Lauby-Secretan, B; Loomis, D; Guyton, KZ; Grosse, Y; El Ghissassi, F; Bouvard, V; Guha, N; Mattock, H; Straif, K				Benbrahim-Tallaa, Lamia; Lauby-Secretan, Beatrice; Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Guha, Neela; Mattock, Heidi; Straif, Kurt		Int Agency Res Canc Monograph Work	Carcinogenicity of perfluorooctanoic acid, tetrafluoroethylene, dichloromethane, 1,2-dichloropropane, and 1,3-propane sultone	LANCET ONCOLOGY			English	News Item							COHORT MORTALITY; WORKERS; CHOLANGIOCARCINOMA; EXPOSURE		[Benbrahim-Tallaa, Lamia; Lauby-Secretan, Beatrice; Loomis, Dana; Guyton, Kathryn Z.; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Guha, Neela; Mattock, Heidi; Straif, Kurt; Int Agency Res Canc Monograph Work] Int Agcy Res Canc, F-69372 Lyon, France		Benbrahim-Tallaa, L (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Loomis, Dana/AAE-3988-2019; Fritschi, Lin/K-2096-2012; Guha, Neela/AAG-3989-2021; Bartell, Scott/M-8919-2013	Fritschi, Lin/0000-0002-7692-3560; Guha, Neela/0000-0003-3991-4662; Ichihara, Gaku/0000-0001-5707-5300; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Rusyn, Ivan/0000-0001-9340-7384; Kjaerheim, Kristina/0000-0003-0691-3735; DeWitt, Jamie/0000-0002-0440-4059; Loomis, Dana/0000-0003-3297-5200; Bartell, Scott/0000-0001-7797-2906; Cherrie, John/0000-0001-8901-6890	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER		Barry V, 2013, ENVIRON HEALTH PERSP, V121, P1313, DOI 10.1289/ehp.1306615; DOAK SMA, 1976, TOXICOLOGY, V6, P139, DOI 10.1016/0300-483X(76)90016-0; Gibbs GW, 1996, J OCCUP ENVIRON MED, V38, P693, DOI 10.1097/00043764-199607000-00012; International Agency for Research on Cancer, 2014, IARC MON EV IN PRESS; Kubo S, 2014, J HEPATO-BIL-PAN SCI, V21, P479, DOI 10.1002/jhbp.86; Kumagai S, 2013, OCCUP ENVIRON MED, V70, P508, DOI 10.1136/oemed-2012-101246; LANES SF, 1993, SCAND J WORK ENV HEA, V19, P426, DOI 10.5271/sjweh.1451; Matsumoto M, 2013, INHAL TOXICOL, V25, P435, DOI 10.3109/08958378.2013.800618; National Toxicology Program, 1986, Natl Toxicol Program Tech Rep Ser, V263, P1; National Toxicology Program, 1986, Natl Toxicol Program Tech Rep Ser, V306, P1; National Toxicology Program, 1997, Natl Toxicol Program Tech Rep Ser, V450, P1; Steenland K, 2012, AM J EPIDEMIOL, V176, P909, DOI 10.1093/aje/kws171; Vieira VM, 2013, ENVIRON HEALTH PERSP, V121, P318, DOI 10.1289/ehp.1205829; Wang R, 2009, AM J EPIDEMIOL, V169, P176, DOI 10.1093/aje/kwn300; WEISBURGER EK, 1981, JNCI-J NATL CANCER I, V67, P75	15	67	68	4	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	AUG	2014	15	9					924	925		10.1016/S1470-2045(14)70316-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	AO4MA	WOS:000341311600034	25225686				2022-02-25	
J	Lee, H; Hernandez-Vargas, H; Biessy, C; Barraza-Villarreal, A; Romieu, I; Herceg, Z				Lee, H.; Hernandez-Vargas, H.; Biessy, C.; Barraza-Villarreal, A.; Romieu, I.; Herceg, Z.			Modulation of Epigenetic States and Infant Immune System by Dietary Supplementation With (Omega)-3 Polyunsaturated Fatty Acid During Pregnancy in an Intervention Study	EUROPEAN JOURNAL OF CANCER			English	Meeting Abstract	22nd Biennial Congress of the European-Association-for-Cancer-Research	JUL 07-10, 2012	Barcelona, SPAIN	European Assoc Canc Res					[Lee, H.; Hernandez-Vargas, H.; Herceg, Z.] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon, France; [Biessy, C.] Int Agcy Res Canc, Nutr Epidemiol Grp, F-69372 Lyon, France									0	1	1	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049			EUR J CANCER	Eur. J. Cancer	JUL	2012	48			5		577	S137	S138		10.1016/S0959-8049(12)71235-2			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	063XX	WOS:000313036501079					2022-02-25	
J	de Martel, C; Franceschi, S				de Martel, Catherine; Franceschi, Silvia			Infections and cancer: Established associations and new hypotheses	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY			English	Review						Infection; Cancer; Risk factor; Helicobacter pylori; Hepatitis B virus; Hepatitis C virus; Human papilloma virus; Epidemiology	EPSTEIN-BARR-VIRUS; HEPATITIS-C VIRUS; HUMAN-PAPILLOMAVIRUS INFECTION; NON-HODGKINS-LYMPHOMA; T-CELL LEUKEMIA; HELICOBACTER-PYLORI ERADICATION; SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INVASIVE CERVICAL-CANCER; HEPATOCELLULAR-CARCINOMA	Around the world, infection is one of the most important causes of cancer. Almost one in every five malignancies can be attributed to infectious agents. Among infection-related neoplasms, cancers of the stomach, liver and cervix uteri detain the highest incidence figures, and are known to be largely attributable to Helicobacter pylori, hepatitis B and C viruses, and human papilloma virus, respectively. Other infectious organisms can also cause cancer; these include the Epstein-Barr virus (nasopharyngeal carcinoma, and different types of lymphoma), Human herpes virus-8 (Kaposi's Sarcoma), human T-cell leukemia virus type I (leukaemia, lymphoma), liver flukes (cholangiocarcinoma) and schistosomiasis (bladder cancer). Infection with human immunodeficiency virus, although strongly associated with an excess of cancer incidence at many cancer sites, is probably not carcinogenic per se, but acts mainly via immunodeficiency. The burden of infection-related cancers is still underestimated worldwide, due to the use of conservative population prevalence and risk ratio estimates. Furthermore, associations with new infectious agents remain yet to be explored. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[de Martel, Catherine; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Agarwal K, 2008, MAYO CLIN PROC, V83, P169, DOI 10.4065/83.2.169; [Anonymous], 1999, Wkly Epidemiol Rec, V74, P425; Appleby P, 2006, INT J CANCER, V119, P1108, DOI 10.1002/ijc.21953; Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; Barth H, 2008, J HEPATOL, V49, P134, DOI 10.1016/j.jhep.2008.03.012; Biggar RJ, 2007, J NATL CANCER I, V99, P962, DOI 10.1093/jnci/djm010; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; Carpenter LM, 2008, INT J CANCER, V122, P1319, DOI 10.1002/ijc.23254; Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Chen LT, 2005, J NATL CANCER I, V97, P1345, DOI 10.1093/jnci/dji277; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; Coscoy L, 2007, NAT REV IMMUNOL, V7, P391, DOI 10.1038/nri2076; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; Custer B, 2004, J CLIN GASTROENTEROL, V38, pS158, DOI 10.1097/00004836-200411003-00008; Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414; Dal Maso L, 2006, CANCER EPIDEM BIOMAR, V15, P2078, DOI 10.1158/1055-9965.EPI-06-0308; de Martel C, 2005, J INFECT DIS, V191, P761, DOI 10.1086/427659; De Vuyst H, 2008, INT J CANCER, V122, P244, DOI 10.1002/ijc.23045; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Du MQ, 2007, J CLIN PATHOL, V60, P1350, DOI 10.1136/jcp.2007.047969; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Ferreri AJM, 2004, J NATL CANCER I, V96, P586, DOI 10.1093/jnci/djh102; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Gasparotto D, 2002, LEUKEMIA LYMPHOMA, V43, P747, DOI 10.1080/10428190290016845; Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Hernandez BY, 2008, J INFECT DIS, V197, P787, DOI 10.1086/528379; Hildesheim A, 2007, JAMA-J AM MED ASSOC, V298, P743, DOI 10.1001/jama.298.7.743; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Honjo S, 2005, INT J CANCER, V117, P854, DOI 10.1002/ijc.21146; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669; *IARC, 1997, IARC MON EV CARC RIS, V70; *IARC, 1996, IARC MON EV CARC RIS, V67; *IARC, 1995, IARC MON EV CARC RIS, V64; IARC: International Agency for Research on Cancer, 2007, IARC MON EV CARC RIS, V90; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; International Agency for Research on Cancer (IARC), 1994, IARC MON EV CARC RIS; Kapatai G, 2007, J CLIN PATHOL, V60, P1342, DOI 10.1136/jcp.2007.050146; Keiser J, 2005, EMERG INFECT DIS, V11, P1507, DOI 10.3201/eid1110.050614; Kim JH, 2002, JPN J CANCER RES, V93, P471, DOI 10.1111/j.1349-7006.2002.tb01280.x; KINLEN L, 1988, LANCET, V2, P1323; Laha T, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-189; Lecuit M, 2004, NEW ENGL J MED, V350, P239, DOI 10.1056/NEJMoa031887; Leung WK, 2004, GUT, V53, P1244, DOI 10.1136/gut.2003.034629; Ley C, 2004, CANCER EPIDEM BIOMAR, V13, P4, DOI 10.1158/1055-9965.EPI-03-0124; Lim MK, 2006, AM J TROP MED HYG, V75, P93, DOI 10.4269/ajtmh.2006.75.93; Malope BI, 2008, AIDS, V22, P519, DOI 10.1097/QAD.0b013e3282f46582; Malope BI, 2007, JAIDS-J ACQ IMM DEF, V44, P351, DOI 10.1097/QAI.0b013e31802f12ea; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Maurer T, 2007, NEW ENGL J MED, V357, P1352, DOI 10.1056/NEJMc070508; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Moore PS, 2003, ANNU REV MICROBIOL, V57, P609, DOI 10.1146/annurev.micro.57.030502.090824; Mostafa MH, 1999, CLIN MICROBIOL REV, V12, P97, DOI 10.1128/CMR.12.1.97; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; Myers E, 2008, GYNECOL ONCOL, V109, pS31, DOI 10.1016/j.ygyno.2008.02.001; Ni YH, 2007, GASTROENTEROLOGY, V132, P1287, DOI 10.1053/j.gastro.2007.02.055; Nsubuga MM, 2008, CANCER LETT, V263, P182, DOI 10.1016/j.canlet.2007.12.025; Orem Jackson, 2007, Afr Health Sci, V7, P166; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PARKIN DM, 1991, INT J CANCER, V48, P323, DOI 10.1002/ijc.2910480302; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Pellicano R, 2008, LANCET INFECT DIS, V8, P254, DOI 10.1016/S1473-3099(08)70066-5; Pioltelli P, 2000, AM J HEMATOL, V64, P95, DOI 10.1002/(SICI)1096-8652(200006)64:2<95::AID-AJH4>3.0.CO;2-A; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; Plummer M, 2007, J NATL CANCER I, V99, P1328, DOI 10.1093/jnci/djm120; Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784; Plummer M, 2007, JNCI-J NATL CANCER I, V99, P137, DOI 10.1093/jnci/djk017; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; Poulin DL, 2006, J CLIN ONCOL, V24, P4356, DOI 10.1200/JCO.2005.03.7101; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; Rajkumar T, 2006, INT J CANCER, V118, P1481; Randi G, 2006, INT J CANCER, V118, P1591, DOI 10.1002/ijc.21683; Raza SA, 2007, BRIT J CANCER, V96, P1127, DOI 10.1038/sj.bjc.6603649; Rupnow MFT, 2000, EMERG INFECT DIS, V6, P228, DOI 10.3201/eid0603.000302; Semino-Mora C, 2003, J INFECT DIS, V187, P1165, DOI 10.1086/368133; Shepard CW, 2006, EPIDEMIOL REV, V28, P112, DOI 10.1093/epirev/mxj009; Shikata K, 2006, INT J CANCER, V119, P196, DOI 10.1002/ijc.21822; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Smith JS, 2004, INT J CANCER, V111, P431, DOI 10.1002/ijc.20257; Suarez F, 2006, BLOOD, V107, P3034, DOI 10.1182/blood-2005-09-3679; Talamini R, 2004, INT J CANCER, V110, P380, DOI 10.1002/ijc.20137; Vaccarella S, 2008, INT J EPIDEMIOL, V37, P536, DOI 10.1093/ije/dyn033; Vaccarella S, 2006, CANCER EPIDEM BIOMAR, V15, P2148, DOI 10.1158/1055-9965.EPI-06-0556; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6; Wang CC, 2007, J INFECT DIS, V196, P1474, DOI 10.1086/522608; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Whittle H, 2002, BMJ-BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569; Winer RL, 2008, J INFECT DIS, V197, P279, DOI 10.1086/524875; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Yood MU, 2007, HEPATOLOGY, V46, P107, DOI 10.1002/hep.21642; You WC, 2006, JNCI-J NATL CANCER I, V98, P974, DOI 10.1093/jnci/djj264; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; [No title captured]; 2007, GLOB IMM COV WHO UNI	118	151	156	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1040-8428	1879-0461		CRIT REV ONCOL HEMAT	Crit. Rev. Oncol./Hematol.	JUN	2009	70	3					183	194		10.1016/j.critrevonc.2008.07.021			12	Oncology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Hematology	454SW	WOS:000266704000001	18805702				2022-02-25	
J	Slimani, N; Deharveng, G; Southgate, DAT; Biessy, C; Chajes, V				Slimani, N.; Deharveng, G.; Southgate, D. A. T.; Biessy, C.; Chajes, V.		EPIC Network	CONTRIBUTION OF HIGHLY PROCESSED FOODS TO NUTRITIONAL PATTERNS IN EUROPEAN POPULATIONS: EPIDEMIOLOGICAL EVIDENCES AND NEW CHALLENGES	ANNALS OF NUTRITION AND METABOLISM			English	Meeting Abstract									[Slimani, N.; Deharveng, G.; Southgate, D. A. T.; Biessy, C.; Chajes, V.; EPIC Network] WHO, Int Agcy Res Canc, Lyon, France									0	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0250-6807			ANN NUTR METAB	Ann. Nutr. Metab.		2009	55			1			478	479					2	Endocrinology & Metabolism; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Nutrition & Dietetics	507CF	WOS:000270827201899					2022-02-25	
J	Cust, A; Kaaks, R; Friedenreich, C; Bonnet, F; Laville, M; Riboli, E				Cust, A.; Kaaks, R.; Friedenreich, C.; Bonnet, F.; Laville, M.; Riboli, E.		EPIC collaborating ctrs I	Metabolic syndrome, plasma lipids, lipoprotein and glucose levels, and endometrial cancer risk in the european investigation into cancer and nutrition (EPIC) cohort.	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Meeting Abstract	40th Annual Meeting of the Society-for-Epidemiologic-Research	JUN 19-22, 2007	Boston, MA	Soc Epidemiol Res					Int Agcy Res Canc, Nutr & Hormones Unit, F-69008 Lyon, France				Cust, Anne/J-1797-2019	Cust, Anne/0000-0002-5331-6370				0	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JUN 1	2007	165	11		S			S60	S60					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Public, Environmental & Occupational Health	175SO	WOS:000247034500240					2022-02-25	
J	Gray, N				Gray, N			The future of tobacco	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon, France		Gray, N (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	nigel@uicc.org					2005, ADDICTION, V100, P84	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					972	972		10.1136/bmj.331.7522.972			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979UR	WOS:000232970900060					2022-02-25	
J	Richardson, L				Richardson, L			Re: "Please read the following paper and write this way!"	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Letter									Int Agcy Res Canc, Radiat Grp, F-69372 Lyon, France		Richardson, L (corresponding author), Int Agcy Res Canc, Radiat Grp, F-69372 Lyon, France.						FRIEDMAN GD, 2005, AM J EPIDEMIOL, V161, P405; Lewis SA, 2005, AM J EPIDEMIOL, V161, P406, DOI 10.1093/aje/kwi059	2	0	0	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	OCT 1	2005	162	7					706	707		10.1093/aje/kwi281			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	967PE	WOS:000232102900016	16120693	Bronze			2022-02-25	
J	Boffetta, P				Boffetta, P			Alcohol and cancer: benefits in addition to risks?	LANCET ONCOLOGY			English	Editorial Material							CONSUMPTION		Int Agcy Res Canc, Gene Environm Epidemiol Grp, F-69372 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, Gene Environm Epidemiol Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	boffetta@iarc.fr					Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Ferlay J., 2001, GLOBOCAN 2000 CANC I; Little JF, 2002, PHYSIOL BEHAV, V76, P691, DOI 10.1016/S0031-9384(02)00804-1; Morton LM, 2005, LANCET ONCOL, V6, P469, DOI 10.1016/S1470-2045(05)70214-X; Rehm J., 2004, COMP QUANTIFICATION, P959; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, V8, P115; STUVER S, 2002, TXB CANC EPIDEMIOLOG, P212; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; *WORLD CANC RES FU, 1997, FOOD NUTR PREV CANC, P398; [No title captured]	10	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUL	2005	6	7					443	444		10.1016/S1470-2045(05)70225-4			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	943PV	WOS:000230367100003	15992691				2022-02-25	
J	Aapro, MS; Aaro, LE; Aro, AR; Bergenmar, M; Bloch, J; Andres, JMB; Bottomley, A; Brug, J; Corner, J; Evered, D; Flechtner, H; Geyer, S; Greimel, E; Hine, D; Johansen, C; Klepp, KI; Lynge, E; Marteau, T; Paltrinieri, B; Poetschke-Langer, M; Rautalahti, M; Razavi, D; Sasco, AJ; Segnan, N; Straif, K; Vertio, H; de Vries, H				Aapro, MS; Aaro, LE; Aro, AR; Bergenmar, M; Bloch, J; Andres, JMB; Bottomley, A; Brug, J; Corner, J; Evered, D; Flechtner, H; Geyer, S; Greimel, E; Hine, D; Johansen, C; Klepp, KI; Lynge, E; Marteau, T; Paltrinieri, B; Poetschke-Langer, M; Rautalahti, M; Razavi, D; Sasco, AJ; Segnan, N; Straif, K; Vertio, H; de Vries, H			Research in the behavioural and social sciences to improve cancer control and care: a strategy for development	EUROPEAN JOURNAL OF CANCER			English	Article						cancer care; cancer control; Europe; interdisplinary approaches; research; behavioural and social aspects of cancer		The need for a better co-ordinated interdisciplinary approach to cancer is widely recognised. An analysis of strengths and weaknesses has emphasised the importance of a better understanding of the behavioural and social factors which determine the success of preventative and screening programmes and those which will enhace the quality of care and support available to patients and their families. The European Commission provided funds to establish a consultation to formulate a strategy for the development of research in the behavioural, social and related sciences relevant to cancer. The key objectives were to inform research organisations of the steps necessary to enhance research capacity in these areas and identify the most productive directions for research in the forseeable future. The expert group identified 11 areas in which research might be expected to improve cancer control and treatment. (C) 2003 Elsevier Ltd. All rights reserved.	IARC, F-69008 Lyon, France		Evered, D (corresponding author), IARC, 150 Cours Albert Thomas, F-69008 Lyon, France.	riviere@iarc.fr	Flechtner, Hans-Hennig/M-4544-2013; Brug, Johannes/A-8242-2018	Flechtner, Hans-Hennig/0000-0001-6978-1587; Brug, Johannes/0000-0002-1904-7349				0	1	1	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	FEB	2004	40	3					316	325		10.1016/S0959-8049(03)00666-X			10	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology	772XN	WOS:000188868200010					2022-02-25	
J	Parikh, S; Brennan, P; Boffetta, P				Parikh, S; Brennan, P; Boffetta, P			Meta-analysis of social inequality and the risk of cervical cancer	INTERNATIONAL JOURNAL OF CANCER			English	Article						meta-analysis; cervical cancer	HUMAN-PAPILLOMAVIRUS INFECTION; ORAL-CONTRACEPTIVE USE; SIMPLEX VIRUS TYPE-2; INTRAEPITHELIAL NEOPLASIA; CIGARETTE-SMOKING; CARCINOMA-INSITU; UTERINE CERVIX; YOUNG-WOMEN; PAP SMEARS; REPRODUCTIVE FACTORS	Previous studies of the relationship between socio-economic status and cervical cancer have been mainly based on record linkage of routine data, such as cancer registry incidence rates and regional measures of social class based on census data. These routine data are liable to substantial misclassification with respect to socio-economic status. Previous reports are also primarily from developed countries, whereas the major burden of cervical cancer is in developing countries. We have therefore pooled the data from previously reported case-control studies of cervical cancer or dysplasia, which contain individual-level information on socioeconomic characteristics to investigate the relationship between cervical cancer, social class, stage of disease, geographical region, age and histological type. Based on 57 studies, we found an increased risk of approximately 100% between high and low social class categories for the development of invasive cervical cancer, and an increased risk of approximately 60% for dysplasia, including carcinoma in situ. Although the difference was observed in all countries, it was stronger in low/middle income countries and in North America than in Europe. No clear differences were observed between squamous cell carcinoma and adenocarcinoma, or between younger and older women. These results indicate that both cervical infection with human papillomavirus, which is linked to both female and male sexual behaviour, and access to adequate cervical cancer screening programmes are likely to be important in explaining the large cervical cancer incidence rates observed in different socioeconomic groups, and that the importance of these factors may vary between different geographical regions.	Int Agcy Res Canc, Unit Environm Canc Epidemiol, F-69008 Lyon, France		Brennan, P (corresponding author), Int Agcy Res Canc, Unit Environm Canc Epidemiol, 150 Cours Albert Thomas, F-69008 Lyon, France.	brennan@iarc.fr					AMBURGEY CF, 1993, NUTR CANCER, V20, P51, DOI 10.1080/01635589309514270; Becker T M, 1993, Alaska Med, V35, P255; BECKER TM, 1994, INT J EPIDEMIOL, V23, P913, DOI 10.1093/ije/23.5.913; Bergmark K, 1999, NEW ENGL J MED, V340, P1383, DOI 10.1056/NEJM199905063401802; BRINTON LA, 1989, AM J EPIDEMIOL, V130, P486, DOI 10.1093/oxfordjournals.aje.a115362; BRINTON LA, 1989, INT J CANCER, V44, P199, DOI 10.1002/ijc.2910440202; BRINTON LA, 1987, CANCER RES, V47, P1706; BROCK KE, 1989, MED J AUSTRALIA, V150, P125, DOI 10.5694/j.1326-5377.1989.tb136389.x; CELENTANO DD, 1987, AM J EPIDEMIOL, V126, P592, DOI 10.1093/oxfordjournals.aje.a114699; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;546::AID-IJC9&gt;3.0.CO;2-T; CLARKE EA, 1979, LANCET, V2, P1; CLARKE EA, 1982, AM J EPIDEMIOL, V115, P59, DOI 10.1093/oxfordjournals.aje.a113279; CLARKE EA, 1985, AM J OBSTET GYNECOL, V151, P612, DOI 10.1016/0002-9378(85)90149-8; COKER AL, 1992, CANCER EPIDEM BIOMAR, V1, P349; CUSIMANO R, 1989, EUR J EPIDEMIOL, V5, P363, DOI 10.1007/BF00144839; Cuzick J, 1996, EUR J CANCER, V32A, P836, DOI 10.1016/0959-8049(95)00650-8; CUZICK J, 1990, EUR J CANCER, V26, P684, DOI 10.1016/0277-5379(90)90117-C; CUZICK J, 1989, BRIT J CANCER, V60, P238, DOI 10.1038/bjc.1989.261; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; de Sanjose S, 1997, IARC Sci Publ, P309; deSanjose S, 1996, AM J PUBLIC HEALTH, V86, P1532, DOI 10.2105/AJPH.86.11.1532; DOSEMECI M, 1993, CANCER CAUSE CONTROL, V4, P313, DOI 10.1007/BF00051333; Dutta P K, 1990, Indian J Cancer, V27, P101; Faggiano F, 1997, IARC Sci Publ, P65; FAGGIANO F, 1994, J EPIDEMIOL COMMUN H, V48, P447, DOI 10.1136/jech.48.5.447; FASAL E, 1981, J NATL CANCER I, V66, P631; Gawande V. V., 1998, Indian Journal of Cancer, V35, P164; Goodman MT, 1998, CANCER EPIDEM BIOMAR, V7, P537; GUIJON FB, 1985, AM J OBSTET GYNECOL, V151, P185, DOI 10.1016/0002-9378(85)90009-2; HELLBERG D, 1986, ACTA OBSTET GYN SCAN, V65, P625, DOI 10.3109/00016348609158400; Hernandez-Avila M, 1998, INT J EPIDEMIOL, V27, P370, DOI 10.1093/ije/27.3.370; HernandezAvila M, 1997, ARCH MED RES, V28, P265; HERRERO R, 1990, CANCER-AM CANCER SOC, V65, P380, DOI 10.1002/1097-0142(19900115)65:2<380::AID-CNCR2820650234>3.0.CO;2-9; HERRERO R, 1992, INT J EPIDEMIOL, V21, P1050, DOI 10.1093/ije/21.6.1050; Hirose K, 1998, J Epidemiol, V8, P6; Ho GYF, 1998, INT J CANCER, V78, P594, DOI 10.1002/(SICI)1097-0215(19981123)78:5&lt;594::AID-IJC11&gt;3.0.CO;2-B; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; Jimenez-Perez M, 1999, INT J CANCER, V82, P804, DOI 10.1002/(SICI)1097-0215(19990909)82:6&lt;804::AID-IJC6&gt;3.0.CO;2-N; JONES CJ, 1990, CANCER RES, V50, P3657; Kjaer SK, 1996, INT J CANCER, V65, P601, DOI 10.1002/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6; KJAER SK, 1992, CANCER CAUSE CONTROL, V3, P339, DOI 10.1007/BF00146887; Kruger-Kjaer S, 1998, INT J CANCER, V76, P613, DOI 10.1002/(SICI)1097-0215(19980529)76:5&lt;613::AID-IJC1&gt;3.0.CO;2-T; LASSISE DL, 1991, INT J EPIDEMIOL, V20, P865, DOI 10.1093/ije/20.4.865; LAZCANOPONCE EC, 1995, REV INVEST CLIN, V47, P377; LIAW KL, 1995, INT J CANCER, V62, P565, DOI 10.1002/ijc.2910620513; LIU TP, 1993, CANCER EPIDEM BIOMAR, V2, P525; MOLINA R, 1988, CANCER RES, V48, P1011; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; MUNOZ N, 1994, MUTAT RES, V305, P293, DOI 10.1016/0027-5107(94)90249-6; Nieminen P, 1999, INT J CANCER, V83, P55, DOI 10.1002/(SICI)1097-0215(19990924)83:1<55::AID-IJC11>3.0.CO;2-U; Olsen AO, 1996, INT J CANCER, V68, P415, DOI 10.1002/(SICI)1097-0215(19961115)68:4<415::AID-IJC2>3.3.CO;2-X; OLSEN AO, 1995, INT J CANCER, V61, P312, DOI 10.1002/ijc.2910610306; PARAZZINI F, 1988, BRIT J CANCER, V57, P201, DOI 10.1038/bjc.1988.43; Parazzini F, 1998, BRIT J CANCER, V77, P838, DOI 10.1038/bjc.1998.136; Parazzini F, 1997, BRIT MED J, V315, P85, DOI 10.1136/bmj.315.7100.85; PARAZZINI F, 1992, CANCER-AM CANCER SOC, V69, P2276, DOI 10.1002/1097-0142(19920501)69:9<2276::AID-CNCR2820690912>3.0.CO;2-Q; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; PENG HQ, 1991, INT J CANCER, V47, P711, DOI 10.1002/ijc.2910470515; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; REEVES WC, 1987, INT J CANCER, V40, P450, DOI 10.1002/ijc.2910400403; REEVES WC, 1985, INT J CANCER, V36, P55, DOI 10.1002/ijc.2910360110; SAVITZ DA, 1995, J OCCUP ENVIRON MED, V37, P357, DOI 10.1097/00043764-199503000-00013; Segnan N, 1997, IARC Sci Publ, P369; Sengupta S, 1999, INT J CANCER, V84, P69, DOI 10.1002/(SICI)1097-0215(19990219)84:1<69::AID-IJC13>3.0.CO;2-J; Slattery M L, 1990, Epidemiology, V1, P8, DOI 10.1097/00001648-199001000-00004; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331; STELLMAN SD, 1980, AM J EPIDEMIOL, V111, P383, DOI 10.1093/oxfordjournals.aje.a112912; Thomas DB, 1996, AM J EPIDEMIOL, V143, P779, DOI 10.1093/oxfordjournals.aje.a008815; Tortolero-Luna G, 1998, Cad Saude Publica, V14 Suppl 3, P149, DOI 10.1590/S0102-311X1998000700015; TREVATHAN E, 1983, JAMA-J AM MED ASSOC, V250, P499, DOI 10.1001/jama.250.4.499; TRUSSELL J, 1992, CONTRACEPTION, V45, P11, DOI 10.1016/0010-7824(92)90137-I; Ursin G, 1996, CANCER CAUSE CONTROL, V7, P391, DOI 10.1007/BF00052946; VANEENWYK J, 1991, INT J CANCER, V48, P34, DOI 10.1002/ijc.2910480107; VERREAULT R, 1989, INT J CANCER, V43, P1050, DOI 10.1002/ijc.2910430616; Wang PD, 1996, GYNECOL ONCOL, V62, P10, DOI 10.1006/gyno.1996.0183; WANGSUPHACHART V, 1987, INT J EPIDEMIOL, V16, P362, DOI 10.1093/ije/16.3.362; WEST DW, 1984, INT J EPIDEMIOL, V13, P235, DOI 10.1093/ije/13.2.235; Wylie-Rosett J A, 1984, Nutr Cancer, V6, P49, DOI 10.1080/01635588509513806; Ylitalo N, 1999, INT J CANCER, V81, P357, DOI 10.1002/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.0.CO;2-1; Yoo K Y, 1997, J Epidemiol, V7, P117; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	81	158	161	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	JUL 10	2003	105	5					687	691		10.1002/ijc.11141			5	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	689CL	WOS:000183474000017	12740919				2022-02-25	
J	Baan, RA; Rice, JM				Baan, RA; Rice, JM			Carcinogenicity of EBDCs: Response	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Letter									Int Agcy Res Canc, Monographs Programme, Lyon, France		Baan, RA (corresponding author), Int Agcy Res Canc, Monographs Programme, Lyon, France.						Capen C.C., 1999, IARC SCI PUBL, V147; IARC, 2001, IARC MON EV CARC RIS, V79, P659; *IARC, 1992, IARC MON EV CARC RIS, V54, P13; International Agency for Research on Cancer (IARC), 2003, IARC MON PROGR EV CA; RAN E, 1996, CANC EPIDEMIOLOGY PR, P1000; Steenland K, 1997, ENVIRON HEALTH PERSP, V105, P1126, DOI 10.2307/3433855	6	1	1	0	0	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2003	111	5					A266	A267		10.1289/ehp.111-a266b			2	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	677CB	WOS:000182788400003		gold			2022-02-25	
J	Vainio, H; Kaaks, R; Bianchini, F				Vainio, H; Kaaks, R; Bianchini, F			Weight control and physical activity in cancer prevention: international evaluation of the evidence	EUROPEAN JOURNAL OF CANCER PREVENTION			English	Article; Proceedings Paper	International Symposium on Antimutagenesis and Anticarcinogenesis	APR 25-26, 2002	NY MED COLL, VALHALLA, NEW YORK	Eastman Kodak Co, Unilever Best Foods, Pepsi Cola Co, Proctor & Gamble	NY MED COLL	body mass index; evidence-based evaluation; cancer prevention; adiposity; energy balance; avoidable causes of cancer; lifestyle factors	BODY-WEIGHT; OVERWEIGHT; MORTALITY; OBESITY; MEN	To evaluate the evidence for the role of weight control and physical activity in cancer prevention and to identify priorities for research and for public health action in relation to the primary prevention of cancer, an international working group of experts was convened in Lyon in February 2001 by the International Agency for Research on Cancer of the World Health Organization. The expert group concluded that limiting weight gain during adult life, thereby avoiding overweight and obesity, reduces the risk of postmenopausal breast cancer and cancers of the colon, endometrium, kidney (renal cell) and esophagus (adenocarcinoma). Limiting weight gain possibly reduces risk of cancer of the thyroid. Weight loss among overweight or obese persons possibly reduces risks of these cancers, but no definite conclusion can be drawn because of the paucity of the epidemiological evidence. The working group also concluded that there was sufficient evidence for the role of physical activity in preventing colon and breast cancers, and limited evidence for the cancers of the prostate and endometrium. Some of these effects were independent of that of the weight control. Taken together, the working group considered that excess body weight and physical inactivity account for approximately a quarter to one-third of cancers of the colon, breast, endometrium, kidney (renal cell) and esophagus (adenocarcinoma). Thus adiposity and physical inactivity appear to be the most important avoidable causes of these cancers. (C) 2002 Lippincott Williams Wilkins.	Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon, France		Vainio, H (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon, France.						Baik I, 2000, AM J EPIDEMIOL, V152, P264, DOI 10.1093/aje/152.3.264; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Hodge AM, 1996, INT J OBESITY, V20, P137; HODGE AM, 1995, OBES RES S2, V3, P77; *IARC, 1999, IARC HDB CANC PREV, V4, P1; IARC, 1998, IARC HDB CANC PREV, V2, P1; IARC, 1998, IARC HDB CANC PREV, V3, P1; *IARC, 1997, IARC HDB CANC PREV, V1, P1; *IARC, 2001, IARC HDB CANC PREV, V5, P1; International Agency for Research on Cancer (IARC), 2002, IARC HDB CANC PREV, V6, P1; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; Livingstone B, 2000, EUR J PEDIATR, V159, pS14, DOI 10.1007/PL00014363; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Martorell R, 2000, INT J OBESITY, V24, P959, DOI 10.1038/sj.ijo.0801264; Molarius A, 1998, INT J OBESITY, V22, P719, DOI 10.1038/sj.ijo.0800660; Pi-Sunyer FX, 1999, MED SCI SPORT EXER, V31, pS602, DOI 10.1097/00005768-199911001-00019; SORKIN JD, 1994, INT J OBESITY, V18, P752; U. S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; World Health Organization, 1998, CONS OB GLOB PREV SE, P17	19	172	177	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-8278			EUR J CANCER PREV	Eur. J. Cancer Prev.	AUG	2002	11			2			S94	S100					7	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	614QC	WOS:000179200000014	12570341				2022-02-25	
J	Tong, WM; Cortes, U; Wang, ZQ				Tong, WM; Cortes, U; Wang, ZQ			Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis	BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER			English	Review						poly(ADP-ribose) polymerase-1; genomic stability; tumorigenesis; p53; DNA-dependent protein kinase	DEPENDENT PROTEIN-KINASE; SISTER-CHROMATID EXCHANGES; ADP-RIBOSE POLYMERASE; BASE EXCISION-REPAIR; DNA-DAMAGE; TELOMERE DYSFUNCTION; GENE-DISRUPTION; HOMOLOGOUS RECOMBINATION; CELLULAR-RESPONSES; MICE RESISTANT	Poly(ADP-ribosyl)ation is an immediate cellular response to DNA damage generated either exogenously or endogenously. This post-translational modification is catalyzed by poly(ADP-ribose) polymerase (PARP, PARP-1, EC 2.4.2.30). It is proposed that this protein plays a multifunctional role in many cellular processes, including DNA repair, recombination, cell proliferation and death, as well as genomic stability. Chemical inhibitors of the enzyme, dominant negative or null mutations of PARP-1 cause a high degree of genomic instability in cells. Inhibition of PARP activity by chemical inhibitors renders mice or rats susceptible to carcinogenic agents in various tumor models, indicating a role for PARP-1 in suppressing tumorigenesis. Despite the above observations, PARP-1 knockout mice are generally not prone to the development of tumors. An enhanced tumor development was observed, however, when the PARP-1 null mutation was introduced into severely compromised immune-deficient mice (a mutation in DNA-dependent protein kinase) or mice lacking other DNA repair or chromosomal guardian molecules, such as p53 or KU80. These studies indicate that PARP-1 functions as a cofactor to suppress tumorigenesis via its role in stabilization of the genome, and/or by interacting with other DNA strand break-sensing molecules. Studies using PARP-1 mutants and chemical inhibitors have started to shed light on the role of this protein and of the specific protein post-translational modification in the control of genomic stability and hence its involvement in cancer. (C) 2001 Elsevier Science B.V. All rights reserved.	Int Agcy Res Canc, IARC, F-69008 Lyon, France		Wang, ZQ (corresponding author), Int Agcy Res Canc, IARC, 150 Cours Albert Thomas, F-69008 Lyon, France.	zqwang@iarc.fr			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA79493-01] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA079493] Funding Source: NIH RePORTER		Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; Ame JC, 2001, J BIOL CHEM, V276, P11092, DOI 10.1074/jbc.M007870200; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Aoufouchi S, 1997, BIOCHEM J, V325, P543, DOI 10.1042/bj3250543; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BERGER NA, 1981, BIOCHEMISTRY-US, V20, P3610, DOI 10.1021/bi00515a047; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Bieche I, 1996, CLIN CANCER RES, V2, P1163; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; di Fagagna FD, 1999, NAT GENET, V23, P76; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; EPSTEIN JH, 1992, CANCER RES, V52, P4053; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; Henning SM, 1997, J NUTR, V127, P30, DOI 10.1093/jn/127.1.30; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HORI T, 1981, BIOCHEM BIOPH RES CO, V102, P38, DOI 10.1016/0006-291X(81)91485-6; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; KLEIHUES P, 2000, PATHOLOGY GENETICS T, P129; KOVACS G, 1981, CANCER GENET CYTOGEN, V3, P125, DOI 10.1016/0165-4608(81)90066-2; KOVACS G, 1978, INT J CANCER, V21, P688, DOI 10.1002/ijc.2910210604; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MALKIN D, 1998, GENETIC BASIS HUMAN, P393; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; MORGAN WF, 1982, MUTAT RES, V104, P361, DOI 10.1016/0165-7992(82)90170-1; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NATARAJAN AT, 1983, TAKAMATSU S, V13, P227; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.0.CO;2-3; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Rickert CH, 2001, AM J PATHOL, V158, P1525, DOI 10.1016/S0002-9440(10)64103-X; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SAWYER JR, 1990, CANCER GENET CYTOGEN, V47, P101, DOI 10.1016/0165-4608(90)90269-G; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SHOCKETT P, 1993, J IMMUNOL, V151, P6962; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TAKAHASHI S, 1984, CARCINOGENESIS, V5, P901, DOI 10.1093/carcin/5.7.901; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2000, COLD SPRING HARB SYM, V65, P583, DOI 10.1101/sqb.2000.65.583; TSUJIUCHI T, 1990, CARCINOGENESIS, V11, P1783, DOI 10.1093/carcin/11.10.1783; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P3481, DOI 10.1073/pnas.90.8.3481; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; WALDMAN AS, 1991, NUCLEIC ACIDS RES, V19, P5943, DOI 10.1093/nar/19.21.5943; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WERNER M, 1993, CANCER GENET CYTOGEN, V66, P130, DOI 10.1016/0165-4608(93)90243-F; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; WesierskaGadek J, 1996, J CELL BIOCHEM, V62, P90, DOI 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wong N, 2000, HEPATOLOGY, V32, P1060, DOI 10.1053/jhep.2000.19349; YAMAGAMI T, 1985, CANCER RES, V45, P1845	124	144	150	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0304-419X	1879-2561		BBA-REV CANCER	Biochim. Biophys. Acta-Rev. Cancer	NOV 30	2001	1552	1					27	37		10.1016/S0304-419X(01)00035-X			11	Biochemistry & Molecular Biology; Biophysics; Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Oncology	519AQ	WOS:000173701600003	11781113				2022-02-25	
J	Pineros, M; Znaor, A; Mery, L; Bray, F				Pineros, Marion; Znaor, Ariana; Mery, Les; Bray, Freddie			A Global Cancer Surveillance Framework Within Noncommunicable Disease Surveillance: Making the Case for Population-Based Cancer Registries	EPIDEMIOLOGIC REVIEWS			English	Article						neoplasms; noncommunicable diseases; registries; surveillance; world health	ADJUSTED LIFE-YEARS; DIABETES REGISTER; LUNG-CANCER; MORTALITY; HEALTH; SURVIVAL; BURDEN; TRENDS; REGISTRATION; PREVALENCE	The growing burden of cancer among several major noncommunicable diseases (NCDs) requires national implementation of tailored public health surveillance. For many emerging economies where emphasis has traditionally been placed on the surveillance of communicable diseases, it is critical to understand the specificities of NCD surveillance and, within it, of cancer surveillance. We propose a general framework for cancer surveillance that permits monitoring the core components of cancer control. We examine communalities in approaches to the surveillance of other major NCDs as well as communicable diseases, illustrating key differences in the function, coverage, and reporting in each system. Although risk factor surveys and vital statistics registration are the foundation of surveillance of NCDs, population-based cancer registries play a unique fundamental role specific to cancer surveillance, providing indicators of population-based incidence and survival. With an onus now placed on governments to collect these data as part of the monitoring of NCD targets, the integration of cancer registries into existing and future NCD surveillance strategies is a vital requirement in all countries worldwide. The Global Initiative for Cancer Registry Development, endorsed by the World Health Organization, provides a means to enhance cancer surveillance capacity in low-and middle-income countries.	[Pineros, Marion; Znaor, Ariana; Mery, Les; Bray, Freddie] Int Agcy Res Canc, Canc Surveillance Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Pineros, M (corresponding author), Int Agcy Res Canc, Canc Surveillance Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	pinerosm@iarc.fr	Piñeros, Marion/K-3255-2019; Znaor, A/H-6718-2019	Piñeros, Marion/0000-0002-4249-7276; Bray, Freddie/0000-0002-3248-7787			Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; [Anonymous], 2013, COMPR GLOB IN PRESS; ARMSTRONG BK, 1992, CANCER CAUSE CONTROL, V3, P569, DOI 10.1007/BF00052754; Armstrong Timothy, 2003, Ethn Dis, V13, pS13; Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4; Ballotari P, 2014, DIABETES RES CLIN PR, V103, P79, DOI 10.1016/j.diabres.2013.11.020; Berrino F, 1997, TUMORI J, V83, P9, DOI 10.1177/030089169708300105; Bloomberg MR, 2015, LANCET, V386, pE18, DOI 10.1016/S0140-6736(15)00400-6; Borg S, 2014, INT J ENV RES PUB HE, V11, P12223, DOI 10.3390/ijerph111212223; Boyle P, 1989, Recent Results Cancer Res, V114, P41; Bray F., 2014, PLANNING DEV POPULAT; Bray F, 2009, EUR J CANCER, V45, P747, DOI 10.1016/j.ejca.2008.11.032; Caldwell JC, 2001, B WORLD HEALTH ORGAN, V79, P159; Centers for Disease Control and Prevention, 2016, FIELD EP TRAIN PROGR; Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06; Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; de Vries E, 2016, REV COLOMB CANCEROL, V20, P45, DOI 10.1016/j.rccan.2016.02.001; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Dickman PW, 2006, J INTERN MED, V260, P103, DOI 10.1111/j.1365-2796.2006.01677.x; Elfgren IMH, 2013, PRIM HEALTH CARE RES, V14, P250, DOI 10.1017/S1463423612000515; Ellis L, 2014, INT J CANCER, V135, P1774, DOI 10.1002/ijc.28990; Eser S, 2010, ASIAN PAC J CANCER P, V11, P1731; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Forman D, 2014, CANC INCIDENCE 5 CON, VX; Fritz A., 2013, INT CLASSIFICATION D, V3rd; Glaser SL, 2005, CANCER CAUSE CONTROL, V16, P1009, DOI 10.1007/s10552-005-4501-2; Hadji M, 2013, ASIAN PAC J CANCER P, V14, P6189, DOI 10.7314/APJCP.2013.14.10.6189; International Agency for Research on Cancer, 2016, GLOB CANC OBS; International Agency for Research on Cancer, 2015, GLOB IN CANC REG DEV; International Cancer Control Partnership, 2016, NAT PLANS; International Diabetes Federation, 2015, IDF DIABETES ATLAS, V7th edn; Jedy-Agba EE, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00186; Jensen OM, 1995, CANC REGISTRATION PR; Jha P, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-19; Jo EC, 2015, HEALTHC INFORM RES, V21, P49, DOI 10.4258/hir.2015.21.1.49; Keys A, 1997, Nutrition, V13, P250; Lortet-Tieulent J, 2014, LUNG CANCER, V84, P13, DOI 10.1016/j.lungcan.2014.01.009; Louis S, 2010, PRINCIPLES PRACTICE; McKeown RE, 2009, AM J LIFESTYLE MED, V3, p19S, DOI 10.1177/1559827609335350; Mendis S, 2010, PROG CARDIOVASC DIS, V53, P10, DOI 10.1016/j.pcad.2010.01.001; Ministerio da Saude Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2015, CANC INC BRAZ; Nelson DE., 2010, PRINCIPLES PRACTICE; O'Brien Kieran S, 2013, J Registry Manag, V40, P70; Pardo Constanza, 2014, J Registry Manag, V41, P128; Pardo Ramos C, 2010, ESTIMATED INCIDENCE; Parkin DM, 2009, EUR J CANCER, V45, P756, DOI 10.1016/j.ejca.2008.11.033; Parkin DM, 2006, NAT REV CANCER, V6, P603, DOI 10.1038/nrc1948; Parkin DM, 2008, INT J CLIN ONCOL, V13, P102, DOI 10.1007/s10147-008-0762-6; Pesch B, 2012, INT J CANCER, V131, P1210, DOI 10.1002/ijc.27339; Pineros M, 2010, ATLAS CANC MORTALITY; Poole C, 2015, ANN EPIDEMIOL, V25, P147, DOI 10.1016/j.annepidem.2014.11.015; Riley L, 2016, AM J PUBLIC HEALTH, V106, P74, DOI 10.2105/AJPH.2015.302962; Sankaranarayanan R, 2011, IARC Sci Publ, P1; Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3; Santosa A, 2014, GLOBAL HEALTH ACTION, V7, P56, DOI 10.3402/gha.v7.23574; Shaw Frederic E, 2011, MMWR Suppl, V60, P7; Singh E, 2015, LANCET ONCOL, V16, pE414, DOI 10.1016/S1470-2045(15)00162-X; Soerjomataram I., 2015, CANC DIS CONTROL PRI, P23, DOI DOI 10.1596/978-1-4648-0349-9_; Soerjomataram I, 2012, LANCET, V380, P1840, DOI 10.1016/S0140-6736(12)60919-2; Soerjomataram I, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-125; Streatfield PK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25362; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Taylor R, 2016, J DIABETES, V8, P766, DOI 10.1111/1753-0407.12447; Teutsch SM, 2010, PRINCIPLES PRACTICE; Thacker SB, 2010, PRINCIPLES PRACTICE; Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2; Warren Charles W, 2009, Glob Health Promot, V16, P4, DOI 10.1177/1757975909342181; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; WHO, 2011, WORLD EC FOR BURD BE; Wild CP, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju353; Wild CP, 2014, LANCET, V384, P1502, DOI 10.1016/S0140-6736(14)61918-8; Wingo PA, 2005, CANCER CAUSE CONTROL, V16, P151, DOI 10.1007/s10552-004-3487-5; World Bank Group WHO, 2014, GLOB CIV REG VIT STA; World Health Organization, 2013, WHO GLOBAL ACTION PL; Zanetti R, 2015, EUR J CANCER, V51, P1091, DOI 10.1016/j.ejca.2013.11.040; Zimmet P, 2016, NAT REV ENDOCRINOL, V12, P616, DOI 10.1038/nrendo.2016.105	77	39	39	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0193-936X	1478-6729		EPIDEMIOL REV	Epidemiol. Rev.	JAN	2017	39	1					161	169		10.1093/epirev/mxx003			9	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	EV9DV	WOS:000402086100012	28472440	Bronze			2022-02-25	
J	Grosse, Y; Loomis, D; Guyton, KZ; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Mattock, H; Straif, K				Grosse, Yann; Loomis, Dana; Guyton, Kathryn Z.; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Mattock, Heidi; Straif, Kurt		Int Agcy Res Canc	Carcinogenicity of some industrial chemicals	LANCET ONCOLOGY			English	News Item							WORKERS; EXPOSURE; CANCER; TETRABROMOBISPHENOL; MORTALITY; HYDRAZINE; MICE		[Grosse, Yann; Loomis, Dana; Guyton, Kathryn Z.; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Mattock, Heidi; Straif, Kurt; Int Agcy Res Canc] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France		Grosse, Y (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Marques, M. Matilde/E-2535-2012; Loomis, Dana/AAE-3988-2019	Marques, M. Matilde/0000-0002-7526-4962; Nomiyama, Tetsuo/0000-0002-1702-5242; Houck, Keith/0000-0002-0055-2249; Loomis, Dana/0000-0003-3297-5200	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01 CA033193] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA033193] Funding Source: NIH RePORTER		Biancifiori C, 1970, Lav Ist Anat Istol Patol Univ Studi Perugia, V30, P89; Boice JD, 2006, J OCCUP ENVIRON MED, V48, P1070, DOI 10.1097/01.jom.0000240661.33413.b5; BOSAN WS, 1987, CARCINOGENESIS, V8, P439, DOI 10.1093/carcin/8.3.439; Collins JJ, 1999, OCCUP ENVIRON MED, V56, P667, DOI 10.1136/oem.56.10.667; DUCATMAN AM, 1986, J UROLOGY, V136, P834, DOI 10.1016/S0022-5347(17)45096-8; Gosavi RA, 2013, ENVIRON HEALTH PERSP, V121, P1194, DOI 10.1289/ehp.1306902; Hofmann PJ, 2009, TOXICOL SCI, V110, P125, DOI 10.1093/toxsci/kfp086; Honkisz E, 2015, TOXICOL IN VITRO, V29, P44, DOI 10.1016/j.tiv.2014.09.003; International Agency for Research on Cancer, 2016, IARC MONOGRAPHS EVAL, V115; Matsumoto M, 2016, REGUL TOXICOL PHARM, V76, P63, DOI 10.1016/j.yrtph.2016.01.006; National Toxicology Program, 1986, NATL TOXICOL PROGRAM, V300, P1; NTP, 2012, NATL TOXICOL PROGRAM, V579, P1; NTP, TOX STUD TETR A CAS; *NTP, 1988, NATL TOXICOL PROGR T, V332, P1; NTP (National Toxicology Program), 2011, NATL TOXICOL PROGRAM, V564, P1; Ritz B, 2006, EPIDEMIOLOGY, V17, P154, DOI 10.1097/01.ede.0000199323.55534.fb; Senoh H, 2004, J OCCUP HEALTH, V46, P429, DOI 10.1539/joh.46.429; Sorahan T, 2008, OCCUP MED-OXFORD, V58, P496, DOI 10.1093/occmed/kqn104; Watanabe W, 2010, INT IMMUNOPHARMACOL, V10, P393, DOI 10.1016/j.intimp.2009.12.014	19	34	36	3	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	APR	2016	17	4					419	420		10.1016/S1470-2045(16)00137-6			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	DI4VN	WOS:000373497600040	26928709				2022-02-25	
J	Saracci, R				Saracci, Rodolfo			Erionite and cancer in a Mexican village	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material							PLEURAL MESOTHELIOMA; CAPPADOCIAN REGION; EXPOSURE; MORTALITY; KARAIN				Saracci, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	saracci@hotmail.com					Ortega-Guerrero MA, 2015, OCCUP ENVIRON MED, V72, P216, DOI 10.1136/oemed-2013-101957; BARIS I, 1987, INT J CANCER, V39, P10, DOI 10.1002/ijc.2910390104; BARIS YI, 1978, THORAX, V33, P181, DOI 10.1136/thx.33.2.181; Baris YI, 2006, JNCI-J NATL CANCER I, V98, P414, DOI 10.1093/jnci/djj106; BARIS YI, 1981, LANCET, V1, P984; Dogan AU, 2001, LANCET, V358, P1813, DOI 10.1016/S0140-6736(01)06817-9; International Agency for Research on Cancer, 2012, IARC MON EV CARC RIS, V100B; McCormack V, 2012, BRIT J CANCER, V106, P575, DOI 10.1038/bjc.2011.563; Roushdy-Hammady I, 2001, LANCET, V357, P444, DOI 10.1016/S0140-6736(00)04013-7; SARACCI R, 1982, BRIT J CANCER, V45, P147, DOI 10.1038/bjc.1982.19; Saracci R, 2001, LANCET, V358, P1813, DOI 10.1016/S0140-6736(01)06816-7; WAGNER JC, 1985, BRIT J CANCER, V51, P727, DOI 10.1038/bjc.1985.108; [No title captured]	13	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	MAR	2015	72	3					163	164		10.1136/oemed-2014-102544			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	CB7JL	WOS:000349802700001	25406477				2022-02-25	
J	Herceg, Z				Herceg, Z.			Interplay between the cancer genome and epigenome: opportunities in elucidating mechanisms of carcinogenesis and cancer prevention	EUROPEAN JOURNAL OF CANCER			English	Meeting Abstract	European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO	SEP 27-OCT 01, 2013	Amsterdam, NETHERLANDS	European Conf Clin Oncol, European Soc Therapeut Radiol & Oncol, European Soc Med Oncol, European Soc Surg Oncol, European Assoc Canc Res, European Oncol Nursing Soc, European Soc Paediat Oncol					[Herceg, Z.] IARC, Mech Carcinogenesis Sect, Epigenet Grp, Lyon, France									0	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	SEP	2013	49			2		319	S73	S73					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	250HY	WOS:000326843600267					2022-02-25	
J	Straif, K				Straif, Kurt			Estimating the burden of occupational cancer as a strategic step to prevention	BRITISH JOURNAL OF CANCER			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon 08, France		Straif, K (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	straifk@iarc.fr					Cherrie JW, 2007, ANN OCCUP HYG, V51, P653, DOI 10.1093/annhyg/mem049; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; IARC, 2012, AG CLASS IARC MON, V1; Jarvholm B, 2013, SCAND J WORK ENV HEA, V39, P106, DOI 10.5271/sjweh.3284; Rushton L, 2008, OCCUP ENVIRON MED, V65, P789, DOI 10.1136/oem.2007.037002; Rushton L, 2010, BRIT J CANCER, V102, P1428, DOI 10.1038/sj.bjc.6605637; Tan E, 2010, BRIT J CANCER, V103, P430, DOI 10.1038/sj.bjc.6605781	7	7	7	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920	1532-1827		BRIT J CANCER	Br. J. Cancer	JUN 19	2012	107			1			S1	S2		10.1038/bjc.2012.135			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	978BM	WOS:000306714400001	22710672	Green Published, hybrid			2022-02-25	
J	Franceschi, S				Franceschi, Silvia			Cervical cancer screening at a turning point in Italy	EPIDEMIOLOGIA & PREVENZIONE			Italian	Editorial Material							HUMAN-PAPILLOMAVIRUS; INFECTION; CYTOLOGY; RISK		Int Agcy Res Canc, Lione, France		Franceschi, S (corresponding author), Int Agcy Res Canc, Lione, France.	franceschis@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Franceschi S, 2011, INT J CANCER, V128, P2765, DOI 10.1002/ijc.25915; Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101; Jeronimo J, 2006, AM J OBSTET GYNECOL, V195, P349, DOI 10.1016/j.ajog.2006.01.091; Katki HA, 2011, LANCET ONCOL, V12, P663, DOI 10.1016/S1470-2045(11)70145-0; Markt SC, 2012, J INFECT DIS, V205, P498, DOI 10.1093/infdis/jir746; Ogilvie G, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000270; Papanicolaou GN, 1941, AM J OBSTET GYNECOL, V42, P193; Plummer M, 2012, INT J CANCER, V130, P2638, DOI 10.1002/ijc.26250; Ronco G, 2011, EUROGIN 2011 LISB PO; Ronco G, 2006, JNCI-J NATL CANCER I, V98, P765, DOI 10.1093/jnci/djj209; Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016/S1470-2045(09)70360-2; SASIENI P, 2009, BMJ BRIT MED J, V0339, DOI DOI 10.1136/bmj.b2968; Sasieni P, 2010, WOMENS HEALTH, V6, P1, DOI 10.2217/WHE.09.69; Shepherd JP, 2011, COCHRANE DB SYST REV, V13, DOI DOI 10.1002/14651858.CD001035..PUB2; Snijders PJF, 2003, J PATHOL, V201, P1, DOI 10.1002/path.1433	15	0	0	0	2	INFERENZE SCARL	MILANO	VIA RICCIARELLI N 29, MILANO, 20148, ITALY	1120-9763			EPIDEMIOL PREV	Epidemiol. Prev.	MAY-AUG	2012	36	3-4					142	144					3	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	979GV	WOS:000306806400002	22828225				2022-02-25	
J	Lauby-Secretan, B; Baan, R; Grosse, Y; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Galichet, L; Straif, K				Lauby-Secretan, Beatrice; Baan, Robert; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Galichet, Laurent; Straif, Kurt		WHO Int Agcy Res Canc Monograph	Bitumens and bitumen emissions, and some heterocyclic polycyclic aromatic hydrocarbons	LANCET ONCOLOGY			English	News Item							EUROPEAN ASPHALT WORKERS; RAT LUNG; FUME EXPOSURE; COAL-TAR; CARCINOGENICITY; URINARY; COHORT		[Lauby-Secretan, Beatrice; Baan, Robert; Grosse, Yann; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Galichet, Laurent; Straif, Kurt; WHO Int Agcy Res Canc Monograph] Int Agcy Res Canc, F-69372 Lyon, France		Lauby-Secretan, B (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		McClean, Michael D/J-2934-2015; Guha, Neela/AAG-3989-2021; Kromhout, Hans/A-9159-2008; Marques, M. Matilde/E-2535-2012; Ahrens, Wolfgang/A-2740-2012	Guha, Neela/0000-0003-3991-4662; Kromhout, Hans/0000-0002-4233-1890; Marques, M. Matilde/0000-0002-7526-4962; Machala, Miroslav/0000-0001-6870-6542; Phillips, David/0000-0001-8509-3485; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Ahrens, Wolfgang/0000-0003-3777-570X			Boffetta P, 2003, AM J IND MED, V43, P18, DOI 10.1002/ajim.10181; BULL RJ, 1985, J APPL TOXICOL, V5, P423; Burgaz S, 1998, MUTAT RES-GEN TOX EN, V419, P123, DOI 10.1016/S1383-5718(98)00136-3; Clark CR, 2011, REGUL TOXICOL PHARM, V61, P9, DOI 10.1016/j.yrtph.2011.04.003; DeMeo M, 1996, CHEM-BIOL INTERACT, V101, P73, DOI 10.1016/0009-2797(96)03705-2; Fuhst R, 2007, J OCCUP ENVIRON HYG, V4, P20, DOI 10.1080/15459620701326257; Gate L, 2006, TOXICOL APPL PHARM, V215, P83, DOI 10.1016/j.taap.2006.01.012; HANSEN ES, 1989, SCAND J WORK ENV HEA, V15, P101, DOI 10.5271/sjweh.1875; IARC, IARC MON EV IN PRESS, V103; International Agency for Research on Cancer (IARC), 2010, IARC MON EV CARC RIS; Lindberg HK, 2008, MUTAT RES-GEN TOX EN, V653, P82, DOI 10.1016/j.mrgentox.2008.03.009; Murray E. B., 2005, Reviews on Environmental Health, V20, P163; Olsson A, 2010, ENVIRON HEALTH PERSP, V118, P1418, DOI 10.1289/ehp.0901800; PARTANEN T, 1994, AM J IND MED, V26, P721, DOI 10.1002/ajim.4700260602; PASQUINI R, 1989, INT ARCH OCC ENV HEA, V61, P335, DOI 10.1007/BF00409389; Qian HW, 1998, TERATOGEN CARCIN MUT, V18, P131, DOI 10.1002/(SICI)1520-6866(1998)18:3<131::AID-TCM4>3.0.CO;2-H; ROBINSON M, 1984, J APPL TOXICOL, V4, P49, DOI 10.1002/jat.2550040110; SIMMERS MH, 1965, IND MED SURG, V34, P255; Wang JJ, 2003, ANAL CHEM, V75, P5953, DOI 10.1021/ac030017a; Zhao HW, 2004, MUTAT RES-GEN TOX EN, V557, P137, DOI 10.1016/j.mrgentox.2003.10.006	20	13	13	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045			LANCET ONCOL	Lancet Oncol.	DEC	2011	12	13					1190	1191		10.1016/S1470-2045(11)70359-X			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	863GG	WOS:000298150200018	22232803				2022-02-25	
J	Finkbeiner, MG; Sawan, C; Ouzounova, M; Murr, R; Herceg, Z				Finkbeiner, Martin G.; Sawan, Carla; Ouzounova, Maria; Murr, Rabih; Herceg, Zdenko			HAT cofactor TRRAP mediates beta-catenin ubiquitination on the chromatin and the regulation of the canonical Wnt pathway	CELL CYCLE			English	Article						beta-catenin; chromatin; TRRAP; ubiquitination; Wnt pathway	ACTIVATION; TARGET; PROTEINS; COMPLEX; SIAH-1; P53	The Wnt pathway is a key regulator of embryonic development and stem cell self-renewal, and hyperactivation of the Wnt signalling is associated with many human cancers. The central player in the Wnt pathway is beta-catenin, a cytoplasmic protein whose function is tightly controlled by ubiquitination and degradation, however the precise regulation of beta-catenin stability/degradation remains elusive. Here, we report a new mechanism of beta-catenin ubiquitination acting in the context of chromatin. This mechanism is mediated by the histone acetyltransferase (HAT) complex component TRRAP and Skp1, an invariable component of the Skp-Cullin-F-box (SCF) ubiquitin ligase complex. TRRAP interacts with Skp1/SCF and mediates its recruitment to beta-catenin target promoter in chromatin. TRRAP deletion leads to a reduced level of beta-catenin ubiquitination, lower degradation rate and accumulation of beta-catenin protein. Furthermore, recruitment of Skp1 to chromatin and ubiquitination of chromatin-bound beta-catenin are abolished upon TRRAP knock-down, leading to an abnormal retention of beta-catenin at the chromatin and concomitant hyperactivation of the canonical Wnt pathway. These results demonstrate that there is a distinct regulatory mechanism for beta-catenin ubiquitination/destruction acting in the nucleus which functionally complements cytoplasmic destruction of beta-catenin and prevents its oncogenic stabilization and chronic activation of the canonical Wnt pathway.	[Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon 08, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	herceg@iarc.fr	Ouzounova, Maria/B-7189-2014	Ouzounova, Maria/0000-0001-8934-3461; Murr, Rabih/0000-0002-3346-6590	Swiss Bridge Award; association pour la Recherche sur le CancerFondation ARC pour la Recherche sur le CancerAustralian Research CouncilEuropean Commission; Ligue Nationale (Francaise) Contre le Cancer, France; Association pour la Recherche sur le Cancer (ARC), FranceFondation ARC pour la Recherche sur le Cancer; Association for International Cancer Research, UK (AICR); la Ligue Nationale (Francaise) contre le Cancer (France)Ligue nationale contre le cancer; Institut National du Cancer (EpiPro Network)Institut National du Cancer (INCA) France; Canceropole (France)	We would like to thank Dirk Bohmann, Hans Clevers, Michael Cole, Rolf Kemler and Michael Pagano, for generous gifts of reagents. We also thank Saadi Khochbin for critical reading of the manuscript and helpful discussions. Further thanks are due to John Daniel for editing the manuscript. C. S. is supported in part by the Swiss Bridge Award and the Ph. D. fellowship from association pour la Recherche sur le Cancer. R. M. is supported by the Ph. D. fellowship from la Ligue Nationale (Francaise) Contre le Cancer, France. This work was supported by grants from the Association pour la Recherche sur le Cancer (ARC), France, the Association for International Cancer Research, UK (AICR), la Ligue Nationale (Francaise) contre le Cancer (France) and Institut National du Cancer (EpiPro Network), Canceropole (France).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ashraf SI, 1998, CURR BIOL, V8, pR683, DOI 10.1016/S0960-9822(98)70435-X; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Feng Y, 2003, CANCER RES, V63, P8726; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806	20	15	16	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	DEC 15	2008	7	24					3908	3914		10.4161/cc.7.24.7354			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	384CC	WOS:000261720500018	19066453	Bronze			2022-02-25	
J	Lambert, R				Lambert, R.			Upper gastrointestinal tumors	ENDOSCOPY			English	Article							EARLY GASTRIC-CANCER; INTESTINAL METAPLASIA; MAGNIFYING ENDOSCOPY; ESOPHAGUS		Screening Grp IARC, F-69372 Lyon 8, France		Lambert, R (corresponding author), Screening Grp IARC, 150 Cours Albert Thomas, F-69372 Lyon 8, France.	lambert@iarc.fr					COLE P, 1971, BRIT J PREV SOC MED, V25, P242; Evans JA, 2007, GASTROINTEST ENDOSC, V65, P50, DOI 10.1016/j.gie.2006.04.027; *FDN PROM CANC RES, 2005, CANC STAT JAP; FERLAY J, 2004, GLOBOCAN 2002; Goda K, 2007, GASTROINTEST ENDOSC, V65, P36, DOI 10.1016/j.gie.2006.03.938; Gotoda T, 2007, GASTRIC CANCER, V10, P1, DOI 10.1007/s10120-006-0408-1; Ishikawa S, 2007, GASTRIC CANCER, V10, P35, DOI 10.1007/s10120-006-0407-2; Kara MA, 2007, DIS ESOPHAGUS, V20, P141, DOI 10.1111/j.1442-2050.2007.00660.x; Kitano S, 2007, ANN SURG, V245, P68, DOI 10.1097/01.sla.0000225364.03133.f8; Liu CG, 2007, WORLD J GASTROENTERO, V13, P4776, DOI 10.3748/wjg.v13.i35.4776; *MIN HLTH LAB WELF, 2004, SURV MED CAR ACT PUB, V2; *MIN HLTH LAB WELF, 2003, REP HLTH CTR ACT HLT, P550; Nakayoshi T, 2004, ENDOSCOPY, V36, P1080, DOI 10.1055/s-2004-825961; Nomura S, 2007, DIGEST SURG, V24, P96, DOI 10.1159/000101895; Oda I, 2006, GASTRIC CANCER, V9, P262, DOI [DOI 10.1007/s10120-006-0389-0, DOI 10.1007/S10120-006-0389-0]]; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Raza SA, 2007, BRIT J CANCER, V96, P1127, DOI 10.1038/sj.bjc.6603649; Suzuki Haruhisa, 2006, Gastric Cancer, V9, P315, DOI 10.1007/s10120-006-0399-y; Takeuchi Y, 2007, GASTROINTEST ENDOSC, V66, P186, DOI 10.1016/j.gie.2007.03.1059; Tangoku Akira, 2007, J Med Invest, V54, P1, DOI 10.2152/jmi.54.1	21	1	1	0	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	FEB	2008	40	2					131	135		10.1055/s-2007-995319			5	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	269UW	WOS:000253676800008	18058617				2022-02-25	
J	Lambert, R; Hainaut, P				Lambert, R.; Hainaut, P.			Esophageal cancer: The precursors (part II)	ENDOSCOPY			English	Review							SQUAMOUS-CELL CARCINOMA; HIGH-RISK POPULATIONS; BARRETTS-ESOPHAGUS; NORTHEASTERN IRAN; GENE-EXPRESSION; TP53 MUTATIONS; CHINA; LESIONS; EPITHELIUM; P53		Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France; Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	lambert@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CRESPI M, 1984, INT J CANCER, V34, P599, DOI 10.1002/ijc.2910340503; CRESPI M, 1979, LANCET, V2, P217; Daniely Y, 2004, AM J PHYSIOL-CELL PH, V287, pC171, DOI 10.1152/ajpcell.00226.2003; DAWSEY SM, 1994, CANCER, V74, P1686, DOI 10.1002/1097-0142(19940915)74:6<1686::AID-CNCR2820740608>3.0.CO;2-V; Endo T, 2002, GASTROINTEST ENDOSC, V55, P641, DOI 10.1067/mge.2002.123420; Hall PA, 2001, GUT, V49, P618, DOI 10.1136/gut.49.5.618; Inoue H, 2001, ENDOSCOPY, V33, P75; Jacob J H, 1993, Eur J Cancer Prev, V2, P53, DOI 10.1097/00008469-199301000-00009; Jankowski JA, 2000, LANCET, V356, P2079, DOI 10.1016/S0140-6736(00)03411-5; JASKIEWICZ K, 1987, J NATL CANCER I, V79, P961; Kamangar F, 2005, ANTICANCER RES, V25, P425; Labenz J, 2004, AM J GASTROENTEROL, V99, P1652, DOI 10.1111/j.1572-0241.2004.30390.x; Lambert R, 2007, ENDOSCOPY, V39, P550, DOI 10.1055/s-2007-966530; Levrero M, 2000, J CELL SCI, V113, P1661; Liu CG, 2005, CANCER RES, V65, P7790, DOI 10.1158/0008-5472.CAN-05-1345; Lu XJ, 2004, WORLD J GASTROENTERO, V10, P2931; Lundell LR, 1999, GUT, V45, P172, DOI 10.1136/gut.45.2.172; Mandard AM, 1997, J PATHOL, V181, P153, DOI 10.1002/(SICI)1096-9896(199702)181:2<153::AID-PATH743>3.0.CO;2-A; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Morita M, 2005, ANTICANCER RES, V25, P3533; MUNOZ N, 1982, LANCET, V1, P876; Noori P, 2001, CARCINOGENESIS, V22, P1825, DOI 10.1093/carcin/22.11.1825; Paris Workshop on Columnar, 2005, ENDOSCOPY, V37, P879, DOI DOI 10.1055/S-2005-870305; Pourshams A, 2005, BRIT J CANCER, V92, P176, DOI 10.1038/sj.bjc.6602249; QIU SL, 1988, CANCER, V62, P551, DOI 10.1002/1097-0142(19880801)62:3<551::AID-CNCR2820620319>3.0.CO;2-Y; Reid Brian J, 2003, Gastrointest Endosc Clin N Am, V13, P369, DOI 10.1016/S1052-5157(03)00006-0; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Sepehr A, 2005, ANTICANCER RES, V25, P543; Sepehr A, 2001, ONCOGENE, V20, P7368, DOI 10.1038/sj.onc.1204912; Shimizu D, 2006, INT J CANCER, V119, P765, DOI 10.1002/ijc.21922; Si HX, 2003, INT J CANCER, V103, P496, DOI 10.1002/ijc.10865; Spechler SJ, 2000, GASTROENTEROLOGY, V119, P587, DOI 10.1053/gast.2000.9849; Takubo K, 2005, HUM PATHOL, V36, P269, DOI 10.1016/j.humpath.2005.01.012; TAKUBO K, 2003, ESOPHAGUS, V1, P37, DOI [10.1007/s10388-003-0004, DOI 10.1007/S10388-003-0004-Y]]; Taniere P, 2002, AM J SURG PATHOL, V26, P1213, DOI 10.1097/00000478-200209000-00012; Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990; TANIERE P, 2005, NATURAL HIST ESOPHAG, P601; Turkdogan MK, 2005, HEPATO-GASTROENTEROL, V52, P496; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; WAHRENDORF J, 1989, LANCET, V2, P1239, DOI 10.1016/S0140-6736(89)91850-3; Wang GQ, 2005, GUT, V54, P187, DOI 10.1136/gut.2004.046631; Wang RW, 2003, CHEM J CHINESE U, V24, P205; Wei WQ, 2005, GUT, V54, P759, DOI 10.1136/gut.2004.062331; YANG GR, 1987, ENDOSCOPY, V19, P91, DOI 10.1055/s-2007-1018250; 2005, UNPUB ZHENGZH U INT	46	13	13	0	4	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X			ENDOSCOPY	Endoscopy	JUL	2007	39	7					659	664		10.1055/S-2007-966589			6	Gastroenterology & Hepatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology; Surgery	195JG	WOS:000248407900016	17611923				2022-02-25	
J	Le Roux, E; Gormally, E; Hainaut, P				Le Roux, E; Gormally, E; Hainaut, P			Somatic mutations in human cancer: applications in molecular epidemiology	REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE			English	Article; Proceedings Paper	Conference on Epidemiology and Public Health	DEC 06, 2004	Paris, FRANCE			p53; fingerprints; prognosis; early detection	HEPATOCELLULAR-CARCINOMA; AFLATOXIN B-1; P53; DNA; TUMOR; TP53; APOPTOSIS; PLASMA; EXPRESSION; THERAPY	The tumour suppressor protein p53 mediates cell-cycle arrest, DNA repair and apoptosis after activation by multiple forms of cellular stresses. When activated, this "master protein" modulates its response depending on the type and intensity of the stress. The TP53 gene with its nearly 20,000 described mutations is the most mutated gene in cancer. Most mutations are missense and occur at over 200 codons within the central portion of the gene. In several cancers, the distribution of mutation types and sites follow a specific pattern reflecting the effects of environmental mutagens. An example for such a "mutagen fingerprint" is TP53 mutation at codon 249 in hepatocellular carcinoma in regions of the world characterised by high levels of the mutagen aflatoxin B1 and endemic HBV infection. Recently, TP53 mutations have been detected in surrogate sources of genetic material such as free circulating DNA isolated from plasma. Plasma TP53 mutations can be detected in the blood of pre-cancer and cancer patients, with potential application for early cancer detection. Thus, TP53 mutations have multiple applications as markers of mutagenic exposures, or as intermediate end-points in assessment of cancer occurrence and progression.	Int Agcy Res Canc, Mol Carcinogenesis Grp, F-69372 Lyon, France		Hainaut, P (corresponding author), Int Agcy Res Canc, Mol Carcinogenesis Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913; ANTONARAKIS SE, 2002, GENETIC BASIS HUMAN, P7; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Berns EMJJ, 2000, CANCER RES, V60, P2155; Borresen-Dale AL, 1998, CLIN CANCER RES, V4, P203; Casson AG, 2003, J THORAC CARDIOV SUR, V125, P1121, DOI 10.1067/mtc.2003.176; Chaturvedi V, 2004, J CELL PHYSIOL, V198, P100, DOI 10.1002/jcp.10392; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Denissenko MF, 1998, ONCOGENE, V17, P3007, DOI 10.1038/sj.onc.1202214; Dogliotti E, 1998, RECENT RES CANCER, V154, P97; ESSIGMANN JM, 1993, TOXICOL LETT, V67, P29, DOI 10.1016/0378-4274(93)90044-X; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanawalt PC, 2003, MUTAT RES-REV MUTAT, V544, P107, DOI 10.1016/j.mrrev.2003.06.002; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.0.CO;2-Z; Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8; Kastan MB, 2001, ACTA ONCOL, V40, P686; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Linke SP, 1997, CANCER RES, V57, P1171; Lunn RM, 1999, CANCER RES, V59, P2557; Mace K, 1997, CARCINOGENESIS, V18, P1291, DOI 10.1093/carcin/18.7.1291; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Moll UM, 2003, MOL CANCER RES, V1, P1001; Montesano R, 1997, IARC Sci Publ, P291; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; PUISIEUX A, 1991, CANCER RES, V51, P6185; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; Smith-Sorensen B, 1998, BRIT J CANCER, V78, P375, DOI 10.1038/bjc.1998.502; STROUN M, 1989, ONCOLOGY, V46, P318; Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vrieling H, 1998, MUTAT RES-FUND MOL M, V400, P135, DOI 10.1016/S0027-5107(98)00064-5; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3	47	6	6	2	4	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0398-7620	1773-0627		REV EPIDEMIOL SANTE	Rev. Epidemiol. Sante Publique	JUN	2005	53	3					257	266		10.1016/S0398-7620(05)84603-6			10	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Public, Environmental & Occupational Health	950WI	WOS:000230889000005	16227913				2022-02-25	
J	Hainaut, P				Hainaut, P			Endogenous DNA damage and TP53 mutation profiles in human cancers	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Meeting Abstract	10th International Congress of Toxicology	JUL 11-15, 2004	Tampere, FINLAND						Int Agcy Res Canc, F-69372 Lyon, France				Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				0	1	1	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	JUN 15	2004	197	3				66	153	154					2	Pharmacology & Pharmacy; Toxicology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	833OZ	WOS:000222348900059					2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R			Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London 17 January 2002 - Cervical cancer in developing countries	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article; Proceedings Paper	Meeting of the Royal-Society-of-Tropical-Medicine-and-Hygiene	DEC 12, 2002	LONDON, ENGLAND	Royal Soc Trop Med & Hyg		cervical cancer; control; diagnosis; incidence; prevention; screening; mortality	VISUAL INSPECTION; ACETIC-ACID; STRATEGIES; TRENDS		Int Agcy Res Canc, F-69372 Lyon 06, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 06, France.	sankar@iarc.fr					Basu P, 2002, INT J CANCER, V100, P92, DOI 10.1002/ijc.10445; Belinson JL, 2001, OBSTET GYNECOL, V98, P441, DOI 10.1016/S0029-7844(01)01454-5; Chia KS, 2001, INT J CANCER, V93, P142, DOI 10.1002/ijc.1293; Denny L, 2000, CANCER-AM CANCER SOC, V89, P826, DOI 10.1002/1097-0142(20000815)89:4&lt;826::AID-CNCR15&gt;3.0.CO;2-5; Denny L, 2002, CANCER-AM CANCER SOC, V94, P1699, DOI 10.1002/cncr.10381; Ferenczy A, 2002, LANCET ONCOL, V3, P11, DOI 10.1016/S1470-2045(01)00617-9; FERLAY J, 2000, 5 IARC; Gaffikin L, 1999, LANCET, V353, P869; Goldie SJ, 2001, JAMA-J AM MED ASSOC, V285, P3107, DOI 10.1001/jama.285.24.3107; *IARC WORK GROUP, 1995, IARC MON EV CARC RIS, V65; JAYANT K, 1998, CANC SURVIVAL DEV CO, P69; Jin F, 1999, INT J CANCER, V83, P435, DOI 10.1002/(SICI)1097-0215(19991112)83:4&lt;435::AID-IJC1&gt;3.0.CO;2-J; Lazcano-Ponce EC, 1998, CANCER CAUSE CONTROL, V9, P241, DOI 10.1023/A:1008875818033; Lazcano-Ponce EC, 1999, ARCH MED RES, V30, P240, DOI 10.1016/S0188-0128(99)00006-8; LazcanoPonce EC, 1997, ACTA CYTOL, V41, P277, DOI 10.1159/000332512; Levin CV, 1999, RADIOTHER ONCOL, V52, P79, DOI 10.1016/S0167-8140(99)00069-9; Megevand E, 1996, OBSTET GYNECOL, V88, P383, DOI 10.1016/0029-7844(96)00189-5; PARKIN D, 1999, THAI J OBSTET GYNAEC, V11, P3; Parkin D, 1992, IARC SCI PUBLICATION, VVI; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; PARKIN DM, 2002, IN PRESS IARC SCI PU; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Robles Sylvia C., 1996, Boletin de la Oficina Sanitaria Panamericana, V121, P478; Sankaranarayanan R, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P411; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1998, CANCER-AM CANCER SOC, V83, P2150, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2150::AID-CNCR13>3.0.CO;2-0; Sankaranarayanan R, 1999, INT J CANCER, V80, P161, DOI 10.1002/(SICI)1097-0215(19990105)80:1<161::AID-IJC28>3.0.CO;2-8; Sankaranarayanan R, 1998, IARC SCI PUBLICATION, V145; STJERNSWARD J, 1987, World Health Forum, V8, P42; Wabinga HR, 2000, BRIT J CANCER, V82, P1585, DOI 10.1054/bjoc.1999.1071; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; *WHO, 2002, NAT CANC CONTR PROGR, P102	33	12	13	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	NOV-DEC	2002	96	6					580	585		10.1016/S0035-9203(02)90317-2			6	Public, Environmental & Occupational Health; Tropical Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Public, Environmental & Occupational Health; Tropical Medicine	648RW	WOS:000181165200002	12625127				2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R			Epidemiology of head and neck cancer	INTERNATIONAL JOURNAL OF CANCER			English	Meeting Abstract									Int Agcy Res Canc, Descript Epidemiol, F-69372 Lyon, France									0	0	0	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0020-7136			INT J CANCER	Int. J. Cancer		2002				13			24	25					2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	565PP	WOS:000176378900080					2022-02-25	
J	Cox, DG; Canzian, F				Cox, DG; Canzian, F			Genotype transposer: automated genotype manipulation for linkage disequilibrium analysis	BIOINFORMATICS			English	Article								The purpose of this work is to provide the modern molecular geneticist with tools to perform more efficient and more accurate analysis of the genotype data they produce. By using Microsoft Excel macros written in Visual Basic, we can translate genotype data into a form readable by the versatile software 'Arlequin', read the Arlequin output, calculate statistics of linkage disequilibrium, and put the results in a format for viewing with the software 'GOLD'.	Int Agcy Res Canc, Genome Anal Grp, F-69008 Lyon, France		Cox, DG (corresponding author), Int Agcy Res Canc, Genome Anal Grp, F-69008 Lyon, France.		Cox, David G/A-2023-2009; Cox, David/ABA-7454-2020; Canzian, Federico/I-2804-2014	Cox, David G/0000-0002-2152-9259; Canzian, Federico/0000-0002-4261-4583; Cox, David/0000-0003-2047-4687			Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; ELBEIN SC, 1992, AM J HUM GENET, V51, P1103; Schneider S., 2000, ARLEQUIN SOFTWARE PO	4	56	58	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1367-4803			BIOINFORMATICS	Bioinformatics	AUG	2001	17	8					738	739		10.1093/bioinformatics/17.8.738			2	Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics	473CB	WOS:000171021000008	11524375	Bronze			2022-02-25	
J	Li, CQ; Pignatelli, B; Ohshima, H				Li, CQ; Pignatelli, B; Ohshima, H			Increased oxidative and nitrative stress in human stomach associated with cagA(+) Helicobacter pylori infection and inflammation	DIGESTIVE DISEASES AND SCIENCES			English	Article						oxidized proteins; nitrotyrosine; Helicobacter pylori; cagA; interleukin-8; inducible nitric oxide synthase	NITRIC-OXIDE SYNTHASE; GASTRIC EPITHELIAL-CELLS; HUMAN SKELETAL-MUSCLE; DNA-DAMAGE; GEL-ELECTROPHORESIS; TYROSINE NITRATION; PROTEINS; NITROTYROSINE; CARCINOGENESIS; PEROXYNITRITE	In order to study the role of Helicobacter pylori infection in gastric carcinogenesis, we have measured oxidized (carbonyls) and nitrated (nitrotyrosine-containing) proteins as markers for oxidative and nitrative stress in 216 human gastric biopsies using dot and western immunoblots and correlated the results with H. pylori, cagA status, expression of interleukin-8 and inducible nitric oxide synthase (iNOS) mRNAs, and gastric pathology. Higher levels of both oxidized and nitrated proteins were found in patients with either chronic gastritis or duodenal ulcer than in those with normal mucosa. The Levels of modified proteins were significantly higher in inflamed samples infected with H. pylori, especially cagA strains, and in those with expression of interleukin-8 and iNOS mRNAs than in those negative for these parameters. These results indicate that infection with cagA(+) H. pylori induces significant oxidative and nitrative stress in stomach mucosa. contributing to the pathogenesis of H. pylori-associated gastroduodenal diseases.	Int Agcy Res Canc, Unit Endogerous Canc Risk Factors, F-69372 Lyon 08, France		Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogerous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Ohshima, Hiroshi/E-8044-2010				Baik SC, 1996, CANCER RES, V56, P1279; Balabanli B, 1999, P NATL ACAD SCI USA, V96, P13136, DOI 10.1073/pnas.96.23.13136; Beckman J.S., 1994, METHODS ENZYMOL, V233, P229, DOI [10.1016/s0076-6879(94)33026-3, DOI 10.1016/S0076-6879(94)33026-3]; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; CRABTREE JE, 1995, J CLIN PATHOL, V48, P967, DOI 10.1136/jcp.48.10.967; Drake IM, 1998, GUT, V42, P768, DOI 10.1136/gut.42.6.768; ENGSTRAND L, 1992, J CLIN MICROBIOL, V30, P2295, DOI 10.1128/JCM.30.9.2295-2301.1992; Farinati F, 1998, GUT, V42, P351, DOI 10.1136/gut.42.3.351; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; GRAY SF, 1986, J CLIN PATHOL, V39, P1280, DOI 10.1136/jcp.39.11.1279-a; Hahm KB, 1998, DIGEST DIS SCI, V43, p72S; IARC Working Group on the Evaluation of Carcinogenic Risks Humans, 1994, IARC MON EV CARC RIS, V61, P177; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Lamb NJ, 1999, CRIT CARE MED, V27, P1738, DOI 10.1097/00003246-199909000-00007; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Li CQ, 2000, DIGEST DIS SCI, V45, P55, DOI 10.1023/A:1005453125433; Liebler Daniel C., 1998, Molecular Carcinogenesis, V22, P209; Mannick EE, 1996, CANCER RES, V56, P3238; Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1; Nakamura A, 1996, J BIOCHEM, V119, P768; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K; Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2; Peek RM, 1997, JNCI-J NATL CANCER I, V89, P863, DOI 10.1093/jnci/89.12.863; Pignatelli B, 1998, EUR J CANCER PREV, V7, P439, DOI 10.1097/00008469-199812000-00003; PIGNATELLI B, 2001, IN PRESS AM J GASTRO; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; PRICE AB, 1991, J GASTROEN HEPATOL, V6, P209, DOI 10.1111/j.1440-1746.1991.tb01468.x; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; SINGH VN, 1991, AM J CLIN NUTR, V53, pS386, DOI 10.1093/ajcn/53.1.386S; Szabo C, 1997, FEBS LETT, V409, P147, DOI 10.1016/S0014-5793(97)00466-3; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; Yan LJ, 1998, ANAL BIOCHEM, V263, P67, DOI 10.1006/abio.1998.2799; Zingarelli B, 1999, GUT, V45, P199, DOI 10.1136/gut.45.2.199	38	46	46	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	APR	2001	46	4					836	844		10.1023/A:1010764720524			9	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	423TX	WOS:000168194800020	11330421				2022-02-25	
J	Cree, IA; White, VA; Indave, BI; Lokuhetty, D				Cree, Ian A.; White, Valerie A.; Indave, B. Iciar; Lokuhetty, Dilani			Revising the WHO classification: female genital tract tumours	HISTOPATHOLOGY			English	Review						cancer; classification; female; genital tract; tumour		The upcoming revision of the World Health Organisation (WHO) classification of tumours of the female genital tract is scheduled for release in the second quarter of 2020. It will feature significant changes compared to earlier editions. In this review, we outline the process of revising this important reference source for those diagnosing tumours or engaged in cancer research and describe the significant changes. TheWHO classification of tumoursis increasingly evidence-based, with a clear update cycle, improved quality of illustrations and content, led by an editorial board comprised mainly of pathologists, but increasingly incorporating input from other disciplines. The advent of the new website allows the use of whole-slide images and hyperlinks to evidence or external bodies that produce guidance on staging or reporting.	[Cree, Ian A.; White, Valerie A.; Indave, B. Iciar; Lokuhetty, Dilani] WHO, Int Agcy Res Canc IARC, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Cree, IA (corresponding author), WHO, Int Agcy Res Canc IARC, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	creei@iarc.fr		Lokuhetty, Dilani/0000-0002-4275-3436			Cree IA, 1996, LANCET, V347, P273, DOI 10.1016/S0140-6736(96)90455-9; Cree IA, 2014, J CLIN PATHOL, V67, P923, DOI 10.1136/jclinpath-2014-202404; Kurman R.J., 2014, WHO CLASSIFICATION T, V4th; Lakhani S. R., 2012, IARC WHO CLASSIFICAT, V4, P240; Lindroth S, 1983, LINNAEUS MAN HIS WOR, pxii; SADLER DW, 1989, LANCET, V1, P785; Swerdlow S., 2017, WHO CLASSIFICATION T; Travis WD, 1998, AM J SURG PATHOL, V22, P934, DOI 10.1097/00000478-199808000-00003	8	17	19	4	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0309-0167	1365-2559		HISTOPATHOLOGY	Histopathology	JAN	2020	76	1			SI		151	156		10.1111/his.13977			6	Cell Biology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Pathology	OB9MV	WOS:000578787600014	31846528				2022-02-25	
J	Kozlakidis, Z				Kozlakidis, Zisis			Strides forward in biobanking ethics	LANCET PUBLIC HEALTH			English	Letter									[Kozlakidis, Zisis] Int Agcy Res Canc, F-69372 Lyon 08, France		Kozlakidis, Z (corresponding author), Int Agcy Res Canc, F-69372 Lyon 08, France.	kozlakidisz@iarc.fr	Kozlakidis, Zisis/AAX-8081-2020	Kozlakidis, Zisis/0000-0002-3836-7209			Ashcroft JW, 2019, LANCET PUBLIC HEALTH, V4, pE274, DOI 10.1016/S2468-2667(19)30081-7; Langhof H, 2017, EUR J HUM GENET, V25, P293, DOI 10.1038/ejhg.2016.172; Maimuna M, 2017, COMMON MINIMUM TECHN; Simeon-Dubach D, 2018, BIOPRESERV BIOBANK, V16, P1, DOI 10.1089/bio.2017.0126; Vaught J, 2016, ANNU REV PHARMACOL, V56, P211, DOI 10.1146/annurev-pharmtox-010715-103246	5	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2468-2667			LANCET PUBLIC HEALTH	Lancet Public Health	OCT	2019	4	10					E495	E495		10.1016/S2468-2667(19)30154-9			1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	JB9BC	WOS:000488875200010	31578984	gold			2022-02-25	
J	Arnold, M; Soerjomataram, I				Arnold, Melina; Soerjomataram, Isabelle			Global chemotherapy demands: a prelude to equal access	LANCET ONCOLOGY			English	Editorial Material									[Arnold, Melina; Soerjomataram, Isabelle] Int Agcy Res Canc, Sect Canc Surveillance, F-69008 Lyon, France		Arnold, M (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, F-69008 Lyon, France.	arnoldm@fellows.iarc.fr	Arnold, Melina/AAO-9525-2020; Arnold, Melina/L-9331-2015	Arnold, Melina/0000-0003-1700-6831			[Anonymous], 2019, SEER PROGR 18 SEER R; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Boerma T, 2018, LANCET, V392, P607, DOI 10.1016/S0140-6736(18)30586-5; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Joko-Fru WY, INT J CANC; WHO, 2017, SEL US ESS MED; Wilson BE, 2019, LANCET ONCOL, V20, P769, DOI 10.1016/S1470-2045(19)30163-9	7	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	JUN	2019	20	6					742	743		10.1016/S1470-2045(19)30284-0			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	IA1QE	WOS:000469336000030	31078460				2022-02-25	
J	Clifford, GM; de Vuyst, H; Tenet, V; Plummer, M; Tully, S; Franceschi, S				Clifford, Gary M.; de Vuyst, Hugo; Tenet, Vanessa; Plummer, Martyn; Tully, Stephen; Franceschi, Silvia			Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa	JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES			English	Article						human papillomavirus; human immunodeficiency virus; cervical cancer; epidemiology; Africa	SQUAMOUS INTRAEPITHELIAL LESIONS; POSITIVE WOMEN; HPV GENOTYPES; CD4 COUNT; PREVALENCE; NEOPLASIA; RISK; CARCINOMA; IMMUNOGENICITY; POPULATION	Objectives: HIV infection is known to worsen the outcome of cervical human papillomavirus (HPV) infection and may do so differentially by HPV type. Design: Twenty-one studies were included in a meta-analysis of invasive cervical cancers (ICC) among women infected with HIV in Africa. Method: Type-specific HPV DNA prevalence was compared with data from a similar meta-analysis of HIV-negative ICC using prevalence ratios (PR). Results: HPV detection was similar in 770 HIV-positive (91.2%) and 3846 HIV-negative (89.6%) ICC, but HIV-positive ICC harbored significantly more multiple HPV infections (PR = 1.75, 95% confidence intervals: 1.18 to 2.58), which were significantly more prevalent in ICC tested from cells than from biopsies. HPV16 was the most frequently detected type in HIV-positive ICC (42.5%), followed by HPV18 (22.2%), HPV45 (14.4%), and HPV35 (7.1%). Nevertheless, HIV-positive ICC were significantly less frequently infected with HPV16 than HIV-negative ICC (PR = 0.88, 95% confidence intervals: 0.79 to 0.99). Other high-risk types were significantly more prevalent in HIV-positive ICC, but only for HPV18 was there a significantly higher prevalence of both single and multiple infections in HIV-positive ICC. Increases for other high-risk types were primarily accounted for by multiple infections. The proportion of HPV-positive ICC estimated attributable to HPV16/18 (71.8% in HIV positive, 73.4% in HIV negative) or HPV16/18/31/33/45/52/58 (88.8%, 89.5%) was not affected by HIV. Conclusions: HIV alters the relative carcinogenicity of HPV types, but prophylactic HPV16/18 vaccines may nevertheless prevent a similar proportion of ICC, irrespective of HIV infection.	[Clifford, Gary M.; de Vuyst, Hugo; Tenet, Vanessa; Plummer, Martyn; Tully, Stephen; Franceschi, Silvia] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Clifford, GM (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	cliffordg@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497	Fondation de FranceFondation de France [00039621]; Bill & Melinda Gates Foundation, USABill & Melinda Gates Foundation [OPP1053353]; International Agency for Research on Cancer; European CommissionEuropean CommissionEuropean Commission Joint Research Centre	Supported by grants from the Fondation de France (Grant number: 00039621) and the Bill & Melinda Gates Foundation, USA (Grant number: OPP1053353). The work of ST was undertaken during the tenure of a Postdoctoral Fellowship from the International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions-People-Co-funding of regional, national, and international programmes (COFUND).	Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V63, pE163, DOI 10.1097/QAI.0b013e31829cb7c3; Adjorlolo-Johnson G, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-242; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; Darwich L, 2011, INT J GYNECOL CANCER, V21, P1486, DOI 10.1097/IGC.0b013e31822a0195; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; De Vuyst H, 2003, SEX TRANSM DIS, V30, P137, DOI 10.1097/00007435-200302000-00009; De Vuyst H, 2012, BRIT J CANCER, V107, P1624, DOI 10.1038/bjc.2012.441; De Vuyst H, 2008, INT J CANCER, V122, P244, DOI 10.1002/ijc.23045; De Vuyst H, 2013, INT J CANCER, V133, P1441, DOI 10.1002/ijc.28131; De Vuyst H, 2012, INT J CANCER, V131, P949, DOI 10.1002/ijc.26470; Denny L, 2014, INT J CANCER, V134, P1389, DOI 10.1002/ijc.28425; Einstein MH, 2011, HUM VACCINES, V7, P1359, DOI 10.4161/hv.7.12.18282; Ermel A, 2015, 30 INT PAP C CLIN PU; Ermel A, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-22; Gravitt PE, 2007, J CLIN MICROBIOL, V45, P3245, DOI 10.1128/JCM.00216-07; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; Hanisch RA, 2013, J CLIN VIROL, V58, P696, DOI 10.1016/j.jcv.2013.10.012; Harris TG, 2005, JAMA-J AM MED ASSOC, V293, P1471, DOI 10.1001/jama.293.12.1471; Hawes S, 2007, 24 INT PAP C CLIN WO; Hawes SE, 2003, J INFECT DIS, V188, P555, DOI 10.1086/376996; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P9; Jamieson DJ, 2002, AM J OBSTET GYNECOL, V186, P21, DOI 10.1067/mob.2002.119776; Joshi S, 2013, AIDS, V27, P607, DOI 10.1097/QAD.0b013e32835b1041; Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044; Keita N, 2009, BRIT J CANCER, V101, P202, DOI 10.1038/sj.bjc.6605140; Klug SJ, 2008, J MED VIROL, V80, P1264, DOI 10.1002/jmv.21191; La Ruche G, 1998, INT J CANCER, V76, P480, DOI 10.1002/(SICI)1097-0215(19980518)76:4&lt;480::AID-IJC6&gt;3.0.CO;2-N; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Maranga Innocent O, 2013, Open Virol J, V7, P19, DOI 10.2174/1874357901307010019; Massad LS, 2014, AIDS, V28, P2601, DOI 10.1097/QAD.0000000000000455; McDonald AC, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00048; Muwonge C, 2010, 26 INT PAP C CLIN PU; Naucler P, 2011, J GEN VIROL, V92, P2784, DOI 10.1099/vir.0.034298-0; Odida M, 2011, INFECT AGENTS CANCER, V6, DOI 10.1186/1750-9378-6-8; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; Ramogola-Masire D, 2011, INT J GYNECOL PATHOL, V30, P591, DOI 10.1097/PGP.0b013e31821bf2a6; Rowhani-Rahbar A, 2007, J INFECT DIS, V196, P887, DOI 10.1086/520883; Sahasrabuddhe VV, 2007, BRIT J CANCER, V96, P1480, DOI 10.1038/sj.bjc.6603737; Strickler HD, 2003, JNCI-J NATL CANCER I, V95, P1062, DOI 10.1093/jnci/95.14.1062; Toft L, 2014, J INFECT DIS, V209, P1165, DOI 10.1093/infdis/jit657; van Aardt MC, 2015, INT J GYNECOL CANCER, V25, P919, DOI 10.1097/IGC.0000000000000422; van der Marel J, 2015, AM J SURG PATHOL, V39, P496, DOI 10.1097/PAS.0000000000000342; Vidal AC, 2011, INFECT AGENTS CANCER, V6, DOI 10.1186/1750-9378-6-20; Wentzensen N, 2009, INT J CANCER, V125, P2151, DOI 10.1002/ijc.24528; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x	47	50	51	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1525-4135	1077-9450		JAIDS-J ACQ IMM DEF	JAIDS	NOV 1	2016	73	3					332	339					8	Immunology; Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases	ED7KV	WOS:000389044000020	27331659	Green Published			2022-02-25	
J	Guyton, KZ; El Ghissassi, F; Benbrahim-Talaa, L; Grosse, Y; Loomis, D; Straif, K				Guyton, K. Z.; El Ghissassi, F.; Benbrahim-Talaa, L.; Grosse, Y.; Loomis, D.; Straif, K.			Recent Progress in Mechanistic Data Evaluation: The IARC Monographs Perspective	ENVIRONMENTAL AND MOLECULAR MUTAGENESIS			English	Meeting Abstract									[Guyton, K. Z.; El Ghissassi, F.; Benbrahim-Talaa, L.; Grosse, Y.; Loomis, D.; Straif, K.] WHO, IARC, Lyon, France				Loomis, Dana/AAE-3988-2019					0	5	5	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0893-6692	1098-2280		ENVIRON MOL MUTAGEN	Environ. Mol. Mutagen.	AUG	2015	56			1		P109	S84	S84					1	Environmental Sciences; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Genetics & Heredity; Toxicology	CP9PJ	WOS:000360226400216					2022-02-25	
J	Scalbert, A; Zamora-Ros, R				Scalbert, Augustin; Zamora-Ros, Raul			Bridging evidence from observational and intervention studies to identify flavonoids most protective for human health	AMERICAN JOURNAL OF CLINICAL NUTRITION			English	Editorial Material							TEA CONSUMPTION; METAANALYSIS; COCOA; RISK		[Scalbert, Augustin; Zamora-Ros, Raul] IARC, F-69372 Lyon 08, France		Scalbert, A (corresponding author), IARC, Nutr & Metab Sect, Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	scalberta@iarc.fr	Zamora-Ros, Raul/AAA-7111-2020; Scalbert, Augustin/AAX-8160-2021	Zamora-Ros, Raul/0000-0002-6236-6804; Scalbert, Augustin/0000-0001-6651-6710			Arab L, 2009, STROKE, V40, P1786, DOI 10.1161/STROKEAHA.108.538470; Dower JI, 2015, AM J CLIN NUTR, V101, P914, DOI 10.3945/ajcn.114.098590; Hollman PCH, 2011, J NUTR, V141, p989S, DOI 10.3945/jn.110.131490; Hooper L, 2012, AM J CLIN NUTR, V95, P740, DOI 10.3945/ajcn.111.023457; Ivey KL, 2015, AM J CLIN NUTR, V101, P1012, DOI 10.3945/ajcn.113.073106; Morand C, 2011, AM J CLIN NUTR, V93, P73, DOI 10.3945/ajcn.110.004945; Perez-Jimenez J, 2011, AM J CLIN NUTR, V93, P1220, DOI 10.3945/ajcn.110.007096; Rothwell JA, 2012, DATABASE-OXFORD, DOI 10.1093/database/bas031; Schaer MY, 2015, AM J CLIN NUTR, V101, P931, DOI 10.3945/ajcn.114.104364; Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103; Yang WS, 2014, BRIT J NUTR, V111, P1329, DOI 10.1017/S0007114513003887; Zamora-Ros R, 2014, AM J CLIN NUTR, V100, P11, DOI 10.3945/ajcn.113.077743; Zamora-Ros R, 2013, BRIT J NUTR, V110, P1500, DOI 10.1017/S0007114513000688	13	8	8	0	12	AMER SOC NUTRITION-ASN	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9165	1938-3207		AM J CLIN NUTR	Am. J. Clin. Nutr.	MAY	2015	101	5					897	898		10.3945/ajcn.115.110205			2	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	CH5KS	WOS:000354075100001	25832341	Bronze			2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, Rengaswamy			Magnivisualizer in the early detection of cervical neoplasia	JOURNAL OF GYNECOLOGIC ONCOLOGY			English	Editorial Material							VISUAL INSPECTION; CANCER PREVENTION; TREAT; INDIA; SEE; MAGNIFICATION; MANAGEMENT		[Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Early Detect & Prevent Sect, F-69372 Lyon 08, France; [Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Screening Grp, F-69372 Lyon 08, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Early Detect & Prevent Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	sankarr@iarc.fr					Aggarwal P, 2011, ARCH GYNECOL OBSTET, V284, P397, DOI 10.1007/s00404-010-1673-0; Arbyn M, 2012, VACCINE, V30, pF88, DOI 10.1016/j.vaccine.2012.06.095; Chigbu CO, 2014, INT J GYNECOL OBSTET, V124, P204, DOI 10.1016/j.ijgo.2013.07.040; Muwonge R, 2014, INT J CANCER, V134, P2902, DOI 10.1002/ijc.28627; Nuranna L, 2012, J GYNECOL ONCOL, V23, P147, DOI 10.3802/jgo.2012.23.3.147; Parashari A, 2014, ANN MED HEALTH SCI R, V4, P146, DOI 10.4103/2141-9248.126628; Parashari A, 2000, B WORLD HEALTH ORGAN, V78, P964; Sankaranarayanan R, 2007, BRIT J CANCER, V96, P738, DOI 10.1038/sj.bjc.6603633; Sankaranarayanan R, 2004, CANCER DETECT PREV, V28, P345, DOI 10.1016/j.cdp.2004.04.004; Shastri SS, 2005, B WORLD HEALTH ORGAN, V83, P186; Singh V, 2013, J OBSTET GYNAECOL, V33, P898, DOI 10.3109/01443615.2013.823389; Singh V, 2014, J GYNECOL ONCOL, V25, P282, DOI 10.3802/jgo.2014.25.4.282; Singla S, 2012, INDIAN J MED RES, V135, P614; Untiet S, 2014, INT J CANCER, V135, P1911, DOI 10.1002/ijc.28834; Winkler JL, 2008, REV PANAM SALUD PUBL, V23, P1, DOI 10.1590/S1020-49892008000100001	15	3	3	0	4	KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY	SEOUL	102-HO, 55-5, NONHYEON-DONG, GANGNAM-GU, SEOUL, 135-010, SOUTH KOREA	2005-0380	2005-0399		J GYNECOL ONCOL	J. Gynecol. Oncol.	OCT	2014	25	4					263	264		10.3802/jgo.2014.25.4.263			2	Oncology; Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Obstetrics & Gynecology	AQ7TR	WOS:000343022600001	25310029	Green Published, Green Submitted			2022-02-25	
J	Schinasi, L; Leon, ME				Schinasi, Leah; Leon, Maria E.			Non-Hodgkin Lymphoma and Occupational Exposure to Agricultural Pesticide Chemical Groups and Active Ingredients: A Systematic Review and Meta-Analysis	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Review						pesticides; insecticides; herbicides; fungicides; lymphoma; non-Hodgkin; occupational; agricultural	HUMAN CANCER-RISK; POOLED ANALYSIS; APPLICATORS; FARMERS; MEN; HEALTH; NEOPLASMS; ATRAZINE; SUBTYPES; SARCOMA	This paper describes results from a systematic review and a series of meta-analyses of nearly three decades worth of epidemiologic research on the relationship between non-Hodgkin lymphoma (NHL) and occupational exposure to agricultural pesticide active ingredients and chemical groups. Estimates of associations of NHL with 21 pesticide chemical groups and 80 active ingredients were extracted from 44 papers, all of which reported results from analyses of studies conducted in high-income countries. Random effects meta-analyses showed that phenoxy herbicides, carbamate insecticides, organophosphorus insecticides and the active ingredient lindane, an organochlorine insecticide, were positively associated with NHL. In a handful of papers, associations between pesticides and NHL subtypes were reported; B cell lymphoma was positively associated with phenoxy herbicides and the organophosphorus herbicide glyphosate. Diffuse large B-cell lymphoma was positively associated with phenoxy herbicide exposure. Despite compelling evidence that NHL is associated with certain chemicals, this review indicates the need for investigations of a larger variety of pesticides in more geographic areas, especially in low- and middle-income countries, which, despite producing a large portion of the world's agriculture, were missing in the literature that were reviewed.	[Schinasi, Leah; Leon, Maria E.] Int Agcy Res Canc, Sect Environm & Radiat, F-69372 Lyon 08, France		Schinasi, L (corresponding author), Int Agcy Res Canc, Sect Environm & Radiat, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	schinasil@fellows.iarc.fr; leonrouxm@iarc.fr			Office National de l'Eau et des Milieux Aquatiques-ONEMA, France	Leah Schinasi is supported by a grant from the Office National de l'Eau et des Milieux Aquatiques-ONEMA, France.	Adamson P, 2007, EUR J CANCER, V43, P391, DOI 10.1016/j.ejca.2006.10.008; Alavanja MCR, 1996, ENVIRON HEALTH PERSP, V104, P362, DOI 10.2307/3432672; Alavanja MCR, 2013, CA-CANCER J CLIN, V63, P120, DOI 10.3322/caac.21170; Alexander DD, 2007, INT J CANCER, P1, DOI 10.1002/ijc.22719; Baris D, 1998, OCCUP ENVIRON MED, V55, P522, DOI 10.1136/oem.55.8.522; Barry KH, 2012, CANCER CAUSE CONTROL, V23, P807, DOI 10.1007/s10552-012-9949-2; Blair A, 1998, AM J IND MED, V33, P82, DOI 10.1002/(SICI)1097-0274(199801)33:1&lt;82::AID-AJIM9&gt;3.0.CO;2-Y; Blair A, 2009, J AGROMEDICINE, V14, P125, DOI 10.1080/10599240902779436; Bonner MR, 2007, AM J EPIDEMIOL, V166, P1023, DOI 10.1093/aje/kwm182; Bonner MR, 2010, CANCER CAUSE CONTROL, V21, P871, DOI 10.1007/s10552-010-9514-9; Bonner MR, 2005, ENVIRON HEALTH PERSP, V113, P285, DOI 10.1289/ehp.7451; CANTOR KP, 1992, CANCER RES, V52, P2447; Chiu BCH, 2006, BLOOD, V108, P1363, DOI 10.1182/blood-2005-12-008755; Chiu BCH, 2009, J AGROMEDICINE, V14, P250, DOI 10.1080/10599240902773140; Cocco P, 2013, INT J CANCER, V132, P2613, DOI 10.1002/ijc.27908; Cocco P, 2013, OCCUP ENVIRON MED, V70, P91, DOI 10.1136/oemed-2012-100845; De Roos AJ, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.9.e11; De Roos AJ, 2005, ENVIRON HEALTH PERSP, V113, P49, DOI 10.1289/ehp.7340; Delancey JOL, 2009, ANN EPIDEMIOL, V19, P388, DOI 10.1016/j.annepidem.2008.12.018; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Egger M, 1998, BRIT MED J, V316, P140; Eltom MA, 2002, J NATL CANCER I, V94, P1204, DOI 10.1093/jnci/94.16.1204; Environmental Protection Agency, PEST; Eriksson M, 2008, INT J CANCER, V123, P1657, DOI 10.1002/ijc.23589; Faustini A, 1996, OCCUP ENVIRON MED, V53, P583, DOI 10.1136/oem.53.9.583; Food and Agriculture Organization of the United Nations, AGR PROD DOM; Freeman LEB, 2012, CANCER CAUSE CONTROL, V23, P663, DOI 10.1007/s10552-012-9921-1; Freeman LEB, 2011, ENVIRON HEALTH PERSP, V119, P1253, DOI 10.1289/ehp.1103561; Freeman LEB, 2005, AM J EPIDEMIOL, V162, P1070, DOI 10.1093/aje/kwi321; Fritschi L, 2005, AM J EPIDEMIOL, V162, P849, DOI 10.1093/aje/kwi292; Hardell L, 2002, LEUKEMIA LYMPHOMA, V43, P1043, DOI 10.1080/10428190290021560; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HOAR SK, 1986, JAMA-J AM MED ASSOC, V256, P1141, DOI 10.1001/jama.256.9.1141; IARC, IARC MONOGRAPHS EVAL; IARC, 1999, IARC MON EV CARC RIS, P1597; IARC, 1987, IARC MON EV CARC RIS, V1-42; IARC, 2012, IARC MONOGRAPHS EVAL, V100F; *IARC, 1991, IARC MON EV CARC RIS; IARC (International Agency for Research on Cancer), 2001, IARC MON EV CARC RIS; IARC (International Agency for Research on Cancer), AGRICOH CONS AGR COH; International Agency for Research on Cancer (IARC), GLOBOCAN 2012 EST CA; Kang D, 2008, ENVIRON RES, V107, P271, DOI 10.1016/j.envres.2008.01.010; Khuder SA, 1998, SCAND J WORK ENV HEA, V24, P255, DOI 10.5271/sjweh.318; Koutros S, 2008, CANCER CAUSE CONTROL, V19, P59, DOI 10.1007/s10552-007-9070-0; Koutros S, 2009, INT J CANCER, V124, P1206, DOI 10.1002/ijc.24020; Lee WJ, 2004, JNCI-J NATL CANCER I, V96, P1781, DOI 10.1093/jnci/djh324; Lee WJ, 2004, AM J EPIDEMIOL, V159, P373, DOI 10.1093/aje/kwh040; Lynch SM, 2006, ENVIRON HEALTH PERSP, V114, P1248, DOI 10.1289/ehp.8997; Lynch SM, 2009, ENVIRON RES, V109, P860, DOI 10.1016/j.envres.2009.06.006; Mahajan R, 2007, INT J CANCER, V121, P1799, DOI 10.1002/ijc.22836; McDuffie HH, 2001, CANCER EPIDEM BIOMAR, V10, P1155; Merhi M, 2007, CANCER CAUSE CONTROL, V18, P1209, DOI 10.1007/s10552-007-9061-1; Miligi L, 2006, ANN NY ACAD SCI, V1076, P366, DOI 10.1196/annals.1371.036; Mills PK, 2005, CANCER CAUSE CONTROL, V16, P823, DOI 10.1007/s10552-005-2703-2; Morton LM, 2007, BLOOD, V110, P695, DOI 10.1182/blood-2006-11-051672; Orsi L, 2009, OCCUP ENVIRON MED, V66, P291, DOI 10.1136/oem.2008.040972; Pahwa M, 2012, INT J CANCER, V131, P2650, DOI 10.1002/ijc.27522; Pearce N, 2005, SCAND J WORK ENV HEA, V31, P18; PEARCE NE, 1987, INT J CANCER, V39, P155, DOI 10.1002/ijc.2910390206; PERSSON B, 1993, CANCER, V72, P1773, DOI 10.1002/1097-0142(19930901)72:5<1773::AID-CNCR2820720542>3.0.CO;2-6; PERSSON B, 1989, BRIT J IND MED, V46, P516; Poole C, 2001, EPIDEMIOLOGY, V12, P291, DOI 10.1097/00001648-200105000-00005; Purdue MP, 2007, INT J CANCER, V120, P642, DOI 10.1002/ijc.22258; Rafnsson V, 2006, EUR J CANCER, V42, P2781, DOI 10.1016/j.ejca.2006.03.035; Rusiecki JA, 2006, INT J CANCER, V118, P3118, DOI 10.1002/ijc.21758; Rusiecki JA, 2009, ENVIRON HEALTH PERSP, V117, P581, DOI 10.1289/ehp.11318; Sathiakumar N, 1996, AM J IND MED, V29, P143, DOI 10.1002/(SICI)1097-0274(199602)29:2&lt;143::AID-AJIM4&gt;3.0.CO;2-T; Schroeder JC, 2001, EPIDEMIOLOGY, V12, P701, DOI 10.1097/00001648-200111000-00020; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; van Bemmel DM, 2008, ENVIRON HEALTH PERSP, V116, P1541, DOI 10.1289/ehp.11371; Waddell BL, 2001, CANCER CAUSE CONTROL, V12, P509, DOI 10.1023/A:1011293208949; Wood A, COMPENDIUM PESTICIDE; WOODS JS, 1987, J NATL CANCER I, V78, P899; Zahm S H, 1990, Epidemiology, V1, P349, DOI 10.1097/00001648-199009000-00004; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353, DOI 10.1080/00039896.1993.9936725; ZAHM SH, 1993, SCAND J WORK ENV HEA, V19, P108, DOI 10.5271/sjweh.1499; Zheng TZ, 2001, J OCCUP ENVIRON MED, V43, P641, DOI 10.1097/00043764-200107000-00012	77	124	132	1	81	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1660-4601		INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	APR	2014	11	4					4449	4527		10.3390/ijerph110404449			79	Environmental Sciences; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	AG9TM	WOS:000335762700051	24762670	Green Published, gold, Green Submitted			2022-02-25	
J	Licaj, I; Romieu, I; Ferrari, P				Licaj, I.; Romieu, I.; Ferrari, P.			The role of alcohol consumption on overall and cause-specific mortality in the European Prospective Investigation into Cancer (EPIC) study: A competing risks analysis	EUROPEAN JOURNAL OF CANCER			English	Meeting Abstract	European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO	SEP 27-OCT 01, 2013	Amsterdam, NETHERLANDS	European Conf Clin Oncol, European Soc Therapeut Radiol & Oncol, European Soc Med Oncol, European Soc Surg Oncol, European Assoc Canc Res, European Oncol Nursing Soc, European Soc Paediat Oncol					[Licaj, I.; Romieu, I.; Ferrari, P.] Int Agcy Res Canc, Nutr Epidemiol Grp, F-69372 Lyon, France				Licaj, Idlir/AAC-2772-2021					0	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	SEP	2013	49			2		1449	S312	S312					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	250HY	WOS:000326843602155					2022-02-25	
J	Scalbert, A				Scalbert, A.			Mining the polyphenol metabolome to identify in population studies its components most protective against chronic diseases	PLANTA MEDICA			English	Meeting Abstract	International Congress on Natural Products Research on Global Change, Natural Products and Human Health/8th Joint Meeting of AFERP, ASP, GA, PSE and SIF	JUL 28-AUG 01, 2012	New York, NY	Amer Soc Pharmacognosy (ASP), Soc Med Plant & Nat Prod Res (GA), Italian Soc Phytochem (SIF), Phytochem Soc Europe (PSE), French Speaking Soc Pharmacognosy (AFERP)			PHENOL-EXPLORER DATABASE		[Scalbert, A.] IARC, Nutr & Metab Sect, Biomarkers Grp, F-69372 Lyon 08, France				Scalbert, Augustin/AAX-8160-2021	Scalbert, Augustin/0000-0001-6651-6710			Perez-Jimenez J, 2010, EUR J CLIN NUTR, V64, pS112, DOI 10.1038/ejcn.2010.221; Perez-Jimenez J, 2011, AM J CLIN NUTR, V93, P1220, DOI 10.3945/ajcn.110.007096; Perez-Jimenez J, 2010, AM J CLIN NUTR, V92, P801, DOI 10.3945/ajcn.2010.29924; Perez-Jimenez J, 2010, J AGR FOOD CHEM, V58, P4959, DOI 10.1021/jf100128b; Scalbert A, 2011, J AGR FOOD CHEM, V59, P4331, DOI 10.1021/jf200591d	5	0	0	0	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0032-0943			PLANTA MED	Planta Med.	AUG	2012	78	11					1042	1042					1	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	982KT	WOS:000307042800044					2022-02-25	
J	Forman, D				Forman, D.			Cancer Incidence and Mortality in Europe - GLOBOCAN 2008	EUROPEAN JOURNAL OF CANCER			English	Meeting Abstract	European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care	SEP 23-27, 2011	Stockholm, SWEDEN						[Forman, D.] IARC, Lyon, France									0	0	0	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049			EUR J CANCER	Eur. J. Cancer	SEP	2011	47			1			S24	S24		10.1016/S0959-8049(11)70308-2			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	831TA	WOS:000295752800078					2022-02-25	
J	Grosse, Y; Baan, R; Secretan-Lauby, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Islami, F; Galichet, L; Straif, K				Grosse, Yann; Baan, Robert; Secretan-Lauby, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Islami, Farhad; Galichet, Laurent; Straif, Kurt		WHO Int Agcy Res Canc Monograph	Carcinogenicity of chemicals in industrial and consumer products, food contaminants and flavourings, and water chlorination byproducts	LANCET ONCOLOGY			English	News Item							ACTIVATED RECEPTOR-ALPHA; RATS; DI(2-ETHYLHEXYL)PHTHALATE; TUMORIGENESIS; HEMOGLOBIN; ADDUCTS; TUMORS; LIVER		[Grosse, Yann; Baan, Robert; Secretan-Lauby, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Islami, Farhad; Galichet, Laurent; Straif, Kurt; WHO Int Agcy Res Canc Monograph] Int Agcy Res Canc, F-69372 Lyon, France		Grosse, Y (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Lachenmeier, Dirk W./A-3210-2008; Guha, Neela/AAG-3989-2021; Lunn, Ruth/AAP-8848-2021	Lachenmeier, Dirk W./0000-0002-3115-864X; Guha, Neela/0000-0003-3991-4662; Lauby-Secretan, Beatrice/0000-0001-6559-3351; Islami, Farhad/0000-0002-7357-5994			David RM, 2000, TOXICOL SCI, V55, P433, DOI 10.1093/toxsci/55.2.433; Hauser R, 2007, HUM REPROD, V22, P688, DOI 10.1093/humrep/del428; *IARC, IARC MON EV IN PRESS, V101; International Agency for Research on Cancer (IARC), 2000, IARC MON EV CARC RIS, V77; Ito Y, 2007, J OCCUP HEALTH, V49, P172, DOI 10.1539/joh.49.172; Jones CR, 2005, CARCINOGENESIS, V26, P133, DOI 10.1093/carcin/bgh286; Jones CR, 2003, CARCINOGENESIS, V24, P779, DOI 10.1093/carcin/24.4.779; Morimura K, 2006, CARCINOGENESIS, V27, P1074, DOI 10.1093/carcin/bgi329; *NAT TOX PROGR, 2002, NATI TOXICOL PROGRAM, V504, P1; National Toxicology Program, 2007, NATL TOXICOL PROGRAM, V535, P1; Sills RC, 2004, CARCINOGENESIS, V25, P605, DOI 10.1093/carcin/bgh044; Voss C, 2005, TOXICOLOGY, V206, P359, DOI 10.1016/j.tox.2004.07.016; Yang Q, 2007, CARCINOGENESIS, V28, P1171, DOI 10.1093/carcin/bgm046	13	64	73	0	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	APR	2011	12	4					328	329		10.1016/S1470-2045(11)70088-2			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	751BZ	WOS:000289593800010	21598447				2022-02-25	
J	Gouas, D				Gouas, Doriane			Effects of the p53 p.R249S mutant in human hepatocellular carcinoma: interaction with hepatitis B virus X protein	BULLETIN DU CANCER			English	Meeting Abstract									[Gouas, Doriane] Int Agcy Res Canc, Lyon, France			gouasd@students.iarc.fr						0	0	0	0	1	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0007-4551			B CANCER	Bull. Cancer	MAR	2011	98			1		73	S54	S55					2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	753HG	WOS:000289762300075					2022-02-25	
J	Straif, K; Baan, R; Grosse, Y; Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Freeman, C; Galichet, L; Cogliano, V				Straif, Kurt; Baan, R.; Grosse, Y.; Secretan, B.; El Ghissassi, F.; Bouvard, V; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; Cogliano, V			THE IARC MONOGRAPHS VOL. 100. A REVIEW AND UPDATE ON OCCUPATIONAL CARCINOGENS	EPIDEMIOLOGIA & PREVENZIONE			English	Meeting Abstract									[Straif, Kurt; Baan, R.; Grosse, Y.; Secretan, B.; El Ghissassi, F.; Bouvard, V; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; Cogliano, V] Int Agcy Res Canc, F-69372 Lyon, France				Freeman, Crystal/AAF-3438-2020					0	0	0	0	0	INFERENZE SCARL	MILANO	VIA RICCIARELLI N 29, MILANO, 20148, ITALY	1120-9763			EPIDEMIOL PREV	Epidemiol. Prev.	SEP-DEC	2010	34	5-6		1			38	38					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	701MF	WOS:000285821300027					2022-02-25	
J	Johansson, M; Relton, C; Ueland, PM; Vollset, SE; Midttun, O; Nygard, O; Slimani, N; Boffetta, P; Jenab, M; Clavel-Chapelon, F; Boutron-Ruault, MC; Fagherazzi, G; Kaaks, R; Rohrmann, S; Boeing, H; Weikert, C; Bueno-de-Mesquita, HB; Ros, MM; van Gils, CH; Peeters, PHM; Agudo, A; Barricarte, A; Navarro, C; Rodriguez, L; Sanchez, MJ; Larranaga, N; Khaw, KT; Wareham, N; Allen, NE; Crowe, F; Gallo, V; Norat, T; Krogh, V; Masala, G; Panico, S; Sacerdote, C; Tumino, R; Trichopoulou, A; Lagiou, P; Trichopoulos, D; Rasmuson, T; Hallmans, G; Riboli, E; Vineis, P; Brennan, P				Johansson, Mattias; Relton, Caroline; Ueland, Per Magne; Vollset, Stein Emil; Midttun, Oivind; Nygard, Ottar; Slimani, Nadia; Boffetta, Paolo; Jenab, Mazda; Clavel-Chapelon, Francoise; Boutron-Ruault, Marie-Christine; Fagherazzi, Guy; Kaaks, Rudolf; Rohrmann, Sabine; Boeing, Heiner; Weikert, Cornelia; Bueno-de-Mesquita, H. Bas; Ros, Martine M.; van Gils, Carla H.; Peeters, Petra H. M.; Agudo, Antonio; Barricarte, Aurelio; Navarro, Carmen; Rodriguez, Laudina; Sanchez, Maria-Jose; Larranaga, Nerea; Khaw, Kay-Tee; Wareham, Nick; Allen, Naomi E.; Crowe, Francesca; Gallo, Valentina; Norat, Teresa; Krogh, Vittorio; Masala, Giovanna; Panico, Salvatore; Sacerdote, Carlotta; Tumino, Rosario; Trichopoulou, Antonia; Lagiou, Pagona; Trichopoulos, Dimitrios; Rasmuson, Torgny; Hallmans, Goeran; Riboli, Elio; Vineis, Paolo; Brennan, Paul			Serum B Vitamin Levels and Risk of Lung Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ONE-CARBON METABOLISM; GENOME-WIDE ASSOCIATION; COLORECTAL-CANCER; PLASMA FOLATE; FOLIC-ACID; MICROBIOLOGICAL ASSAY; BREAST-CANCER; NEVER SMOKERS; HOMOCYSTEINE; PREVENTION	Context B vitamins and factors related to 1-carbonmetabolism help to maintain DNA integrity and regulate gene expression and may affect cancer risk. Objective To investigate if 1-carbon metabolism factors are associated with onset of lung cancer. Design, Setting, and Participants The European Prospective Investigation into Cancer and Nutrition (EPIC) recruited 519 978 participants from 10 countries between 1992 and 2000, of whom 385 747 donated blood. By 2006, 899 lung cancer cases were identified and 1770 control participants were individually matched by country, sex, date of birth, and date of blood collection. Serum levels were measured for 6 factors of 1-carbon metabolism and cotinine. Main Outcome Measure Odds ratios (ORs) of lung cancer by serum levels of 4 B vitamins (B-2, B-6, folate [B-9], and B-12), methionine, and homocysteine. Results Within the entire EPIC cohort, the age-standardized incidence rates of lung cancer (standardized to the world population, aged 35-79 years) were 6.6, 44.9, and 156.1 per 100 000 person-years among never, former, and current smokers for men, respectively. The corresponding incidence rates for women were 7.1, 23.9, and 100.9 per 100 000 person-years, respectively. After accounting for smoking, a lower risk for lung cancer was seen for elevated serum levels of B6 (fourth vs first quartile OR, 0.44; 95% confidence interval [CI], 0.33-0.60; P for trend<.000001), as well as for serum methionine (fourth vs first quartile OR, 0.52; 95% CI, 0.39-0.69; P for trend<.000001). Similar and consistent decreases in risk were observed in never, former, and current smokers, indicating that results were not due to confounding by smoking. The magnitude of risk was also constant with increasing length of follow-up, indicating that the associations were not explained by preclinical disease. A lower risk was also seen for serum folate (fourth vs first quartile OR, 0.68; 95% CI, 0.51-0.90; P for trend=.001), although this was apparent only for former and current smokers. When participants were classified by median levels of serum methionine and B6, having above-median levels of both was associated with a lower lung cancer risk overall (OR, 0.41; 95% CI, 0.31-0.54), as well as separately among never (OR, 0.36; 95% CI, 0.18-0.72), former(OR, 0.51; 95% CI, 0.34-0.76), and current smokers(OR, 0.42; 95% CI, 0.27-0.65). Conclusion Serum levels of vitamin B6 and methionine were inversely associated with risk of lung cancer. JAMA. 2010; 303(23): 2377-2385	[Brennan, Paul] Int Agcy Res Canc, Genet Epidemiol Grp, F-69372 Lyon, France		Brennan, P (corresponding author), Int Agcy Res Canc, Genet Epidemiol Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	Brennan@iarc.fr	Panico, Salvatore/K-6506-2016; Krogh, Vittorio/K-2628-2016; Krogh, Vittorio/AAA-9171-2019; Ueland, Per M/C-7340-2013; Khaw, Kay-Tee/AAZ-3209-2021; Fagherazzi, Guy/P-3534-2017; Relton, Caroline/AAC-5904-2019; TRICHOPOULOU, ANTONIA/ABF-8727-2021; Fagherazzi, Guy/ABB-2555-2020; Masala, Giovanna/AAC-5474-2022; Gallo, Valentina/J-3089-2012; Sánchez, Maria-José/D-1087-2011; Johansson, Mattias/ABF-3365-2020; Boutron-Ruault, Marie-Christine/H-3936-2014; Rohrmann, Sabine/D-2113-2012; Clavel-Chapelon, Francoise/G-6733-2014; Gallo, Valentina/X-1139-2018; Agudo, Antonio/J-1805-2016	Panico, Salvatore/0000-0002-5498-8312; Krogh, Vittorio/0000-0003-0122-8624; Krogh, Vittorio/0000-0003-0122-8624; Fagherazzi, Guy/0000-0001-5033-5966; TRICHOPOULOU, ANTONIA/0000-0002-7204-6396; Fagherazzi, Guy/0000-0001-5033-5966; Masala, Giovanna/0000-0002-5758-9069; Sánchez, Maria-José/0000-0003-4817-0757; Boutron-Ruault, Marie-Christine/0000-0002-5956-5693; Rohrmann, Sabine/0000-0002-2215-1200; Gallo, Valentina/0000-0002-1268-8629; Larranaga, Nerea/0000-0002-9993-9880; Relton, Caroline/0000-0003-2052-4840; Johansson, Mattias/0000-0002-3116-5081; Ueland, Per Magne/0000-0002-1903-0571; Jenab, Mazda/0000-0002-0573-1852; Agudo, Antonio/0000-0001-9900-5677; Riboli, Elio/0000-0001-6795-6080; Crowe, Francesca/0000-0003-4026-1726; Navarro, Carmen/0000-0001-8896-7483; tumino, rosario/0000-0003-2666-414X; Sacerdote, Carlotta/0000-0002-8008-5096	World Cancer Research Fund (United Kingdom); European Commission (SANCO)European CommissionEuropean Commission Joint Research Centre; Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, German Federal Ministry of Education and ResearchDeutsche KrebshilfeFederal Ministry of Education & Research (BMBF); Danish Cancer SocietyDanish Cancer Society; Spanish Ministry of Health, Spanish Regional Government of Andalucia; Spanish Ministry of Health, Spanish Regional Government of Asturias; Spanish Ministry of Health, Spanish Regional Government of Basque Country; Spanish Ministry of Health, Spanish Regional Government of Murcia; Spanish Ministry of Health, Spanish Regional Government of Navarra; ISCIII Network RCESP, Spain [C03/09]; ISCIII of the Spanish Ministry of HealthSpanish Government [RETICC DR06/0020]; Cancer Research UKCancer Research UK; Medical Research Council, United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Greek Ministry of HealthGreek Ministry of Development-GSRT; Stavros Niarchos Foundation; Hellenic Health Foundation; Italian Association for Research on Cancer (AIRC)Fondazione AIRC per la ricerca sul cancro; Italian National Research Council, Fondazione-Istituto Banco Napoli, ItalyConsiglio Nazionale delle Ricerche (CNR); Compagnia di San PaoloCompagnia di San Paolo; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research FundWorld Cancer Research Fund International (WCRF); Swedish Cancer SocietySwedish Cancer Society; Swedish Scientific Council; Regional Government of Vasterbotten, Sweden; Norwegian Cancer SocietyNorwegian Cancer Society; Research Council of NorwayResearch Council of Norway; French League against Cancer (LNCC); National Institute for Health and Medical Research (INSERM), FranceInstitut National de la Sante et de la Recherche Medicale (Inserm); Mutuelle Generale de l'Education Nationale (MGEN), France; 3M Co, France3M; Gustave Roussy Institute (IGR), France; General Councils of France; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0401527, MC_U106179471] Funding Source: researchfish	World Cancer Research Fund (United Kingdom) funded the biochemical analyses for the study. The EPIC study has been supported by the Europe Against Cancer Program of the European Commission (SANCO); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health, Spanish Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra; the ISCIII Network RCESP (C03/09), Spain; the ISCIII of the Spanish Ministry of Health (RETICC DR06/0020); Cancer Research UK; Medical Research Council, United Kingdom; Greek Ministry of Health; Stavros Niarchos Foundation; Hellenic Health Foundation; Italian Association for Research on Cancer (AIRC); Italian National Research Council, Fondazione-Istituto Banco Napoli, Italy; Compagnia di San Paolo; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Swedish Cancer Society; Swedish Scientific Council; Regional Government of Vasterbotten, Sweden; Norwegian Cancer Society; Research Council of Norway; French League against Cancer (LNCC); National Institute for Health and Medical Research (INSERM), France; Mutuelle Generale de l'Education Nationale (MGEN), France; 3M Co, France; Gustave Roussy Institute (IGR), France; and General Councils of France.	Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Bray F., 2002, CANC INCIDENCE 5 CON, VVIII; Chou YC, 2007, BREAST CANCER RES TR, V101, P199, DOI 10.1007/s10549-006-9278-9; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351; Dahlin AM, 2008, INT J CANCER, V122, P2057, DOI 10.1002/ijc.23299; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Dierkes J, 2007, AM J CLIN NUTR, V86, P214; Drake BF, 2009, JAMA-J AM MED ASSOC, V302, P2152, DOI 10.1001/jama.2009.1691; Ebbing M, 2008, JAMA-J AM MED ASSOC, V300, P795, DOI 10.1001/jama.300.7.795; Ebbing M, 2009, JAMA-J AM MED ASSOC, V302, P2119, DOI 10.1001/jama.2009.1622; Figueiredo JC, 2008, CANCER EPIDEM BIOMAR, V17, P2136, DOI 10.1158/1055-9965.EPI-07-2895; Gibson A, 2008, QJM-INT J MED, V101, P881, DOI 10.1093/qjmed/hcn112; Hartman TJ, 2001, AM J EPIDEMIOL, V153, P688, DOI 10.1093/aje/153.7.688; Johansson M, 2008, CANCER EPIDEM BIOMAR, V17, P279, DOI 10.1158/1055-9965.EPI-07-0657; Johansson M, 2009, CANCER EPIDEM BIOMAR, V18, P1538, DOI 10.1158/1055-9965.EPI-08-1193; KELLEHER BP, 1991, J CLIN PATHOL, V44, P592, DOI 10.1136/jcp.44.7.592; Kim YI, 2003, J NUTR, V133, p3731S, DOI 10.1093/jn/133.11.3731S; Kim YI, 2007, MOL NUTR FOOD RES, V51, P267, DOI 10.1002/mnfr.200600191; Laufer EM, 2004, EUR J CLIN NUTR, V58, P1518, DOI 10.1038/sj.ejcn.1602002; Le Marchand L, 2009, CANCER EPIDEM BIOMAR, V18, P2195, DOI 10.1158/1055-9965.EPI-09-0141; Lee JE, 2009, CANCER EPIDEM BIOMAR, V18, P1197, DOI 10.1158/1055-9965.EPI-08-1001; Lin J, 2008, AM J CLIN NUTR, V87, P734, DOI 10.1093/ajcn/87.3.734; Logan RFA, 2008, GASTROENTEROLOGY, V134, P29, DOI 10.1053/j.gastro.2007.10.014; Midttun O, 2009, RAPID COMMUN MASS SP, V23, P1371, DOI 10.1002/rcm.4013; Molloy AM, 1997, METHOD ENZYMOL, V281, P43; NIH Office of Dietary Supplements, DIET SUPPL FACT SHEE; Olsen A, 2009, EUR J CLIN NUTR, V63, pS122, DOI 10.1038/ejcn.2009.78; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; Rudin CM, 2009, CLIN CANCER RES, V15, P5622, DOI 10.1158/1078-0432.CCR-09-0373; Schernhammer E, 2007, CANCER RES, V67, P5553, DOI 10.1158/0008-5472.CAN-06-4463; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Tanaka T, 2009, AM J HUM GENET, V84, P477, DOI 10.1016/j.ajhg.2009.02.011; Ueland P., FOLATE SERUM; Ueland PM, 2007, CLIN CHEM LAB MED, V45, P1737, DOI 10.1515/CCLM.2007.339; Ulrich CM, 2007, JAMA-J AM MED ASSOC, V297, P2408, DOI 10.1001/jama.297.21.2408; Verkleij-Hagoort AC, 2007, EUR J CLIN NUTR, V61, P610, DOI 10.1038/sj.ejcn.1602581; Vollset SE, 2007, CANCER EPIDEM BIOMAR, V16, P2416, DOI 10.1158/1055-9965.EPI-07-0256; Wei EK, 2005, J NATL CANCER I, V97, P684, DOI 10.1093/jnci/dji116; Weinstein SJ, 2008, CANCER EPIDEM BIOMAR, V17, P3233, DOI 10.1158/1055-9965.EPI-08-0459; Weisberg IS, 2001, ATHEROSCLEROSIS, V156, P409, DOI 10.1016/S0021-9150(00)00671-7; WILLET W, 1998, NUTR EPIDEMIOLOGY, P124; Yoshino K, 2010, INT J FOOD SCI NUTR, V61, P61, DOI 10.3109/09637480903286363; Zhang SM, 2003, J NATL CANCER I, V95, P373, DOI 10.1093/jnci/95.5.373	47	109	110	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	2010	303	23					2377	2385		10.1001/jama.2010.808			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	610TE	WOS:000278759200027	20551408	Bronze, Green Accepted			2022-02-25	
J	Cogliano, V; Straif, K				Cogliano, Vincent; Straif, Kurt			Re: False-Positive Results in Cancer Epidemiology: A Plea for Epistemological Modesty	JOURNAL OF THE NATIONAL CANCER INSTITUTE			English	Letter									[Cogliano, Vincent; Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon 08, France		Cogliano, V (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	cogliano@iarc.fr					[Anonymous], 2006, IARC MON EV CARC RIS, V88, P39; Boffetta P, 2008, JNCI-J NATL CANCER I, V100, P988, DOI 10.1093/jnci/djn191; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1999, IARC MON EV CARC RIS, V71, P43; *INT AG RES CANC, 1979, IARC MON EV CARC RIS, V19, P73; *INT AG RES CANC, 1987, IARC MON EV CARC S7, V1, P211; *INT AG RES CANC, 1987, IARC MON S7, V1, P79; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V62, P217; *INT AG RES CANC, 1997, IARC MON EV CARC RIS, V69, P33; International Agency for research on Cancer, 1982, IARC MON EV CARC RIS, V29, P345	10	5	5	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0027-8874			J NATL CANCER I	J. Natl. Cancer Inst.	JAN 20	2010	102	2					134	134		10.1093/jnci/djp446			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Oncology	549YO	WOS:000274091200013	20007526	Bronze			2022-02-25	
J	Autier, P				Autier, P.			Sunscreen abuse for intentional sun exposure	BRITISH JOURNAL OF DERMATOLOGY			English	Review						behaviour; melanoma; radiation; skin cancer; sunscreen; ultraviolet	RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; PROTECTION; ULTRAVIOLET; RADIATION; SPECTRUM; MELANOMA; BETACAROTENE; PREVENTION; DOSIMETRY	P>Skin cancer is caused by exposure to ultraviolet radiation (UV) and the sun is the main source of this radiation. Sunscreens were initially formulated to prevent sunburns; laboratory studies later revealed that in rodents they could reduce UV-induced skin cancer which resembles human squamous cell carcinoma. Three randomized trials in older adults showed the ability of sunscreens to moderately reduce the occurrence of solar keratoses and of squamous cell carcinoma. However, no effect was observed for basal cell carcinoma. There is no animal model for human melanoma and observational studies often found sunscreen use associated with a higher risk of nevus, melanoma and basal cell carcinoma. These higher risks were found when sun exposure appeared to be intentional, that is, with the desire to acquire a tan, a healthy look or simply to spend as long as possible in the sun with as much skin exposed as possible. Three randomized trials showed that sunscreen use by sun sensitive subjects engaging in intentional sun exposure could increase the duration of exposure without decreasing sunburn occurrence. This increased duration could be the reason why melanoma risk is increased when sunscreen is used. Hence, sunscreen abuse may extend sun exposure duration thus allowing sun exposure behaviours that would not be possible otherwise. Advertising for sunscreens and labeling of sunscreen bottles should inform consumers of the carcinogenic hazards associated with sunscreen abuse. It would be good to use a personal UV dosimeter which would give an alert when one's individual sunburn threshold in the absence of sunscreen use is nearing. The combination of sunscreen and a UV dosimeter may be an option for reducing the melanoma risk among sun worshippers.	Int Agcy Res Canc, F-69372 Lyon, France		Autier, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	autierp@iarc.fr	Autier, Philippe/A-4402-2014	Autier, Philippe/0000-0003-1538-5321			Albert MR, 2003, J AM ACAD DERMATOL, V49, P1096, DOI 10.1016/S0190-9622(03)00021-5; Autier P, 2000, BRIT J CANCER, V83, P1243, DOI 10.1054/bjoc.2000.1429; Autier P, 1999, JNCI-J NATL CANCER I, V91, P1304, DOI 10.1093/jnci/91.15.1304; Autier P, 1998, JNCI-J NATL CANCER I, V90, P1873, DOI 10.1093/jnci/90.24.1873; Autier P, 2007, INT J CANCER, V121, P1, DOI 10.1002/ijc.22745; Bauer J, 2009, AM J EPIDEMIOL, V161, P620; De Fabo EC, 2006, PROG BIOPHYS MOL BIO, V92, P97, DOI 10.1016/j.pbiomolbio.2006.02.024; Diffey B., 2009, International Journal of Cosmetic Science, V31, P63, DOI 10.1111/j.1468-2494.2008.00471.x; Dupuy A, 2005, ARCH DERMATOL, V141, P950, DOI 10.1001/archderm.141.8.950; Gallagher RDP, 2000, JAMA-J AM MED ASSOC, V283, P2955, DOI 10.1001/jama.283.22.2955; Green A, 1999, LANCET, V354, P2163, DOI 10.1016/S0140-6736(05)77065-3; Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2; HOLMAN CDJ, 1986, J NATL CANCER I, V76, P403; Hunter David J., 1990, Annals of Epidemiology, V1, P13; *INT AG RES CANC, 2001, IARC HDB CANC PREV, V5; Mills A, 2009, ANALYST, V134, P845, DOI 10.1039/b820288e; Moehrle M, 2000, DERMATOLOGY, V200, P1, DOI 10.1159/000018306; NAYLOR MF, 1995, ARCH DERMATOL, V131, P170, DOI 10.1001/archderm.131.2.170; Stanton WR, 2004, HEALTH PROMOT INT, V19, P369, DOI 10.1093/heapro/dah310; *SUP COURT STAT CA, 2006, 4352 JCCP SUP COURT; Thieden E, 2005, ARCH DERMATOL, V141, P967, DOI 10.1001/archderm.141.8.967; Thieden E, 2000, PHOTODERMATOL PHOTO, V16, P57, DOI 10.1034/j.1600-0781.2000.d01-4.x; THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602; WOLF P, 1994, J NATL CANCER I, V86, P99, DOI 10.1093/jnci/86.2.99; Young AR, 2000, J INVEST DERMATOL, V115, P37, DOI 10.1046/j.1523-1747.2000.00012.x	25	64	65	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-0963	1365-2133		BRIT J DERMATOL	Br. J. Dermatol.	NOV	2009	161			3			40	45		10.1111/j.1365-2133.2009.09448.x			6	Dermatology	Science Citation Index Expanded (SCI-EXPANDED)	Dermatology	498GN	WOS:000270125400008	19775356				2022-02-25	
J	Chapot, B; Secretan, B; Robert, A; Hainaut, P				Chapot, Brigitte; Secretan, Beatrice; Robert, Annie; Hainaut, Pierre			Exposure to Hazardous Substances in a Standard Molecular Biology Laboratory Environment: Evaluation of Exposures in IARC Laboratories	ANNALS OF OCCUPATIONAL HYGIENE			English	Article						carcinogens; molecular biology research; occupational exposure	CANCER INCIDENCE; BIOMEDICAL-RESEARCH; ROUTINE LABORATORIES; WORKERS; MORTALITY; RISK; PERSONNEL; COHORT; ISRAEL; HEALTH	Working in a molecular biology laboratory environment implies regular exposure to a wide range of hazardous substances. Several recent studies have shown that laboratory workers may have an elevated risk of certain cancers. Data on the nature and frequency of exposures in such settings are scanty. The frequency of use of 163 agents by staff working in molecular biology laboratories was evaluated over a period of 4 years by self-administered questionnaire. Of the agents listed, ethanol was used by the largest proportion of staff (70%), followed by ethidium bromide (55%). Individual patterns of use showed three patterns, namely (i) frequent use of a narrow range of products, (ii) occasional use of a wide range of products, and (iii) frequent and occasional use of an intermediate range of products. Among known or suspected carcinogens (International Agency for Research on Cancer Group 1 and 2A, respectively), those most frequently used included formaldehyde (17%), oncogenic viruses (4%), and acrylamide (32%). The type of exposure encountered in research laboratories is extremely diverse. Few carcinogenic agents are used frequently but many laboratory workers may be exposed occasionally to known human carcinogens. In addition, many of the chemicals handled by staff represent a health hazard. The results enabled the staff physician to develop an individual approach to medical surveillance and to draw a personal history of occupational exposures for laboratory staff.	[Chapot, Brigitte; Secretan, Beatrice; Robert, Annie; Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon 08, France		Chapot, B (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	chapot@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610; Lauby-Secretan, Beatrice/0000-0001-6559-3351			BELLI S, 1992, SCAND J WORK ENV HEA, V18, P64, DOI 10.5271/sjweh.1607; Brown TP, 1996, BRIT J CANCER, V73, P1152, DOI 10.1038/bjc.1996.221; Kauppinen T, 2003, AM J IND MED, V44, P343, DOI 10.1002/ajim.10278; Labreche FP, 1997, AM J IND MED, V32, P1; Rachet B, 2000, AM J IND MED, V38, P651, DOI 10.1002/1097-0274(200012)38:6<651::AID-AJIM6>3.0.CO;2-J; SASCO AJ, 1989, MED SCI, V7, P489; Shaham J, 2003, AM J IND MED, V44, P600, DOI 10.1002/ajim.10311; Shaham J, 2003, AM J IND MED, V44, P611, DOI 10.1002/ajim.10312; van Barneveld TA, 2004, CANCER CAUSE CONTROL, V15, P55, DOI 10.1023/B:CACO.0000016607.70457.47; Vecchio D, 2003, AM J IND MED, V43, P369, DOI 10.1002/ajim.10191; Wennborg H, 1999, AM J IND MED, V35, P382, DOI 10.1002/(SICI)1097-0274(199904)35:4<382::AID-AJIM9>3.3.CO;2-6; Wennborg H, 2001, INT ARCH OCC ENV HEA, V74, P558, DOI 10.1007/s004200100267	12	3	3	1	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0003-4878			ANN OCCUP HYG	Ann. Occup. Hyg.	JUL	2009	53	5					485	490		10.1093/annhyg/mep029			6	Public, Environmental & Occupational Health; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Toxicology	466MH	WOS:000267665800004	19474073				2022-02-25	
J	Clifford, G; Franceschi, S				Clifford, G.; Franceschi, S.			HPV genotype distribution in women with and without cervical cancer worldwide	BULLETIN DU CANCER			English	Meeting Abstract									[Clifford, G.; Franceschi, S.] Int Agcy Res Canc, F-69372 Lyon, France			clifford@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071				0	0	0	0	1	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0007-4551			B CANCER	Bull. Cancer	MAR	2008	95				SI		S34	S34					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	277PE	WOS:000254225900055					2022-02-25	
J	Sankaranarayanan, R				Sankaranarayanan, R.			Overview of cervical cancer in the developing world	INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; SCREENING-PROGRAMS; PARTICLE VACCINE; FOLLOW-UP; NEOPLASIA; ACCURACY; SURVIVAL; EFFICACY; CYTOLOGY; INDIA		Int Agcy Res Canc, Screening Grp, WHO, F-69372 Lyon 08, France		Sankaranarayanan, R (corresponding author), Int Agcy Res Canc, Screening Grp, WHO, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	sankar@iarc.fr					Alliance for Cervical Cancer Prevention (ACCP), 2004, PLANN IMPL CERV CANC; BLUMENTHAL P, 2005, INT J GYNAECOL OB S2, V89, pS4; Cervix cancer screening/IARC working group on the evaluation of cancer - preventive strategies, 2004, IARC HDB CANC PREV, V10; Chokunonga E, 2004, INT J CANCER, V109, P274, DOI 10.1002/ijc.11670; Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9; Denny L, 2005, JAMA-J AM MED ASSOC, V294, P2173, DOI 10.1001/jama.294.17.2173; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Ferlay J, 2004, IARC CANCERBASE 5 VE; Franco Eduardo L, 2003, J Natl Cancer Inst Monogr, P89; Gaffikin L, 2003, LANCET, V361, P814, DOI 10.1016/S0140-6736(03)12707-9; Goldie SJ, 2005, NEW ENGL J MED, V353, P2158, DOI 10.1056/NEJMsa044278; Gondos A, 2005, BRIT J CANCER, V92, P1808, DOI 10.1038/sj.bjc.6602540; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; *IARC, IN PRESS IARC MON EV, V90; *IARC, 2004, HDB CANC PREV, V10; Mao C, 2006, OBSTET GYNECOL, V107, P18, DOI 10.1097/01.AOG.0000192397.41191.fb; Mathers Lawrence J, 2005, J Low Genit Tract Dis, V9, P232, DOI 10.1097/01.lgt.0000179864.59951.91; MCINTOSH N, 2001, JHPIEGO TECHNICAL MA; Mitchell MF, 1998, OBSTET GYNECOL, V91, P626, DOI 10.1016/S0029-7844(98)00006-4; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; Parkin D, 2002, CANC INCIDENCE 5 CON, VVIII, P155; SANGWALUGOMA G, 2006, INT J CANC      0407; SANKARANARAYANA.R, 2003, IARC TECHNICAL PUBLI, P41; Sankaranarayanan R, 2005, INT J CANCER, V116, P617, DOI 10.1002/ijc.21050; Sankaranarayanan R, 2005, INT J GYNECOL OBSTET, V89, pS4, DOI 10.1016/j.ijgo.2005.01.009; Sankaranarayanan R, 2004, INT J CANCER, V110, P907, DOI 10.1002/ijc.20190; Sankaranarayanan R, 2004, INT J CANCER, V109, P461, DOI 10.1002/ijc.11726; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1988, CANC SURVIVAL DEV CO, P15; Sarian LO, 2005, J MED SCREEN, V12, P142, DOI 10.1258/0969141054855328; Sepulveda C, 2005, CANCER DETECT PREV, V29, P405, DOI 10.1016/j.cdp.2005.07.001; Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7; Wang H, 2003, AM J OBSTET GYNECOL, V188, P324, DOI 10.1067/mob.2003.89	33	61	64	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7292	1879-3479		INT J GYNECOL OBSTET	Int. J. Gynecol. Obstet.	NOV	2006	95			1			S205	S210		10.1016/S0020-7292(06)60035-0			6	Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology	119IY	WOS:000243007200012	17161159				2022-02-25	
J	Brem, R; Hall, J				Brem, R; Hall, J			XRCC1 is required for DNA single-strand break repair in human cells	NUCLEIC ACIDS RESEARCH			English	Article							SISTER-CHROMATID-EXCHANGE; POLY(ADP-RIBOSE) POLYMERASE; CANCER RISK; LIGASE-III; LUNG-CANCER; GENE XRCC1; MUTANT EM9; IN-VITRO; POLYMORPHISMS; EXCISION	The X-ray repair cross complementing 1 (XRCC1) protein is required for viability and efficient repair of DNA single-strand breaks (SSBs) in rodents. XRCC1-deficient mouse or hamster cells are hypersensitive to DNA damaging agents generating SSBs and display genetic instability after such DNA damage. The presence of certain polymorphisms in the human XRCC1 gene has been associated with altered cancer risk, but the role of XRCC1 in SSB repair (SSBR) in human cells is poorly defined. To elucidate this role, we used RNA interference to modulate XRCC1 protein levels in human cell lines. A reduction in XRCC1 protein levels resulted in decreased SSBR capacity as measured by the comet assay and intracellular NAD(P)H levels, hypersensitivity to the cell killing effects of the DNA damaging agents methyl methanesulfonate (MMS), hydrogen peroxide and ionizing radiation and enhanced formation of micronuclei following exposure to MMS. Lowered XRCC1 protein levels were also associated with a significant delay in S-phase progression after exposure to MMS. These data clearly demonstrate that XRCC1 is required for efficient SSBR and genomic stability in human cells.	Int Agcy Res Canc, DNA Repair Team, F-69372 Lyon, France		Hall, J (corresponding author), Int Agcy Res Canc, DNA Repair Team, 150 Cours Albert Thomas, F-69372 Lyon, France.	hall@iarc.fr	hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295; Brem, Reto/0000-0002-0171-1248			Angelini S, 2005, MUTAT RES-FUND MOL M, V570, P105, DOI 10.1016/j.mrfmmm.2004.10.007; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CARRANO AV, 1986, MUTAT RES, V162, P233, DOI 10.1016/0027-5107(86)90090-4; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; DILLEHAY LE, 1983, MUTAT RES, V109, P283, DOI 10.1016/0027-5107(83)90053-2; Dominguez I, 1998, MUTAT RES-FUND MOL M, V398, P67, DOI 10.1016/S0027-5107(97)00241-8; Fan JS, 2004, NUCLEIC ACIDS RES, V32, P2193, DOI 10.1093/nar/gkh556; Fernet M, 2005, HUM MOL GENET, V14, P307, DOI 10.1093/hmg/ddi027; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Gutierrez-Enriquez S, 2003, MUTAT RES-GEN TOX EN, V535, P1, DOI 10.1016/S1383-5718(02)00280-2; Han J, 2004, BRIT J CANCER, V91, P1604, DOI 10.1038/sj.bjc.6602174; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Harms C, 2004, ENVIRON MOL MUTAGEN, V44, P74, DOI 10.1002/em.20031; Ito H, 2004, CARCINOGENESIS, V25, P1395, DOI 10.1093/carcin/bgh153; Kelsey KT, 2004, CANCER EPIDEM BIOMAR, V13, P1337; Kubota Y, 2003, DNA REPAIR, V2, P407, DOI 10.1016/S1568-7864(02)00242-2; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lan L, 2004, P NATL ACAD SCI USA, V101, P13738, DOI 10.1073/pnas.0406048101; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Marsin S, 2003, J BIOL CHEM, V278, P44068, DOI 10.1074/jbc.M306160200; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Moullan N, 2003, CANCER EPIDEM BIOMAR, V12, P1168; Nagasubramanian R, 2003, ANNU REV MED, V54, P437, DOI 10.1146/annurev.med.54.101601.152352; Nakamura J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng105; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Olive PL, 1998, NAT MED, V4, P103, DOI 10.1038/nm0198-103; Ratnasinghe LD, 2004, CANCER LETT, V216, P157, DOI 10.1016/j.canlet.2004.03.012; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Sossou M, 2005, NUCLEIC ACIDS RES, V33, P298, DOI 10.1093/nar/gki173; Tae K, 2004, INT J CANCER, V111, P805, DOI 10.1002/ijc.20338; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; Taylor RM, 2002, MOL CELL BIOL, V22, P2556, DOI 10.1128/MCB.22.8.2556-2563.2002; Tebbs RS, 2003, DNA REPAIR, V2, P1405, DOI 10.1016/j.dnarep.2003.08.007; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; THOMPSON LH, 1982, SOMAT CELL GENET, V8, P759, DOI 10.1007/BF01543017; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; VELD CWOH, 1994, CANCER RES, V54, P3001; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Wang LE, 2004, CANCER RES, V64, P5560, DOI 10.1158/0008-5472.CAN-03-2181; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837; ZDZIENICKA MZ, 1992, MUTAGENESIS, V7, P265, DOI 10.1093/mutage/7.4.265	52	146	154	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0305-1048	1362-4962		NUCLEIC ACIDS RES	Nucleic Acids Res.		2005	33	8					2512	2520		10.1093/nar/gki543			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	926HC	WOS:000229113100026	15867196	Green Published, gold, Green Submitted			2022-02-25	
J	Kleihues, P				Kleihues, P			Integrity of the conduct of the IARC Monographs program	INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH			English	Letter									WHO, Int Agcy Res Canc, F-69008 Lyon, France		Kleihues, P (corresponding author), WHO, Int Agcy Res Canc, 150 Albert Thomas, F-69008 Lyon, France.							0	4	4	0	1	ABEL PUBLICATION SERVICES	BURLINGTON	1611 AQUINAS COURT, BURLINGTON, NC 27215 USA	1077-3525			INT J OCCUP ENV HEAL	Int. J. Occup. Environ. Health	JAN-MAR	2003	9	1					78	78					1	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	669EW	WOS:000182339800011	12749635				2022-02-25	
J	Lambert, R; Rey, JF				Lambert, R; Rey, JF			Appropriateness of diagnostic digestive endoscopy	DIGESTIVE DISEASES			English	Review						gastroscopy; colonoscopy; surveillance; diagnostic endoscopy; indications for endoscopy	UPPER GASTROINTESTINAL ENDOSCOPY; OPEN-ACCESS ENDOSCOPY; COLORECTAL-CANCER; QUALITY-ASSURANCE; COLONOSCOPY; YIELD; ADENOMAS; THERAPY; OVERUSE; IMPACT	The indications of diagnostic endoscopy - upper gastrointestinal endoscopy or colonoscopy - in the exploration of the digestive tract are classified as appropriate or inappropriate with regard to criteria established in guidelines supported by national scientific societies and by insurance companies. This applies to the exploration of symptomatic patients and to screening protocols for malignant lesions. Functional or nonstructural diseases being more frequent than structural diseases, negative findings in endoscopy are common. However this reassures the patient and should not be considered as overuse. On the other hand excess in the repetition of negative endoscopic procedures during surveillance raises ethical problems, increased costs, and may be considered as unethical. Copyright (C) 2002 S. Karger AG, Basel.	Int Agcy Res Canc, F-69008 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	lambert@iarc.fr					[Anonymous], 2000, Gastrointest Endosc, V52, P827; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; Bytzer P, 1996, EUR J GASTROEN HEPAT, V8, P359, DOI 10.1097/00042737-199604000-00014; Cash BD, 1999, GASTROINTEST ENDOSC, V49, P163, DOI 10.1016/S0016-5107(99)70481-5; de Bosset V, 2002, ENDOSCOPY, V34, P360, DOI 10.1055/s-2002-25277; Delco F, 1999, GASTROENTEROLOGY, V116, pA394; DIMENAS E, 1997, ALIM PHARM THER S2, V11, P73; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P13, DOI 10.1016/S0016-5107(97)70330-4; Froehlich F, 2000, GASTROINTEST ENDOSC, V52, P333, DOI 10.1067/mge.2000.107906; Froehlich F, 1997, GASTROENTEROLOGY, V112, P690, DOI 10.1053/gast.1997.v112.pm9041229; Helfand M, 1997, MED DECIS MAKING, V17, P315, DOI 10.1177/0272989X9701700308; Hosokawa O, 1998, ENDOSCOPY, V30, P669, DOI 10.1055/s-2007-1001386; HUNGIN APS, 1994, BRIT J GEN PRACT, V44, P519; Johanson J F, 1999, Gastrointest Endosc Clin N Am, V9, P559; Johanson JF, 2000, GASTROINTEST ENDOSC, V52, P827, DOI 10.1016/S0016-5107(00)70218-5; Johanson John F, 2002, Gastrointest Endosc Clin N Am, V12, P351, DOI 10.1016/S1052-5157(01)00015-0; Kavanagh AM, 1998, CANCER CAUSE CONTROL, V9, P455; Lambert R, 1999, ITAL J GASTROENTEROL, V31, P761; Manes G, 2002, ALIMENT PHARM THERAP, V16, P105, DOI 10.1046/j.1365-2036.2002.01136.x; Minoli G, 2000, GASTROINTEST ENDOSC, V52, P39, DOI 10.1067/mge.2000.106683; Minoli G, 1999, ENDOSCOPY, V31, P522; Morini S, 2001, GASTROINTEST ENDOSC, V54, P175, DOI 10.1067/mge.2001.116565; Olson A D, 2001, Gastrointest Endosc Clin N Am, V11, P557; Painter J, 1999, ENDOSCOPY, V31, P227, DOI 10.1055/s-1999-13673; Rex DK, 1996, GASTROENTEROLOGY, V111, P1178, DOI 10.1053/gast.1996.v111.pm8898630; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; SAPIENZA PE, 1992, GASTROENTEROLOGY, V102, P387, DOI 10.1016/0016-5085(92)90081-9; THOMPSON WG, 1995, CAN MED ASSOC J, V153, P293; Trevisani L, 2001, DIGEST DIS SCI, V46, P2695, DOI 10.1023/A:1012775429096; Vader JP, 1999, ENDOSCOPY, V31, P572; Vader JP, 2000, GASTROINTEST ENDOSC, V52, P593, DOI 10.1067/mge.2000.108716; Wiklund I, 1998, GASTROINTEST ENDOSC, V47, P449, DOI 10.1016/S0016-5107(98)70243-3; WIKLUND IK, 1998, EUR J SURG S, P1	34	3	3	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0257-2753	1421-9875		DIGEST DIS	Dig. Dis.		2002	20	3-4					236	241		10.1159/000067674			6	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	640TQ	WOS:000180704400007	12566606				2022-02-25	
J	Schubauer-Berigan, MK				Schubauer-Berigan, Mary K.			Hazards at 10 000 m: studies of aircrew and their importance in understanding cancer risks from cosmic radiation and circadian disruption	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material						shift work; cancer; melanoma; radiation	QUALITY FACTOR; COHORT; MORTALITY		[Schubauer-Berigan, Mary K.] Int Agcy Res Canc, Evidence Synth & Classificat Sect, F-69372 Lyon, France		Schubauer-Berigan, MK (corresponding author), Int Agcy Res Canc, Evidence Synth & Classificat Sect, F-69372 Lyon, France.	BeriganM@iarc.fr	Schubauer-Berigan, Mary/ABC-7996-2020; Schubauer-Berigan, Mary/B-3149-2009	Schubauer-Berigan, Mary/0000-0002-5175-924X	International Agency for Research on Cancer	Funding for this work was provided by the International Agency for Research on Cancer.	Burda O, 2013, J RADIOL PROT, V33, P339, DOI 10.1088/0952-4746/33/2/339; Dreger S, 2020, OCCUP ENVIRON MED, V77, P285, DOI 10.1136/oemed-2019-106165; Hammer GP, 2012, EUR J EPIDEMIOL, V27, P419, DOI 10.1007/s10654-012-9698-2; Meier MM, 2010, ADV SPACE RES, V45, P1178, DOI 10.1016/j.asr.2009.08.008; Pinkerton LE, 2016, SCAND J WORK ENV HEA, V42, P538, DOI 10.5271/sjweh.3586; Pinkerton LE, 2012, AM J IND MED, V55, P25, DOI 10.1002/ajim.21011; Pukkala E, 2012, INT J CANCER, V131, P2886, DOI 10.1002/ijc.27551; Schubauer-Berigan MK, 2015, AM J IND MED, V58, P252, DOI 10.1002/ajim.22419; Schuz J, 2014, OCCUP ENVIRON MED, V71, P307, DOI 10.1136/oemed-2013-102026; Ward EM, 2019, LANCET ONCOL, V20, P1058, DOI 10.1016/S1470-2045(19)30455-3; Yong LC, 2014, AM J IND MED, V57, P906, DOI 10.1002/ajim.22318; Zeeb H, 2010, RADIAT ENVIRON BIOPH, V49, P187, DOI 10.1007/s00411-009-0248-6	12	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	MAY	2020	77	5					283	284		10.1136/oemed-2020-106432			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	LL9MF	WOS:000531877700002	32179634				2022-02-25	
J	Steliarova-Foucher, E				Steliarova-Foucher, Eva			How can global incidence estimates support childhood cancer control?	LANCET ONCOLOGY			English	Editorial Material									[Steliarova-Foucher, Eva] WHO, Int Agcy Res Canc, Sect Canc Surveillance, Lyon 08, France		Steliarova-Foucher, E (corresponding author), WHO, Int Agcy Res Canc, Sect Canc Surveillance, Lyon 08, France.	steliarova@iarc.fr					Barr AL, 2016, GLOB HEALTH EPIDEM G, V1, DOI 10.1017/gheg.2016.16; Boerma T, 2018, LANCET, V392, P607, DOI 10.1016/S0140-6736(18)30586-5; Kruger M, 2014, PEDIATR BLOOD CANCER, V61, P587, DOI 10.1002/pbc.24845; Kruk ME, 2018, LANCET, V392, P2203, DOI [10.1016/S0140-6736(18)31668-4, 10.1016/s0140-6736(18)31668-4]; Magrath I, 2013, LANCET ONCOL, V14, pE104, DOI 10.1016/S1470-2045(13)70008-1; Steliarova-Foucher E, 2017, INT INCIDENCE CHILDH, VIII; Ward ZJ, 2019, LANCET ONCOL, V20, P483, DOI 10.1016/S1470-2045(18)30909-4	7	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	APR	2019	20	4					460	461		10.1016/S1470-2045(19)30039-7			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	HR3AU	WOS:000463009600018	30824205				2022-02-25	
J	Zhivagui, M; Korenjak, M; Zavadil, J				Zhivagui, Maria; Korenjak, Michael; Zavadil, Jiri			Modelling Mutation Spectra of Human Carcinogens Using Experimental Systems	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article; Proceedings Paper	Annual Meeting of the European-Environmental-Mutagenesis-and-Genomics-Society (EEMGS)	AUG 14-18, 2016	Copenhagen, DENMARK	European Environm Mutagenesis & Genom Soc, European Consensus Platform Alternatives			NICKEL CARCINOGENESIS; OXIDATIVE STRESS; MOLECULAR-MECHANISMS; STRAND BREAKAGE; RAT-KIDNEY; DNA-DAMAGE; CANCER; GENOTOXICITY; CELLS; EXPOSURE	Mutation spectra in cancer genomes provide information on the disease aetiology and the causality underlying the evolution and progression of cancer. Genome-wide mutation patterns reflect the effects of mutagenic insults and can thus reveal past carcinogen-specific exposures and inform hypotheses on the causative factors for specific cancer types. To identify mutation profiles in human cancers, single-gene studies were first employed, focusing mainly on the tumour suppressor gene TP53. Furthermore, experimental studies had been developed in model organisms. They allowed the characterization of the mutation patterns specific to known human carcinogens, such as polycyclic aromatic hydrocarbons or ultraviolet light. With the advent of massively parallel sequencing, mutation landscapes become revealed on a large scale, in human primary tumours and in experimental models, enabling deeper investigations of the functional and structural impact of mutations on the genome, including exposure-specific base-change fingerprints known as mutational signatures. These studies can now accelerate the identification of aetiological factors, contribute to carcinogen evaluation and classification and ultimately inform cancer prevention measures.	[Zhivagui, Maria; Korenjak, Michael; Zavadil, Jiri] Int Agcy Res Canc WHO, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Zavadil, J (corresponding author), Int Agcy Res Canc WHO, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	zavadilj@iarc.fr	Zavadil, Jiri/ABG-1780-2020	Zavadil, Jiri/0000-0003-0640-5562; Zhivagui, Maria/0000-0002-3410-4014	European Environmental Mutagenesis and Genomics Society Young Scientist grant; INCa-INSERM Plan Cancer grant	M.Z. is a recipient of the European Environmental Mutagenesis and Genomics Society 2016 Young Scientist grant. The study was partially supported by the INCa-INSERM Plan Cancer 2015 grant to J.Z.	Andersen A, 1996, OCCUP ENVIRON MED, V53, P708, DOI 10.1136/oem.53.10.708; ATSDR, 2005, TOX PROF NICK; Barbante C, 2002, J ENVIRON MONITOR, V4, P960, DOI 10.1039/b208142c; Benbrahim-Tallaa L, 2009, ENVIRON HEALTH PERSP, V117, P1847, DOI 10.1289/ehp.0900999; Cameron Keyuna S., 2011, Reviews on Environmental Health, V26, P81, DOI 10.1515/REVEH.2011.012; Cangul H, 2002, TOXICOL LETT, V127, P69, DOI 10.1016/S0378-4274(01)00485-4; Chakrabarti SK, 2001, TOXICOL APPL PHARM, V170, P153, DOI 10.1006/taap.2000.9097; Chen CY, 2010, J TOXICOL ENV HEAL A, V73, P529, DOI 10.1080/15287390903421250; Chen CY, 2003, TOXICOL APPL PHARM, V189, P153, DOI 10.1016/S0041-008X(03)00086-3; Clarkson TW, 1986, BIOL MONITORING META; COSTA M, 1991, ANNU REV PHARMACOL, V31, P321; Costa M, 1984, Adv Inorg Biochem, V6, P285; DIWAN BA, 1992, CARCINOGENESIS, V13, P1351, DOI 10.1093/carcin/13.8.1351; Doreswamy K, 2004, J ANDROL, V25, P996; HARTWIG A, 1994, TOXICOL LETT, V72, P353, DOI 10.1016/0378-4274(94)90048-5; HAYASHI Y, 1992, EXP TOXICOL PATHOL, V44, P465, DOI 10.1016/S0940-2993(11)80159-4; Hernandez LG, 2009, MUTAT RES-REV MUTAT, V682, P94, DOI 10.1016/j.mrrev.2009.07.002; HUANG X, 1994, ENVIRON HEALTH PERSP, V102, P281, DOI 10.2307/3431802; IARC, 2012, IARC MONOGRAPHS EVAL, p100F; IARC, 1990, IARC MON EV CARC RIS, P691; IPCS, 1991, NICKEL; Jia J, 2008, ENVIRON TOXICOL, V23, P401, DOI 10.1002/tox.20346; Kasprzak KS, 2003, MUTAT RES-FUND MOL M, V533, P67, DOI 10.1016/j.mrfmmm.2003.08.021; KASPRZAK KS, 1990, CARCINOGENESIS, V11, P647, DOI 10.1093/carcin/11.4.647; Lei Y, 1995, Zhonghua Yu Fang Yi Xue Za Zhi, V29, P202; MISRA M, 1993, CHEM RES TOXICOL, V6, P33, DOI 10.1021/tx00031a005; National Toxicology Program (U.S.), 2013, REP CARC MON; Nohl H, 2003, BIOCHEM SOC T, V31, P1308; Patterson TJ, 2007, TOXICOL APPL PHARM, V221, P119, DOI 10.1016/j.taap.2007.02.003; Qu W, 2012, ENVIRON HEALTH PERSP, V120, P1265, DOI 10.1289/ehp.1205082; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; ROBISON SH, 1982, CARCINOGENESIS, V3, P657, DOI 10.1093/carcin/3.6.657; STINSON TJ, 1992, TOXICOL APPL PHARM, V117, P98, DOI 10.1016/0041-008X(92)90222-E; Uddin AN, 2007, TOXICOL APPL PHARM, V221, P329, DOI 10.1016/j.taap.2007.03.030; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Waalkes MP, 2008, CANCER RES, V68, P8278, DOI 10.1158/0008-5472.CAN-08-2099; Wang L, 2016, TOXICOL SCI, V151, P376, DOI 10.1093/toxsci/kfw044; Wang L, 2012, J ENVIRON PATHOL TOX, V31, P245, DOI 10.1615/JEnvironPatholToxicolOncol.v31.i3.60; Waris G, 2006, J CARCINOG, V5, P14, DOI [10.1186/1477-3163-5-14, DOI 10.1186/1477-3163-5-14]; WHO, 2007, NICK DRINK WAT; Wu Danli, 2011, J Vis Exp, DOI 10.3791/3357	41	7	7	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	SEP	2017	121			3	SI		16	22		10.1111/bcpt.12690			7	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pharmacology & Pharmacy; Toxicology	FH3HM	WOS:000411036200004	27754614	Bronze			2022-02-25	
J	Franceschi, S; Clifford, GM				Franceschi, Silvia; Clifford, Gary M.			Cervical screening: toward an equal risk/equal management approach, irrespective of HIV status	AIDS			English	Editorial Material						cervical cancer; HIV; human papillomavirus; screening	INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS; INFECTED WOMEN; POSITIVE WOMEN; CANCER RISK; PREVENTION; GUIDELINES; TREAT		[Franceschi, Silvia; Clifford, Gary M.] Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France		Franceschi, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	franceschis@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071			Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V63, pE163, DOI 10.1097/QAI.0b013e31829cb7c3; Anastos K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013525; Carlander C, 2016, INT J CANCER, V139, P1471, DOI 10.1002/ijc.30188; Clifford GM, 2017, CLIN INFECT DIS, V64, P1228, DOI 10.1093/cid/cix135; Clifford GM, 2016, INT J CANCER, V138, P1732, DOI 10.1002/ijc.29913; Dal Maso L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-310; Franceschi S, 2010, AIDS, V24, P2570, DOI 10.1097/QAD.0b013e32833f39b2; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; Huh WK, 2015, OBSTET GYNECOL, V125, P330, DOI [10.1016/j.ygyno.2014.12.022, 10.1097/AOG.0000000000000669]; Katki HA, 2011, LANCET ONCOL, V12, P663, DOI 10.1016/S1470-2045(11)70145-0; Keller MJ, 2015, CLIN INFECT DIS, V61, P1573, DOI 10.1093/cid/civ569; Kitchener H, 2007, INT J CANCER, V121, P2484, DOI 10.1002/ijc.22947; Kuhn L, 2010, AIDS, V24, P2545, DOI 10.1097/QAD.0b013e32833e163e; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Robbins HA, 2017, AIDS, V31, P1035, DOI 10.1097/QAD.0000000000001450; Santesso N, 2016, INT J GYNECOL OBSTET, V132, P252, DOI 10.1016/j.ijgo.2015.07.038	16	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0269-9370	1473-5571		AIDS	Aids	APR 24	2017	31	7					1045	1046		10.1097/QAD.0000000000001453			2	Immunology; Infectious Diseases; Virology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases; Virology	ES7IN	WOS:000399723500016	28350579				2022-02-25	
J	Abedi-Ardekani, B; Foll, PHAM; Olivier, M; Carreira, C; Scelo, G; Mckay, JD				Abedi-Ardekani, Behnoush; Foll, Patrice H. Avogbe Matthieu; Olivier, Magali; Carreira, Christine; Scelo, Ghislaine; Mckay, James D.			Detection of Somatic Mutations in Histologically Normal Lung Tissue: Sectioning and Genomic Method	MODERN PATHOLOGY			English	Meeting Abstract	106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)	MAR 04-10, 2017	San Antonio, TX	US & Canadian Acad Pathol					[Abedi-Ardekani, Behnoush; Foll, Patrice H. Avogbe Matthieu; Olivier, Magali; Carreira, Christine; Scelo, Ghislaine; Mckay, James D.] Int Agcy Res Canc, Lyon, France				Abedi-Ardekani, Behnoush/O-7829-2016	Abedi-Ardekani, Behnoush/0000-0002-0980-0587				0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	FEB	2017	30			2		1821	453A	453A					1	Pathology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pathology	EL2RO	WOS:000394467302394					2022-02-25	
J	Karsa, L				Von Karsa, Lawrence			Hpv Supplements To European Guidelines For Quality Assurance In Cervical Cancer Screening	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Meeting Abstract						cervical cancer; population-based screening; human papillomavirus (HPV); quality assurance; European guidelines			[Von Karsa, Lawrence] Int Agcy Res Canc, Qual Assurance Grp, Lyon, France									0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	SEP	2016	26			2		PP-122	70	70					1	Oncology; Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Obstetrics & Gynecology	EB1JW	WOS:000387108300061					2022-02-25	
J	Ferlay, J; Partensky, C; Bray, F				Ferlay, J.; Partensky, C.; Bray, F.			More deaths from pancreatic cancer than breast cancer in the EU by 2017	ACTA ONCOLOGICA			English	Article							COUNTRIES; MORTALITY; SURVIVAL; EUROPE; TRENDS	Introduction: Pancreatic cancer currently ranks below female breast cancer in terms of the number of deaths in both males and females in the EU. While breast cancer mortality rates have been declining in many higher income EU countries during recent decades, rates of pancreatic cancer in contrast are either stable or moderately increasing; a comparative analysis of the short-term future rates of both is warranted.Methods: We extracted the annual number of deaths from cancers of the pancreas and breast by gender together with population at risk in each of 28 countries of the EU for the period 2001-2010. We fitted cancer- and gender-specific time-linear regression models and predicted deaths from pancreatic and breast cancer mortality for the years 2011-2025.Results: We estimated that by the year 2017 more deaths from pancreatic cancer will occur (91 500 annual deaths) than breast cancer (91000) in the EU. By 2025, deaths from cancer of the pancreas are predicted to be 25% higher (111500 and 90000, respectively). Pancreatic cancer may become the third leading cause of death from cancer in the EU after lung and colorectal cancers.Conclusion: Although strategies may emerge in the near future that will enhance the prospects of improving the very poor five-year survival from pancreatic cancer, coordinated efforts are necessary to reduce the foreseeable high mortality burden of disease within the EU.	[Ferlay, J.; Bray, F.] Int Agcy Res Canc, Sect Canc Surveillance, Lyon, France; [Partensky, C.] Int Agcy Res Canc, Sect Infect & Canc Epidemiol, Lyon, France		Ferlay, J (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, Lyon, France.	ferlayj@iarc.fr	Ferlay, Jacques/ABD-5058-2021	Bray, Freddie/0000-0002-3248-7787			Binder-Foucard F, 2013, ESTIMATION NATL IN 1; De Angelis R, 2014, LANCET ONCOL, V15, P23, DOI 10.1016/S1470-2045(13)70546-1; [Department of Economic and Social Affairs United Nations], WORLD POP PROSP 2012; Dyba T, 2000, STAT MED, V19, P1741, DOI 10.1002/1097-0258(20000715)19:13<1741::AID-SIM496>3.0.CO;2-O; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C, V11; Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050; Hery C, 2008, ANN ONCOL, V19, P1187, DOI 10.1093/annonc/mdn025; Karim-Kos HE, 2008, EUR J CANCER, V44, P1345, DOI 10.1016/j.ejca.2007.12.015; Klint A, 2010, ACTA ONCOL, V49, P578, DOI 10.3109/02841861003739330; Ma JM, 2013, JNCI-J NATL CANCER I, V105, P1694, DOI 10.1093/jnci/djt292; Partensky C, 2013, PANCREAS, V42, P729, DOI 10.1097/MPA.0b013e318288107a; Qiu DM, 2005, J EPIDEMIOL, V15, pS157, DOI 10.2188/jea.15.S157; Sitas F, 2015, MED J AUSTRALIA, V202, P401, DOI 10.5694/mja15.00137; World Health Organization, MORT DAT; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	16	137	142	3	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0284-186X	1651-226X		ACTA ONCOL	Acta Oncol.		2016	55	9-10					1158	1160		10.1080/0284186X.2016.1197419			3	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	DZ0UC	WOS:000385554200015	27551890	Bronze			2022-02-25	
J	Edmands, WMB; Ferrari, P; Scalbert, A				Edmands, William M. B.; Ferrari, Pietro; Scalbert, Augustin			Normalization to Specific Gravity Prior to Analysis Improves Information Recovery from High Resolution Mass Spectrometry Metabolomic Profiles of Human Urine	ANALYTICAL CHEMISTRY			English	Article							ELECTROSPRAY-IONIZATION; METABONOMIC ANALYSIS; DAY REPRODUCIBILITY; MS; CALIBRATION; CREATININE; ALIGNMENT; DILUTION	Extraction of meaningful biological information from urinary metabolomic profiles obtained by liquid-chromatography coupled to mass spectrometry (MS) necessitates the control of unwanted sources of variability associated with large differences in urine sample concentrations. Different methods of normalization either before analysis (preacquisition normalization) through dilution of urine samples to the lowest specific gravity measured by refractometry, or after analysis (postacquisition normalization) to urine volume, specific gravity and median fold change are compared for their capacity to recover lead metabolites for a potential future use as dietary biomarkers. Twenty-four urine samples of 19 subjects from the European Prospective Investigation into Cancer and nutrition (EPIC) cohort were selected based on their high and low/nonconsumption of six polyphenol-rich foods as assessed with a 24 h dietary recall. MS features selected on the basis of minimum discriminant selection criteria were related to each dietary item by means of orthogonal partial least-squares discriminant analysis models. Normalization methods ranked in the following decreasing order when comparing the number of total discriminant MS features recovered to that obtained in the absence of normalization: preacquisition normalization to specific gravity (4.2-fold), postacquisition normalization to specific gravity (2.3-fold), postacquisition median fold change normalization (1.8-fold increase), postacquisition normalization to urinary volume (0.79-fold). A preventative preacquisition normalization based on urine specific gravity was found to be superior to all curative postacquisition normalization methods tested for discovery of MS features discriminant of dietary intake in these urinary metabolomic datasets.	[Edmands, William M. B.; Ferrari, Pietro; Scalbert, Augustin] Int Agcy Res Canc IARC, Biomarkers Grp, Nutr & Metab Sect, F-69372 Lyon 08, France		Scalbert, A (corresponding author), Int Agcy Res Canc IARC, Biomarkers Grp, Nutr & Metab Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	scalberta@iarc.fr	Scalbert, Augustin/AAX-8160-2021	Scalbert, Augustin/0000-0001-6651-6710	European Union (NutriTech FP7-KBBE-2011-5 Grant) [289511]; European Union (EUROCAN FP7-KBBE-2010.2.4.1-2 Grant) [260791]	This work was supported by the European Union (NutriTech FP7-KBBE-2011-5 Grant #289511, EUROCAN FP7-KBBE-2010.2.4.1-2 Grant #260791).	Barr DB, 2005, ENVIRON HEALTH PERSP, V113, P192, DOI 10.1289/ehp.7337; Beach DG, 2013, ANAL CHEM, V85, P2127, DOI 10.1021/ac3027542; Benton HP, 2012, ANAL CHEM, V84, P2424, DOI 10.1021/ac203200x; BERLINER RW, 1958, AM J MED, V24, P730, DOI 10.1016/0002-9343(58)90377-2; Boudonck KJ, 2009, BIOANALYSIS, V1, P1645, DOI 10.4155/BIO.09.142; Chen YH, 2013, ANAL CHEM, V85, P7659, DOI 10.1021/ac401400b; Dieterle F, 2006, ANAL CHEM, V78, P4281, DOI 10.1021/ac051632c; Dunn WB, 2011, CHEM SOC REV, V40, P387, DOI 10.1039/b906712b; Durbin B P, 2002, Bioinformatics, V18 Suppl 1, pS105; Enke CG, 1997, ANAL CHEM, V69, P4885, DOI 10.1021/ac970095w; Gika HG, 2007, J PROTEOME RES, V6, P3291, DOI 10.1021/pr070183p; Gika HG, 2012, BIOANALYSIS, V4, P2239, DOI [10.4155/BIO.12.212, 10.4155/bio.12.212]; Jacob CC, 2014, METABOLOMICS, V10, P627, DOI 10.1007/s11306-013-0604-z; Kebarle P, 2009, MASS SPECTROM REV, V28, P898, DOI 10.1002/mas.20247; Kessner D, 2008, BIOINFORMATICS, V24, P2534, DOI 10.1093/bioinformatics/btn323; Mattarucchi E, 2012, BIOMED CHROMATOGR, V26, P512, DOI 10.1002/bmc.1697; Mattarucchi E, 2011, ANAL CHEM, V83, P9719, DOI 10.1021/ac202416r; Perez-Jimenez J, 2010, J AGR FOOD CHEM, V58, P4959, DOI 10.1021/jf100128b; Prince JT, 2006, ANAL CHEM, V78, P6140, DOI 10.1021/ac0605344; Saude EJ, 2007, METABOLOMICS, V3, P439, DOI 10.1007/s11306-007-0091-1; Slimani N, 2003, CANCER EPIDEM BIOMAR, V12, P784; Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y; Swinton J., 2009, VENNERABLE VENN EULE; Tang KQ, 2004, J AM SOC MASS SPECTR, V15, P1416, DOI 10.1016/j.jasms.2004.04.034; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; Veselkov KA, 2011, ANAL CHEM, V83, P5864, DOI 10.1021/ac201065j; Walsh MC, 2006, AM J CLIN NUTR, V84, P531, DOI 10.1093/ajcn/84.3.531; Want EJ, 2010, NAT PROTOC, V5, P1005, DOI 10.1038/nprot.2010.50; Warrack BM, 2009, J CHROMATOGR B, V877, P547, DOI 10.1016/j.jchromb.2009.01.007; Wilson ID, 2005, J CHROMATOGR B, V817, P67, DOI 10.1016/j.jchromb.2004.07.045; Wold S, 1998, CHEMOMETR INTELL LAB, V44, P175, DOI 10.1016/S0169-7439(98)00109-9; Wong MCY, 2008, J CHROMATOGR B, V871, P341, DOI 10.1016/j.jchromb.2008.06.033	32	51	51	1	36	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	NOV 4	2014	86	21					10925	10931		10.1021/ac503190m			7	Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry	AS8PK	WOS:000344510200059	25285402				2022-02-25	
J	Benbrahim-Tallaa, L; Baan, R; Grosse, Y; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Guha, N; Loomis, D; Straif, K				Benbrahim-Tallaa, Lamia; Baan, Robert; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Guha, Neela; Loomis, Dana; Straif, Kurt			Carcinogenicity of diesel-(DEE) and gasoline-engine exhausts (GEE)	TOXICOLOGY LETTERS			English	Meeting Abstract	50th Congress of the European-Societies-of-Toxicology	SEP 07-10, 2014	Edinburgh, SCOTLAND	European Soc Toxicol, British Toxicol Soc, Soc Toxicol					[Benbrahim-Tallaa, Lamia; Baan, Robert; Grosse, Yann; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Guha, Neela; Loomis, Dana; Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon, France				Loomis, Dana/AAE-3988-2019					0	0	0	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-4274	1879-3169		TOXICOL LETT	Toxicol. Lett.	SEP 10	2014	229			S		PS2.4-O3	S24	S24		10.1016/j.toxlet.2014.06.118			1	Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Toxicology	AO2FY	WOS:000341134000075					2022-02-25	
J	Crispim, SP; Nicolas, G; Casagrande, C; Knaze, V; Illner, AK; Huybrechts, I; Slimani, N				Crispim, Sandra P.; Nicolas, Genevieve; Casagrande, Corinne; Knaze, Viktoria; Illner, Anne-Kathrin; Huybrechts, Inge; Slimani, Nadia			Quality assurance of the international computerised 24 h dietary recall method (EPIC-Soft)	BRITISH JOURNAL OF NUTRITION			English	Article						Diets; 24h Dietary recall; Quality controls; Methods	POTASSIUM INTAKE; MONITORING SURVEYS; ENERGY; PROTEIN; CALIBRATION; VALIDATION; CANCER; RECOMMENDATIONS; CONCLUSIONS; POPULATION	The interview-administered 24h dietary recall (24-HDR) EPIC-Soft((R)) has a series of controls to guarantee the quality of dietary data across countries. These comprise all steps that are part of fieldwork preparation, data collection and data management; however, a complete characterisation of these quality controls is still lacking. The present paper describes in detail the quality controls applied in EPIC-Soft, which are, to a large extent, built on the basis of the EPIC-Soft error model and are present in three phases: (1) before, (2) during and (3) after the 24-HDR interviews. Quality controls for consistency and harmonisation are implemented before the interviews while preparing the seventy databases constituting an EPIC-Soft version (e.g. pre-defined and coded foods and recipes). During the interviews, EPIC-Soft uses a cognitive approach by helping the respondent to recall the dietary intake information in a stepwise manner and includes controls for consistency (e.g. probing questions) as well as for completeness of the collected data (e.g. system calculation for some unknown amounts). After the interviews, a series of controls can be applied by dietitians and data managers to further guarantee data quality. For example, the interview-specific note files' that were created to track any problems or missing information during the interviews can be checked to clarify the information initially provided. Overall, the quality controls employed in the EPIC-Soft methodology are not always perceivable, but prove to be of assistance for its overall standardisation and possibly for the accuracy of the collected data.	[Crispim, Sandra P.; Nicolas, Genevieve; Casagrande, Corinne; Knaze, Viktoria; Illner, Anne-Kathrin; Huybrechts, Inge; Slimani, Nadia] IARC, Sect Nutr & Metab, Dietary Exposure Assessment Grp, F-69372 Lyon 08, France		Crispim, SP (corresponding author), IARC, Sect Nutr & Metab, Dietary Exposure Assessment Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	sandracrispim@gmail.com	Crispim, Sandra P./G-9983-2011	Crispim, Sandra P./0000-0002-2257-9899			Bingham SA, 1997, AM J CLIN NUTR, V65, P1130; Black AE, 2000, INT J OBESITY, V24, P1119, DOI 10.1038/sj.ijo.0801376; Bornhorst C, 2013, CLIN NUTR; Brussaard JH, 2002, EUR J CLIN NUTR, V56, pS89, DOI 10.1038/sj.ejcn.1601432; Conrad FG, 2000, PUBLIC OPIN QUART, V64, P1, DOI 10.1086/316757; Crispim SP, 2012, EUR J NUTR, V51, P997, DOI 10.1007/s00394-011-0279-z; Crispim SP, 2011, BRIT J NUTR, V105, P447, DOI 10.1017/S0007114510003648; de Boer EJ, 2011, EUR J CLIN NUTR, V65, pS102, DOI 10.1038/ejcn.2011.94; FESKANICH D, 1989, COMPUT METH PROG BIO, V30, P47, DOI 10.1016/0169-2607(89)90122-3; Freedman LS, 2004, J NUTR, V134, P1836, DOI 10.1093/jn/134.7.1836; GOLDBERG GR, 1991, EUR J CLIN NUTR, V45, P569; Heerstrass DW, 1998, INT J EPIDEMIOL, V27, P186, DOI 10.1093/ije/27.2.186; Huybrechts I, 2011, EUR J CLIN NUTR, V65, pS16, DOI 10.1038/ejcn.2011.84; Illner AK, 2012, INT J EPIDEMIOL, V41, P1187, DOI 10.1093/ije/dys105; Kahn Harold A., 1995, Annals of Epidemiology, V5, P484, DOI 10.1016/1047-2797(95)00065-8; Moshfegh AJ, 2008, AM J CLIN NUTR, V88, P324; Ocke MC, 2011, EUR J CLIN NUTR, V65, pS48, DOI 10.1038/ejcn.2011.87; Raper N, 2004, J FOOD COMPOS ANAL, V17, P545, DOI 10.1016/j.jfca.2004.02.013; Schober MF, 1997, PUBLIC OPIN QUART, V61, P576, DOI 10.1086/297818; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; Slimani N, 2002, PUBLIC HEALTH NUTR, V5, P1125, DOI 10.1079/PHN2002395; Slimani N, 2011, EUR J CLIN NUTR, V65, pS5, DOI 10.1038/ejcn.2011.83; Slimani N, 2003, CANCER EPIDEM BIOMAR, V12, P784; Slimani N, 2002, EUR J CLIN NUTR, V56, pS63, DOI 10.1038/sj.ejcn.1601430; Slimani N, 2000, EUR J CLIN NUTR, V54, P900, DOI 10.1038/sj.ejcn.1601107; Slimani N, 1999, COMPUT METH PROG BIO, V58, P251, DOI 10.1016/S0169-2607(98)00088-1; Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092; SUCHMAN L, 1990, J AM STAT ASSOC, V85, P232, DOI 10.2307/2289550; Vereecken CA, 2008, INT J OBESITY, V32, pS26, DOI 10.1038/ijo.2008.180; Westat, 1992, NHANES 3 DIET INT MA	30	25	26	1	7	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	0007-1145	1475-2662		BRIT J NUTR	Br. J. Nutr.	FEB 14	2014	111	3					506	515		10.1017/S0007114513002766			10	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	AC3WI	WOS:000332451700015	24001201	Bronze			2022-02-25	
J	Baussano, I; Franceschi, S; Plummer, M				Baussano, I.; Franceschi, S.; Plummer, M.			Infection transmission and chronic disease models in the study of infection-associated cancers	BRITISH JOURNAL OF CANCER			English	Review						cancer epidemiology; infectious diseases epidemiology; mathematical model	HUMAN-PAPILLOMAVIRUS; MARKOV-MODELS; MATHEMATICAL-MODELS; NATURAL-HISTORY; VACCINATION; NEOPLASIA; VACCINES; IMPACT; WOMEN; RISK	In the last three decades, the appreciation of the role of infections in cancer aetiology has greatly expanded. Among the 13 million new cancer cases that occurred worldwide in 2008, around 2 million (16%) were attributable to infections. Concurrently, the approach to prevention of infection-related cancers is shifting from cancer control to infection control, for example, vaccination and the detection of infected individuals. In support of this change, the use of infection transmission models has entered the field of infection-related cancer epidemiology. These models are useful to understand the infection transmission processes, to estimate the key parameters that govern the spread of infection, and to project the potential impact of different preventive measures. However, the concepts, terminology, and methods used to study infection transmission are not yet well known in the domain of cancer epidemiology. This review aims to concisely illustrate the main principles of transmission dynamics, the basic structure of infection transmission models, and their use in combination with empirical data. We also briefly summarise models of carcinogenesis and discuss their specificities and possible integration with models of infection natural history.	[Baussano, I.; Franceschi, S.; Plummer, M.] Int Agcy Res Canc, F-69372 Lyon 08, France		Baussano, I (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	baussanoi@iarc.fr	franceschi, silvia/M-2452-2014	franceschi, silvia/0000-0003-4181-8071; Plummer, Martyn/0000-0001-5130-6497	European CommunityEuropean Commission [242061]; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1053353]	We thank Fulvio Lazzarato and Guglielmo Ronco for their helpful discussions. Dr Baussano is on leave from the University of Piemonte Orientale, Novara, Italy. This work was supported by the European Community's Seventh Framework programme (FP7/2007-2013) under grant agreement No. 242061 (acronym PREHDICT); and by the Bill & Melinda Gates Foundation (grant number OPP1053353).	ANDERSON R M, 1991; Barnabas RV, 2006, PLOS MED, V3, P624, DOI 10.1371/journal.pmed.0030138; Baussano I, 2013, INT J CANCER, V133, P1876, DOI 10.1002/ijc.28197; Baussano I, 2010, EPIDEMICS-NETH, V2, P21, DOI 10.1016/j.epidem.2010.02.002; Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0; Box G.E.P., 1987, EMPIRICAL MODEL BUIL; Burchell AN, 2006, AM J EPIDEMIOL, V163, P534, DOI 10.1093/aje/kwj077; Bureau A, 2003, STAT MED, V22, P441, DOI 10.1002/sim.1270; Rodriguez AC, 2010, JNCI-J NATL CANCER I, V102, P315, DOI 10.1093/jnci/djq001; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Garnett GP, 2011, LANCET, V378, P515, DOI 10.1016/S0140-6736(10)61505-X; GARNETT GP, 1994, IMA J MATH APPL MED, V11, P161; Garnett GP, 2005, J INFECT DIS, V191, pS97, DOI 10.1086/425271; Grassly NC, 2008, NAT REV MICROBIOL, V6, P477, DOI 10.1038/nrmicro1845; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485; Hoare A, 2008, THEOR BIOL MED MODEL, V5, DOI 10.1186/1742-4682-5-4; Hughes JP, 2002, EPIDEMIOLOGY, V13, P631, DOI 10.1097/00001648-200211000-00006; Jit M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5775; Keeling M, 2008, MODELING INFECT DIS; Kim JJ, 2007, BRIT J CANCER, V97, P1322, DOI 10.1038/sj.bjc.6604023; Kim JJ, 2007, AM J EPIDEMIOL, V166, P137, DOI 10.1093/aje/kwm086; Kretzschmar M, 2002, EPIDEMIOL INFECT, V128, P229, DOI 10.1017/S0950268801006562; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Liljeros F, 2003, MICROBES INFECT, V5, P189, DOI 10.1016/S1286-4579(02)00058-8; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222; Titman AC, 2010, BIOMETRICS, V66, P742, DOI 10.1111/j.1541-0420.2009.01339.x; Toni T, 2009, J R SOC INTERFACE, V6, P187, DOI 10.1098/rsif.2008.0172; Uhry Z, 2010, STAT METHODS MED RES, V19, P463, DOI 10.1177/0962280209359848; VANOORTMARSSEN GJ, 1991, BRIT J CANCER, V64, P559, DOI 10.1038/bjc.1991.350	32	4	4	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-0920	1532-1827		BRIT J CANCER	Br. J. Cancer	JAN 7	2014	110	1					7	11		10.1038/bjc.2013.740			5	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	286UH	WOS:000329493700003	24300979	Green Published, hybrid			2022-02-25	
J	Chajes, V; Romieu, I				Chajes, Veronique; Romieu, Isabelle			Nutrition and breast cancer	MATURITAS			English	Review						Nutrition; Breast cancer; Epidemiology	DIETARY FIBER INTAKE; GLYCEMIC INDEX; 25-HYDROXYVITAMIN D; FATTY-ACIDS; VITAMIN-D; RISK; PATTERNS; METAANALYSIS; HEALTH; LOAD	Breast cancer incidence is rising worldwide with an increase in aggressive neoplasias in young women. Suspected factors responsible for the global increase include lifestyle changes, notably diet. Currently accepted risk factors directly linked to diet are greater body weight and alcohol consumption. Weight gain in adulthood is associated with increased risk of breast cancer in post-menopausal women, suggesting that weight gain before and around menopausal age may be determinant for breast cancer development among postmenopausal women. Numerous studies also show an impact of specific diets and nutrients fatty acids, carbohydrates, vitamins B, D, carotenoids, phytoestrogens, fiber - on breast cancer risk, and evidence supports a mechanistic basis for an influence of specific nutrients. However, these studies are plagued with conflicting results. In this review, a new examination of the relationship between nutrition and breast cancer is proposed in light of recent epidemiological studies. Successful development of breast cancer prevention strategies will require identification of biological markers of dietary exposure, and to coordinate worldwide research to discern the effects of diet. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Chajes, Veronique; Romieu, Isabelle] Int Agcy Res Canc, F-69373 Lyon, France		Romieu, I (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69373 Lyon, France.	romieui@iarc.fr					Adebamowo CA, 2005, ANN EPIDEMIOL, V15, P789, DOI 10.1016/j.annepidem.2005.01.008; Amadou A, 2013, OBES REV, V14, P665, DOI 10.1111/obr.12028; Aune D, 2012, ANN ONCOL, V23, P1394, DOI 10.1093/annonc/mdr589; Aune D, 2012, AM J CLIN NUTR, V96, P356, DOI 10.3945/ajcn.112.034165; Bauer SR, 2013, MEDICINE, V92, P123, DOI 10.1097/MD.0b013e3182943bc2; Berstad P, 2010, CANCER EPIDEM BIOMAR, V19, P1532, DOI 10.1158/1055-9965.EPI-10-0025; Brooks PJ, 2013, ALCOHOL CLIN EXP RES, V37, P23, DOI 10.1111/j.1530-0277.2012.01888.x; Cade JE, 2010, NUTR CANCER, V62, P300, DOI 10.1080/01635580903441246; Chajes V, 2008, AM J EPIDEMIOL, V167, P1312, DOI 10.1093/aje/kwn069; Chajes V, 2012, CANCER EPIDEM BIOMAR, V21, P319, DOI 10.1158/1055-9965.EPI-11-0896; Chajes V, 2011, CURR OPIN LIPIDOL, V22, P6, DOI 10.1097/MOL.0b013e3283404552; Cheraghi Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051446; Choi Y, 2012, BRIT J NUTR, V108, P1934, DOI 10.1017/S0007114512003984; Cottet V, 2009, AM J EPIDEMIOL, V170, P1257, DOI 10.1093/aje/kwp257; Elias SG, 2007, FERTIL STERIL, V88, P1101, DOI 10.1016/j.fertnstert.2006.12.043; Ericson U, 2010, J NUTR, V140, P1661, DOI 10.3945/jn.110.124313; Fedirko V, 2012, CANCER CAUSE CONTROL, V23, P1149, DOI 10.1007/s10552-012-9984-z; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ferrari P, 2013, AM J CLIN NUTR, V97, P344, DOI 10.3945/ajcn.112.034025; Franco-Marina F, 2009, SALUD PUBLICA MEXICO, V51, pS157, DOI 10.1590/s0036-36342009000800005; Freedman LS, 2008, CANCER J, V14, P69, DOI 10.1097/PPO.0b013e31816a5e02; Giles GG, 2006, INT J CANCER, V118, P1843, DOI 10.1002/ijc.21548; Harris HR, 2011, JNCI-J NATL CANCER I, V103, P273, DOI 10.1093/jnci/djq500; Hu JF, 2011, EUR J CANCER PREV, V20, P530, DOI 10.1097/CEJ.0b013e328348fbfb; Khandekar MJ, 2011, NAT REV CANCER, V11, P886, DOI 10.1038/nrc3174; Korde LA, 2009, CANCER EPIDEM BIOMAR, V18, P1050, DOI 10.1158/1055-9965.EPI-08-0405; Kuhn T, 2013, INT J CANCER, V133, P1689, DOI 10.1002/ijc.28172; Lajous M, 2006, CANCER EPIDEM BIOMAR, V15, P443, DOI 10.1158/1055-9965.EPI-05-0532; Linos E, 2010, CANCER EPIDEM BIOMAR, V19, P689, DOI 10.1158/1055-9965.EPI-09-0802; Gomez LM, 2009, SALUD PUBLICA MEXICO, V51, pS621, DOI 10.1590/S0036-36342009001000017; Michels KB, 2007, CANCER-AM CANCER SOC, V109, P2712, DOI 10.1002/cncr.22654; Mourouti N, 2013, MATURITAS; Norat T CD, 2008, ASS FOOD NUTR PHYS A; Park Y, 2009, AM J CLIN NUTR, V90, P664, DOI 10.3945/ajcn.2009.27758; Pischon T, 2008, P NUTR SOC, V67, P128, DOI 10.1017/S0029665108006976; Porter P, 2008, NEW ENGL J MED, V358, P213, DOI 10.1056/NEJMp0708307; Romieu I, 2004, CANCER EPIDEM BIOMAR, V13, P1283; Romieu I, 2012, AM J CLIN NUTR, V96, P345, DOI 10.3945/ajcn.111.026724; Schulz M, 2008, BRIT J NUTR, V100, P942, DOI 10.1017/S0007114508966149; Shao T, 2012, ONCOLOGIST, V17, P36, DOI 10.1634/theoncologist.2011-0278; Shikany JM, 2011, NUTR CANCER, V63, P899, DOI 10.1080/01635581.2011.587227; Sieri S, 2004, CANCER EPIDEM BIOMAR, V13, P567; Sperati F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069269; Suzuki R, 2008, INT J CANCER, V122, P1832, DOI 10.1002/ijc.23184; Teegarden D, 2012, NUTR RES REV, V25, P68, DOI 10.1017/S0954422411000199; Velie EM, 2005, AM J CLIN NUTR, V82, P1308, DOI 10.1093/ajcn/82.6.1308; Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648; World Cancer Research Fund and American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P, P289; Xu XR, 2009, J GENET GENOMICS, V36, P203, DOI 10.1016/S1673-8527(08)60108-3; Zheng JS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3706	50	32	34	0	38	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-5122	1873-4111		MATURITAS	Maturitas	JAN	2014	77	1					7	11		10.1016/j.maturitas.2013.10.004			5	Geriatrics & Gerontology; Obstetrics & Gynecology	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Obstetrics & Gynecology	295XQ	WOS:000330150100003	24215727				2022-02-25	
J	Vaccarella, S; Lortet-Tieulent, J; Plummer, M; Franceschi, S; Bray, F				Vaccarella, Salvatore; Lortet-Tieulent, Joannie; Plummer, Martyn; Franceschi, Silvia; Bray, Freddie			Worldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors	EUROPEAN JOURNAL OF CANCER			English	Article						Cervical cancer; Incidence trends; Age-period-cohort models; Impact of screening	AGE-PERIOD; HUMAN-PAPILLOMAVIRUS; TEMPORAL VARIATION; PREVENTION; CARCINOMA; BEHAVIORS; COUNTRIES; MORTALITY; TYPE-16; BURDEN	Background: Cervical cancer trends in a given country mainly depend on the existence of effective screening programmes and time changes in disease risk factors, notably exposure to human papillomavirus (HPV). Screening primarily influences variations by period of diagnosis, whereas changes in risk factors chiefly manifest themselves as variations in risk across successive birth cohorts of women. Methods: We assessed trends in cervical cancer across 38 countries in five continents, age group 30-74 years, using age-standardised incidence rates (ASRs) and age-period-cohort (APC) models. Non-identifiability in APC models was circumvented by making assumptions based on a consistent relationship between age and cervical cancer incidence (i.e. approximately constant rates after age 45 years). Findings: ASRs decreased in several countries, except in most of Eastern European populations, Thailand as well as Uganda, although the direction and magnitude of period and birth cohort effects varied substantially. Strong downward trends in cervical cancer risk by period were found in the highest-income countries, whereas no clear changes by period were found in lower-resourced settings. Successive generations of women born after 1940 or 1950 exhibited either an increase in risk of cervical cancer (in most European countries, Japan, China), no substantial changes (North America and Australia) or a decrease (Ecuador and India). Interpretation: In countries where effective screening has been in place for a long time the consequences of underlying increases in cohort-specific risk were largely avoided. In the absence of screening, cohort-led increases or, stable, cervical cancer ASRs were observed. Our study underscores the importance of strengthening screening efforts and augmenting existing cancer control efforts with HPV vaccination, notably in those countries where unfavourable cohort effects are continuing or emerging. (C) 2013 Elsevier Ltd. All rights reserved.	[Vaccarella, Salvatore; Lortet-Tieulent, Joannie; Plummer, Martyn; Franceschi, Silvia; Bray, Freddie] Int Agcy Res Canc, F-69372 Lyon 08, France		Vaccarella, S (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	vaccarellas@iarc.fr	Lortet-Tieulent, Joannie/AAE-9099-2019; franceschi, silvia/M-2452-2014	Lortet-Tieulent, Joannie/0000-0002-8816-7475; franceschi, silvia/0000-0003-4181-8071; Bray, Freddie/0000-0002-3248-7787; Plummer, Martyn/0000-0001-5130-6497; Vaccarella, Salvatore/0000-0002-2516-2167; Lukac, Azra/0000-0002-4329-1368	Bill and Melinda Gates Foundation (BMGF), USABill & Melinda Gates Foundation [OPP1053353]	This work was supported by a grant from the Bill and Melinda Gates Foundation (BMGF), USA, (Grant Number OPP1053353).	Af Geijersstam V, 1998, INT J CANCER, V76, P341, DOI 10.1002/(SICI)1097-0215(19980504)76:3&lt;341::AID-IJC10&gt;3.0.CO;2-E; Anttila A, 2009, EUR J CANCER, V45, P2649, DOI 10.1016/j.ejca.2009.07.020; Anttila A, 2009, EUR J CANCER, V45, P2685, DOI 10.1016/j.ejca.2009.07.017; Appleby P, 2006, INT J CANCER, V119, P1108, DOI 10.1002/ijc.21953; Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5; Arbyn M, 2011, INT J CANCER, V128, P1899, DOI 10.1002/ijc.25525; Arbyn M, 2009, EUR J CANCER, V45, P2640, DOI 10.1016/j.ejca.2009.07.018; Bajos N, 2010, AIDS, V24, P1185, DOI 10.1097/QAD.0b013e328336ad52; Bray F, 2005, CANCER EPIDEM BIOMAR, V14, P677, DOI 10.1158/1055-9965.EPI-04-0569; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; Curado M.P., 2007, CANC INCIDENCE 5 CON, V160; de Quadros CAT, 2004, REV PANAM SALUD PUBL, V16, P223, DOI 10.1590/S1020-49892004001000001; Dhillon PK, 2011, BRIT J CANCER, V105, P723, DOI 10.1038/bjc.2011.301; Ferlay J, 2010, GLOBOCAN 2008; Gakidou E, 2008, PLOS MED, V5, P863, DOI 10.1371/journal.pmed.0050132; Haldre K, 2012, EUR J CONTRACEP REPR, V17, P351, DOI 10.3109/13625187.2012.696751; Hogan DP, 2000, AM J PUBLIC HEALTH, V90, P1421, DOI 10.2105/AJPH.90.9.1421; Holford T., 1998, ENCY BIOSTATISTICS, V1, P82; IARC, 2012, MON EV CARC RISKS B, V100B; International Collaboration of Epidemiological Studies of Cervical Cancer, 2006, Int J Cancer, V118, P1481, DOI 10.1002/ijc.21493; Laukkanen P, 2003, J GEN VIROL, V84, P2105, DOI 10.1099/vir.0.18995-0; LYNGE E, 1989, CANCER RES, V49, P2157; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9; Peto J, 2004, BRIT J CANCER, V91, P942, DOI 10.1038/sj.bjc.6602049; Pike MC, 2004, ONCOGENE, V23, P6379, DOI 10.1038/sj.onc.1207899; Plummer M, 2012, INT J CANCER, V130, P2638, DOI 10.1002/ijc.26250; Reimers LL, 2009, CANCER EPIDEM BIOMAR, V18, P792, DOI 10.1158/1055-9965.EPI-08-0965; Ronco G, 2009, EUR J CANCER, V45, P2659, DOI 10.1016/j.ejca.2009.07.022; Samandari G, 2010, INT PERSPECT SEX R H, V36, P26, DOI 10.1363/ipsrh.36.026.10; Segi M, 1960, CANC MORTALITY SELEC; Shavit O, 2012, APPL HEALTH ECON HEA, V10, P87, DOI 10.2165/11594780-000000000-00000; Wabinga HR, 2000, BRIT J CANCER, V82, P1585, DOI 10.1054/bjoc.1999.1071; Zeferino Luiz Carlos, 2006, Cad. Saúde Pública, V22, P1909, DOI 10.1590/S0102-311X2006000900022	35	265	280	4	37	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049	1879-0852		EUR J CANCER	Eur. J. Cancer	OCT	2013	49	15					3262	3273		10.1016/j.ejca.2013.04.024			12	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	226AA	WOS:000325005200024	23751569		Y	N	2022-02-25	
J	Grosse, Y; Loomis, D; Lauby-Secretan, B; El Ghissassi, F; Bouvard, V; Benbrahim-Tallaa, L; Guha, N; Baan, R; Mattock, H; Straif, K				Grosse, Yann; Loomis, Dana; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Baan, Robert; Mattock, Heidi; Straif, Kurt		Int Agcy Res Canc Monograph	Carcinogenicity of some drugs and herbal products	LANCET ONCOLOGY			English	News Item							CANCER; PIOGLITAZONE; RISK; DIGOXIN; BLADDER		[Grosse, Yann; Loomis, Dana; Lauby-Secretan, Beatrice; El Ghissassi, Fatiha; Bouvard, Veronique; Benbrahim-Tallaa, Lamia; Guha, Neela; Baan, Robert; Mattock, Heidi; Straif, Kurt; Int Agcy Res Canc Monograph] Int Agcy Res Canc, F-69372 Lyon, France		Grosse, Y (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.		Loomis, Dana/AAE-3988-2019; Lunn, Ruth/AAP-8848-2021; Guha, Neela/AAG-3989-2021; Marques, M. Matilde/E-2535-2012; Lachenmeier, Dirk W./A-3210-2008; GHANTOUS, Akram/C-1689-2017	Guha, Neela/0000-0003-3991-4662; Marques, M. Matilde/0000-0002-7526-4962; Lachenmeier, Dirk W./0000-0002-3115-864X; GHANTOUS, Akram/0000-0002-2582-6402; Loomis, Dana/0000-0003-3297-5200; Lauby-Secretan, Beatrice/0000-0001-6559-3351			Azoulay L, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3645; Biggar RJ, 2011, J CLIN ONCOL, V29, P2165, DOI 10.1200/JCO.2010.32.8146; Friedman GD, 2012, ARCH INTERN MED, V172, P1246, DOI 10.1001/archinternmed.2012.2754; IARC, IARC MON EV CARC RIS, V108; Jahan-Tigh RR, 2013, CANCER-AM CANCER SOC, V119, P825, DOI 10.1002/cncr.27740; Lewis JD, 2008, GASTROENTEROLOGY, V135, P1914, DOI 10.1053/j.gastro.2008.09.004; National Toxicology Program, 2013, TOX CARC STUD NOND W; Platz EA, 2011, CANCER DISCOV, V1, P68, DOI 10.1158/2159-8274.CD-10-0020; Sato K, 2011, TOXICOL APPL PHARM, V251, P234, DOI 10.1016/j.taap.2011.01.006; Smith U, 2001, INT J CLIN PRACT, P13; U.S. Food and Drug Administration CDER, 1999, REV EV PHARM TOX DAT	11	22	23	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	AUG	2013	14	9					807	808		10.1016/S1470-2045(13)70329-2			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	205DZ	WOS:000323423400037	24058961				2022-02-25	
J	Romieu, I				Romieu, I.			Lifestyle Factors and Breast Cancer - Recent Study Results and What They Mean	EUROPEAN JOURNAL OF CANCER			English	Meeting Abstract	8th European Breast Cancer Conference (EBCC)	MAR 21-24, 2012	Vienna, AUSTRIA	European Canc Org (ECCO)					[Romieu, I.] IARC, Lyon, France									0	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-8049			EUR J CANCER	Eur. J. Cancer	MAR	2012	48			1			S165	S165					1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	926AV	WOS:000302804600416					2022-02-25	
J	Herceg, Z; Vaissiere, T				Herceg, Zdenko; Vaissiere, Thomas			Epigenetic mechanisms and cancer An interface between the environment and the genome	EPIGENETICS			English	Review						epigenome; environment; DNA methylation; lung cancer; biomarkers	ABERRANT DNA METHYLATION; DE-NOVO METHYLATION; CELL LUNG-CANCER; CPG ISLAND HYPERMETHYLATION; GENE PROMOTER METHYLATION; TUMOR-RELATED GENES; HISTONE MODIFICATIONS; S-ADENOSYLMETHIONINE; NORMAL-TISSUES; EARLY EVENT	Although epidemiological studies support the role of the environment in a wide range of human cancers, the precise mechanisms by which environmental exposures promote cancer development and progression remain poorly understood. Environmental factors have been proposed to promote the development of malignancies by eliciting epigenetic changes; however, it is only with recent advances in epigenetics and epigenomics that target genes and the mechanisms underlying environmental influences are beginning to be elucidated. Because epigenetic mechanisms may function as an interface between environmental factors and the genome, deregulation of the epigenome by environmental stressors is likely to disrupt different cellular processes and contribute to cancer risk. In addition, the early appearance and ubiquity of epigenetic changes in virtually all steps of tumor development and progression in most, if not all, human neoplasms, make them attractive targets for biomarker discovery and targeted prevention. At the cellular level, aberrant epigenetic changes associated with environmental exposures may deregulate key cellular processes (including transcriptional control, DNA repair, cell cycle control and carcinogen detoxification), which can be further modulated by environmental stressors, thus defining not only the phenotype of the disease but also potential biomarkers. This review summarizes recent progress in our understanding of the epigenetic mechanisms through which environmental factors may promote tumor development, with a particular focus on human lung cancer.	[Herceg, Zdenko; Vaissiere, Thomas] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	herceg@iarc.fr; tvaissie@scripps.edu	Vaissiere, Thomas/E-1121-2011		l'Agence Nationale de Recherche Contre le Sida et Hepatites Virales (ANRS, France)ANRS; l'Association pour la Recherche sur le Cancer (ARC), FranceFondation ARC pour la Recherche sur le Cancer; la Ligue Nationale (Francaise) Contre le Cancer, FranceLigue nationale contre le cancer	The work in the Epigenetics Group at the International Agency for Research on Cancer (Lyon, France) is supported by grants from l'Agence Nationale de Recherche Contre le Sida et Hepatites Virales (ANRS, France), l'Association pour la Recherche sur le Cancer (ARC), France; and la Ligue Nationale (Francaise) Contre le Cancer, France (to Z.H.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Arai E, 2006, INT J CANCER, V119, P288, DOI 10.1002/ijc.21807; ARNAUD M, 1985, BIOCHIM BIOPHYS ACTA, V826, P108, DOI 10.1016/0167-4781(85)90115-0; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 2007, BRIT J CANCER, V96, P1278, DOI 10.1038/sj.bjc.6603721; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bestor TH, 1998, CIBA F SYMP, V214, P187; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Boyle P, 2009, WORLD CANC REPORT; Brena RM, 2007, PLOS MED, V4, P572, DOI 10.1371/journal.pmed.0040108; Brock HW, 2009, BIOCHEM CELL BIOL, V87, P27, DOI 10.1139/O08-108; Brown KD, 2007, NAT GENET, V39, P289, DOI 10.1038/ng0307-289; Buchen L, 2010, NATURE, V467, P146, DOI 10.1038/467146a; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; CANTONI GL, 1951, J BIOL CHEM, V189, P203; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640; Cortazar D, 2007, DNA REPAIR, V6, P489, DOI 10.1016/j.dnarep.2006.10.013; Costa FF, 2005, GENE, V357, P83, DOI 10.1016/j.gene.2005.06.019; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; DANTE R, 1992, ANTICANCER RES, V12, P559; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849; Davalos V, 2010, CURR OPIN ONCOL, V22, P35, DOI 10.1097/CCO.0b013e328333dcbb; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; FEINBERG AP, 1988, CANCER RES, V48, P1159; Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Feng QH, 2008, CANCER EPIDEM BIOMAR, V17, P645, DOI 10.1158/1055-9965.EPI-07-2518; Ferguson-Smith AC, 2007, NATURE, V449, P148, DOI 10.1038/449148a; FERLAY J, 2008, IARC CANCERBASE, V10; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Franchina M, 2000, DNA CELL BIOL, V19, P521, DOI 10.1089/104454900439755; FRANKLIN WA, 2004, CHEST, V125, P90; Fremont M, 1997, NUCLEIC ACIDS RES, V25, P2375, DOI 10.1093/nar/25.12.2375; Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S; Fuks Z, 2005, CANCER CELL, V8, P89, DOI 10.1016/j.ccr.2005.07.014; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gehring M, 2006, CELL, V124, P495, DOI 10.1016/j.cell.2005.12.034; Gehring M, 2009, TRENDS GENET, V25, P82, DOI 10.1016/j.tig.2008.12.001; Glass JL, 2009, MAMM GENOME, V20, P633, DOI 10.1007/s00335-009-9232-3; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Gopalakrishnan S, 2008, MUTAT RES-FUND MOL M, V647, P30, DOI 10.1016/j.mrfmmm.2008.08.006; Gordian E, 2009, ANTICANCER RES, V29, P3207; Grillo MA, 2008, AMINO ACIDS, V34, P187, DOI 10.1007/s00726-007-0500-9; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hartman TJ, 2001, AM J EPIDEMIOL, V153, P688, DOI 10.1093/aje/153.7.688; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Heijmans BT, 2003, CANCER RES, V63, P1249; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749; Holst CR, 2003, CANCER RES, V63, P1596; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Imamura T, 2004, BIOCHEM BIOPH RES CO, V322, P593, DOI 10.1016/j.bbrc.2004.07.159; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jaenisch R, 2004, NEW ENGL J MED, V351, P2787, DOI 10.1056/NEJMp048304; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980; Jarmalaite S, 2003, INT J CANCER, V106, P913, DOI 10.1002/ijc.11322; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073; JIA D, 2007, NATURE; Jin MJ, 2009, CANCER SCI, V100, P2325, DOI 10.1111/j.1349-7006.2009.01321.x; Jin SG, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000013; Johanning GL, 2002, J NUTR, V132, p3814S, DOI 10.1093/jn/132.12.3814S; Johansson M, 2010, JAMA-J AM MED ASSOC, V303, P2377, DOI 10.1001/jama.2010.808; John RM, 2000, CELL, V101, P585, DOI 10.1016/S0092-8674(00)80870-3; Jones PA, 2005, CANCER RES, V65, P11241, DOI 10.1158/0008-5472.CAN-05-3865; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kim DH, 2001, CANCER RES, V61, P3419; Kim JS, 2005, CANCER, V104, P1825, DOI 10.1002/cncr.21409; Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456; KONDO M, 1995, ONCOGENE, V10, P1193; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li YQ, 2007, NUCLEIC ACIDS RES, V35, P390, DOI 10.1093/nar/gkl1052; Lima SC, 2010, CURR OPIN MOL THER, V12, P316; Lin CH, 2001, CANCER RES, V61, P4238; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Ma DKK, 2009, CELL CYCLE, V8, P1526, DOI 10.4161/cc.8.10.8500; Machida EO, 2006, CANCER RES, V66, P6210, DOI 10.1158/0008-5472.CAN-05-4447; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051; McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Michie AM, 2010, FEBS J, V277, P74, DOI 10.1111/j.1742-4658.2009.07414.x; MONK M, 1987, DEVELOPMENT, V99, P371; Morales-Ruiz T, 2006, P NATL ACAD SCI USA, V103, P6853, DOI 10.1073/pnas.0601109103; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MULLER SZ, 2001, CANCER RES, V61, P249; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; Oakey RJ, 2002, TRENDS GENET, V18, P359, DOI 10.1016/S0168-9525(02)02708-7; Okada Y, 2010, NATURE, V463, P554, DOI 10.1038/nature08732; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Paliwal A, 2010, CANCER RES, V70, P2779, DOI 10.1158/0008-5472.CAN-09-4550; Palmisano WA, 2000, CANCER RES, V60, P5954; Park Jong, 2005, Cancer Biomarkers, V1, P193; Patra SK, 2008, CANCER METAST REV, V27, P315, DOI 10.1007/s10555-008-9118-y; Paz MF, 2002, CANCER RES, V62, P4519; Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361; Peng G, 2010, BRIT J CANCER, V103, P542, DOI 10.1038/sj.bjc.6605810; Penterman J, 2007, P NATL ACAD SCI USA, V104, P6752, DOI 10.1073/pnas.0701861104; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; Pfeifer GP, 2009, SEMIN CANCER BIOL, V19, P181, DOI 10.1016/j.semcancer.2009.02.008; Pfeifer GP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P576, DOI 10.1007/s10541-005-0151-y; Plass C, 2006, CURR TOP MICROBIOL, V310, P179; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Rai K, 2010, CELL, V142, P930, DOI 10.1016/j.cell.2010.08.030; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Rando OJ, 2007, CELL, V128, P655, DOI 10.1016/j.cell.2007.01.023; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; Reik W, 1999, NAT GENET, V23, P380, DOI 10.1038/70476; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Risch A, 2008, INT J CANCER, V123, P1, DOI 10.1002/ijc.23605; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002; Sawan C, 2010, ADV GENET, V70, P57, DOI [10.1016/S0065-2660(10)70003-1, 10.1016/B978-0-12-380866-0.60003-4]; Schaefer M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001414; SCHLESINGER Y, 2006, NAT GENET; Schwartz AG, 2007, CARCINOGENESIS, V28, P507, DOI 10.1093/carcin/bgl253; Seike M, 2000, CLIN CANCER RES, V6, P4307; SEIVWRIGHT C, 1993, J GEN VIROL, V74, P1405, DOI 10.1099/0022-1317-74-7-1405; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Sharath AN, 2000, BIOCHEMISTRY-US, V39, P14611, DOI 10.1021/bi001610e; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sincic N, 2011, CURR OPIN ONCOL, V23, P69, DOI 10.1097/CCO.0b013e3283412eb4; Stanger O, 2002, CURR DRUG METAB, V3, P211, DOI 10.2174/1389200024605163; Stidley CA, 2010, CANCER RES, V70, P568, DOI 10.1158/0008-5472.CAN-09-3410; Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3; Szyf M, 2007, REPROD TOXICOL, V24, P9, DOI 10.1016/j.reprotox.2007.05.001; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Teugels Erik, 2005, Hum Mutat, V26, P284, DOI 10.1002/humu.9366; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Ting AH, 2006, CANCER RES, V66, P729, DOI 10.1158/0008-5472.CAN-05-1537; Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353; Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; VAISSIERE T, 2008, MUTAT RES; Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489; Vaissiere T, 2009, EPIGENETICS-US, V4, P221, DOI 10.4161/epi.8833; Veerla S, 2008, GENE CHROMOSOME CANC, V47, P368, DOI 10.1002/gcc.20542; Vineis P, 2011, EPIGENETICS-US, V6, P195, DOI 10.4161/epi.6.2.13573; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wakeling LA, 2009, AGE, V31, P327, DOI 10.1007/s11357-009-9104-5; Whitelaw E, 2001, NAT GENET, V27, P361, DOI 10.1038/86850; Widschwendter A, 2004, INT J CANCER, V109, P163, DOI 10.1002/ijc.11706; Wild L, 2010, BBA-REV CANCER, V1806, P50, DOI 10.1016/j.bbcan.2010.03.003; Wilkins JF, 2005, TRENDS GENET, V21, P356, DOI 10.1016/j.tig.2005.04.005; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Wu H, 2006, PEDIATR RES, V59, p21R, DOI 10.1203/01.pdr.0000203565.76028.2a; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485; Wu JJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-131; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zeisel SH, 2009, AM J CLIN NUTR, V89, p673S, DOI 10.3945/ajcn.2008.26811D; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041; Zhu JK, 2009, ANNU REV GENET, V43, P143, DOI 10.1146/annurev-genet-102108-134205	238	141	146	0	25	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1559-2294	1559-2308		EPIGENETICS-US	Epigenetics	JUL	2011	6	7					804	819		10.4161/epi.6.7.16262			16	Biochemistry & Molecular Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Genetics & Heredity	786HP	WOS:000292295000004	21758002	Bronze			2022-02-25	
J	Von Karsa, L				Von Karsa, L.			Mammography screening - what is going on in Europe	EJC SUPPLEMENTS			English	Meeting Abstract	European Breast Cancer Conference	MAR 24-24, 2010	Barcelona, SPAIN						[Von Karsa, L.] IARC, Qual Assurance Grp, Lyon, France								Perry N, 2008, ANN ONCOL, V19, P614, DOI 10.1093/annonc/mdm481; vonKarsa L, 2008, CANC SCREENING EUROP; [No title captured]; [No title captured]; [No title captured]	5	0	0	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6349			EJC SUPPL	EJC Suppl.	MAR	2010	8	3					189	189		10.1016/S1359-6349(10)70468-7			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	584MT	WOS:000276756900465					2022-02-25	
J	Marcel, V; Hainaut, P				Marcel, V.; Hainaut, P.			p53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Review						p53; isoforms; cancer; mutations; p53 response.	TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA; WILD-TYPE; REGULATORY ELEMENT; BINDING-SITE; PROTEIN P53; DNA-BINDING; CELL-CYCLE; GENE; TRANSLATION	For 25 years, the p53 tumor suppressor protein was considered the only protein expressed by the (TP53) gene. However, in several studies the existence of p53 alternative transcripts in mouse and human cells has been documented, while their expression patterns and functions remained a mystery. Since 2002, several groups have identified and described the existence of up to 10 p53 isoforms and have demonstrated their roles in modulation of p53 suppressive activity. It is now clear that the patterns of p53 expression are much more complex than previously recognized and that these isoforms have the potential to act either synergistically or antagonistically, depending on their structure and mechanism of production. This review focuses on the different ways to produce p53 isoforms, on their specific properties, on their effect on p53 suppressive activity as well as on their implication in a new potential mechanism involved in p53 deregulation in cancer.	[Marcel, V.; Hainaut, P.] Int Agcy Res Canc, F-69372 Lyon 08, France		Hainaut, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Marcel, Virginie/H-3037-2011; MARCEL, Virginie/ABF-1904-2020; Hainaut, Pierre/B-6018-2012	Marcel, Virginie/0000-0002-9557-8221; MARCEL, Virginie/0000-0002-9557-8221; Hainaut, Pierre/0000-0002-1303-1610			Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Anczukow O, 2008, HUM MUTAT, V29, P65, DOI 10.1002/humu.20590; Anensen N, 2006, CLIN CANCER RES, V12, P3985, DOI 10.1158/1078-0432.CCR-05-1970; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Baumbusch LO, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-47; Boggs K, 2006, ONCOGENE, V25, P555, DOI 10.1038/sj.onc.1209076; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Chan WM, 2007, CANCER RES, V67, P1959, DOI 10.1158/0008-5472.CAN-06-3602; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Christian KJ, 2008, MOL PHARMACOL, V73, P1558, DOI 10.1124/mol.107.042507; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; de Moraes E, 2007, INT J CANCER, V121, P929, DOI 10.1002/ijc.22899; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Ebrahimi M, 2008, ORAL ONCOL, V44, P156, DOI 10.1016/j.oraloncology.2007.01.014; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Flaman JM, 1996, ONCOGENE, V12, P813; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Holmila R, 2003, Hum Mutat, V21, P101, DOI 10.1002/humu.9104; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hrstka R, 2008, ANTI-CANCER DRUG, V19, P369, DOI 10.1097/CAD.0b013e3282f7f500; Ishimoto O, 2002, CANCER RES, V62, P636; Kashkin KN, 2007, BIOCHEMISTRY-MOSCOW+, V72, P282, DOI 10.1134/S0006297907030054; KHOCHBIN S, 1992, ANN NY ACAD SCI, V660, P77, DOI 10.1111/j.1749-6632.1992.tb21060.x; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Laverdiere M, 2000, NUCLEIC ACIDS RES, V28, P1489, DOI 10.1093/nar/28.6.1489; LEACH FS, 1993, CANCER RES, V53, P2231; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Pekova S, 2008, LEUKEMIA RES, V32, P395, DOI 10.1016/j.leukres.2007.06.022; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Reisman D, 1996, GENOMICS, V38, P364, DOI 10.1006/geno.1996.0639; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Sayan AE, 2007, ANN NY ACAD SCI, V1095, P315, DOI 10.1196/annals.1397.035; Sayan AE, 2004, BIOCHEM BIOPH RES CO, V313, P765, DOI 10.1016/j.bbrc.2003.12.014; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shamsher M, 1996, GENE, V176, P259, DOI 10.1016/0378-1119(96)00000-5; Stiewe T, 2002, CANCER RES, V62, P3598; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Takagi M, 2006, LEUKEMIA RES, V30, P987, DOI 10.1016/j.leukres.2005.12.009; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Varley JM, 2001, ONCOGENE, V20, P2647, DOI 10.1038/sj.onc.1204369; Venables JP, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl592; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WILL K, 1995, NUCLEIC ACIDS RES, V23, P4023, DOI 10.1093/nar/23.20.4023; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	92	48	49	1	6	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X	1420-9071		CELL MOL LIFE SCI	Cell. Mol. Life Sci.	FEB	2009	66	3					391	406		10.1007/s00018-008-8336-3			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	402GT	WOS:000263002900004	18854945				2022-02-25	
J	Cardis, E				Cardis, Elisabeth			Current status and epidemiological research needs for achieving a better understanding of the consequences of the Chernobyl accident	HEALTH PHYSICS			English	Article; Proceedings Paper	42nd Annual Meeting of the National-Council-on-Radiation-Protection-and-Measurements	2006	Arlington, VA	Natl Council Radiat Protect & Measurements		National Council on Radiation Protection and Measurements; cancer; risk analysis; accidents; nuclear	SOLID CANCER INCIDENCE; THYROID-CANCER; RADIATION; WORKERS; RUSSIA; RISK	Twenty years after the Chernobyl accident, there is no clearly demonstrated increase in the incidence of cancers in the most affected populations that can be attributed to radiation from the accident, except for the dramatic increase in thyroid cancer incidence among those exposed in childhood and adolescence. Increases in the incidence of cancers and other diseases have been reported in Belarus, the Russian Federation, and Ukraine, but much of the increase appears to be due to other factors, including improvements in diagnosis, reporting, and registration. Recent findings indicate a possible doubling of leukemia risk among Chernobyl liquidators and a small increase in the incidence of premenopausal breast cancer in the very most contaminated districts. Increased risks of cardiovascular diseases and cataracts have also been reported. These findings, however, need confirmation in well-designed analytical epidemiological studies with careful individual dose reconstruction. The absence of demonstrated increases in cancer risk-apart from thyroid cancer-is not the proof that no increase has in fact occurred. Based on the experience of atomic bomb survivors, and assuming that there is a linear, no-threshold dose-response relationship between exposure to ionizing radiation and the development of cancer in humans, a small increase in the relative risk of cancer is expected, even at the low to moderate doses received. Given the large number of individuals exposed, the absolute number of cancer cases caused could be substantial, particularly in the future. It is therefore essential to continue to use population registries to monitor trends in disease morbidity and mortality in the most contaminated areas, as well as among liquidators, in order to assess the public health impact of the accident. Studies of selected populations and diseases are also essential in order to study the real effect of the accident and compare it to predictions. Careful studies may in particular provide important information on the effect of exposure rate and exposure type in the low to medium dose range and on factors that may modify radiation effects. As such, they may have important consequences for the radiation protection of patients and of the general population in case of further nuclear emergencies.	Int Agcy Res Canc, F-69372 Lyon, France		Cardis, E (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	cardis@iarc.fr	Cardis, Elisabeth/C-3904-2017	Cardis, Elisabeth/0000-0003-0999-6839			Cardis E, 2005, JNCI-J NATL CANCER I, V97, P724, DOI 10.1093/jnci/dji129; Cardis E, 1996, P INT C 1 DEC CHERN, P241; Cardis E, 2006, INT J CANCER, V119, P1224, DOI 10.1002/ijc.22037; Cardis E, 2006, J RADIOL PROT, V26, P127, DOI 10.1088/0952-4746/26/2/001; Gaya AM, 2005, CLIN ONCOL-UK, V17, P153, DOI 10.1016/j.clon.2004.09.016; Ivanov V, 2004, J RADIAT RES, V45, P41, DOI 10.1269/jrr.45.41; Ivanov VK, 2007, HEALTH PHYS, V93, P470, DOI 10.1097/01.HP.0000282195.34508.b0; Ivanov VK, 2004, RADIAT ENVIRON BIOPH, V43, P35, DOI 10.1007/s00411-003-0223-6; *NAT AC SCI NAT RE, 2006, 7 BEIR; Pukkala E, 2006, INT J CANCER, V119, P651, DOI 10.1002/ijc.21885; Shakhtarin VV, 2003, INT J EPIDEMIOL, V32, P584, DOI 10.1093/ije/dyg205; *UN, 2006, HLTH EFF CHERN ACC S; *UN SCI COMM EFF A, 2000, 2000 REP GEN ASS, V2, P453; Yamada M, 2004, RADIAT RES, V161, P622, DOI 10.1667/RR3183	14	8	9	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0017-9078	1538-5159		HEALTH PHYS	Health Phys.	NOV	2007	93	5					542	546		10.1097/01.HP.0000281174.30093.d6			5	Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	221HG	WOS:000250217400021	18049232				2022-02-25	
J	Le Moal, J; Eilstein, D; Straif, K; Ledrans, M				Le Moal, J.; Eilstein, D.; Straif, K.; Ledrans, M.			Ranking cancer sites for monitoring and studying possible associations with environmental exposures	EPIDEMIOLOGY			English	Meeting Abstract	ISEE/ISEA 2006 Conference	2006	Paris, FRANCE	ISEE, ISEA					IARC, Lyon, France									0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	NOV	2006	17	6		S			S312	S312					1	Public, Environmental & Occupational Health	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	097JL	WOS:000241443401349					2022-02-25	
J	Straif, K; Baan, R; Cogliano, V				Straif, K; Baan, R; Cogliano, V			Butadiene or styrene or butadiene and styrene or else?	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material							IARC MONOGRAPHS		Int Agcy Res Canc, F-69372 Lyon 08, France		Straif, K (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	straif@iarc.fr					ALBERTINI RJ, 2003, RES REP HLTH EFF I, V116, P1; *AM C GOV IND HYG, 2004, DOC THRESH LIM VAL B; *DFG, 2005, 41 DFG; Huff J, 2003, INT J OCCUP ENV HEAL, V9, P83; Huff J, 2002, INT J OCCUP ENV HEAL, V8, P249, DOI 10.1179/oeh.2002.8.3.249; *IARC, 2002, MON EV CARC RISK CHE; IARC, 1999, MON EV CARC RISK CHE; Macaluso M, 1996, TOXICOLOGY, V113, P190, DOI 10.1016/0300-483X(96)03444-0; *NTP, 2004, REP CARC; Sathiakumar N, 2005, OCCUP ENVIRON MED, V62, P822, DOI 10.1136/oem.2004.018176; Tomatis L, 2002, INT J OCCUP ENV HEAL, V8, P144; *US EPA, 2002, EPA600P98001; VANDENBERG JJ, IN PRESS AIR POLLUTI	13	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	MAR	2006	63	3					157	158		10.1136/oem.2005.023986			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	015ED	WOS:000235533800001	16497855	Green Published			2022-02-25	
J	Plummer, M				Plummer, Martyn			Deviance Information Criteria for Missing Data Models Comment	BAYESIAN ANALYSIS			English	Editorial Material									Int Agcy Res Canc, F-69372 Lyon, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.						CELEUX G, 2006, BAYESIAN AN IN PRESS; Plummer M., 2002, Journal of the Royal Statistical Society: Series B (Statistical Methodology), V64, DOI [10.1111/1467-9868.00353, DOI 10.1111/1467-9868.00353]; Richardson S, 1997, J ROY STAT SOC B MET, V59, P731, DOI 10.1111/1467-9868.00095; Spiegelhalter D., 2004, WINBUGS USER MANUAL; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353	5	9	9	0	3	INT SOC BAYESIAN ANALYSIS	PITTSBURGH	CARNEGIE MELLON UNIV, DEPT STTISTICS, PITTSBURGH, PA 15213 USA	1931-6690			BAYESIAN ANAL	Bayesian Anal.		2006	1	4					681	686		10.1214/06-BA122C			6	Mathematics, Interdisciplinary Applications; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Mathematics	V10EK	WOS:000207447100004		hybrid, Green Submitted			2022-02-25	
J	Lambert, R				Lambert, R			Treatment of early gastric cancer in the elderly: leave it, cut out, peel out?	GASTROINTESTINAL ENDOSCOPY			English	Editorial Material							ENDOSCOPIC MUCOSAL RESECTION; STOMACH; TUMORS; KNIFE		Int Agcy Res Canc, F-69372 Lyon, France		Lambert, R (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.						Axon A, 2005, ENDOSCOPY, V37, P570, DOI 10.1055/s-2005-861352; Etoh T, 2005, GASTROINTEST ENDOSC, V62, P868, DOI 10.1016/j.gie.2005.09.012; Everett SM, 1998, LANCET, V351, P1350, DOI 10.1016/S0140-6736(98)04365-7; Ferlay F, 2004, GLOBOCAN 2002 CANC I; Inoue H, 2002, J GASTROEN HEPATOL, V17, P382, DOI 10.1046/j.1440-1746.2002.02732.x; Lambert R, 2003, ENDOSCOPY, V35, P118, DOI 10.1055/s-2003-37016; Lambert R, 2002, INT J CANCER, V97, P811, DOI 10.1002/ijc.10150; Matsushita I, 2002, J CLIN GASTROENTEROL, V35, P29, DOI 10.1097/00004836-200207000-00008; Miyamoto S, 2002, GASTROINTEST ENDOSC, V55, P576, DOI 10.1067/mge.2002.122579; Ohkuwa M, 2001, ENDOSCOPY, V33, P221, DOI 10.1055/s-2001-12805; Ono H, 2001, GUT, V48, P225, DOI 10.1136/gut.48.2.225; Shim CS, 2001, ENDOSCOPY, V33, P271, DOI 10.1055/s-2001-12816; Suzuki H, 2001, Gastrointest Endosc Clin N Am, V11, P511; Tanabe S, 2002, GASTROINTEST ENDOSC, V56, P708, DOI 10.1067/mge.2002.129085; Tsukuma H, 2000, GUT, V47, P618, DOI 10.1136/gut.47.5.618; Tsunada S, 2003, GASTROINTEST ENDOSC, V57, P948, DOI 10.1016/S0016-5107(03)70051-0; Yamamoto H, 2003, ENDOSCOPY, V35, P690	17	7	8	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	DEC	2005	62	6					872	874		10.1016/j.gie.2005.06.039			3	Gastroenterology & Hepatology	Science Citation Index Expanded (SCI-EXPANDED)	Gastroenterology & Hepatology	989UQ	WOS:000233699800010	16301029				2022-02-25	
J	Gray, N				Gray, N			Time to change attitudes to tobacco: product regulation over five years?	ADDICTION			English	Editorial Material							CIGARETTE; MARKET; SMOKE		Int Agcy Res Canc, Directors Off, F-69372 Lyon, France		Gray, N (corresponding author), Int Agcy Res Canc, Directors Off, 150 Cours Albert Thomas, F-69372 Lyon, France.	nigel@uicc.org					BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; Borland R, 2004, ADDICTION, V99, P529, DOI 10.1111/j.1360-0443.2004.00649.x; Gray N, 2004, LANCET, V364, P231, DOI 10.1016/S0140-6736(04)16692-0; Gray N, 2003, ANN ONCOL, V14, P353, DOI 10.1093/annonc/mdg103; Gray N, 2000, ANN ONCOL, V11, P909, DOI 10.1023/A:1008313631233; GRAY N, 2004, NICOTINE TOB RES, V6, P769; Henningfield JE, 2004, NICOTINE TOB RES, V6, P199; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; *US PHS, 1996, FTC METH DET TAR NIC; World Health Organization, 2004, FRAM CONV TOB CONTR	10	3	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	MAY	2005	100	5					575	576		10.1111/j.1360-0443.2005.01007.x			2	Substance Abuse; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Substance Abuse; Psychiatry	919TZ	WOS:000228641800001	15847611	Bronze			2022-02-25	
J	Li, H; Cuenin, C; Murr, R; Wang, ZQ; Herceg, Z				Li, H; Cuenin, C; Murr, R; Wang, ZQ; Herceg, Z			HAT cofactor Trrap regulates the mitotic checkpoint by modulation of Mad1 and Mad2 expression	EMBO JOURNAL			English	Article						chromatin acetylation; Mad1 and 2; mitotic checkpoint; transcription regulation; Trrap	HISTONE ACETYLASE COMPLEX; CELL-CYCLE PROGRESSION; ACETYLTRANSFERASE COMPLEX; SPINDLE CHECKPOINT; GENE-EXPRESSION; DNA-REPAIR; C-MYC; PROTEIN; RECRUITMENT; INSTABILITY	As a component of chromatin-modifying complexes with histone acetyltransferase (HAT) activity, TRRAP has been shown to be involved in various cellular processes including gene transcription and oncogenic transformation. Inactivation of Trrap, the murine ortholog of TRRAP, in mice revealed its function in development and cell cycle progression. However, the underlying mechanism is unknown. Here, we show that the loss of Trrap in mammalian cells leads to chromosome missegregation, mitotic exit failure and compromised mitotic checkpoint. These mitotic checkpoint defects are caused by defective Trrap-mediated transcription of the mitotic checkpoint proteins Mad1 and Mad2. The mode of regulation by Trrap involves acetylation of histones H4 and H3 at the gene promoter of these mitotic players. Trrap associated with the HAT Tip60 and PCAF at the Mad1 and Mad2 promoters in a cell cycle-dependent manner and Trrap depletion abolished recruitment of these HATs. Finally, ectopic expression of Mad1 and Mad2 fully restores the mitotic checkpoint in Trrap-deficient cells. These results demonstrate that Trrap controls the mitotic checkpoint integrity by specifically regulating Mad1 and Mad2 genes.	Int Agcy Res Canc, Grp Gene Environm Biol, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Grp Gene Environm Biol, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr		Murr, Rabih/0000-0002-3346-6590			Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lin SF, 2002, LEUKEMIA LYMPHOMA, V43, P385, DOI 10.1080/10428190290006206; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Takahashi N, 1999, SOFTWARE STUDIES, V2, P55; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001	51	44	45	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0261-4189	1460-2075		EMBO J	Embo J.	DEC 8	2004	23	24					4824	4834		10.1038/sj.emboj.7600479			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	884TU	WOS:000226110100012	15549134	Green Published			2022-02-25	
J	Fernet, M; Hall, J				Fernet, M; Hall, J			Genetic biomarkers of therapeutic radiation sensitivity	DNA REPAIR			English	Review						therapeutic radiation sensitivity; genetics; in vitro assays	BREAST-CANCER PATIENTS; DNA-REPAIR GENES; ACID SUBSTITUTION VARIANTS; SUPEROXIDE-DISMUTASE GENE; ATAXIA-TELANGIECTASIA; INDIVIDUAL RADIOSENSITIVITY; CLINICAL RADIOSENSITIVITY; PROTEIN EXPRESSION; RADIOTHERAPY; RISK	The occurrence of acute or late normal tissue reactions after therapeutic radiotherapy and cellular responses in in vitro radiosensitivity assays do not correlate well suggesting that to date no one test system is suitable for predicting the risk or severity of such reactions. New insights into the underlying molecular mechanisms of this sensitivity are coming from studies that assess associations between common polymorphisms in DNA damage detection and repair genes and the development of adverse reactions to radiotherapy. The presence of such variants may alter protein function and an individual's capacity to repair damaged DNA modifying the response of the normal tissue. Polymorphisms in the XRCC1, ATM, hHR21 and TGFbeta1 genes have been shown to be associated with an increased risk of developing an adverse normal tissue reaction to radiotherapy, whilst one variant in the ATM gene has been reported to be radioprotective. Functional studies, taking into account either the haplotypes or the combined genotypes when multiple polymorphisms in a gene are present, will be necessary to establish the mechanistic basis of these associations. In the future association studies can only benefit from the analysis of multiple genes in large, well-characterized cohorts in particular to identify genetic factors that might specifically influence the temporal occurrence of these adverse reactions. (C) 2004 Elsevier B.V. All rights reserved.	Int Agcy Res Canc, DNA Repair Grp, F-69372 Lyon 08, France		Hall, J (corresponding author), Int Agcy Res Canc, DNA Repair Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hall@iarc.fr	hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295			Ambrosone CB, 1999, CANCER RES, V59, P602; Andreassen CN, 2002, RADIOTHER ONCOL, V64, P131, DOI 10.1016/S0167-8140(02)00154-8; Angele S, 2003, CANCER RES, V63, P8717; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Borgstahl GEO, 1996, BIOCHEMISTRY-US, V35, P4287, DOI 10.1021/bi951892w; Bremer M., 2003, International Journal of Radiation Oncology Biology Physics, V57, pS204, DOI 10.1016/S0360-3016(03)01009-5; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Carlomagno F, 2000, INT J CANCER, V85, P845, DOI 10.1002/(SICI)1097-0215(20000315)85:6<845::AID-IJC18>3.3.CO;2-3; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Dikomey E, 2003, INT J RADIAT ONCOL, V56, P1194, DOI 10.1016/S0360-3016(03)00188-3; Fernet M, 2004, BRIT J CANCER, V90, P866, DOI 10.1038/sj.bjc.6601549; Fiets WE, 2003, EUR J CANCER, V39, P1081, DOI 10.1016/S0959-8049(03)00178-3; Fu YP, 2003, CANCER RES, V63, P2440; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Green H, 2002, RADIOTHER ONCOL, V63, P213, DOI 10.1016/S0167-8140(02)00079-8; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Haghdoost S, 2001, INT J RADIAT ONCOL, V50, P405, DOI 10.1016/S0360-3016(00)01580-7; Iannuzzi CM, 2002, INT J RADIAT ONCOL, V52, P606, DOI 10.1016/S0360-3016(01)02684-0; Leong T, 2003, BRIT J CANCER, V88, P1251, DOI 10.1038/sj.bjc.6600897; Leong T, 2000, INT J RADIAT ONCOL, V48, P959, DOI 10.1016/S0360-3016(00)00728-8; Li CG, 1999, INT J CANCER, V84, P155, DOI 10.1002/(SICI)1097-0215(19990420)84:2<155::AID-IJC11>3.0.CO;2-S; Marcou Y, 2001, RADIOTHER ONCOL, V60, P75, DOI 10.1016/S0167-8140(01)00370-X; Mitrunen K, 2001, CARCINOGENESIS, V22, P827, DOI 10.1093/carcin/22.5.827; Mohrenweiser HW, 2002, CANCER EPIDEM BIOMAR, V11, P1054; Moullan N, 2003, CANCER EPIDEM BIOMAR, V12, P1168; Oppitz U, 2002, INT J RADIAT BIOL, V78, P611, DOI 10.1080/09553000210126466; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Pierce LJ, 2000, J CLIN ONCOL, V18, P3360, DOI 10.1200/JCO.2000.18.19.3360; Popanda O, 2003, INT J RADIAT ONCOL, V55, P1216, DOI 10.1016/S0360-3016(02)04415-2; Quarmby S, 2003, INT J RADIAT BIOL, V79, P137, DOI 10.1080/0955300021000045673; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; RUIZ DAM, 2002, RADIOTHER ONCOL, V62, P327; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Severin DM, 2001, INT J RADIAT ONCOL, V50, P1323, DOI 10.1016/S0360-3016(01)01608-X; Shen MR, 1998, CANCER RES, V58, P604; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; ShimodaMatsubayashi S, 1996, BIOCHEM BIOPH RES CO, V226, P561, DOI 10.1006/bbrc.1996.1394; Su Y, 2000, ANN INTERN MED, V133, P770, DOI 10.7326/0003-4819-133-10-200011210-00009; SWIFT M, 1986, AM J HUM GENET, V39, P573; Tell R, 2003, ANTICANCER RES, V23, P3077; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; Twardella D, 2002, RADIOTHER ONCOL, V62, P249, DOI 10.1016/S0167-8140(01)00491-1; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; WOODS CG, 1990, HUM GENET, V84, P555; Xia F, 2002, SEMIN RADIAT ONCOL, V12, P296, DOI 10.1053/srao.2002.35250	47	70	74	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1568-7864	1568-7856		DNA REPAIR	DNA Repair	AUG-SEP	2004	3	8-9					1237	1243		10.1016/j.dnarep.2004.03.019			7	Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity; Toxicology	850YQ	WOS:000223650700050	15279812				2022-02-25	
J	Pluquet, O; Hainaut, P				Pluquet, O; Hainaut, P			Genotoxic and non-genotoxic pathways of p53 induction	CANCER LETTERS			English	Review						p53; DNA damage; phosphorylation; non-genotoxic stress; hypoxia; p14(arf)	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGING AGENTS; PROTEASOME-MEDIATED DEGRADATION; INDUCIBLE FACTOR 1-ALPHA; CELL-CYCLE ARREST; WILD-TYPE P53; KINASE-C; IN-VITRO; RIBONUCLEOTIDE DEPLETION; INDUCED PHOSPHORYLATION	Since the initial concept of p53 as a sensor of DNA-damage, the picture of the role of p53 has widened to include the sensing of much more diverse forms of stress, including hypoxia and constitutive activation of growth-promoting cascades. The pathways by which these processes regulate p53 are partially overlapping, but imply different patterns of post-translational modifications. In this review, we summarize current knowledge on post-translational modifications of p53, and we discuss how hypoxia and oncogene activation stresses may induce p53 independently of DNA damage. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France		Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610			Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Alarcon R, 1999, CANCER RES, V59, P6046; Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BOND JA, 1994, ONCOGENE, V9, P1885; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chehab NH, 2000, GENE DEV, V14, P278; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; ELLEDGE RM, 1995, J NATL CANCER I, V87, P1254, DOI 10.1093/jnci/87.16.1254; Fernet M, 2000, INT J RADIAT BIOL, V76, P1621; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GOTLIEB WH, 1994, AM J OBSTET GYNECOL, V170, P1121, DOI 10.1016/S0002-9378(94)70106-7; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 2001, IN PRESS ZINC BINDIN; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HICKMAN AW, 1994, CANCER RES, V54, P5797; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang TS, 1996, ONCOGENE, V13, P625; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1991, CANCER RES, V51, P6304; KEM SE, 1992, SCIENCE, V256, P827; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Khan SH, 1998, CANCER RES, V58, P396; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kramer DL, 1999, CANCER RES, V59, P1278; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; MAGNELLI L, 1995, BIOCHEM BIOPH RES CO, V215, P641, DOI 10.1006/bbrc.1995.2512; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; MILNE DM, 1992, ONCOGENE, V7, P1361; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nigro JM, 1997, CANCER RES, V57, P3635; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PRICE BD, 1995, ONCOGENE, V11, P73; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Ravi R, 2000, GENE DEV, V14, P34; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Rocha S, 2000, CELL GROWTH DIFFER, V11, P491; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; RUSSO CA, 1995, CANCER RES, V55, P1122; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TISHLER RB, 1993, CANCER RES, V53, P2212; Wang XJ, 1996, CANCER LETT, V104, P79, DOI 10.1016/0304-3835(96)04235-8; Wang XJ, 1996, ANTICANCER RES, V16, P1671; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	126	134	139	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3835	1872-7980		CANCER LETT	Cancer Lett.	DEC 10	2001	174	1					1	15		10.1016/S0304-3835(01)00698-X			15	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	491PQ	WOS:000172117700001	11675147				2022-02-25	
J	Vainio, H				Vainio, H			Is COX-2 inhibition a panacea for cancer prevention?	INTERNATIONAL JOURNAL OF CANCER			English	Review						cyclooxygenase-deficient mice; carcinogenesis; prostaglandins; nonsteroidal anti-inflammatory agent; cycloocygenase-2	CYCLOOXYGENASE-2 INHIBITOR; GENE DISRUPTION; COLON-CANCER; MICE; INFLAMMATION; POLYPOSIS	The epidemiologic evidence and rodent studies suggest strongly that nonselective inhibitors of cyclooxygenase (COX) enzymes such as aspirin, inhibiting both COX-1 and COX-2 isoforms, reduce the incidence of and mortality from intestinal tumors. Genetically manipulated animals show that both Cox-1 and Cox-2 disruptions decrease the tumor yield, both in genetically predisposed and in carcinogen-treated mice. The mechanisms by which COX-1 and COX-2 deficiency decrease tumorigenesis are still unknown. Cox-2 overexpression increased the tumor yield in mammary glands of the multiparous, but not virginal female transgenic mice using the murine mammary tumor virus promoter. The Cox-2 protein was strongly induced during pregnancy and lactation. These data suggest that Cox-2 overexpression may be an important target for cancer chemoprevention. This finding was supported by the observed cancer-preventive effects of the COX-2-specific inhibitors in humans and in rodents. However, based on the available data, we cannot totally attribute the cancer preventive effects of nonsteroidal antiinflammatory drugs (NSAIDs) to COX-2 alone even COX-1 may have an important role in cancer prevention as suggested by the Cox-l-deficient Min mice. It is likely that COX-1 plays a more important role in NSAID-induced toxicity in humans, such as in gastric ulcer formation-but inhibition of COX-2 may not be without toxic manifestations either, as suggested by the poor survival of the Cox-2-nulled mice. Combinations of COX-2 inhibitors with other agents that target other pathways in carcinogenesis may be a more efficacious and a less toxic strategy in cancer chemoprevention. (C) 2001 Wiley-Liss, Inc.	Int Agcy Res Canc, Unit Chemoprevent, F-69372 Lyon, France		Vainio, H (corresponding author), Int Agcy Res Canc, Unit Chemoprevent, 150 Cours Albert Thomas, F-69372 Lyon, France.	vainio@iarc.fr					Brenner DE, 2000, J CELL BIOCHEM, P121; Chan G, 1999, CANCER RES, V59, P991; Chulada P. C., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P195; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; DuBois RN, 2001, CARCINOGENESIS, V22, P691, DOI 10.1093/carcin/22.5.691; *IARC, 1997, IARC HDB CANC PREV, V1, P1; Kishi K, 2000, CANCER RES, V60, P1326; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Langenbach R, 1999, ANN NY ACAD SCI, V889, P52, DOI 10.1111/j.1749-6632.1999.tb08723.x; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Meyskens FL, 1998, JNCI-J NATL CANCER I, V90, P1212, DOI 10.1093/jnci/90.16.1212; MOORE RJ, 2000, P AM ASSOC CANC RES, V41, P409; Morgan G, 1998, EUR J CANCER PREV, V7, P195, DOI 10.1097/00008469-199806000-00003; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534	20	34	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0020-7136	1097-0215		INT J CANCER	Int. J. Cancer	DEC 1	2001	94	5					613	614		10.1002/ijc.1518			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	489BR	WOS:000171972600001	11745453	Bronze			2022-02-25	
J	Fernandez-Cuesta, L				Fernandez-Cuesta, L.			New Insights into the Molecular Characteristics and Intra-Tumor Heterogeneity of Malignant Pleural Mesothelioma from the MESOMICS Project	JOURNAL OF THORACIC ONCOLOGY			English	Meeting Abstract						MESOMICS; genomics; intra-tumor heterogeneity			[Fernandez-Cuesta, L.] Int Agcy Res Canc Iarc Who, Genet Sect, Lyon, France									0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	OCT	2019	14	10		S		ES17.04	S57	S57		10.1016/j.jtho.2019.08.147			1	Oncology; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Respiratory System	JG6DQ	WOS:000492162200098		Bronze			2022-02-25	
J	Van den Berg, M; Kafferlein, HU; Perbellini, L; Matsumoto, M; Nomiyama, T; Ogawa, K; Sone, H; Cherrie, JW; Cattley, R; Dorman, DC; Dunnick, JK; Gohlke, JM; Jinot, J; Kopylev, L				Van den Berg, M.; Kaefferlein, H. U.; Perbellini, L.; Matsumoto, M.; Nomiyama, T.; Ogawa, K.; Sone, H.; Cherrie, J. W.; Cattley, R.; Dorman, D. C.; Dunnick, J. K.; Gohlke, J. M.; Jinot, J.; Kopylev, L.		IARC Monographs Vol 123 Grp	Carcinogenicity of some nitrobenzenes and other industrial chemicals	LANCET ONCOLOGY			English	News Item							CHRONIC TOXICITY; RATS; MICE; CHLORONITROBENZENE		[IARC Monographs Vol 123 Grp] Int Agcy Res Canc, Lyon, France					Nomiyama, Tetsuo/0000-0002-1702-5242; Kafferlein, Heiko Udo/0000-0001-5150-4979; Hall, Amy/0000-0003-1502-2694			IARC (International Agency for Research on Cancer), 2003, IARC TECHNICAL PUBLI, V39, P1; International Agency for Research on Cancer, 1999, IARC SCI PUBL, V147, P1; International Agency for Research on Cancer, 2018, IARC MONOGR EVAL CAR, V123; Japan Bioassay Research Center, 2004, SUMM FEED CARC STUD; Japan Bioassay Research Center, 2013, SUMM INH CARC STUD N; Japan Bioassay Research Center, 2008, SUMM FEED CARC STUD; Kano H, 2012, ARCH TOXICOL, V86, P1763, DOI 10.1007/s00204-012-0890-7; Matsumoto M, 2006, J ENVIRON PATHOL TOX, V25, P571, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i3.20; Matsumoto M, 2012, ARCH TOXICOL, V86, P791, DOI 10.1007/s00204-012-0800-z; Matsumoto Michiharu, 2006, Journal of Toxicological Sciences, V31, P9, DOI 10.2131/jts.31.247; WEISBURGER EK, 1978, J ENVIRON PATHOL TOX, V2, P325; Yamazaki K, 2006, IND HEALTH, V44, P230, DOI 10.2486/indhealth.44.230; Yamazaki K, 2009, J OCCUP HEALTH, V51, P249, DOI 10.1539/joh.L8178	13	2	2	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	DEC	2018	19	12					E681	E682		10.1016/S1470-2045(18)30823-4			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	HC2LP	WOS:000451633800032	30392807	Green Published			2022-02-25	
J	Pineros, M; Sierra, MS; Forman, D				Pineros, Marion; Sierra, Monica S.; Forman, David			Descriptive epidemiology of lung cancer and current status of tobacco control measures in Central and South America	CANCER EPIDEMIOLOGY			English	Article						Neoplasms; Epidemiology; Lung; Americas; Tobacco control; Developing countries	DRINKING-WATER; SMOKING PREVALENCE; MORTALITY; TRENDS; EXPOSURE; MEXICO; BRAZIL; SMOKERS; RATES	Rationale and objective: Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death in the world. In Central and South America lung cancer is now one of most frequent cancers and the leading cause of cancer-related death in both sexes. We describe patterns and trends in lung cancer incidence and mortality in Central and South America and give a brief overview of the current status of tobacco control measures based on the most recent MPOWER report. Methods: We obtained regional and national-level incidence data from 48 population- based cancer registries in 13 countries and cancer deaths from the WHO mortality database for 18 countries. We estimated world population age-standardized incidence and mortality rates per 100,000 person-years. Incidence of lung cancer by histological subtype were only available from high-quality population-based cancer registries for the period 2003-2007. Results: The highest incidence and mortality rates in the region were seen among males in Argentina, Cuba, Chile and Uruguay. Adenocarcinoma was the most frequent histological type overall, though squamous carcinoma was more frequent in Antofagasta-Chile and Villa Clara-Cuba. Smoke-free policies and warnings are widely implemented tobacco control measures; cessation is offered but the costs are not covered by health systems in the majority of countries. Conclusion: The high burden of lung cancer in the region highlights the need to improve long term information and strengthen current tobacco control policies including aggressive taxing measures and supporting smoking cessation in order to achieve the targeted reductions in smoking prevalence. (C) 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd.	[Pineros, Marion; Sierra, Monica S.; Forman, David] Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69008 Lyon, France		Pineros, M (corresponding author), Int Agcy Res Canc, Sect Canc Surveillance, 150 Cours Albert Thomas, F-69008 Lyon, France.	pinerosm@iarc.fr	Piñeros, Marion/K-3255-2019; Sierra, Monica S./H-1751-2015	Piñeros, Marion/0000-0002-4249-7276; Sierra, Monica S./0000-0003-1286-057X	International Agency for Research on Cancer; European Commission FP7 Marie Curie Actions	This work was undertaken during the tenure of a Postdoctoral Fellowship to Dr Monica S. Sierra from The International Agency for Research on Cancer, partially supported by the European Commission FP7 Marie Curie Actions - People - Co-funding of regional, national and international Programmes (COFUND).	Abascal W, 2012, LANCET, V380, P1575, DOI 10.1016/S0140-6736(12)60826-5; [Anonymous], 2015, WHO REP GLOB TOB EP; Barbosa VC, 2012, REV SAUDE PUBL, V46, P901, DOI 10.1590/S0034-89102012000500018; Barrios E., 2010, 3 ATLAS INCIDENCIA C, pIII; Bianco E., 2005, PREVENTION CONTROL, V1, P311, DOI DOI 10.1016/J.PRECON.2006.05.001; Bosetti C, 2005, ANN ONCOL, V16, P489, DOI 10.1093/annonc/mdi086; Bravo LE, 2012, COLOMB MEDICA, V43, P246; Cha Q, 1997, LUNG CANCER-J IASLC, V17, P219, DOI 10.1016/S0169-5002(97)00028-7; Chatenoud L., 2014, ANN ONCOL; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Doll R., 1966, UNION INT CANC MONOG, VI; Esteve J, 1994, IARC Sci Publ, P1; Ferlay J, 2013, CANC INCIDENCE MORTA, V11; Ferreccio C, 2000, EPIDEMIOLOGY, V11, P673, DOI 10.1097/00001648-200011000-00010; Ferreccio C., 1998, CAD SAUDE PUBLICA S3, V14, P193; Ferreccio C, 2013, AM J EPIDEMIOL, V178, P813, DOI 10.1093/aje/kwt059; Forman D, 2014, IARC SCI PUBLICATION, VX; Forman D, 2013, CANC INCIDENCE 5 CON, VX; Gigliotti A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-327; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; Gobierno de Chile-Ministerio de Salud, 2016, ENC NAT SAL 2009 201; Gruer L, 2012, PUBLIC HEALTH, V126, P227, DOI 10.1016/j.puhe.2011.12.005; Olivera-Chavez RI, 2010, SALUD PUBLICA MEXICO, V52, pS197, DOI 10.1590/S0036-36342010000800015; Jemal A., 2014, CANC ATLAS; Jha P, 2014, NEW ENGL J MED, V370, P60, DOI 10.1056/NEJMra1308383; King BA, 2013, TOB CONTROL, V22, DOI 10.1136/tobaccocontrol-2012-050582; Loria Dora, 2010, Rev Cubana Salud Pública, V36, P115, DOI 10.1590/s0864-34662010000200004; Lortet-Tieulent J, 2014, LUNG CANCER, V84, P13, DOI 10.1016/j.lungcan.2014.01.009; Marshall G, 2007, JNCI-J NATL CANCER I, V99, P920, DOI 10.1093/jnci/djm004; Mendez D, 1998, AM J EPIDEMIOL, V148, P249; Monteiro CA, 2007, B WORLD HEALTH ORGAN, V85, P527, DOI 10.2471/BLT.06.039073; Reynales-Shigematsu LM, 2015, REV PANAM SALUD PUBL, V38, P316; Panamerican Health Organization, 2013, CANC AM BAS IND; Pesch B, 2012, INT J CANCER, V131, P1210, DOI 10.1002/ijc.27339; Portes LH, 2015, REV PANAM SALUD PUBL, V38, P370; Presidencia de la Nacion- Ministerio de Salud INDEC Panamerican Health Organization PAHO CDC, 2012, GLOB AD TOB SURV; Presidencia de la Nacion- Ministerio de Salud Panamerican Health Organization PAHO CDC, 2009, GLOB AD TOB SURV; Rivas H, 2011, P R HEALTH SCI J, V30, P176; Segi M., 1963, TRENDS CANC MORTALIT; Siegel R, 2012, CA-CANCER J CLIN, V62, DOI 10.3322/caac.21153; StataCorp LP, 2011, STAT DAT AN STAT SOF; Steinmaus CM, 2013, CANCER EPIDEM BIOMAR, V22, P623, DOI 10.1158/1055-9965.EPI-12-1190; Szklo AS, 2012, PREV MED, V54, P162, DOI 10.1016/j.ypmed.2011.12.005; Szklo AS, 2013, CAD SAUDE PUBLICA, V29, P485, DOI 10.1590/S0102-311X2013000300007; Thrasher JF, 2013, HEALTH POLICY PLANN, V28, P789, DOI 10.1093/heapol/czs118; Thun M, 2014, WORLD CANC REPORT 20; Tovar-Guzman VJ, 2005, REV PANAM SALUD PUBL, V17, P254, DOI 10.1590/S1020-49892005000400006; Valdes-Salgado R., 2010, SALUD PUBLICA MEX S2, V52, pS321; Warren C.W., 2009, THE GTSS ATLAS; WHO Global Health Data Repository, 2014, WHO GLOB HLTH DAT RE; World Health Organisation, 2013, DRAFT COMPR GLOB MON; World Health Organization, 2013, STAT WHO FRAM CONV T; World Health Organization, 2004, RISK FACT EST 2014 A; World Health Organization, 2019, WHO REPORT GLOBAL TO; World Health Organization, 2011, WHO REP GLOB TOB EP; World Health Organization, GLOB ACT PLAN PREV C; Wynder EL, 1995, ENVIRON HEALTH PERSP, V103, P143, DOI 10.2307/3432301; Yepez MC, 2012, COLOMB MEDICA, V43, P256	58	15	16	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	SEP	2016	44			1			S90	S99		10.1016/j.canep.2016.03.002			10	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	EE3RT	WOS:000389515600010	27678327	hybrid			2022-02-25	
J	Esposti, DD; Voegele, C; Cahais, V; Forey, N; Kelm, FL; McKay, J; Hernandez-Vargas, H; Herceg, Z				Esposti, Davide Degli; Voegele, Catherine; Cahais, Vincent; Forey, Nathalie; Kelm, Florence Le Calvez; McKay, James; Hernandez-Vargas, Hector; Herceg, Zdenko			Deciphering the role of long noncoding RNAs in the progression of hepatocellular carcinoma using next-generation sequencing	CANCER RESEARCH			English	Meeting Abstract	106th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 18-22, 2015	Philadelphia, PA	Amer Assoc Canc Res					[Esposti, Davide Degli; Voegele, Catherine; Cahais, Vincent; Forey, Nathalie; Kelm, Florence Le Calvez; McKay, James; Hernandez-Vargas, Hector; Herceg, Zdenko] Int Agcy Res Canc, F-69372 Lyon, France				Degli Esposti, Davide/M-1917-2015	Degli Esposti, Davide/0000-0003-1390-4845				0	0	0	0	1	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	AUG 1	2015	75			15		171				10.1158/1538-7445.AM2015-171			1	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	DF8AH	WOS:000371578500162					2022-02-25	
J	Herceg, Z				Herceg, Zdenko			Characterizing the epigenome and exposome in evaluating environmental exposures and cancer risk Zdenko Herceg	MUTAGENESIS			English	Meeting Abstract									[Herceg, Zdenko] Int Agcy Res Canc, Lyon, France									0	0	0	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0267-8357	1464-3804		MUTAGENESIS	Mutagenesis	NOV	2014	29	6					500	500					1	Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity; Toxicology	AT0KI	WOS:000344624700025					2022-02-25	
J	Ambatipudi, S; Chajes, V; Le Calvez-Kelm, F; Cuenin, C; Durand, G; Romieu, I; Herceg, Z				Ambatipudi, Srikant; Chajes, Veronique; Le Calvez-Kelm, Florence; Cuenin, Cyrille; Durand, Geoffroy; Romieu, Isabelle; Herceg, Zdenko			Epigenome-wide association study to predict breast cancer risk in European Prospective Investigation into Cancer and Nutrition (EPIC) cohort	CANCER RESEARCH			English	Meeting Abstract	105th Annual Meeting of the American-Association-for-Cancer-Research (AACR)	APR 05-09, 2014	San Diego, CA	Amer Assoc Canc Res					[Ambatipudi, Srikant; Chajes, Veronique; Le Calvez-Kelm, Florence; Cuenin, Cyrille; Durand, Geoffroy; Romieu, Isabelle; Herceg, Zdenko] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	4	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	OCT 1	2014	74	19		S		386				10.1158/1538-7445.AM2014-386			2	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Oncology	CB8UN	WOS:000349906904353					2022-02-25	
J	Wild, CP				Wild, Christopher Paul			The Role of Cancer Research in Noncommunicable Disease Control	JOURNAL OF THE NATIONAL CANCER INSTITUTE			English	Editorial Material							HEALTH; ENVIRONMENT	Noncommunicable diseases were estimated to claim more than 36 million lives worldwide in 2008. Major contributors to this burden were cardiovascular disease, cancer, chronic respiratory diseases, and diabetes. The United Nations General Assembly held a high-level meeting on noncommunicable diseases in September 2011 for heads of states and governments, conscious of the projected increases in disease incidence, particularly in low- and middle-income countries. This meeting followed the Special Session on HIV/AIDS in 2001, the only other high-level meeting to discuss a health topic and orient the global political agenda toward a growing threat to human development. Proposed strategies for control of noncommunicable diseases focused mainly on the shared risk factors of tobacco, harmful use of alcohol, physical inactivity, and unhealthy diet. However, for cancer, a broader response is required. Notably, the heterogeneity of cancer with respect to its geographical distribution, etiology, and pathology all demand a more nuanced, regional, or even local approach. Preparations for the meeting elicited enormous attention from governments and nongovernmental organizations, but the engagement of the research community was less evident. This commentary calls for the involvement of the cancer research community in response to the further action detailed in the United Nations Political Declaration emanating from the meeting, identifies a number of cancer-specific priorities, including vaccination against hepatitis B virus and human papillomavirus, cervical cancer screening, and early detection of breast cancer, and suggests areas where cancer research can provide the evidence base for cancer control, notably in improving the quality and coverage of cancer registration, elucidating cancer etiology, and evaluating interventions, including their implementation in low-resource health-care settings. Finally, the need for global cooperation in developing a research agenda for low- and middle-income countries is highlighted.	Int Agcy Res Canc, F-69372 Lyon 08, France		Wild, CP (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	director@iarc.fr	Wild, Christopher/ABC-6260-2020	Wild, Christopher/0000-0003-0249-8669			Beaglehole R, 2011, LANCET, V378, P449, DOI 10.1016/S0140-6736(11)60879-9; Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; Bray F, LANCET ONCO IN PRESS; Cogliano VJ, 2011, JNCI-J NATL CANCER I, V103, P1827, DOI 10.1093/jnci/djr483; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Farmer P, 2010, LANCET, V376, P1186, DOI 10.1016/S0140-6736(10)61152-X; Ferlay J, 2011, IARC CANC BASE; Franceschi S, 2011, INT J CANCER, V128, P2765, DOI 10.1002/ijc.25915; Goldie SJ, 2011, JNCI-J NATL CANCER I, V103, P1373, DOI 10.1093/jnci/djr303; Harford JB, 2011, LANCET ONCOL, V12, P306, DOI 10.1016/S1470-2045(10)70273-4; Institute of Medicine of the National Academies Committee on Cancer Control in Low- and Middle-Income Countries, 2007, CANC CONTR OPP LOW M; Knaul FM, 2011, SHULMAN L GLOBAL TAS; Kreimer AR, 2011, JNCI-J NATL CANCER I, V103, P1444, DOI 10.1093/jnci/djr319; Rappaport SM, 2010, SCIENCE, V330, P460, DOI 10.1126/science.1192603; Sankaranarayanan R, 2011, JNCI-J NATL CANCER I, V103, P1476, DOI 10.1093/jnci/djr304; Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3; Wild CP, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-S1-S15; Wild CP, 2011, CANCER EPIDEM BIOMAR, V20, P580, DOI 10.1158/1055-9965.EPI-11-0187; Wild CP, 2010, CARCINOGENESIS, V31, P71, DOI 10.1093/carcin/bgp264; Wild CP, 2005, CANCER EPIDEM BIOMAR, V14, P1847, DOI 10.1158/1055-9965.EPI-05-0456; [World Cancer Research Fund American Institute for Cancer Research (AICR)], 2007, FOOD NUTR PHYS ACT P; World Health Organization, 2010, GLOBAL STATUS REPORT	22	26	26	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0027-8874			J NATL CANCER I	J. Natl. Cancer Inst.	JUL	2012	104	14					1051	1058		10.1093/jnci/djs262			8	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	981LG	WOS:000306969100007	22781435	hybrid, Green Published			2022-02-25	
J	Martin, M; Herceg, Z				Martin, Marion; Herceg, Zdenko			From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms	GENOME MEDICINE			English	Article						Cancer stem cells; epigenetic mechanisms; epigenetic switch; hepatitis; hepatocellular carcinoma; inflammation	NF-KAPPA-B; ALCOHOLIC LIVER-DISEASE; NON-TUMOROUS TISSUES; VIRUS CORE PROTEIN; GROWTH-FACTOR-BETA; CANCER STEM-CELLS; MICRORNA EXPRESSION; GENE-EXPRESSION; DNA METHYLATION; PROGENITOR CELLS	Inflammation represents the body's natural response to tissue damage; however, chronic inflammation may activate cell proliferation and induce deregulation of cell death in affected tissues. Chronic inflammation is an important factor in the development of hepatocellular carcinoma (HCC), although the precise underlying mechanism remains unknown. Epigenetic events, which are considered key mechanisms in the regulation of gene activity states, are also commonly deregulated in HCC. Here, we review the evidence that chronic inflammation might deregulate epigenetic processes, thus promoting oncogenic transformation, and we propose a working hypothesis that epigenetic deregulation is an underlying mechanism by which inflammation might promote HCC development. In this scenario, different components of the inflammatory response might directly and indirectly induce changes in epigenetic machineries ('epigenetic switch'), including those involved in setting and propagating normal patterns of DNA methylation, histone modifications and non-coding RNAs in hepatocytes. We discuss the possibility that self-reinforcing cross-talk between inflammation and epigenetic mechanisms might amplify inflammatory signals and maintain a chronic state of inflammation culminating in cancer development. The potential role of inflammation-epigenome interactions in the emergence and maintenance of cancer stem cells is also discussed.	[Martin, Marion; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon 08, France		Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	herceg@iarc.fr			l'Agence Nationale de Recherche Contre le Sida et Hepatites Virales (ANRS, France)ANRS; l'Association pour la Recherche sur le Cancer (ARC), FranceFondation ARC pour la Recherche sur le Cancer; la Ligue Nationale (Francaise) Contre le Cancer, FranceLigue nationale contre le cancer	We apologize to authors whose relevant publications were not cited due to space limitations. The work in the Epigenetics Group at the International Agency for Research on Cancer (Lyon, France) is supported by grants from l'Agence Nationale de Recherche Contre le Sida et Hepatites Virales (ANRS, France), l'Association pour la Recherche sur le Cancer (ARC), France, and la Ligue Nationale (Francaise) Contre le Cancer, France (to ZH). The founders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alison MR, 2009, J PATHOL, V217, P282, DOI 10.1002/path.2453; Alison MR, 2005, CELL PROLIFERAT, V38, P407, DOI 10.1111/j.1365-2184.2005.00354.x; Amin Rupen, 2008, Gastrointest Cancer Res, V2, pS27; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Assenat E, 2006, EUR J CANCER, V42, P785, DOI 10.1016/j.ejca.2006.01.005; Ballestar E, 2008, ADV GENET, V61, P247, DOI 10.1016/S0065-2660(07)00009-0; Bartsch H, 2006, LANGENBECK ARCH SURG, V391, P499, DOI 10.1007/s00423-006-0073-1; Beckebaum S, 2004, CLIN CANCER RES, V10, P7260, DOI 10.1158/1078-0432.CCR-04-0872; Berasain C, 2009, ANN NY ACAD SCI, V1155, P206, DOI 10.1111/j.1749-6632.2009.03704.x; Bertoletti A, 2010, ANTIVIR THER, V15, P15, DOI 10.3851/IMP1620; Bortolami M, 2002, DIGEST LIVER DIS, V34, P794, DOI 10.1016/S1590-8658(02)80073-1; Bouchard MJ, 2011, CANCER LETT, V305, P123, DOI 10.1016/j.canlet.2010.11.014; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Brait M, 2011, TOXICOL MECH METHOD, V21, P275, DOI 10.3109/15376516.2011.562671; Brechot C, 2010, PATHOL BIOL, V58, P278, DOI 10.1016/j.patbio.2010.05.001; Brooling JT, 2005, HEPATOLOGY, V41, P906, DOI 10.1002/hep.20645; Budhu A, 2006, J LEUKOCYTE BIOL, V80, P1197, DOI 10.1189/jlb.0506297; But DYK, 2008, WORLD J GASTROENTERO, V14, P1652, DOI 10.3748/wjg.14.1652; Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006; CASELMANN WH, 1995, J HEPATOL, V22, P34; Chang QS, 2009, J HEPATOL, V50, P323, DOI 10.1016/j.jhep.2008.07.037; Chia CS, 2002, IMMUNOL LETT, V84, P163, DOI 10.1016/S0165-2478(02)00176-1; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Deny P, 2010, PATHOL BIOL, V58, P245, DOI 10.1016/j.patbio.2010.05.002; Ding W, 2009, HEPATOLOGY, V49, P1277, DOI 10.1002/hep.22743; Dolganiuc A, 2009, ALCOHOL CLIN EXP RES, V33, P1704, DOI 10.1111/j.1530-0277.2009.01007.x; Elsharkawy AM, 2010, J HEPATOL, V53, P519, DOI 10.1016/j.jhep.2010.03.025; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Feo F, 2009, EXP BIOL MED, V234, P726, DOI 10.3181/0901-MR-40; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Gao B, 2005, CELL MOL IMMUNOL, V2, P92; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092; Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gurtsevitch VE, 2008, BIOCHEMISTRY-MOSCOW+, V73, P504, DOI 10.1134/S0006297908050039; Hamilton JP, 2010, EPIGENOMICS-UK, V2, P233, DOI 10.2217/EPI.10.9; Haybaeck J, 2009, CANCER CELL, V16, P295, DOI 10.1016/j.ccr.2009.08.021; He G, 2011, CANCER CELL, V17, P286; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herceg Z, 2011, MUTAT RES-REV MUTAT, V727, P55, DOI 10.1016/j.mrrev.2011.04.001; Hernandez-Vargas H, 2009, EPIGENOMICS-UK, V1, P261, DOI [10.2217/epi.09.19, 10.2217/EPI.09.19]; Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749; Holt AP, 2008, CLIN LIVER DIS, V12, P861, DOI 10.1016/j.cld.2008.07.002; Hsia CY, 2007, EJSO-EUR J SURG ONC, V33, P208, DOI 10.1016/j.ejso.2006.10.036; Hu RH, 1999, J FORMOS MED ASSOC, V98, P85; Huang J, 2009, SCI CHINA SER C, V52, P31, DOI 10.1007/s11427-009-0014-7; Huang WX, 1999, MULT SCLER, V5, P342; Huang Y S, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P327; Huang YS, 2008, J GASTROEN HEPATOL, V23, P87, DOI 10.1111/j.1440-1746.2007.05223.x; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ji JF, 2009, CANCER BIOL THER, V8, P1683, DOI 10.4161/cbt.8.18.8898; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; Katoh H, 2006, AM J PATHOL, V168, P1375, DOI 10.2353/ajpath.2006.050989; Kitaoka S, 2003, HEPATO-GASTROENTEROL, V50, P1569; Kitisin Krit, 2007, Gastrointest Cancer Res, V1, pS13; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; Knight B, 2008, GASTROENTEROLOGY, V135, P969, DOI 10.1053/j.gastro.2008.05.077; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027; Lata J, 2010, DIGEST DIS, V28, P596, DOI 10.1159/000320057; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lee HS, 2009, CLIN CANCER RES, V15, P812, DOI 10.1158/1078-0432.CCR-08-0266; Libbrecht L, 2006, WORLD J GASTROENTERO, V12, P6261, DOI 10.3748/wjg.v12.i39.6261; Lim R, 2006, HEPATOLOGY, V43, P1074, DOI 10.1002/hep.21170; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Lima SC, 2010, CURR OPIN MOL THER, V12, P316; Lin CH, 2001, CANCER RES, V61, P4238; Liu P, 2002, J HEPATOL, V37, P63, DOI 10.1016/S0168-8278(02)00064-8; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lu SC, 2006, J GASTROEN HEPATOL, V21, pS61, DOI 10.1111/j.1440-1746.2006.04575.x; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Luedde T, 2006, LIVER INT, V26, P1163, DOI 10.1111/j.1478-3231.2006.01366.x; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Mandrekar P, 2011, WORLD J GASTROENTERO, V17, P2456, DOI 10.3748/wjg.v17.i20.2456; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Mishra L, 2009, HEPATOLOGY, V49, P318, DOI 10.1002/hep.22704; Muller C, 2006, WIEN MED WOCHENSCHR, V156, P391, DOI 10.1007/s10354-006-0314-5; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Murakami Y, 2005, GUT, V54, P1162, DOI 10.1136/gut.2004.054452; Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547; NAKAZAKI H, 1992, CANCER, V70, P709, DOI 10.1002/1097-0142(19920801)70:3<709::AID-CNCR2820700328>3.0.CO;2-O; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nguyen LN, 2007, HEPATOLOGY, V45, P31, DOI 10.1002/hep.21466; Niwa T, 2010, ADV GENET, V71, P41, DOI [10.1016/B978-0-12-380864-6.00002-X, 10.1016/S0065-2660(10)71002-6]; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Park PH, 2005, AM J PHYSIOL-GASTR L, V289, pG1124, DOI 10.1152/ajpgi.00091.2005; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pogribny I. P., 2010, Experimental Oncology, V32, P132; Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364; Preisegger KH, 1999, LAB INVEST, V79, P103; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1997, J BIOL CHEM, V272, P10983; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Roskams T, 2003, J HEPATOL, V39, P431, DOI 10.1016/S0168-8278(03)00333-7; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sincic N, 2011, CURR OPIN ONCOL, V23, P69, DOI 10.1097/CCO.0b013e3283412eb4; Song LH, 2003, J CLIN VIROL, V28, P93, DOI 10.1016/S1386-6532(02)00271-8; Tacke F, 2009, CLIN REV ALLERG IMMU, V36, P4, DOI 10.1007/s12016-008-8091-0; Tang Y, 2008, P NATL ACAD SCI USA, V105, P2445, DOI 10.1073/pnas.0705395105; Tangkijvanich P, 2007, WORLD J GASTROENTERO, V13, P4345, DOI 10.3748/wjg.v13.i32.4345; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004; Viebahn CS, 2008, INT J BIOCHEM CELL B, V40, P855, DOI 10.1016/j.biocel.2007.11.025; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200; Won C, 2010, ANTICANCER RES, V30, P481; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003; Wu PC, 1996, AM J PATHOL, V149, P1167; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Yamashita T, 2010, CANCER RES, V70, P4687, DOI 10.1158/0008-5472.CAN-09-4210; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang SQ, 2004, HEPATOLOGY, V39, P403, DOI 10.1002/hep.20082; Yao JY, 2010, J BIOL CHEM, V285, P18828, DOI 10.1074/jbc.M109.077974; Yeoh GCT, 2007, HEPATOLOGY, V45, P486, DOI 10.1002/hep.21535; Yoon DS, 1999, YONSEI MED J, V40, P472, DOI 10.3349/ymj.1999.40.5.472; You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544; Yuen MF, 2002, SCAND J GASTROENTERO, V37, P233, DOI 10.1080/003655202753416939; Zekri ARN, 2005, WORLD J GASTROENTERO, V11, P6624, DOI 10.3748/wjg.v11.i42.6624; Zhang CH, 2010, J SURG RES; Zhang CJ, 2010, J HEPATOL, V53, P889, DOI 10.1016/j.jhep.2010.05.012; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhao J, 2010, HEPATOLOGY, V51, P142, DOI 10.1002/hep.23247; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zulehner G, 2010, AM J PATHOL, V176, P472, DOI 10.2353/ajpath.2010.090300	138	37	39	1	28	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1756-994X			GENOME MED	Genome Med.	JAN 31	2012	4								8	10.1186/gm307			13	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	084UN	WOS:000314564700001	22293089	gold, Green Published			2022-02-25	
J	Brennan, P; McKay, J; Hashibe, M				Brennan, Paul; McKay, James; Hashibe, Mia		INHANCE Consortium Genetic Epidem	Genome-wide study of head and neck cancers	CANCER RESEARCH			English	Meeting Abstract									[Brennan, Paul; McKay, James; Hashibe, Mia; INHANCE Consortium Genetic Epidem] Int Agcy Res Canc, F-69372 Lyon, France									0	0	0	0	1	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	0008-5472	1538-7445		CANCER RES	Cancer Res.	MAY 1	2009	69			9		98							1	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	V43TC	WOS:000209702704048					2022-02-25	
J	Boffetta, P				Boffetta, Paolo			Tobacco smoking and risk of bladder cancer	SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY			English	Article						Involuntary smoke; smokeless tobacco; tobacco smoking; urinary bladder cancer	CIGARETTE-SMOKING; FOLLOW-UP; UROTHELIAL CANCER; BLACK TOBACCO; LIFE-STYLE; MORTALITY; MEN; MALES; POPULATION; OCCUPATION	Tobacco smoking is the main known cause of urinary bladder cancer in humans. In most populations, over half of cases in men and a sizeable proportion in women are attributable to this habit. Epidemiological studies conducted in different populations have shown a linear relationship between intensity and duration of smoking and risk. Quitting smoking reduces the risk of bladder cancer. Smoking black (air-cured) cigarettes results in a higher risk than smoking blond (flue-cured) tobacco cigarettes; results on inhalation patterns and use of filter are not consistent. Cigar and pipe smoking also increases the risk of bladder cancer; data on other tobacco products are limited. The evidence for non-transitional bladder carcinoma is limited, but consistent with an increased risk. The available evidence does not point towards a different carcinogenic effect of tobacco smoking in men and women or in whites and blacks. Data on involuntary smoke and use of smokeless tobacco products are limited, but do not suggest an increased risk of bladder cancer.	Int Agcy Res Canc, Lifestyle Environm & Canc Grp, F-69008 Lyon, France		Boffetta, P (corresponding author), Int Agcy Res Canc, Lifestyle Environm & Canc Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr					AKIBA S, 1990, ENVIRON HEALTH PERSP, V87, P19, DOI 10.2307/3431001; Bedwani R, 1998, BRIT J CANCER, V77, P1186, DOI 10.1038/bjc.1998.197; Brennan P, 2000, INT J CANCER, V86, P289, DOI 10.1002/(SICI)1097-0215(20000415)86:2<289::AID-IJC21>3.0.CO;2-M; Brennan P, 2001, CANCER CAUSE CONTROL, V12, P411, DOI 10.1023/A:1011214222810; BURCH JD, 1989, INT J CANCER, V44, P622, DOI 10.1002/ijc.2910440411; BURNS PB, 1991, CANCER CAUSE CONTROL, V2, P371, DOI 10.1007/BF00054297; CARTWRIGHT RA, 1983, J EPIDEMIOL COMMUN H, V37, P256, DOI 10.1136/jech.37.4.256; Castelao JE, 2001, JNCI-J NATL CANCER I, V93, P538, DOI 10.1093/jnci/93.7.538; CEDERLOF R, 1975, RELATIONSHIP SMOKI 1; CLAUDE J, 1986, AM J EPIDEMIOL, V124, P578, DOI 10.1093/oxfordjournals.aje.a114430; CLAVEL J, 1989, INT J CANCER, V44, P605, DOI 10.1002/ijc.2910440408; DAVANZO B, 1990, EUR J CANCER, V26, P714, DOI 10.1016/0277-5379(90)90124-C; DESTEFANI E, 1991, CANCER-AM CANCER SOC, V67, P536, DOI 10.1002/1097-0142(19910115)67:2<536::AID-CNCR2820670236>3.0.CO;2-8; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Engeland A, 1996, CANCER CAUSE CONTROL, V7, P497, DOI 10.1007/BF00051881; Fortuny J, 1999, INT J CANCER, V80, P44, DOI 10.1002/(SICI)1097-0215(19990105)80:1&lt;44::AID-IJC9&gt;3.0.CO;2-8; Gandini S, 2008, INT J CANCER, V122, P155, DOI 10.1002/ijc.23033; HAMMOND E C, 1958, J Am Med Assoc, V166, P1159; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; HARTGE P, 1985, CANCER-AM CANCER SOC, V55, P901, DOI 10.1002/1097-0142(19850215)55:4<901::AID-CNCR2820550432>3.0.CO;2-Q; HOWE GR, 1980, JNCI-J NATL CANCER I, V64, P701; IARC, 2004, IARC MON EV CARC RIS, V83, P53; *INT AG RES CANC, 1986, IARC MON EV CARC RIS, V38; KAHN HAROLD A., 1966, NAT CANCER INST MONOGR, V19, P1; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; KUNZE E, 1992, CANCER-AM CANCER SOC, V69, P1776, DOI 10.1002/1097-0142(19920401)69:7<1776::AID-CNCR2820690721>3.0.CO;2-P; LOPEZABENTE G, 1991, AM J EPIDEMIOL, V134, P830, DOI 10.1093/oxfordjournals.aje.a116158; LOSSING EH, 1966, CANADIAN STUDY SMOKI; MCLAUGHLIN JK, 1992, CANCER RES, V52, P254; MCLAUGHLIN JK, 1995, INT J CANCER, V60, P190, DOI 10.1002/ijc.2910600211; MILLS PK, 1991, AM J EPIDEMIOL, V133, P230, DOI 10.1093/oxfordjournals.aje.a115867; MOMAS I, 1994, EUR J EPIDEMIOL, V10, P599, DOI 10.1007/BF01719579; MOMMSEN S, 1982, EUR J CANCER CLIN ON, V18, P1205, DOI 10.1016/0277-5379(82)90103-1; Murata M, 1996, CANCER DETECT PREV, V20, P557; Nordlund LA, 1997, INT J CANCER, V73, P625, DOI 10.1002/(SICI)1097-0215(19971127)73:5<625::AID-IJC2>3.0.CO;2-Z; Pitard A, 2001, CANCER CAUSE CONTROL, V12, P551, DOI 10.1023/A:1011291015233; Pohlabeln H, 1999, EUR J EPIDEMIOL, V15, P411, DOI 10.1023/A:1007595809278; SANDLER DP, 1985, AM J EPIDEMIOL, V121, P37, DOI 10.1093/oxfordjournals.aje.a113980; SLATTERY ML, 1988, CANCER, V61, P402, DOI 10.1002/1097-0142(19880115)61:2<402::AID-CNCR2820610233>3.0.CO;2-U; SORAHAN T, 1994, BRIT J UROL, V74, P753, DOI 10.1111/j.1464-410X.1994.tb07120.x; STEINECK G, 1988, ACTA ONCOL, V27, P323, DOI 10.3109/02841868809093549; Tulinius H, 1997, CANCER EPIDEM BIOMAR, V6, P863; VINEIS P, 1984, INT J CANCER, V34, P165, DOI 10.1002/ijc.2910340205; Vineis P, 1997, CANCER CAUSE CONTROL, V8, P346, DOI 10.1023/A:1018453104303; VIZCAINO P, 1994, CANCER CAUSE CONTROL, V5, P517, DOI 10.1007/BF01831379; WEIR JM, 1970, CANCER, V25, P105, DOI 10.1002/1097-0142(197001)25:1<105::AID-CNCR2820250115>3.0.CO;2-Z; WYNDER EL, 1977, CANCER-AM CANCER SOC, V40, P1246, DOI 10.1002/1097-0142(197709)40:3<1246::AID-CNCR2820400340>3.0.CO;2-5; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; Zeegers MPA, 2002, CANCER CAUSE CONTROL, V13, P83, DOI 10.1023/A:1013954932343; [No title captured]	51	70	70	2	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0036-5599			SCAND J UROL NEPHROL	Scand. J. Urol. Nephrol.	SEP	2008	42			218			45	54		10.1080/03008880802283664			10	Urology & Nephrology	Science Citation Index Expanded (SCI-EXPANDED)	Urology & Nephrology	375BE	WOS:000261086700007	18815916				2022-02-25	
J	Sawan, C; Vaissiere, T; Murr, R; Herceg, Z				Sawan, Carla; Vaissiere, Thomas; Murr, Rabih; Herceg, Zdenko			Epigenetic drivers and genetic passengers on the road to cancer	MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS			English	Review						epigenetic changes; genetic changes; DNA methylation; histone modifications; gene silencing; cancer	METHYLATED CPG DINUCLEOTIDES; MITOTIC CHECKPOINT GENES; H3 LYSINE-56 ACETYLATION; PROMOTER HYPERMETHYLATION; DNA-DAMAGE; HISTONE ACETYLATION; REPAIR GENE; MICROSATELLITE INSTABILITY; HOT-SPOTS; P53 GENE	Cancer is traditionally viewed as a primarily genetic disorder, however it is now becoming accepted that cancer is also a consequence of abnormal epigenetic events. Genetic changes and aneuploidy are associated with alterations in DNA sequence, and they are a hallmark of the malignant process. Epigenetic alterations are universally present in human cancer and result in heritable changes in gene expression and chromatin structure over many cell generations without changes in DNA sequence, leading to functional consequences equivalent to those induced by genetic alterations. Importantly, intriguing evidence emerged suggesting that epigenetic changes may precede and provoke genetic changes. In this scenario, epigenetic events are primary events while genetic changes (such as mutations) may simply be a consequence of disrupted epigenetic states. This fact may explain why many genetic screens proved to be limited with regard to cancer causality and pathogenesis. Aberrant epigenetic events affect multiple genes and cellular pathways in a non-random fashion and this can predispose to induction and accumulation of genetic changes in the course of tumour initiation and progression. These considerations are critical for a better understanding of tumourigenesis and molecular events underlying the acquisition of drug resistance, as well as development of novel strategies for cancer therapy and prevention. (C) 2008 Elsevier B.V. All rights reserved.	[Sawan, Carla; Vaissiere, Thomas; Murr, Rabih; Herceg, Zdenko] Int Agcy Res Canc, F-69008 Lyon, France		Herceg, Z (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr	Vaissiere, Thomas/E-1121-2011	Murr, Rabih/0000-0002-3346-6590			AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)82074-2; Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; Delaval K, 2004, CURR OPIN GENET DEV, V14, P188, DOI 10.1016/j.gde.2004.01.005; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2000, CANCER RES, V60, P2368; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fisher BL, 1999, DIGEST DIS SCI, V44, P2290, DOI 10.1023/A:1026617106755; Fleisher AS, 2000, CANCER RES, V60, P4864; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fryxell KJ, 2005, MOL BIOL EVOL, V22, P650, DOI 10.1093/molbev/msi043; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herceg Z, 2007, MOL ONCOL, V1, P26, DOI 10.1016/j.molonc.2007.01.004; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Hyland EA, 2005, MOL CELL BIOL, V25, P10060, DOI 10.1128/MCB.25.22.10060-10070.2005; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JACINTO FV, 2007, MUTAGENESIS; Jascur T, 2006, INT J CANCER, V119, P2030, DOI 10.1002/ijc.22023; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2005, CANCER RES, V65, P11241, DOI 10.1158/0008-5472.CAN-05-3865; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kohya N, 2003, INT J MOL MED, V11, P65; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; LINDAHL T, 1993, COLD SPRING HARB SYM, V58, P619, DOI 10.1101/SQB.1993.058.01.068; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; Loizou JI, 2006, CELL CYCLE, V5, P696, DOI 10.4161/cc.5.7.2616; Lutsenko E, 1999, MUTAT RES-REV MUTAT, V437, P11, DOI 10.1016/S1383-5742(99)00065-4; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Ozdemir A, 2006, CELL CYCLE, V5, P2602, DOI 10.4161/cc.5.22.3473; PARSONS R, 1995, CANCER RES, V55, P5548; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PEGG AE, 1990, CANCER RES, V50, P6119; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Sato N, 2003, CANCER RES, V63, P4158; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHUKLA V, 2007, MUTAT RES; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Stirzaker C, 1997, CANCER RES, V57, P2229; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tommasi S, 1997, CANCER RES, V57, P4727; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; van Steensel B, 2003, BIOTECHNIQUES, V35, P346; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Whitehall VLJ, 2001, CANCER RES, V61, P827; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Yoon JH, 2001, CANCER RES, V61, P7110; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	123	107	109	0	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1386-1964	1873-135X		MUTAT RES-FUND MOL M	Mutat. Res.-Fundam. Mol. Mech. Mutagen.	JUL 3	2008	642	1-2					1	13		10.1016/j.mrfmmm.2008.03.002			13	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	326DO	WOS:000257638500001	18471836				2022-02-25	
J	Autier, P; Boniol, M; Hery, C; Masuyer, E; Ferlay, J				Autier, Philippe; Boniol, Mathieu; Hery, Clarisse; Masuyer, Eric; Ferlay, Jacques			Cancer survival statistics should be viewed with caution	LANCET ONCOLOGY			English	Editorial Material							DATA REPORTING CONTRIBUTE; BREAST-CANCER; PROSTATE-CANCER; EUROPE; EUROCARE-4; DIAGNOSIS; TRENDS; RATES		[Autier, Philippe; Boniol, Mathieu; Hery, Clarisse; Masuyer, Eric; Ferlay, Jacques] Int Agcy Res Canc, F-69372 Lyon, France		Autier, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.	autierp@iarc.fr	Ferlay, Jacques/ABD-5058-2021; Boniol, Mathieu/F-9623-2011; Autier, Philippe/A-4402-2014	Boniol, Mathieu/0000-0003-1052-5604; Autier, Philippe/0000-0003-1538-5321			[Anonymous], WHO DAT; Berrino F, 2007, LANCET ONCOL, V8, P773, DOI 10.1016/S1470-2045(07)70245-0; Butler CA, 2005, JNCI-J NATL CANCER I, V97, P1385, DOI 10.1093/jnci/dji285; Butler CA, 2006, RESP MED, V100, P1642, DOI 10.1016/j.rmed.2005.12.006; DOLL R, 1981, CAUSES CACNER APPEND; Fracheboud J, 2004, BRIT J CANCER, V91, P861, DOI 10.1038/sj.bjc.6602075; Gatta G, 2000, GUT, V47, P533, DOI 10.1136/gut.47.4.533; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; *HLTH EUR UN, REP SEPT 2007; Lipsker DM, 1999, ARCH DERMATOL, V135, P1451, DOI 10.1001/archderm.135.12.1451; PARKIN DM, 2005, 7 IARC; Quaglia A, 2003, EUR J CANCER PREV, V12, P145, DOI 10.1097/00008469-200304000-00008; Richards M, 2007, LANCET ONCOL, V8, P752, DOI 10.1016/S1470-2045(07)70247-4; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P153; Sant M, 2003, INT J CANCER, V106, P416, DOI 10.1002/ijc.11226; Sant M, 2006, INT J CANCER, V119, P2417, DOI 10.1002/ijc.22160; *UK DEP HLTH, NHS CANC PLAN; *US NAT CANC I, SURV EP END RES; Verdecchia A, 2007, LANCET ONCOL, V8, P784, DOI 10.1016/S1470-2045(07)70246-2; 2007, LANCET ONCOL, V8, P747	20	19	19	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1470-2045			LANCET ONCOL	Lancet Oncol.	DEC	2007	8	12					1050	1054		10.1016/S1470-2045(07)70354-6			5	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	242YR	WOS:000251762600008	18054874				2022-02-25	
J	Kaaks, R				Kaaks, R			Insulin-like growth factor-I and mammographic breast density	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Letter							IGF-BINDING PROTEIN-3		Int Agcy Res Canc, Nutr & Hormones Grp, Lyon, France		Kaaks, R (corresponding author), Int Agcy Res Canc, Nutr & Hormones Grp, Lyon, France.						Boyd NF, 2002, BRIT J CANCER, V87, P876, DOI 10.1038/sj.bjc.6600537; Byrne C, 2000, CANCER RES, V60, P3744; Diorio C, 2005, CANCER EPIDEM BIOMAR, V14, P1065, DOI 10.1158/1055-9965.EPI-04-0706; KATO I, 1995, CANCER CAUSE CONTROL, V6, P431, DOI 10.1007/BF00052183; Maskarinec G, 2000, BREAST CANCER RES TR, V63, P153, DOI 10.1023/A:1006486319848; Maskarinec G, 2003, INT J CANCER, V107, P991, DOI 10.1002/ijc.11505	6	6	6	0	0	AMER ASSOC CANCER RESEARCH	PHILADELPHIA	615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA	1055-9965			CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	DEC	2005	14	12					3019	3019		10.1158/1055-9965.EPI-05-0607			1	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	994UB	WOS:000234055600037	16365031	Bronze			2022-02-25	
J	Ohnishi, S; Sawa, T				Ohnishi, S; Sawa, T			Endogenous DNA damage in carcinogenesis	SEIKAGAKU			Japanese	Review							NITRIC-OXIDE SYNTHASE; CHRONIC INFLAMMATION; 8-NITROGUANINE; P53; PEROXYNITRITE; ACCUMULATION; INFECTION; APOPTOSIS; CELLS		Int Agcy Res Canc, WHO, Endogenous Risk Factors Grp, F-69372 Lyon, France		Ohnishi, S (corresponding author), Int Agcy Res Canc, WHO, Endogenous Risk Factors Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.						Akaike T, 2003, P NATL ACAD SCI USA, V100, P685, DOI 10.1073/pnas.0235623100; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Fukunaga-Takenaka R, 2003, BIOCHEM BIOPH RES CO, V308, P966, DOI 10.1016/S0006-291X(03)01516-X; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Li CQ, 2002, P NATL ACAD SCI USA, V99, P10364, DOI 10.1073/pnas.162356399; Lirk Philipp, 2002, Current Drug Targets - Inflammation and Allergy, V1, P89, DOI 10.2174/1568010023344913; Ma N, 2004, BIOCHEM BIOPH RES CO, V319, P506, DOI 10.1016/j.bbrc.2004.04.193; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pinlaor S, 2004, CARCINOGENESIS, V25, P1535, DOI 10.1093/carcin/bgh157; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Tatemichi M, 2005, CANCER LETT, V217, P197, DOI 10.1016/j.canlet.2004.09.002; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6	17	0	0	0	0	JAPANESE BIOCHEMICAL SOC	TOKYO	ISHIKAWA BLDG-3F, 25-16 HONGO-5-CHOME, BUNKYO-KU, TOKYO, 113, JAPAN	0037-1017			SEIKAGAKU	Seikagaku	NOV	2005	77	11					1427	1431					5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	990LQ	WOS:000233745000011	16370364				2022-02-25	
J	Parkin, DM; Bray, F; Ferlay, J; Pisani, P				Parkin, DM; Bray, F; Ferlay, J; Pisani, P			Global cancer statistics, 2002	CA-A CANCER JOURNAL FOR CLINICIANS			English	Article							HEMOGLOBIN ADDUCT LEVELS; S-TRANSFERASE M1; INTERNATIONAL TRENDS; HELICOBACTER-PYLORI; KAPOSIS-SARCOMA; WORLDWIDE INCIDENCE; LYMPHOMA INCIDENCE; HODGKINS-DISEASE; INFECTION-RATES; MAJOR CANCERS	Estimates of the worldwide incidence, mortality and prevalence of 26 cancers in the year 2002 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. The results are presented here in summary form, including the geographic variation between 20 large "areas" of the world. Overall, there were 10.9 million new cases, 6.7 million deaths, and 24.6 million persons alive with cancer (within three years of diagnosis). The most commonly diagnosed cancers are lung (1.35 million), breast (1.15 million), and colorectal (1 million); the most common causes of cancer death are lung cancer (1.18 million deaths), stomach cancer (700,000 deaths), and liver cancer (598,000 deaths). The most prevalent cancer in the world is breast cancer (4.4 million survivors up to 5 years following diagnosis). There are striking variations in the risk of different cancers by geographic area. Most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.	Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon, France		Parkin, DM (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon, France.		SALAZAR, ANTONIO/A-5806-2013; Ibrahim, Essam H./G-1960-2018; Ferlay, Jacques/ABD-5058-2021	SALAZAR, ANTONIO/0000-0003-2639-2340; Ibrahim, Essam H./0000-0003-0130-2257; 			[Anonymous], 2003, WORLD POP PROSP 2002; [Anonymous], 1992, IARC SCI PUBLICATION, V119; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Arisawa K, 2000, INT J CANCER, V85, P319, DOI 10.1002/(SICI)1097-0215(20000201)85:3<319::AID-IJC4>3.0.CO;2-B; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Baade PD, 2004, CANCER CAUSE CONTROL, V15, P237, DOI 10.1023/B:CACO.0000024212.66334.26; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; BIGGAR RJ, 1984, J NATL CANCER I, V73, P89; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; BOUCHARDY C, 1991, CANCER EPIDEM BIOMAR, V1, P21; Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3; Bray F, 2004, EUR J CANCER, V40, P96, DOI 10.1016/j.ejca.2003.08.005; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; Chu KC, 2003, CANCER-AM CANCER SOC, V97, P1507, DOI 10.1002/cncr.11212; COGGON D, 1990, BRIT J CANCER, V61, P573, DOI 10.1038/bjc.1990.128; COZEN W, 1992, CANCER EPIDEM BIOMAR, V1, P261; Doll Richard, 1981, CAUSES CANC; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Dorn HF, 1959, PUBLIC HLTH MONOGRAP, V56; Eltom MA, 2002, J NATL CANCER I, V94, P1204, DOI 10.1093/jnci/94.16.1204; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Ferlay J., 2001, GLOBOCAN 2000 CANC I; Giovannucci E, 2002, GASTROENTEROL CLIN N, V31, P925, DOI 10.1016/S0889-8553(02)00057-2; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; GOEDDE HW, 1992, HUM GENET, V88, P344; Gondos A, 2004, INT J CANCER, V112, P860, DOI 10.1002/ijc.20471; GONDOS A, 2005, IN PRESS BR J CANC; Gustafsson L, 1997, INT J CANCER, V71, P159, DOI 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#; HARGGE P, 1992, CANC RES S, V52, pS5566; Hewitt M, 1999, J NATL CANCER I, V91, P1480, DOI 10.1093/jnci/91.17.1480; HOLCOMBE C, 1992, GUT, V33, P429, DOI 10.1136/gut.33.4.429; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; *IARC, 1994, IARC MON EV CARC RIS, V61; *IARC, 1997, IRC MON EV CARC RISK, V70; *INT AG RES CANC, 1999, IARC MON EV CARC RIS, V72; *INT AG RES CTR, 2002, IARC HDB CANC PREV, V7; International Agency for Research on Cancer, 2004, IARC MON EV CARC RIS, V83; Jaffe E. S., 2001, WHO CLASSIFICATION T; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P277, DOI 10.1093/jnci/93.4.277; KOLONEL LN, 1980, GENETIC ENV FACTORS, P327; Lagergren J, 1999, ANN INTERN MED, V130, P883, DOI 10.7326/0003-4819-130-11-199906010-00003; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MCMICHAEL AJ, 1980, INT J CANCER, V25, P431, DOI 10.1002/ijc.2910250402; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; MELBYE M, 2002, TXB CANC EPIDEMIOLOG; Miller BA, 1996, NIH PUBLICATION, V96-4104; MUELLER NE, 1996, CANC EPIDEMIOLOGY PR, P893; Munoz N, 1997, SALUD PUBLICA MEXICO, V39, P318; Munoz N, 1996, CANC EPIDEMIOLOGY PR; NEWTON R, 2002, AIDS AFRICA; OETTLE AG, 1962, ACTA UNION INT CONTR, V18, P330; Oliver SE, 2001, INT J CANCER, V92, P893, DOI 10.1002/ijc.1260; Palli D, 2000, J GASTROENTEROL, V35, pS84; Parkin D M, 1991, IARC Sci Publ, P159; Parkin D.M., 2002, IARC SCI PUBLICATION, VVIII; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Parkin DM, 1999, CANCER SURV, V33, P5; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARKIN DM, 1993, CANCER EPIDEM BIOMAR, V2, P537; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Parkin DM, 2003, IARC SCI PUBLICATION, V153; Peto R, 1994, MORTALITY SMOKING DE; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; Remick, 1995, Cancer Control, V2, P97; Ries L, 1975, SEER CANC STAT REV; Roosendaal R, 1997, AM J GASTROENTEROL, V92, P1480; Sadjadi A, 2003, INT J CANCER, V107, P113, DOI 10.1002/ijc.11359; SANKARANARAYAN R, 1988, IARC SCI PUBLICATION, V15; Sant M, 2003, ANN ONCOL, V14, pV61, DOI 10.1093/annonc/mdg754; Shibata A, 1997, PROSTATE, V32, P65; Sitas F, 2000, INT J CANCER, V88, P489, DOI 10.1002/1097-0215(20001101)88:3&lt;489::AID-IJC25&gt;3.0.CO;2-Q; SITAS F, 1992, GUT, V33, P1582, DOI 10.1136/gut.33.11.1582; SMITH P, 1987, IARC SCI PUBLICATION, V88; Sriplung H, 2004, CANCER-AM CANCER SOC, V101, P2660, DOI 10.1002/cncr.20622; TANAKA H, 1994, CANCER CAUSE CONTROL, V5, P409, DOI 10.1007/BF01694754; Templeton A C, 1981, Pathol Annu, V16, P315; Tyczynski JE, 2004, INT J CANCER, V109, P598, DOI 10.1002/ijc.20019; Vizcaino AP, 2002, INT J CANCER, V99, P860, DOI 10.1002/ijc.10427; *WCRF PAN, 1997, DIET NUTR PREV CANC; Yokoyama A, 2002, CARCINOGENESIS, V23, P1851, DOI 10.1093/carcin/23.11.1851; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712; YU MC, 1995, CANCER EPIDEM BIOMAR, V4, P861; 2002, INT J CANCER, V104, P213	93	20112	21839	44	1884	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-9235	1542-4863		CA-CANCER J CLIN	CA-Cancer J. Clin.	MAR-APR	2005	55	2					74	108		10.3322/canjclin.55.2.74			35	Oncology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology	958YL	WOS:000231484000005	15761078	gold			2022-02-25	
J	Plummer, M				Plummer, M			Improved estimates of floating absolute risk	STATISTICS IN MEDICINE			English	Article						dose response; relative risk; misspecified models; EM algorithm	PRESENTING STATISTICAL UNCERTAINTY; DOSE-RESPONSE RELATIONS; BREAST-CANCER; TRENDS; MODELS; RE	Floating absolute risks are an alternative way of presenting relative risk estimates for polychotomous risk factors. Instead of choosing one level of the risk factor as a reference category, each level is assigned a 'floated' variance which describes the uncertainty in risk without reference to another level. In this paper, a method for estimating the floated variances is presented that improves on the previously proposed 'heuristic' method. The estimates may be calculated iteratively with a simple algorithm. A benchmark for validating the floated variance estimates is also proposed and an interpretation of floating confidence intervals is given. Copyright (C) 2004 John Wiley Sons, Ltd.	Int Agcy Res Canc, F-69372 Lyon 08, France		Plummer, M (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	plummer@iarc.fr		Plummer, Martyn/0000-0001-5130-6497			BOX GEP, 1979, ROBUSTNESS STAT; CHILVERS C, 1989, LANCET, V1, P973; de Menezes R. X., 1999, THESIS U OXFORD, p[4, 13]; Easton D, 2000, AM J EPIDEMIOL, V152, P393, DOI 10.1093/aje/152.4.393; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Greenland S, 1999, AM J EPIDEMIOL, V149, P1077; Greenland S, 2000, AM J EPIDEMIOL, V152, P394; Huber PJ, 1967, P 5 BERK S MATH STAT P 5 BERK S MATH STAT; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Little J.L., 1987, STAT ANAL MISSING DA; Michels KB, 1997, LANCET, V349, P502, DOI 10.1016/S0140-6736(05)61213-5; Peto R, 1997, LANCET, V349, P501, DOI 10.1016/S0140-6736(97)26007-1; PLUMMER M, 1993, STAT MED, V12, P925, DOI 10.1002/sim.4780121004; SAS Institute Inc, 1999, SAS STAT US GUID VER; VINCENT MD, 1996, EUROPEAN J CANC CLIN, V23, P1598; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526	16	176	177	0	4	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0277-6715			STAT MED	Stat. Med.	JAN 15	2004	23	1					93	104		10.1002/sim.1485			12	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics	760YB	WOS:000187861900007	14695642				2022-02-25	
J	Suzuki, T; Friesen, MD; Ohshima, H				Suzuki, T; Friesen, MD; Ohshima, H			Identification of products formed by reaction of 3 ',5 '-di-O-acetyl-2 '-deoxyguanosine with hypochlorous acid or a myeloperoxidase-H2O2-Cl- system	CHEMICAL RESEARCH IN TOXICOLOGY			English	Article							ONE-ELECTRON OXIDATION; DNA-SYNTHESIS OPPOSITE; CALF THYMUS DNA; SPIROIMINODIHYDANTOIN NUCLEOSIDE; IMIDAZOLONE NUCLEOSIDES; HYDANTOIN PRODUCTS; HUMAN-NEUTROPHILS; ESCHERICHIA-COLI; 8-OXO-7,8-DIHYDROGUANOSINE; 2'-DEOXYGUANOSINE	Hypochlorous acid (HOCl), generated by myeloperoxidase from H2O2 and Cl-, plays an important role in host defense and inflammatory tissue injury. We have studied the reaction of 3',5'-di-O-acetyl-2'-deoxyguanosine with reagent HOCl and with a human myeloperoxidase H2O2-Cl- system in order to characterize polar reaction products. When 100 muM 3',5'-di-O-acetyl-2'-deoxyguanosine was reacted with 100 muM HOCl at pH 7.4 and 37 degreesC and the reaction was terminated by N-acetylcysteine, 3',5'-di-O-acetyl derivatives of previously reported products, such as diastereomers of spiroiminodihydantoin nucleoside, a diimino-imidazole nucleoside, an amino-imidazolone nucleoside, and 8-chloro-2'-deoxyguanosine were formed. In addition, we report the formation of 3',5'-di-O-acetyl derivatives of a guanidinohydantoin nucleoside, an iminoallantoin nucleoside, and a diamino-oxazolone nucleoside in this system. The identification of the products was based on their identical ESI-MS and UV spectra and HPLC retention times with authentic compounds synthesized with other oxidation systems. All of these products were also formed in the reaction of 3',5'-di-O-acetyl-2'-deoxyguanosine with the myeloperoxidase-H2O2-Cl- system under mildly acidic conditions. The yields of the products were greatly affected by the pH of the reaction mixture. The total yields of these products formed by HOCl at pH 7.4 and by the myeloperoxidase-H2O2-Cl- system at pH 4.5 were 72 and 43% of the consumed 3',5'-di-O-acetyl-2'-deoxyguanosine, respectively, indicating that nearly half of the consumption of 3',5'-di-O-acetyl-2'-deoxyguanosine by HOCl and the myeloperoxidase-H2O2-Cl- system can be accounted for by the formation of these products.	Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, F-69372 Lyon 08, France; Int Agcy Res Canc, Unit Nutr & Canc, F-69372 Lyon, France		Ohshima, H (corresponding author), Int Agcy Res Canc, Unit Endogenous Canc Risk Factors, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Friesen, Marlin D/D-7328-2012; Ohshima, Hiroshi/E-8044-2010				BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; BERNOFSKY C, 1990, FREE RADICAL RES COM, V9, P303, DOI 10.3109/10715769009145689; BREZONIK PL, 1994, CHEM KINETICS PROCES, P236; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; Duarte V, 2000, NUCLEIC ACIDS RES, V28, P1555, DOI 10.1093/nar/28.7.1555; Duarte V, 1999, NUCLEIC ACIDS RES, V27, P496, DOI 10.1093/nar/27.2.496; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Fujikawa K, 2002, FEBS LETT, V512, P149, DOI 10.1016/S0014-5793(02)02240-8; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazra TK, 2001, NUCLEIC ACIDS RES, V29, P1967, DOI 10.1093/nar/29.9.1967; Henderson PT, 2002, BIOCHEMISTRY-US, V41, P914, DOI 10.1021/bi0156355; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KOPPENOL WH, 1994, FEBS LETT, V347, P5, DOI 10.1016/0014-5793(94)00494-3; Kornyushyna O, 2002, BIOCHEMISTRY-US, V41, P15304, DOI 10.1021/bi0264925; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Luo WC, 2001, ORG LETT, V3, P2801, DOI 10.1021/ol0161763; Luo WC, 2001, CHEM RES TOXICOL, V14, P927, DOI 10.1021/tx010072j; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; MATSUDA A, 1986, SYNTHESIS-STUTTGART, P385; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; Raoul S, 1996, J CHEM SOC PERK T 2, P371, DOI 10.1039/p29960000371; RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P379, DOI 10.1021/tx00045a009; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Suzuki T, 2002, NUCLEIC ACIDS RES, V30, P2555, DOI 10.1093/nar/30.11.2555; Suzuki T, 2002, FEBS LETT, V516, P67, DOI 10.1016/S0014-5793(02)02503-6; Suzuki T, 2001, CHEM RES TOXICOL, V14, P1163, DOI 10.1021/tx010024z; Vialas C, 1998, J AM CHEM SOC, V120, P11548, DOI 10.1021/ja981597+; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 1999, BIOMARKERS, V4, P303, DOI 10.1080/135475099230831; YANAGAWA H, 1992, J BIOL CHEM, V267, P13320	38	28	28	0	4	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0893-228X			CHEM RES TOXICOL	Chem. Res. Toxicol.	MAR	2003	16	3					382	389		10.1021/tx025638y			8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Chemistry; Toxicology	661QL	WOS:000181901200016	12641439				2022-02-25	
J	Parkin, DM				Parkin, Donald Maxwell			Population risk factors for late-stage presentation of cervical cancer in sub-Saharan Africa. Stewart et al Cancer Epidemiol. 2018 Apr; 53:81-92	CANCER EPIDEMIOLOGY			English	Letter									[Parkin, Donald Maxwell] Int Agcy Res Canc, F-69372 Lyon 08, France		Parkin, DM (corresponding author), Int Agcy Res Canc, F-69372 Lyon 08, France.	max.parkin@ctsu.ox.ac.uk		Parkin, Donald Maxwell/0000-0002-3229-1784				0	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1877-7821	1877-783X		CANCER EPIDEMIOL	Cancer Epidemiol.	DEC	2019	63								101599	10.1016/j.canep.2019.101599			1	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	JY8LJ	WOS:000504659600013	31591050				2022-02-25	
J	Byrnes, G				Byrnes, Graham			Modern statistics, multiple testing and wishful thinking	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Editorial Material						epidemiology; statistics; multivariate analysis; false detection rate			[Byrnes, Graham] Int Agcy Res Canc, Sect Environm & Radiat, F-69008 Lyon, France		Byrnes, G (corresponding author), Int Agcy Res Canc, Sect Environm & Radiat, F-69008 Lyon, France.	ByrnesG@iarc.fr		Byrnes, Graham/0000-0003-3893-7539			Amrhein V, 2017, PEERJ, V5, DOI 10.7717/peerj.3544; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Efron B., 2010, IMS MONOGRAPHS; Forstmeier W, 2017, BIOL REV, V92, P1941, DOI 10.1111/brv.12315; Hastie T., 2013, ELEMENTS STAT LEARNI, V2; Lenters V, 2018, OCCUP ENVIRON MED, V75, P522, DOI 10.1136/oemed-2016-104231; Miller R.G., 1981, SURVIVAL ANAL; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226	8	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711	1470-7926		OCCUP ENVIRON MED	Occup. Environ. Med.	JUL	2018	75	7					477	478		10.1136/oemed-2017-104807			2	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	GM3VT	WOS:000438040000002	29523703				2022-02-25	
